ArticleId,PMCid,TableName,SpecPragmatics,CellContent,Header,Stub,SuperRow,rowN,columnN,function,hasAge,actual,predicted,error,prediction
19,1090597,Table 1,BaselineCharacteristic,xx.x (xx.x),n (%) ; ,None,None,20,1,,yes,2:yes,1:No,+,0.62
2811,2758901,Table 1,BaselineCharacteristic,xx-xx,Gefitinib ; No ;  ; xxx ;  ; ,?Range, ,15,1,,yes,2:yes,1:No,+,0.567
2811,2758901,Table 1,BaselineCharacteristic,xx-xx,Erlotinib ; No ;  ; xx ;  ; ,?Range, ,15,3,,yes,2:yes,1:No,+,0.543
2864,2774660,Table 1,BaselineCharacteristic,x.x,Total ; ,Age (years),None,4,1,3,yes,2:yes,1:No,+,0.56
2864,2774660,Table 1,BaselineCharacteristic,x.x,Phase x - treatment ; ,Age (years),None,4,2,3,yes,2:yes,1:No,+,0.51
3308,2905428,Table 1,BaselineCharacteristic,xx,No (%) ; ,, Age,3,2,3,yes,2:yes,1:No,+,0.551
4246,3165084,Table 1,BaselineCharacteristic,xx–xx,Number(percent) ; xx(xxx) ;  ; ,,,4,1,,yes,2:yes,1:No,+,0.504
4585,3247194,Table 1,BaselineCharacteristic,xx.x (x.x),COPD Subjects ; xxx ;  ; ,None,None,3,2,,yes,2:yes,1:No,+,0.576
4585,3247194,Table 1,BaselineCharacteristic,xx.x (x.x),Smoker Controls ; xx ;  ; ,None,None,3,3,,yes,2:yes,1:No,+,0.502
4585,3247194,Table 1,BaselineCharacteristic,xx.x (x.x),Non-smoker Controls ; xx ;  ; ,None,None,3,4,,yes,2:yes,1:No,+,0.505
19,1090597,Table 1,BaselineCharacteristic,xx (xx),n (%) ; ,Male,,2,1,,No,1:No,2:yes,+,0.512
19,1090597,Table 1,BaselineCharacteristic,xx (xx),n (%) ; ,Female,,3,1,,No,1:No,2:yes,+,0.502
164,1386704,Table 1,BaselineCharacteristic,xx.x ± xx.x,,"FVC% pred, x ± SD",None,2,1,3,No,1:No,2:yes,+,0.62
164,1386704,Table 1,BaselineCharacteristic,xx.x ± xx.x,,"FEVx%pred, x ± SD",None,3,1,3,No,1:No,2:yes,+,0.59
164,1386704,Table 1,BaselineCharacteristic,xx.x ± x.x,,"TLC% pred, x ± SD",None,4,1,3,No,1:No,2:yes,+,0.53
215,1488867,Table 1,BaselineCharacteristic,xx(xx%),n(%) ; ,?P. S x–x, Age (years),5,1,3,No,1:No,2:yes,+,0.63
309,1586008,Table 1,BaselineCharacteristic,x.xx ± x.x,N° (%) ; ,Mean Body Surface Area (mx),None,3,1,3,No,1:No,2:yes,+,0.52
449,1885552,Table 1,BaselineCharacteristic,Age (years),,Intervention group (number of subjects),None,0,1,1,No,1:No,2:yes,+,0.509
449,1885552,Table 1,BaselineCharacteristic,"xx,x ± xx,x",Weight (kp) ; ,Stretching (xx),None,1,2,3,No,1:No,2:yes,+,0.504
449,1885552,Table 1,BaselineCharacteristic,"xxx ± xx,x",Height (cm) ; ,Stretching (xx),None,1,3,3,No,1:No,2:yes,+,0.514
449,1885552,Table 1,BaselineCharacteristic,"xxx ± xx,x",Systolic blood pressure (mm Hg) ; ,Stretching (xx),None,1,4,3,No,1:No,2:yes,+,0.534
449,1885552,Table 1,BaselineCharacteristic,"xxx ± x,x",Height (cm) ; ,Strength (xx),None,2,3,3,No,1:No,2:yes,+,0.514
449,1885552,Table 1,BaselineCharacteristic,"xxx ± xx,x",Systolic blood pressure (mm Hg) ; ,Strength (xx),None,2,4,3,No,1:No,2:yes,+,0.524
449,1885552,Table 1,BaselineCharacteristic,"xxx ± x,x",Height (cm) ; ,Vibration (xx),None,3,3,3,No,1:No,2:yes,+,0.53
449,1885552,Table 1,BaselineCharacteristic,"xxx ± xx,x",Systolic blood pressure (mm Hg) ; ,Vibration (xx),None,3,4,3,No,1:No,2:yes,+,0.54
1233,2259321,Table 1,BaselineCharacteristic,xx (xx),Celecoxib Dose ;  ; xxx mg twice daily ;  ; NAF (plasma) ; ,Samples,,5,1,3,No,1:No,2:yes,+,0.605
1233,2259321,Table 1,BaselineCharacteristic,xx (xxx,Celecoxib Dose ;  ; xxx mg twice daily ;  ; NAF(plasma) ; ,Samples,,5,2,3,No,1:No,2:yes,+,0.595
1233,2259321,Table 1,BaselineCharacteristic,,Celecoxib Dose ;  ; xxx mg twice daily ;  ; NAF (plasma) ; ,Age (years),None,6,1,43,No,1:No,2:yes,+,0.651
1233,2259321,Table 1,BaselineCharacteristic,,Celecoxib Dose ;  ; xxx mg twice daily ;  ; NAF(plasma) ; ,Age (years),None,6,2,43,No,1:No,2:yes,+,0.651
1233,2259321,Table 1,BaselineCharacteristic,xx (xx),Celecoxib Dose ;  ; xxx mg twice daily ;  ; NAF(plasma) ; ,Premenopausal,,9,2,3,No,1:No,2:yes,+,0.545
1233,2259321,Table 1,BaselineCharacteristic,xx (xx),Celecoxib Dose ;  ; xxx mg twice daily ;  ; NAF (plasma) ; ,?White, Race,11,1,3,No,1:No,2:yes,+,0.525
1233,2259321,Table 1,BaselineCharacteristic,xx (xx),Celecoxib Dose ;  ; xxx mg twice daily ;  ; NAF(plasma) ; ,?White, Race,11,2,3,No,1:No,2:yes,+,0.515
1273,2359721,Table 1,BaselineCharacteristic,"Median age, years",,None,None,2,0,12,No,1:No,2:yes,+,0.545
1283,2359964,Table 1,BaselineCharacteristic,Median age (range),,None,None,0,0,12,No,1:No,2:yes,+,0.505
1376,2360764,Table 1,BaselineCharacteristic,"Age, years (range)", ; Characteristics ; ,"Age, years (range)",,2,0,2,No,1:No,2:yes,+,0.518
1376,2360764,Table 1,BaselineCharacteristic,,% ; xxx ; ,"Age, years (range)",,2,2,3,No,1:No,2:yes,+,0.71
1423,2361378,Table 1,BaselineCharacteristic,xx,n (%) ; ,Patients enrolled,,1,1,3,No,1:No,2:yes,+,0.524
1504,2361889,Table 1,BaselineCharacteristic,Median (range),,Median (range), Age (years),2,0,2,No,1:No,2:yes,+,0.518
1504,2361889,Table 1,BaselineCharacteristic,xx (xx.x%),,Postmenopause, Age (years),3,1,3,No,1:No,2:yes,+,0.58
1504,2361889,Table 1,BaselineCharacteristic,x (xx.x%),,Premenopause, Age (years),4,1,3,No,1:No,2:yes,+,0.54
2207,2481444,Table 1,BaselineCharacteristic,xx,"Age, years ; ",x,None,1,3,3,No,1:No,2:yes,+,0.6
2207,2481444,Table 1,BaselineCharacteristic,xx,"Age, years ; ",x,None,2,3,3,No,1:No,2:yes,+,0.56
2207,2481444,Table 1,BaselineCharacteristic,xx,"Age, years ; ",x,None,3,3,3,No,1:No,2:yes,+,0.55
2207,2481444,Table 1,BaselineCharacteristic,xx,"Age, years ; ",x,None,4,3,3,No,1:No,2:yes,+,0.51
2207,2481444,Table 1,BaselineCharacteristic,xx,"Age, years ; ",x,None,5,3,3,No,1:No,2:yes,+,0.51
2246,2527821,Table 1,BaselineCharacteristic,"Median age (range), years", ; ,"Median age (range), years",,2,0,2,No,1:No,2:yes,+,0.57
2269,2551676,TABLE 1,BaselineCharacteristic,xx,Recipient  ; x ; ,Age (years),None,2,1,3,No,1:No,2:yes,+,0.58
2269,2551676,TABLE 1,BaselineCharacteristic,xx,Recipient  ; x ; ,Age (years),None,2,2,3,No,1:No,2:yes,+,0.54
2269,2551676,TABLE 1,BaselineCharacteristic,xx,Recipient  ; x ; ,Age (years),None,2,3,3,No,1:No,2:yes,+,0.55
2269,2551676,TABLE 1,BaselineCharacteristic,xx,Recipient  ; x ; ,Age (years),None,2,4,3,No,1:No,2:yes,+,0.52
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Age (years) ; ,????x, Patient x   ,2,1,3,No,1:No,2:yes,+,0.59
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Age (years) ; ,????x*, Patient x   ,3,1,3,No,1:No,2:yes,+,0.55
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Age (years) ; ,????x*, Patient x   ,4,1,3,No,1:No,2:yes,+,0.52
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Age (years) ; ,????x, Patient x   ,5,1,3,No,1:No,2:yes,+,0.55
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Age (years) ; ,????x, Patient x   ,7,1,3,No,1:No,2:yes,+,0.52
2370,2599890,Table 1,BaselineCharacteristic,xx (xx–xx),Mean (range) MAP (mmHg)x ; ,x,None,1,10,3,No,1:No,2:yes,+,0.505
2478,2656521,Table 1,BaselineCharacteristic,xx.x ± x.x,Steatohepatitis (n xx) ; ,BMI (kg\mx),None,2,1,3,No,1:No,2:yes,+,0.56
2478,2656521,Table 1,BaselineCharacteristic,xx.x ± x.x,Focal Fatty Liver (n x) ; ,BMI (kg\mx),None,2,3,3,No,1:No,2:yes,+,0.52
2478,2656521,Table 1,BaselineCharacteristic,xx.x ± xx.x,Steatohepatitis (n xx) ; ,ALT (U\l),None,3,1,3,No,1:No,2:yes,+,0.57
2478,2656521,Table 1,BaselineCharacteristic,xx.x ± xx.x,Focal Fatty Liver (n x) ; ,ALT (U\l),None,3,3,3,No,1:No,2:yes,+,0.56
2478,2656521,Table 1,BaselineCharacteristic,xx.x ± xx.x,Steatohepatitis (n xx) ; ,AST (U\l),None,4,1,3,No,1:No,2:yes,+,0.534
2478,2656521,Table 1,BaselineCharacteristic,xx.x ± x.x,Focal Fatty Liver (n x) ; ,AST (U\l),None,4,3,3,No,1:No,2:yes,+,0.514
2478,2656521,Table 1,BaselineCharacteristic,xx.x ± x.x,Steatohepatitis (n xx) ; ,GGT,None,5,1,3,No,1:No,2:yes,+,0.554
2478,2656521,Table 1,BaselineCharacteristic,xx.x ± x.x,Focal Fatty Liver (n x) ; ,GGT,None,5,3,3,No,1:No,2:yes,+,0.524
2478,2656521,Table 1,BaselineCharacteristic,xxx.x ± xx.x,Steatohepatitis (n xx) ; ,Cholesterol (mg\dl),None,6,1,3,No,1:No,2:yes,+,0.544
2478,2656521,Table 1,BaselineCharacteristic,xxx.x ± xx.x,Focal Fatty Liver (n x) ; ,Cholesterol (mg\dl),None,6,3,3,No,1:No,2:yes,+,0.544
2478,2656521,Table 1,BaselineCharacteristic,xxx.x ± xx.x,Steatohepatitis (n xx) ; ,Triglyceride (mg\dl),None,7,1,3,No,1:No,2:yes,+,0.514
2486,2659603,Table 1,BaselineCharacteristic,xx.xx,FS (%) ; ,x,None,1,3,3,No,1:No,2:yes,+,0.558
2486,2659603,Table 1,BaselineCharacteristic,xx.xx,FS (%) ; ,x,None,2,3,3,No,1:No,2:yes,+,0.508
2486,2659603,Table 1,BaselineCharacteristic,xx.x,FS (%) ; ,x,None,3,3,3,No,1:No,2:yes,+,0.504
2688,2718192,Table 1,BaselineCharacteristic,xx.x (xx.x–xxx.x),x.xxx mg dose ; ,"Weight (mean (range), kg)",,2,1,3,No,1:No,2:yes,+,0.605
2688,2718192,Table 1,BaselineCharacteristic,xx.x (xx.x–xx.x),x.xxxx mg dose ; ,"Weight (mean (range), kg)",,2,2,3,No,1:No,2:yes,+,0.64
2688,2718192,Table 1,BaselineCharacteristic,x.xx (x.xx–x.xx),x.xxx mg dose ; ,"Dose PRAM (mean (range), mg/kg x xxx)",,3,1,3,No,1:No,2:yes,+,0.635
2688,2718192,Table 1,BaselineCharacteristic,x.xx (x.xx–x.xx),x.xxxx mg dose ; ,"Dose PRAM (mean (range), mg/kg x xxx)",,3,2,3,No,1:No,2:yes,+,0.645
2688,2718192,Table 1,BaselineCharacteristic,xx.x (x.x–xxx.x),x.xxxx mg dose ; ,"Daily caffeine intake (mean (range), mg)",,4,2,3,No,1:No,2:yes,+,0.525
2688,2718192,Table 1,BaselineCharacteristic,xx (x–xx),x.xxx mg dose ; ,, Personality scale scores (mean (range)) TPQ,7,1,3,No,1:No,2:yes,+,0.53
2688,2718192,Table 1,BaselineCharacteristic,xx (x–xx),x.xxxx mg dose ; ,, Personality scale scores (mean (range)) TPQ,7,2,3,No,1:No,2:yes,+,0.52
2688,2718192,Table 1,BaselineCharacteristic,xx (xx–xx),x.xxxx mg dose ; ,, Personality scale scores (mean (range)) TPQ,9,2,3,No,1:No,2:yes,+,0.515
2737,2734077,Table 1,BaselineCharacteristic,Healthy Participants (n = xx; xx men),,,None,0,1,1,No,1:No,2:yes,+,0.611
2737,2734077,Table 1,BaselineCharacteristic,Healthy Participants (n = xx; xx men),Healthy Participants (n = xx; xx men) ; ,,None,1,1,1,No,1:No,2:yes,+,0.618
2737,2734077,Table 1,BaselineCharacteristic,"CBT+TAU Group (n = xx, xx men)",Patients ; ,,None,1,2,1,No,1:No,2:yes,+,0.598
2737,2734077,Table 1,BaselineCharacteristic,"TAU-Alone Group (n = xx, xx men)",Patients ; ,,None,1,3,1,No,1:No,2:yes,+,0.568
2737,2734077,Table 1,BaselineCharacteristic,Mean (SD),Healthy Participants (n = xx; xx men) ; Healthy Participants (n = xx; xx men) ; ,Demographics,,2,1,3,No,1:No,2:yes,+,0.684
2737,2734077,Table 1,BaselineCharacteristic,Mean (SD),"Patients ; CBT+TAU Group (n = xx, xx men) ; ",Demographics,,2,2,3,No,1:No,2:yes,+,0.619
2737,2734077,Table 1,BaselineCharacteristic,Mean (SD),"Patients ; TAU-Alone Group (n = xx, xx men) ; ",Demographics,,2,3,3,No,1:No,2:yes,+,0.634
2737,2734077,Table 1,BaselineCharacteristic,xx.xx (x.xx),Healthy Participants (n = xx; xx men) ; Healthy Participants (n = xx; xx men) ; ,Education (Years),,4,1,3,No,1:No,2:yes,+,0.579
2737,2734077,Table 1,BaselineCharacteristic,?xxx.xx (x.xx),Healthy Participants (n = xx; xx men) ; Healthy Participants (n = xx; xx men) ; ,Predicted IQa,,5,1,3,No,1:No,2:yes,+,0.649
2737,2734077,Table 1,BaselineCharacteristic,xxx.xx (x.xx),"Patients ; CBT+TAU Group (n = xx, xx men) ; ",Predicted IQa,,5,2,3,No,1:No,2:yes,+,0.563
2737,2734077,Table 1,BaselineCharacteristic,xxx.xx (x.xx),"Patients ; TAU-Alone Group (n = xx, xx men) ; ",Predicted IQa,,5,3,3,No,1:No,2:yes,+,0.559
2737,2734077,Table 1,BaselineCharacteristic,xx.xx (x.xx),Healthy Participants (n = xx; xx men) ; Healthy Participants (n = xx; xx men) ; ,, Accuracy (%; Chance Performance = xx%),8,1,3,No,1:No,2:yes,+,0.534
2737,2734077,Table 1,BaselineCharacteristic,xx.xx (x.xx),Healthy Participants (n = xx; xx men) ; Healthy Participants (n = xx; xx men) ; ,, Accuracy (%; Chance Performance = xx%),9,1,3,No,1:No,2:yes,+,0.514
2737,2734077,Table 1,BaselineCharacteristic,xx.xx (x.xx),Patients Only ; TAU-alone Group Mean (SD) ; Baseline ; ,Age at Illness Onset (Years),None,3,4,3,No,1:No,2:yes,+,0.504
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; % ;  ;  ;  ; ,?Avg. age, ,13,2,,No,1:No,2:yes,+,0.5
2834,2765955,Table 1,BaselineCharacteristic,(n = xx),Males ; ,None,None,1,1,,No,1:No,2:yes,+,0.626
2834,2765955,Table 1,BaselineCharacteristic,(n = xx),Females ; ,None,None,1,2,,No,1:No,2:yes,+,0.631
2834,2765955,Table 1,BaselineCharacteristic,,Males ; (n = xx) ; xx.x (xx.x) ; ,None,None,3,1,,No,1:No,2:yes,+,0.661
2834,2765955,Table 1,BaselineCharacteristic,,Females ; (n = xx) ; xx.x (x.x) ; ,None,None,3,2,,No,1:No,2:yes,+,0.655
2834,2765955,Table 1,BaselineCharacteristic,x.xx (x.x),Males ; (n = xx) ; xx.x (xx.x) ;  ; ,None,None,4,1,,No,1:No,2:yes,+,0.599
2834,2765955,Table 1,BaselineCharacteristic,x.xx (x.x),Females ; (n = xx) ; xx.x (x.x) ;  ; ,None,None,4,2,,No,1:No,2:yes,+,0.598
2834,2765955,Table 1,BaselineCharacteristic,,Males ; (n = xx) ; xx.x (xx.x) ;  ; x.xx (x.x) ; ,None,None,5,1,,No,1:No,2:yes,+,0.598
2834,2765955,Table 1,BaselineCharacteristic,,Females ; (n = xx) ; xx.x (x.x) ;  ; x.xx (x.x) ; ,None,None,5,2,,No,1:No,2:yes,+,0.607
2834,2765955,Table 1,BaselineCharacteristic,xx.x (xx.x),Males ; (n = xx) ; xx.x (xx.x) ;  ; x.xx (x.x) ;  ; ,None,None,6,1,,No,1:No,2:yes,+,0.577
2834,2765955,Table 1,BaselineCharacteristic,xx.x (xx.x),Females ; (n = xx) ; xx.x (x.x) ;  ; x.xx (x.x) ;  ; ,None,None,6,2,,No,1:No,2:yes,+,0.587
2834,2765955,Table 1,BaselineCharacteristic,,Males ; (n = xx) ; xx.x (xx.x) ;  ; x.xx (x.x) ;  ; xx.x (xx.x) ; ,None,None,7,1,,No,1:No,2:yes,+,0.558
2834,2765955,Table 1,BaselineCharacteristic,,Females ; (n = xx) ; xx.x (x.x) ;  ; x.xx (x.x) ;  ; xx.x (xx.x) ; ,None,None,7,2,,No,1:No,2:yes,+,0.568
2834,2765955,Table 1,BaselineCharacteristic,xx.x (x.x),Males ; (n = xx) ; xx.x (xx.x) ;  ; x.xx (x.x) ;  ; xx.x (xx.x) ;  ; ,None,None,8,1,,No,1:No,2:yes,+,0.534
2834,2765955,Table 1,BaselineCharacteristic,xx.x (x.x),Females ; (n = xx) ; xx.x (x.x) ;  ; x.xx (x.x) ;  ; xx.x (xx.x) ;  ; ,None,None,8,2,,No,1:No,2:yes,+,0.545
2834,2765955,Table 1,BaselineCharacteristic,,Males ; (n = xx) ; xx.x (xx.x) ;  ; x.xx (x.x) ;  ; xx.x (xx.x) ;  ; xx.x (x.x) ; ,None,None,9,1,,No,1:No,2:yes,+,0.514
2834,2765955,Table 1,BaselineCharacteristic,,Females ; (n = xx) ; xx.x (x.x) ;  ; x.xx (x.x) ;  ; xx.x (xx.x) ;  ; xx.x (x.x) ; ,None,None,9,2,,No,1:No,2:yes,+,0.522
2864,2774660,Table 1,BaselineCharacteristic,xx,Phase x - placebo ; ,Total Participants,None,1,3,3,No,1:No,2:yes,+,0.604
2864,2774660,Table 1,BaselineCharacteristic,xx,Phase x - placebo ; ,Male,None,2,3,3,No,1:No,2:yes,+,0.574
3023,2816665,Table 1,BaselineCharacteristic,xx,Subgroup A ; ,Patient number,None,1,2,3,No,1:No,2:yes,+,0.544
3023,2816665,Table 1,BaselineCharacteristic,xx,Subgroup B ; ,Patient number,None,1,3,3,No,1:No,2:yes,+,0.534
3023,2816665,Table 1,BaselineCharacteristic,xx,Subgroup C ; ,Patient number,None,1,4,3,No,1:No,2:yes,+,0.534
3023,2816665,Table 1,BaselineCharacteristic,xx (xx),All patients ; ,Male (%),None,3,1,3,No,1:No,2:yes,+,0.54
3023,2816665,Table 1,BaselineCharacteristic,xx (xx),Subgroup A ; ,Male (%),None,3,2,3,No,1:No,2:yes,+,0.539
3023,2816665,Table 1,BaselineCharacteristic,xx (xx),Subgroup B ; ,Male (%),None,3,3,3,No,1:No,2:yes,+,0.529
3023,2816665,Table 1,BaselineCharacteristic,xx (x),All patients ; ,PS x (%),None,4,1,3,No,1:No,2:yes,+,0.53
3044,2822223,Table 1,BaselineCharacteristic,xx,Healthy donors ; Age (years) ; ,x,None,2,1,3,No,1:No,2:yes,+,0.59
3044,2822223,Table 1,BaselineCharacteristic,xx,Patients ; Age (years) ; ,x,None,2,3,3,No,1:No,2:yes,+,0.56
3044,2822223,Table 1,BaselineCharacteristic,xx,Healthy donors ; Age (years) ; ,x,None,3,1,3,No,1:No,2:yes,+,0.58
3044,2822223,Table 1,BaselineCharacteristic,xx,Patients ; Age (years) ; ,x,None,3,3,3,No,1:No,2:yes,+,0.55
3044,2822223,Table 1,BaselineCharacteristic,xx,Healthy donors ; Age (years) ; ,x,None,4,1,3,No,1:No,2:yes,+,0.55
3044,2822223,Table 1,BaselineCharacteristic,xx,Patients ; Age (years) ; ,x,None,4,3,3,No,1:No,2:yes,+,0.51
3044,2822223,Table 1,BaselineCharacteristic,xx,Healthy donors ; Age (years) ; ,x,None,5,1,3,No,1:No,2:yes,+,0.55
3044,2822223,Table 1,BaselineCharacteristic,xx,Patients ; Age (years) ; ,x,None,5,3,3,No,1:No,2:yes,+,0.51
3044,2822223,Table 1,BaselineCharacteristic,xx,Healthy donors ; Age (years) ; ,x,None,6,1,3,No,1:No,2:yes,+,0.54
3044,2822223,Table 1,BaselineCharacteristic,xx,Healthy donors ; Age (years) ; ,x,None,7,1,3,No,1:No,2:yes,+,0.52
3085,2828459,Table 1,BaselineCharacteristic,xx.x (x.x),mean (SD) ; ,Gestational age (weeks),None,1,1,3,No,1:No,2:yes,+,0.88
3085,2828459,Table 1,BaselineCharacteristic,xx.x (x.x),mean (SD) ; ,Length (cm),None,3,1,3,No,1:No,2:yes,+,0.68
3085,2828459,Table 1,BaselineCharacteristic,xx.x (x.x),mean (SD) ; ,Head circumference (cm),None,4,1,3,No,1:No,2:yes,+,0.6
3097,2835652,Table 1,BaselineCharacteristic,xx,xx ?g ; xx ; ,"Male, no (%)",,2,3,3,No,1:No,2:yes,+,0.504
3097,2835652,Table 1,BaselineCharacteristic,"Median age (range), years","HSPPC-xx Dose Level ; Enrolled, no. ; ","Median age (range), years",,3,0,2,No,1:No,2:yes,+,0.565
3105,2837631,Table 1,BaselineCharacteristic,median (range) xx (x-xx),,Tumor diameter (mm),,18,1,3,No,1:No,2:yes,+,0.7
3105,2837631,Table 1,BaselineCharacteristic,median (range) xx(xx-xx),,Follow-up (months),,43,1,3,No,1:No,2:yes,+,0.68
3162,2855860,Table 1,BaselineCharacteristic,xxx (xx),Sunitinib (N = xxx) ; ,," ECOG PS, n (%)a",5,1,3,No,1:No,2:yes,+,0.564
3162,2855860,Table 1,BaselineCharacteristic,xxx (xx),Capecitabine (N = xxx) ; ,," ECOG PS, n (%)a",5,2,3,No,1:No,2:yes,+,0.539
3275,2894785,Table 1,BaselineCharacteristic,"Age, mean ± SD (years)",Characteristics ; ,"Age, mean ± SD (years)",,1,0,,No,1:No,2:yes,+,0.532
3275,2894785,Table 1,BaselineCharacteristic,?Min,Characteristics ; ,?Min," Age, mean ± SD (years)",2,0,,No,1:No,2:yes,+,0.532
3275,2894785,Table 1,BaselineCharacteristic,xx,Intervention Groupn = xx ; ,?Min," Age, mean ± SD (years)",2,1,,No,1:No,2:yes,+,0.797
3275,2894785,Table 1,BaselineCharacteristic,xx,ControlGroupn = xxx ; ,?Min," Age, mean ± SD (years)",2,2,,No,1:No,2:yes,+,0.847
3275,2894785,Table 1,BaselineCharacteristic,?Max,Characteristics ; ,?Max," Age, mean ± SD (years)",3,0,,No,1:No,2:yes,+,0.522
3275,2894785,Table 1,BaselineCharacteristic,xx,Intervention Groupn = xx ; ,?Max," Age, mean ± SD (years)",3,1,,No,1:No,2:yes,+,0.798
3275,2894785,Table 1,BaselineCharacteristic,xx,ControlGroupn = xxx ; ,?Max," Age, mean ± SD (years)",3,2,,No,1:No,2:yes,+,0.847
3275,2894785,Table 1,BaselineCharacteristic,xx (xx.x%),Intervention Groupn = xx ; ,?female," Age, mean ± SD (years)",6,1,,No,1:No,2:yes,+,0.712
3275,2894785,Table 1,BaselineCharacteristic,xx (xx.x%),ControlGroupn = xxx ; ,?female," Age, mean ± SD (years)",6,2,,No,1:No,2:yes,+,0.759
3275,2894785,Table 1,BaselineCharacteristic,xx (xx.x%),Intervention Groupn = xx ; ,?male," Age, mean ± SD (years)",7,1,,No,1:No,2:yes,+,0.702
3275,2894785,Table 1,BaselineCharacteristic,xxx (xx.x%),ControlGroupn = xxx ; ,?male," Age, mean ± SD (years)",7,2,,No,1:No,2:yes,+,0.739
3275,2894785,Table 1,BaselineCharacteristic,xx (xx.x%),Intervention Groupn = xx ; ,?TIA," Age, mean ± SD (years)",10,1,,No,1:No,2:yes,+,0.599
3275,2894785,Table 1,BaselineCharacteristic,xx (xx.x%),ControlGroupn = xxx ; ,?TIA," Age, mean ± SD (years)",10,2,,No,1:No,2:yes,+,0.667
3275,2894785,Table 1,BaselineCharacteristic,xx (xx.x%),Intervention Groupn = xx ; ,?Ischemic stroke," Age, mean ± SD (years)",11,1,,No,1:No,2:yes,+,0.589
3275,2894785,Table 1,BaselineCharacteristic,xxx (xx.x%),ControlGroupn = xxx ; ,?Ischemic stroke," Age, mean ± SD (years)",11,2,,No,1:No,2:yes,+,0.667
3275,2894785,Table 1,BaselineCharacteristic,xx (xx.x%),Intervention Groupn = xx ; ,?hypertension," Age, mean ± SD (years)",16,1,,No,1:No,2:yes,+,0.599
3275,2894785,Table 1,BaselineCharacteristic,xx (xx.x%),ControlGroupn = xxx ; ,?hypertension," Age, mean ± SD (years)",16,2,,No,1:No,2:yes,+,0.677
3275,2894785,Table 1,BaselineCharacteristic,x (x.x%),Intervention Groupn = xx ; ,?hyperlipidemia," Age, mean ± SD (years)",17,1,,No,1:No,2:yes,+,0.6
3275,2894785,Table 1,BaselineCharacteristic,x (x.x%),ControlGroupn = xxx ; ,?hyperlipidemia," Age, mean ± SD (years)",17,2,,No,1:No,2:yes,+,0.591
3275,2894785,Table 1,BaselineCharacteristic,x (x.x%),Intervention Groupn = xx ; ,?diabetes mellitus," Age, mean ± SD (years)",18,1,,No,1:No,2:yes,+,0.601
3275,2894785,Table 1,BaselineCharacteristic,x (x.x%),ControlGroupn = xxx ; ,?diabetes mellitus," Age, mean ± SD (years)",18,2,,No,1:No,2:yes,+,0.582
3275,2894785,Table 1,BaselineCharacteristic,xx (xx.x%),Intervention Groupn = xx ; ,?hypertension+hyperlipidemia," Age, mean ± SD (years)",19,1,,No,1:No,2:yes,+,0.599
3275,2894785,Table 1,BaselineCharacteristic,xx (xx.x%),ControlGroupn = xxx ; ,?hypertension+hyperlipidemia," Age, mean ± SD (years)",19,2,,No,1:No,2:yes,+,0.677
3275,2894785,Table 1,BaselineCharacteristic,x (x.x%),Intervention Groupn = xx ; ,?hypertension+diabetes mellitus," Age, mean ± SD (years)",20,1,,No,1:No,2:yes,+,0.601
3275,2894785,Table 1,BaselineCharacteristic,xx (xx.x%),ControlGroupn = xxx ; ,?hypertension+diabetes mellitus," Age, mean ± SD (years)",20,2,,No,1:No,2:yes,+,0.677
3275,2894785,Table 1,BaselineCharacteristic,--,Intervention Groupn = xx ; ,?diabetes mellitus+hyperlipidemia," Age, mean ± SD (years)",21,1,,No,1:No,2:yes,+,0.64
3275,2894785,Table 1,BaselineCharacteristic,x (x.x%),ControlGroupn = xxx ; ,?diabetes mellitus+hyperlipidemia," Age, mean ± SD (years)",21,2,,No,1:No,2:yes,+,0.591
3275,2894785,Table 1,BaselineCharacteristic,x (x.x%),Intervention Groupn = xx ; ,?mellitus+hyperlipidemia," Age, mean ± SD (years)",23,1,,No,1:No,2:yes,+,0.6
3275,2894785,Table 1,BaselineCharacteristic,xx (x.x%),ControlGroupn = xxx ; ,?mellitus+hyperlipidemia," Age, mean ± SD (years)",23,2,,No,1:No,2:yes,+,0.699
3275,2894785,Table 1,BaselineCharacteristic,x (x.x%),Intervention Groupn = xx ; ,?None," Age, mean ± SD (years)",24,1,,No,1:No,2:yes,+,0.6
3275,2894785,Table 1,BaselineCharacteristic,xx (x.x%),ControlGroupn = xxx ; ,?None," Age, mean ± SD (years)",24,2,,No,1:No,2:yes,+,0.699
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Control(mean) ; ,,,2,2,3,No,1:No,2:yes,+,0.58
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Intervention(mean) ; ,,,2,3,3,No,1:No,2:yes,+,0.71
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Control(mean) ; ,,,3,2,3,No,1:No,2:yes,+,0.56
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Intervention(mean) ; ,,,3,3,3,No,1:No,2:yes,+,0.69
3276,2894820,Table 4,BaselineCharacteristic,xx.x,Intervention(mean) ; ,,,4,3,3,No,1:No,2:yes,+,0.56
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Intervention(mean) ; ,,,5,3,3,No,1:No,2:yes,+,0.56
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Intervention(mean) ; ,,,6,3,3,No,1:No,2:yes,+,0.53
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Intervention(mean) ; ,,,7,3,3,No,1:No,2:yes,+,0.51
3291,2902493,Table 1,BaselineCharacteristic,,xx ; xx [xx-xx] ; ,None,None,2,2,,No,1:No,2:yes,+,0.548
3291,2902493,Table 1,BaselineCharacteristic,xx (xx%),xx ; xx [xx-xx] ;  ; ,Stage T,,3,2,,No,1:No,2:yes,+,0.513
3324,2910694,Table 1,BaselineCharacteristic,,Number ; xx (range xx-xx) ; ,None,None,2,1,,No,1:No,2:yes,+,0.685
3324,2910694,Table 1,BaselineCharacteristic,x,Number ; xx (range xx-xx) ;  ; ,None,None,3,1,,No,1:No,2:yes,+,0.501
3561,2990606,Table 1,BaselineCharacteristic,"Age in years, median (range)",,"Age in years, median (range)",,4,0,2,No,1:No,2:yes,+,0.618
3950,3080287,Table 2,BaselineCharacteristic,xx,median dose/GyE or Gy ; ,Cxx,,1,1,3,No,1:No,2:yes,+,0.59
3950,3080287,Table 2,BaselineCharacteristic,xx,median dose/GyE or Gy ; ,IMRT,,2,1,3,No,1:No,2:yes,+,0.59
3950,3080287,Table 2,BaselineCharacteristic,xx,median dose/GyE or Gy ; ,total,,3,1,43,No,1:No,2:yes,+,0.55
3974,3086082,Table 1,BaselineCharacteristic,"Age, in years, median (range)",Parameter ; ,None,None,1,0,24,No,1:No,2:yes,+,0.665
3974,3086082,Table 1,BaselineCharacteristic,"Age, in years, median (range)", ; ,"Age, in years, median (range)",None,1,1,43,No,1:No,2:yes,+,0.745
3974,3086082,Table 1,BaselineCharacteristic,?Median,Parameter ; ,?Median," Age, in years, median (range)",2,0,2,No,1:No,2:yes,+,0.578
3974,3086082,Table 1,BaselineCharacteristic,"?Minimum, maximum",Parameter ; ,"?Minimum, maximum"," Age, in years, median (range)",3,0,2,No,1:No,2:yes,+,0.588
4011,3097354,Table 1,BaselineCharacteristic,"Intervention group, N?=?xx",,"Intervention group, N?=?xx",None,0,2,1,No,1:No,2:yes,+,0.53
4011,3097354,Table 1,BaselineCharacteristic,"Control group, N?=?xx",,"Intervention group, N?=?xx",None,0,3,1,No,1:No,2:yes,+,0.52
4011,3097354,Table 1,BaselineCharacteristic,"Control group, N?=?xx",,"Intervention group, N?=?xx",None,0,4,1,No,1:No,2:yes,+,0.52
4011,3097354,Table 1,BaselineCharacteristic,"Age (median, range)","Intervention group, N?=?xx ; ","Age (median, range)",None,1,0,2,No,1:No,2:yes,+,0.672
4011,3097354,Table 1,BaselineCharacteristic,,"Intervention group, N?=?xx ; ","Age (median, range)",None,1,1,3,No,1:No,2:yes,+,0.83
4011,3097354,Table 1,BaselineCharacteristic,,"Control group, N?=?xx ; ","Age (median, range)",None,1,3,3,No,1:No,2:yes,+,0.81
4185,3152943,Table 1,BaselineCharacteristic,"Canakinumab xxx mg SC qxwk, n = xx",,None,None,0,1,,No,1:No,2:yes,+,0.792
4185,3152943,Table 1,BaselineCharacteristic,"Canakinumab xxx mg SC qxwk, n = xx",,None,None,0,2,,No,1:No,2:yes,+,0.814
4185,3152943,Table 1,BaselineCharacteristic,"Canakinumab xxx mg SC qxwk + xxx mg IV loading dose, n = xx",,None,None,0,3,,No,1:No,2:yes,+,0.762
4185,3152943,Table 1,BaselineCharacteristic,xx (xx.x),"Canakinumab xxx mg SC qxwk, n = xx ; ",None,None,1,1,,No,1:No,2:yes,+,0.859
4185,3152943,Table 1,BaselineCharacteristic,xx (xx.x),"Canakinumab xxx mg SC qxwk, n = xx ; ",None,None,1,2,,No,1:No,2:yes,+,0.871
4185,3152943,Table 1,BaselineCharacteristic,xx (xx.x),"Canakinumab xxx mg SC qxwk + xxx mg IV loading dose, n = xx ; ",None,None,1,3,,No,1:No,2:yes,+,0.847
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ; ",None,None,2,1,,No,1:No,2:yes,+,0.859
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ; ",None,None,2,2,,No,1:No,2:yes,+,0.871
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk + xxx mg IV loading dose, n = xx ; xx (xx.x) ; ",None,None,2,3,,No,1:No,2:yes,+,0.847
4185,3152943,Table 1,BaselineCharacteristic,"Age, mean (SD) years","Variable ; Female sex, n (%) ;  ; ",None,None,3,0,,No,1:No,2:yes,+,0.547
4185,3152943,Table 1,BaselineCharacteristic,,"Variable ; Female sex, n (%) ;  ; Age, mean (SD) years ; ",None,None,4,0,,No,1:No,2:yes,+,0.547
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ; ",None,None,4,1,,No,1:No,2:yes,+,0.805
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ; ",None,None,4,2,,No,1:No,2:yes,+,0.817
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk + xxx mg IV loading dose, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ; ",None,None,4,3,,No,1:No,2:yes,+,0.792
4185,3152943,Table 1,BaselineCharacteristic,"Duration of RA, mean (SD) years","Variable ; Female sex, n (%) ;  ; Age, mean (SD) years ;  ; ",None,None,5,0,,No,1:No,2:yes,+,0.517
4185,3152943,Table 1,BaselineCharacteristic,xx.xx (x.xxx),"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; ",None,None,5,1,,No,1:No,2:yes,+,0.805
4185,3152943,Table 1,BaselineCharacteristic,xx.xx (x.xxx),"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; ",None,None,5,2,,No,1:No,2:yes,+,0.817
4185,3152943,Table 1,BaselineCharacteristic,x.xx (x.xxx),"Canakinumab xxx mg SC qxwk + xxx mg IV loading dose, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; ",None,None,5,3,,No,1:No,2:yes,+,0.792
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ; ",None,None,6,1,,No,1:No,2:yes,+,0.775
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ; ",None,None,6,2,,No,1:No,2:yes,+,0.787
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk + xxx mg IV loading dose, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ; ",None,None,6,3,,No,1:No,2:yes,+,0.762
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ",None,None,7,1,,No,1:No,2:yes,+,0.766
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ",None,None,7,2,,No,1:No,2:yes,+,0.778
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk + xxx mg IV loading dose, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ",None,None,7,3,,No,1:No,2:yes,+,0.753
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ",None,None,8,1,,No,1:No,2:yes,+,0.755
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ",None,None,8,2,,No,1:No,2:yes,+,0.767
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk + xxx mg IV loading dose, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ",None,None,8,3,,No,1:No,2:yes,+,0.743
4185,3152943,Table 1,BaselineCharacteristic,?x,"Variable ; Female sex, n (%) ;  ; Age, mean (SD) years ;  ; Duration of RA, mean (SD) years ;  ; ",?x, ,9,0,,No,1:No,2:yes,+,0.506
4185,3152943,Table 1,BaselineCharacteristic,xx (xx.x),"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ",?x, ,9,1,,No,1:No,2:yes,+,0.725
4185,3152943,Table 1,BaselineCharacteristic,xx (xx.x),"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ",?x, ,9,2,,No,1:No,2:yes,+,0.737
4185,3152943,Table 1,BaselineCharacteristic,xx (xx.x),"Canakinumab xxx mg SC qxwk + xxx mg IV loading dose, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ",?x, ,9,3,,No,1:No,2:yes,+,0.713
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ",None,None,10,1,,No,1:No,2:yes,+,0.657
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ",None,None,10,2,,No,1:No,2:yes,+,0.669
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk + xxx mg IV loading dose, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ",None,None,10,3,,No,1:No,2:yes,+,0.653
4185,3152943,Table 1,BaselineCharacteristic,xx (xx.x),"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ",?x, ,11,1,,No,1:No,2:yes,+,0.647
4185,3152943,Table 1,BaselineCharacteristic,xx (xx.x),"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ",?x, ,11,2,,No,1:No,2:yes,+,0.659
4185,3152943,Table 1,BaselineCharacteristic,xx (xx.x),"Canakinumab xxx mg SC qxwk + xxx mg IV loading dose, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ",?x, ,11,3,,No,1:No,2:yes,+,0.643
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ",None,None,12,1,,No,1:No,2:yes,+,0.647
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ",None,None,12,2,,No,1:No,2:yes,+,0.659
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk + xxx mg IV loading dose, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ",None,None,12,3,,No,1:No,2:yes,+,0.643
4185,3152943,Table 1,BaselineCharacteristic,x (x.x),"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ",?> x, ,13,1,,No,1:No,2:yes,+,0.617
4185,3152943,Table 1,BaselineCharacteristic,x (x.x),"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ",?> x, ,13,2,,No,1:No,2:yes,+,0.636
4185,3152943,Table 1,BaselineCharacteristic,x (x.x),"Canakinumab xxx mg SC qxwk + xxx mg IV loading dose, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ",?> x, ,13,3,,No,1:No,2:yes,+,0.611
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ",None,None,14,1,,No,1:No,2:yes,+,0.637
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ",None,None,14,2,,No,1:No,2:yes,+,0.649
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk + xxx mg IV loading dose, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ",None,None,14,3,,No,1:No,2:yes,+,0.633
4185,3152943,Table 1,BaselineCharacteristic,x.xxx (x.xxxx),"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ","DASxx, mean (SD) score",,15,1,,No,1:No,2:yes,+,0.724
4185,3152943,Table 1,BaselineCharacteristic,x.xxx (x.xxx),"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ","DASxx, mean (SD) score",,15,2,,No,1:No,2:yes,+,0.743
4185,3152943,Table 1,BaselineCharacteristic,x.xxx (x.xxxx),"Canakinumab xxx mg SC qxwk + xxx mg IV loading dose, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ","DASxx, mean (SD) score",,15,3,,No,1:No,2:yes,+,0.708
4185,3152943,Table 1,BaselineCharacteristic,x.xxx (x.xxxx),"Placebo, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ","DASxx, mean (SD) score",,15,4,,No,1:No,2:yes,+,0.552
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ",None,None,16,1,,No,1:No,2:yes,+,0.637
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ",None,None,16,2,,No,1:No,2:yes,+,0.649
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk + xxx mg IV loading dose, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ",None,None,16,3,,No,1:No,2:yes,+,0.633
4185,3152943,Table 1,BaselineCharacteristic,xxx.x (xxx.xx),"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ","RF (kIU/L), mean (SD)",,17,1,,No,1:No,2:yes,+,0.744
4185,3152943,Table 1,BaselineCharacteristic,xxx.x (xxx.xx),"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ","RF (kIU/L), mean (SD)",,17,2,,No,1:No,2:yes,+,0.763
4185,3152943,Table 1,BaselineCharacteristic,xxx.x (xxx.xx),"Canakinumab xxx mg SC qxwk + xxx mg IV loading dose, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ","RF (kIU/L), mean (SD)",,17,3,,No,1:No,2:yes,+,0.728
4185,3152943,Table 1,BaselineCharacteristic,xxx.x (xxx.xx),"Placebo, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ","RF (kIU/L), mean (SD)",,17,4,,No,1:No,2:yes,+,0.592
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ",None,None,18,1,,No,1:No,2:yes,+,0.637
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ",None,None,18,2,,No,1:No,2:yes,+,0.649
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk + xxx mg IV loading dose, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ",None,None,18,3,,No,1:No,2:yes,+,0.633
4185,3152943,Table 1,BaselineCharacteristic,x.xxx (x.xxxx),"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ","HAQ, mean (SD) score",,19,1,,No,1:No,2:yes,+,0.724
4185,3152943,Table 1,BaselineCharacteristic,x.xxx (x.xxxx),"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ","HAQ, mean (SD) score",,19,2,,No,1:No,2:yes,+,0.743
4185,3152943,Table 1,BaselineCharacteristic,x.xxx (x.xxxx),"Canakinumab xxx mg SC qxwk + xxx mg IV loading dose, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ","HAQ, mean (SD) score",,19,3,,No,1:No,2:yes,+,0.708
4185,3152943,Table 1,BaselineCharacteristic,x.xxx (x.xxxx),"Placebo, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ","HAQ, mean (SD) score",,19,4,,No,1:No,2:yes,+,0.552
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ",None,None,20,1,,No,1:No,2:yes,+,0.647
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ",None,None,20,2,,No,1:No,2:yes,+,0.659
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk + xxx mg IV loading dose, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ",None,None,20,3,,No,1:No,2:yes,+,0.643
4185,3152943,Table 1,BaselineCharacteristic,xx.x ± x.xx,"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ","Number of tender joints, mean (SD)",,21,1,,No,1:No,2:yes,+,0.772
4185,3152943,Table 1,BaselineCharacteristic,xx.x ± x.xx,"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ","Number of tender joints, mean (SD)",,21,2,,No,1:No,2:yes,+,0.78
4185,3152943,Table 1,BaselineCharacteristic,xx.x ± x.xx,"Canakinumab xxx mg SC qxwk + xxx mg IV loading dose, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ","Number of tender joints, mean (SD)",,21,3,,No,1:No,2:yes,+,0.747
4185,3152943,Table 1,BaselineCharacteristic,xx ± x.xx,"Placebo, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ","Number of tender joints, mean (SD)",,21,4,,No,1:No,2:yes,+,0.621
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ",None,None,22,1,,No,1:No,2:yes,+,0.637
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ",None,None,22,2,,No,1:No,2:yes,+,0.649
4185,3152943,Table 1,BaselineCharacteristic,,"Canakinumab xxx mg SC qxwk + xxx mg IV loading dose, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ",None,None,22,3,,No,1:No,2:yes,+,0.633
4185,3152943,Table 1,BaselineCharacteristic,xx.x (x.xx),"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ","Number of swollen joints, mean (SD)",,23,1,,No,1:No,2:yes,+,0.744
4185,3152943,Table 1,BaselineCharacteristic,xx.x (x.xx),"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; xx.xx (x.xxx) ;  ; ","Number of swollen joints, mean (SD)",,23,2,,No,1:No,2:yes,+,0.763
4185,3152943,Table 1,BaselineCharacteristic,xx.x (x.xx),"Canakinumab xxx mg SC qxwk + xxx mg IV loading dose, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ","Number of swollen joints, mean (SD)",,23,3,,No,1:No,2:yes,+,0.728
4185,3152943,Table 1,BaselineCharacteristic,xx.x(x.xx),"Placebo, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ","Number of swollen joints, mean (SD)",,23,4,,No,1:No,2:yes,+,0.592
4246,3165084,Table 1,BaselineCharacteristic,Age in years (median),Patient Characteristics ; Total patients ;  ; ,Age in years (median),,3,0,,No,1:No,2:yes,+,0.563
4375,3195264,Table 1,BaselineCharacteristic,Iobitridol xxx (n?=?xx),,,None,0,1,1,No,1:No,2:yes,+,0.559
4375,3195264,Table 1,BaselineCharacteristic,Iodixanol xxx (n?=?xx),,,None,0,2,1,No,1:No,2:yes,+,0.595
4375,3195264,Table 1,BaselineCharacteristic,Baseline characteristics,Iobitridol xxx (n?=?xx) ; ,Baseline characteristics,None,1,1,43,No,1:No,2:yes,+,0.606
4375,3195264,Table 1,BaselineCharacteristic,Baseline characteristics,Iodixanol xxx (n?=?xx) ; ,Baseline characteristics,None,1,2,43,No,1:No,2:yes,+,0.606
4375,3195264,Table 1,BaselineCharacteristic,xx ( xx.x % ),Iobitridol xxx (n?=?xx) ; ,, Baseline characteristics,3,1,3,No,1:No,2:yes,+,0.66
4375,3195264,Table 1,BaselineCharacteristic,xx (xx.x %),Iodixanol xxx (n?=?xx) ; ,, Baseline characteristics,3,2,3,No,1:No,2:yes,+,0.64
4375,3195264,Table 1,BaselineCharacteristic,xx (xx.x %),Total (n?=?xxx) ; ,, Baseline characteristics,3,3,3,No,1:No,2:yes,+,0.62
4375,3195264,Table 1,BaselineCharacteristic,xx ( xx.x % ),Iobitridol xxx (n?=?xx) ; ,, Baseline characteristics,4,1,3,No,1:No,2:yes,+,0.624
4375,3195264,Table 1,BaselineCharacteristic,xx (xx.x % ),Iodixanol xxx (n?=?xx) ; ,, Baseline characteristics,4,2,3,No,1:No,2:yes,+,0.594
4375,3195264,Table 1,BaselineCharacteristic,xx.x ±x.x (xx.x–xx.x),Iobitridol xxx (n?=?xx) ; ,, Baseline characteristics,5,1,3,No,1:No,2:yes,+,0.754
4375,3195264,Table 1,BaselineCharacteristic,xx.x ±x.x (xx.x–xx.x),Iodixanol xxx (n?=?xx) ; ,, Baseline characteristics,5,2,3,No,1:No,2:yes,+,0.714
4375,3195264,Table 1,BaselineCharacteristic,xx.x ±x.x (xx.x–xx.x),Total (n?=?xxx) ; ,, Baseline characteristics,5,3,3,No,1:No,2:yes,+,0.694
4375,3195264,Table 1,BaselineCharacteristic,xx.x ±xx.x (xx.x–xx.x),Iobitridol xxx (n?=?xx) ; ,, Baseline characteristics,6,1,3,No,1:No,2:yes,+,0.709
4375,3195264,Table 1,BaselineCharacteristic,xx.x ±xx.x (xx.x–xx.x),Iodixanol xxx (n?=?xx) ; ,, Baseline characteristics,6,2,3,No,1:No,2:yes,+,0.669
4375,3195264,Table 1,BaselineCharacteristic,xx.x ±xx.x (xx.x–xx.x),Total (n?=?xxx) ; ,, Baseline characteristics,6,3,3,No,1:No,2:yes,+,0.654
4375,3195264,Table 1,BaselineCharacteristic,xxx.x ±xx.x (xx.x–xxx.x),Iobitridol xxx (n?=?xx) ; ,, Baseline characteristics,7,1,3,No,1:No,2:yes,+,0.619
4375,3195264,Table 1,BaselineCharacteristic,xxx.x ±xx.x (xx.x–xxx.x),Iodixanol xxx (n?=?xx) ; ,, Baseline characteristics,7,2,3,No,1:No,2:yes,+,0.569
4375,3195264,Table 1,BaselineCharacteristic,xxx.x ±xx.x (xx.x–xxx.x),Total (n?=?xxx) ; ,, Baseline characteristics,7,3,3,No,1:No,2:yes,+,0.554
4375,3195264,Table 4,BaselineCharacteristic,Gender/ age (years),,Patients,None,0,1,1,No,1:No,2:yes,+,0.572
4375,3195264,Table 4,BaselineCharacteristic,Iobitridol,Gender/ age (years) ; ,Iobitridol,None,1,1,43,No,1:No,2:yes,+,0.625
4375,3195264,Table 4,BaselineCharacteristic,Female/xx,Gender/ age (years) ; ,#x, Iobitridol,2,1,3,No,1:No,2:yes,+,0.67
4375,3195264,Table 4,BaselineCharacteristic,Male/x,Gender/ age (years) ; ,#x, Iobitridol,3,1,3,No,1:No,2:yes,+,0.65
4375,3195264,Table 4,BaselineCharacteristic,Male/x,Gender/ age (years) ; ,#x, Iobitridol,4,1,3,No,1:No,2:yes,+,0.66
4375,3195264,Table 4,BaselineCharacteristic,Iodixanol,Gender/ age (years) ; ,Iodixanol,None,5,1,43,No,1:No,2:yes,+,0.565
4375,3195264,Table 4,BaselineCharacteristic,Female/xx,Gender/ age (years) ; ,#x, Iodixanol,6,1,3,No,1:No,2:yes,+,0.66
4375,3195264,Table 4,BaselineCharacteristic,Male/x,Gender/ age (years) ; ,#x, Iodixanol,7,1,3,No,1:No,2:yes,+,0.65
4375,3195264,Table 4,BaselineCharacteristic,Female/x,Gender/ age (years) ; ,#x, Iodixanol,8,1,3,No,1:No,2:yes,+,0.63
4375,3195264,Table 4,BaselineCharacteristic,Female/xx,Gender/ age (years) ; ,#x, Iodixanol,9,1,3,No,1:No,2:yes,+,0.61
4375,3195264,Table 4,BaselineCharacteristic,Female/x,Gender/ age (years) ; ,#x, Iodixanol,10,1,3,No,1:No,2:yes,+,0.56
4375,3195264,Table 4,BaselineCharacteristic,Male/x,Gender/ age (years) ; ,#x, Iodixanol,11,1,3,No,1:No,2:yes,+,0.55
4375,3195264,Table 4,BaselineCharacteristic,Female/xx,Gender/ age (years) ; ,#xx, Iodixanol,12,1,3,No,1:No,2:yes,+,0.54
4713,3281202,Table 3,BaselineCharacteristic,"Age (years), mean?±?SD", ;  ; ,None,None,2,0,24,No,1:No,2:yes,+,0.51
4713,3281202,Table 3,BaselineCharacteristic,"Age (years), mean?±?SD",ISSAAC ; N?=?xxx ; ,"Age (years), mean?±?SD",None,2,1,43,No,1:No,2:yes,+,0.68
4713,3281202,Table 3,BaselineCharacteristic,"Age (years), mean?±?SD",INSECT ; N?=?xxx ; ,"Age (years), mean?±?SD",None,2,2,43,No,1:No,2:yes,+,0.66
4713,3281202,Table 3,BaselineCharacteristic,x.xx,p value ; p value ; ,Male," Age (years), mean?±?SD",3,3,3,No,1:No,2:yes,+,0.54
4713,3281202,Table 3,BaselineCharacteristic,xx.x?±?x.x,ISSAAC ; N?=?xxx ; ,"BMI (kg/mx), mean?±?SD", Gender,8,1,3,No,1:No,2:yes,+,0.68
4713,3281202,Table 3,BaselineCharacteristic,xx.x?±?x.x,INSECT ; N?=?xxx ; ,"BMI (kg/mx), mean?±?SD", Gender,8,2,3,No,1:No,2:yes,+,0.66
4713,3281202,Table 3,BaselineCharacteristic,xx.x?±?x.x,ISSAAC ; N?=?xxx ; ,"Length of abdominal wound (cm)a, mean?±?SD", Surgical procedures,21,1,3,No,1:No,2:yes,+,0.69
4713,3281202,Table 3,BaselineCharacteristic,xx.x?±?x.x,INSECT ; N?=?xxx ; ,"Length of abdominal wound (cm)a, mean?±?SD", Surgical procedures,21,2,3,No,1:No,2:yes,+,0.68
4733,3285050,Table 1,BaselineCharacteristic,median (range),,Age (years),None,0,1,3,No,1:No,2:yes,+,0.76
4733,3285050,Table 1,BaselineCharacteristic,median (range),,Follow-up (months),None,5,1,3,No,1:No,2:yes,+,0.53
4744,3291838,Table 1,BaselineCharacteristic,xx (xx.x),Value ; ,"Caucasian, n (%)",,2,1,3,No,1:No,2:yes,+,0.544
4908,3338391,Table 1,BaselineCharacteristic,xxx,Study sites ;  ; High transmission ;  ; Ampasimanjeva ; ,None,None,5,1,,No,1:No,2:yes,+,0.514
4908,3338391,Table 1,BaselineCharacteristic,xxx,Study sites ;  ; High transmission ;  ; Vohimasy ; ,None,None,5,2,,No,1:No,2:yes,+,0.531
4908,3338391,Table 1,BaselineCharacteristic,,Study sites ;  ; High transmission ;  ; Vohimasy ; xxx ; ,None,None,6,2,,No,1:No,2:yes,+,0.502
4908,3338391,Table 1,BaselineCharacteristic,,Study sites ;  ; High transmission ;  ; Ampasimanjeva ; xxx ;  ; xx.x ; ,None,None,8,1,,No,1:No,2:yes,+,0.788
4908,3338391,Table 1,BaselineCharacteristic,,Study sites ;  ; High transmission ;  ; Vohimasy ; xxx ;  ; xx.x ; ,None,None,8,2,,No,1:No,2:yes,+,0.73
4908,3338391,Table 1,BaselineCharacteristic,,Study sites ;  ; Low transmission ;  ; Ampasimpotsy ; xxx ;  ; xx.x ; ,None,None,8,3,,No,1:No,2:yes,+,0.713
4908,3338391,Table 1,BaselineCharacteristic,,Study sites ;  ; Low transmission ;  ; Andasibe ; xxx ;  ; xx.x ; ,None,None,8,4,,No,1:No,2:yes,+,0.662
4908,3338391,Table 1,BaselineCharacteristic,x,Study sites ;  ; High transmission ;  ; Ampasimanjeva ; xxx ;  ; xx.x ;  ; ,None,None,9,1,,No,1:No,2:yes,+,0.751
4908,3338391,Table 1,BaselineCharacteristic,x.xx,Study sites ;  ; High transmission ;  ; Vohimasy ; xxx ;  ; xx.x ;  ; ,None,None,9,2,,No,1:No,2:yes,+,0.693
4908,3338391,Table 1,BaselineCharacteristic,x.xx,Study sites ;  ; Low transmission ;  ; Ampasimpotsy ; xxx ;  ; xx.x ;  ; ,None,None,9,3,,No,1:No,2:yes,+,0.676
4908,3338391,Table 1,BaselineCharacteristic,x.xx,Study sites ;  ; Low transmission ;  ; Andasibe ; xxx ;  ; xx.x ;  ; ,None,None,9,4,,No,1:No,2:yes,+,0.612
4908,3338391,Table 1,BaselineCharacteristic,,Study sites ;  ; High transmission ;  ; Ampasimanjeva ; xxx ;  ; xx.x ;  ; x ; ,None,None,10,1,,No,1:No,2:yes,+,0.669
4908,3338391,Table 1,BaselineCharacteristic,,Study sites ;  ; High transmission ;  ; Vohimasy ; xxx ;  ; xx.x ;  ; x.xx ; ,None,None,10,2,,No,1:No,2:yes,+,0.62
4908,3338391,Table 1,BaselineCharacteristic,,Study sites ;  ; Low transmission ;  ; Ampasimpotsy ; xxx ;  ; xx.x ;  ; x.xx ; ,None,None,10,3,,No,1:No,2:yes,+,0.603
4908,3338391,Table 1,BaselineCharacteristic,xxx,Study sites ;  ; High transmission ;  ; Ampasimanjeva ; xxx ;  ; xx.x ;  ; x ;  ; ,None,None,11,1,,No,1:No,2:yes,+,0.669
4908,3338391,Table 1,BaselineCharacteristic,xxx,Study sites ;  ; High transmission ;  ; Vohimasy ; xxx ;  ; xx.x ;  ; x.xx ;  ; ,None,None,11,2,,No,1:No,2:yes,+,0.62
4908,3338391,Table 1,BaselineCharacteristic,xx,Study sites ;  ; Low transmission ;  ; Ampasimpotsy ; xxx ;  ; xx.x ;  ; x.xx ;  ; ,None,None,11,3,,No,1:No,2:yes,+,0.603
4908,3338391,Table 1,BaselineCharacteristic,,Study sites ;  ; High transmission ;  ; Ampasimanjeva ; xxx ;  ; xx.x ;  ; x ;  ; xxx ; ,None,None,12,1,,No,1:No,2:yes,+,0.669
4908,3338391,Table 1,BaselineCharacteristic,,Study sites ;  ; High transmission ;  ; Vohimasy ; xxx ;  ; xx.x ;  ; x.xx ;  ; xxx ; ,None,None,12,2,,No,1:No,2:yes,+,0.62
4908,3338391,Table 1,BaselineCharacteristic,,Study sites ;  ; Low transmission ;  ; Ampasimpotsy ; xxx ;  ; xx.x ;  ; x.xx ;  ; xx ; ,None,None,12,3,,No,1:No,2:yes,+,0.603
4908,3338391,Table 1,BaselineCharacteristic,xx%,Study sites ;  ; High transmission ;  ; Ampasimanjeva ; xxx ;  ; xx.x ;  ; x ;  ; xxx ;  ; ,None,None,13,1,,No,1:No,2:yes,+,0.605
4908,3338391,Table 1,BaselineCharacteristic,xx%,Study sites ;  ; High transmission ;  ; Vohimasy ; xxx ;  ; xx.x ;  ; x.xx ;  ; xxx ;  ; ,None,None,13,2,,No,1:No,2:yes,+,0.556
4908,3338391,Table 1,BaselineCharacteristic,,Study sites ;  ; High transmission ;  ; Ampasimanjeva ; xxx ;  ; xx.x ;  ; x ;  ; xxx ;  ; xx% ; ,None,None,14,1,,No,1:No,2:yes,+,0.605
4908,3338391,Table 1,BaselineCharacteristic,,Study sites ;  ; High transmission ;  ; Vohimasy ; xxx ;  ; xx.x ;  ; x.xx ;  ; xxx ;  ; xx% ; ,None,None,14,2,,No,1:No,2:yes,+,0.556
4908,3338391,Table 1,BaselineCharacteristic,xx%,Study sites ;  ; High transmission ;  ; Ampasimanjeva ; xxx ;  ; xx.x ;  ; x ;  ; xxx ;  ; xx% ;  ; ,Microscopy + (%),,15,1,,No,1:No,2:yes,+,0.536
4908,3338391,Table 1,BaselineCharacteristic,xx%,Study sites ;  ; High transmission ;  ; Vohimasy ; xxx ;  ; xx.x ;  ; x.xx ;  ; xxx ;  ; xx% ;  ; ,Microscopy + (%),,15,2,,No,1:No,2:yes,+,0.517
4914,3338924,Table 1,BaselineCharacteristic,xx.x (x.x),Age (years) ; ,Healthy controls,None,1,1,3,No,1:No,2:yes,+,0.77
4914,3338924,Table 1,BaselineCharacteristic,,Parkinson’s disease duration (years) ; ,Healthy controls,None,1,3,3,No,1:No,2:yes,+,0.535
4914,3338924,Table 1,BaselineCharacteristic,xx.x (x.x),Age (years) ; ,Parkinson’s disease controls,None,2,1,3,No,1:No,2:yes,+,0.77
4914,3338924,Table 1,BaselineCharacteristic,xx.x (x.x),Parkinson’s disease duration (years) ; ,Parkinson’s disease controls,None,2,3,3,No,1:No,2:yes,+,0.685
4914,3338924,Table 1,BaselineCharacteristic,xx.x (x.x),MMSE ; ,Parkinson’s disease controls,None,2,4,3,No,1:No,2:yes,+,0.689
4914,3338924,Table 1,BaselineCharacteristic,xx.x (x.x),R-UPDRS OFF meds/stim ; ,Parkinson’s disease controls,None,2,5,3,No,1:No,2:yes,+,0.625
4914,3338924,Table 1,BaselineCharacteristic,xx.x (x.x),Age (years) ; ,PD FOG,None,3,1,3,No,1:No,2:yes,+,0.56
4958,3349177,Table 1,BaselineCharacteristic,"Age, years (median, range)", ; ,"Age, years (median, range)",,2,0,2,No,1:No,2:yes,+,0.558
4958,3349177,Table 1,BaselineCharacteristic,,% ; ,"Age, years (median, range)",,2,2,3,No,1:No,2:yes,+,0.74
5055,3368715,Table 1,BaselineCharacteristic,Febuxostat xx mgN = xxx,,Variable,None,0,1,1,No,1:No,2:yes,+,0.591
5055,3368715,Table 1,BaselineCharacteristic,Febuxostat xx mgN = xxx,,Variable,None,0,2,1,No,1:No,2:yes,+,0.607
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,"Gender, n (%)",None,1,1,43,No,1:No,2:yes,+,0.618
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,"Gender, n (%)",None,1,2,43,No,1:No,2:yes,+,0.628
5055,3368715,Table 1,BaselineCharacteristic,xxx (xx.x),Febuxostat xx mgN = xxx ; ,Male," Gender, n (%)",2,1,3,No,1:No,2:yes,+,0.724
5055,3368715,Table 1,BaselineCharacteristic,xxx (xx.x),Febuxostat xx mgN = xxx ; ,Male," Gender, n (%)",2,2,3,No,1:No,2:yes,+,0.704
5055,3368715,Table 1,BaselineCharacteristic,xxx (xx.x),Allopurinol xxx/xxx mgN = xxx ; ,Male," Gender, n (%)",2,3,3,No,1:No,2:yes,+,0.674
5055,3368715,Table 1,BaselineCharacteristic,xx (x.x),Febuxostat xx mgN = xxx ; ,Female," Gender, n (%)",3,1,3,No,1:No,2:yes,+,0.684
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,Female," Gender, n (%)",3,2,3,No,1:No,2:yes,+,0.664
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Allopurinol xxx/xxx mgN = xxx ; ,Female," Gender, n (%)",3,3,3,No,1:No,2:yes,+,0.644
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,4,1,3,No,1:No,2:yes,+,0.608
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,4,2,3,No,1:No,2:yes,+,0.588
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,"Race, n (%)",None,5,1,43,No,1:No,2:yes,+,0.588
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,"Race, n (%)",None,5,2,43,No,1:No,2:yes,+,0.588
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,6,1,3,No,1:No,2:yes,+,0.568
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,6,2,3,No,1:No,2:yes,+,0.548
5055,3368715,Table 1,BaselineCharacteristic,x (x.x),Febuxostat xx mgN = xxx ; ,American Indian or Alaska Native,,7,1,3,No,1:No,2:yes,+,0.518
5055,3368715,Table 1,BaselineCharacteristic,x (x.x),Febuxostat xx mgN = xxx ; ,Asian,,8,1,3,No,1:No,2:yes,+,0.588
5055,3368715,Table 1,BaselineCharacteristic,x (x.x),Febuxostat xx mgN = xxx ; ,Asian,,8,2,3,No,1:No,2:yes,+,0.558
5055,3368715,Table 1,BaselineCharacteristic,xx (x.x),Febuxostat xx mgN = xxx ; ,Black or African American,,9,1,3,No,1:No,2:yes,+,0.528
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,Black or African American,,9,2,3,No,1:No,2:yes,+,0.508
5055,3368715,Table 1,BaselineCharacteristic,x (x.x),Febuxostat xx mgN = xxx ; ,Native Hawaiian or Other Pacific Islander,,10,1,3,No,1:No,2:yes,+,0.518
5055,3368715,Table 1,BaselineCharacteristic,x (x.x),Febuxostat xx mgN = xxx ; ,Native Hawaiian or Other Pacific Islander,,10,2,3,No,1:No,2:yes,+,0.508
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,White,,11,1,3,No,1:No,2:yes,+,0.563
5055,3368715,Table 1,BaselineCharacteristic,xxx (xx.x),Febuxostat xx mgN = xxx ; ,White,,11,2,3,No,1:No,2:yes,+,0.553
5055,3368715,Table 1,BaselineCharacteristic,xxx (xx.x),Allopurinol xxx/xxx mgN = xxx ; ,White,,11,3,3,No,1:No,2:yes,+,0.518
5055,3368715,Table 1,BaselineCharacteristic,x (x.x),Febuxostat xx mgN = xxx ; ,Other,,12,1,3,No,1:No,2:yes,+,0.568
5055,3368715,Table 1,BaselineCharacteristic,x (x.x),Febuxostat xx mgN = xxx ; ,Other,,12,2,3,No,1:No,2:yes,+,0.558
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,13,1,3,No,1:No,2:yes,+,0.568
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,13,2,3,No,1:No,2:yes,+,0.558
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,17,1,3,No,1:No,2:yes,+,0.568
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,17,2,3,No,1:No,2:yes,+,0.558
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,18,1,3,No,1:No,2:yes,+,0.568
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,18,2,3,No,1:No,2:yes,+,0.558
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,21,1,3,No,1:No,2:yes,+,0.558
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,21,2,3,No,1:No,2:yes,+,0.548
5055,3368715,Table 1,BaselineCharacteristic,xx.x ± x.xx,Febuxostat xx mgN = xxx ; ,Mean ± SD, Body mass index (kg/mx),23,1,3,No,1:No,2:yes,+,0.72
5055,3368715,Table 1,BaselineCharacteristic,xx.x ± x.xx,Febuxostat xx mgN = xxx ; ,Mean ± SD, Body mass index (kg/mx),23,2,3,No,1:No,2:yes,+,0.7
5055,3368715,Table 1,BaselineCharacteristic,xx.x ± x.xx,Allopurinol xxx/xxx mgN = xxx ; ,Mean ± SD, Body mass index (kg/mx),23,3,3,No,1:No,2:yes,+,0.705
5055,3368715,Table 1,BaselineCharacteristic,xx-xx,Febuxostat xx mgN = xxx ; ,Range, Body mass index (kg/mx),24,1,3,No,1:No,2:yes,+,0.72
5055,3368715,Table 1,BaselineCharacteristic,xx-xx,Febuxostat xx mgN = xxx ; ,Range, Body mass index (kg/mx),24,2,3,No,1:No,2:yes,+,0.72
5055,3368715,Table 1,BaselineCharacteristic,xx-xx,Allopurinol xxx/xxx mgN = xxx ; ,Range, Body mass index (kg/mx),24,3,3,No,1:No,2:yes,+,0.665
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,25,1,3,No,1:No,2:yes,+,0.548
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,25,2,3,No,1:No,2:yes,+,0.538
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,26,1,3,No,1:No,2:yes,+,0.548
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,26,2,3,No,1:No,2:yes,+,0.538
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,Non-/Ex-drinker,,27,1,3,No,1:No,2:yes,+,0.538
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,Non-/Ex-drinker,,27,2,3,No,1:No,2:yes,+,0.528
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,Drinker (x-xx drinks/week),,28,1,3,No,1:No,2:yes,+,0.538
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,Drinker (x-xx drinks/week),,28,2,3,No,1:No,2:yes,+,0.528
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,29,1,3,No,1:No,2:yes,+,0.528
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,29,2,3,No,1:No,2:yes,+,0.518
5055,3368715,Table 1,BaselineCharacteristic,x.x ± x.xx,Febuxostat xx mgN = xxx ; ,Mean ± SD, Serum urate (mg/dL),31,1,3,No,1:No,2:yes,+,0.78
5055,3368715,Table 1,BaselineCharacteristic,x.x ± x.xx,Febuxostat xx mgN = xxx ; ,Mean ± SD, Serum urate (mg/dL),31,2,3,No,1:No,2:yes,+,0.75
5055,3368715,Table 1,BaselineCharacteristic,x.x ± x.xx,Allopurinol xxx/xxx mgN = xxx ; ,Mean ± SD, Serum urate (mg/dL),31,3,3,No,1:No,2:yes,+,0.745
5055,3368715,Table 1,BaselineCharacteristic,x-xx,Febuxostat xx mgN = xxx ; ,Range, Serum urate (mg/dL),32,1,3,No,1:No,2:yes,+,0.528
5055,3368715,Table 1,BaselineCharacteristic,x-xx,Febuxostat xx mgN = xxx ; ,Range, Serum urate (mg/dL),32,2,3,No,1:No,2:yes,+,0.518
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,33,1,3,No,1:No,2:yes,+,0.528
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,33,2,3,No,1:No,2:yes,+,0.518
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,34,1,3,No,1:No,2:yes,+,0.528
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,34,2,3,No,1:No,2:yes,+,0.518
5055,3368715,Table 1,BaselineCharacteristic,xx.x ± xx.x,Febuxostat xx mgN = xxx ; ,Mean ± SD,,35,1,3,No,1:No,2:yes,+,0.78
5055,3368715,Table 1,BaselineCharacteristic,xx.x ± xx.xx,Febuxostat xx mgN = xxx ; ,Mean ± SD,,35,2,3,No,1:No,2:yes,+,0.75
5055,3368715,Table 1,BaselineCharacteristic,xx.x ± xx.xx,Allopurinol xxx/xxx mgN = xxx ; ,Mean ± SD,,35,3,3,No,1:No,2:yes,+,0.745
5055,3368715,Table 1,BaselineCharacteristic,x-xx,Febuxostat xx mgN = xxx ; ,Range,,36,1,3,No,1:No,2:yes,+,0.528
5055,3368715,Table 1,BaselineCharacteristic,x-xx,Febuxostat xx mgN = xxx ; ,Range,,36,2,3,No,1:No,2:yes,+,0.518
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,37,1,3,No,1:No,2:yes,+,0.528
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,37,2,3,No,1:No,2:yes,+,0.518
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,No," Tophi present, n (%)",39,1,3,No,1:No,2:yes,+,0.509
5055,3368715,Table 1,BaselineCharacteristic,xxx (xx.x),Febuxostat xx mgN = xxx ; ,No," Tophi present, n (%)",39,2,3,No,1:No,2:yes,+,0.509
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,Yes," Tophi present, n (%)",40,1,3,No,1:No,2:yes,+,0.509
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,Yes," Tophi present, n (%)",40,2,3,No,1:No,2:yes,+,0.509
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,41,1,3,No,1:No,2:yes,+,0.528
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,41,2,3,No,1:No,2:yes,+,0.518
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,42,1,3,No,1:No,2:yes,+,0.528
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,42,2,3,No,1:No,2:yes,+,0.518
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,Yes,,43,1,3,No,1:No,2:yes,+,0.538
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,Yes,,43,2,3,No,1:No,2:yes,+,0.528
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,44,1,3,No,1:No,2:yes,+,0.528
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,44,2,3,No,1:No,2:yes,+,0.518
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,No," Prior urate lowering therapies, n (%)",46,1,3,No,1:No,2:yes,+,0.509
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,No," Prior urate lowering therapies, n (%)",46,2,3,No,1:No,2:yes,+,0.509
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,Yes (any)," Prior urate lowering therapies, n (%)",47,1,3,No,1:No,2:yes,+,0.509
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,Yes (any)," Prior urate lowering therapies, n (%)",47,2,3,No,1:No,2:yes,+,0.509
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,Febuxostat," Prior urate lowering therapies, n (%)",48,1,3,No,1:No,2:yes,+,0.509
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,Febuxostat," Prior urate lowering therapies, n (%)",48,2,3,No,1:No,2:yes,+,0.509
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Allopurinol xxx/xxx mgN = xxx ; ,Febuxostat," Prior urate lowering therapies, n (%)",48,3,3,No,1:No,2:yes,+,0.519
5055,3368715,Table 1,BaselineCharacteristic,x (x.x),Febuxostat xx mgN = xxx ; ,Probenecid," Prior urate lowering therapies, n (%)",50,1,3,No,1:No,2:yes,+,0.509
5055,3368715,Table 1,BaselineCharacteristic,x (x.x),Febuxostat xx mgN = xxx ; ,Probenecid," Prior urate lowering therapies, n (%)",50,2,3,No,1:No,2:yes,+,0.509
5055,3368715,Table 1,BaselineCharacteristic,x (x.x),Febuxostat xx mgN = xxx ; ,Other," Prior urate lowering therapies, n (%)",51,1,3,No,1:No,2:yes,+,0.509
5055,3368715,Table 1,BaselineCharacteristic,x (x.x),Febuxostat xx mgN = xxx ; ,Other," Prior urate lowering therapies, n (%)",51,2,3,No,1:No,2:yes,+,0.509
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,52,1,3,No,1:No,2:yes,+,0.528
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,52,2,3,No,1:No,2:yes,+,0.518
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,53,1,3,No,1:No,2:yes,+,0.528
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,53,2,3,No,1:No,2:yes,+,0.518
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,Moderately Impaired,,54,1,3,No,1:No,2:yes,+,0.538
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,Moderately Impaired,,54,2,3,No,1:No,2:yes,+,0.528
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,Mildly Impaired,,55,1,3,No,1:No,2:yes,+,0.538
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,Mildly Impaired,,55,2,3,No,1:No,2:yes,+,0.528
5055,3368715,Table 1,BaselineCharacteristic,x (x.x),Febuxostat xx mgN = xxx ; ,Normal,,56,1,3,No,1:No,2:yes,+,0.538
5055,3368715,Table 1,BaselineCharacteristic,x (x.x),Febuxostat xx mgN = xxx ; ,Normal,,56,2,3,No,1:No,2:yes,+,0.528
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,57,1,3,No,1:No,2:yes,+,0.528
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,57,2,3,No,1:No,2:yes,+,0.518
5055,3368715,Table 1,BaselineCharacteristic,xxx (xx.x),Febuxostat xx mgN = xxx ; ,Any cardiovascular diseased," Medical History, n (%)",59,1,3,No,1:No,2:yes,+,0.509
5055,3368715,Table 1,BaselineCharacteristic,xxx (xx.x),Febuxostat xx mgN = xxx ; ,Any cardiovascular diseased," Medical History, n (%)",59,2,3,No,1:No,2:yes,+,0.509
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,Hypertension," Medical History, n (%)",60,1,3,No,1:No,2:yes,+,0.509
5055,3368715,Table 1,BaselineCharacteristic,xxx (xx.x),Febuxostat xx mgN = xxx ; ,Hypertension," Medical History, n (%)",60,2,3,No,1:No,2:yes,+,0.509
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,Coronary artery disease," Medical History, n (%)",61,1,3,No,1:No,2:yes,+,0.509
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,Coronary artery disease," Medical History, n (%)",61,2,3,No,1:No,2:yes,+,0.509
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,62,1,3,No,1:No,2:yes,+,0.528
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,None,None,62,2,3,No,1:No,2:yes,+,0.518
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,Cardiac arrhythmia," Medical History, n (%)",63,1,3,No,1:No,2:yes,+,0.509
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,Cardiac arrhythmia," Medical History, n (%)",63,2,3,No,1:No,2:yes,+,0.509
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,Diabetes," Medical History, n (%)",64,1,3,No,1:No,2:yes,+,0.509
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,Diabetes," Medical History, n (%)",64,2,3,No,1:No,2:yes,+,0.509
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,Hypercholesterolemia," Medical History, n (%)",65,1,3,No,1:No,2:yes,+,0.509
5055,3368715,Table 1,BaselineCharacteristic,xx (x.x),Febuxostat xx mgN = xxx ; ,Hypercholesterolemia," Medical History, n (%)",65,2,3,No,1:No,2:yes,+,0.509
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,Hyperlipidemia," Medical History, n (%)",66,1,3,No,1:No,2:yes,+,0.509
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,Hyperlipidemia," Medical History, n (%)",66,2,3,No,1:No,2:yes,+,0.509
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,Use of low-dose aspirin (?xxx mg daily)," Medical History, n (%)",67,1,3,No,1:No,2:yes,+,0.544
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,Use of low-dose aspirin (?xxx mg daily)," Medical History, n (%)",67,2,3,No,1:No,2:yes,+,0.564
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Allopurinol xxx/xxx mgN = xxx ; ,Use of low-dose aspirin (?xxx mg daily)," Medical History, n (%)",67,3,3,No,1:No,2:yes,+,0.524
5267,3407730,Table 1,BaselineCharacteristic,xx (xx.xx),Result ; ,??Male?," Sex, n (%) ",3,1,3,No,1:No,2:yes,+,0.604
5267,3407730,Table 1,BaselineCharacteristic,xx (xx.xx),Result ; ,??Female?," Sex, n (%) ",4,1,3,No,1:No,2:yes,+,0.559
5267,3407730,Table 1,BaselineCharacteristic,x (xx.xx),Result ; ,??Stagea I?," NSCLC, n (%) ",7,1,3,No,1:No,2:yes,+,0.544
5267,3407730,Table 2,BaselineCharacteristic,xx (xx.xx),Result ; ,??Male?," Sex, n (%) ",3,1,3,No,1:No,2:yes,+,0.604
5267,3407730,Table 2,BaselineCharacteristic,x (xx.xx),Result ; ,??Female?," Sex, n (%) ",4,1,3,No,1:No,2:yes,+,0.589
5330,3414800,Table 1,BaselineCharacteristic,AHI x – xx n=xx, ; mild/moderate ; ,,None,2,2,1,No,1:No,2:yes,+,0.571
5330,3414800,Table 1,BaselineCharacteristic,xx.x,OSA ; snorers ; AHI<x n=xx ; ,Males (%),None,4,1,3,No,1:No,2:yes,+,0.62
5330,3414800,Table 1,BaselineCharacteristic,xx.x, ; mild/moderate ; AHI x – xx n=xx ; ,Males (%),None,4,2,3,No,1:No,2:yes,+,0.68
5330,3414800,Table 1,BaselineCharacteristic,xx.x, ; severe ; AHI?xx n=xx ; ,Males (%),None,4,3,3,No,1:No,2:yes,+,0.68
5330,3414800,Table 1,BaselineCharacteristic,xx.x±x.x, ; mild/moderate ; AHI x – xx n=xx ; ,AHI (events/h),None,5,2,3,No,1:No,2:yes,+,0.55
5330,3414800,Table 1,BaselineCharacteristic,xx.x±xx.x, ; severe ; AHI?xx n=xx ; ,AHI (events/h),None,5,3,3,No,1:No,2:yes,+,0.61
5330,3414800,Table 1,BaselineCharacteristic,"xx,x±x,x", ; mild/moderate ; AHI x – xx n=xx ; ,Average SaO²,None,6,2,3,No,1:No,2:yes,+,0.54
5330,3414800,Table 1,BaselineCharacteristic,"xxx,x±xx,x", ; mild/moderate ; AHI x – xx n=xx ; ,Waist circumference (cm),None,8,2,3,No,1:No,2:yes,+,0.59
5330,3414800,Table 1,BaselineCharacteristic,"xxx,x±xx,x", ; severe ; AHI?xx n=xx ; ,Waist circumference (cm),None,8,3,3,No,1:No,2:yes,+,0.57
5330,3414800,Table 1,BaselineCharacteristic,"xxx,x±xx,x", ; severe ; AHI?xx n=xx ; ,Hip circumference (cm),None,9,3,3,No,1:No,2:yes,+,0.52
5330,3414800,Table 1,BaselineCharacteristic,xxx.x±xx.x, ; mild/moderate ; AHI x – xx n=xx ; ,Blood glucose (mg/dl),None,10,2,3,No,1:No,2:yes,+,0.55
5330,3414800,Table 1,BaselineCharacteristic,xxx.x±xx.x, ; severe ; AHI?xx n=xx ; ,Blood glucose (mg/dl),None,10,3,3,No,1:No,2:yes,+,0.5
5330,3414800,Table 1,BaselineCharacteristic,xx.x±xx.x, ; mild/moderate ; AHI x – xx n=xx ; ,Insulin (?U/mL),None,11,2,3,No,1:No,2:yes,+,0.55
5330,3414800,Table 1,BaselineCharacteristic,xxx.x±xx.x, ; mild/moderate ; AHI x – xx n=xx ; ,Total cholesterol (mg/dl),None,13,2,3,No,1:No,2:yes,+,0.55
5330,3414800,Table 1,BaselineCharacteristic,xxx.x±xx.x, ; severe ; AHI?xx n=xx ; ,Total cholesterol (mg/dl),None,13,3,3,No,1:No,2:yes,+,0.5
5330,3414800,Table 1,BaselineCharacteristic,xxx.x±xx.x, ; mild/moderate ; AHI x – xx n=xx ; ,LDL-cholesterol (mg/dl),None,14,2,3,No,1:No,2:yes,+,0.53
5330,3414800,Table 1,BaselineCharacteristic,xx.x±xx.x, ; mild/moderate ; AHI x – xx n=xx ; ,HDL-cholesterol (mg/dl),None,15,2,3,No,1:No,2:yes,+,0.52
5330,3414800,Table 1,BaselineCharacteristic,xxx.x±xx.x, ; mild/moderate ; AHI x – xx n=xx ; ,Triglycerides (mg/dl),None,16,2,3,No,1:No,2:yes,+,0.53
5330,3414800,Table 1,BaselineCharacteristic,"xxx.x±xx,x", ; mild/moderate ; AHI x – xx n=xx ; ,Urinary x-iso-PGFx? (pg/mg creatinine),None,17,2,3,No,1:No,2:yes,+,0.54
5330,3414800,Table 1,BaselineCharacteristic,"xx.x±xx,x", ; mild/moderate ; AHI x – xx n=xx ; ,Serum NOx (uM/ml),None,19,2,3,No,1:No,2:yes,+,0.52
5383,3427446,Table 1,BaselineCharacteristic,xx.x?±?xx.x,Values (N?=?xx) ; ,Duration of complaints in months (mean ± SD),None,6,1,3,No,1:No,2:yes,+,0.7
5383,3427446,Table 1,BaselineCharacteristic,x.x?±?x.x,Values (N?=?xx) ; ,VAS ADL score (mean ± SD),None,7,1,3,No,1:No,2:yes,+,0.69
5383,3427446,Table 1,BaselineCharacteristic,x.x?±?x.x,Values (N?=?xx) ; ,VAS work score (mean ± SD),None,8,1,3,No,1:No,2:yes,+,0.67
5383,3427446,Table 1,BaselineCharacteristic,x.x?±?x.x,Values (N?=?xx) ; ,VAS sport score (mean ± SD),None,9,1,3,No,1:No,2:yes,+,0.66
5383,3427446,Table 1,BaselineCharacteristic,xx.x?±?xx.x,Values (N?=?xx) ; ,VISA-P total score (mean ± SD),None,10,1,3,No,1:No,2:yes,+,0.56
5383,3427446,Table 2,BaselineCharacteristic,x.xxx,P-value ; ,Age (mean ± SD),,2,3,3,No,1:No,2:yes,+,0.53
5383,3427446,Table 2,BaselineCharacteristic,xx.x?±?xx.x,Group x (N?=?xx) ; ,Duration of complaints in months (mean ± SD),,6,1,3,No,1:No,2:yes,+,0.69
5383,3427446,Table 2,BaselineCharacteristic,xx.x?±?xx.x,Group x (N?=?xx) ; ,Duration of complaints in months (mean ± SD),,6,2,3,No,1:No,2:yes,+,0.68
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,ATIV (%) ; ,Female,,1,1,3,No,1:No,2:yes,+,0.518
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,TIV (%) ; ,Female,,1,2,3,No,1:No,2:yes,+,0.528
5561,3465101,Table 1.,BaselineCharacteristic,Efavirenz arm (n?=?xx),,Parameter,None,0,1,1,No,1:No,2:yes,+,0.511
5561,3465101,Table 1.,BaselineCharacteristic,Nevirapine arm (n?=?xx),,Parameter,None,0,2,1,No,1:No,2:yes,+,0.527
5561,3465101,Table 1.,BaselineCharacteristic,xx (xx),Efavirenz arm (n?=?xx) ; ,"Females, n (%)",None,1,1,3,No,1:No,2:yes,+,0.59
5561,3465101,Table 1.,BaselineCharacteristic,xx (xx),Nevirapine arm (n?=?xx) ; ,"Females, n (%)",None,1,2,3,No,1:No,2:yes,+,0.62
5561,3465101,Table 1.,BaselineCharacteristic,xx (xx–xx),Efavirenz arm (n?=?xx) ; ,"Weight (kg), median (IQR)",None,3,1,3,No,1:No,2:yes,+,0.79
5561,3465101,Table 1.,BaselineCharacteristic,xx (xx–xx),Nevirapine arm (n?=?xx) ; ,"Weight (kg), median (IQR)",None,3,2,3,No,1:No,2:yes,+,0.82
5561,3465101,Table 1.,BaselineCharacteristic,xxx (xxx–xxx),Efavirenz arm (n?=?xx) ; ,"Height (cm), median (IQR)",None,4,1,3,No,1:No,2:yes,+,0.68
5561,3465101,Table 1.,BaselineCharacteristic,xxx (xxx–xxx),Nevirapine arm (n?=?xx) ; ,"Height (cm), median (IQR)",None,4,2,3,No,1:No,2:yes,+,0.7
5561,3465101,Table 1.,BaselineCharacteristic,xx (xx–xx),Efavirenz arm (n?=?xx) ; ,"BMI (kg/mx), median (IQR)",None,5,1,3,No,1:No,2:yes,+,0.67
5561,3465101,Table 1.,BaselineCharacteristic,xx (xx–xx),Nevirapine arm (n?=?xx) ; ,"BMI (kg/mx), median (IQR)",None,5,2,3,No,1:No,2:yes,+,0.69
5569,3466131,Table 3,BaselineCharacteristic,xxx.xx,SD ; ,Baseline samples, NO (?mol/L),2,4,3,No,1:No,2:yes,+,0.549
5578,3468079,Table 1.,BaselineCharacteristic,"Cohort x (xxx mg of posaconazole), n?=?xx",,,None,0,1,1,No,1:No,2:yes,+,0.589
5578,3468079,Table 1.,BaselineCharacteristic,"All subjects, n?=?xx",,,None,0,4,1,No,1:No,2:yes,+,0.601
5578,3468079,Table 1.,BaselineCharacteristic,,"Cohort x (xxx mg of posaconazole), n?=?xx ; ",None,None,1,1,3,No,1:No,2:yes,+,0.59
5578,3468079,Table 1.,BaselineCharacteristic,,"All subjects, n?=?xx ; ",None,None,1,4,3,No,1:No,2:yes,+,0.574
5578,3468079,Table 1.,BaselineCharacteristic,x (xx),"Cohort x (xxx mg of posaconazole), n?=?xx ; ","Gender, male, n (%)",,2,1,3,No,1:No,2:yes,+,0.59
5578,3468079,Table 1.,BaselineCharacteristic,x (xx),"Cohort x (xxx mg of posaconazole), n?=?x ; ","Gender, male, n (%)",,2,2,3,No,1:No,2:yes,+,0.62
5578,3468079,Table 1.,BaselineCharacteristic,xx (xx),"All subjects, n?=?xx ; ","Gender, male, n (%)",,2,4,3,No,1:No,2:yes,+,0.564
5578,3468079,Table 1.,BaselineCharacteristic,"Race, n (%)","Cohort x (xxx mg of posaconazole), n?=?xx ; ","Race, n (%)",None,3,1,43,No,1:No,2:yes,+,0.563
5578,3468079,Table 1.,BaselineCharacteristic,xx (xxx),"All subjects, n?=?xx ; ",?White," Race, n (%)",4,4,3,No,1:No,2:yes,+,0.52
5578,3468079,Table 1.,BaselineCharacteristic,"Ethnicity, n (%)","Cohort x (xxx mg of posaconazole), n?=?xx ; ","Ethnicity, n (%)",None,5,1,43,No,1:No,2:yes,+,0.513
5578,3468079,Table 1.,BaselineCharacteristic,"Age, years","Cohort x (xxx mg of posaconazole), n?=?xx ; ","Age, years",None,7,1,43,No,1:No,2:yes,+,0.654
5578,3468079,Table 1.,BaselineCharacteristic,"Age, years","Cohort x (xxx mg of posaconazole), n?=?x ; ","Age, years",None,7,2,43,No,1:No,2:yes,+,0.56
5578,3468079,Table 1.,BaselineCharacteristic,"Age, years","All subjects, n?=?xx ; ","Age, years",None,7,4,43,No,1:No,2:yes,+,0.508
5578,3468079,Table 1.,BaselineCharacteristic,?median (range), ; ,?median (range)," Age, years",9,0,2,No,1:No,2:yes,+,0.538
5578,3468079,Table 1.,BaselineCharacteristic,xx.xx (xx.xx),"Cohort x (xxx mg of posaconazole), n?=?xx ; ",?mean (SD)," Weight, kg",11,1,3,No,1:No,2:yes,+,0.68
5578,3468079,Table 1.,BaselineCharacteristic,xx.xx (x.xx),"Cohort x (xxx mg of posaconazole), n?=?x ; ",?mean (SD)," Weight, kg",11,2,3,No,1:No,2:yes,+,0.69
5578,3468079,Table 1.,BaselineCharacteristic,xx.xx (x.xx),"Placebo, n?=?x ; ",?mean (SD)," Weight, kg",11,3,3,No,1:No,2:yes,+,0.6
5578,3468079,Table 1.,BaselineCharacteristic,xx.xx (xx.xx),"All subjects, n?=?xx ; ",?mean (SD)," Weight, kg",11,4,3,No,1:No,2:yes,+,0.59
5578,3468079,Table 1.,BaselineCharacteristic,xx (xx–xxx),"Cohort x (xxx mg of posaconazole), n?=?xx ; ",?median (range)," Weight, kg",12,1,3,No,1:No,2:yes,+,0.64
5578,3468079,Table 1.,BaselineCharacteristic,xx (xx–xx),"Cohort x (xxx mg of posaconazole), n?=?x ; ",?median (range)," Weight, kg",12,2,3,No,1:No,2:yes,+,0.69
5578,3468079,Table 1.,BaselineCharacteristic,xx (xx–xx),"Placebo, n?=?x ; ",?median (range)," Weight, kg",12,3,3,No,1:No,2:yes,+,0.71
5578,3468079,Table 1.,BaselineCharacteristic,xx (xx–xxx),"All subjects, n?=?xx ; ",?median (range)," Weight, kg",12,4,3,No,1:No,2:yes,+,0.71
5578,3468079,Table 1.,BaselineCharacteristic,xxx.xx (x.xx),"Cohort x (xxx mg of posaconazole), n?=?xx ; ",?mean (SD)," Height, cm",14,1,3,No,1:No,2:yes,+,0.65
5578,3468079,Table 1.,BaselineCharacteristic,xxx.xx (x.xx),"Cohort x (xxx mg of posaconazole), n?=?x ; ",?mean (SD)," Height, cm",14,2,3,No,1:No,2:yes,+,0.66
5578,3468079,Table 1.,BaselineCharacteristic,xxx.xx (x.xx),"Placebo, n?=?x ; ",?mean (SD)," Height, cm",14,3,3,No,1:No,2:yes,+,0.6
5578,3468079,Table 1.,BaselineCharacteristic,xxx.xx (x.xx),"All subjects, n?=?xx ; ",?mean (SD)," Height, cm",14,4,3,No,1:No,2:yes,+,0.63
5578,3468079,Table 1.,BaselineCharacteristic,xxx (xxx–xxx),"Cohort x (xxx mg of posaconazole), n?=?xx ; ",?median (range)," Height, cm",15,1,3,No,1:No,2:yes,+,0.61
5578,3468079,Table 1.,BaselineCharacteristic,xxx (xxx–xxx),"Cohort x (xxx mg of posaconazole), n?=?x ; ",?median (range)," Height, cm",15,2,3,No,1:No,2:yes,+,0.53
5578,3468079,Table 1.,BaselineCharacteristic,xxx (xxx–xxx),"Placebo, n?=?x ; ",?median (range)," Height, cm",15,3,3,No,1:No,2:yes,+,0.55
5578,3468079,Table 1.,BaselineCharacteristic,xxx (xxx–xxx),"All subjects, n?=?xx ; ",?median (range)," Height, cm",15,4,3,No,1:No,2:yes,+,0.66
5636,3483202,Table 1,BaselineCharacteristic,"Diabetes mellitus, n?=?xx",,,None,0,1,1,No,1:No,2:yes,+,0.505
5636,3483202,Table 1,BaselineCharacteristic,xx,"No diabetes mellitus, n?=?xxx ; ",Smokers,,3,2,3,No,1:No,2:yes,+,0.509
5636,3483202,Table 1,BaselineCharacteristic,xx (x–xx),"Diabetes mellitus, n?=?xx ; ",Dialysis vintage years,,10,1,3,No,1:No,2:yes,+,0.544
5636,3483202,Table 1,BaselineCharacteristic,xx (x–xx),"No diabetes mellitus, n?=?xxx ; ",Dialysis vintage years,,10,2,3,No,1:No,2:yes,+,0.554
5696,3493663,Table 2,BaselineCharacteristic,xx,Age (years) ; ,m,None,1,1,3,No,1:No,2:yes,+,0.574
5696,3493663,Table 2,BaselineCharacteristic,xx,Age (years) ; ,m,None,2,1,3,No,1:No,2:yes,+,0.564
5696,3493663,Table 2,BaselineCharacteristic,xx,Age (years) ; ,f,None,3,1,3,No,1:No,2:yes,+,0.594
5696,3493663,Table 2,BaselineCharacteristic,xx,Age (years) ; ,f,None,4,1,3,No,1:No,2:yes,+,0.564
5696,3493663,Table 2,BaselineCharacteristic,xx,Age (years) ; ,m,None,5,1,3,No,1:No,2:yes,+,0.534
5696,3493663,Table 2,BaselineCharacteristic,xx,Age (years) ; ,f,None,6,1,3,No,1:No,2:yes,+,0.544
5696,3493663,Table 2,BaselineCharacteristic,xx,Age (years) ; ,f,None,7,1,3,No,1:No,2:yes,+,0.534
5758,3502482,Table 1,BaselineCharacteristic,xx Gy step (n?=?xx),,,None,0,1,1,No,1:No,2:yes,+,0.585
5758,3502482,Table 1,BaselineCharacteristic,xx Gy step (n?=?xx),,,None,0,2,1,No,1:No,2:yes,+,0.591
5758,3502482,Table 1,BaselineCharacteristic,xx (x–xx),xx Gy step (n?=?xx) ; ,Median tumor size (mm) (min-max),,2,1,3,No,1:No,2:yes,+,0.634
5758,3502482,Table 1,BaselineCharacteristic,xx (x–xx),xx Gy step (n?=?xx) ; ,Median tumor size (mm) (min-max),,2,2,3,No,1:No,2:yes,+,0.594
5758,3502482,Table 2,BaselineCharacteristic,xx Gy (n?=?xx),,Characteristic,None,0,1,1,No,1:No,2:yes,+,0.555
5758,3502482,Table 2,BaselineCharacteristic,xx Gy (n?=?xx),,Characteristic,None,0,2,1,No,1:No,2:yes,+,0.561
5758,3502482,Table 2,BaselineCharacteristic,"xx Gy (n?=?xx patients, xx tumors)",,Characteristic,None,0,3,1,No,1:No,2:yes,+,0.531
5758,3502482,Table 2,BaselineCharacteristic,"xx Gy (n?=?xx patients, xx tumors)",,Characteristic,None,0,4,1,No,1:No,2:yes,+,0.511
5758,3502482,Table 2,BaselineCharacteristic,Median,xx Gy (n?=?xx) ; ,,None,1,1,1,No,1:No,2:yes,+,0.562
5758,3502482,Table 2,BaselineCharacteristic,Min - max,xx Gy (n?=?xx) ; ,,None,1,2,1,No,1:No,2:yes,+,0.55
5758,3502482,Table 2,BaselineCharacteristic,Median,"xx Gy (n?=?xx patients, xx tumors) ; ",,None,1,3,1,No,1:No,2:yes,+,0.538
5758,3502482,Table 2,BaselineCharacteristic,PTV coverage,xx Gy (n?=?xx) ; Median ; ,PTV coverage,,2,1,3,No,1:No,2:yes,+,0.554
5758,3502482,Table 2,BaselineCharacteristic,PTV coverage,xx Gy (n?=?xx) ; Min - max ; ,PTV coverage,,2,2,3,No,1:No,2:yes,+,0.5
5758,3502482,Table 2,BaselineCharacteristic,xx,xx Gy (n?=?xx) ; Median ; ,Vxxx%,,3,1,3,No,1:No,2:yes,+,0.504
5758,3502482,Table 2,BaselineCharacteristic,xx - xxx,xx Gy (n?=?xx) ; Min - max ; ,Vxxx%,,3,2,3,No,1:No,2:yes,+,0.56
5758,3502482,Table 2,BaselineCharacteristic,xx - xxx,"xx Gy (n?=?xx patients, xx tumors) ; Min - max ; ",Vxxx%,,3,4,3,No,1:No,2:yes,+,0.51
5758,3502482,Table 2,BaselineCharacteristic,xxx,xx Gy (n?=?xx) ; Median ; ,Vxx%,,4,1,3,No,1:No,2:yes,+,0.519
5758,3502482,Table 2,BaselineCharacteristic,xxx,xx Gy (n?=?xx) ; Median ; ,Vxx%,,5,1,3,No,1:No,2:yes,+,0.519
5807,3511174,Table 1,BaselineCharacteristic,xx years (x.x years),Group B (n?=?x) ; ,Mean age (SD),None,1,1,3,No,1:No,2:yes,+,0.924
5807,3511174,Table 1,BaselineCharacteristic,xx.x years (x.x years),Group BT (n?=?x) ; ,Mean age (SD),None,1,2,3,No,1:No,2:yes,+,0.904
5842,3519573,Table 1,BaselineCharacteristic,xx (xx.x%),Total (N?=?xxx) ; ,"Gender, n (%male)",None,2,1,3,No,1:No,2:yes,+,0.509
5842,3519573,Table 1,BaselineCharacteristic,xx.x (x.x),Total (N?=?xxx) ; ,"Height (inches), mean (SD)",None,3,1,3,No,1:No,2:yes,+,0.84
5842,3519573,Table 1,BaselineCharacteristic,xx.x (xx.x),Total (N?=?xxx) ; ,"Weight (pounds), mean (SD)",None,4,1,3,No,1:No,2:yes,+,0.78
5842,3519573,Table 1,BaselineCharacteristic,xx (xx.x%),Total (N?=?xxx) ; ,Small for gestational age,None,18,1,3,No,1:No,2:yes,+,0.514
5842,3519573,Table 1,BaselineCharacteristic,x.x (x.x),Total (N?=?xxx) ; ,"Time since diagnosis (years), mean (SD)",None,24,1,3,No,1:No,2:yes,+,0.54
5842,3519573,Table 2,BaselineCharacteristic,x.x (x.x),Total (N?=?xxx) ; ,"Length of time using reusable pen(years), mean (SD)",None,6,1,3,No,1:No,2:yes,+,0.63
5842,3519573,Table 7,BaselineCharacteristic,xx.x,SD ; ,Preparing the pen,None,2,3,3,No,1:No,2:yes,+,0.524
5842,3519573,Table 8,BaselineCharacteristic,xx.x,SD ; ,Preparing pen,None,2,3,3,No,1:No,2:yes,+,0.584
5937,3539065,Table 3,BaselineCharacteristic,xx,"Cohort x ; Lapatinib x,xxx mg + placebo ; ","Modified intent-to-treat population, n",,2,1,3,No,1:No,2:yes,+,0.594
5937,3539065,Table 3,BaselineCharacteristic,xx,"Cohort x ; Lapatinib x,xxx mg + pazopanib xxx mg ; ","Modified intent-to-treat population, n",,2,2,3,No,1:No,2:yes,+,0.574
5937,3539065,Table 3,BaselineCharacteristic,xx,"Cohort x ; Lapatinib x,xxx mg + placebo ; ","Modified intent-to-treat population, n",,2,3,3,No,1:No,2:yes,+,0.584
5937,3539065,Table 3,BaselineCharacteristic,xx,"Cohort x ; Lapatinib x,xxx mg + pazopanib xxx mg ; ","Modified intent-to-treat population, n",,2,4,3,No,1:No,2:yes,+,0.544
5937,3539065,Table 3,BaselineCharacteristic,xx,Cohort x ; Pazopanib xxx mg ; ,"Modified intent-to-treat population, n",,2,5,3,No,1:No,2:yes,+,0.52
5937,3539065,Table 3,BaselineCharacteristic,xx (xx),"Cohort x ; Lapatinib x,xxx mg + placebo ; ","White, n (%)",,4,1,3,No,1:No,2:yes,+,0.544
5937,3539065,Table 3,BaselineCharacteristic,xx (xx),"Cohort x ; Lapatinib x,xxx mg + pazopanib xxx mg ; ","White, n (%)",,4,2,3,No,1:No,2:yes,+,0.514
5937,3539065,Table 3,BaselineCharacteristic,xx (xx),"Cohort x ; Lapatinib x,xxx mg + placebo ; ","White, n (%)",,4,3,3,No,1:No,2:yes,+,0.534
5937,3539065,Table 3,BaselineCharacteristic,xx (xx),"Cohort x ; Lapatinib x,xxx mg + placebo ; ","Asian, n (%)",,5,1,3,No,1:No,2:yes,+,0.579
5937,3539065,Table 3,BaselineCharacteristic,x (xx),"Cohort x ; Lapatinib x,xxx mg + pazopanib xxx mg ; ","Asian, n (%)",,5,2,3,No,1:No,2:yes,+,0.549
5937,3539065,Table 3,BaselineCharacteristic,xx (xx),"Cohort x ; Lapatinib x,xxx mg + placebo ; ","Asian, n (%)",,5,3,3,No,1:No,2:yes,+,0.569
5937,3539065,Table 3,BaselineCharacteristic,xx (xx),"Cohort x ; Lapatinib x,xxx mg + pazopanib xxx mg ; ","Asian, n (%)",,5,4,3,No,1:No,2:yes,+,0.519
5937,3539065,Table 3,BaselineCharacteristic,x (xx),Cohort x ; Pazopanib xxx mg ; ,"Asian, n (%)",,5,5,3,No,1:No,2:yes,+,0.514
5937,3539065,Table 3,BaselineCharacteristic,xx (xx),"Cohort x ; Lapatinib x,xxx mg + placebo ; ","Radiologically measurable disease, n (%)a",,6,1,3,No,1:No,2:yes,+,0.559
5937,3539065,Table 3,BaselineCharacteristic,xx (xx),"Cohort x ; Lapatinib x,xxx mg + pazopanib xxx mg ; ","Radiologically measurable disease, n (%)a",,6,2,3,No,1:No,2:yes,+,0.519
5937,3539065,Table 3,BaselineCharacteristic,xx (xx),"Cohort x ; Lapatinib x,xxx mg + placebo ; ","Radiologically measurable disease, n (%)a",,6,3,3,No,1:No,2:yes,+,0.549
5937,3539065,Table 3,BaselineCharacteristic,xx (xx),"Cohort x ; Lapatinib x,xxx mg + placebo ; ","Cutaneous disease, n (%)b",,7,1,3,No,1:No,2:yes,+,0.559
5937,3539065,Table 3,BaselineCharacteristic,xx (xx),"Cohort x ; Lapatinib x,xxx mg + pazopanib xxx mg ; ","Cutaneous disease, n (%)b",,7,2,3,No,1:No,2:yes,+,0.519
5937,3539065,Table 3,BaselineCharacteristic,xx (xxx),"Cohort x ; Lapatinib x,xxx mg + placebo ; ","Cutaneous disease, n (%)b",,7,3,3,No,1:No,2:yes,+,0.599
5937,3539065,Table 3,BaselineCharacteristic,xx (xxx),"Cohort x ; Lapatinib x,xxx mg + pazopanib xxx mg ; ","Cutaneous disease, n (%)b",,7,4,3,No,1:No,2:yes,+,0.559
5937,3539065,Table 3,BaselineCharacteristic,xx (xxx),Cohort x ; Pazopanib xxx mg ; ,"Cutaneous disease, n (%)b",,7,5,3,No,1:No,2:yes,+,0.544
6191,3588608,Table 1,BaselineCharacteristic,Age means ± SD (years),,Group,None,0,1,1,No,1:No,2:yes,+,0.552
6191,3588608,Table 1,BaselineCharacteristic,x.xx ± x.xx,Years post diagnosis means ± SD ; ,A (n = xx),None,1,3,3,No,1:No,2:yes,+,0.66
6191,3588608,Table 1,BaselineCharacteristic,x.xx ± x.xx,Years post diagnosis means ± SD ; ,B (n = xx),None,2,3,3,No,1:No,2:yes,+,0.66
6191,3588608,Table 1,BaselineCharacteristic,xx.xx ± x.xx,Years post diagnosis means ± SD ; ,C (n = x),None,3,3,3,No,1:No,2:yes,+,0.61
6191,3588608,Table 1,BaselineCharacteristic,x.xx ± x.xx,Years post diagnosis means ± SD ; ,Entire group (n = xx),None,4,3,3,No,1:No,2:yes,+,0.6
6286,3599166,Table 1,BaselineCharacteristic,–,High (n = xx) ; POST ; ,Age (years),None,2,4,3,No,1:No,2:yes,+,0.55
6311,3600043,Table 1,BaselineCharacteristic,Manic n?=?xx,,,None,0,1,1,No,1:No,2:yes,+,0.515
6311,3600043,Table 1,BaselineCharacteristic,Hypomanic n?=?xx,,,None,0,2,1,No,1:No,2:yes,+,0.531
6311,3600043,Table 1,BaselineCharacteristic,Mixed n?=?xx,,,None,0,3,1,No,1:No,2:yes,+,0.571
6311,3600043,Table 1,BaselineCharacteristic,Depressive n?=?xx,,,None,0,4,1,No,1:No,2:yes,+,0.501
6311,3600043,Table 1,BaselineCharacteristic,,Manic n?=?xx ; ,Sociodemographic characteristics,None,1,1,43,No,1:No,2:yes,+,0.578
6311,3600043,Table 1,BaselineCharacteristic,,Hypomanic n?=?xx ; ,Sociodemographic characteristics,None,1,2,43,No,1:No,2:yes,+,0.598
6311,3600043,Table 1,BaselineCharacteristic,,Mixed n?=?xx ; ,Sociodemographic characteristics,None,1,3,43,No,1:No,2:yes,+,0.608
6311,3600043,Table 1,BaselineCharacteristic,,Depressive n?=?xx ; ,Sociodemographic characteristics,None,1,4,43,No,1:No,2:yes,+,0.558
6311,3600043,Table 1,BaselineCharacteristic,xx (xx.x),Manic n?=?xx ; ,"Sex, female (n,%)", Sociodemographic characteristics,2,1,3,No,1:No,2:yes,+,0.66
6311,3600043,Table 1,BaselineCharacteristic,xx (xx.x),Hypomanic n?=?xx ; ,"Sex, female (n,%)", Sociodemographic characteristics,2,2,3,No,1:No,2:yes,+,0.63
6311,3600043,Table 1,BaselineCharacteristic,xx (xx.x),Mixed n?=?xx ; ,"Sex, female (n,%)", Sociodemographic characteristics,2,3,3,No,1:No,2:yes,+,0.64
6311,3600043,Table 1,BaselineCharacteristic,xx (xx.x),Depressive n?=?xx ; ,"Sex, female (n,%)", Sociodemographic characteristics,2,4,3,No,1:No,2:yes,+,0.61
6311,3600043,Table 1,BaselineCharacteristic,xx (xx.x),Global N?=?xxx ; ,"Sex, female (n,%)", Sociodemographic characteristics,2,5,3,No,1:No,2:yes,+,0.69
6311,3600043,Table 1,BaselineCharacteristic,xx.x (x.x),Manic n?=?xx ; ,"BMI (mean, SD)", Sociodemographic characteristics,4,1,3,No,1:No,2:yes,+,0.76
6311,3600043,Table 1,BaselineCharacteristic,xx.x (x.x),Hypomanic n?=?xx ; ,"BMI (mean, SD)", Sociodemographic characteristics,4,2,3,No,1:No,2:yes,+,0.75
6311,3600043,Table 1,BaselineCharacteristic,xx.x (x.x),Mixed n?=?xx ; ,"BMI (mean, SD)", Sociodemographic characteristics,4,3,3,No,1:No,2:yes,+,0.79
6311,3600043,Table 1,BaselineCharacteristic,xx.x (x.x),Depressive n?=?xx ; ,"BMI (mean, SD)", Sociodemographic characteristics,4,4,3,No,1:No,2:yes,+,0.75
6311,3600043,Table 1,BaselineCharacteristic,xx.x (x.x),Global N?=?xxx ; ,"BMI (mean, SD)", Sociodemographic characteristics,4,5,3,No,1:No,2:yes,+,0.81
6311,3600043,Table 1,BaselineCharacteristic,xx (xx.x),Manic n?=?xx ; ,"Status, inpatient (n,%)", Sociodemographic characteristics,5,1,3,No,1:No,2:yes,+,0.574
6311,3600043,Table 1,BaselineCharacteristic,xx (xx.x),Hypomanic n?=?xx ; ,"Status, inpatient (n,%)", Sociodemographic characteristics,5,2,3,No,1:No,2:yes,+,0.544
6311,3600043,Table 1,BaselineCharacteristic,xx (xx.x),Mixed n?=?xx ; ,"Status, inpatient (n,%)", Sociodemographic characteristics,5,3,3,No,1:No,2:yes,+,0.564
6311,3600043,Table 1,BaselineCharacteristic,xx (xx.x),Depressive n?=?xx ; ,"Status, inpatient (n,%)", Sociodemographic characteristics,5,4,3,No,1:No,2:yes,+,0.544
6311,3600043,Table 1,BaselineCharacteristic,xx (xx.x),Global N?=?xxx ; ,"Status, inpatient (n,%)", Sociodemographic characteristics,5,5,3,No,1:No,2:yes,+,0.644
6311,3600043,Table 1,BaselineCharacteristic,xx.x (xx.x),Manic n?=?xx ; ,"Age at onset (mean, SD)",,10,1,3,No,1:No,2:yes,+,0.56
6311,3600043,Table 1,BaselineCharacteristic,xx.x (xx.x),Hypomanic n?=?xx ; ,"Age at onset (mean, SD)",,10,2,3,No,1:No,2:yes,+,0.55
6311,3600043,Table 1,BaselineCharacteristic,xx.x (xx.x),Mixed n?=?xx ; ,"Age at onset (mean, SD)",,10,3,3,No,1:No,2:yes,+,0.6
6311,3600043,Table 1,BaselineCharacteristic,xx.x (xx.x),Depressive n?=?xx ; ,"Age at onset (mean, SD)",,10,4,3,No,1:No,2:yes,+,0.53
6311,3600043,Table 1,BaselineCharacteristic,xx.x (xx.x),Global N?=?xxx ; ,"Age at onset (mean, SD)",,10,5,3,No,1:No,2:yes,+,0.55
6311,3600043,Table 1,BaselineCharacteristic,xx.x (xx.x),Manic n?=?xx ; ,"Duration of illness in years (mean, SD)",,11,1,3,No,1:No,2:yes,+,0.69
6311,3600043,Table 1,BaselineCharacteristic,xx.x (x.x),Hypomanic n?=?xx ; ,"Duration of illness in years (mean, SD)",,11,2,3,No,1:No,2:yes,+,0.7
6311,3600043,Table 1,BaselineCharacteristic,xx.x (xx.x),Mixed n?=?xx ; ,"Duration of illness in years (mean, SD)",,11,3,3,No,1:No,2:yes,+,0.72
6311,3600043,Table 1,BaselineCharacteristic,xx.x (xx.x),Depressive n?=?xx ; ,"Duration of illness in years (mean, SD)",,11,4,3,No,1:No,2:yes,+,0.66
6311,3600043,Table 1,BaselineCharacteristic,xx.x (xx.x),Global N?=?xxx ; ,"Duration of illness in years (mean, SD)",,11,5,3,No,1:No,2:yes,+,0.61
6311,3600043,Table 1,BaselineCharacteristic,x.x (x.x),Manic n?=?xx ; ,"Number of episodes lifetime (mean, SD)",,12,1,3,No,1:No,2:yes,+,0.58
6311,3600043,Table 1,BaselineCharacteristic,x.x (x.x),Hypomanic n?=?xx ; ,"Number of episodes lifetime (mean, SD)",,12,2,3,No,1:No,2:yes,+,0.57
6311,3600043,Table 1,BaselineCharacteristic,x.x (x.x),Mixed n?=?xx ; ,"Number of episodes lifetime (mean, SD)",,12,3,3,No,1:No,2:yes,+,0.65
6311,3600043,Table 1,BaselineCharacteristic,x.x (x.x),Depressive n?=?xx ; ,"Number of episodes lifetime (mean, SD)",,12,4,3,No,1:No,2:yes,+,0.54
6311,3600043,Table 1,BaselineCharacteristic,x.x (x.x),Manic n?=?xx ; ,"Duration of current episode in months (mean, SD)",,13,1,3,No,1:No,2:yes,+,0.57
6311,3600043,Table 1,BaselineCharacteristic,x.x (x.x),Hypomanic n?=?xx ; ,"Duration of current episode in months (mean, SD)",,13,2,3,No,1:No,2:yes,+,0.57
6311,3600043,Table 1,BaselineCharacteristic,x.x (x.x),Mixed n?=?xx ; ,"Duration of current episode in months (mean, SD)",,13,3,3,No,1:No,2:yes,+,0.65
6311,3600043,Table 1,BaselineCharacteristic,x.x (x.x),Depressive n?=?xx ; ,"Duration of current episode in months (mean, SD)",,13,4,3,No,1:No,2:yes,+,0.55
6311,3600043,Table 1,BaselineCharacteristic,xxx.x (xx.x),Manic n?=?xx ; ,"MAThyS total score (mean, SD)",,21,1,3,No,1:No,2:yes,+,0.55
6311,3600043,Table 1,BaselineCharacteristic,xxx.x (xx.x),Hypomanic n?=?xx ; ,"MAThyS total score (mean, SD)",,21,2,3,No,1:No,2:yes,+,0.55
6311,3600043,Table 1,BaselineCharacteristic,xxx.x (xx.x),Mixed n?=?xx ; ,"MAThyS total score (mean, SD)",,21,3,3,No,1:No,2:yes,+,0.59
6311,3600043,Table 1,BaselineCharacteristic,xxx.xx (xx.x),Global N?=?xxx ; ,"MAThyS total score (mean, SD)",,21,5,3,No,1:No,2:yes,+,0.54
6311,3600043,Table 1,BaselineCharacteristic,xx.x (x.x),Mixed n?=?xx ; ,"HAMD-xx total score (mean, SD)",,22,3,3,No,1:No,2:yes,+,0.545
6311,3600043,Table 1,BaselineCharacteristic,xx.x (x.x)-,Global N?=?xxx ; ,"HAMD-xx total score (mean, SD)",,22,5,3,No,1:No,2:yes,+,0.52
6311,3600043,Table 1,BaselineCharacteristic,xx.x (x.x),Mixed n?=?xx ; ,"YMRS total score (mean, SD)",,23,3,3,No,1:No,2:yes,+,0.545
6311,3600043,Table 1,BaselineCharacteristic,xx.x (xx.x)-,Global N?=?xxx ; ,"YMRS total score (mean, SD)",,23,5,3,No,1:No,2:yes,+,0.52
6311,3600043,Table 1,BaselineCharacteristic,xx.x (x.x),Mixed n?=?xx ; ,"HAMA total score (mean, SD)",,24,3,3,No,1:No,2:yes,+,0.545
6311,3600043,Table 1,BaselineCharacteristic,xx.x (x.x),Global N?=?xxx ; ,"HAMA total score (mean, SD)",,24,5,3,No,1:No,2:yes,+,0.54
6382,394324,Table 1,BaselineCharacteristic,xx ± x,mean time to relapse (in weeks) ; ,L. GG,None,1,7,3,No,1:No,2:yes,+,0.58
6382,394324,Table 1,BaselineCharacteristic,xx ± x.x**,mean time to relapse (in weeks) ; ,Placebo,None,2,7,3,No,1:No,2:yes,+,0.58
6540,60660,Table 1,BaselineCharacteristic,Mean age years,,Volunteers,None,0,2,1,No,1:No,2:yes,+,0.533
6540,60660,Table 1,BaselineCharacteristic,xx.x ± x.x (x.x–xx)*,Tx ; ,UV exposed,None,1,3,3,No,1:No,2:yes,+,0.514
6540,60660,Table 1,BaselineCharacteristic,xx.x ± x.x (x.x–xx)*,Tx ; ,Non-exposed,None,2,3,3,No,1:No,2:yes,+,0.514
25,1131894,Table 3,BaselineCharacteristic,xx.x (xx–xx years),,Mean Age,,1,1,3,yes,2:yes,2:yes,,0.74
164,1386704,Table 1,BaselineCharacteristic,xx–xx (xx ± x.x),,"Age, range, yr (mean ± SD)",None,1,1,3,yes,2:yes,2:yes,,0.82
215,1488867,Table 1,BaselineCharacteristic,xx,n(%) ; ,?Median, Age (years),2,1,3,yes,2:yes,2:yes,,0.71
215,1488867,Table 1,BaselineCharacteristic,xx–xx,n(%) ; ,?Range, Age (years),3,1,3,yes,2:yes,2:yes,,0.59
309,1586008,Table 1,BaselineCharacteristic,xx.x ± x.x,N° (%) ; ,Mean age (years),None,2,1,3,yes,2:yes,2:yes,,0.89
449,1885552,Table 1,BaselineCharacteristic,"xx,x ± x,x",Age (years) ; ,Stretching (xx),None,1,1,3,yes,2:yes,2:yes,,0.67
449,1885552,Table 1,BaselineCharacteristic,"xx,x ± x,x",Age (years) ; ,Strength (xx),None,2,1,3,yes,2:yes,2:yes,,0.63
449,1885552,Table 1,BaselineCharacteristic,"xx,x ± x,x",Age (years) ; ,Vibration (xx),None,3,1,3,yes,2:yes,2:yes,,0.65
1118,2204057,Table 1,BaselineCharacteristic,xx.x (x.x),Mean AGE (SD) ; ,Group x,None,1,2,3,yes,2:yes,2:yes,,0.574
1118,2204057,Table 1,BaselineCharacteristic,xx.x (x.x),Mean AGE (SD) ; ,Group x,None,2,2,3,yes,2:yes,2:yes,,0.554
1118,2204057,Table 1,BaselineCharacteristic,xx (x.x),Mean AGE (SD) ; ,Controls,None,3,2,3,yes,2:yes,2:yes,,0.534
1233,2259321,Table 1,BaselineCharacteristic,xx (xx),Celecoxib Dose ;  ; xxx mg twice daily ;  ; NAF (plasma) ; ,?Median, Age (years),7,1,3,yes,2:yes,2:yes,,0.765
1233,2259321,Table 1,BaselineCharacteristic,xx.x (xx.x),Celecoxib Dose ;  ; xxx mg twice daily ;  ; NAF(plasma) ; ,?Median, Age (years),7,2,3,yes,2:yes,2:yes,,0.715
1233,2259321,Table 1,BaselineCharacteristic,xx–xx (xx–xx),Celecoxib Dose ;  ; xxx mg twice daily ;  ; NAF (plasma) ; ,?Range, Age (years),8,1,3,yes,2:yes,2:yes,,0.755
1233,2259321,Table 1,BaselineCharacteristic,xx–xx (xx–xx),Celecoxib Dose ;  ; xxx mg twice daily ;  ; NAF(plasma) ; ,?Range, Age (years),8,2,3,yes,2:yes,2:yes,,0.755
1273,2359721,Table 1,BaselineCharacteristic,xx,,"Median age, years",None,2,1,1,yes,2:yes,2:yes,,0.718
1273,2359721,Table 1,BaselineCharacteristic,xx–xx,,"Range, years",None,3,1,1,yes,2:yes,2:yes,,0.655
1283,2359964,Table 1,BaselineCharacteristic,xx (xx–xx),,Median age (range),None,0,1,1,yes,2:yes,2:yes,,0.776
1287,2360042,Table 1,BaselineCharacteristic,xx.x,No ; ,?Median," Age, years",4,1,3,yes,2:yes,2:yes,,0.55
1287,2360042,Table 1,BaselineCharacteristic,xx–xx,No ; ,?Range," Age, years",5,1,3,yes,2:yes,2:yes,,0.63
1376,2360764,Table 1,BaselineCharacteristic,Median xx (xx–xx),No. of patients ; xx ; ,"Age, years (range)",,2,1,3,yes,2:yes,2:yes,,0.84
1410,2361304,Table 1,BaselineCharacteristic,xx years (xx–xx),Number ; ,Median age (range),,1,1,3,yes,2:yes,2:yes,,0.96
1423,2361378,Table 1,BaselineCharacteristic,xx,n (%) ; ,?Median, Age (years),3,1,3,yes,2:yes,2:yes,,0.69
1423,2361378,Table 1,BaselineCharacteristic,xx–xx,n (%) ; ,?Range, Age (years),4,1,3,yes,2:yes,2:yes,,0.6
1446,2361514,Table 2,BaselineCharacteristic,xx,n ; ,?Median (years), Age,6,1,3,yes,2:yes,2:yes,,0.62
1446,2361514,Table 2,BaselineCharacteristic,xx–xx,n ; ,?Range (years), Age,7,1,3,yes,2:yes,2:yes,,0.57
1504,2361889,Table 1,BaselineCharacteristic,xx.x (xx.x–xx.x),,Median (range), Age (years),2,1,3,yes,2:yes,2:yes,,0.75
2165,2441954,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Median, Age (years),7,1,3,yes,2:yes,2:yes,,0.55
2165,2441954,Table 1,BaselineCharacteristic,xx–xx,No. of patients ; ,?Range, Age (years),8,1,3,yes,2:yes,2:yes,,0.61
2246,2527821,Table 1,BaselineCharacteristic,xx (xx–xx),na (%) ; ,"Median age (range), years",,2,1,3,yes,2:yes,2:yes,,0.96
2478,2656521,Table 1,BaselineCharacteristic,xx.x ± xx.x,Steatohepatitis (n xx) ; ,Age(years),None,1,1,3,yes,2:yes,2:yes,,0.72
2478,2656521,Table 1,BaselineCharacteristic,xx.x ± x.x,Diffuse Steatosis(n xx) ; ,Age(years),None,1,2,3,yes,2:yes,2:yes,,0.63
2478,2656521,Table 1,BaselineCharacteristic,xx.x ± x.x,Focal Fatty Liver (n x) ; ,Age(years),None,1,3,3,yes,2:yes,2:yes,,0.69
2478,2656521,Table 1,BaselineCharacteristic,xx.x ± xx.x,Controls (n xx) ; ,Age(years),None,1,4,3,yes,2:yes,2:yes,,0.63
2656,270679,Table 1,BaselineCharacteristic,xx (xx–xx),,Age (years),,0,1,3,yes,2:yes,2:yes,,0.774
2688,2718192,Table 1,BaselineCharacteristic,xx.x (xx–xx),x.xxx mg dose ; ,"Age (mean (range), years)",,1,1,3,yes,2:yes,2:yes,,0.785
2688,2718192,Table 1,BaselineCharacteristic,xx.x (xx.x–xx.x),x.xxxx mg dose ; ,"Age (mean (range), years)",,1,2,3,yes,2:yes,2:yes,,0.73
2737,2734077,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Healthy Participants (n = xx; xx men) ; Healthy Participants (n = xx; xx men) ; ,Age (Years),,3,1,3,yes,2:yes,2:yes,,0.684
2737,2734077,Table 1,BaselineCharacteristic,xx.xx (x.xx),"Patients ; CBT+TAU Group (n = xx, xx men) ; ",Age (Years),,3,2,3,yes,2:yes,2:yes,,0.529
2737,2734077,Table 1,BaselineCharacteristic,xx.xx (xx.xx),"Patients ; TAU-Alone Group (n = xx, xx men) ; ",Age (Years),,3,3,3,yes,2:yes,2:yes,,0.574
2811,2758901,Table 1,BaselineCharacteristic,xx.xx,Gefitinib ; No ;  ; xxx ;  ; ,?Avg. age, ,13,1,,yes,2:yes,2:yes,,0.606
2811,2758901,Table 1,BaselineCharacteristic,xx.xx,Erlotinib ; No ;  ; xx ;  ; ,?Avg. age, ,13,3,,yes,2:yes,2:yes,,0.669
2834,2765955,Table 1,BaselineCharacteristic,xx.x (xx.x),Males ; (n = xx) ; ,None,None,2,1,,yes,2:yes,2:yes,,0.709
2834,2765955,Table 1,BaselineCharacteristic,xx.x (x.x),Females ; (n = xx) ; ,None,None,2,2,,yes,2:yes,2:yes,,0.711
2864,2774660,Table 1,BaselineCharacteristic,x.x,Phase x - placebo ; ,Age (years),None,4,3,3,yes,2:yes,2:yes,,0.67
3023,2816665,Table 1,BaselineCharacteristic,xx (xx–xx),All patients ; ,Median age (range),None,2,1,3,yes,2:yes,2:yes,,0.87
3023,2816665,Table 1,BaselineCharacteristic,xx (xx–xx),Subgroup A ; ,Median age (range),None,2,2,3,yes,2:yes,2:yes,,0.96
3023,2816665,Table 1,BaselineCharacteristic,xx (xx–xx),Subgroup B ; ,Median age (range),None,2,3,3,yes,2:yes,2:yes,,0.96
3023,2816665,Table 1,BaselineCharacteristic,xx (xx–xx),Subgroup C ; ,Median age (range),None,2,4,3,yes,2:yes,2:yes,,0.95
3097,2835652,Table 1,BaselineCharacteristic,xx (xx-xx),Total ; xx ; ,"Median age (range), years",,3,1,3,yes,2:yes,2:yes,,0.93
3097,2835652,Table 1,BaselineCharacteristic,xx,x.x ?g ; xx ; ,"Median age (range), years",,3,2,3,yes,2:yes,2:yes,,0.88
3097,2835652,Table 1,BaselineCharacteristic,xx,xx ?g ; xx ; ,"Median age (range), years",,3,3,3,yes,2:yes,2:yes,,0.89
3097,2835652,Table 1,BaselineCharacteristic,xx,xxx ?g ; x ; ,"Median age (range), years",,3,4,3,yes,2:yes,2:yes,,0.88
3105,2837631,Table 1,BaselineCharacteristic,median (range) xx (xx-xx),,Age (years),,0,1,3,yes,2:yes,2:yes,,0.95
3162,2855860,Table 1,BaselineCharacteristic,xx,Sunitinib (N = xxx) ; ,," Age, years",2,1,3,yes,2:yes,2:yes,,0.694
3162,2855860,Table 1,BaselineCharacteristic,xx,Capecitabine (N = xxx) ; ,," Age, years",2,2,3,yes,2:yes,2:yes,,0.604
3162,2855860,Table 1,BaselineCharacteristic,xx–xx,Sunitinib (N = xxx) ; ,," Age, years",3,1,3,yes,2:yes,2:yes,,0.67
3162,2855860,Table 1,BaselineCharacteristic,xx–xx,Capecitabine (N = xxx) ; ,," Age, years",3,2,3,yes,2:yes,2:yes,,0.62
3275,2894785,Table 1,BaselineCharacteristic,xx.x (± x.x),Intervention Groupn = xx ; ,"Age, mean ± SD (years)",,1,1,,yes,2:yes,2:yes,,0.828
3275,2894785,Table 1,BaselineCharacteristic,xx.x (± xx.x),ControlGroupn = xxx ; ,"Age, mean ± SD (years)",,1,2,,yes,2:yes,2:yes,,0.879
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Control(mean) ; ,Child,,1,2,43,yes,2:yes,2:yes,,0.711
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Intervention(mean) ; ,Child,,1,3,43,yes,2:yes,2:yes,,0.766
3291,2902493,Table 1,BaselineCharacteristic,xx [xx-xx],xx ; ,None,None,1,2,,yes,2:yes,2:yes,,0.613
3308,2905428,Table 1,BaselineCharacteristic,xx-xx,No (%) ; ,, Age,2,2,3,yes,2:yes,2:yes,,0.57
3324,2910694,Table 1,BaselineCharacteristic,xx (range xx-xx),Number ; ,None,None,1,1,,yes,2:yes,2:yes,,0.761
3561,2990606,Table 1,BaselineCharacteristic,xx (xx–xx),,"Age in years, median (range)",,4,1,3,yes,2:yes,2:yes,,0.94
3652,3015370,Table 1.,BaselineCharacteristic,xx.x (+/? x.x),Estrogen ; ,Age (years),None,1,1,3,yes,2:yes,2:yes,,0.66
3652,3015370,Table 1.,BaselineCharacteristic,xx.x (+/? x.x),Placebo ; ,Age (years),None,1,2,3,yes,2:yes,2:yes,,0.65
3974,3086082,Table 1,BaselineCharacteristic,xx, ; ,?Median," Age, in years, median (range)",2,1,3,yes,2:yes,2:yes,,0.94
3974,3086082,Table 1,BaselineCharacteristic,"xx, xx", ; ,"?Minimum, maximum"," Age, in years, median (range)",3,1,3,yes,2:yes,2:yes,,0.94
4011,3097354,Table 1,BaselineCharacteristic,xx (xx–xx),"Intervention group, N?=?xx ; ","Age (median, range)",None,1,2,3,yes,2:yes,2:yes,,0.89
4011,3097354,Table 1,BaselineCharacteristic,xx (xx–xx),"Control group, N?=?xx ; ","Age (median, range)",None,1,4,3,yes,2:yes,2:yes,,0.83
4024,3102212,Table 2,BaselineCharacteristic,xx (xx–xx),No. patients (n = xx) ; ,None,None,2,1,3,yes,2:yes,2:yes,,0.61
4113,3128267,Table 1,BaselineCharacteristic,xx,Patient I ; ,Age (years),None,1,1,3,yes,2:yes,2:yes,,0.684
4113,3128267,Table 1,BaselineCharacteristic,xx,Patient II ; ,Age (years),None,1,2,3,yes,2:yes,2:yes,,0.66
4185,3152943,Table 1,BaselineCharacteristic,xx.xx (xx.xxx),"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; ",None,None,3,1,,yes,2:yes,2:yes,,0.841
4185,3152943,Table 1,BaselineCharacteristic,xx.xx (xx.xxx),"Canakinumab xxx mg SC qxwk, n = xx ; xx (xx.x) ;  ; ",None,None,3,2,,yes,2:yes,2:yes,,0.853
4185,3152943,Table 1,BaselineCharacteristic,xx.xx (xx.xxx),"Canakinumab xxx mg SC qxwk + xxx mg IV loading dose, n = xx ; xx (xx.x) ;  ; ",None,None,3,3,,yes,2:yes,2:yes,,0.828
4185,3152943,Table 1,BaselineCharacteristic,xx.xx (xx.xxx),"Placebo, n = xx ; xx (xx.x) ;  ; ",None,None,3,4,,yes,2:yes,2:yes,,0.532
4246,3165084,Table 1,BaselineCharacteristic,xx,Number(percent) ; xx(xxx) ;  ; ,Age in years (median),,3,1,,yes,2:yes,2:yes,,0.78
4305,3176247,Table 1,BaselineCharacteristic,xx,First-line ;  ; No ; ,"Age, median",,5,2,3,yes,2:yes,2:yes,,0.62
4305,3176247,Table 1,BaselineCharacteristic,(xx-xx),First-line ;  ; (%) ; ,"Age, median",,5,3,3,yes,2:yes,2:yes,,0.63
4305,3176247,Table 1,BaselineCharacteristic,xx,Second-line ;  ; No ; ,"Age, median",,5,4,3,yes,2:yes,2:yes,,0.68
4305,3176247,Table 1,BaselineCharacteristic,(xx-xx),Second-line ;  ; (%) ; ,"Age, median",,5,5,3,yes,2:yes,2:yes,,0.72
4305,3176247,Table 1,BaselineCharacteristic,xx.x(xx~xx),All patients ;  ;  ; ,"Age, median",,5,6,3,yes,2:yes,2:yes,,0.7
4305,3176247,Table 1,BaselineCharacteristic,xx.x(xx~xx),(%) ;  ;  ; ,"Age, median",,5,7,3,yes,2:yes,2:yes,,0.77
4375,3195264,Table 1,BaselineCharacteristic,x.x ±x.x (x.x–xx.x),Iobitridol xxx (n?=?xx) ; ,, Baseline characteristics,2,1,3,yes,2:yes,2:yes,,0.8
4375,3195264,Table 1,BaselineCharacteristic,x.x ±x.x (x.x–xx.x),Iodixanol xxx (n?=?xx) ; ,, Baseline characteristics,2,2,3,yes,2:yes,2:yes,,0.77
4375,3195264,Table 1,BaselineCharacteristic,x.x ±x.x (x.x–xx.x),Total (n?=?xxx) ; ,, Baseline characteristics,2,3,3,yes,2:yes,2:yes,,0.54
4428,3208500,Table 1,BaselineCharacteristic,xx,Number of patients ; ,?Mean, Age (years),8,1,3,yes,2:yes,2:yes,,0.52
4428,3208500,Table 1,BaselineCharacteristic,xx–xx,Number of patients ; ,?Range, Age (years),9,1,3,yes,2:yes,2:yes,,0.62
4713,3281202,Table 3,BaselineCharacteristic,xx.x?±?xx.x,ISSAAC ; N?=?xxx ; ,Male," Age (years), mean?±?SD",3,1,3,yes,2:yes,2:yes,,0.87
4713,3281202,Table 3,BaselineCharacteristic,xx.x?±?xx.x.,INSECT ; N?=?xxx ; ,Male," Age (years), mean?±?SD",3,2,3,yes,2:yes,2:yes,,0.86
4713,3281202,Table 3,BaselineCharacteristic,xx.x?±?xx.x,ISSAAC ; N?=?xxx ; ,Female," Age (years), mean?±?SD",4,1,3,yes,2:yes,2:yes,,0.84
4713,3281202,Table 3,BaselineCharacteristic,xx.x?±?xx.x,INSECT ; N?=?xxx ; ,Female," Age (years), mean?±?SD",4,2,3,yes,2:yes,2:yes,,0.83
4733,3285050,Table 1,BaselineCharacteristic,xx (xx-xx),,Age (years),None,0,2,3,yes,2:yes,2:yes,,0.724
4744,3291838,Table 1,BaselineCharacteristic,xx (xx–xx),Value ; ,"Age, years",,5,1,3,yes,2:yes,2:yes,,0.734
4908,3338391,Table 1,BaselineCharacteristic,xx.x,Study sites ;  ; High transmission ;  ; Ampasimanjeva ; xxx ;  ; ,None,None,7,1,,yes,2:yes,2:yes,,0.8
4908,3338391,Table 1,BaselineCharacteristic,xx.x,Study sites ;  ; High transmission ;  ; Vohimasy ; xxx ;  ; ,None,None,7,2,,yes,2:yes,2:yes,,0.759
4908,3338391,Table 1,BaselineCharacteristic,xx.x,Study sites ;  ; Low transmission ;  ; Ampasimpotsy ; xxx ;  ; ,None,None,7,3,,yes,2:yes,2:yes,,0.759
4908,3338391,Table 1,BaselineCharacteristic,xx.x,Study sites ;  ; Low transmission ;  ; Andasibe ; xxx ;  ; ,None,None,7,4,,yes,2:yes,2:yes,,0.71
4958,3349177,Table 1,BaselineCharacteristic,xx (xx–xx),No. of patients ; ,"Age, years (median, range)",,2,1,3,yes,2:yes,2:yes,,0.92
5055,3368715,Table 1,BaselineCharacteristic,xx.x ± x.xx,Febuxostat xx mgN = xxx ; ,Mean ± SD,,19,1,3,yes,2:yes,2:yes,,0.8
5055,3368715,Table 1,BaselineCharacteristic,xx.x ± x.xx,Febuxostat xx mgN = xxx ; ,Mean ± SD,,19,2,3,yes,2:yes,2:yes,,0.77
5055,3368715,Table 1,BaselineCharacteristic,xx.x ± x.xx,Allopurinol xxx/xxx mgN = xxx ; ,Mean ± SD,,19,3,3,yes,2:yes,2:yes,,0.775
5055,3368715,Table 1,BaselineCharacteristic,xx-xx,Febuxostat xx mgN = xxx ; ,Range,,20,1,3,yes,2:yes,2:yes,,0.85
5055,3368715,Table 1,BaselineCharacteristic,xx-xx,Febuxostat xx mgN = xxx ; ,Range,,20,2,3,yes,2:yes,2:yes,,0.85
5055,3368715,Table 1,BaselineCharacteristic,xx-xx,Allopurinol xxx/xxx mgN = xxx ; ,Range,,20,3,3,yes,2:yes,2:yes,,0.735
5162,3397213,Table 1,BaselineCharacteristic,xx.x,Lapatinib plus bevacizumab ; (N = xx) ; ,"Median age, years",None,2,1,3,yes,2:yes,2:yes,,0.9
5267,3407730,Table 1,BaselineCharacteristic,xx?±?xx,Result ; ,"Age, years, mean",,1,1,3,yes,2:yes,2:yes,,0.84
5267,3407730,Table 2,BaselineCharacteristic,xx?±?xx,Result ; ,"Age, years, mean",,1,1,3,yes,2:yes,2:yes,,0.84
5330,3414800,Table 1,BaselineCharacteristic,xx.x±xx.x,OSA ; snorers ; AHI<x n=xx ; ,Age,None,3,1,3,yes,2:yes,2:yes,,0.65
5330,3414800,Table 1,BaselineCharacteristic,xx.x±xx.x, ; mild/moderate ; AHI x – xx n=xx ; ,Age,None,3,2,3,yes,2:yes,2:yes,,0.74
5330,3414800,Table 1,BaselineCharacteristic,xx.x±x.x, ; severe ; AHI?xx n=xx ; ,Age,None,3,3,3,yes,2:yes,2:yes,,0.59
5383,3427446,Table 1,BaselineCharacteristic,xx.x?±?xx.x,Values (N?=?xx) ; ,Age (mean ± SD),None,2,1,3,yes,2:yes,2:yes,,0.86
5383,3427446,Table 2,BaselineCharacteristic,xx.x?±?x.x,Group x (N?=?xx) ; ,Age (mean ± SD),,2,1,3,yes,2:yes,2:yes,,0.85
5383,3427446,Table 2,BaselineCharacteristic,xx.x?±?xx.x,Group x (N?=?xx) ; ,Age (mean ± SD),,2,2,3,yes,2:yes,2:yes,,0.83
5561,3465101,Table 1.,BaselineCharacteristic,xx (xx–xx),Efavirenz arm (n?=?xx) ; ,"Age (years), median (IQR)",None,2,1,3,yes,2:yes,2:yes,,0.91
5561,3465101,Table 1.,BaselineCharacteristic,xx (xx–xx),Nevirapine arm (n?=?xx) ; ,"Age (years), median (IQR)",None,2,2,3,yes,2:yes,2:yes,,0.91
5569,3466131,Table 1,BaselineCharacteristic,xx (xx–xx),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,Median (range), Age,4,1,3,yes,2:yes,2:yes,,0.754
5569,3466131,Table 1,BaselineCharacteristic,xx (xx–xx),Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,Median (range), Age,4,2,3,yes,2:yes,2:yes,,0.774
5578,3468079,Table 1.,BaselineCharacteristic,xx.x (x.x),"Cohort x (xxx mg of posaconazole), n?=?xx ; ",?mean (SD)," Age, years",8,1,3,yes,2:yes,2:yes,,0.82
5578,3468079,Table 1.,BaselineCharacteristic,xx.x (x.x),"Cohort x (xxx mg of posaconazole), n?=?x ; ",?mean (SD)," Age, years",8,2,3,yes,2:yes,2:yes,,0.83
5578,3468079,Table 1.,BaselineCharacteristic,xx.x (x.x),"Placebo, n?=?x ; ",?mean (SD)," Age, years",8,3,3,yes,2:yes,2:yes,,0.77
5578,3468079,Table 1.,BaselineCharacteristic,xx.x (x.x),"All subjects, n?=?xx ; ",?mean (SD)," Age, years",8,4,3,yes,2:yes,2:yes,,0.78
5578,3468079,Table 1.,BaselineCharacteristic,xx.x (xx–xx),"Cohort x (xxx mg of posaconazole), n?=?xx ; ",?median (range)," Age, years",9,1,3,yes,2:yes,2:yes,,0.82
5578,3468079,Table 1.,BaselineCharacteristic,xx.x (xx–xx),"Cohort x (xxx mg of posaconazole), n?=?x ; ",?median (range)," Age, years",9,2,3,yes,2:yes,2:yes,,0.84
5578,3468079,Table 1.,BaselineCharacteristic,xx.x (xx–xx),"Placebo, n?=?x ; ",?median (range)," Age, years",9,3,3,yes,2:yes,2:yes,,0.83
5578,3468079,Table 1.,BaselineCharacteristic,xx.x (xx–xx),"All subjects, n?=?xx ; ",?median (range)," Age, years",9,4,3,yes,2:yes,2:yes,,0.845
5636,3483202,Table 1,BaselineCharacteristic,"xx.x (xx,x)","Diabetes mellitus, n?=?xx ; ",Age years,,1,1,3,yes,2:yes,2:yes,,0.614
5636,3483202,Table 1,BaselineCharacteristic,xx.x (xx.x),"No diabetes mellitus, n?=?xxx ; ",Age years,,1,2,3,yes,2:yes,2:yes,,0.694
5637,3483844,Table 1.,BaselineCharacteristic,xx,Value ; ,?Mean, Age (years),5,1,3,yes,2:yes,2:yes,,0.574
5637,3483844,Table 1.,BaselineCharacteristic,xx–xx,Value ; ,?Range, Age (years),6,1,3,yes,2:yes,2:yes,,0.63
5696,3493663,Table 1,BaselineCharacteristic,xx.x (xx.x–xx.x),ITT xx (xxx.x %) ; ,Median age/years (range), Gender,4,1,3,yes,2:yes,2:yes,,0.77
5696,3493663,Table 1,BaselineCharacteristic,xx.x (xx.x–xx.x),PP xx (xxx.x %) ; ,Median age/years (range), Gender,4,2,3,yes,2:yes,2:yes,,0.74
5758,3502482,Table 1,BaselineCharacteristic,xx (xx–xx),xx Gy step (n?=?xx) ; ,Median age (years)(min-max),,1,1,3,yes,2:yes,2:yes,,0.904
5758,3502482,Table 1,BaselineCharacteristic,xx (xx–xx),xx Gy step (n?=?xx) ; ,Median age (years)(min-max),,1,2,3,yes,2:yes,2:yes,,0.894
5842,3519573,Table 1,BaselineCharacteristic,xx.x (x.x),Total (N?=?xxx) ; ,"Age (years), mean (SD)",None,1,1,3,yes,2:yes,2:yes,,0.86
5937,3539065,Table 3,BaselineCharacteristic,xx (x.x),"Cohort x ; Lapatinib x,xxx mg + placebo ; ","Mean age, years (SD)",,3,1,3,yes,2:yes,2:yes,,0.88
5937,3539065,Table 3,BaselineCharacteristic,xx (xx.x),"Cohort x ; Lapatinib x,xxx mg + pazopanib xxx mg ; ","Mean age, years (SD)",,3,2,3,yes,2:yes,2:yes,,0.84
5937,3539065,Table 3,BaselineCharacteristic,xx (xx.x),"Cohort x ; Lapatinib x,xxx mg + placebo ; ","Mean age, years (SD)",,3,3,3,yes,2:yes,2:yes,,0.84
5937,3539065,Table 3,BaselineCharacteristic,xx (xx.x),"Cohort x ; Lapatinib x,xxx mg + pazopanib xxx mg ; ","Mean age, years (SD)",,3,4,3,yes,2:yes,2:yes,,0.8
5937,3539065,Table 3,BaselineCharacteristic,xx (xx.x),Cohort x ; Pazopanib xxx mg ; ,"Mean age, years (SD)",,3,5,3,yes,2:yes,2:yes,,0.77
6034,3553405,Table 1,BaselineCharacteristic,xx.x (xx.x–xx.x),Cilengitide xxx mg/mxn?=?xx ; ,"Mean age (range), yrs",,2,1,3,yes,2:yes,2:yes,,0.914
6034,3553405,Table 1,BaselineCharacteristic,xx.x (xx.x–xx.x),Cilengitide xxx mg/mxn?=?xx ; ,"Mean age (range), yrs",,2,2,3,yes,2:yes,2:yes,,0.904
6034,3553405,Table 1,BaselineCharacteristic,xx.x (xx.x–xx.x),Cilengitide xxx mg/mxn?=?xx ; ,"Mean age (range), yrs",,2,3,3,yes,2:yes,2:yes,,0.904
6034,3553405,Table 1,BaselineCharacteristic,xx.x (xx.x–xx.x),Docetaxel xx mg/mxn?=?xx ; ,"Mean age (range), yrs",,2,4,3,yes,2:yes,2:yes,,0.844
6034,3553405,Table 1,BaselineCharacteristic,xx.x (xx.x–xx.x),Total n?=?xxx ; ,"Mean age (range), yrs",,2,5,3,yes,2:yes,2:yes,,0.89
6191,3588608,Table 1,BaselineCharacteristic,xx.xx ± xx.xx,Age means ± SD (years) ; ,A (n = xx),None,1,1,3,yes,2:yes,2:yes,,0.84
6191,3588608,Table 1,BaselineCharacteristic,xx.xx ± xx.xx,Age means ± SD (years) ; ,B (n = xx),None,2,1,3,yes,2:yes,2:yes,,0.83
6191,3588608,Table 1,BaselineCharacteristic,xx.xx ± xx.xx,Age means ± SD (years) ; ,C (n = x),None,3,1,3,yes,2:yes,2:yes,,0.84
6191,3588608,Table 1,BaselineCharacteristic,xx.xx ± xx.xx,Age means ± SD (years) ; ,Entire group (n = xx),None,4,1,3,yes,2:yes,2:yes,,0.8
6286,3599166,Table 1,BaselineCharacteristic,xx.x ± x.x,Moderate (n = x) ; PRE ; ,Age (years),None,2,1,3,yes,2:yes,2:yes,,0.64
6286,3599166,Table 1,BaselineCharacteristic,xx.x ± x.x,High (n = xx) ; PRE ; ,Age (years),None,2,3,3,yes,2:yes,2:yes,,0.71
6311,3600043,Table 1,BaselineCharacteristic,xx.x (xx.x),Manic n?=?xx ; ,"Age (mean, SD)", Sociodemographic characteristics,3,1,3,yes,2:yes,2:yes,,0.86
6311,3600043,Table 1,BaselineCharacteristic,xx.x (xx.x),Hypomanic n?=?xx ; ,"Age (mean, SD)", Sociodemographic characteristics,3,2,3,yes,2:yes,2:yes,,0.85
6311,3600043,Table 1,BaselineCharacteristic,xx.x (xx.x),Mixed n?=?xx ; ,"Age (mean, SD)", Sociodemographic characteristics,3,3,3,yes,2:yes,2:yes,,0.89
6311,3600043,Table 1,BaselineCharacteristic,xx.x (xx.x),Depressive n?=?xx ; ,"Age (mean, SD)", Sociodemographic characteristics,3,4,3,yes,2:yes,2:yes,,0.86
6311,3600043,Table 1,BaselineCharacteristic,xx.x (xx.x),Global N?=?xxx ; ,"Age (mean, SD)", Sociodemographic characteristics,3,5,3,yes,2:yes,2:yes,,0.9
6540,60660,Table 1,BaselineCharacteristic,xx.x (xx–xx)*,Mean age years ; ,UV exposed,None,1,2,3,yes,2:yes,2:yes,,0.83
6540,60660,Table 1,BaselineCharacteristic,xx.x (xx–xx)*,Mean age years ; ,Non-exposed,None,2,2,3,yes,2:yes,2:yes,,0.82
19,1090597,Table 1,BaselineCharacteristic,,,None,None,0,0,,No,1:No,1:No,,0.907
19,1090597,Table 1,BaselineCharacteristic,n (%),,None,None,0,1,,No,1:No,1:No,,0.687
19,1090597,Table 1,BaselineCharacteristic,Gender, ; ,None,None,1,0,,No,1:No,1:No,,0.905
19,1090597,Table 1,BaselineCharacteristic,,n (%) ; ,None,None,1,1,,No,1:No,1:No,,0.667
19,1090597,Table 1,BaselineCharacteristic,Male, ; ,Male,,2,0,,No,1:No,1:No,,0.922
19,1090597,Table 1,BaselineCharacteristic,Female, ; ,Female,,3,0,,No,1:No,1:No,,0.932
19,1090597,Table 1,BaselineCharacteristic,, ; ,None,None,4,0,,No,1:No,1:No,,0.927
19,1090597,Table 1,BaselineCharacteristic,,n (%) ; ,None,None,4,1,,No,1:No,1:No,,0.693
19,1090597,Table 1,BaselineCharacteristic,Schizophrenia subtype, ; ,None,None,5,0,,No,1:No,1:No,,0.927
19,1090597,Table 1,BaselineCharacteristic,,n (%) ; ,None,None,5,1,,No,1:No,1:No,,0.694
19,1090597,Table 1,BaselineCharacteristic,Paranoid, ; ,Paranoid,,6,0,,No,1:No,1:No,,0.964
19,1090597,Table 1,BaselineCharacteristic,xx (xx),n (%) ; ,Paranoid,,6,1,,No,1:No,1:No,,0.596
19,1090597,Table 1,BaselineCharacteristic,Undifferentiated, ; ,Undifferentiated,,7,0,,No,1:No,1:No,,0.973
19,1090597,Table 1,BaselineCharacteristic,xx (xx.x),n (%) ; ,Undifferentiated,,7,1,,No,1:No,1:No,,0.562
19,1090597,Table 1,BaselineCharacteristic,Disorganized, ; ,Disorganized,,8,0,,No,1:No,1:No,,0.98
19,1090597,Table 1,BaselineCharacteristic,x (x.x),n (%) ; ,Disorganized,,8,1,,No,1:No,1:No,,0.817
19,1090597,Table 1,BaselineCharacteristic,Residual, ; ,Residual,,9,0,,No,1:No,1:No,,0.99
19,1090597,Table 1,BaselineCharacteristic,x (x.x),n (%) ; ,Residual,,9,1,,No,1:No,1:No,,0.824
19,1090597,Table 1,BaselineCharacteristic,, ; ,None,None,10,0,,No,1:No,1:No,,0.999
19,1090597,Table 1,BaselineCharacteristic,,n (%) ; ,None,None,10,1,,No,1:No,1:No,,0.856
19,1090597,Table 1,BaselineCharacteristic,Inpatients, ; ,Inpatients,,11,0,,No,1:No,1:No,,0.999
19,1090597,Table 1,BaselineCharacteristic,xx (xx),n (%) ; ,Inpatients,,11,1,,No,1:No,1:No,,0.71
19,1090597,Table 1,BaselineCharacteristic,Outpatients, ; ,Outpatients,,12,0,,No,1:No,1:No,,0.999
19,1090597,Table 1,BaselineCharacteristic,xx (xx),n (%) ; ,Outpatients,,12,1,,No,1:No,1:No,,0.71
19,1090597,Table 1,BaselineCharacteristic,, ; ,None,None,13,0,,No,1:No,1:No,,0.999
19,1090597,Table 1,BaselineCharacteristic,,n (%) ; ,None,None,13,1,,No,1:No,1:No,,0.856
19,1090597,Table 1,BaselineCharacteristic,Switched from previous antipsychotic, ; ,Switched from previous antipsychotic,,14,0,,No,1:No,1:No,,0.999
19,1090597,Table 1,BaselineCharacteristic,xx (xx),n (%) ; ,Switched from previous antipsychotic,,14,1,,No,1:No,1:No,,0.776
19,1090597,Table 1,BaselineCharacteristic,Noncompliance, ; ,Noncompliance,,15,0,,No,1:No,1:No,,0.999
19,1090597,Table 1,BaselineCharacteristic,xx (xx),n (%) ; ,Noncompliance,,15,1,,No,1:No,1:No,,0.721
19,1090597,Table 1,BaselineCharacteristic,First Episode, ; ,First Episode,,16,0,,No,1:No,1:No,,0.999
19,1090597,Table 1,BaselineCharacteristic,xx (xx),n (%) ; ,First Episode,,16,1,,No,1:No,1:No,,0.721
19,1090597,Table 1,BaselineCharacteristic,, ; ,None,None,17,0,,No,1:No,1:No,,0.999
19,1090597,Table 1,BaselineCharacteristic,,n (%) ; ,None,None,17,1,,No,1:No,1:No,,0.847
19,1090597,Table 1,BaselineCharacteristic,, ; ,,,18,0,,No,1:No,1:No,,0.989
19,1090597,Table 1,BaselineCharacteristic,Mean (S.D.),n (%) ; ,,,18,1,,No,1:No,1:No,,0.837
19,1090597,Table 1,BaselineCharacteristic,, ; ,None,None,19,0,,No,1:No,1:No,,0.989
19,1090597,Table 1,BaselineCharacteristic,,n (%) ; ,None,None,19,1,,No,1:No,1:No,,0.827
19,1090597,Table 1,BaselineCharacteristic,Age, ; ,None,None,20,0,,No,1:No,1:No,,0.989
19,1090597,Table 1,BaselineCharacteristic,, ; ,None,None,21,0,,No,1:No,1:No,,0.989
19,1090597,Table 1,BaselineCharacteristic,,n (%) ; ,None,None,21,1,,No,1:No,1:No,,0.827
19,1090597,Table 1,BaselineCharacteristic,Age at onset, ; ,Age at onset,,22,0,,No,1:No,1:No,,0.999
19,1090597,Table 1,BaselineCharacteristic,xx.x (x.x),n (%) ; ,Age at onset,,22,1,,No,1:No,1:No,,0.693
19,1090597,Table 1,BaselineCharacteristic,, ; ,None,None,23,0,,No,1:No,1:No,,0.999
19,1090597,Table 1,BaselineCharacteristic,,n (%) ; ,None,None,23,1,,No,1:No,1:No,,0.847
19,1090597,Table 1,BaselineCharacteristic,Length of illness (yr.), ; ,Length of illness (yr.),,24,0,,No,1:No,1:No,,0.969
19,1090597,Table 1,BaselineCharacteristic,xx.x (x.x),n (%) ; ,Length of illness (yr.),,24,1,,No,1:No,1:No,,0.63
19,1090597,Table 1,BaselineCharacteristic,, ; ,None,None,25,0,,No,1:No,1:No,,0.999
19,1090597,Table 1,BaselineCharacteristic,,n (%) ; ,None,None,25,1,,No,1:No,1:No,,0.847
19,1090597,Table 1,BaselineCharacteristic,PANSS total score, ; ,PANSS total score,,26,0,,No,1:No,1:No,,0.969
19,1090597,Table 1,BaselineCharacteristic,xx.x (xx.x),n (%) ; ,PANSS total score,,26,1,,No,1:No,1:No,,0.679
25,1131894,Table 3,BaselineCharacteristic,Number,,Number,,0,0,2,No,1:No,1:No,,0.94
25,1131894,Table 3,BaselineCharacteristic,xx,,Number,,0,1,3,No,1:No,1:No,,0.658
25,1131894,Table 3,BaselineCharacteristic,Mean Age,,Mean Age,,1,0,2,No,1:No,1:No,,0.94
25,1131894,Table 3,BaselineCharacteristic,Histology,,None,None,2,0,24,No,1:No,1:No,,0.912
25,1131894,Table 3,BaselineCharacteristic,,,Histology,None,2,1,43,No,1:No,1:No,,0.884
25,1131894,Table 3,BaselineCharacteristic,Squamous,,Squamous, Histology,3,0,24,No,1:No,1:No,,0.922
25,1131894,Table 3,BaselineCharacteristic,xx (xxx%),,Squamous, Histology,3,1,43,No,1:No,1:No,,0.701
25,1131894,Table 3,BaselineCharacteristic,FIGO Stage*,,None,None,4,0,2,No,1:No,1:No,,0.98
25,1131894,Table 3,BaselineCharacteristic,,,None,None,4,1,3,No,1:No,1:No,,0.89
25,1131894,Table 3,BaselineCharacteristic,??IIB,,??IIB, FIGO Stage* Squamous,5,0,2,No,1:No,1:No,,0.98
25,1131894,Table 3,BaselineCharacteristic,x (xx%),,??IIB, FIGO Stage* Squamous,5,1,3,No,1:No,1:No,,0.95
25,1131894,Table 3,BaselineCharacteristic,??IIIB,,??IIIB, FIGO Stage* Squamous,6,0,2,No,1:No,1:No,,0.99
25,1131894,Table 3,BaselineCharacteristic,x (xx%),,??IIIB, FIGO Stage* Squamous,6,1,3,No,1:No,1:No,,0.96
25,1131894,Table 3,BaselineCharacteristic,Performance Status**,,None,None,7,0,2,No,1:No,1:No,,0.99
25,1131894,Table 3,BaselineCharacteristic,,,None,None,7,1,3,No,1:No,1:No,,0.95
25,1131894,Table 3,BaselineCharacteristic,x,,x,,8,0,2,No,1:No,1:No,,0.972
25,1131894,Table 3,BaselineCharacteristic,xx (xx%),,x,,8,1,3,No,1:No,1:No,,0.866
25,1131894,Table 3,BaselineCharacteristic,x,,x,,9,0,2,No,1:No,1:No,,0.982
25,1131894,Table 3,BaselineCharacteristic,x (xx%),,x,,9,1,3,No,1:No,1:No,,0.99
164,1386704,Table 1,BaselineCharacteristic,Sex (Male/Female),,Sex (Male/Female),None,0,0,2,No,1:No,1:No,,0.94
164,1386704,Table 1,BaselineCharacteristic,xx/x,,Sex (Male/Female),None,0,1,3,No,1:No,1:No,,0.87
164,1386704,Table 1,BaselineCharacteristic,"Age, range, yr (mean ± SD)",,"Age, range, yr (mean ± SD)",None,1,0,2,No,1:No,1:No,,0.57
164,1386704,Table 1,BaselineCharacteristic,"FVC% pred, x ± SD",,"FVC% pred, x ± SD",None,2,0,2,No,1:No,1:No,,0.72
164,1386704,Table 1,BaselineCharacteristic,"FEVx%pred, x ± SD",,"FEVx%pred, x ± SD",None,3,0,2,No,1:No,1:No,,0.74
164,1386704,Table 1,BaselineCharacteristic,"TLC% pred, x ± SD",,"TLC% pred, x ± SD",None,4,0,2,No,1:No,1:No,,0.76
164,1386704,Table 1,BaselineCharacteristic,"TLCO% pred, x+SD",,"TLCO% pred, x+SD",None,5,0,2,No,1:No,1:No,,0.97
164,1386704,Table 1,BaselineCharacteristic,xx.x ± xx.x,,"TLCO% pred, x+SD",None,5,1,3,No,1:No,1:No,,0.62
166,1389847,Table I.,BaselineCharacteristic,PatientID,,None,None,0,0,12,No,1:No,1:No,,0.905
166,1389847,Table I.,BaselineCharacteristic,Age,,PatientID,None,0,1,1,No,1:No,1:No,,0.903
166,1389847,Table I.,BaselineCharacteristic,Sex,,PatientID,None,0,2,1,No,1:No,1:No,,0.903
166,1389847,Table I.,BaselineCharacteristic,Diagnosis,,PatientID,None,0,3,1,No,1:No,1:No,,0.903
166,1389847,Table I.,BaselineCharacteristic,Stage,,PatientID,None,0,4,1,No,1:No,1:No,,0.913
166,1389847,Table I.,BaselineCharacteristic,Previous therapy,,PatientID,None,0,5,1,No,1:No,1:No,,0.946
166,1389847,Table I.,BaselineCharacteristic,Disease statusat entry,,PatientID,None,0,6,1,No,1:No,1:No,,0.935
166,1389847,Table I.,BaselineCharacteristic,Diseaseat study entry,,PatientID,None,0,7,1,No,1:No,1:No,,0.866
166,1389847,Table I.,BaselineCharacteristic,Best responseon study,,PatientID,None,0,8,1,No,1:No,1:No,,0.886
166,1389847,Table I.,BaselineCharacteristic,Durationon study,,PatientID,None,0,9,1,No,1:No,1:No,,0.866
166,1389847,Table I.,BaselineCharacteristic,Currentstatus,,PatientID,None,0,10,1,No,1:No,1:No,,0.945
166,1389847,Table I.,BaselineCharacteristic,,PatientID ; ,None,None,1,0,2,No,1:No,1:No,,0.94
166,1389847,Table I.,BaselineCharacteristic,yr,Age ; ,None,None,1,1,3,No,1:No,1:No,,0.84
166,1389847,Table I.,BaselineCharacteristic,,Sex ; ,None,None,1,2,3,No,1:No,1:No,,0.88
166,1389847,Table I.,BaselineCharacteristic,,Diagnosis ; ,None,None,1,3,3,No,1:No,1:No,,0.88
166,1389847,Table I.,BaselineCharacteristic,,Stage ; ,None,None,1,4,3,No,1:No,1:No,,0.87
166,1389847,Table I.,BaselineCharacteristic,,Previous therapy ; ,None,None,1,5,3,No,1:No,1:No,,0.9
166,1389847,Table I.,BaselineCharacteristic,,Disease statusat entry ; ,None,None,1,6,3,No,1:No,1:No,,0.89
166,1389847,Table I.,BaselineCharacteristic,,Diseaseat study entry ; ,None,None,1,7,3,No,1:No,1:No,,0.835
166,1389847,Table I.,BaselineCharacteristic,,Best responseon study ; ,None,None,1,8,3,No,1:No,1:No,,0.865
166,1389847,Table I.,BaselineCharacteristic,mo,Durationon study ; ,None,None,1,9,3,No,1:No,1:No,,0.845
166,1389847,Table I.,BaselineCharacteristic,,Currentstatus ; ,None,None,1,10,3,No,1:No,1:No,,0.89
166,1389847,Table II.,BaselineCharacteristic,Patient ID,,None,None,0,0,12,No,1:No,1:No,,0.905
166,1389847,Table II.,BaselineCharacteristic,DC injection no.,,Patient ID,None,0,1,1,No,1:No,1:No,,0.857
166,1389847,Table II.,BaselineCharacteristic,Dose,,Patient ID,None,0,2,1,No,1:No,1:No,,0.903
166,1389847,Table II.,BaselineCharacteristic,Viability,,Patient ID,None,0,3,1,No,1:No,1:No,,0.903
166,1389847,Table II.,BaselineCharacteristic,Purity,,Patient ID,None,0,4,1,No,1:No,1:No,,0.913
166,1389847,Table II.,BaselineCharacteristic,Maturity,,Patient ID,None,0,5,1,No,1:No,1:No,,0.935
166,1389847,Table II.,BaselineCharacteristic,Injection-related toxicity,,Patient ID,None,0,6,1,No,1:No,1:No,,0.935
166,1389847,Table II.,BaselineCharacteristic,,Patient ID ; ,None,None,1,0,2,No,1:No,1:No,,0.94
166,1389847,Table II.,BaselineCharacteristic,,DC injection no. ; ,None,None,1,1,3,No,1:No,1:No,,0.835
166,1389847,Table II.,BaselineCharacteristic,xxx cells,Dose ; ,None,None,1,2,3,No,1:No,1:No,,0.83
166,1389847,Table II.,BaselineCharacteristic,,Viability ; ,None,None,1,3,3,No,1:No,1:No,,0.88
166,1389847,Table II.,BaselineCharacteristic,,Purity ; ,None,None,1,4,3,No,1:No,1:No,,0.87
166,1389847,Table II.,BaselineCharacteristic,% CDxx+,Maturity ; ,None,None,1,5,3,No,1:No,1:No,,0.75
166,1389847,Table II.,BaselineCharacteristic,,Injection-related toxicity ; ,None,None,1,6,3,No,1:No,1:No,,0.89
215,1488867,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,0,12,No,1:No,1:No,,0.905
215,1488867,Table 1,BaselineCharacteristic,n(%),,Characteristic,None,0,1,1,No,1:No,1:No,,0.704
215,1488867,Table 1,BaselineCharacteristic,Age (years),Characteristic ; ,None,None,1,0,24,No,1:No,1:No,,0.665
215,1488867,Table 1,BaselineCharacteristic,,n(%) ; ,Age (years),None,1,1,43,No,1:No,1:No,,0.579
215,1488867,Table 1,BaselineCharacteristic,?Median,Characteristic ; ,?Median, Age (years),2,0,2,No,1:No,1:No,,0.65
215,1488867,Table 1,BaselineCharacteristic,?Range,Characteristic ; ,?Range, Age (years),3,0,2,No,1:No,1:No,,0.66
215,1488867,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,4,0,2,No,1:No,1:No,,0.97
215,1488867,Table 1,BaselineCharacteristic,,n(%) ; ,None,None,4,1,3,No,1:No,1:No,,0.676
215,1488867,Table 1,BaselineCharacteristic,?P. S x–x,Characteristic ; ,?P. S x–x, Age (years),5,0,2,No,1:No,1:No,,0.67
215,1488867,Table 1,BaselineCharacteristic,?P. S x,Characteristic ; ,?P. S x, Age (years),6,0,2,No,1:No,1:No,,0.68
215,1488867,Table 1,BaselineCharacteristic,x (xx%),n(%) ; ,?P. S x, Age (years),6,1,3,No,1:No,1:No,,0.56
215,1488867,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,7,0,2,No,1:No,1:No,,0.99
215,1488867,Table 1,BaselineCharacteristic,,n(%) ; ,None,None,7,1,3,No,1:No,1:No,,0.776
215,1488867,Table 1,BaselineCharacteristic,Histology,Characteristic ; ,None,None,8,0,24,No,1:No,1:No,,0.974
215,1488867,Table 1,BaselineCharacteristic,,n(%) ; ,Histology,None,8,1,43,No,1:No,1:No,,0.839
215,1488867,Table 1,BaselineCharacteristic,?Infiltrating ductal ca,Characteristic ; ,?Infiltrating ductal ca, Histology,9,0,2,No,1:No,1:No,,1
215,1488867,Table 1,BaselineCharacteristic,xx (xx),n(%) ; ,?Infiltrating ductal ca, Histology,9,1,3,No,1:No,1:No,,0.681
215,1488867,Table 1,BaselineCharacteristic,?Infiltrating lobular ca,Characteristic ; ,?Infiltrating lobular ca, Histology,10,0,2,No,1:No,1:No,,1
215,1488867,Table 1,BaselineCharacteristic,x (xx),n(%) ; ,?Infiltrating lobular ca, Histology,10,1,3,No,1:No,1:No,,0.671
215,1488867,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,11,0,2,No,1:No,1:No,,1
215,1488867,Table 1,BaselineCharacteristic,,n(%) ; ,None,None,11,1,3,No,1:No,1:No,,0.856
215,1488867,Table 1,BaselineCharacteristic,Estrogen status,Characteristic ; ,None,None,12,0,24,No,1:No,1:No,,0.995
215,1488867,Table 1,BaselineCharacteristic,,n(%) ; ,Estrogen status,None,12,1,43,No,1:No,1:No,,0.89
215,1488867,Table 1,BaselineCharacteristic,?ER+,Characteristic ; ,?ER+, Estrogen status,13,0,2,No,1:No,1:No,,1
215,1488867,Table 1,BaselineCharacteristic,xx (xx),n(%) ; ,?ER+, Estrogen status,13,1,3,No,1:No,1:No,,0.741
215,1488867,Table 1,BaselineCharacteristic,?ER -,Characteristic ; ,?ER -, Estrogen status,14,0,2,No,1:No,1:No,,0.97
215,1488867,Table 1,BaselineCharacteristic,x (xx),n(%) ; ,?ER -, Estrogen status,14,1,3,No,1:No,1:No,,0.681
215,1488867,Table 1,BaselineCharacteristic,?Unknown,Characteristic ; ,?Unknown, Estrogen status,15,0,2,No,1:No,1:No,,1
215,1488867,Table 1,BaselineCharacteristic,x (xx),n(%) ; ,?Unknown, Estrogen status,15,1,3,No,1:No,1:No,,0.681
215,1488867,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,16,0,2,No,1:No,1:No,,1
215,1488867,Table 1,BaselineCharacteristic,,n(%) ; ,None,None,16,1,3,No,1:No,1:No,,0.846
215,1488867,Table 1,BaselineCharacteristic,Dominant sites of metastases,Characteristic ; ,None,None,17,0,24,No,1:No,1:No,,0.98
215,1488867,Table 1,BaselineCharacteristic,,n(%) ; ,Dominant sites of metastases,None,17,1,43,No,1:No,1:No,,0.87
215,1488867,Table 1,BaselineCharacteristic,?Nodes,Characteristic ; ,?Nodes, Dominant sites of metastases,18,0,2,No,1:No,1:No,,0.992
215,1488867,Table 1,BaselineCharacteristic,xx(xx),n(%) ; ,?Nodes, Dominant sites of metastases,18,1,3,No,1:No,1:No,,0.696
215,1488867,Table 1,BaselineCharacteristic,?Soft tissues,Characteristic ; ,?Soft tissues, Dominant sites of metastases,19,0,2,No,1:No,1:No,,0.992
215,1488867,Table 1,BaselineCharacteristic,x(x),n(%) ; ,?Soft tissues, Dominant sites of metastases,19,1,3,No,1:No,1:No,,0.83
215,1488867,Table 1,BaselineCharacteristic,?Bone,Characteristic ; ,?Bone, Dominant sites of metastases,20,0,2,No,1:No,1:No,,0.992
215,1488867,Table 1,BaselineCharacteristic,x(xx),n(%) ; ,?Bone, Dominant sites of metastases,20,1,3,No,1:No,1:No,,0.646
215,1488867,Table 1,BaselineCharacteristic,?Liver,Characteristic ; ,?Liver, Dominant sites of metastases,21,0,2,No,1:No,1:No,,0.992
215,1488867,Table 1,BaselineCharacteristic,x(xx),n(%) ; ,?Liver, Dominant sites of metastases,21,1,3,No,1:No,1:No,,0.646
215,1488867,Table 1,BaselineCharacteristic,?Lung,Characteristic ; ,?Lung, Dominant sites of metastases,22,0,2,No,1:No,1:No,,0.992
215,1488867,Table 1,BaselineCharacteristic,x(xx),n(%) ; ,?Lung, Dominant sites of metastases,22,1,3,No,1:No,1:No,,0.646
215,1488867,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,23,0,2,No,1:No,1:No,,1
215,1488867,Table 1,BaselineCharacteristic,,n(%) ; ,None,None,23,1,3,No,1:No,1:No,,0.846
215,1488867,Table 1,BaselineCharacteristic,Pretreatment with antracyclines,Characteristic ; ,None,None,24,0,24,No,1:No,1:No,,0.995
215,1488867,Table 1,BaselineCharacteristic,,n(%) ; ,Pretreatment with antracyclines,None,24,1,43,No,1:No,1:No,,0.889
215,1488867,Table 1,BaselineCharacteristic,?Adjuvant CT,Characteristic ; ,?Adjuvant CT, Pretreatment with antracyclines,25,0,2,No,1:No,1:No,,1
215,1488867,Table 1,BaselineCharacteristic,xx(xx),n(%) ; ,?Adjuvant CT, Pretreatment with antracyclines,25,1,3,No,1:No,1:No,,0.721
215,1488867,Table 1,BaselineCharacteristic,?Not adjuvant CT,Characteristic ; ,?Not adjuvant CT, Pretreatment with antracyclines,26,0,2,No,1:No,1:No,,1
215,1488867,Table 1,BaselineCharacteristic,xx(xx),n(%) ; ,?Not adjuvant CT, Pretreatment with antracyclines,26,1,3,No,1:No,1:No,,0.731
309,1586008,Table 1,BaselineCharacteristic,Variables,,None,None,0,0,12,No,1:No,1:No,,0.905
309,1586008,Table 1,BaselineCharacteristic,N° (%),,Variables,None,0,1,1,No,1:No,1:No,,0.813
309,1586008,Table 1,BaselineCharacteristic,Females/males,Variables ; ,Females/males,None,1,0,2,No,1:No,1:No,,0.94
309,1586008,Table 1,BaselineCharacteristic,xx/x,N° (%) ; ,Females/males,None,1,1,3,No,1:No,1:No,,0.73
309,1586008,Table 1,BaselineCharacteristic,Mean age (years),Variables ; ,Mean age (years),None,2,0,2,No,1:No,1:No,,0.528
309,1586008,Table 1,BaselineCharacteristic,Mean Body Surface Area (mx),Variables ; ,Mean Body Surface Area (mx),None,3,0,2,No,1:No,1:No,,0.96
309,1586008,Table 1,BaselineCharacteristic,Mean Body Mass Index (Kg/mx),Variables ; ,Mean Body Mass Index (Kg/mx),None,4,0,2,No,1:No,1:No,,0.97
309,1586008,Table 1,BaselineCharacteristic,xx.x ± x.x,N° (%) ; ,Mean Body Mass Index (Kg/mx),None,4,1,3,No,1:No,1:No,,0.55
309,1586008,Table 1,BaselineCharacteristic,Diabetes,Variables ; ,Diabetes,None,5,0,2,No,1:No,1:No,,0.97
309,1586008,Table 1,BaselineCharacteristic,x (xx),N° (%) ; ,Diabetes,None,5,1,3,No,1:No,1:No,,0.606
309,1586008,Table 1,BaselineCharacteristic,Coronary Artery Disease history,Variables ; ,Coronary Artery Disease history,None,6,0,2,No,1:No,1:No,,0.99
309,1586008,Table 1,BaselineCharacteristic,x (xx),N° (%) ; ,Coronary Artery Disease history,None,6,1,3,No,1:No,1:No,,0.656
309,1586008,Table 1,BaselineCharacteristic,Hypertension,Variables ; ,Hypertension,None,7,0,2,No,1:No,1:No,,0.99
309,1586008,Table 1,BaselineCharacteristic,x (xx),N° (%) ; ,Hypertension,None,7,1,3,No,1:No,1:No,,0.706
309,1586008,Table 1,BaselineCharacteristic,Hypothyroidism,Variables ; ,Hypothyroidism,None,8,0,2,No,1:No,1:No,,0.99
309,1586008,Table 1,BaselineCharacteristic,x (xx.x),N° (%) ; ,Hypothyroidism,None,8,1,3,No,1:No,1:No,,0.746
309,1586008,Table 1,BaselineCharacteristic,Smoking history,Variables ; ,Smoking history,None,9,0,2,No,1:No,1:No,,1
309,1586008,Table 1,BaselineCharacteristic,x (xx.x),N° (%) ; ,Smoking history,None,9,1,3,No,1:No,1:No,,0.786
309,1586008,Table 1,BaselineCharacteristic,Previous Transient Ischemic Attack,Variables ; ,Previous Transient Ischemic Attack,None,10,0,2,No,1:No,1:No,,1
309,1586008,Table 1,BaselineCharacteristic,x (xx),N° (%) ; ,Previous Transient Ischemic Attack,None,10,1,3,No,1:No,1:No,,0.816
309,1586008,Table 1,BaselineCharacteristic,Previous carotid endarterectomy,Variables ; ,Previous carotid endarterectomy,None,11,0,2,No,1:No,1:No,,1
309,1586008,Table 1,BaselineCharacteristic,x (x.x),N° (%) ; ,Previous carotid endarterectomy,None,11,1,3,No,1:No,1:No,,0.95
309,1586008,Table 1,BaselineCharacteristic,Peripheral vascular disease,Variables ; ,Peripheral vascular disease,None,12,0,2,No,1:No,1:No,,1
309,1586008,Table 1,BaselineCharacteristic,x (xx.x),N° (%) ; ,Peripheral vascular disease,None,12,1,3,No,1:No,1:No,,0.816
309,1586008,Table 1,BaselineCharacteristic,Atrial fibrillation,Variables ; ,Atrial fibrillation,None,13,0,2,No,1:No,1:No,,1
309,1586008,Table 1,BaselineCharacteristic,x (x.x),N° (%) ; ,Atrial fibrillation,None,13,1,3,No,1:No,1:No,,0.95
309,1586008,Table 1,BaselineCharacteristic,Chronic obstructive pulmonary disease,Variables ; ,Chronic obstructive pulmonary disease,None,14,0,2,No,1:No,1:No,,1
309,1586008,Table 1,BaselineCharacteristic,x (xx),N° (%) ; ,Chronic obstructive pulmonary disease,None,14,1,3,No,1:No,1:No,,0.816
309,1586008,Table 1,BaselineCharacteristic,Mean New York Heart Association Functional class,Variables ; ,Mean New York Heart Association Functional class,None,15,0,2,No,1:No,1:No,,1
309,1586008,Table 1,BaselineCharacteristic,x.xx ± x.xx,N° (%) ; ,Mean New York Heart Association Functional class,None,15,1,3,No,1:No,1:No,,0.78
309,1586008,Table 1,BaselineCharacteristic,Mean Canadian cardiovascular Class,Variables ; ,Mean Canadian cardiovascular Class,None,16,0,2,No,1:No,1:No,,1
309,1586008,Table 1,BaselineCharacteristic,x.xx ± x.xx,N° (%) ; ,Mean Canadian cardiovascular Class,None,16,1,3,No,1:No,1:No,,0.78
309,1586008,Table 1,BaselineCharacteristic,Left ventricular ejection fraction <xx%,Variables ; ,Left ventricular ejection fraction <xx%,None,17,0,2,No,1:No,1:No,,1
309,1586008,Table 1,BaselineCharacteristic,x (x.x),N° (%) ; ,Left ventricular ejection fraction <xx%,None,17,1,3,No,1:No,1:No,,0.93
309,1586008,Table 1,BaselineCharacteristic,Mitral valve disease,Variables ; ,Mitral valve disease,None,18,0,2,No,1:No,1:No,,0.99
309,1586008,Table 1,BaselineCharacteristic,x (xx.x),N° (%) ; ,Mitral valve disease,None,18,1,3,No,1:No,1:No,,0.801
449,1885552,Table 1,BaselineCharacteristic,Intervention group (number of subjects),,None,None,0,0,12,No,1:No,1:No,,0.755
449,1885552,Table 1,BaselineCharacteristic,Weight (kp),,Intervention group (number of subjects),None,0,2,1,No,1:No,1:No,,0.76
449,1885552,Table 1,BaselineCharacteristic,Height (cm),,Intervention group (number of subjects),None,0,3,1,No,1:No,1:No,,0.76
449,1885552,Table 1,BaselineCharacteristic,Systolic blood pressure (mm Hg),,Intervention group (number of subjects),None,0,4,1,No,1:No,1:No,,0.75
449,1885552,Table 1,BaselineCharacteristic,Diastolic blood pressure (mm Hg),,Intervention group (number of subjects),None,0,5,1,No,1:No,1:No,,0.77
449,1885552,Table 1,BaselineCharacteristic,Stretching (xx),Intervention group (number of subjects) ; ,Stretching (xx),None,1,0,2,No,1:No,1:No,,0.645
449,1885552,Table 1,BaselineCharacteristic,"xx ± x,x",Diastolic blood pressure (mm Hg) ; ,Stretching (xx),None,1,5,3,No,1:No,1:No,,0.556
449,1885552,Table 1,BaselineCharacteristic,Strength (xx),Intervention group (number of subjects) ; ,Strength (xx),None,2,0,2,No,1:No,1:No,,0.635
449,1885552,Table 1,BaselineCharacteristic,"xx,x ± xx,x",Weight (kp) ; ,Strength (xx),None,2,2,3,No,1:No,1:No,,0.536
449,1885552,Table 1,BaselineCharacteristic,"xx ± xx,x",Diastolic blood pressure (mm Hg) ; ,Strength (xx),None,2,5,3,No,1:No,1:No,,0.576
449,1885552,Table 1,BaselineCharacteristic,Vibration (xx),Intervention group (number of subjects) ; ,Vibration (xx),None,3,0,2,No,1:No,1:No,,0.645
449,1885552,Table 1,BaselineCharacteristic,"xx,x ± xx,x",Weight (kp) ; ,Vibration (xx),None,3,2,3,No,1:No,1:No,,0.52
449,1885552,Table 1,BaselineCharacteristic,"xx ± x,x",Diastolic blood pressure (mm Hg) ; ,Vibration (xx),None,3,5,3,No,1:No,1:No,,0.56
715,1998889,Table 1,BaselineCharacteristic,Age (yrs),,None,None,0,0,12,No,1:No,1:No,,0.815
715,1998889,Table 1,BaselineCharacteristic,Sex,,Age (yrs),None,0,1,1,No,1:No,1:No,,0.813
715,1998889,Table 1,BaselineCharacteristic,WHO,,Age (yrs),None,0,2,1,No,1:No,1:No,,0.813
715,1998889,Table 1,BaselineCharacteristic,Surgery,,Age (yrs),None,0,3,1,No,1:No,1:No,,0.813
715,1998889,Table 1,BaselineCharacteristic,RIT cycles,,Age (yrs),None,0,4,1,No,1:No,1:No,,0.843
715,1998889,Table 1,BaselineCharacteristic,Cum. activity (MBq)/nuclide,,Age (yrs),None,0,5,1,No,1:No,1:No,,0.855
715,1998889,Table 1,BaselineCharacteristic,RIT,,Age (yrs),None,0,6,1,No,1:No,1:No,,0.855
715,1998889,Table 1,BaselineCharacteristic,No. of PET scans,,Age (yrs),None,0,7,1,No,1:No,1:No,,0.865
715,1998889,Table 1,BaselineCharacteristic,TUmax/BG: baseline,,Age (yrs),None,0,8,1,No,1:No,1:No,,0.825
715,1998889,Table 1,BaselineCharacteristic,TUmax/BG: peak ,,Age (yrs),None,0,9,1,No,1:No,1:No,,0.855
715,1998889,Table 1,BaselineCharacteristic,TUmax/BG: last follow-up ,,Age (yrs),None,0,10,1,No,1:No,1:No,,0.855
715,1998889,Table 1,BaselineCharacteristic,Survival (mo.) post surgery,,Age (yrs),None,0,11,1,No,1:No,1:No,,0.885
715,1998889,Table 1,BaselineCharacteristic,Serial FET PET monitoring started after the end of RIT,Age (yrs) ; ,None,None,1,0,24,No,1:No,1:No,,0.899
715,1998889,Table 1,BaselineCharacteristic,Serial FET PET monitoring started after the end of RIT,Sex ; ,Serial FET PET monitoring started after the end of RIT,None,1,1,43,No,1:No,1:No,,0.959
715,1998889,Table 1,BaselineCharacteristic,Serial FET PET monitoring started after the end of RIT,WHO ; ,Serial FET PET monitoring started after the end of RIT,None,1,2,43,No,1:No,1:No,,0.958
715,1998889,Table 1,BaselineCharacteristic,Serial FET PET monitoring started after the end of RIT,Surgery ; ,Serial FET PET monitoring started after the end of RIT,None,1,3,43,No,1:No,1:No,,0.958
715,1998889,Table 1,BaselineCharacteristic,Serial FET PET monitoring started after the end of RIT,RIT cycles ; ,Serial FET PET monitoring started after the end of RIT,None,1,4,43,No,1:No,1:No,,0.959
715,1998889,Table 1,BaselineCharacteristic,Serial FET PET monitoring started after the end of RIT,Cum. activity (MBq)/nuclide ; ,Serial FET PET monitoring started after the end of RIT,None,1,5,43,No,1:No,1:No,,0.958
715,1998889,Table 1,BaselineCharacteristic,Serial FET PET monitoring started after the end of RIT,RIT ; ,Serial FET PET monitoring started after the end of RIT,None,1,6,43,No,1:No,1:No,,0.958
715,1998889,Table 1,BaselineCharacteristic,Serial FET PET monitoring started after the end of RIT,No. of PET scans ; ,Serial FET PET monitoring started after the end of RIT,None,1,7,43,No,1:No,1:No,,0.968
715,1998889,Table 1,BaselineCharacteristic,Serial FET PET monitoring started after the end of RIT,TUmax/BG: baseline ; ,Serial FET PET monitoring started after the end of RIT,None,1,8,43,No,1:No,1:No,,0.938
715,1998889,Table 1,BaselineCharacteristic,Serial FET PET monitoring started after the end of RIT,TUmax/BG: peak  ; ,Serial FET PET monitoring started after the end of RIT,None,1,9,43,No,1:No,1:No,,0.958
715,1998889,Table 1,BaselineCharacteristic,Serial FET PET monitoring started after the end of RIT,TUmax/BG: last follow-up  ; ,Serial FET PET monitoring started after the end of RIT,None,1,10,43,No,1:No,1:No,,0.958
715,1998889,Table 1,BaselineCharacteristic,Serial FET PET monitoring started after the end of RIT,Survival (mo.) post surgery ; ,Serial FET PET monitoring started after the end of RIT,None,1,11,43,No,1:No,1:No,,0.958
715,1998889,Table 1,BaselineCharacteristic,xx,Age (yrs) ; ,xx, Serial FET PET monitoring started after the end of RIT,2,0,2,No,1:No,1:No,,0.876
715,1998889,Table 1,BaselineCharacteristic,f,Sex ; ,xx, Serial FET PET monitoring started after the end of RIT,2,1,3,No,1:No,1:No,,0.926
715,1998889,Table 1,BaselineCharacteristic,III,WHO ; ,xx, Serial FET PET monitoring started after the end of RIT,2,2,3,No,1:No,1:No,,0.916
715,1998889,Table 1,BaselineCharacteristic,xx/xx,Surgery ; ,xx, Serial FET PET monitoring started after the end of RIT,2,3,3,No,1:No,1:No,,0.916
715,1998889,Table 1,BaselineCharacteristic,x,RIT cycles ; ,xx, Serial FET PET monitoring started after the end of RIT,2,4,3,No,1:No,1:No,,0.93
715,1998889,Table 1,BaselineCharacteristic,"x,xxx/xxxI",Cum. activity (MBq)/nuclide ; ,xx, Serial FET PET monitoring started after the end of RIT,2,5,3,No,1:No,1:No,,0.95
715,1998889,Table 1,BaselineCharacteristic,xx/xx–xx/xx,RIT ; ,xx, Serial FET PET monitoring started after the end of RIT,2,6,3,No,1:No,1:No,,0.936
715,1998889,Table 1,BaselineCharacteristic,x,No. of PET scans ; ,xx, Serial FET PET monitoring started after the end of RIT,2,7,3,No,1:No,1:No,,0.94
715,1998889,Table 1,BaselineCharacteristic,–,TUmax/BG: baseline ; ,xx, Serial FET PET monitoring started after the end of RIT,2,8,3,No,1:No,1:No,,0.906
715,1998889,Table 1,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: peak  ; ,xx, Serial FET PET monitoring started after the end of RIT,2,9,3,No,1:No,1:No,,0.93
715,1998889,Table 1,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: last follow-up  ; ,xx, Serial FET PET monitoring started after the end of RIT,2,10,3,No,1:No,1:No,,0.93
715,1998889,Table 1,BaselineCharacteristic,xx (l.c.),Survival (mo.) post surgery ; ,xx, Serial FET PET monitoring started after the end of RIT,2,11,3,No,1:No,1:No,,0.966
715,1998889,Table 1,BaselineCharacteristic,xx,Age (yrs) ; ,xx, Serial FET PET monitoring started after the end of RIT,3,0,2,No,1:No,1:No,,0.876
715,1998889,Table 1,BaselineCharacteristic,m,Sex ; ,xx, Serial FET PET monitoring started after the end of RIT,3,1,3,No,1:No,1:No,,0.936
715,1998889,Table 1,BaselineCharacteristic,III,WHO ; ,xx, Serial FET PET monitoring started after the end of RIT,3,2,3,No,1:No,1:No,,0.916
715,1998889,Table 1,BaselineCharacteristic,xx/xx,Surgery ; ,xx, Serial FET PET monitoring started after the end of RIT,3,3,3,No,1:No,1:No,,0.916
715,1998889,Table 1,BaselineCharacteristic,x,RIT cycles ; ,xx, Serial FET PET monitoring started after the end of RIT,3,4,3,No,1:No,1:No,,0.93
715,1998889,Table 1,BaselineCharacteristic,"x,xxx/xxxI",Cum. activity (MBq)/nuclide ; ,xx, Serial FET PET monitoring started after the end of RIT,3,5,3,No,1:No,1:No,,0.95
715,1998889,Table 1,BaselineCharacteristic,xx/xx–xx/xx,RIT ; ,xx, Serial FET PET monitoring started after the end of RIT,3,6,3,No,1:No,1:No,,0.936
715,1998889,Table 1,BaselineCharacteristic,x,No. of PET scans ; ,xx, Serial FET PET monitoring started after the end of RIT,3,7,3,No,1:No,1:No,,0.94
715,1998889,Table 1,BaselineCharacteristic,–,TUmax/BG: baseline ; ,xx, Serial FET PET monitoring started after the end of RIT,3,8,3,No,1:No,1:No,,0.906
715,1998889,Table 1,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: peak  ; ,xx, Serial FET PET monitoring started after the end of RIT,3,9,3,No,1:No,1:No,,0.93
715,1998889,Table 1,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: last follow-up  ; ,xx, Serial FET PET monitoring started after the end of RIT,3,10,3,No,1:No,1:No,,0.93
715,1998889,Table 1,BaselineCharacteristic,xx (l.c.),Survival (mo.) post surgery ; ,xx, Serial FET PET monitoring started after the end of RIT,3,11,3,No,1:No,1:No,,0.966
715,1998889,Table 1,BaselineCharacteristic,xx,Age (yrs) ; ,xx, Serial FET PET monitoring started after the end of RIT,4,0,2,No,1:No,1:No,,0.896
715,1998889,Table 1,BaselineCharacteristic,f,Sex ; ,xx, Serial FET PET monitoring started after the end of RIT,4,1,3,No,1:No,1:No,,0.936
715,1998889,Table 1,BaselineCharacteristic,IV,WHO ; ,xx, Serial FET PET monitoring started after the end of RIT,4,2,3,No,1:No,1:No,,0.906
715,1998889,Table 1,BaselineCharacteristic,xx/xx,Surgery ; ,xx, Serial FET PET monitoring started after the end of RIT,4,3,3,No,1:No,1:No,,0.926
715,1998889,Table 1,BaselineCharacteristic,x,RIT cycles ; ,xx, Serial FET PET monitoring started after the end of RIT,4,4,3,No,1:No,1:No,,0.95
715,1998889,Table 1,BaselineCharacteristic,"x,xxx/xxxI",Cum. activity (MBq)/nuclide ; ,xx, Serial FET PET monitoring started after the end of RIT,4,5,3,No,1:No,1:No,,0.97
715,1998889,Table 1,BaselineCharacteristic,xx/xx,RIT ; ,xx, Serial FET PET monitoring started after the end of RIT,4,6,3,No,1:No,1:No,,0.946
715,1998889,Table 1,BaselineCharacteristic,xx,No. of PET scans ; ,xx, Serial FET PET monitoring started after the end of RIT,4,7,3,No,1:No,1:No,,0.956
715,1998889,Table 1,BaselineCharacteristic,–,TUmax/BG: baseline ; ,xx, Serial FET PET monitoring started after the end of RIT,4,8,3,No,1:No,1:No,,0.916
715,1998889,Table 1,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: peak  ; ,xx, Serial FET PET monitoring started after the end of RIT,4,9,3,No,1:No,1:No,,0.95
715,1998889,Table 1,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: last follow-up  ; ,xx, Serial FET PET monitoring started after the end of RIT,4,10,3,No,1:No,1:No,,0.95
715,1998889,Table 1,BaselineCharacteristic,xx (l.c.),Survival (mo.) post surgery ; ,xx, Serial FET PET monitoring started after the end of RIT,4,11,3,No,1:No,1:No,,0.966
715,1998889,Table 1,BaselineCharacteristic,xx,Age (yrs) ; ,xx, Serial FET PET monitoring started after the end of RIT,5,0,2,No,1:No,1:No,,0.896
715,1998889,Table 1,BaselineCharacteristic,f,Sex ; ,xx, Serial FET PET monitoring started after the end of RIT,5,1,3,No,1:No,1:No,,0.936
715,1998889,Table 1,BaselineCharacteristic,IV,WHO ; ,xx, Serial FET PET monitoring started after the end of RIT,5,2,3,No,1:No,1:No,,0.906
715,1998889,Table 1,BaselineCharacteristic,xx/xx,Surgery ; ,xx, Serial FET PET monitoring started after the end of RIT,5,3,3,No,1:No,1:No,,0.926
715,1998889,Table 1,BaselineCharacteristic,x,RIT cycles ; ,xx, Serial FET PET monitoring started after the end of RIT,5,4,3,No,1:No,1:No,,0.95
715,1998889,Table 1,BaselineCharacteristic,"x,xxx/xxxI",Cum. activity (MBq)/nuclide ; ,xx, Serial FET PET monitoring started after the end of RIT,5,5,3,No,1:No,1:No,,0.97
715,1998889,Table 1,BaselineCharacteristic,xx/xx–xx/xx,RIT ; ,xx, Serial FET PET monitoring started after the end of RIT,5,6,3,No,1:No,1:No,,0.946
715,1998889,Table 1,BaselineCharacteristic,x,No. of PET scans ; ,xx, Serial FET PET monitoring started after the end of RIT,5,7,3,No,1:No,1:No,,0.96
715,1998889,Table 1,BaselineCharacteristic,–,TUmax/BG: baseline ; ,xx, Serial FET PET monitoring started after the end of RIT,5,8,3,No,1:No,1:No,,0.916
715,1998889,Table 1,BaselineCharacteristic,peak missed,TUmax/BG: peak  ; ,xx, Serial FET PET monitoring started after the end of RIT,5,9,3,No,1:No,1:No,,0.946
715,1998889,Table 1,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: last follow-up  ; ,xx, Serial FET PET monitoring started after the end of RIT,5,10,3,No,1:No,1:No,,0.95
715,1998889,Table 1,BaselineCharacteristic,xx (l.c.),Survival (mo.) post surgery ; ,xx, Serial FET PET monitoring started after the end of RIT,5,11,3,No,1:No,1:No,,0.966
715,1998889,Table 1,BaselineCharacteristic,Serial FET PET monitoring during and after RIT,Age (yrs) ; ,None,None,6,0,24,No,1:No,1:No,,0.924
715,1998889,Table 1,BaselineCharacteristic,Serial FET PET monitoring during and after RIT,Sex ; ,Serial FET PET monitoring during and after RIT,None,6,1,43,No,1:No,1:No,,0.973
715,1998889,Table 1,BaselineCharacteristic,Serial FET PET monitoring during and after RIT,WHO ; ,Serial FET PET monitoring during and after RIT,None,6,2,43,No,1:No,1:No,,0.978
715,1998889,Table 1,BaselineCharacteristic,Serial FET PET monitoring during and after RIT,Surgery ; ,Serial FET PET monitoring during and after RIT,None,6,3,43,No,1:No,1:No,,0.978
715,1998889,Table 1,BaselineCharacteristic,Serial FET PET monitoring during and after RIT,RIT cycles ; ,Serial FET PET monitoring during and after RIT,None,6,4,43,No,1:No,1:No,,0.979
715,1998889,Table 1,BaselineCharacteristic,Serial FET PET monitoring during and after RIT,Cum. activity (MBq)/nuclide ; ,Serial FET PET monitoring during and after RIT,None,6,5,43,No,1:No,1:No,,0.968
715,1998889,Table 1,BaselineCharacteristic,Serial FET PET monitoring during and after RIT,RIT ; ,Serial FET PET monitoring during and after RIT,None,6,6,43,No,1:No,1:No,,0.968
715,1998889,Table 1,BaselineCharacteristic,Serial FET PET monitoring during and after RIT,No. of PET scans ; ,Serial FET PET monitoring during and after RIT,None,6,7,43,No,1:No,1:No,,0.963
715,1998889,Table 1,BaselineCharacteristic,Serial FET PET monitoring during and after RIT,TUmax/BG: baseline ; ,Serial FET PET monitoring during and after RIT,None,6,8,43,No,1:No,1:No,,0.948
715,1998889,Table 1,BaselineCharacteristic,Serial FET PET monitoring during and after RIT,TUmax/BG: peak  ; ,Serial FET PET monitoring during and after RIT,None,6,9,43,No,1:No,1:No,,0.968
715,1998889,Table 1,BaselineCharacteristic,Serial FET PET monitoring during and after RIT,TUmax/BG: last follow-up  ; ,Serial FET PET monitoring during and after RIT,None,6,10,43,No,1:No,1:No,,0.968
715,1998889,Table 1,BaselineCharacteristic,Serial FET PET monitoring during and after RIT,Survival (mo.) post surgery ; ,Serial FET PET monitoring during and after RIT,None,6,11,43,No,1:No,1:No,,0.978
715,1998889,Table 1,BaselineCharacteristic,xx,Age (yrs) ; ,xx, Serial FET PET monitoring during and after RIT,7,0,2,No,1:No,1:No,,0.892
715,1998889,Table 1,BaselineCharacteristic,f,Sex ; ,xx, Serial FET PET monitoring during and after RIT,7,1,3,No,1:No,1:No,,0.946
715,1998889,Table 1,BaselineCharacteristic,IV,WHO ; ,xx, Serial FET PET monitoring during and after RIT,7,2,3,No,1:No,1:No,,0.936
715,1998889,Table 1,BaselineCharacteristic,xx/xx,Surgery ; ,xx, Serial FET PET monitoring during and after RIT,7,3,3,No,1:No,1:No,,0.956
715,1998889,Table 1,BaselineCharacteristic,x,RIT cycles ; ,xx, Serial FET PET monitoring during and after RIT,7,4,3,No,1:No,1:No,,0.94
715,1998889,Table 1,BaselineCharacteristic,"x,xxx/xxxI",Cum. activity (MBq)/nuclide ; ,xx, Serial FET PET monitoring during and after RIT,7,5,3,No,1:No,1:No,,0.97
715,1998889,Table 1,BaselineCharacteristic,xx/xx,RIT ; ,xx, Serial FET PET monitoring during and after RIT,7,6,3,No,1:No,1:No,,0.976
715,1998889,Table 1,BaselineCharacteristic,x,No. of PET scans ; ,xx, Serial FET PET monitoring during and after RIT,7,7,3,No,1:No,1:No,,0.96
715,1998889,Table 1,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: baseline ; ,xx, Serial FET PET monitoring during and after RIT,7,8,3,No,1:No,1:No,,0.96
715,1998889,Table 1,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: peak  ; ,xx, Serial FET PET monitoring during and after RIT,7,9,3,No,1:No,1:No,,0.96
715,1998889,Table 1,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: last follow-up  ; ,xx, Serial FET PET monitoring during and after RIT,7,10,3,No,1:No,1:No,,0.96
715,1998889,Table 1,BaselineCharacteristic,xx (l.c.),Survival (mo.) post surgery ; ,xx, Serial FET PET monitoring during and after RIT,7,11,3,No,1:No,1:No,,0.976
715,1998889,Table 1,BaselineCharacteristic,xx,Age (yrs) ; ,xx, Serial FET PET monitoring during and after RIT,8,0,2,No,1:No,1:No,,0.901
715,1998889,Table 1,BaselineCharacteristic,f,Sex ; ,xx, Serial FET PET monitoring during and after RIT,8,1,3,No,1:No,1:No,,0.956
715,1998889,Table 1,BaselineCharacteristic,IV,WHO ; ,xx, Serial FET PET monitoring during and after RIT,8,2,3,No,1:No,1:No,,0.946
715,1998889,Table 1,BaselineCharacteristic,xx/xx,Surgery ; ,xx, Serial FET PET monitoring during and after RIT,8,3,3,No,1:No,1:No,,0.966
715,1998889,Table 1,BaselineCharacteristic,x,RIT cycles ; ,xx, Serial FET PET monitoring during and after RIT,8,4,3,No,1:No,1:No,,0.96
715,1998889,Table 1,BaselineCharacteristic,"x,xxx/xxxI",Cum. activity (MBq)/nuclide ; ,xx, Serial FET PET monitoring during and after RIT,8,5,3,No,1:No,1:No,,0.98
715,1998889,Table 1,BaselineCharacteristic,xx/xx–xx/xx,RIT ; ,xx, Serial FET PET monitoring during and after RIT,8,6,3,No,1:No,1:No,,0.986
715,1998889,Table 1,BaselineCharacteristic,x,No. of PET scans ; ,xx, Serial FET PET monitoring during and after RIT,8,7,3,No,1:No,1:No,,0.98
715,1998889,Table 1,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: baseline ; ,xx, Serial FET PET monitoring during and after RIT,8,8,3,No,1:No,1:No,,0.97
715,1998889,Table 1,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: peak  ; ,xx, Serial FET PET monitoring during and after RIT,8,9,3,No,1:No,1:No,,0.98
715,1998889,Table 1,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: last follow-up  ; ,xx, Serial FET PET monitoring during and after RIT,8,10,3,No,1:No,1:No,,0.98
715,1998889,Table 1,BaselineCharacteristic,xx (l.c.),Survival (mo.) post surgery ; ,xx, Serial FET PET monitoring during and after RIT,8,11,3,No,1:No,1:No,,0.986
715,1998889,Table 1,BaselineCharacteristic,xx,Age (yrs) ; ,xx, Serial FET PET monitoring during and after RIT,9,0,2,No,1:No,1:No,,0.911
715,1998889,Table 1,BaselineCharacteristic,f,Sex ; ,xx, Serial FET PET monitoring during and after RIT,9,1,3,No,1:No,1:No,,0.976
715,1998889,Table 1,BaselineCharacteristic,IV,WHO ; ,xx, Serial FET PET monitoring during and after RIT,9,2,3,No,1:No,1:No,,0.966
715,1998889,Table 1,BaselineCharacteristic,xx/xx,Surgery ; ,xx, Serial FET PET monitoring during and after RIT,9,3,3,No,1:No,1:No,,0.986
715,1998889,Table 1,BaselineCharacteristic,x,RIT cycles ; ,xx, Serial FET PET monitoring during and after RIT,9,4,3,No,1:No,1:No,,0.97
715,1998889,Table 1,BaselineCharacteristic,xxx/xxxRe,Cum. activity (MBq)/nuclide ; ,xx, Serial FET PET monitoring during and after RIT,9,5,3,No,1:No,1:No,,0.996
715,1998889,Table 1,BaselineCharacteristic,xx/xx,RIT ; ,xx, Serial FET PET monitoring during and after RIT,9,6,3,No,1:No,1:No,,0.996
715,1998889,Table 1,BaselineCharacteristic,x,No. of PET scans ; ,xx, Serial FET PET monitoring during and after RIT,9,7,3,No,1:No,1:No,,0.98
715,1998889,Table 1,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: baseline ; ,xx, Serial FET PET monitoring during and after RIT,9,8,3,No,1:No,1:No,,0.98
715,1998889,Table 1,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: peak  ; ,xx, Serial FET PET monitoring during and after RIT,9,9,3,No,1:No,1:No,,0.99
715,1998889,Table 1,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: last follow-up  ; ,xx, Serial FET PET monitoring during and after RIT,9,10,3,No,1:No,1:No,,0.99
715,1998889,Table 1,BaselineCharacteristic,xx (l.c.),Survival (mo.) post surgery ; ,xx, Serial FET PET monitoring during and after RIT,9,11,3,No,1:No,1:No,,0.986
715,1998889,Table 2,BaselineCharacteristic,Age (yrs),,None,None,0,0,12,No,1:No,1:No,,0.815
715,1998889,Table 2,BaselineCharacteristic,Sex,,Age (yrs),None,0,1,1,No,1:No,1:No,,0.813
715,1998889,Table 2,BaselineCharacteristic,WHO,,Age (yrs),None,0,2,1,No,1:No,1:No,,0.813
715,1998889,Table 2,BaselineCharacteristic,Surgery,,Age (yrs),None,0,3,1,No,1:No,1:No,,0.813
715,1998889,Table 2,BaselineCharacteristic,RIT cycles,,Age (yrs),None,0,4,1,No,1:No,1:No,,0.843
715,1998889,Table 2,BaselineCharacteristic,Cum. activity (MBq)/nuclide,,Age (yrs),None,0,5,1,No,1:No,1:No,,0.855
715,1998889,Table 2,BaselineCharacteristic,RIT,,Age (yrs),None,0,6,1,No,1:No,1:No,,0.855
715,1998889,Table 2,BaselineCharacteristic,No. of PET scans,,Age (yrs),None,0,7,1,No,1:No,1:No,,0.865
715,1998889,Table 2,BaselineCharacteristic,TUmax/BG: baseline,,Age (yrs),None,0,8,1,No,1:No,1:No,,0.825
715,1998889,Table 2,BaselineCharacteristic,TUmax/BG: last follow-up ,,Age (yrs),None,0,9,1,No,1:No,1:No,,0.855
715,1998889,Table 2,BaselineCharacteristic,Survival (mo.) post surgery,,Age (yrs),None,0,10,1,No,1:No,1:No,,0.885
715,1998889,Table 2,BaselineCharacteristic,Patients without obvious tumour at baseline followed by tumour recurrence,Age (yrs) ; ,None,None,1,0,24,No,1:No,1:No,,0.812
715,1998889,Table 2,BaselineCharacteristic,Patients without obvious tumour at baseline followed by tumour recurrence,Sex ; ,Patients without obvious tumour at baseline followed by tumour recurrence,None,1,1,43,No,1:No,1:No,,0.844
715,1998889,Table 2,BaselineCharacteristic,Patients without obvious tumour at baseline followed by tumour recurrence,WHO ; ,Patients without obvious tumour at baseline followed by tumour recurrence,None,1,2,43,No,1:No,1:No,,0.839
715,1998889,Table 2,BaselineCharacteristic,Patients without obvious tumour at baseline followed by tumour recurrence,Surgery ; ,Patients without obvious tumour at baseline followed by tumour recurrence,None,1,3,43,No,1:No,1:No,,0.839
715,1998889,Table 2,BaselineCharacteristic,Patients without obvious tumour at baseline followed by tumour recurrence,RIT cycles ; ,Patients without obvious tumour at baseline followed by tumour recurrence,None,1,4,43,No,1:No,1:No,,0.85
715,1998889,Table 2,BaselineCharacteristic,Patients without obvious tumour at baseline followed by tumour recurrence,Cum. activity (MBq)/nuclide ; ,Patients without obvious tumour at baseline followed by tumour recurrence,None,1,5,43,No,1:No,1:No,,0.846
715,1998889,Table 2,BaselineCharacteristic,Patients without obvious tumour at baseline followed by tumour recurrence,RIT ; ,Patients without obvious tumour at baseline followed by tumour recurrence,None,1,6,43,No,1:No,1:No,,0.849
715,1998889,Table 2,BaselineCharacteristic,Patients without obvious tumour at baseline followed by tumour recurrence,No. of PET scans ; ,Patients without obvious tumour at baseline followed by tumour recurrence,None,1,7,43,No,1:No,1:No,,0.865
715,1998889,Table 2,BaselineCharacteristic,Patients without obvious tumour at baseline followed by tumour recurrence,TUmax/BG: baseline ; ,Patients without obvious tumour at baseline followed by tumour recurrence,None,1,8,43,No,1:No,1:No,,0.839
715,1998889,Table 2,BaselineCharacteristic,Patients without obvious tumour at baseline followed by tumour recurrence,TUmax/BG: last follow-up  ; ,Patients without obvious tumour at baseline followed by tumour recurrence,None,1,9,43,No,1:No,1:No,,0.839
715,1998889,Table 2,BaselineCharacteristic,Patients without obvious tumour at baseline followed by tumour recurrence,Survival (mo.) post surgery ; ,Patients without obvious tumour at baseline followed by tumour recurrence,None,1,10,43,No,1:No,1:No,,0.849
715,1998889,Table 2,BaselineCharacteristic,xx,Age (yrs) ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,2,0,2,No,1:No,1:No,,0.76
715,1998889,Table 2,BaselineCharacteristic,m,Sex ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,2,1,3,No,1:No,1:No,,0.782
715,1998889,Table 2,BaselineCharacteristic,III,WHO ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,2,2,3,No,1:No,1:No,,0.762
715,1998889,Table 2,BaselineCharacteristic,xx/xx,Surgery ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,2,3,3,No,1:No,1:No,,0.762
715,1998889,Table 2,BaselineCharacteristic,x,RIT cycles ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,2,4,3,No,1:No,1:No,,0.776
715,1998889,Table 2,BaselineCharacteristic,"x,xxx/xxxI",Cum. activity (MBq)/nuclide ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,2,5,3,No,1:No,1:No,,0.79
715,1998889,Table 2,BaselineCharacteristic,xx/xx–xx/xx,RIT ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,2,6,3,No,1:No,1:No,,0.792
715,1998889,Table 2,BaselineCharacteristic,x,No. of PET scans ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,2,7,3,No,1:No,1:No,,0.796
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: baseline ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,2,8,3,No,1:No,1:No,,0.796
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: last follow-up  ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,2,9,3,No,1:No,1:No,,0.796
715,1998889,Table 2,BaselineCharacteristic,xx (†),Survival (mo.) post surgery ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,2,10,3,No,1:No,1:No,,0.852
715,1998889,Table 2,BaselineCharacteristic,xx,Age (yrs) ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,3,0,2,No,1:No,1:No,,0.76
715,1998889,Table 2,BaselineCharacteristic,m,Sex ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,3,1,3,No,1:No,1:No,,0.776
715,1998889,Table 2,BaselineCharacteristic,IV,WHO ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,3,2,3,No,1:No,1:No,,0.746
715,1998889,Table 2,BaselineCharacteristic,xx/xx,Surgery ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,3,3,3,No,1:No,1:No,,0.756
715,1998889,Table 2,BaselineCharacteristic,x,RIT cycles ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,3,4,3,No,1:No,1:No,,0.77
715,1998889,Table 2,BaselineCharacteristic,"x,xxx/xxxI",Cum. activity (MBq)/nuclide ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,3,5,3,No,1:No,1:No,,0.79
715,1998889,Table 2,BaselineCharacteristic,xx/xx,RIT ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,3,6,3,No,1:No,1:No,,0.786
715,1998889,Table 2,BaselineCharacteristic,x,No. of PET scans ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,3,7,3,No,1:No,1:No,,0.79
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: baseline ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,3,8,3,No,1:No,1:No,,0.79
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: last follow-up  ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,3,9,3,No,1:No,1:No,,0.79
715,1998889,Table 2,BaselineCharacteristic,xx (†),Survival (mo.) post surgery ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,3,10,3,No,1:No,1:No,,0.846
715,1998889,Table 2,BaselineCharacteristic,xx,Age (yrs) ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,4,0,2,No,1:No,1:No,,0.79
715,1998889,Table 2,BaselineCharacteristic,f,Sex ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,4,1,3,No,1:No,1:No,,0.806
715,1998889,Table 2,BaselineCharacteristic,IV,WHO ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,4,2,3,No,1:No,1:No,,0.786
715,1998889,Table 2,BaselineCharacteristic,xx/xx,Surgery ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,4,3,3,No,1:No,1:No,,0.796
715,1998889,Table 2,BaselineCharacteristic,x,RIT cycles ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,4,4,3,No,1:No,1:No,,0.82
715,1998889,Table 2,BaselineCharacteristic,"x,xxx/xxxI",Cum. activity (MBq)/nuclide ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,4,5,3,No,1:No,1:No,,0.83
715,1998889,Table 2,BaselineCharacteristic,xx/xx–xx/xx,RIT ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,4,6,3,No,1:No,1:No,,0.826
715,1998889,Table 2,BaselineCharacteristic,x,No. of PET scans ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,4,7,3,No,1:No,1:No,,0.84
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: baseline ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,4,8,3,No,1:No,1:No,,0.83
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: last follow-up  ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,4,9,3,No,1:No,1:No,,0.83
715,1998889,Table 2,BaselineCharacteristic,xx (†),Survival (mo.) post surgery ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,4,10,3,No,1:No,1:No,,0.866
715,1998889,Table 2,BaselineCharacteristic,xx,Age (yrs) ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,5,0,2,No,1:No,1:No,,0.78
715,1998889,Table 2,BaselineCharacteristic,m,Sex ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,5,1,3,No,1:No,1:No,,0.806
715,1998889,Table 2,BaselineCharacteristic,IV,WHO ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,5,2,3,No,1:No,1:No,,0.776
715,1998889,Table 2,BaselineCharacteristic,xx/xx,Surgery ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,5,3,3,No,1:No,1:No,,0.786
715,1998889,Table 2,BaselineCharacteristic,x,RIT cycles ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,5,4,3,No,1:No,1:No,,0.82
715,1998889,Table 2,BaselineCharacteristic,"x,xxx/xxxI",Cum. activity (MBq)/nuclide ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,5,5,3,No,1:No,1:No,,0.81
715,1998889,Table 2,BaselineCharacteristic,xx/xx–xx/xx,RIT ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,5,6,3,No,1:No,1:No,,0.806
715,1998889,Table 2,BaselineCharacteristic,x,No. of PET scans ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,5,7,3,No,1:No,1:No,,0.82
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: baseline ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,5,8,3,No,1:No,1:No,,0.82
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: last follow-up  ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,5,9,3,No,1:No,1:No,,0.82
715,1998889,Table 2,BaselineCharacteristic,xx (†),Survival (mo.) post surgery ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,5,10,3,No,1:No,1:No,,0.856
715,1998889,Table 2,BaselineCharacteristic,xx,Age (yrs) ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,6,0,2,No,1:No,1:No,,0.81
715,1998889,Table 2,BaselineCharacteristic,m,Sex ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,6,1,3,No,1:No,1:No,,0.846
715,1998889,Table 2,BaselineCharacteristic,IV,WHO ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,6,2,3,No,1:No,1:No,,0.816
715,1998889,Table 2,BaselineCharacteristic,xx/xx,Surgery ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,6,3,3,No,1:No,1:No,,0.826
715,1998889,Table 2,BaselineCharacteristic,x,RIT cycles ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,6,4,3,No,1:No,1:No,,0.82
715,1998889,Table 2,BaselineCharacteristic,xxx/xxxRe,Cum. activity (MBq)/nuclide ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,6,5,3,No,1:No,1:No,,0.846
715,1998889,Table 2,BaselineCharacteristic,xx/xx–xx/xx,RIT ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,6,6,3,No,1:No,1:No,,0.846
715,1998889,Table 2,BaselineCharacteristic,x,No. of PET scans ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,6,7,3,No,1:No,1:No,,0.82
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: baseline ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,6,8,3,No,1:No,1:No,,0.82
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: last follow-up  ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,6,9,3,No,1:No,1:No,,0.82
715,1998889,Table 2,BaselineCharacteristic,xx (l.c.),Survival (mo.) post surgery ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,6,10,3,No,1:No,1:No,,0.916
715,1998889,Table 2,BaselineCharacteristic,xx,Age (yrs) ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,7,0,2,No,1:No,1:No,,0.82
715,1998889,Table 2,BaselineCharacteristic,m,Sex ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,7,1,3,No,1:No,1:No,,0.866
715,1998889,Table 2,BaselineCharacteristic,IV,WHO ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,7,2,3,No,1:No,1:No,,0.836
715,1998889,Table 2,BaselineCharacteristic,xx/xx,Surgery ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,7,3,3,No,1:No,1:No,,0.846
715,1998889,Table 2,BaselineCharacteristic,x,RIT cycles ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,7,4,3,No,1:No,1:No,,0.86
715,1998889,Table 2,BaselineCharacteristic,"x,xxx/xxxI",Cum. activity (MBq)/nuclide ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,7,5,3,No,1:No,1:No,,0.85
715,1998889,Table 2,BaselineCharacteristic,xx/xx–xx/xx,RIT ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,7,6,3,No,1:No,1:No,,0.876
715,1998889,Table 2,BaselineCharacteristic,x,No. of PET scans ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,7,7,3,No,1:No,1:No,,0.84
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: baseline ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,7,8,3,No,1:No,1:No,,0.86
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: last follow-up  ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,7,9,3,No,1:No,1:No,,0.86
715,1998889,Table 2,BaselineCharacteristic,xx (†),Survival (mo.) post surgery ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,7,10,3,No,1:No,1:No,,0.916
715,1998889,Table 2,BaselineCharacteristic,xx,Age (yrs) ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,8,0,2,No,1:No,1:No,,0.829
715,1998889,Table 2,BaselineCharacteristic,m,Sex ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,8,1,3,No,1:No,1:No,,0.866
715,1998889,Table 2,BaselineCharacteristic,IV,WHO ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,8,2,3,No,1:No,1:No,,0.836
715,1998889,Table 2,BaselineCharacteristic,xx/xx,Surgery ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,8,3,3,No,1:No,1:No,,0.846
715,1998889,Table 2,BaselineCharacteristic,x,RIT cycles ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,8,4,3,No,1:No,1:No,,0.87
715,1998889,Table 2,BaselineCharacteristic,"x,xxx/xxxI",Cum. activity (MBq)/nuclide ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,8,5,3,No,1:No,1:No,,0.85
715,1998889,Table 2,BaselineCharacteristic,xx/xx,RIT ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,8,6,3,No,1:No,1:No,,0.876
715,1998889,Table 2,BaselineCharacteristic,x,No. of PET scans ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,8,7,3,No,1:No,1:No,,0.85
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: baseline ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,8,8,3,No,1:No,1:No,,0.87
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: last follow-up  ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,8,9,3,No,1:No,1:No,,0.87
715,1998889,Table 2,BaselineCharacteristic,xx (l.c.),Survival (mo.) post surgery ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,8,10,3,No,1:No,1:No,,0.926
715,1998889,Table 2,BaselineCharacteristic,xx,Age (yrs) ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,9,0,2,No,1:No,1:No,,0.839
715,1998889,Table 2,BaselineCharacteristic,m,Sex ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,9,1,3,No,1:No,1:No,,0.896
715,1998889,Table 2,BaselineCharacteristic,IV,WHO ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,9,2,3,No,1:No,1:No,,0.866
715,1998889,Table 2,BaselineCharacteristic,xx/xx,Surgery ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,9,3,3,No,1:No,1:No,,0.876
715,1998889,Table 2,BaselineCharacteristic,x,RIT cycles ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,9,4,3,No,1:No,1:No,,0.89
715,1998889,Table 2,BaselineCharacteristic,"x,xxx/xxxI",Cum. activity (MBq)/nuclide ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,9,5,3,No,1:No,1:No,,0.86
715,1998889,Table 2,BaselineCharacteristic,xx/xx,RIT ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,9,6,3,No,1:No,1:No,,0.896
715,1998889,Table 2,BaselineCharacteristic,x,No. of PET scans ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,9,7,3,No,1:No,1:No,,0.86
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: baseline ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,9,8,3,No,1:No,1:No,,0.89
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: last follow-up  ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,9,9,3,No,1:No,1:No,,0.89
715,1998889,Table 2,BaselineCharacteristic,xx (l.c.),Survival (mo.) post surgery ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,9,10,3,No,1:No,1:No,,0.926
715,1998889,Table 2,BaselineCharacteristic,xx,Age (yrs) ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,10,0,2,No,1:No,1:No,,0.839
715,1998889,Table 2,BaselineCharacteristic,f,Sex ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,10,1,3,No,1:No,1:No,,0.906
715,1998889,Table 2,BaselineCharacteristic,III,WHO ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,10,2,3,No,1:No,1:No,,0.886
715,1998889,Table 2,BaselineCharacteristic,xx/xx,Surgery ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,10,3,3,No,1:No,1:No,,0.886
715,1998889,Table 2,BaselineCharacteristic,x,RIT cycles ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,10,4,3,No,1:No,1:No,,0.91
715,1998889,Table 2,BaselineCharacteristic,"x,xxx/xxxI",Cum. activity (MBq)/nuclide ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,10,5,3,No,1:No,1:No,,0.89
715,1998889,Table 2,BaselineCharacteristic,xx/xx–xx/xx,RIT ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,10,6,3,No,1:No,1:No,,0.906
715,1998889,Table 2,BaselineCharacteristic,x,No. of PET scans ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,10,7,3,No,1:No,1:No,,0.9
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: baseline ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,10,8,3,No,1:No,1:No,,0.91
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: last follow-up  ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,10,9,3,No,1:No,1:No,,0.91
715,1998889,Table 2,BaselineCharacteristic,xx (l.c.),Survival (mo.) post surgery ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,10,10,3,No,1:No,1:No,,0.926
715,1998889,Table 2,BaselineCharacteristic,xx,Age (yrs) ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,11,0,2,No,1:No,1:No,,0.839
715,1998889,Table 2,BaselineCharacteristic,f,Sex ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,11,1,3,No,1:No,1:No,,0.906
715,1998889,Table 2,BaselineCharacteristic,IV,WHO ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,11,2,3,No,1:No,1:No,,0.876
715,1998889,Table 2,BaselineCharacteristic,xx/xx,Surgery ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,11,3,3,No,1:No,1:No,,0.886
715,1998889,Table 2,BaselineCharacteristic,x,RIT cycles ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,11,4,3,No,1:No,1:No,,0.91
715,1998889,Table 2,BaselineCharacteristic,"x,xxx/xxxI",Cum. activity (MBq)/nuclide ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,11,5,3,No,1:No,1:No,,0.89
715,1998889,Table 2,BaselineCharacteristic,xx/xx–xx/xx,RIT ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,11,6,3,No,1:No,1:No,,0.906
715,1998889,Table 2,BaselineCharacteristic,x,No. of PET scans ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,11,7,3,No,1:No,1:No,,0.9
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: baseline ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,11,8,3,No,1:No,1:No,,0.91
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: last follow-up  ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,11,9,3,No,1:No,1:No,,0.91
715,1998889,Table 2,BaselineCharacteristic,xx (l.c.),Survival (mo.) post surgery ; ,xx, Patients without obvious tumour at baseline followed by tumour recurrence,11,10,3,No,1:No,1:No,,0.926
715,1998889,Table 2,BaselineCharacteristic,Patients with small residual tumour at baseline followed by tumour progression,Age (yrs) ; ,None,None,12,0,24,No,1:No,1:No,,0.89
715,1998889,Table 2,BaselineCharacteristic,Patients with small residual tumour at baseline followed by tumour progression,Sex ; ,Patients with small residual tumour at baseline followed by tumour progression,None,12,1,43,No,1:No,1:No,,0.933
715,1998889,Table 2,BaselineCharacteristic,Patients with small residual tumour at baseline followed by tumour progression,WHO ; ,Patients with small residual tumour at baseline followed by tumour progression,None,12,2,43,No,1:No,1:No,,0.933
715,1998889,Table 2,BaselineCharacteristic,Patients with small residual tumour at baseline followed by tumour progression,Surgery ; ,Patients with small residual tumour at baseline followed by tumour progression,None,12,3,43,No,1:No,1:No,,0.933
715,1998889,Table 2,BaselineCharacteristic,Patients with small residual tumour at baseline followed by tumour progression,RIT cycles ; ,Patients with small residual tumour at baseline followed by tumour progression,None,12,4,43,No,1:No,1:No,,0.943
715,1998889,Table 2,BaselineCharacteristic,Patients with small residual tumour at baseline followed by tumour progression,Cum. activity (MBq)/nuclide ; ,Patients with small residual tumour at baseline followed by tumour progression,None,12,5,43,No,1:No,1:No,,0.933
715,1998889,Table 2,BaselineCharacteristic,Patients with small residual tumour at baseline followed by tumour progression,RIT ; ,Patients with small residual tumour at baseline followed by tumour progression,None,12,6,43,No,1:No,1:No,,0.943
715,1998889,Table 2,BaselineCharacteristic,Patients with small residual tumour at baseline followed by tumour progression,No. of PET scans ; ,Patients with small residual tumour at baseline followed by tumour progression,None,12,7,43,No,1:No,1:No,,0.94
715,1998889,Table 2,BaselineCharacteristic,Patients with small residual tumour at baseline followed by tumour progression,TUmax/BG: baseline ; ,Patients with small residual tumour at baseline followed by tumour progression,None,12,8,43,No,1:No,1:No,,0.933
715,1998889,Table 2,BaselineCharacteristic,Patients with small residual tumour at baseline followed by tumour progression,TUmax/BG: last follow-up  ; ,Patients with small residual tumour at baseline followed by tumour progression,None,12,9,43,No,1:No,1:No,,0.933
715,1998889,Table 2,BaselineCharacteristic,Patients with small residual tumour at baseline followed by tumour progression,Survival (mo.) post surgery ; ,Patients with small residual tumour at baseline followed by tumour progression,None,12,10,43,No,1:No,1:No,,0.933
715,1998889,Table 2,BaselineCharacteristic,xx,Age (yrs) ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,13,0,2,No,1:No,1:No,,0.839
715,1998889,Table 2,BaselineCharacteristic,m,Sex ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,13,1,3,No,1:No,1:No,,0.9
715,1998889,Table 2,BaselineCharacteristic,III,WHO ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,13,2,3,No,1:No,1:No,,0.88
715,1998889,Table 2,BaselineCharacteristic,xx/xx,Surgery ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,13,3,3,No,1:No,1:No,,0.88
715,1998889,Table 2,BaselineCharacteristic,x,RIT cycles ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,13,4,3,No,1:No,1:No,,0.9
715,1998889,Table 2,BaselineCharacteristic,"x,xxx/xxxI",Cum. activity (MBq)/nuclide ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,13,5,3,No,1:No,1:No,,0.89
715,1998889,Table 2,BaselineCharacteristic,xx/xx,RIT ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,13,6,3,No,1:No,1:No,,0.9
715,1998889,Table 2,BaselineCharacteristic,x,No. of PET scans ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,13,7,3,No,1:No,1:No,,0.9
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: baseline ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,13,8,3,No,1:No,1:No,,0.91
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: last follow-up  ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,13,9,3,No,1:No,1:No,,0.91
715,1998889,Table 2,BaselineCharacteristic,xx (†),Survival (mo.) post surgery ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,13,10,3,No,1:No,1:No,,0.92
715,1998889,Table 2,BaselineCharacteristic,xx,Age (yrs) ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,14,0,2,No,1:No,1:No,,0.859
715,1998889,Table 2,BaselineCharacteristic,m,Sex ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,14,1,3,No,1:No,1:No,,0.92
715,1998889,Table 2,BaselineCharacteristic,IV,WHO ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,14,2,3,No,1:No,1:No,,0.89
715,1998889,Table 2,BaselineCharacteristic,xx/xx,Surgery ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,14,3,3,No,1:No,1:No,,0.9
715,1998889,Table 2,BaselineCharacteristic,x,RIT cycles ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,14,4,3,No,1:No,1:No,,0.91
715,1998889,Table 2,BaselineCharacteristic,"x,xxx/xxxI",Cum. activity (MBq)/nuclide ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,14,5,3,No,1:No,1:No,,0.9
715,1998889,Table 2,BaselineCharacteristic,xx/xx–xx/xx,RIT ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,14,6,3,No,1:No,1:No,,0.91
715,1998889,Table 2,BaselineCharacteristic,x,No. of PET scans ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,14,7,3,No,1:No,1:No,,0.91
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: baseline ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,14,8,3,No,1:No,1:No,,0.92
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: last follow-up  ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,14,9,3,No,1:No,1:No,,0.92
715,1998889,Table 2,BaselineCharacteristic,xx (†),Survival (mo.) post surgery ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,14,10,3,No,1:No,1:No,,0.93
715,1998889,Table 2,BaselineCharacteristic,xx,Age (yrs) ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,15,0,2,No,1:No,1:No,,0.859
715,1998889,Table 2,BaselineCharacteristic,m,Sex ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,15,1,3,No,1:No,1:No,,0.92
715,1998889,Table 2,BaselineCharacteristic,IV,WHO ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,15,2,3,No,1:No,1:No,,0.89
715,1998889,Table 2,BaselineCharacteristic,xx/xx,Surgery ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,15,3,3,No,1:No,1:No,,0.9
715,1998889,Table 2,BaselineCharacteristic,x,RIT cycles ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,15,4,3,No,1:No,1:No,,0.91
715,1998889,Table 2,BaselineCharacteristic,"x,xxx/xxxI",Cum. activity (MBq)/nuclide ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,15,5,3,No,1:No,1:No,,0.9
715,1998889,Table 2,BaselineCharacteristic,xx/xx–xx/xx,RIT ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,15,6,3,No,1:No,1:No,,0.91
715,1998889,Table 2,BaselineCharacteristic,x,No. of PET scans ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,15,7,3,No,1:No,1:No,,0.91
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: baseline ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,15,8,3,No,1:No,1:No,,0.92
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: last follow-up  ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,15,9,3,No,1:No,1:No,,0.92
715,1998889,Table 2,BaselineCharacteristic,xx (†),Survival (mo.) post surgery ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,15,10,3,No,1:No,1:No,,0.93
715,1998889,Table 2,BaselineCharacteristic,xx,Age (yrs) ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,16,0,2,No,1:No,1:No,,0.859
715,1998889,Table 2,BaselineCharacteristic,m,Sex ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,16,1,3,No,1:No,1:No,,0.92
715,1998889,Table 2,BaselineCharacteristic,IV,WHO ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,16,2,3,No,1:No,1:No,,0.9
715,1998889,Table 2,BaselineCharacteristic,xx/xx,Surgery ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,16,3,3,No,1:No,1:No,,0.91
715,1998889,Table 2,BaselineCharacteristic,x,RIT cycles ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,16,4,3,No,1:No,1:No,,0.92
715,1998889,Table 2,BaselineCharacteristic,xxx/xxxRe,Cum. activity (MBq)/nuclide ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,16,5,3,No,1:No,1:No,,0.91
715,1998889,Table 2,BaselineCharacteristic,xx/xx,RIT ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,16,6,3,No,1:No,1:No,,0.92
715,1998889,Table 2,BaselineCharacteristic,x,No. of PET scans ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,16,7,3,No,1:No,1:No,,0.91
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: baseline ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,16,8,3,No,1:No,1:No,,0.93
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: last follow-up  ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,16,9,3,No,1:No,1:No,,0.93
715,1998889,Table 2,BaselineCharacteristic,xx (l.c.),Survival (mo.) post surgery ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,16,10,3,No,1:No,1:No,,0.93
715,1998889,Table 2,BaselineCharacteristic,xx,Age (yrs) ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,17,0,2,No,1:No,1:No,,0.859
715,1998889,Table 2,BaselineCharacteristic,m,Sex ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,17,1,3,No,1:No,1:No,,0.92
715,1998889,Table 2,BaselineCharacteristic,IV,WHO ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,17,2,3,No,1:No,1:No,,0.9
715,1998889,Table 2,BaselineCharacteristic,xx/xx,Surgery ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,17,3,3,No,1:No,1:No,,0.91
715,1998889,Table 2,BaselineCharacteristic,x,RIT cycles ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,17,4,3,No,1:No,1:No,,0.92
715,1998889,Table 2,BaselineCharacteristic,xxx/xxxRe,Cum. activity (MBq)/nuclide ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,17,5,3,No,1:No,1:No,,0.91
715,1998889,Table 2,BaselineCharacteristic,xx/xx,RIT ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,17,6,3,No,1:No,1:No,,0.92
715,1998889,Table 2,BaselineCharacteristic,x,No. of PET scans ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,17,7,3,No,1:No,1:No,,0.91
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: baseline ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,17,8,3,No,1:No,1:No,,0.93
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: last follow-up  ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,17,9,3,No,1:No,1:No,,0.93
715,1998889,Table 2,BaselineCharacteristic,xx (l.c.),Survival (mo.) post surgery ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,17,10,3,No,1:No,1:No,,0.93
715,1998889,Table 2,BaselineCharacteristic,xx,Age (yrs) ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,18,0,2,No,1:No,1:No,,0.854
715,1998889,Table 2,BaselineCharacteristic,m,Sex ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,18,1,3,No,1:No,1:No,,0.915
715,1998889,Table 2,BaselineCharacteristic,IV,WHO ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,18,2,3,No,1:No,1:No,,0.895
715,1998889,Table 2,BaselineCharacteristic,xx/xx,Surgery ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,18,3,3,No,1:No,1:No,,0.905
715,1998889,Table 2,BaselineCharacteristic,x,RIT cycles ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,18,4,3,No,1:No,1:No,,0.915
715,1998889,Table 2,BaselineCharacteristic,"x,xxx/xxxI",Cum. activity (MBq)/nuclide ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,18,5,3,No,1:No,1:No,,0.905
715,1998889,Table 2,BaselineCharacteristic,xx/xx,RIT ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,18,6,3,No,1:No,1:No,,0.915
715,1998889,Table 2,BaselineCharacteristic,x,No. of PET scans ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,18,7,3,No,1:No,1:No,,0.91
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: baseline ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,18,8,3,No,1:No,1:No,,0.925
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: last follow-up  ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,18,9,3,No,1:No,1:No,,0.925
715,1998889,Table 2,BaselineCharacteristic,xx (l.c.),Survival (mo.) post surgery ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,18,10,3,No,1:No,1:No,,0.925
715,1998889,Table 2,BaselineCharacteristic,xx,Age (yrs) ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,19,0,2,No,1:No,1:No,,0.854
715,1998889,Table 2,BaselineCharacteristic,m,Sex ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,19,1,3,No,1:No,1:No,,0.915
715,1998889,Table 2,BaselineCharacteristic,IV,WHO ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,19,2,3,No,1:No,1:No,,0.895
715,1998889,Table 2,BaselineCharacteristic,xx/xx,Surgery ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,19,3,3,No,1:No,1:No,,0.905
715,1998889,Table 2,BaselineCharacteristic,x,RIT cycles ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,19,4,3,No,1:No,1:No,,0.915
715,1998889,Table 2,BaselineCharacteristic,"x,xxx/xxxI",Cum. activity (MBq)/nuclide ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,19,5,3,No,1:No,1:No,,0.905
715,1998889,Table 2,BaselineCharacteristic,xx/xx–xx/xx,RIT ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,19,6,3,No,1:No,1:No,,0.915
715,1998889,Table 2,BaselineCharacteristic,x,No. of PET scans ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,19,7,3,No,1:No,1:No,,0.91
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: baseline ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,19,8,3,No,1:No,1:No,,0.925
715,1998889,Table 2,BaselineCharacteristic,x.x (xx/xx),TUmax/BG: last follow-up  ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,19,9,3,No,1:No,1:No,,0.925
715,1998889,Table 2,BaselineCharacteristic,xx (l.c.),Survival (mo.) post surgery ; ,xx, Patients with small residual tumour at baseline followed by tumour progression,19,10,3,No,1:No,1:No,,0.925
1118,2204057,Table 1,BaselineCharacteristic,Group,,None,None,0,0,12,No,1:No,1:No,,0.905
1118,2204057,Table 1,BaselineCharacteristic,N,,Group,None,0,1,1,No,1:No,1:No,,0.903
1118,2204057,Table 1,BaselineCharacteristic,Mean AGE (SD),,Group,None,0,2,1,No,1:No,1:No,,0.765
1118,2204057,Table 1,BaselineCharacteristic,Min AGE,,Group,None,0,3,1,No,1:No,1:No,,0.903
1118,2204057,Table 1,BaselineCharacteristic,Max AGE,,Group,None,0,4,1,No,1:No,1:No,,0.913
1118,2204057,Table 1,BaselineCharacteristic,No. FEMALE (%),,Group,None,0,5,1,No,1:No,1:No,,0.845
1118,2204057,Table 1,BaselineCharacteristic,No. MALE (%),,Group,None,0,6,1,No,1:No,1:No,,0.845
1118,2204057,Table 1,BaselineCharacteristic,Group x,Group ; ,Group x,None,1,0,2,No,1:No,1:No,,0.915
1118,2204057,Table 1,BaselineCharacteristic,xx,N ; ,Group x,None,1,1,3,No,1:No,1:No,,0.612
1118,2204057,Table 1,BaselineCharacteristic,xx,Min AGE ; ,Group x,None,1,3,3,No,1:No,1:No,,0.562
1118,2204057,Table 1,BaselineCharacteristic,xx,Max AGE ; ,Group x,None,1,4,3,No,1:No,1:No,,0.582
1118,2204057,Table 1,BaselineCharacteristic,x (xx),No. FEMALE (%) ; ,Group x,None,1,5,3,No,1:No,1:No,,0.506
1118,2204057,Table 1,BaselineCharacteristic,x (xx),No. MALE (%) ; ,Group x,None,1,6,3,No,1:No,1:No,,0.506
1118,2204057,Table 1,BaselineCharacteristic,Group x,Group ; ,Group x,None,2,0,2,No,1:No,1:No,,0.935
1118,2204057,Table 1,BaselineCharacteristic,xx,N ; ,Group x,None,2,1,3,No,1:No,1:No,,0.632
1118,2204057,Table 1,BaselineCharacteristic,xx,Min AGE ; ,Group x,None,2,3,3,No,1:No,1:No,,0.612
1118,2204057,Table 1,BaselineCharacteristic,xx,Max AGE ; ,Group x,None,2,4,3,No,1:No,1:No,,0.632
1118,2204057,Table 1,BaselineCharacteristic,x (xx),No. FEMALE (%) ; ,Group x,None,2,5,3,No,1:No,1:No,,0.546
1118,2204057,Table 1,BaselineCharacteristic,x (xx),No. MALE (%) ; ,Group x,None,2,6,3,No,1:No,1:No,,0.546
1118,2204057,Table 1,BaselineCharacteristic,Controls,Group ; ,Controls,None,3,0,2,No,1:No,1:No,,0.96
1118,2204057,Table 1,BaselineCharacteristic,x,N ; ,Controls,None,3,1,3,No,1:No,1:No,,0.93
1118,2204057,Table 1,BaselineCharacteristic,xx,Min AGE ; ,Controls,None,3,3,3,No,1:No,1:No,,0.661
1118,2204057,Table 1,BaselineCharacteristic,xx,Max AGE ; ,Controls,None,3,4,3,No,1:No,1:No,,0.681
1118,2204057,Table 1,BaselineCharacteristic,x (xx),No. FEMALE (%) ; ,Controls,None,3,5,3,No,1:No,1:No,,0.55
1118,2204057,Table 1,BaselineCharacteristic,x (xx),No. MALE (%) ; ,Controls,None,3,6,3,No,1:No,1:No,,0.55
1118,2204057,Table 1,BaselineCharacteristic,TOTAL COHORT,Group ; ,TOTAL COHORT,None,4,0,2,No,1:No,1:No,,0.97
1118,2204057,Table 1,BaselineCharacteristic,xx,N ; ,TOTAL COHORT,None,4,1,3,No,1:No,1:No,,0.741
1118,2204057,Table 1,BaselineCharacteristic,,Mean AGE (SD) ; ,TOTAL COHORT,None,4,2,3,No,1:No,1:No,,0.81
1118,2204057,Table 1,BaselineCharacteristic,xx,Min AGE ; ,TOTAL COHORT,None,4,3,3,No,1:No,1:No,,0.741
1118,2204057,Table 1,BaselineCharacteristic,xx,Max AGE ; ,TOTAL COHORT,None,4,4,3,No,1:No,1:No,,0.761
1118,2204057,Table 1,BaselineCharacteristic,xx (xx),No. FEMALE (%) ; ,TOTAL COHORT,None,4,5,3,No,1:No,1:No,,0.696
1118,2204057,Table 1,BaselineCharacteristic,xx (xx),No. MALE (%) ; ,TOTAL COHORT,None,4,6,3,No,1:No,1:No,,0.696
1233,2259321,Table 1,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
1233,2259321,Table 1,BaselineCharacteristic,Celecoxib Dose,,,None,0,1,1,No,1:No,1:No,,0.823
1233,2259321,Table 1,BaselineCharacteristic,Celecoxib Dose,,,None,0,2,1,No,1:No,1:No,,0.825
1233,2259321,Table 1,BaselineCharacteristic,, ; ,None,None,1,0,12,No,1:No,1:No,,0.898
1233,2259321,Table 1,BaselineCharacteristic,,Celecoxib Dose ; ,,None,1,1,1,No,1:No,1:No,,0.815
1233,2259321,Table 1,BaselineCharacteristic,,Celecoxib Dose ; ,,None,1,2,1,No,1:No,1:No,,0.817
1233,2259321,Table 1,BaselineCharacteristic,, ;  ; ,None,None,2,0,12,No,1:No,1:No,,0.913
1233,2259321,Table 1,BaselineCharacteristic,xxx mg twice daily,Celecoxib Dose ;  ; ,,None,2,1,1,No,1:No,1:No,,0.608
1233,2259321,Table 1,BaselineCharacteristic,xxx mg twice daily,Celecoxib Dose ;  ; ,,None,2,2,1,No,1:No,1:No,,0.622
1233,2259321,Table 1,BaselineCharacteristic,, ;  ;  ; ,None,None,3,0,12,No,1:No,1:No,,0.923
1233,2259321,Table 1,BaselineCharacteristic,,Celecoxib Dose ;  ; xxx mg twice daily ; ,,None,3,1,1,No,1:No,1:No,,0.611
1233,2259321,Table 1,BaselineCharacteristic,,Celecoxib Dose ;  ; xxx mg twice daily ; ,,None,3,2,1,No,1:No,1:No,,0.625
1233,2259321,Table 1,BaselineCharacteristic,, ;  ;  ;  ; ,None,None,4,0,12,No,1:No,1:No,,0.93
1233,2259321,Table 1,BaselineCharacteristic,NAF (plasma),Celecoxib Dose ;  ; xxx mg twice daily ;  ; ,,None,4,1,1,No,1:No,1:No,,0.531
1233,2259321,Table 1,BaselineCharacteristic,NAF(plasma),Celecoxib Dose ;  ; xxx mg twice daily ;  ; ,,None,4,2,1,No,1:No,1:No,,0.545
1233,2259321,Table 1,BaselineCharacteristic,Samples, ;  ;  ;  ;  ; ,Samples,,5,0,2,No,1:No,1:No,,0.97
1233,2259321,Table 1,BaselineCharacteristic,Age (years), ;  ;  ;  ;  ; ,None,None,6,0,24,No,1:No,1:No,,0.705
1233,2259321,Table 1,BaselineCharacteristic,?Median, ;  ;  ;  ;  ; ,?Median, Age (years),7,0,2,No,1:No,1:No,,0.67
1233,2259321,Table 1,BaselineCharacteristic,?Range, ;  ;  ;  ;  ; ,?Range, Age (years),8,0,2,No,1:No,1:No,,0.68
1233,2259321,Table 1,BaselineCharacteristic,Premenopausal, ;  ;  ;  ;  ; ,Premenopausal,,9,0,2,No,1:No,1:No,,1
1233,2259321,Table 1,BaselineCharacteristic,x (x),Celecoxib Dose ;  ; xxx mg twice daily ;  ; NAF (plasma) ; ,Premenopausal,,9,1,3,No,1:No,1:No,,0.605
1233,2259321,Table 1,BaselineCharacteristic,Race, ;  ;  ;  ;  ; ,None,None,10,0,24,No,1:No,1:No,,0.995
1233,2259321,Table 1,BaselineCharacteristic,,Celecoxib Dose ;  ; xxx mg twice daily ;  ; NAF (plasma) ; ,Race,None,10,1,43,No,1:No,1:No,,0.572
1233,2259321,Table 1,BaselineCharacteristic,,Celecoxib Dose ;  ; xxx mg twice daily ;  ; NAF(plasma) ; ,Race,None,10,2,43,No,1:No,1:No,,0.592
1233,2259321,Table 1,BaselineCharacteristic,?White, ;  ;  ;  ;  ; ,?White, Race,11,0,2,No,1:No,1:No,,1
1233,2259321,Table 1,BaselineCharacteristic,?Black, ;  ;  ;  ;  ; ,?Black, Race,12,0,2,No,1:No,1:No,,1
1233,2259321,Table 1,BaselineCharacteristic,x,Celecoxib Dose ;  ; xxx mg twice daily ;  ; NAF (plasma) ; ,?Black, Race,12,1,3,No,1:No,1:No,,0.615
1233,2259321,Table 1,BaselineCharacteristic,x,Celecoxib Dose ;  ; xxx mg twice daily ;  ; NAF(plasma) ; ,?Black, Race,12,2,3,No,1:No,1:No,,0.635
1233,2259321,Table 1,BaselineCharacteristic,?Asian, ;  ;  ;  ;  ; ,?Asian, Race,13,0,2,No,1:No,1:No,,1
1233,2259321,Table 1,BaselineCharacteristic,x,Celecoxib Dose ;  ; xxx mg twice daily ;  ; NAF (plasma) ; ,?Asian, Race,13,1,3,No,1:No,1:No,,0.625
1233,2259321,Table 1,BaselineCharacteristic,x,Celecoxib Dose ;  ; xxx mg twice daily ;  ; NAF(plasma) ; ,?Asian, Race,13,2,3,No,1:No,1:No,,0.645
1233,2259321,Table 1,BaselineCharacteristic,?American Indian, ;  ;  ;  ;  ; ,?American Indian, Race,14,0,2,No,1:No,1:No,,1
1233,2259321,Table 1,BaselineCharacteristic,x,Celecoxib Dose ;  ; xxx mg twice daily ;  ; NAF (plasma) ; ,?American Indian, Race,14,1,3,No,1:No,1:No,,0.625
1233,2259321,Table 1,BaselineCharacteristic,x (x),Celecoxib Dose ;  ; xxx mg twice daily ;  ; NAF(plasma) ; ,?American Indian, Race,14,2,3,No,1:No,1:No,,0.645
1233,2259321,Table 1,BaselineCharacteristic,Primary Risk Factors for Enrollment, ;  ;  ;  ;  ; ,None,None,15,0,24,No,1:No,1:No,,0.995
1233,2259321,Table 1,BaselineCharacteristic,,Celecoxib Dose ;  ; xxx mg twice daily ;  ; NAF (plasma) ; ,Primary Risk Factors for Enrollment,None,15,1,43,No,1:No,1:No,,0.645
1233,2259321,Table 1,BaselineCharacteristic,,Celecoxib Dose ;  ; xxx mg twice daily ;  ; NAF(plasma) ; ,Primary Risk Factors for Enrollment,None,15,2,43,No,1:No,1:No,,0.665
1233,2259321,Table 1,BaselineCharacteristic,?Family History, ;  ;  ;  ;  ; ,?Family History, Primary Risk Factors for Enrollment,16,0,2,No,1:No,1:No,,1
1233,2259321,Table 1,BaselineCharacteristic,xx (xx),Celecoxib Dose ;  ; xxx mg twice daily ;  ; NAF (plasma) ; ,?Family History, Primary Risk Factors for Enrollment,16,1,3,No,1:No,1:No,,0.555
1233,2259321,Table 1,BaselineCharacteristic,xx (xx),Celecoxib Dose ;  ; xxx mg twice daily ;  ; NAF(plasma) ; ,?Family History, Primary Risk Factors for Enrollment,16,2,3,No,1:No,1:No,,0.565
1233,2259321,Table 1,BaselineCharacteristic,?Hyperplasia with/without atypia, ;  ;  ;  ;  ; ,?Hyperplasia with/without atypia, Primary Risk Factors for Enrollment,17,0,2,No,1:No,1:No,,1
1233,2259321,Table 1,BaselineCharacteristic,x (x),Celecoxib Dose ;  ; xxx mg twice daily ;  ; NAF (plasma) ; ,?Hyperplasia with/without atypia, Primary Risk Factors for Enrollment,17,1,3,No,1:No,1:No,,0.675
1233,2259321,Table 1,BaselineCharacteristic,x (x),Celecoxib Dose ;  ; xxx mg twice daily ;  ; NAF(plasma) ; ,?Hyperplasia with/without atypia, Primary Risk Factors for Enrollment,17,2,3,No,1:No,1:No,,0.695
1233,2259321,Table 1,BaselineCharacteristic,?History of Breast Cancer, ;  ;  ;  ;  ; ,?History of Breast Cancer, Primary Risk Factors for Enrollment,18,0,2,No,1:No,1:No,,0.99
1233,2259321,Table 1,BaselineCharacteristic,x (x),Celecoxib Dose ;  ; xxx mg twice daily ;  ; NAF (plasma) ; ,?History of Breast Cancer, Primary Risk Factors for Enrollment,18,1,3,No,1:No,1:No,,0.685
1233,2259321,Table 1,BaselineCharacteristic,x (x),Celecoxib Dose ;  ; xxx mg twice daily ;  ; NAF(plasma) ; ,?History of Breast Cancer, Primary Risk Factors for Enrollment,18,2,3,No,1:No,1:No,,0.705
1233,2259321,Table 1,BaselineCharacteristic,?History Prior Breast Biopsy, ;  ;  ;  ;  ; ,?History Prior Breast Biopsy, Primary Risk Factors for Enrollment,19,0,2,No,1:No,1:No,,0.99
1233,2259321,Table 1,BaselineCharacteristic,x (x),Celecoxib Dose ;  ; xxx mg twice daily ;  ; NAF (plasma) ; ,?History Prior Breast Biopsy, Primary Risk Factors for Enrollment,19,1,3,No,1:No,1:No,,0.675
1233,2259321,Table 1,BaselineCharacteristic,x,Celecoxib Dose ;  ; xxx mg twice daily ;  ; NAF(plasma) ; ,?History Prior Breast Biopsy, Primary Risk Factors for Enrollment,19,2,3,No,1:No,1:No,,0.695
1273,2359721,Table 1,BaselineCharacteristic,Total,,None,None,0,0,12,No,1:No,1:No,,0.905
1273,2359721,Table 1,BaselineCharacteristic,xx,,Total,None,0,1,1,No,1:No,1:No,,0.729
1273,2359721,Table 1,BaselineCharacteristic,Male/female,,None,None,1,0,12,No,1:No,1:No,,0.898
1273,2359721,Table 1,BaselineCharacteristic,xx/xx,,Male/female,None,1,1,1,No,1:No,1:No,,0.895
1273,2359721,Table 1,BaselineCharacteristic,"Range, years",,None,None,3,0,12,No,1:No,1:No,,0.625
1273,2359721,Table 1,BaselineCharacteristic,,,None,None,4,0,2,No,1:No,1:No,,0.97
1273,2359721,Table 1,BaselineCharacteristic,,,None,None,4,1,3,No,1:No,1:No,,0.89
1273,2359721,Table 1,BaselineCharacteristic,Prior chemotherapy,,None,None,5,0,24,No,1:No,1:No,,0.929
1273,2359721,Table 1,BaselineCharacteristic,Prior chemotherapy,,Prior chemotherapy,None,5,1,43,No,1:No,1:No,,0.908
1273,2359721,Table 1,BaselineCharacteristic,?None,,?None, Prior chemotherapy,6,0,2,No,1:No,1:No,,0.99
1273,2359721,Table 1,BaselineCharacteristic,x,,?None, Prior chemotherapy,6,1,3,No,1:No,1:No,,0.95
1273,2359721,Table 1,BaselineCharacteristic,?x–x prior regimens,,?x–x prior regimens, Prior chemotherapy,7,0,2,No,1:No,1:No,,0.99
1273,2359721,Table 1,BaselineCharacteristic,xx,,?x–x prior regimens, Prior chemotherapy,7,1,3,No,1:No,1:No,,0.846
1273,2359721,Table 1,BaselineCharacteristic,??x prior regimens,,??x prior regimens, Prior chemotherapy,8,0,2,No,1:No,1:No,,0.979
1273,2359721,Table 1,BaselineCharacteristic,xx,,??x prior regimens, Prior chemotherapy,8,1,3,No,1:No,1:No,,0.84
1273,2359721,Table 1,BaselineCharacteristic,,,None,None,9,0,2,No,1:No,1:No,,1
1273,2359721,Table 1,BaselineCharacteristic,,,None,None,9,1,3,No,1:No,1:No,,0.97
1273,2359721,Table 1,BaselineCharacteristic,Prior radiotherapy,,None,None,10,0,24,No,1:No,1:No,,0.995
1273,2359721,Table 1,BaselineCharacteristic,Prior radiotherapy,,Prior radiotherapy,None,10,1,43,No,1:No,1:No,,0.977
1273,2359721,Table 1,BaselineCharacteristic,?No,,?No, Prior radiotherapy,11,0,2,No,1:No,1:No,,1
1273,2359721,Table 1,BaselineCharacteristic,xx,,?No, Prior radiotherapy,11,1,3,No,1:No,1:No,,0.921
1273,2359721,Table 1,BaselineCharacteristic,?Yes,,?Yes, Prior radiotherapy,12,0,2,No,1:No,1:No,,1
1273,2359721,Table 1,BaselineCharacteristic,xx,,?Yes, Prior radiotherapy,12,1,3,No,1:No,1:No,,0.921
1273,2359721,Table 1,BaselineCharacteristic,,,None,None,13,0,2,No,1:No,1:No,,1
1273,2359721,Table 1,BaselineCharacteristic,,,None,None,13,1,3,No,1:No,1:No,,0.99
1273,2359721,Table 1,BaselineCharacteristic,Prior hormonal therapy,,None,None,14,0,24,No,1:No,1:No,,0.995
1273,2359721,Table 1,BaselineCharacteristic,Prior hormonal therapy,,Prior hormonal therapy,None,14,1,43,No,1:No,1:No,,0.977
1273,2359721,Table 1,BaselineCharacteristic,?No,,?No, Prior hormonal therapy,15,0,2,No,1:No,1:No,,1
1273,2359721,Table 1,BaselineCharacteristic,xx,,?No, Prior hormonal therapy,15,1,3,No,1:No,1:No,,0.951
1273,2359721,Table 1,BaselineCharacteristic,?Yes,,?Yes, Prior hormonal therapy,16,0,2,No,1:No,1:No,,1
1273,2359721,Table 1,BaselineCharacteristic,x,,?Yes, Prior hormonal therapy,16,1,3,No,1:No,1:No,,1
1273,2359721,Table 1,BaselineCharacteristic,,,None,None,17,0,2,No,1:No,1:No,,1
1273,2359721,Table 1,BaselineCharacteristic,,,None,None,17,1,3,No,1:No,1:No,,0.98
1273,2359721,Table 1,BaselineCharacteristic,Tumour type,,None,None,18,0,2,No,1:No,1:No,,0.99
1273,2359721,Table 1,BaselineCharacteristic,,,None,None,18,1,3,No,1:No,1:No,,0.97
1273,2359721,Table 1,BaselineCharacteristic,Colorectal carcinoma,,Colorectal carcinoma,,19,0,2,No,1:No,1:No,,0.99
1273,2359721,Table 1,BaselineCharacteristic,xx,,Colorectal carcinoma,,19,1,3,No,1:No,1:No,,0.927
1273,2359721,Table 1,BaselineCharacteristic,Oesophageal carcinoma,,Oesophageal carcinoma,,20,0,2,No,1:No,1:No,,0.99
1273,2359721,Table 1,BaselineCharacteristic,x,,Oesophageal carcinoma,,20,1,3,No,1:No,1:No,,0.98
1273,2359721,Table 1,BaselineCharacteristic,Renal cell carcinoma,,Renal cell carcinoma,,21,0,2,No,1:No,1:No,,0.99
1273,2359721,Table 1,BaselineCharacteristic,x,,Renal cell carcinoma,,21,1,3,No,1:No,1:No,,0.98
1273,2359721,Table 1,BaselineCharacteristic,Nonsmall cell lung cancer,,Nonsmall cell lung cancer,,22,0,2,No,1:No,1:No,,1
1273,2359721,Table 1,BaselineCharacteristic,x,,Nonsmall cell lung cancer,,22,1,3,No,1:No,1:No,,0.99
1273,2359721,Table 1,BaselineCharacteristic,ACUP,,ACUP,,23,0,2,No,1:No,1:No,,1
1273,2359721,Table 1,BaselineCharacteristic,x,,ACUP,,23,1,3,No,1:No,1:No,,0.99
1273,2359721,Table 1,BaselineCharacteristic,Pancreatic carcinoma,,Pancreatic carcinoma,,24,0,2,No,1:No,1:No,,1
1273,2359721,Table 1,BaselineCharacteristic,x,,Pancreatic carcinoma,,24,1,3,No,1:No,1:No,,0.99
1273,2359721,Table 1,BaselineCharacteristic,Miscellaneous,,Miscellaneous,,25,0,2,No,1:No,1:No,,1
1273,2359721,Table 1,BaselineCharacteristic,xx,,Miscellaneous,,25,1,3,No,1:No,1:No,,0.937
1283,2359964,Table 1,BaselineCharacteristic,Median Karnofsky performance status:,,None,None,1,0,12,No,1:No,1:No,,0.898
1283,2359964,Table 1,BaselineCharacteristic,xx (xx–xx),,Median Karnofsky performance status:,None,1,1,1,No,1:No,1:No,,0.51
1283,2359964,Table 1,BaselineCharacteristic,Adenocarcinoma?:?squamous,,None,None,2,0,12,No,1:No,1:No,,0.913
1283,2359964,Table 1,BaselineCharacteristic,xx?:?xx,,Adenocarcinoma?:?squamous,None,2,1,1,No,1:No,1:No,,0.792
1283,2359964,Table 1,BaselineCharacteristic,,,None,None,3,0,2,No,1:No,1:No,,0.96
1283,2359964,Table 1,BaselineCharacteristic,,,None,None,3,1,3,No,1:No,1:No,,0.9
1283,2359964,Table 1,BaselineCharacteristic,Stage,,None,None,4,0,24,No,1:No,1:No,,0.929
1283,2359964,Table 1,BaselineCharacteristic,Stage,,Stage,None,4,1,43,No,1:No,1:No,,0.902
1283,2359964,Table 1,BaselineCharacteristic,?TxNx,,?TxNx, Stage,5,0,2,No,1:No,1:No,,0.97
1283,2359964,Table 1,BaselineCharacteristic,x (x%),,?TxNx, Stage,5,1,3,No,1:No,1:No,,0.94
1283,2359964,Table 1,BaselineCharacteristic,?TxNX,,?TxNX, Stage,6,0,2,No,1:No,1:No,,0.99
1283,2359964,Table 1,BaselineCharacteristic,x (xx%),,?TxNX, Stage,6,1,3,No,1:No,1:No,,0.96
1283,2359964,Table 1,BaselineCharacteristic,?TxNx,,?TxNx, Stage,7,0,2,No,1:No,1:No,,0.99
1283,2359964,Table 1,BaselineCharacteristic,xx (xx%),,?TxNx, Stage,7,1,3,No,1:No,1:No,,0.871
1283,2359964,Table 1,BaselineCharacteristic,?TxNx,,?TxNx, Stage,8,0,2,No,1:No,1:No,,0.99
1283,2359964,Table 1,BaselineCharacteristic,x (xx%),,?TxNx, Stage,8,1,3,No,1:No,1:No,,0.98
1283,2359964,Table 1,BaselineCharacteristic,?TxNx,,?TxNx, Stage,9,0,2,No,1:No,1:No,,1
1283,2359964,Table 1,BaselineCharacteristic,x (xx%),,?TxNx, Stage,9,1,3,No,1:No,1:No,,0.99
1283,2359964,Table 1,BaselineCharacteristic,,,None,None,10,0,2,No,1:No,1:No,,1
1283,2359964,Table 1,BaselineCharacteristic,,,None,None,10,1,3,No,1:No,1:No,,0.99
1283,2359964,Table 1,BaselineCharacteristic,Comorbidities,,None,None,11,0,24,No,1:No,1:No,,0.995
1283,2359964,Table 1,BaselineCharacteristic,Comorbidities,,Comorbidities,None,11,1,43,No,1:No,1:No,,0.977
1283,2359964,Table 1,BaselineCharacteristic,?Diabetes,,?Diabetes, Comorbidities,12,0,2,No,1:No,1:No,,1
1283,2359964,Table 1,BaselineCharacteristic,x (xx%),,?Diabetes, Comorbidities,12,1,3,No,1:No,1:No,,1
1283,2359964,Table 1,BaselineCharacteristic,?Pulmonary disease,,?Pulmonary disease, Comorbidities,13,0,2,No,1:No,1:No,,1
1283,2359964,Table 1,BaselineCharacteristic,x (xx%),,?Pulmonary disease, Comorbidities,13,1,3,No,1:No,1:No,,1
1283,2359964,Table 1,BaselineCharacteristic,?Coronary artery or peripheral vascular,,?Coronary artery or peripheral vascular, Comorbidities,14,0,2,No,1:No,1:No,,1
1283,2359964,Table 1,BaselineCharacteristic,x (xx%),,?Coronary artery or peripheral vascular, Comorbidities,14,1,3,No,1:No,1:No,,1
1283,2359964,Table 1,BaselineCharacteristic,,,None,None,15,0,2,No,1:No,1:No,,1
1283,2359964,Table 1,BaselineCharacteristic,,,None,None,15,1,3,No,1:No,1:No,,0.98
1283,2359964,Table 1,BaselineCharacteristic,Disease,,None,None,16,0,24,No,1:No,1:No,,0.995
1283,2359964,Table 1,BaselineCharacteristic,Disease,,Disease,None,16,1,43,No,1:No,1:No,,0.967
1283,2359964,Table 1,BaselineCharacteristic,?Median Charlson score,,?Median Charlson score, Disease,17,0,2,No,1:No,1:No,,1
1283,2359964,Table 1,BaselineCharacteristic,x,,?Median Charlson score, Disease,17,1,3,No,1:No,1:No,,0.99
1283,2359964,Table 1,BaselineCharacteristic,?Charlson score x or more,,?Charlson score x or more, Disease,18,0,2,No,1:No,1:No,,0.982
1283,2359964,Table 1,BaselineCharacteristic,xx (xx%),,?Charlson score x or more, Disease,18,1,3,No,1:No,1:No,,0.97
1287,2360042,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,0,12,No,1:No,1:No,,0.905
1287,2360042,Table 1,BaselineCharacteristic,No,,Characteristic,None,0,1,1,No,1:No,1:No,,0.903
1287,2360042,Table 1,BaselineCharacteristic,%,,Characteristic,None,0,2,1,No,1:No,1:No,,0.803
1287,2360042,Table 1,BaselineCharacteristic,Characteristic,,Characteristic,None,0,3,1,No,1:No,1:No,,0.903
1287,2360042,Table 1,BaselineCharacteristic,Characteristic,,Characteristic,None,0,4,1,No,1:No,1:No,,0.913
1287,2360042,Table 1,BaselineCharacteristic,No,,Characteristic,None,0,5,1,No,1:No,1:No,,0.935
1287,2360042,Table 1,BaselineCharacteristic,%,,Characteristic,None,0,6,1,No,1:No,1:No,,0.845
1287,2360042,Table 1,BaselineCharacteristic,Total,Characteristic ; ,Total,,1,0,2,No,1:No,1:No,,0.94
1287,2360042,Table 1,BaselineCharacteristic,xx,No ; ,Total,,1,1,3,No,1:No,1:No,,0.658
1287,2360042,Table 1,BaselineCharacteristic,xxx,% ; ,Total,,1,2,3,No,1:No,1:No,,0.7
1287,2360042,Table 1,BaselineCharacteristic,Male,Characteristic ; ,Total,,1,3,3,No,1:No,1:No,,0.89
1287,2360042,Table 1,BaselineCharacteristic,Male,Characteristic ; ,Total,,1,4,3,No,1:No,1:No,,0.88
1287,2360042,Table 1,BaselineCharacteristic,xx,No ; ,Total,,1,5,3,No,1:No,1:No,,0.662
1287,2360042,Table 1,BaselineCharacteristic,xx,% ; ,Total,,1,6,3,No,1:No,1:No,,0.592
1287,2360042,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,2,0,2,No,1:No,1:No,,0.95
1287,2360042,Table 1,BaselineCharacteristic,,No ; ,None,None,2,1,3,No,1:No,1:No,,0.89
1287,2360042,Table 1,BaselineCharacteristic,,% ; ,None,None,2,2,3,No,1:No,1:No,,0.73
1287,2360042,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,2,3,3,No,1:No,1:No,,0.9
1287,2360042,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,2,4,3,No,1:No,1:No,,0.89
1287,2360042,Table 1,BaselineCharacteristic,,No ; ,None,None,2,5,3,No,1:No,1:No,,0.9
1287,2360042,Table 1,BaselineCharacteristic,,% ; ,None,None,2,6,3,No,1:No,1:No,,0.76
1287,2360042,Table 1,BaselineCharacteristic,"Age, years",Characteristic ; ,"Age, years",,3,0,24,No,1:No,1:No,,0.695
1287,2360042,Table 1,BaselineCharacteristic,"Age, years",No ; ,"Age, years",,3,1,43,No,1:No,1:No,,0.634
1287,2360042,Table 1,BaselineCharacteristic,"Age, years",% ; ,"Age, years",,3,2,43,No,1:No,1:No,,0.719
1287,2360042,Table 1,BaselineCharacteristic,Previous therapy,Characteristic ; ,"Age, years",,3,3,43,No,1:No,1:No,,0.689
1287,2360042,Table 1,BaselineCharacteristic,Previous therapy,Characteristic ; ,"Age, years",,3,4,43,No,1:No,1:No,,0.689
1287,2360042,Table 1,BaselineCharacteristic,Previous therapy,No ; ,"Age, years",,3,5,43,No,1:No,1:No,,0.699
1287,2360042,Table 1,BaselineCharacteristic,Previous therapy,% ; ,"Age, years",,3,6,43,No,1:No,1:No,,0.739
1287,2360042,Table 1,BaselineCharacteristic,?Median,Characteristic ; ,?Median," Age, years",4,0,2,No,1:No,1:No,,0.67
1287,2360042,Table 1,BaselineCharacteristic,—,% ; ,?Median," Age, years",4,2,3,No,1:No,1:No,,0.55
1287,2360042,Table 1,BaselineCharacteristic,?Median no of treatments,Characteristic ; ,?Median," Age, years",4,3,3,No,1:No,1:No,,0.55
1287,2360042,Table 1,BaselineCharacteristic,?Median no of treatments,Characteristic ; ,?Median," Age, years",4,4,3,No,1:No,1:No,,0.55
1287,2360042,Table 1,BaselineCharacteristic,x,No ; ,?Median," Age, years",4,5,3,No,1:No,1:No,,0.65
1287,2360042,Table 1,BaselineCharacteristic,—,% ; ,?Median," Age, years",4,6,3,No,1:No,1:No,,0.61
1287,2360042,Table 1,BaselineCharacteristic,?Range,Characteristic ; ,?Range," Age, years",5,0,2,No,1:No,1:No,,0.67
1287,2360042,Table 1,BaselineCharacteristic,—,% ; ,?Range," Age, years",5,2,3,No,1:No,1:No,,0.55
1287,2360042,Table 1,BaselineCharacteristic,?Range,Characteristic ; ,?Range," Age, years",5,3,3,No,1:No,1:No,,0.57
1287,2360042,Table 1,BaselineCharacteristic,?Range,Characteristic ; ,?Range," Age, years",5,4,3,No,1:No,1:No,,0.6
1287,2360042,Table 1,BaselineCharacteristic,x–x,No ; ,?Range," Age, years",5,5,3,No,1:No,1:No,,0.62
1287,2360042,Table 1,BaselineCharacteristic,—,% ; ,?Range," Age, years",5,6,3,No,1:No,1:No,,0.61
1287,2360042,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,6,0,2,No,1:No,1:No,,0.99
1287,2360042,Table 1,BaselineCharacteristic,,No ; ,None,None,6,1,3,No,1:No,1:No,,0.94
1287,2360042,Table 1,BaselineCharacteristic,,% ; ,None,None,6,2,3,No,1:No,1:No,,0.83
1287,2360042,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,6,3,3,No,1:No,1:No,,0.96
1287,2360042,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,6,4,3,No,1:No,1:No,,0.95
1287,2360042,Table 1,BaselineCharacteristic,,No ; ,None,None,6,5,3,No,1:No,1:No,,0.94
1287,2360042,Table 1,BaselineCharacteristic,,% ; ,None,None,6,6,3,No,1:No,1:No,,0.85
1287,2360042,Table 1,BaselineCharacteristic,,Characteristic ; ,,,7,0,2,No,1:No,1:No,,0.99
1287,2360042,Table 1,BaselineCharacteristic,,No ; ,,,7,1,3,No,1:No,1:No,,0.95
1287,2360042,Table 1,BaselineCharacteristic,,% ; ,,,7,2,3,No,1:No,1:No,,0.85
1287,2360042,Table 1,BaselineCharacteristic,Radiation,Characteristic ; ,,,7,3,3,No,1:No,1:No,,0.96
1287,2360042,Table 1,BaselineCharacteristic,Radiation,Characteristic ; ,,,7,4,3,No,1:No,1:No,,0.96
1287,2360042,Table 1,BaselineCharacteristic,x,No ; ,,,7,5,3,No,1:No,1:No,,0.95
1287,2360042,Table 1,BaselineCharacteristic,xx,% ; ,,,7,6,3,No,1:No,1:No,,0.806
1287,2360042,Table 1,BaselineCharacteristic,Karnofsky performance status (%),Characteristic ; ,Karnofsky performance status (%),,8,0,24,No,1:No,1:No,,0.944
1287,2360042,Table 1,BaselineCharacteristic,Karnofsky performance status (%),No ; ,Karnofsky performance status (%),,8,1,43,No,1:No,1:No,,0.904
1287,2360042,Table 1,BaselineCharacteristic,Karnofsky performance status (%),% ; ,Karnofsky performance status (%),,8,2,43,No,1:No,1:No,,0.913
1287,2360042,Table 1,BaselineCharacteristic,IL-x,Characteristic ; ,Karnofsky performance status (%),,8,3,43,No,1:No,1:No,,0.923
1287,2360042,Table 1,BaselineCharacteristic,IL-x,Characteristic ; ,Karnofsky performance status (%),,8,4,43,No,1:No,1:No,,0.923
1287,2360042,Table 1,BaselineCharacteristic,xx,No ; ,Karnofsky performance status (%),,8,5,43,No,1:No,1:No,,0.839
1287,2360042,Table 1,BaselineCharacteristic,xx,% ; ,Karnofsky performance status (%),,8,6,43,No,1:No,1:No,,0.829
1287,2360042,Table 1,BaselineCharacteristic,?xxx,Characteristic ; ,?xxx, Karnofsky performance status (%),9,0,2,No,1:No,1:No,,0.876
1287,2360042,Table 1,BaselineCharacteristic,x,No ; ,?xxx, Karnofsky performance status (%),9,1,3,No,1:No,1:No,,0.91
1287,2360042,Table 1,BaselineCharacteristic,xx,% ; ,?xxx, Karnofsky performance status (%),9,2,3,No,1:No,1:No,,0.781
1287,2360042,Table 1,BaselineCharacteristic,IFN,Characteristic ; ,?xxx, Karnofsky performance status (%),9,3,3,No,1:No,1:No,,0.87
1287,2360042,Table 1,BaselineCharacteristic,IFN,Characteristic ; ,?xxx, Karnofsky performance status (%),9,4,3,No,1:No,1:No,,0.88
1287,2360042,Table 1,BaselineCharacteristic,xx,No ; ,?xxx, Karnofsky performance status (%),9,5,3,No,1:No,1:No,,0.836
1287,2360042,Table 1,BaselineCharacteristic,xx,% ; ,?xxx, Karnofsky performance status (%),9,6,3,No,1:No,1:No,,0.826
1287,2360042,Table 1,BaselineCharacteristic,?xx,Characteristic ; ,?xx, Karnofsky performance status (%),10,0,2,No,1:No,1:No,,0.915
1287,2360042,Table 1,BaselineCharacteristic,xx,No ; ,?xx, Karnofsky performance status (%),10,1,3,No,1:No,1:No,,0.861
1287,2360042,Table 1,BaselineCharacteristic,xx,% ; ,?xx, Karnofsky performance status (%),10,2,3,No,1:No,1:No,,0.851
1287,2360042,Table 1,BaselineCharacteristic,Chemotherapy,Characteristic ; ,?xx, Karnofsky performance status (%),10,3,3,No,1:No,1:No,,0.851
1287,2360042,Table 1,BaselineCharacteristic,Chemotherapy,Characteristic ; ,?xx, Karnofsky performance status (%),10,4,3,No,1:No,1:No,,0.871
1287,2360042,Table 1,BaselineCharacteristic,x,No ; ,?xx, Karnofsky performance status (%),10,5,3,No,1:No,1:No,,0.85
1287,2360042,Table 1,BaselineCharacteristic,xx,% ; ,?xx, Karnofsky performance status (%),10,6,3,No,1:No,1:No,,0.876
1287,2360042,Table 1,BaselineCharacteristic,?xx,Characteristic ; ,?xx, Karnofsky performance status (%),11,0,2,No,1:No,1:No,,0.915
1287,2360042,Table 1,BaselineCharacteristic,x,No ; ,?xx, Karnofsky performance status (%),11,1,3,No,1:No,1:No,,0.826
1287,2360042,Table 1,BaselineCharacteristic,xx,% ; ,?xx, Karnofsky performance status (%),11,2,3,No,1:No,1:No,,0.851
1287,2360042,Table 1,BaselineCharacteristic,None,Characteristic ; ,?xx, Karnofsky performance status (%),11,3,3,No,1:No,1:No,,0.851
1287,2360042,Table 1,BaselineCharacteristic,None,Characteristic ; ,?xx, Karnofsky performance status (%),11,4,3,No,1:No,1:No,,0.871
1287,2360042,Table 1,BaselineCharacteristic,x,No ; ,?xx, Karnofsky performance status (%),11,5,3,No,1:No,1:No,,0.85
1287,2360042,Table 1,BaselineCharacteristic,xx,% ; ,?xx, Karnofsky performance status (%),11,6,3,No,1:No,1:No,,0.876
1287,2360042,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,12,0,2,No,1:No,1:No,,1
1287,2360042,Table 1,BaselineCharacteristic,,No ; ,None,None,12,1,3,No,1:No,1:No,,0.99
1287,2360042,Table 1,BaselineCharacteristic,,% ; ,None,None,12,2,3,No,1:No,1:No,,0.91
1287,2360042,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,12,3,3,No,1:No,1:No,,1
1287,2360042,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,12,4,3,No,1:No,1:No,,1
1287,2360042,Table 1,BaselineCharacteristic,,No ; ,None,None,12,5,3,No,1:No,1:No,,1
1287,2360042,Table 1,BaselineCharacteristic,,% ; ,None,None,12,6,3,No,1:No,1:No,,0.92
1287,2360042,Table 1,BaselineCharacteristic,Motzer risk factor,Characteristic ; ,Motzer risk factor,,13,0,24,No,1:No,1:No,,0.995
1287,2360042,Table 1,BaselineCharacteristic,Motzer risk factor,No ; ,Motzer risk factor,,13,1,43,No,1:No,1:No,,0.987
1287,2360042,Table 1,BaselineCharacteristic,Motzer risk factor,% ; ,Motzer risk factor,,13,2,43,No,1:No,1:No,,0.919
1287,2360042,Table 1,BaselineCharacteristic,Patients with metastatic disease,Characteristic ; ,Motzer risk factor,,13,3,43,No,1:No,1:No,,0.972
1287,2360042,Table 1,BaselineCharacteristic,Patients with metastatic disease,Characteristic ; ,Motzer risk factor,,13,4,43,No,1:No,1:No,,0.982
1287,2360042,Table 1,BaselineCharacteristic,xx,No ; ,Motzer risk factor,,13,5,43,No,1:No,1:No,,0.924
1287,2360042,Table 1,BaselineCharacteristic,xxx,% ; ,Motzer risk factor,,13,6,43,No,1:No,1:No,,0.875
1287,2360042,Table 1,BaselineCharacteristic,?x=low,Characteristic ; ,?x=low, Motzer risk factor,14,0,2,No,1:No,1:No,,1
1287,2360042,Table 1,BaselineCharacteristic,xx,No ; ,?x=low, Motzer risk factor,14,1,3,No,1:No,1:No,,0.951
1287,2360042,Table 1,BaselineCharacteristic,xx,% ; ,?x=low, Motzer risk factor,14,2,3,No,1:No,1:No,,0.861
1287,2360042,Table 1,BaselineCharacteristic,?Lung,Characteristic ; ,?x=low, Motzer risk factor,14,3,3,No,1:No,1:No,,0.99
1287,2360042,Table 1,BaselineCharacteristic,?Lung,Characteristic ; ,?x=low, Motzer risk factor,14,4,3,No,1:No,1:No,,1
1287,2360042,Table 1,BaselineCharacteristic,xx,No ; ,?x=low, Motzer risk factor,14,5,3,No,1:No,1:No,,0.946
1287,2360042,Table 1,BaselineCharacteristic,xx,% ; ,?x=low, Motzer risk factor,14,6,3,No,1:No,1:No,,0.896
1287,2360042,Table 1,BaselineCharacteristic,?x=intermediate,Characteristic ; ,?x=intermediate, Motzer risk factor,15,0,2,No,1:No,1:No,,1
1287,2360042,Table 1,BaselineCharacteristic,xx,No ; ,?x=intermediate, Motzer risk factor,15,1,3,No,1:No,1:No,,0.951
1287,2360042,Table 1,BaselineCharacteristic,xx,% ; ,?x=intermediate, Motzer risk factor,15,2,3,No,1:No,1:No,,0.861
1287,2360042,Table 1,BaselineCharacteristic,?Liver,Characteristic ; ,?x=intermediate, Motzer risk factor,15,3,3,No,1:No,1:No,,0.99
1287,2360042,Table 1,BaselineCharacteristic,?Liver,Characteristic ; ,?x=intermediate, Motzer risk factor,15,4,3,No,1:No,1:No,,1
1287,2360042,Table 1,BaselineCharacteristic,x,No ; ,?x=intermediate, Motzer risk factor,15,5,3,No,1:No,1:No,,1
1287,2360042,Table 1,BaselineCharacteristic,x,% ; ,?x=intermediate, Motzer risk factor,15,6,3,No,1:No,1:No,,0.93
1287,2360042,Table 1,BaselineCharacteristic,?=high,Characteristic ; ,?=high, Motzer risk factor,16,0,2,No,1:No,1:No,,1
1287,2360042,Table 1,BaselineCharacteristic,x,No ; ,?=high, Motzer risk factor,16,1,3,No,1:No,1:No,,0.99
1287,2360042,Table 1,BaselineCharacteristic,x,% ; ,?=high, Motzer risk factor,16,2,3,No,1:No,1:No,,0.93
1287,2360042,Table 1,BaselineCharacteristic,?Lymph nodes,Characteristic ; ,?=high, Motzer risk factor,16,3,3,No,1:No,1:No,,0.99
1287,2360042,Table 1,BaselineCharacteristic,?Lymph nodes,Characteristic ; ,?=high, Motzer risk factor,16,4,3,No,1:No,1:No,,1
1287,2360042,Table 1,BaselineCharacteristic,xx,No ; ,?=high, Motzer risk factor,16,5,3,No,1:No,1:No,,0.956
1287,2360042,Table 1,BaselineCharacteristic,xx,% ; ,?=high, Motzer risk factor,16,6,3,No,1:No,1:No,,0.906
1287,2360042,Table 1,BaselineCharacteristic,,Characteristic ; ,,,17,0,2,No,1:No,1:No,,1
1287,2360042,Table 1,BaselineCharacteristic,,No ; ,,,17,1,3,No,1:No,1:No,,0.98
1287,2360042,Table 1,BaselineCharacteristic,,% ; ,,,17,2,3,No,1:No,1:No,,0.9
1287,2360042,Table 1,BaselineCharacteristic,?Other (including bone),Characteristic ; ,,,17,3,3,No,1:No,1:No,,0.99
1287,2360042,Table 1,BaselineCharacteristic,?Other (including bone),Characteristic ; ,,,17,4,3,No,1:No,1:No,,1
1287,2360042,Table 1,BaselineCharacteristic,xx,No ; ,,,17,5,3,No,1:No,1:No,,0.946
1287,2360042,Table 1,BaselineCharacteristic,xx,% ; ,,,17,6,3,No,1:No,1:No,,0.896
1287,2360042,Table 1,BaselineCharacteristic,Histology,Characteristic ; ,Histology,,18,0,24,No,1:No,1:No,,0.985
1287,2360042,Table 1,BaselineCharacteristic,Histology,No ; ,Histology,,18,1,43,No,1:No,1:No,,0.957
1287,2360042,Table 1,BaselineCharacteristic,Histology,% ; ,Histology,,18,2,43,No,1:No,1:No,,0.899
1287,2360042,Table 1,BaselineCharacteristic,,Characteristic ; ,Histology,,18,3,43,No,1:No,1:No,,0.962
1287,2360042,Table 1,BaselineCharacteristic,,Characteristic ; ,Histology,,18,4,43,No,1:No,1:No,,0.972
1287,2360042,Table 1,BaselineCharacteristic,,No ; ,Histology,,18,5,43,No,1:No,1:No,,0.972
1287,2360042,Table 1,BaselineCharacteristic,,% ; ,Histology,,18,6,43,No,1:No,1:No,,0.929
1287,2360042,Table 1,BaselineCharacteristic,?Clear cell,Characteristic ; ,?Clear cell, Histology,19,0,2,No,1:No,1:No,,0.99
1287,2360042,Table 1,BaselineCharacteristic,xx,No ; ,?Clear cell, Histology,19,1,3,No,1:No,1:No,,0.927
1287,2360042,Table 1,BaselineCharacteristic,xx,% ; ,?Clear cell, Histology,19,2,3,No,1:No,1:No,,0.847
1287,2360042,Table 1,BaselineCharacteristic,Dosing with ABR-xxxxxx (cycle x),Characteristic ; ,?Clear cell, Histology,19,3,3,No,1:No,1:No,,0.99
1287,2360042,Table 1,BaselineCharacteristic,Dosing with ABR-xxxxxx (cycle x),Characteristic ; ,?Clear cell, Histology,19,4,3,No,1:No,1:No,,0.99
1287,2360042,Table 1,BaselineCharacteristic,Dosing with ABR-xxxxxx (cycle x),No ; ,?Clear cell, Histology,19,5,3,No,1:No,1:No,,0.99
1287,2360042,Table 1,BaselineCharacteristic,Dosing with ABR-xxxxxx (cycle x),% ; ,?Clear cell, Histology,19,6,3,No,1:No,1:No,,0.92
1287,2360042,Table 1,BaselineCharacteristic,?Papillary,Characteristic ; ,?Papillary, Histology,20,0,2,No,1:No,1:No,,0.99
1287,2360042,Table 1,BaselineCharacteristic,x,No ; ,?Papillary, Histology,20,1,3,No,1:No,1:No,,0.98
1287,2360042,Table 1,BaselineCharacteristic,x,% ; ,?Papillary, Histology,20,2,3,No,1:No,1:No,,0.91
1287,2360042,Table 1,BaselineCharacteristic,?-SEA titre pmol?ml?x,Characteristic ; ,?Papillary, Histology,20,3,3,No,1:No,1:No,,0.99
1287,2360042,Table 1,BaselineCharacteristic,Dose ng?kg?x,Characteristic ; ,?Papillary, Histology,20,4,3,No,1:No,1:No,,0.99
1287,2360042,Table 1,BaselineCharacteristic,,No ; ,?Papillary, Histology,20,5,3,No,1:No,1:No,,0.99
1287,2360042,Table 1,BaselineCharacteristic,,% ; ,?Papillary, Histology,20,6,3,No,1:No,1:No,,0.91
1287,2360042,Table 1,BaselineCharacteristic,?Ductal,Characteristic ; ,?Ductal, Histology,21,0,2,No,1:No,1:No,,0.99
1287,2360042,Table 1,BaselineCharacteristic,x,No ; ,?Ductal, Histology,21,1,3,No,1:No,1:No,,0.98
1287,2360042,Table 1,BaselineCharacteristic,x,% ; ,?Ductal, Histology,21,2,3,No,1:No,1:No,,0.91
1287,2360042,Table 1,BaselineCharacteristic,<xx,Characteristic ; ,?Ductal, Histology,21,3,3,No,1:No,1:No,,0.98
1287,2360042,Table 1,BaselineCharacteristic,xx,Characteristic ; ,?Ductal, Histology,21,4,3,No,1:No,1:No,,0.927
1287,2360042,Table 1,BaselineCharacteristic,x,No ; ,?Ductal, Histology,21,5,3,No,1:No,1:No,,0.99
1287,2360042,Table 1,BaselineCharacteristic,x,% ; ,?Ductal, Histology,21,6,3,No,1:No,1:No,,0.92
1287,2360042,Table 1,BaselineCharacteristic,?Unspecified,Characteristic ; ,?Unspecified, Histology,22,0,2,No,1:No,1:No,,1
1287,2360042,Table 1,BaselineCharacteristic,xx,No ; ,?Unspecified, Histology,22,1,3,No,1:No,1:No,,0.937
1287,2360042,Table 1,BaselineCharacteristic,xx,% ; ,?Unspecified, Histology,22,2,3,No,1:No,1:No,,0.867
1287,2360042,Table 1,BaselineCharacteristic,xx–xx,Characteristic ; ,?Unspecified, Histology,22,3,3,No,1:No,1:No,,0.78
1287,2360042,Table 1,BaselineCharacteristic,xxx,Characteristic ; ,?Unspecified, Histology,22,4,3,No,1:No,1:No,,0.94
1287,2360042,Table 1,BaselineCharacteristic,x,No ; ,?Unspecified, Histology,22,5,3,No,1:No,1:No,,1
1287,2360042,Table 1,BaselineCharacteristic,xx,% ; ,?Unspecified, Histology,22,6,3,No,1:No,1:No,,0.891
1287,2360042,Table 1,BaselineCharacteristic,,Characteristic ; ,,,23,0,2,No,1:No,1:No,,1
1287,2360042,Table 1,BaselineCharacteristic,,No ; ,,,23,1,3,No,1:No,1:No,,0.98
1287,2360042,Table 1,BaselineCharacteristic,,% ; ,,,23,2,3,No,1:No,1:No,,0.9
1287,2360042,Table 1,BaselineCharacteristic,xx–xx,Characteristic ; ,,,23,3,3,No,1:No,1:No,,0.78
1287,2360042,Table 1,BaselineCharacteristic,xxx,Characteristic ; ,,,23,4,3,No,1:No,1:No,,0.94
1287,2360042,Table 1,BaselineCharacteristic,xx,No ; ,,,23,5,3,No,1:No,1:No,,0.941
1287,2360042,Table 1,BaselineCharacteristic,xx,% ; ,,,23,6,3,No,1:No,1:No,,0.891
1287,2360042,Table 1,BaselineCharacteristic,Drug exposure (Dose:?-SEA),Characteristic ; ,Drug exposure (Dose:?-SEA),,24,0,24,No,1:No,1:No,,0.995
1287,2360042,Table 1,BaselineCharacteristic,Drug exposure (Dose:?-SEA),No ; ,Drug exposure (Dose:?-SEA),,24,1,43,No,1:No,1:No,,0.967
1287,2360042,Table 1,BaselineCharacteristic,Drug exposure (Dose:?-SEA),% ; ,Drug exposure (Dose:?-SEA),,24,2,43,No,1:No,1:No,,0.909
1287,2360042,Table 1,BaselineCharacteristic,xx–xxx,Characteristic ; ,Drug exposure (Dose:?-SEA),,24,3,43,No,1:No,1:No,,0.972
1287,2360042,Table 1,BaselineCharacteristic,xxx,Characteristic ; ,Drug exposure (Dose:?-SEA),,24,4,43,No,1:No,1:No,,0.908
1287,2360042,Table 1,BaselineCharacteristic,x,No ; ,Drug exposure (Dose:?-SEA),,24,5,43,No,1:No,1:No,,0.973
1287,2360042,Table 1,BaselineCharacteristic,xx,% ; ,Drug exposure (Dose:?-SEA),,24,6,43,No,1:No,1:No,,0.884
1287,2360042,Table 1,BaselineCharacteristic,?High (>xx),Characteristic ; ,?High (>xx), Drug exposure (Dose:?-SEA),25,0,2,No,1:No,1:No,,0.9
1287,2360042,Table 1,BaselineCharacteristic,xx,No ; ,?High (>xx), Drug exposure (Dose:?-SEA),25,1,3,No,1:No,1:No,,0.781
1287,2360042,Table 1,BaselineCharacteristic,xx,% ; ,?High (>xx), Drug exposure (Dose:?-SEA),25,2,3,No,1:No,1:No,,0.721
1287,2360042,Table 1,BaselineCharacteristic,xxx–xxx,Characteristic ; ,?High (>xx), Drug exposure (Dose:?-SEA),25,3,3,No,1:No,1:No,,0.86
1287,2360042,Table 1,BaselineCharacteristic,xxx,Characteristic ; ,?High (>xx), Drug exposure (Dose:?-SEA),25,4,3,No,1:No,1:No,,0.82
1287,2360042,Table 1,BaselineCharacteristic,x,No ; ,?High (>xx), Drug exposure (Dose:?-SEA),25,5,3,No,1:No,1:No,,0.89
1287,2360042,Table 1,BaselineCharacteristic,xx,% ; ,?High (>xx), Drug exposure (Dose:?-SEA),25,6,3,No,1:No,1:No,,0.771
1287,2360042,Table 1,BaselineCharacteristic,?Low (<xx),Characteristic ; ,?Low (<xx), Drug exposure (Dose:?-SEA),26,0,2,No,1:No,1:No,,0.93
1287,2360042,Table 1,BaselineCharacteristic,xx,No ; ,?Low (<xx), Drug exposure (Dose:?-SEA),26,1,3,No,1:No,1:No,,0.867
1287,2360042,Table 1,BaselineCharacteristic,xx,% ; ,?Low (<xx), Drug exposure (Dose:?-SEA),26,2,3,No,1:No,1:No,,0.817
1287,2360042,Table 1,BaselineCharacteristic,>xxx,Characteristic ; ,?Low (<xx), Drug exposure (Dose:?-SEA),26,3,3,No,1:No,1:No,,0.93
1287,2360042,Table 1,BaselineCharacteristic,xxxx,Characteristic ; ,?Low (<xx), Drug exposure (Dose:?-SEA),26,4,3,No,1:No,1:No,,0.94
1287,2360042,Table 1,BaselineCharacteristic,x,No ; ,?Low (<xx), Drug exposure (Dose:?-SEA),26,5,3,No,1:No,1:No,,0.94
1287,2360042,Table 1,BaselineCharacteristic,xx,% ; ,?Low (<xx), Drug exposure (Dose:?-SEA),26,6,3,No,1:No,1:No,,0.851
1287,2360042,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,27,0,2,No,1:No,1:No,,1
1287,2360042,Table 1,BaselineCharacteristic,,No ; ,None,None,27,1,3,No,1:No,1:No,,0.98
1287,2360042,Table 1,BaselineCharacteristic,,% ; ,None,None,27,2,3,No,1:No,1:No,,0.9
1287,2360042,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,27,3,3,No,1:No,1:No,,0.99
1287,2360042,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,27,4,3,No,1:No,1:No,,1
1287,2360042,Table 1,BaselineCharacteristic,,No ; ,None,None,27,5,3,No,1:No,1:No,,1
1287,2360042,Table 1,BaselineCharacteristic,,% ; ,None,None,27,6,3,No,1:No,1:No,,0.92
1287,2360042,Table 1,BaselineCharacteristic,Previous surgery,Characteristic ; ,Previous surgery,,28,0,24,No,1:No,1:No,,0.995
1287,2360042,Table 1,BaselineCharacteristic,Previous surgery,No ; ,Previous surgery,,28,1,43,No,1:No,1:No,,0.967
1287,2360042,Table 1,BaselineCharacteristic,Previous surgery,% ; ,Previous surgery,,28,2,43,No,1:No,1:No,,0.919
1287,2360042,Table 1,BaselineCharacteristic,Best overall response (day xx),Characteristic ; ,Previous surgery,,28,3,43,No,1:No,1:No,,0.951
1287,2360042,Table 1,BaselineCharacteristic,Best overall response (day xx),Characteristic ; ,Previous surgery,,28,4,43,No,1:No,1:No,,0.961
1287,2360042,Table 1,BaselineCharacteristic,Best overall response (day xx),No ; ,Previous surgery,,28,5,43,No,1:No,1:No,,0.966
1287,2360042,Table 1,BaselineCharacteristic,Best overall response (day xx),% ; ,Previous surgery,,28,6,43,No,1:No,1:No,,0.92
1287,2360042,Table 1,BaselineCharacteristic,?Nephrectomy,Characteristic ; ,?Nephrectomy, Previous surgery,29,0,2,No,1:No,1:No,,1
1287,2360042,Table 1,BaselineCharacteristic,xx,No ; ,?Nephrectomy, Previous surgery,29,1,3,No,1:No,1:No,,0.937
1287,2360042,Table 1,BaselineCharacteristic,xx,% ; ,?Nephrectomy, Previous surgery,29,2,3,No,1:No,1:No,,0.877
1287,2360042,Table 1,BaselineCharacteristic,?PR,Characteristic ; ,?Nephrectomy, Previous surgery,29,3,3,No,1:No,1:No,,0.99
1287,2360042,Table 1,BaselineCharacteristic,?PR,Characteristic ; ,?Nephrectomy, Previous surgery,29,4,3,No,1:No,1:No,,1
1287,2360042,Table 1,BaselineCharacteristic,x,No ; ,?Nephrectomy, Previous surgery,29,5,3,No,1:No,1:No,,1
1287,2360042,Table 1,BaselineCharacteristic,x,% ; ,?Nephrectomy, Previous surgery,29,6,3,No,1:No,1:No,,0.95
1287,2360042,Table 1,BaselineCharacteristic,?Removal of metastases,Characteristic ; ,?Removal of metastases, Previous surgery,30,0,2,No,1:No,1:No,,0.99
1287,2360042,Table 1,BaselineCharacteristic,x,No ; ,?Removal of metastases, Previous surgery,30,1,3,No,1:No,1:No,,0.97
1287,2360042,Table 1,BaselineCharacteristic,xx,% ; ,?Removal of metastases, Previous surgery,30,2,3,No,1:No,1:No,,0.886
1287,2360042,Table 1,BaselineCharacteristic,?SD,Characteristic ; ,?Removal of metastases, Previous surgery,30,3,3,No,1:No,1:No,,0.88
1287,2360042,Table 1,BaselineCharacteristic,?SD,Characteristic ; ,?Removal of metastases, Previous surgery,30,4,3,No,1:No,1:No,,0.9
1287,2360042,Table 1,BaselineCharacteristic,xx,No ; ,?Removal of metastases, Previous surgery,30,5,3,No,1:No,1:No,,0.96
1287,2360042,Table 1,BaselineCharacteristic,xx,% ; ,?Removal of metastases, Previous surgery,30,6,3,No,1:No,1:No,,0.91
1287,2360042,Table 1,BaselineCharacteristic,?None,Characteristic ; ,?None, Previous surgery,31,0,2,No,1:No,1:No,,1
1287,2360042,Table 1,BaselineCharacteristic,x,No ; ,?None, Previous surgery,31,1,3,No,1:No,1:No,,0.99
1287,2360042,Table 1,BaselineCharacteristic,xx,% ; ,?None, Previous surgery,31,2,3,No,1:No,1:No,,0.877
1287,2360042,Table 1,BaselineCharacteristic,?PD,Characteristic ; ,?None, Previous surgery,31,3,3,No,1:No,1:No,,0.99
1287,2360042,Table 1,BaselineCharacteristic,?PD,Characteristic ; ,?None, Previous surgery,31,4,3,No,1:No,1:No,,1
1287,2360042,Table 1,BaselineCharacteristic,xx,No ; ,?None, Previous surgery,31,5,3,No,1:No,1:No,,0.941
1287,2360042,Table 1,BaselineCharacteristic,xx,% ; ,?None, Previous surgery,31,6,3,No,1:No,1:No,,0.901
1287,2360042,Table 1,BaselineCharacteristic,,Characteristic ; ,,,32,0,2,No,1:No,1:No,,1
1287,2360042,Table 1,BaselineCharacteristic,,No ; ,,,32,1,3,No,1:No,1:No,,0.98
1287,2360042,Table 1,BaselineCharacteristic,,% ; ,,,32,2,3,No,1:No,1:No,,0.9
1287,2360042,Table 1,BaselineCharacteristic,?N/A,Characteristic ; ,,,32,3,3,No,1:No,1:No,,0.99
1287,2360042,Table 1,BaselineCharacteristic,,Characteristic ; ,,,32,4,3,No,1:No,1:No,,1
1287,2360042,Table 1,BaselineCharacteristic,x,No ; ,,,32,5,3,No,1:No,1:No,,1
1287,2360042,Table 1,BaselineCharacteristic,x,% ; ,,,32,6,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,Patient,,None,None,0,0,12,No,1:No,1:No,,0.905
1291,2360092,Table 1,BaselineCharacteristic,Age,,Patient,None,0,1,1,No,1:No,1:No,,0.903
1291,2360092,Table 1,BaselineCharacteristic,Gender,,Patient,None,0,2,1,No,1:No,1:No,,0.903
1291,2360092,Table 1,BaselineCharacteristic,PS,,Patient,None,0,3,1,No,1:No,1:No,,0.91
1291,2360092,Table 1,BaselineCharacteristic,Histotype,,Patient,None,0,4,1,No,1:No,1:No,,0.913
1291,2360092,Table 1,BaselineCharacteristic,First line,,Patient,None,0,5,1,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,Number of lines,,Patient,None,0,6,1,No,1:No,1:No,,0.925
1291,2360092,Table 1,BaselineCharacteristic,Lesions,,Patient,None,0,7,1,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,RT,,Patient,None,0,8,1,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,Failure,,Patient,None,0,9,1,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,TFTF,,Patient,None,0,10,1,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,OR,,Patient,None,0,11,1,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,Duration,,Patient,None,0,12,1,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,Survival,,Patient,None,0,13,1,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic, x,Patient ; , x,,1,0,2,No,1:No,1:No,,0.915
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; , x,,1,1,3,No,1:No,1:No,,0.612
1291,2360092,Table 1,BaselineCharacteristic,Male,Gender ; , x,,1,2,3,No,1:No,1:No,,0.9
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; , x,,1,3,3,No,1:No,1:No,,0.89
1291,2360092,Table 1,BaselineCharacteristic,DLC,Histotype ; , x,,1,4,3,No,1:No,1:No,,0.88
1291,2360092,Table 1,BaselineCharacteristic,MVP,First line ; , x,,1,5,3,No,1:No,1:No,,0.9
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; , x,,1,6,3,No,1:No,1:No,,0.9
1291,2360092,Table 1,BaselineCharacteristic,Single,Lesions ; , x,,1,7,3,No,1:No,1:No,,0.89
1291,2360092,Table 1,BaselineCharacteristic,+,RT ; , x,,1,8,3,No,1:No,1:No,,0.91
1291,2360092,Table 1,BaselineCharacteristic,R,Failure ; , x,,1,9,3,No,1:No,1:No,,0.9
1291,2360092,Table 1,BaselineCharacteristic,x,TFTF ; , x,,1,10,3,No,1:No,1:No,,0.9
1291,2360092,Table 1,BaselineCharacteristic,CR,OR ; , x,,1,11,3,No,1:No,1:No,,0.9
1291,2360092,Table 1,BaselineCharacteristic,xx.x+,Duration ; , x,,1,12,3,No,1:No,1:No,,0.646
1291,2360092,Table 1,BaselineCharacteristic,xx.x+,Survival ; , x,,1,13,3,No,1:No,1:No,,0.646
1291,2360092,Table 1,BaselineCharacteristic, x,Patient ; , x,,2,0,2,No,1:No,1:No,,0.935
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; , x,,2,1,3,No,1:No,1:No,,0.632
1291,2360092,Table 1,BaselineCharacteristic,Male,Gender ; , x,,2,2,3,No,1:No,1:No,,0.92
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; , x,,2,3,3,No,1:No,1:No,,0.91
1291,2360092,Table 1,BaselineCharacteristic,DLC,Histotype ; , x,,2,4,3,No,1:No,1:No,,0.9
1291,2360092,Table 1,BaselineCharacteristic,MVP,First line ; , x,,2,5,3,No,1:No,1:No,,0.91
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; , x,,2,6,3,No,1:No,1:No,,0.91
1291,2360092,Table 1,BaselineCharacteristic,Multiple,Lesions ; , x,,2,7,3,No,1:No,1:No,,0.9
1291,2360092,Table 1,BaselineCharacteristic,+,RT ; , x,,2,8,3,No,1:No,1:No,,0.92
1291,2360092,Table 1,BaselineCharacteristic,R,Failure ; , x,,2,9,3,No,1:No,1:No,,0.91
1291,2360092,Table 1,BaselineCharacteristic,xx,TFTF ; , x,,2,10,3,No,1:No,1:No,,0.686
1291,2360092,Table 1,BaselineCharacteristic,PR,OR ; , x,,2,11,3,No,1:No,1:No,,0.91
1291,2360092,Table 1,BaselineCharacteristic,x.x,Duration ; , x,,2,12,3,No,1:No,1:No,,0.91
1291,2360092,Table 1,BaselineCharacteristic,x.x,Survival ; , x,,2,13,3,No,1:No,1:No,,0.91
1291,2360092,Table 1,BaselineCharacteristic, x,Patient ; , x,,3,0,2,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; , x,,3,1,3,No,1:No,1:No,,0.646
1291,2360092,Table 1,BaselineCharacteristic,Female,Gender ; , x,,3,2,3,No,1:No,1:No,,0.94
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; , x,,3,3,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,DLC,Histotype ; , x,,3,4,3,No,1:No,1:No,,0.92
1291,2360092,Table 1,BaselineCharacteristic,MA,First line ; , x,,3,5,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; , x,,3,6,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,Multiple,Lesions ; , x,,3,7,3,No,1:No,1:No,,0.92
1291,2360092,Table 1,BaselineCharacteristic,?,RT ; , x,,3,8,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,R,Failure ; , x,,3,9,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,xx,TFTF ; , x,,3,10,3,No,1:No,1:No,,0.69
1291,2360092,Table 1,BaselineCharacteristic,PD,OR ; , x,,3,11,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,,Duration ; , x,,3,12,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,x.x,Survival ; , x,,3,13,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic, x,Patient ; , x,,4,0,2,No,1:No,1:No,,0.965
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; , x,,4,1,3,No,1:No,1:No,,0.726
1291,2360092,Table 1,BaselineCharacteristic,Male,Gender ; , x,,4,2,3,No,1:No,1:No,,0.94
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; , x,,4,3,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,DLC,Histotype ; , x,,4,4,3,No,1:No,1:No,,0.92
1291,2360092,Table 1,BaselineCharacteristic,MBAVm,First line ; , x,,4,5,3,No,1:No,1:No,,0.92
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; , x,,4,6,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,Multiple,Lesions ; , x,,4,7,3,No,1:No,1:No,,0.91
1291,2360092,Table 1,BaselineCharacteristic,+,RT ; , x,,4,8,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,R,Failure ; , x,,4,9,3,No,1:No,1:No,,0.92
1291,2360092,Table 1,BaselineCharacteristic,xx,TFTF ; , x,,4,10,3,No,1:No,1:No,,0.77
1291,2360092,Table 1,BaselineCharacteristic,ED,OR ; , x,,4,11,3,No,1:No,1:No,,0.92
1291,2360092,Table 1,BaselineCharacteristic,,Duration ; , x,,4,12,3,No,1:No,1:No,,0.92
1291,2360092,Table 1,BaselineCharacteristic,x.x,Survival ; , x,,4,13,3,No,1:No,1:No,,0.92
1291,2360092,Table 1,BaselineCharacteristic, x,Patient ; , x,,5,0,2,No,1:No,1:No,,0.963
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; , x,,5,1,3,No,1:No,1:No,,0.726
1291,2360092,Table 1,BaselineCharacteristic,Male,Gender ; , x,,5,2,3,No,1:No,1:No,,0.94
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; , x,,5,3,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,DLC,Histotype ; , x,,5,4,3,No,1:No,1:No,,0.92
1291,2360092,Table 1,BaselineCharacteristic,MATI,First line ; , x,,5,5,3,No,1:No,1:No,,0.91
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; , x,,5,6,3,No,1:No,1:No,,0.92
1291,2360092,Table 1,BaselineCharacteristic,Single,Lesions ; , x,,5,7,3,No,1:No,1:No,,0.9
1291,2360092,Table 1,BaselineCharacteristic,?,RT ; , x,,5,8,3,No,1:No,1:No,,0.91
1291,2360092,Table 1,BaselineCharacteristic,PD,Failure ; , x,,5,9,3,No,1:No,1:No,,0.91
1291,2360092,Table 1,BaselineCharacteristic,x,TFTF ; , x,,5,10,3,No,1:No,1:No,,0.91
1291,2360092,Table 1,BaselineCharacteristic,PD,OR ; , x,,5,11,3,No,1:No,1:No,,0.91
1291,2360092,Table 1,BaselineCharacteristic,,Duration ; , x,,5,12,3,No,1:No,1:No,,0.91
1291,2360092,Table 1,BaselineCharacteristic,x.x,Survival ; , x,,5,13,3,No,1:No,1:No,,0.91
1291,2360092,Table 1,BaselineCharacteristic, x,Patient ; , x,,6,0,2,No,1:No,1:No,,0.973
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; , x,,6,1,3,No,1:No,1:No,,0.746
1291,2360092,Table 1,BaselineCharacteristic,Male,Gender ; , x,,6,2,3,No,1:No,1:No,,0.96
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; , x,,6,3,3,No,1:No,1:No,,0.95
1291,2360092,Table 1,BaselineCharacteristic,DLC,Histotype ; , x,,6,4,3,No,1:No,1:No,,0.94
1291,2360092,Table 1,BaselineCharacteristic,CVOD/BVAM,First line ; , x,,6,5,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; , x,,6,6,3,No,1:No,1:No,,0.94
1291,2360092,Table 1,BaselineCharacteristic,Multiple,Lesions ; , x,,6,7,3,No,1:No,1:No,,0.92
1291,2360092,Table 1,BaselineCharacteristic,+,RT ; , x,,6,8,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,R,Failure ; , x,,6,9,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,xx,TFTF ; , x,,6,10,3,No,1:No,1:No,,0.78
1291,2360092,Table 1,BaselineCharacteristic,ED,OR ; , x,,6,11,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,,Duration ; , x,,6,12,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,x.x,Survival ; , x,,6,13,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic, x,Patient ; , x,,7,0,2,No,1:No,1:No,,0.973
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; , x,,7,1,3,No,1:No,1:No,,0.786
1291,2360092,Table 1,BaselineCharacteristic,Female,Gender ; , x,,7,2,3,No,1:No,1:No,,0.97
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; , x,,7,3,3,No,1:No,1:No,,0.96
1291,2360092,Table 1,BaselineCharacteristic,DLC,Histotype ; , x,,7,4,3,No,1:No,1:No,,0.96
1291,2360092,Table 1,BaselineCharacteristic,MATI,First line ; , x,,7,5,3,No,1:No,1:No,,0.96
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; , x,,7,6,3,No,1:No,1:No,,0.96
1291,2360092,Table 1,BaselineCharacteristic,Multiple,Lesions ; , x,,7,7,3,No,1:No,1:No,,0.95
1291,2360092,Table 1,BaselineCharacteristic,+,RT ; , x,,7,8,3,No,1:No,1:No,,0.96
1291,2360092,Table 1,BaselineCharacteristic,R,Failure ; , x,,7,9,3,No,1:No,1:No,,0.96
1291,2360092,Table 1,BaselineCharacteristic,xx,TFTF ; , x,,7,10,3,No,1:No,1:No,,0.84
1291,2360092,Table 1,BaselineCharacteristic,PD,OR ; , x,,7,11,3,No,1:No,1:No,,0.96
1291,2360092,Table 1,BaselineCharacteristic,,Duration ; , x,,7,12,3,No,1:No,1:No,,0.96
1291,2360092,Table 1,BaselineCharacteristic,x.x,Survival ; , x,,7,13,3,No,1:No,1:No,,0.96
1291,2360092,Table 1,BaselineCharacteristic, x,Patient ; , x,,8,0,2,No,1:No,1:No,,0.972
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; , x,,8,1,3,No,1:No,1:No,,0.806
1291,2360092,Table 1,BaselineCharacteristic,Male,Gender ; , x,,8,2,3,No,1:No,1:No,,0.98
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; , x,,8,3,3,No,1:No,1:No,,0.97
1291,2360092,Table 1,BaselineCharacteristic,LP,Histotype ; , x,,8,4,3,No,1:No,1:No,,0.97
1291,2360092,Table 1,BaselineCharacteristic,M,First line ; , x,,8,5,3,No,1:No,1:No,,0.97
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; , x,,8,6,3,No,1:No,1:No,,0.97
1291,2360092,Table 1,BaselineCharacteristic,Multiple,Lesions ; , x,,8,7,3,No,1:No,1:No,,0.97
1291,2360092,Table 1,BaselineCharacteristic,+,RT ; , x,,8,8,3,No,1:No,1:No,,0.98
1291,2360092,Table 1,BaselineCharacteristic,PD,Failure ; , x,,8,9,3,No,1:No,1:No,,0.98
1291,2360092,Table 1,BaselineCharacteristic,xx,TFTF ; , x,,8,10,3,No,1:No,1:No,,0.87
1291,2360092,Table 1,BaselineCharacteristic,SD,OR ; , x,,8,11,3,No,1:No,1:No,,0.83
1291,2360092,Table 1,BaselineCharacteristic,xx.x,Duration ; , x,,8,12,3,No,1:No,1:No,,0.87
1291,2360092,Table 1,BaselineCharacteristic,xx.x+,Survival ; , x,,8,13,3,No,1:No,1:No,,0.87
1291,2360092,Table 1,BaselineCharacteristic, x,Patient ; , x,,9,0,2,No,1:No,1:No,,0.982
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; , x,,9,1,3,No,1:No,1:No,,0.846
1291,2360092,Table 1,BaselineCharacteristic,Male,Gender ; , x,,9,2,3,No,1:No,1:No,,0.99
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; , x,,9,3,3,No,1:No,1:No,,0.99
1291,2360092,Table 1,BaselineCharacteristic,DLC,Histotype ; , x,,9,4,3,No,1:No,1:No,,0.99
1291,2360092,Table 1,BaselineCharacteristic,none,First line ; , x,,9,5,3,No,1:No,1:No,,0.99
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; , x,,9,6,3,No,1:No,1:No,,0.98
1291,2360092,Table 1,BaselineCharacteristic,Multiple,Lesions ; , x,,9,7,3,No,1:No,1:No,,0.99
1291,2360092,Table 1,BaselineCharacteristic,+,RT ; , x,,9,8,3,No,1:No,1:No,,1
1291,2360092,Table 1,BaselineCharacteristic,R,Failure ; , x,,9,9,3,No,1:No,1:No,,1
1291,2360092,Table 1,BaselineCharacteristic,xx,TFTF ; , x,,9,10,3,No,1:No,1:No,,0.91
1291,2360092,Table 1,BaselineCharacteristic,PD,OR ; , x,,9,11,3,No,1:No,1:No,,1
1291,2360092,Table 1,BaselineCharacteristic,,Duration ; , x,,9,12,3,No,1:No,1:No,,1
1291,2360092,Table 1,BaselineCharacteristic,x.x,Survival ; , x,,9,13,3,No,1:No,1:No,,1
1291,2360092,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,,10,0,2,No,1:No,1:No,,0.935
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; ,xx,,10,1,3,No,1:No,1:No,,0.921
1291,2360092,Table 1,BaselineCharacteristic,Male,Gender ; ,xx,,10,2,3,No,1:No,1:No,,0.911
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; ,xx,,10,3,3,No,1:No,1:No,,0.856
1291,2360092,Table 1,BaselineCharacteristic,DLC,Histotype ; ,xx,,10,4,3,No,1:No,1:No,,0.921
1291,2360092,Table 1,BaselineCharacteristic,MATI,First line ; ,xx,,10,5,3,No,1:No,1:No,,0.936
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; ,xx,,10,6,3,No,1:No,1:No,,0.91
1291,2360092,Table 1,BaselineCharacteristic,Single,Lesions ; ,xx,,10,7,3,No,1:No,1:No,,0.936
1291,2360092,Table 1,BaselineCharacteristic,+,RT ; ,xx,,10,8,3,No,1:No,1:No,,0.946
1291,2360092,Table 1,BaselineCharacteristic,R,Failure ; ,xx,,10,9,3,No,1:No,1:No,,0.946
1291,2360092,Table 1,BaselineCharacteristic,xx,TFTF ; ,xx,,10,10,3,No,1:No,1:No,,0.946
1291,2360092,Table 1,BaselineCharacteristic,SD,OR ; ,xx,,10,11,3,No,1:No,1:No,,0.746
1291,2360092,Table 1,BaselineCharacteristic,x.x,Duration ; ,xx,,10,12,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,x.x,Survival ; ,xx,,10,13,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,,11,0,2,No,1:No,1:No,,0.935
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; ,xx,,11,1,3,No,1:No,1:No,,0.921
1291,2360092,Table 1,BaselineCharacteristic,Male,Gender ; ,xx,,11,2,3,No,1:No,1:No,,0.911
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; ,xx,,11,3,3,No,1:No,1:No,,0.856
1291,2360092,Table 1,BaselineCharacteristic,DLC,Histotype ; ,xx,,11,4,3,No,1:No,1:No,,0.921
1291,2360092,Table 1,BaselineCharacteristic,MA,First line ; ,xx,,11,5,3,No,1:No,1:No,,0.936
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; ,xx,,11,6,3,No,1:No,1:No,,0.91
1291,2360092,Table 1,BaselineCharacteristic,Multiple,Lesions ; ,xx,,11,7,3,No,1:No,1:No,,0.936
1291,2360092,Table 1,BaselineCharacteristic,+,RT ; ,xx,,11,8,3,No,1:No,1:No,,0.946
1291,2360092,Table 1,BaselineCharacteristic,R,Failure ; ,xx,,11,9,3,No,1:No,1:No,,0.946
1291,2360092,Table 1,BaselineCharacteristic,xx,TFTF ; ,xx,,11,10,3,No,1:No,1:No,,0.946
1291,2360092,Table 1,BaselineCharacteristic,CR,OR ; ,xx,,11,11,3,No,1:No,1:No,,0.97
1291,2360092,Table 1,BaselineCharacteristic,x.x,Duration ; ,xx,,11,12,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,xx.x,Survival ; ,xx,,11,13,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,,12,0,2,No,1:No,1:No,,0.935
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; ,xx,,12,1,3,No,1:No,1:No,,0.921
1291,2360092,Table 1,BaselineCharacteristic,Female,Gender ; ,xx,,12,2,3,No,1:No,1:No,,0.911
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; ,xx,,12,3,3,No,1:No,1:No,,0.856
1291,2360092,Table 1,BaselineCharacteristic,DLC,Histotype ; ,xx,,12,4,3,No,1:No,1:No,,0.921
1291,2360092,Table 1,BaselineCharacteristic,F-MACHOPn,First line ; ,xx,,12,5,3,No,1:No,1:No,,0.936
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; ,xx,,12,6,3,No,1:No,1:No,,0.91
1291,2360092,Table 1,BaselineCharacteristic,Multiple,Lesions ; ,xx,,12,7,3,No,1:No,1:No,,0.936
1291,2360092,Table 1,BaselineCharacteristic,+,RT ; ,xx,,12,8,3,No,1:No,1:No,,0.946
1291,2360092,Table 1,BaselineCharacteristic,R,Failure ; ,xx,,12,9,3,No,1:No,1:No,,0.946
1291,2360092,Table 1,BaselineCharacteristic,xxx,TFTF ; ,xx,,12,10,3,No,1:No,1:No,,0.896
1291,2360092,Table 1,BaselineCharacteristic,PD,OR ; ,xx,,12,11,3,No,1:No,1:No,,0.956
1291,2360092,Table 1,BaselineCharacteristic,,Duration ; ,xx,,12,12,3,No,1:No,1:No,,0.946
1291,2360092,Table 1,BaselineCharacteristic,x.x,Survival ; ,xx,,12,13,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,,13,0,2,No,1:No,1:No,,0.935
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; ,xx,,13,1,3,No,1:No,1:No,,0.921
1291,2360092,Table 1,BaselineCharacteristic,Male,Gender ; ,xx,,13,2,3,No,1:No,1:No,,0.911
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; ,xx,,13,3,3,No,1:No,1:No,,0.856
1291,2360092,Table 1,BaselineCharacteristic,DLC,Histotype ; ,xx,,13,4,3,No,1:No,1:No,,0.921
1291,2360092,Table 1,BaselineCharacteristic,MAI,First line ; ,xx,,13,5,3,No,1:No,1:No,,0.936
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; ,xx,,13,6,3,No,1:No,1:No,,0.91
1291,2360092,Table 1,BaselineCharacteristic,Single,Lesions ; ,xx,,13,7,3,No,1:No,1:No,,0.936
1291,2360092,Table 1,BaselineCharacteristic,+,RT ; ,xx,,13,8,3,No,1:No,1:No,,0.946
1291,2360092,Table 1,BaselineCharacteristic,R,Failure ; ,xx,,13,9,3,No,1:No,1:No,,0.946
1291,2360092,Table 1,BaselineCharacteristic,xx,TFTF ; ,xx,,13,10,3,No,1:No,1:No,,0.946
1291,2360092,Table 1,BaselineCharacteristic,PD,OR ; ,xx,,13,11,3,No,1:No,1:No,,0.956
1291,2360092,Table 1,BaselineCharacteristic,,Duration ; ,xx,,13,12,3,No,1:No,1:No,,0.946
1291,2360092,Table 1,BaselineCharacteristic,x.x,Survival ; ,xx,,13,13,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,,14,0,2,No,1:No,1:No,,0.955
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; ,xx,,14,1,3,No,1:No,1:No,,0.941
1291,2360092,Table 1,BaselineCharacteristic,Female,Gender ; ,xx,,14,2,3,No,1:No,1:No,,0.931
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; ,xx,,14,3,3,No,1:No,1:No,,0.876
1291,2360092,Table 1,BaselineCharacteristic,DLC,Histotype ; ,xx,,14,4,3,No,1:No,1:No,,0.931
1291,2360092,Table 1,BaselineCharacteristic,MVP,First line ; ,xx,,14,5,3,No,1:No,1:No,,0.946
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; ,xx,,14,6,3,No,1:No,1:No,,0.92
1291,2360092,Table 1,BaselineCharacteristic,Multiple,Lesions ; ,xx,,14,7,3,No,1:No,1:No,,0.946
1291,2360092,Table 1,BaselineCharacteristic,+,RT ; ,xx,,14,8,3,No,1:No,1:No,,0.956
1291,2360092,Table 1,BaselineCharacteristic,R,Failure ; ,xx,,14,9,3,No,1:No,1:No,,0.956
1291,2360092,Table 1,BaselineCharacteristic,xx,TFTF ; ,xx,,14,10,3,No,1:No,1:No,,0.956
1291,2360092,Table 1,BaselineCharacteristic,PD,OR ; ,xx,,14,11,3,No,1:No,1:No,,0.966
1291,2360092,Table 1,BaselineCharacteristic,,Duration ; ,xx,,14,12,3,No,1:No,1:No,,0.956
1291,2360092,Table 1,BaselineCharacteristic,xx.x,Survival ; ,xx,,14,13,3,No,1:No,1:No,,0.94
1291,2360092,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,,15,0,2,No,1:No,1:No,,0.955
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; ,xx,,15,1,3,No,1:No,1:No,,0.941
1291,2360092,Table 1,BaselineCharacteristic,Female,Gender ; ,xx,,15,2,3,No,1:No,1:No,,0.931
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; ,xx,,15,3,3,No,1:No,1:No,,0.876
1291,2360092,Table 1,BaselineCharacteristic,UN,Histotype ; ,xx,,15,4,3,No,1:No,1:No,,0.931
1291,2360092,Table 1,BaselineCharacteristic,M,First line ; ,xx,,15,5,3,No,1:No,1:No,,0.946
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; ,xx,,15,6,3,No,1:No,1:No,,0.92
1291,2360092,Table 1,BaselineCharacteristic,Single,Lesions ; ,xx,,15,7,3,No,1:No,1:No,,0.946
1291,2360092,Table 1,BaselineCharacteristic,+,RT ; ,xx,,15,8,3,No,1:No,1:No,,0.956
1291,2360092,Table 1,BaselineCharacteristic,R,Failure ; ,xx,,15,9,3,No,1:No,1:No,,0.956
1291,2360092,Table 1,BaselineCharacteristic,xx,TFTF ; ,xx,,15,10,3,No,1:No,1:No,,0.956
1291,2360092,Table 1,BaselineCharacteristic,CR,OR ; ,xx,,15,11,3,No,1:No,1:No,,0.98
1291,2360092,Table 1,BaselineCharacteristic,xx.x+,Duration ; ,xx,,15,12,3,No,1:No,1:No,,0.956
1291,2360092,Table 1,BaselineCharacteristic,xx.x+,Survival ; ,xx,,15,13,3,No,1:No,1:No,,0.956
1291,2360092,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,,16,0,2,No,1:No,1:No,,0.955
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; ,xx,,16,1,3,No,1:No,1:No,,0.941
1291,2360092,Table 1,BaselineCharacteristic,Male,Gender ; ,xx,,16,2,3,No,1:No,1:No,,0.941
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; ,xx,,16,3,3,No,1:No,1:No,,0.886
1291,2360092,Table 1,BaselineCharacteristic,DLC,Histotype ; ,xx,,16,4,3,No,1:No,1:No,,0.941
1291,2360092,Table 1,BaselineCharacteristic,MVP,First line ; ,xx,,16,5,3,No,1:No,1:No,,0.956
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; ,xx,,16,6,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,Single,Lesions ; ,xx,,16,7,3,No,1:No,1:No,,0.956
1291,2360092,Table 1,BaselineCharacteristic,?,RT ; ,xx,,16,8,3,No,1:No,1:No,,0.966
1291,2360092,Table 1,BaselineCharacteristic,R,Failure ; ,xx,,16,9,3,No,1:No,1:No,,0.966
1291,2360092,Table 1,BaselineCharacteristic,xx,TFTF ; ,xx,,16,10,3,No,1:No,1:No,,0.966
1291,2360092,Table 1,BaselineCharacteristic,PD,OR ; ,xx,,16,11,3,No,1:No,1:No,,0.976
1291,2360092,Table 1,BaselineCharacteristic,,Duration ; ,xx,,16,12,3,No,1:No,1:No,,0.966
1291,2360092,Table 1,BaselineCharacteristic,xx.x,Survival ; ,xx,,16,13,3,No,1:No,1:No,,0.95
1291,2360092,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,,17,0,2,No,1:No,1:No,,0.955
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; ,xx,,17,1,3,No,1:No,1:No,,0.941
1291,2360092,Table 1,BaselineCharacteristic,Female,Gender ; ,xx,,17,2,3,No,1:No,1:No,,0.941
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; ,xx,,17,3,3,No,1:No,1:No,,0.886
1291,2360092,Table 1,BaselineCharacteristic,DLC,Histotype ; ,xx,,17,4,3,No,1:No,1:No,,0.941
1291,2360092,Table 1,BaselineCharacteristic,VPAL,First line ; ,xx,,17,5,3,No,1:No,1:No,,0.956
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; ,xx,,17,6,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,Multiple,Lesions ; ,xx,,17,7,3,No,1:No,1:No,,0.956
1291,2360092,Table 1,BaselineCharacteristic,+,RT ; ,xx,,17,8,3,No,1:No,1:No,,0.966
1291,2360092,Table 1,BaselineCharacteristic,R,Failure ; ,xx,,17,9,3,No,1:No,1:No,,0.966
1291,2360092,Table 1,BaselineCharacteristic,xx,TFTF ; ,xx,,17,10,3,No,1:No,1:No,,0.966
1291,2360092,Table 1,BaselineCharacteristic,SD,OR ; ,xx,,17,11,3,No,1:No,1:No,,0.756
1291,2360092,Table 1,BaselineCharacteristic,x.x,Duration ; ,xx,,17,12,3,No,1:No,1:No,,0.95
1291,2360092,Table 1,BaselineCharacteristic,x.x,Survival ; ,xx,,17,13,3,No,1:No,1:No,,0.95
1291,2360092,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,,18,0,2,No,1:No,1:No,,0.941
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; ,xx,,18,1,3,No,1:No,1:No,,0.927
1291,2360092,Table 1,BaselineCharacteristic,Male,Gender ; ,xx,,18,2,3,No,1:No,1:No,,0.927
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; ,xx,,18,3,3,No,1:No,1:No,,0.871
1291,2360092,Table 1,BaselineCharacteristic,UN,Histotype ; ,xx,,18,4,3,No,1:No,1:No,,0.927
1291,2360092,Table 1,BaselineCharacteristic,MVP,First line ; ,xx,,18,5,3,No,1:No,1:No,,0.946
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; ,xx,,18,6,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,Single,Lesions ; ,xx,,18,7,3,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,?,RT ; ,xx,,18,8,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,R,Failure ; ,xx,,18,9,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,xx,TFTF ; ,xx,,18,10,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,CR,OR ; ,xx,,18,11,3,No,1:No,1:No,,0.985
1291,2360092,Table 1,BaselineCharacteristic,x.x,Duration ; ,xx,,18,12,3,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,xx.x+,Survival ; ,xx,,18,13,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,,19,0,2,No,1:No,1:No,,0.941
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; ,xx,,19,1,3,No,1:No,1:No,,0.927
1291,2360092,Table 1,BaselineCharacteristic,Male,Gender ; ,xx,,19,2,3,No,1:No,1:No,,0.927
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; ,xx,,19,3,3,No,1:No,1:No,,0.871
1291,2360092,Table 1,BaselineCharacteristic,UN,Histotype ; ,xx,,19,4,3,No,1:No,1:No,,0.927
1291,2360092,Table 1,BaselineCharacteristic,MVP,First line ; ,xx,,19,5,3,No,1:No,1:No,,0.946
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; ,xx,,19,6,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,Multiple,Lesions ; ,xx,,19,7,3,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,+,RT ; ,xx,,19,8,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,PD,Failure ; ,xx,,19,9,3,No,1:No,1:No,,0.971
1291,2360092,Table 1,BaselineCharacteristic,x,TFTF ; ,xx,,19,10,3,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,ED,OR ; ,xx,,19,11,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,,Duration ; ,xx,,19,12,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,x.x,Survival ; ,xx,,19,13,3,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,,20,0,2,No,1:No,1:No,,0.941
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; ,xx,,20,1,3,No,1:No,1:No,,0.927
1291,2360092,Table 1,BaselineCharacteristic,Male,Gender ; ,xx,,20,2,3,No,1:No,1:No,,0.927
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; ,xx,,20,3,3,No,1:No,1:No,,0.871
1291,2360092,Table 1,BaselineCharacteristic,DLC,Histotype ; ,xx,,20,4,3,No,1:No,1:No,,0.927
1291,2360092,Table 1,BaselineCharacteristic,A,First line ; ,xx,,20,5,3,No,1:No,1:No,,0.946
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; ,xx,,20,6,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,Multiple,Lesions ; ,xx,,20,7,3,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,+,RT ; ,xx,,20,8,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,R,Failure ; ,xx,,20,9,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,xx,TFTF ; ,xx,,20,10,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,ED,OR ; ,xx,,20,11,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,,Duration ; ,xx,,20,12,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,x.x,Survival ; ,xx,,20,13,3,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,,21,0,2,No,1:No,1:No,,0.941
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; ,xx,,21,1,3,No,1:No,1:No,,0.927
1291,2360092,Table 1,BaselineCharacteristic,Male,Gender ; ,xx,,21,2,3,No,1:No,1:No,,0.927
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; ,xx,,21,3,3,No,1:No,1:No,,0.871
1291,2360092,Table 1,BaselineCharacteristic,DLC,Histotype ; ,xx,,21,4,3,No,1:No,1:No,,0.927
1291,2360092,Table 1,BaselineCharacteristic,A,First line ; ,xx,,21,5,3,No,1:No,1:No,,0.946
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; ,xx,,21,6,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,Single,Lesions ; ,xx,,21,7,3,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,+,RT ; ,xx,,21,8,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,R,Failure ; ,xx,,21,9,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,xx,TFTF ; ,xx,,21,10,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,SD,OR ; ,xx,,21,11,3,No,1:No,1:No,,0.751
1291,2360092,Table 1,BaselineCharacteristic,x.x,Duration ; ,xx,,21,12,3,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,xx.x+,Survival ; ,xx,,21,13,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,,22,0,2,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; ,xx,,22,1,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,Male,Gender ; ,xx,,22,2,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; ,xx,,22,3,3,No,1:No,1:No,,0.881
1291,2360092,Table 1,BaselineCharacteristic,DLC,Histotype ; ,xx,,22,4,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,MA,First line ; ,xx,,22,5,3,No,1:No,1:No,,0.956
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; ,xx,,22,6,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,Single,Lesions ; ,xx,,22,7,3,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,+,RT ; ,xx,,22,8,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,R,Failure ; ,xx,,22,9,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,xx,TFTF ; ,xx,,22,10,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,CR,OR ; ,xx,,22,11,3,No,1:No,1:No,,0.985
1291,2360092,Table 1,BaselineCharacteristic,x.x,Duration ; ,xx,,22,12,3,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,x.x,Survival ; ,xx,,22,13,3,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,,23,0,2,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; ,xx,,23,1,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,Female,Gender ; ,xx,,23,2,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; ,xx,,23,3,3,No,1:No,1:No,,0.881
1291,2360092,Table 1,BaselineCharacteristic,DLC,Histotype ; ,xx,,23,4,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,MA,First line ; ,xx,,23,5,3,No,1:No,1:No,,0.956
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; ,xx,,23,6,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,Multiple,Lesions ; ,xx,,23,7,3,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,+,RT ; ,xx,,23,8,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,R,Failure ; ,xx,,23,9,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,xx,TFTF ; ,xx,,23,10,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,PD,OR ; ,xx,,23,11,3,No,1:No,1:No,,0.971
1291,2360092,Table 1,BaselineCharacteristic,,Duration ; ,xx,,23,12,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,x.x,Survival ; ,xx,,23,13,3,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,,24,0,2,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; ,xx,,24,1,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,Male,Gender ; ,xx,,24,2,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; ,xx,,24,3,3,No,1:No,1:No,,0.881
1291,2360092,Table 1,BaselineCharacteristic,DLC,Histotype ; ,xx,,24,4,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,none,First line ; ,xx,,24,5,3,No,1:No,1:No,,0.966
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; ,xx,,24,6,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,Multiple,Lesions ; ,xx,,24,7,3,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,+,RT ; ,xx,,24,8,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,R,Failure ; ,xx,,24,9,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,xx,TFTF ; ,xx,,24,10,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,PR,OR ; ,xx,,24,11,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,x.x,Duration ; ,xx,,24,12,3,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,x.x,Survival ; ,xx,,24,13,3,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,,25,0,2,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; ,xx,,25,1,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,Female,Gender ; ,xx,,25,2,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; ,xx,,25,3,3,No,1:No,1:No,,0.881
1291,2360092,Table 1,BaselineCharacteristic,DLC,Histotype ; ,xx,,25,4,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,MATI,First line ; ,xx,,25,5,3,No,1:No,1:No,,0.956
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; ,xx,,25,6,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,Multiple,Lesions ; ,xx,,25,7,3,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,+,RT ; ,xx,,25,8,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,PD,Failure ; ,xx,,25,9,3,No,1:No,1:No,,0.971
1291,2360092,Table 1,BaselineCharacteristic,x,TFTF ; ,xx,,25,10,3,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,PD,OR ; ,xx,,25,11,3,No,1:No,1:No,,0.971
1291,2360092,Table 1,BaselineCharacteristic,,Duration ; ,xx,,25,12,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,x.x,Survival ; ,xx,,25,13,3,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,,26,0,2,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; ,xx,,26,1,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,Male,Gender ; ,xx,,26,2,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; ,xx,,26,3,3,No,1:No,1:No,,0.881
1291,2360092,Table 1,BaselineCharacteristic,DLC,Histotype ; ,xx,,26,4,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,"MA,P, PBSCT",First line ; ,xx,,26,5,3,No,1:No,1:No,,0.956
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; ,xx,,26,6,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,Multiple,Lesions ; ,xx,,26,7,3,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,+,RT ; ,xx,,26,8,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,PD,Failure ; ,xx,,26,9,3,No,1:No,1:No,,0.971
1291,2360092,Table 1,BaselineCharacteristic,xx,TFTF ; ,xx,,26,10,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,CR,OR ; ,xx,,26,11,3,No,1:No,1:No,,0.985
1291,2360092,Table 1,BaselineCharacteristic,x.x,Duration ; ,xx,,26,12,3,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,x.x,Survival ; ,xx,,26,13,3,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,,27,0,2,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; ,xx,,27,1,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,Male,Gender ; ,xx,,27,2,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; ,xx,,27,3,3,No,1:No,1:No,,0.881
1291,2360092,Table 1,BaselineCharacteristic,DLC,Histotype ; ,xx,,27,4,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,MABET,First line ; ,xx,,27,5,3,No,1:No,1:No,,0.956
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; ,xx,,27,6,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,Multiple,Lesions ; ,xx,,27,7,3,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,+,RT ; ,xx,,27,8,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,PD,Failure ; ,xx,,27,9,3,No,1:No,1:No,,0.971
1291,2360092,Table 1,BaselineCharacteristic,x,TFTF ; ,xx,,27,10,3,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,ED,OR ; ,xx,,27,11,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,,Duration ; ,xx,,27,12,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,x.x,Survival ; ,xx,,27,13,3,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,,28,0,2,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; ,xx,,28,1,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,Male,Gender ; ,xx,,28,2,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; ,xx,,28,3,3,No,1:No,1:No,,0.881
1291,2360092,Table 1,BaselineCharacteristic,DLC,Histotype ; ,xx,,28,4,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,MATI,First line ; ,xx,,28,5,3,No,1:No,1:No,,0.956
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; ,xx,,28,6,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,Single,Lesions ; ,xx,,28,7,3,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,+,RT ; ,xx,,28,8,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,R,Failure ; ,xx,,28,9,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,x,TFTF ; ,xx,,28,10,3,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,ED,OR ; ,xx,,28,11,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,,Duration ; ,xx,,28,12,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,x.x,Survival ; ,xx,,28,13,3,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,,29,0,2,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; ,xx,,29,1,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,Female,Gender ; ,xx,,29,2,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; ,xx,,29,3,3,No,1:No,1:No,,0.881
1291,2360092,Table 1,BaselineCharacteristic,DLC,Histotype ; ,xx,,29,4,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,"M, Me, N, R, PBSCT",First line ; ,xx,,29,5,3,No,1:No,1:No,,0.956
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; ,xx,,29,6,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,Multiple,Lesions ; ,xx,,29,7,3,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,?,RT ; ,xx,,29,8,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,R,Failure ; ,xx,,29,9,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,xx,TFTF ; ,xx,,29,10,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,PD,OR ; ,xx,,29,11,3,No,1:No,1:No,,0.971
1291,2360092,Table 1,BaselineCharacteristic,,Duration ; ,xx,,29,12,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,x.x,Survival ; ,xx,,29,13,3,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,,30,0,2,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; ,xx,,30,1,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,Female,Gender ; ,xx,,30,2,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; ,xx,,30,3,3,No,1:No,1:No,,0.881
1291,2360092,Table 1,BaselineCharacteristic,DLC,Histotype ; ,xx,,30,4,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,MATI,First line ; ,xx,,30,5,3,No,1:No,1:No,,0.956
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; ,xx,,30,6,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,Multiple,Lesions ; ,xx,,30,7,3,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,+,RT ; ,xx,,30,8,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,R,Failure ; ,xx,,30,9,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,x,TFTF ; ,xx,,30,10,3,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,PD,OR ; ,xx,,30,11,3,No,1:No,1:No,,0.971
1291,2360092,Table 1,BaselineCharacteristic,,Duration ; ,xx,,30,12,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,x.x,Survival ; ,xx,,30,13,3,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,,31,0,2,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; ,xx,,31,1,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,Female,Gender ; ,xx,,31,2,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; ,xx,,31,3,3,No,1:No,1:No,,0.881
1291,2360092,Table 1,BaselineCharacteristic,DLC,Histotype ; ,xx,,31,4,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,MATI,First line ; ,xx,,31,5,3,No,1:No,1:No,,0.956
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; ,xx,,31,6,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,Multiple,Lesions ; ,xx,,31,7,3,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,+,RT ; ,xx,,31,8,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,R,Failure ; ,xx,,31,9,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,xx,TFTF ; ,xx,,31,10,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,CR,OR ; ,xx,,31,11,3,No,1:No,1:No,,0.985
1291,2360092,Table 1,BaselineCharacteristic,xx.x+,Duration ; ,xx,,31,12,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,xx.x+,Survival ; ,xx,,31,13,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,,32,0,2,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; ,xx,,32,1,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,Female,Gender ; ,xx,,32,2,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; ,xx,,32,3,3,No,1:No,1:No,,0.881
1291,2360092,Table 1,BaselineCharacteristic,DLC,Histotype ; ,xx,,32,4,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,MATI,First line ; ,xx,,32,5,3,No,1:No,1:No,,0.956
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; ,xx,,32,6,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,Multiple,Lesions ; ,xx,,32,7,3,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,+,RT ; ,xx,,32,8,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,R,Failure ; ,xx,,32,9,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,xx,TFTF ; ,xx,,32,10,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,CR,OR ; ,xx,,32,11,3,No,1:No,1:No,,0.985
1291,2360092,Table 1,BaselineCharacteristic,x.x,Duration ; ,xx,,32,12,3,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,xx.x,Survival ; ,xx,,32,13,3,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,,33,0,2,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; ,xx,,33,1,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,Male,Gender ; ,xx,,33,2,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; ,xx,,33,3,3,No,1:No,1:No,,0.881
1291,2360092,Table 1,BaselineCharacteristic,DLC,Histotype ; ,xx,,33,4,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,MATI,First line ; ,xx,,33,5,3,No,1:No,1:No,,0.956
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; ,xx,,33,6,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,Multple,Lesions ; ,xx,,33,7,3,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,+,RT ; ,xx,,33,8,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,R,Failure ; ,xx,,33,9,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,xx,TFTF ; ,xx,,33,10,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,PD,OR ; ,xx,,33,11,3,No,1:No,1:No,,0.971
1291,2360092,Table 1,BaselineCharacteristic,,Duration ; ,xx,,33,12,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,x.x,Survival ; ,xx,,33,13,3,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,,34,0,2,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; ,xx,,34,1,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,Male,Gender ; ,xx,,34,2,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; ,xx,,34,3,3,No,1:No,1:No,,0.881
1291,2360092,Table 1,BaselineCharacteristic,HG,Histotype ; ,xx,,34,4,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,MA,First line ; ,xx,,34,5,3,No,1:No,1:No,,0.956
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; ,xx,,34,6,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,Multiple,Lesions ; ,xx,,34,7,3,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,+,RT ; ,xx,,34,8,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,PD,Failure ; ,xx,,34,9,3,No,1:No,1:No,,0.971
1291,2360092,Table 1,BaselineCharacteristic,x,TFTF ; ,xx,,34,10,3,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,CR,OR ; ,xx,,34,11,3,No,1:No,1:No,,0.985
1291,2360092,Table 1,BaselineCharacteristic,x.x+,Duration ; ,xx,,34,12,3,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,xx.x+,Survival ; ,xx,,34,13,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,,35,0,2,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; ,xx,,35,1,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,Male,Gender ; ,xx,,35,2,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; ,xx,,35,3,3,No,1:No,1:No,,0.881
1291,2360092,Table 1,BaselineCharacteristic,DLC,Histotype ; ,xx,,35,4,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,—,First line ; ,xx,,35,5,3,No,1:No,1:No,,0.956
1291,2360092,Table 1,BaselineCharacteristic,—,Number of lines ; ,xx,,35,6,3,No,1:No,1:No,,0.956
1291,2360092,Table 1,BaselineCharacteristic,Single,Lesions ; ,xx,,35,7,3,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,+,RT ; ,xx,,35,8,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,PD,Failure ; ,xx,,35,9,3,No,1:No,1:No,,0.971
1291,2360092,Table 1,BaselineCharacteristic,x,TFTF ; ,xx,,35,10,3,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,SD,OR ; ,xx,,35,11,3,No,1:No,1:No,,0.751
1291,2360092,Table 1,BaselineCharacteristic,x.x,Duration ; ,xx,,35,12,3,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,x.x,Survival ; ,xx,,35,13,3,No,1:No,1:No,,0.945
1291,2360092,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,,36,0,2,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,xx,Age ; ,xx,,36,1,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,Male,Gender ; ,xx,,36,2,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,x,PS ; ,xx,,36,3,3,No,1:No,1:No,,0.881
1291,2360092,Table 1,BaselineCharacteristic,DLC,Histotype ; ,xx,,36,4,3,No,1:No,1:No,,0.937
1291,2360092,Table 1,BaselineCharacteristic,M,First line ; ,xx,,36,5,3,No,1:No,1:No,,0.956
1291,2360092,Table 1,BaselineCharacteristic,x,Number of lines ; ,xx,,36,6,3,No,1:No,1:No,,0.93
1291,2360092,Table 1,BaselineCharacteristic,Multiple,Lesions ; ,xx,,36,7,3,No,1:No,1:No,,0.951
1291,2360092,Table 1,BaselineCharacteristic,+,RT ; ,xx,,36,8,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,R,Failure ; ,xx,,36,9,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,xx,TFTF ; ,xx,,36,10,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,PD,OR ; ,xx,,36,11,3,No,1:No,1:No,,0.971
1291,2360092,Table 1,BaselineCharacteristic,,Duration ; ,xx,,36,12,3,No,1:No,1:No,,0.961
1291,2360092,Table 1,BaselineCharacteristic,x.x,Survival ; ,xx,,36,13,3,No,1:No,1:No,,0.945
1359,2360595,Table 1,BaselineCharacteristic,Number of patients,,None,None,0,0,12,No,1:No,1:No,,0.835
1359,2360595,Table 1,BaselineCharacteristic,xx,,Number of patients,None,0,1,1,No,1:No,1:No,,0.718
1359,2360595,Table 1,BaselineCharacteristic,Sex,Number of patients ; ,None,None,1,0,24,No,1:No,1:No,,0.845
1359,2360595,Table 1,BaselineCharacteristic,Sex,xx ; ,Sex,None,1,1,43,No,1:No,1:No,,0.666
1359,2360595,Table 1,BaselineCharacteristic,?Male,Number of patients ; ,?Male, Sex,2,0,2,No,1:No,1:No,,0.88
1359,2360595,Table 1,BaselineCharacteristic,xx,xx ; ,?Male, Sex,2,1,3,No,1:No,1:No,,0.688
1359,2360595,Table 1,BaselineCharacteristic,?Female,Number of patients ; ,?Female, Sex,3,0,2,No,1:No,1:No,,0.89
1359,2360595,Table 1,BaselineCharacteristic,xx,xx ; ,?Female, Sex,3,1,3,No,1:No,1:No,,0.681
1359,2360595,Table 1,BaselineCharacteristic,,Number of patients ; ,None,None,4,0,2,No,1:No,1:No,,0.9
1359,2360595,Table 1,BaselineCharacteristic,,xx ; ,None,None,4,1,3,No,1:No,1:No,,0.741
1359,2360595,Table 1,BaselineCharacteristic,Performance status,Number of patients ; ,None,None,5,0,24,No,1:No,1:No,,0.855
1359,2360595,Table 1,BaselineCharacteristic,Performance status,xx ; ,Performance status,None,5,1,43,No,1:No,1:No,,0.75
1359,2360595,Table 1,BaselineCharacteristic,?x,Number of patients ; ,?x, Performance status,6,0,2,No,1:No,1:No,,0.885
1359,2360595,Table 1,BaselineCharacteristic,xx,xx ; ,?x, Performance status,6,1,3,No,1:No,1:No,,0.756
1359,2360595,Table 1,BaselineCharacteristic,?x,Number of patients ; ,?x, Performance status,7,0,2,No,1:No,1:No,,0.885
1359,2360595,Table 1,BaselineCharacteristic,xx,xx ; ,?x, Performance status,7,1,3,No,1:No,1:No,,0.796
1359,2360595,Table 1,BaselineCharacteristic,?x,Number of patients ; ,?x, Performance status,8,0,2,No,1:No,1:No,,0.884
1359,2360595,Table 1,BaselineCharacteristic,x,xx ; ,?x, Performance status,8,1,3,No,1:No,1:No,,0.816
1359,2360595,Table 1,BaselineCharacteristic,,Number of patients ; ,None,None,9,0,2,No,1:No,1:No,,0.9
1359,2360595,Table 1,BaselineCharacteristic,,xx ; ,None,None,9,1,3,No,1:No,1:No,,0.881
1359,2360595,Table 1,BaselineCharacteristic,Sarcoma type,Number of patients ; ,None,None,10,0,24,No,1:No,1:No,,0.875
1359,2360595,Table 1,BaselineCharacteristic,Sarcoma type,xx ; ,Sarcoma type,None,10,1,43,No,1:No,1:No,,0.925
1359,2360595,Table 1,BaselineCharacteristic,?Leiomyosarcoma,Number of patients ; ,?Leiomyosarcoma, Sarcoma type,11,0,2,No,1:No,1:No,,0.9
1359,2360595,Table 1,BaselineCharacteristic,xx,xx ; ,?Leiomyosarcoma, Sarcoma type,11,1,3,No,1:No,1:No,,0.931
1359,2360595,Table 1,BaselineCharacteristic,?Malignant fibrous histiocytoma,Number of patients ; ,?Malignant fibrous histiocytoma, Sarcoma type,12,0,2,No,1:No,1:No,,0.9
1359,2360595,Table 1,BaselineCharacteristic,xx,xx ; ,?Malignant fibrous histiocytoma, Sarcoma type,12,1,3,No,1:No,1:No,,0.931
1359,2360595,Table 1,BaselineCharacteristic,?Angiosarcoma,Number of patients ; ,?Angiosarcoma, Sarcoma type,13,0,2,No,1:No,1:No,,0.9
1359,2360595,Table 1,BaselineCharacteristic,x,xx ; ,?Angiosarcoma, Sarcoma type,13,1,3,No,1:No,1:No,,0.886
1359,2360595,Table 1,BaselineCharacteristic,?Epithelioid sarcoma,Number of patients ; ,?Epithelioid sarcoma, Sarcoma type,14,0,2,No,1:No,1:No,,0.9
1359,2360595,Table 1,BaselineCharacteristic,x,xx ; ,?Epithelioid sarcoma, Sarcoma type,14,1,3,No,1:No,1:No,,0.906
1359,2360595,Table 1,BaselineCharacteristic,?Liposarcoma,Number of patients ; ,?Liposarcoma, Sarcoma type,15,0,2,No,1:No,1:No,,0.9
1359,2360595,Table 1,BaselineCharacteristic,x,xx ; ,?Liposarcoma, Sarcoma type,15,1,3,No,1:No,1:No,,0.906
1359,2360595,Table 1,BaselineCharacteristic,?Neurofibrosarcoma,Number of patients ; ,?Neurofibrosarcoma, Sarcoma type,16,0,2,No,1:No,1:No,,0.9
1359,2360595,Table 1,BaselineCharacteristic,x,xx ; ,?Neurofibrosarcoma, Sarcoma type,16,1,3,No,1:No,1:No,,0.906
1359,2360595,Table 1,BaselineCharacteristic,?Unclassified,Number of patients ; ,?Unclassified, Sarcoma type,17,0,2,No,1:No,1:No,,0.9
1359,2360595,Table 1,BaselineCharacteristic,x,xx ; ,?Unclassified, Sarcoma type,17,1,3,No,1:No,1:No,,0.906
1359,2360595,Table 1,BaselineCharacteristic,?Alveolar rhabdomyosarcoma,Number of patients ; ,?Alveolar rhabdomyosarcoma, Sarcoma type,18,0,2,No,1:No,1:No,,0.9
1359,2360595,Table 1,BaselineCharacteristic,x,xx ; ,?Alveolar rhabdomyosarcoma, Sarcoma type,18,1,3,No,1:No,1:No,,0.891
1359,2360595,Table 1,BaselineCharacteristic,?Synoviosarcoma,Number of patients ; ,?Synoviosarcoma, Sarcoma type,19,0,2,No,1:No,1:No,,0.9
1359,2360595,Table 1,BaselineCharacteristic,x,xx ; ,?Synoviosarcoma, Sarcoma type,19,1,3,No,1:No,1:No,,0.891
1359,2360595,Table 1,BaselineCharacteristic,?Extra-skeletal osteosarcoma,Number of patients ; ,?Extra-skeletal osteosarcoma, Sarcoma type,20,0,2,No,1:No,1:No,,0.9
1359,2360595,Table 1,BaselineCharacteristic,x,xx ; ,?Extra-skeletal osteosarcoma, Sarcoma type,20,1,3,No,1:No,1:No,,0.891
1359,2360595,Table 1,BaselineCharacteristic,?Malignant hemangiopericytoma,Number of patients ; ,?Malignant hemangiopericytoma, Sarcoma type,21,0,2,No,1:No,1:No,,0.9
1359,2360595,Table 1,BaselineCharacteristic,x,xx ; ,?Malignant hemangiopericytoma, Sarcoma type,21,1,3,No,1:No,1:No,,0.891
1359,2360595,Table 1,BaselineCharacteristic,,Number of patients ; ,None,None,22,0,2,No,1:No,1:No,,0.9
1359,2360595,Table 1,BaselineCharacteristic,,xx ; ,None,None,22,1,3,No,1:No,1:No,,0.937
1359,2360595,Table 1,BaselineCharacteristic,Differentiation grade,Number of patients ; ,None,None,23,0,24,No,1:No,1:No,,0.885
1359,2360595,Table 1,BaselineCharacteristic,Differentiation grade,xx ; ,Differentiation grade,None,23,1,43,No,1:No,1:No,,0.949
1359,2360595,Table 1,BaselineCharacteristic,?x,Number of patients ; ,?x, Differentiation grade,24,0,2,No,1:No,1:No,,0.874
1359,2360595,Table 1,BaselineCharacteristic,x,xx ; ,?x, Differentiation grade,24,1,3,No,1:No,1:No,,0.921
1359,2360595,Table 1,BaselineCharacteristic,?x,Number of patients ; ,?x, Differentiation grade,25,0,2,No,1:No,1:No,,0.874
1359,2360595,Table 1,BaselineCharacteristic,xx,xx ; ,?x, Differentiation grade,25,1,3,No,1:No,1:No,,0.921
1359,2360595,Table 1,BaselineCharacteristic,?x,Number of patients ; ,?x, Differentiation grade,26,0,2,No,1:No,1:No,,0.874
1359,2360595,Table 1,BaselineCharacteristic,xx,xx ; ,?x, Differentiation grade,26,1,3,No,1:No,1:No,,0.921
1359,2360595,Table 1,BaselineCharacteristic,?Unknown,Number of patients ; ,?Unknown, Differentiation grade,27,0,2,No,1:No,1:No,,0.9
1359,2360595,Table 1,BaselineCharacteristic,x,xx ; ,?Unknown, Differentiation grade,27,1,3,No,1:No,1:No,,0.921
1359,2360595,Table 1,BaselineCharacteristic,,Number of patients ; ,None,None,28,0,2,No,1:No,1:No,,0.9
1359,2360595,Table 1,BaselineCharacteristic,,xx ; ,None,None,28,1,3,No,1:No,1:No,,0.937
1359,2360595,Table 1,BaselineCharacteristic,Tumour location,Number of patients ; ,None,None,29,0,24,No,1:No,1:No,,0.885
1359,2360595,Table 1,BaselineCharacteristic,Tumour location,xx ; ,Tumour location,None,29,1,43,No,1:No,1:No,,0.976
1359,2360595,Table 1,BaselineCharacteristic,?Localised,Number of patients ; ,?Localised, Tumour location,30,0,2,No,1:No,1:No,,0.9
1359,2360595,Table 1,BaselineCharacteristic,xx,xx ; ,?Localised, Tumour location,30,1,3,No,1:No,1:No,,0.967
1359,2360595,Table 1,BaselineCharacteristic,?Metastatic,Number of patients ; ,?Metastatic, Tumour location,31,0,2,No,1:No,1:No,,0.9
1359,2360595,Table 1,BaselineCharacteristic,xx,xx ; ,?Metastatic, Tumour location,31,1,3,No,1:No,1:No,,0.967
1359,2360595,Table 1,BaselineCharacteristic,?Lung,Number of patients ; ,?Lung, Tumour location,32,0,2,No,1:No,1:No,,0.9
1359,2360595,Table 1,BaselineCharacteristic,xx,xx ; ,?Lung, Tumour location,32,1,3,No,1:No,1:No,,0.967
1359,2360595,Table 1,BaselineCharacteristic,?Lymph nodes,Number of patients ; ,?Lymph nodes, Tumour location,33,0,2,No,1:No,1:No,,0.9
1359,2360595,Table 1,BaselineCharacteristic,xx,xx ; ,?Lymph nodes, Tumour location,33,1,3,No,1:No,1:No,,0.967
1359,2360595,Table 1,BaselineCharacteristic,?Liver,Number of patients ; ,?Liver, Tumour location,34,0,2,No,1:No,1:No,,0.9
1359,2360595,Table 1,BaselineCharacteristic,x,xx ; ,?Liver, Tumour location,34,1,3,No,1:No,1:No,,0.941
1359,2360595,Table 1,BaselineCharacteristic,?Bone,Number of patients ; ,?Bone, Tumour location,35,0,2,No,1:No,1:No,,0.9
1359,2360595,Table 1,BaselineCharacteristic,x,xx ; ,?Bone, Tumour location,35,1,3,No,1:No,1:No,,0.941
1359,2360595,Table 1,BaselineCharacteristic,?Soft tissue,Number of patients ; ,?Soft tissue, Tumour location,36,0,2,No,1:No,1:No,,0.9
1359,2360595,Table 1,BaselineCharacteristic,x,xx ; ,?Soft tissue, Tumour location,36,1,3,No,1:No,1:No,,0.941
1359,2360595,Table 1,BaselineCharacteristic,?Pancreas,Number of patients ; ,?Pancreas, Tumour location,37,0,2,No,1:No,1:No,,0.9
1359,2360595,Table 1,BaselineCharacteristic,x,xx ; ,?Pancreas, Tumour location,37,1,3,No,1:No,1:No,,0.941
1359,2360595,Table 1,BaselineCharacteristic,?Kidney,Number of patients ; ,?Kidney, Tumour location,38,0,2,No,1:No,1:No,,0.9
1359,2360595,Table 1,BaselineCharacteristic,x,xx ; ,?Kidney, Tumour location,38,1,3,No,1:No,1:No,,0.941
1359,2360595,Table 1,BaselineCharacteristic,?Peritoneum,Number of patients ; ,?Peritoneum, Tumour location,39,0,2,No,1:No,1:No,,0.9
1359,2360595,Table 1,BaselineCharacteristic,x,xx ; ,?Peritoneum, Tumour location,39,1,3,No,1:No,1:No,,0.941
1362,2360617,Table 1,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
1362,2360617,Table 1,BaselineCharacteristic,,,,None,0,1,1,No,1:No,1:No,,0.903
1362,2360617,Table 1,BaselineCharacteristic,,,,None,0,2,1,No,1:No,1:No,,0.903
1362,2360617,Table 1,BaselineCharacteristic,,,,None,0,3,1,No,1:No,1:No,,0.903
1362,2360617,Table 1,BaselineCharacteristic,,,,None,0,4,1,No,1:No,1:No,,0.913
1362,2360617,Table 1,BaselineCharacteristic,THC treatment,,,None,0,5,1,No,1:No,1:No,,0.935
1362,2360617,Table 1,BaselineCharacteristic,THC treatment,,,None,0,6,1,No,1:No,1:No,,0.935
1362,2360617,Table 1,BaselineCharacteristic,THC treatment,,,None,0,7,1,No,1:No,1:No,,0.945
1362,2360617,Table 1,BaselineCharacteristic,,,,None,0,8,1,No,1:No,1:No,,0.945
1362,2360617,Table 1,BaselineCharacteristic,,,,None,0,9,1,No,1:No,1:No,,0.945
1362,2360617,Table 1,BaselineCharacteristic,Patient, ; ,None,None,1,0,12,No,1:No,1:No,,0.898
1362,2360617,Table 1,BaselineCharacteristic,Age (sex), ; ,Patient,None,1,1,1,No,1:No,1:No,,0.902
1362,2360617,Table 1,BaselineCharacteristic,KPS, ; ,Patient,None,1,2,1,No,1:No,1:No,,0.896
1362,2360617,Table 1,BaselineCharacteristic,Tumour location, ; ,Patient,None,1,3,1,No,1:No,1:No,,0.896
1362,2360617,Table 1,BaselineCharacteristic,Recurrent-tumour volume (cmx), ; ,Patient,None,1,4,1,No,1:No,1:No,,0.907
1362,2360617,Table 1,BaselineCharacteristic,Total days,THC treatment ; ,Patient,None,1,5,1,No,1:No,1:No,,0.945
1362,2360617,Table 1,BaselineCharacteristic,Number of cycles,THC treatment ; ,Patient,None,1,6,1,No,1:No,1:No,,0.935
1362,2360617,Table 1,BaselineCharacteristic,Total dose (mg),THC treatment ; ,Patient,None,1,7,1,No,1:No,1:No,,0.876
1362,2360617,Table 1,BaselineCharacteristic,Time between first and second surgery (wk), ; ,Patient,None,1,8,1,No,1:No,1:No,,0.963
1362,2360617,Table 1,BaselineCharacteristic,Time from second surgery to death (wk), ; ,Patient,None,1,9,1,No,1:No,1:No,,0.948
1362,2360617,Table 1,BaselineCharacteristic,x, ; Patient ; ,x,None,2,0,2,No,1:No,1:No,,0.935
1362,2360617,Table 1,BaselineCharacteristic,xx (m), ; Age (sex) ; ,x,None,2,1,3,No,1:No,1:No,,0.752
1362,2360617,Table 1,BaselineCharacteristic,xx, ; KPS ; ,x,None,2,2,3,No,1:No,1:No,,0.652
1362,2360617,Table 1,BaselineCharacteristic,L–O, ; Tumour location ; ,x,None,2,3,3,No,1:No,1:No,,0.91
1362,2360617,Table 1,BaselineCharacteristic,xxx, ; Recurrent-tumour volume (cmx) ; ,x,None,2,4,3,No,1:No,1:No,,0.83
1362,2360617,Table 1,BaselineCharacteristic,xx,THC treatment ; Total days ; ,x,None,2,5,3,No,1:No,1:No,,0.796
1362,2360617,Table 1,BaselineCharacteristic,x,THC treatment ; Number of cycles ; ,x,None,2,6,3,No,1:No,1:No,,0.93
1362,2360617,Table 1,BaselineCharacteristic,x.xx,THC treatment ; Total dose (mg) ; ,x,None,2,7,3,No,1:No,1:No,,0.761
1362,2360617,Table 1,BaselineCharacteristic,xx, ; Time between first and second surgery (wk) ; ,x,None,2,8,3,No,1:No,1:No,,0.77
1362,2360617,Table 1,BaselineCharacteristic,xx, ; Time from second surgery to death (wk) ; ,x,None,2,9,3,No,1:No,1:No,,0.726
1362,2360617,Table 1,BaselineCharacteristic,x, ; Patient ; ,x,None,3,0,2,No,1:No,1:No,,0.945
1362,2360617,Table 1,BaselineCharacteristic,xx (m), ; Age (sex) ; ,x,None,3,1,3,No,1:No,1:No,,0.766
1362,2360617,Table 1,BaselineCharacteristic,xx, ; KPS ; ,x,None,3,2,3,No,1:No,1:No,,0.656
1362,2360617,Table 1,BaselineCharacteristic,R–T, ; Tumour location ; ,x,None,3,3,3,No,1:No,1:No,,0.93
1362,2360617,Table 1,BaselineCharacteristic,xx, ; Recurrent-tumour volume (cmx) ; ,x,None,3,4,3,No,1:No,1:No,,0.656
1362,2360617,Table 1,BaselineCharacteristic,xx,THC treatment ; Total days ; ,x,None,3,5,3,No,1:No,1:No,,0.8
1362,2360617,Table 1,BaselineCharacteristic,x,THC treatment ; Number of cycles ; ,x,None,3,6,3,No,1:No,1:No,,0.95
1362,2360617,Table 1,BaselineCharacteristic,x.xx,THC treatment ; Total dose (mg) ; ,x,None,3,7,3,No,1:No,1:No,,0.765
1362,2360617,Table 1,BaselineCharacteristic,xx, ; Time between first and second surgery (wk) ; ,x,None,3,8,3,No,1:No,1:No,,0.78
1362,2360617,Table 1,BaselineCharacteristic,xx, ; Time from second surgery to death (wk) ; ,x,None,3,9,3,No,1:No,1:No,,0.73
1362,2360617,Table 1,BaselineCharacteristic,x, ; Patient ; ,x,None,4,0,2,No,1:No,1:No,,0.965
1362,2360617,Table 1,BaselineCharacteristic,xx (m), ; Age (sex) ; ,x,None,4,1,3,No,1:No,1:No,,0.836
1362,2360617,Table 1,BaselineCharacteristic,xx, ; KPS ; ,x,None,4,2,3,No,1:No,1:No,,0.746
1362,2360617,Table 1,BaselineCharacteristic,L–T, ; Tumour location ; ,x,None,4,3,3,No,1:No,1:No,,0.93
1362,2360617,Table 1,BaselineCharacteristic,xx, ; Recurrent-tumour volume (cmx) ; ,x,None,4,4,3,No,1:No,1:No,,0.756
1362,2360617,Table 1,BaselineCharacteristic,xx,THC treatment ; Total days ; ,x,None,4,5,3,No,1:No,1:No,,0.87
1362,2360617,Table 1,BaselineCharacteristic,x,THC treatment ; Number of cycles ; ,x,None,4,6,3,No,1:No,1:No,,0.95
1362,2360617,Table 1,BaselineCharacteristic,x.xx,THC treatment ; Total dose (mg) ; ,x,None,4,7,3,No,1:No,1:No,,0.795
1362,2360617,Table 1,BaselineCharacteristic,x, ; Time between first and second surgery (wk) ; ,x,None,4,8,3,No,1:No,1:No,,0.94
1362,2360617,Table 1,BaselineCharacteristic,xx, ; Time from second surgery to death (wk) ; ,x,None,4,9,3,No,1:No,1:No,,0.79
1362,2360617,Table 1,BaselineCharacteristic,x, ; Patient ; ,x,None,5,0,2,No,1:No,1:No,,0.963
1362,2360617,Table 1,BaselineCharacteristic,xx (m), ; Age (sex) ; ,x,None,5,1,3,No,1:No,1:No,,0.836
1362,2360617,Table 1,BaselineCharacteristic,xx, ; KPS ; ,x,None,5,2,3,No,1:No,1:No,,0.746
1362,2360617,Table 1,BaselineCharacteristic,R–T, ; Tumour location ; ,x,None,5,3,3,No,1:No,1:No,,0.93
1362,2360617,Table 1,BaselineCharacteristic,xx, ; Recurrent-tumour volume (cmx) ; ,x,None,5,4,3,No,1:No,1:No,,0.756
1362,2360617,Table 1,BaselineCharacteristic,xx,THC treatment ; Total days ; ,x,None,5,5,3,No,1:No,1:No,,0.85
1362,2360617,Table 1,BaselineCharacteristic,x,THC treatment ; Number of cycles ; ,x,None,5,6,3,No,1:No,1:No,,0.94
1362,2360617,Table 1,BaselineCharacteristic,x.xx,THC treatment ; Total dose (mg) ; ,x,None,5,7,3,No,1:No,1:No,,0.775
1362,2360617,Table 1,BaselineCharacteristic,xx, ; Time between first and second surgery (wk) ; ,x,None,5,8,3,No,1:No,1:No,,0.81
1362,2360617,Table 1,BaselineCharacteristic,xx, ; Time from second surgery to death (wk) ; ,x,None,5,9,3,No,1:No,1:No,,0.78
1362,2360617,Table 1,BaselineCharacteristic,x, ; Patient ; ,x,None,6,0,2,No,1:No,1:No,,0.973
1362,2360617,Table 1,BaselineCharacteristic,xx (f), ; Age (sex) ; ,x,None,6,1,3,No,1:No,1:No,,0.816
1362,2360617,Table 1,BaselineCharacteristic,xx, ; KPS ; ,x,None,6,2,3,No,1:No,1:No,,0.766
1362,2360617,Table 1,BaselineCharacteristic,R–P, ; Tumour location ; ,x,None,6,3,3,No,1:No,1:No,,0.95
1362,2360617,Table 1,BaselineCharacteristic,xx, ; Recurrent-tumour volume (cmx) ; ,x,None,6,4,3,No,1:No,1:No,,0.776
1362,2360617,Table 1,BaselineCharacteristic,xx,THC treatment ; Total days ; ,x,None,6,5,3,No,1:No,1:No,,0.87
1362,2360617,Table 1,BaselineCharacteristic,x,THC treatment ; Number of cycles ; ,x,None,6,6,3,No,1:No,1:No,,0.96
1362,2360617,Table 1,BaselineCharacteristic,x.xx,THC treatment ; Total dose (mg) ; ,x,None,6,7,3,No,1:No,1:No,,0.775
1362,2360617,Table 1,BaselineCharacteristic,xx, ; Time between first and second surgery (wk) ; ,x,None,6,8,3,No,1:No,1:No,,0.83
1362,2360617,Table 1,BaselineCharacteristic,xx, ; Time from second surgery to death (wk) ; ,x,None,6,9,3,No,1:No,1:No,,0.8
1362,2360617,Table 1,BaselineCharacteristic,x, ; Patient ; ,x,None,7,0,2,No,1:No,1:No,,0.973
1362,2360617,Table 1,BaselineCharacteristic,xx (f), ; Age (sex) ; ,x,None,7,1,3,No,1:No,1:No,,0.826
1362,2360617,Table 1,BaselineCharacteristic,xx, ; KPS ; ,x,None,7,2,3,No,1:No,1:No,,0.806
1362,2360617,Table 1,BaselineCharacteristic,R–T, ; Tumour location ; ,x,None,7,3,3,No,1:No,1:No,,0.96
1362,2360617,Table 1,BaselineCharacteristic,xx, ; Recurrent-tumour volume (cmx) ; ,x,None,7,4,3,No,1:No,1:No,,0.826
1362,2360617,Table 1,BaselineCharacteristic,xx,THC treatment ; Total days ; ,x,None,7,5,3,No,1:No,1:No,,0.89
1362,2360617,Table 1,BaselineCharacteristic,x,THC treatment ; Number of cycles ; ,x,None,7,6,3,No,1:No,1:No,,0.98
1362,2360617,Table 1,BaselineCharacteristic,x.xx,THC treatment ; Total dose (mg) ; ,x,None,7,7,3,No,1:No,1:No,,0.805
1362,2360617,Table 1,BaselineCharacteristic,x, ; Time between first and second surgery (wk) ; ,x,None,7,8,3,No,1:No,1:No,,0.98
1362,2360617,Table 1,BaselineCharacteristic,x, ; Time from second surgery to death (wk) ; ,x,None,7,9,3,No,1:No,1:No,,0.97
1362,2360617,Table 1,BaselineCharacteristic,x, ; Patient ; ,x,None,8,0,2,No,1:No,1:No,,0.972
1362,2360617,Table 1,BaselineCharacteristic,xx (f), ; Age (sex) ; ,x,None,8,1,3,No,1:No,1:No,,0.846
1362,2360617,Table 1,BaselineCharacteristic,xx, ; KPS ; ,x,None,8,2,3,No,1:No,1:No,,0.826
1362,2360617,Table 1,BaselineCharacteristic,L–T, ; Tumour location ; ,x,None,8,3,3,No,1:No,1:No,,0.97
1362,2360617,Table 1,BaselineCharacteristic,xx, ; Recurrent-tumour volume (cmx) ; ,x,None,8,4,3,No,1:No,1:No,,0.846
1362,2360617,Table 1,BaselineCharacteristic,xx,THC treatment ; Total days ; ,x,None,8,5,3,No,1:No,1:No,,0.9
1362,2360617,Table 1,BaselineCharacteristic,x,THC treatment ; Number of cycles ; ,x,None,8,6,3,No,1:No,1:No,,0.99
1362,2360617,Table 1,BaselineCharacteristic,x.xx,THC treatment ; Total dose (mg) ; ,x,None,8,7,3,No,1:No,1:No,,0.815
1362,2360617,Table 1,BaselineCharacteristic,xxx, ; Time between first and second surgery (wk) ; ,x,None,8,8,3,No,1:No,1:No,,0.96
1362,2360617,Table 1,BaselineCharacteristic,xx, ; Time from second surgery to death (wk) ; ,x,None,8,9,3,No,1:No,1:No,,0.88
1362,2360617,Table 1,BaselineCharacteristic,x, ; Patient ; ,x,None,9,0,2,No,1:No,1:No,,0.982
1362,2360617,Table 1,BaselineCharacteristic,xx (f), ; Age (sex) ; ,x,None,9,1,3,No,1:No,1:No,,0.876
1362,2360617,Table 1,BaselineCharacteristic,xx, ; KPS ; ,x,None,9,2,3,No,1:No,1:No,,0.856
1362,2360617,Table 1,BaselineCharacteristic,R–F, ; Tumour location ; ,x,None,9,3,3,No,1:No,1:No,,0.99
1362,2360617,Table 1,BaselineCharacteristic,xx, ; Recurrent-tumour volume (cmx) ; ,x,None,9,4,3,No,1:No,1:No,,0.876
1362,2360617,Table 1,BaselineCharacteristic,xx,THC treatment ; Total days ; ,x,None,9,5,3,No,1:No,1:No,,0.92
1362,2360617,Table 1,BaselineCharacteristic,x,THC treatment ; Number of cycles ; ,x,None,9,6,3,No,1:No,1:No,,0.98
1362,2360617,Table 1,BaselineCharacteristic,x.xx,THC treatment ; Total dose (mg) ; ,x,None,9,7,3,No,1:No,1:No,,0.835
1362,2360617,Table 1,BaselineCharacteristic,xx, ; Time between first and second surgery (wk) ; ,x,None,9,8,3,No,1:No,1:No,,0.92
1362,2360617,Table 1,BaselineCharacteristic,xx, ; Time from second surgery to death (wk) ; ,x,None,9,9,3,No,1:No,1:No,,0.91
1362,2360617,Table 1,BaselineCharacteristic,x, ; Patient ; ,x,None,10,0,2,No,1:No,1:No,,0.982
1362,2360617,Table 1,BaselineCharacteristic,xx (f), ; Age (sex) ; ,x,None,10,1,3,No,1:No,1:No,,0.906
1362,2360617,Table 1,BaselineCharacteristic,xx, ; KPS ; ,x,None,10,2,3,No,1:No,1:No,,0.876
1362,2360617,Table 1,BaselineCharacteristic,L–T, ; Tumour location ; ,x,None,10,3,3,No,1:No,1:No,,1
1362,2360617,Table 1,BaselineCharacteristic,xx, ; Recurrent-tumour volume (cmx) ; ,x,None,10,4,3,No,1:No,1:No,,0.896
1362,2360617,Table 1,BaselineCharacteristic,xx,THC treatment ; Total days ; ,x,None,10,5,3,No,1:No,1:No,,0.93
1362,2360617,Table 1,BaselineCharacteristic,x,THC treatment ; Number of cycles ; ,x,None,10,6,3,No,1:No,1:No,,0.98
1362,2360617,Table 1,BaselineCharacteristic,x.xx,THC treatment ; Total dose (mg) ; ,x,None,10,7,3,No,1:No,1:No,,0.865
1362,2360617,Table 1,BaselineCharacteristic,xx, ; Time between first and second surgery (wk) ; ,x,None,10,8,3,No,1:No,1:No,,0.94
1362,2360617,Table 1,BaselineCharacteristic,xx, ; Time from second surgery to death (wk) ; ,x,None,10,9,3,No,1:No,1:No,,0.93
1376,2360764,Table 1,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
1376,2360764,Table 1,BaselineCharacteristic,No. of patients,,,None,0,1,1,No,1:No,1:No,,0.853
1376,2360764,Table 1,BaselineCharacteristic,%,,,None,0,2,1,No,1:No,1:No,,0.803
1376,2360764,Table 1,BaselineCharacteristic,Characteristics, ; ,None,None,1,0,12,No,1:No,1:No,,0.898
1376,2360764,Table 1,BaselineCharacteristic,xx,No. of patients ; ,Characteristics,None,1,1,1,No,1:No,1:No,,0.711
1376,2360764,Table 1,BaselineCharacteristic,xxx,% ; ,Characteristics,None,1,2,1,No,1:No,1:No,,0.714
1376,2360764,Table 1,BaselineCharacteristic,, ; Characteristics ; ,None,None,3,0,2,No,1:No,1:No,,0.96
1376,2360764,Table 1,BaselineCharacteristic,,No. of patients ; xx ; ,None,None,3,1,3,No,1:No,1:No,,0.69
1376,2360764,Table 1,BaselineCharacteristic,,% ; xxx ; ,None,None,3,2,3,No,1:No,1:No,,0.69
1376,2360764,Table 1,BaselineCharacteristic,Sex, ; Characteristics ; ,None,None,4,0,24,No,1:No,1:No,,0.929
1376,2360764,Table 1,BaselineCharacteristic,,No. of patients ; xx ; ,Sex,None,4,1,43,No,1:No,1:No,,0.75
1376,2360764,Table 1,BaselineCharacteristic,,% ; xxx ; ,Sex,None,4,2,43,No,1:No,1:No,,0.73
1376,2360764,Table 1,BaselineCharacteristic,?Male, ; Characteristics ; ,?Male, Sex,5,0,2,No,1:No,1:No,,0.97
1376,2360764,Table 1,BaselineCharacteristic,xx,No. of patients ; xx ; ,?Male, Sex,5,1,3,No,1:No,1:No,,0.71
1376,2360764,Table 1,BaselineCharacteristic,xx.x,% ; xxx ; ,?Male, Sex,5,2,3,No,1:No,1:No,,0.556
1376,2360764,Table 1,BaselineCharacteristic,?Female, ; Characteristics ; ,?Female, Sex,6,0,2,No,1:No,1:No,,0.99
1376,2360764,Table 1,BaselineCharacteristic,x,No. of patients ; xx ; ,?Female, Sex,6,1,3,No,1:No,1:No,,0.67
1376,2360764,Table 1,BaselineCharacteristic,x.x,% ; xxx ; ,?Female, Sex,6,2,3,No,1:No,1:No,,0.84
1376,2360764,Table 1,BaselineCharacteristic,, ; Characteristics ; ,None,None,7,0,2,No,1:No,1:No,,0.99
1376,2360764,Table 1,BaselineCharacteristic,,No. of patients ; xx ; ,None,None,7,1,3,No,1:No,1:No,,0.75
1376,2360764,Table 1,BaselineCharacteristic,,% ; xxx ; ,None,None,7,2,3,No,1:No,1:No,,0.81
1376,2360764,Table 1,BaselineCharacteristic,ECOG PS, ; Characteristics ; ,None,None,8,0,24,No,1:No,1:No,,0.974
1376,2360764,Table 1,BaselineCharacteristic,ECOG PS,No. of patients ; xx ; ,ECOG PS,None,8,1,43,No,1:No,1:No,,0.79
1376,2360764,Table 1,BaselineCharacteristic,ECOG PS,% ; xxx ; ,ECOG PS,None,8,2,43,No,1:No,1:No,,0.815
1376,2360764,Table 1,BaselineCharacteristic,?x, ; Characteristics ; ,?x, ECOG PS,9,0,2,No,1:No,1:No,,0.982
1376,2360764,Table 1,BaselineCharacteristic,x,No. of patients ; xx ; ,?x, ECOG PS,9,1,3,No,1:No,1:No,,0.75
1376,2360764,Table 1,BaselineCharacteristic,x.x,% ; xxx ; ,?x, ECOG PS,9,2,3,No,1:No,1:No,,0.92
1376,2360764,Table 1,BaselineCharacteristic,?x, ; Characteristics ; ,?x, ECOG PS,10,0,2,No,1:No,1:No,,0.982
1376,2360764,Table 1,BaselineCharacteristic,xx,No. of patients ; xx ; ,?x, ECOG PS,10,1,3,No,1:No,1:No,,0.8
1376,2360764,Table 1,BaselineCharacteristic,xx.x,% ; xxx ; ,?x, ECOG PS,10,2,3,No,1:No,1:No,,0.756
1376,2360764,Table 1,BaselineCharacteristic,?x, ; Characteristics ; ,?x, ECOG PS,11,0,2,No,1:No,1:No,,0.982
1376,2360764,Table 1,BaselineCharacteristic,xx,No. of patients ; xx ; ,?x, ECOG PS,11,1,3,No,1:No,1:No,,0.8
1376,2360764,Table 1,BaselineCharacteristic,xx.x,% ; xxx ; ,?x, ECOG PS,11,2,3,No,1:No,1:No,,0.756
1376,2360764,Table 1,BaselineCharacteristic,?x, ; Characteristics ; ,?x, ECOG PS,12,0,2,No,1:No,1:No,,0.982
1376,2360764,Table 1,BaselineCharacteristic,x,No. of patients ; xx ; ,?x, ECOG PS,12,1,3,No,1:No,1:No,,0.8
1376,2360764,Table 1,BaselineCharacteristic,x.x,% ; xxx ; ,?x, ECOG PS,12,2,3,No,1:No,1:No,,0.94
1376,2360764,Table 1,BaselineCharacteristic,, ; Characteristics ; ,None,None,13,0,2,No,1:No,1:No,,1
1376,2360764,Table 1,BaselineCharacteristic,,No. of patients ; xx ; ,None,None,13,1,3,No,1:No,1:No,,0.84
1376,2360764,Table 1,BaselineCharacteristic,,% ; xxx ; ,None,None,13,2,3,No,1:No,1:No,,0.87
1376,2360764,Table 1,BaselineCharacteristic,No. of distant metastatic sites, ; Characteristics ; ,None,None,14,0,24,No,1:No,1:No,,0.965
1376,2360764,Table 1,BaselineCharacteristic,No. of distant metastatic sites,No. of patients ; xx ; ,No. of distant metastatic sites,None,14,1,43,No,1:No,1:No,,0.794
1376,2360764,Table 1,BaselineCharacteristic,No. of distant metastatic sites,% ; xxx ; ,No. of distant metastatic sites,None,14,2,43,No,1:No,1:No,,0.851
1376,2360764,Table 1,BaselineCharacteristic,?x, ; Characteristics ; ,?x, No. of distant metastatic sites,15,0,2,No,1:No,1:No,,0.952
1376,2360764,Table 1,BaselineCharacteristic,x,No. of patients ; xx ; ,?x, No. of distant metastatic sites,15,1,3,No,1:No,1:No,,0.76
1376,2360764,Table 1,BaselineCharacteristic,xx.x,% ; xxx ; ,?x, No. of distant metastatic sites,15,2,3,No,1:No,1:No,,0.686
1376,2360764,Table 1,BaselineCharacteristic,?x, ; Characteristics ; ,?x, No. of distant metastatic sites,16,0,2,No,1:No,1:No,,0.952
1376,2360764,Table 1,BaselineCharacteristic,xx,No. of patients ; xx ; ,?x, No. of distant metastatic sites,16,1,3,No,1:No,1:No,,0.76
1376,2360764,Table 1,BaselineCharacteristic,xx.x,% ; xxx ; ,?x, No. of distant metastatic sites,16,2,3,No,1:No,1:No,,0.686
1376,2360764,Table 1,BaselineCharacteristic,?x, ; Characteristics ; ,?x, No. of distant metastatic sites,17,0,2,No,1:No,1:No,,0.952
1376,2360764,Table 1,BaselineCharacteristic,xx,No. of patients ; xx ; ,?x, No. of distant metastatic sites,17,1,3,No,1:No,1:No,,0.76
1376,2360764,Table 1,BaselineCharacteristic,xx.x,% ; xxx ; ,?x, No. of distant metastatic sites,17,2,3,No,1:No,1:No,,0.686
1376,2360764,Table 1,BaselineCharacteristic,??x, ; Characteristics ; ,??x, No. of distant metastatic sites,18,0,2,No,1:No,1:No,,0.952
1376,2360764,Table 1,BaselineCharacteristic,xx,No. of patients ; xx ; ,??x, No. of distant metastatic sites,18,1,3,No,1:No,1:No,,0.76
1376,2360764,Table 1,BaselineCharacteristic,xx.x,% ; xxx ; ,??x, No. of distant metastatic sites,18,2,3,No,1:No,1:No,,0.686
1376,2360764,Table 1,BaselineCharacteristic,, ; Characteristics ; ,None,None,19,0,2,No,1:No,1:No,,0.99
1376,2360764,Table 1,BaselineCharacteristic,,No. of patients ; xx ; ,None,None,19,1,3,No,1:No,1:No,,0.86
1376,2360764,Table 1,BaselineCharacteristic,,% ; xxx ; ,None,None,19,2,3,No,1:No,1:No,,0.85
1376,2360764,Table 1,BaselineCharacteristic,Metastatic sites, ; Characteristics ; ,None,None,20,0,24,No,1:No,1:No,,0.945
1376,2360764,Table 1,BaselineCharacteristic,Metastatic sites,No. of patients ; xx ; ,Metastatic sites,None,20,1,43,No,1:No,1:No,,0.804
1376,2360764,Table 1,BaselineCharacteristic,Metastatic sites,% ; xxx ; ,Metastatic sites,None,20,2,43,No,1:No,1:No,,0.821
1376,2360764,Table 1,BaselineCharacteristic,?Lymph nodes, ; Characteristics ; ,?Lymph nodes, Metastatic sites,21,0,2,No,1:No,1:No,,0.972
1376,2360764,Table 1,BaselineCharacteristic,xx,No. of patients ; xx ; ,?Lymph nodes, Metastatic sites,21,1,3,No,1:No,1:No,,0.79
1376,2360764,Table 1,BaselineCharacteristic,xx.x,% ; xxx ; ,?Lymph nodes, Metastatic sites,21,2,3,No,1:No,1:No,,0.676
1376,2360764,Table 1,BaselineCharacteristic,?Brain, ; Characteristics ; ,?Brain, Metastatic sites,22,0,2,No,1:No,1:No,,0.982
1376,2360764,Table 1,BaselineCharacteristic,xx,No. of patients ; xx ; ,?Brain, Metastatic sites,22,1,3,No,1:No,1:No,,0.8
1376,2360764,Table 1,BaselineCharacteristic,xx.x,% ; xxx ; ,?Brain, Metastatic sites,22,2,3,No,1:No,1:No,,0.69
1376,2360764,Table 1,BaselineCharacteristic,?Bone, ; Characteristics ; ,?Bone, Metastatic sites,23,0,2,No,1:No,1:No,,0.982
1376,2360764,Table 1,BaselineCharacteristic,xx,No. of patients ; xx ; ,?Bone, Metastatic sites,23,1,3,No,1:No,1:No,,0.79
1376,2360764,Table 1,BaselineCharacteristic,xx.x,% ; xxx ; ,?Bone, Metastatic sites,23,2,3,No,1:No,1:No,,0.686
1376,2360764,Table 1,BaselineCharacteristic,?Pleural effusion or seeding, ; Characteristics ; ,?Pleural effusion or seeding, Metastatic sites,24,0,2,No,1:No,1:No,,0.982
1376,2360764,Table 1,BaselineCharacteristic,xx,No. of patients ; xx ; ,?Pleural effusion or seeding, Metastatic sites,24,1,3,No,1:No,1:No,,0.8
1376,2360764,Table 1,BaselineCharacteristic,xx.x,% ; xxx ; ,?Pleural effusion or seeding, Metastatic sites,24,2,3,No,1:No,1:No,,0.746
1376,2360764,Table 1,BaselineCharacteristic,?Liver, ; Characteristics ; ,?Liver, Metastatic sites,25,0,2,No,1:No,1:No,,0.982
1376,2360764,Table 1,BaselineCharacteristic,xx,No. of patients ; xx ; ,?Liver, Metastatic sites,25,1,3,No,1:No,1:No,,0.79
1376,2360764,Table 1,BaselineCharacteristic,xx.x,% ; xxx ; ,?Liver, Metastatic sites,25,2,3,No,1:No,1:No,,0.686
1376,2360764,Table 1,BaselineCharacteristic,?Adrenal glands, ; Characteristics ; ,?Adrenal glands, Metastatic sites,26,0,2,No,1:No,1:No,,0.982
1376,2360764,Table 1,BaselineCharacteristic,xx,No. of patients ; xx ; ,?Adrenal glands, Metastatic sites,26,1,3,No,1:No,1:No,,0.79
1376,2360764,Table 1,BaselineCharacteristic,xx.x,% ; xxx ; ,?Adrenal glands, Metastatic sites,26,2,3,No,1:No,1:No,,0.686
1376,2360764,Table 1,BaselineCharacteristic,?Initial LDH (IU?l) levels, ; Characteristics ; ,?Initial LDH (IU?l) levels, Metastatic sites,27,0,2,No,1:No,1:No,,0.982
1376,2360764,Table 1,BaselineCharacteristic,Median xxx (xxx–xxxx),No. of patients ; xx ; ,?Initial LDH (IU?l) levels, Metastatic sites,27,1,3,No,1:No,1:No,,0.73
1376,2360764,Table 1,BaselineCharacteristic,,% ; xxx ; ,?Initial LDH (IU?l) levels, Metastatic sites,27,2,3,No,1:No,1:No,,0.85
1410,2361304,Table 1,BaselineCharacteristic,Parameter,,None,None,0,0,12,No,1:No,1:No,,0.915
1410,2361304,Table 1,BaselineCharacteristic,Number,,Parameter,None,0,1,1,No,1:No,1:No,,0.913
1410,2361304,Table 1,BaselineCharacteristic,Median age (range),Parameter ; ,Median age (range),,1,0,2,No,1:No,1:No,,0.59
1410,2361304,Table 1,BaselineCharacteristic,,Parameter ; ,None,None,2,0,2,No,1:No,1:No,,0.95
1410,2361304,Table 1,BaselineCharacteristic,,Number ; ,None,None,2,1,3,No,1:No,1:No,,0.89
1410,2361304,Table 1,BaselineCharacteristic,ECOG PS at entry,Parameter ; ,None,None,3,0,24,No,1:No,1:No,,0.942
1410,2361304,Table 1,BaselineCharacteristic,,Number ; ,ECOG PS at entry,None,3,1,43,No,1:No,1:No,,0.904
1410,2361304,Table 1,BaselineCharacteristic,?x,Parameter ; ,?x, ECOG PS at entry,4,0,2,No,1:No,1:No,,0.965
1410,2361304,Table 1,BaselineCharacteristic,x,Number ; ,?x, ECOG PS at entry,4,1,3,No,1:No,1:No,,0.94
1410,2361304,Table 1,BaselineCharacteristic,?x,Parameter ; ,?x, ECOG PS at entry,5,0,2,No,1:No,1:No,,0.965
1410,2361304,Table 1,BaselineCharacteristic,xx,Number ; ,?x, ECOG PS at entry,5,1,3,No,1:No,1:No,,0.776
1410,2361304,Table 1,BaselineCharacteristic,Median number of sites (range),Parameter ; ,Median number of sites (range),,6,0,2,No,1:No,1:No,,0.734
1410,2361304,Table 1,BaselineCharacteristic,x (x–x),Number ; ,Median number of sites (range),,6,1,3,No,1:No,1:No,,0.63
1410,2361304,Table 1,BaselineCharacteristic,,Parameter ; ,None,None,7,0,2,No,1:No,1:No,,0.99
1410,2361304,Table 1,BaselineCharacteristic,,Number ; ,None,None,7,1,3,No,1:No,1:No,,0.95
1410,2361304,Table 1,BaselineCharacteristic,Site of disease,Parameter ; ,None,None,8,0,24,No,1:No,1:No,,0.984
1410,2361304,Table 1,BaselineCharacteristic,,Number ; ,Site of disease,None,8,1,43,No,1:No,1:No,,0.957
1410,2361304,Table 1,BaselineCharacteristic,?Liver,Parameter ; ,?Liver, Site of disease,9,0,2,No,1:No,1:No,,0.99
1410,2361304,Table 1,BaselineCharacteristic,xx,Number ; ,?Liver, Site of disease,9,1,3,No,1:No,1:No,,0.891
1410,2361304,Table 1,BaselineCharacteristic,?Lung,Parameter ; ,?Lung, Site of disease,10,0,2,No,1:No,1:No,,0.99
1410,2361304,Table 1,BaselineCharacteristic,xx,Number ; ,?Lung, Site of disease,10,1,3,No,1:No,1:No,,0.941
1410,2361304,Table 1,BaselineCharacteristic,?Bone,Parameter ; ,?Bone, Site of disease,11,0,2,No,1:No,1:No,,0.99
1410,2361304,Table 1,BaselineCharacteristic,xx,Number ; ,?Bone, Site of disease,11,1,3,No,1:No,1:No,,0.941
1410,2361304,Table 1,BaselineCharacteristic,?Nodes,Parameter ; ,?Nodes, Site of disease,12,0,2,No,1:No,1:No,,0.99
1410,2361304,Table 1,BaselineCharacteristic,xx,Number ; ,?Nodes, Site of disease,12,1,3,No,1:No,1:No,,0.941
1410,2361304,Table 1,BaselineCharacteristic,?Breast,Parameter ; ,?Breast, Site of disease,13,0,2,No,1:No,1:No,,0.99
1410,2361304,Table 1,BaselineCharacteristic,x,Number ; ,?Breast, Site of disease,13,1,3,No,1:No,1:No,,0.98
1410,2361304,Table 1,BaselineCharacteristic,?Skin,Parameter ; ,?Skin, Site of disease,14,0,2,No,1:No,1:No,,0.99
1410,2361304,Table 1,BaselineCharacteristic,x,Number ; ,?Skin, Site of disease,14,1,3,No,1:No,1:No,,0.98
1410,2361304,Table 1,BaselineCharacteristic,?Pleura,Parameter ; ,?Pleura, Site of disease,15,0,2,No,1:No,1:No,,0.99
1410,2361304,Table 1,BaselineCharacteristic,x,Number ; ,?Pleura, Site of disease,15,1,3,No,1:No,1:No,,0.97
1410,2361304,Table 1,BaselineCharacteristic,,Parameter ; ,None,None,16,0,2,No,1:No,1:No,,1
1410,2361304,Table 1,BaselineCharacteristic,,Number ; ,None,None,16,1,3,No,1:No,1:No,,0.98
1410,2361304,Table 1,BaselineCharacteristic,Previous therapies,Parameter ; ,None,None,17,0,24,No,1:No,1:No,,0.995
1410,2361304,Table 1,BaselineCharacteristic,,Number ; ,Previous therapies,None,17,1,43,No,1:No,1:No,,0.967
1410,2361304,Table 1,BaselineCharacteristic,?Surgery,Parameter ; ,?Surgery, Previous therapies,18,0,2,No,1:No,1:No,,0.99
1410,2361304,Table 1,BaselineCharacteristic,xx,Number ; ,?Surgery, Previous therapies,18,1,3,No,1:No,1:No,,0.927
1410,2361304,Table 1,BaselineCharacteristic,?Radiotherapy,Parameter ; ,?Radiotherapy, Previous therapies,19,0,2,No,1:No,1:No,,0.99
1410,2361304,Table 1,BaselineCharacteristic,xx,Number ; ,?Radiotherapy, Previous therapies,19,1,3,No,1:No,1:No,,0.927
1410,2361304,Table 1,BaselineCharacteristic,,Parameter ; ,None,None,20,0,2,No,1:No,1:No,,0.99
1410,2361304,Table 1,BaselineCharacteristic,,Number ; ,None,None,20,1,3,No,1:No,1:No,,0.97
1410,2361304,Table 1,BaselineCharacteristic,Chemotherapy,Parameter ; ,None,None,21,0,2,No,1:No,1:No,,0.99
1410,2361304,Table 1,BaselineCharacteristic,,Number ; ,None,None,21,1,3,No,1:No,1:No,,0.97
1410,2361304,Table 1,BaselineCharacteristic,Median number of previous lines (range),Parameter ; ,Median number of previous lines (range),,22,0,2,No,1:No,1:No,,0.742
1410,2361304,Table 1,BaselineCharacteristic,x (x–x),Number ; ,Median number of previous lines (range),,22,1,3,No,1:No,1:No,,0.7
1410,2361304,Table 1,BaselineCharacteristic,Median number of previous agents (range),Parameter ; ,Median number of previous agents (range),,23,0,2,No,1:No,1:No,,0.742
1410,2361304,Table 1,BaselineCharacteristic,x (x–x),Number ; ,Median number of previous agents (range),,23,1,3,No,1:No,1:No,,0.7
1410,2361304,Table 1,BaselineCharacteristic,,Parameter ; ,None,None,24,0,2,No,1:No,1:No,,1
1410,2361304,Table 1,BaselineCharacteristic,,Number ; ,None,None,24,1,3,No,1:No,1:No,,0.98
1410,2361304,Table 1,BaselineCharacteristic,Previous exposure,Parameter ; ,None,None,25,0,24,No,1:No,1:No,,0.995
1410,2361304,Table 1,BaselineCharacteristic,,Number ; ,Previous exposure,None,25,1,43,No,1:No,1:No,,0.967
1410,2361304,Table 1,BaselineCharacteristic,?Anthracyclines,Parameter ; ,?Anthracyclines, Previous exposure,26,0,2,No,1:No,1:No,,1
1410,2361304,Table 1,BaselineCharacteristic,xx,Number ; ,?Anthracyclines, Previous exposure,26,1,3,No,1:No,1:No,,0.937
1410,2361304,Table 1,BaselineCharacteristic,?Taxanes,Parameter ; ,?Taxanes, Previous exposure,27,0,2,No,1:No,1:No,,1
1410,2361304,Table 1,BaselineCharacteristic,xx,Number ; ,?Taxanes, Previous exposure,27,1,3,No,1:No,1:No,,0.937
1410,2361304,Table 2,BaselineCharacteristic,Age,,None,None,0,0,12,No,1:No,1:No,,0.905
1410,2361304,Table 2,BaselineCharacteristic,PS,,Age,None,0,1,1,No,1:No,1:No,,0.91
1410,2361304,Table 2,BaselineCharacteristic,Prior CT linesa,,Age,None,0,2,1,No,1:No,1:No,,0.903
1410,2361304,Table 2,BaselineCharacteristic,Prior CT agents,,Age,None,0,3,1,No,1:No,1:No,,0.903
1410,2361304,Table 2,BaselineCharacteristic,Anthra clinical resistance,,Age,None,0,4,1,No,1:No,1:No,,0.913
1410,2361304,Table 2,BaselineCharacteristic,Tax clinical resistance,,Age,None,0,5,1,No,1:No,1:No,,0.935
1410,2361304,Table 2,BaselineCharacteristic,Site of disease,,Age,None,0,6,1,No,1:No,1:No,,0.925
1410,2361304,Table 2,BaselineCharacteristic,OR,,Age,None,0,7,1,No,1:No,1:No,,0.945
1410,2361304,Table 2,BaselineCharacteristic,Number of cycles,,Age,None,0,8,1,No,1:No,1:No,,0.945
1410,2361304,Table 2,BaselineCharacteristic,Baseline CA xx.x,,Age,None,0,9,1,No,1:No,1:No,,0.676
1410,2361304,Table 2,BaselineCharacteristic,CA xx.x Maximal nadir,,Age,None,0,10,1,No,1:No,1:No,,0.676
1410,2361304,Table 2,BaselineCharacteristic,TTP,,Age,None,0,11,1,No,1:No,1:No,,0.945
1410,2361304,Table 2,BaselineCharacteristic,xx,Age ; ,xx,None,1,0,2,No,1:No,1:No,,0.767
1410,2361304,Table 2,BaselineCharacteristic,x,PS ; ,xx,None,1,1,3,No,1:No,1:No,,0.612
1410,2361304,Table 2,BaselineCharacteristic,x+x,Prior CT linesa ; ,xx,None,1,2,3,No,1:No,1:No,,0.618
1410,2361304,Table 2,BaselineCharacteristic,x,Prior CT agents ; ,xx,None,1,3,3,No,1:No,1:No,,0.562
1410,2361304,Table 2,BaselineCharacteristic,E,Anthra clinical resistance ; ,xx,None,1,4,3,No,1:No,1:No,,0.652
1410,2361304,Table 2,BaselineCharacteristic,E,Tax clinical resistance ; ,xx,None,1,5,3,No,1:No,1:No,,0.672
1410,2361304,Table 2,BaselineCharacteristic,"Lung, mediastinal nodes",Site of disease ; ,xx,None,1,6,3,No,1:No,1:No,,0.702
1410,2361304,Table 2,BaselineCharacteristic,PR,OR ; ,xx,None,1,7,3,No,1:No,1:No,,0.692
1410,2361304,Table 2,BaselineCharacteristic,x,Number of cycles ; ,xx,None,1,8,3,No,1:No,1:No,,0.706
1410,2361304,Table 2,BaselineCharacteristic,xx,Baseline CA xx.x ; ,xx,None,1,9,3,No,1:No,1:No,,0.646
1410,2361304,Table 2,BaselineCharacteristic,x,CA xx.x Maximal nadir ; ,xx,None,1,10,3,No,1:No,1:No,,0.646
1410,2361304,Table 2,BaselineCharacteristic,x.x,TTP ; ,xx,None,1,11,3,No,1:No,1:No,,0.646
1410,2361304,Table 2,BaselineCharacteristic,xx,Age ; ,xx,None,2,0,2,No,1:No,1:No,,0.807
1410,2361304,Table 2,BaselineCharacteristic,x,PS ; ,xx,None,2,1,3,No,1:No,1:No,,0.632
1410,2361304,Table 2,BaselineCharacteristic,x+x,Prior CT linesa ; ,xx,None,2,2,3,No,1:No,1:No,,0.678
1410,2361304,Table 2,BaselineCharacteristic,x,Prior CT agents ; ,xx,None,2,3,3,No,1:No,1:No,,0.612
1410,2361304,Table 2,BaselineCharacteristic,E,Anthra clinical resistance ; ,xx,None,2,4,3,No,1:No,1:No,,0.702
1410,2361304,Table 2,BaselineCharacteristic,NA,Tax clinical resistance ; ,xx,None,2,5,3,No,1:No,1:No,,0.722
1410,2361304,Table 2,BaselineCharacteristic,"Skin, mediastinal nodes",Site of disease ; ,xx,None,2,6,3,No,1:No,1:No,,0.742
1410,2361304,Table 2,BaselineCharacteristic,PR,OR ; ,xx,None,2,7,3,No,1:No,1:No,,0.742
1410,2361304,Table 2,BaselineCharacteristic,xx,Number of cycles ; ,xx,None,2,8,3,No,1:No,1:No,,0.786
1410,2361304,Table 2,BaselineCharacteristic,xx,Baseline CA xx.x ; ,xx,None,2,9,3,No,1:No,1:No,,0.686
1410,2361304,Table 2,BaselineCharacteristic,xx,CA xx.x Maximal nadir ; ,xx,None,2,10,3,No,1:No,1:No,,0.686
1410,2361304,Table 2,BaselineCharacteristic,xx.x,TTP ; ,xx,None,2,11,3,No,1:No,1:No,,0.686
1410,2361304,Table 2,BaselineCharacteristic,xx,Age ; ,xx,None,3,0,2,No,1:No,1:No,,0.807
1410,2361304,Table 2,BaselineCharacteristic,x,PS ; ,xx,None,3,1,3,No,1:No,1:No,,0.646
1410,2361304,Table 2,BaselineCharacteristic,x+x,Prior CT linesa ; ,xx,None,3,2,3,No,1:No,1:No,,0.671
1410,2361304,Table 2,BaselineCharacteristic,x,Prior CT agents ; ,xx,None,3,3,3,No,1:No,1:No,,0.616
1410,2361304,Table 2,BaselineCharacteristic,E,Anthra clinical resistance ; ,xx,None,3,4,3,No,1:No,1:No,,0.696
1410,2361304,Table 2,BaselineCharacteristic,E,Tax clinical resistance ; ,xx,None,3,5,3,No,1:No,1:No,,0.716
1410,2361304,Table 2,BaselineCharacteristic,"Lung, liver",Site of disease ; ,xx,None,3,6,3,No,1:No,1:No,,0.716
1410,2361304,Table 2,BaselineCharacteristic,PR,OR ; ,xx,None,3,7,3,No,1:No,1:No,,0.736
1410,2361304,Table 2,BaselineCharacteristic,xx,Number of cycles ; ,xx,None,3,8,3,No,1:No,1:No,,0.78
1410,2361304,Table 2,BaselineCharacteristic,xxxx,Baseline CA xx.x ; ,xx,None,3,9,3,No,1:No,1:No,,0.69
1410,2361304,Table 2,BaselineCharacteristic,xxx,CA xx.x Maximal nadir ; ,xx,None,3,10,3,No,1:No,1:No,,0.61
1410,2361304,Table 2,BaselineCharacteristic,x.x,TTP ; ,xx,None,3,11,3,No,1:No,1:No,,0.69
1410,2361304,Table 2,BaselineCharacteristic,xx,Age ; ,xx,None,4,0,2,No,1:No,1:No,,0.857
1410,2361304,Table 2,BaselineCharacteristic,x,PS ; ,xx,None,4,1,3,No,1:No,1:No,,0.726
1410,2361304,Table 2,BaselineCharacteristic,x+x,Prior CT linesa ; ,xx,None,4,2,3,No,1:No,1:No,,0.741
1410,2361304,Table 2,BaselineCharacteristic,x,Prior CT agents ; ,xx,None,4,3,3,No,1:No,1:No,,0.716
1410,2361304,Table 2,BaselineCharacteristic,E,Anthra clinical resistance ; ,xx,None,4,4,3,No,1:No,1:No,,0.766
1410,2361304,Table 2,BaselineCharacteristic,R,Tax clinical resistance ; ,xx,None,4,5,3,No,1:No,1:No,,0.776
1410,2361304,Table 2,BaselineCharacteristic,"Breast, axillary & peritoneal nodes",Site of disease ; ,xx,None,4,6,3,No,1:No,1:No,,0.796
1410,2361304,Table 2,BaselineCharacteristic,UPR,OR ; ,xx,None,4,7,3,No,1:No,1:No,,0.806
1410,2361304,Table 2,BaselineCharacteristic,x,Number of cycles ; ,xx,None,4,8,3,No,1:No,1:No,,0.81
1410,2361304,Table 2,BaselineCharacteristic,xxxx,Baseline CA xx.x ; ,xx,None,4,9,3,No,1:No,1:No,,0.77
1410,2361304,Table 2,BaselineCharacteristic,xxxx,CA xx.x Maximal nadir ; ,xx,None,4,10,3,No,1:No,1:No,,0.77
1410,2361304,Table 2,BaselineCharacteristic,x.x,TTP ; ,xx,None,4,11,3,No,1:No,1:No,,0.77
1410,2361304,Table 2,BaselineCharacteristic,xx,Age ; ,xx,None,5,0,2,No,1:No,1:No,,0.847
1410,2361304,Table 2,BaselineCharacteristic,x,PS ; ,xx,None,5,1,3,No,1:No,1:No,,0.726
1410,2361304,Table 2,BaselineCharacteristic,x+x,Prior CT linesa ; ,xx,None,5,2,3,No,1:No,1:No,,0.731
1410,2361304,Table 2,BaselineCharacteristic,x,Prior CT agents ; ,xx,None,5,3,3,No,1:No,1:No,,0.716
1410,2361304,Table 2,BaselineCharacteristic,E,Anthra clinical resistance ; ,xx,None,5,4,3,No,1:No,1:No,,0.756
1410,2361304,Table 2,BaselineCharacteristic,E,Tax clinical resistance ; ,xx,None,5,5,3,No,1:No,1:No,,0.756
1410,2361304,Table 2,BaselineCharacteristic,Liver,Site of disease ; ,xx,None,5,6,3,No,1:No,1:No,,0.776
1410,2361304,Table 2,BaselineCharacteristic,MR,OR ; ,xx,None,5,7,3,No,1:No,1:No,,0.786
1410,2361304,Table 2,BaselineCharacteristic,x,Number of cycles ; ,xx,None,5,8,3,No,1:No,1:No,,0.8
1410,2361304,Table 2,BaselineCharacteristic,xxx,Baseline CA xx.x ; ,xx,None,5,9,3,No,1:No,1:No,,0.64
1410,2361304,Table 2,BaselineCharacteristic,xx,CA xx.x Maximal nadir ; ,xx,None,5,10,3,No,1:No,1:No,,0.76
1410,2361304,Table 2,BaselineCharacteristic,x.x,TTP ; ,xx,None,5,11,3,No,1:No,1:No,,0.76
1410,2361304,Table 2,BaselineCharacteristic,xx,Age ; ,xx,None,6,0,2,No,1:No,1:No,,0.877
1410,2361304,Table 2,BaselineCharacteristic,x,PS ; ,xx,None,6,1,3,No,1:No,1:No,,0.746
1410,2361304,Table 2,BaselineCharacteristic,x+x,Prior CT linesa ; ,xx,None,6,2,3,No,1:No,1:No,,0.791
1410,2361304,Table 2,BaselineCharacteristic,x,Prior CT agents ; ,xx,None,6,3,3,No,1:No,1:No,,0.736
1410,2361304,Table 2,BaselineCharacteristic,E,Anthra clinical resistance ; ,xx,None,6,4,3,No,1:No,1:No,,0.816
1410,2361304,Table 2,BaselineCharacteristic,E,Tax clinical resistance ; ,xx,None,6,5,3,No,1:No,1:No,,0.816
1410,2361304,Table 2,BaselineCharacteristic,"Lung, pre-external soft tissue",Site of disease ; ,xx,None,6,6,3,No,1:No,1:No,,0.836
1410,2361304,Table 2,BaselineCharacteristic,MR,OR ; ,xx,None,6,7,3,No,1:No,1:No,,0.846
1410,2361304,Table 2,BaselineCharacteristic,x,Number of cycles ; ,xx,None,6,8,3,No,1:No,1:No,,0.82
1410,2361304,Table 2,BaselineCharacteristic,xx,Baseline CA xx.x ; ,xx,None,6,9,3,No,1:No,1:No,,0.78
1410,2361304,Table 2,BaselineCharacteristic,xx,CA xx.x Maximal nadir ; ,xx,None,6,10,3,No,1:No,1:No,,0.78
1410,2361304,Table 2,BaselineCharacteristic,x.x,TTP ; ,xx,None,6,11,3,No,1:No,1:No,,0.78
1423,2361378,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,0,12,No,1:No,1:No,,0.905
1423,2361378,Table 1,BaselineCharacteristic,n (%),,Characteristic,None,0,1,1,No,1:No,1:No,,0.704
1423,2361378,Table 1,BaselineCharacteristic,Patients enrolled,Characteristic ; ,Patients enrolled,,1,0,2,No,1:No,1:No,,0.94
1423,2361378,Table 1,BaselineCharacteristic,Age (years),Characteristic ; ,None,None,2,0,24,No,1:No,1:No,,0.675
1423,2361378,Table 1,BaselineCharacteristic,Age (years),n (%) ; ,Age (years),None,2,1,43,No,1:No,1:No,,0.599
1423,2361378,Table 1,BaselineCharacteristic,?Median,Characteristic ; ,?Median, Age (years),3,0,2,No,1:No,1:No,,0.66
1423,2361378,Table 1,BaselineCharacteristic,?Range,Characteristic ; ,?Range, Age (years),4,0,2,No,1:No,1:No,,0.67
1423,2361378,Table 1,BaselineCharacteristic,Sex,Characteristic ; ,None,None,5,0,24,No,1:No,1:No,,0.929
1423,2361378,Table 1,BaselineCharacteristic,Sex,n (%) ; ,Sex,None,5,1,43,No,1:No,1:No,,0.729
1423,2361378,Table 1,BaselineCharacteristic,?Male,Characteristic ; ,?Male, Sex,6,0,2,No,1:No,1:No,,0.99
1423,2361378,Table 1,BaselineCharacteristic,xx (xx),n (%) ; ,?Male, Sex,6,1,3,No,1:No,1:No,,0.581
1423,2361378,Table 1,BaselineCharacteristic,?Female,Characteristic ; ,?Female, Sex,7,0,2,No,1:No,1:No,,0.99
1423,2361378,Table 1,BaselineCharacteristic,xx (xx),n (%) ; ,?Female, Sex,7,1,3,No,1:No,1:No,,0.621
1423,2361378,Table 1,BaselineCharacteristic,Karnofsky PS,Characteristic ; ,None,None,8,0,24,No,1:No,1:No,,0.974
1423,2361378,Table 1,BaselineCharacteristic,Karnofsky PS,n (%) ; ,Karnofsky PS,None,8,1,43,No,1:No,1:No,,0.839
1423,2361378,Table 1,BaselineCharacteristic,?xx–xx,Characteristic ; ,?xx–xx, Karnofsky PS,9,0,2,No,1:No,1:No,,0.79
1423,2361378,Table 1,BaselineCharacteristic,xx (xx),n (%) ; ,?xx–xx, Karnofsky PS,9,1,3,No,1:No,1:No,,0.551
1423,2361378,Table 1,BaselineCharacteristic,?xx–xxx,Characteristic ; ,?xx–xxx, Karnofsky PS,10,0,2,No,1:No,1:No,,1
1423,2361378,Table 1,BaselineCharacteristic,xx (xx),n (%) ; ,?xx–xxx, Karnofsky PS,10,1,3,No,1:No,1:No,,0.711
1423,2361378,Table 1,BaselineCharacteristic,Site of metastases,Characteristic ; ,None,None,11,0,24,No,1:No,1:No,,0.99
1423,2361378,Table 1,BaselineCharacteristic,Site of metastases,n (%) ; ,Site of metastases,None,11,1,43,No,1:No,1:No,,0.87
1423,2361378,Table 1,BaselineCharacteristic,?Liver,Characteristic ; ,?Liver, Site of metastases,12,0,2,No,1:No,1:No,,0.99
1423,2361378,Table 1,BaselineCharacteristic,xx (xx),n (%) ; ,?Liver, Site of metastases,12,1,3,No,1:No,1:No,,0.731
1423,2361378,Table 1,BaselineCharacteristic,?Lymphnodes,Characteristic ; ,?Lymphnodes, Site of metastases,13,0,2,No,1:No,1:No,,0.99
1423,2361378,Table 1,BaselineCharacteristic,x (xx),n (%) ; ,?Lymphnodes, Site of metastases,13,1,3,No,1:No,1:No,,0.691
1423,2361378,Table 1,BaselineCharacteristic,?Lung,Characteristic ; ,?Lung, Site of metastases,14,0,2,No,1:No,1:No,,0.99
1423,2361378,Table 1,BaselineCharacteristic,xx (xx),n (%) ; ,?Lung, Site of metastases,14,1,3,No,1:No,1:No,,0.741
1423,2361378,Table 1,BaselineCharacteristic,?Peritoneum,Characteristic ; ,?Peritoneum, Site of metastases,15,0,2,No,1:No,1:No,,0.99
1423,2361378,Table 1,BaselineCharacteristic,x (xx),n (%) ; ,?Peritoneum, Site of metastases,15,1,3,No,1:No,1:No,,0.681
1423,2361378,Table 1,BaselineCharacteristic,Number of metastatic lesions,Characteristic ; ,None,None,16,0,24,No,1:No,1:No,,0.985
1423,2361378,Table 1,BaselineCharacteristic,Number of metastatic lesions,n (%) ; ,Number of metastatic lesions,None,16,1,43,No,1:No,1:No,,0.859
1423,2361378,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, Number of metastatic lesions,17,0,2,No,1:No,1:No,,0.974
1423,2361378,Table 1,BaselineCharacteristic,x (x),n (%) ; ,?x, Number of metastatic lesions,17,1,3,No,1:No,1:No,,0.826
1423,2361378,Table 1,BaselineCharacteristic,?x–x,Characteristic ; ,?x–x, Number of metastatic lesions,18,0,2,No,1:No,1:No,,0.99
1423,2361378,Table 1,BaselineCharacteristic,xx (xx),n (%) ; ,?x–x, Number of metastatic lesions,18,1,3,No,1:No,1:No,,0.741
1423,2361378,Table 1,BaselineCharacteristic,?>x,Characteristic ; ,?>x, Number of metastatic lesions,19,0,2,No,1:No,1:No,,0.99
1423,2361378,Table 1,BaselineCharacteristic,xx (xx),n (%) ; ,?>x, Number of metastatic lesions,19,1,3,No,1:No,1:No,,0.731
1423,2361378,Table 1,BaselineCharacteristic,Prior therapy,Characteristic ; ,None,None,20,0,24,No,1:No,1:No,,0.985
1423,2361378,Table 1,BaselineCharacteristic,Prior therapy,n (%) ; ,Prior therapy,None,20,1,43,No,1:No,1:No,,0.859
1423,2361378,Table 1,BaselineCharacteristic,?Prior pancreatic surgery,Characteristic ; ,?Prior pancreatic surgery, Prior therapy,21,0,2,No,1:No,1:No,,1
1423,2361378,Table 1,BaselineCharacteristic,xx (xx),n (%) ; ,?Prior pancreatic surgery, Prior therapy,21,1,3,No,1:No,1:No,,0.727
1423,2361378,Table 1,BaselineCharacteristic,?Prior radiotherapy,Characteristic ; ,?Prior radiotherapy, Prior therapy,22,0,2,No,1:No,1:No,,1
1423,2361378,Table 1,BaselineCharacteristic,xx (xx),n (%) ; ,?Prior radiotherapy, Prior therapy,22,1,3,No,1:No,1:No,,0.727
1423,2361378,Table 1,BaselineCharacteristic,Prior chemotherapy lines,Characteristic ; ,None,None,23,0,24,No,1:No,1:No,,0.995
1423,2361378,Table 1,BaselineCharacteristic,Prior chemotherapy lines,n (%) ; ,Prior chemotherapy lines,None,23,1,43,No,1:No,1:No,,0.899
1423,2361378,Table 1,BaselineCharacteristic,?n=x,Characteristic ; ,?n=x, Prior chemotherapy lines,24,0,2,No,1:No,1:No,,1
1423,2361378,Table 1,BaselineCharacteristic,xx (xx)*,n (%) ; ,?n=x, Prior chemotherapy lines,24,1,3,No,1:No,1:No,,0.801
1423,2361378,Table 1,BaselineCharacteristic,?n>x,Characteristic ; ,?n>x, Prior chemotherapy lines,25,0,2,No,1:No,1:No,,1
1423,2361378,Table 1,BaselineCharacteristic,x (xx),n (%) ; ,?n>x, Prior chemotherapy lines,25,1,3,No,1:No,1:No,,0.761
1423,2361378,Table 1,BaselineCharacteristic,?*Gemcitabine alone,Characteristic ; ,?*Gemcitabine alone, Prior chemotherapy lines,26,0,2,No,1:No,1:No,,1
1423,2361378,Table 1,BaselineCharacteristic,xx (xx),n (%) ; ,?*Gemcitabine alone, Prior chemotherapy lines,26,1,3,No,1:No,1:No,,0.791
1423,2361378,Table 1,BaselineCharacteristic,?*Combination,Characteristic ; ,?*Combination, Prior chemotherapy lines,27,0,2,No,1:No,1:No,,1
1423,2361378,Table 1,BaselineCharacteristic,xx (xx),n (%) ; ,?*Combination, Prior chemotherapy lines,27,1,3,No,1:No,1:No,,0.791
1446,2361514,Table 2,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
1446,2361514,Table 2,BaselineCharacteristic,n,,,None,0,1,1,No,1:No,1:No,,0.714
1446,2361514,Table 2,BaselineCharacteristic,Gender, ; ,None,None,1,0,24,No,1:No,1:No,,0.897
1446,2361514,Table 2,BaselineCharacteristic,Gender,n ; ,Gender,None,1,1,43,No,1:No,1:No,,0.735
1446,2361514,Table 2,BaselineCharacteristic,?Male, ; ,?Male, Gender,2,0,2,No,1:No,1:No,,0.95
1446,2361514,Table 2,BaselineCharacteristic,xx,n ; ,?Male, Gender,2,1,3,No,1:No,1:No,,0.506
1446,2361514,Table 2,BaselineCharacteristic,?Female, ; ,?Female, Gender,3,0,2,No,1:No,1:No,,0.96
1446,2361514,Table 2,BaselineCharacteristic,xx,n ; ,?Female, Gender,3,1,3,No,1:No,1:No,,0.526
1446,2361514,Table 2,BaselineCharacteristic,, ; ,None,None,4,0,2,No,1:No,1:No,,0.97
1446,2361514,Table 2,BaselineCharacteristic,,n ; ,None,None,4,1,3,No,1:No,1:No,,0.716
1446,2361514,Table 2,BaselineCharacteristic,Age, ; ,None,None,5,0,24,No,1:No,1:No,,0.929
1446,2361514,Table 2,BaselineCharacteristic,Age,n ; ,Age,None,5,1,43,No,1:No,1:No,,0.775
1446,2361514,Table 2,BaselineCharacteristic,?Median (years), ; ,?Median (years), Age,6,0,2,No,1:No,1:No,,0.67
1446,2361514,Table 2,BaselineCharacteristic,?Range (years), ; ,?Range (years), Age,7,0,2,No,1:No,1:No,,0.67
1446,2361514,Table 2,BaselineCharacteristic,, ; ,None,None,8,0,2,No,1:No,1:No,,0.99
1446,2361514,Table 2,BaselineCharacteristic,,n ; ,None,None,8,1,3,No,1:No,1:No,,0.826
1446,2361514,Table 2,BaselineCharacteristic,Race, ; ,None,None,9,0,24,No,1:No,1:No,,0.984
1446,2361514,Table 2,BaselineCharacteristic,Race,n ; ,Race,None,9,1,43,No,1:No,1:No,,0.875
1446,2361514,Table 2,BaselineCharacteristic,?White, ; ,?White, Race,10,0,2,No,1:No,1:No,,1
1446,2361514,Table 2,BaselineCharacteristic,xx,n ; ,?White, Race,10,1,3,No,1:No,1:No,,0.786
1446,2361514,Table 2,BaselineCharacteristic,?Black, ; ,?Black, Race,11,0,2,No,1:No,1:No,,1
1446,2361514,Table 2,BaselineCharacteristic,x,n ; ,?Black, Race,11,1,3,No,1:No,1:No,,0.876
1446,2361514,Table 2,BaselineCharacteristic,, ; ,None,None,12,0,2,No,1:No,1:No,,1
1446,2361514,Table 2,BaselineCharacteristic,,n ; ,None,None,12,1,3,No,1:No,1:No,,0.856
1446,2361514,Table 2,BaselineCharacteristic,No. of cycles of tipifarnib+gemcitabine and cisplatin, ; ,None,None,13,0,24,No,1:No,1:No,,0.985
1446,2361514,Table 2,BaselineCharacteristic,No. of cycles of tipifarnib+gemcitabine and cisplatin,n ; ,No. of cycles of tipifarnib+gemcitabine and cisplatin,None,13,1,43,No,1:No,1:No,,0.885
1446,2361514,Table 2,BaselineCharacteristic,?x–x, ; ,?x–x, No. of cycles of tipifarnib+gemcitabine and cisplatin,14,0,2,No,1:No,1:No,,0.99
1446,2361514,Table 2,BaselineCharacteristic,xx,n ; ,?x–x, No. of cycles of tipifarnib+gemcitabine and cisplatin,14,1,3,No,1:No,1:No,,0.821
1446,2361514,Table 2,BaselineCharacteristic,?x–x, ; ,?x–x, No. of cycles of tipifarnib+gemcitabine and cisplatin,15,0,2,No,1:No,1:No,,0.99
1446,2361514,Table 2,BaselineCharacteristic,x,n ; ,?x–x, No. of cycles of tipifarnib+gemcitabine and cisplatin,15,1,3,No,1:No,1:No,,0.846
1446,2361514,Table 2,BaselineCharacteristic,?x–x, ; ,?x–x, No. of cycles of tipifarnib+gemcitabine and cisplatin,16,0,2,No,1:No,1:No,,0.99
1446,2361514,Table 2,BaselineCharacteristic,x,n ; ,?x–x, No. of cycles of tipifarnib+gemcitabine and cisplatin,16,1,3,No,1:No,1:No,,0.846
1446,2361514,Table 2,BaselineCharacteristic,?x–x, ; ,?x–x, No. of cycles of tipifarnib+gemcitabine and cisplatin,17,0,2,No,1:No,1:No,,0.99
1446,2361514,Table 2,BaselineCharacteristic,x,n ; ,?x–x, No. of cycles of tipifarnib+gemcitabine and cisplatin,17,1,3,No,1:No,1:No,,0.846
1446,2361514,Table 2,BaselineCharacteristic,?>x, ; ,?>x, No. of cycles of tipifarnib+gemcitabine and cisplatin,18,0,2,No,1:No,1:No,,0.99
1446,2361514,Table 2,BaselineCharacteristic,x,n ; ,?>x, No. of cycles of tipifarnib+gemcitabine and cisplatin,18,1,3,No,1:No,1:No,,0.846
1446,2361514,Table 2,BaselineCharacteristic,, ; ,None,None,19,0,2,No,1:No,1:No,,0.99
1446,2361514,Table 2,BaselineCharacteristic,,n ; ,None,None,19,1,3,No,1:No,1:No,,0.836
1446,2361514,Table 2,BaselineCharacteristic,Tumour types, ; ,None,None,20,0,24,No,1:No,1:No,,0.985
1446,2361514,Table 2,BaselineCharacteristic,Tumour types,n ; ,Tumour types,None,20,1,43,No,1:No,1:No,,0.875
1446,2361514,Table 2,BaselineCharacteristic,?Pancreatic, ; ,?Pancreatic, Tumour types,21,0,2,No,1:No,1:No,,0.99
1446,2361514,Table 2,BaselineCharacteristic,x,n ; ,?Pancreatic, Tumour types,21,1,3,No,1:No,1:No,,0.856
1446,2361514,Table 2,BaselineCharacteristic,?ACUP (adenocarcinoma of unknown primary), ; ,?ACUP (adenocarcinoma of unknown primary), Tumour types,22,0,2,No,1:No,1:No,,1
1446,2361514,Table 2,BaselineCharacteristic,x,n ; ,?ACUP (adenocarcinoma of unknown primary), Tumour types,22,1,3,No,1:No,1:No,,0.886
1446,2361514,Table 2,BaselineCharacteristic,?Ovary, ; ,?Ovary, Tumour types,23,0,2,No,1:No,1:No,,1
1446,2361514,Table 2,BaselineCharacteristic,x,n ; ,?Ovary, Tumour types,23,1,3,No,1:No,1:No,,0.866
1446,2361514,Table 2,BaselineCharacteristic,?Colorectal, ; ,?Colorectal, Tumour types,24,0,2,No,1:No,1:No,,1
1446,2361514,Table 2,BaselineCharacteristic,x,n ; ,?Colorectal, Tumour types,24,1,3,No,1:No,1:No,,0.866
1446,2361514,Table 2,BaselineCharacteristic,?Gastric, ; ,?Gastric, Tumour types,25,0,2,No,1:No,1:No,,1
1446,2361514,Table 2,BaselineCharacteristic,x,n ; ,?Gastric, Tumour types,25,1,3,No,1:No,1:No,,0.866
1446,2361514,Table 2,BaselineCharacteristic,?Anal canal, ; ,?Anal canal, Tumour types,26,0,2,No,1:No,1:No,,1
1446,2361514,Table 2,BaselineCharacteristic,x,n ; ,?Anal canal, Tumour types,26,1,3,No,1:No,1:No,,0.866
1446,2361514,Table 2,BaselineCharacteristic,?Bile duct carcinoma, ; ,?Bile duct carcinoma, Tumour types,27,0,2,No,1:No,1:No,,1
1446,2361514,Table 2,BaselineCharacteristic,x,n ; ,?Bile duct carcinoma, Tumour types,27,1,3,No,1:No,1:No,,0.866
1446,2361514,Table 2,BaselineCharacteristic,?Head and neck, ; ,?Head and neck, Tumour types,28,0,2,No,1:No,1:No,,1
1446,2361514,Table 2,BaselineCharacteristic,x,n ; ,?Head and neck, Tumour types,28,1,3,No,1:No,1:No,,0.866
1446,2361514,Table 2,BaselineCharacteristic,?Mesothelioma, ; ,?Mesothelioma, Tumour types,29,0,2,No,1:No,1:No,,1
1446,2361514,Table 2,BaselineCharacteristic,x,n ; ,?Mesothelioma, Tumour types,29,1,3,No,1:No,1:No,,0.866
1446,2361514,Table 2,BaselineCharacteristic,?Sarcoma, ; ,?Sarcoma, Tumour types,30,0,2,No,1:No,1:No,,1
1446,2361514,Table 2,BaselineCharacteristic,x,n ; ,?Sarcoma, Tumour types,30,1,3,No,1:No,1:No,,0.866
1446,2361514,Table 2,BaselineCharacteristic,?Oesophagus, ; ,?Oesophagus, Tumour types,31,0,2,No,1:No,1:No,,1
1446,2361514,Table 2,BaselineCharacteristic,x,n ; ,?Oesophagus, Tumour types,31,1,3,No,1:No,1:No,,0.866
1446,2361514,Table 2,BaselineCharacteristic,, ; ,None,None,32,0,2,No,1:No,1:No,,1
1446,2361514,Table 2,BaselineCharacteristic,,n ; ,None,None,32,1,3,No,1:No,1:No,,0.846
1446,2361514,Table 2,BaselineCharacteristic,Performance status, ; ,None,None,33,0,24,No,1:No,1:No,,0.995
1446,2361514,Table 2,BaselineCharacteristic,Performance status,n ; ,Performance status,None,33,1,43,No,1:No,1:No,,0.896
1446,2361514,Table 2,BaselineCharacteristic,?x, ; ,?x, Performance status,34,0,2,No,1:No,1:No,,0.982
1446,2361514,Table 2,BaselineCharacteristic,xx,n ; ,?x, Performance status,34,1,3,No,1:No,1:No,,0.787
1446,2361514,Table 2,BaselineCharacteristic,?x, ; ,?x, Performance status,35,0,2,No,1:No,1:No,,0.982
1446,2361514,Table 2,BaselineCharacteristic,xx,n ; ,?x, Performance status,35,1,3,No,1:No,1:No,,0.787
1446,2361514,Table 2,BaselineCharacteristic,?x, ; ,?x, Performance status,36,0,2,No,1:No,1:No,,0.982
1446,2361514,Table 2,BaselineCharacteristic,x,n ; ,?x, Performance status,36,1,3,No,1:No,1:No,,0.886
1446,2361514,Table 2,BaselineCharacteristic,, ; ,None,None,37,0,2,No,1:No,1:No,,1
1446,2361514,Table 2,BaselineCharacteristic,,n ; ,None,None,37,1,3,No,1:No,1:No,,0.846
1446,2361514,Table 2,BaselineCharacteristic,Previous therapy, ; ,None,None,38,0,24,No,1:No,1:No,,0.995
1446,2361514,Table 2,BaselineCharacteristic,Previous therapy,n ; ,Previous therapy,None,38,1,43,No,1:No,1:No,,0.898
1446,2361514,Table 2,BaselineCharacteristic,?Surgery, ; ,?Surgery, Previous therapy,39,0,2,No,1:No,1:No,,1
1446,2361514,Table 2,BaselineCharacteristic,xx,n ; ,?Surgery, Previous therapy,39,1,3,No,1:No,1:No,,0.807
1446,2361514,Table 2,BaselineCharacteristic,?Radiotherapy, ; ,?Radiotherapy, Previous therapy,40,0,2,No,1:No,1:No,,1
1446,2361514,Table 2,BaselineCharacteristic,x,n ; ,?Radiotherapy, Previous therapy,40,1,3,No,1:No,1:No,,0.896
1446,2361514,Table 2,BaselineCharacteristic,?Chemotherapy, ; ,?Chemotherapy, Previous therapy,41,0,2,No,1:No,1:No,,1
1446,2361514,Table 2,BaselineCharacteristic,xx,n ; ,?Chemotherapy, Previous therapy,41,1,3,No,1:No,1:No,,0.807
1504,2361889,Table 1,BaselineCharacteristic,Characteristics,,Characteristics,,0,0,2,No,1:No,1:No,,0.94
1504,2361889,Table 1,BaselineCharacteristic,Patients (N=xx),,Characteristics,,0,1,3,No,1:No,1:No,,0.87
1504,2361889,Table 1,BaselineCharacteristic,Age (years),,None,None,1,0,24,No,1:No,1:No,,0.665
1504,2361889,Table 1,BaselineCharacteristic,,,Age (years),None,1,1,43,No,1:No,1:No,,0.594
1504,2361889,Table 1,BaselineCharacteristic,Postmenopause,,Postmenopause, Age (years),3,0,2,No,1:No,1:No,,0.66
1504,2361889,Table 1,BaselineCharacteristic,Premenopause,,Premenopause, Age (years),4,0,2,No,1:No,1:No,,0.67
1504,2361889,Table 1,BaselineCharacteristic,Performance statusa,,None,None,5,0,24,No,1:No,1:No,,0.929
1504,2361889,Table 1,BaselineCharacteristic,,,Performance statusa,None,5,1,43,No,1:No,1:No,,0.902
1504,2361889,Table 1,BaselineCharacteristic,?x,,?x, Performance statusa,6,0,2,No,1:No,1:No,,0.973
1504,2361889,Table 1,BaselineCharacteristic,xx (xx.x%),,?x, Performance statusa,6,1,3,No,1:No,1:No,,0.776
1504,2361889,Table 1,BaselineCharacteristic,?x,,?x, Performance statusa,7,0,2,No,1:No,1:No,,0.973
1504,2361889,Table 1,BaselineCharacteristic,xx (xx.x%),,?x, Performance statusa,7,1,3,No,1:No,1:No,,0.796
1504,2361889,Table 1,BaselineCharacteristic,?x,,?x, Performance statusa,8,0,2,No,1:No,1:No,,0.972
1504,2361889,Table 1,BaselineCharacteristic,x (x.x%),,?x, Performance statusa,8,1,3,No,1:No,1:No,,0.98
1504,2361889,Table 1,BaselineCharacteristic,?x,,?x, Performance statusa,9,0,2,No,1:No,1:No,,0.982
1504,2361889,Table 1,BaselineCharacteristic,x (x.x%),,?x, Performance statusa,9,1,3,No,1:No,1:No,,0.98
1504,2361889,Table 1,BaselineCharacteristic,Oestrogen receptor status,,None,None,10,0,24,No,1:No,1:No,,0.995
1504,2361889,Table 1,BaselineCharacteristic,,,Oestrogen receptor status,None,10,1,43,No,1:No,1:No,,0.978
1504,2361889,Table 1,BaselineCharacteristic,?Positive,,?Positive, Oestrogen receptor status,11,0,2,No,1:No,1:No,,1
1504,2361889,Table 1,BaselineCharacteristic,xx (xx.x%),,?Positive, Oestrogen receptor status,11,1,3,No,1:No,1:No,,0.946
1504,2361889,Table 1,BaselineCharacteristic,?Negative,,?Negative, Oestrogen receptor status,12,0,2,No,1:No,1:No,,1
1504,2361889,Table 1,BaselineCharacteristic,xx (xx.x%),,?Negative, Oestrogen receptor status,12,1,3,No,1:No,1:No,,0.946
1504,2361889,Table 1,BaselineCharacteristic,?Unknown,,?Unknown, Oestrogen receptor status,13,0,2,No,1:No,1:No,,1
1504,2361889,Table 1,BaselineCharacteristic,x (x.x%),,?Unknown, Oestrogen receptor status,13,1,3,No,1:No,1:No,,1
1504,2361889,Table 1,BaselineCharacteristic,?Disease-free interval (months),,?Disease-free interval (months), Oestrogen receptor status,14,0,2,No,1:No,1:No,,1
1504,2361889,Table 1,BaselineCharacteristic,xx.x (x–xxx.x),,?Disease-free interval (months), Oestrogen receptor status,14,1,3,No,1:No,1:No,,0.926
1504,2361889,Table 1,BaselineCharacteristic,Previous treatments,,None,None,15,0,24,No,1:No,1:No,,0.995
1504,2361889,Table 1,BaselineCharacteristic,,,Previous treatments,None,15,1,43,No,1:No,1:No,,0.967
1504,2361889,Table 1,BaselineCharacteristic,?Surgery,,?Surgery, Previous treatments,16,0,2,No,1:No,1:No,,1
1504,2361889,Table 1,BaselineCharacteristic,xx (xx.x%),,?Surgery, Previous treatments,16,1,3,No,1:No,1:No,,0.966
1504,2361889,Table 1,BaselineCharacteristic,?Radiation therapy,,?Radiation therapy, Previous treatments,17,0,2,No,1:No,1:No,,1
1504,2361889,Table 1,BaselineCharacteristic,xx (xx.x%),,?Radiation therapy, Previous treatments,17,1,3,No,1:No,1:No,,0.966
1504,2361889,Table 1,BaselineCharacteristic,?Adjuvant anthracycline chemotherapy,,?Adjuvant anthracycline chemotherapy, Previous treatments,18,0,2,No,1:No,1:No,,0.99
1504,2361889,Table 1,BaselineCharacteristic,xx (xxx.x%),,?Adjuvant anthracycline chemotherapy, Previous treatments,18,1,3,No,1:No,1:No,,0.916
1504,2361889,Table 1,BaselineCharacteristic,Previous endocrine therapy,,None,None,19,0,24,No,1:No,1:No,,0.985
1504,2361889,Table 1,BaselineCharacteristic,,,Previous endocrine therapy,None,19,1,43,No,1:No,1:No,,0.967
1504,2361889,Table 1,BaselineCharacteristic,?Adjuvant,,?Adjuvant, Previous endocrine therapy,20,0,2,No,1:No,1:No,,0.99
1504,2361889,Table 1,BaselineCharacteristic,xx (xx.x%),,?Adjuvant, Previous endocrine therapy,20,1,3,No,1:No,1:No,,0.951
1504,2361889,Table 1,BaselineCharacteristic,?Advanced disease,,?Advanced disease, Previous endocrine therapy,21,0,2,No,1:No,1:No,,0.99
1504,2361889,Table 1,BaselineCharacteristic,xx (xx.x%),,?Advanced disease, Previous endocrine therapy,21,1,3,No,1:No,1:No,,0.951
1504,2361889,Table 1,BaselineCharacteristic,Disease sites,,None,None,22,0,24,No,1:No,1:No,,0.955
1504,2361889,Table 1,BaselineCharacteristic,,,Disease sites,None,22,1,43,No,1:No,1:No,,0.927
1504,2361889,Table 1,BaselineCharacteristic,?Skin/lymph nodes,,?Skin/lymph nodes, Disease sites,23,0,2,No,1:No,1:No,,0.982
1504,2361889,Table 1,BaselineCharacteristic,xx (xx.x%),,?Skin/lymph nodes, Disease sites,23,1,3,No,1:No,1:No,,0.881
1504,2361889,Table 1,BaselineCharacteristic,?Bone,,?Bone, Disease sites,24,0,2,No,1:No,1:No,,0.982
1504,2361889,Table 1,BaselineCharacteristic,xx (xx.x%),,?Bone, Disease sites,24,1,3,No,1:No,1:No,,0.881
1504,2361889,Table 1,BaselineCharacteristic,?Lung,,?Lung, Disease sites,25,0,2,No,1:No,1:No,,0.982
1504,2361889,Table 1,BaselineCharacteristic,xx (xx.x%),,?Lung, Disease sites,25,1,3,No,1:No,1:No,,0.881
1504,2361889,Table 1,BaselineCharacteristic,?Liver,,?Liver, Disease sites,26,0,2,No,1:No,1:No,,0.982
1504,2361889,Table 1,BaselineCharacteristic,xx (xx.x%),,?Liver, Disease sites,26,1,3,No,1:No,1:No,,0.881
1504,2361889,Table 1,BaselineCharacteristic,?Other,,?Other, Disease sites,27,0,2,No,1:No,1:No,,0.982
1504,2361889,Table 1,BaselineCharacteristic,x (x.x%),,?Other, Disease sites,27,1,3,No,1:No,1:No,,0.95
1504,2361889,Table 1,BaselineCharacteristic,Number of sites of disease,,None,None,28,0,24,No,1:No,1:No,,0.965
1504,2361889,Table 1,BaselineCharacteristic,,,Number of sites of disease,None,28,1,43,No,1:No,1:No,,0.937
1504,2361889,Table 1,BaselineCharacteristic,?x,,?x, Number of sites of disease,29,0,2,No,1:No,1:No,,0.952
1504,2361889,Table 1,BaselineCharacteristic,xx (xx.x%),,?x, Number of sites of disease,29,1,3,No,1:No,1:No,,0.836
1504,2361889,Table 1,BaselineCharacteristic,?x,,?x, Number of sites of disease,30,0,2,No,1:No,1:No,,0.952
1504,2361889,Table 1,BaselineCharacteristic,xx (xx.x%),,?x, Number of sites of disease,30,1,3,No,1:No,1:No,,0.836
1504,2361889,Table 1,BaselineCharacteristic,?x,,?x, Number of sites of disease,31,0,2,No,1:No,1:No,,0.952
1504,2361889,Table 1,BaselineCharacteristic,xx (xx.x%),,?x, Number of sites of disease,31,1,3,No,1:No,1:No,,0.836
1504,2361889,Table 1,BaselineCharacteristic,?x,,?x, Number of sites of disease,32,0,2,No,1:No,1:No,,0.952
1504,2361889,Table 1,BaselineCharacteristic,x (x.x%),,?x, Number of sites of disease,32,1,3,No,1:No,1:No,,0.94
1985,2395315,Table 1,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
1985,2395315,Table 1,BaselineCharacteristic,EMP & VBL,,,None,0,1,1,No,1:No,1:No,,0.913
1985,2395315,Table 1,BaselineCharacteristic,EMP alone,,,None,0,2,1,No,1:No,1:No,,0.913
1985,2395315,Table 1,BaselineCharacteristic,n=, ; ,None,None,1,0,12,No,1:No,1:No,,0.898
1985,2395315,Table 1,BaselineCharacteristic,xx,EMP & VBL ; ,n=,None,1,1,1,No,1:No,1:No,,0.796
1985,2395315,Table 1,BaselineCharacteristic,xx,EMP alone ; ,n=,None,1,2,1,No,1:No,1:No,,0.713
1985,2395315,Table 1,BaselineCharacteristic,New mets within the last x weeks, ; n= ; ,New mets within the last x weeks,,2,0,2,No,1:No,1:No,,0.935
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP & VBL ; xx ; ,New mets within the last x weeks,,2,1,3,No,1:No,1:No,,0.77
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP alone ; xx ; ,New mets within the last x weeks,,2,2,3,No,1:No,1:No,,0.756
1985,2395315,Table 1,BaselineCharacteristic,"Deterioration of performance status, pain or weight loss", ; n= ; ,"Deterioration of performance status, pain or weight loss",,3,0,2,No,1:No,1:No,,0.96
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP & VBL ; xx ; ,"Deterioration of performance status, pain or weight loss",,3,1,3,No,1:No,1:No,,0.81
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP alone ; xx ; ,"Deterioration of performance status, pain or weight loss",,3,2,3,No,1:No,1:No,,0.786
1985,2395315,Table 1,BaselineCharacteristic,, ; n= ; ,None,None,4,0,2,No,1:No,1:No,,0.97
1985,2395315,Table 1,BaselineCharacteristic,,EMP & VBL ; xx ; ,None,None,4,1,3,No,1:No,1:No,,0.786
1985,2395315,Table 1,BaselineCharacteristic,,EMP alone ; xx ; ,None,None,4,2,3,No,1:No,1:No,,0.761
1985,2395315,Table 1,BaselineCharacteristic,WHO performance status, ; n= ; ,None,None,5,0,24,No,1:No,1:No,,0.929
1985,2395315,Table 1,BaselineCharacteristic,,EMP & VBL ; xx ; ,WHO performance status,None,5,1,43,No,1:No,1:No,,0.803
1985,2395315,Table 1,BaselineCharacteristic,,EMP alone ; xx ; ,WHO performance status,None,5,2,43,No,1:No,1:No,,0.765
1985,2395315,Table 1,BaselineCharacteristic,?x, ; n= ; ,?x, WHO performance status,6,0,2,No,1:No,1:No,,0.973
1985,2395315,Table 1,BaselineCharacteristic,x (xx.x%),EMP & VBL ; xx ; ,?x, WHO performance status,6,1,3,No,1:No,1:No,,0.83
1985,2395315,Table 1,BaselineCharacteristic,x (xx.x%),EMP alone ; xx ; ,?x, WHO performance status,6,2,3,No,1:No,1:No,,0.816
1985,2395315,Table 1,BaselineCharacteristic,?x, ; n= ; ,?x, WHO performance status,7,0,2,No,1:No,1:No,,0.973
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP & VBL ; xx ; ,?x, WHO performance status,7,1,3,No,1:No,1:No,,0.84
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP alone ; xx ; ,?x, WHO performance status,7,2,3,No,1:No,1:No,,0.826
1985,2395315,Table 1,BaselineCharacteristic,?x, ; n= ; ,?x, WHO performance status,8,0,2,No,1:No,1:No,,0.972
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP & VBL ; xx ; ,?x, WHO performance status,8,1,3,No,1:No,1:No,,0.86
1985,2395315,Table 1,BaselineCharacteristic,x (xx.x%),EMP alone ; xx ; ,?x, WHO performance status,8,2,3,No,1:No,1:No,,0.846
1985,2395315,Table 1,BaselineCharacteristic,, ; n= ; ,None,None,9,0,2,No,1:No,1:No,,1
1985,2395315,Table 1,BaselineCharacteristic,,EMP & VBL ; xx ; ,None,None,9,1,3,No,1:No,1:No,,0.896
1985,2395315,Table 1,BaselineCharacteristic,,EMP alone ; xx ; ,None,None,9,2,3,No,1:No,1:No,,0.891
1985,2395315,Table 1,BaselineCharacteristic,Degree of pain from metastases, ; n= ; ,None,None,10,0,24,No,1:No,1:No,,0.99
1985,2395315,Table 1,BaselineCharacteristic,,EMP & VBL ; xx ; ,Degree of pain from metastases,None,10,1,43,No,1:No,1:No,,0.958
1985,2395315,Table 1,BaselineCharacteristic,,EMP alone ; xx ; ,Degree of pain from metastases,None,10,2,43,No,1:No,1:No,,0.931
1985,2395315,Table 1,BaselineCharacteristic,?None, ; n= ; ,?None, Degree of pain from metastases,11,0,2,No,1:No,1:No,,0.99
1985,2395315,Table 1,BaselineCharacteristic,x (xx.x%),EMP & VBL ; xx ; ,?None, Degree of pain from metastases,11,1,3,No,1:No,1:No,,0.95
1985,2395315,Table 1,BaselineCharacteristic,x (xx.x%),EMP alone ; xx ; ,?None, Degree of pain from metastases,11,2,3,No,1:No,1:No,,0.906
1985,2395315,Table 1,BaselineCharacteristic,?Mild, ; n= ; ,?Mild, Degree of pain from metastases,12,0,2,No,1:No,1:No,,0.99
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP & VBL ; xx ; ,?Mild, Degree of pain from metastases,12,1,3,No,1:No,1:No,,0.96
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP alone ; xx ; ,?Mild, Degree of pain from metastases,12,2,3,No,1:No,1:No,,0.936
1985,2395315,Table 1,BaselineCharacteristic,?Moderate, ; n= ; ,?Moderate, Degree of pain from metastases,13,0,2,No,1:No,1:No,,0.97
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP & VBL ; xx ; ,?Moderate, Degree of pain from metastases,13,1,3,No,1:No,1:No,,0.92
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP alone ; xx ; ,?Moderate, Degree of pain from metastases,13,2,3,No,1:No,1:No,,0.896
1985,2395315,Table 1,BaselineCharacteristic,?Severe, ; n= ; ,?Severe, Degree of pain from metastases,14,0,2,No,1:No,1:No,,0.99
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP & VBL ; xx ; ,?Severe, Degree of pain from metastases,14,1,3,No,1:No,1:No,,0.97
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP alone ; xx ; ,?Severe, Degree of pain from metastases,14,2,3,No,1:No,1:No,,0.946
1985,2395315,Table 1,BaselineCharacteristic,?Intractable, ; n= ; ,?Intractable, Degree of pain from metastases,15,0,2,No,1:No,1:No,,0.99
1985,2395315,Table 1,BaselineCharacteristic,x (x.x%),EMP & VBL ; xx ; ,?Intractable, Degree of pain from metastases,15,1,3,No,1:No,1:No,,0.95
1985,2395315,Table 1,BaselineCharacteristic,—,EMP alone ; xx ; ,?Intractable, Degree of pain from metastases,15,2,3,No,1:No,1:No,,0.936
1985,2395315,Table 1,BaselineCharacteristic,?Unspecified, ; n= ; ,?Unspecified, Degree of pain from metastases,16,0,2,No,1:No,1:No,,0.99
1985,2395315,Table 1,BaselineCharacteristic,—,EMP & VBL ; xx ; ,?Unspecified, Degree of pain from metastases,16,1,3,No,1:No,1:No,,0.96
1985,2395315,Table 1,BaselineCharacteristic,x (x.x%),EMP alone ; xx ; ,?Unspecified, Degree of pain from metastases,16,2,3,No,1:No,1:No,,0.916
1985,2395315,Table 1,BaselineCharacteristic,, ; n= ; ,None,None,17,0,2,No,1:No,1:No,,1
1985,2395315,Table 1,BaselineCharacteristic,,EMP & VBL ; xx ; ,None,None,17,1,3,No,1:No,1:No,,0.956
1985,2395315,Table 1,BaselineCharacteristic,,EMP alone ; xx ; ,None,None,17,2,3,No,1:No,1:No,,0.951
1985,2395315,Table 1,BaselineCharacteristic,Recent weight loss >x?kg, ; n= ; ,Recent weight loss >x?kg,,18,0,2,No,1:No,1:No,,1
1985,2395315,Table 1,BaselineCharacteristic,x (xx.x%),EMP & VBL ; xx ; ,Recent weight loss >x?kg,,18,1,3,No,1:No,1:No,,0.98
1985,2395315,Table 1,BaselineCharacteristic,x (xx.x%),EMP alone ; xx ; ,Recent weight loss >x?kg,,18,2,3,No,1:No,1:No,,0.946
1985,2395315,Table 1,BaselineCharacteristic,Bone mets at entry, ; n= ; ,None,None,19,0,24,No,1:No,1:No,,0.985
1985,2395315,Table 1,BaselineCharacteristic,,EMP & VBL ; xx ; ,Bone mets at entry,None,19,1,43,No,1:No,1:No,,0.952
1985,2395315,Table 1,BaselineCharacteristic,,EMP alone ; xx ; ,Bone mets at entry,None,19,2,43,No,1:No,1:No,,0.94
1985,2395315,Table 1,BaselineCharacteristic,?None, ; n= ; ,?None, Bone mets at entry,20,0,2,No,1:No,1:No,,0.99
1985,2395315,Table 1,BaselineCharacteristic,x (x.x%),EMP & VBL ; xx ; ,?None, Bone mets at entry,20,1,3,No,1:No,1:No,,0.945
1985,2395315,Table 1,BaselineCharacteristic,x (x.x%),EMP alone ; xx ; ,?None, Bone mets at entry,20,2,3,No,1:No,1:No,,0.911
1985,2395315,Table 1,BaselineCharacteristic,?<x, ; n= ; ,?<x, Bone mets at entry,21,0,2,No,1:No,1:No,,0.99
1985,2395315,Table 1,BaselineCharacteristic,x (x.x%),EMP & VBL ; xx ; ,?<x, Bone mets at entry,21,1,3,No,1:No,1:No,,0.945
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP alone ; xx ; ,?<x, Bone mets at entry,21,2,3,No,1:No,1:No,,0.951
1985,2395315,Table 1,BaselineCharacteristic,?x–xx, ; n= ; ,?x–xx, Bone mets at entry,22,0,2,No,1:No,1:No,,0.98
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP & VBL ; xx ; ,?x–xx, Bone mets at entry,22,1,3,No,1:No,1:No,,0.925
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP alone ; xx ; ,?x–xx, Bone mets at entry,22,2,3,No,1:No,1:No,,0.891
1985,2395315,Table 1,BaselineCharacteristic,?>xx superscan, ; n= ; ,?>xx superscan, Bone mets at entry,23,0,2,No,1:No,1:No,,1
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP & VBL ; xx ; ,?>xx superscan, Bone mets at entry,23,1,3,No,1:No,1:No,,0.965
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP alone ; xx ; ,?>xx superscan, Bone mets at entry,23,2,3,No,1:No,1:No,,0.961
1985,2395315,Table 1,BaselineCharacteristic,, ; n= ; ,None,None,24,0,2,No,1:No,1:No,,1
1985,2395315,Table 1,BaselineCharacteristic,,EMP & VBL ; xx ; ,None,None,24,1,3,No,1:No,1:No,,0.951
1985,2395315,Table 1,BaselineCharacteristic,,EMP alone ; xx ; ,None,None,24,2,3,No,1:No,1:No,,0.947
1985,2395315,Table 1,BaselineCharacteristic,Visceral mets, ; n= ; ,Visceral mets,,25,0,2,No,1:No,1:No,,1
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP & VBL ; xx ; ,Visceral mets,,25,1,3,No,1:No,1:No,,0.965
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP alone ; xx ; ,Visceral mets,,25,2,3,No,1:No,1:No,,0.961
1985,2395315,Table 1,BaselineCharacteristic,, ; n= ; ,None,None,26,0,2,No,1:No,1:No,,1
1985,2395315,Table 1,BaselineCharacteristic,,EMP & VBL ; xx ; ,None,None,26,1,3,No,1:No,1:No,,0.951
1985,2395315,Table 1,BaselineCharacteristic,,EMP alone ; xx ; ,None,None,26,2,3,No,1:No,1:No,,0.947
1985,2395315,Table 1,BaselineCharacteristic,Pretreatment PSA, ; n= ; ,None,None,27,0,24,No,1:No,1:No,,0.995
1985,2395315,Table 1,BaselineCharacteristic,,EMP & VBL ; xx ; ,Pretreatment PSA,None,27,1,43,No,1:No,1:No,,0.958
1985,2395315,Table 1,BaselineCharacteristic,,EMP alone ; xx ; ,Pretreatment PSA,None,27,2,43,No,1:No,1:No,,0.946
1985,2395315,Table 1,BaselineCharacteristic,?x.x–xx × normal, ; n= ; ,?x.x–xx × normal, Pretreatment PSA,28,0,2,No,1:No,1:No,,0.972
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP & VBL ; xx ; ,?x.x–xx × normal, Pretreatment PSA,28,1,3,No,1:No,1:No,,0.925
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP alone ; xx ; ,?x.x–xx × normal, Pretreatment PSA,28,2,3,No,1:No,1:No,,0.891
1985,2395315,Table 1,BaselineCharacteristic,?xx–xx × normal, ; n= ; ,?xx–xx × normal, Pretreatment PSA,29,0,2,No,1:No,1:No,,0.8
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP & VBL ; xx ; ,?xx–xx × normal, Pretreatment PSA,29,1,3,No,1:No,1:No,,0.775
1985,2395315,Table 1,BaselineCharacteristic,x (xx.x%),EMP alone ; xx ; ,?xx–xx × normal, Pretreatment PSA,29,2,3,No,1:No,1:No,,0.791
1985,2395315,Table 1,BaselineCharacteristic,?xx–xxx × normal, ; n= ; ,?xx–xxx × normal, Pretreatment PSA,30,0,2,No,1:No,1:No,,1
1985,2395315,Table 1,BaselineCharacteristic,x (xx.x%),EMP & VBL ; xx ; ,?xx–xxx × normal, Pretreatment PSA,30,1,3,No,1:No,1:No,,0.955
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP alone ; xx ; ,?xx–xxx × normal, Pretreatment PSA,30,2,3,No,1:No,1:No,,0.961
1985,2395315,Table 1,BaselineCharacteristic,?xxx–xxxx × normal, ; n= ; ,?xxx–xxxx × normal, Pretreatment PSA,31,0,2,No,1:No,1:No,,1
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP & VBL ; xx ; ,?xxx–xxxx × normal, Pretreatment PSA,31,1,3,No,1:No,1:No,,0.965
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP alone ; xx ; ,?xxx–xxxx × normal, Pretreatment PSA,31,2,3,No,1:No,1:No,,0.961
1985,2395315,Table 1,BaselineCharacteristic,, ; n= ; ,None,None,32,0,2,No,1:No,1:No,,1
1985,2395315,Table 1,BaselineCharacteristic,,EMP & VBL ; xx ; ,None,None,32,1,3,No,1:No,1:No,,0.951
1985,2395315,Table 1,BaselineCharacteristic,,EMP alone ; xx ; ,None,None,32,2,3,No,1:No,1:No,,0.947
1985,2395315,Table 1,BaselineCharacteristic,Type of previous hormonal treatment, ; n= ; ,None,None,33,0,24,No,1:No,1:No,,0.995
1985,2395315,Table 1,BaselineCharacteristic,,EMP & VBL ; xx ; ,Type of previous hormonal treatment,None,33,1,43,No,1:No,1:No,,0.96
1985,2395315,Table 1,BaselineCharacteristic,,EMP alone ; xx ; ,Type of previous hormonal treatment,None,33,2,43,No,1:No,1:No,,0.94
1985,2395315,Table 1,BaselineCharacteristic,?LHRH agonists, ; n= ; ,?LHRH agonists, Type of previous hormonal treatment,34,0,2,No,1:No,1:No,,1
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP & VBL ; xx ; ,?LHRH agonists, Type of previous hormonal treatment,34,1,3,No,1:No,1:No,,0.98
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP alone ; xx ; ,?LHRH agonists, Type of previous hormonal treatment,34,2,3,No,1:No,1:No,,0.966
1985,2395315,Table 1,BaselineCharacteristic,?Orchiectomy, ; n= ; ,?Orchiectomy, Type of previous hormonal treatment,35,0,2,No,1:No,1:No,,1
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP & VBL ; xx ; ,?Orchiectomy, Type of previous hormonal treatment,35,1,3,No,1:No,1:No,,0.98
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP alone ; xx ; ,?Orchiectomy, Type of previous hormonal treatment,35,2,3,No,1:No,1:No,,0.966
1985,2395315,Table 1,BaselineCharacteristic,?Oestrogens, ; n= ; ,?Oestrogens, Type of previous hormonal treatment,36,0,2,No,1:No,1:No,,1
1985,2395315,Table 1,BaselineCharacteristic,x (x.x%),EMP & VBL ; xx ; ,?Oestrogens, Type of previous hormonal treatment,36,1,3,No,1:No,1:No,,0.96
1985,2395315,Table 1,BaselineCharacteristic,—,EMP alone ; xx ; ,?Oestrogens, Type of previous hormonal treatment,36,2,3,No,1:No,1:No,,0.951
1985,2395315,Table 1,BaselineCharacteristic,?MAB, ; n= ; ,?MAB, Type of previous hormonal treatment,37,0,2,No,1:No,1:No,,1
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP & VBL ; xx ; ,?MAB, Type of previous hormonal treatment,37,1,3,No,1:No,1:No,,0.98
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP alone ; xx ; ,?MAB, Type of previous hormonal treatment,37,2,3,No,1:No,1:No,,0.966
1985,2395315,Table 1,BaselineCharacteristic,?Antiandrogens, ; n= ; ,?Antiandrogens, Type of previous hormonal treatment,38,0,2,No,1:No,1:No,,1
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP & VBL ; xx ; ,?Antiandrogens, Type of previous hormonal treatment,38,1,3,No,1:No,1:No,,0.98
1985,2395315,Table 1,BaselineCharacteristic,xx (xx.x%),EMP alone ; xx ; ,?Antiandrogens, Type of previous hormonal treatment,38,2,3,No,1:No,1:No,,0.966
1985,2395315,Table 1,BaselineCharacteristic,?Other, ; n= ; ,?Other, Type of previous hormonal treatment,39,0,2,No,1:No,1:No,,1
1985,2395315,Table 1,BaselineCharacteristic,x (x.x%),EMP & VBL ; xx ; ,?Other, Type of previous hormonal treatment,39,1,3,No,1:No,1:No,,0.96
1985,2395315,Table 1,BaselineCharacteristic,x (x.x%),EMP alone ; xx ; ,?Other, Type of previous hormonal treatment,39,2,3,No,1:No,1:No,,0.946
1985,2395315,Table 1,BaselineCharacteristic,, ; n= ; ,None,None,40,0,2,No,1:No,1:No,,1
1985,2395315,Table 1,BaselineCharacteristic,,EMP & VBL ; xx ; ,None,None,40,1,3,No,1:No,1:No,,0.951
1985,2395315,Table 1,BaselineCharacteristic,,EMP alone ; xx ; ,None,None,40,2,3,No,1:No,1:No,,0.947
1985,2395315,Table 1,BaselineCharacteristic,Time since the first histological confirmation of prostate cancer, ; n= ; ,None,None,41,0,24,No,1:No,1:No,,0.985
1985,2395315,Table 1,BaselineCharacteristic,,EMP & VBL ; xx ; ,Time since the first histological confirmation of prostate cancer,None,41,1,43,No,1:No,1:No,,0.991
1985,2395315,Table 1,BaselineCharacteristic,,EMP alone ; xx ; ,Time since the first histological confirmation of prostate cancer,None,41,2,43,No,1:No,1:No,,0.974
1985,2395315,Table 1,BaselineCharacteristic,?Minimum, ; n= ; ,?Minimum, Time since the first histological confirmation of prostate cancer,42,0,2,No,1:No,1:No,,0.98
1985,2395315,Table 1,BaselineCharacteristic,x.x years,EMP & VBL ; xx ; ,?Minimum, Time since the first histological confirmation of prostate cancer,42,1,3,No,1:No,1:No,,0.77
1985,2395315,Table 1,BaselineCharacteristic,x.x years,EMP alone ; xx ; ,?Minimum, Time since the first histological confirmation of prostate cancer,42,2,3,No,1:No,1:No,,0.73
1985,2395315,Table 1,BaselineCharacteristic,?Median, ; n= ; ,?Median, Time since the first histological confirmation of prostate cancer,43,0,2,No,1:No,1:No,,0.99
1985,2395315,Table 1,BaselineCharacteristic,x.x years,EMP & VBL ; xx ; ,?Median, Time since the first histological confirmation of prostate cancer,43,1,3,No,1:No,1:No,,0.77
1985,2395315,Table 1,BaselineCharacteristic,x.x years,EMP alone ; xx ; ,?Median, Time since the first histological confirmation of prostate cancer,43,2,3,No,1:No,1:No,,0.74
1985,2395315,Table 1,BaselineCharacteristic,?Maximum, ; n= ; ,?Maximum, Time since the first histological confirmation of prostate cancer,44,0,2,No,1:No,1:No,,0.99
1985,2395315,Table 1,BaselineCharacteristic,xx.x years,EMP & VBL ; xx ; ,?Maximum, Time since the first histological confirmation of prostate cancer,44,1,3,No,1:No,1:No,,0.77
1985,2395315,Table 1,BaselineCharacteristic,xx.x years,EMP alone ; xx ; ,?Maximum, Time since the first histological confirmation of prostate cancer,44,2,3,No,1:No,1:No,,0.74
2165,2441954,Table 1,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
2165,2441954,Table 1,BaselineCharacteristic,No. of patients,,,None,0,1,1,No,1:No,1:No,,0.853
2165,2441954,Table 1,BaselineCharacteristic,Total, ; ,Total,,1,0,2,No,1:No,1:No,,0.94
2165,2441954,Table 1,BaselineCharacteristic,xx,No. of patients ; ,Total,,1,1,3,No,1:No,1:No,,0.67
2165,2441954,Table 1,BaselineCharacteristic,Sex, ; ,None,None,2,0,24,No,1:No,1:No,,0.912
2165,2441954,Table 1,BaselineCharacteristic,,No. of patients ; ,Sex,None,2,1,43,No,1:No,1:No,,0.834
2165,2441954,Table 1,BaselineCharacteristic,?Male, ; ,?Male, Sex,3,0,2,No,1:No,1:No,,0.96
2165,2441954,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Male, Sex,3,1,3,No,1:No,1:No,,0.69
2165,2441954,Table 1,BaselineCharacteristic,?Female, ; ,?Female, Sex,4,0,2,No,1:No,1:No,,0.97
2165,2441954,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Female, Sex,4,1,3,No,1:No,1:No,,0.71
2165,2441954,Table 1,BaselineCharacteristic,, ; ,None,None,5,0,2,No,1:No,1:No,,0.97
2165,2441954,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,5,1,3,No,1:No,1:No,,0.81
2165,2441954,Table 1,BaselineCharacteristic,Age (years), ; ,None,None,6,0,24,No,1:No,1:No,,0.705
2165,2441954,Table 1,BaselineCharacteristic,,No. of patients ; ,Age (years),None,6,1,43,No,1:No,1:No,,0.564
2165,2441954,Table 1,BaselineCharacteristic,?Median, ; ,?Median, Age (years),7,0,2,No,1:No,1:No,,0.67
2165,2441954,Table 1,BaselineCharacteristic,?Range, ; ,?Range, Age (years),8,0,2,No,1:No,1:No,,0.68
2165,2441954,Table 1,BaselineCharacteristic,, ; ,None,None,9,0,2,No,1:No,1:No,,1
2165,2441954,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,9,1,3,No,1:No,1:No,,0.83
2165,2441954,Table 1,BaselineCharacteristic,Performance status, ; ,None,None,10,0,24,No,1:No,1:No,,0.995
2165,2441954,Table 1,BaselineCharacteristic,,No. of patients ; ,Performance status,None,10,1,43,No,1:No,1:No,,0.865
2165,2441954,Table 1,BaselineCharacteristic,?x, ; ,?x, Performance status,11,0,2,No,1:No,1:No,,0.982
2165,2441954,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?x, Performance status,11,1,3,No,1:No,1:No,,0.8
2165,2441954,Table 1,BaselineCharacteristic,?x, ; ,?x, Performance status,12,0,2,No,1:No,1:No,,0.982
2165,2441954,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?x, Performance status,12,1,3,No,1:No,1:No,,0.8
2165,2441954,Table 1,BaselineCharacteristic,?x, ; ,?x, Performance status,13,0,2,No,1:No,1:No,,0.982
2165,2441954,Table 1,BaselineCharacteristic,x,No. of patients ; ,?x, Performance status,13,1,3,No,1:No,1:No,,0.86
2165,2441954,Table 1,BaselineCharacteristic,?Unknown, ; ,?Unknown, Performance status,14,0,2,No,1:No,1:No,,1
2165,2441954,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Unknown, Performance status,14,1,3,No,1:No,1:No,,0.86
2165,2441954,Table 1,BaselineCharacteristic,, ; ,None,None,15,0,2,No,1:No,1:No,,1
2165,2441954,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,15,1,3,No,1:No,1:No,,0.84
2165,2441954,Table 1,BaselineCharacteristic,Primary tumour location, ; ,None,None,16,0,24,No,1:No,1:No,,1
2165,2441954,Table 1,BaselineCharacteristic,,No. of patients ; ,Primary tumour location,None,16,1,43,No,1:No,1:No,,0.86
2165,2441954,Table 1,BaselineCharacteristic,?Colorectal, ; ,?Colorectal, Primary tumour location,17,0,2,No,1:No,1:No,,1
2165,2441954,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Colorectal, Primary tumour location,17,1,3,No,1:No,1:No,,0.84
2165,2441954,Table 1,BaselineCharacteristic,?Breast, ; ,?Breast, Primary tumour location,18,0,2,No,1:No,1:No,,0.99
2165,2441954,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Breast, Primary tumour location,18,1,3,No,1:No,1:No,,0.84
2165,2441954,Table 1,BaselineCharacteristic,?Oesophagus, ; ,?Oesophagus, Primary tumour location,19,0,2,No,1:No,1:No,,0.99
2165,2441954,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Oesophagus, Primary tumour location,19,1,3,No,1:No,1:No,,0.84
2165,2441954,Table 1,BaselineCharacteristic,?Skin/soft tissue, ; ,?Skin/soft tissue, Primary tumour location,20,0,2,No,1:No,1:No,,0.99
2165,2441954,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Skin/soft tissue, Primary tumour location,20,1,3,No,1:No,1:No,,0.84
2165,2441954,Table 1,BaselineCharacteristic,?Pancreas, ; ,?Pancreas, Primary tumour location,21,0,2,No,1:No,1:No,,0.99
2165,2441954,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Pancreas, Primary tumour location,21,1,3,No,1:No,1:No,,0.84
2165,2441954,Table 1,BaselineCharacteristic,?Kidney, ; ,?Kidney, Primary tumour location,22,0,2,No,1:No,1:No,,1
2165,2441954,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Kidney, Primary tumour location,22,1,3,No,1:No,1:No,,0.84
2165,2441954,Table 1,BaselineCharacteristic,?Liver, ; ,?Liver, Primary tumour location,23,0,2,No,1:No,1:No,,1
2165,2441954,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Liver, Primary tumour location,23,1,3,No,1:No,1:No,,0.84
2165,2441954,Table 1,BaselineCharacteristic,?Other, ; ,?Other, Primary tumour location,24,0,2,No,1:No,1:No,,1
2165,2441954,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Other, Primary tumour location,24,1,3,No,1:No,1:No,,0.84
2165,2441954,Table 1,BaselineCharacteristic,?Unknown, ; ,?Unknown, Primary tumour location,25,0,2,No,1:No,1:No,,1
2165,2441954,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Unknown, Primary tumour location,25,1,3,No,1:No,1:No,,0.84
2165,2441954,Table 1,BaselineCharacteristic,, ; ,None,None,26,0,2,No,1:No,1:No,,1
2165,2441954,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,26,1,3,No,1:No,1:No,,0.85
2165,2441954,Table 1,BaselineCharacteristic,Previous therapy, ; ,None,None,27,0,24,No,1:No,1:No,,0.995
2165,2441954,Table 1,BaselineCharacteristic,,No. of patients ; ,Previous therapy,None,27,1,43,No,1:No,1:No,,0.904
2165,2441954,Table 1,BaselineCharacteristic,?Chemotherapy, ; ,?Chemotherapy, Previous therapy,28,0,2,No,1:No,1:No,,1
2165,2441954,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Chemotherapy, Previous therapy,28,1,3,No,1:No,1:No,,0.89
2165,2441954,Table 1,BaselineCharacteristic,?Radiotherapy, ; ,?Radiotherapy, Previous therapy,29,0,2,No,1:No,1:No,,1
2165,2441954,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Radiotherapy, Previous therapy,29,1,3,No,1:No,1:No,,0.89
2165,2441954,Table 1,BaselineCharacteristic,?Other therapy, ; ,?Other therapy, Previous therapy,30,0,2,No,1:No,1:No,,1
2165,2441954,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Other therapy, Previous therapy,30,1,3,No,1:No,1:No,,0.89
2207,2481444,Table 1,BaselineCharacteristic,Patient,,None,None,0,0,12,No,1:No,1:No,,0.905
2207,2481444,Table 1,BaselineCharacteristic,Delirium (CAM-ICU criteria),,Patient,None,0,1,1,No,1:No,1:No,,0.903
2207,2481444,Table 1,BaselineCharacteristic,Gender,,Patient,None,0,2,1,No,1:No,1:No,,0.903
2207,2481444,Table 1,BaselineCharacteristic,"Age, years",,Patient,None,0,3,1,No,1:No,1:No,,0.584
2207,2481444,Table 1,BaselineCharacteristic,APACHE II score,,Patient,None,0,4,1,No,1:No,1:No,,0.913
2207,2481444,Table 1,BaselineCharacteristic,Source of sepsis,,Patient,None,0,5,1,No,1:No,1:No,,0.925
2207,2481444,Table 1,BaselineCharacteristic,Causative organism,,Patient,None,0,6,1,No,1:No,1:No,,0.935
2207,2481444,Table 1,BaselineCharacteristic,x,Patient ; ,x,None,1,0,2,No,1:No,1:No,,0.915
2207,2481444,Table 1,BaselineCharacteristic,"Yes (I, II, III)",Delirium (CAM-ICU criteria) ; ,x,None,1,1,3,No,1:No,1:No,,0.87
2207,2481444,Table 1,BaselineCharacteristic,Male,Gender ; ,x,None,1,2,3,No,1:No,1:No,,0.9
2207,2481444,Table 1,BaselineCharacteristic,xx,APACHE II score ; ,x,None,1,4,3,No,1:No,1:No,,0.756
2207,2481444,Table 1,BaselineCharacteristic,Pneumonia,Source of sepsis ; ,x,None,1,5,3,No,1:No,1:No,,0.89
2207,2481444,Table 1,BaselineCharacteristic,Unknown,Causative organism ; ,x,None,1,6,3,No,1:No,1:No,,0.9
2207,2481444,Table 1,BaselineCharacteristic,x,Patient ; ,x,None,2,0,2,No,1:No,1:No,,0.935
2207,2481444,Table 1,BaselineCharacteristic,"Yes (I, II, III, IV)",Delirium (CAM-ICU criteria) ; ,x,None,2,1,3,No,1:No,1:No,,0.85
2207,2481444,Table 1,BaselineCharacteristic,Male,Gender ; ,x,None,2,2,3,No,1:No,1:No,,0.92
2207,2481444,Table 1,BaselineCharacteristic,xx,APACHE II score ; ,x,None,2,4,3,No,1:No,1:No,,0.786
2207,2481444,Table 1,BaselineCharacteristic,Pneumonia,Source of sepsis ; ,x,None,2,5,3,No,1:No,1:No,,0.9
2207,2481444,Table 1,BaselineCharacteristic,Unknown,Causative organism ; ,x,None,2,6,3,No,1:No,1:No,,0.91
2207,2481444,Table 1,BaselineCharacteristic,x,Patient ; ,x,None,3,0,2,No,1:No,1:No,,0.945
2207,2481444,Table 1,BaselineCharacteristic,"Yes (I, II, III, IV)",Delirium (CAM-ICU criteria) ; ,x,None,3,1,3,No,1:No,1:No,,0.87
2207,2481444,Table 1,BaselineCharacteristic,Male,Gender ; ,x,None,3,2,3,No,1:No,1:No,,0.94
2207,2481444,Table 1,BaselineCharacteristic,xx,APACHE II score ; ,x,None,3,4,3,No,1:No,1:No,,0.79
2207,2481444,Table 1,BaselineCharacteristic,Pneumonia,Source of sepsis ; ,x,None,3,5,3,No,1:No,1:No,,0.92
2207,2481444,Table 1,BaselineCharacteristic,Streptococcus pneumoniae,Causative organism ; ,x,None,3,6,3,No,1:No,1:No,,0.93
2207,2481444,Table 1,BaselineCharacteristic,x,Patient ; ,x,None,4,0,2,No,1:No,1:No,,0.965
2207,2481444,Table 1,BaselineCharacteristic,"Yes (I, II, IV)a",Delirium (CAM-ICU criteria) ; ,x,None,4,1,3,No,1:No,1:No,,0.81
2207,2481444,Table 1,BaselineCharacteristic,Male,Gender ; ,x,None,4,2,3,No,1:No,1:No,,0.94
2207,2481444,Table 1,BaselineCharacteristic,xx,APACHE II score ; ,x,None,4,4,3,No,1:No,1:No,,0.86
2207,2481444,Table 1,BaselineCharacteristic,Abdominal,Source of sepsis ; ,x,None,4,5,3,No,1:No,1:No,,0.92
2207,2481444,Table 1,BaselineCharacteristic,Unknown,Causative organism ; ,x,None,4,6,3,No,1:No,1:No,,0.92
2207,2481444,Table 1,BaselineCharacteristic,x,Patient ; ,x,None,5,0,2,No,1:No,1:No,,0.963
2207,2481444,Table 1,BaselineCharacteristic,"Yes (I, II, IV)a",Delirium (CAM-ICU criteria) ; ,x,None,5,1,3,No,1:No,1:No,,0.81
2207,2481444,Table 1,BaselineCharacteristic,Male,Gender ; ,x,None,5,2,3,No,1:No,1:No,,0.94
2207,2481444,Table 1,BaselineCharacteristic,xx,APACHE II score ; ,x,None,5,4,3,No,1:No,1:No,,0.86
2207,2481444,Table 1,BaselineCharacteristic,Pneumonia,Source of sepsis ; ,x,None,5,5,3,No,1:No,1:No,,0.91
2207,2481444,Table 1,BaselineCharacteristic,Enterobacter cloacae,Causative organism ; ,x,None,5,6,3,No,1:No,1:No,,0.91
2207,2481444,Table 1,BaselineCharacteristic,x,Patient ; ,x,None,6,0,2,No,1:No,1:No,,0.973
2207,2481444,Table 1,BaselineCharacteristic,"Yes (I, II, IV)",Delirium (CAM-ICU criteria) ; ,x,None,6,1,3,No,1:No,1:No,,0.89
2207,2481444,Table 1,BaselineCharacteristic,Female,Gender ; ,x,None,6,2,3,No,1:No,1:No,,0.96
2207,2481444,Table 1,BaselineCharacteristic,xx,"Age, years ; ",x,None,6,3,3,No,1:No,1:No,,0.5
2207,2481444,Table 1,BaselineCharacteristic,xx,APACHE II score ; ,x,None,6,4,3,No,1:No,1:No,,0.88
2207,2481444,Table 1,BaselineCharacteristic,Abdominal,Source of sepsis ; ,x,None,6,5,3,No,1:No,1:No,,0.93
2207,2481444,Table 1,BaselineCharacteristic,Escherichia coli,Causative organism ; ,x,None,6,6,3,No,1:No,1:No,,0.93
2207,2481444,Table 1,BaselineCharacteristic,x,Patient ; ,x,None,7,0,2,No,1:No,1:No,,0.973
2207,2481444,Table 1,BaselineCharacteristic,"Yes (I, II, IV)a",Delirium (CAM-ICU criteria) ; ,x,None,7,1,3,No,1:No,1:No,,0.85
2207,2481444,Table 1,BaselineCharacteristic,Female,Gender ; ,x,None,7,2,3,No,1:No,1:No,,0.97
2207,2481444,Table 1,BaselineCharacteristic,xx,"Age, years ; ",x,None,7,3,3,No,1:No,1:No,,0.52
2207,2481444,Table 1,BaselineCharacteristic,xx,APACHE II score ; ,x,None,7,4,3,No,1:No,1:No,,0.9
2207,2481444,Table 1,BaselineCharacteristic,Pneumonia,Source of sepsis ; ,x,None,7,5,3,No,1:No,1:No,,0.95
2207,2481444,Table 1,BaselineCharacteristic,Streptococcus pyogenes,Causative organism ; ,x,None,7,6,3,No,1:No,1:No,,0.96
2207,2481444,Table 1,BaselineCharacteristic,x,Patient ; ,x,None,8,0,2,No,1:No,1:No,,0.972
2207,2481444,Table 1,BaselineCharacteristic,"Yes (I, II, IV)a",Delirium (CAM-ICU criteria) ; ,x,None,8,1,3,No,1:No,1:No,,0.85
2207,2481444,Table 1,BaselineCharacteristic,Female,Gender ; ,x,None,8,2,3,No,1:No,1:No,,0.98
2207,2481444,Table 1,BaselineCharacteristic,xx,"Age, years ; ",x,None,8,3,3,No,1:No,1:No,,0.57
2207,2481444,Table 1,BaselineCharacteristic,xx,APACHE II score ; ,x,None,8,4,3,No,1:No,1:No,,0.92
2207,2481444,Table 1,BaselineCharacteristic,Prosthetic joint infection,Source of sepsis ; ,x,None,8,5,3,No,1:No,1:No,,0.96
2207,2481444,Table 1,BaselineCharacteristic,Staphylococcus aureus,Causative organism ; ,x,None,8,6,3,No,1:No,1:No,,0.98
2207,2481444,Table 1,BaselineCharacteristic,x,Patient ; ,x,None,9,0,2,No,1:No,1:No,,0.982
2207,2481444,Table 1,BaselineCharacteristic,"Yes (I, II, IV)a",Delirium (CAM-ICU criteria) ; ,x,None,9,1,3,No,1:No,1:No,,0.86
2207,2481444,Table 1,BaselineCharacteristic,Female,Gender ; ,x,None,9,2,3,No,1:No,1:No,,0.99
2207,2481444,Table 1,BaselineCharacteristic,xx,"Age, years ; ",x,None,9,3,3,No,1:No,1:No,,0.6
2207,2481444,Table 1,BaselineCharacteristic,xx,APACHE II score ; ,x,None,9,4,3,No,1:No,1:No,,0.95
2207,2481444,Table 1,BaselineCharacteristic,Abdominal,Source of sepsis ; ,x,None,9,5,3,No,1:No,1:No,,0.97
2207,2481444,Table 1,BaselineCharacteristic,Unknown,Causative organism ; ,x,None,9,6,3,No,1:No,1:No,,1
2207,2481444,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,None,10,0,2,No,1:No,1:No,,0.935
2207,2481444,Table 1,BaselineCharacteristic,"Yes (I, II, IV)",Delirium (CAM-ICU criteria) ; ,xx,None,10,1,3,No,1:No,1:No,,0.8
2207,2481444,Table 1,BaselineCharacteristic,Male,Gender ; ,xx,None,10,2,3,No,1:No,1:No,,0.911
2207,2481444,Table 1,BaselineCharacteristic,xx,"Age, years ; ",xx,None,10,3,3,No,1:No,1:No,,0.686
2207,2481444,Table 1,BaselineCharacteristic,xx,APACHE II score ; ,xx,None,10,4,3,No,1:No,1:No,,0.96
2207,2481444,Table 1,BaselineCharacteristic,Pneumonia,Source of sepsis ; ,xx,None,10,5,3,No,1:No,1:No,,0.936
2207,2481444,Table 1,BaselineCharacteristic,Enterobacter aerogenes,Causative organism ; ,xx,None,10,6,3,No,1:No,1:No,,0.926
2207,2481444,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,None,11,0,2,No,1:No,1:No,,0.935
2207,2481444,Table 1,BaselineCharacteristic,"Yes (I, II, IV)",Delirium (CAM-ICU criteria) ; ,xx,None,11,1,3,No,1:No,1:No,,0.8
2207,2481444,Table 1,BaselineCharacteristic,Male,Gender ; ,xx,None,11,2,3,No,1:No,1:No,,0.911
2207,2481444,Table 1,BaselineCharacteristic,xx,"Age, years ; ",xx,None,11,3,3,No,1:No,1:No,,0.706
2207,2481444,Table 1,BaselineCharacteristic,xx,APACHE II score ; ,xx,None,11,4,3,No,1:No,1:No,,0.96
2207,2481444,Table 1,BaselineCharacteristic,Abdominal,Source of sepsis ; ,xx,None,11,5,3,No,1:No,1:No,,0.936
2207,2481444,Table 1,BaselineCharacteristic,Bacteroides fragilis,Causative organism ; ,xx,None,11,6,3,No,1:No,1:No,,0.926
2207,2481444,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,None,12,0,2,No,1:No,1:No,,0.935
2207,2481444,Table 1,BaselineCharacteristic,"Yes (I, II, IV)a",Delirium (CAM-ICU criteria) ; ,xx,None,12,1,3,No,1:No,1:No,,0.71
2207,2481444,Table 1,BaselineCharacteristic,Male,Gender ; ,xx,None,12,2,3,No,1:No,1:No,,0.911
2207,2481444,Table 1,BaselineCharacteristic,xx,"Age, years ; ",xx,None,12,3,3,No,1:No,1:No,,0.716
2207,2481444,Table 1,BaselineCharacteristic,xx,APACHE II score ; ,xx,None,12,4,3,No,1:No,1:No,,0.96
2207,2481444,Table 1,BaselineCharacteristic,Abdominal,Source of sepsis ; ,xx,None,12,5,3,No,1:No,1:No,,0.936
2207,2481444,Table 1,BaselineCharacteristic,Bacteroides fragilis,Causative organism ; ,xx,None,12,6,3,No,1:No,1:No,,0.926
2207,2481444,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,None,13,0,2,No,1:No,1:No,,0.935
2207,2481444,Table 1,BaselineCharacteristic,No,Delirium (CAM-ICU criteria) ; ,xx,None,13,1,3,No,1:No,1:No,,0.921
2207,2481444,Table 1,BaselineCharacteristic,Female,Gender ; ,xx,None,13,2,3,No,1:No,1:No,,0.911
2207,2481444,Table 1,BaselineCharacteristic,xx,"Age, years ; ",xx,None,13,3,3,No,1:No,1:No,,0.716
2207,2481444,Table 1,BaselineCharacteristic,xx,APACHE II score ; ,xx,None,13,4,3,No,1:No,1:No,,0.96
2207,2481444,Table 1,BaselineCharacteristic,Pneumonia,Source of sepsis ; ,xx,None,13,5,3,No,1:No,1:No,,0.936
2207,2481444,Table 1,BaselineCharacteristic,Unknown,Causative organism ; ,xx,None,13,6,3,No,1:No,1:No,,0.926
2207,2481444,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,None,14,0,2,No,1:No,1:No,,0.955
2207,2481444,Table 1,BaselineCharacteristic,No,Delirium (CAM-ICU criteria) ; ,xx,None,14,1,3,No,1:No,1:No,,0.941
2207,2481444,Table 1,BaselineCharacteristic,Male,Gender ; ,xx,None,14,2,3,No,1:No,1:No,,0.931
2207,2481444,Table 1,BaselineCharacteristic,xx,"Age, years ; ",xx,None,14,3,3,No,1:No,1:No,,0.726
2207,2481444,Table 1,BaselineCharacteristic,x,APACHE II score ; ,xx,None,14,4,3,No,1:No,1:No,,0.96
2207,2481444,Table 1,BaselineCharacteristic,Pneumonia,Source of sepsis ; ,xx,None,14,5,3,No,1:No,1:No,,0.946
2207,2481444,Table 1,BaselineCharacteristic,Streptococcus pneumoniae,Causative organism ; ,xx,None,14,6,3,No,1:No,1:No,,0.936
2207,2481444,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,None,15,0,2,No,1:No,1:No,,0.955
2207,2481444,Table 1,BaselineCharacteristic,No,Delirium (CAM-ICU criteria) ; ,xx,None,15,1,3,No,1:No,1:No,,0.941
2207,2481444,Table 1,BaselineCharacteristic,Male,Gender ; ,xx,None,15,2,3,No,1:No,1:No,,0.931
2207,2481444,Table 1,BaselineCharacteristic,xx,"Age, years ; ",xx,None,15,3,3,No,1:No,1:No,,0.726
2207,2481444,Table 1,BaselineCharacteristic,xx,APACHE II score ; ,xx,None,15,4,3,No,1:No,1:No,,0.97
2207,2481444,Table 1,BaselineCharacteristic,Necrotizing cholecystitis,Source of sepsis ; ,xx,None,15,5,3,No,1:No,1:No,,0.946
2207,2481444,Table 1,BaselineCharacteristic,Klebsiella oxytoca,Causative organism ; ,xx,None,15,6,3,No,1:No,1:No,,0.936
2207,2481444,Table 1,BaselineCharacteristic,xx,Patient ; ,xx,None,16,0,2,No,1:No,1:No,,0.955
2207,2481444,Table 1,BaselineCharacteristic,No,Delirium (CAM-ICU criteria) ; ,xx,None,16,1,3,No,1:No,1:No,,0.941
2207,2481444,Table 1,BaselineCharacteristic,Female,Gender ; ,xx,None,16,2,3,No,1:No,1:No,,0.941
2207,2481444,Table 1,BaselineCharacteristic,xx,"Age, years ; ",xx,None,16,3,3,No,1:No,1:No,,0.736
2207,2481444,Table 1,BaselineCharacteristic,xx,APACHE II score ; ,xx,None,16,4,3,No,1:No,1:No,,0.98
2207,2481444,Table 1,BaselineCharacteristic,Pneumonia,Source of sepsis ; ,xx,None,16,5,3,No,1:No,1:No,,0.956
2207,2481444,Table 1,BaselineCharacteristic,Unknown,Causative organism ; ,xx,None,16,6,3,No,1:No,1:No,,0.946
2207,2481444,Table 2,BaselineCharacteristic,Patient,,None,None,0,0,12,No,1:No,1:No,,0.905
2207,2481444,Table 2,BaselineCharacteristic,Timea,,Patient,None,0,1,1,No,1:No,1:No,,0.903
2207,2481444,Table 2,BaselineCharacteristic,Intubated,,Patient,None,0,2,1,No,1:No,1:No,,0.903
2207,2481444,Table 2,BaselineCharacteristic,PaOxb,,Patient,None,0,3,1,No,1:No,1:No,,0.903
2207,2481444,Table 2,BaselineCharacteristic,Glcc,,Patient,None,0,4,1,No,1:No,1:No,,0.913
2207,2481444,Table 2,BaselineCharacteristic,"Heparin, IU/xx hours",,Patient,None,0,5,1,No,1:No,1:No,,0.935
2207,2481444,Table 2,BaselineCharacteristic,NAd,,Patient,None,0,6,1,No,1:No,1:No,,0.935
2207,2481444,Table 2,BaselineCharacteristic,DOBe,,Patient,None,0,7,1,No,1:No,1:No,,0.945
2207,2481444,Table 2,BaselineCharacteristic,Steroidsf,,Patient,None,0,8,1,No,1:No,1:No,,0.945
2207,2481444,Table 2,BaselineCharacteristic,Sedationg,,Patient,None,0,9,1,No,1:No,1:No,,0.945
2207,2481444,Table 2,BaselineCharacteristic,x,Patient ; ,x,None,1,0,2,No,1:No,1:No,,0.915
2207,2481444,Table 2,BaselineCharacteristic,xx,Timea ; ,x,None,1,1,3,No,1:No,1:No,,0.662
2207,2481444,Table 2,BaselineCharacteristic,,Intubated ; ,x,None,1,2,3,No,1:No,1:No,,0.9
2207,2481444,Table 2,BaselineCharacteristic,xx.x (x.x),PaOxb ; ,x,None,1,3,3,No,1:No,1:No,,0.562
2207,2481444,Table 2,BaselineCharacteristic,xx.x,Glcc ; ,x,None,1,4,3,No,1:No,1:No,,0.582
2207,2481444,Table 2,BaselineCharacteristic,"xx,xxx","Heparin, IU/xx hours ; ",x,None,1,5,3,No,1:No,1:No,,0.566
2207,2481444,Table 2,BaselineCharacteristic,,NAd ; ,x,None,1,6,3,No,1:No,1:No,,0.9
2207,2481444,Table 2,BaselineCharacteristic,,DOBe ; ,x,None,1,7,3,No,1:No,1:No,,0.89
2207,2481444,Table 2,BaselineCharacteristic,,Steroidsf ; ,x,None,1,8,3,No,1:No,1:No,,0.9
2207,2481444,Table 2,BaselineCharacteristic,"L, H",Sedationg ; ,x,None,1,9,3,No,1:No,1:No,,0.9
2207,2481444,Table 2,BaselineCharacteristic,x,Patient ; ,x,None,2,0,2,No,1:No,1:No,,0.935
2207,2481444,Table 2,BaselineCharacteristic,xx,Timea ; ,x,None,2,1,3,No,1:No,1:No,,0.672
2207,2481444,Table 2,BaselineCharacteristic,,Intubated ; ,x,None,2,2,3,No,1:No,1:No,,0.92
2207,2481444,Table 2,BaselineCharacteristic,xx.x (xx.x),PaOxb ; ,x,None,2,3,3,No,1:No,1:No,,0.612
2207,2481444,Table 2,BaselineCharacteristic,x.x,Glcc ; ,x,None,2,4,3,No,1:No,1:No,,0.9
2207,2481444,Table 2,BaselineCharacteristic,"xx,xxx","Heparin, IU/xx hours ; ",x,None,2,5,3,No,1:No,1:No,,0.586
2207,2481444,Table 2,BaselineCharacteristic,,NAd ; ,x,None,2,6,3,No,1:No,1:No,,0.91
2207,2481444,Table 2,BaselineCharacteristic,,DOBe ; ,x,None,2,7,3,No,1:No,1:No,,0.9
2207,2481444,Table 2,BaselineCharacteristic,,Steroidsf ; ,x,None,2,8,3,No,1:No,1:No,,0.91
2207,2481444,Table 2,BaselineCharacteristic,"L, H, Q",Sedationg ; ,x,None,2,9,3,No,1:No,1:No,,0.91
2207,2481444,Table 2,BaselineCharacteristic,x,Patient ; ,x,None,3,0,2,No,1:No,1:No,,0.945
2207,2481444,Table 2,BaselineCharacteristic,xx,Timea ; ,x,None,3,1,3,No,1:No,1:No,,0.686
2207,2481444,Table 2,BaselineCharacteristic,X,Intubated ; ,x,None,3,2,3,No,1:No,1:No,,0.94
2207,2481444,Table 2,BaselineCharacteristic,x.x (x.x),PaOxb ; ,x,None,3,3,3,No,1:No,1:No,,0.93
2207,2481444,Table 2,BaselineCharacteristic,x.x,Glcc ; ,x,None,3,4,3,No,1:No,1:No,,0.92
2207,2481444,Table 2,BaselineCharacteristic,"xx,xxx","Heparin, IU/xx hours ; ",x,None,3,5,3,No,1:No,1:No,,0.58
2207,2481444,Table 2,BaselineCharacteristic,,NAd ; ,x,None,3,6,3,No,1:No,1:No,,0.93
2207,2481444,Table 2,BaselineCharacteristic,,DOBe ; ,x,None,3,7,3,No,1:No,1:No,,0.92
2207,2481444,Table 2,BaselineCharacteristic,X,Steroidsf ; ,x,None,3,8,3,No,1:No,1:No,,0.93
2207,2481444,Table 2,BaselineCharacteristic,"M, F",Sedationg ; ,x,None,3,9,3,No,1:No,1:No,,0.93
2207,2481444,Table 2,BaselineCharacteristic,x,Patient ; ,x,None,4,0,2,No,1:No,1:No,,0.965
2207,2481444,Table 2,BaselineCharacteristic,xx,Timea ; ,x,None,4,1,3,No,1:No,1:No,,0.766
2207,2481444,Table 2,BaselineCharacteristic,,Intubated ; ,x,None,4,2,3,No,1:No,1:No,,0.94
2207,2481444,Table 2,BaselineCharacteristic,x.x (x.x),PaOxb ; ,x,None,4,3,3,No,1:No,1:No,,0.93
2207,2481444,Table 2,BaselineCharacteristic,x.x,Glcc ; ,x,None,4,4,3,No,1:No,1:No,,0.92
2207,2481444,Table 2,BaselineCharacteristic,"LMWH x,xxx","Heparin, IU/xx hours ; ",x,None,4,5,3,No,1:No,1:No,,0.84
2207,2481444,Table 2,BaselineCharacteristic,,NAd ; ,x,None,4,6,3,No,1:No,1:No,,0.92
2207,2481444,Table 2,BaselineCharacteristic,,DOBe ; ,x,None,4,7,3,No,1:No,1:No,,0.91
2207,2481444,Table 2,BaselineCharacteristic,X,Steroidsf ; ,x,None,4,8,3,No,1:No,1:No,,0.92
2207,2481444,Table 2,BaselineCharacteristic,"P, M",Sedationg ; ,x,None,4,9,3,No,1:No,1:No,,0.92
2207,2481444,Table 2,BaselineCharacteristic,x,Patient ; ,x,None,5,0,2,No,1:No,1:No,,0.963
2207,2481444,Table 2,BaselineCharacteristic,xx,Timea ; ,x,None,5,1,3,No,1:No,1:No,,0.766
2207,2481444,Table 2,BaselineCharacteristic,X,Intubated ; ,x,None,5,2,3,No,1:No,1:No,,0.94
2207,2481444,Table 2,BaselineCharacteristic,xx.x (x.x),PaOxb ; ,x,None,5,3,3,No,1:No,1:No,,0.716
2207,2481444,Table 2,BaselineCharacteristic,x.x,Glcc ; ,x,None,5,4,3,No,1:No,1:No,,0.92
2207,2481444,Table 2,BaselineCharacteristic,"xx,xxx","Heparin, IU/xx hours ; ",x,None,5,5,3,No,1:No,1:No,,0.61
2207,2481444,Table 2,BaselineCharacteristic,xx,NAd ; ,x,None,5,6,3,No,1:No,1:No,,0.73
2207,2481444,Table 2,BaselineCharacteristic,,DOBe ; ,x,None,5,7,3,No,1:No,1:No,,0.9
2207,2481444,Table 2,BaselineCharacteristic,,Steroidsf ; ,x,None,5,8,3,No,1:No,1:No,,0.91
2207,2481444,Table 2,BaselineCharacteristic,"P, M",Sedationg ; ,x,None,5,9,3,No,1:No,1:No,,0.91
2207,2481444,Table 2,BaselineCharacteristic,x,Patient ; ,x,None,6,0,2,No,1:No,1:No,,0.973
2207,2481444,Table 2,BaselineCharacteristic,xx,Timea ; ,x,None,6,1,3,No,1:No,1:No,,0.786
2207,2481444,Table 2,BaselineCharacteristic,X,Intubated ; ,x,None,6,2,3,No,1:No,1:No,,0.96
2207,2481444,Table 2,BaselineCharacteristic,xx.x (x.x),PaOxb ; ,x,None,6,3,3,No,1:No,1:No,,0.736
2207,2481444,Table 2,BaselineCharacteristic,x.x,Glcc ; ,x,None,6,4,3,No,1:No,1:No,,0.94
2207,2481444,Table 2,BaselineCharacteristic,"xx,xxx","Heparin, IU/xx hours ; ",x,None,6,5,3,No,1:No,1:No,,0.64
2207,2481444,Table 2,BaselineCharacteristic,xx,NAd ; ,x,None,6,6,3,No,1:No,1:No,,0.75
2207,2481444,Table 2,BaselineCharacteristic,,DOBe ; ,x,None,6,7,3,No,1:No,1:No,,0.92
2207,2481444,Table 2,BaselineCharacteristic,X,Steroidsf ; ,x,None,6,8,3,No,1:No,1:No,,0.93
2207,2481444,Table 2,BaselineCharacteristic,"P, Mi, M",Sedationg ; ,x,None,6,9,3,No,1:No,1:No,,0.93
2207,2481444,Table 2,BaselineCharacteristic,x,Patient ; ,x,None,7,0,2,No,1:No,1:No,,0.973
2207,2481444,Table 2,BaselineCharacteristic,xx,Timea ; ,x,None,7,1,3,No,1:No,1:No,,0.816
2207,2481444,Table 2,BaselineCharacteristic,,Intubated ; ,x,None,7,2,3,No,1:No,1:No,,0.97
2207,2481444,Table 2,BaselineCharacteristic,xx.x (x.x),PaOxb ; ,x,None,7,3,3,No,1:No,1:No,,0.776
2207,2481444,Table 2,BaselineCharacteristic,x.x,Glcc ; ,x,None,7,4,3,No,1:No,1:No,,0.96
2207,2481444,Table 2,BaselineCharacteristic,"xx,xxx","Heparin, IU/xx hours ; ",x,None,7,5,3,No,1:No,1:No,,0.7
2207,2481444,Table 2,BaselineCharacteristic,x,NAd ; ,x,None,7,6,3,No,1:No,1:No,,0.96
2207,2481444,Table 2,BaselineCharacteristic,xxx,DOBe ; ,x,None,7,7,3,No,1:No,1:No,,0.9
2207,2481444,Table 2,BaselineCharacteristic,,Steroidsf ; ,x,None,7,8,3,No,1:No,1:No,,0.96
2207,2481444,Table 2,BaselineCharacteristic,None,Sedationg ; ,x,None,7,9,3,No,1:No,1:No,,0.96
2207,2481444,Table 2,BaselineCharacteristic,x,Patient ; ,x,None,8,0,2,No,1:No,1:No,,0.972
2207,2481444,Table 2,BaselineCharacteristic,xx,Timea ; ,x,None,8,1,3,No,1:No,1:No,,0.836
2207,2481444,Table 2,BaselineCharacteristic,,Intubated ; ,x,None,8,2,3,No,1:No,1:No,,0.98
2207,2481444,Table 2,BaselineCharacteristic,x.x (x.x),PaOxb ; ,x,None,8,3,3,No,1:No,1:No,,0.97
2207,2481444,Table 2,BaselineCharacteristic,x.x,Glcc ; ,x,None,8,4,3,No,1:No,1:No,,0.97
2207,2481444,Table 2,BaselineCharacteristic,"xx,xxx","Heparin, IU/xx hours ; ",x,None,8,5,3,No,1:No,1:No,,0.76
2207,2481444,Table 2,BaselineCharacteristic,xx,NAd ; ,x,None,8,6,3,No,1:No,1:No,,0.84
2207,2481444,Table 2,BaselineCharacteristic,xxx,DOBe ; ,x,None,8,7,3,No,1:No,1:No,,0.93
2207,2481444,Table 2,BaselineCharacteristic,,Steroidsf ; ,x,None,8,8,3,No,1:No,1:No,,0.98
2207,2481444,Table 2,BaselineCharacteristic,M,Sedationg ; ,x,None,8,9,3,No,1:No,1:No,,0.98
2207,2481444,Table 2,BaselineCharacteristic,x,Patient ; ,x,None,9,0,2,No,1:No,1:No,,0.982
2207,2481444,Table 2,BaselineCharacteristic,xx,Timea ; ,x,None,9,1,3,No,1:No,1:No,,0.876
2207,2481444,Table 2,BaselineCharacteristic,X,Intubated ; ,x,None,9,2,3,No,1:No,1:No,,0.99
2207,2481444,Table 2,BaselineCharacteristic,xx.x (xx.x),PaOxb ; ,x,None,9,3,3,No,1:No,1:No,,0.836
2207,2481444,Table 2,BaselineCharacteristic,x.x,Glcc ; ,x,None,9,4,3,No,1:No,1:No,,0.99
2207,2481444,Table 2,BaselineCharacteristic,"xx,xxx","Heparin, IU/xx hours ; ",x,None,9,5,3,No,1:No,1:No,,0.79
2207,2481444,Table 2,BaselineCharacteristic,xx,NAd ; ,x,None,9,6,3,No,1:No,1:No,,0.88
2207,2481444,Table 2,BaselineCharacteristic,,DOBe ; ,x,None,9,7,3,No,1:No,1:No,,0.99
2207,2481444,Table 2,BaselineCharacteristic,X,Steroidsf ; ,x,None,9,8,3,No,1:No,1:No,,1
2207,2481444,Table 2,BaselineCharacteristic,"Mi, M",Sedationg ; ,x,None,9,9,3,No,1:No,1:No,,1
2207,2481444,Table 2,BaselineCharacteristic,xx,Patient ; ,xx,None,10,0,2,No,1:No,1:No,,0.935
2207,2481444,Table 2,BaselineCharacteristic,xx,Timea ; ,xx,None,10,1,3,No,1:No,1:No,,0.956
2207,2481444,Table 2,BaselineCharacteristic,X,Intubated ; ,xx,None,10,2,3,No,1:No,1:No,,0.911
2207,2481444,Table 2,BaselineCharacteristic,xx.x (xx.x),PaOxb ; ,xx,None,10,3,3,No,1:No,1:No,,0.856
2207,2481444,Table 2,BaselineCharacteristic,x.x,Glcc ; ,xx,None,10,4,3,No,1:No,1:No,,0.886
2207,2481444,Table 2,BaselineCharacteristic,"LMWH x,xxx","Heparin, IU/xx hours ; ",xx,None,10,5,3,No,1:No,1:No,,0.82
2207,2481444,Table 2,BaselineCharacteristic,xx,NAd ; ,xx,None,10,6,3,No,1:No,1:No,,0.926
2207,2481444,Table 2,BaselineCharacteristic,,DOBe ; ,xx,None,10,7,3,No,1:No,1:No,,0.936
2207,2481444,Table 2,BaselineCharacteristic,X,Steroidsf ; ,xx,None,10,8,3,No,1:No,1:No,,0.946
2207,2481444,Table 2,BaselineCharacteristic,"Mi, F, M",Sedationg ; ,xx,None,10,9,3,No,1:No,1:No,,0.946
2207,2481444,Table 2,BaselineCharacteristic,xx,Patient ; ,xx,None,11,0,2,No,1:No,1:No,,0.935
2207,2481444,Table 2,BaselineCharacteristic,xx,Timea ; ,xx,None,11,1,3,No,1:No,1:No,,0.956
2207,2481444,Table 2,BaselineCharacteristic,X,Intubated ; ,xx,None,11,2,3,No,1:No,1:No,,0.911
2207,2481444,Table 2,BaselineCharacteristic,xx.x (x.x),PaOxb ; ,xx,None,11,3,3,No,1:No,1:No,,0.856
2207,2481444,Table 2,BaselineCharacteristic,x.x,Glcc ; ,xx,None,11,4,3,No,1:No,1:No,,0.886
2207,2481444,Table 2,BaselineCharacteristic,"LMWH x,xxx","Heparin, IU/xx hours ; ",xx,None,11,5,3,No,1:No,1:No,,0.82
2207,2481444,Table 2,BaselineCharacteristic,xx,NAd ; ,xx,None,11,6,3,No,1:No,1:No,,0.926
2207,2481444,Table 2,BaselineCharacteristic,,DOBe ; ,xx,None,11,7,3,No,1:No,1:No,,0.936
2207,2481444,Table 2,BaselineCharacteristic,X,Steroidsf ; ,xx,None,11,8,3,No,1:No,1:No,,0.946
2207,2481444,Table 2,BaselineCharacteristic,"P, M, R",Sedationg ; ,xx,None,11,9,3,No,1:No,1:No,,0.946
2207,2481444,Table 2,BaselineCharacteristic,xx,Patient ; ,xx,None,12,0,2,No,1:No,1:No,,0.935
2207,2481444,Table 2,BaselineCharacteristic,xx,Timea ; ,xx,None,12,1,3,No,1:No,1:No,,0.956
2207,2481444,Table 2,BaselineCharacteristic,,Intubated ; ,xx,None,12,2,3,No,1:No,1:No,,0.911
2207,2481444,Table 2,BaselineCharacteristic,xx.x (xx.x),PaOxb ; ,xx,None,12,3,3,No,1:No,1:No,,0.856
2207,2481444,Table 2,BaselineCharacteristic,x.x,Glcc ; ,xx,None,12,4,3,No,1:No,1:No,,0.886
2207,2481444,Table 2,BaselineCharacteristic,"xx,xxx","Heparin, IU/xx hours ; ",xx,None,12,5,3,No,1:No,1:No,,0.876
2207,2481444,Table 2,BaselineCharacteristic,,NAd ; ,xx,None,12,6,3,No,1:No,1:No,,0.926
2207,2481444,Table 2,BaselineCharacteristic,,DOBe ; ,xx,None,12,7,3,No,1:No,1:No,,0.936
2207,2481444,Table 2,BaselineCharacteristic,,Steroidsf ; ,xx,None,12,8,3,No,1:No,1:No,,0.946
2207,2481444,Table 2,BaselineCharacteristic,"P, M",Sedationg ; ,xx,None,12,9,3,No,1:No,1:No,,0.946
2207,2481444,Table 2,BaselineCharacteristic,xx,Patient ; ,xx,None,13,0,2,No,1:No,1:No,,0.935
2207,2481444,Table 2,BaselineCharacteristic,xx,Timea ; ,xx,None,13,1,3,No,1:No,1:No,,0.956
2207,2481444,Table 2,BaselineCharacteristic,X,Intubated ; ,xx,None,13,2,3,No,1:No,1:No,,0.911
2207,2481444,Table 2,BaselineCharacteristic,xx.x (x.x),PaOxb ; ,xx,None,13,3,3,No,1:No,1:No,,0.856
2207,2481444,Table 2,BaselineCharacteristic,x.x,Glcc ; ,xx,None,13,4,3,No,1:No,1:No,,0.886
2207,2481444,Table 2,BaselineCharacteristic,"LMWH x,xxx","Heparin, IU/xx hours ; ",xx,None,13,5,3,No,1:No,1:No,,0.82
2207,2481444,Table 2,BaselineCharacteristic,,NAd ; ,xx,None,13,6,3,No,1:No,1:No,,0.926
2207,2481444,Table 2,BaselineCharacteristic,,DOBe ; ,xx,None,13,7,3,No,1:No,1:No,,0.936
2207,2481444,Table 2,BaselineCharacteristic,,Steroidsf ; ,xx,None,13,8,3,No,1:No,1:No,,0.946
2207,2481444,Table 2,BaselineCharacteristic,"P, F",Sedationg ; ,xx,None,13,9,3,No,1:No,1:No,,0.946
2207,2481444,Table 2,BaselineCharacteristic,xx,Patient ; ,xx,None,14,0,2,No,1:No,1:No,,0.955
2207,2481444,Table 2,BaselineCharacteristic,x,Timea ; ,xx,None,14,1,3,No,1:No,1:No,,0.916
2207,2481444,Table 2,BaselineCharacteristic,,Intubated ; ,xx,None,14,2,3,No,1:No,1:No,,0.931
2207,2481444,Table 2,BaselineCharacteristic,xx.x (xx.x),PaOxb ; ,xx,None,14,3,3,No,1:No,1:No,,0.876
2207,2481444,Table 2,BaselineCharacteristic,x.x,Glcc ; ,xx,None,14,4,3,No,1:No,1:No,,0.896
2207,2481444,Table 2,BaselineCharacteristic,None,"Heparin, IU/xx hours ; ",xx,None,14,5,3,No,1:No,1:No,,0.936
2207,2481444,Table 2,BaselineCharacteristic,,NAd ; ,xx,None,14,6,3,No,1:No,1:No,,0.936
2207,2481444,Table 2,BaselineCharacteristic,,DOBe ; ,xx,None,14,7,3,No,1:No,1:No,,0.946
2207,2481444,Table 2,BaselineCharacteristic,X,Steroidsf ; ,xx,None,14,8,3,No,1:No,1:No,,0.956
2207,2481444,Table 2,BaselineCharacteristic,None,Sedationg ; ,xx,None,14,9,3,No,1:No,1:No,,0.956
2207,2481444,Table 2,BaselineCharacteristic,xx,Patient ; ,xx,None,15,0,2,No,1:No,1:No,,0.955
2207,2481444,Table 2,BaselineCharacteristic,xx,Timea ; ,xx,None,15,1,3,No,1:No,1:No,,0.966
2207,2481444,Table 2,BaselineCharacteristic,,Intubated ; ,xx,None,15,2,3,No,1:No,1:No,,0.931
2207,2481444,Table 2,BaselineCharacteristic,xx.x (xx.x),PaOxb ; ,xx,None,15,3,3,No,1:No,1:No,,0.876
2207,2481444,Table 2,BaselineCharacteristic,x.x,Glcc ; ,xx,None,15,4,3,No,1:No,1:No,,0.896
2207,2481444,Table 2,BaselineCharacteristic,"LMWH x,xxx","Heparin, IU/xx hours ; ",xx,None,15,5,3,No,1:No,1:No,,0.83
2207,2481444,Table 2,BaselineCharacteristic,,NAd ; ,xx,None,15,6,3,No,1:No,1:No,,0.936
2207,2481444,Table 2,BaselineCharacteristic,xxx,DOBe ; ,xx,None,15,7,3,No,1:No,1:No,,0.886
2207,2481444,Table 2,BaselineCharacteristic,,Steroidsf ; ,xx,None,15,8,3,No,1:No,1:No,,0.956
2207,2481444,Table 2,BaselineCharacteristic,"M, H",Sedationg ; ,xx,None,15,9,3,No,1:No,1:No,,0.956
2207,2481444,Table 2,BaselineCharacteristic,xx,Patient ; ,xx,None,16,0,2,No,1:No,1:No,,0.955
2207,2481444,Table 2,BaselineCharacteristic,xx,Timea ; ,xx,None,16,1,3,No,1:No,1:No,,0.966
2207,2481444,Table 2,BaselineCharacteristic,,Intubated ; ,xx,None,16,2,3,No,1:No,1:No,,0.941
2207,2481444,Table 2,BaselineCharacteristic,xx.x (xx.x),PaOxb ; ,xx,None,16,3,3,No,1:No,1:No,,0.886
2207,2481444,Table 2,BaselineCharacteristic,x.x,Glcc ; ,xx,None,16,4,3,No,1:No,1:No,,0.906
2207,2481444,Table 2,BaselineCharacteristic,"LMWH x,xxx","Heparin, IU/xx hours ; ",xx,None,16,5,3,No,1:No,1:No,,0.83
2207,2481444,Table 2,BaselineCharacteristic,,NAd ; ,xx,None,16,6,3,No,1:No,1:No,,0.946
2207,2481444,Table 2,BaselineCharacteristic,,DOBe ; ,xx,None,16,7,3,No,1:No,1:No,,0.956
2207,2481444,Table 2,BaselineCharacteristic,,Steroidsf ; ,xx,None,16,8,3,No,1:No,1:No,,0.966
2207,2481444,Table 2,BaselineCharacteristic,None,Sedationg ; ,xx,None,16,9,3,No,1:No,1:No,,0.966
2230,2517161,Table 1,BaselineCharacteristic,Patient number,,None,None,0,0,12,No,1:No,1:No,,0.805
2230,2517161,Table 1,BaselineCharacteristic,Procedure time (min),,Patient number,None,0,1,1,No,1:No,1:No,,0.827
2230,2517161,Table 1,BaselineCharacteristic,Fluoroscopy time (min),,Patient number,None,0,2,1,No,1:No,1:No,,0.843
2230,2517161,Table 1,BaselineCharacteristic,LVL fluoroscopy (min),,Patient number,None,0,3,1,No,1:No,1:No,,0.856
2230,2517161,Table 1,BaselineCharacteristic,Target SB accessed w/guidewire,,Patient number,None,0,4,1,No,1:No,1:No,,0.833
2230,2517161,Table 1,BaselineCharacteristic,Final LVL location,,Patient number,None,0,5,1,No,1:No,1:No,,0.853
2230,2517161,Table 1,BaselineCharacteristic,Pacing threshold (mV),,Patient number,None,0,6,1,No,1:No,1:No,,0.853
2230,2517161,Table 1,BaselineCharacteristic,x,Patient number ; ,x,None,1,0,2,No,1:No,1:No,,0.868
2230,2517161,Table 1,BaselineCharacteristic,xxx,Procedure time (min) ; ,x,None,1,1,3,No,1:No,1:No,,0.85
2230,2517161,Table 1,BaselineCharacteristic,xx.x,Fluoroscopy time (min) ; ,x,None,1,2,3,No,1:No,1:No,,0.712
2230,2517161,Table 1,BaselineCharacteristic,x.x,LVL fluoroscopy (min) ; ,x,None,1,3,3,No,1:No,1:No,,0.92
2230,2517161,Table 1,BaselineCharacteristic,Yes,Target SB accessed w/guidewire ; ,x,None,1,4,3,No,1:No,1:No,,0.88
2230,2517161,Table 1,BaselineCharacteristic,PL,Final LVL location ; ,x,None,1,5,3,No,1:No,1:No,,0.89
2230,2517161,Table 1,BaselineCharacteristic,x,Pacing threshold (mV) ; ,x,None,1,6,3,No,1:No,1:No,,0.9
2230,2517161,Table 1,BaselineCharacteristic,x,Patient number ; ,x,None,2,0,2,No,1:No,1:No,,0.878
2230,2517161,Table 1,BaselineCharacteristic,xx,Procedure time (min) ; ,x,None,2,1,3,No,1:No,1:No,,0.732
2230,2517161,Table 1,BaselineCharacteristic,xx.x,Fluoroscopy time (min) ; ,x,None,2,2,3,No,1:No,1:No,,0.752
2230,2517161,Table 1,BaselineCharacteristic,x,LVL fluoroscopy (min) ; ,x,None,2,3,3,No,1:No,1:No,,0.93
2230,2517161,Table 1,BaselineCharacteristic,Yes,Target SB accessed w/guidewire ; ,x,None,2,4,3,No,1:No,1:No,,0.9
2230,2517161,Table 1,BaselineCharacteristic,AL,Final LVL location ; ,x,None,2,5,3,No,1:No,1:No,,0.9
2230,2517161,Table 1,BaselineCharacteristic,x.x,Pacing threshold (mV) ; ,x,None,2,6,3,No,1:No,1:No,,0.91
2230,2517161,Table 1,BaselineCharacteristic,x,Patient number ; ,x,None,3,0,2,No,1:No,1:No,,0.888
2230,2517161,Table 1,BaselineCharacteristic,xx,Procedure time (min) ; ,x,None,3,1,3,No,1:No,1:No,,0.746
2230,2517161,Table 1,BaselineCharacteristic,xx.x,Fluoroscopy time (min) ; ,x,None,3,2,3,No,1:No,1:No,,0.756
2230,2517161,Table 1,BaselineCharacteristic,x.xx,LVL fluoroscopy (min) ; ,x,None,3,3,3,No,1:No,1:No,,0.72
2230,2517161,Table 1,BaselineCharacteristic,Yes,Target SB accessed w/guidewire ; ,x,None,3,4,3,No,1:No,1:No,,0.92
2230,2517161,Table 1,BaselineCharacteristic,PL,Final LVL location ; ,x,None,3,5,3,No,1:No,1:No,,0.92
2230,2517161,Table 1,BaselineCharacteristic,x.x,Pacing threshold (mV) ; ,x,None,3,6,3,No,1:No,1:No,,0.93
2230,2517161,Table 1,BaselineCharacteristic,x,Patient number ; ,x,None,4,0,2,No,1:No,1:No,,0.888
2230,2517161,Table 1,BaselineCharacteristic,–,Procedure time (min) ; ,x,None,4,1,3,No,1:No,1:No,,0.9
2230,2517161,Table 1,BaselineCharacteristic,–,Fluoroscopy time (min) ; ,x,None,4,2,3,No,1:No,1:No,,0.91
2230,2517161,Table 1,BaselineCharacteristic,–,LVL fluoroscopy (min) ; ,x,None,4,3,3,No,1:No,1:No,,0.89
2230,2517161,Table 1,BaselineCharacteristic,Yes,Target SB accessed w/guidewire ; ,x,None,4,4,3,No,1:No,1:No,,0.92
2230,2517161,Table 1,BaselineCharacteristic,PL,Final LVL location ; ,x,None,4,5,3,No,1:No,1:No,,0.91
2230,2517161,Table 1,BaselineCharacteristic,x.x,Pacing threshold (mV) ; ,x,None,4,6,3,No,1:No,1:No,,0.92
2230,2517161,Table 1,BaselineCharacteristic,x,Patient number ; ,x,None,5,0,2,No,1:No,1:No,,0.893
2230,2517161,Table 1,BaselineCharacteristic,xx,Procedure time (min) ; ,x,None,5,1,3,No,1:No,1:No,,0.806
2230,2517161,Table 1,BaselineCharacteristic,xx.x,Fluoroscopy time (min) ; ,x,None,5,2,3,No,1:No,1:No,,0.826
2230,2517161,Table 1,BaselineCharacteristic,x.xx,LVL fluoroscopy (min) ; ,x,None,5,3,3,No,1:No,1:No,,0.79
2230,2517161,Table 1,BaselineCharacteristic,Yes,Target SB accessed w/guidewire ; ,x,None,5,4,3,No,1:No,1:No,,0.92
2230,2517161,Table 1,BaselineCharacteristic,PL,Final LVL location ; ,x,None,5,5,3,No,1:No,1:No,,0.9
2230,2517161,Table 1,BaselineCharacteristic,x.x,Pacing threshold (mV) ; ,x,None,5,6,3,No,1:No,1:No,,0.91
2230,2517161,Table 1,BaselineCharacteristic,x,Patient number ; ,x,None,6,0,2,No,1:No,1:No,,0.903
2230,2517161,Table 1,BaselineCharacteristic,xxx,Procedure time (min) ; ,x,None,6,1,3,No,1:No,1:No,,0.91
2230,2517161,Table 1,BaselineCharacteristic,xx,Fluoroscopy time (min) ; ,x,None,6,2,3,No,1:No,1:No,,0.836
2230,2517161,Table 1,BaselineCharacteristic,x.xx,LVL fluoroscopy (min) ; ,x,None,6,3,3,No,1:No,1:No,,0.8
2230,2517161,Table 1,BaselineCharacteristic,Yes,Target SB accessed w/guidewire ; ,x,None,6,4,3,No,1:No,1:No,,0.94
2230,2517161,Table 1,BaselineCharacteristic,Ant,Final LVL location ; ,x,None,6,5,3,No,1:No,1:No,,0.92
2230,2517161,Table 1,BaselineCharacteristic,x.x,Pacing threshold (mV) ; ,x,None,6,6,3,No,1:No,1:No,,0.93
2230,2517161,Table 1,BaselineCharacteristic,x,Patient number ; ,x,None,7,0,2,No,1:No,1:No,,0.893
2230,2517161,Table 1,BaselineCharacteristic,xx,Procedure time (min) ; ,x,None,7,1,3,No,1:No,1:No,,0.856
2230,2517161,Table 1,BaselineCharacteristic,xx.xx,Fluoroscopy time (min) ; ,x,None,7,2,3,No,1:No,1:No,,0.876
2230,2517161,Table 1,BaselineCharacteristic,x.x,LVL fluoroscopy (min) ; ,x,None,7,3,3,No,1:No,1:No,,0.97
2230,2517161,Table 1,BaselineCharacteristic,Yes,Target SB accessed w/guidewire ; ,x,None,7,4,3,No,1:No,1:No,,0.96
2230,2517161,Table 1,BaselineCharacteristic,L,Final LVL location ; ,x,None,7,5,3,No,1:No,1:No,,0.95
2230,2517161,Table 1,BaselineCharacteristic,x,Pacing threshold (mV) ; ,x,None,7,6,3,No,1:No,1:No,,0.96
2230,2517161,Table 1,BaselineCharacteristic,x,Patient number ; ,x,None,8,0,2,No,1:No,1:No,,0.893
2230,2517161,Table 1,BaselineCharacteristic,xxx,Procedure time (min) ; ,x,None,8,1,3,No,1:No,1:No,,0.93
2230,2517161,Table 1,BaselineCharacteristic,xx.x,Fluoroscopy time (min) ; ,x,None,8,2,3,No,1:No,1:No,,0.886
2230,2517161,Table 1,BaselineCharacteristic,x.xx,LVL fluoroscopy (min) ; ,x,None,8,3,3,No,1:No,1:No,,0.84
2230,2517161,Table 1,BaselineCharacteristic,Yes,Target SB accessed w/guidewire ; ,x,None,8,4,3,No,1:No,1:No,,0.97
2230,2517161,Table 1,BaselineCharacteristic,L,Final LVL location ; ,x,None,8,5,3,No,1:No,1:No,,0.97
2230,2517161,Table 1,BaselineCharacteristic,x.x,Pacing threshold (mV) ; ,x,None,8,6,3,No,1:No,1:No,,0.98
2230,2517161,Table 1,BaselineCharacteristic,x,Patient number ; ,x,None,9,0,2,No,1:No,1:No,,0.903
2230,2517161,Table 1,BaselineCharacteristic,xx,Procedure time (min) ; ,x,None,9,1,3,No,1:No,1:No,,0.896
2230,2517161,Table 1,BaselineCharacteristic,xx.x,Fluoroscopy time (min) ; ,x,None,9,2,3,No,1:No,1:No,,0.906
2230,2517161,Table 1,BaselineCharacteristic,x.xx,LVL fluoroscopy (min) ; ,x,None,9,3,3,No,1:No,1:No,,0.87
2230,2517161,Table 1,BaselineCharacteristic,Yes,Target SB accessed w/guidewire ; ,x,None,9,4,3,No,1:No,1:No,,0.99
2230,2517161,Table 1,BaselineCharacteristic,PL,Final LVL location ; ,x,None,9,5,3,No,1:No,1:No,,0.99
2230,2517161,Table 1,BaselineCharacteristic,x.x,Pacing threshold (mV) ; ,x,None,9,6,3,No,1:No,1:No,,1
2230,2517161,Table 1,BaselineCharacteristic,xx,Patient number ; ,xx,None,10,0,2,No,1:No,1:No,,0.859
2230,2517161,Table 1,BaselineCharacteristic,xx,Procedure time (min) ; ,xx,None,10,1,3,No,1:No,1:No,,0.931
2230,2517161,Table 1,BaselineCharacteristic,x.x,Fluoroscopy time (min) ; ,xx,None,10,2,3,No,1:No,1:No,,0.926
2230,2517161,Table 1,BaselineCharacteristic,x.xx,LVL fluoroscopy (min) ; ,xx,None,10,3,3,No,1:No,1:No,,0.89
2230,2517161,Table 1,BaselineCharacteristic,Yes,Target SB accessed w/guidewire ; ,xx,None,10,4,3,No,1:No,1:No,,0.921
2230,2517161,Table 1,BaselineCharacteristic,L,Final LVL location ; ,xx,None,10,5,3,No,1:No,1:No,,0.956
2230,2517161,Table 1,BaselineCharacteristic,x.x,Pacing threshold (mV) ; ,xx,None,10,6,3,No,1:No,1:No,,0.9
2230,2517161,Table 1,BaselineCharacteristic,xx,Patient number ; ,xx,None,11,0,2,No,1:No,1:No,,0.859
2230,2517161,Table 1,BaselineCharacteristic,xx,Procedure time (min) ; ,xx,None,11,1,3,No,1:No,1:No,,0.931
2230,2517161,Table 1,BaselineCharacteristic,xx.xx,Fluoroscopy time (min) ; ,xx,None,11,2,3,No,1:No,1:No,,0.921
2230,2517161,Table 1,BaselineCharacteristic,x.xx,LVL fluoroscopy (min) ; ,xx,None,11,3,3,No,1:No,1:No,,0.89
2230,2517161,Table 1,BaselineCharacteristic,Yes,Target SB accessed w/guidewire ; ,xx,None,11,4,3,No,1:No,1:No,,0.921
2230,2517161,Table 1,BaselineCharacteristic,L,Final LVL location ; ,xx,None,11,5,3,No,1:No,1:No,,0.956
2230,2517161,Table 1,BaselineCharacteristic,x.x,Pacing threshold (mV) ; ,xx,None,11,6,3,No,1:No,1:No,,0.9
2230,2517161,Table 1,BaselineCharacteristic,xx,Patient number ; ,xx,None,12,0,2,No,1:No,1:No,,0.859
2230,2517161,Table 1,BaselineCharacteristic,xxx,Procedure time (min) ; ,xx,None,12,1,3,No,1:No,1:No,,0.861
2230,2517161,Table 1,BaselineCharacteristic,x.xx,Fluoroscopy time (min) ; ,xx,None,12,2,3,No,1:No,1:No,,0.926
2230,2517161,Table 1,BaselineCharacteristic,x.xx,LVL fluoroscopy (min) ; ,xx,None,12,3,3,No,1:No,1:No,,0.89
2230,2517161,Table 1,BaselineCharacteristic,Yes,Target SB accessed w/guidewire ; ,xx,None,12,4,3,No,1:No,1:No,,0.921
2230,2517161,Table 1,BaselineCharacteristic,Ant,Final LVL location ; ,xx,None,12,5,3,No,1:No,1:No,,0.956
2230,2517161,Table 1,BaselineCharacteristic,x.x,Pacing threshold (mV) ; ,xx,None,12,6,3,No,1:No,1:No,,0.9
2230,2517161,Table 1,BaselineCharacteristic,xx,Patient number ; ,xx,None,13,0,2,No,1:No,1:No,,0.859
2230,2517161,Table 1,BaselineCharacteristic,xx,Procedure time (min) ; ,xx,None,13,1,3,No,1:No,1:No,,0.931
2230,2517161,Table 1,BaselineCharacteristic,xx.xx,Fluoroscopy time (min) ; ,xx,None,13,2,3,No,1:No,1:No,,0.921
2230,2517161,Table 1,BaselineCharacteristic,x,LVL fluoroscopy (min) ; ,xx,None,13,3,3,No,1:No,1:No,,0.89
2230,2517161,Table 1,BaselineCharacteristic,Yes,Target SB accessed w/guidewire ; ,xx,None,13,4,3,No,1:No,1:No,,0.921
2230,2517161,Table 1,BaselineCharacteristic,PL,Final LVL location ; ,xx,None,13,5,3,No,1:No,1:No,,0.956
2230,2517161,Table 1,BaselineCharacteristic,x,Pacing threshold (mV) ; ,xx,None,13,6,3,No,1:No,1:No,,0.9
2230,2517161,Table 1,BaselineCharacteristic,xx,Patient number ; ,xx,None,14,0,2,No,1:No,1:No,,0.879
2230,2517161,Table 1,BaselineCharacteristic,xx,Procedure time (min) ; ,xx,None,14,1,3,No,1:No,1:No,,0.951
2230,2517161,Table 1,BaselineCharacteristic,x.x,Fluoroscopy time (min) ; ,xx,None,14,2,3,No,1:No,1:No,,0.946
2230,2517161,Table 1,BaselineCharacteristic,x.xx,LVL fluoroscopy (min) ; ,xx,None,14,3,3,No,1:No,1:No,,0.91
2230,2517161,Table 1,BaselineCharacteristic,Yes,Target SB accessed w/guidewire ; ,xx,None,14,4,3,No,1:No,1:No,,0.931
2230,2517161,Table 1,BaselineCharacteristic,L,Final LVL location ; ,xx,None,14,5,3,No,1:No,1:No,,0.966
2230,2517161,Table 1,BaselineCharacteristic,x.x,Pacing threshold (mV) ; ,xx,None,14,6,3,No,1:No,1:No,,0.91
2230,2517161,Table 1,BaselineCharacteristic,xx,Patient number ; ,xx,None,15,0,2,No,1:No,1:No,,0.879
2230,2517161,Table 1,BaselineCharacteristic,xxx,Procedure time (min) ; ,xx,None,15,1,3,No,1:No,1:No,,0.871
2230,2517161,Table 1,BaselineCharacteristic,xx.xx,Fluoroscopy time (min) ; ,xx,None,15,2,3,No,1:No,1:No,,0.941
2230,2517161,Table 1,BaselineCharacteristic,x.x,LVL fluoroscopy (min) ; ,xx,None,15,3,3,No,1:No,1:No,,0.91
2230,2517161,Table 1,BaselineCharacteristic,Yes,Target SB accessed w/guidewire ; ,xx,None,15,4,3,No,1:No,1:No,,0.931
2230,2517161,Table 1,BaselineCharacteristic,PL,Final LVL location ; ,xx,None,15,5,3,No,1:No,1:No,,0.966
2230,2517161,Table 1,BaselineCharacteristic,x.x,Pacing threshold (mV) ; ,xx,None,15,6,3,No,1:No,1:No,,0.91
2230,2517161,Table 1,BaselineCharacteristic,xx,Patient number ; ,xx,None,16,0,2,No,1:No,1:No,,0.879
2230,2517161,Table 1,BaselineCharacteristic,xxx,Procedure time (min) ; ,xx,None,16,1,3,No,1:No,1:No,,0.871
2230,2517161,Table 1,BaselineCharacteristic,xx,Fluoroscopy time (min) ; ,xx,None,16,2,3,No,1:No,1:No,,0.951
2230,2517161,Table 1,BaselineCharacteristic,x.x,LVL fluoroscopy (min) ; ,xx,None,16,3,3,No,1:No,1:No,,0.92
2230,2517161,Table 1,BaselineCharacteristic,Yes,Target SB accessed w/guidewire ; ,xx,None,16,4,3,No,1:No,1:No,,0.941
2230,2517161,Table 1,BaselineCharacteristic,L,Final LVL location ; ,xx,None,16,5,3,No,1:No,1:No,,0.976
2230,2517161,Table 1,BaselineCharacteristic,x.x,Pacing threshold (mV) ; ,xx,None,16,6,3,No,1:No,1:No,,0.92
2230,2517161,Table 1,BaselineCharacteristic,Mean (SD),Patient number ; ,Mean (SD),None,17,0,2,No,1:No,1:No,,0.832
2230,2517161,Table 1,BaselineCharacteristic,xx.x (xx),Procedure time (min) ; ,Mean (SD),None,17,1,3,No,1:No,1:No,,0.706
2230,2517161,Table 1,BaselineCharacteristic,xx.x (xx),Fluoroscopy time (min) ; ,Mean (SD),None,17,2,3,No,1:No,1:No,,0.706
2230,2517161,Table 1,BaselineCharacteristic,x.x (x.x),LVL fluoroscopy (min) ; ,Mean (SD),None,17,3,3,No,1:No,1:No,,0.83
2230,2517161,Table 1,BaselineCharacteristic,,Target SB accessed w/guidewire ; ,Mean (SD),None,17,4,3,No,1:No,1:No,,0.88
2230,2517161,Table 1,BaselineCharacteristic,,Final LVL location ; ,Mean (SD),None,17,5,3,No,1:No,1:No,,0.89
2230,2517161,Table 1,BaselineCharacteristic,x.x (x),Pacing threshold (mV) ; ,Mean (SD),None,17,6,3,No,1:No,1:No,,0.86
2246,2527821,Table 1,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
2246,2527821,Table 1,BaselineCharacteristic,na (%),,,None,0,1,1,No,1:No,1:No,,0.813
2246,2527821,Table 1,BaselineCharacteristic,Patients, ; ,Patients,,1,0,2,No,1:No,1:No,,0.94
2246,2527821,Table 1,BaselineCharacteristic,xx,na (%) ; ,Patients,,1,1,3,No,1:No,1:No,,0.538
2246,2527821,Table 1,BaselineCharacteristic,Males/females, ; ,Males/females,,3,0,2,No,1:No,1:No,,0.96
2246,2527821,Table 1,BaselineCharacteristic,xx?:?xx,na (%) ; ,Males/females,,3,1,3,No,1:No,1:No,,0.561
2246,2527821,Table 1,BaselineCharacteristic,, ; ,None,None,4,0,2,No,1:No,1:No,,0.97
2246,2527821,Table 1,BaselineCharacteristic,,na (%) ; ,None,None,4,1,3,No,1:No,1:No,,0.73
2246,2527821,Table 1,BaselineCharacteristic,Histological group, ; ,None,None,5,0,24,No,1:No,1:No,,0.915
2246,2527821,Table 1,BaselineCharacteristic,Histological group,na (%) ; ,Histological group,None,5,1,43,No,1:No,1:No,,0.824
2246,2527821,Table 1,BaselineCharacteristic,?DPAM, ; ,?DPAM, Histological group,6,0,2,No,1:No,1:No,,0.96
2246,2527821,Table 1,BaselineCharacteristic,xx (xx),na (%) ; ,?DPAM, Histological group,6,1,3,No,1:No,1:No,,0.67
2246,2527821,Table 1,BaselineCharacteristic,?PMCA-I/D, ; ,?PMCA-I/D, Histological group,7,0,2,No,1:No,1:No,,0.96
2246,2527821,Table 1,BaselineCharacteristic,xx (xx),na (%) ; ,?PMCA-I/D, Histological group,7,1,3,No,1:No,1:No,,0.69
2246,2527821,Table 1,BaselineCharacteristic,?PMCA, ; ,?PMCA, Histological group,8,0,2,No,1:No,1:No,,0.97
2246,2527821,Table 1,BaselineCharacteristic,x,na (%) ; ,?PMCA, Histological group,8,1,3,No,1:No,1:No,,0.94
2246,2527821,Table 1,BaselineCharacteristic,, ; ,None,None,9,0,2,No,1:No,1:No,,1
2246,2527821,Table 1,BaselineCharacteristic,,na (%) ; ,None,None,9,1,3,No,1:No,1:No,,0.88
2246,2527821,Table 1,BaselineCharacteristic,Previous laparotomies, ; ,None,None,10,0,24,No,1:No,1:No,,0.995
2246,2527821,Table 1,BaselineCharacteristic,Previous laparotomies,na (%) ; ,Previous laparotomies,None,10,1,43,No,1:No,1:No,,0.914
2246,2527821,Table 1,BaselineCharacteristic,?No previous laparotomies, ; ,?No previous laparotomies, Previous laparotomies,11,0,2,No,1:No,1:No,,1
2246,2527821,Table 1,BaselineCharacteristic,x,na (%) ; ,?No previous laparotomies, Previous laparotomies,11,1,3,No,1:No,1:No,,0.97
2246,2527821,Table 1,BaselineCharacteristic,?x, ; ,?x, Previous laparotomies,12,0,2,No,1:No,1:No,,0.982
2246,2527821,Table 1,BaselineCharacteristic,xx (xx),na (%) ; ,?x, Previous laparotomies,12,1,3,No,1:No,1:No,,0.816
2246,2527821,Table 1,BaselineCharacteristic,?x, ; ,?x, Previous laparotomies,13,0,2,No,1:No,1:No,,0.982
2246,2527821,Table 1,BaselineCharacteristic,xx (xx),na (%) ; ,?x, Previous laparotomies,13,1,3,No,1:No,1:No,,0.816
2246,2527821,Table 1,BaselineCharacteristic,??x, ; ,??x, Previous laparotomies,14,0,2,No,1:No,1:No,,0.982
2246,2527821,Table 1,BaselineCharacteristic,x,na (%) ; ,??x, Previous laparotomies,14,1,3,No,1:No,1:No,,0.94
2246,2527821,Table 1,BaselineCharacteristic,, ; ,None,None,15,0,2,No,1:No,1:No,,1
2246,2527821,Table 1,BaselineCharacteristic,,na (%) ; ,None,None,15,1,3,No,1:No,1:No,,0.89
2246,2527821,Table 1,BaselineCharacteristic,WHO performance status, ; ,None,None,16,0,24,No,1:No,1:No,,0.995
2246,2527821,Table 1,BaselineCharacteristic,WHO performance status,na (%) ; ,WHO performance status,None,16,1,43,No,1:No,1:No,,0.935
2246,2527821,Table 1,BaselineCharacteristic,?x, ; ,?x, WHO performance status,17,0,2,No,1:No,1:No,,0.982
2246,2527821,Table 1,BaselineCharacteristic,xx (xx),na (%) ; ,?x, WHO performance status,17,1,3,No,1:No,1:No,,0.826
2246,2527821,Table 1,BaselineCharacteristic,?x, ; ,?x, WHO performance status,18,0,2,No,1:No,1:No,,0.972
2246,2527821,Table 1,BaselineCharacteristic,x,na (%) ; ,?x, WHO performance status,18,1,3,No,1:No,1:No,,0.94
2246,2527821,Table 1,BaselineCharacteristic,?x, ; ,?x, WHO performance status,19,0,2,No,1:No,1:No,,0.972
2246,2527821,Table 1,BaselineCharacteristic,x,na (%) ; ,?x, WHO performance status,19,1,3,No,1:No,1:No,,0.93
2269,2551676,TABLE 1,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
2269,2551676,TABLE 1,BaselineCharacteristic,Recipient ,,,None,0,1,1,No,1:No,1:No,,0.913
2269,2551676,TABLE 1,BaselineCharacteristic,Recipient ,,,None,0,2,1,No,1:No,1:No,,0.913
2269,2551676,TABLE 1,BaselineCharacteristic,Recipient ,,,None,0,3,1,No,1:No,1:No,,0.913
2269,2551676,TABLE 1,BaselineCharacteristic,Recipient ,,,None,0,4,1,No,1:No,1:No,,0.923
2269,2551676,TABLE 1,BaselineCharacteristic,Recipient ,,,None,0,5,1,No,1:No,1:No,,0.945
2269,2551676,TABLE 1,BaselineCharacteristic,Recipient ,,,None,0,6,1,No,1:No,1:No,,0.945
2269,2551676,TABLE 1,BaselineCharacteristic,Recipient ,,,None,0,7,1,No,1:No,1:No,,0.955
2269,2551676,TABLE 1,BaselineCharacteristic,, ; ,None,None,1,0,12,No,1:No,1:No,,0.898
2269,2551676,TABLE 1,BaselineCharacteristic,x,Recipient  ; ,,None,1,1,1,No,1:No,1:No,,0.87
2269,2551676,TABLE 1,BaselineCharacteristic,x,Recipient  ; ,,None,1,2,1,No,1:No,1:No,,0.851
2269,2551676,TABLE 1,BaselineCharacteristic,x,Recipient  ; ,,None,1,3,1,No,1:No,1:No,,0.851
2269,2551676,TABLE 1,BaselineCharacteristic,x,Recipient  ; ,,None,1,4,1,No,1:No,1:No,,0.861
2269,2551676,TABLE 1,BaselineCharacteristic,x,Recipient  ; ,,None,1,5,1,No,1:No,1:No,,0.892
2269,2551676,TABLE 1,BaselineCharacteristic,x,Recipient  ; ,,None,1,6,1,No,1:No,1:No,,0.892
2269,2551676,TABLE 1,BaselineCharacteristic,x,Recipient  ; ,,None,1,7,1,No,1:No,1:No,,0.892
2269,2551676,TABLE 1,BaselineCharacteristic,Age (years), ;  ; ,Age (years),None,2,0,2,No,1:No,1:No,,0.65
2269,2551676,TABLE 1,BaselineCharacteristic,xx,Recipient  ; x ; ,Age (years),None,2,5,3,No,1:No,1:No,,0.51
2269,2551676,TABLE 1,BaselineCharacteristic,xx,Recipient  ; x ; ,Age (years),None,2,6,3,No,1:No,1:No,,0.51
2269,2551676,TABLE 1,BaselineCharacteristic,xx,Recipient  ; x ; ,Age (years),None,2,7,3,No,1:No,1:No,,0.51
2269,2551676,TABLE 1,BaselineCharacteristic,Sex, ;  ; ,Sex,None,3,0,2,No,1:No,1:No,,0.96
2269,2551676,TABLE 1,BaselineCharacteristic,F,Recipient  ; x ; ,Sex,None,3,1,3,No,1:No,1:No,,0.95
2269,2551676,TABLE 1,BaselineCharacteristic,F,Recipient  ; x ; ,Sex,None,3,2,3,No,1:No,1:No,,0.96
2269,2551676,TABLE 1,BaselineCharacteristic,F,Recipient  ; x ; ,Sex,None,3,3,3,No,1:No,1:No,,0.96
2269,2551676,TABLE 1,BaselineCharacteristic,M,Recipient  ; x ; ,Sex,None,3,4,3,No,1:No,1:No,,0.95
2269,2551676,TABLE 1,BaselineCharacteristic,M,Recipient  ; x ; ,Sex,None,3,5,3,No,1:No,1:No,,0.95
2269,2551676,TABLE 1,BaselineCharacteristic,M,Recipient  ; x ; ,Sex,None,3,6,3,No,1:No,1:No,,0.96
2269,2551676,TABLE 1,BaselineCharacteristic,F,Recipient  ; x ; ,Sex,None,3,7,3,No,1:No,1:No,,0.95
2269,2551676,TABLE 1,BaselineCharacteristic,Body weight (kg), ;  ; ,Body weight (kg),None,4,0,2,No,1:No,1:No,,0.97
2269,2551676,TABLE 1,BaselineCharacteristic,xx,Recipient  ; x ; ,Body weight (kg),None,4,1,3,No,1:No,1:No,,0.756
2269,2551676,TABLE 1,BaselineCharacteristic,xx,Recipient  ; x ; ,Body weight (kg),None,4,2,3,No,1:No,1:No,,0.766
2269,2551676,TABLE 1,BaselineCharacteristic,xx,Recipient  ; x ; ,Body weight (kg),None,4,3,3,No,1:No,1:No,,0.746
2269,2551676,TABLE 1,BaselineCharacteristic,xx,Recipient  ; x ; ,Body weight (kg),None,4,4,3,No,1:No,1:No,,0.766
2269,2551676,TABLE 1,BaselineCharacteristic,xx,Recipient  ; x ; ,Body weight (kg),None,4,5,3,No,1:No,1:No,,0.78
2269,2551676,TABLE 1,BaselineCharacteristic,xx,Recipient  ; x ; ,Body weight (kg),None,4,6,3,No,1:No,1:No,,0.78
2269,2551676,TABLE 1,BaselineCharacteristic,xx,Recipient  ; x ; ,Body weight (kg),None,4,7,3,No,1:No,1:No,,0.79
2269,2551676,TABLE 1,BaselineCharacteristic,BMI (kg/mx), ;  ; ,BMI (kg/mx),None,5,0,2,No,1:No,1:No,,0.98
2269,2551676,TABLE 1,BaselineCharacteristic,xx.x,Recipient  ; x ; ,BMI (kg/mx),None,5,1,3,No,1:No,1:No,,0.826
2269,2551676,TABLE 1,BaselineCharacteristic,xx.x,Recipient  ; x ; ,BMI (kg/mx),None,5,2,3,No,1:No,1:No,,0.836
2269,2551676,TABLE 1,BaselineCharacteristic,xx.x,Recipient  ; x ; ,BMI (kg/mx),None,5,3,3,No,1:No,1:No,,0.816
2269,2551676,TABLE 1,BaselineCharacteristic,xx.x,Recipient  ; x ; ,BMI (kg/mx),None,5,4,3,No,1:No,1:No,,0.836
2269,2551676,TABLE 1,BaselineCharacteristic,xx.x,Recipient  ; x ; ,BMI (kg/mx),None,5,5,3,No,1:No,1:No,,0.82
2269,2551676,TABLE 1,BaselineCharacteristic,xx.x,Recipient  ; x ; ,BMI (kg/mx),None,5,6,3,No,1:No,1:No,,0.82
2269,2551676,TABLE 1,BaselineCharacteristic,xx.x,Recipient  ; x ; ,BMI (kg/mx),None,5,7,3,No,1:No,1:No,,0.82
2269,2551676,TABLE 1,BaselineCharacteristic,Diabetes duration (years), ;  ; ,Diabetes duration (years),None,6,0,2,No,1:No,1:No,,0.71
2269,2551676,TABLE 1,BaselineCharacteristic,xx,Recipient  ; x ; ,Diabetes duration (years),None,6,1,3,No,1:No,1:No,,0.52
2269,2551676,TABLE 1,BaselineCharacteristic,xx,Recipient  ; x ; ,Diabetes duration (years),None,6,2,3,No,1:No,1:No,,0.56
2269,2551676,TABLE 1,BaselineCharacteristic,xx,Recipient  ; x ; ,Diabetes duration (years),None,6,3,3,No,1:No,1:No,,0.55
2269,2551676,TABLE 1,BaselineCharacteristic,xx,Recipient  ; x ; ,Diabetes duration (years),None,6,4,3,No,1:No,1:No,,0.58
2269,2551676,TABLE 1,BaselineCharacteristic,xx,Recipient  ; x ; ,Diabetes duration (years),None,6,5,3,No,1:No,1:No,,0.59
2269,2551676,TABLE 1,BaselineCharacteristic,x,Recipient  ; x ; ,Diabetes duration (years),None,6,6,3,No,1:No,1:No,,0.71
2269,2551676,TABLE 1,BaselineCharacteristic,xx,Recipient  ; x ; ,Diabetes duration (years),None,6,7,3,No,1:No,1:No,,0.59
2269,2551676,TABLE 1,BaselineCharacteristic,Daily insulin (IU/day), ;  ; ,Daily insulin (IU/day),None,7,0,2,No,1:No,1:No,,0.99
2269,2551676,TABLE 1,BaselineCharacteristic,xx,Recipient  ; x ; ,Daily insulin (IU/day),None,7,1,3,No,1:No,1:No,,0.806
2269,2551676,TABLE 1,BaselineCharacteristic,xx,Recipient  ; x ; ,Daily insulin (IU/day),None,7,2,3,No,1:No,1:No,,0.826
2269,2551676,TABLE 1,BaselineCharacteristic,xx,Recipient  ; x ; ,Daily insulin (IU/day),None,7,3,3,No,1:No,1:No,,0.806
2269,2551676,TABLE 1,BaselineCharacteristic,xx,Recipient  ; x ; ,Daily insulin (IU/day),None,7,4,3,No,1:No,1:No,,0.836
2269,2551676,TABLE 1,BaselineCharacteristic,xx,Recipient  ; x ; ,Daily insulin (IU/day),None,7,5,3,No,1:No,1:No,,0.84
2269,2551676,TABLE 1,BaselineCharacteristic,xx,Recipient  ; x ; ,Daily insulin (IU/day),None,7,6,3,No,1:No,1:No,,0.84
2269,2551676,TABLE 1,BaselineCharacteristic,xx,Recipient  ; x ; ,Daily insulin (IU/day),None,7,7,3,No,1:No,1:No,,0.85
2269,2551676,TABLE 1,BaselineCharacteristic,AxC (%), ;  ; ,AxC (%),None,8,0,2,No,1:No,1:No,,0.94
2269,2551676,TABLE 1,BaselineCharacteristic,x.x,Recipient  ; x ; ,AxC (%),None,8,1,3,No,1:No,1:No,,0.92
2269,2551676,TABLE 1,BaselineCharacteristic,x.x,Recipient  ; x ; ,AxC (%),None,8,2,3,No,1:No,1:No,,0.93
2269,2551676,TABLE 1,BaselineCharacteristic,x.x,Recipient  ; x ; ,AxC (%),None,8,3,3,No,1:No,1:No,,0.93
2269,2551676,TABLE 1,BaselineCharacteristic,x.x,Recipient  ; x ; ,AxC (%),None,8,4,3,No,1:No,1:No,,0.92
2269,2551676,TABLE 1,BaselineCharacteristic,x.x,Recipient  ; x ; ,AxC (%),None,8,5,3,No,1:No,1:No,,0.92
2269,2551676,TABLE 1,BaselineCharacteristic,xx.x,Recipient  ; x ; ,AxC (%),None,8,6,3,No,1:No,1:No,,0.8
2269,2551676,TABLE 1,BaselineCharacteristic,x.x,Recipient  ; x ; ,AxC (%),None,8,7,3,No,1:No,1:No,,0.92
2269,2551676,TABLE 1,BaselineCharacteristic,Baseline glucose level (mmol/l), ;  ; ,Baseline glucose level (mmol/l),None,9,0,2,No,1:No,1:No,,1
2269,2551676,TABLE 1,BaselineCharacteristic,x.x,Recipient  ; x ; ,Baseline glucose level (mmol/l),None,9,1,3,No,1:No,1:No,,0.98
2269,2551676,TABLE 1,BaselineCharacteristic,x.x,Recipient  ; x ; ,Baseline glucose level (mmol/l),None,9,2,3,No,1:No,1:No,,0.99
2269,2551676,TABLE 1,BaselineCharacteristic,x.x,Recipient  ; x ; ,Baseline glucose level (mmol/l),None,9,3,3,No,1:No,1:No,,0.99
2269,2551676,TABLE 1,BaselineCharacteristic,x.x,Recipient  ; x ; ,Baseline glucose level (mmol/l),None,9,4,3,No,1:No,1:No,,0.99
2269,2551676,TABLE 1,BaselineCharacteristic,x.x,Recipient  ; x ; ,Baseline glucose level (mmol/l),None,9,5,3,No,1:No,1:No,,0.99
2269,2551676,TABLE 1,BaselineCharacteristic,x.x,Recipient  ; x ; ,Baseline glucose level (mmol/l),None,9,6,3,No,1:No,1:No,,1
2269,2551676,TABLE 1,BaselineCharacteristic,x.x,Recipient  ; x ; ,Baseline glucose level (mmol/l),None,9,7,3,No,1:No,1:No,,0.99
2269,2551676,TABLE 1,BaselineCharacteristic,Hemodialysis (months), ;  ; ,Hemodialysis (months),None,10,0,2,No,1:No,1:No,,1
2269,2551676,TABLE 1,BaselineCharacteristic,x,Recipient  ; x ; ,Hemodialysis (months),None,10,1,3,No,1:No,1:No,,1
2269,2551676,TABLE 1,BaselineCharacteristic,x,Recipient  ; x ; ,Hemodialysis (months),None,10,2,3,No,1:No,1:No,,1
2269,2551676,TABLE 1,BaselineCharacteristic,xx,Recipient  ; x ; ,Hemodialysis (months),None,10,3,3,No,1:No,1:No,,0.876
2269,2551676,TABLE 1,BaselineCharacteristic,x,Recipient  ; x ; ,Hemodialysis (months),None,10,4,3,No,1:No,1:No,,1
2269,2551676,TABLE 1,BaselineCharacteristic,x,Recipient  ; x ; ,Hemodialysis (months),None,10,5,3,No,1:No,1:No,,1
2269,2551676,TABLE 1,BaselineCharacteristic,xx,Recipient  ; x ; ,Hemodialysis (months),None,10,6,3,No,1:No,1:No,,0.92
2269,2551676,TABLE 1,BaselineCharacteristic,x,Recipient  ; x ; ,Hemodialysis (months),None,10,7,3,No,1:No,1:No,,0.99
2269,2551676,TABLE 1,BaselineCharacteristic,Serum creatinine (?mol/l), ;  ; ,Serum creatinine (?mol/l),None,11,0,2,No,1:No,1:No,,1
2269,2551676,TABLE 1,BaselineCharacteristic,xxx,Recipient  ; x ; ,Serum creatinine (?mol/l),None,11,1,3,No,1:No,1:No,,0.96
2269,2551676,TABLE 1,BaselineCharacteristic,xxx,Recipient  ; x ; ,Serum creatinine (?mol/l),None,11,2,3,No,1:No,1:No,,0.96
2269,2551676,TABLE 1,BaselineCharacteristic,xxx,Recipient  ; x ; ,Serum creatinine (?mol/l),None,11,3,3,No,1:No,1:No,,0.96
2269,2551676,TABLE 1,BaselineCharacteristic,xxx,Recipient  ; x ; ,Serum creatinine (?mol/l),None,11,4,3,No,1:No,1:No,,0.97
2269,2551676,TABLE 1,BaselineCharacteristic,xxx,Recipient  ; x ; ,Serum creatinine (?mol/l),None,11,5,3,No,1:No,1:No,,0.97
2269,2551676,TABLE 1,BaselineCharacteristic,xxx,Recipient  ; x ; ,Serum creatinine (?mol/l),None,11,6,3,No,1:No,1:No,,0.97
2269,2551676,TABLE 1,BaselineCharacteristic,xxx,Recipient  ; x ; ,Serum creatinine (?mol/l),None,11,7,3,No,1:No,1:No,,0.96
2269,2551676,TABLE 1,BaselineCharacteristic,Panel reactive antibodies (%), ;  ; ,Panel reactive antibodies (%),None,12,0,2,No,1:No,1:No,,0.96
2269,2551676,TABLE 1,BaselineCharacteristic,x,Recipient  ; x ; ,Panel reactive antibodies (%),None,12,1,3,No,1:No,1:No,,0.95
2269,2551676,TABLE 1,BaselineCharacteristic,x,Recipient  ; x ; ,Panel reactive antibodies (%),None,12,2,3,No,1:No,1:No,,0.95
2269,2551676,TABLE 1,BaselineCharacteristic,x.x,Recipient  ; x ; ,Panel reactive antibodies (%),None,12,3,3,No,1:No,1:No,,0.95
2269,2551676,TABLE 1,BaselineCharacteristic,x,Recipient  ; x ; ,Panel reactive antibodies (%),None,12,4,3,No,1:No,1:No,,0.94
2269,2551676,TABLE 1,BaselineCharacteristic,x.x,Recipient  ; x ; ,Panel reactive antibodies (%),None,12,5,3,No,1:No,1:No,,0.94
2269,2551676,TABLE 1,BaselineCharacteristic,x,Recipient  ; x ; ,Panel reactive antibodies (%),None,12,6,3,No,1:No,1:No,,0.94
2269,2551676,TABLE 1,BaselineCharacteristic,x.x,Recipient  ; x ; ,Panel reactive antibodies (%),None,12,7,3,No,1:No,1:No,,0.93
2269,2551676,TABLE 1,BaselineCharacteristic,"HLA mismatch* (A, B, DR)", ;  ; ,"HLA mismatch* (A, B, DR)",None,13,0,2,No,1:No,1:No,,1
2269,2551676,TABLE 1,BaselineCharacteristic,x,Recipient  ; x ; ,"HLA mismatch* (A, B, DR)",None,13,1,3,No,1:No,1:No,,1
2269,2551676,TABLE 1,BaselineCharacteristic,x,Recipient  ; x ; ,"HLA mismatch* (A, B, DR)",None,13,2,3,No,1:No,1:No,,1
2269,2551676,TABLE 1,BaselineCharacteristic,x,Recipient  ; x ; ,"HLA mismatch* (A, B, DR)",None,13,3,3,No,1:No,1:No,,1
2269,2551676,TABLE 1,BaselineCharacteristic,x,Recipient  ; x ; ,"HLA mismatch* (A, B, DR)",None,13,4,3,No,1:No,1:No,,1
2269,2551676,TABLE 1,BaselineCharacteristic,x,Recipient  ; x ; ,"HLA mismatch* (A, B, DR)",None,13,5,3,No,1:No,1:No,,1
2269,2551676,TABLE 1,BaselineCharacteristic,x,Recipient  ; x ; ,"HLA mismatch* (A, B, DR)",None,13,6,3,No,1:No,1:No,,1
2269,2551676,TABLE 1,BaselineCharacteristic,x,Recipient  ; x ; ,"HLA mismatch* (A, B, DR)",None,13,7,3,No,1:No,1:No,,0.99
2269,2551676,TABLE 2,BaselineCharacteristic,Patient and infusion procedure no.,,None,None,0,0,12,No,1:No,1:No,,0.88
2269,2551676,TABLE 2,BaselineCharacteristic,Age (years),,Patient and infusion procedure no.,None,0,1,1,No,1:No,1:No,,0.608
2269,2551676,TABLE 2,BaselineCharacteristic,BMI (kg/mx),,Patient and infusion procedure no.,None,0,2,1,No,1:No,1:No,,0.908
2269,2551676,TABLE 2,BaselineCharacteristic,Duration of cold ischemia (hours),,Patient and infusion procedure no.,None,0,3,1,No,1:No,1:No,,0.898
2269,2551676,TABLE 2,BaselineCharacteristic,Weight of pancreas (g),,Patient and infusion procedure no.,None,0,4,1,No,1:No,1:No,,0.868
2269,2551676,TABLE 2,BaselineCharacteristic,Islet yield (IEQ),,Patient and infusion procedure no.,None,0,5,1,No,1:No,1:No,,0.898
2269,2551676,TABLE 2,BaselineCharacteristic,Islet viability (%),,Patient and infusion procedure no.,None,0,6,1,No,1:No,1:No,,0.846
2269,2551676,TABLE 2,BaselineCharacteristic,Stimulus index,,Patient and infusion procedure no.,None,0,7,1,No,1:No,1:No,,0.908
2269,2551676,TABLE 2,BaselineCharacteristic,Cross-match (%),,Patient and infusion procedure no.,None,0,8,1,No,1:No,1:No,,0.846
2269,2551676,TABLE 2,BaselineCharacteristic,Patient x,Patient and infusion procedure no. ; ,None,None,1,0,24,No,1:No,1:No,,0.912
2269,2551676,TABLE 2,BaselineCharacteristic,,Age (years) ; ,Patient x,None,1,1,43,No,1:No,1:No,,0.614
2269,2551676,TABLE 2,BaselineCharacteristic,,BMI (kg/mx) ; ,Patient x,None,1,2,43,No,1:No,1:No,,0.886
2269,2551676,TABLE 2,BaselineCharacteristic,,Duration of cold ischemia (hours) ; ,Patient x,None,1,3,43,No,1:No,1:No,,0.865
2269,2551676,TABLE 2,BaselineCharacteristic,,Weight of pancreas (g) ; ,Patient x,None,1,4,43,No,1:No,1:No,,0.77
2269,2551676,TABLE 2,BaselineCharacteristic,,Islet yield (IEQ) ; ,Patient x,None,1,5,43,No,1:No,1:No,,0.865
2269,2551676,TABLE 2,BaselineCharacteristic,,Islet viability (%) ; ,Patient x,None,1,6,43,No,1:No,1:No,,0.761
2269,2551676,TABLE 2,BaselineCharacteristic,,Stimulus index ; ,Patient x,None,1,7,43,No,1:No,1:No,,0.865
2269,2551676,TABLE 2,BaselineCharacteristic,,Cross-match (%) ; ,Patient x,None,1,8,43,No,1:No,1:No,,0.751
2269,2551676,TABLE 2,BaselineCharacteristic,????x,Patient and infusion procedure no. ; ,????x, Patient x   ,2,0,2,No,1:No,1:No,,0.938
2269,2551676,TABLE 2,BaselineCharacteristic,xx,BMI (kg/mx) ; ,????x, Patient x   ,2,2,3,No,1:No,1:No,,0.772
2269,2551676,TABLE 2,BaselineCharacteristic,x,Duration of cold ischemia (hours) ; ,????x, Patient x   ,2,3,3,No,1:No,1:No,,0.91
2269,2551676,TABLE 2,BaselineCharacteristic,xx.x,Weight of pancreas (g) ; ,????x, Patient x   ,2,4,3,No,1:No,1:No,,0.622
2269,2551676,TABLE 2,BaselineCharacteristic,"xxx,xxx",Islet yield (IEQ) ; ,????x, Patient x   ,2,5,3,No,1:No,1:No,,0.84
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Islet viability (%) ; ,????x, Patient x   ,2,6,3,No,1:No,1:No,,0.606
2269,2551676,TABLE 2,BaselineCharacteristic,x.xx,Stimulus index ; ,????x, Patient x   ,2,7,3,No,1:No,1:No,,0.696
2269,2551676,TABLE 2,BaselineCharacteristic,x,Cross-match (%) ; ,????x, Patient x   ,2,8,3,No,1:No,1:No,,0.77
2269,2551676,TABLE 2,BaselineCharacteristic,????x*,Patient and infusion procedure no. ; ,????x*, Patient x   ,3,0,2,No,1:No,1:No,,0.938
2269,2551676,TABLE 2,BaselineCharacteristic,xx.x,BMI (kg/mx) ; ,????x*, Patient x   ,3,2,3,No,1:No,1:No,,0.786
2269,2551676,TABLE 2,BaselineCharacteristic,x,Duration of cold ischemia (hours) ; ,????x*, Patient x   ,3,3,3,No,1:No,1:No,,0.93
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Weight of pancreas (g) ; ,????x*, Patient x   ,3,4,3,No,1:No,1:No,,0.646
2269,2551676,TABLE 2,BaselineCharacteristic,"xxx,xxx",Islet yield (IEQ) ; ,????x*, Patient x   ,3,5,3,No,1:No,1:No,,0.86
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Islet viability (%) ; ,????x*, Patient x   ,3,6,3,No,1:No,1:No,,0.62
2269,2551676,TABLE 2,BaselineCharacteristic,x.xx,Stimulus index ; ,????x*, Patient x   ,3,7,3,No,1:No,1:No,,0.71
2269,2551676,TABLE 2,BaselineCharacteristic,x,Cross-match (%) ; ,????x*, Patient x   ,3,8,3,No,1:No,1:No,,0.82
2269,2551676,TABLE 2,BaselineCharacteristic,????x*,Patient and infusion procedure no. ; ,????x*, Patient x   ,4,0,2,No,1:No,1:No,,0.938
2269,2551676,TABLE 2,BaselineCharacteristic,xx.x,BMI (kg/mx) ; ,????x*, Patient x   ,4,2,3,No,1:No,1:No,,0.836
2269,2551676,TABLE 2,BaselineCharacteristic,x,Duration of cold ischemia (hours) ; ,????x*, Patient x   ,4,3,3,No,1:No,1:No,,0.93
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Weight of pancreas (g) ; ,????x*, Patient x   ,4,4,3,No,1:No,1:No,,0.716
2269,2551676,TABLE 2,BaselineCharacteristic,"xxx,xxx",Islet yield (IEQ) ; ,????x*, Patient x   ,4,5,3,No,1:No,1:No,,0.85
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Islet viability (%) ; ,????x*, Patient x   ,4,6,3,No,1:No,1:No,,0.7
2269,2551676,TABLE 2,BaselineCharacteristic,x.xx,Stimulus index ; ,????x*, Patient x   ,4,7,3,No,1:No,1:No,,0.8
2269,2551676,TABLE 2,BaselineCharacteristic,x,Cross-match (%) ; ,????x*, Patient x   ,4,8,3,No,1:No,1:No,,0.83
2269,2551676,TABLE 2,BaselineCharacteristic,????x,Patient and infusion procedure no. ; ,????x, Patient x   ,5,0,2,No,1:No,1:No,,0.936
2269,2551676,TABLE 2,BaselineCharacteristic,xx.x,BMI (kg/mx) ; ,????x, Patient x   ,5,2,3,No,1:No,1:No,,0.826
2269,2551676,TABLE 2,BaselineCharacteristic,x.xx,Duration of cold ischemia (hours) ; ,????x, Patient x   ,5,3,3,No,1:No,1:No,,0.756
2269,2551676,TABLE 2,BaselineCharacteristic,xxx.x,Weight of pancreas (g) ; ,????x, Patient x   ,5,4,3,No,1:No,1:No,,0.81
2269,2551676,TABLE 2,BaselineCharacteristic,"xxx,xxx",Islet yield (IEQ) ; ,????x, Patient x   ,5,5,3,No,1:No,1:No,,0.84
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Islet viability (%) ; ,????x, Patient x   ,5,6,3,No,1:No,1:No,,0.67
2269,2551676,TABLE 2,BaselineCharacteristic,x.xx,Stimulus index ; ,????x, Patient x   ,5,7,3,No,1:No,1:No,,0.77
2269,2551676,TABLE 2,BaselineCharacteristic,x,Cross-match (%) ; ,????x, Patient x   ,5,8,3,No,1:No,1:No,,0.79
2269,2551676,TABLE 2,BaselineCharacteristic,Patient x,Patient and infusion procedure no. ; ,None,None,6,0,24,No,1:No,1:No,,0.967
2269,2551676,TABLE 2,BaselineCharacteristic,,Age (years) ; ,Patient x,None,6,1,43,No,1:No,1:No,,0.644
2269,2551676,TABLE 2,BaselineCharacteristic,,BMI (kg/mx) ; ,Patient x,None,6,2,43,No,1:No,1:No,,0.948
2269,2551676,TABLE 2,BaselineCharacteristic,,Duration of cold ischemia (hours) ; ,Patient x,None,6,3,43,No,1:No,1:No,,0.932
2269,2551676,TABLE 2,BaselineCharacteristic,,Weight of pancreas (g) ; ,Patient x,None,6,4,43,No,1:No,1:No,,0.837
2269,2551676,TABLE 2,BaselineCharacteristic,,Islet yield (IEQ) ; ,Patient x,None,6,5,43,No,1:No,1:No,,0.902
2269,2551676,TABLE 2,BaselineCharacteristic,,Islet viability (%) ; ,Patient x,None,6,6,43,No,1:No,1:No,,0.829
2269,2551676,TABLE 2,BaselineCharacteristic,,Stimulus index ; ,Patient x,None,6,7,43,No,1:No,1:No,,0.902
2269,2551676,TABLE 2,BaselineCharacteristic,,Cross-match (%) ; ,Patient x,None,6,8,43,No,1:No,1:No,,0.824
2269,2551676,TABLE 2,BaselineCharacteristic,????x,Patient and infusion procedure no. ; ,????x, Patient x   ,7,0,2,No,1:No,1:No,,0.956
2269,2551676,TABLE 2,BaselineCharacteristic,xx.x,BMI (kg/mx) ; ,????x, Patient x   ,7,2,3,No,1:No,1:No,,0.876
2269,2551676,TABLE 2,BaselineCharacteristic,x.x,Duration of cold ischemia (hours) ; ,????x, Patient x   ,7,3,3,No,1:No,1:No,,0.95
2269,2551676,TABLE 2,BaselineCharacteristic,xx.x,Weight of pancreas (g) ; ,????x, Patient x   ,7,4,3,No,1:No,1:No,,0.746
2269,2551676,TABLE 2,BaselineCharacteristic,"xxx,xxx",Islet yield (IEQ) ; ,????x, Patient x   ,7,5,3,No,1:No,1:No,,0.9
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Islet viability (%) ; ,????x, Patient x   ,7,6,3,No,1:No,1:No,,0.79
2269,2551676,TABLE 2,BaselineCharacteristic,x.xx,Stimulus index ; ,????x, Patient x   ,7,7,3,No,1:No,1:No,,0.83
2269,2551676,TABLE 2,BaselineCharacteristic,x,Cross-match (%) ; ,????x, Patient x   ,7,8,3,No,1:No,1:No,,0.91
2269,2551676,TABLE 2,BaselineCharacteristic,????x*,Patient and infusion procedure no. ; ,????x*, Patient x   ,8,0,2,No,1:No,1:No,,0.956
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Age (years) ; ,????x*, Patient x   ,8,1,3,No,1:No,1:No,,0.55
2269,2551676,TABLE 2,BaselineCharacteristic,xx.x,BMI (kg/mx) ; ,????x*, Patient x   ,8,2,3,No,1:No,1:No,,0.896
2269,2551676,TABLE 2,BaselineCharacteristic,x,Duration of cold ischemia (hours) ; ,????x*, Patient x   ,8,3,3,No,1:No,1:No,,0.96
2269,2551676,TABLE 2,BaselineCharacteristic,xx.x,Weight of pancreas (g) ; ,????x*, Patient x   ,8,4,3,No,1:No,1:No,,0.766
2269,2551676,TABLE 2,BaselineCharacteristic,"xxx,xxx",Islet yield (IEQ) ; ,????x*, Patient x   ,8,5,3,No,1:No,1:No,,0.93
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Islet viability (%) ; ,????x*, Patient x   ,8,6,3,No,1:No,1:No,,0.83
2269,2551676,TABLE 2,BaselineCharacteristic,x.xx,Stimulus index ; ,????x*, Patient x   ,8,7,3,No,1:No,1:No,,0.87
2269,2551676,TABLE 2,BaselineCharacteristic,x,Cross-match (%) ; ,????x*, Patient x   ,8,8,3,No,1:No,1:No,,0.94
2269,2551676,TABLE 2,BaselineCharacteristic,????x*,Patient and infusion procedure no. ; ,????x*, Patient x   ,9,0,2,No,1:No,1:No,,0.956
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Age (years) ; ,????x*, Patient x   ,9,1,3,No,1:No,1:No,,0.58
2269,2551676,TABLE 2,BaselineCharacteristic,xx.x,BMI (kg/mx) ; ,????x*, Patient x   ,9,2,3,No,1:No,1:No,,0.926
2269,2551676,TABLE 2,BaselineCharacteristic,x.x,Duration of cold ischemia (hours) ; ,????x*, Patient x   ,9,3,3,No,1:No,1:No,,0.97
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Weight of pancreas (g) ; ,????x*, Patient x   ,9,4,3,No,1:No,1:No,,0.796
2269,2551676,TABLE 2,BaselineCharacteristic,"xxx,xxx",Islet yield (IEQ) ; ,????x*, Patient x   ,9,5,3,No,1:No,1:No,,0.95
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Islet viability (%) ; ,????x*, Patient x   ,9,6,3,No,1:No,1:No,,0.86
2269,2551676,TABLE 2,BaselineCharacteristic,x.xx,Stimulus index ; ,????x*, Patient x   ,9,7,3,No,1:No,1:No,,0.9
2269,2551676,TABLE 2,BaselineCharacteristic,x,Cross-match (%) ; ,????x*, Patient x   ,9,8,3,No,1:No,1:No,,0.97
2269,2551676,TABLE 2,BaselineCharacteristic,Patient x,Patient and infusion procedure no. ; ,None,None,10,0,24,No,1:No,1:No,,0.958
2269,2551676,TABLE 2,BaselineCharacteristic,,Age (years) ; ,Patient x,None,10,1,43,No,1:No,1:No,,0.714
2269,2551676,TABLE 2,BaselineCharacteristic,,BMI (kg/mx) ; ,Patient x,None,10,2,43,No,1:No,1:No,,0.973
2269,2551676,TABLE 2,BaselineCharacteristic,,Duration of cold ischemia (hours) ; ,Patient x,None,10,3,43,No,1:No,1:No,,0.963
2269,2551676,TABLE 2,BaselineCharacteristic,,Weight of pancreas (g) ; ,Patient x,None,10,4,43,No,1:No,1:No,,0.908
2269,2551676,TABLE 2,BaselineCharacteristic,,Islet yield (IEQ) ; ,Patient x,None,10,5,43,No,1:No,1:No,,0.973
2269,2551676,TABLE 2,BaselineCharacteristic,,Islet viability (%) ; ,Patient x,None,10,6,43,No,1:No,1:No,,0.92
2269,2551676,TABLE 2,BaselineCharacteristic,,Stimulus index ; ,Patient x,None,10,7,43,No,1:No,1:No,,0.963
2269,2551676,TABLE 2,BaselineCharacteristic,,Cross-match (%) ; ,Patient x,None,10,8,43,No,1:No,1:No,,0.92
2269,2551676,TABLE 2,BaselineCharacteristic,????x,Patient and infusion procedure no. ; ,????x, Patient x   ,11,0,2,No,1:No,1:No,,0.946
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Age (years) ; ,????x, Patient x   ,11,1,3,No,1:No,1:No,,0.65
2269,2551676,TABLE 2,BaselineCharacteristic,xx,BMI (kg/mx) ; ,????x, Patient x   ,11,2,3,No,1:No,1:No,,0.946
2269,2551676,TABLE 2,BaselineCharacteristic,x,Duration of cold ischemia (hours) ; ,????x, Patient x   ,11,3,3,No,1:No,1:No,,0.98
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Weight of pancreas (g) ; ,????x, Patient x   ,11,4,3,No,1:No,1:No,,0.826
2269,2551676,TABLE 2,BaselineCharacteristic,"xxx,xxx",Islet yield (IEQ) ; ,????x, Patient x   ,11,5,3,No,1:No,1:No,,0.97
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Islet viability (%) ; ,????x, Patient x   ,11,6,3,No,1:No,1:No,,0.87
2269,2551676,TABLE 2,BaselineCharacteristic,x.xx,Stimulus index ; ,????x, Patient x   ,11,7,3,No,1:No,1:No,,0.91
2269,2551676,TABLE 2,BaselineCharacteristic,x,Cross-match (%) ; ,????x, Patient x   ,11,8,3,No,1:No,1:No,,0.95
2269,2551676,TABLE 2,BaselineCharacteristic,Patient x,Patient and infusion procedure no. ; ,None,None,12,0,24,No,1:No,1:No,,0.958
2269,2551676,TABLE 2,BaselineCharacteristic,,Age (years) ; ,Patient x,None,12,1,43,No,1:No,1:No,,0.734
2269,2551676,TABLE 2,BaselineCharacteristic,,BMI (kg/mx) ; ,Patient x,None,12,2,43,No,1:No,1:No,,0.973
2269,2551676,TABLE 2,BaselineCharacteristic,,Duration of cold ischemia (hours) ; ,Patient x,None,12,3,43,No,1:No,1:No,,0.963
2269,2551676,TABLE 2,BaselineCharacteristic,,Weight of pancreas (g) ; ,Patient x,None,12,4,43,No,1:No,1:No,,0.908
2269,2551676,TABLE 2,BaselineCharacteristic,,Islet yield (IEQ) ; ,Patient x,None,12,5,43,No,1:No,1:No,,0.973
2269,2551676,TABLE 2,BaselineCharacteristic,,Islet viability (%) ; ,Patient x,None,12,6,43,No,1:No,1:No,,0.92
2269,2551676,TABLE 2,BaselineCharacteristic,,Stimulus index ; ,Patient x,None,12,7,43,No,1:No,1:No,,0.963
2269,2551676,TABLE 2,BaselineCharacteristic,,Cross-match (%) ; ,Patient x,None,12,8,43,No,1:No,1:No,,0.92
2269,2551676,TABLE 2,BaselineCharacteristic,????x*,Patient and infusion procedure no. ; ,????x*, Patient x   ,13,0,2,No,1:No,1:No,,0.946
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Age (years) ; ,????x*, Patient x   ,13,1,3,No,1:No,1:No,,0.69
2269,2551676,TABLE 2,BaselineCharacteristic,xx.x,BMI (kg/mx) ; ,????x*, Patient x   ,13,2,3,No,1:No,1:No,,0.946
2269,2551676,TABLE 2,BaselineCharacteristic,x,Duration of cold ischemia (hours) ; ,????x*, Patient x   ,13,3,3,No,1:No,1:No,,0.98
2269,2551676,TABLE 2,BaselineCharacteristic,xxx.x,Weight of pancreas (g) ; ,????x*, Patient x   ,13,4,3,No,1:No,1:No,,0.88
2269,2551676,TABLE 2,BaselineCharacteristic,"xxx,xxx",Islet yield (IEQ) ; ,????x*, Patient x   ,13,5,3,No,1:No,1:No,,0.97
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Islet viability (%) ; ,????x*, Patient x   ,13,6,3,No,1:No,1:No,,0.89
2269,2551676,TABLE 2,BaselineCharacteristic,x.xx,Stimulus index ; ,????x*, Patient x   ,13,7,3,No,1:No,1:No,,0.92
2269,2551676,TABLE 2,BaselineCharacteristic,x,Cross-match (%) ; ,????x*, Patient x   ,13,8,3,No,1:No,1:No,,0.97
2269,2551676,TABLE 2,BaselineCharacteristic,????x*,Patient and infusion procedure no. ; ,????x*, Patient x   ,14,0,2,No,1:No,1:No,,0.936
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Age (years) ; ,????x*, Patient x   ,14,1,3,No,1:No,1:No,,0.7
2269,2551676,TABLE 2,BaselineCharacteristic,xx.x,BMI (kg/mx) ; ,????x*, Patient x   ,14,2,3,No,1:No,1:No,,0.956
2269,2551676,TABLE 2,BaselineCharacteristic,xx.x,Duration of cold ischemia (hours) ; ,????x*, Patient x   ,14,3,3,No,1:No,1:No,,0.896
2269,2551676,TABLE 2,BaselineCharacteristic,xx.x,Weight of pancreas (g) ; ,????x*, Patient x   ,14,4,3,No,1:No,1:No,,0.846
2269,2551676,TABLE 2,BaselineCharacteristic,"xxx,xxx",Islet yield (IEQ) ; ,????x*, Patient x   ,14,5,3,No,1:No,1:No,,0.97
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Islet viability (%) ; ,????x*, Patient x   ,14,6,3,No,1:No,1:No,,0.88
2269,2551676,TABLE 2,BaselineCharacteristic,x.xx,Stimulus index ; ,????x*, Patient x   ,14,7,3,No,1:No,1:No,,0.93
2269,2551676,TABLE 2,BaselineCharacteristic,x,Cross-match (%) ; ,????x*, Patient x   ,14,8,3,No,1:No,1:No,,0.96
2269,2551676,TABLE 2,BaselineCharacteristic,????x*,Patient and infusion procedure no. ; ,????x*, Patient x   ,15,0,2,No,1:No,1:No,,0.936
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Age (years) ; ,????x*, Patient x   ,15,1,3,No,1:No,1:No,,0.7
2269,2551676,TABLE 2,BaselineCharacteristic,xx.x,BMI (kg/mx) ; ,????x*, Patient x   ,15,2,3,No,1:No,1:No,,0.956
2269,2551676,TABLE 2,BaselineCharacteristic,x.x,Duration of cold ischemia (hours) ; ,????x*, Patient x   ,15,3,3,No,1:No,1:No,,0.98
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Weight of pancreas (g) ; ,????x*, Patient x   ,15,4,3,No,1:No,1:No,,0.846
2269,2551676,TABLE 2,BaselineCharacteristic,"xxx,xxx",Islet yield (IEQ) ; ,????x*, Patient x   ,15,5,3,No,1:No,1:No,,0.97
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Islet viability (%) ; ,????x*, Patient x   ,15,6,3,No,1:No,1:No,,0.88
2269,2551676,TABLE 2,BaselineCharacteristic,x.xx,Stimulus index ; ,????x*, Patient x   ,15,7,3,No,1:No,1:No,,0.93
2269,2551676,TABLE 2,BaselineCharacteristic,x,Cross-match (%) ; ,????x*, Patient x   ,15,8,3,No,1:No,1:No,,0.96
2269,2551676,TABLE 2,BaselineCharacteristic,????x*,Patient and infusion procedure no. ; ,????x*, Patient x   ,16,0,2,No,1:No,1:No,,0.936
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Age (years) ; ,????x*, Patient x   ,16,1,3,No,1:No,1:No,,0.7
2269,2551676,TABLE 2,BaselineCharacteristic,xx,BMI (kg/mx) ; ,????x*, Patient x   ,16,2,3,No,1:No,1:No,,0.966
2269,2551676,TABLE 2,BaselineCharacteristic,x,Duration of cold ischemia (hours) ; ,????x*, Patient x   ,16,3,3,No,1:No,1:No,,0.98
2269,2551676,TABLE 2,BaselineCharacteristic,xxx.x,Weight of pancreas (g) ; ,????x*, Patient x   ,16,4,3,No,1:No,1:No,,0.88
2269,2551676,TABLE 2,BaselineCharacteristic,"xxx,xxx",Islet yield (IEQ) ; ,????x*, Patient x   ,16,5,3,No,1:No,1:No,,0.97
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Islet viability (%) ; ,????x*, Patient x   ,16,6,3,No,1:No,1:No,,0.89
2269,2551676,TABLE 2,BaselineCharacteristic,x.xx,Stimulus index ; ,????x*, Patient x   ,16,7,3,No,1:No,1:No,,0.94
2269,2551676,TABLE 2,BaselineCharacteristic,x,Cross-match (%) ; ,????x*, Patient x   ,16,8,3,No,1:No,1:No,,0.96
2269,2551676,TABLE 2,BaselineCharacteristic,Patient x,Patient and infusion procedure no. ; ,None,None,17,0,24,No,1:No,1:No,,0.948
2269,2551676,TABLE 2,BaselineCharacteristic,,Age (years) ; ,Patient x,None,17,1,43,No,1:No,1:No,,0.724
2269,2551676,TABLE 2,BaselineCharacteristic,,BMI (kg/mx) ; ,Patient x,None,17,2,43,No,1:No,1:No,,0.973
2269,2551676,TABLE 2,BaselineCharacteristic,,Duration of cold ischemia (hours) ; ,Patient x,None,17,3,43,No,1:No,1:No,,0.963
2269,2551676,TABLE 2,BaselineCharacteristic,,Weight of pancreas (g) ; ,Patient x,None,17,4,43,No,1:No,1:No,,0.908
2269,2551676,TABLE 2,BaselineCharacteristic,,Islet yield (IEQ) ; ,Patient x,None,17,5,43,No,1:No,1:No,,0.973
2269,2551676,TABLE 2,BaselineCharacteristic,,Islet viability (%) ; ,Patient x,None,17,6,43,No,1:No,1:No,,0.91
2269,2551676,TABLE 2,BaselineCharacteristic,,Stimulus index ; ,Patient x,None,17,7,43,No,1:No,1:No,,0.963
2269,2551676,TABLE 2,BaselineCharacteristic,,Cross-match (%) ; ,Patient x,None,17,8,43,No,1:No,1:No,,0.91
2269,2551676,TABLE 2,BaselineCharacteristic,????x,Patient and infusion procedure no. ; ,????x, Patient x   ,18,0,2,No,1:No,1:No,,0.926
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Age (years) ; ,????x, Patient x   ,18,1,3,No,1:No,1:No,,0.67
2269,2551676,TABLE 2,BaselineCharacteristic,xx.x,BMI (kg/mx) ; ,????x, Patient x   ,18,2,3,No,1:No,1:No,,0.951
2269,2551676,TABLE 2,BaselineCharacteristic,x,Duration of cold ischemia (hours) ; ,????x, Patient x   ,18,3,3,No,1:No,1:No,,0.98
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Weight of pancreas (g) ; ,????x, Patient x   ,18,4,3,No,1:No,1:No,,0.846
2269,2551676,TABLE 2,BaselineCharacteristic,"xxx,xxx",Islet yield (IEQ) ; ,????x, Patient x   ,18,5,3,No,1:No,1:No,,0.97
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Islet viability (%) ; ,????x, Patient x   ,18,6,3,No,1:No,1:No,,0.88
2269,2551676,TABLE 2,BaselineCharacteristic,x.xx,Stimulus index ; ,????x, Patient x   ,18,7,3,No,1:No,1:No,,0.925
2269,2551676,TABLE 2,BaselineCharacteristic,x,Cross-match (%) ; ,????x, Patient x   ,18,8,3,No,1:No,1:No,,0.94
2269,2551676,TABLE 2,BaselineCharacteristic,????x,Patient and infusion procedure no. ; ,????x, Patient x   ,19,0,2,No,1:No,1:No,,0.926
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Age (years) ; ,????x, Patient x   ,19,1,3,No,1:No,1:No,,0.67
2269,2551676,TABLE 2,BaselineCharacteristic,xx.x,BMI (kg/mx) ; ,????x, Patient x   ,19,2,3,No,1:No,1:No,,0.951
2269,2551676,TABLE 2,BaselineCharacteristic,x,Duration of cold ischemia (hours) ; ,????x, Patient x   ,19,3,3,No,1:No,1:No,,0.98
2269,2551676,TABLE 2,BaselineCharacteristic,xxx.x,Weight of pancreas (g) ; ,????x, Patient x   ,19,4,3,No,1:No,1:No,,0.88
2269,2551676,TABLE 2,BaselineCharacteristic,"xxx,xxx",Islet yield (IEQ) ; ,????x, Patient x   ,19,5,3,No,1:No,1:No,,0.97
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Islet viability (%) ; ,????x, Patient x   ,19,6,3,No,1:No,1:No,,0.87
2269,2551676,TABLE 2,BaselineCharacteristic,x.xx,Stimulus index ; ,????x, Patient x   ,19,7,3,No,1:No,1:No,,0.925
2269,2551676,TABLE 2,BaselineCharacteristic,x,Cross-match (%) ; ,????x, Patient x   ,19,8,3,No,1:No,1:No,,0.93
2269,2551676,TABLE 2,BaselineCharacteristic,Patient x,Patient and infusion procedure no. ; ,Patient x,,20,0,2,No,1:No,1:No,,0.926
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Age (years) ; ,Patient x,,20,1,3,No,1:No,1:No,,0.67
2269,2551676,TABLE 2,BaselineCharacteristic,xx,BMI (kg/mx) ; ,Patient x,,20,2,3,No,1:No,1:No,,0.951
2269,2551676,TABLE 2,BaselineCharacteristic,x.x,Duration of cold ischemia (hours) ; ,Patient x,,20,3,3,No,1:No,1:No,,0.98
2269,2551676,TABLE 2,BaselineCharacteristic,xxx.x,Weight of pancreas (g) ; ,Patient x,,20,4,3,No,1:No,1:No,,0.88
2269,2551676,TABLE 2,BaselineCharacteristic,"xxx,xxx",Islet yield (IEQ) ; ,Patient x,,20,5,3,No,1:No,1:No,,0.97
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Islet viability (%) ; ,Patient x,,20,6,3,No,1:No,1:No,,0.87
2269,2551676,TABLE 2,BaselineCharacteristic,x.xx,Stimulus index ; ,Patient x,,20,7,3,No,1:No,1:No,,0.925
2269,2551676,TABLE 2,BaselineCharacteristic,x,Cross-match (%) ; ,Patient x,,20,8,3,No,1:No,1:No,,0.93
2269,2551676,TABLE 2,BaselineCharacteristic,Patient x,Patient and infusion procedure no. ; ,Patient x,,21,0,2,No,1:No,1:No,,0.936
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Age (years) ; ,Patient x,,21,1,3,No,1:No,1:No,,0.67
2269,2551676,TABLE 2,BaselineCharacteristic,xx.x,BMI (kg/mx) ; ,Patient x,,21,2,3,No,1:No,1:No,,0.951
2269,2551676,TABLE 2,BaselineCharacteristic,x.xx,Duration of cold ischemia (hours) ; ,Patient x,,21,3,3,No,1:No,1:No,,0.896
2269,2551676,TABLE 2,BaselineCharacteristic,xx.x,Weight of pancreas (g) ; ,Patient x,,21,4,3,No,1:No,1:No,,0.846
2269,2551676,TABLE 2,BaselineCharacteristic,"xxx,xxx",Islet yield (IEQ) ; ,Patient x,,21,5,3,No,1:No,1:No,,0.97
2269,2551676,TABLE 2,BaselineCharacteristic,xx,Islet viability (%) ; ,Patient x,,21,6,3,No,1:No,1:No,,0.87
2269,2551676,TABLE 2,BaselineCharacteristic,x.xx,Stimulus index ; ,Patient x,,21,7,3,No,1:No,1:No,,0.925
2269,2551676,TABLE 2,BaselineCharacteristic,x,Cross-match (%) ; ,Patient x,,21,8,3,No,1:No,1:No,,0.93
2269,2551676,TABLE 3,BaselineCharacteristic,Subject,,None,None,0,0,12,No,1:No,1:No,,0.905
2269,2551676,TABLE 3,BaselineCharacteristic,Baseline insulin requirement (IU/day),,Subject,None,0,1,1,No,1:No,1:No,,0.903
2269,2551676,TABLE 3,BaselineCharacteristic,Total transplantations,,Subject,None,0,2,1,No,1:No,1:No,,0.903
2269,2551676,TABLE 3,BaselineCharacteristic,Insulin requirement after the last transplantation (IU/day) ,,Subject,None,0,3,1,No,1:No,1:No,,0.933
2269,2551676,TABLE 3,BaselineCharacteristic,Insulin requirement after the last transplantation (IU/day) ,,Subject,None,0,4,1,No,1:No,1:No,,0.933
2269,2551676,TABLE 3,BaselineCharacteristic,Insulin requirement after the last transplantation (IU/day) ,,Subject,None,0,5,1,No,1:No,1:No,,0.945
2269,2551676,TABLE 3,BaselineCharacteristic,Insulin requirement after the last transplantation (IU/day) ,,Subject,None,0,6,1,No,1:No,1:No,,0.945
2269,2551676,TABLE 3,BaselineCharacteristic,Insulin requirement after the last transplantation (IU/day) ,,Subject,None,0,7,1,No,1:No,1:No,,0.955
2269,2551676,TABLE 3,BaselineCharacteristic,Insulin independent time (months),,Subject,None,0,8,1,No,1:No,1:No,,0.946
2269,2551676,TABLE 3,BaselineCharacteristic,Subject,Subject ; ,None,None,1,0,12,No,1:No,1:No,,0.898
2269,2551676,TABLE 3,BaselineCharacteristic,Baseline insulin requirement (IU/day),Baseline insulin requirement (IU/day) ; ,Subject,None,1,1,1,No,1:No,1:No,,0.895
2269,2551676,TABLE 3,BaselineCharacteristic,Total transplantations,Total transplantations ; ,Subject,None,1,2,1,No,1:No,1:No,,0.896
2269,2551676,TABLE 3,BaselineCharacteristic,x month,Insulin requirement after the last transplantation (IU/day)  ; ,Subject,None,1,3,1,No,1:No,1:No,,0.868
2269,2551676,TABLE 3,BaselineCharacteristic,x months,Insulin requirement after the last transplantation (IU/day)  ; ,Subject,None,1,4,1,No,1:No,1:No,,0.88
2269,2551676,TABLE 3,BaselineCharacteristic,x months,Insulin requirement after the last transplantation (IU/day)  ; ,Subject,None,1,5,1,No,1:No,1:No,,0.901
2269,2551676,TABLE 3,BaselineCharacteristic,x months,Insulin requirement after the last transplantation (IU/day)  ; ,Subject,None,1,6,1,No,1:No,1:No,,0.901
2269,2551676,TABLE 3,BaselineCharacteristic,xx months,Insulin requirement after the last transplantation (IU/day)  ; ,Subject,None,1,7,1,No,1:No,1:No,,0.81
2269,2551676,TABLE 3,BaselineCharacteristic,Insulin independent time (months),Insulin independent time (months) ; ,Subject,None,1,8,1,No,1:No,1:No,,0.939
2269,2551676,TABLE 3,BaselineCharacteristic,x,Subject ; Subject ; ,x,None,2,0,2,No,1:No,1:No,,0.935
2269,2551676,TABLE 3,BaselineCharacteristic,xx,Baseline insulin requirement (IU/day) ; Baseline insulin requirement (IU/day) ; ,x,None,2,1,3,No,1:No,1:No,,0.632
2269,2551676,TABLE 3,BaselineCharacteristic,x,Total transplantations ; Total transplantations ; ,x,None,2,2,3,No,1:No,1:No,,0.92
2269,2551676,TABLE 3,BaselineCharacteristic,xx,Insulin requirement after the last transplantation (IU/day)  ; x month ; ,x,None,2,3,3,No,1:No,1:No,,0.696
2269,2551676,TABLE 3,BaselineCharacteristic,x,Insulin requirement after the last transplantation (IU/day)  ; x months ; ,x,None,2,4,3,No,1:No,1:No,,0.94
2269,2551676,TABLE 3,BaselineCharacteristic,x,Insulin requirement after the last transplantation (IU/day)  ; x months ; ,x,None,2,5,3,No,1:No,1:No,,0.94
2269,2551676,TABLE 3,BaselineCharacteristic,x,Insulin requirement after the last transplantation (IU/day)  ; x months ; ,x,None,2,6,3,No,1:No,1:No,,0.95
2269,2551676,TABLE 3,BaselineCharacteristic,x,Insulin requirement after the last transplantation (IU/day)  ; xx months ; ,x,None,2,7,3,No,1:No,1:No,,0.75
2269,2551676,TABLE 3,BaselineCharacteristic,xx,Insulin independent time (months) ; Insulin independent time (months) ; ,x,None,2,8,3,No,1:No,1:No,,0.746
2269,2551676,TABLE 3,BaselineCharacteristic,x,Subject ; Subject ; ,x,None,3,0,2,No,1:No,1:No,,0.945
2269,2551676,TABLE 3,BaselineCharacteristic,xx,Baseline insulin requirement (IU/day) ; Baseline insulin requirement (IU/day) ; ,x,None,3,1,3,No,1:No,1:No,,0.646
2269,2551676,TABLE 3,BaselineCharacteristic,x,Total transplantations ; Total transplantations ; ,x,None,3,2,3,No,1:No,1:No,,0.94
2269,2551676,TABLE 3,BaselineCharacteristic,xx,Insulin requirement after the last transplantation (IU/day)  ; x month ; ,x,None,3,3,3,No,1:No,1:No,,0.706
2269,2551676,TABLE 3,BaselineCharacteristic,xx,Insulin requirement after the last transplantation (IU/day)  ; x months ; ,x,None,3,4,3,No,1:No,1:No,,0.726
2269,2551676,TABLE 3,BaselineCharacteristic,x,Insulin requirement after the last transplantation (IU/day)  ; x months ; ,x,None,3,5,3,No,1:No,1:No,,0.96
2269,2551676,TABLE 3,BaselineCharacteristic,x,Insulin requirement after the last transplantation (IU/day)  ; x months ; ,x,None,3,6,3,No,1:No,1:No,,0.97
2269,2551676,TABLE 3,BaselineCharacteristic,x,Insulin requirement after the last transplantation (IU/day)  ; xx months ; ,x,None,3,7,3,No,1:No,1:No,,0.76
2269,2551676,TABLE 3,BaselineCharacteristic,xx,Insulin independent time (months) ; Insulin independent time (months) ; ,x,None,3,8,3,No,1:No,1:No,,0.75
2269,2551676,TABLE 3,BaselineCharacteristic,x,Subject ; Subject ; ,x,None,4,0,2,No,1:No,1:No,,0.965
2269,2551676,TABLE 3,BaselineCharacteristic,xx,Baseline insulin requirement (IU/day) ; Baseline insulin requirement (IU/day) ; ,x,None,4,1,3,No,1:No,1:No,,0.726
2269,2551676,TABLE 3,BaselineCharacteristic,x,Total transplantations ; Total transplantations ; ,x,None,4,2,3,No,1:No,1:No,,0.94
2269,2551676,TABLE 3,BaselineCharacteristic,xx,Insulin requirement after the last transplantation (IU/day)  ; x month ; ,x,None,4,3,3,No,1:No,1:No,,0.786
2269,2551676,TABLE 3,BaselineCharacteristic,x,Insulin requirement after the last transplantation (IU/day)  ; x months ; ,x,None,4,4,3,No,1:No,1:No,,0.96
2269,2551676,TABLE 3,BaselineCharacteristic,x,Insulin requirement after the last transplantation (IU/day)  ; x months ; ,x,None,4,5,3,No,1:No,1:No,,0.96
2269,2551676,TABLE 3,BaselineCharacteristic,x,Insulin requirement after the last transplantation (IU/day)  ; x months ; ,x,None,4,6,3,No,1:No,1:No,,0.97
2269,2551676,TABLE 3,BaselineCharacteristic,x,Insulin requirement after the last transplantation (IU/day)  ; xx months ; ,x,None,4,7,3,No,1:No,1:No,,0.84
2269,2551676,TABLE 3,BaselineCharacteristic,xx,Insulin independent time (months) ; Insulin independent time (months) ; ,x,None,4,8,3,No,1:No,1:No,,0.84
2269,2551676,TABLE 3,BaselineCharacteristic,x,Subject ; Subject ; ,x,None,5,0,2,No,1:No,1:No,,0.963
2269,2551676,TABLE 3,BaselineCharacteristic,xx,Baseline insulin requirement (IU/day) ; Baseline insulin requirement (IU/day) ; ,x,None,5,1,3,No,1:No,1:No,,0.726
2269,2551676,TABLE 3,BaselineCharacteristic,x,Total transplantations ; Total transplantations ; ,x,None,5,2,3,No,1:No,1:No,,0.94
2269,2551676,TABLE 3,BaselineCharacteristic,xx,Insulin requirement after the last transplantation (IU/day)  ; x month ; ,x,None,5,3,3,No,1:No,1:No,,0.786
2269,2551676,TABLE 3,BaselineCharacteristic,xx,Insulin requirement after the last transplantation (IU/day)  ; x months ; ,x,None,5,4,3,No,1:No,1:No,,0.806
2269,2551676,TABLE 3,BaselineCharacteristic,x,Insulin requirement after the last transplantation (IU/day)  ; x months ; ,x,None,5,5,3,No,1:No,1:No,,0.95
2269,2551676,TABLE 3,BaselineCharacteristic,x,Insulin requirement after the last transplantation (IU/day)  ; x months ; ,x,None,5,6,3,No,1:No,1:No,,0.96
2269,2551676,TABLE 3,BaselineCharacteristic,x,Insulin requirement after the last transplantation (IU/day)  ; xx months ; ,x,None,5,7,3,No,1:No,1:No,,0.82
2269,2551676,TABLE 3,BaselineCharacteristic,xx,Insulin independent time (months) ; Insulin independent time (months) ; ,x,None,5,8,3,No,1:No,1:No,,0.83
2269,2551676,TABLE 3,BaselineCharacteristic,x,Subject ; Subject ; ,x,None,6,0,2,No,1:No,1:No,,0.973
2269,2551676,TABLE 3,BaselineCharacteristic,xx,Baseline insulin requirement (IU/day) ; Baseline insulin requirement (IU/day) ; ,x,None,6,1,3,No,1:No,1:No,,0.746
2269,2551676,TABLE 3,BaselineCharacteristic,x,Total transplantations ; Total transplantations ; ,x,None,6,2,3,No,1:No,1:No,,0.96
2269,2551676,TABLE 3,BaselineCharacteristic,xx,Insulin requirement after the last transplantation (IU/day)  ; x month ; ,x,None,6,3,3,No,1:No,1:No,,0.806
2269,2551676,TABLE 3,BaselineCharacteristic,xx,Insulin requirement after the last transplantation (IU/day)  ; x months ; ,x,None,6,4,3,No,1:No,1:No,,0.826
2269,2551676,TABLE 3,BaselineCharacteristic,xx,Insulin requirement after the last transplantation (IU/day)  ; x months ; ,x,None,6,5,3,No,1:No,1:No,,0.83
2269,2551676,TABLE 3,BaselineCharacteristic,xx,Insulin requirement after the last transplantation (IU/day)  ; x months ; ,x,None,6,6,3,No,1:No,1:No,,0.83
2269,2551676,TABLE 3,BaselineCharacteristic,x,Insulin requirement after the last transplantation (IU/day)  ; xx months ; ,x,None,6,7,3,No,1:No,1:No,,0.84
2269,2551676,TABLE 3,BaselineCharacteristic,xx%*,Insulin independent time (months) ; Insulin independent time (months) ; ,x,None,6,8,3,No,1:No,1:No,,0.95
2269,2551676,TABLE 3,BaselineCharacteristic,x,Subject ; Subject ; ,x,None,7,0,2,No,1:No,1:No,,0.973
2269,2551676,TABLE 3,BaselineCharacteristic,xx,Baseline insulin requirement (IU/day) ; Baseline insulin requirement (IU/day) ; ,x,None,7,1,3,No,1:No,1:No,,0.786
2269,2551676,TABLE 3,BaselineCharacteristic,x,Total transplantations ; Total transplantations ; ,x,None,7,2,3,No,1:No,1:No,,0.97
2269,2551676,TABLE 3,BaselineCharacteristic,xx,Insulin requirement after the last transplantation (IU/day)  ; x month ; ,x,None,7,3,3,No,1:No,1:No,,0.826
2269,2551676,TABLE 3,BaselineCharacteristic,xx,Insulin requirement after the last transplantation (IU/day)  ; x months ; ,x,None,7,4,3,No,1:No,1:No,,0.856
2269,2551676,TABLE 3,BaselineCharacteristic,xx,Insulin requirement after the last transplantation (IU/day)  ; x months ; ,x,None,7,5,3,No,1:No,1:No,,0.87
2269,2551676,TABLE 3,BaselineCharacteristic,xx,Insulin requirement after the last transplantation (IU/day)  ; x months ; ,x,None,7,6,3,No,1:No,1:No,,0.87
2269,2551676,TABLE 3,BaselineCharacteristic,xx,Insulin requirement after the last transplantation (IU/day)  ; xx months ; ,x,None,7,7,3,No,1:No,1:No,,0.88
2269,2551676,TABLE 3,BaselineCharacteristic,xx%*†,Insulin independent time (months) ; Insulin independent time (months) ; ,x,None,7,8,3,No,1:No,1:No,,0.98
2269,2551676,TABLE 3,BaselineCharacteristic,x,Subject ; Subject ; ,x,None,8,0,2,No,1:No,1:No,,0.972
2269,2551676,TABLE 3,BaselineCharacteristic,xx,Baseline insulin requirement (IU/day) ; Baseline insulin requirement (IU/day) ; ,x,None,8,1,3,No,1:No,1:No,,0.806
2269,2551676,TABLE 3,BaselineCharacteristic,x,Total transplantations ; Total transplantations ; ,x,None,8,2,3,No,1:No,1:No,,0.98
2269,2551676,TABLE 3,BaselineCharacteristic,xx,Insulin requirement after the last transplantation (IU/day)  ; x month ; ,x,None,8,3,3,No,1:No,1:No,,0.836
2269,2551676,TABLE 3,BaselineCharacteristic,xx,Insulin requirement after the last transplantation (IU/day)  ; x months ; ,x,None,8,4,3,No,1:No,1:No,,0.866
2269,2551676,TABLE 3,BaselineCharacteristic,xx,Insulin requirement after the last transplantation (IU/day)  ; x months ; ,x,None,8,5,3,No,1:No,1:No,,0.88
2269,2551676,TABLE 3,BaselineCharacteristic,xx,Insulin requirement after the last transplantation (IU/day)  ; x months ; ,x,None,8,6,3,No,1:No,1:No,,0.88
2269,2551676,TABLE 3,BaselineCharacteristic,xx,Insulin requirement after the last transplantation (IU/day)  ; xx months ; ,x,None,8,7,3,No,1:No,1:No,,0.89
2269,2551676,TABLE 3,BaselineCharacteristic,xx%*†,Insulin independent time (months) ; Insulin independent time (months) ; ,x,None,8,8,3,No,1:No,1:No,,0.99
2370,2599890,Table 1,BaselineCharacteristic,Nox,,None,None,0,0,12,No,1:No,1:No,,0.905
2370,2599890,Table 1,BaselineCharacteristic,Age (y),,Nox,None,0,1,1,No,1:No,1:No,,0.903
2370,2599890,Table 1,BaselineCharacteristic,Weight (kg),,Nox,None,0,2,1,No,1:No,1:No,,0.903
2370,2599890,Table 1,BaselineCharacteristic,Surgeryx,,Nox,None,0,3,1,No,1:No,1:No,,0.903
2370,2599890,Table 1,BaselineCharacteristic,Duration surgery (hr),,Nox,None,0,4,1,No,1:No,1:No,,0.935
2370,2599890,Table 1,BaselineCharacteristic,Historyx,,Nox,None,0,5,1,No,1:No,1:No,,0.935
2370,2599890,Table 1,BaselineCharacteristic,Early complicationsx,,Nox,None,0,6,1,No,1:No,1:No,,0.935
2370,2599890,Table 1,BaselineCharacteristic,Blood loss (ml/kg)x,,Nox,None,0,7,1,No,1:No,1:No,,0.9
2370,2599890,Table 1,BaselineCharacteristic,Fluid in (ml/kg)x,,Nox,None,0,8,1,No,1:No,1:No,,0.892
2370,2599890,Table 1,BaselineCharacteristic,Diuresis (ml/kg/hr)x,,Nox,None,0,9,1,No,1:No,1:No,,0.9
2370,2599890,Table 1,BaselineCharacteristic,Mean (range) MAP (mmHg)x,,Nox,None,0,10,1,No,1:No,1:No,,0.811
2370,2599890,Table 1,BaselineCharacteristic,Mean (range) lactate (mmol/l)x,,Nox,None,0,11,1,No,1:No,1:No,,0.781
2370,2599890,Table 1,BaselineCharacteristic,x,Nox ; ,x,None,1,0,2,No,1:No,1:No,,0.915
2370,2599890,Table 1,BaselineCharacteristic,x,Age (y) ; ,x,None,1,1,3,No,1:No,1:No,,0.89
2370,2599890,Table 1,BaselineCharacteristic,xx,Weight (kg) ; ,x,None,1,2,3,No,1:No,1:No,,0.612
2370,2599890,Table 1,BaselineCharacteristic,ASF Tx-Lx,Surgeryx ; ,x,None,1,3,3,No,1:No,1:No,,0.89
2370,2599890,Table 1,BaselineCharacteristic,x,Duration surgery (hr) ; ,x,None,1,4,3,No,1:No,1:No,,0.93
2370,2599890,Table 1,BaselineCharacteristic,"spina bifida, hydrocephalus",Historyx ; ,x,None,1,5,3,No,1:No,1:No,,0.89
2370,2599890,Table 1,BaselineCharacteristic,"fever, UTI",Early complicationsx ; ,x,None,1,6,3,No,1:No,1:No,,0.91
2370,2599890,Table 1,BaselineCharacteristic,xx,Blood loss (ml/kg)x ; ,x,None,1,7,3,No,1:No,1:No,,0.646
2370,2599890,Table 1,BaselineCharacteristic,xxx,Fluid in (ml/kg)x ; ,x,None,1,8,3,No,1:No,1:No,,0.8
2370,2599890,Table 1,BaselineCharacteristic,x.x,Diuresis (ml/kg/hr)x ; ,x,None,1,9,3,No,1:No,1:No,,0.9
2370,2599890,Table 1,BaselineCharacteristic,x.x (x.x–x.x),Mean (range) lactate (mmol/l)x ; ,x,None,1,11,3,No,1:No,1:No,,0.76
2370,2599890,Table 1,BaselineCharacteristic,x,Nox ; ,x,None,2,0,2,No,1:No,1:No,,0.935
2370,2599890,Table 1,BaselineCharacteristic,xx,Age (y) ; ,x,None,2,1,3,No,1:No,1:No,,0.632
2370,2599890,Table 1,BaselineCharacteristic,xx,Weight (kg) ; ,x,None,2,2,3,No,1:No,1:No,,0.652
2370,2599890,Table 1,BaselineCharacteristic,ASF+PSF Tx-Sx,Surgeryx ; ,x,None,2,3,3,No,1:No,1:No,,0.91
2370,2599890,Table 1,BaselineCharacteristic,x,Duration surgery (hr) ; ,x,None,2,4,3,No,1:No,1:No,,0.95
2370,2599890,Table 1,BaselineCharacteristic,"cerebral palsy, spastic diplegia, IVH",Historyx ; ,x,None,2,5,3,No,1:No,1:No,,0.9
2370,2599890,Table 1,BaselineCharacteristic,,Early complicationsx ; ,x,None,2,6,3,No,1:No,1:No,,0.92
2370,2599890,Table 1,BaselineCharacteristic,xx,Blood loss (ml/kg)x ; ,x,None,2,7,3,No,1:No,1:No,,0.686
2370,2599890,Table 1,BaselineCharacteristic,xxx,Fluid in (ml/kg)x ; ,x,None,2,8,3,No,1:No,1:No,,0.79
2370,2599890,Table 1,BaselineCharacteristic,x.x,Diuresis (ml/kg/hr)x ; ,x,None,2,9,3,No,1:No,1:No,,0.91
2370,2599890,Table 1,BaselineCharacteristic,xx (xx–xx),Mean (range) MAP (mmHg)x ; ,x,None,2,10,3,No,1:No,1:No,,0.525
2370,2599890,Table 1,BaselineCharacteristic,x.x (x.x–x.x),Mean (range) lactate (mmol/l)x ; ,x,None,2,11,3,No,1:No,1:No,,0.76
2370,2599890,Table 1,BaselineCharacteristic,x,Nox ; ,x,None,3,0,2,No,1:No,1:No,,0.945
2370,2599890,Table 1,BaselineCharacteristic,xx,Age (y) ; ,x,None,3,1,3,No,1:No,1:No,,0.646
2370,2599890,Table 1,BaselineCharacteristic,xx,Weight (kg) ; ,x,None,3,2,3,No,1:No,1:No,,0.656
2370,2599890,Table 1,BaselineCharacteristic,ASF+PSF Txx-Lx,Surgeryx ; ,x,None,3,3,3,No,1:No,1:No,,0.93
2370,2599890,Table 1,BaselineCharacteristic,x,Duration surgery (hr) ; ,x,None,3,4,3,No,1:No,1:No,,0.97
2370,2599890,Table 1,BaselineCharacteristic,-,Historyx ; ,x,None,3,5,3,No,1:No,1:No,,0.83
2370,2599890,Table 1,BaselineCharacteristic,"fever, pneumonia",Early complicationsx ; ,x,None,3,6,3,No,1:No,1:No,,0.94
2370,2599890,Table 1,BaselineCharacteristic,xx,Blood loss (ml/kg)x ; ,x,None,3,7,3,No,1:No,1:No,,0.69
2370,2599890,Table 1,BaselineCharacteristic,xxx,Fluid in (ml/kg)x ; ,x,None,3,8,3,No,1:No,1:No,,0.81
2370,2599890,Table 1,BaselineCharacteristic,x.x,Diuresis (ml/kg/hr)x ; ,x,None,3,9,3,No,1:No,1:No,,0.93
2370,2599890,Table 1,BaselineCharacteristic,xx (xx–xx),Mean (range) MAP (mmHg)x ; ,x,None,3,10,3,No,1:No,1:No,,0.525
2370,2599890,Table 1,BaselineCharacteristic,x.x (x.x–x.x),Mean (range) lactate (mmol/l)x ; ,x,None,3,11,3,No,1:No,1:No,,0.75
2370,2599890,Table 1,BaselineCharacteristic,x,Nox ; ,x,None,4,0,2,No,1:No,1:No,,0.965
2370,2599890,Table 1,BaselineCharacteristic,xx,Age (y) ; ,x,None,4,1,3,No,1:No,1:No,,0.726
2370,2599890,Table 1,BaselineCharacteristic,xx,Weight (kg) ; ,x,None,4,2,3,No,1:No,1:No,,0.746
2370,2599890,Table 1,BaselineCharacteristic,ASF+PSF Tx-Sx,Surgeryx ; ,x,None,4,3,3,No,1:No,1:No,,0.93
2370,2599890,Table 1,BaselineCharacteristic,x,Duration surgery (hr) ; ,x,None,4,4,3,No,1:No,1:No,,0.97
2370,2599890,Table 1,BaselineCharacteristic,DiGeorge syndrome; vascular spinal cord lesion,Historyx ; ,x,None,4,5,3,No,1:No,1:No,,0.91
2370,2599890,Table 1,BaselineCharacteristic,melaena,Early complicationsx ; ,x,None,4,6,3,No,1:No,1:No,,0.93
2370,2599890,Table 1,BaselineCharacteristic,xx,Blood loss (ml/kg)x ; ,x,None,4,7,3,No,1:No,1:No,,0.76
2370,2599890,Table 1,BaselineCharacteristic,xxx,Fluid in (ml/kg)x ; ,x,None,4,8,3,No,1:No,1:No,,0.8
2370,2599890,Table 1,BaselineCharacteristic,x.x,Diuresis (ml/kg/hr)x ; ,x,None,4,9,3,No,1:No,1:No,,0.92
2370,2599890,Table 1,BaselineCharacteristic,xx (xx–xx),Mean (range) MAP (mmHg)x ; ,x,None,4,10,3,No,1:No,1:No,,0.585
2370,2599890,Table 1,BaselineCharacteristic,x.x (x.x–x.x),Mean (range) lactate (mmol/l)x ; ,x,None,4,11,3,No,1:No,1:No,,0.75
2370,2599890,Table 1,BaselineCharacteristic,x,Nox ; ,x,None,5,0,2,No,1:No,1:No,,0.963
2370,2599890,Table 1,BaselineCharacteristic,xx,Age (y) ; ,x,None,5,1,3,No,1:No,1:No,,0.726
2370,2599890,Table 1,BaselineCharacteristic,xx,Weight (kg) ; ,x,None,5,2,3,No,1:No,1:No,,0.746
2370,2599890,Table 1,BaselineCharacteristic,PSF Tx-Lx,Surgeryx ; ,x,None,5,3,3,No,1:No,1:No,,0.93
2370,2599890,Table 1,BaselineCharacteristic,x,Duration surgery (hr) ; ,x,None,5,4,3,No,1:No,1:No,,0.97
2370,2599890,Table 1,BaselineCharacteristic,cleft lip nose deformity,Historyx ; ,x,None,5,5,3,No,1:No,1:No,,0.9
2370,2599890,Table 1,BaselineCharacteristic,-,Early complicationsx ; ,x,None,5,6,3,No,1:No,1:No,,0.83
2370,2599890,Table 1,BaselineCharacteristic,xx,Blood loss (ml/kg)x ; ,x,None,5,7,3,No,1:No,1:No,,0.74
2370,2599890,Table 1,BaselineCharacteristic,xxx,Fluid in (ml/kg)x ; ,x,None,5,8,3,No,1:No,1:No,,0.79
2370,2599890,Table 1,BaselineCharacteristic,x.x,Diuresis (ml/kg/hr)x ; ,x,None,5,9,3,No,1:No,1:No,,0.91
2370,2599890,Table 1,BaselineCharacteristic,xx (xx–xx),Mean (range) MAP (mmHg)x ; ,x,None,5,10,3,No,1:No,1:No,,0.605
2370,2599890,Table 1,BaselineCharacteristic,x.x (x.x–x.x),Mean (range) lactate (mmol/l)x ; ,x,None,5,11,3,No,1:No,1:No,,0.76
2370,2599890,Table 1,BaselineCharacteristic,x,Nox ; ,x,None,6,0,2,No,1:No,1:No,,0.973
2370,2599890,Table 1,BaselineCharacteristic,xx,Age (y) ; ,x,None,6,1,3,No,1:No,1:No,,0.746
2370,2599890,Table 1,BaselineCharacteristic,xx,Weight (kg) ; ,x,None,6,2,3,No,1:No,1:No,,0.766
2370,2599890,Table 1,BaselineCharacteristic,PSF Tx-Txx,Surgeryx ; ,x,None,6,3,3,No,1:No,1:No,,0.95
2370,2599890,Table 1,BaselineCharacteristic,x,Duration surgery (hr) ; ,x,None,6,4,3,No,1:No,1:No,,0.98
2370,2599890,Table 1,BaselineCharacteristic,spina bifida occulta,Historyx ; ,x,None,6,5,3,No,1:No,1:No,,0.92
2370,2599890,Table 1,BaselineCharacteristic,-,Early complicationsx ; ,x,None,6,6,3,No,1:No,1:No,,0.87
2370,2599890,Table 1,BaselineCharacteristic,xx,Blood loss (ml/kg)x ; ,x,None,6,7,3,No,1:No,1:No,,0.76
2370,2599890,Table 1,BaselineCharacteristic,xx,Fluid in (ml/kg)x ; ,x,None,6,8,3,No,1:No,1:No,,0.72
2370,2599890,Table 1,BaselineCharacteristic,x.x,Diuresis (ml/kg/hr)x ; ,x,None,6,9,3,No,1:No,1:No,,0.93
2370,2599890,Table 1,BaselineCharacteristic,xx (xx–xx),Mean (range) MAP (mmHg)x ; ,x,None,6,10,3,No,1:No,1:No,,0.615
2370,2599890,Table 1,BaselineCharacteristic,x.x (x.x–x.x),Mean (range) lactate (mmol/l)x ; ,x,None,6,11,3,No,1:No,1:No,,0.78
2370,2599890,Table 1,BaselineCharacteristic,x,Nox ; ,x,None,7,0,2,No,1:No,1:No,,0.973
2370,2599890,Table 1,BaselineCharacteristic,x,Age (y) ; ,x,None,7,1,3,No,1:No,1:No,,0.96
2370,2599890,Table 1,BaselineCharacteristic,xx,Weight (kg) ; ,x,None,7,2,3,No,1:No,1:No,,0.806
2370,2599890,Table 1,BaselineCharacteristic,PSF Tx-Lx,Surgeryx ; ,x,None,7,3,3,No,1:No,1:No,,0.96
2370,2599890,Table 1,BaselineCharacteristic,x,Duration surgery (hr) ; ,x,None,7,4,3,No,1:No,1:No,,0.99
2370,2599890,Table 1,BaselineCharacteristic,spinal muscular atrophy,Historyx ; ,x,None,7,5,3,No,1:No,1:No,,0.95
2370,2599890,Table 1,BaselineCharacteristic,-,Early complicationsx ; ,x,None,7,6,3,No,1:No,1:No,,0.89
2370,2599890,Table 1,BaselineCharacteristic,xx,Blood loss (ml/kg)x ; ,x,None,7,7,3,No,1:No,1:No,,0.82
2370,2599890,Table 1,BaselineCharacteristic,xx,Fluid in (ml/kg)x ; ,x,None,7,8,3,No,1:No,1:No,,0.77
2370,2599890,Table 1,BaselineCharacteristic,x.x,Diuresis (ml/kg/hr)x ; ,x,None,7,9,3,No,1:No,1:No,,0.96
2370,2599890,Table 1,BaselineCharacteristic,xx (xx–xx),Mean (range) MAP (mmHg)x ; ,x,None,7,10,3,No,1:No,1:No,,0.635
2370,2599890,Table 1,BaselineCharacteristic,x.x (x.x–x.x),Mean (range) lactate (mmol/l)x ; ,x,None,7,11,3,No,1:No,1:No,,0.81
2370,2599890,Table 1,BaselineCharacteristic,x,Nox ; ,x,None,8,0,2,No,1:No,1:No,,0.972
2370,2599890,Table 1,BaselineCharacteristic,xx,Age (y) ; ,x,None,8,1,3,No,1:No,1:No,,0.806
2370,2599890,Table 1,BaselineCharacteristic,xx,Weight (kg) ; ,x,None,8,2,3,No,1:No,1:No,,0.826
2370,2599890,Table 1,BaselineCharacteristic,ASF Tx-Txx,Surgeryx ; ,x,None,8,3,3,No,1:No,1:No,,0.97
2370,2599890,Table 1,BaselineCharacteristic,x,Duration surgery (hr) ; ,x,None,8,4,3,No,1:No,1:No,,0.99
2370,2599890,Table 1,BaselineCharacteristic,-,Historyx ; ,x,None,8,5,3,No,1:No,1:No,,0.91
2370,2599890,Table 1,BaselineCharacteristic,-,Early complicationsx ; ,x,None,8,6,3,No,1:No,1:No,,0.92
2370,2599890,Table 1,BaselineCharacteristic,xx,Blood loss (ml/kg)x ; ,x,None,8,7,3,No,1:No,1:No,,0.85
2370,2599890,Table 1,BaselineCharacteristic,xx,Fluid in (ml/kg)x ; ,x,None,8,8,3,No,1:No,1:No,,0.8
2370,2599890,Table 1,BaselineCharacteristic,x.x,Diuresis (ml/kg/hr)x ; ,x,None,8,9,3,No,1:No,1:No,,0.98
2370,2599890,Table 1,BaselineCharacteristic,xx (xx–xx),Mean (range) MAP (mmHg)x ; ,x,None,8,10,3,No,1:No,1:No,,0.645
2370,2599890,Table 1,BaselineCharacteristic,x.x (x.x–x.x),Mean (range) lactate (mmol/l)x ; ,x,None,8,11,3,No,1:No,1:No,,0.82
2370,2599890,Table 1,BaselineCharacteristic,x,Nox ; ,x,None,9,0,2,No,1:No,1:No,,0.982
2370,2599890,Table 1,BaselineCharacteristic,xx,Age (y) ; ,x,None,9,1,3,No,1:No,1:No,,0.846
2370,2599890,Table 1,BaselineCharacteristic,xx,Weight (kg) ; ,x,None,9,2,3,No,1:No,1:No,,0.856
2370,2599890,Table 1,BaselineCharacteristic,PSF Tx-Sx,Surgeryx ; ,x,None,9,3,3,No,1:No,1:No,,0.99
2370,2599890,Table 1,BaselineCharacteristic,x,Duration surgery (hr) ; ,x,None,9,4,3,No,1:No,1:No,,0.99
2370,2599890,Table 1,BaselineCharacteristic,"spastic tetraplegia, panencephalitis",Historyx ; ,x,None,9,5,3,No,1:No,1:No,,0.99
2370,2599890,Table 1,BaselineCharacteristic,-,Early complicationsx ; ,x,None,9,6,3,No,1:No,1:No,,0.93
2370,2599890,Table 1,BaselineCharacteristic,xx,Blood loss (ml/kg)x ; ,x,None,9,7,3,No,1:No,1:No,,0.88
2370,2599890,Table 1,BaselineCharacteristic,xxx,Fluid in (ml/kg)x ; ,x,None,9,8,3,No,1:No,1:No,,0.89
2370,2599890,Table 1,BaselineCharacteristic,x.x,Diuresis (ml/kg/hr)x ; ,x,None,9,9,3,No,1:No,1:No,,1
2370,2599890,Table 1,BaselineCharacteristic,xx (xx–xx),Mean (range) MAP (mmHg)x ; ,x,None,9,10,3,No,1:No,1:No,,0.685
2370,2599890,Table 1,BaselineCharacteristic,x.x (x.x–x.x),Mean (range) lactate (mmol/l)x ; ,x,None,9,11,3,No,1:No,1:No,,0.82
2370,2599890,Table 1,BaselineCharacteristic,xx,Nox ; ,xx,None,10,0,2,No,1:No,1:No,,0.945
2370,2599890,Table 1,BaselineCharacteristic,xx,Age (y) ; ,xx,None,10,1,3,No,1:No,1:No,,0.921
2370,2599890,Table 1,BaselineCharacteristic,xx,Weight (kg) ; ,xx,None,10,2,3,No,1:No,1:No,,0.911
2370,2599890,Table 1,BaselineCharacteristic,ASF Tx-Txx,Surgeryx ; ,xx,None,10,3,3,No,1:No,1:No,,0.901
2370,2599890,Table 1,BaselineCharacteristic,x,Duration surgery (hr) ; ,xx,None,10,4,3,No,1:No,1:No,,0.896
2370,2599890,Table 1,BaselineCharacteristic,-,Historyx ; ,xx,None,10,5,3,No,1:No,1:No,,0.886
2370,2599890,Table 1,BaselineCharacteristic,-,Early complicationsx ; ,xx,None,10,6,3,No,1:No,1:No,,0.91
2370,2599890,Table 1,BaselineCharacteristic,x,Blood loss (ml/kg)x ; ,xx,None,10,7,3,No,1:No,1:No,,0.9
2370,2599890,Table 1,BaselineCharacteristic,xxx,Fluid in (ml/kg)x ; ,xx,None,10,8,3,No,1:No,1:No,,0.76
2370,2599890,Table 1,BaselineCharacteristic,x.x,Diuresis (ml/kg/hr)x ; ,xx,None,10,9,3,No,1:No,1:No,,0.92
2370,2599890,Table 1,BaselineCharacteristic,xx (xx–xxx),Mean (range) MAP (mmHg)x ; ,xx,None,10,10,3,No,1:No,1:No,,0.8
2370,2599890,Table 1,BaselineCharacteristic,x.x (x.x–x.x),Mean (range) lactate (mmol/l)x ; ,xx,None,10,11,3,No,1:No,1:No,,0.78
2370,2599890,Table 1,BaselineCharacteristic,xx,Nox ; ,xx,None,11,0,2,No,1:No,1:No,,0.945
2370,2599890,Table 1,BaselineCharacteristic,x,Age (y) ; ,xx,None,11,1,3,No,1:No,1:No,,0.886
2370,2599890,Table 1,BaselineCharacteristic,x,Weight (kg) ; ,xx,None,11,2,3,No,1:No,1:No,,0.876
2370,2599890,Table 1,BaselineCharacteristic,ASF Txx-Lx,Surgeryx ; ,xx,None,11,3,3,No,1:No,1:No,,0.901
2370,2599890,Table 1,BaselineCharacteristic,x,Duration surgery (hr) ; ,xx,None,11,4,3,No,1:No,1:No,,0.896
2370,2599890,Table 1,BaselineCharacteristic,Conradi-Hünermann-Happle syndrome,Historyx ; ,xx,None,11,5,3,No,1:No,1:No,,0.926
2370,2599890,Table 1,BaselineCharacteristic,-,Early complicationsx ; ,xx,None,11,6,3,No,1:No,1:No,,0.91
2370,2599890,Table 1,BaselineCharacteristic,x,Blood loss (ml/kg)x ; ,xx,None,11,7,3,No,1:No,1:No,,0.9
2370,2599890,Table 1,BaselineCharacteristic,xx,Fluid in (ml/kg)x ; ,xx,None,11,8,3,No,1:No,1:No,,0.83
2370,2599890,Table 1,BaselineCharacteristic,x.x,Diuresis (ml/kg/hr)x ; ,xx,None,11,9,3,No,1:No,1:No,,0.92
2370,2599890,Table 1,BaselineCharacteristic,xx (xx–xx),Mean (range) MAP (mmHg)x ; ,xx,None,11,10,3,No,1:No,1:No,,0.735
2370,2599890,Table 1,BaselineCharacteristic,x.x (x.x–x.x),Mean (range) lactate (mmol/l)x ; ,xx,None,11,11,3,No,1:No,1:No,,0.78
2370,2599890,Table 1,BaselineCharacteristic,xx,Nox ; ,xx,None,12,0,2,No,1:No,1:No,,0.945
2370,2599890,Table 1,BaselineCharacteristic,xx,Age (y) ; ,xx,None,12,1,3,No,1:No,1:No,,0.921
2370,2599890,Table 1,BaselineCharacteristic,xx,Weight (kg) ; ,xx,None,12,2,3,No,1:No,1:No,,0.911
2370,2599890,Table 1,BaselineCharacteristic,ASF+PSF Tx-Sx,Surgeryx ; ,xx,None,12,3,3,No,1:No,1:No,,0.901
2370,2599890,Table 1,BaselineCharacteristic,x,Duration surgery (hr) ; ,xx,None,12,4,3,No,1:No,1:No,,0.896
2370,2599890,Table 1,BaselineCharacteristic,"cerebral palsy, spastic tertraparesis",Historyx ; ,xx,None,12,5,3,No,1:No,1:No,,0.926
2370,2599890,Table 1,BaselineCharacteristic,-,Early complicationsx ; ,xx,None,12,6,3,No,1:No,1:No,,0.91
2370,2599890,Table 1,BaselineCharacteristic,x,Blood loss (ml/kg)x ; ,xx,None,12,7,3,No,1:No,1:No,,0.9
2370,2599890,Table 1,BaselineCharacteristic,xxx,Fluid in (ml/kg)x ; ,xx,None,12,8,3,No,1:No,1:No,,0.76
2370,2599890,Table 1,BaselineCharacteristic,x.x,Diuresis (ml/kg/hr)x ; ,xx,None,12,9,3,No,1:No,1:No,,0.92
2370,2599890,Table 1,BaselineCharacteristic,xx (xx–xx),Mean (range) MAP (mmHg)x ; ,xx,None,12,10,3,No,1:No,1:No,,0.735
2370,2599890,Table 1,BaselineCharacteristic,x.x (x.x–x.x),Mean (range) lactate (mmol/l)x ; ,xx,None,12,11,3,No,1:No,1:No,,0.78
2370,2599890,Table 1,BaselineCharacteristic,xx,Nox ; ,xx,None,13,0,2,No,1:No,1:No,,0.945
2370,2599890,Table 1,BaselineCharacteristic,xx,Age (y) ; ,xx,None,13,1,3,No,1:No,1:No,,0.921
2370,2599890,Table 1,BaselineCharacteristic,xx,Weight (kg) ; ,xx,None,13,2,3,No,1:No,1:No,,0.911
2370,2599890,Table 1,BaselineCharacteristic,ASF+PSF Tx-Lx,Surgeryx ; ,xx,None,13,3,3,No,1:No,1:No,,0.891
2370,2599890,Table 1,BaselineCharacteristic,x.x,Duration surgery (hr) ; ,xx,None,13,4,3,No,1:No,1:No,,0.896
2370,2599890,Table 1,BaselineCharacteristic,-,Historyx ; ,xx,None,13,5,3,No,1:No,1:No,,0.886
2370,2599890,Table 1,BaselineCharacteristic,"fever, wound infection",Early complicationsx ; ,xx,None,13,6,3,No,1:No,1:No,,0.95
2370,2599890,Table 1,BaselineCharacteristic,xx,Blood loss (ml/kg)x ; ,xx,None,13,7,3,No,1:No,1:No,,0.9
2370,2599890,Table 1,BaselineCharacteristic,xxx,Fluid in (ml/kg)x ; ,xx,None,13,8,3,No,1:No,1:No,,0.76
2370,2599890,Table 1,BaselineCharacteristic,x.x,Diuresis (ml/kg/hr)x ; ,xx,None,13,9,3,No,1:No,1:No,,0.92
2370,2599890,Table 1,BaselineCharacteristic,xx (xx–xx),Mean (range) MAP (mmHg)x ; ,xx,None,13,10,3,No,1:No,1:No,,0.735
2370,2599890,Table 1,BaselineCharacteristic,x.x (x.x–x.x),Mean (range) lactate (mmol/l)x ; ,xx,None,13,11,3,No,1:No,1:No,,0.78
2370,2599890,Table 1,BaselineCharacteristic,xx,Nox ; ,xx,None,14,0,2,No,1:No,1:No,,0.965
2370,2599890,Table 1,BaselineCharacteristic,xx,Age (y) ; ,xx,None,14,1,3,No,1:No,1:No,,0.941
2370,2599890,Table 1,BaselineCharacteristic,xx,Weight (kg) ; ,xx,None,14,2,3,No,1:No,1:No,,0.931
2370,2599890,Table 1,BaselineCharacteristic,ASF Tx-Txx,Surgeryx ; ,xx,None,14,3,3,No,1:No,1:No,,0.911
2370,2599890,Table 1,BaselineCharacteristic,x,Duration surgery (hr) ; ,xx,None,14,4,3,No,1:No,1:No,,0.906
2370,2599890,Table 1,BaselineCharacteristic,-,Historyx ; ,xx,None,14,5,3,No,1:No,1:No,,0.896
2370,2599890,Table 1,BaselineCharacteristic,-,Early complicationsx ; ,xx,None,14,6,3,No,1:No,1:No,,0.92
2370,2599890,Table 1,BaselineCharacteristic,x,Blood loss (ml/kg)x ; ,xx,None,14,7,3,No,1:No,1:No,,0.91
2370,2599890,Table 1,BaselineCharacteristic,xx,Fluid in (ml/kg)x ; ,xx,None,14,8,3,No,1:No,1:No,,0.84
2370,2599890,Table 1,BaselineCharacteristic,x.x,Diuresis (ml/kg/hr)x ; ,xx,None,14,9,3,No,1:No,1:No,,0.93
2370,2599890,Table 1,BaselineCharacteristic,xx (xx–xx),Mean (range) MAP (mmHg)x ; ,xx,None,14,10,3,No,1:No,1:No,,0.735
2370,2599890,Table 1,BaselineCharacteristic,x.x (x.x–x.x),Mean (range) lactate (mmol/l)x ; ,xx,None,14,11,3,No,1:No,1:No,,0.78
2370,2599890,Table 1,BaselineCharacteristic,xx,Nox ; ,xx,None,15,0,2,No,1:No,1:No,,0.965
2370,2599890,Table 1,BaselineCharacteristic,xx,Age (y) ; ,xx,None,15,1,3,No,1:No,1:No,,0.941
2370,2599890,Table 1,BaselineCharacteristic,xx,Weight (kg) ; ,xx,None,15,2,3,No,1:No,1:No,,0.931
2370,2599890,Table 1,BaselineCharacteristic,PSF Tx-Sx,Surgeryx ; ,xx,None,15,3,3,No,1:No,1:No,,0.911
2370,2599890,Table 1,BaselineCharacteristic,x,Duration surgery (hr) ; ,xx,None,15,4,3,No,1:No,1:No,,0.906
2370,2599890,Table 1,BaselineCharacteristic,spina bifida; Arnold Chiari type x malformation,Historyx ; ,xx,None,15,5,3,No,1:No,1:No,,0.91
2370,2599890,Table 1,BaselineCharacteristic,peroperative anaphylactic shock to Venofundin,Early complicationsx ; ,xx,None,15,6,3,No,1:No,1:No,,0.96
2370,2599890,Table 1,BaselineCharacteristic,xx,Blood loss (ml/kg)x ; ,xx,None,15,7,3,No,1:No,1:No,,0.91
2370,2599890,Table 1,BaselineCharacteristic,xxx,Fluid in (ml/kg)x ; ,xx,None,15,8,3,No,1:No,1:No,,0.77
2370,2599890,Table 1,BaselineCharacteristic,x.x,Diuresis (ml/kg/hr)x ; ,xx,None,15,9,3,No,1:No,1:No,,0.93
2370,2599890,Table 1,BaselineCharacteristic,xx (xx–xx),Mean (range) MAP (mmHg)x ; ,xx,None,15,10,3,No,1:No,1:No,,0.735
2370,2599890,Table 1,BaselineCharacteristic,x.x (x.x–x.x),Mean (range) lactate (mmol/l)x ; ,xx,None,15,11,3,No,1:No,1:No,,0.78
2370,2599890,Table 1,BaselineCharacteristic,xx,Nox ; ,xx,None,16,0,2,No,1:No,1:No,,0.965
2370,2599890,Table 1,BaselineCharacteristic,xx,Age (y) ; ,xx,None,16,1,3,No,1:No,1:No,,0.941
2370,2599890,Table 1,BaselineCharacteristic,xx,Weight (kg) ; ,xx,None,16,2,3,No,1:No,1:No,,0.941
2370,2599890,Table 1,BaselineCharacteristic,PSF Tx-Lx,Surgeryx ; ,xx,None,16,3,3,No,1:No,1:No,,0.921
2370,2599890,Table 1,BaselineCharacteristic,x,Duration surgery (hr) ; ,xx,None,16,4,3,No,1:No,1:No,,0.906
2370,2599890,Table 1,BaselineCharacteristic,Ullrich disease,Historyx ; ,xx,None,16,5,3,No,1:No,1:No,,0.946
2370,2599890,Table 1,BaselineCharacteristic,-,Early complicationsx ; ,xx,None,16,6,3,No,1:No,1:No,,0.93
2370,2599890,Table 1,BaselineCharacteristic,xx,Blood loss (ml/kg)x ; ,xx,None,16,7,3,No,1:No,1:No,,0.92
2370,2599890,Table 1,BaselineCharacteristic,xxx,Fluid in (ml/kg)x ; ,xx,None,16,8,3,No,1:No,1:No,,0.77
2370,2599890,Table 1,BaselineCharacteristic,x.x,Diuresis (ml/kg/hr)x ; ,xx,None,16,9,3,No,1:No,1:No,,0.94
2370,2599890,Table 1,BaselineCharacteristic,xx (xx–xx),Mean (range) MAP (mmHg)x ; ,xx,None,16,10,3,No,1:No,1:No,,0.735
2370,2599890,Table 1,BaselineCharacteristic,x.x (x.x–x.x),Mean (range) lactate (mmol/l)x ; ,xx,None,16,11,3,No,1:No,1:No,,0.78
2370,2599890,Table 1,BaselineCharacteristic,xx,Nox ; ,xx,None,17,0,2,No,1:No,1:No,,0.965
2370,2599890,Table 1,BaselineCharacteristic,x,Age (y) ; ,xx,None,17,1,3,No,1:No,1:No,,0.906
2370,2599890,Table 1,BaselineCharacteristic,xx,Weight (kg) ; ,xx,None,17,2,3,No,1:No,1:No,,0.941
2370,2599890,Table 1,BaselineCharacteristic,PSF Tx-Lx,Surgeryx ; ,xx,None,17,3,3,No,1:No,1:No,,0.921
2370,2599890,Table 1,BaselineCharacteristic,x,Duration surgery (hr) ; ,xx,None,17,4,3,No,1:No,1:No,,0.906
2370,2599890,Table 1,BaselineCharacteristic,Pierre Robin Sequence; acampolic campomelic dysplasia,Historyx ; ,xx,None,17,5,3,No,1:No,1:No,,0.946
2370,2599890,Table 1,BaselineCharacteristic,-,Early complicationsx ; ,xx,None,17,6,3,No,1:No,1:No,,0.93
2370,2599890,Table 1,BaselineCharacteristic,x,Blood loss (ml/kg)x ; ,xx,None,17,7,3,No,1:No,1:No,,0.92
2370,2599890,Table 1,BaselineCharacteristic,xx,Fluid in (ml/kg)x ; ,xx,None,17,8,3,No,1:No,1:No,,0.85
2370,2599890,Table 1,BaselineCharacteristic,x.x,Diuresis (ml/kg/hr)x ; ,xx,None,17,9,3,No,1:No,1:No,,0.94
2370,2599890,Table 1,BaselineCharacteristic,xx (xx–xx),Mean (range) MAP (mmHg)x ; ,xx,None,17,10,3,No,1:No,1:No,,0.735
2370,2599890,Table 1,BaselineCharacteristic,x.x (x.x–x.x),Mean (range) lactate (mmol/l)x ; ,xx,None,17,11,3,No,1:No,1:No,,0.78
2370,2599890,Table 1,BaselineCharacteristic,xx,Nox ; ,xx,None,18,0,2,No,1:No,1:No,,0.951
2370,2599890,Table 1,BaselineCharacteristic,xx,Age (y) ; ,xx,None,18,1,3,No,1:No,1:No,,0.927
2370,2599890,Table 1,BaselineCharacteristic,xx,Weight (kg) ; ,xx,None,18,2,3,No,1:No,1:No,,0.927
2370,2599890,Table 1,BaselineCharacteristic,PSF Tx-Lx,Surgeryx ; ,xx,None,18,3,3,No,1:No,1:No,,0.907
2370,2599890,Table 1,BaselineCharacteristic,x,Duration surgery (hr) ; ,xx,None,18,4,3,No,1:No,1:No,,0.901
2370,2599890,Table 1,BaselineCharacteristic,-,Historyx ; ,xx,None,18,5,3,No,1:No,1:No,,0.891
2370,2599890,Table 1,BaselineCharacteristic,UTI,Early complicationsx ; ,xx,None,18,6,3,No,1:No,1:No,,0.965
2370,2599890,Table 1,BaselineCharacteristic,x,Blood loss (ml/kg)x ; ,xx,None,18,7,3,No,1:No,1:No,,0.92
2370,2599890,Table 1,BaselineCharacteristic,xx,Fluid in (ml/kg)x ; ,xx,None,18,8,3,No,1:No,1:No,,0.845
2370,2599890,Table 1,BaselineCharacteristic,x.x,Diuresis (ml/kg/hr)x ; ,xx,None,18,9,3,No,1:No,1:No,,0.935
2370,2599890,Table 1,BaselineCharacteristic,xx (xx–xx),Mean (range) MAP (mmHg)x ; ,xx,None,18,10,3,No,1:No,1:No,,0.735
2370,2599890,Table 1,BaselineCharacteristic,x.x (x.x–x.x),Mean (range) lactate (mmol/l)x ; ,xx,None,18,11,3,No,1:No,1:No,,0.775
2370,2599890,Table 1,BaselineCharacteristic,xx,Nox ; ,xx,None,19,0,2,No,1:No,1:No,,0.951
2370,2599890,Table 1,BaselineCharacteristic,xx,Age (y) ; ,xx,None,19,1,3,No,1:No,1:No,,0.927
2370,2599890,Table 1,BaselineCharacteristic,xx,Weight (kg) ; ,xx,None,19,2,3,No,1:No,1:No,,0.927
2370,2599890,Table 1,BaselineCharacteristic,PSF Tx-Lx,Surgeryx ; ,xx,None,19,3,3,No,1:No,1:No,,0.907
2370,2599890,Table 1,BaselineCharacteristic,x.x,Duration surgery (hr) ; ,xx,None,19,4,3,No,1:No,1:No,,0.901
2370,2599890,Table 1,BaselineCharacteristic,-,Historyx ; ,xx,None,19,5,3,No,1:No,1:No,,0.891
2370,2599890,Table 1,BaselineCharacteristic,-,Early complicationsx ; ,xx,None,19,6,3,No,1:No,1:No,,0.925
2370,2599890,Table 1,BaselineCharacteristic,xx,Blood loss (ml/kg)x ; ,xx,None,19,7,3,No,1:No,1:No,,0.92
2370,2599890,Table 1,BaselineCharacteristic,xxx,Fluid in (ml/kg)x ; ,xx,None,19,8,3,No,1:No,1:No,,0.77
2370,2599890,Table 1,BaselineCharacteristic,x.x,Diuresis (ml/kg/hr)x ; ,xx,None,19,9,3,No,1:No,1:No,,0.935
2370,2599890,Table 1,BaselineCharacteristic,xx (xx–xx),Mean (range) MAP (mmHg)x ; ,xx,None,19,10,3,No,1:No,1:No,,0.735
2370,2599890,Table 1,BaselineCharacteristic,x.x (x.x–x.x),Mean (range) lactate (mmol/l)x ; ,xx,None,19,11,3,No,1:No,1:No,,0.775
2370,2599890,Table 1,BaselineCharacteristic,xx,Nox ; ,xx,None,20,0,2,No,1:No,1:No,,0.951
2370,2599890,Table 1,BaselineCharacteristic,xx,Age (y) ; ,xx,None,20,1,3,No,1:No,1:No,,0.927
2370,2599890,Table 1,BaselineCharacteristic,xx,Weight (kg) ; ,xx,None,20,2,3,No,1:No,1:No,,0.927
2370,2599890,Table 1,BaselineCharacteristic,PSF Lx-Sx,Surgeryx ; ,xx,None,20,3,3,No,1:No,1:No,,0.907
2370,2599890,Table 1,BaselineCharacteristic,x,Duration surgery (hr) ; ,xx,None,20,4,3,No,1:No,1:No,,0.901
2370,2599890,Table 1,BaselineCharacteristic,spondylolisthesis,Historyx ; ,xx,None,20,5,3,No,1:No,1:No,,0.931
2370,2599890,Table 1,BaselineCharacteristic,-,Early complicationsx ; ,xx,None,20,6,3,No,1:No,1:No,,0.925
2370,2599890,Table 1,BaselineCharacteristic,xx,Blood loss (ml/kg)x ; ,xx,None,20,7,3,No,1:No,1:No,,0.92
2370,2599890,Table 1,BaselineCharacteristic,xxx,Fluid in (ml/kg)x ; ,xx,None,20,8,3,No,1:No,1:No,,0.77
2370,2599890,Table 1,BaselineCharacteristic,x.x,Diuresis (ml/kg/hr)x ; ,xx,None,20,9,3,No,1:No,1:No,,0.935
2370,2599890,Table 1,BaselineCharacteristic,xx (xx–xx),Mean (range) MAP (mmHg)x ; ,xx,None,20,10,3,No,1:No,1:No,,0.735
2370,2599890,Table 1,BaselineCharacteristic,x.x (x.x–x.x),Mean (range) lactate (mmol/l)x ; ,xx,None,20,11,3,No,1:No,1:No,,0.775
2478,2656521,Table 1,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
2478,2656521,Table 1,BaselineCharacteristic,Steatohepatitis (n xx),,,None,0,1,1,No,1:No,1:No,,0.523
2478,2656521,Table 1,BaselineCharacteristic,Diffuse Steatosis(n xx),,,None,0,2,1,No,1:No,1:No,,0.565
2478,2656521,Table 1,BaselineCharacteristic,Focal Fatty Liver (n x),,,None,0,3,1,No,1:No,1:No,,0.653
2478,2656521,Table 1,BaselineCharacteristic,Controls (n xx),,,None,0,4,1,No,1:No,1:No,,0.575
2478,2656521,Table 1,BaselineCharacteristic,Age(years), ; ,Age(years),None,1,0,2,No,1:No,1:No,,0.65
2478,2656521,Table 1,BaselineCharacteristic,BMI (kg\mx), ; ,BMI (kg\mx),None,2,0,2,No,1:No,1:No,,0.95
2478,2656521,Table 1,BaselineCharacteristic,xx.x ± x.x,Diffuse Steatosis(n xx) ; ,BMI (kg\mx),None,2,2,3,No,1:No,1:No,,0.56
2478,2656521,Table 1,BaselineCharacteristic,xx.x ± x.x*,Controls (n xx) ; ,BMI (kg\mx),None,2,4,3,No,1:No,1:No,,0.57
2478,2656521,Table 1,BaselineCharacteristic,ALT (U\l), ; ,ALT (U\l),None,3,0,2,No,1:No,1:No,,0.97
2478,2656521,Table 1,BaselineCharacteristic,xx.x ± xx.x,Diffuse Steatosis(n xx) ; ,ALT (U\l),None,3,2,3,No,1:No,1:No,,0.52
2478,2656521,Table 1,BaselineCharacteristic,xx.x ± x.x*,Controls (n xx) ; ,ALT (U\l),None,3,4,3,No,1:No,1:No,,0.53
2478,2656521,Table 1,BaselineCharacteristic,AST (U\l), ; ,AST (U\l),None,4,0,2,No,1:No,1:No,,0.97
2478,2656521,Table 1,BaselineCharacteristic,xx.x ± x.x,Diffuse Steatosis(n xx) ; ,AST (U\l),None,4,2,3,No,1:No,1:No,,0.56
2478,2656521,Table 1,BaselineCharacteristic,xx.x ± x.x*,Controls (n xx) ; ,AST (U\l),None,4,4,3,No,1:No,1:No,,0.576
2478,2656521,Table 1,BaselineCharacteristic,GGT, ; ,GGT,None,5,0,2,No,1:No,1:No,,0.97
2478,2656521,Table 1,BaselineCharacteristic,xx.x ± x.x,Diffuse Steatosis(n xx) ; ,GGT,None,5,2,3,No,1:No,1:No,,0.56
2478,2656521,Table 1,BaselineCharacteristic,xx.x ± x.x,Controls (n xx) ; ,GGT,None,5,4,3,No,1:No,1:No,,0.566
2478,2656521,Table 1,BaselineCharacteristic,Cholesterol (mg\dl), ; ,Cholesterol (mg\dl),None,6,0,2,No,1:No,1:No,,0.99
2478,2656521,Table 1,BaselineCharacteristic,xxx.x ± xx.x,Diffuse Steatosis(n xx) ; ,Cholesterol (mg\dl),None,6,2,3,No,1:No,1:No,,0.51
2478,2656521,Table 1,BaselineCharacteristic,xxx ± xx.x,Controls (n xx) ; ,Cholesterol (mg\dl),None,6,4,3,No,1:No,1:No,,0.546
2478,2656521,Table 1,BaselineCharacteristic,Triglyceride (mg\dl), ; ,Triglyceride (mg\dl),None,7,0,2,No,1:No,1:No,,0.99
2478,2656521,Table 1,BaselineCharacteristic,xxx.x ± xx.x,Diffuse Steatosis(n xx) ; ,Triglyceride (mg\dl),None,7,2,3,No,1:No,1:No,,0.54
2478,2656521,Table 1,BaselineCharacteristic,xx.x ± xx.x,Focal Fatty Liver (n x) ; ,Triglyceride (mg\dl),None,7,3,3,No,1:No,1:No,,0.556
2478,2656521,Table 1,BaselineCharacteristic,xx ± xx.x,Controls (n xx) ; ,Triglyceride (mg\dl),None,7,4,3,No,1:No,1:No,,0.656
2478,2656521,Table 1,BaselineCharacteristic,HOMA-IR, ; ,HOMA-IR,None,8,0,2,No,1:No,1:No,,0.99
2478,2656521,Table 1,BaselineCharacteristic,x.x ± x.x,Steatohepatitis (n xx) ; ,HOMA-IR,None,8,1,3,No,1:No,1:No,,0.586
2478,2656521,Table 1,BaselineCharacteristic,x.x ± x.x,Diffuse Steatosis(n xx) ; ,HOMA-IR,None,8,2,3,No,1:No,1:No,,0.67
2478,2656521,Table 1,BaselineCharacteristic,x.x ± x.x,Focal Fatty Liver (n x) ; ,HOMA-IR,None,8,3,3,No,1:No,1:No,,0.786
2478,2656521,Table 1,BaselineCharacteristic,x.x ± x.x*,Controls (n xx) ; ,HOMA-IR,None,8,4,3,No,1:No,1:No,,0.716
2478,2656521,Table 1,BaselineCharacteristic,USG Steatosis Grade, ; ,USG Steatosis Grade,None,9,0,2,No,1:No,1:No,,0.98
2478,2656521,Table 1,BaselineCharacteristic,x.xx ± x.xx,Steatohepatitis (n xx) ; ,USG Steatosis Grade,None,9,1,3,No,1:No,1:No,,0.58
2478,2656521,Table 1,BaselineCharacteristic,x.xx ± x.xx,Diffuse Steatosis(n xx) ; ,USG Steatosis Grade,None,9,2,3,No,1:No,1:No,,0.68
2478,2656521,Table 1,BaselineCharacteristic,x,Focal Fatty Liver (n x) ; ,USG Steatosis Grade,None,9,3,3,No,1:No,1:No,,0.81
2478,2656521,Table 1,BaselineCharacteristic,x,Controls (n xx) ; ,USG Steatosis Grade,None,9,4,3,No,1:No,1:No,,0.726
2486,2659603,Table 1,BaselineCharacteristic,Patient,,None,None,0,0,12,No,1:No,1:No,,0.905
2486,2659603,Table 1,BaselineCharacteristic,Age,,Patient,None,0,1,1,No,1:No,1:No,,0.903
2486,2659603,Table 1,BaselineCharacteristic,LAD (cm),,Patient,None,0,2,1,No,1:No,1:No,,0.903
2486,2659603,Table 1,BaselineCharacteristic,FS (%),,Patient,None,0,3,1,No,1:No,1:No,,0.813
2486,2659603,Table 1,BaselineCharacteristic,No. of AADs,,Patient,None,0,4,1,No,1:No,1:No,,0.903
2486,2659603,Table 1,BaselineCharacteristic,Arrhythmia duration (years),,Patient,None,0,5,1,No,1:No,1:No,,0.677
2486,2659603,Table 1,BaselineCharacteristic,x,Patient ; ,x,None,1,0,2,No,1:No,1:No,,0.915
2486,2659603,Table 1,BaselineCharacteristic,xx,Age ; ,x,None,1,1,3,No,1:No,1:No,,0.612
2486,2659603,Table 1,BaselineCharacteristic,x.xx,LAD (cm) ; ,x,None,1,2,3,No,1:No,1:No,,0.632
2486,2659603,Table 1,BaselineCharacteristic,x,No. of AADs ; ,x,None,1,4,3,No,1:No,1:No,,0.88
2486,2659603,Table 1,BaselineCharacteristic,x,Arrhythmia duration (years) ; ,x,None,1,5,3,No,1:No,1:No,,0.65
2486,2659603,Table 1,BaselineCharacteristic,x,Patient ; ,x,None,2,0,2,No,1:No,1:No,,0.935
2486,2659603,Table 1,BaselineCharacteristic,xx,Age ; ,x,None,2,1,3,No,1:No,1:No,,0.632
2486,2659603,Table 1,BaselineCharacteristic,x.xx,LAD (cm) ; ,x,None,2,2,3,No,1:No,1:No,,0.662
2486,2659603,Table 1,BaselineCharacteristic,x,No. of AADs ; ,x,None,2,4,3,No,1:No,1:No,,0.9
2486,2659603,Table 1,BaselineCharacteristic,x,Arrhythmia duration (years) ; ,x,None,2,5,3,No,1:No,1:No,,0.66
2486,2659603,Table 1,BaselineCharacteristic,x,Patient ; ,x,None,3,0,2,No,1:No,1:No,,0.945
2486,2659603,Table 1,BaselineCharacteristic,xx,Age ; ,x,None,3,1,3,No,1:No,1:No,,0.646
2486,2659603,Table 1,BaselineCharacteristic,x.xx,LAD (cm) ; ,x,None,3,2,3,No,1:No,1:No,,0.666
2486,2659603,Table 1,BaselineCharacteristic,x,No. of AADs ; ,x,None,3,4,3,No,1:No,1:No,,0.92
2486,2659603,Table 1,BaselineCharacteristic,x,Arrhythmia duration (years) ; ,x,None,3,5,3,No,1:No,1:No,,0.68
2486,2659603,Table 1,BaselineCharacteristic,x,Patient ; ,x,None,4,0,2,No,1:No,1:No,,0.965
2486,2659603,Table 1,BaselineCharacteristic,xx,Age ; ,x,None,4,1,3,No,1:No,1:No,,0.726
2486,2659603,Table 1,BaselineCharacteristic,x.xx,LAD (cm) ; ,x,None,4,2,3,No,1:No,1:No,,0.746
2486,2659603,Table 1,BaselineCharacteristic,xx.x,FS (%) ; ,x,None,4,3,3,No,1:No,1:No,,0.586
2486,2659603,Table 1,BaselineCharacteristic,x,No. of AADs ; ,x,None,4,4,3,No,1:No,1:No,,0.92
2486,2659603,Table 1,BaselineCharacteristic,x,Arrhythmia duration (years) ; ,x,None,4,5,3,No,1:No,1:No,,0.68
2486,2659603,Table 1,BaselineCharacteristic,x,Patient ; ,x,None,5,0,2,No,1:No,1:No,,0.963
2486,2659603,Table 1,BaselineCharacteristic,xx,Age ; ,x,None,5,1,3,No,1:No,1:No,,0.726
2486,2659603,Table 1,BaselineCharacteristic,x.x,LAD (cm) ; ,x,None,5,2,3,No,1:No,1:No,,0.94
2486,2659603,Table 1,BaselineCharacteristic,xx.xx,FS (%) ; ,x,None,5,3,3,No,1:No,1:No,,0.586
2486,2659603,Table 1,BaselineCharacteristic,x,No. of AADs ; ,x,None,5,4,3,No,1:No,1:No,,0.92
2486,2659603,Table 1,BaselineCharacteristic,x,Arrhythmia duration (years) ; ,x,None,5,5,3,No,1:No,1:No,,0.68
2486,2659603,Table 1,BaselineCharacteristic,x,Patient ; ,x,None,6,0,2,No,1:No,1:No,,0.973
2486,2659603,Table 1,BaselineCharacteristic,xx,Age ; ,x,None,6,1,3,No,1:No,1:No,,0.746
2486,2659603,Table 1,BaselineCharacteristic,x.xx,LAD (cm) ; ,x,None,6,2,3,No,1:No,1:No,,0.766
2486,2659603,Table 1,BaselineCharacteristic,xx.xx,FS (%) ; ,x,None,6,3,3,No,1:No,1:No,,0.636
2486,2659603,Table 1,BaselineCharacteristic,x,No. of AADs ; ,x,None,6,4,3,No,1:No,1:No,,0.94
2486,2659603,Table 1,BaselineCharacteristic,x,Arrhythmia duration (years) ; ,x,None,6,5,3,No,1:No,1:No,,0.68
2656,270679,Table 1,BaselineCharacteristic,Age (years),,Age (years),,0,0,2,No,1:No,1:No,,0.65
2656,270679,Table 1,BaselineCharacteristic,Sex (male/female),,Sex (male/female),,1,0,2,No,1:No,1:No,,0.94
2656,270679,Table 1,BaselineCharacteristic,xx/xx,,Sex (male/female),,1,1,3,No,1:No,1:No,,0.87
2656,270679,Table 1,BaselineCharacteristic,Acute Physiology and Chronic Health Evaluation II,,Acute Physiology and Chronic Health Evaluation II,,2,0,2,No,1:No,1:No,,0.96
2656,270679,Table 1,BaselineCharacteristic,xx (x–xx),,Acute Physiology and Chronic Health Evaluation II,,2,1,3,No,1:No,1:No,,0.646
2656,270679,Table 1,BaselineCharacteristic,Mechanical ventilation (%),,Mechanical ventilation (%),,3,0,2,No,1:No,1:No,,0.85
2656,270679,Table 1,BaselineCharacteristic,xx,,Mechanical ventilation (%),,3,1,3,No,1:No,1:No,,0.561
2656,270679,Table 1,BaselineCharacteristic,Standardised mortality ratio,,Standardised mortality ratio,,4,0,2,No,1:No,1:No,,0.97
2656,270679,Table 1,BaselineCharacteristic,x.xx,,Standardised mortality ratio,,4,1,3,No,1:No,1:No,,0.726
2656,270679,Table 1,BaselineCharacteristic,Hospital mortality (%),,Hospital mortality (%),,5,0,2,No,1:No,1:No,,0.87
2656,270679,Table 1,BaselineCharacteristic,xx,,Hospital mortality (%),,5,1,3,No,1:No,1:No,,0.621
2656,270679,Table 1,BaselineCharacteristic,Diagnosis,,None,None,6,0,24,No,1:No,1:No,,0.969
2656,270679,Table 1,BaselineCharacteristic,,,Diagnosis,None,6,1,43,No,1:No,1:No,,0.952
2656,270679,Table 1,BaselineCharacteristic,?Septic shock,,?Septic shock, Diagnosis,7,0,2,No,1:No,1:No,,0.99
2656,270679,Table 1,BaselineCharacteristic,xx,,?Septic shock, Diagnosis,7,1,3,No,1:No,1:No,,0.811
2656,270679,Table 1,BaselineCharacteristic,?Hypovolemic shock,,?Hypovolemic shock, Diagnosis,8,0,2,No,1:No,1:No,,0.99
2656,270679,Table 1,BaselineCharacteristic,xx,,?Hypovolemic shock, Diagnosis,8,1,3,No,1:No,1:No,,0.821
2656,270679,Table 1,BaselineCharacteristic,?Cardiogenic shock,,?Cardiogenic shock, Diagnosis,9,0,2,No,1:No,1:No,,1
2656,270679,Table 1,BaselineCharacteristic,x,,?Cardiogenic shock, Diagnosis,9,1,3,No,1:No,1:No,,0.98
2656,270679,Table 1,BaselineCharacteristic,?Other,,?Other, Diagnosis,10,0,2,No,1:No,1:No,,1
2656,270679,Table 1,BaselineCharacteristic,x,,?Other, Diagnosis,10,1,3,No,1:No,1:No,,1
2688,2718192,Table 1,BaselineCharacteristic,Subject characteristics,,None,None,0,0,12,No,1:No,1:No,,0.825
2688,2718192,Table 1,BaselineCharacteristic,x.xxx mg dose,,Subject characteristics,None,0,1,1,No,1:No,1:No,,0.849
2688,2718192,Table 1,BaselineCharacteristic,x.xxxx mg dose,,Subject characteristics,None,0,2,1,No,1:No,1:No,,0.837
2688,2718192,Table 1,BaselineCharacteristic,"Age (mean (range), years)",Subject characteristics ; ,"Age (mean (range), years)",,1,0,2,No,1:No,1:No,,0.503
2688,2718192,Table 1,BaselineCharacteristic,"Weight (mean (range), kg)",Subject characteristics ; ,"Weight (mean (range), kg)",,2,0,2,No,1:No,1:No,,0.663
2688,2718192,Table 1,BaselineCharacteristic,"Dose PRAM (mean (range), mg/kg x xxx)",Subject characteristics ; ,"Dose PRAM (mean (range), mg/kg x xxx)",,3,0,2,No,1:No,1:No,,0.567
2688,2718192,Table 1,BaselineCharacteristic,"Daily caffeine intake (mean (range), mg)",Subject characteristics ; ,"Daily caffeine intake (mean (range), mg)",,4,0,2,No,1:No,1:No,,0.653
2688,2718192,Table 1,BaselineCharacteristic,xxx.x (x.x-xxx.x),x.xxx mg dose ; ,"Daily caffeine intake (mean (range), mg)",,4,1,3,No,1:No,1:No,,0.565
2688,2718192,Table 1,BaselineCharacteristic,Personality scale scores (mean (range)),Subject characteristics ; ,None,None,5,0,2,No,1:No,1:No,,0.703
2688,2718192,Table 1,BaselineCharacteristic,,x.xxx mg dose ; ,None,None,5,1,3,No,1:No,1:No,,0.905
2688,2718192,Table 1,BaselineCharacteristic,,x.xxxx mg dose ; ,None,None,5,2,3,No,1:No,1:No,,0.935
2688,2718192,Table 1,BaselineCharacteristic,TPQ,Subject characteristics ; ,None,None,6,0,24,No,1:No,1:No,,0.884
2688,2718192,Table 1,BaselineCharacteristic,,x.xxx mg dose ; ,TPQ,None,6,1,43,No,1:No,1:No,,0.918
2688,2718192,Table 1,BaselineCharacteristic,,x.xxxx mg dose ; ,TPQ,None,6,2,43,No,1:No,1:No,,0.933
2688,2718192,Table 1,BaselineCharacteristic,,Subject characteristics ; ,, Personality scale scores (mean (range)) TPQ,7,0,2,No,1:No,1:No,,0.713
2688,2718192,Table 1,BaselineCharacteristic,,Subject characteristics ; ,, Personality scale scores (mean (range)) TPQ,8,0,2,No,1:No,1:No,,0.723
2688,2718192,Table 1,BaselineCharacteristic,x (x–xx),x.xxx mg dose ; ,, Personality scale scores (mean (range)) TPQ,8,1,3,No,1:No,1:No,,0.64
2688,2718192,Table 1,BaselineCharacteristic,x (x–xx),x.xxxx mg dose ; ,, Personality scale scores (mean (range)) TPQ,8,2,3,No,1:No,1:No,,0.66
2688,2718192,Table 1,BaselineCharacteristic,,Subject characteristics ; ,, Personality scale scores (mean (range)) TPQ,9,0,2,No,1:No,1:No,,0.723
2688,2718192,Table 1,BaselineCharacteristic,xx (x–xx),x.xxx mg dose ; ,, Personality scale scores (mean (range)) TPQ,9,1,3,No,1:No,1:No,,0.51
2688,2718192,Table 1,BaselineCharacteristic,SSS,Subject characteristics ; ,None,None,10,0,24,No,1:No,1:No,,0.895
2688,2718192,Table 1,BaselineCharacteristic,,x.xxx mg dose ; ,SSS,None,10,1,43,No,1:No,1:No,,0.953
2688,2718192,Table 1,BaselineCharacteristic,,x.xxxx mg dose ; ,SSS,None,10,2,43,No,1:No,1:No,,0.968
2688,2718192,Table 1,BaselineCharacteristic,,Subject characteristics ; ,, Personality scale scores (mean (range)) SSS,11,0,2,No,1:No,1:No,,0.743
2688,2718192,Table 1,BaselineCharacteristic,xx (xx–xx),x.xxx mg dose ; ,, Personality scale scores (mean (range)) SSS,11,1,3,No,1:No,1:No,,0.515
2688,2718192,Table 1,BaselineCharacteristic,xx (x–xx),x.xxxx mg dose ; ,, Personality scale scores (mean (range)) SSS,11,2,3,No,1:No,1:No,,0.56
2688,2718192,Table 1,BaselineCharacteristic,EPQ,Subject characteristics ; ,None,None,12,0,24,No,1:No,1:No,,0.895
2688,2718192,Table 1,BaselineCharacteristic,,x.xxx mg dose ; ,EPQ,None,12,1,43,No,1:No,1:No,,0.953
2688,2718192,Table 1,BaselineCharacteristic,,x.xxxx mg dose ; ,EPQ,None,12,2,43,No,1:No,1:No,,0.968
2688,2718192,Table 1,BaselineCharacteristic,,Subject characteristics ; ,, Personality scale scores (mean (range)) EPQ,13,0,2,No,1:No,1:No,,0.743
2688,2718192,Table 1,BaselineCharacteristic,xx (x–xx),x.xxx mg dose ; ,, Personality scale scores (mean (range)) EPQ,13,1,3,No,1:No,1:No,,0.55
2688,2718192,Table 1,BaselineCharacteristic,xx (x–xx),x.xxxx mg dose ; ,, Personality scale scores (mean (range)) EPQ,13,2,3,No,1:No,1:No,,0.56
2737,2734077,Table 1,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
2737,2734077,Table 1,BaselineCharacteristic,Patients,,,None,0,2,1,No,1:No,1:No,,0.903
2737,2734077,Table 1,BaselineCharacteristic,Patients,,,None,0,3,1,No,1:No,1:No,,0.903
2737,2734077,Table 1,BaselineCharacteristic,, ; ,None,None,1,0,12,No,1:No,1:No,,0.898
2737,2734077,Table 1,BaselineCharacteristic,Demographics, ;  ; ,Demographics,,2,0,2,No,1:No,1:No,,0.95
2737,2734077,Table 1,BaselineCharacteristic,Age (Years), ;  ; ,Age (Years),,3,0,2,No,1:No,1:No,,0.96
2737,2734077,Table 1,BaselineCharacteristic,Education (Years), ;  ; ,Education (Years),,4,0,2,No,1:No,1:No,,0.97
2737,2734077,Table 1,BaselineCharacteristic,xx.xx (x.xx),"Patients ; CBT+TAU Group (n = xx, xx men) ; ",Education (Years),,4,2,3,No,1:No,1:No,,0.547
2737,2734077,Table 1,BaselineCharacteristic,xx.xx (x.xx),"Patients ; TAU-Alone Group (n = xx, xx men) ; ",Education (Years),,4,3,3,No,1:No,1:No,,0.551
2737,2734077,Table 1,BaselineCharacteristic,Predicted IQa, ;  ; ,Predicted IQa,,5,0,2,No,1:No,1:No,,0.97
2737,2734077,Table 1,BaselineCharacteristic,Performance, ;  ; ,Performance,,6,0,2,No,1:No,1:No,,0.99
2737,2734077,Table 1,BaselineCharacteristic,Mean (SEM),Healthy Participants (n = xx; xx men) ; Healthy Participants (n = xx; xx men) ; ,Performance,,6,1,3,No,1:No,1:No,,0.521
2737,2734077,Table 1,BaselineCharacteristic,Mean (SEM),"Patients ; CBT+TAU Group (n = xx, xx men) ; ",Performance,,6,2,3,No,1:No,1:No,,0.637
2737,2734077,Table 1,BaselineCharacteristic,Mean (SEM),"Patients ; TAU-Alone Group (n = xx, xx men) ; ",Performance,,6,3,3,No,1:No,1:No,,0.661
2737,2734077,Table 1,BaselineCharacteristic,Accuracy (%; Chance Performance = xx%), ;  ; ,None,None,7,0,24,No,1:No,1:No,,0.897
2737,2734077,Table 1,BaselineCharacteristic,,Healthy Participants (n = xx; xx men) ; Healthy Participants (n = xx; xx men) ; ,Accuracy (%; Chance Performance = xx%),None,7,1,43,No,1:No,1:No,,0.6
2737,2734077,Table 1,BaselineCharacteristic,,"Patients ; CBT+TAU Group (n = xx, xx men) ; ",Accuracy (%; Chance Performance = xx%),None,7,2,43,No,1:No,1:No,,0.676
2737,2734077,Table 1,BaselineCharacteristic,,"Patients ; TAU-Alone Group (n = xx, xx men) ; ",Accuracy (%; Chance Performance = xx%),None,7,3,43,No,1:No,1:No,,0.716
2737,2734077,Table 1,BaselineCharacteristic,, ;  ; ,, Accuracy (%; Chance Performance = xx%),8,0,2,No,1:No,1:No,,0.887
2737,2734077,Table 1,BaselineCharacteristic,xx.xx (x.xx),"Patients ; CBT+TAU Group (n = xx, xx men) ; ",, Accuracy (%; Chance Performance = xx%),8,2,3,No,1:No,1:No,,0.561
2737,2734077,Table 1,BaselineCharacteristic,xx.xx (x.xx),"Patients ; TAU-Alone Group (n = xx, xx men) ; ",, Accuracy (%; Chance Performance = xx%),8,3,3,No,1:No,1:No,,0.581
2737,2734077,Table 1,BaselineCharacteristic,, ;  ; ,, Accuracy (%; Chance Performance = xx%),9,0,2,No,1:No,1:No,,0.907
2737,2734077,Table 1,BaselineCharacteristic,xx.xx (x.xx),"Patients ; CBT+TAU Group (n = xx, xx men) ; ",, Accuracy (%; Chance Performance = xx%),9,2,3,No,1:No,1:No,,0.571
2737,2734077,Table 1,BaselineCharacteristic,xx.xx (x.xx),"Patients ; TAU-Alone Group (n = xx, xx men) ; ",, Accuracy (%; Chance Performance = xx%),9,3,3,No,1:No,1:No,,0.591
2737,2734077,Table 1,BaselineCharacteristic,, ;  ; ,, Accuracy (%; Chance Performance = xx%),10,0,2,No,1:No,1:No,,0.917
2737,2734077,Table 1,BaselineCharacteristic,xx.xx (x.xx),Healthy Participants (n = xx; xx men) ; Healthy Participants (n = xx; xx men) ; ,, Accuracy (%; Chance Performance = xx%),10,1,3,No,1:No,1:No,,0.516
2737,2734077,Table 1,BaselineCharacteristic,xx.xx (x.xx),"Patients ; CBT+TAU Group (n = xx, xx men) ; ",, Accuracy (%; Chance Performance = xx%),10,2,3,No,1:No,1:No,,0.601
2737,2734077,Table 1,BaselineCharacteristic,xx.xx (x.xx),"Patients ; TAU-Alone Group (n = xx, xx men) ; ",, Accuracy (%; Chance Performance = xx%),10,3,3,No,1:No,1:No,,0.621
2737,2734077,Table 1,BaselineCharacteristic,Reaction Time (msec), ;  ; ,None,None,11,0,24,No,1:No,1:No,,0.995
2737,2734077,Table 1,BaselineCharacteristic,,Healthy Participants (n = xx; xx men) ; Healthy Participants (n = xx; xx men) ; ,Reaction Time (msec),None,11,1,43,No,1:No,1:No,,0.644
2737,2734077,Table 1,BaselineCharacteristic,,"Patients ; CBT+TAU Group (n = xx, xx men) ; ",Reaction Time (msec),None,11,2,43,No,1:No,1:No,,0.7
2737,2734077,Table 1,BaselineCharacteristic,,"Patients ; TAU-Alone Group (n = xx, xx men) ; ",Reaction Time (msec),None,11,3,43,No,1:No,1:No,,0.744
2737,2734077,Table 1,BaselineCharacteristic,, ;  ; ,, Reaction Time (msec),12,0,2,No,1:No,1:No,,1
2737,2734077,Table 1,BaselineCharacteristic,xxx.xx (xx.xx),Healthy Participants (n = xx; xx men) ; Healthy Participants (n = xx; xx men) ; ,, Reaction Time (msec),12,1,3,No,1:No,1:No,,0.501
2737,2734077,Table 1,BaselineCharacteristic,?xxx.xx (xx.xx),"Patients ; CBT+TAU Group (n = xx, xx men) ; ",, Reaction Time (msec),12,2,3,No,1:No,1:No,,0.587
2737,2734077,Table 1,BaselineCharacteristic,?xxx.xx (xx.xx),"Patients ; TAU-Alone Group (n = xx, xx men) ; ",, Reaction Time (msec),12,3,3,No,1:No,1:No,,0.611
2737,2734077,Table 1,BaselineCharacteristic,, ;  ; ,, Reaction Time (msec),13,0,2,No,1:No,1:No,,1
2737,2734077,Table 1,BaselineCharacteristic,xxx.xx (xx.xx),Healthy Participants (n = xx; xx men) ; Healthy Participants (n = xx; xx men) ; ,, Reaction Time (msec),13,1,3,No,1:No,1:No,,0.501
2737,2734077,Table 1,BaselineCharacteristic,?xxx.xx (xx.xx),"Patients ; CBT+TAU Group (n = xx, xx men) ; ",, Reaction Time (msec),13,2,3,No,1:No,1:No,,0.587
2737,2734077,Table 1,BaselineCharacteristic,?xxx.xx (xx.xx),"Patients ; TAU-Alone Group (n = xx, xx men) ; ",, Reaction Time (msec),13,3,3,No,1:No,1:No,,0.611
2737,2734077,Table 1,BaselineCharacteristic,, ;  ; ,, Reaction Time (msec),14,0,2,No,1:No,1:No,,1
2737,2734077,Table 1,BaselineCharacteristic,xxx.xx (xx.xx),Healthy Participants (n = xx; xx men) ; Healthy Participants (n = xx; xx men) ; ,, Reaction Time (msec),14,1,3,No,1:No,1:No,,0.501
2737,2734077,Table 1,BaselineCharacteristic,?xxx.xx (xx.xx),"Patients ; CBT+TAU Group (n = xx, xx men) ; ",, Reaction Time (msec),14,2,3,No,1:No,1:No,,0.597
2737,2734077,Table 1,BaselineCharacteristic,?xxx.xx (xx.xx),"Patients ; TAU-Alone Group (n = xx, xx men) ; ",, Reaction Time (msec),14,3,3,No,1:No,1:No,,0.621
2737,2734077,Table 1,BaselineCharacteristic,Patients Only,,None,None,0,0,12,No,1:No,1:No,,0.905
2737,2734077,Table 1,BaselineCharacteristic,Patients Only,,Patients Only,None,0,1,1,No,1:No,1:No,,0.903
2737,2734077,Table 1,BaselineCharacteristic,Patients Only,,Patients Only,None,0,2,1,No,1:No,1:No,,0.903
2737,2734077,Table 1,BaselineCharacteristic,Patients Only,,Patients Only,None,0,3,1,No,1:No,1:No,,0.903
2737,2734077,Table 1,BaselineCharacteristic,Patients Only,,Patients Only,None,0,4,1,No,1:No,1:No,,0.913
2737,2734077,Table 1,BaselineCharacteristic,Patients Only,,Patients Only,None,0,5,1,No,1:No,1:No,,0.935
2737,2734077,Table 1,BaselineCharacteristic,Patients Only,,Patients Only,None,0,6,1,No,1:No,1:No,,0.935
2737,2734077,Table 1,BaselineCharacteristic,,Patients Only ; ,None,None,1,0,12,No,1:No,1:No,,0.898
2737,2734077,Table 1,BaselineCharacteristic,CBT+TAU Group Mean (SD),Patients Only ; ,,None,1,1,1,No,1:No,1:No,,0.775
2737,2734077,Table 1,BaselineCharacteristic,CBT+TAU Group Mean (SD),Patients Only ; ,,None,1,2,1,No,1:No,1:No,,0.768
2737,2734077,Table 1,BaselineCharacteristic,CBT+TAU Group Mean (SD),Patients Only ; ,,None,1,3,1,No,1:No,1:No,,0.768
2737,2734077,Table 1,BaselineCharacteristic,TAU-alone Group Mean (SD),Patients Only ; ,,None,1,4,1,No,1:No,1:No,,0.748
2737,2734077,Table 1,BaselineCharacteristic,TAU-alone Group Mean (SD),Patients Only ; ,,None,1,5,1,No,1:No,1:No,,0.769
2737,2734077,Table 1,BaselineCharacteristic,TAU-alone Group Mean (SD),Patients Only ; ,,None,1,6,1,No,1:No,1:No,,0.769
2737,2734077,Table 1,BaselineCharacteristic,Clinical Variables,Patients Only ;  ; ,None,None,2,0,12,No,1:No,1:No,,0.913
2737,2734077,Table 1,BaselineCharacteristic,Baseline,Patients Only ; CBT+TAU Group Mean (SD) ; ,Clinical Variables,None,2,1,1,No,1:No,1:No,,0.785
2737,2734077,Table 1,BaselineCharacteristic,Follow-up,Patients Only ; CBT+TAU Group Mean (SD) ; ,Clinical Variables,None,2,2,1,No,1:No,1:No,,0.778
2737,2734077,Table 1,BaselineCharacteristic,Change (Baseline Minus Follow-up),Patients Only ; CBT+TAU Group Mean (SD) ; ,Clinical Variables,None,2,3,1,No,1:No,1:No,,0.778
2737,2734077,Table 1,BaselineCharacteristic,Baseline,Patients Only ; TAU-alone Group Mean (SD) ; ,Clinical Variables,None,2,4,1,No,1:No,1:No,,0.748
2737,2734077,Table 1,BaselineCharacteristic,Follow-up,Patients Only ; TAU-alone Group Mean (SD) ; ,Clinical Variables,None,2,5,1,No,1:No,1:No,,0.769
2737,2734077,Table 1,BaselineCharacteristic,Change (Baseline Minus Follow-up),Patients Only ; TAU-alone Group Mean (SD) ; ,Clinical Variables,None,2,6,1,No,1:No,1:No,,0.769
2737,2734077,Table 1,BaselineCharacteristic,Age at Illness Onset (Years),Patients Only ;  ; Clinical Variables ; ,Age at Illness Onset (Years),None,3,0,2,No,1:No,1:No,,0.97
2737,2734077,Table 1,BaselineCharacteristic,xx.xx (x.xx),Patients Only ; CBT+TAU Group Mean (SD) ; Baseline ; ,Age at Illness Onset (Years),None,3,1,3,No,1:No,1:No,,0.516
2737,2734077,Table 1,BaselineCharacteristic,,Patients Only ; CBT+TAU Group Mean (SD) ; Follow-up ; ,Age at Illness Onset (Years),None,3,2,3,No,1:No,1:No,,0.81
2737,2734077,Table 1,BaselineCharacteristic,,Patients Only ; CBT+TAU Group Mean (SD) ; Change (Baseline Minus Follow-up) ; ,Age at Illness Onset (Years),None,3,3,3,No,1:No,1:No,,0.81
2737,2734077,Table 1,BaselineCharacteristic,,Patients Only ; TAU-alone Group Mean (SD) ; Follow-up ; ,Age at Illness Onset (Years),None,3,5,3,No,1:No,1:No,,0.8
2737,2734077,Table 1,BaselineCharacteristic,,Patients Only ; TAU-alone Group Mean (SD) ; Change (Baseline Minus Follow-up) ; ,Age at Illness Onset (Years),None,3,6,3,No,1:No,1:No,,0.8
2737,2734077,Table 1,BaselineCharacteristic,Duration of Illness (Years),Patients Only ;  ; Clinical Variables ; ,Duration of Illness (Years),None,4,0,2,No,1:No,1:No,,0.97
2737,2734077,Table 1,BaselineCharacteristic,xx.xx (x.xx),Patients Only ; CBT+TAU Group Mean (SD) ; Baseline ; ,Duration of Illness (Years),None,4,1,3,No,1:No,1:No,,0.566
2737,2734077,Table 1,BaselineCharacteristic,,Patients Only ; CBT+TAU Group Mean (SD) ; Follow-up ; ,Duration of Illness (Years),None,4,2,3,No,1:No,1:No,,0.83
2737,2734077,Table 1,BaselineCharacteristic,,Patients Only ; CBT+TAU Group Mean (SD) ; Change (Baseline Minus Follow-up) ; ,Duration of Illness (Years),None,4,3,3,No,1:No,1:No,,0.83
2737,2734077,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Patients Only ; TAU-alone Group Mean (SD) ; Baseline ; ,Duration of Illness (Years),None,4,4,3,No,1:No,1:No,,0.611
2737,2734077,Table 1,BaselineCharacteristic,,Patients Only ; TAU-alone Group Mean (SD) ; Follow-up ; ,Duration of Illness (Years),None,4,5,3,No,1:No,1:No,,0.83
2737,2734077,Table 1,BaselineCharacteristic,,Patients Only ; TAU-alone Group Mean (SD) ; Change (Baseline Minus Follow-up) ; ,Duration of Illness (Years),None,4,6,3,No,1:No,1:No,,0.83
2737,2734077,Table 1,BaselineCharacteristic,bPositive Symptoms,Patients Only ;  ; Clinical Variables ; ,bPositive Symptoms,None,5,0,2,No,1:No,1:No,,0.97
2737,2734077,Table 1,BaselineCharacteristic,xx.xx (x.xx),Patients Only ; CBT+TAU Group Mean (SD) ; Baseline ; ,bPositive Symptoms,None,5,1,3,No,1:No,1:No,,0.516
2737,2734077,Table 1,BaselineCharacteristic,?xx.xx (x.xx),Patients Only ; CBT+TAU Group Mean (SD) ; Follow-up ; ,bPositive Symptoms,None,5,2,3,No,1:No,1:No,,0.526
2737,2734077,Table 1,BaselineCharacteristic,?x.xx (x.xx),Patients Only ; CBT+TAU Group Mean (SD) ; Change (Baseline Minus Follow-up) ; ,bPositive Symptoms,None,5,3,3,No,1:No,1:No,,0.506
2737,2734077,Table 1,BaselineCharacteristic,xx.xx (x.xx),Patients Only ; TAU-alone Group Mean (SD) ; Baseline ; ,bPositive Symptoms,None,5,4,3,No,1:No,1:No,,0.516
2737,2734077,Table 1,BaselineCharacteristic,xx.xx (x.xx),Patients Only ; TAU-alone Group Mean (SD) ; Follow-up ; ,bPositive Symptoms,None,5,5,3,No,1:No,1:No,,0.53
2737,2734077,Table 1,BaselineCharacteristic,x.xx (x.xx),Patients Only ; TAU-alone Group Mean (SD) ; Change (Baseline Minus Follow-up) ; ,bPositive Symptoms,None,5,6,3,No,1:No,1:No,,0.53
2737,2734077,Table 1,BaselineCharacteristic,bNegative Symptoms,Patients Only ;  ; Clinical Variables ; ,bNegative Symptoms,None,6,0,2,No,1:No,1:No,,0.99
2737,2734077,Table 1,BaselineCharacteristic,xx.xx (x.xx),Patients Only ; CBT+TAU Group Mean (SD) ; Baseline ; ,bNegative Symptoms,None,6,1,3,No,1:No,1:No,,0.536
2737,2734077,Table 1,BaselineCharacteristic,xx.xx (x.xx),Patients Only ; CBT+TAU Group Mean (SD) ; Follow-up ; ,bNegative Symptoms,None,6,2,3,No,1:No,1:No,,0.546
2737,2734077,Table 1,BaselineCharacteristic,?x.xx (x.xx),Patients Only ; CBT+TAU Group Mean (SD) ; Change (Baseline Minus Follow-up) ; ,bNegative Symptoms,None,6,3,3,No,1:No,1:No,,0.526
2737,2734077,Table 1,BaselineCharacteristic,xx.xx (x.xx),Patients Only ; TAU-alone Group Mean (SD) ; Baseline ; ,bNegative Symptoms,None,6,4,3,No,1:No,1:No,,0.536
2737,2734077,Table 1,BaselineCharacteristic,xx.xx (x.xx),Patients Only ; TAU-alone Group Mean (SD) ; Follow-up ; ,bNegative Symptoms,None,6,5,3,No,1:No,1:No,,0.55
2737,2734077,Table 1,BaselineCharacteristic,?x.xx (x.xx),Patients Only ; TAU-alone Group Mean (SD) ; Change (Baseline Minus Follow-up) ; ,bNegative Symptoms,None,6,6,3,No,1:No,1:No,,0.55
2737,2734077,Table 1,BaselineCharacteristic,bGeneral Psychopathology,Patients Only ;  ; Clinical Variables ; ,bGeneral Psychopathology,None,7,0,2,No,1:No,1:No,,0.99
2737,2734077,Table 1,BaselineCharacteristic,xx.xx (x.xx),Patients Only ; CBT+TAU Group Mean (SD) ; Baseline ; ,bGeneral Psychopathology,None,7,1,3,No,1:No,1:No,,0.566
2737,2734077,Table 1,BaselineCharacteristic,?xx.xx (x.xx),Patients Only ; CBT+TAU Group Mean (SD) ; Follow-up ; ,bGeneral Psychopathology,None,7,2,3,No,1:No,1:No,,0.576
2737,2734077,Table 1,BaselineCharacteristic,?x.xx (x.xx),Patients Only ; CBT+TAU Group Mean (SD) ; Change (Baseline Minus Follow-up) ; ,bGeneral Psychopathology,None,7,3,3,No,1:No,1:No,,0.556
2737,2734077,Table 1,BaselineCharacteristic,xx.xx (x.xx),Patients Only ; TAU-alone Group Mean (SD) ; Baseline ; ,bGeneral Psychopathology,None,7,4,3,No,1:No,1:No,,0.576
2737,2734077,Table 1,BaselineCharacteristic,xx.xx (x.xx),Patients Only ; TAU-alone Group Mean (SD) ; Follow-up ; ,bGeneral Psychopathology,None,7,5,3,No,1:No,1:No,,0.59
2737,2734077,Table 1,BaselineCharacteristic,x.xx (x.xx),Patients Only ; TAU-alone Group Mean (SD) ; Change (Baseline Minus Follow-up) ; ,bGeneral Psychopathology,None,7,6,3,No,1:No,1:No,,0.59
2737,2734077,Table 1,BaselineCharacteristic,bTotal Symptoms,Patients Only ;  ; Clinical Variables ; ,bTotal Symptoms,None,8,0,2,No,1:No,1:No,,0.99
2737,2734077,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Patients Only ; CBT+TAU Group Mean (SD) ; Baseline ; ,bTotal Symptoms,None,8,1,3,No,1:No,1:No,,0.641
2737,2734077,Table 1,BaselineCharacteristic,?xx.xx (xx.xx),Patients Only ; CBT+TAU Group Mean (SD) ; Follow-up ; ,bTotal Symptoms,None,8,2,3,No,1:No,1:No,,0.631
2737,2734077,Table 1,BaselineCharacteristic,?x.xx (xx.xx),Patients Only ; CBT+TAU Group Mean (SD) ; Change (Baseline Minus Follow-up) ; ,bTotal Symptoms,None,8,3,3,No,1:No,1:No,,0.576
2737,2734077,Table 1,BaselineCharacteristic,xx.xx (x.xx),Patients Only ; TAU-alone Group Mean (SD) ; Baseline ; ,bTotal Symptoms,None,8,4,3,No,1:No,1:No,,0.596
2737,2734077,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Patients Only ; TAU-alone Group Mean (SD) ; Follow-up ; ,bTotal Symptoms,None,8,5,3,No,1:No,1:No,,0.666
2737,2734077,Table 1,BaselineCharacteristic,?x.xx (xx.xx),Patients Only ; TAU-alone Group Mean (SD) ; Change (Baseline Minus Follow-up) ; ,bTotal Symptoms,None,8,6,3,No,1:No,1:No,,0.61
2737,2734077,Table 1,BaselineCharacteristic,Antipsychotic medication,Patients Only ;  ; Clinical Variables ; ,Antipsychotic medication,None,9,0,2,No,1:No,1:No,,1
2737,2734077,Table 1,BaselineCharacteristic,xx patients on atypical and x on both atypical and typical antipsychotics.,Patients Only ; CBT+TAU Group Mean (SD) ; Baseline ; ,Antipsychotic medication,None,9,1,3,No,1:No,1:No,,0.62
2737,2734077,Table 1,BaselineCharacteristic,As baseline,Patients Only ; CBT+TAU Group Mean (SD) ; Follow-up ; ,Antipsychotic medication,None,9,2,3,No,1:No,1:No,,0.84
2737,2734077,Table 1,BaselineCharacteristic,,Patients Only ; CBT+TAU Group Mean (SD) ; Change (Baseline Minus Follow-up) ; ,Antipsychotic medication,None,9,3,3,No,1:No,1:No,,0.88
2737,2734077,Table 1,BaselineCharacteristic,xx patients on atypical and x on both atypical and typical antipsychotics.,Patients Only ; TAU-alone Group Mean (SD) ; Baseline ; ,Antipsychotic medication,None,9,4,3,No,1:No,1:No,,0.63
2737,2734077,Table 1,BaselineCharacteristic,As baseline,Patients Only ; TAU-alone Group Mean (SD) ; Follow-up ; ,Antipsychotic medication,None,9,5,3,No,1:No,1:No,,0.83
2737,2734077,Table 1,BaselineCharacteristic,,Patients Only ; TAU-alone Group Mean (SD) ; Change (Baseline Minus Follow-up) ; ,Antipsychotic medication,None,9,6,3,No,1:No,1:No,,0.86
2737,2734077,Table 1,BaselineCharacteristic,Antipsychotic Dose in Chlorpromazine Equivalents (mg),Patients Only ;  ; Clinical Variables ; ,Antipsychotic Dose in Chlorpromazine Equivalents (mg),None,10,0,2,No,1:No,1:No,,0.87
2737,2734077,Table 1,BaselineCharacteristic,xxx.xx (xxx.xx),Patients Only ; CBT+TAU Group Mean (SD) ; Baseline ; ,Antipsychotic Dose in Chlorpromazine Equivalents (mg),None,10,1,3,No,1:No,1:No,,0.501
2737,2734077,Table 1,BaselineCharacteristic,As baseline,Patients Only ; CBT+TAU Group Mean (SD) ; Follow-up ; ,Antipsychotic Dose in Chlorpromazine Equivalents (mg),None,10,2,3,No,1:No,1:No,,0.72
2737,2734077,Table 1,BaselineCharacteristic,,Patients Only ; CBT+TAU Group Mean (SD) ; Change (Baseline Minus Follow-up) ; ,Antipsychotic Dose in Chlorpromazine Equivalents (mg),None,10,3,3,No,1:No,1:No,,0.74
2737,2734077,Table 1,BaselineCharacteristic,xxx.xx (xxx.xx),Patients Only ; TAU-alone Group Mean (SD) ; Baseline ; ,Antipsychotic Dose in Chlorpromazine Equivalents (mg),None,10,4,3,No,1:No,1:No,,0.501
2737,2734077,Table 1,BaselineCharacteristic,As baseline,Patients Only ; TAU-alone Group Mean (SD) ; Follow-up ; ,Antipsychotic Dose in Chlorpromazine Equivalents (mg),None,10,5,3,No,1:No,1:No,,0.73
2737,2734077,Table 1,BaselineCharacteristic,,Patients Only ; TAU-alone Group Mean (SD) ; Change (Baseline Minus Follow-up) ; ,Antipsychotic Dose in Chlorpromazine Equivalents (mg),None,10,6,3,No,1:No,1:No,,0.75
2809,2757022,Table 1,BaselineCharacteristic,• Financing basis of public health is contribution and tax based,,None,None,0,0,3,No,1:No,1:No,,0.91
2809,2757022,Table 1,BaselineCharacteristic,• Health expenditure amounts to x.x% of gross domestic product (GDP),,None,None,1,0,3,No,1:No,1:No,,0.91
2809,2757022,Table 1,BaselineCharacteristic,• Health care expenditure per capita is xxxx (in US$ PPP),,None,None,2,0,3,No,1:No,1:No,,0.83
2809,2757022,Table 1,BaselineCharacteristic,• Coverage of population by public health is almost universal (compulsory),,None,None,3,0,3,No,1:No,1:No,,0.93
2809,2757022,Table 1,BaselineCharacteristic,• Out of pocket payments (proportion of total health expenditure) equals xx%,,None,None,4,0,3,No,1:No,1:No,,0.92
2809,2757022,Table 1,BaselineCharacteristic,• Payment of GP is mainly fee-for-service with a limited capitation fee for registered patients,,None,None,5,0,3,No,1:No,1:No,,0.84
2809,2757022,Table 1,BaselineCharacteristic,• GP to population ratio x:xxx,,None,None,6,0,3,No,1:No,1:No,,0.92
2809,2757022,Table 1,BaselineCharacteristic,• GP has no gatekeeper function; voluntary patient registration with a GP (since xxxx),,None,None,7,0,3,No,1:No,1:No,,0.901
2809,2757022,Table 1,BaselineCharacteristic,• Approximately xx% of the GPs are working in single-handed practices,,None,None,8,0,3,No,1:No,1:No,,0.9
2809,2757022,Table 1,BaselineCharacteristic,• About xx% of the GPs are using an electronic medical record (EMR),,None,None,9,0,3,No,1:No,1:No,,0.98
2811,2758901,Table 1,BaselineCharacteristic,,,None,None,0,0,,No,1:No,1:No,,0.907
2811,2758901,Table 1,BaselineCharacteristic,Gefitinib,,None,None,0,1,,No,1:No,1:No,,0.874
2811,2758901,Table 1,BaselineCharacteristic,Gefitinib,,None,None,0,2,,No,1:No,1:No,,0.875
2811,2758901,Table 1,BaselineCharacteristic,Erlotinib,,None,None,0,3,,No,1:No,1:No,,0.826
2811,2758901,Table 1,BaselineCharacteristic,Erlotinib,,None,None,0,4,,No,1:No,1:No,,0.818
2811,2758901,Table 1,BaselineCharacteristic,, ; ,None,None,1,0,,No,1:No,1:No,,0.905
2811,2758901,Table 1,BaselineCharacteristic,No,Gefitinib ; ,None,None,1,1,,No,1:No,1:No,,0.871
2811,2758901,Table 1,BaselineCharacteristic,%,Gefitinib ; ,None,None,1,2,,No,1:No,1:No,,0.749
2811,2758901,Table 1,BaselineCharacteristic,No,Erlotinib ; ,None,None,1,3,,No,1:No,1:No,,0.823
2811,2758901,Table 1,BaselineCharacteristic,%,Erlotinib ; ,None,None,1,4,,No,1:No,1:No,,0.763
2811,2758901,Table 1,BaselineCharacteristic,, ;  ; ,None,None,2,0,,No,1:No,1:No,,0.922
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; No ; ,None,None,2,1,,No,1:No,1:No,,0.887
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; % ; ,None,None,2,2,,No,1:No,1:No,,0.749
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; No ; ,None,None,2,3,,No,1:No,1:No,,0.839
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; % ; ,None,None,2,4,,No,1:No,1:No,,0.762
2811,2758901,Table 1,BaselineCharacteristic,TOTAL, ;  ;  ; ,None,None,3,0,,No,1:No,1:No,,0.932
2811,2758901,Table 1,BaselineCharacteristic,xxx,Gefitinib ; No ;  ; ,None,None,3,1,,No,1:No,1:No,,0.8
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; % ;  ; ,None,None,3,2,,No,1:No,1:No,,0.756
2811,2758901,Table 1,BaselineCharacteristic,xx,Erlotinib ; No ;  ; ,None,None,3,3,,No,1:No,1:No,,0.602
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; % ;  ; ,None,None,3,4,,No,1:No,1:No,,0.769
2811,2758901,Table 1,BaselineCharacteristic,, ;  ;  ; TOTAL ; ,None,None,4,0,,No,1:No,1:No,,0.927
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; No ;  ; xxx ; ,None,None,4,1,,No,1:No,1:No,,0.798
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; % ;  ;  ; ,None,None,4,2,,No,1:No,1:No,,0.771
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; No ;  ; xx ; ,None,None,4,3,,No,1:No,1:No,,0.663
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; % ;  ;  ; ,None,None,4,4,,No,1:No,1:No,,0.774
2811,2758901,Table 1,BaselineCharacteristic,Gender, ;  ;  ; TOTAL ;  ; ,None,None,5,0,,No,1:No,1:No,,0.927
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; No ;  ; xxx ;  ; ,None,None,5,1,,No,1:No,1:No,,0.805
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; % ;  ;  ;  ; ,None,None,5,2,,No,1:No,1:No,,0.771
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; No ;  ; xx ;  ; ,None,None,5,3,,No,1:No,1:No,,0.653
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; % ;  ;  ;  ; ,None,None,5,4,,No,1:No,1:No,,0.774
2811,2758901,Table 1,BaselineCharacteristic,, ;  ;  ; TOTAL ;  ; ,None,None,6,0,,No,1:No,1:No,,0.964
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; No ;  ; xxx ;  ; ,None,None,6,1,,No,1:No,1:No,,0.861
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; % ;  ;  ;  ; ,None,None,6,2,,No,1:No,1:No,,0.84
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; No ;  ; xx ;  ; ,None,None,6,3,,No,1:No,1:No,,0.709
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; % ;  ;  ;  ; ,None,None,6,4,,No,1:No,1:No,,0.843
2811,2758901,Table 1,BaselineCharacteristic,?Female, ;  ;  ; TOTAL ;  ; ,?Female, ,7,0,,No,1:No,1:No,,0.973
2811,2758901,Table 1,BaselineCharacteristic,xx,Gefitinib ; No ;  ; xxx ;  ; ,?Female, ,7,1,,No,1:No,1:No,,0.715
2811,2758901,Table 1,BaselineCharacteristic,xx,Gefitinib ; % ;  ;  ;  ; ,?Female, ,7,2,,No,1:No,1:No,,0.742
2811,2758901,Table 1,BaselineCharacteristic,xx,Erlotinib ; No ;  ; xx ;  ; ,?Female, ,7,3,,No,1:No,1:No,,0.73
2811,2758901,Table 1,BaselineCharacteristic,xx,Erlotinib ; % ;  ;  ;  ; ,?Female, ,7,4,,No,1:No,1:No,,0.749
2811,2758901,Table 1,BaselineCharacteristic,, ;  ;  ; TOTAL ;  ; ,None,None,8,0,,No,1:No,1:No,,0.98
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; No ;  ; xxx ;  ; ,None,None,8,1,,No,1:No,1:No,,0.868
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; % ;  ;  ;  ; ,None,None,8,2,,No,1:No,1:No,,0.874
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; No ;  ; xx ;  ; ,None,None,8,3,,No,1:No,1:No,,0.745
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; % ;  ;  ;  ; ,None,None,8,4,,No,1:No,1:No,,0.881
2811,2758901,Table 1,BaselineCharacteristic,?Male, ;  ;  ; TOTAL ;  ; ,?Male, ,9,0,,No,1:No,1:No,,0.99
2811,2758901,Table 1,BaselineCharacteristic,xx,Gefitinib ; No ;  ; xxx ;  ; ,?Male, ,9,1,,No,1:No,1:No,,0.787
2811,2758901,Table 1,BaselineCharacteristic,xx,Gefitinib ; % ;  ;  ;  ; ,?Male, ,9,2,,No,1:No,1:No,,0.807
2811,2758901,Table 1,BaselineCharacteristic,xx,Erlotinib ; No ;  ; xx ;  ; ,?Male, ,9,3,,No,1:No,1:No,,0.79
2811,2758901,Table 1,BaselineCharacteristic,xx,Erlotinib ; % ;  ;  ;  ; ,?Male, ,9,4,,No,1:No,1:No,,0.788
2811,2758901,Table 1,BaselineCharacteristic,, ;  ;  ; TOTAL ;  ; ,None,None,10,0,,No,1:No,1:No,,0.999
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; No ;  ; xxx ;  ; ,None,None,10,1,,No,1:No,1:No,,0.905
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; % ;  ;  ;  ; ,None,None,10,2,,No,1:No,1:No,,0.91
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; No ;  ; xx ;  ; ,None,None,10,3,,No,1:No,1:No,,0.791
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; % ;  ;  ;  ; ,None,None,10,4,,No,1:No,1:No,,0.91
2811,2758901,Table 1,BaselineCharacteristic,Age, ;  ;  ; TOTAL ;  ; ,None,None,11,0,,No,1:No,1:No,,0.999
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; No ;  ; xxx ;  ; ,None,None,11,1,,No,1:No,1:No,,0.905
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; % ;  ;  ;  ; ,None,None,11,2,,No,1:No,1:No,,0.91
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; No ;  ; xx ;  ; ,None,None,11,3,,No,1:No,1:No,,0.791
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; % ;  ;  ;  ; ,None,None,11,4,,No,1:No,1:No,,0.91
2811,2758901,Table 1,BaselineCharacteristic,, ;  ;  ; TOTAL ;  ; ,None,None,12,0,,No,1:No,1:No,,0.999
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; No ;  ; xxx ;  ; ,None,None,12,1,,No,1:No,1:No,,0.905
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; % ;  ;  ;  ; ,None,None,12,2,,No,1:No,1:No,,0.91
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; No ;  ; xx ;  ; ,None,None,12,3,,No,1:No,1:No,,0.791
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; % ;  ;  ;  ; ,None,None,12,4,,No,1:No,1:No,,0.91
2811,2758901,Table 1,BaselineCharacteristic,?Avg. age, ;  ;  ; TOTAL ;  ; ,?Avg. age, ,13,0,,No,1:No,1:No,,0.629
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; % ;  ;  ;  ; ,?Avg. age, ,13,4,,No,1:No,1:No,,0.544
2811,2758901,Table 1,BaselineCharacteristic,, ;  ;  ; TOTAL ;  ; ,None,None,14,0,,No,1:No,1:No,,0.999
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; No ;  ; xxx ;  ; ,None,None,14,1,,No,1:No,1:No,,0.905
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; % ;  ;  ;  ; ,None,None,14,2,,No,1:No,1:No,,0.911
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; No ;  ; xx ;  ; ,None,None,14,3,,No,1:No,1:No,,0.811
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; % ;  ;  ;  ; ,None,None,14,4,,No,1:No,1:No,,0.921
2811,2758901,Table 1,BaselineCharacteristic,?Range, ;  ;  ; TOTAL ;  ; ,?Range, ,15,0,,No,1:No,1:No,,0.999
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; % ;  ;  ;  ; ,?Range, ,15,2,,No,1:No,1:No,,0.901
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; % ;  ;  ;  ; ,?Range, ,15,4,,No,1:No,1:No,,0.921
2811,2758901,Table 1,BaselineCharacteristic,, ;  ;  ; TOTAL ;  ; ,None,None,16,0,,No,1:No,1:No,,0.999
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; No ;  ; xxx ;  ; ,None,None,16,1,,No,1:No,1:No,,0.895
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; % ;  ;  ;  ; ,None,None,16,2,,No,1:No,1:No,,0.901
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; No ;  ; xx ;  ; ,None,None,16,3,,No,1:No,1:No,,0.821
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; % ;  ;  ;  ; ,None,None,16,4,,No,1:No,1:No,,0.921
2811,2758901,Table 1,BaselineCharacteristic,Smoking history, ;  ;  ; TOTAL ;  ; ,None,None,17,0,,No,1:No,1:No,,0.999
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; No ;  ; xxx ;  ; ,None,None,17,1,,No,1:No,1:No,,0.895
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; % ;  ;  ;  ; ,None,None,17,2,,No,1:No,1:No,,0.901
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; No ;  ; xx ;  ; ,None,None,17,3,,No,1:No,1:No,,0.821
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; % ;  ;  ;  ; ,None,None,17,4,,No,1:No,1:No,,0.921
2811,2758901,Table 1,BaselineCharacteristic,, ;  ;  ; TOTAL ;  ; ,None,None,18,0,,No,1:No,1:No,,0.989
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; No ;  ; xxx ;  ; ,None,None,18,1,,No,1:No,1:No,,0.895
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; % ;  ;  ;  ; ,None,None,18,2,,No,1:No,1:No,,0.891
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; No ;  ; xx ;  ; ,None,None,18,3,,No,1:No,1:No,,0.821
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; % ;  ;  ;  ; ,None,None,18,4,,No,1:No,1:No,,0.921
2811,2758901,Table 1,BaselineCharacteristic,?Smokers, ;  ;  ; TOTAL ;  ; ,?Smokers, ,19,0,,No,1:No,1:No,,0.989
2811,2758901,Table 1,BaselineCharacteristic,xxx,Gefitinib ; No ;  ; xxx ;  ; ,?Smokers, ,19,1,,No,1:No,1:No,,0.895
2811,2758901,Table 1,BaselineCharacteristic,xx,Gefitinib ; % ;  ;  ;  ; ,?Smokers, ,19,2,,No,1:No,1:No,,0.839
2811,2758901,Table 1,BaselineCharacteristic,xx,Erlotinib ; No ;  ; xx ;  ; ,?Smokers, ,19,3,,No,1:No,1:No,,0.821
2811,2758901,Table 1,BaselineCharacteristic,xx,Erlotinib ; % ;  ;  ;  ; ,?Smokers, ,19,4,,No,1:No,1:No,,0.809
2811,2758901,Table 1,BaselineCharacteristic,, ;  ;  ; TOTAL ;  ; ,None,None,20,0,,No,1:No,1:No,,0.989
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; No ;  ; xxx ;  ; ,None,None,20,1,,No,1:No,1:No,,0.895
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; % ;  ;  ;  ; ,None,None,20,2,,No,1:No,1:No,,0.881
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; No ;  ; xx ;  ; ,None,None,20,3,,No,1:No,1:No,,0.821
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; % ;  ;  ;  ; ,None,None,20,4,,No,1:No,1:No,,0.911
2811,2758901,Table 1,BaselineCharacteristic,?Non-smokers, ;  ;  ; TOTAL ;  ; ,?Non-smokers, ,21,0,,No,1:No,1:No,,0.989
2811,2758901,Table 1,BaselineCharacteristic,x,Gefitinib ; No ;  ; xxx ;  ; ,?Non-smokers, ,21,1,,No,1:No,1:No,,0.933
2811,2758901,Table 1,BaselineCharacteristic,x,Gefitinib ; % ;  ;  ;  ; ,?Non-smokers, ,21,2,,No,1:No,1:No,,0.891
2811,2758901,Table 1,BaselineCharacteristic,x,Erlotinib ; No ;  ; xx ;  ; ,?Non-smokers, ,21,3,,No,1:No,1:No,,0.792
2811,2758901,Table 1,BaselineCharacteristic,x,Erlotinib ; % ;  ;  ;  ; ,?Non-smokers, ,21,4,,No,1:No,1:No,,0.888
2811,2758901,Table 1,BaselineCharacteristic,, ;  ;  ; TOTAL ;  ; ,None,None,22,0,,No,1:No,1:No,,0.999
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; No ;  ; xxx ;  ; ,None,None,22,1,,No,1:No,1:No,,0.895
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; % ;  ;  ;  ; ,None,None,22,2,,No,1:No,1:No,,0.901
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; No ;  ; xx ;  ; ,None,None,22,3,,No,1:No,1:No,,0.821
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; % ;  ;  ;  ; ,None,None,22,4,,No,1:No,1:No,,0.921
2811,2758901,Table 1,BaselineCharacteristic,?Unknown, ;  ;  ; TOTAL ;  ; ,?Unknown, ,23,0,,No,1:No,1:No,,0.999
2811,2758901,Table 1,BaselineCharacteristic,x,Gefitinib ; No ;  ; xxx ;  ; ,?Unknown, ,23,1,,No,1:No,1:No,,0.933
2811,2758901,Table 1,BaselineCharacteristic,x,Gefitinib ; % ;  ;  ;  ; ,?Unknown, ,23,2,,No,1:No,1:No,,0.911
2811,2758901,Table 1,BaselineCharacteristic,x,Erlotinib ; No ;  ; xx ;  ; ,?Unknown, ,23,3,,No,1:No,1:No,,0.792
2811,2758901,Table 1,BaselineCharacteristic,x,Erlotinib ; % ;  ;  ;  ; ,?Unknown, ,23,4,,No,1:No,1:No,,0.898
2811,2758901,Table 1,BaselineCharacteristic,, ;  ;  ; TOTAL ;  ; ,None,None,24,0,,No,1:No,1:No,,0.999
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; No ;  ; xxx ;  ; ,None,None,24,1,,No,1:No,1:No,,0.895
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; % ;  ;  ;  ; ,None,None,24,2,,No,1:No,1:No,,0.901
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; No ;  ; xx ;  ; ,None,None,24,3,,No,1:No,1:No,,0.821
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; % ;  ;  ;  ; ,None,None,24,4,,No,1:No,1:No,,0.921
2811,2758901,Table 1,BaselineCharacteristic,?Avg. pack-years, ;  ;  ; TOTAL ;  ; ,?Avg. pack-years, ,25,0,,No,1:No,1:No,,0.904
2811,2758901,Table 1,BaselineCharacteristic,xx.x,Gefitinib ; No ;  ; xxx ;  ; ,?Avg. pack-years, ,25,1,,No,1:No,1:No,,0.654
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; % ;  ;  ;  ; ,?Avg. pack-years, ,25,2,,No,1:No,1:No,,0.818
2811,2758901,Table 1,BaselineCharacteristic,xx.x,Erlotinib ; No ;  ; xx ;  ; ,?Avg. pack-years, ,25,3,,No,1:No,1:No,,0.658
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; % ;  ;  ;  ; ,?Avg. pack-years, ,25,4,,No,1:No,1:No,,0.839
2811,2758901,Table 1,BaselineCharacteristic,, ;  ;  ; TOTAL ;  ; ,None,None,26,0,,No,1:No,1:No,,0.999
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; No ;  ; xxx ;  ; ,None,None,26,1,,No,1:No,1:No,,0.895
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; % ;  ;  ;  ; ,None,None,26,2,,No,1:No,1:No,,0.901
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; No ;  ; xx ;  ; ,None,None,26,3,,No,1:No,1:No,,0.821
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; % ;  ;  ;  ; ,None,None,26,4,,No,1:No,1:No,,0.921
2811,2758901,Table 1,BaselineCharacteristic,Histology, ;  ;  ; TOTAL ;  ; ,None,None,27,0,,No,1:No,1:No,,0.999
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; No ;  ; xxx ;  ; ,None,None,27,1,,No,1:No,1:No,,0.895
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; % ;  ;  ;  ; ,None,None,27,2,,No,1:No,1:No,,0.901
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; No ;  ; xx ;  ; ,None,None,27,3,,No,1:No,1:No,,0.821
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; % ;  ;  ;  ; ,None,None,27,4,,No,1:No,1:No,,0.921
2811,2758901,Table 1,BaselineCharacteristic,, ;  ;  ; TOTAL ;  ; ,None,None,28,0,,No,1:No,1:No,,0.999
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; No ;  ; xxx ;  ; ,None,None,28,1,,No,1:No,1:No,,0.895
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; % ;  ;  ;  ; ,None,None,28,2,,No,1:No,1:No,,0.901
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; No ;  ; xx ;  ; ,None,None,28,3,,No,1:No,1:No,,0.821
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; % ;  ;  ;  ; ,None,None,28,4,,No,1:No,1:No,,0.921
2811,2758901,Table 1,BaselineCharacteristic,?Adenocarcinoma, ;  ;  ; TOTAL ;  ; ,?Adenocarcinoma, ,29,0,,No,1:No,1:No,,0.999
2811,2758901,Table 1,BaselineCharacteristic,xx,Gefitinib ; No ;  ; xxx ;  ; ,?Adenocarcinoma, ,29,1,,No,1:No,1:No,,0.843
2811,2758901,Table 1,BaselineCharacteristic,xx,Gefitinib ; % ;  ;  ;  ; ,?Adenocarcinoma, ,29,2,,No,1:No,1:No,,0.859
2811,2758901,Table 1,BaselineCharacteristic,xx,Erlotinib ; No ;  ; xx ;  ; ,?Adenocarcinoma, ,29,3,,No,1:No,1:No,,0.821
2811,2758901,Table 1,BaselineCharacteristic,xx,Erlotinib ; % ;  ;  ;  ; ,?Adenocarcinoma, ,29,4,,No,1:No,1:No,,0.819
2811,2758901,Table 1,BaselineCharacteristic,, ;  ;  ; TOTAL ;  ; ,None,None,30,0,,No,1:No,1:No,,0.999
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; No ;  ; xxx ;  ; ,None,None,30,1,,No,1:No,1:No,,0.895
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; % ;  ;  ;  ; ,None,None,30,2,,No,1:No,1:No,,0.901
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; No ;  ; xx ;  ; ,None,None,30,3,,No,1:No,1:No,,0.821
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; % ;  ;  ;  ; ,None,None,30,4,,No,1:No,1:No,,0.921
2811,2758901,Table 1,BaselineCharacteristic,?Squamous, ;  ;  ; TOTAL ;  ; ,?Squamous, ,31,0,,No,1:No,1:No,,0.999
2811,2758901,Table 1,BaselineCharacteristic,xx,Gefitinib ; No ;  ; xxx ;  ; ,?Squamous, ,31,1,,No,1:No,1:No,,0.843
2811,2758901,Table 1,BaselineCharacteristic,xx,Gefitinib ; % ;  ;  ;  ; ,?Squamous, ,31,2,,No,1:No,1:No,,0.859
2811,2758901,Table 1,BaselineCharacteristic,x,Erlotinib ; No ;  ; xx ;  ; ,?Squamous, ,31,3,,No,1:No,1:No,,0.792
2811,2758901,Table 1,BaselineCharacteristic,xx,Erlotinib ; % ;  ;  ;  ; ,?Squamous, ,31,4,,No,1:No,1:No,,0.819
2811,2758901,Table 1,BaselineCharacteristic,, ;  ;  ; TOTAL ;  ; ,None,None,32,0,,No,1:No,1:No,,0.999
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; No ;  ; xxx ;  ; ,None,None,32,1,,No,1:No,1:No,,0.895
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; % ;  ;  ;  ; ,None,None,32,2,,No,1:No,1:No,,0.901
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; No ;  ; xx ;  ; ,None,None,32,3,,No,1:No,1:No,,0.821
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; % ;  ;  ;  ; ,None,None,32,4,,No,1:No,1:No,,0.921
2811,2758901,Table 1,BaselineCharacteristic,?Bronchioalveolar, ;  ;  ; TOTAL ;  ; ,?Bronchioalveolar, ,33,0,,No,1:No,1:No,,0.999
2811,2758901,Table 1,BaselineCharacteristic,x,Gefitinib ; No ;  ; xxx ;  ; ,?Bronchioalveolar, ,33,1,,No,1:No,1:No,,0.933
2811,2758901,Table 1,BaselineCharacteristic,x,Gefitinib ; % ;  ;  ;  ; ,?Bronchioalveolar, ,33,2,,No,1:No,1:No,,0.911
2811,2758901,Table 1,BaselineCharacteristic,x,Erlotinib ; No ;  ; xx ;  ; ,?Bronchioalveolar, ,33,3,,No,1:No,1:No,,0.792
2811,2758901,Table 1,BaselineCharacteristic,x,Erlotinib ; % ;  ;  ;  ; ,?Bronchioalveolar, ,33,4,,No,1:No,1:No,,0.898
2811,2758901,Table 1,BaselineCharacteristic,, ;  ;  ; TOTAL ;  ; ,None,None,34,0,,No,1:No,1:No,,0.999
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; No ;  ; xxx ;  ; ,None,None,34,1,,No,1:No,1:No,,0.895
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; % ;  ;  ;  ; ,None,None,34,2,,No,1:No,1:No,,0.901
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; No ;  ; xx ;  ; ,None,None,34,3,,No,1:No,1:No,,0.821
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; % ;  ;  ;  ; ,None,None,34,4,,No,1:No,1:No,,0.921
2811,2758901,Table 1,BaselineCharacteristic,?Large cell, ;  ;  ; TOTAL ;  ; ,?Large cell, ,35,0,,No,1:No,1:No,,0.999
2811,2758901,Table 1,BaselineCharacteristic,x,Gefitinib ; No ;  ; xxx ;  ; ,?Large cell, ,35,1,,No,1:No,1:No,,0.933
2811,2758901,Table 1,BaselineCharacteristic,x,Gefitinib ; % ;  ;  ;  ; ,?Large cell, ,35,2,,No,1:No,1:No,,0.911
2811,2758901,Table 1,BaselineCharacteristic,x,Erlotinib ; No ;  ; xx ;  ; ,?Large cell, ,35,3,,No,1:No,1:No,,0.792
2811,2758901,Table 1,BaselineCharacteristic,x,Erlotinib ; % ;  ;  ;  ; ,?Large cell, ,35,4,,No,1:No,1:No,,0.898
2811,2758901,Table 1,BaselineCharacteristic,, ;  ;  ; TOTAL ;  ; ,None,None,36,0,,No,1:No,1:No,,0.999
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; No ;  ; xxx ;  ; ,None,None,36,1,,No,1:No,1:No,,0.895
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; % ;  ;  ;  ; ,None,None,36,2,,No,1:No,1:No,,0.901
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; No ;  ; xx ;  ; ,None,None,36,3,,No,1:No,1:No,,0.821
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; % ;  ;  ;  ; ,None,None,36,4,,No,1:No,1:No,,0.921
2811,2758901,Table 1,BaselineCharacteristic,?Mixed, ;  ;  ; TOTAL ;  ; ,?Mixed, ,37,0,,No,1:No,1:No,,0.969
2811,2758901,Table 1,BaselineCharacteristic,x,Gefitinib ; No ;  ; xxx ;  ; ,?Mixed, ,37,1,,No,1:No,1:No,,0.946
2811,2758901,Table 1,BaselineCharacteristic,x,Gefitinib ; % ;  ;  ;  ; ,?Mixed, ,37,2,,No,1:No,1:No,,0.885
2811,2758901,Table 1,BaselineCharacteristic,x,Erlotinib ; No ;  ; xx ;  ; ,?Mixed, ,37,3,,No,1:No,1:No,,0.756
2811,2758901,Table 1,BaselineCharacteristic,x,Erlotinib ; % ;  ;  ;  ; ,?Mixed, ,37,4,,No,1:No,1:No,,0.859
2811,2758901,Table 1,BaselineCharacteristic,, ;  ;  ; TOTAL ;  ; ,None,None,38,0,,No,1:No,1:No,,0.999
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; No ;  ; xxx ;  ; ,None,None,38,1,,No,1:No,1:No,,0.895
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; % ;  ;  ;  ; ,None,None,38,2,,No,1:No,1:No,,0.901
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; No ;  ; xx ;  ; ,None,None,38,3,,No,1:No,1:No,,0.821
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; % ;  ;  ;  ; ,None,None,38,4,,No,1:No,1:No,,0.921
2811,2758901,Table 1,BaselineCharacteristic,?NSC not further specified, ;  ;  ; TOTAL ;  ; ,?NSC not further specified, ,39,0,,No,1:No,1:No,,0.999
2811,2758901,Table 1,BaselineCharacteristic,xx,Gefitinib ; No ;  ; xxx ;  ; ,?NSC not further specified, ,39,1,,No,1:No,1:No,,0.843
2811,2758901,Table 1,BaselineCharacteristic,xx,Gefitinib ; % ;  ;  ;  ; ,?NSC not further specified, ,39,2,,No,1:No,1:No,,0.859
2811,2758901,Table 1,BaselineCharacteristic,xx,Erlotinib ; No ;  ; xx ;  ; ,?NSC not further specified, ,39,3,,No,1:No,1:No,,0.821
2811,2758901,Table 1,BaselineCharacteristic,xx,Erlotinib ; % ;  ;  ;  ; ,?NSC not further specified, ,39,4,,No,1:No,1:No,,0.819
2811,2758901,Table 1,BaselineCharacteristic,, ;  ;  ; TOTAL ;  ; ,None,None,40,0,,No,1:No,1:No,,0.999
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; No ;  ; xxx ;  ; ,None,None,40,1,,No,1:No,1:No,,0.895
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; % ;  ;  ;  ; ,None,None,40,2,,No,1:No,1:No,,0.901
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; No ;  ; xx ;  ; ,None,None,40,3,,No,1:No,1:No,,0.821
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; % ;  ;  ;  ; ,None,None,40,4,,No,1:No,1:No,,0.921
2811,2758901,Table 1,BaselineCharacteristic,Avg. ECOG, ;  ;  ; TOTAL ;  ; ,Avg. ECOG,,41,0,,No,1:No,1:No,,0.904
2811,2758901,Table 1,BaselineCharacteristic,x.xx,Gefitinib ; No ;  ; xxx ;  ; ,Avg. ECOG,,41,1,,No,1:No,1:No,,0.654
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; % ;  ;  ;  ; ,Avg. ECOG,,41,2,,No,1:No,1:No,,0.818
2811,2758901,Table 1,BaselineCharacteristic,x.xx,Erlotinib ; No ;  ; xx ;  ; ,Avg. ECOG,,41,3,,No,1:No,1:No,,0.658
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; % ;  ;  ;  ; ,Avg. ECOG,,41,4,,No,1:No,1:No,,0.839
2811,2758901,Table 1,BaselineCharacteristic,, ;  ;  ; TOTAL ;  ; ,None,None,42,0,,No,1:No,1:No,,0.999
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; No ;  ; xxx ;  ; ,None,None,42,1,,No,1:No,1:No,,0.895
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; % ;  ;  ;  ; ,None,None,42,2,,No,1:No,1:No,,0.901
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; No ;  ; xx ;  ; ,None,None,42,3,,No,1:No,1:No,,0.821
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; % ;  ;  ;  ; ,None,None,42,4,,No,1:No,1:No,,0.921
2811,2758901,Table 1,BaselineCharacteristic,Avg. previous lines of chemo, ;  ;  ; TOTAL ;  ; ,Avg. previous lines of chemo,,43,0,,No,1:No,1:No,,0.915
2811,2758901,Table 1,BaselineCharacteristic,x.xx,Gefitinib ; No ;  ; xxx ;  ; ,Avg. previous lines of chemo,,43,1,,No,1:No,1:No,,0.684
2811,2758901,Table 1,BaselineCharacteristic,,Gefitinib ; % ;  ;  ;  ; ,Avg. previous lines of chemo,,43,2,,No,1:No,1:No,,0.859
2811,2758901,Table 1,BaselineCharacteristic,x.xx,Erlotinib ; No ;  ; xx ;  ; ,Avg. previous lines of chemo,,43,3,,No,1:No,1:No,,0.739
2811,2758901,Table 1,BaselineCharacteristic,,Erlotinib ; % ;  ;  ;  ; ,Avg. previous lines of chemo,,43,4,,No,1:No,1:No,,0.88
2834,2765955,Table 1,BaselineCharacteristic,,,None,None,0,0,,No,1:No,1:No,,0.907
2834,2765955,Table 1,BaselineCharacteristic,Males,,None,None,0,1,,No,1:No,1:No,,0.769
2834,2765955,Table 1,BaselineCharacteristic,Females,,None,None,0,2,,No,1:No,1:No,,0.736
2834,2765955,Table 1,BaselineCharacteristic,P*,,None,None,0,3,,No,1:No,1:No,,0.875
2834,2765955,Table 1,BaselineCharacteristic,, ; ,None,None,1,0,,No,1:No,1:No,,0.905
2834,2765955,Table 1,BaselineCharacteristic,,P* ; ,None,None,1,3,,No,1:No,1:No,,0.872
2834,2765955,Table 1,BaselineCharacteristic,Age, ;  ; ,None,None,2,0,,No,1:No,1:No,,0.922
2834,2765955,Table 1,BaselineCharacteristic,x.x,P* ;  ; ,None,None,2,3,,No,1:No,1:No,,0.884
2834,2765955,Table 1,BaselineCharacteristic,, ;  ; Age ; ,None,None,3,0,,No,1:No,1:No,,0.932
2834,2765955,Table 1,BaselineCharacteristic,,P* ;  ; x.x ; ,None,None,3,3,,No,1:No,1:No,,0.899
2834,2765955,Table 1,BaselineCharacteristic,Height (m), ;  ; Age ;  ; ,None,None,4,0,,No,1:No,1:No,,0.944
2834,2765955,Table 1,BaselineCharacteristic,<x.xxx,P* ;  ; x.x ;  ; ,None,None,4,3,,No,1:No,1:No,,0.845
2834,2765955,Table 1,BaselineCharacteristic,, ;  ; Age ;  ; Height (m) ; ,None,None,5,0,,No,1:No,1:No,,0.944
2834,2765955,Table 1,BaselineCharacteristic,,P* ;  ; x.x ;  ; <x.xxx ; ,None,None,5,3,,No,1:No,1:No,,0.853
2834,2765955,Table 1,BaselineCharacteristic,Weight (kg), ;  ; Age ;  ; Height (m) ;  ; ,None,None,6,0,,No,1:No,1:No,,0.972
2834,2765955,Table 1,BaselineCharacteristic,<x.xxx,P* ;  ; x.x ;  ; <x.xxx ;  ; ,None,None,6,3,,No,1:No,1:No,,0.882
2834,2765955,Table 1,BaselineCharacteristic,, ;  ; Age ;  ; Height (m) ;  ; Weight (kg) ; ,None,None,7,0,,No,1:No,1:No,,0.981
2834,2765955,Table 1,BaselineCharacteristic,,P* ;  ; x.x ;  ; <x.xxx ;  ; <x.xxx ; ,None,None,7,3,,No,1:No,1:No,,0.899
2834,2765955,Table 1,BaselineCharacteristic,BMI (kg/mx), ;  ; Age ;  ; Height (m) ;  ; Weight (kg) ;  ; ,None,None,8,0,,No,1:No,1:No,,0.991
2834,2765955,Table 1,BaselineCharacteristic,x.x,P* ;  ; x.x ;  ; <x.xxx ;  ; <x.xxx ;  ; ,None,None,8,3,,No,1:No,1:No,,0.904
2834,2765955,Table 1,BaselineCharacteristic,, ;  ; Age ;  ; Height (m) ;  ; Weight (kg) ;  ; BMI (kg/mx) ; ,None,None,9,0,,No,1:No,1:No,,0.991
2834,2765955,Table 1,BaselineCharacteristic,,P* ;  ; x.x ;  ; <x.xxx ;  ; <x.xxx ;  ; x.x ; ,None,None,9,3,,No,1:No,1:No,,0.919
2834,2765955,Table 1,BaselineCharacteristic,K&L Grade x, ;  ; Age ;  ; Height (m) ;  ; Weight (kg) ;  ; BMI (kg/mx) ;  ; ,None,None,10,0,,No,1:No,1:No,,0.995
2834,2765955,Table 1,BaselineCharacteristic,x,Males ; (n = xx) ; xx.x (xx.x) ;  ; x.xx (x.x) ;  ; xx.x (xx.x) ;  ; xx.x (x.x) ;  ; ,None,None,10,1,,No,1:No,1:No,,0.544
2834,2765955,Table 1,BaselineCharacteristic,xx,Females ; (n = xx) ; xx.x (x.x) ;  ; x.xx (x.x) ;  ; xx.x (xx.x) ;  ; xx.x (x.x) ;  ; ,None,None,10,2,,No,1:No,1:No,,0.518
2834,2765955,Table 1,BaselineCharacteristic,,P* ;  ; x.x ;  ; <x.xxx ;  ; <x.xxx ;  ; x.x ;  ; ,None,None,10,3,,No,1:No,1:No,,0.942
2834,2765955,Table 1,BaselineCharacteristic,, ;  ; Age ;  ; Height (m) ;  ; Weight (kg) ;  ; BMI (kg/mx) ;  ; K&L Grade x ; ,None,None,11,0,,No,1:No,1:No,,0.995
2834,2765955,Table 1,BaselineCharacteristic,,Males ; (n = xx) ; xx.x (xx.x) ;  ; x.xx (x.x) ;  ; xx.x (xx.x) ;  ; xx.x (x.x) ;  ; x ; ,None,None,11,1,,No,1:No,1:No,,0.554
2834,2765955,Table 1,BaselineCharacteristic,,Females ; (n = xx) ; xx.x (x.x) ;  ; x.xx (x.x) ;  ; xx.x (xx.x) ;  ; xx.x (x.x) ;  ; xx ; ,None,None,11,2,,No,1:No,1:No,,0.538
2834,2765955,Table 1,BaselineCharacteristic,,P* ;  ; x.x ;  ; <x.xxx ;  ; <x.xxx ;  ; x.x ;  ;  ; ,None,None,11,3,,No,1:No,1:No,,0.942
2834,2765955,Table 1,BaselineCharacteristic,K&L Grade x, ;  ; Age ;  ; Height (m) ;  ; Weight (kg) ;  ; BMI (kg/mx) ;  ; K&L Grade x ;  ; ,None,None,12,0,,No,1:No,1:No,,0.995
2834,2765955,Table 1,BaselineCharacteristic,x,Males ; (n = xx) ; xx.x (xx.x) ;  ; x.xx (x.x) ;  ; xx.x (xx.x) ;  ; xx.x (x.x) ;  ; x ;  ; ,None,None,12,1,,No,1:No,1:No,,0.554
2834,2765955,Table 1,BaselineCharacteristic,xx,Females ; (n = xx) ; xx.x (x.x) ;  ; x.xx (x.x) ;  ; xx.x (xx.x) ;  ; xx.x (x.x) ;  ; xx ;  ; ,None,None,12,2,,No,1:No,1:No,,0.538
2834,2765955,Table 1,BaselineCharacteristic,,P* ;  ; x.x ;  ; <x.xxx ;  ; <x.xxx ;  ; x.x ;  ;  ;  ; ,None,None,12,3,,No,1:No,1:No,,0.942
2834,2765955,Table 1,BaselineCharacteristic,, ;  ; Age ;  ; Height (m) ;  ; Weight (kg) ;  ; BMI (kg/mx) ;  ; K&L Grade x ;  ; K&L Grade x ; ,None,None,13,0,,No,1:No,1:No,,0.995
2834,2765955,Table 1,BaselineCharacteristic,,Males ; (n = xx) ; xx.x (xx.x) ;  ; x.xx (x.x) ;  ; xx.x (xx.x) ;  ; xx.x (x.x) ;  ; x ;  ; x ; ,None,None,13,1,,No,1:No,1:No,,0.554
2834,2765955,Table 1,BaselineCharacteristic,,Females ; (n = xx) ; xx.x (x.x) ;  ; x.xx (x.x) ;  ; xx.x (xx.x) ;  ; xx.x (x.x) ;  ; xx ;  ; xx ; ,None,None,13,2,,No,1:No,1:No,,0.538
2834,2765955,Table 1,BaselineCharacteristic,,P* ;  ; x.x ;  ; <x.xxx ;  ; <x.xxx ;  ; x.x ;  ;  ;  ;  ; ,None,None,13,3,,No,1:No,1:No,,0.942
2834,2765955,Table 1,BaselineCharacteristic,K&L Grade x, ;  ; Age ;  ; Height (m) ;  ; Weight (kg) ;  ; BMI (kg/mx) ;  ; K&L Grade x ;  ; K&L Grade x ;  ; ,None,None,14,0,,No,1:No,1:No,,0.995
2834,2765955,Table 1,BaselineCharacteristic,xx,Males ; (n = xx) ; xx.x (xx.x) ;  ; x.xx (x.x) ;  ; xx.x (xx.x) ;  ; xx.x (x.x) ;  ; x ;  ; x ;  ; ,None,None,14,1,,No,1:No,1:No,,0.564
2834,2765955,Table 1,BaselineCharacteristic,xx,Females ; (n = xx) ; xx.x (x.x) ;  ; x.xx (x.x) ;  ; xx.x (xx.x) ;  ; xx.x (x.x) ;  ; xx ;  ; xx ;  ; ,None,None,14,2,,No,1:No,1:No,,0.549
2834,2765955,Table 1,BaselineCharacteristic,,P* ;  ; x.x ;  ; <x.xxx ;  ; <x.xxx ;  ; x.x ;  ;  ;  ;  ;  ; ,None,None,14,3,,No,1:No,1:No,,0.942
2834,2765955,Table 1,BaselineCharacteristic,, ;  ; Age ;  ; Height (m) ;  ; Weight (kg) ;  ; BMI (kg/mx) ;  ; K&L Grade x ;  ; K&L Grade x ;  ; K&L Grade x ; ,None,None,15,0,,No,1:No,1:No,,0.995
2834,2765955,Table 1,BaselineCharacteristic,,Males ; (n = xx) ; xx.x (xx.x) ;  ; x.xx (x.x) ;  ; xx.x (xx.x) ;  ; xx.x (x.x) ;  ; x ;  ; x ;  ; xx ; ,None,None,15,1,,No,1:No,1:No,,0.564
2834,2765955,Table 1,BaselineCharacteristic,,Females ; (n = xx) ; xx.x (x.x) ;  ; x.xx (x.x) ;  ; xx.x (xx.x) ;  ; xx.x (x.x) ;  ; xx ;  ; xx ;  ; xx ; ,None,None,15,2,,No,1:No,1:No,,0.549
2834,2765955,Table 1,BaselineCharacteristic,,P* ;  ; x.x ;  ; <x.xxx ;  ; <x.xxx ;  ; x.x ;  ;  ;  ;  ;  ;  ; ,None,None,15,3,,No,1:No,1:No,,0.942
2834,2765955,Table 1,BaselineCharacteristic,K&L Grade x, ;  ; Age ;  ; Height (m) ;  ; Weight (kg) ;  ; BMI (kg/mx) ;  ; K&L Grade x ;  ; K&L Grade x ;  ; K&L Grade x ;  ; ,K&L Grade x,,16,0,,No,1:No,1:No,,0.995
2834,2765955,Table 1,BaselineCharacteristic,xx,Males ; (n = xx) ; xx.x (xx.x) ;  ; x.xx (x.x) ;  ; xx.x (xx.x) ;  ; xx.x (x.x) ;  ; x ;  ; x ;  ; xx ;  ; ,K&L Grade x,,16,1,,No,1:No,1:No,,0.564
2834,2765955,Table 1,BaselineCharacteristic,xx,Females ; (n = xx) ; xx.x (x.x) ;  ; x.xx (x.x) ;  ; xx.x (xx.x) ;  ; xx.x (x.x) ;  ; xx ;  ; xx ;  ; xx ;  ; ,K&L Grade x,,16,2,,No,1:No,1:No,,0.549
2834,2765955,Table 1,BaselineCharacteristic,x.xx,P* ;  ; x.x ;  ; <x.xxx ;  ; <x.xxx ;  ; x.x ;  ;  ;  ;  ;  ;  ;  ; ,K&L Grade x,,16,3,,No,1:No,1:No,,0.787
2864,2774660,Table 1,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
2864,2774660,Table 1,BaselineCharacteristic,Total,,,None,0,1,1,No,1:No,1:No,,0.903
2864,2774660,Table 1,BaselineCharacteristic,Phase x - treatment,,,None,0,2,1,No,1:No,1:No,,0.758
2864,2774660,Table 1,BaselineCharacteristic,Phase x - placebo,,,None,0,3,1,No,1:No,1:No,,0.62
2864,2774660,Table 1,BaselineCharacteristic,Total Participants, ; ,Total Participants,None,1,0,2,No,1:No,1:No,,0.93
2864,2774660,Table 1,BaselineCharacteristic,xx,Total ; ,Total Participants,None,1,1,3,No,1:No,1:No,,0.648
2864,2774660,Table 1,BaselineCharacteristic,xx,Phase x - treatment ; ,Total Participants,None,1,2,3,No,1:No,1:No,,0.552
2864,2774660,Table 1,BaselineCharacteristic,Male, ; ,Male,None,2,0,2,No,1:No,1:No,,0.95
2864,2774660,Table 1,BaselineCharacteristic,xx,Total ; ,Male,None,2,1,3,No,1:No,1:No,,0.688
2864,2774660,Table 1,BaselineCharacteristic,xx,Phase x - treatment ; ,Male,None,2,2,3,No,1:No,1:No,,0.592
2864,2774660,Table 1,BaselineCharacteristic,Female, ; ,Female,None,3,0,2,No,1:No,1:No,,0.96
2864,2774660,Table 1,BaselineCharacteristic,x,Total ; ,Female,None,3,1,3,No,1:No,1:No,,0.93
2864,2774660,Table 1,BaselineCharacteristic,x,Phase x - treatment ; ,Female,None,3,2,3,No,1:No,1:No,,0.78
2864,2774660,Table 1,BaselineCharacteristic,x,Phase x - placebo ; ,Female,None,3,3,3,No,1:No,1:No,,0.59
2864,2774660,Table 1,BaselineCharacteristic,Age (years), ; ,Age (years),None,4,0,2,No,1:No,1:No,,0.67
2864,2774660,Table 1,BaselineCharacteristic,Diagnosis, ; ,Diagnosis,None,5,0,2,No,1:No,1:No,,0.97
2864,2774660,Table 1,BaselineCharacteristic,"xx% autism, x% PDD/NOS, x% Asperger\'s",Total ; ,Diagnosis,None,5,1,3,No,1:No,1:No,,0.92
2864,2774660,Table 1,BaselineCharacteristic,"xx% Autism, x% Aspergers",Phase x - treatment ; ,Diagnosis,None,5,2,3,No,1:No,1:No,,0.82
2864,2774660,Table 1,BaselineCharacteristic,xxx% Autism,Phase x - placebo ; ,Diagnosis,None,5,3,3,No,1:No,1:No,,0.6
3023,2816665,Table 1,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
3023,2816665,Table 1,BaselineCharacteristic,All patients,,,None,0,1,1,No,1:No,1:No,,0.793
3023,2816665,Table 1,BaselineCharacteristic,Subgroup A,,,None,0,2,1,No,1:No,1:No,,0.823
3023,2816665,Table 1,BaselineCharacteristic,Subgroup B,,,None,0,3,1,No,1:No,1:No,,0.823
3023,2816665,Table 1,BaselineCharacteristic,Subgroup C,,,None,0,4,1,No,1:No,1:No,,0.833
3023,2816665,Table 1,BaselineCharacteristic,Patient number, ; ,Patient number,None,1,0,2,No,1:No,1:No,,0.865
3023,2816665,Table 1,BaselineCharacteristic,xxx,All patients ; ,Patient number,None,1,1,3,No,1:No,1:No,,0.66
3023,2816665,Table 1,BaselineCharacteristic,Median age (range), ; ,Median age (range),None,2,0,2,No,1:No,1:No,,0.58
3023,2816665,Table 1,BaselineCharacteristic,Male (%), ; ,Male (%),None,3,0,2,No,1:No,1:No,,0.85
3023,2816665,Table 1,BaselineCharacteristic,xx (xx),Subgroup C ; ,Male (%),None,3,4,3,No,1:No,1:No,,0.501
3023,2816665,Table 1,BaselineCharacteristic,PS x (%), ; ,PS x (%),None,4,0,2,No,1:No,1:No,,0.855
3023,2816665,Table 1,BaselineCharacteristic,x (xx),Subgroup A ; ,PS x (%),None,4,2,3,No,1:No,1:No,,0.526
3023,2816665,Table 1,BaselineCharacteristic,x (x),Subgroup B ; ,PS x (%),None,4,3,3,No,1:No,1:No,,0.69
3023,2816665,Table 1,BaselineCharacteristic,x (x),Subgroup C ; ,PS x (%),None,4,4,3,No,1:No,1:No,,0.7
3023,2816665,Table 1,BaselineCharacteristic,Primary in-situ at study entry, ; ,Primary in-situ at study entry,None,5,0,2,No,1:No,1:No,,0.9
3023,2816665,Table 1,BaselineCharacteristic,,All patients ; ,Primary in-situ at study entry,None,5,1,3,No,1:No,1:No,,0.71
3023,2816665,Table 1,BaselineCharacteristic,xx%,Subgroup A ; ,Primary in-situ at study entry,None,5,2,3,No,1:No,1:No,,0.79
3023,2816665,Table 1,BaselineCharacteristic,xx%,Subgroup B ; ,Primary in-situ at study entry,None,5,3,3,No,1:No,1:No,,0.79
3023,2816665,Table 1,BaselineCharacteristic,xx%,Subgroup C ; ,Primary in-situ at study entry,None,5,4,3,No,1:No,1:No,,0.785
3023,2816665,Table 1,BaselineCharacteristic,Metachronous presentation of >xx months, ; ,Metachronous presentation of >xx months,None,6,0,2,No,1:No,1:No,,0.99
3023,2816665,Table 1,BaselineCharacteristic,,All patients ; ,Metachronous presentation of >xx months,None,6,1,3,No,1:No,1:No,,0.75
3023,2816665,Table 1,BaselineCharacteristic,xx%,Subgroup A ; ,Metachronous presentation of >xx months,None,6,2,3,No,1:No,1:No,,0.87
3023,2816665,Table 1,BaselineCharacteristic,x%,Subgroup B ; ,Metachronous presentation of >xx months,None,6,3,3,No,1:No,1:No,,0.88
3023,2816665,Table 1,BaselineCharacteristic,xx%,Subgroup C ; ,Metachronous presentation of >xx months,None,6,4,3,No,1:No,1:No,,0.87
3023,2816665,Table 1,BaselineCharacteristic,aSynchronous presentation, ; ,aSynchronous presentation,None,7,0,2,No,1:No,1:No,,0.99
3023,2816665,Table 1,BaselineCharacteristic,,All patients ; ,aSynchronous presentation,None,7,1,3,No,1:No,1:No,,0.73
3023,2816665,Table 1,BaselineCharacteristic,,Subgroup A ; ,aSynchronous presentation,None,7,2,3,No,1:No,1:No,,0.87
3023,2816665,Table 1,BaselineCharacteristic,xx%,Subgroup B ; ,aSynchronous presentation,None,7,3,3,No,1:No,1:No,,0.87
3023,2816665,Table 1,BaselineCharacteristic,xx%,Subgroup C ; ,aSynchronous presentation,None,7,4,3,No,1:No,1:No,,0.88
3023,2816665,Table 1,BaselineCharacteristic,Median number of liver deposits (range), ; ,Median number of liver deposits (range),None,8,0,2,No,1:No,1:No,,0.674
3023,2816665,Table 1,BaselineCharacteristic,,All patients ; ,Median number of liver deposits (range),None,8,1,3,No,1:No,1:No,,0.55
3023,2816665,Table 1,BaselineCharacteristic,,Subgroup A ; ,Median number of liver deposits (range),None,8,2,3,No,1:No,1:No,,0.52
3023,2816665,Table 1,BaselineCharacteristic,x (x–xx),Subgroup B ; ,Median number of liver deposits (range),None,8,3,3,No,1:No,1:No,,0.54
3023,2816665,Table 1,BaselineCharacteristic,x (x–x),Subgroup C ; ,Median number of liver deposits (range),None,8,4,3,No,1:No,1:No,,0.6
3030,2820141,Table 5,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
3030,2820141,Table 5,BaselineCharacteristic,,,,None,0,1,1,No,1:No,1:No,,0.903
3030,2820141,Table 5,BaselineCharacteristic,Event-free Survival ± SE (%),,,None,0,2,1,No,1:No,1:No,,0.903
3030,2820141,Table 5,BaselineCharacteristic,Event-free Survival ± SE (%),,,None,0,3,1,No,1:No,1:No,,0.903
3030,2820141,Table 5,BaselineCharacteristic,Event-free Survival ± SE (%),,,None,0,4,1,No,1:No,1:No,,0.903
3030,2820141,Table 5,BaselineCharacteristic,Event-free Survival ± SE (%),,,None,0,5,1,No,1:No,1:No,,0.913
3030,2820141,Table 5,BaselineCharacteristic,Overall Survival ± SE (%),,,None,0,6,1,No,1:No,1:No,,0.868
3030,2820141,Table 5,BaselineCharacteristic,Overall Survival ± SE (%),,,None,0,7,1,No,1:No,1:No,,0.878
3030,2820141,Table 5,BaselineCharacteristic,Overall Survival ± SE (%),,,None,0,8,1,No,1:No,1:No,,0.878
3030,2820141,Table 5,BaselineCharacteristic,Overall Survival ± SE (%),,,None,0,9,1,No,1:No,1:No,,0.878
3030,2820141,Table 5,BaselineCharacteristic,, ; ,None,None,1,0,12,No,1:No,1:No,,0.898
3030,2820141,Table 5,BaselineCharacteristic,, ; ,,None,1,1,1,No,1:No,1:No,,0.895
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ; ,,None,1,2,1,No,1:No,1:No,,0.903
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ; ,,None,1,3,1,No,1:No,1:No,,0.903
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ; ,,None,1,4,1,No,1:No,1:No,,0.903
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ; ,,None,1,5,1,No,1:No,1:No,,0.913
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ; ,,None,1,6,1,No,1:No,1:No,,0.868
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ; ,,None,1,7,1,No,1:No,1:No,,0.878
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ; ,,None,1,8,1,No,1:No,1:No,,0.878
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ; ,,None,1,9,1,No,1:No,1:No,,0.878
3030,2820141,Table 5,BaselineCharacteristic,Protocol, ;  ; ,None,None,2,0,12,No,1:No,1:No,,0.923
3030,2820141,Table 5,BaselineCharacteristic,N, ;  ; ,Protocol,None,2,1,1,No,1:No,1:No,,0.915
3030,2820141,Table 5,BaselineCharacteristic,x-yr EFS,Event-free Survival ± SE (%) ;  ; ,Protocol,None,2,2,1,No,1:No,1:No,,0.943
3030,2820141,Table 5,BaselineCharacteristic,xx-yr EFS,Event-free Survival ± SE (%) ;  ; ,Protocol,None,2,3,1,No,1:No,1:No,,0.943
3030,2820141,Table 5,BaselineCharacteristic,xx-yr EFS,Event-free Survival ± SE (%) ;  ; ,Protocol,None,2,4,1,No,1:No,1:No,,0.943
3030,2820141,Table 5,BaselineCharacteristic,p-value,Event-free Survival ± SE (%) ;  ; ,Protocol,None,2,5,1,No,1:No,1:No,,0.923
3030,2820141,Table 5,BaselineCharacteristic,x-yr OS,Overall Survival ± SE (%) ;  ; ,Protocol,None,2,6,1,No,1:No,1:No,,0.905
3030,2820141,Table 5,BaselineCharacteristic,xx-yr OS,Overall Survival ± SE (%) ;  ; ,Protocol,None,2,7,1,No,1:No,1:No,,0.915
3030,2820141,Table 5,BaselineCharacteristic,xx-yr OS,Overall Survival ± SE (%) ;  ; ,Protocol,None,2,8,1,No,1:No,1:No,,0.915
3030,2820141,Table 5,BaselineCharacteristic,p-value,Overall Survival ± SE (%) ;  ; ,Protocol,None,2,9,1,No,1:No,1:No,,0.878
3030,2820141,Table 5,BaselineCharacteristic,Overall, ;  ; Protocol ; ,Overall,,3,0,2,No,1:No,1:No,,0.96
3030,2820141,Table 5,BaselineCharacteristic,xxx, ;  ; N ; ,Overall,,3,1,3,No,1:No,1:No,,0.81
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,Overall,,3,2,3,No,1:No,1:No,,0.8
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Overall,,3,3,3,No,1:No,1:No,,0.8
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Overall,,3,4,3,No,1:No,1:No,,0.81
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,Overall,,3,5,3,No,1:No,1:No,,0.9
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,Overall,,3,6,3,No,1:No,1:No,,0.76
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Overall,,3,7,3,No,1:No,1:No,,0.76
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Overall,,3,8,3,No,1:No,1:No,,0.77
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,Overall,,3,9,3,No,1:No,1:No,,0.85
3030,2820141,Table 5,BaselineCharacteristic,Immunophenotype, ;  ; Protocol ; ,None,None,4,0,24,No,1:No,1:No,,0.939
3030,2820141,Table 5,BaselineCharacteristic,, ;  ; N ; ,Immunophenotype,None,4,1,43,No,1:No,1:No,,0.902
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,Immunophenotype,None,4,2,43,No,1:No,1:No,,0.955
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Immunophenotype,None,4,3,43,No,1:No,1:No,,0.965
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Immunophenotype,None,4,4,43,No,1:No,1:No,,0.955
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,Immunophenotype,None,4,5,43,No,1:No,1:No,,0.905
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,Immunophenotype,None,4,6,43,No,1:No,1:No,,0.905
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Immunophenotype,None,4,7,43,No,1:No,1:No,,0.915
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Immunophenotype,None,4,8,43,No,1:No,1:No,,0.915
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,Immunophenotype,None,4,9,43,No,1:No,1:No,,0.875
3030,2820141,Table 5,BaselineCharacteristic,, ;  ; Protocol ; ,, Immunophenotype,5,0,2,No,1:No,1:No,,0.97
3030,2820141,Table 5,BaselineCharacteristic,xxx, ;  ; N ; ,, Immunophenotype,5,1,3,No,1:No,1:No,,0.81
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Immunophenotype,5,2,3,No,1:No,1:No,,0.84
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Immunophenotype,5,3,3,No,1:No,1:No,,0.85
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Immunophenotype,5,4,3,No,1:No,1:No,,0.86
3030,2820141,Table 5,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, Immunophenotype,5,5,3,No,1:No,1:No,,0.9
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Immunophenotype,5,6,3,No,1:No,1:No,,0.8
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Immunophenotype,5,7,3,No,1:No,1:No,,0.79
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Immunophenotype,5,8,3,No,1:No,1:No,,0.8
3030,2820141,Table 5,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, Immunophenotype,5,9,3,No,1:No,1:No,,0.83
3030,2820141,Table 5,BaselineCharacteristic,, ;  ; Protocol ; ,, Immunophenotype,6,0,2,No,1:No,1:No,,0.99
3030,2820141,Table 5,BaselineCharacteristic,xx, ;  ; N ; ,, Immunophenotype,6,1,3,No,1:No,1:No,,0.791
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Immunophenotype,6,2,3,No,1:No,1:No,,0.87
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Immunophenotype,6,3,3,No,1:No,1:No,,0.87
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Immunophenotype,6,4,3,No,1:No,1:No,,0.88
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, Immunophenotype,6,5,3,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Immunophenotype,6,6,3,No,1:No,1:No,,0.83
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Immunophenotype,6,7,3,No,1:No,1:No,,0.81
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Immunophenotype,6,8,3,No,1:No,1:No,,0.82
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, Immunophenotype,6,9,3,No,1:No,1:No,,0.91
3030,2820141,Table 5,BaselineCharacteristic,B-precursor†, ;  ; Protocol ; ,None,None,7,0,24,No,1:No,1:No,,0.974
3030,2820141,Table 5,BaselineCharacteristic,, ;  ; N ; ,B-precursor†,None,7,1,43,No,1:No,1:No,,0.967
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,B-precursor†,None,7,2,43,No,1:No,1:No,,0.98
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,B-precursor†,None,7,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,B-precursor†,None,7,4,43,No,1:No,1:No,,0.98
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,B-precursor†,None,7,5,43,No,1:No,1:No,,0.95
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,B-precursor†,None,7,6,43,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,B-precursor†,None,7,7,43,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,B-precursor†,None,7,8,43,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,B-precursor†,None,7,9,43,No,1:No,1:No,,0.92
3030,2820141,Table 5,BaselineCharacteristic,, ;  ; Protocol ; ,, B-precursor†,8,0,2,No,1:No,1:No,,0.99
3030,2820141,Table 5,BaselineCharacteristic,xxx, ;  ; N ; ,, B-precursor†,8,1,3,No,1:No,1:No,,0.89
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, B-precursor†,8,2,3,No,1:No,1:No,,0.93
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, B-precursor†,8,3,3,No,1:No,1:No,,0.93
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, B-precursor†,8,4,3,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, B-precursor†,8,5,3,No,1:No,1:No,,0.95
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, B-precursor†,8,6,3,No,1:No,1:No,,0.89
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, B-precursor†,8,7,3,No,1:No,1:No,,0.88
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, B-precursor†,8,8,3,No,1:No,1:No,,0.88
3030,2820141,Table 5,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, B-precursor†,8,9,3,No,1:No,1:No,,0.9
3030,2820141,Table 5,BaselineCharacteristic,, ;  ; Protocol ; ,, B-precursor†,9,0,2,No,1:No,1:No,,1
3030,2820141,Table 5,BaselineCharacteristic,xx, ;  ; N ; ,, B-precursor†,9,1,3,No,1:No,1:No,,0.891
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, B-precursor†,9,2,3,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, B-precursor†,9,3,3,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, B-precursor†,9,4,3,No,1:No,1:No,,0.95
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, B-precursor†,9,5,3,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, B-precursor†,9,6,3,No,1:No,1:No,,0.91
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, B-precursor†,9,7,3,No,1:No,1:No,,0.9
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, B-precursor†,9,8,3,No,1:No,1:No,,0.9
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, B-precursor†,9,9,3,No,1:No,1:No,,0.92
3030,2820141,Table 5,BaselineCharacteristic,T-lineage†, ;  ; Protocol ; ,None,None,10,0,24,No,1:No,1:No,,0.995
3030,2820141,Table 5,BaselineCharacteristic,, ;  ; N ; ,T-lineage†,None,10,1,43,No,1:No,1:No,,0.977
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,T-lineage†,None,10,2,43,No,1:No,1:No,,0.98
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,T-lineage†,None,10,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,T-lineage†,None,10,4,43,No,1:No,1:No,,0.98
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,T-lineage†,None,10,5,43,No,1:No,1:No,,0.95
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,T-lineage†,None,10,6,43,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,T-lineage†,None,10,7,43,No,1:No,1:No,,0.95
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,T-lineage†,None,10,8,43,No,1:No,1:No,,0.95
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,T-lineage†,None,10,9,43,No,1:No,1:No,,0.93
3030,2820141,Table 5,BaselineCharacteristic,, ;  ; Protocol ; ,, T-lineage†,11,0,2,No,1:No,1:No,,1
3030,2820141,Table 5,BaselineCharacteristic,x, ;  ; N ; ,, T-lineage†,11,1,3,No,1:No,1:No,,1
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, T-lineage†,11,2,3,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, T-lineage†,11,3,3,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, T-lineage†,11,4,3,No,1:No,1:No,,0.95
3030,2820141,Table 5,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, T-lineage†,11,5,3,No,1:No,1:No,,0.97
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, T-lineage†,11,6,3,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, T-lineage†,11,7,3,No,1:No,1:No,,0.92
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, T-lineage†,11,8,3,No,1:No,1:No,,0.93
3030,2820141,Table 5,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, T-lineage†,11,9,3,No,1:No,1:No,,0.96
3030,2820141,Table 5,BaselineCharacteristic,, ;  ; Protocol ; ,, T-lineage†,12,0,2,No,1:No,1:No,,1
3030,2820141,Table 5,BaselineCharacteristic,xx, ;  ; N ; ,, T-lineage†,12,1,3,No,1:No,1:No,,0.921
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, T-lineage†,12,2,3,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, T-lineage†,12,3,3,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, T-lineage†,12,4,3,No,1:No,1:No,,0.95
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, T-lineage†,12,5,3,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, T-lineage†,12,6,3,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, T-lineage†,12,7,3,No,1:No,1:No,,0.92
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, T-lineage†,12,8,3,No,1:No,1:No,,0.93
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, T-lineage†,12,9,3,No,1:No,1:No,,0.92
3030,2820141,Table 5,BaselineCharacteristic,Sex, ;  ; Protocol ; ,None,None,13,0,24,No,1:No,1:No,,0.995
3030,2820141,Table 5,BaselineCharacteristic,, ;  ; N ; ,Sex,None,13,1,43,No,1:No,1:No,,0.977
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,Sex,None,13,2,43,No,1:No,1:No,,0.98
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Sex,None,13,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Sex,None,13,4,43,No,1:No,1:No,,0.98
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,Sex,None,13,5,43,No,1:No,1:No,,0.95
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,Sex,None,13,6,43,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Sex,None,13,7,43,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Sex,None,13,8,43,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,Sex,None,13,9,43,No,1:No,1:No,,0.92
3030,2820141,Table 5,BaselineCharacteristic,, ;  ; Protocol ; ,, Sex,14,0,2,No,1:No,1:No,,1
3030,2820141,Table 5,BaselineCharacteristic,xxx, ;  ; N ; ,, Sex,14,1,3,No,1:No,1:No,,0.92
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Sex,14,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Sex,14,3,3,No,1:No,1:No,,0.95
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Sex,14,4,3,No,1:No,1:No,,0.95
3030,2820141,Table 5,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, Sex,14,5,3,No,1:No,1:No,,0.97
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Sex,14,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Sex,14,7,3,No,1:No,1:No,,0.91
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Sex,14,8,3,No,1:No,1:No,,0.92
3030,2820141,Table 5,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, Sex,14,9,3,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,, ;  ; Protocol ; ,, Sex,15,0,2,No,1:No,1:No,,1
3030,2820141,Table 5,BaselineCharacteristic,xxx, ;  ; N ; ,, Sex,15,1,3,No,1:No,1:No,,0.91
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Sex,15,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Sex,15,3,3,No,1:No,1:No,,0.95
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Sex,15,4,3,No,1:No,1:No,,0.95
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, Sex,15,5,3,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Sex,15,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Sex,15,7,3,No,1:No,1:No,,0.91
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Sex,15,8,3,No,1:No,1:No,,0.92
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, Sex,15,9,3,No,1:No,1:No,,0.91
3030,2820141,Table 5,BaselineCharacteristic,Age at Diagnosis, ;  ; Protocol ; ,None,None,16,0,24,No,1:No,1:No,,0.995
3030,2820141,Table 5,BaselineCharacteristic,, ;  ; N ; ,Age at Diagnosis,None,16,1,43,No,1:No,1:No,,0.967
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,Age at Diagnosis,None,16,2,43,No,1:No,1:No,,0.97
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Age at Diagnosis,None,16,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Age at Diagnosis,None,16,4,43,No,1:No,1:No,,0.98
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,Age at Diagnosis,None,16,5,43,No,1:No,1:No,,0.95
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,Age at Diagnosis,None,16,6,43,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Age at Diagnosis,None,16,7,43,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Age at Diagnosis,None,16,8,43,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,Age at Diagnosis,None,16,9,43,No,1:No,1:No,,0.92
3030,2820141,Table 5,BaselineCharacteristic,, ;  ; Protocol ; ,, Age at Diagnosis,17,0,2,No,1:No,1:No,,1
3030,2820141,Table 5,BaselineCharacteristic,xx, ;  ; N ; ,, Age at Diagnosis,17,1,3,No,1:No,1:No,,0.951
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Age at Diagnosis,17,2,3,No,1:No,1:No,,0.97
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Age at Diagnosis,17,3,3,No,1:No,1:No,,0.97
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Age at Diagnosis,17,4,3,No,1:No,1:No,,0.97
3030,2820141,Table 5,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, Age at Diagnosis,17,5,3,No,1:No,1:No,,0.97
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Age at Diagnosis,17,6,3,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Age at Diagnosis,17,7,3,No,1:No,1:No,,0.92
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Age at Diagnosis,17,8,3,No,1:No,1:No,,0.93
3030,2820141,Table 5,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, Age at Diagnosis,17,9,3,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,, ;  ; Protocol ; ,, Age at Diagnosis,18,0,2,No,1:No,1:No,,0.99
3030,2820141,Table 5,BaselineCharacteristic,xxx, ;  ; N ; ,, Age at Diagnosis,18,1,3,No,1:No,1:No,,0.92
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Age at Diagnosis,18,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Age at Diagnosis,18,3,3,No,1:No,1:No,,0.965
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Age at Diagnosis,18,4,3,No,1:No,1:No,,0.965
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, Age at Diagnosis,18,5,3,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Age at Diagnosis,18,6,3,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Age at Diagnosis,18,7,3,No,1:No,1:No,,0.915
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Age at Diagnosis,18,8,3,No,1:No,1:No,,0.925
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, Age at Diagnosis,18,9,3,No,1:No,1:No,,0.92
3030,2820141,Table 5,BaselineCharacteristic,, ;  ; Protocol ; ,, Age at Diagnosis,19,0,2,No,1:No,1:No,,0.99
3030,2820141,Table 5,BaselineCharacteristic,xx, ;  ; N ; ,, Age at Diagnosis,19,1,3,No,1:No,1:No,,0.937
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Age at Diagnosis,19,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Age at Diagnosis,19,3,3,No,1:No,1:No,,0.965
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Age at Diagnosis,19,4,3,No,1:No,1:No,,0.965
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, Age at Diagnosis,19,5,3,No,1:No,1:No,,0.93
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Age at Diagnosis,19,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Age at Diagnosis,19,7,3,No,1:No,1:No,,0.905
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Age at Diagnosis,19,8,3,No,1:No,1:No,,0.915
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, Age at Diagnosis,19,9,3,No,1:No,1:No,,0.91
3030,2820141,Table 5,BaselineCharacteristic,WBC (× xxx/L), ;  ; Protocol ; ,None,None,20,0,24,No,1:No,1:No,,0.995
3030,2820141,Table 5,BaselineCharacteristic,, ;  ; N ; ,WBC (× xxx/L),None,20,1,43,No,1:No,1:No,,0.988
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,WBC (× xxx/L),None,20,2,43,No,1:No,1:No,,0.99
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,WBC (× xxx/L),None,20,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,WBC (× xxx/L),None,20,4,43,No,1:No,1:No,,0.98
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,WBC (× xxx/L),None,20,5,43,No,1:No,1:No,,0.96
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,WBC (× xxx/L),None,20,6,43,No,1:No,1:No,,0.96
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,WBC (× xxx/L),None,20,7,43,No,1:No,1:No,,0.95
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,WBC (× xxx/L),None,20,8,43,No,1:No,1:No,,0.95
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,WBC (× xxx/L),None,20,9,43,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,, ;  ; Protocol ; ,, WBC (× xxx/L),21,0,2,No,1:No,1:No,,1
3030,2820141,Table 5,BaselineCharacteristic,xx, ;  ; N ; ,, WBC (× xxx/L),21,1,3,No,1:No,1:No,,0.951
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, WBC (× xxx/L),21,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, WBC (× xxx/L),21,3,3,No,1:No,1:No,,0.96
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, WBC (× xxx/L),21,4,3,No,1:No,1:No,,0.96
3030,2820141,Table 5,BaselineCharacteristic,x.xxxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, WBC (× xxx/L),21,5,3,No,1:No,1:No,,0.98
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, WBC (× xxx/L),21,6,3,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, WBC (× xxx/L),21,7,3,No,1:No,1:No,,0.93
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, WBC (× xxx/L),21,8,3,No,1:No,1:No,,0.93
3030,2820141,Table 5,BaselineCharacteristic,x.xxxx,Overall Survival ± SE (%) ;  ; p-value ; ,, WBC (× xxx/L),21,9,3,No,1:No,1:No,,0.95
3030,2820141,Table 5,BaselineCharacteristic,, ;  ; Protocol ; ,, WBC (× xxx/L),22,0,2,No,1:No,1:No,,1
3030,2820141,Table 5,BaselineCharacteristic,xx, ;  ; N ; ,, WBC (× xxx/L),22,1,3,No,1:No,1:No,,0.951
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, WBC (× xxx/L),22,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, WBC (× xxx/L),22,3,3,No,1:No,1:No,,0.96
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, WBC (× xxx/L),22,4,3,No,1:No,1:No,,0.96
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, WBC (× xxx/L),22,5,3,No,1:No,1:No,,0.96
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, WBC (× xxx/L),22,6,3,No,1:No,1:No,,0.95
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, WBC (× xxx/L),22,7,3,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, WBC (× xxx/L),22,8,3,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, WBC (× xxx/L),22,9,3,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,, ;  ; Protocol ; ,, WBC (× xxx/L),23,0,2,No,1:No,1:No,,1
3030,2820141,Table 5,BaselineCharacteristic,xx, ;  ; N ; ,, WBC (× xxx/L),23,1,3,No,1:No,1:No,,0.951
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, WBC (× xxx/L),23,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, WBC (× xxx/L),23,3,3,No,1:No,1:No,,0.96
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, WBC (× xxx/L),23,4,3,No,1:No,1:No,,0.96
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, WBC (× xxx/L),23,5,3,No,1:No,1:No,,0.96
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, WBC (× xxx/L),23,6,3,No,1:No,1:No,,0.95
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, WBC (× xxx/L),23,7,3,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, WBC (× xxx/L),23,8,3,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, WBC (× xxx/L),23,9,3,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,, ;  ; Protocol ; ,, WBC (× xxx/L),24,0,2,No,1:No,1:No,,1
3030,2820141,Table 5,BaselineCharacteristic,xx, ;  ; N ; ,, WBC (× xxx/L),24,1,3,No,1:No,1:No,,0.951
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, WBC (× xxx/L),24,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, WBC (× xxx/L),24,3,3,No,1:No,1:No,,0.96
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, WBC (× xxx/L),24,4,3,No,1:No,1:No,,0.96
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, WBC (× xxx/L),24,5,3,No,1:No,1:No,,0.96
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, WBC (× xxx/L),24,6,3,No,1:No,1:No,,0.95
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, WBC (× xxx/L),24,7,3,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, WBC (× xxx/L),24,8,3,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, WBC (× xxx/L),24,9,3,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,CNS leukemia, ;  ; Protocol ; ,None,None,25,0,24,No,1:No,1:No,,0.995
3030,2820141,Table 5,BaselineCharacteristic,, ;  ; N ; ,CNS leukemia,None,25,1,43,No,1:No,1:No,,0.967
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,CNS leukemia,None,25,2,43,No,1:No,1:No,,0.98
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,CNS leukemia,None,25,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,CNS leukemia,None,25,4,43,No,1:No,1:No,,0.98
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,CNS leukemia,None,25,5,43,No,1:No,1:No,,0.96
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,CNS leukemia,None,25,6,43,No,1:No,1:No,,0.96
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,CNS leukemia,None,25,7,43,No,1:No,1:No,,0.95
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,CNS leukemia,None,25,8,43,No,1:No,1:No,,0.95
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,CNS leukemia,None,25,9,43,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,, ;  ; Protocol ; ,, CNS leukemia,26,0,2,No,1:No,1:No,,1
3030,2820141,Table 5,BaselineCharacteristic,x, ;  ; N ; ,, CNS leukemia,26,1,3,No,1:No,1:No,,0.99
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, CNS leukemia,26,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, CNS leukemia,26,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, CNS leukemia,26,4,3,No,1:No,1:No,,0.945
3030,2820141,Table 5,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, CNS leukemia,26,5,3,No,1:No,1:No,,0.97
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, CNS leukemia,26,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, CNS leukemia,26,7,3,No,1:No,1:No,,0.905
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, CNS leukemia,26,8,3,No,1:No,1:No,,0.915
3030,2820141,Table 5,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, CNS leukemia,26,9,3,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,, ;  ; Protocol ; ,, CNS leukemia,27,0,2,No,1:No,1:No,,1
3030,2820141,Table 5,BaselineCharacteristic,xxx, ;  ; N ; ,, CNS leukemia,27,1,3,No,1:No,1:No,,0.91
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, CNS leukemia,27,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, CNS leukemia,27,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, CNS leukemia,27,4,3,No,1:No,1:No,,0.945
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, CNS leukemia,27,5,3,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, CNS leukemia,27,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, CNS leukemia,27,7,3,No,1:No,1:No,,0.905
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, CNS leukemia,27,8,3,No,1:No,1:No,,0.915
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, CNS leukemia,27,9,3,No,1:No,1:No,,0.92
3030,2820141,Table 5,BaselineCharacteristic,t(x;xx), ;  ; Protocol ; ,None,None,28,0,24,No,1:No,1:No,,0.88
3030,2820141,Table 5,BaselineCharacteristic,, ;  ; N ; ,t(x;xx),None,28,1,43,No,1:No,1:No,,0.875
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,t(x;xx),None,28,2,43,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,t(x;xx),None,28,3,43,No,1:No,1:No,,0.95
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,t(x;xx),None,28,4,43,No,1:No,1:No,,0.95
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,t(x;xx),None,28,5,43,No,1:No,1:No,,0.93
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,t(x;xx),None,28,6,43,No,1:No,1:No,,0.91
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,t(x;xx),None,28,7,43,No,1:No,1:No,,0.9
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,t(x;xx),None,28,8,43,No,1:No,1:No,,0.91
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,t(x;xx),None,28,9,43,No,1:No,1:No,,0.89
3030,2820141,Table 5,BaselineCharacteristic,, ;  ; Protocol ; ,, t(x;xx),29,0,2,No,1:No,1:No,,0.915
3030,2820141,Table 5,BaselineCharacteristic,x, ;  ; N ; ,, t(x;xx),29,1,3,No,1:No,1:No,,0.901
3030,2820141,Table 5,BaselineCharacteristic,x.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, t(x;xx),29,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 5,BaselineCharacteristic,x.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, t(x;xx),29,3,3,No,1:No,1:No,,0.955
3030,2820141,Table 5,BaselineCharacteristic,x.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, t(x;xx),29,4,3,No,1:No,1:No,,0.955
3030,2820141,Table 5,BaselineCharacteristic,<x.xxxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, t(x;xx),29,5,3,No,1:No,1:No,,0.945
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, t(x;xx),29,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, t(x;xx),29,7,3,No,1:No,1:No,,0.905
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, t(x;xx),29,8,3,No,1:No,1:No,,0.915
3030,2820141,Table 5,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, t(x;xx),29,9,3,No,1:No,1:No,,0.89
3030,2820141,Table 5,BaselineCharacteristic,, ;  ; Protocol ; ,, t(x;xx),30,0,2,No,1:No,1:No,,0.915
3030,2820141,Table 5,BaselineCharacteristic,xxx, ;  ; N ; ,, t(x;xx),30,1,3,No,1:No,1:No,,0.806
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, t(x;xx),30,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, t(x;xx),30,3,3,No,1:No,1:No,,0.955
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, t(x;xx),30,4,3,No,1:No,1:No,,0.955
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, t(x;xx),30,5,3,No,1:No,1:No,,0.945
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, t(x;xx),30,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, t(x;xx),30,7,3,No,1:No,1:No,,0.905
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, t(x;xx),30,8,3,No,1:No,1:No,,0.915
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, t(x;xx),30,9,3,No,1:No,1:No,,0.905
3030,2820141,Table 5,BaselineCharacteristic,DFCI Risk Group, ;  ; Protocol ; ,None,None,31,0,24,No,1:No,1:No,,0.995
3030,2820141,Table 5,BaselineCharacteristic,, ;  ; N ; ,DFCI Risk Group,None,31,1,43,No,1:No,1:No,,0.967
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,DFCI Risk Group,None,31,2,43,No,1:No,1:No,,0.97
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,DFCI Risk Group,None,31,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,DFCI Risk Group,None,31,4,43,No,1:No,1:No,,0.98
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,DFCI Risk Group,None,31,5,43,No,1:No,1:No,,0.95
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,DFCI Risk Group,None,31,6,43,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,DFCI Risk Group,None,31,7,43,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,DFCI Risk Group,None,31,8,43,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,DFCI Risk Group,None,31,9,43,No,1:No,1:No,,0.92
3030,2820141,Table 5,BaselineCharacteristic,, ;  ; Protocol ; ,, DFCI Risk Group,32,0,2,No,1:No,1:No,,1
3030,2820141,Table 5,BaselineCharacteristic,xx, ;  ; N ; ,, DFCI Risk Group,32,1,3,No,1:No,1:No,,0.937
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, DFCI Risk Group,32,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, DFCI Risk Group,32,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, DFCI Risk Group,32,4,3,No,1:No,1:No,,0.945
3030,2820141,Table 5,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, DFCI Risk Group,32,5,3,No,1:No,1:No,,0.97
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, DFCI Risk Group,32,6,3,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, DFCI Risk Group,32,7,3,No,1:No,1:No,,0.905
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, DFCI Risk Group,32,8,3,No,1:No,1:No,,0.915
3030,2820141,Table 5,BaselineCharacteristic,x.xxxx,Overall Survival ± SE (%) ;  ; p-value ; ,, DFCI Risk Group,32,9,3,No,1:No,1:No,,0.95
3030,2820141,Table 5,BaselineCharacteristic,, ;  ; Protocol ; ,, DFCI Risk Group,33,0,2,No,1:No,1:No,,1
3030,2820141,Table 5,BaselineCharacteristic,xxx, ;  ; N ; ,, DFCI Risk Group,33,1,3,No,1:No,1:No,,0.92
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, DFCI Risk Group,33,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, DFCI Risk Group,33,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, DFCI Risk Group,33,4,3,No,1:No,1:No,,0.945
3030,2820141,Table 5,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, DFCI Risk Group,33,5,3,No,1:No,1:No,,0.95
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, DFCI Risk Group,33,6,3,No,1:No,1:No,,0.94
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, DFCI Risk Group,33,7,3,No,1:No,1:No,,0.905
3030,2820141,Table 5,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, DFCI Risk Group,33,8,3,No,1:No,1:No,,0.915
3030,2820141,Table 5,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, DFCI Risk Group,33,9,3,No,1:No,1:No,,0.92
3030,2820141,Table 6,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
3030,2820141,Table 6,BaselineCharacteristic,,,,None,0,1,1,No,1:No,1:No,,0.903
3030,2820141,Table 6,BaselineCharacteristic,Event-free Survival ± SE (%),,,None,0,2,1,No,1:No,1:No,,0.903
3030,2820141,Table 6,BaselineCharacteristic,Event-free Survival ± SE (%),,,None,0,3,1,No,1:No,1:No,,0.903
3030,2820141,Table 6,BaselineCharacteristic,Event-free Survival ± SE (%),,,None,0,4,1,No,1:No,1:No,,0.903
3030,2820141,Table 6,BaselineCharacteristic,Event-free Survival ± SE (%),,,None,0,5,1,No,1:No,1:No,,0.913
3030,2820141,Table 6,BaselineCharacteristic,Overall Survival ± SE (%),,,None,0,6,1,No,1:No,1:No,,0.868
3030,2820141,Table 6,BaselineCharacteristic,Overall Survival ± SE (%),,,None,0,7,1,No,1:No,1:No,,0.878
3030,2820141,Table 6,BaselineCharacteristic,Overall Survival ± SE (%),,,None,0,8,1,No,1:No,1:No,,0.878
3030,2820141,Table 6,BaselineCharacteristic,Overall Survival ± SE (%),,,None,0,9,1,No,1:No,1:No,,0.878
3030,2820141,Table 6,BaselineCharacteristic,, ; ,None,None,1,0,12,No,1:No,1:No,,0.898
3030,2820141,Table 6,BaselineCharacteristic,, ; ,,None,1,1,1,No,1:No,1:No,,0.895
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ; ,,None,1,2,1,No,1:No,1:No,,0.903
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ; ,,None,1,3,1,No,1:No,1:No,,0.903
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ; ,,None,1,4,1,No,1:No,1:No,,0.903
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ; ,,None,1,5,1,No,1:No,1:No,,0.913
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ; ,,None,1,6,1,No,1:No,1:No,,0.868
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ; ,,None,1,7,1,No,1:No,1:No,,0.878
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ; ,,None,1,8,1,No,1:No,1:No,,0.878
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ; ,,None,1,9,1,No,1:No,1:No,,0.878
3030,2820141,Table 6,BaselineCharacteristic,Protocol, ;  ; ,None,None,2,0,12,No,1:No,1:No,,0.923
3030,2820141,Table 6,BaselineCharacteristic,N, ;  ; ,Protocol,None,2,1,1,No,1:No,1:No,,0.915
3030,2820141,Table 6,BaselineCharacteristic,x-yr EFS,Event-free Survival ± SE (%) ;  ; ,Protocol,None,2,2,1,No,1:No,1:No,,0.943
3030,2820141,Table 6,BaselineCharacteristic,xx-yr EFS,Event-free Survival ± SE (%) ;  ; ,Protocol,None,2,3,1,No,1:No,1:No,,0.943
3030,2820141,Table 6,BaselineCharacteristic,xx-yr EFS,Event-free Survival ± SE (%) ;  ; ,Protocol,None,2,4,1,No,1:No,1:No,,0.943
3030,2820141,Table 6,BaselineCharacteristic,p-value,Event-free Survival ± SE (%) ;  ; ,Protocol,None,2,5,1,No,1:No,1:No,,0.923
3030,2820141,Table 6,BaselineCharacteristic,x-yr OS,Overall Survival ± SE (%) ;  ; ,Protocol,None,2,6,1,No,1:No,1:No,,0.905
3030,2820141,Table 6,BaselineCharacteristic,xx-yr OS,Overall Survival ± SE (%) ;  ; ,Protocol,None,2,7,1,No,1:No,1:No,,0.915
3030,2820141,Table 6,BaselineCharacteristic,xx-yr OS,Overall Survival ± SE (%) ;  ; ,Protocol,None,2,8,1,No,1:No,1:No,,0.915
3030,2820141,Table 6,BaselineCharacteristic,p-value,Overall Survival ± SE (%) ;  ; ,Protocol,None,2,9,1,No,1:No,1:No,,0.878
3030,2820141,Table 6,BaselineCharacteristic,Overall, ;  ; Protocol ; ,Overall,,3,0,2,No,1:No,1:No,,0.96
3030,2820141,Table 6,BaselineCharacteristic,xxx, ;  ; N ; ,Overall,,3,1,3,No,1:No,1:No,,0.81
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,Overall,,3,2,3,No,1:No,1:No,,0.8
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Overall,,3,3,3,No,1:No,1:No,,0.8
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Overall,,3,4,3,No,1:No,1:No,,0.81
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,Overall,,3,5,3,No,1:No,1:No,,0.9
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,Overall,,3,6,3,No,1:No,1:No,,0.76
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Overall,,3,7,3,No,1:No,1:No,,0.76
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Overall,,3,8,3,No,1:No,1:No,,0.77
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,Overall,,3,9,3,No,1:No,1:No,,0.85
3030,2820141,Table 6,BaselineCharacteristic,Immunophenotype, ;  ; Protocol ; ,None,None,4,0,24,No,1:No,1:No,,0.939
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; N ; ,Immunophenotype,None,4,1,43,No,1:No,1:No,,0.902
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,Immunophenotype,None,4,2,43,No,1:No,1:No,,0.955
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Immunophenotype,None,4,3,43,No,1:No,1:No,,0.965
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Immunophenotype,None,4,4,43,No,1:No,1:No,,0.955
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,Immunophenotype,None,4,5,43,No,1:No,1:No,,0.905
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,Immunophenotype,None,4,6,43,No,1:No,1:No,,0.905
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Immunophenotype,None,4,7,43,No,1:No,1:No,,0.915
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Immunophenotype,None,4,8,43,No,1:No,1:No,,0.915
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,Immunophenotype,None,4,9,43,No,1:No,1:No,,0.875
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; Protocol ; ,, Immunophenotype,5,0,2,No,1:No,1:No,,0.97
3030,2820141,Table 6,BaselineCharacteristic,xxx, ;  ; N ; ,, Immunophenotype,5,1,3,No,1:No,1:No,,0.81
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Immunophenotype,5,2,3,No,1:No,1:No,,0.84
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Immunophenotype,5,3,3,No,1:No,1:No,,0.85
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Immunophenotype,5,4,3,No,1:No,1:No,,0.86
3030,2820141,Table 6,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, Immunophenotype,5,5,3,No,1:No,1:No,,0.9
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Immunophenotype,5,6,3,No,1:No,1:No,,0.8
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Immunophenotype,5,7,3,No,1:No,1:No,,0.79
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Immunophenotype,5,8,3,No,1:No,1:No,,0.8
3030,2820141,Table 6,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, Immunophenotype,5,9,3,No,1:No,1:No,,0.83
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; Protocol ; ,, Immunophenotype,6,0,2,No,1:No,1:No,,0.99
3030,2820141,Table 6,BaselineCharacteristic,xx, ;  ; N ; ,, Immunophenotype,6,1,3,No,1:No,1:No,,0.791
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Immunophenotype,6,2,3,No,1:No,1:No,,0.87
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Immunophenotype,6,3,3,No,1:No,1:No,,0.87
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Immunophenotype,6,4,3,No,1:No,1:No,,0.88
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, Immunophenotype,6,5,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Immunophenotype,6,6,3,No,1:No,1:No,,0.83
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Immunophenotype,6,7,3,No,1:No,1:No,,0.81
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Immunophenotype,6,8,3,No,1:No,1:No,,0.82
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, Immunophenotype,6,9,3,No,1:No,1:No,,0.91
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; Protocol ; ,, Immunophenotype,7,0,2,No,1:No,1:No,,0.99
3030,2820141,Table 6,BaselineCharacteristic,x, ;  ; N ; ,, Immunophenotype,7,1,3,No,1:No,1:No,,0.96
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Immunophenotype,7,2,3,No,1:No,1:No,,0.89
3030,2820141,Table 6,BaselineCharacteristic,N/A,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Immunophenotype,7,3,3,No,1:No,1:No,,0.97
3030,2820141,Table 6,BaselineCharacteristic,N/A,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Immunophenotype,7,4,3,No,1:No,1:No,,0.97
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, Immunophenotype,7,5,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Immunophenotype,7,6,3,No,1:No,1:No,,0.86
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Immunophenotype,7,7,3,No,1:No,1:No,,0.84
3030,2820141,Table 6,BaselineCharacteristic,N/A,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Immunophenotype,7,8,3,No,1:No,1:No,,0.92
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, Immunophenotype,7,9,3,No,1:No,1:No,,0.91
3030,2820141,Table 6,BaselineCharacteristic,B-precursor†, ;  ; Protocol ; ,None,None,8,0,24,No,1:No,1:No,,0.974
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; N ; ,B-precursor†,None,8,1,43,No,1:No,1:No,,0.967
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,B-precursor†,None,8,2,43,No,1:No,1:No,,0.98
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,B-precursor†,None,8,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,B-precursor†,None,8,4,43,No,1:No,1:No,,0.98
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,B-precursor†,None,8,5,43,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,B-precursor†,None,8,6,43,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,B-precursor†,None,8,7,43,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,B-precursor†,None,8,8,43,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,B-precursor†,None,8,9,43,No,1:No,1:No,,0.92
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; Protocol ; ,, B-precursor†,9,0,2,No,1:No,1:No,,1
3030,2820141,Table 6,BaselineCharacteristic,xxx, ;  ; N ; ,, B-precursor†,9,1,3,No,1:No,1:No,,0.91
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, B-precursor†,9,2,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, B-precursor†,9,3,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, B-precursor†,9,4,3,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, B-precursor†,9,5,3,No,1:No,1:No,,0.96
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, B-precursor†,9,6,3,No,1:No,1:No,,0.91
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, B-precursor†,9,7,3,No,1:No,1:No,,0.9
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, B-precursor†,9,8,3,No,1:No,1:No,,0.9
3030,2820141,Table 6,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, B-precursor†,9,9,3,No,1:No,1:No,,0.93
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; Protocol ; ,, B-precursor†,10,0,2,No,1:No,1:No,,1
3030,2820141,Table 6,BaselineCharacteristic,xx, ;  ; N ; ,, B-precursor†,10,1,3,No,1:No,1:No,,0.931
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, B-precursor†,10,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, B-precursor†,10,3,3,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, B-precursor†,10,4,3,No,1:No,1:No,,0.96
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, B-precursor†,10,5,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, B-precursor†,10,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, B-precursor†,10,7,3,No,1:No,1:No,,0.92
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, B-precursor†,10,8,3,No,1:No,1:No,,0.92
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, B-precursor†,10,9,3,No,1:No,1:No,,0.92
3030,2820141,Table 6,BaselineCharacteristic,T-lineage†, ;  ; Protocol ; ,None,None,11,0,24,No,1:No,1:No,,0.995
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; N ; ,T-lineage†,None,11,1,43,No,1:No,1:No,,0.977
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,T-lineage†,None,11,2,43,No,1:No,1:No,,0.98
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,T-lineage†,None,11,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,T-lineage†,None,11,4,43,No,1:No,1:No,,0.98
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,T-lineage†,None,11,5,43,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,T-lineage†,None,11,6,43,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,T-lineage†,None,11,7,43,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,T-lineage†,None,11,8,43,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,T-lineage†,None,11,9,43,No,1:No,1:No,,0.93
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; Protocol ; ,, T-lineage†,12,0,2,No,1:No,1:No,,1
3030,2820141,Table 6,BaselineCharacteristic,xx, ;  ; N ; ,, T-lineage†,12,1,3,No,1:No,1:No,,0.921
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, T-lineage†,12,2,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, T-lineage†,12,3,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, T-lineage†,12,4,3,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, T-lineage†,12,5,3,No,1:No,1:No,,0.97
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, T-lineage†,12,6,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, T-lineage†,12,7,3,No,1:No,1:No,,0.92
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, T-lineage†,12,8,3,No,1:No,1:No,,0.93
3030,2820141,Table 6,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, T-lineage†,12,9,3,No,1:No,1:No,,0.96
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; Protocol ; ,, T-lineage†,13,0,2,No,1:No,1:No,,1
3030,2820141,Table 6,BaselineCharacteristic,xx, ;  ; N ; ,, T-lineage†,13,1,3,No,1:No,1:No,,0.921
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, T-lineage†,13,2,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, T-lineage†,13,3,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, T-lineage†,13,4,3,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, T-lineage†,13,5,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, T-lineage†,13,6,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, T-lineage†,13,7,3,No,1:No,1:No,,0.92
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, T-lineage†,13,8,3,No,1:No,1:No,,0.93
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, T-lineage†,13,9,3,No,1:No,1:No,,0.92
3030,2820141,Table 6,BaselineCharacteristic,Sex, ;  ; Protocol ; ,None,None,14,0,24,No,1:No,1:No,,0.995
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; N ; ,Sex,None,14,1,43,No,1:No,1:No,,0.977
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,Sex,None,14,2,43,No,1:No,1:No,,0.98
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Sex,None,14,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Sex,None,14,4,43,No,1:No,1:No,,0.98
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,Sex,None,14,5,43,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,Sex,None,14,6,43,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Sex,None,14,7,43,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Sex,None,14,8,43,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,Sex,None,14,9,43,No,1:No,1:No,,0.92
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; Protocol ; ,, Sex,15,0,2,No,1:No,1:No,,1
3030,2820141,Table 6,BaselineCharacteristic,xxx, ;  ; N ; ,, Sex,15,1,3,No,1:No,1:No,,0.91
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Sex,15,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Sex,15,3,3,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Sex,15,4,3,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, Sex,15,5,3,No,1:No,1:No,,0.97
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Sex,15,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Sex,15,7,3,No,1:No,1:No,,0.91
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Sex,15,8,3,No,1:No,1:No,,0.92
3030,2820141,Table 6,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, Sex,15,9,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; Protocol ; ,, Sex,16,0,2,No,1:No,1:No,,1
3030,2820141,Table 6,BaselineCharacteristic,xxx, ;  ; N ; ,, Sex,16,1,3,No,1:No,1:No,,0.91
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Sex,16,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Sex,16,3,3,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Sex,16,4,3,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, Sex,16,5,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Sex,16,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Sex,16,7,3,No,1:No,1:No,,0.91
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Sex,16,8,3,No,1:No,1:No,,0.92
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, Sex,16,9,3,No,1:No,1:No,,0.91
3030,2820141,Table 6,BaselineCharacteristic,Age at Diagnosis, ;  ; Protocol ; ,None,None,17,0,24,No,1:No,1:No,,0.995
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; N ; ,Age at Diagnosis,None,17,1,43,No,1:No,1:No,,0.967
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,Age at Diagnosis,None,17,2,43,No,1:No,1:No,,0.97
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Age at Diagnosis,None,17,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Age at Diagnosis,None,17,4,43,No,1:No,1:No,,0.98
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,Age at Diagnosis,None,17,5,43,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,Age at Diagnosis,None,17,6,43,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Age at Diagnosis,None,17,7,43,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Age at Diagnosis,None,17,8,43,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,Age at Diagnosis,None,17,9,43,No,1:No,1:No,,0.92
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; Protocol ; ,, Age at Diagnosis,18,0,2,No,1:No,1:No,,0.99
3030,2820141,Table 6,BaselineCharacteristic,x, ;  ; N ; ,, Age at Diagnosis,18,1,3,No,1:No,1:No,,0.98
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Age at Diagnosis,18,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Age at Diagnosis,18,3,3,No,1:No,1:No,,0.965
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Age at Diagnosis,18,4,3,No,1:No,1:No,,0.965
3030,2820141,Table 6,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, Age at Diagnosis,18,5,3,No,1:No,1:No,,0.97
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Age at Diagnosis,18,6,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Age at Diagnosis,18,7,3,No,1:No,1:No,,0.915
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Age at Diagnosis,18,8,3,No,1:No,1:No,,0.925
3030,2820141,Table 6,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, Age at Diagnosis,18,9,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; Protocol ; ,, Age at Diagnosis,19,0,2,No,1:No,1:No,,0.99
3030,2820141,Table 6,BaselineCharacteristic,xxx, ;  ; N ; ,, Age at Diagnosis,19,1,3,No,1:No,1:No,,0.92
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Age at Diagnosis,19,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Age at Diagnosis,19,3,3,No,1:No,1:No,,0.965
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Age at Diagnosis,19,4,3,No,1:No,1:No,,0.965
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, Age at Diagnosis,19,5,3,No,1:No,1:No,,0.93
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Age at Diagnosis,19,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Age at Diagnosis,19,7,3,No,1:No,1:No,,0.905
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Age at Diagnosis,19,8,3,No,1:No,1:No,,0.915
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, Age at Diagnosis,19,9,3,No,1:No,1:No,,0.91
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; Protocol ; ,, Age at Diagnosis,20,0,2,No,1:No,1:No,,0.99
3030,2820141,Table 6,BaselineCharacteristic,xx, ;  ; N ; ,, Age at Diagnosis,20,1,3,No,1:No,1:No,,0.937
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Age at Diagnosis,20,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Age at Diagnosis,20,3,3,No,1:No,1:No,,0.965
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Age at Diagnosis,20,4,3,No,1:No,1:No,,0.965
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, Age at Diagnosis,20,5,3,No,1:No,1:No,,0.93
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Age at Diagnosis,20,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Age at Diagnosis,20,7,3,No,1:No,1:No,,0.905
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Age at Diagnosis,20,8,3,No,1:No,1:No,,0.915
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, Age at Diagnosis,20,9,3,No,1:No,1:No,,0.91
3030,2820141,Table 6,BaselineCharacteristic,WBC (× xxx/L), ;  ; Protocol ; ,None,None,21,0,24,No,1:No,1:No,,0.995
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; N ; ,WBC (× xxx/L),None,21,1,43,No,1:No,1:No,,0.988
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,WBC (× xxx/L),None,21,2,43,No,1:No,1:No,,0.99
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,WBC (× xxx/L),None,21,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,WBC (× xxx/L),None,21,4,43,No,1:No,1:No,,0.98
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,WBC (× xxx/L),None,21,5,43,No,1:No,1:No,,0.96
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,WBC (× xxx/L),None,21,6,43,No,1:No,1:No,,0.96
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,WBC (× xxx/L),None,21,7,43,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,WBC (× xxx/L),None,21,8,43,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,WBC (× xxx/L),None,21,9,43,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; Protocol ; ,, WBC (× xxx/L),22,0,2,No,1:No,1:No,,1
3030,2820141,Table 6,BaselineCharacteristic,xxx, ;  ; N ; ,, WBC (× xxx/L),22,1,3,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, WBC (× xxx/L),22,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, WBC (× xxx/L),22,3,3,No,1:No,1:No,,0.96
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, WBC (× xxx/L),22,4,3,No,1:No,1:No,,0.96
3030,2820141,Table 6,BaselineCharacteristic,x.xxxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, WBC (× xxx/L),22,5,3,No,1:No,1:No,,0.99
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, WBC (× xxx/L),22,6,3,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, WBC (× xxx/L),22,7,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, WBC (× xxx/L),22,8,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, WBC (× xxx/L),22,9,3,No,1:No,1:No,,0.96
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; Protocol ; ,, WBC (× xxx/L),23,0,2,No,1:No,1:No,,1
3030,2820141,Table 6,BaselineCharacteristic,xxx, ;  ; N ; ,, WBC (× xxx/L),23,1,3,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, WBC (× xxx/L),23,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, WBC (× xxx/L),23,3,3,No,1:No,1:No,,0.96
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, WBC (× xxx/L),23,4,3,No,1:No,1:No,,0.96
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, WBC (× xxx/L),23,5,3,No,1:No,1:No,,0.96
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, WBC (× xxx/L),23,6,3,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, WBC (× xxx/L),23,7,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, WBC (× xxx/L),23,8,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, WBC (× xxx/L),23,9,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; Protocol ; ,, WBC (× xxx/L),24,0,2,No,1:No,1:No,,1
3030,2820141,Table 6,BaselineCharacteristic,xx, ;  ; N ; ,, WBC (× xxx/L),24,1,3,No,1:No,1:No,,0.951
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, WBC (× xxx/L),24,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, WBC (× xxx/L),24,3,3,No,1:No,1:No,,0.96
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, WBC (× xxx/L),24,4,3,No,1:No,1:No,,0.96
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, WBC (× xxx/L),24,5,3,No,1:No,1:No,,0.96
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, WBC (× xxx/L),24,6,3,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, WBC (× xxx/L),24,7,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, WBC (× xxx/L),24,8,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, WBC (× xxx/L),24,9,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; Protocol ; ,, WBC (× xxx/L),25,0,2,No,1:No,1:No,,1
3030,2820141,Table 6,BaselineCharacteristic,xx, ;  ; N ; ,, WBC (× xxx/L),25,1,3,No,1:No,1:No,,0.951
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, WBC (× xxx/L),25,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, WBC (× xxx/L),25,3,3,No,1:No,1:No,,0.96
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, WBC (× xxx/L),25,4,3,No,1:No,1:No,,0.96
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, WBC (× xxx/L),25,5,3,No,1:No,1:No,,0.96
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, WBC (× xxx/L),25,6,3,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, WBC (× xxx/L),25,7,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, WBC (× xxx/L),25,8,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, WBC (× xxx/L),25,9,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,CNS leukemia, ;  ; Protocol ; ,None,None,26,0,24,No,1:No,1:No,,0.995
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; N ; ,CNS leukemia,None,26,1,43,No,1:No,1:No,,0.967
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,CNS leukemia,None,26,2,43,No,1:No,1:No,,0.98
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,CNS leukemia,None,26,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,CNS leukemia,None,26,4,43,No,1:No,1:No,,0.98
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,CNS leukemia,None,26,5,43,No,1:No,1:No,,0.96
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,CNS leukemia,None,26,6,43,No,1:No,1:No,,0.96
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,CNS leukemia,None,26,7,43,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,CNS leukemia,None,26,8,43,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,CNS leukemia,None,26,9,43,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; Protocol ; ,, CNS leukemia,27,0,2,No,1:No,1:No,,1
3030,2820141,Table 6,BaselineCharacteristic,x, ;  ; N ; ,, CNS leukemia,27,1,3,No,1:No,1:No,,0.99
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, CNS leukemia,27,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, CNS leukemia,27,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, CNS leukemia,27,4,3,No,1:No,1:No,,0.945
3030,2820141,Table 6,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, CNS leukemia,27,5,3,No,1:No,1:No,,0.97
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, CNS leukemia,27,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, CNS leukemia,27,7,3,No,1:No,1:No,,0.905
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, CNS leukemia,27,8,3,No,1:No,1:No,,0.915
3030,2820141,Table 6,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, CNS leukemia,27,9,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; Protocol ; ,, CNS leukemia,28,0,2,No,1:No,1:No,,1
3030,2820141,Table 6,BaselineCharacteristic,xxx, ;  ; N ; ,, CNS leukemia,28,1,3,No,1:No,1:No,,0.91
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, CNS leukemia,28,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, CNS leukemia,28,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, CNS leukemia,28,4,3,No,1:No,1:No,,0.945
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, CNS leukemia,28,5,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, CNS leukemia,28,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, CNS leukemia,28,7,3,No,1:No,1:No,,0.905
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, CNS leukemia,28,8,3,No,1:No,1:No,,0.915
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, CNS leukemia,28,9,3,No,1:No,1:No,,0.92
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; Protocol ; ,, CNS leukemia,29,0,2,No,1:No,1:No,,1
3030,2820141,Table 6,BaselineCharacteristic,x, ;  ; N ; ,, CNS leukemia,29,1,3,No,1:No,1:No,,0.99
3030,2820141,Table 6,BaselineCharacteristic,xxx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, CNS leukemia,29,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 6,BaselineCharacteristic,xxx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, CNS leukemia,29,3,3,No,1:No,1:No,,0.97
3030,2820141,Table 6,BaselineCharacteristic,xxx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, CNS leukemia,29,4,3,No,1:No,1:No,,0.98
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, CNS leukemia,29,5,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,xxx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, CNS leukemia,29,6,3,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,xxx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, CNS leukemia,29,7,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,xxx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, CNS leukemia,29,8,3,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, CNS leukemia,29,9,3,No,1:No,1:No,,0.92
3030,2820141,Table 6,BaselineCharacteristic,t(x;xx), ;  ; Protocol ; ,None,None,30,0,24,No,1:No,1:No,,0.88
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; N ; ,t(x;xx),None,30,1,43,No,1:No,1:No,,0.875
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,t(x;xx),None,30,2,43,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,t(x;xx),None,30,3,43,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,t(x;xx),None,30,4,43,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,t(x;xx),None,30,5,43,No,1:No,1:No,,0.93
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,t(x;xx),None,30,6,43,No,1:No,1:No,,0.91
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,t(x;xx),None,30,7,43,No,1:No,1:No,,0.9
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,t(x;xx),None,30,8,43,No,1:No,1:No,,0.91
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,t(x;xx),None,30,9,43,No,1:No,1:No,,0.89
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; Protocol ; ,, t(x;xx),31,0,2,No,1:No,1:No,,0.915
3030,2820141,Table 6,BaselineCharacteristic,x, ;  ; N ; ,, t(x;xx),31,1,3,No,1:No,1:No,,0.901
3030,2820141,Table 6,BaselineCharacteristic,x.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, t(x;xx),31,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 6,BaselineCharacteristic,x.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, t(x;xx),31,3,3,No,1:No,1:No,,0.955
3030,2820141,Table 6,BaselineCharacteristic,x.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, t(x;xx),31,4,3,No,1:No,1:No,,0.955
3030,2820141,Table 6,BaselineCharacteristic,<x.xxxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, t(x;xx),31,5,3,No,1:No,1:No,,0.945
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, t(x;xx),31,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, t(x;xx),31,7,3,No,1:No,1:No,,0.905
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, t(x;xx),31,8,3,No,1:No,1:No,,0.915
3030,2820141,Table 6,BaselineCharacteristic,<x.xxxx,Overall Survival ± SE (%) ;  ; p-value ; ,, t(x;xx),31,9,3,No,1:No,1:No,,0.905
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; Protocol ; ,, t(x;xx),32,0,2,No,1:No,1:No,,0.915
3030,2820141,Table 6,BaselineCharacteristic,xxx, ;  ; N ; ,, t(x;xx),32,1,3,No,1:No,1:No,,0.806
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, t(x;xx),32,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, t(x;xx),32,3,3,No,1:No,1:No,,0.955
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, t(x;xx),32,4,3,No,1:No,1:No,,0.955
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, t(x;xx),32,5,3,No,1:No,1:No,,0.945
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, t(x;xx),32,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, t(x;xx),32,7,3,No,1:No,1:No,,0.905
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, t(x;xx),32,8,3,No,1:No,1:No,,0.915
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, t(x;xx),32,9,3,No,1:No,1:No,,0.905
3030,2820141,Table 6,BaselineCharacteristic,DFCI Risk Group, ;  ; Protocol ; ,None,None,33,0,24,No,1:No,1:No,,0.995
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; N ; ,DFCI Risk Group,None,33,1,43,No,1:No,1:No,,0.967
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,DFCI Risk Group,None,33,2,43,No,1:No,1:No,,0.97
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,DFCI Risk Group,None,33,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,DFCI Risk Group,None,33,4,43,No,1:No,1:No,,0.98
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,DFCI Risk Group,None,33,5,43,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,DFCI Risk Group,None,33,6,43,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,DFCI Risk Group,None,33,7,43,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,DFCI Risk Group,None,33,8,43,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,DFCI Risk Group,None,33,9,43,No,1:No,1:No,,0.92
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; Protocol ; ,, DFCI Risk Group,34,0,2,No,1:No,1:No,,1
3030,2820141,Table 6,BaselineCharacteristic,xxx, ;  ; N ; ,, DFCI Risk Group,34,1,3,No,1:No,1:No,,0.92
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, DFCI Risk Group,34,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, DFCI Risk Group,34,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, DFCI Risk Group,34,4,3,No,1:No,1:No,,0.945
3030,2820141,Table 6,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, DFCI Risk Group,34,5,3,No,1:No,1:No,,0.97
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, DFCI Risk Group,34,6,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, DFCI Risk Group,34,7,3,No,1:No,1:No,,0.905
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, DFCI Risk Group,34,8,3,No,1:No,1:No,,0.915
3030,2820141,Table 6,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, DFCI Risk Group,34,9,3,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; Protocol ; ,, DFCI Risk Group,35,0,2,No,1:No,1:No,,1
3030,2820141,Table 6,BaselineCharacteristic,xxx, ;  ; N ; ,, DFCI Risk Group,35,1,3,No,1:No,1:No,,0.92
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, DFCI Risk Group,35,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, DFCI Risk Group,35,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, DFCI Risk Group,35,4,3,No,1:No,1:No,,0.945
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, DFCI Risk Group,35,5,3,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, DFCI Risk Group,35,6,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, DFCI Risk Group,35,7,3,No,1:No,1:No,,0.905
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, DFCI Risk Group,35,8,3,No,1:No,1:No,,0.915
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, DFCI Risk Group,35,9,3,No,1:No,1:No,,0.92
3030,2820141,Table 6,BaselineCharacteristic,Methotrexate-inductiondose (randomized), ;  ; Protocol ; ,None,None,36,0,24,No,1:No,1:No,,0.995
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; N ; ,Methotrexate-inductiondose (randomized),None,36,1,43,No,1:No,1:No,,0.967
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,Methotrexate-inductiondose (randomized),None,36,2,43,No,1:No,1:No,,0.97
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Methotrexate-inductiondose (randomized),None,36,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Methotrexate-inductiondose (randomized),None,36,4,43,No,1:No,1:No,,0.98
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,Methotrexate-inductiondose (randomized),None,36,5,43,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,Methotrexate-inductiondose (randomized),None,36,6,43,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Methotrexate-inductiondose (randomized),None,36,7,43,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Methotrexate-inductiondose (randomized),None,36,8,43,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,Methotrexate-inductiondose (randomized),None,36,9,43,No,1:No,1:No,,0.92
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; Protocol ; ,, Methotrexate-inductiondose (randomized),37,0,2,No,1:No,1:No,,1
3030,2820141,Table 6,BaselineCharacteristic,xxx, ;  ; N ; ,, Methotrexate-inductiondose (randomized),37,1,3,No,1:No,1:No,,0.91
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Methotrexate-inductiondose (randomized),37,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Methotrexate-inductiondose (randomized),37,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Methotrexate-inductiondose (randomized),37,4,3,No,1:No,1:No,,0.945
3030,2820141,Table 6,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, Methotrexate-inductiondose (randomized),37,5,3,No,1:No,1:No,,0.97
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Methotrexate-inductiondose (randomized),37,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Methotrexate-inductiondose (randomized),37,7,3,No,1:No,1:No,,0.905
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Methotrexate-inductiondose (randomized),37,8,3,No,1:No,1:No,,0.915
3030,2820141,Table 6,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, Methotrexate-inductiondose (randomized),37,9,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,, ;  ; Protocol ; ,, Methotrexate-inductiondose (randomized),38,0,2,No,1:No,1:No,,1
3030,2820141,Table 6,BaselineCharacteristic,xxx, ;  ; N ; ,, Methotrexate-inductiondose (randomized),38,1,3,No,1:No,1:No,,0.91
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Methotrexate-inductiondose (randomized),38,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Methotrexate-inductiondose (randomized),38,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Methotrexate-inductiondose (randomized),38,4,3,No,1:No,1:No,,0.945
3030,2820141,Table 6,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, Methotrexate-inductiondose (randomized),38,5,3,No,1:No,1:No,,0.94
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Methotrexate-inductiondose (randomized),38,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Methotrexate-inductiondose (randomized),38,7,3,No,1:No,1:No,,0.905
3030,2820141,Table 6,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Methotrexate-inductiondose (randomized),38,8,3,No,1:No,1:No,,0.915
3030,2820141,Table 6,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, Methotrexate-inductiondose (randomized),38,9,3,No,1:No,1:No,,0.91
3030,2820141,Table 7,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
3030,2820141,Table 7,BaselineCharacteristic,,,,None,0,1,1,No,1:No,1:No,,0.903
3030,2820141,Table 7,BaselineCharacteristic,Event-free Survival ± SE (%),,,None,0,2,1,No,1:No,1:No,,0.903
3030,2820141,Table 7,BaselineCharacteristic,Event-free Survival ± SE (%),,,None,0,3,1,No,1:No,1:No,,0.903
3030,2820141,Table 7,BaselineCharacteristic,Event-free Survival ± SE (%),,,None,0,4,1,No,1:No,1:No,,0.903
3030,2820141,Table 7,BaselineCharacteristic,Event-free Survival ± SE (%),,,None,0,5,1,No,1:No,1:No,,0.913
3030,2820141,Table 7,BaselineCharacteristic,Overall Survival ± SE (%),,,None,0,6,1,No,1:No,1:No,,0.868
3030,2820141,Table 7,BaselineCharacteristic,Overall Survival ± SE (%),,,None,0,7,1,No,1:No,1:No,,0.878
3030,2820141,Table 7,BaselineCharacteristic,Overall Survival ± SE (%),,,None,0,8,1,No,1:No,1:No,,0.878
3030,2820141,Table 7,BaselineCharacteristic,Overall Survival ± SE (%),,,None,0,9,1,No,1:No,1:No,,0.878
3030,2820141,Table 7,BaselineCharacteristic,, ; ,None,None,1,0,12,No,1:No,1:No,,0.898
3030,2820141,Table 7,BaselineCharacteristic,, ; ,,None,1,1,1,No,1:No,1:No,,0.895
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ; ,,None,1,2,1,No,1:No,1:No,,0.903
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ; ,,None,1,3,1,No,1:No,1:No,,0.903
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ; ,,None,1,4,1,No,1:No,1:No,,0.903
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ; ,,None,1,5,1,No,1:No,1:No,,0.913
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ; ,,None,1,6,1,No,1:No,1:No,,0.868
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ; ,,None,1,7,1,No,1:No,1:No,,0.878
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ; ,,None,1,8,1,No,1:No,1:No,,0.878
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ; ,,None,1,9,1,No,1:No,1:No,,0.878
3030,2820141,Table 7,BaselineCharacteristic,Protocol, ;  ; ,None,None,2,0,12,No,1:No,1:No,,0.923
3030,2820141,Table 7,BaselineCharacteristic,N, ;  ; ,Protocol,None,2,1,1,No,1:No,1:No,,0.915
3030,2820141,Table 7,BaselineCharacteristic,x-yr EFS,Event-free Survival ± SE (%) ;  ; ,Protocol,None,2,2,1,No,1:No,1:No,,0.943
3030,2820141,Table 7,BaselineCharacteristic,xx-yr EFS,Event-free Survival ± SE (%) ;  ; ,Protocol,None,2,3,1,No,1:No,1:No,,0.943
3030,2820141,Table 7,BaselineCharacteristic,xx-yr EFS,Event-free Survival ± SE (%) ;  ; ,Protocol,None,2,4,1,No,1:No,1:No,,0.943
3030,2820141,Table 7,BaselineCharacteristic,p-value,Event-free Survival ± SE (%) ;  ; ,Protocol,None,2,5,1,No,1:No,1:No,,0.923
3030,2820141,Table 7,BaselineCharacteristic,x-yr OS,Overall Survival ± SE (%) ;  ; ,Protocol,None,2,6,1,No,1:No,1:No,,0.905
3030,2820141,Table 7,BaselineCharacteristic,xx-yr OS,Overall Survival ± SE (%) ;  ; ,Protocol,None,2,7,1,No,1:No,1:No,,0.915
3030,2820141,Table 7,BaselineCharacteristic,xx-yr OS,Overall Survival ± SE (%) ;  ; ,Protocol,None,2,8,1,No,1:No,1:No,,0.915
3030,2820141,Table 7,BaselineCharacteristic,p-value,Overall Survival ± SE (%) ;  ; ,Protocol,None,2,9,1,No,1:No,1:No,,0.878
3030,2820141,Table 7,BaselineCharacteristic,Overall, ;  ; Protocol ; ,Overall,,3,0,2,No,1:No,1:No,,0.96
3030,2820141,Table 7,BaselineCharacteristic,xxx, ;  ; N ; ,Overall,,3,1,3,No,1:No,1:No,,0.81
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,Overall,,3,2,3,No,1:No,1:No,,0.8
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Overall,,3,3,3,No,1:No,1:No,,0.8
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Overall,,3,4,3,No,1:No,1:No,,0.81
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,Overall,,3,5,3,No,1:No,1:No,,0.9
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,Overall,,3,6,3,No,1:No,1:No,,0.76
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Overall,,3,7,3,No,1:No,1:No,,0.76
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Overall,,3,8,3,No,1:No,1:No,,0.77
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,Overall,,3,9,3,No,1:No,1:No,,0.85
3030,2820141,Table 7,BaselineCharacteristic,Immunophenotype, ;  ; Protocol ; ,None,None,4,0,24,No,1:No,1:No,,0.939
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; N ; ,Immunophenotype,None,4,1,43,No,1:No,1:No,,0.902
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,Immunophenotype,None,4,2,43,No,1:No,1:No,,0.955
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Immunophenotype,None,4,3,43,No,1:No,1:No,,0.965
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Immunophenotype,None,4,4,43,No,1:No,1:No,,0.955
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,Immunophenotype,None,4,5,43,No,1:No,1:No,,0.905
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,Immunophenotype,None,4,6,43,No,1:No,1:No,,0.905
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Immunophenotype,None,4,7,43,No,1:No,1:No,,0.915
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Immunophenotype,None,4,8,43,No,1:No,1:No,,0.915
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,Immunophenotype,None,4,9,43,No,1:No,1:No,,0.875
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; Protocol ; ,, Immunophenotype,5,0,2,No,1:No,1:No,,0.97
3030,2820141,Table 7,BaselineCharacteristic,xxx, ;  ; N ; ,, Immunophenotype,5,1,3,No,1:No,1:No,,0.81
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Immunophenotype,5,2,3,No,1:No,1:No,,0.84
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Immunophenotype,5,3,3,No,1:No,1:No,,0.85
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Immunophenotype,5,4,3,No,1:No,1:No,,0.86
3030,2820141,Table 7,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, Immunophenotype,5,5,3,No,1:No,1:No,,0.9
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Immunophenotype,5,6,3,No,1:No,1:No,,0.8
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Immunophenotype,5,7,3,No,1:No,1:No,,0.79
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Immunophenotype,5,8,3,No,1:No,1:No,,0.8
3030,2820141,Table 7,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, Immunophenotype,5,9,3,No,1:No,1:No,,0.83
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; Protocol ; ,, Immunophenotype,6,0,2,No,1:No,1:No,,0.99
3030,2820141,Table 7,BaselineCharacteristic,xx, ;  ; N ; ,, Immunophenotype,6,1,3,No,1:No,1:No,,0.791
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Immunophenotype,6,2,3,No,1:No,1:No,,0.87
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Immunophenotype,6,3,3,No,1:No,1:No,,0.87
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Immunophenotype,6,4,3,No,1:No,1:No,,0.88
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, Immunophenotype,6,5,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Immunophenotype,6,6,3,No,1:No,1:No,,0.83
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Immunophenotype,6,7,3,No,1:No,1:No,,0.81
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Immunophenotype,6,8,3,No,1:No,1:No,,0.82
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, Immunophenotype,6,9,3,No,1:No,1:No,,0.91
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; Protocol ; ,, Immunophenotype,7,0,2,No,1:No,1:No,,0.99
3030,2820141,Table 7,BaselineCharacteristic,x, ;  ; N ; ,, Immunophenotype,7,1,3,No,1:No,1:No,,0.96
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Immunophenotype,7,2,3,No,1:No,1:No,,0.89
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Immunophenotype,7,3,3,No,1:No,1:No,,0.89
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Immunophenotype,7,4,3,No,1:No,1:No,,0.9
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, Immunophenotype,7,5,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Immunophenotype,7,6,3,No,1:No,1:No,,0.86
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Immunophenotype,7,7,3,No,1:No,1:No,,0.84
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Immunophenotype,7,8,3,No,1:No,1:No,,0.85
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, Immunophenotype,7,9,3,No,1:No,1:No,,0.91
3030,2820141,Table 7,BaselineCharacteristic,B-precursor†, ;  ; Protocol ; ,None,None,8,0,24,No,1:No,1:No,,0.974
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; N ; ,B-precursor†,None,8,1,43,No,1:No,1:No,,0.967
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,B-precursor†,None,8,2,43,No,1:No,1:No,,0.98
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,B-precursor†,None,8,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,B-precursor†,None,8,4,43,No,1:No,1:No,,0.98
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,B-precursor†,None,8,5,43,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,B-precursor†,None,8,6,43,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,B-precursor†,None,8,7,43,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,B-precursor†,None,8,8,43,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,B-precursor†,None,8,9,43,No,1:No,1:No,,0.92
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; Protocol ; ,, B-precursor†,9,0,2,No,1:No,1:No,,1
3030,2820141,Table 7,BaselineCharacteristic,xxx, ;  ; N ; ,, B-precursor†,9,1,3,No,1:No,1:No,,0.91
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, B-precursor†,9,2,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, B-precursor†,9,3,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, B-precursor†,9,4,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, B-precursor†,9,5,3,No,1:No,1:No,,0.96
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, B-precursor†,9,6,3,No,1:No,1:No,,0.91
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, B-precursor†,9,7,3,No,1:No,1:No,,0.9
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, B-precursor†,9,8,3,No,1:No,1:No,,0.9
3030,2820141,Table 7,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, B-precursor†,9,9,3,No,1:No,1:No,,0.93
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; Protocol ; ,, B-precursor†,10,0,2,No,1:No,1:No,,1
3030,2820141,Table 7,BaselineCharacteristic,xx, ;  ; N ; ,, B-precursor†,10,1,3,No,1:No,1:No,,0.931
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, B-precursor†,10,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, B-precursor†,10,3,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, B-precursor†,10,4,3,No,1:No,1:No,,0.96
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, B-precursor†,10,5,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, B-precursor†,10,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, B-precursor†,10,7,3,No,1:No,1:No,,0.92
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, B-precursor†,10,8,3,No,1:No,1:No,,0.92
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, B-precursor†,10,9,3,No,1:No,1:No,,0.92
3030,2820141,Table 7,BaselineCharacteristic,T-lineage†, ;  ; Protocol ; ,None,None,11,0,24,No,1:No,1:No,,0.995
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; N ; ,T-lineage†,None,11,1,43,No,1:No,1:No,,0.977
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,T-lineage†,None,11,2,43,No,1:No,1:No,,0.98
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,T-lineage†,None,11,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,T-lineage†,None,11,4,43,No,1:No,1:No,,0.98
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,T-lineage†,None,11,5,43,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,T-lineage†,None,11,6,43,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,T-lineage†,None,11,7,43,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,T-lineage†,None,11,8,43,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,T-lineage†,None,11,9,43,No,1:No,1:No,,0.93
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; Protocol ; ,, T-lineage†,12,0,2,No,1:No,1:No,,1
3030,2820141,Table 7,BaselineCharacteristic,x, ;  ; N ; ,, T-lineage†,12,1,3,No,1:No,1:No,,1
3030,2820141,Table 7,BaselineCharacteristic,xxx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, T-lineage†,12,2,3,No,1:No,1:No,,0.97
3030,2820141,Table 7,BaselineCharacteristic,xxx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, T-lineage†,12,3,3,No,1:No,1:No,,0.97
3030,2820141,Table 7,BaselineCharacteristic,xxx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, T-lineage†,12,4,3,No,1:No,1:No,,0.98
3030,2820141,Table 7,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, T-lineage†,12,5,3,No,1:No,1:No,,0.97
3030,2820141,Table 7,BaselineCharacteristic,xxx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, T-lineage†,12,6,3,No,1:No,1:No,,0.96
3030,2820141,Table 7,BaselineCharacteristic,xxx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, T-lineage†,12,7,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,xxx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, T-lineage†,12,8,3,No,1:No,1:No,,0.96
3030,2820141,Table 7,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, T-lineage†,12,9,3,No,1:No,1:No,,0.96
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; Protocol ; ,, T-lineage†,13,0,2,No,1:No,1:No,,1
3030,2820141,Table 7,BaselineCharacteristic,xx, ;  ; N ; ,, T-lineage†,13,1,3,No,1:No,1:No,,0.921
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, T-lineage†,13,2,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, T-lineage†,13,3,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, T-lineage†,13,4,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, T-lineage†,13,5,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, T-lineage†,13,6,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, T-lineage†,13,7,3,No,1:No,1:No,,0.92
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, T-lineage†,13,8,3,No,1:No,1:No,,0.93
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, T-lineage†,13,9,3,No,1:No,1:No,,0.92
3030,2820141,Table 7,BaselineCharacteristic,Sex, ;  ; Protocol ; ,None,None,14,0,24,No,1:No,1:No,,0.995
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; N ; ,Sex,None,14,1,43,No,1:No,1:No,,0.977
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,Sex,None,14,2,43,No,1:No,1:No,,0.98
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Sex,None,14,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Sex,None,14,4,43,No,1:No,1:No,,0.98
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,Sex,None,14,5,43,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,Sex,None,14,6,43,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Sex,None,14,7,43,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Sex,None,14,8,43,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,Sex,None,14,9,43,No,1:No,1:No,,0.92
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; Protocol ; ,, Sex,15,0,2,No,1:No,1:No,,1
3030,2820141,Table 7,BaselineCharacteristic,xxx, ;  ; N ; ,, Sex,15,1,3,No,1:No,1:No,,0.91
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Sex,15,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Sex,15,3,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Sex,15,4,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, Sex,15,5,3,No,1:No,1:No,,0.97
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Sex,15,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Sex,15,7,3,No,1:No,1:No,,0.91
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Sex,15,8,3,No,1:No,1:No,,0.92
3030,2820141,Table 7,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, Sex,15,9,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; Protocol ; ,, Sex,16,0,2,No,1:No,1:No,,1
3030,2820141,Table 7,BaselineCharacteristic,xxx, ;  ; N ; ,, Sex,16,1,3,No,1:No,1:No,,0.91
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Sex,16,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Sex,16,3,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Sex,16,4,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, Sex,16,5,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Sex,16,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Sex,16,7,3,No,1:No,1:No,,0.91
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Sex,16,8,3,No,1:No,1:No,,0.92
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, Sex,16,9,3,No,1:No,1:No,,0.91
3030,2820141,Table 7,BaselineCharacteristic,Age at Diagnosis, ;  ; Protocol ; ,None,None,17,0,24,No,1:No,1:No,,0.995
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; N ; ,Age at Diagnosis,None,17,1,43,No,1:No,1:No,,0.967
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,Age at Diagnosis,None,17,2,43,No,1:No,1:No,,0.97
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Age at Diagnosis,None,17,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Age at Diagnosis,None,17,4,43,No,1:No,1:No,,0.98
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,Age at Diagnosis,None,17,5,43,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,Age at Diagnosis,None,17,6,43,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Age at Diagnosis,None,17,7,43,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Age at Diagnosis,None,17,8,43,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,Age at Diagnosis,None,17,9,43,No,1:No,1:No,,0.92
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; Protocol ; ,, Age at Diagnosis,18,0,2,No,1:No,1:No,,0.99
3030,2820141,Table 7,BaselineCharacteristic,x, ;  ; N ; ,, Age at Diagnosis,18,1,3,No,1:No,1:No,,0.98
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Age at Diagnosis,18,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Age at Diagnosis,18,3,3,No,1:No,1:No,,0.965
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Age at Diagnosis,18,4,3,No,1:No,1:No,,0.965
3030,2820141,Table 7,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, Age at Diagnosis,18,5,3,No,1:No,1:No,,0.97
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Age at Diagnosis,18,6,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Age at Diagnosis,18,7,3,No,1:No,1:No,,0.915
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Age at Diagnosis,18,8,3,No,1:No,1:No,,0.925
3030,2820141,Table 7,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, Age at Diagnosis,18,9,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; Protocol ; ,, Age at Diagnosis,19,0,2,No,1:No,1:No,,0.99
3030,2820141,Table 7,BaselineCharacteristic,xxx, ;  ; N ; ,, Age at Diagnosis,19,1,3,No,1:No,1:No,,0.92
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Age at Diagnosis,19,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Age at Diagnosis,19,3,3,No,1:No,1:No,,0.965
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Age at Diagnosis,19,4,3,No,1:No,1:No,,0.965
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, Age at Diagnosis,19,5,3,No,1:No,1:No,,0.93
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Age at Diagnosis,19,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Age at Diagnosis,19,7,3,No,1:No,1:No,,0.905
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Age at Diagnosis,19,8,3,No,1:No,1:No,,0.915
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, Age at Diagnosis,19,9,3,No,1:No,1:No,,0.91
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; Protocol ; ,, Age at Diagnosis,20,0,2,No,1:No,1:No,,0.99
3030,2820141,Table 7,BaselineCharacteristic,xx, ;  ; N ; ,, Age at Diagnosis,20,1,3,No,1:No,1:No,,0.937
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Age at Diagnosis,20,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Age at Diagnosis,20,3,3,No,1:No,1:No,,0.965
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Age at Diagnosis,20,4,3,No,1:No,1:No,,0.965
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, Age at Diagnosis,20,5,3,No,1:No,1:No,,0.93
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Age at Diagnosis,20,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Age at Diagnosis,20,7,3,No,1:No,1:No,,0.905
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Age at Diagnosis,20,8,3,No,1:No,1:No,,0.915
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, Age at Diagnosis,20,9,3,No,1:No,1:No,,0.91
3030,2820141,Table 7,BaselineCharacteristic,WBC (× xxx/L), ;  ; Protocol ; ,None,None,21,0,24,No,1:No,1:No,,0.995
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; N ; ,WBC (× xxx/L),None,21,1,43,No,1:No,1:No,,0.988
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,WBC (× xxx/L),None,21,2,43,No,1:No,1:No,,0.99
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,WBC (× xxx/L),None,21,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,WBC (× xxx/L),None,21,4,43,No,1:No,1:No,,0.98
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,WBC (× xxx/L),None,21,5,43,No,1:No,1:No,,0.96
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,WBC (× xxx/L),None,21,6,43,No,1:No,1:No,,0.96
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,WBC (× xxx/L),None,21,7,43,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,WBC (× xxx/L),None,21,8,43,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,WBC (× xxx/L),None,21,9,43,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; Protocol ; ,, WBC (× xxx/L),22,0,2,No,1:No,1:No,,1
3030,2820141,Table 7,BaselineCharacteristic,xxx, ;  ; N ; ,, WBC (× xxx/L),22,1,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, WBC (× xxx/L),22,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, WBC (× xxx/L),22,3,3,No,1:No,1:No,,0.96
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, WBC (× xxx/L),22,4,3,No,1:No,1:No,,0.96
3030,2820141,Table 7,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, WBC (× xxx/L),22,5,3,No,1:No,1:No,,0.99
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, WBC (× xxx/L),22,6,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, WBC (× xxx/L),22,7,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, WBC (× xxx/L),22,8,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, WBC (× xxx/L),22,9,3,No,1:No,1:No,,0.96
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; Protocol ; ,, WBC (× xxx/L),23,0,2,No,1:No,1:No,,1
3030,2820141,Table 7,BaselineCharacteristic,xxx, ;  ; N ; ,, WBC (× xxx/L),23,1,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, WBC (× xxx/L),23,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, WBC (× xxx/L),23,3,3,No,1:No,1:No,,0.96
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, WBC (× xxx/L),23,4,3,No,1:No,1:No,,0.96
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, WBC (× xxx/L),23,5,3,No,1:No,1:No,,0.96
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, WBC (× xxx/L),23,6,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, WBC (× xxx/L),23,7,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, WBC (× xxx/L),23,8,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, WBC (× xxx/L),23,9,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; Protocol ; ,, WBC (× xxx/L),24,0,2,No,1:No,1:No,,1
3030,2820141,Table 7,BaselineCharacteristic,xx, ;  ; N ; ,, WBC (× xxx/L),24,1,3,No,1:No,1:No,,0.951
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, WBC (× xxx/L),24,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, WBC (× xxx/L),24,3,3,No,1:No,1:No,,0.96
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, WBC (× xxx/L),24,4,3,No,1:No,1:No,,0.96
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, WBC (× xxx/L),24,5,3,No,1:No,1:No,,0.96
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, WBC (× xxx/L),24,6,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, WBC (× xxx/L),24,7,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, WBC (× xxx/L),24,8,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, WBC (× xxx/L),24,9,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; Protocol ; ,, WBC (× xxx/L),25,0,2,No,1:No,1:No,,1
3030,2820141,Table 7,BaselineCharacteristic,xx, ;  ; N ; ,, WBC (× xxx/L),25,1,3,No,1:No,1:No,,0.951
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, WBC (× xxx/L),25,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, WBC (× xxx/L),25,3,3,No,1:No,1:No,,0.96
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, WBC (× xxx/L),25,4,3,No,1:No,1:No,,0.96
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, WBC (× xxx/L),25,5,3,No,1:No,1:No,,0.96
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, WBC (× xxx/L),25,6,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, WBC (× xxx/L),25,7,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, WBC (× xxx/L),25,8,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, WBC (× xxx/L),25,9,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,CNS leukemia, ;  ; Protocol ; ,None,None,26,0,24,No,1:No,1:No,,0.995
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; N ; ,CNS leukemia,None,26,1,43,No,1:No,1:No,,0.967
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,CNS leukemia,None,26,2,43,No,1:No,1:No,,0.98
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,CNS leukemia,None,26,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,CNS leukemia,None,26,4,43,No,1:No,1:No,,0.98
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,CNS leukemia,None,26,5,43,No,1:No,1:No,,0.96
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,CNS leukemia,None,26,6,43,No,1:No,1:No,,0.96
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,CNS leukemia,None,26,7,43,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,CNS leukemia,None,26,8,43,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,CNS leukemia,None,26,9,43,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; Protocol ; ,, CNS leukemia,27,0,2,No,1:No,1:No,,1
3030,2820141,Table 7,BaselineCharacteristic,x, ;  ; N ; ,, CNS leukemia,27,1,3,No,1:No,1:No,,0.99
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, CNS leukemia,27,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, CNS leukemia,27,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, CNS leukemia,27,4,3,No,1:No,1:No,,0.945
3030,2820141,Table 7,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, CNS leukemia,27,5,3,No,1:No,1:No,,0.97
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, CNS leukemia,27,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, CNS leukemia,27,7,3,No,1:No,1:No,,0.905
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, CNS leukemia,27,8,3,No,1:No,1:No,,0.915
3030,2820141,Table 7,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, CNS leukemia,27,9,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; Protocol ; ,, CNS leukemia,28,0,2,No,1:No,1:No,,1
3030,2820141,Table 7,BaselineCharacteristic,xxx, ;  ; N ; ,, CNS leukemia,28,1,3,No,1:No,1:No,,0.91
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, CNS leukemia,28,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, CNS leukemia,28,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, CNS leukemia,28,4,3,No,1:No,1:No,,0.945
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, CNS leukemia,28,5,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, CNS leukemia,28,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, CNS leukemia,28,7,3,No,1:No,1:No,,0.905
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, CNS leukemia,28,8,3,No,1:No,1:No,,0.915
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, CNS leukemia,28,9,3,No,1:No,1:No,,0.92
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; Protocol ; ,, CNS leukemia,29,0,2,No,1:No,1:No,,1
3030,2820141,Table 7,BaselineCharacteristic,x, ;  ; N ; ,, CNS leukemia,29,1,3,No,1:No,1:No,,0.99
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, CNS leukemia,29,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, CNS leukemia,29,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, CNS leukemia,29,4,3,No,1:No,1:No,,0.945
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, CNS leukemia,29,5,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, CNS leukemia,29,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, CNS leukemia,29,7,3,No,1:No,1:No,,0.905
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, CNS leukemia,29,8,3,No,1:No,1:No,,0.915
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, CNS leukemia,29,9,3,No,1:No,1:No,,0.92
3030,2820141,Table 7,BaselineCharacteristic,t(x;xx), ;  ; Protocol ; ,None,None,30,0,24,No,1:No,1:No,,0.88
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; N ; ,t(x;xx),None,30,1,43,No,1:No,1:No,,0.875
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,t(x;xx),None,30,2,43,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,t(x;xx),None,30,3,43,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,t(x;xx),None,30,4,43,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,t(x;xx),None,30,5,43,No,1:No,1:No,,0.93
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,t(x;xx),None,30,6,43,No,1:No,1:No,,0.91
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,t(x;xx),None,30,7,43,No,1:No,1:No,,0.9
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,t(x;xx),None,30,8,43,No,1:No,1:No,,0.91
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,t(x;xx),None,30,9,43,No,1:No,1:No,,0.89
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; Protocol ; ,, t(x;xx),31,0,2,No,1:No,1:No,,0.915
3030,2820141,Table 7,BaselineCharacteristic,x, ;  ; N ; ,, t(x;xx),31,1,3,No,1:No,1:No,,0.901
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, t(x;xx),31,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, t(x;xx),31,3,3,No,1:No,1:No,,0.955
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, t(x;xx),31,4,3,No,1:No,1:No,,0.955
3030,2820141,Table 7,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, t(x;xx),31,5,3,No,1:No,1:No,,0.92
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, t(x;xx),31,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, t(x;xx),31,7,3,No,1:No,1:No,,0.905
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, t(x;xx),31,8,3,No,1:No,1:No,,0.915
3030,2820141,Table 7,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, t(x;xx),31,9,3,No,1:No,1:No,,0.89
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; Protocol ; ,, t(x;xx),32,0,2,No,1:No,1:No,,0.915
3030,2820141,Table 7,BaselineCharacteristic,xxx, ;  ; N ; ,, t(x;xx),32,1,3,No,1:No,1:No,,0.806
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, t(x;xx),32,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, t(x;xx),32,3,3,No,1:No,1:No,,0.955
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, t(x;xx),32,4,3,No,1:No,1:No,,0.955
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, t(x;xx),32,5,3,No,1:No,1:No,,0.945
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, t(x;xx),32,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, t(x;xx),32,7,3,No,1:No,1:No,,0.905
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, t(x;xx),32,8,3,No,1:No,1:No,,0.915
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, t(x;xx),32,9,3,No,1:No,1:No,,0.905
3030,2820141,Table 7,BaselineCharacteristic,DFCI Risk Group, ;  ; Protocol ; ,None,None,33,0,24,No,1:No,1:No,,0.995
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; N ; ,DFCI Risk Group,None,33,1,43,No,1:No,1:No,,0.967
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,DFCI Risk Group,None,33,2,43,No,1:No,1:No,,0.97
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,DFCI Risk Group,None,33,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,DFCI Risk Group,None,33,4,43,No,1:No,1:No,,0.98
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,DFCI Risk Group,None,33,5,43,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,DFCI Risk Group,None,33,6,43,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,DFCI Risk Group,None,33,7,43,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,DFCI Risk Group,None,33,8,43,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,DFCI Risk Group,None,33,9,43,No,1:No,1:No,,0.92
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; Protocol ; ,, DFCI Risk Group,34,0,2,No,1:No,1:No,,1
3030,2820141,Table 7,BaselineCharacteristic,xxx, ;  ; N ; ,, DFCI Risk Group,34,1,3,No,1:No,1:No,,0.92
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, DFCI Risk Group,34,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, DFCI Risk Group,34,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, DFCI Risk Group,34,4,3,No,1:No,1:No,,0.945
3030,2820141,Table 7,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, DFCI Risk Group,34,5,3,No,1:No,1:No,,0.97
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, DFCI Risk Group,34,6,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, DFCI Risk Group,34,7,3,No,1:No,1:No,,0.905
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, DFCI Risk Group,34,8,3,No,1:No,1:No,,0.915
3030,2820141,Table 7,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, DFCI Risk Group,34,9,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; Protocol ; ,, DFCI Risk Group,35,0,2,No,1:No,1:No,,1
3030,2820141,Table 7,BaselineCharacteristic,xxx, ;  ; N ; ,, DFCI Risk Group,35,1,3,No,1:No,1:No,,0.92
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, DFCI Risk Group,35,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, DFCI Risk Group,35,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, DFCI Risk Group,35,4,3,No,1:No,1:No,,0.945
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, DFCI Risk Group,35,5,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, DFCI Risk Group,35,6,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, DFCI Risk Group,35,7,3,No,1:No,1:No,,0.905
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, DFCI Risk Group,35,8,3,No,1:No,1:No,,0.915
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, DFCI Risk Group,35,9,3,No,1:No,1:No,,0.92
3030,2820141,Table 7,BaselineCharacteristic,Randomizations, ;  ; Protocol ; ,None,None,36,0,2,No,1:No,1:No,,1
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; N ; ,None,None,36,1,3,No,1:No,1:No,,0.98
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,None,None,36,2,3,No,1:No,1:No,,0.97
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,None,None,36,3,3,No,1:No,1:No,,0.97
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,None,None,36,4,3,No,1:No,1:No,,0.97
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,None,None,36,5,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,None,None,36,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,None,None,36,7,3,No,1:No,1:No,,0.92
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,None,None,36,8,3,No,1:No,1:No,,0.92
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,None,None,36,9,3,No,1:No,1:No,,0.91
3030,2820141,Table 7,BaselineCharacteristic,x-MP, ;  ; Protocol ; ,None,None,37,0,24,No,1:No,1:No,,0.995
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; N ; ,x-MP,None,37,1,43,No,1:No,1:No,,0.967
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,x-MP,None,37,2,43,No,1:No,1:No,,0.97
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,x-MP,None,37,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,x-MP,None,37,4,43,No,1:No,1:No,,0.98
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,x-MP,None,37,5,43,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,x-MP,None,37,6,43,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,x-MP,None,37,7,43,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,x-MP,None,37,8,43,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,x-MP,None,37,9,43,No,1:No,1:No,,0.92
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; Protocol ; ,, Randomizations x-MP,38,0,2,No,1:No,1:No,,1
3030,2820141,Table 7,BaselineCharacteristic,xxx, ;  ; N ; ,, Randomizations x-MP,38,1,3,No,1:No,1:No,,0.91
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Randomizations x-MP,38,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Randomizations x-MP,38,3,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Randomizations x-MP,38,4,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, Randomizations x-MP,38,5,3,No,1:No,1:No,,0.97
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Randomizations x-MP,38,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Randomizations x-MP,38,7,3,No,1:No,1:No,,0.91
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Randomizations x-MP,38,8,3,No,1:No,1:No,,0.92
3030,2820141,Table 7,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, Randomizations x-MP,38,9,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; Protocol ; ,, Randomizations x-MP,39,0,2,No,1:No,1:No,,1
3030,2820141,Table 7,BaselineCharacteristic,xxx, ;  ; N ; ,, Randomizations x-MP,39,1,3,No,1:No,1:No,,0.91
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Randomizations x-MP,39,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Randomizations x-MP,39,3,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Randomizations x-MP,39,4,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, Randomizations x-MP,39,5,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Randomizations x-MP,39,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Randomizations x-MP,39,7,3,No,1:No,1:No,,0.91
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Randomizations x-MP,39,8,3,No,1:No,1:No,,0.92
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, Randomizations x-MP,39,9,3,No,1:No,1:No,,0.91
3030,2820141,Table 7,BaselineCharacteristic,Asparaginase, ;  ; Protocol ; ,None,None,40,0,24,No,1:No,1:No,,0.995
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; N ; ,Asparaginase,None,40,1,43,No,1:No,1:No,,0.967
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,Asparaginase,None,40,2,43,No,1:No,1:No,,0.97
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Asparaginase,None,40,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Asparaginase,None,40,4,43,No,1:No,1:No,,0.98
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,Asparaginase,None,40,5,43,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,Asparaginase,None,40,6,43,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Asparaginase,None,40,7,43,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Asparaginase,None,40,8,43,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,Asparaginase,None,40,9,43,No,1:No,1:No,,0.92
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; Protocol ; ,, Randomizations Asparaginase,41,0,2,No,1:No,1:No,,1
3030,2820141,Table 7,BaselineCharacteristic,xx, ;  ; N ; ,, Randomizations Asparaginase,41,1,3,No,1:No,1:No,,0.941
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Randomizations Asparaginase,41,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Randomizations Asparaginase,41,3,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Randomizations Asparaginase,41,4,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, Randomizations Asparaginase,41,5,3,No,1:No,1:No,,0.97
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Randomizations Asparaginase,41,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Randomizations Asparaginase,41,7,3,No,1:No,1:No,,0.91
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Randomizations Asparaginase,41,8,3,No,1:No,1:No,,0.92
3030,2820141,Table 7,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, Randomizations Asparaginase,41,9,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; Protocol ; ,, Randomizations Asparaginase,42,0,2,No,1:No,1:No,,1
3030,2820141,Table 7,BaselineCharacteristic,xxx, ;  ; N ; ,, Randomizations Asparaginase,42,1,3,No,1:No,1:No,,0.91
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Randomizations Asparaginase,42,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Randomizations Asparaginase,42,3,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Randomizations Asparaginase,42,4,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, Randomizations Asparaginase,42,5,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Randomizations Asparaginase,42,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Randomizations Asparaginase,42,7,3,No,1:No,1:No,,0.91
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Randomizations Asparaginase,42,8,3,No,1:No,1:No,,0.92
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, Randomizations Asparaginase,42,9,3,No,1:No,1:No,,0.91
3030,2820141,Table 7,BaselineCharacteristic,Doxorubicin (HR only), ;  ; Protocol ; ,None,None,43,0,24,No,1:No,1:No,,1
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; N ; ,Doxorubicin (HR only),None,43,1,43,No,1:No,1:No,,0.973
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,Doxorubicin (HR only),None,43,2,43,No,1:No,1:No,,0.97
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Doxorubicin (HR only),None,43,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Doxorubicin (HR only),None,43,4,43,No,1:No,1:No,,0.98
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,Doxorubicin (HR only),None,43,5,43,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,Doxorubicin (HR only),None,43,6,43,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Doxorubicin (HR only),None,43,7,43,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Doxorubicin (HR only),None,43,8,43,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,Doxorubicin (HR only),None,43,9,43,No,1:No,1:No,,0.93
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; Protocol ; ,, Randomizations Doxorubicin (HR only),44,0,2,No,1:No,1:No,,1
3030,2820141,Table 7,BaselineCharacteristic,xxx, ;  ; N ; ,, Randomizations Doxorubicin (HR only),44,1,3,No,1:No,1:No,,0.91
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Randomizations Doxorubicin (HR only),44,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Randomizations Doxorubicin (HR only),44,3,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Randomizations Doxorubicin (HR only),44,4,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, Randomizations Doxorubicin (HR only),44,5,3,No,1:No,1:No,,0.97
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Randomizations Doxorubicin (HR only),44,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Randomizations Doxorubicin (HR only),44,7,3,No,1:No,1:No,,0.93
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Randomizations Doxorubicin (HR only),44,8,3,No,1:No,1:No,,0.93
3030,2820141,Table 7,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, Randomizations Doxorubicin (HR only),44,9,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,, ;  ; Protocol ; ,, Randomizations Doxorubicin (HR only),45,0,2,No,1:No,1:No,,1
3030,2820141,Table 7,BaselineCharacteristic,xxx, ;  ; N ; ,, Randomizations Doxorubicin (HR only),45,1,3,No,1:No,1:No,,0.91
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Randomizations Doxorubicin (HR only),45,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Randomizations Doxorubicin (HR only),45,3,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Randomizations Doxorubicin (HR only),45,4,3,No,1:No,1:No,,0.95
3030,2820141,Table 7,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, Randomizations Doxorubicin (HR only),45,5,3,No,1:No,1:No,,0.94
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Randomizations Doxorubicin (HR only),45,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Randomizations Doxorubicin (HR only),45,7,3,No,1:No,1:No,,0.93
3030,2820141,Table 7,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Randomizations Doxorubicin (HR only),45,8,3,No,1:No,1:No,,0.93
3030,2820141,Table 7,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, Randomizations Doxorubicin (HR only),45,9,3,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
3030,2820141,Table 8,BaselineCharacteristic,,,,None,0,1,1,No,1:No,1:No,,0.903
3030,2820141,Table 8,BaselineCharacteristic,Event-free Survival ± SE (%),,,None,0,2,1,No,1:No,1:No,,0.903
3030,2820141,Table 8,BaselineCharacteristic,Event-free Survival ± SE (%),,,None,0,3,1,No,1:No,1:No,,0.903
3030,2820141,Table 8,BaselineCharacteristic,Event-free Survival ± SE (%),,,None,0,4,1,No,1:No,1:No,,0.903
3030,2820141,Table 8,BaselineCharacteristic,Overall Survival ± SE (%),,,None,0,5,1,No,1:No,1:No,,0.868
3030,2820141,Table 8,BaselineCharacteristic,Overall Survival ± SE (%),,,None,0,6,1,No,1:No,1:No,,0.868
3030,2820141,Table 8,BaselineCharacteristic,Overall Survival ± SE (%),,,None,0,7,1,No,1:No,1:No,,0.878
3030,2820141,Table 8,BaselineCharacteristic,, ; ,None,None,1,0,12,No,1:No,1:No,,0.898
3030,2820141,Table 8,BaselineCharacteristic,, ; ,,None,1,1,1,No,1:No,1:No,,0.895
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ; ,,None,1,2,1,No,1:No,1:No,,0.903
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ; ,,None,1,3,1,No,1:No,1:No,,0.903
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ; ,,None,1,4,1,No,1:No,1:No,,0.903
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ; ,,None,1,5,1,No,1:No,1:No,,0.868
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ; ,,None,1,6,1,No,1:No,1:No,,0.868
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ; ,,None,1,7,1,No,1:No,1:No,,0.878
3030,2820141,Table 8,BaselineCharacteristic,Protocol, ;  ; ,None,None,2,0,12,No,1:No,1:No,,0.923
3030,2820141,Table 8,BaselineCharacteristic,N, ;  ; ,Protocol,None,2,1,1,No,1:No,1:No,,0.915
3030,2820141,Table 8,BaselineCharacteristic,x-yr EFS,Event-free Survival ± SE (%) ;  ; ,Protocol,None,2,2,1,No,1:No,1:No,,0.943
3030,2820141,Table 8,BaselineCharacteristic,xx-yr EFS,Event-free Survival ± SE (%) ;  ; ,Protocol,None,2,3,1,No,1:No,1:No,,0.943
3030,2820141,Table 8,BaselineCharacteristic,p-value,Event-free Survival ± SE (%) ;  ; ,Protocol,None,2,4,1,No,1:No,1:No,,0.913
3030,2820141,Table 8,BaselineCharacteristic,x-yr OS,Overall Survival ± SE (%) ;  ; ,Protocol,None,2,5,1,No,1:No,1:No,,0.905
3030,2820141,Table 8,BaselineCharacteristic,xx-yr OS,Overall Survival ± SE (%) ;  ; ,Protocol,None,2,6,1,No,1:No,1:No,,0.905
3030,2820141,Table 8,BaselineCharacteristic,p-value,Overall Survival ± SE (%) ;  ; ,Protocol,None,2,7,1,No,1:No,1:No,,0.878
3030,2820141,Table 8,BaselineCharacteristic,Overall, ;  ; Protocol ; ,Overall,,3,0,2,No,1:No,1:No,,0.96
3030,2820141,Table 8,BaselineCharacteristic,xxx, ;  ; N ; ,Overall,,3,1,3,No,1:No,1:No,,0.81
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,Overall,,3,2,3,No,1:No,1:No,,0.8
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Overall,,3,3,3,No,1:No,1:No,,0.8
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,Overall,,3,4,3,No,1:No,1:No,,0.89
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,Overall,,3,5,3,No,1:No,1:No,,0.76
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Overall,,3,6,3,No,1:No,1:No,,0.78
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,Overall,,3,7,3,No,1:No,1:No,,0.85
3030,2820141,Table 8,BaselineCharacteristic,Immunophenotype, ;  ; Protocol ; ,None,None,4,0,24,No,1:No,1:No,,0.939
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; N ; ,Immunophenotype,None,4,1,43,No,1:No,1:No,,0.902
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,Immunophenotype,None,4,2,43,No,1:No,1:No,,0.955
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Immunophenotype,None,4,3,43,No,1:No,1:No,,0.965
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,Immunophenotype,None,4,4,43,No,1:No,1:No,,0.905
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,Immunophenotype,None,4,5,43,No,1:No,1:No,,0.895
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Immunophenotype,None,4,6,43,No,1:No,1:No,,0.915
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,Immunophenotype,None,4,7,43,No,1:No,1:No,,0.875
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, Immunophenotype,5,0,2,No,1:No,1:No,,0.97
3030,2820141,Table 8,BaselineCharacteristic,xxx, ;  ; N ; ,, Immunophenotype,5,1,3,No,1:No,1:No,,0.81
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Immunophenotype,5,2,3,No,1:No,1:No,,0.84
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Immunophenotype,5,3,3,No,1:No,1:No,,0.85
3030,2820141,Table 8,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, Immunophenotype,5,4,3,No,1:No,1:No,,0.91
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Immunophenotype,5,5,3,No,1:No,1:No,,0.8
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Immunophenotype,5,6,3,No,1:No,1:No,,0.81
3030,2820141,Table 8,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, Immunophenotype,5,7,3,No,1:No,1:No,,0.82
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, Immunophenotype,6,0,2,No,1:No,1:No,,0.99
3030,2820141,Table 8,BaselineCharacteristic,xx, ;  ; N ; ,, Immunophenotype,6,1,3,No,1:No,1:No,,0.791
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Immunophenotype,6,2,3,No,1:No,1:No,,0.87
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Immunophenotype,6,3,3,No,1:No,1:No,,0.87
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, Immunophenotype,6,4,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Immunophenotype,6,5,3,No,1:No,1:No,,0.83
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Immunophenotype,6,6,3,No,1:No,1:No,,0.83
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, Immunophenotype,6,7,3,No,1:No,1:No,,0.91
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, Immunophenotype,7,0,2,No,1:No,1:No,,0.99
3030,2820141,Table 8,BaselineCharacteristic,x, ;  ; N ; ,, Immunophenotype,7,1,3,No,1:No,1:No,,0.96
3030,2820141,Table 8,BaselineCharacteristic,N/A,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Immunophenotype,7,2,3,No,1:No,1:No,,0.98
3030,2820141,Table 8,BaselineCharacteristic,N/A,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Immunophenotype,7,3,3,No,1:No,1:No,,0.97
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, Immunophenotype,7,4,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,N/A,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Immunophenotype,7,5,3,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,N/A,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Immunophenotype,7,6,3,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, Immunophenotype,7,7,3,No,1:No,1:No,,0.91
3030,2820141,Table 8,BaselineCharacteristic,B-lineage†, ;  ; Protocol ; ,None,None,8,0,24,No,1:No,1:No,,0.974
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; N ; ,B-lineage†,None,8,1,43,No,1:No,1:No,,0.957
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,B-lineage†,None,8,2,43,No,1:No,1:No,,0.98
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,B-lineage†,None,8,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,B-lineage†,None,8,4,43,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,B-lineage†,None,8,5,43,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,B-lineage†,None,8,6,43,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,B-lineage†,None,8,7,43,No,1:No,1:No,,0.91
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, B-lineage†,9,0,2,No,1:No,1:No,,1
3030,2820141,Table 8,BaselineCharacteristic,xxx, ;  ; N ; ,, B-lineage†,9,1,3,No,1:No,1:No,,0.9
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, B-lineage†,9,2,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, B-lineage†,9,3,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, B-lineage†,9,4,3,No,1:No,1:No,,0.96
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, B-lineage†,9,5,3,No,1:No,1:No,,0.91
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, B-lineage†,9,6,3,No,1:No,1:No,,0.91
3030,2820141,Table 8,BaselineCharacteristic,x.xxxx,Overall Survival ± SE (%) ;  ; p-value ; ,, B-lineage†,9,7,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, B-lineage†,10,0,2,No,1:No,1:No,,1
3030,2820141,Table 8,BaselineCharacteristic,xxx, ;  ; N ; ,, B-lineage†,10,1,3,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, B-lineage†,10,2,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, B-lineage†,10,3,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, B-lineage†,10,4,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, B-lineage†,10,5,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, B-lineage†,10,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, B-lineage†,10,7,3,No,1:No,1:No,,0.91
3030,2820141,Table 8,BaselineCharacteristic,T-lineage†, ;  ; Protocol ; ,None,None,11,0,24,No,1:No,1:No,,0.995
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; N ; ,T-lineage†,None,11,1,43,No,1:No,1:No,,0.977
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,T-lineage†,None,11,2,43,No,1:No,1:No,,0.98
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,T-lineage†,None,11,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,T-lineage†,None,11,4,43,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,T-lineage†,None,11,5,43,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,T-lineage†,None,11,6,43,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,T-lineage†,None,11,7,43,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, T-lineage†,12,0,2,No,1:No,1:No,,1
3030,2820141,Table 8,BaselineCharacteristic,xx, ;  ; N ; ,, T-lineage†,12,1,3,No,1:No,1:No,,0.921
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, T-lineage†,12,2,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, T-lineage†,12,3,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, T-lineage†,12,4,3,No,1:No,1:No,,0.97
3030,2820141,Table 8,BaselineCharacteristic,xxx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, T-lineage†,12,5,3,No,1:No,1:No,,0.96
3030,2820141,Table 8,BaselineCharacteristic,xxx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, T-lineage†,12,6,3,No,1:No,1:No,,0.96
3030,2820141,Table 8,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, T-lineage†,12,7,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, T-lineage†,13,0,2,No,1:No,1:No,,1
3030,2820141,Table 8,BaselineCharacteristic,xx, ;  ; N ; ,, T-lineage†,13,1,3,No,1:No,1:No,,0.921
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, T-lineage†,13,2,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, T-lineage†,13,3,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, T-lineage†,13,4,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, T-lineage†,13,5,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, T-lineage†,13,6,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, T-lineage†,13,7,3,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,Sex, ;  ; Protocol ; ,None,None,14,0,24,No,1:No,1:No,,0.995
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; N ; ,Sex,None,14,1,43,No,1:No,1:No,,0.977
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,Sex,None,14,2,43,No,1:No,1:No,,0.98
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Sex,None,14,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,Sex,None,14,4,43,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,Sex,None,14,5,43,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Sex,None,14,6,43,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,Sex,None,14,7,43,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, Sex,15,0,2,No,1:No,1:No,,1
3030,2820141,Table 8,BaselineCharacteristic,xxx, ;  ; N ; ,, Sex,15,1,3,No,1:No,1:No,,0.91
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Sex,15,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Sex,15,3,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, Sex,15,4,3,No,1:No,1:No,,0.97
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Sex,15,5,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Sex,15,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, Sex,15,7,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, Sex,16,0,2,No,1:No,1:No,,1
3030,2820141,Table 8,BaselineCharacteristic,xxx, ;  ; N ; ,, Sex,16,1,3,No,1:No,1:No,,0.91
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Sex,16,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Sex,16,3,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, Sex,16,4,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Sex,16,5,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Sex,16,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, Sex,16,7,3,No,1:No,1:No,,0.91
3030,2820141,Table 8,BaselineCharacteristic,Age at Diagnosis, ;  ; Protocol ; ,None,None,17,0,24,No,1:No,1:No,,0.995
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; N ; ,Age at Diagnosis,None,17,1,43,No,1:No,1:No,,0.967
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,Age at Diagnosis,None,17,2,43,No,1:No,1:No,,0.97
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Age at Diagnosis,None,17,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,Age at Diagnosis,None,17,4,43,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,Age at Diagnosis,None,17,5,43,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Age at Diagnosis,None,17,6,43,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,Age at Diagnosis,None,17,7,43,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, Age at Diagnosis,18,0,2,No,1:No,1:No,,0.99
3030,2820141,Table 8,BaselineCharacteristic,xx, ;  ; N ; ,, Age at Diagnosis,18,1,3,No,1:No,1:No,,0.937
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Age at Diagnosis,18,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Age at Diagnosis,18,3,3,No,1:No,1:No,,0.965
3030,2820141,Table 8,BaselineCharacteristic,<x.xxxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, Age at Diagnosis,18,4,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Age at Diagnosis,18,5,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Age at Diagnosis,18,6,3,No,1:No,1:No,,0.935
3030,2820141,Table 8,BaselineCharacteristic,<x.xxxx,Overall Survival ± SE (%) ;  ; p-value ; ,, Age at Diagnosis,18,7,3,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, Age at Diagnosis,19,0,2,No,1:No,1:No,,0.99
3030,2820141,Table 8,BaselineCharacteristic,xxx, ;  ; N ; ,, Age at Diagnosis,19,1,3,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Age at Diagnosis,19,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Age at Diagnosis,19,3,3,No,1:No,1:No,,0.965
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, Age at Diagnosis,19,4,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Age at Diagnosis,19,5,3,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Age at Diagnosis,19,6,3,No,1:No,1:No,,0.925
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, Age at Diagnosis,19,7,3,No,1:No,1:No,,0.91
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, Age at Diagnosis,20,0,2,No,1:No,1:No,,0.99
3030,2820141,Table 8,BaselineCharacteristic,xx, ;  ; N ; ,, Age at Diagnosis,20,1,3,No,1:No,1:No,,0.937
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Age at Diagnosis,20,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Age at Diagnosis,20,3,3,No,1:No,1:No,,0.965
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, Age at Diagnosis,20,4,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Age at Diagnosis,20,5,3,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Age at Diagnosis,20,6,3,No,1:No,1:No,,0.925
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, Age at Diagnosis,20,7,3,No,1:No,1:No,,0.91
3030,2820141,Table 8,BaselineCharacteristic,WBC, ;  ; Protocol ; ,None,None,21,0,24,No,1:No,1:No,,0.985
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; N ; ,WBC,None,21,1,43,No,1:No,1:No,,0.967
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,WBC,None,21,2,43,No,1:No,1:No,,0.98
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,WBC,None,21,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,WBC,None,21,4,43,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,WBC,None,21,5,43,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,WBC,None,21,6,43,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,WBC,None,21,7,43,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, WBC,22,0,2,No,1:No,1:No,,1
3030,2820141,Table 8,BaselineCharacteristic,xxx, ;  ; N ; ,, WBC,22,1,3,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, WBC,22,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, WBC,22,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 8,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, WBC,22,4,3,No,1:No,1:No,,0.98
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, WBC,22,5,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, WBC,22,6,3,No,1:No,1:No,,0.935
3030,2820141,Table 8,BaselineCharacteristic,x.xxxx,Overall Survival ± SE (%) ;  ; p-value ; ,, WBC,22,7,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, WBC,23,0,2,No,1:No,1:No,,1
3030,2820141,Table 8,BaselineCharacteristic,xxx, ;  ; N ; ,, WBC,23,1,3,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, WBC,23,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, WBC,23,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, WBC,23,4,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, WBC,23,5,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, WBC,23,6,3,No,1:No,1:No,,0.935
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, WBC,23,7,3,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, WBC,24,0,2,No,1:No,1:No,,1
3030,2820141,Table 8,BaselineCharacteristic,xx, ;  ; N ; ,, WBC,24,1,3,No,1:No,1:No,,0.937
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, WBC,24,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, WBC,24,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, WBC,24,4,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, WBC,24,5,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, WBC,24,6,3,No,1:No,1:No,,0.935
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, WBC,24,7,3,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, WBC,25,0,2,No,1:No,1:No,,1
3030,2820141,Table 8,BaselineCharacteristic,xx, ;  ; N ; ,, WBC,25,1,3,No,1:No,1:No,,0.937
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, WBC,25,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, WBC,25,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, WBC,25,4,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, WBC,25,5,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, WBC,25,6,3,No,1:No,1:No,,0.935
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, WBC,25,7,3,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,CNS leukemia, ;  ; Protocol ; ,None,None,26,0,24,No,1:No,1:No,,0.995
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; N ; ,CNS leukemia,None,26,1,43,No,1:No,1:No,,0.967
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,CNS leukemia,None,26,2,43,No,1:No,1:No,,0.98
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,CNS leukemia,None,26,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,CNS leukemia,None,26,4,43,No,1:No,1:No,,0.96
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,CNS leukemia,None,26,5,43,No,1:No,1:No,,0.96
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,CNS leukemia,None,26,6,43,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,CNS leukemia,None,26,7,43,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, CNS leukemia,27,0,2,No,1:No,1:No,,1
3030,2820141,Table 8,BaselineCharacteristic,xxx, ;  ; N ; ,, CNS leukemia,27,1,3,No,1:No,1:No,,0.91
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, CNS leukemia,27,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, CNS leukemia,27,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 8,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, CNS leukemia,27,4,3,No,1:No,1:No,,0.97
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, CNS leukemia,27,5,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, CNS leukemia,27,6,3,No,1:No,1:No,,0.925
3030,2820141,Table 8,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, CNS leukemia,27,7,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, CNS leukemia,28,0,2,No,1:No,1:No,,1
3030,2820141,Table 8,BaselineCharacteristic,xx, ;  ; N ; ,, CNS leukemia,28,1,3,No,1:No,1:No,,0.937
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, CNS leukemia,28,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, CNS leukemia,28,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, CNS leukemia,28,4,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, CNS leukemia,28,5,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, CNS leukemia,28,6,3,No,1:No,1:No,,0.925
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, CNS leukemia,28,7,3,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, CNS leukemia,29,0,2,No,1:No,1:No,,1
3030,2820141,Table 8,BaselineCharacteristic,xx, ;  ; N ; ,, CNS leukemia,29,1,3,No,1:No,1:No,,0.937
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, CNS leukemia,29,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,NA,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, CNS leukemia,29,3,3,No,1:No,1:No,,0.97
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, CNS leukemia,29,4,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, CNS leukemia,29,5,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, CNS leukemia,29,6,3,No,1:No,1:No,,0.925
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, CNS leukemia,29,7,3,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, CNS leukemia,30,0,2,No,1:No,1:No,,1
3030,2820141,Table 8,BaselineCharacteristic,xx, ;  ; N ; ,, CNS leukemia,30,1,3,No,1:No,1:No,,0.937
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, CNS leukemia,30,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, CNS leukemia,30,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, CNS leukemia,30,4,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, CNS leukemia,30,5,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, CNS leukemia,30,6,3,No,1:No,1:No,,0.925
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, CNS leukemia,30,7,3,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, CNS leukemia,31,0,2,No,1:No,1:No,,1
3030,2820141,Table 8,BaselineCharacteristic,x, ;  ; N ; ,, CNS leukemia,31,1,3,No,1:No,1:No,,0.99
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, CNS leukemia,31,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, CNS leukemia,31,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, CNS leukemia,31,4,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, CNS leukemia,31,5,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, CNS leukemia,31,6,3,No,1:No,1:No,,0.925
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, CNS leukemia,31,7,3,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,Down Syndrome, ;  ; Protocol ; ,None,None,32,0,24,No,1:No,1:No,,0.995
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; N ; ,Down Syndrome,None,32,1,43,No,1:No,1:No,,0.967
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,Down Syndrome,None,32,2,43,No,1:No,1:No,,0.97
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Down Syndrome,None,32,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,Down Syndrome,None,32,4,43,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,Down Syndrome,None,32,5,43,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Down Syndrome,None,32,6,43,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,Down Syndrome,None,32,7,43,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, Down Syndrome,33,0,2,No,1:No,1:No,,1
3030,2820141,Table 8,BaselineCharacteristic,xx, ;  ; N ; ,, Down Syndrome,33,1,3,No,1:No,1:No,,0.937
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Down Syndrome,33,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± xx.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Down Syndrome,33,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 8,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, Down Syndrome,33,4,3,No,1:No,1:No,,0.97
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Down Syndrome,33,5,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± xx.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Down Syndrome,33,6,3,No,1:No,1:No,,0.925
3030,2820141,Table 8,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, Down Syndrome,33,7,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, Down Syndrome,34,0,2,No,1:No,1:No,,1
3030,2820141,Table 8,BaselineCharacteristic,xxx, ;  ; N ; ,, Down Syndrome,34,1,3,No,1:No,1:No,,0.91
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Down Syndrome,34,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Down Syndrome,34,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, Down Syndrome,34,4,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Down Syndrome,34,5,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Down Syndrome,34,6,3,No,1:No,1:No,,0.925
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, Down Syndrome,34,7,3,No,1:No,1:No,,0.91
3030,2820141,Table 8,BaselineCharacteristic,DNA Index, ;  ; Protocol ; ,None,None,35,0,24,No,1:No,1:No,,0.995
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; N ; ,DNA Index,None,35,1,43,No,1:No,1:No,,0.967
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,DNA Index,None,35,2,43,No,1:No,1:No,,0.97
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,DNA Index,None,35,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,DNA Index,None,35,4,43,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,DNA Index,None,35,5,43,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,DNA Index,None,35,6,43,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,DNA Index,None,35,7,43,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, DNA Index,36,0,2,No,1:No,1:No,,1
3030,2820141,Table 8,BaselineCharacteristic,xx, ;  ; N ; ,, DNA Index,36,1,3,No,1:No,1:No,,0.937
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, DNA Index,36,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, DNA Index,36,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 8,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, DNA Index,36,4,3,No,1:No,1:No,,0.97
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, DNA Index,36,5,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, DNA Index,36,6,3,No,1:No,1:No,,0.925
3030,2820141,Table 8,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, DNA Index,36,7,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, DNA Index,37,0,2,No,1:No,1:No,,1
3030,2820141,Table 8,BaselineCharacteristic,xxx, ;  ; N ; ,, DNA Index,37,1,3,No,1:No,1:No,,0.91
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, DNA Index,37,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, DNA Index,37,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, DNA Index,37,4,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, DNA Index,37,5,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, DNA Index,37,6,3,No,1:No,1:No,,0.925
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, DNA Index,37,7,3,No,1:No,1:No,,0.91
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, DNA Index,38,0,2,No,1:No,1:No,,1
3030,2820141,Table 8,BaselineCharacteristic,xxx, ;  ; N ; ,, DNA Index,38,1,3,No,1:No,1:No,,0.91
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, DNA Index,38,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, DNA Index,38,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, DNA Index,38,4,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, DNA Index,38,5,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, DNA Index,38,6,3,No,1:No,1:No,,0.925
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, DNA Index,38,7,3,No,1:No,1:No,,0.91
3030,2820141,Table 8,BaselineCharacteristic,TEL/AMLx*, ;  ; Protocol ; ,None,None,39,0,24,No,1:No,1:No,,0.995
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; N ; ,TEL/AMLx*,None,39,1,43,No,1:No,1:No,,0.967
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,TEL/AMLx*,None,39,2,43,No,1:No,1:No,,0.97
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,TEL/AMLx*,None,39,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,TEL/AMLx*,None,39,4,43,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,TEL/AMLx*,None,39,5,43,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,TEL/AMLx*,None,39,6,43,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,TEL/AMLx*,None,39,7,43,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, TEL/AMLx*,40,0,2,No,1:No,1:No,,1
3030,2820141,Table 8,BaselineCharacteristic,xx, ;  ; N ; ,, TEL/AMLx*,40,1,3,No,1:No,1:No,,0.937
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, TEL/AMLx*,40,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, TEL/AMLx*,40,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 8,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, TEL/AMLx*,40,4,3,No,1:No,1:No,,0.97
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, TEL/AMLx*,40,5,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, TEL/AMLx*,40,6,3,No,1:No,1:No,,0.925
3030,2820141,Table 8,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, TEL/AMLx*,40,7,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, TEL/AMLx*,41,0,2,No,1:No,1:No,,1
3030,2820141,Table 8,BaselineCharacteristic,xxx, ;  ; N ; ,, TEL/AMLx*,41,1,3,No,1:No,1:No,,0.91
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, TEL/AMLx*,41,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, TEL/AMLx*,41,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, TEL/AMLx*,41,4,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, TEL/AMLx*,41,5,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, TEL/AMLx*,41,6,3,No,1:No,1:No,,0.925
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, TEL/AMLx*,41,7,3,No,1:No,1:No,,0.91
3030,2820141,Table 8,BaselineCharacteristic,t(x;xx), ;  ; Protocol ; ,None,None,42,0,24,No,1:No,1:No,,0.88
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; N ; ,t(x;xx),None,42,1,43,No,1:No,1:No,,0.875
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,t(x;xx),None,42,2,43,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,t(x;xx),None,42,3,43,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,t(x;xx),None,42,4,43,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,t(x;xx),None,42,5,43,No,1:No,1:No,,0.91
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,t(x;xx),None,42,6,43,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,t(x;xx),None,42,7,43,No,1:No,1:No,,0.88
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, t(x;xx),43,0,2,No,1:No,1:No,,0.915
3030,2820141,Table 8,BaselineCharacteristic,x, ;  ; N ; ,, t(x;xx),43,1,3,No,1:No,1:No,,0.901
3030,2820141,Table 8,BaselineCharacteristic,x.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, t(x;xx),43,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 8,BaselineCharacteristic,x.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, t(x;xx),43,3,3,No,1:No,1:No,,0.955
3030,2820141,Table 8,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, t(x;xx),43,4,3,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,x.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, t(x;xx),43,5,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,x.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, t(x;xx),43,6,3,No,1:No,1:No,,0.925
3030,2820141,Table 8,BaselineCharacteristic,x.xxxx,Overall Survival ± SE (%) ;  ; p-value ; ,, t(x;xx),43,7,3,No,1:No,1:No,,0.895
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, t(x;xx),44,0,2,No,1:No,1:No,,0.915
3030,2820141,Table 8,BaselineCharacteristic,xxx, ;  ; N ; ,, t(x;xx),44,1,3,No,1:No,1:No,,0.806
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, t(x;xx),44,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, t(x;xx),44,3,3,No,1:No,1:No,,0.955
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, t(x;xx),44,4,3,No,1:No,1:No,,0.935
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, t(x;xx),44,5,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, t(x;xx),44,6,3,No,1:No,1:No,,0.925
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, t(x;xx),44,7,3,No,1:No,1:No,,0.895
3030,2820141,Table 8,BaselineCharacteristic,MRD Day xx**, ;  ; Protocol ; ,None,None,45,0,24,No,1:No,1:No,,0.995
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; N ; ,MRD Day xx**,None,45,1,43,No,1:No,1:No,,0.967
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,MRD Day xx**,None,45,2,43,No,1:No,1:No,,0.97
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,MRD Day xx**,None,45,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,MRD Day xx**,None,45,4,43,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,MRD Day xx**,None,45,5,43,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,MRD Day xx**,None,45,6,43,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,MRD Day xx**,None,45,7,43,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, MRD Day xx**,46,0,2,No,1:No,1:No,,1
3030,2820141,Table 8,BaselineCharacteristic,xxx, ;  ; N ; ,, MRD Day xx**,46,1,3,No,1:No,1:No,,0.91
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, MRD Day xx**,46,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, MRD Day xx**,46,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 8,BaselineCharacteristic,<x.xxxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, MRD Day xx**,46,4,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, MRD Day xx**,46,5,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, MRD Day xx**,46,6,3,No,1:No,1:No,,0.925
3030,2820141,Table 8,BaselineCharacteristic,<x.xxxx,Overall Survival ± SE (%) ;  ; p-value ; ,, MRD Day xx**,46,7,3,No,1:No,1:No,,0.91
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, MRD Day xx**,47,0,2,No,1:No,1:No,,1
3030,2820141,Table 8,BaselineCharacteristic,xx, ;  ; N ; ,, MRD Day xx**,47,1,3,No,1:No,1:No,,0.937
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, MRD Day xx**,47,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, MRD Day xx**,47,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, MRD Day xx**,47,4,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, MRD Day xx**,47,5,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, MRD Day xx**,47,6,3,No,1:No,1:No,,0.925
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, MRD Day xx**,47,7,3,No,1:No,1:No,,0.91
3030,2820141,Table 8,BaselineCharacteristic,DFCI Risk Group, ;  ; Protocol ; ,None,None,48,0,24,No,1:No,1:No,,0.995
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; N ; ,DFCI Risk Group,None,48,1,43,No,1:No,1:No,,0.967
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,DFCI Risk Group,None,48,2,43,No,1:No,1:No,,0.97
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,DFCI Risk Group,None,48,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,DFCI Risk Group,None,48,4,43,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,DFCI Risk Group,None,48,5,43,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,DFCI Risk Group,None,48,6,43,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,DFCI Risk Group,None,48,7,43,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, DFCI Risk Group,49,0,2,No,1:No,1:No,,1
3030,2820141,Table 8,BaselineCharacteristic,xxx, ;  ; N ; ,, DFCI Risk Group,49,1,3,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, DFCI Risk Group,49,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, DFCI Risk Group,49,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 8,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, DFCI Risk Group,49,4,3,No,1:No,1:No,,0.97
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, DFCI Risk Group,49,5,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, DFCI Risk Group,49,6,3,No,1:No,1:No,,0.925
3030,2820141,Table 8,BaselineCharacteristic,x.xxxx,Overall Survival ± SE (%) ;  ; p-value ; ,, DFCI Risk Group,49,7,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, DFCI Risk Group,50,0,2,No,1:No,1:No,,1
3030,2820141,Table 8,BaselineCharacteristic,xxx, ;  ; N ; ,, DFCI Risk Group,50,1,3,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, DFCI Risk Group,50,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, DFCI Risk Group,50,3,3,No,1:No,1:No,,0.945
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, DFCI Risk Group,50,4,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, DFCI Risk Group,50,5,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, DFCI Risk Group,50,6,3,No,1:No,1:No,,0.925
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, DFCI Risk Group,50,7,3,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,Randomizations, ;  ; Protocol ; ,None,None,51,0,2,No,1:No,1:No,,1
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; N ; ,None,None,51,1,3,No,1:No,1:No,,0.98
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,None,None,51,2,3,No,1:No,1:No,,0.97
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,None,None,51,3,3,No,1:No,1:No,,0.97
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,None,None,51,4,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,None,None,51,5,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,None,None,51,6,3,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,None,None,51,7,3,No,1:No,1:No,,0.91
3030,2820141,Table 8,BaselineCharacteristic,Asparaginase, ;  ; Protocol ; ,None,None,52,0,24,No,1:No,1:No,,0.995
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; N ; ,Asparaginase,None,52,1,43,No,1:No,1:No,,0.967
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,Asparaginase,None,52,2,43,No,1:No,1:No,,0.97
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Asparaginase,None,52,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,Asparaginase,None,52,4,43,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,Asparaginase,None,52,5,43,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Asparaginase,None,52,6,43,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,Asparaginase,None,52,7,43,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, Randomizations Asparaginase,53,0,2,No,1:No,1:No,,1
3030,2820141,Table 8,BaselineCharacteristic,xxx, ;  ; N ; ,, Randomizations Asparaginase,53,1,3,No,1:No,1:No,,0.91
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Randomizations Asparaginase,53,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Randomizations Asparaginase,53,3,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, Randomizations Asparaginase,53,4,3,No,1:No,1:No,,0.97
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Randomizations Asparaginase,53,5,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Randomizations Asparaginase,53,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, Randomizations Asparaginase,53,7,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, Randomizations Asparaginase,54,0,2,No,1:No,1:No,,1
3030,2820141,Table 8,BaselineCharacteristic,xxx, ;  ; N ; ,, Randomizations Asparaginase,54,1,3,No,1:No,1:No,,0.91
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Randomizations Asparaginase,54,2,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Randomizations Asparaginase,54,3,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, Randomizations Asparaginase,54,4,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Randomizations Asparaginase,54,5,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Randomizations Asparaginase,54,6,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, Randomizations Asparaginase,54,7,3,No,1:No,1:No,,0.91
3030,2820141,Table 8,BaselineCharacteristic,Doxurubicin (HR only), ;  ; Protocol ; ,None,None,55,0,24,No,1:No,1:No,,0.995
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; N ; ,Doxurubicin (HR only),None,55,1,43,No,1:No,1:No,,0.967
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,Doxurubicin (HR only),None,55,2,43,No,1:No,1:No,,0.97
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,Doxurubicin (HR only),None,55,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,Doxurubicin (HR only),None,55,4,43,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,Doxurubicin (HR only),None,55,5,43,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,Doxurubicin (HR only),None,55,6,43,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,Doxurubicin (HR only),None,55,7,43,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, Randomizations Doxurubicin (HR only),56,0,2,No,1:No,1:No,,1
3030,2820141,Table 8,BaselineCharacteristic,xxx, ;  ; N ; ,, Randomizations Doxurubicin (HR only),56,1,3,No,1:No,1:No,,0.91
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Randomizations Doxurubicin (HR only),56,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Randomizations Doxurubicin (HR only),56,3,3,No,1:No,1:No,,0.96
3030,2820141,Table 8,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, Randomizations Doxurubicin (HR only),56,4,3,No,1:No,1:No,,0.97
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Randomizations Doxurubicin (HR only),56,5,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Randomizations Doxurubicin (HR only),56,6,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, Randomizations Doxurubicin (HR only),56,7,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, Randomizations Doxurubicin (HR only),57,0,2,No,1:No,1:No,,1
3030,2820141,Table 8,BaselineCharacteristic,xxx, ;  ; N ; ,, Randomizations Doxurubicin (HR only),57,1,3,No,1:No,1:No,,0.91
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Randomizations Doxurubicin (HR only),57,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Randomizations Doxurubicin (HR only),57,3,3,No,1:No,1:No,,0.96
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, Randomizations Doxurubicin (HR only),57,4,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Randomizations Doxurubicin (HR only),57,5,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Randomizations Doxurubicin (HR only),57,6,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, Randomizations Doxurubicin (HR only),57,7,3,No,1:No,1:No,,0.92
3030,2820141,Table 8,BaselineCharacteristic,CNS-directed therapy(SR only), ;  ; Protocol ; ,None,None,58,0,24,No,1:No,1:No,,0.995
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; N ; ,CNS-directed therapy(SR only),None,58,1,43,No,1:No,1:No,,0.977
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,CNS-directed therapy(SR only),None,58,2,43,No,1:No,1:No,,0.98
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,CNS-directed therapy(SR only),None,58,3,43,No,1:No,1:No,,0.98
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,CNS-directed therapy(SR only),None,58,4,43,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; x-yr OS ; ,CNS-directed therapy(SR only),None,58,5,43,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,CNS-directed therapy(SR only),None,58,6,43,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,CNS-directed therapy(SR only),None,58,7,43,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, Randomizations CNS-directed therapy(SR only),59,0,2,No,1:No,1:No,,1
3030,2820141,Table 8,BaselineCharacteristic,xx, ;  ; N ; ,, Randomizations CNS-directed therapy(SR only),59,1,3,No,1:No,1:No,,0.956
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Randomizations CNS-directed therapy(SR only),59,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Randomizations CNS-directed therapy(SR only),59,3,3,No,1:No,1:No,,0.96
3030,2820141,Table 8,BaselineCharacteristic,x.xxx,Event-free Survival ± SE (%) ;  ; p-value ; ,, Randomizations CNS-directed therapy(SR only),59,4,3,No,1:No,1:No,,0.97
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Randomizations CNS-directed therapy(SR only),59,5,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Randomizations CNS-directed therapy(SR only),59,6,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,x.xxx,Overall Survival ± SE (%) ;  ; p-value ; ,, Randomizations CNS-directed therapy(SR only),59,7,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,, ;  ; Protocol ; ,, Randomizations CNS-directed therapy(SR only),60,0,2,No,1:No,1:No,,1
3030,2820141,Table 8,BaselineCharacteristic,xx, ;  ; N ; ,, Randomizations CNS-directed therapy(SR only),60,1,3,No,1:No,1:No,,0.956
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; x-yr EFS ; ,, Randomizations CNS-directed therapy(SR only),60,2,3,No,1:No,1:No,,0.96
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Event-free Survival ± SE (%) ;  ; xx-yr EFS ; ,, Randomizations CNS-directed therapy(SR only),60,3,3,No,1:No,1:No,,0.96
3030,2820141,Table 8,BaselineCharacteristic,,Event-free Survival ± SE (%) ;  ; p-value ; ,, Randomizations CNS-directed therapy(SR only),60,4,3,No,1:No,1:No,,0.95
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; x-yr OS ; ,, Randomizations CNS-directed therapy(SR only),60,5,3,No,1:No,1:No,,0.93
3030,2820141,Table 8,BaselineCharacteristic,xx.x ± x.x,Overall Survival ± SE (%) ;  ; xx-yr OS ; ,, Randomizations CNS-directed therapy(SR only),60,6,3,No,1:No,1:No,,0.94
3030,2820141,Table 8,BaselineCharacteristic,,Overall Survival ± SE (%) ;  ; p-value ; ,, Randomizations CNS-directed therapy(SR only),60,7,3,No,1:No,1:No,,0.93
3044,2822223,Table 1,BaselineCharacteristic,Healthy donors,,None,None,0,0,12,No,1:No,1:No,,0.885
3044,2822223,Table 1,BaselineCharacteristic,Healthy donors,,Healthy donors,None,0,1,1,No,1:No,1:No,,0.902
3044,2822223,Table 1,BaselineCharacteristic,Patients,,Healthy donors,None,0,2,1,No,1:No,1:No,,0.91
3044,2822223,Table 1,BaselineCharacteristic,Patients,,Healthy donors,None,0,3,1,No,1:No,1:No,,0.91
3044,2822223,Table 1,BaselineCharacteristic,Patients,,Healthy donors,None,0,4,1,No,1:No,1:No,,0.91
3044,2822223,Table 1,BaselineCharacteristic,Patients,,Healthy donors,None,0,5,1,No,1:No,1:No,,0.931
3044,2822223,Table 1,BaselineCharacteristic,Number,Healthy donors ; ,None,None,1,0,12,No,1:No,1:No,,0.878
3044,2822223,Table 1,BaselineCharacteristic,Age (years),Healthy donors ; ,Number,None,1,1,1,No,1:No,1:No,,0.564
3044,2822223,Table 1,BaselineCharacteristic,Number,Patients ; ,Number,None,1,2,1,No,1:No,1:No,,0.896
3044,2822223,Table 1,BaselineCharacteristic,Age (years),Patients ; ,Number,None,1,3,1,No,1:No,1:No,,0.576
3044,2822223,Table 1,BaselineCharacteristic,Tumour stage,Patients ; ,Number,None,1,4,1,No,1:No,1:No,,0.906
3044,2822223,Table 1,BaselineCharacteristic,Percentage of irradiated bone marrow volume,Patients ; ,Number,None,1,5,1,No,1:No,1:No,,0.918
3044,2822223,Table 1,BaselineCharacteristic,x,Healthy donors ; Number ; ,x,None,2,0,2,No,1:No,1:No,,0.905
3044,2822223,Table 1,BaselineCharacteristic,x,Patients ; Number ; ,x,None,2,2,3,No,1:No,1:No,,0.92
3044,2822223,Table 1,BaselineCharacteristic,Txb Nx Mx,Patients ; Tumour stage ; ,x,None,2,4,3,No,1:No,1:No,,0.91
3044,2822223,Table 1,BaselineCharacteristic,xx,Patients ; Percentage of irradiated bone marrow volume ; ,x,None,2,5,3,No,1:No,1:No,,0.746
3044,2822223,Table 1,BaselineCharacteristic,x,Healthy donors ; Number ; ,x,None,3,0,2,No,1:No,1:No,,0.915
3044,2822223,Table 1,BaselineCharacteristic,x,Patients ; Number ; ,x,None,3,2,3,No,1:No,1:No,,0.94
3044,2822223,Table 1,BaselineCharacteristic,Txc Nx Mx,Patients ; Tumour stage ; ,x,None,3,4,3,No,1:No,1:No,,0.93
3044,2822223,Table 1,BaselineCharacteristic,xx,Patients ; Percentage of irradiated bone marrow volume ; ,x,None,3,5,3,No,1:No,1:No,,0.75
3044,2822223,Table 1,BaselineCharacteristic,x,Healthy donors ; Number ; ,x,None,4,0,2,No,1:No,1:No,,0.935
3044,2822223,Table 1,BaselineCharacteristic,x,Patients ; Number ; ,x,None,4,2,3,No,1:No,1:No,,0.94
3044,2822223,Table 1,BaselineCharacteristic,Txc Nx Mx,Patients ; Tumour stage ; ,x,None,4,4,3,No,1:No,1:No,,0.93
3044,2822223,Table 1,BaselineCharacteristic,xx,Patients ; Percentage of irradiated bone marrow volume ; ,x,None,4,5,3,No,1:No,1:No,,0.83
3044,2822223,Table 1,BaselineCharacteristic,x,Healthy donors ; Number ; ,x,None,5,0,2,No,1:No,1:No,,0.933
3044,2822223,Table 1,BaselineCharacteristic,x,Patients ; Number ; ,x,None,5,2,3,No,1:No,1:No,,0.94
3044,2822223,Table 1,BaselineCharacteristic,Txc Nx Mx,Patients ; Tumour stage ; ,x,None,5,4,3,No,1:No,1:No,,0.93
3044,2822223,Table 1,BaselineCharacteristic,xx,Patients ; Percentage of irradiated bone marrow volume ; ,x,None,5,5,3,No,1:No,1:No,,0.81
3044,2822223,Table 1,BaselineCharacteristic,x,Healthy donors ; Number ; ,x,None,6,0,2,No,1:No,1:No,,0.943
3044,2822223,Table 1,BaselineCharacteristic,x,Patients ; Number ; ,x,None,6,2,3,No,1:No,1:No,,0.96
3044,2822223,Table 1,BaselineCharacteristic,xx,Patients ; Age (years) ; ,x,None,6,3,3,No,1:No,1:No,,0.5
3044,2822223,Table 1,BaselineCharacteristic,Txc Nx Mx,Patients ; Tumour stage ; ,x,None,6,4,3,No,1:No,1:No,,0.94
3044,2822223,Table 1,BaselineCharacteristic,xx,Patients ; Percentage of irradiated bone marrow volume ; ,x,None,6,5,3,No,1:No,1:No,,0.82
3044,2822223,Table 1,BaselineCharacteristic,x,Healthy donors ; Number ; ,x,None,7,0,2,No,1:No,1:No,,0.943
3044,2822223,Table 1,BaselineCharacteristic,x,Patients ; Number ; ,x,None,7,2,3,No,1:No,1:No,,0.97
3044,2822223,Table 1,BaselineCharacteristic,xx,Patients ; Age (years) ; ,x,None,7,3,3,No,1:No,1:No,,0.52
3044,2822223,Table 1,BaselineCharacteristic,Txc Nx Mx,Patients ; Tumour stage ; ,x,None,7,4,3,No,1:No,1:No,,0.96
3044,2822223,Table 1,BaselineCharacteristic,xx,Patients ; Percentage of irradiated bone marrow volume ; ,x,None,7,5,3,No,1:No,1:No,,0.86
3044,2822223,Table 1,BaselineCharacteristic,x,Healthy donors ; Number ; ,x,None,8,0,2,No,1:No,1:No,,0.942
3044,2822223,Table 1,BaselineCharacteristic,xx,Healthy donors ; Age (years) ; ,x,None,8,1,3,No,1:No,1:No,,0.52
3044,2822223,Table 1,BaselineCharacteristic,x,Patients ; Number ; ,x,None,8,2,3,No,1:No,1:No,,0.98
3044,2822223,Table 1,BaselineCharacteristic,xx,Patients ; Age (years) ; ,x,None,8,3,3,No,1:No,1:No,,0.57
3044,2822223,Table 1,BaselineCharacteristic,Txc Nx Mx,Patients ; Tumour stage ; ,x,None,8,4,3,No,1:No,1:No,,0.97
3044,2822223,Table 1,BaselineCharacteristic,xx,Patients ; Percentage of irradiated bone marrow volume ; ,x,None,8,5,3,No,1:No,1:No,,0.88
3044,2822223,Table 1,BaselineCharacteristic,x,Healthy donors ; Number ; ,x,None,9,0,2,No,1:No,1:No,,0.952
3044,2822223,Table 1,BaselineCharacteristic,xx,Healthy donors ; Age (years) ; ,x,None,9,1,3,No,1:No,1:No,,0.55
3044,2822223,Table 1,BaselineCharacteristic,x,Patients ; Number ; ,x,None,9,2,3,No,1:No,1:No,,0.99
3044,2822223,Table 1,BaselineCharacteristic,xx,Patients ; Age (years) ; ,x,None,9,3,3,No,1:No,1:No,,0.6
3044,2822223,Table 1,BaselineCharacteristic,Txa Nx Mx,Patients ; Tumour stage ; ,x,None,9,4,3,No,1:No,1:No,,0.99
3044,2822223,Table 1,BaselineCharacteristic,xx,Patients ; Percentage of irradiated bone marrow volume ; ,x,None,9,5,3,No,1:No,1:No,,0.91
3044,2822223,Table 1,BaselineCharacteristic,x,Healthy donors ; Number ; ,x,None,10,0,2,No,1:No,1:No,,0.952
3044,2822223,Table 1,BaselineCharacteristic,xx,Healthy donors ; Age (years) ; ,x,None,10,1,3,No,1:No,1:No,,0.6
3044,2822223,Table 1,BaselineCharacteristic,x,Patients ; Number ; ,x,None,10,2,3,No,1:No,1:No,,1
3044,2822223,Table 1,BaselineCharacteristic,xx,Patients ; Age (years) ; ,x,None,10,3,3,No,1:No,1:No,,0.64
3044,2822223,Table 1,BaselineCharacteristic,Txa pNx Mx,Patients ; Tumour stage ; ,x,None,10,4,3,No,1:No,1:No,,1
3044,2822223,Table 1,BaselineCharacteristic,xx,Patients ; Percentage of irradiated bone marrow volume ; ,x,None,10,5,3,No,1:No,1:No,,0.94
3044,2822223,Table 1,BaselineCharacteristic,xx,Healthy donors ; Number ; ,xx,None,11,0,2,No,1:No,1:No,,0.905
3044,2822223,Table 1,BaselineCharacteristic,xx,Healthy donors ; Age (years) ; ,xx,None,11,1,3,No,1:No,1:No,,0.656
3044,2822223,Table 1,BaselineCharacteristic,xx,Patients ; Number ; ,xx,None,11,2,3,No,1:No,1:No,,0.911
3044,2822223,Table 1,BaselineCharacteristic,xx,Patients ; Age (years) ; ,xx,None,11,3,3,No,1:No,1:No,,0.706
3044,2822223,Table 1,BaselineCharacteristic,Txb Nx Mx,Patients ; Tumour stage ; ,xx,None,11,4,3,No,1:No,1:No,,0.94
3044,2822223,Table 1,BaselineCharacteristic,xx,Patients ; Percentage of irradiated bone marrow volume ; ,xx,None,11,5,3,No,1:No,1:No,,0.946
3085,2828459,Table 1,BaselineCharacteristic,Study population characteristics,,None,None,0,0,12,No,1:No,1:No,,0.825
3085,2828459,Table 1,BaselineCharacteristic,mean (SD),,Study population characteristics,None,0,1,1,No,1:No,1:No,,0.638
3085,2828459,Table 1,BaselineCharacteristic,Gestational age (weeks),Study population characteristics ; ,Gestational age (weeks),None,1,0,2,No,1:No,1:No,,0.706
3085,2828459,Table 1,BaselineCharacteristic,Weight (g),Study population characteristics ; ,Weight (g),None,2,0,2,No,1:No,1:No,,0.86
3085,2828459,Table 1,BaselineCharacteristic,xxxx (xxx),mean (SD) ; ,Weight (g),None,2,1,3,No,1:No,1:No,,0.58
3085,2828459,Table 1,BaselineCharacteristic,Length (cm),Study population characteristics ; ,Length (cm),None,3,0,2,No,1:No,1:No,,0.89
3085,2828459,Table 1,BaselineCharacteristic,Head circumference (cm),Study population characteristics ; ,Head circumference (cm),None,4,0,2,No,1:No,1:No,,0.9
3085,2828459,Table 1,BaselineCharacteristic,Apgar score at x minute,Study population characteristics ; ,Apgar score at x minute,None,5,0,2,No,1:No,1:No,,0.912
3085,2828459,Table 1,BaselineCharacteristic,x (x),mean (SD) ; ,Apgar score at x minute,None,5,1,3,No,1:No,1:No,,0.66
3085,2828459,Table 1,BaselineCharacteristic,Apgar score at x minutes,Study population characteristics ; ,Apgar score at x minutes,None,6,0,2,No,1:No,1:No,,0.932
3085,2828459,Table 1,BaselineCharacteristic,x (x),mean (SD) ; ,Apgar score at x minutes,None,6,1,3,No,1:No,1:No,,0.67
3088,2829127,Table 1,BaselineCharacteristic,No,,None,None,0,0,12,No,1:No,1:No,,0.905
3088,2829127,Table 1,BaselineCharacteristic,Age,,No,None,0,1,1,No,1:No,1:No,,0.903
3088,2829127,Table 1,BaselineCharacteristic,Sex,,No,None,0,2,1,No,1:No,1:No,,0.903
3088,2829127,Table 1,BaselineCharacteristic,Symptom,,No,None,0,3,1,No,1:No,1:No,,0.903
3088,2829127,Table 1,BaselineCharacteristic,Diagnosis,,No,None,0,4,1,No,1:No,1:No,,0.913
3088,2829127,Table 1,BaselineCharacteristic,Operation name,,No,None,0,5,1,No,1:No,1:No,,0.935
3088,2829127,Table 1,BaselineCharacteristic,Occlusion time (min),,No,None,0,6,1,No,1:No,1:No,,0.935
3088,2829127,Table 1,BaselineCharacteristic,Intraop. sonographic patency,,No,None,0,7,1,No,1:No,1:No,,0.945
3088,2829127,Table 1,BaselineCharacteristic,Postop. CTA patency(x days),,No,None,0,8,1,No,1:No,1:No,,0.945
3088,2829127,Table 1,BaselineCharacteristic,Peioperative complication,,No,None,0,9,1,No,1:No,1:No,,0.945
3088,2829127,Table 1,BaselineCharacteristic,x,No ; ,x,None,1,0,2,No,1:No,1:No,,0.915
3088,2829127,Table 1,BaselineCharacteristic,xx,Age ; ,x,None,1,1,3,No,1:No,1:No,,0.612
3088,2829127,Table 1,BaselineCharacteristic,F,Sex ; ,x,None,1,2,3,No,1:No,1:No,,0.9
3088,2829127,Table 1,BaselineCharacteristic,Rt. Arm monoparesis,Symptom ; ,x,None,1,3,3,No,1:No,1:No,,0.89
3088,2829127,Table 1,BaselineCharacteristic,Lt ICA stenosis,Diagnosis ; ,x,None,1,4,3,No,1:No,1:No,,0.88
3088,2829127,Table 1,BaselineCharacteristic,EIAB,Operation name ; ,x,None,1,5,3,No,1:No,1:No,,0.91
3088,2829127,Table 1,BaselineCharacteristic,xx,Occlusion time (min) ; ,x,None,1,6,3,No,1:No,1:No,,0.706
3088,2829127,Table 1,BaselineCharacteristic,Good,Intraop. sonographic patency ; ,x,None,1,7,3,No,1:No,1:No,,0.9
3088,2829127,Table 1,BaselineCharacteristic,Good,Postop. CTA patency(x days) ; ,x,None,1,8,3,No,1:No,1:No,,0.92
3088,2829127,Table 1,BaselineCharacteristic,,Peioperative complication ; ,x,None,1,9,3,No,1:No,1:No,,0.9
3088,2829127,Table 1,BaselineCharacteristic,x,No ; ,x,None,2,0,2,No,1:No,1:No,,0.935
3088,2829127,Table 1,BaselineCharacteristic,xx,Age ; ,x,None,2,1,3,No,1:No,1:No,,0.632
3088,2829127,Table 1,BaselineCharacteristic,M,Sex ; ,x,None,2,2,3,No,1:No,1:No,,0.92
3088,2829127,Table 1,BaselineCharacteristic,Lt. hemiparesis,Symptom ; ,x,None,2,3,3,No,1:No,1:No,,0.91
3088,2829127,Table 1,BaselineCharacteristic,Rt MCA total occlusion,Diagnosis ; ,x,None,2,4,3,No,1:No,1:No,,0.85
3088,2829127,Table 1,BaselineCharacteristic,EIAB,Operation name ; ,x,None,2,5,3,No,1:No,1:No,,0.92
3088,2829127,Table 1,BaselineCharacteristic,xx,Occlusion time (min) ; ,x,None,2,6,3,No,1:No,1:No,,0.736
3088,2829127,Table 1,BaselineCharacteristic,Good,Intraop. sonographic patency ; ,x,None,2,7,3,No,1:No,1:No,,0.91
3088,2829127,Table 1,BaselineCharacteristic,Good,Postop. CTA patency(x days) ; ,x,None,2,8,3,No,1:No,1:No,,0.93
3088,2829127,Table 1,BaselineCharacteristic,Subdural hygroma,Peioperative complication ; ,x,None,2,9,3,No,1:No,1:No,,0.91
3088,2829127,Table 1,BaselineCharacteristic,x,No ; ,x,None,3,0,2,No,1:No,1:No,,0.945
3088,2829127,Table 1,BaselineCharacteristic,xx,Age ; ,x,None,3,1,3,No,1:No,1:No,,0.646
3088,2829127,Table 1,BaselineCharacteristic,M,Sex ; ,x,None,3,2,3,No,1:No,1:No,,0.94
3088,2829127,Table 1,BaselineCharacteristic,Rt. hemiparesis,Symptom ; ,x,None,3,3,3,No,1:No,1:No,,0.93
3088,2829127,Table 1,BaselineCharacteristic,Lt ICA total occlusion,Diagnosis ; ,x,None,3,4,3,No,1:No,1:No,,0.87
3088,2829127,Table 1,BaselineCharacteristic,EIAB,Operation name ; ,x,None,3,5,3,No,1:No,1:No,,0.94
3088,2829127,Table 1,BaselineCharacteristic,xx,Occlusion time (min) ; ,x,None,3,6,3,No,1:No,1:No,,0.74
3088,2829127,Table 1,BaselineCharacteristic,Good,Intraop. sonographic patency ; ,x,None,3,7,3,No,1:No,1:No,,0.93
3088,2829127,Table 1,BaselineCharacteristic,Good,Postop. CTA patency(x days) ; ,x,None,3,8,3,No,1:No,1:No,,0.95
3088,2829127,Table 1,BaselineCharacteristic,,Peioperative complication ; ,x,None,3,9,3,No,1:No,1:No,,0.93
3088,2829127,Table 1,BaselineCharacteristic,x,No ; ,x,None,4,0,2,No,1:No,1:No,,0.965
3088,2829127,Table 1,BaselineCharacteristic,xx,Age ; ,x,None,4,1,3,No,1:No,1:No,,0.726
3088,2829127,Table 1,BaselineCharacteristic,M,Sex ; ,x,None,4,2,3,No,1:No,1:No,,0.94
3088,2829127,Table 1,BaselineCharacteristic,Lt. hemiparesis,Symptom ; ,x,None,4,3,3,No,1:No,1:No,,0.93
3088,2829127,Table 1,BaselineCharacteristic,Rt ICA total occlusion,Diagnosis ; ,x,None,4,4,3,No,1:No,1:No,,0.87
3088,2829127,Table 1,BaselineCharacteristic,EIAB,Operation name ; ,x,None,4,5,3,No,1:No,1:No,,0.93
3088,2829127,Table 1,BaselineCharacteristic,xx,Occlusion time (min) ; ,x,None,4,6,3,No,1:No,1:No,,0.82
3088,2829127,Table 1,BaselineCharacteristic,Good,Intraop. sonographic patency ; ,x,None,4,7,3,No,1:No,1:No,,0.92
3088,2829127,Table 1,BaselineCharacteristic,Good,Postop. CTA patency(x days) ; ,x,None,4,8,3,No,1:No,1:No,,0.94
3088,2829127,Table 1,BaselineCharacteristic,,Peioperative complication ; ,x,None,4,9,3,No,1:No,1:No,,0.92
3088,2829127,Table 1,BaselineCharacteristic,x,No ; ,x,None,5,0,2,No,1:No,1:No,,0.963
3088,2829127,Table 1,BaselineCharacteristic,xx,Age ; ,x,None,5,1,3,No,1:No,1:No,,0.726
3088,2829127,Table 1,BaselineCharacteristic,M,Sex ; ,x,None,5,2,3,No,1:No,1:No,,0.94
3088,2829127,Table 1,BaselineCharacteristic,Lt. hemiparesis,Symptom ; ,x,None,5,3,3,No,1:No,1:No,,0.93
3088,2829127,Table 1,BaselineCharacteristic,Rt ICA total occlusion,Diagnosis ; ,x,None,5,4,3,No,1:No,1:No,,0.87
3088,2829127,Table 1,BaselineCharacteristic,EIAB,Operation name ; ,x,None,5,5,3,No,1:No,1:No,,0.92
3088,2829127,Table 1,BaselineCharacteristic,xx,Occlusion time (min) ; ,x,None,5,6,3,No,1:No,1:No,,0.8
3088,2829127,Table 1,BaselineCharacteristic,Good,Intraop. sonographic patency ; ,x,None,5,7,3,No,1:No,1:No,,0.91
3088,2829127,Table 1,BaselineCharacteristic,Good,Postop. CTA patency(x days) ; ,x,None,5,8,3,No,1:No,1:No,,0.93
3088,2829127,Table 1,BaselineCharacteristic,Chornic subdural hemorrahge,Peioperative complication ; ,x,None,5,9,3,No,1:No,1:No,,0.91
3088,2829127,Table 1,BaselineCharacteristic,x,No ; ,x,None,6,0,2,No,1:No,1:No,,0.973
3088,2829127,Table 1,BaselineCharacteristic,xx,Age ; ,x,None,6,1,3,No,1:No,1:No,,0.746
3088,2829127,Table 1,BaselineCharacteristic,F,Sex ; ,x,None,6,2,3,No,1:No,1:No,,0.96
3088,2829127,Table 1,BaselineCharacteristic,Rt. hemiparesis,Symptom ; ,x,None,6,3,3,No,1:No,1:No,,0.95
3088,2829127,Table 1,BaselineCharacteristic,Moyamoya disease,Diagnosis ; ,x,None,6,4,3,No,1:No,1:No,,0.94
3088,2829127,Table 1,BaselineCharacteristic,EIAB + EMS,Operation name ; ,x,None,6,5,3,No,1:No,1:No,,0.94
3088,2829127,Table 1,BaselineCharacteristic,xx,Occlusion time (min) ; ,x,None,6,6,3,No,1:No,1:No,,0.81
3088,2829127,Table 1,BaselineCharacteristic,Good,Intraop. sonographic patency ; ,x,None,6,7,3,No,1:No,1:No,,0.93
3088,2829127,Table 1,BaselineCharacteristic,Good,Postop. CTA patency(x days) ; ,x,None,6,8,3,No,1:No,1:No,,0.95
3088,2829127,Table 1,BaselineCharacteristic,,Peioperative complication ; ,x,None,6,9,3,No,1:No,1:No,,0.93
3088,2829127,Table 1,BaselineCharacteristic,x,No ; ,x,None,7,0,2,No,1:No,1:No,,0.973
3088,2829127,Table 1,BaselineCharacteristic,xx,Age ; ,x,None,7,1,3,No,1:No,1:No,,0.786
3088,2829127,Table 1,BaselineCharacteristic,M,Sex ; ,x,None,7,2,3,No,1:No,1:No,,0.97
3088,2829127,Table 1,BaselineCharacteristic,Dizziness,Symptom ; ,x,None,7,3,3,No,1:No,1:No,,0.96
3088,2829127,Table 1,BaselineCharacteristic,Rt MCA total occlusion,Diagnosis ; ,x,None,7,4,3,No,1:No,1:No,,0.9
3088,2829127,Table 1,BaselineCharacteristic,EIAB,Operation name ; ,x,None,7,5,3,No,1:No,1:No,,0.95
3088,2829127,Table 1,BaselineCharacteristic,xx,Occlusion time (min) ; ,x,None,7,6,3,No,1:No,1:No,,0.87
3088,2829127,Table 1,BaselineCharacteristic,Good,Intraop. sonographic patency ; ,x,None,7,7,3,No,1:No,1:No,,0.95
3088,2829127,Table 1,BaselineCharacteristic,Good,Postop. CTA patency(x days) ; ,x,None,7,8,3,No,1:No,1:No,,0.97
3088,2829127,Table 1,BaselineCharacteristic,,Peioperative complication ; ,x,None,7,9,3,No,1:No,1:No,,0.96
3088,2829127,Table 1,BaselineCharacteristic,x,No ; ,x,None,8,0,2,No,1:No,1:No,,0.972
3088,2829127,Table 1,BaselineCharacteristic,xx,Age ; ,x,None,8,1,3,No,1:No,1:No,,0.806
3088,2829127,Table 1,BaselineCharacteristic,M,Sex ; ,x,None,8,2,3,No,1:No,1:No,,0.98
3088,2829127,Table 1,BaselineCharacteristic,Rt. hemiparesis,Symptom ; ,x,None,8,3,3,No,1:No,1:No,,0.97
3088,2829127,Table 1,BaselineCharacteristic,Lt MCA stenosis,Diagnosis ; ,x,None,8,4,3,No,1:No,1:No,,0.97
3088,2829127,Table 1,BaselineCharacteristic,EIAB,Operation name ; ,x,None,8,5,3,No,1:No,1:No,,0.97
3088,2829127,Table 1,BaselineCharacteristic,xx,Occlusion time (min) ; ,x,None,8,6,3,No,1:No,1:No,,0.89
3088,2829127,Table 1,BaselineCharacteristic,Good,Intraop. sonographic patency ; ,x,None,8,7,3,No,1:No,1:No,,0.97
3088,2829127,Table 1,BaselineCharacteristic,Good,Postop. CTA patency(x days) ; ,x,None,8,8,3,No,1:No,1:No,,0.99
3088,2829127,Table 1,BaselineCharacteristic,,Peioperative complication ; ,x,None,8,9,3,No,1:No,1:No,,0.98
3088,2829127,Table 1,BaselineCharacteristic,x,No ; ,x,None,9,0,2,No,1:No,1:No,,0.982
3088,2829127,Table 1,BaselineCharacteristic,xx,Age ; ,x,None,9,1,3,No,1:No,1:No,,0.846
3088,2829127,Table 1,BaselineCharacteristic,M,Sex ; ,x,None,9,2,3,No,1:No,1:No,,0.99
3088,2829127,Table 1,BaselineCharacteristic,Rt. hemiparesis,Symptom ; ,x,None,9,3,3,No,1:No,1:No,,0.99
3088,2829127,Table 1,BaselineCharacteristic,Moyamoya disease,Diagnosis ; ,x,None,9,4,3,No,1:No,1:No,,0.99
3088,2829127,Table 1,BaselineCharacteristic,EIAB + EMS,Operation name ; ,x,None,9,5,3,No,1:No,1:No,,0.99
3088,2829127,Table 1,BaselineCharacteristic,xx,Occlusion time (min) ; ,x,None,9,6,3,No,1:No,1:No,,0.92
3088,2829127,Table 1,BaselineCharacteristic,Good,Intraop. sonographic patency ; ,x,None,9,7,3,No,1:No,1:No,,0.99
3088,2829127,Table 1,BaselineCharacteristic,Good,Postop. CTA patency(x days) ; ,x,None,9,8,3,No,1:No,1:No,,1
3088,2829127,Table 1,BaselineCharacteristic,,Peioperative complication ; ,x,None,9,9,3,No,1:No,1:No,,1
3088,2829127,Table 1,BaselineCharacteristic,xx,No ; ,xx,None,10,0,2,No,1:No,1:No,,0.935
3088,2829127,Table 1,BaselineCharacteristic,xx,Age ; ,xx,None,10,1,3,No,1:No,1:No,,0.921
3088,2829127,Table 1,BaselineCharacteristic,F,Sex ; ,xx,None,10,2,3,No,1:No,1:No,,0.911
3088,2829127,Table 1,BaselineCharacteristic,Rt. hemiparesis,Symptom ; ,xx,None,10,3,3,No,1:No,1:No,,0.901
3088,2829127,Table 1,BaselineCharacteristic,Moyamoya disease,Diagnosis ; ,xx,None,10,4,3,No,1:No,1:No,,0.921
3088,2829127,Table 1,BaselineCharacteristic,EIAB + EMS (bilateral),Operation name ; ,xx,None,10,5,3,No,1:No,1:No,,0.96
3088,2829127,Table 1,BaselineCharacteristic,xx,Occlusion time (min) ; ,xx,None,10,6,3,No,1:No,1:No,,0.936
3088,2829127,Table 1,BaselineCharacteristic,Good,Intraop. sonographic patency ; ,xx,None,10,7,3,No,1:No,1:No,,0.936
3088,2829127,Table 1,BaselineCharacteristic,Good,Postop. CTA patency(x days) ; ,xx,None,10,8,3,No,1:No,1:No,,0.946
3088,2829127,Table 1,BaselineCharacteristic,,Peioperative complication ; ,xx,None,10,9,3,No,1:No,1:No,,0.966
3088,2829127,Table 1,BaselineCharacteristic,xx,No ; ,xx,None,11,0,2,No,1:No,1:No,,0.935
3088,2829127,Table 1,BaselineCharacteristic,xx,Age ; ,xx,None,11,1,3,No,1:No,1:No,,0.921
3088,2829127,Table 1,BaselineCharacteristic,M,Sex ; ,xx,None,11,2,3,No,1:No,1:No,,0.911
3088,2829127,Table 1,BaselineCharacteristic,Rt. hemiparesis,Symptom ; ,xx,None,11,3,3,No,1:No,1:No,,0.901
3088,2829127,Table 1,BaselineCharacteristic,Lt ICA occlusion,Diagnosis ; ,xx,None,11,4,3,No,1:No,1:No,,0.921
3088,2829127,Table 1,BaselineCharacteristic,EIAB,Operation name ; ,xx,None,11,5,3,No,1:No,1:No,,0.96
3088,2829127,Table 1,BaselineCharacteristic,xx,Occlusion time (min) ; ,xx,None,11,6,3,No,1:No,1:No,,0.936
3088,2829127,Table 1,BaselineCharacteristic,Good,Intraop. sonographic patency ; ,xx,None,11,7,3,No,1:No,1:No,,0.936
3088,2829127,Table 1,BaselineCharacteristic,Good,Postop. CTA patency(x days) ; ,xx,None,11,8,3,No,1:No,1:No,,0.946
3088,2829127,Table 1,BaselineCharacteristic,,Peioperative complication ; ,xx,None,11,9,3,No,1:No,1:No,,0.966
3088,2829127,Table 1,BaselineCharacteristic,xx,No ; ,xx,None,12,0,2,No,1:No,1:No,,0.935
3088,2829127,Table 1,BaselineCharacteristic,xx,Age ; ,xx,None,12,1,3,No,1:No,1:No,,0.921
3088,2829127,Table 1,BaselineCharacteristic,M,Sex ; ,xx,None,12,2,3,No,1:No,1:No,,0.911
3088,2829127,Table 1,BaselineCharacteristic,Lt. hemiparesis,Symptom ; ,xx,None,12,3,3,No,1:No,1:No,,0.901
3088,2829127,Table 1,BaselineCharacteristic,Rt. ICA occlusion,Diagnosis ; ,xx,None,12,4,3,No,1:No,1:No,,0.921
3088,2829127,Table 1,BaselineCharacteristic,EIAB,Operation name ; ,xx,None,12,5,3,No,1:No,1:No,,0.96
3088,2829127,Table 1,BaselineCharacteristic,xx,Occlusion time (min) ; ,xx,None,12,6,3,No,1:No,1:No,,0.936
3088,2829127,Table 1,BaselineCharacteristic,Good,Intraop. sonographic patency ; ,xx,None,12,7,3,No,1:No,1:No,,0.936
3088,2829127,Table 1,BaselineCharacteristic,Good,Postop. CTA patency(x days) ; ,xx,None,12,8,3,No,1:No,1:No,,0.946
3088,2829127,Table 1,BaselineCharacteristic,,Peioperative complication ; ,xx,None,12,9,3,No,1:No,1:No,,0.966
3088,2829127,Table 1,BaselineCharacteristic,xx,No ; ,xx,None,13,0,2,No,1:No,1:No,,0.935
3088,2829127,Table 1,BaselineCharacteristic,xx,Age ; ,xx,None,13,1,3,No,1:No,1:No,,0.921
3088,2829127,Table 1,BaselineCharacteristic,M,Sex ; ,xx,None,13,2,3,No,1:No,1:No,,0.911
3088,2829127,Table 1,BaselineCharacteristic,Rt. hemiparesis,Symptom ; ,xx,None,13,3,3,No,1:No,1:No,,0.891
3088,2829127,Table 1,BaselineCharacteristic,Both ICA stenosis,Diagnosis ; ,xx,None,13,4,3,No,1:No,1:No,,0.921
3088,2829127,Table 1,BaselineCharacteristic,EIAB,Operation name ; ,xx,None,13,5,3,No,1:No,1:No,,0.96
3088,2829127,Table 1,BaselineCharacteristic,xx,Occlusion time (min) ; ,xx,None,13,6,3,No,1:No,1:No,,0.936
3088,2829127,Table 1,BaselineCharacteristic,Good,Intraop. sonographic patency ; ,xx,None,13,7,3,No,1:No,1:No,,0.936
3088,2829127,Table 1,BaselineCharacteristic,Good,Postop. CTA patency(x days) ; ,xx,None,13,8,3,No,1:No,1:No,,0.946
3088,2829127,Table 1,BaselineCharacteristic,,Peioperative complication ; ,xx,None,13,9,3,No,1:No,1:No,,0.966
3088,2829127,Table 1,BaselineCharacteristic,xx,No ; ,xx,None,14,0,2,No,1:No,1:No,,0.955
3088,2829127,Table 1,BaselineCharacteristic,xx,Age ; ,xx,None,14,1,3,No,1:No,1:No,,0.941
3088,2829127,Table 1,BaselineCharacteristic,M,Sex ; ,xx,None,14,2,3,No,1:No,1:No,,0.931
3088,2829127,Table 1,BaselineCharacteristic,Seizure,Symptom ; ,xx,None,14,3,3,No,1:No,1:No,,0.911
3088,2829127,Table 1,BaselineCharacteristic,Moyamoya disease,Diagnosis ; ,xx,None,14,4,3,No,1:No,1:No,,0.931
3088,2829127,Table 1,BaselineCharacteristic,EIAB + EMS,Operation name ; ,xx,None,14,5,3,No,1:No,1:No,,0.97
3088,2829127,Table 1,BaselineCharacteristic,xx,Occlusion time (min) ; ,xx,None,14,6,3,No,1:No,1:No,,0.946
3088,2829127,Table 1,BaselineCharacteristic,Good,Intraop. sonographic patency ; ,xx,None,14,7,3,No,1:No,1:No,,0.946
3088,2829127,Table 1,BaselineCharacteristic,Good,Postop. CTA patency(x days) ; ,xx,None,14,8,3,No,1:No,1:No,,0.956
3088,2829127,Table 1,BaselineCharacteristic,,Peioperative complication ; ,xx,None,14,9,3,No,1:No,1:No,,0.976
3088,2829127,Table 1,BaselineCharacteristic,xx,No ; ,xx,None,15,0,2,No,1:No,1:No,,0.955
3088,2829127,Table 1,BaselineCharacteristic,xx,Age ; ,xx,None,15,1,3,No,1:No,1:No,,0.941
3088,2829127,Table 1,BaselineCharacteristic,M,Sex ; ,xx,None,15,2,3,No,1:No,1:No,,0.931
3088,2829127,Table 1,BaselineCharacteristic,Rt. hemiparesis,Symptom ; ,xx,None,15,3,3,No,1:No,1:No,,0.911
3088,2829127,Table 1,BaselineCharacteristic,Both ICA stenosis,Diagnosis ; ,xx,None,15,4,3,No,1:No,1:No,,0.931
3088,2829127,Table 1,BaselineCharacteristic,EIAB,Operation name ; ,xx,None,15,5,3,No,1:No,1:No,,0.97
3088,2829127,Table 1,BaselineCharacteristic,xx,Occlusion time (min) ; ,xx,None,15,6,3,No,1:No,1:No,,0.946
3088,2829127,Table 1,BaselineCharacteristic,Good,Intraop. sonographic patency ; ,xx,None,15,7,3,No,1:No,1:No,,0.946
3088,2829127,Table 1,BaselineCharacteristic,Good,Postop. CTA patency(x days) ; ,xx,None,15,8,3,No,1:No,1:No,,0.956
3088,2829127,Table 1,BaselineCharacteristic,,Peioperative complication ; ,xx,None,15,9,3,No,1:No,1:No,,0.976
3094,2831811,Table 1,BaselineCharacteristic,Patients,,None,None,0,0,,No,1:No,1:No,,0.907
3094,2831811,Table 1,BaselineCharacteristic,Age,,None,None,0,1,,No,1:No,1:No,,0.874
3094,2831811,Table 1,BaselineCharacteristic,Gender,,None,None,0,2,,No,1:No,1:No,,0.875
3094,2831811,Table 1,BaselineCharacteristic,Ethnicity,,None,None,0,3,,No,1:No,1:No,,0.875
3094,2831811,Table 1,BaselineCharacteristic,Response,,None,None,0,4,,No,1:No,1:No,,0.868
3094,2831811,Table 1,BaselineCharacteristic,PASI Baseline,,None,None,0,5,,No,1:No,1:No,,0.889
3094,2831811,Table 1,BaselineCharacteristic,PASI End of treatment,,None,None,0,6,,No,1:No,1:No,,0.893
3094,2831811,Table 1,BaselineCharacteristic,x,Patients ; ,None,None,1,0,,No,1:No,1:No,,0.886
3094,2831811,Table 1,BaselineCharacteristic,xx,Age ; ,None,None,1,1,,No,1:No,1:No,,0.672
3094,2831811,Table 1,BaselineCharacteristic,M,Gender ; ,None,None,1,2,,No,1:No,1:No,,0.872
3094,2831811,Table 1,BaselineCharacteristic,Caucasian,Ethnicity ; ,None,None,1,3,,No,1:No,1:No,,0.893
3094,2831811,Table 1,BaselineCharacteristic,NR,Response ; ,None,None,1,4,,No,1:No,1:No,,0.875
3094,2831811,Table 1,BaselineCharacteristic,x.x,PASI Baseline ; ,None,None,1,5,,No,1:No,1:No,,0.879
3094,2831811,Table 1,BaselineCharacteristic,x.x,PASI End of treatment ; ,None,None,1,6,,No,1:No,1:No,,0.896
3094,2831811,Table 1,BaselineCharacteristic,,Patients ; x ; ,None,None,2,0,,No,1:No,1:No,,0.905
3094,2831811,Table 1,BaselineCharacteristic,,Age ; xx ; ,None,None,2,1,,No,1:No,1:No,,0.707
3094,2831811,Table 1,BaselineCharacteristic,,Gender ; M ; ,None,None,2,2,,No,1:No,1:No,,0.888
3094,2831811,Table 1,BaselineCharacteristic,,Ethnicity ; Caucasian ; ,None,None,2,3,,No,1:No,1:No,,0.901
3094,2831811,Table 1,BaselineCharacteristic,,Response ; NR ; ,None,None,2,4,,No,1:No,1:No,,0.889
3094,2831811,Table 1,BaselineCharacteristic,,PASI Baseline ; x.x ; ,None,None,2,5,,No,1:No,1:No,,0.888
3094,2831811,Table 1,BaselineCharacteristic,,PASI End of treatment ; x.x ; ,None,None,2,6,,No,1:No,1:No,,0.906
3094,2831811,Table 1,BaselineCharacteristic,x,Patients ; x ;  ; ,None,None,3,0,,No,1:No,1:No,,0.923
3094,2831811,Table 1,BaselineCharacteristic,xx,Age ; xx ;  ; ,None,None,3,1,,No,1:No,1:No,,0.701
3094,2831811,Table 1,BaselineCharacteristic,M,Gender ; M ;  ; ,None,None,3,2,,No,1:No,1:No,,0.895
3094,2831811,Table 1,BaselineCharacteristic,Caucasian,Ethnicity ; Caucasian ;  ; ,None,None,3,3,,No,1:No,1:No,,0.907
3094,2831811,Table 1,BaselineCharacteristic,NR,Response ; NR ;  ; ,None,None,3,4,,No,1:No,1:No,,0.896
3094,2831811,Table 1,BaselineCharacteristic,x.x,PASI Baseline ; x.x ;  ; ,None,None,3,5,,No,1:No,1:No,,0.903
3094,2831811,Table 1,BaselineCharacteristic,x.x,PASI End of treatment ; x.x ;  ; ,None,None,3,6,,No,1:No,1:No,,0.924
3094,2831811,Table 1,BaselineCharacteristic,,Patients ; x ;  ; x ; ,None,None,4,0,,No,1:No,1:No,,0.926
3094,2831811,Table 1,BaselineCharacteristic,,Age ; xx ;  ; xx ; ,None,None,4,1,,No,1:No,1:No,,0.752
3094,2831811,Table 1,BaselineCharacteristic,,Gender ; M ;  ; M ; ,None,None,4,2,,No,1:No,1:No,,0.9
3094,2831811,Table 1,BaselineCharacteristic,,Ethnicity ; Caucasian ;  ; Caucasian ; ,None,None,4,3,,No,1:No,1:No,,0.91
3094,2831811,Table 1,BaselineCharacteristic,,Response ; NR ;  ; NR ; ,None,None,4,4,,No,1:No,1:No,,0.901
3094,2831811,Table 1,BaselineCharacteristic,,PASI Baseline ; x.x ;  ; x.x ; ,None,None,4,5,,No,1:No,1:No,,0.904
3094,2831811,Table 1,BaselineCharacteristic,,PASI End of treatment ; x.x ;  ; x.x ; ,None,None,4,6,,No,1:No,1:No,,0.933
3094,2831811,Table 1,BaselineCharacteristic,x,Patients ; x ;  ; x ;  ; ,None,None,5,0,,No,1:No,1:No,,0.926
3094,2831811,Table 1,BaselineCharacteristic,xx,Age ; xx ;  ; xx ;  ; ,None,None,5,1,,No,1:No,1:No,,0.742
3094,2831811,Table 1,BaselineCharacteristic,M,Gender ; M ;  ; M ;  ; ,None,None,5,2,,No,1:No,1:No,,0.9
3094,2831811,Table 1,BaselineCharacteristic,Hispanic,Ethnicity ; Caucasian ;  ; Caucasian ;  ; ,None,None,5,3,,No,1:No,1:No,,0.911
3094,2831811,Table 1,BaselineCharacteristic,NR,Response ; NR ;  ; NR ;  ; ,None,None,5,4,,No,1:No,1:No,,0.901
3094,2831811,Table 1,BaselineCharacteristic,xx.x,PASI Baseline ; x.x ;  ; x.x ;  ; ,None,None,5,5,,No,1:No,1:No,,0.729
3094,2831811,Table 1,BaselineCharacteristic,xx.x,PASI End of treatment ; x.x ;  ; x.x ;  ; ,None,None,5,6,,No,1:No,1:No,,0.81
3094,2831811,Table 1,BaselineCharacteristic,,Patients ; x ;  ; x ;  ; x ; ,None,None,6,0,,No,1:No,1:No,,0.944
3094,2831811,Table 1,BaselineCharacteristic,,Age ; xx ;  ; xx ;  ; xx ; ,None,None,6,1,,No,1:No,1:No,,0.798
3094,2831811,Table 1,BaselineCharacteristic,,Gender ; M ;  ; M ;  ; M ; ,None,None,6,2,,No,1:No,1:No,,0.946
3094,2831811,Table 1,BaselineCharacteristic,,Ethnicity ; Caucasian ;  ; Caucasian ;  ; Hispanic ; ,None,None,6,3,,No,1:No,1:No,,0.957
3094,2831811,Table 1,BaselineCharacteristic,,Response ; NR ;  ; NR ;  ; NR ; ,None,None,6,4,,No,1:No,1:No,,0.938
3094,2831811,Table 1,BaselineCharacteristic,,PASI Baseline ; x.x ;  ; x.x ;  ; xx.x ; ,None,None,6,5,,No,1:No,1:No,,0.748
3094,2831811,Table 1,BaselineCharacteristic,,PASI End of treatment ; x.x ;  ; x.x ;  ; xx.x ; ,None,None,6,6,,No,1:No,1:No,,0.829
3094,2831811,Table 1,BaselineCharacteristic,x,Patients ; x ;  ; x ;  ; x ;  ; ,None,None,7,0,,No,1:No,1:No,,0.96
3094,2831811,Table 1,BaselineCharacteristic,xx,Age ; xx ;  ; xx ;  ; xx ;  ; ,None,None,7,1,,No,1:No,1:No,,0.819
3094,2831811,Table 1,BaselineCharacteristic,M,Gender ; M ;  ; M ;  ; M ;  ; ,None,None,7,2,,No,1:No,1:No,,0.947
3094,2831811,Table 1,BaselineCharacteristic,Caucasian,Ethnicity ; Caucasian ;  ; Caucasian ;  ; Hispanic ;  ; ,None,None,7,3,,No,1:No,1:No,,0.958
3094,2831811,Table 1,BaselineCharacteristic,NR,Response ; NR ;  ; NR ;  ; NR ;  ; ,None,None,7,4,,No,1:No,1:No,,0.951
3094,2831811,Table 1,BaselineCharacteristic,xx.x,PASI Baseline ; x.x ;  ; x.x ;  ; xx.x ;  ; ,None,None,7,5,,No,1:No,1:No,,0.807
3094,2831811,Table 1,BaselineCharacteristic,xx.x,PASI End of treatment ; x.x ;  ; x.x ;  ; xx.x ;  ; ,None,None,7,6,,No,1:No,1:No,,0.87
3094,2831811,Table 1,BaselineCharacteristic,,Patients ; x ;  ; x ;  ; x ;  ; x ; ,None,None,8,0,,No,1:No,1:No,,0.967
3094,2831811,Table 1,BaselineCharacteristic,,Age ; xx ;  ; xx ;  ; xx ;  ; xx ; ,None,None,8,1,,No,1:No,1:No,,0.828
3094,2831811,Table 1,BaselineCharacteristic,,Gender ; M ;  ; M ;  ; M ;  ; M ; ,None,None,8,2,,No,1:No,1:No,,0.961
3094,2831811,Table 1,BaselineCharacteristic,,Ethnicity ; Caucasian ;  ; Caucasian ;  ; Hispanic ;  ; Caucasian ; ,None,None,8,3,,No,1:No,1:No,,0.966
3094,2831811,Table 1,BaselineCharacteristic,,Response ; NR ;  ; NR ;  ; NR ;  ; NR ; ,None,None,8,4,,No,1:No,1:No,,0.965
3094,2831811,Table 1,BaselineCharacteristic,,PASI Baseline ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ; ,None,None,8,5,,No,1:No,1:No,,0.835
3094,2831811,Table 1,BaselineCharacteristic,,PASI End of treatment ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ; ,None,None,8,6,,No,1:No,1:No,,0.879
3094,2831811,Table 1,BaselineCharacteristic,x,Patients ; x ;  ; x ;  ; x ;  ; x ;  ; ,None,None,9,0,,No,1:No,1:No,,0.977
3094,2831811,Table 1,BaselineCharacteristic,xx,Age ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; ,None,None,9,1,,No,1:No,1:No,,0.879
3094,2831811,Table 1,BaselineCharacteristic,M,Gender ; M ;  ; M ;  ; M ;  ; M ;  ; ,None,None,9,2,,No,1:No,1:No,,0.968
3094,2831811,Table 1,BaselineCharacteristic,Caucasian,Ethnicity ; Caucasian ;  ; Caucasian ;  ; Hispanic ;  ; Caucasian ;  ; ,None,None,9,3,,No,1:No,1:No,,0.972
3094,2831811,Table 1,BaselineCharacteristic,NR,Response ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; ,None,None,9,4,,No,1:No,1:No,,0.975
3094,2831811,Table 1,BaselineCharacteristic,xx.x,PASI Baseline ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; ,None,None,9,5,,No,1:No,1:No,,0.873
3094,2831811,Table 1,BaselineCharacteristic,*NA,PASI End of treatment ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; ,None,None,9,6,,No,1:No,1:No,,0.909
3094,2831811,Table 1,BaselineCharacteristic,,Patients ; x ;  ; x ;  ; x ;  ; x ;  ; x ; ,None,None,10,0,,No,1:No,1:No,,0.994
3094,2831811,Table 1,BaselineCharacteristic,,Age ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ; ,None,None,10,1,,No,1:No,1:No,,0.912
3094,2831811,Table 1,BaselineCharacteristic,,Gender ; M ;  ; M ;  ; M ;  ; M ;  ; M ; ,None,None,10,2,,No,1:No,1:No,,0.987
3094,2831811,Table 1,BaselineCharacteristic,,Ethnicity ; Caucasian ;  ; Caucasian ;  ; Hispanic ;  ; Caucasian ;  ; Caucasian ; ,None,None,10,3,,No,1:No,1:No,,0.989
3094,2831811,Table 1,BaselineCharacteristic,,Response ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ; ,None,None,10,4,,No,1:No,1:No,,0.994
3094,2831811,Table 1,BaselineCharacteristic,,PASI Baseline ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ; ,None,None,10,5,,No,1:No,1:No,,0.894
3094,2831811,Table 1,BaselineCharacteristic,,PASI End of treatment ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; *NA ; ,None,None,10,6,,No,1:No,1:No,,0.938
3094,2831811,Table 1,BaselineCharacteristic,x,Patients ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; ,None,None,11,0,,No,1:No,1:No,,0.994
3094,2831811,Table 1,BaselineCharacteristic,xx,Age ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; ,None,None,11,1,,No,1:No,1:No,,0.912
3094,2831811,Table 1,BaselineCharacteristic,M,Gender ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; ,None,None,11,2,,No,1:No,1:No,,0.987
3094,2831811,Table 1,BaselineCharacteristic,Caucasian,Ethnicity ; Caucasian ;  ; Caucasian ;  ; Hispanic ;  ; Caucasian ;  ; Caucasian ;  ; ,None,None,11,3,,No,1:No,1:No,,0.989
3094,2831811,Table 1,BaselineCharacteristic,NR,Response ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; ,None,None,11,4,,No,1:No,1:No,,0.994
3094,2831811,Table 1,BaselineCharacteristic,xx.x,PASI Baseline ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; ,None,None,11,5,,No,1:No,1:No,,0.894
3094,2831811,Table 1,BaselineCharacteristic,xx.x,PASI End of treatment ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; *NA ;  ; ,None,None,11,6,,No,1:No,1:No,,0.938
3094,2831811,Table 1,BaselineCharacteristic,,Patients ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ; ,None,None,12,0,,No,1:No,1:No,,0.994
3094,2831811,Table 1,BaselineCharacteristic,,Age ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ; ,None,None,12,1,,No,1:No,1:No,,0.912
3094,2831811,Table 1,BaselineCharacteristic,,Gender ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ; ,None,None,12,2,,No,1:No,1:No,,0.987
3094,2831811,Table 1,BaselineCharacteristic,,Ethnicity ; Caucasian ;  ; Caucasian ;  ; Hispanic ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ; ,None,None,12,3,,No,1:No,1:No,,0.989
3094,2831811,Table 1,BaselineCharacteristic,,Response ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ; ,None,None,12,4,,No,1:No,1:No,,0.994
3094,2831811,Table 1,BaselineCharacteristic,,PASI Baseline ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ; ,None,None,12,5,,No,1:No,1:No,,0.894
3094,2831811,Table 1,BaselineCharacteristic,,PASI End of treatment ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; *NA ;  ; xx.x ; ,None,None,12,6,,No,1:No,1:No,,0.938
3094,2831811,Table 1,BaselineCharacteristic,x,Patients ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; ,None,None,13,0,,No,1:No,1:No,,0.994
3094,2831811,Table 1,BaselineCharacteristic,xx,Age ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; ,None,None,13,1,,No,1:No,1:No,,0.912
3094,2831811,Table 1,BaselineCharacteristic,M,Gender ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; ,None,None,13,2,,No,1:No,1:No,,0.987
3094,2831811,Table 1,BaselineCharacteristic,Caucasian,Ethnicity ; Caucasian ;  ; Caucasian ;  ; Hispanic ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; ,None,None,13,3,,No,1:No,1:No,,0.979
3094,2831811,Table 1,BaselineCharacteristic,NR,Response ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; ,None,None,13,4,,No,1:No,1:No,,0.994
3094,2831811,Table 1,BaselineCharacteristic,x.x,PASI Baseline ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; ,None,None,13,5,,No,1:No,1:No,,0.894
3094,2831811,Table 1,BaselineCharacteristic,x.x,PASI End of treatment ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; *NA ;  ; xx.x ;  ; ,None,None,13,6,,No,1:No,1:No,,0.938
3094,2831811,Table 1,BaselineCharacteristic,,Patients ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ; ,None,None,14,0,,No,1:No,1:No,,0.994
3094,2831811,Table 1,BaselineCharacteristic,,Age ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ; ,None,None,14,1,,No,1:No,1:No,,0.932
3094,2831811,Table 1,BaselineCharacteristic,,Gender ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ; ,None,None,14,2,,No,1:No,1:No,,0.988
3094,2831811,Table 1,BaselineCharacteristic,,Ethnicity ; Caucasian ;  ; Caucasian ;  ; Hispanic ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ; ,None,None,14,3,,No,1:No,1:No,,0.979
3094,2831811,Table 1,BaselineCharacteristic,,Response ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ; ,None,None,14,4,,No,1:No,1:No,,0.995
3094,2831811,Table 1,BaselineCharacteristic,,PASI Baseline ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; x.x ; ,None,None,14,5,,No,1:No,1:No,,0.904
3094,2831811,Table 1,BaselineCharacteristic,,PASI End of treatment ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; *NA ;  ; xx.x ;  ; x.x ; ,None,None,14,6,,No,1:No,1:No,,0.938
3094,2831811,Table 1,BaselineCharacteristic,x,Patients ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; ,None,None,15,0,,No,1:No,1:No,,0.994
3094,2831811,Table 1,BaselineCharacteristic,xx,Age ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; ,None,None,15,1,,No,1:No,1:No,,0.932
3094,2831811,Table 1,BaselineCharacteristic,M,Gender ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; ,None,None,15,2,,No,1:No,1:No,,0.978
3094,2831811,Table 1,BaselineCharacteristic,Caucasian,Ethnicity ; Caucasian ;  ; Caucasian ;  ; Hispanic ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; ,None,None,15,3,,No,1:No,1:No,,0.979
3094,2831811,Table 1,BaselineCharacteristic,R,Response ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; ,None,None,15,4,,No,1:No,1:No,,0.995
3094,2831811,Table 1,BaselineCharacteristic,xx.x,PASI Baseline ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; x.x ;  ; ,None,None,15,5,,No,1:No,1:No,,0.904
3094,2831811,Table 1,BaselineCharacteristic,x.x,PASI End of treatment ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; *NA ;  ; xx.x ;  ; x.x ;  ; ,None,None,15,6,,No,1:No,1:No,,0.938
3094,2831811,Table 1,BaselineCharacteristic,,Patients ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ; ,None,None,16,0,,No,1:No,1:No,,0.994
3094,2831811,Table 1,BaselineCharacteristic,,Age ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ; ,None,None,16,1,,No,1:No,1:No,,0.932
3094,2831811,Table 1,BaselineCharacteristic,,Gender ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ; ,None,None,16,2,,No,1:No,1:No,,0.978
3094,2831811,Table 1,BaselineCharacteristic,,Ethnicity ; Caucasian ;  ; Caucasian ;  ; Hispanic ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ; ,None,None,16,3,,No,1:No,1:No,,0.979
3094,2831811,Table 1,BaselineCharacteristic,,Response ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; R ; ,None,None,16,4,,No,1:No,1:No,,0.995
3094,2831811,Table 1,BaselineCharacteristic,,PASI Baseline ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; x.x ;  ; xx.x ; ,None,None,16,5,,No,1:No,1:No,,0.914
3094,2831811,Table 1,BaselineCharacteristic,,PASI End of treatment ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; *NA ;  ; xx.x ;  ; x.x ;  ; x.x ; ,None,None,16,6,,No,1:No,1:No,,0.948
3094,2831811,Table 1,BaselineCharacteristic,x,Patients ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; ,None,None,17,0,,No,1:No,1:No,,0.994
3094,2831811,Table 1,BaselineCharacteristic,xx,Age ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; ,None,None,17,1,,No,1:No,1:No,,0.932
3094,2831811,Table 1,BaselineCharacteristic,M,Gender ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; ,None,None,17,2,,No,1:No,1:No,,0.978
3094,2831811,Table 1,BaselineCharacteristic,Caucasian,Ethnicity ; Caucasian ;  ; Caucasian ;  ; Hispanic ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; ,None,None,17,3,,No,1:No,1:No,,0.979
3094,2831811,Table 1,BaselineCharacteristic,R,Response ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; R ;  ; ,None,None,17,4,,No,1:No,1:No,,0.995
3094,2831811,Table 1,BaselineCharacteristic,xx.x,PASI Baseline ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; x.x ;  ; xx.x ;  ; ,None,None,17,5,,No,1:No,1:No,,0.914
3094,2831811,Table 1,BaselineCharacteristic,xx.x,PASI End of treatment ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; *NA ;  ; xx.x ;  ; x.x ;  ; x.x ;  ; ,None,None,17,6,,No,1:No,1:No,,0.948
3094,2831811,Table 1,BaselineCharacteristic,,Patients ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ; ,None,None,18,0,,No,1:No,1:No,,0.984
3094,2831811,Table 1,BaselineCharacteristic,,Age ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ; ,None,None,18,1,,No,1:No,1:No,,0.919
3094,2831811,Table 1,BaselineCharacteristic,,Gender ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ; ,None,None,18,2,,No,1:No,1:No,,0.968
3094,2831811,Table 1,BaselineCharacteristic,,Ethnicity ; Caucasian ;  ; Caucasian ;  ; Hispanic ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ; ,None,None,18,3,,No,1:No,1:No,,0.969
3094,2831811,Table 1,BaselineCharacteristic,,Response ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; R ;  ; R ; ,None,None,18,4,,No,1:No,1:No,,0.985
3094,2831811,Table 1,BaselineCharacteristic,,PASI Baseline ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; x.x ;  ; xx.x ;  ; xx.x ; ,None,None,18,5,,No,1:No,1:No,,0.9
3094,2831811,Table 1,BaselineCharacteristic,,PASI End of treatment ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; *NA ;  ; xx.x ;  ; x.x ;  ; x.x ;  ; xx.x ; ,None,None,18,6,,No,1:No,1:No,,0.948
3094,2831811,Table 1,BaselineCharacteristic,xx,Patients ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; ,None,None,19,0,,No,1:No,1:No,,0.884
3094,2831811,Table 1,BaselineCharacteristic,xx,Age ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; ,None,None,19,1,,No,1:No,1:No,,0.919
3094,2831811,Table 1,BaselineCharacteristic,M,Gender ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; ,None,None,19,2,,No,1:No,1:No,,0.968
3094,2831811,Table 1,BaselineCharacteristic,African American,Ethnicity ; Caucasian ;  ; Caucasian ;  ; Hispanic ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; ,None,None,19,3,,No,1:No,1:No,,0.969
3094,2831811,Table 1,BaselineCharacteristic,R,Response ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; R ;  ; R ;  ; ,None,None,19,4,,No,1:No,1:No,,0.985
3094,2831811,Table 1,BaselineCharacteristic,xx.x,PASI Baseline ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; ,None,None,19,5,,No,1:No,1:No,,0.9
3094,2831811,Table 1,BaselineCharacteristic,x.x,PASI End of treatment ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; *NA ;  ; xx.x ;  ; x.x ;  ; x.x ;  ; xx.x ;  ; ,None,None,19,6,,No,1:No,1:No,,0.948
3094,2831811,Table 1,BaselineCharacteristic,,Patients ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; xx ; ,None,None,20,0,,No,1:No,1:No,,0.884
3094,2831811,Table 1,BaselineCharacteristic,,Age ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ; ,None,None,20,1,,No,1:No,1:No,,0.919
3094,2831811,Table 1,BaselineCharacteristic,,Gender ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ; ,None,None,20,2,,No,1:No,1:No,,0.968
3094,2831811,Table 1,BaselineCharacteristic,,Ethnicity ; Caucasian ;  ; Caucasian ;  ; Hispanic ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; African American ; ,None,None,20,3,,No,1:No,1:No,,0.969
3094,2831811,Table 1,BaselineCharacteristic,,Response ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; R ;  ; R ;  ; R ; ,None,None,20,4,,No,1:No,1:No,,0.985
3094,2831811,Table 1,BaselineCharacteristic,,PASI Baseline ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ; ,None,None,20,5,,No,1:No,1:No,,0.9
3094,2831811,Table 1,BaselineCharacteristic,,PASI End of treatment ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; *NA ;  ; xx.x ;  ; x.x ;  ; x.x ;  ; xx.x ;  ; x.x ; ,None,None,20,6,,No,1:No,1:No,,0.948
3094,2831811,Table 1,BaselineCharacteristic,xx,Patients ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; xx ;  ; ,None,None,21,0,,No,1:No,1:No,,0.884
3094,2831811,Table 1,BaselineCharacteristic,xx,Age ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; ,None,None,21,1,,No,1:No,1:No,,0.919
3094,2831811,Table 1,BaselineCharacteristic,M,Gender ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; ,None,None,21,2,,No,1:No,1:No,,0.968
3094,2831811,Table 1,BaselineCharacteristic,Asian,Ethnicity ; Caucasian ;  ; Caucasian ;  ; Hispanic ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; African American ;  ; ,None,None,21,3,,No,1:No,1:No,,0.969
3094,2831811,Table 1,BaselineCharacteristic,R,Response ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; R ;  ; R ;  ; R ;  ; ,None,None,21,4,,No,1:No,1:No,,0.985
3094,2831811,Table 1,BaselineCharacteristic,xx.x,PASI Baseline ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; ,None,None,21,5,,No,1:No,1:No,,0.9
3094,2831811,Table 1,BaselineCharacteristic,x.x,PASI End of treatment ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; *NA ;  ; xx.x ;  ; x.x ;  ; x.x ;  ; xx.x ;  ; x.x ;  ; ,None,None,21,6,,No,1:No,1:No,,0.948
3094,2831811,Table 1,BaselineCharacteristic,,Patients ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; xx ;  ; xx ; ,None,None,22,0,,No,1:No,1:No,,0.894
3094,2831811,Table 1,BaselineCharacteristic,,Age ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ; ,None,None,22,1,,No,1:No,1:No,,0.929
3094,2831811,Table 1,BaselineCharacteristic,,Gender ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ; ,None,None,22,2,,No,1:No,1:No,,0.978
3094,2831811,Table 1,BaselineCharacteristic,,Ethnicity ; Caucasian ;  ; Caucasian ;  ; Hispanic ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; African American ;  ; Asian ; ,None,None,22,3,,No,1:No,1:No,,0.979
3094,2831811,Table 1,BaselineCharacteristic,,Response ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; R ;  ; R ;  ; R ;  ; R ; ,None,None,22,4,,No,1:No,1:No,,0.995
3094,2831811,Table 1,BaselineCharacteristic,,PASI Baseline ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ; ,None,None,22,5,,No,1:No,1:No,,0.91
3094,2831811,Table 1,BaselineCharacteristic,,PASI End of treatment ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; *NA ;  ; xx.x ;  ; x.x ;  ; x.x ;  ; xx.x ;  ; x.x ;  ; x.x ; ,None,None,22,6,,No,1:No,1:No,,0.948
3094,2831811,Table 1,BaselineCharacteristic,xx,Patients ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; xx ;  ; xx ;  ; ,None,None,23,0,,No,1:No,1:No,,0.894
3094,2831811,Table 1,BaselineCharacteristic,xx,Age ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; ,None,None,23,1,,No,1:No,1:No,,0.929
3094,2831811,Table 1,BaselineCharacteristic,M,Gender ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; ,None,None,23,2,,No,1:No,1:No,,0.978
3094,2831811,Table 1,BaselineCharacteristic,Hispanic,Ethnicity ; Caucasian ;  ; Caucasian ;  ; Hispanic ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; African American ;  ; Asian ;  ; ,None,None,23,3,,No,1:No,1:No,,0.979
3094,2831811,Table 1,BaselineCharacteristic,R,Response ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; R ;  ; R ;  ; R ;  ; R ;  ; ,None,None,23,4,,No,1:No,1:No,,0.995
3094,2831811,Table 1,BaselineCharacteristic,xx.x,PASI Baseline ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; ,None,None,23,5,,No,1:No,1:No,,0.91
3094,2831811,Table 1,BaselineCharacteristic,x.x,PASI End of treatment ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; *NA ;  ; xx.x ;  ; x.x ;  ; x.x ;  ; xx.x ;  ; x.x ;  ; x.x ;  ; ,None,None,23,6,,No,1:No,1:No,,0.948
3094,2831811,Table 1,BaselineCharacteristic,,Patients ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; xx ;  ; xx ;  ; xx ; ,None,None,24,0,,No,1:No,1:No,,0.894
3094,2831811,Table 1,BaselineCharacteristic,,Age ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ; ,None,None,24,1,,No,1:No,1:No,,0.929
3094,2831811,Table 1,BaselineCharacteristic,,Gender ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ; ,None,None,24,2,,No,1:No,1:No,,0.978
3094,2831811,Table 1,BaselineCharacteristic,,Ethnicity ; Caucasian ;  ; Caucasian ;  ; Hispanic ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; African American ;  ; Asian ;  ; Hispanic ; ,None,None,24,3,,No,1:No,1:No,,0.979
3094,2831811,Table 1,BaselineCharacteristic,,Response ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; R ;  ; R ;  ; R ;  ; R ;  ; R ; ,None,None,24,4,,No,1:No,1:No,,0.995
3094,2831811,Table 1,BaselineCharacteristic,,PASI Baseline ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ; ,None,None,24,5,,No,1:No,1:No,,0.91
3094,2831811,Table 1,BaselineCharacteristic,,PASI End of treatment ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; *NA ;  ; xx.x ;  ; x.x ;  ; x.x ;  ; xx.x ;  ; x.x ;  ; x.x ;  ; x.x ; ,None,None,24,6,,No,1:No,1:No,,0.948
3094,2831811,Table 1,BaselineCharacteristic,xx,Patients ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; xx ;  ; xx ;  ; xx ;  ; ,None,None,25,0,,No,1:No,1:No,,0.894
3094,2831811,Table 1,BaselineCharacteristic,xx,Age ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; ,None,None,25,1,,No,1:No,1:No,,0.929
3094,2831811,Table 1,BaselineCharacteristic,M,Gender ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; ,None,None,25,2,,No,1:No,1:No,,0.978
3094,2831811,Table 1,BaselineCharacteristic,Caucasian,Ethnicity ; Caucasian ;  ; Caucasian ;  ; Hispanic ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; African American ;  ; Asian ;  ; Hispanic ;  ; ,None,None,25,3,,No,1:No,1:No,,0.979
3094,2831811,Table 1,BaselineCharacteristic,R,Response ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; R ;  ; R ;  ; R ;  ; R ;  ; R ;  ; ,None,None,25,4,,No,1:No,1:No,,0.995
3094,2831811,Table 1,BaselineCharacteristic,xx.x,PASI Baseline ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; ,None,None,25,5,,No,1:No,1:No,,0.91
3094,2831811,Table 1,BaselineCharacteristic,x.x,PASI End of treatment ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; *NA ;  ; xx.x ;  ; x.x ;  ; x.x ;  ; xx.x ;  ; x.x ;  ; x.x ;  ; x.x ;  ; ,None,None,25,6,,No,1:No,1:No,,0.948
3094,2831811,Table 1,BaselineCharacteristic,,Patients ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; xx ;  ; xx ;  ; xx ;  ; xx ; ,None,None,26,0,,No,1:No,1:No,,0.894
3094,2831811,Table 1,BaselineCharacteristic,,Age ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ; ,None,None,26,1,,No,1:No,1:No,,0.929
3094,2831811,Table 1,BaselineCharacteristic,,Gender ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ; ,None,None,26,2,,No,1:No,1:No,,0.978
3094,2831811,Table 1,BaselineCharacteristic,,Ethnicity ; Caucasian ;  ; Caucasian ;  ; Hispanic ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; African American ;  ; Asian ;  ; Hispanic ;  ; Caucasian ; ,None,None,26,3,,No,1:No,1:No,,0.979
3094,2831811,Table 1,BaselineCharacteristic,,Response ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; R ;  ; R ;  ; R ;  ; R ;  ; R ;  ; R ; ,None,None,26,4,,No,1:No,1:No,,0.995
3094,2831811,Table 1,BaselineCharacteristic,,PASI Baseline ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ; ,None,None,26,5,,No,1:No,1:No,,0.91
3094,2831811,Table 1,BaselineCharacteristic,,PASI End of treatment ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; *NA ;  ; xx.x ;  ; x.x ;  ; x.x ;  ; xx.x ;  ; x.x ;  ; x.x ;  ; x.x ;  ; x.x ; ,None,None,26,6,,No,1:No,1:No,,0.948
3094,2831811,Table 1,BaselineCharacteristic,xx,Patients ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; ,None,None,27,0,,No,1:No,1:No,,0.894
3094,2831811,Table 1,BaselineCharacteristic,xx,Age ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; ,None,None,27,1,,No,1:No,1:No,,0.929
3094,2831811,Table 1,BaselineCharacteristic,M,Gender ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; ,None,None,27,2,,No,1:No,1:No,,0.978
3094,2831811,Table 1,BaselineCharacteristic,Caucasian,Ethnicity ; Caucasian ;  ; Caucasian ;  ; Hispanic ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; African American ;  ; Asian ;  ; Hispanic ;  ; Caucasian ;  ; ,None,None,27,3,,No,1:No,1:No,,0.979
3094,2831811,Table 1,BaselineCharacteristic,R,Response ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; R ;  ; R ;  ; R ;  ; R ;  ; R ;  ; R ;  ; ,None,None,27,4,,No,1:No,1:No,,0.995
3094,2831811,Table 1,BaselineCharacteristic,xx.x,PASI Baseline ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; ,None,None,27,5,,No,1:No,1:No,,0.91
3094,2831811,Table 1,BaselineCharacteristic,xx.x,PASI End of treatment ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; *NA ;  ; xx.x ;  ; x.x ;  ; x.x ;  ; xx.x ;  ; x.x ;  ; x.x ;  ; x.x ;  ; x.x ;  ; ,None,None,27,6,,No,1:No,1:No,,0.948
3094,2831811,Table 1,BaselineCharacteristic,,Patients ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ; ,None,None,28,0,,No,1:No,1:No,,0.894
3094,2831811,Table 1,BaselineCharacteristic,,Age ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ; ,None,None,28,1,,No,1:No,1:No,,0.929
3094,2831811,Table 1,BaselineCharacteristic,,Gender ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ; ,None,None,28,2,,No,1:No,1:No,,0.978
3094,2831811,Table 1,BaselineCharacteristic,,Ethnicity ; Caucasian ;  ; Caucasian ;  ; Hispanic ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; African American ;  ; Asian ;  ; Hispanic ;  ; Caucasian ;  ; Caucasian ; ,None,None,28,3,,No,1:No,1:No,,0.979
3094,2831811,Table 1,BaselineCharacteristic,,Response ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; R ;  ; R ;  ; R ;  ; R ;  ; R ;  ; R ;  ; R ; ,None,None,28,4,,No,1:No,1:No,,0.995
3094,2831811,Table 1,BaselineCharacteristic,,PASI Baseline ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ; ,None,None,28,5,,No,1:No,1:No,,0.91
3094,2831811,Table 1,BaselineCharacteristic,,PASI End of treatment ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; *NA ;  ; xx.x ;  ; x.x ;  ; x.x ;  ; xx.x ;  ; x.x ;  ; x.x ;  ; x.x ;  ; x.x ;  ; xx.x ; ,None,None,28,6,,No,1:No,1:No,,0.948
3094,2831811,Table 1,BaselineCharacteristic,xx,Patients ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; ,None,None,29,0,,No,1:No,1:No,,0.894
3094,2831811,Table 1,BaselineCharacteristic,xx,Age ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; ,None,None,29,1,,No,1:No,1:No,,0.929
3094,2831811,Table 1,BaselineCharacteristic,M,Gender ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; ,None,None,29,2,,No,1:No,1:No,,0.978
3094,2831811,Table 1,BaselineCharacteristic,Caucasian,Ethnicity ; Caucasian ;  ; Caucasian ;  ; Hispanic ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; African American ;  ; Asian ;  ; Hispanic ;  ; Caucasian ;  ; Caucasian ;  ; ,None,None,29,3,,No,1:No,1:No,,0.979
3094,2831811,Table 1,BaselineCharacteristic,R,Response ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; R ;  ; R ;  ; R ;  ; R ;  ; R ;  ; R ;  ; R ;  ; ,None,None,29,4,,No,1:No,1:No,,0.995
3094,2831811,Table 1,BaselineCharacteristic,x.x,PASI Baseline ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; ,None,None,29,5,,No,1:No,1:No,,0.91
3094,2831811,Table 1,BaselineCharacteristic,x.x,PASI End of treatment ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; *NA ;  ; xx.x ;  ; x.x ;  ; x.x ;  ; xx.x ;  ; x.x ;  ; x.x ;  ; x.x ;  ; x.x ;  ; xx.x ;  ; ,None,None,29,6,,No,1:No,1:No,,0.948
3094,2831811,Table 1,BaselineCharacteristic,,Patients ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ; ,None,None,30,0,,No,1:No,1:No,,0.894
3094,2831811,Table 1,BaselineCharacteristic,,Age ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ; ,None,None,30,1,,No,1:No,1:No,,0.929
3094,2831811,Table 1,BaselineCharacteristic,,Gender ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ; ,None,None,30,2,,No,1:No,1:No,,0.978
3094,2831811,Table 1,BaselineCharacteristic,,Ethnicity ; Caucasian ;  ; Caucasian ;  ; Hispanic ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; African American ;  ; Asian ;  ; Hispanic ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ; ,None,None,30,3,,No,1:No,1:No,,0.979
3094,2831811,Table 1,BaselineCharacteristic,,Response ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; R ;  ; R ;  ; R ;  ; R ;  ; R ;  ; R ;  ; R ;  ; R ; ,None,None,30,4,,No,1:No,1:No,,0.995
3094,2831811,Table 1,BaselineCharacteristic,,PASI Baseline ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; x.x ; ,None,None,30,5,,No,1:No,1:No,,0.91
3094,2831811,Table 1,BaselineCharacteristic,,PASI End of treatment ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; *NA ;  ; xx.x ;  ; x.x ;  ; x.x ;  ; xx.x ;  ; x.x ;  ; x.x ;  ; x.x ;  ; x.x ;  ; xx.x ;  ; x.x ; ,None,None,30,6,,No,1:No,1:No,,0.948
3094,2831811,Table 1,BaselineCharacteristic,xx,Patients ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; ,xx,,31,0,,No,1:No,1:No,,0.894
3094,2831811,Table 1,BaselineCharacteristic,xx,Age ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; ,xx,,31,1,,No,1:No,1:No,,0.929
3094,2831811,Table 1,BaselineCharacteristic,F,Gender ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; M ;  ; ,xx,,31,2,,No,1:No,1:No,,0.928
3094,2831811,Table 1,BaselineCharacteristic,Hispanic,Ethnicity ; Caucasian ;  ; Caucasian ;  ; Hispanic ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; African American ;  ; Asian ;  ; Hispanic ;  ; Caucasian ;  ; Caucasian ;  ; Caucasian ;  ; ,xx,,31,3,,No,1:No,1:No,,0.92
3094,2831811,Table 1,BaselineCharacteristic,R,Response ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; NR ;  ; R ;  ; R ;  ; R ;  ; R ;  ; R ;  ; R ;  ; R ;  ; R ;  ; ,xx,,31,4,,No,1:No,1:No,,0.938
3094,2831811,Table 1,BaselineCharacteristic,xx.x,PASI Baseline ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; xx.x ;  ; x.x ;  ; ,xx,,31,5,,No,1:No,1:No,,0.91
3094,2831811,Table 1,BaselineCharacteristic,x.x,PASI End of treatment ; x.x ;  ; x.x ;  ; xx.x ;  ; xx.x ;  ; *NA ;  ; xx.x ;  ; x.x ;  ; x.x ;  ; xx.x ;  ; x.x ;  ; x.x ;  ; x.x ;  ; x.x ;  ; xx.x ;  ; x.x ;  ; ,xx,,31,6,,No,1:No,1:No,,0.948
3097,2835652,Table 1,BaselineCharacteristic,HSPPC-xx Dose Level,,None,None,0,0,12,No,1:No,1:No,,0.945
3097,2835652,Table 1,BaselineCharacteristic,Total,,HSPPC-xx Dose Level,None,0,1,1,No,1:No,1:No,,0.939
3097,2835652,Table 1,BaselineCharacteristic,x.x ?g,,HSPPC-xx Dose Level,None,0,2,1,No,1:No,1:No,,0.834
3097,2835652,Table 1,BaselineCharacteristic,xx ?g,,HSPPC-xx Dose Level,None,0,3,1,No,1:No,1:No,,0.683
3097,2835652,Table 1,BaselineCharacteristic,xxx ?g,,HSPPC-xx Dose Level,None,0,4,1,No,1:No,1:No,,0.839
3097,2835652,Table 1,BaselineCharacteristic,"Enrolled, no.",HSPPC-xx Dose Level ; ,None,None,1,0,12,No,1:No,1:No,,0.89
3097,2835652,Table 1,BaselineCharacteristic,xx,Total ; ,"Enrolled, no.",None,1,1,1,No,1:No,1:No,,0.673
3097,2835652,Table 1,BaselineCharacteristic,xx,x.x ?g ; ,"Enrolled, no.",None,1,2,1,No,1:No,1:No,,0.6
3097,2835652,Table 1,BaselineCharacteristic,xx,xx ?g ; ,"Enrolled, no.",None,1,3,1,No,1:No,1:No,,0.615
3097,2835652,Table 1,BaselineCharacteristic,x,xxx ?g ; ,"Enrolled, no.",None,1,4,1,No,1:No,1:No,,0.758
3097,2835652,Table 1,BaselineCharacteristic,"Male, no (%)","HSPPC-xx Dose Level ; Enrolled, no. ; ","Male, no (%)",,2,0,2,No,1:No,1:No,,0.893
3097,2835652,Table 1,BaselineCharacteristic,xx (xx%),Total ; xx ; ,"Male, no (%)",,2,1,3,No,1:No,1:No,,0.606
3097,2835652,Table 1,BaselineCharacteristic,x,x.x ?g ; xx ; ,"Male, no (%)",,2,2,3,No,1:No,1:No,,0.526
3097,2835652,Table 1,BaselineCharacteristic,x,xxx ?g ; x ; ,"Male, no (%)",,2,4,3,No,1:No,1:No,,0.69
3097,2835652,Table 1,BaselineCharacteristic,Karnofsky performance status,"HSPPC-xx Dose Level ; Enrolled, no. ; ",None,None,4,0,24,No,1:No,1:No,,0.889
3097,2835652,Table 1,BaselineCharacteristic,,Total ; xx ; ,Karnofsky performance status,None,4,1,43,No,1:No,1:No,,0.76
3097,2835652,Table 1,BaselineCharacteristic,,x.x ?g ; xx ; ,Karnofsky performance status,None,4,2,43,No,1:No,1:No,,0.645
3097,2835652,Table 1,BaselineCharacteristic,,xx ?g ; xx ; ,Karnofsky performance status,None,4,3,43,No,1:No,1:No,,0.694
3097,2835652,Table 1,BaselineCharacteristic,,xxx ?g ; x ; ,Karnofsky performance status,None,4,4,43,No,1:No,1:No,,0.794
3097,2835652,Table 1,BaselineCharacteristic,?xx%,"HSPPC-xx Dose Level ; Enrolled, no. ; ",?xx%, Karnofsky performance status,5,0,2,No,1:No,1:No,,0.935
3097,2835652,Table 1,BaselineCharacteristic,xx,Total ; xx ; ,?xx%, Karnofsky performance status,5,1,3,No,1:No,1:No,,0.781
3097,2835652,Table 1,BaselineCharacteristic,x,x.x ?g ; xx ; ,?xx%, Karnofsky performance status,5,2,3,No,1:No,1:No,,0.736
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,?xx%, Karnofsky performance status,5,3,3,No,1:No,1:No,,0.716
3097,2835652,Table 1,BaselineCharacteristic,x,xxx ?g ; x ; ,?xx%, Karnofsky performance status,5,4,3,No,1:No,1:No,,0.84
3097,2835652,Table 1,BaselineCharacteristic,?xx%,"HSPPC-xx Dose Level ; Enrolled, no. ; ",?xx%, Karnofsky performance status,6,0,2,No,1:No,1:No,,0.965
3097,2835652,Table 1,BaselineCharacteristic,xx,Total ; xx ; ,?xx%, Karnofsky performance status,6,1,3,No,1:No,1:No,,0.841
3097,2835652,Table 1,BaselineCharacteristic,x,x.x ?g ; xx ; ,?xx%, Karnofsky performance status,6,2,3,No,1:No,1:No,,0.756
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,?xx%, Karnofsky performance status,6,3,3,No,1:No,1:No,,0.736
3097,2835652,Table 1,BaselineCharacteristic,x,xxx ?g ; x ; ,?xx%, Karnofsky performance status,6,4,3,No,1:No,1:No,,0.87
3097,2835652,Table 1,BaselineCharacteristic,,"HSPPC-xx Dose Level ; Enrolled, no. ; ",None,None,7,0,2,No,1:No,1:No,,0.965
3097,2835652,Table 1,BaselineCharacteristic,,Total ; xx ; ,None,None,7,1,3,No,1:No,1:No,,0.811
3097,2835652,Table 1,BaselineCharacteristic,,x.x ?g ; xx ; ,None,None,7,2,3,No,1:No,1:No,,0.736
3097,2835652,Table 1,BaselineCharacteristic,,xx ?g ; xx ; ,None,None,7,3,3,No,1:No,1:No,,0.751
3097,2835652,Table 1,BaselineCharacteristic,,xxx ?g ; x ; ,None,None,7,4,3,No,1:No,1:No,,0.86
3097,2835652,Table 1,BaselineCharacteristic,Prior treatment: no. of regimens,"HSPPC-xx Dose Level ; Enrolled, no. ; ",None,None,8,0,24,No,1:No,1:No,,0.954
3097,2835652,Table 1,BaselineCharacteristic,,Total ; xx ; ,Prior treatment: no. of regimens,None,8,1,43,No,1:No,1:No,,0.848
3097,2835652,Table 1,BaselineCharacteristic,,x.x ?g ; xx ; ,Prior treatment: no. of regimens,None,8,2,43,No,1:No,1:No,,0.81
3097,2835652,Table 1,BaselineCharacteristic,,xx ?g ; xx ; ,Prior treatment: no. of regimens,None,8,3,43,No,1:No,1:No,,0.81
3097,2835652,Table 1,BaselineCharacteristic,,xxx ?g ; x ; ,Prior treatment: no. of regimens,None,8,4,43,No,1:No,1:No,,0.869
3097,2835652,Table 1,BaselineCharacteristic,?x,"HSPPC-xx Dose Level ; Enrolled, no. ; ",?x, Prior treatment: no. of regimens,9,0,2,No,1:No,1:No,,0.948
3097,2835652,Table 1,BaselineCharacteristic,x,Total ; xx ; ,?x, Prior treatment: no. of regimens,9,1,3,No,1:No,1:No,,0.82
3097,2835652,Table 1,BaselineCharacteristic,,x.x ?g ; xx ; ,?x, Prior treatment: no. of regimens,9,2,3,No,1:No,1:No,,0.81
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,?x, Prior treatment: no. of regimens,9,3,3,No,1:No,1:No,,0.81
3097,2835652,Table 1,BaselineCharacteristic,x,xxx ?g ; x ; ,?x, Prior treatment: no. of regimens,9,4,3,No,1:No,1:No,,0.87
3097,2835652,Table 1,BaselineCharacteristic,?x,"HSPPC-xx Dose Level ; Enrolled, no. ; ",?x, Prior treatment: no. of regimens,10,0,2,No,1:No,1:No,,0.938
3097,2835652,Table 1,BaselineCharacteristic,xx,Total ; xx ; ,?x, Prior treatment: no. of regimens,10,1,3,No,1:No,1:No,,0.86
3097,2835652,Table 1,BaselineCharacteristic,x,x.x ?g ; xx ; ,?x, Prior treatment: no. of regimens,10,2,3,No,1:No,1:No,,0.85
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,?x, Prior treatment: no. of regimens,10,3,3,No,1:No,1:No,,0.85
3097,2835652,Table 1,BaselineCharacteristic,x,xxx ?g ; x ; ,?x, Prior treatment: no. of regimens,10,4,3,No,1:No,1:No,,0.88
3097,2835652,Table 1,BaselineCharacteristic,?x,"HSPPC-xx Dose Level ; Enrolled, no. ; ",?x, Prior treatment: no. of regimens,11,0,2,No,1:No,1:No,,0.938
3097,2835652,Table 1,BaselineCharacteristic,x,Total ; xx ; ,?x, Prior treatment: no. of regimens,11,1,3,No,1:No,1:No,,0.86
3097,2835652,Table 1,BaselineCharacteristic,x,x.x ?g ; xx ; ,?x, Prior treatment: no. of regimens,11,2,3,No,1:No,1:No,,0.85
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,?x, Prior treatment: no. of regimens,11,3,3,No,1:No,1:No,,0.85
3097,2835652,Table 1,BaselineCharacteristic,x,xxx ?g ; x ; ,?x, Prior treatment: no. of regimens,11,4,3,No,1:No,1:No,,0.87
3097,2835652,Table 1,BaselineCharacteristic,?? x,"HSPPC-xx Dose Level ; Enrolled, no. ; ",?? x, Prior treatment: no. of regimens,12,0,2,No,1:No,1:No,,0.938
3097,2835652,Table 1,BaselineCharacteristic,x,Total ; xx ; ,?? x, Prior treatment: no. of regimens,12,1,3,No,1:No,1:No,,0.86
3097,2835652,Table 1,BaselineCharacteristic,x,x.x ?g ; xx ; ,?? x, Prior treatment: no. of regimens,12,2,3,No,1:No,1:No,,0.85
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,?? x, Prior treatment: no. of regimens,12,3,3,No,1:No,1:No,,0.85
3097,2835652,Table 1,BaselineCharacteristic,,xxx ?g ; x ; ,?? x, Prior treatment: no. of regimens,12,4,3,No,1:No,1:No,,0.87
3097,2835652,Table 1,BaselineCharacteristic,Prior treatment: type,"HSPPC-xx Dose Level ; Enrolled, no. ; ",None,None,13,0,2,No,1:No,1:No,,0.935
3097,2835652,Table 1,BaselineCharacteristic,,Total ; xx ; ,None,None,13,1,3,No,1:No,1:No,,0.921
3097,2835652,Table 1,BaselineCharacteristic,,x.x ?g ; xx ; ,None,None,13,2,3,No,1:No,1:No,,0.806
3097,2835652,Table 1,BaselineCharacteristic,,xx ?g ; xx ; ,None,None,13,3,3,No,1:No,1:No,,0.831
3097,2835652,Table 1,BaselineCharacteristic,,xxx ?g ; x ; ,None,None,13,4,3,No,1:No,1:No,,0.89
3097,2835652,Table 1,BaselineCharacteristic,IFN-?x alone,"HSPPC-xx Dose Level ; Enrolled, no. ; ",IFN-?x alone,,14,0,2,No,1:No,1:No,,0.936
3097,2835652,Table 1,BaselineCharacteristic,xx,Total ; xx ; ,IFN-?x alone,,14,1,3,No,1:No,1:No,,0.906
3097,2835652,Table 1,BaselineCharacteristic,x,x.x ?g ; xx ; ,IFN-?x alone,,14,2,3,No,1:No,1:No,,0.826
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,IFN-?x alone,,14,3,3,No,1:No,1:No,,0.806
3097,2835652,Table 1,BaselineCharacteristic,x,xxx ?g ; x ; ,IFN-?x alone,,14,4,3,No,1:No,1:No,,0.89
3097,2835652,Table 1,BaselineCharacteristic,IL-x alone,"HSPPC-xx Dose Level ; Enrolled, no. ; ",IL-x alone,,15,0,2,No,1:No,1:No,,0.931
3097,2835652,Table 1,BaselineCharacteristic,x,Total ; xx ; ,IL-x alone,,15,1,3,No,1:No,1:No,,0.91
3097,2835652,Table 1,BaselineCharacteristic,x,x.x ?g ; xx ; ,IL-x alone,,15,2,3,No,1:No,1:No,,0.83
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,IL-x alone,,15,3,3,No,1:No,1:No,,0.81
3097,2835652,Table 1,BaselineCharacteristic,,xxx ?g ; x ; ,IL-x alone,,15,4,3,No,1:No,1:No,,0.89
3097,2835652,Table 1,BaselineCharacteristic,IFN + IL-x,"HSPPC-xx Dose Level ; Enrolled, no. ; ",IFN + IL-x,,16,0,2,No,1:No,1:No,,0.941
3097,2835652,Table 1,BaselineCharacteristic,x,Total ; xx ; ,IFN + IL-x,,16,1,3,No,1:No,1:No,,0.96
3097,2835652,Table 1,BaselineCharacteristic,x,x.x ?g ; xx ; ,IFN + IL-x,,16,2,3,No,1:No,1:No,,0.91
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,IFN + IL-x,,16,3,3,No,1:No,1:No,,0.9
3097,2835652,Table 1,BaselineCharacteristic,,xxx ?g ; x ; ,IFN + IL-x,,16,4,3,No,1:No,1:No,,0.93
3097,2835652,Table 1,BaselineCharacteristic,Chemotherapy + IFN + IL-x,"HSPPC-xx Dose Level ; Enrolled, no. ; ",Chemotherapy + IFN + IL-x,,17,0,2,No,1:No,1:No,,0.941
3097,2835652,Table 1,BaselineCharacteristic,xx,Total ; xx ; ,Chemotherapy + IFN + IL-x,,17,1,3,No,1:No,1:No,,0.976
3097,2835652,Table 1,BaselineCharacteristic,x,x.x ?g ; xx ; ,Chemotherapy + IFN + IL-x,,17,2,3,No,1:No,1:No,,0.91
3097,2835652,Table 1,BaselineCharacteristic,xx,xx ?g ; xx ; ,Chemotherapy + IFN + IL-x,,17,3,3,No,1:No,1:No,,0.926
3097,2835652,Table 1,BaselineCharacteristic,x,xxx ?g ; x ; ,Chemotherapy + IFN + IL-x,,17,4,3,No,1:No,1:No,,0.93
3097,2835652,Table 1,BaselineCharacteristic,Chemotherapy + IFN,"HSPPC-xx Dose Level ; Enrolled, no. ; ",Chemotherapy + IFN,,18,0,2,No,1:No,1:No,,0.925
3097,2835652,Table 1,BaselineCharacteristic,x,Total ; xx ; ,Chemotherapy + IFN,,18,1,3,No,1:No,1:No,,0.95
3097,2835652,Table 1,BaselineCharacteristic,,x.x ?g ; xx ; ,Chemotherapy + IFN,,18,2,3,No,1:No,1:No,,0.9
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,Chemotherapy + IFN,,18,3,3,No,1:No,1:No,,0.89
3097,2835652,Table 1,BaselineCharacteristic,,xxx ?g ; x ; ,Chemotherapy + IFN,,18,4,3,No,1:No,1:No,,0.93
3097,2835652,Table 1,BaselineCharacteristic,Systemic chemotherapy alone,"HSPPC-xx Dose Level ; Enrolled, no. ; ",Systemic chemotherapy alone,,19,0,2,No,1:No,1:No,,0.915
3097,2835652,Table 1,BaselineCharacteristic,xx,Total ; xx ; ,Systemic chemotherapy alone,,19,1,3,No,1:No,1:No,,0.947
3097,2835652,Table 1,BaselineCharacteristic,x,x.x ?g ; xx ; ,Systemic chemotherapy alone,,19,2,3,No,1:No,1:No,,0.851
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,Systemic chemotherapy alone,,19,3,3,No,1:No,1:No,,0.831
3097,2835652,Table 1,BaselineCharacteristic,x,xxx ?g ; x ; ,Systemic chemotherapy alone,,19,4,3,No,1:No,1:No,,0.9
3097,2835652,Table 1,BaselineCharacteristic,,"HSPPC-xx Dose Level ; Enrolled, no. ; ",None,None,20,0,2,No,1:No,1:No,,0.915
3097,2835652,Table 1,BaselineCharacteristic,,Total ; xx ; ,None,None,20,1,3,No,1:No,1:No,,0.927
3097,2835652,Table 1,BaselineCharacteristic,,x.x ?g ; xx ; ,None,None,20,2,3,No,1:No,1:No,,0.821
3097,2835652,Table 1,BaselineCharacteristic,,xx ?g ; xx ; ,None,None,20,3,3,No,1:No,1:No,,0.847
3097,2835652,Table 1,BaselineCharacteristic,,xxx ?g ; x ; ,None,None,20,4,3,No,1:No,1:No,,0.89
3097,2835652,Table 1,BaselineCharacteristic,Elevated serum LDH level,"HSPPC-xx Dose Level ; Enrolled, no. ; ",Elevated serum LDH level,,21,0,2,No,1:No,1:No,,0.933
3097,2835652,Table 1,BaselineCharacteristic,x,Total ; xx ; ,Elevated serum LDH level,,21,1,3,No,1:No,1:No,,0.891
3097,2835652,Table 1,BaselineCharacteristic,x,x.x ?g ; xx ; ,Elevated serum LDH level,,21,2,3,No,1:No,1:No,,0.821
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,Elevated serum LDH level,,21,3,3,No,1:No,1:No,,0.801
3097,2835652,Table 1,BaselineCharacteristic,x,xxx ?g ; x ; ,Elevated serum LDH level,,21,4,3,No,1:No,1:No,,0.89
3097,2835652,Table 1,BaselineCharacteristic,Serum level albumin <x.x mg/dl,"HSPPC-xx Dose Level ; Enrolled, no. ; ",Serum level albumin <x.x mg/dl,,22,0,2,No,1:No,1:No,,0.973
3097,2835652,Table 1,BaselineCharacteristic,x,Total ; xx ; ,Serum level albumin <x.x mg/dl,,22,1,3,No,1:No,1:No,,0.901
3097,2835652,Table 1,BaselineCharacteristic,x,x.x ?g ; xx ; ,Serum level albumin <x.x mg/dl,,22,2,3,No,1:No,1:No,,0.831
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,Serum level albumin <x.x mg/dl,,22,3,3,No,1:No,1:No,,0.811
3097,2835652,Table 1,BaselineCharacteristic,x,xxx ?g ; x ; ,Serum level albumin <x.x mg/dl,,22,4,3,No,1:No,1:No,,0.9
3097,2835652,Table 1,BaselineCharacteristic,,"HSPPC-xx Dose Level ; Enrolled, no. ; ",None,None,23,0,2,No,1:No,1:No,,0.935
3097,2835652,Table 1,BaselineCharacteristic,,Total ; xx ; ,None,None,23,1,3,No,1:No,1:No,,0.937
3097,2835652,Table 1,BaselineCharacteristic,,x.x ?g ; xx ; ,None,None,23,2,3,No,1:No,1:No,,0.831
3097,2835652,Table 1,BaselineCharacteristic,,xx ?g ; xx ; ,None,None,23,3,3,No,1:No,1:No,,0.857
3097,2835652,Table 1,BaselineCharacteristic,,xxx ?g ; x ; ,None,None,23,4,3,No,1:No,1:No,,0.89
3097,2835652,Table 1,BaselineCharacteristic,Melanoma Characteristics,"HSPPC-xx Dose Level ; Enrolled, no. ; ",None,None,24,0,2,No,1:No,1:No,,0.935
3097,2835652,Table 1,BaselineCharacteristic,,Total ; xx ; ,None,None,24,1,3,No,1:No,1:No,,0.937
3097,2835652,Table 1,BaselineCharacteristic,,x.x ?g ; xx ; ,None,None,24,2,3,No,1:No,1:No,,0.831
3097,2835652,Table 1,BaselineCharacteristic,,xx ?g ; xx ; ,None,None,24,3,3,No,1:No,1:No,,0.857
3097,2835652,Table 1,BaselineCharacteristic,,xxx ?g ; x ; ,None,None,24,4,3,No,1:No,1:No,,0.89
3097,2835652,Table 1,BaselineCharacteristic,Regional nodal disease alone,"HSPPC-xx Dose Level ; Enrolled, no. ; ",Regional nodal disease alone,,25,0,2,No,1:No,1:No,,0.945
3097,2835652,Table 1,BaselineCharacteristic,x (xx%),Total ; xx ; ,Regional nodal disease alone,,25,1,3,No,1:No,1:No,,0.941
3097,2835652,Table 1,BaselineCharacteristic,x,x.x ?g ; xx ; ,Regional nodal disease alone,,25,2,3,No,1:No,1:No,,0.841
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,Regional nodal disease alone,,25,3,3,No,1:No,1:No,,0.821
3097,2835652,Table 1,BaselineCharacteristic,x,xxx ?g ; x ; ,Regional nodal disease alone,,25,4,3,No,1:No,1:No,,0.89
3097,2835652,Table 1,BaselineCharacteristic,Regional nodal and in-transit disease,"HSPPC-xx Dose Level ; Enrolled, no. ; ",Regional nodal and in-transit disease,,26,0,2,No,1:No,1:No,,0.955
3097,2835652,Table 1,BaselineCharacteristic,x (xx%),Total ; xx ; ,Regional nodal and in-transit disease,,26,1,3,No,1:No,1:No,,0.941
3097,2835652,Table 1,BaselineCharacteristic,x,x.x ?g ; xx ; ,Regional nodal and in-transit disease,,26,2,3,No,1:No,1:No,,0.851
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,Regional nodal and in-transit disease,,26,3,3,No,1:No,1:No,,0.831
3097,2835652,Table 1,BaselineCharacteristic,,xxx ?g ; x ; ,Regional nodal and in-transit disease,,26,4,3,No,1:No,1:No,,0.89
3097,2835652,Table 1,BaselineCharacteristic,Advanced disease,"HSPPC-xx Dose Level ; Enrolled, no. ; ",Advanced disease,,27,0,2,No,1:No,1:No,,0.945
3097,2835652,Table 1,BaselineCharacteristic,xx (xx%),Total ; xx ; ,Advanced disease,,27,1,3,No,1:No,1:No,,0.957
3097,2835652,Table 1,BaselineCharacteristic,x,x.x ?g ; xx ; ,Advanced disease,,27,2,3,No,1:No,1:No,,0.831
3097,2835652,Table 1,BaselineCharacteristic,xx,xx ?g ; xx ; ,Advanced disease,,27,3,3,No,1:No,1:No,,0.857
3097,2835652,Table 1,BaselineCharacteristic,x,xxx ?g ; x ; ,Advanced disease,,27,4,3,No,1:No,1:No,,0.89
3097,2835652,Table 1,BaselineCharacteristic,?No. of visceral organs involved,"HSPPC-xx Dose Level ; Enrolled, no. ; ",None,None,28,0,24,No,1:No,1:No,,0.935
3097,2835652,Table 1,BaselineCharacteristic,,Total ; xx ; ,?No. of visceral organs involved,None,28,1,43,No,1:No,1:No,,0.955
3097,2835652,Table 1,BaselineCharacteristic,,x.x ?g ; xx ; ,?No. of visceral organs involved,None,28,2,43,No,1:No,1:No,,0.836
3097,2835652,Table 1,BaselineCharacteristic,,xx ?g ; xx ; ,?No. of visceral organs involved,None,28,3,43,No,1:No,1:No,,0.885
3097,2835652,Table 1,BaselineCharacteristic,,xxx ?g ; x ; ,?No. of visceral organs involved,None,28,4,43,No,1:No,1:No,,0.864
3097,2835652,Table 1,BaselineCharacteristic,"??x (subcutaneous, nodal)","HSPPC-xx Dose Level ; Enrolled, no. ; ","??x (subcutaneous, nodal)", Advanced disease ?No. of visceral organs involved,29,0,24,No,1:No,1:No,,0.973
3097,2835652,Table 1,BaselineCharacteristic,x,Total ; xx ; ,"??x (subcutaneous, nodal)", Advanced disease ?No. of visceral organs involved,29,1,43,No,1:No,1:No,,0.897
3097,2835652,Table 1,BaselineCharacteristic,x,x.x ?g ; xx ; ,"??x (subcutaneous, nodal)", Advanced disease ?No. of visceral organs involved,29,2,43,No,1:No,1:No,,0.848
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,"??x (subcutaneous, nodal)", Advanced disease ?No. of visceral organs involved,29,3,43,No,1:No,1:No,,0.848
3097,2835652,Table 1,BaselineCharacteristic,x,xxx ?g ; x ; ,"??x (subcutaneous, nodal)", Advanced disease ?No. of visceral organs involved,29,4,43,No,1:No,1:No,,0.864
3097,2835652,Table 1,BaselineCharacteristic,???x,"HSPPC-xx Dose Level ; Enrolled, no. ; ",???x," Advanced disease ?No. of visceral organs involved ??x (subcutaneous, nodal)",30,0,2,No,1:No,1:No,,0.958
3097,2835652,Table 1,BaselineCharacteristic,xx,Total ; xx ; ,???x," Advanced disease ?No. of visceral organs involved ??x (subcutaneous, nodal)",30,1,3,No,1:No,1:No,,0.916
3097,2835652,Table 1,BaselineCharacteristic,x,x.x ?g ; xx ; ,???x," Advanced disease ?No. of visceral organs involved ??x (subcutaneous, nodal)",30,2,3,No,1:No,1:No,,0.866
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,???x," Advanced disease ?No. of visceral organs involved ??x (subcutaneous, nodal)",30,3,3,No,1:No,1:No,,0.866
3097,2835652,Table 1,BaselineCharacteristic,x,xxx ?g ; x ; ,???x," Advanced disease ?No. of visceral organs involved ??x (subcutaneous, nodal)",30,4,3,No,1:No,1:No,,0.89
3097,2835652,Table 1,BaselineCharacteristic,???x,"HSPPC-xx Dose Level ; Enrolled, no. ; ",???x," Advanced disease ?No. of visceral organs involved ??x (subcutaneous, nodal)",31,0,2,No,1:No,1:No,,0.958
3097,2835652,Table 1,BaselineCharacteristic,x,Total ; xx ; ,???x," Advanced disease ?No. of visceral organs involved ??x (subcutaneous, nodal)",31,1,3,No,1:No,1:No,,0.916
3097,2835652,Table 1,BaselineCharacteristic,x,x.x ?g ; xx ; ,???x," Advanced disease ?No. of visceral organs involved ??x (subcutaneous, nodal)",31,2,3,No,1:No,1:No,,0.866
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,???x," Advanced disease ?No. of visceral organs involved ??x (subcutaneous, nodal)",31,3,3,No,1:No,1:No,,0.866
3097,2835652,Table 1,BaselineCharacteristic,,xxx ?g ; x ; ,???x," Advanced disease ?No. of visceral organs involved ??x (subcutaneous, nodal)",31,4,3,No,1:No,1:No,,0.89
3097,2835652,Table 1,BaselineCharacteristic,???x,"HSPPC-xx Dose Level ; Enrolled, no. ; ",???x," Advanced disease ?No. of visceral organs involved ??x (subcutaneous, nodal)",32,0,2,No,1:No,1:No,,0.958
3097,2835652,Table 1,BaselineCharacteristic,x,Total ; xx ; ,???x," Advanced disease ?No. of visceral organs involved ??x (subcutaneous, nodal)",32,1,3,No,1:No,1:No,,0.916
3097,2835652,Table 1,BaselineCharacteristic,,x.x ?g ; xx ; ,???x," Advanced disease ?No. of visceral organs involved ??x (subcutaneous, nodal)",32,2,3,No,1:No,1:No,,0.866
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,???x," Advanced disease ?No. of visceral organs involved ??x (subcutaneous, nodal)",32,3,3,No,1:No,1:No,,0.866
3097,2835652,Table 1,BaselineCharacteristic,,xxx ?g ; x ; ,???x," Advanced disease ?No. of visceral organs involved ??x (subcutaneous, nodal)",32,4,3,No,1:No,1:No,,0.89
3097,2835652,Table 1,BaselineCharacteristic,??Visceral sites of disease,"HSPPC-xx Dose Level ; Enrolled, no. ; ",None,None,33,0,2,No,1:No,1:No,,0.936
3097,2835652,Table 1,BaselineCharacteristic,,Total ; xx ; ,None,None,33,1,3,No,1:No,1:No,,0.937
3097,2835652,Table 1,BaselineCharacteristic,,x.x ?g ; xx ; ,None,None,33,2,3,No,1:No,1:No,,0.831
3097,2835652,Table 1,BaselineCharacteristic,,xx ?g ; xx ; ,None,None,33,3,3,No,1:No,1:No,,0.857
3097,2835652,Table 1,BaselineCharacteristic,,xxx ?g ; x ; ,None,None,33,4,3,No,1:No,1:No,,0.89
3097,2835652,Table 1,BaselineCharacteristic,Lung alone,"HSPPC-xx Dose Level ; Enrolled, no. ; ",Lung alone,,34,0,2,No,1:No,1:No,,0.945
3097,2835652,Table 1,BaselineCharacteristic,xx,Total ; xx ; ,Lung alone,,34,1,3,No,1:No,1:No,,0.937
3097,2835652,Table 1,BaselineCharacteristic,x,x.x ?g ; xx ; ,Lung alone,,34,2,3,No,1:No,1:No,,0.831
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,Lung alone,,34,3,3,No,1:No,1:No,,0.811
3097,2835652,Table 1,BaselineCharacteristic,x,xxx ?g ; x ; ,Lung alone,,34,4,3,No,1:No,1:No,,0.89
3097,2835652,Table 1,BaselineCharacteristic,Gastrointestinal tract alone,"HSPPC-xx Dose Level ; Enrolled, no. ; ",Gastrointestinal tract alone,,35,0,2,No,1:No,1:No,,0.945
3097,2835652,Table 1,BaselineCharacteristic,x,Total ; xx ; ,Gastrointestinal tract alone,,35,1,3,No,1:No,1:No,,0.901
3097,2835652,Table 1,BaselineCharacteristic,,x.x ?g ; xx ; ,Gastrointestinal tract alone,,35,2,3,No,1:No,1:No,,0.831
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,Gastrointestinal tract alone,,35,3,3,No,1:No,1:No,,0.811
3097,2835652,Table 1,BaselineCharacteristic,,xxx ?g ; x ; ,Gastrointestinal tract alone,,35,4,3,No,1:No,1:No,,0.89
3097,2835652,Table 1,BaselineCharacteristic,Brain alone,"HSPPC-xx Dose Level ; Enrolled, no. ; ",Brain alone,,36,0,2,No,1:No,1:No,,0.951
3097,2835652,Table 1,BaselineCharacteristic,x,Total ; xx ; ,Brain alone,,36,1,3,No,1:No,1:No,,0.905
3097,2835652,Table 1,BaselineCharacteristic,x,x.x ?g ; xx ; ,Brain alone,,36,2,3,No,1:No,1:No,,0.835
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,Brain alone,,36,3,3,No,1:No,1:No,,0.815
3097,2835652,Table 1,BaselineCharacteristic,,xxx ?g ; x ; ,Brain alone,,36,4,3,No,1:No,1:No,,0.89
3097,2835652,Table 1,BaselineCharacteristic,Lung + x other visceral organ,"HSPPC-xx Dose Level ; Enrolled, no. ; ",Lung + x other visceral organ,,37,0,2,No,1:No,1:No,,0.956
3097,2835652,Table 1,BaselineCharacteristic,x,Total ; xx ; ,Lung + x other visceral organ,,37,1,3,No,1:No,1:No,,0.935
3097,2835652,Table 1,BaselineCharacteristic,x,x.x ?g ; xx ; ,Lung + x other visceral organ,,37,2,3,No,1:No,1:No,,0.885
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,Lung + x other visceral organ,,37,3,3,No,1:No,1:No,,0.865
3097,2835652,Table 1,BaselineCharacteristic,,xxx ?g ; x ; ,Lung + x other visceral organ,,37,4,3,No,1:No,1:No,,0.92
3097,2835652,Table 1,BaselineCharacteristic,Liver + x other visceral organ,"HSPPC-xx Dose Level ; Enrolled, no. ; ",Liver + x other visceral organ,,38,0,2,No,1:No,1:No,,0.956
3097,2835652,Table 1,BaselineCharacteristic,x,Total ; xx ; ,Liver + x other visceral organ,,38,1,3,No,1:No,1:No,,0.935
3097,2835652,Table 1,BaselineCharacteristic,x,x.x ?g ; xx ; ,Liver + x other visceral organ,,38,2,3,No,1:No,1:No,,0.885
3097,2835652,Table 1,BaselineCharacteristic,,xx ?g ; xx ; ,Liver + x other visceral organ,,38,3,3,No,1:No,1:No,,0.865
3097,2835652,Table 1,BaselineCharacteristic,,xxx ?g ; x ; ,Liver + x other visceral organ,,38,4,3,No,1:No,1:No,,0.92
3097,2835652,Table 1,BaselineCharacteristic,Brain + x-x other visceral organs,"HSPPC-xx Dose Level ; Enrolled, no. ; ",Brain + x-x other visceral organs,,39,0,2,No,1:No,1:No,,0.971
3097,2835652,Table 1,BaselineCharacteristic,x,Total ; xx ; ,Brain + x-x other visceral organs,,39,1,3,No,1:No,1:No,,0.935
3097,2835652,Table 1,BaselineCharacteristic,,x.x ?g ; xx ; ,Brain + x-x other visceral organs,,39,2,3,No,1:No,1:No,,0.885
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,Brain + x-x other visceral organs,,39,3,3,No,1:No,1:No,,0.865
3097,2835652,Table 1,BaselineCharacteristic,,xxx ?g ; x ; ,Brain + x-x other visceral organs,,39,4,3,No,1:No,1:No,,0.92
3097,2835652,Table 1,BaselineCharacteristic,,"HSPPC-xx Dose Level ; Enrolled, no. ; ",None,None,40,0,2,No,1:No,1:No,,0.945
3097,2835652,Table 1,BaselineCharacteristic,,Total ; xx ; ,None,None,40,1,3,No,1:No,1:No,,0.937
3097,2835652,Table 1,BaselineCharacteristic,,x.x ?g ; xx ; ,None,None,40,2,3,No,1:No,1:No,,0.831
3097,2835652,Table 1,BaselineCharacteristic,,xx ?g ; xx ; ,None,None,40,3,3,No,1:No,1:No,,0.857
3097,2835652,Table 1,BaselineCharacteristic,,xxx ?g ; x ; ,None,None,40,4,3,No,1:No,1:No,,0.89
3097,2835652,Table 1,BaselineCharacteristic,HSPPC-xx derivation,"HSPPC-xx Dose Level ; Enrolled, no. ; ",None,None,41,0,2,No,1:No,1:No,,0.945
3097,2835652,Table 1,BaselineCharacteristic,,Total ; xx ; ,None,None,41,1,3,No,1:No,1:No,,0.937
3097,2835652,Table 1,BaselineCharacteristic,,x.x ?g ; xx ; ,None,None,41,2,3,No,1:No,1:No,,0.831
3097,2835652,Table 1,BaselineCharacteristic,,xx ?g ; xx ; ,None,None,41,3,3,No,1:No,1:No,,0.857
3097,2835652,Table 1,BaselineCharacteristic,,xxx ?g ; x ; ,None,None,41,4,3,No,1:No,1:No,,0.89
3097,2835652,Table 1,BaselineCharacteristic,Subcutaneous metastases,"HSPPC-xx Dose Level ; Enrolled, no. ; ",Subcutaneous metastases,,42,0,2,No,1:No,1:No,,0.945
3097,2835652,Table 1,BaselineCharacteristic,x,Total ; xx ; ,Subcutaneous metastases,,42,1,3,No,1:No,1:No,,0.901
3097,2835652,Table 1,BaselineCharacteristic,x,x.x ?g ; xx ; ,Subcutaneous metastases,,42,2,3,No,1:No,1:No,,0.831
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,Subcutaneous metastases,,42,3,3,No,1:No,1:No,,0.811
3097,2835652,Table 1,BaselineCharacteristic,,xxx ?g ; x ; ,Subcutaneous metastases,,42,4,3,No,1:No,1:No,,0.89
3097,2835652,Table 1,BaselineCharacteristic,Lymph node metastases,"HSPPC-xx Dose Level ; Enrolled, no. ; ",Lymph node metastases,,43,0,2,No,1:No,1:No,,0.945
3097,2835652,Table 1,BaselineCharacteristic,xx,Total ; xx ; ,Lymph node metastases,,43,1,3,No,1:No,1:No,,0.941
3097,2835652,Table 1,BaselineCharacteristic,x,x.x ?g ; xx ; ,Lymph node metastases,,43,2,3,No,1:No,1:No,,0.831
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,Lymph node metastases,,43,3,3,No,1:No,1:No,,0.811
3097,2835652,Table 1,BaselineCharacteristic,x,xxx ?g ; x ; ,Lymph node metastases,,43,4,3,No,1:No,1:No,,0.89
3097,2835652,Table 1,BaselineCharacteristic,Lung metastases,"HSPPC-xx Dose Level ; Enrolled, no. ; ",Lung metastases,,44,0,2,No,1:No,1:No,,0.945
3097,2835652,Table 1,BaselineCharacteristic,x,Total ; xx ; ,Lung metastases,,44,1,3,No,1:No,1:No,,0.901
3097,2835652,Table 1,BaselineCharacteristic,x,x.x ?g ; xx ; ,Lung metastases,,44,2,3,No,1:No,1:No,,0.831
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,Lung metastases,,44,3,3,No,1:No,1:No,,0.811
3097,2835652,Table 1,BaselineCharacteristic,x,xxx ?g ; x ; ,Lung metastases,,44,4,3,No,1:No,1:No,,0.89
3097,2835652,Table 1,BaselineCharacteristic,Liver or GI metastases,"HSPPC-xx Dose Level ; Enrolled, no. ; ",Liver or GI metastases,,45,0,2,No,1:No,1:No,,0.945
3097,2835652,Table 1,BaselineCharacteristic,x,Total ; xx ; ,Liver or GI metastases,,45,1,3,No,1:No,1:No,,0.936
3097,2835652,Table 1,BaselineCharacteristic,x,x.x ?g ; xx ; ,Liver or GI metastases,,45,2,3,No,1:No,1:No,,0.866
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,Liver or GI metastases,,45,3,3,No,1:No,1:No,,0.846
3097,2835652,Table 1,BaselineCharacteristic,,xxx ?g ; x ; ,Liver or GI metastases,,45,4,3,No,1:No,1:No,,0.89
3097,2835652,Table 1,BaselineCharacteristic,,"HSPPC-xx Dose Level ; Enrolled, no. ; ",None,None,46,0,2,No,1:No,1:No,,0.945
3097,2835652,Table 1,BaselineCharacteristic,,Total ; xx ; ,None,None,46,1,3,No,1:No,1:No,,0.937
3097,2835652,Table 1,BaselineCharacteristic,,x.x ?g ; xx ; ,None,None,46,2,3,No,1:No,1:No,,0.831
3097,2835652,Table 1,BaselineCharacteristic,,xx ?g ; xx ; ,None,None,46,3,3,No,1:No,1:No,,0.857
3097,2835652,Table 1,BaselineCharacteristic,,xxx ?g ; x ; ,None,None,46,4,3,No,1:No,1:No,,0.89
3097,2835652,Table 1,BaselineCharacteristic,HSPPC-xx treatment setting,"HSPPC-xx Dose Level ; Enrolled, no. ; ",None,None,47,0,2,No,1:No,1:No,,0.945
3097,2835652,Table 1,BaselineCharacteristic,,Total ; xx ; ,None,None,47,1,3,No,1:No,1:No,,0.937
3097,2835652,Table 1,BaselineCharacteristic,,x.x ?g ; xx ; ,None,None,47,2,3,No,1:No,1:No,,0.831
3097,2835652,Table 1,BaselineCharacteristic,,xx ?g ; xx ; ,None,None,47,3,3,No,1:No,1:No,,0.857
3097,2835652,Table 1,BaselineCharacteristic,,xxx ?g ; x ; ,None,None,47,4,3,No,1:No,1:No,,0.89
3097,2835652,Table 1,BaselineCharacteristic,???Indicators,"HSPPC-xx Dose Level ; Enrolled, no. ; ",???Indicators, HSPPC-xx treatment setting ?No. of visceral organs involved ??Visceral sites of disease,48,0,2,No,1:No,1:No,,0.946
3097,2835652,Table 1,BaselineCharacteristic,xx (xx%),Total ; xx ; ,???Indicators, HSPPC-xx treatment setting ?No. of visceral organs involved ??Visceral sites of disease,48,1,3,No,1:No,1:No,,0.911
3097,2835652,Table 1,BaselineCharacteristic,x,x.x ?g ; xx ; ,???Indicators, HSPPC-xx treatment setting ?No. of visceral organs involved ??Visceral sites of disease,48,2,3,No,1:No,1:No,,0.846
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,???Indicators, HSPPC-xx treatment setting ?No. of visceral organs involved ??Visceral sites of disease,48,3,3,No,1:No,1:No,,0.856
3097,2835652,Table 1,BaselineCharacteristic,x,xxx ?g ; x ; ,???Indicators, HSPPC-xx treatment setting ?No. of visceral organs involved ??Visceral sites of disease,48,4,3,No,1:No,1:No,,0.93
3097,2835652,Table 1,BaselineCharacteristic,Stage III disease,"HSPPC-xx Dose Level ; Enrolled, no. ; ",Stage III disease,,49,0,2,No,1:No,1:No,,0.945
3097,2835652,Table 1,BaselineCharacteristic,x,Total ; xx ; ,Stage III disease,,49,1,3,No,1:No,1:No,,0.901
3097,2835652,Table 1,BaselineCharacteristic,,x.x ?g ; xx ; ,Stage III disease,,49,2,3,No,1:No,1:No,,0.831
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,Stage III disease,,49,3,3,No,1:No,1:No,,0.811
3097,2835652,Table 1,BaselineCharacteristic,,xxx ?g ; x ; ,Stage III disease,,49,4,3,No,1:No,1:No,,0.89
3097,2835652,Table 1,BaselineCharacteristic,Stage IV disease,"HSPPC-xx Dose Level ; Enrolled, no. ; ",Stage IV disease,,50,0,2,No,1:No,1:No,,0.921
3097,2835652,Table 1,BaselineCharacteristic,xx,Total ; xx ; ,Stage IV disease,,50,1,3,No,1:No,1:No,,0.907
3097,2835652,Table 1,BaselineCharacteristic,x,x.x ?g ; xx ; ,Stage IV disease,,50,2,3,No,1:No,1:No,,0.801
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,Stage IV disease,,50,3,3,No,1:No,1:No,,0.781
3097,2835652,Table 1,BaselineCharacteristic,x,xxx ?g ; x ; ,Stage IV disease,,50,4,3,No,1:No,1:No,,0.86
3097,2835652,Table 1,BaselineCharacteristic,???Adjuvant,"HSPPC-xx Dose Level ; Enrolled, no. ; ",???Adjuvant, Stage IV disease ?No. of visceral organs involved ??Visceral sites of disease,51,0,2,No,1:No,1:No,,0.913
3097,2835652,Table 1,BaselineCharacteristic,xx (xx%),Total ; xx ; ,???Adjuvant, Stage IV disease ?No. of visceral organs involved ??Visceral sites of disease,51,1,3,No,1:No,1:No,,0.861
3097,2835652,Table 1,BaselineCharacteristic,x,x.x ?g ; xx ; ,???Adjuvant, Stage IV disease ?No. of visceral organs involved ??Visceral sites of disease,51,2,3,No,1:No,1:No,,0.746
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,???Adjuvant, Stage IV disease ?No. of visceral organs involved ??Visceral sites of disease,51,3,3,No,1:No,1:No,,0.756
3097,2835652,Table 1,BaselineCharacteristic,x,xxx ?g ; x ; ,???Adjuvant, Stage IV disease ?No. of visceral organs involved ??Visceral sites of disease,51,4,3,No,1:No,1:No,,0.85
3097,2835652,Table 1,BaselineCharacteristic,Stage III disease,"HSPPC-xx Dose Level ; Enrolled, no. ; ",Stage III disease,,52,0,2,No,1:No,1:No,,0.945
3097,2835652,Table 1,BaselineCharacteristic,x,Total ; xx ; ,Stage III disease,,52,1,3,No,1:No,1:No,,0.901
3097,2835652,Table 1,BaselineCharacteristic,x,x.x ?g ; xx ; ,Stage III disease,,52,2,3,No,1:No,1:No,,0.831
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,Stage III disease,,52,3,3,No,1:No,1:No,,0.811
3097,2835652,Table 1,BaselineCharacteristic,x,xxx ?g ; x ; ,Stage III disease,,52,4,3,No,1:No,1:No,,0.89
3097,2835652,Table 1,BaselineCharacteristic,Stage IV disease,"HSPPC-xx Dose Level ; Enrolled, no. ; ",Stage IV disease,,53,0,2,No,1:No,1:No,,0.921
3097,2835652,Table 1,BaselineCharacteristic,xx,Total ; xx ; ,Stage IV disease,,53,1,3,No,1:No,1:No,,0.907
3097,2835652,Table 1,BaselineCharacteristic,x,x.x ?g ; xx ; ,Stage IV disease,,53,2,3,No,1:No,1:No,,0.801
3097,2835652,Table 1,BaselineCharacteristic,x,xx ?g ; xx ; ,Stage IV disease,,53,3,3,No,1:No,1:No,,0.781
3097,2835652,Table 1,BaselineCharacteristic,x,xxx ?g ; x ; ,Stage IV disease,,53,4,3,No,1:No,1:No,,0.86
3105,2837631,Table 1,BaselineCharacteristic,Age (years),,Age (years),,0,0,2,No,1:No,1:No,,0.65
3105,2837631,Table 1,BaselineCharacteristic,Menopausal status,,None,None,1,0,24,No,1:No,1:No,,0.897
3105,2837631,Table 1,BaselineCharacteristic,,,Menopausal status,None,1,1,43,No,1:No,1:No,,0.86
3105,2837631,Table 1,BaselineCharacteristic,?Pre,,?Pre, Menopausal status,2,0,2,No,1:No,1:No,,0.82
3105,2837631,Table 1,BaselineCharacteristic,x,,?Pre, Menopausal status,2,1,3,No,1:No,1:No,,0.74
3105,2837631,Table 1,BaselineCharacteristic,?Post,,?Post, Menopausal status,3,0,2,No,1:No,1:No,,0.96
3105,2837631,Table 1,BaselineCharacteristic,xx,,?Post, Menopausal status,3,1,3,No,1:No,1:No,,0.681
3105,2837631,Table 1,BaselineCharacteristic,Smoking habits,,None,None,4,0,24,No,1:No,1:No,,0.929
3105,2837631,Table 1,BaselineCharacteristic,,,Smoking habits,None,4,1,43,No,1:No,1:No,,0.902
3105,2837631,Table 1,BaselineCharacteristic,?Smokers/Ex smokers,,?Smokers/Ex smokers, Smoking habits,5,0,2,No,1:No,1:No,,0.97
3105,2837631,Table 1,BaselineCharacteristic,x,,?Smokers/Ex smokers, Smoking habits,5,1,3,No,1:No,1:No,,0.93
3105,2837631,Table 1,BaselineCharacteristic,?Non smokers,,?Non smokers, Smoking habits,6,0,2,No,1:No,1:No,,0.99
3105,2837631,Table 1,BaselineCharacteristic,xx,,?Non smokers, Smoking habits,6,1,3,No,1:No,1:No,,0.801
3105,2837631,Table 1,BaselineCharacteristic,Histologic type,,None,None,7,0,24,No,1:No,1:No,,0.974
3105,2837631,Table 1,BaselineCharacteristic,,,Histologic type,None,7,1,43,No,1:No,1:No,,0.967
3105,2837631,Table 1,BaselineCharacteristic,?Invasive ductal,,?Invasive ductal, Histologic type,8,0,2,No,1:No,1:No,,0.99
3105,2837631,Table 1,BaselineCharacteristic,xx,,?Invasive ductal, Histologic type,8,1,3,No,1:No,1:No,,0.831
3105,2837631,Table 1,BaselineCharacteristic,?Invasive lobular,,?Invasive lobular, Histologic type,9,0,2,No,1:No,1:No,,1
3105,2837631,Table 1,BaselineCharacteristic,x,,?Invasive lobular, Histologic type,9,1,3,No,1:No,1:No,,0.98
3105,2837631,Table 1,BaselineCharacteristic,?Mixed ductal/lobular,,?Mixed ductal/lobular, Histologic type,10,0,2,No,1:No,1:No,,0.97
3105,2837631,Table 1,BaselineCharacteristic,x,,?Mixed ductal/lobular, Histologic type,10,1,3,No,1:No,1:No,,0.97
3105,2837631,Table 1,BaselineCharacteristic,?Other,,?Other, Histologic type,11,0,2,No,1:No,1:No,,1
3105,2837631,Table 1,BaselineCharacteristic,x,,?Other, Histologic type,11,1,3,No,1:No,1:No,,1
3105,2837631,Table 1,BaselineCharacteristic,?DCIS,,?DCIS, Histologic type,12,0,2,No,1:No,1:No,,1
3105,2837631,Table 1,BaselineCharacteristic,x,,?DCIS, Histologic type,12,1,3,No,1:No,1:No,,1
3105,2837631,Table 1,BaselineCharacteristic,Grading,,None,None,13,0,24,No,1:No,1:No,,0.995
3105,2837631,Table 1,BaselineCharacteristic,,,Grading,None,13,1,43,No,1:No,1:No,,0.977
3105,2837631,Table 1,BaselineCharacteristic,?x,,?x, Grading,14,0,2,No,1:No,1:No,,0.982
3105,2837631,Table 1,BaselineCharacteristic,x,,?x, Grading,14,1,3,No,1:No,1:No,,1
3105,2837631,Table 1,BaselineCharacteristic,?x,,?x, Grading,15,0,2,No,1:No,1:No,,0.982
3105,2837631,Table 1,BaselineCharacteristic,xx,,?x, Grading,15,1,3,No,1:No,1:No,,0.906
3105,2837631,Table 1,BaselineCharacteristic,?x,,?x, Grading,16,0,2,No,1:No,1:No,,0.982
3105,2837631,Table 1,BaselineCharacteristic,x,,?x, Grading,16,1,3,No,1:No,1:No,,0.99
3105,2837631,Table 1,BaselineCharacteristic,?Not evaluable,,?Not evaluable, Grading,17,0,2,No,1:No,1:No,,1
3105,2837631,Table 1,BaselineCharacteristic,x,,?Not evaluable, Grading,17,1,3,No,1:No,1:No,,0.99
3105,2837631,Table 1,BaselineCharacteristic,Tumor diameter (mm),,Tumor diameter (mm),,18,0,2,No,1:No,1:No,,0.99
3105,2837631,Table 1,BaselineCharacteristic,pT stage,,None,None,19,0,24,No,1:No,1:No,,0.985
3105,2837631,Table 1,BaselineCharacteristic,,,pT stage,None,19,1,43,No,1:No,1:No,,0.957
3105,2837631,Table 1,BaselineCharacteristic,?pTis,,?pTis, pT stage,20,0,2,No,1:No,1:No,,0.99
3105,2837631,Table 1,BaselineCharacteristic,x,,?pTis, pT stage,20,1,3,No,1:No,1:No,,0.98
3105,2837631,Table 1,BaselineCharacteristic,?pTx mic,,?pTx mic, pT stage,21,0,2,No,1:No,1:No,,0.99
3105,2837631,Table 1,BaselineCharacteristic,x,,?pTx mic, pT stage,21,1,3,No,1:No,1:No,,0.98
3105,2837631,Table 1,BaselineCharacteristic,?pTxa,,?pTxa, pT stage,22,0,2,No,1:No,1:No,,1
3105,2837631,Table 1,BaselineCharacteristic,x,,?pTxa, pT stage,22,1,3,No,1:No,1:No,,0.99
3105,2837631,Table 1,BaselineCharacteristic,?pTxb,,?pTxb, pT stage,23,0,2,No,1:No,1:No,,1
3105,2837631,Table 1,BaselineCharacteristic,x,,?pTxb, pT stage,23,1,3,No,1:No,1:No,,0.99
3105,2837631,Table 1,BaselineCharacteristic,?pTxc,,?pTxc, pT stage,24,0,2,No,1:No,1:No,,1
3105,2837631,Table 1,BaselineCharacteristic,xx,,?pTxc, pT stage,24,1,3,No,1:No,1:No,,0.945
3105,2837631,Table 1,BaselineCharacteristic,?pTx,,?pTx, pT stage,25,0,2,No,1:No,1:No,,1
3105,2837631,Table 1,BaselineCharacteristic,x,,?pTx, pT stage,25,1,3,No,1:No,1:No,,0.99
3105,2837631,Table 1,BaselineCharacteristic,pN stage (not including DCIS),,None,None,26,0,24,No,1:No,1:No,,0.995
3105,2837631,Table 1,BaselineCharacteristic,,,pN stage (not including DCIS),None,26,1,43,No,1:No,1:No,,0.967
3105,2837631,Table 1,BaselineCharacteristic,?pN stage,,None,None,27,0,2,No,1:No,1:No,,1
3105,2837631,Table 1,BaselineCharacteristic,,,None,None,27,1,3,No,1:No,1:No,,0.98
3105,2837631,Table 1,BaselineCharacteristic,?pNx,,?pNx, pN stage (not including DCIS) pN stage (not including DCIS),28,0,2,No,1:No,1:No,,1
3105,2837631,Table 1,BaselineCharacteristic,xx,,?pNx, pN stage (not including DCIS) pN stage (not including DCIS),28,1,3,No,1:No,1:No,,0.945
3105,2837631,Table 1,BaselineCharacteristic,?pNx (? x),,?pNx (? x), pN stage (not including DCIS) pN stage (not including DCIS),29,0,2,No,1:No,1:No,,0.982
3105,2837631,Table 1,BaselineCharacteristic,x,,?pNx (? x), pN stage (not including DCIS) pN stage (not including DCIS),29,1,3,No,1:No,1:No,,0.99
3105,2837631,Table 1,BaselineCharacteristic,Estrogen receptor status,,None,None,30,0,24,No,1:No,1:No,,0.995
3105,2837631,Table 1,BaselineCharacteristic,,,Estrogen receptor status,None,30,1,43,No,1:No,1:No,,0.978
3105,2837631,Table 1,BaselineCharacteristic,?positive,,?positive, pN stage (not including DCIS) Estrogen receptor status,31,0,2,No,1:No,1:No,,1
3105,2837631,Table 1,BaselineCharacteristic,xx,,?positive, pN stage (not including DCIS) Estrogen receptor status,31,1,3,No,1:No,1:No,,0.945
3105,2837631,Table 1,BaselineCharacteristic,?negative,,?negative, pN stage (not including DCIS) Estrogen receptor status,32,0,2,No,1:No,1:No,,1
3105,2837631,Table 1,BaselineCharacteristic,x,,?negative, pN stage (not including DCIS) Estrogen receptor status,32,1,3,No,1:No,1:No,,1
3105,2837631,Table 1,BaselineCharacteristic,Progesteron receptor status,,None,None,33,0,24,No,1:No,1:No,,0.995
3105,2837631,Table 1,BaselineCharacteristic,,,Progesteron receptor status,None,33,1,43,No,1:No,1:No,,0.978
3105,2837631,Table 1,BaselineCharacteristic,?positive,,?positive, pN stage (not including DCIS) Progesteron receptor status,34,0,2,No,1:No,1:No,,1
3105,2837631,Table 1,BaselineCharacteristic,xx,,?positive, pN stage (not including DCIS) Progesteron receptor status,34,1,3,No,1:No,1:No,,0.945
3105,2837631,Table 1,BaselineCharacteristic,?negative,,?negative, pN stage (not including DCIS) Progesteron receptor status,35,0,2,No,1:No,1:No,,1
3105,2837631,Table 1,BaselineCharacteristic,x,,?negative, pN stage (not including DCIS) Progesteron receptor status,35,1,3,No,1:No,1:No,,1
3105,2837631,Table 1,BaselineCharacteristic,Chemotherapy,,None,None,36,0,24,No,1:No,1:No,,0.995
3105,2837631,Table 1,BaselineCharacteristic,,,Chemotherapy,None,36,1,43,No,1:No,1:No,,0.967
3105,2837631,Table 1,BaselineCharacteristic,?Yes,,?Yes, pN stage (not including DCIS) Chemotherapy,37,0,2,No,1:No,1:No,,1
3105,2837631,Table 1,BaselineCharacteristic,xx,,?Yes, pN stage (not including DCIS) Chemotherapy,37,1,3,No,1:No,1:No,,0.945
3105,2837631,Table 1,BaselineCharacteristic,?No,,?No, pN stage (not including DCIS) Chemotherapy,38,0,2,No,1:No,1:No,,1
3105,2837631,Table 1,BaselineCharacteristic,xx,,?No, pN stage (not including DCIS) Chemotherapy,38,1,3,No,1:No,1:No,,0.945
3105,2837631,Table 1,BaselineCharacteristic,Ormonotherapy,,None,None,39,0,24,No,1:No,1:No,,0.995
3105,2837631,Table 1,BaselineCharacteristic,,,Ormonotherapy,None,39,1,43,No,1:No,1:No,,0.967
3105,2837631,Table 1,BaselineCharacteristic,?No,,?No, pN stage (not including DCIS) Ormonotherapy,40,0,2,No,1:No,1:No,,1
3105,2837631,Table 1,BaselineCharacteristic,x,,?No, pN stage (not including DCIS) Ormonotherapy,40,1,3,No,1:No,1:No,,0.99
3105,2837631,Table 1,BaselineCharacteristic,?Tamoxifen,,?Tamoxifen, pN stage (not including DCIS) Ormonotherapy,41,0,2,No,1:No,1:No,,1
3105,2837631,Table 1,BaselineCharacteristic,xx,,?Tamoxifen, pN stage (not including DCIS) Ormonotherapy,41,1,3,No,1:No,1:No,,0.945
3105,2837631,Table 1,BaselineCharacteristic,?Anastrozole,,?Anastrozole, pN stage (not including DCIS) Ormonotherapy,42,0,2,No,1:No,1:No,,1
3105,2837631,Table 1,BaselineCharacteristic,xx,,?Anastrozole, pN stage (not including DCIS) Ormonotherapy,42,1,3,No,1:No,1:No,,0.945
3105,2837631,Table 1,BaselineCharacteristic,Follow-up (months),,Follow-up (months),,43,0,2,No,1:No,1:No,,1
3162,2855860,Table 1,BaselineCharacteristic,Patient characteristics,,None,None,0,0,12,No,1:No,1:No,,0.825
3162,2855860,Table 1,BaselineCharacteristic,Sunitinib (N = xxx),,Patient characteristics,None,0,1,1,No,1:No,1:No,,0.813
3162,2855860,Table 1,BaselineCharacteristic,Capecitabine (N = xxx),,Patient characteristics,None,0,2,1,No,1:No,1:No,,0.825
3162,2855860,Table 1,BaselineCharacteristic,"Age, years",Patient characteristics ; ,None,None,1,0,24,No,1:No,1:No,,0.655
3162,2855860,Table 1,BaselineCharacteristic,"Age, years",Sunitinib (N = xxx) ; ,"Age, years",None,1,1,43,No,1:No,1:No,,0.534
3162,2855860,Table 1,BaselineCharacteristic,"Age, years",Capecitabine (N = xxx) ; ,"Age, years",None,1,2,43,No,1:No,1:No,,0.589
3162,2855860,Table 1,BaselineCharacteristic,,Patient characteristics ; ,," Age, years",2,0,2,No,1:No,1:No,,0.67
3162,2855860,Table 1,BaselineCharacteristic,,Patient characteristics ; ,," Age, years",3,0,2,No,1:No,1:No,,0.68
3162,2855860,Table 1,BaselineCharacteristic,"ECOG PS, n (%)a",Patient characteristics ; ,None,None,4,0,24,No,1:No,1:No,,0.75
3162,2855860,Table 1,BaselineCharacteristic,"ECOG PS, n (%)a",Sunitinib (N = xxx) ; ,"ECOG PS, n (%)a",None,4,1,43,No,1:No,1:No,,0.669
3162,2855860,Table 1,BaselineCharacteristic,"ECOG PS, n (%)a",Capecitabine (N = xxx) ; ,"ECOG PS, n (%)a",None,4,2,43,No,1:No,1:No,,0.695
3162,2855860,Table 1,BaselineCharacteristic,,Patient characteristics ; ,," ECOG PS, n (%)a",5,0,2,No,1:No,1:No,,0.786
3162,2855860,Table 1,BaselineCharacteristic,,Patient characteristics ; ,," ECOG PS, n (%)a",6,0,2,No,1:No,1:No,,0.836
3162,2855860,Table 1,BaselineCharacteristic,xx (xx),Sunitinib (N = xxx) ; ,," ECOG PS, n (%)a",6,1,3,No,1:No,1:No,,0.506
3162,2855860,Table 1,BaselineCharacteristic,xxx (xx),Capecitabine (N = xxx) ; ,," ECOG PS, n (%)a",6,2,3,No,1:No,1:No,,0.541
3162,2855860,Table 1,BaselineCharacteristic,,Patient characteristics ; ,," ECOG PS, n (%)a",7,0,2,No,1:No,1:No,,0.836
3162,2855860,Table 1,BaselineCharacteristic,x (x),Sunitinib (N = xxx) ; ,," ECOG PS, n (%)a",7,1,3,No,1:No,1:No,,0.726
3162,2855860,Table 1,BaselineCharacteristic,x (x),Capecitabine (N = xxx) ; ,," ECOG PS, n (%)a",7,2,3,No,1:No,1:No,,0.776
3162,2855860,Table 1,BaselineCharacteristic,"Primary diagnosis, n (%)",Patient characteristics ; ,None,None,8,0,24,No,1:No,1:No,,0.84
3162,2855860,Table 1,BaselineCharacteristic,"Primary diagnosis, n (%)",Sunitinib (N = xxx) ; ,"Primary diagnosis, n (%)",None,8,1,43,No,1:No,1:No,,0.84
3162,2855860,Table 1,BaselineCharacteristic,"Primary diagnosis, n (%)",Capecitabine (N = xxx) ; ,"Primary diagnosis, n (%)",None,8,2,43,No,1:No,1:No,,0.88
3162,2855860,Table 1,BaselineCharacteristic,,Patient characteristics ; ,," Primary diagnosis, n (%)",9,0,2,No,1:No,1:No,,0.866
3162,2855860,Table 1,BaselineCharacteristic,xxx (xx),Sunitinib (N = xxx) ; ,," Primary diagnosis, n (%)",9,1,3,No,1:No,1:No,,0.686
3162,2855860,Table 1,BaselineCharacteristic,xxx (xx),Capecitabine (N = xxx) ; ,," Primary diagnosis, n (%)",9,2,3,No,1:No,1:No,,0.691
3162,2855860,Table 1,BaselineCharacteristic,,Patient characteristics ; ,," Primary diagnosis, n (%)",10,0,2,No,1:No,1:No,,0.876
3162,2855860,Table 1,BaselineCharacteristic,xx (x),Sunitinib (N = xxx) ; ,," Primary diagnosis, n (%)",10,1,3,No,1:No,1:No,,0.666
3162,2855860,Table 1,BaselineCharacteristic,xx (x),Capecitabine (N = xxx) ; ,," Primary diagnosis, n (%)",10,2,3,No,1:No,1:No,,0.701
3162,2855860,Table 1,BaselineCharacteristic,"Histologic classification, n (%)",Patient characteristics ; ,None,None,11,0,24,No,1:No,1:No,,0.83
3162,2855860,Table 1,BaselineCharacteristic,"Histologic classification, n (%)",Sunitinib (N = xxx) ; ,"Histologic classification, n (%)",None,11,1,43,No,1:No,1:No,,0.84
3162,2855860,Table 1,BaselineCharacteristic,"Histologic classification, n (%)",Capecitabine (N = xxx) ; ,"Histologic classification, n (%)",None,11,2,43,No,1:No,1:No,,0.87
3162,2855860,Table 1,BaselineCharacteristic,,Patient characteristics ; ,," Histologic classification, n (%)",12,0,2,No,1:No,1:No,,0.876
3162,2855860,Table 1,BaselineCharacteristic,xxx (xx),Sunitinib (N = xxx) ; ,," Histologic classification, n (%)",12,1,3,No,1:No,1:No,,0.736
3162,2855860,Table 1,BaselineCharacteristic,xxx (xx),Capecitabine (N = xxx) ; ,," Histologic classification, n (%)",12,2,3,No,1:No,1:No,,0.741
3162,2855860,Table 1,BaselineCharacteristic,,Patient characteristics ; ,," Histologic classification, n (%)",13,0,2,No,1:No,1:No,,0.876
3162,2855860,Table 1,BaselineCharacteristic,xx (xx),Sunitinib (N = xxx) ; ,," Histologic classification, n (%)",13,1,3,No,1:No,1:No,,0.706
3162,2855860,Table 1,BaselineCharacteristic,xx (x),Capecitabine (N = xxx) ; ,," Histologic classification, n (%)",13,2,3,No,1:No,1:No,,0.741
3162,2855860,Table 1,BaselineCharacteristic,,Patient characteristics ; ,," Histologic classification, n (%)",14,0,2,No,1:No,1:No,,0.876
3162,2855860,Table 1,BaselineCharacteristic,xx (x),Sunitinib (N = xxx) ; ,," Histologic classification, n (%)",14,1,3,No,1:No,1:No,,0.706
3162,2855860,Table 1,BaselineCharacteristic,x (x),Capecitabine (N = xxx) ; ,," Histologic classification, n (%)",14,2,3,No,1:No,1:No,,0.896
3162,2855860,Table 1,BaselineCharacteristic,"Location of disease, n (%)",Patient characteristics ; ,None,None,15,0,24,No,1:No,1:No,,0.85
3162,2855860,Table 1,BaselineCharacteristic,"Location of disease, n (%)",Sunitinib (N = xxx) ; ,"Location of disease, n (%)",None,15,1,43,No,1:No,1:No,,0.819
3162,2855860,Table 1,BaselineCharacteristic,"Location of disease, n (%)",Capecitabine (N = xxx) ; ,"Location of disease, n (%)",None,15,2,43,No,1:No,1:No,,0.845
3162,2855860,Table 1,BaselineCharacteristic,,Patient characteristics ; ,," Location of disease, n (%)",16,0,2,No,1:No,1:No,,0.876
3162,2855860,Table 1,BaselineCharacteristic,xxx (xx),Sunitinib (N = xxx) ; ,," Location of disease, n (%)",16,1,3,No,1:No,1:No,,0.686
3162,2855860,Table 1,BaselineCharacteristic,xxx (xx),Capecitabine (N = xxx) ; ,," Location of disease, n (%)",16,2,3,No,1:No,1:No,,0.701
3162,2855860,Table 1,BaselineCharacteristic,,Patient characteristics ; ,," Location of disease, n (%)",17,0,2,No,1:No,1:No,,0.876
3162,2855860,Table 1,BaselineCharacteristic,xx (xx),Sunitinib (N = xxx) ; ,," Location of disease, n (%)",17,1,3,No,1:No,1:No,,0.676
3162,2855860,Table 1,BaselineCharacteristic,xx (xx),Capecitabine (N = xxx) ; ,," Location of disease, n (%)",17,2,3,No,1:No,1:No,,0.711
3162,2855860,Table 1,BaselineCharacteristic,"Number of involved sites, n (%)a",Patient characteristics ; ,None,None,18,0,24,No,1:No,1:No,,0.84
3162,2855860,Table 1,BaselineCharacteristic,"Number of involved sites, n (%)a",Sunitinib (N = xxx) ; ,"Number of involved sites, n (%)a",None,18,1,43,No,1:No,1:No,,0.819
3162,2855860,Table 1,BaselineCharacteristic,"Number of involved sites, n (%)a",Capecitabine (N = xxx) ; ,"Number of involved sites, n (%)a",None,18,2,43,No,1:No,1:No,,0.835
3162,2855860,Table 1,BaselineCharacteristic,,Patient characteristics ; ,," Number of involved sites, n (%)a",19,0,2,No,1:No,1:No,,0.858
3162,2855860,Table 1,BaselineCharacteristic,xx (xx),Sunitinib (N = xxx) ; ,," Number of involved sites, n (%)a",19,1,3,No,1:No,1:No,,0.62
3162,2855860,Table 1,BaselineCharacteristic,xx (xx),Capecitabine (N = xxx) ; ,," Number of involved sites, n (%)a",19,2,3,No,1:No,1:No,,0.646
3162,2855860,Table 1,BaselineCharacteristic,,Patient characteristics ; ,," Number of involved sites, n (%)a",20,0,2,No,1:No,1:No,,0.858
3162,2855860,Table 1,BaselineCharacteristic,xxx (xx),Sunitinib (N = xxx) ; ,," Number of involved sites, n (%)a",20,1,3,No,1:No,1:No,,0.64
3162,2855860,Table 1,BaselineCharacteristic,xxx (xx),Capecitabine (N = xxx) ; ,," Number of involved sites, n (%)a",20,2,3,No,1:No,1:No,,0.646
3162,2855860,Table 1,BaselineCharacteristic,"Most commonly affected sites, n (%)",Patient characteristics ; ,None,None,21,0,24,No,1:No,1:No,,0.82
3162,2855860,Table 1,BaselineCharacteristic,"Most commonly affected sites, n (%)",Sunitinib (N = xxx) ; ,"Most commonly affected sites, n (%)",None,21,1,43,No,1:No,1:No,,0.809
3162,2855860,Table 1,BaselineCharacteristic,"Most commonly affected sites, n (%)",Capecitabine (N = xxx) ; ,"Most commonly affected sites, n (%)",None,21,2,43,No,1:No,1:No,,0.825
3162,2855860,Table 1,BaselineCharacteristic,,Patient characteristics ; ,," Most commonly affected sites, n (%)",22,0,2,No,1:No,1:No,,0.858
3162,2855860,Table 1,BaselineCharacteristic,xxx (xx),Sunitinib (N = xxx) ; ,," Most commonly affected sites, n (%)",22,1,3,No,1:No,1:No,,0.66
3162,2855860,Table 1,BaselineCharacteristic,xxx (xx),Capecitabine (N = xxx) ; ,," Most commonly affected sites, n (%)",22,2,3,No,1:No,1:No,,0.676
3162,2855860,Table 1,BaselineCharacteristic,,Patient characteristics ; ,," Most commonly affected sites, n (%)",23,0,2,No,1:No,1:No,,0.858
3162,2855860,Table 1,BaselineCharacteristic,xxx (xx),Sunitinib (N = xxx) ; ,," Most commonly affected sites, n (%)",23,1,3,No,1:No,1:No,,0.66
3162,2855860,Table 1,BaselineCharacteristic,xxx (xx),Capecitabine (N = xxx) ; ,," Most commonly affected sites, n (%)",23,2,3,No,1:No,1:No,,0.676
3162,2855860,Table 1,BaselineCharacteristic,,Patient characteristics ; ,," Most commonly affected sites, n (%)",24,0,2,No,1:No,1:No,,0.858
3162,2855860,Table 1,BaselineCharacteristic,xxx (xx),Sunitinib (N = xxx) ; ,," Most commonly affected sites, n (%)",24,1,3,No,1:No,1:No,,0.66
3162,2855860,Table 1,BaselineCharacteristic,xxx (xx),Capecitabine (N = xxx) ; ,," Most commonly affected sites, n (%)",24,2,3,No,1:No,1:No,,0.676
3162,2855860,Table 1,BaselineCharacteristic,,Patient characteristics ; ,," Most commonly affected sites, n (%)",25,0,2,No,1:No,1:No,,0.858
3162,2855860,Table 1,BaselineCharacteristic,xxx (xx),Sunitinib (N = xxx) ; ,," Most commonly affected sites, n (%)",25,1,3,No,1:No,1:No,,0.66
3162,2855860,Table 1,BaselineCharacteristic,xx (xx),Capecitabine (N = xxx) ; ,," Most commonly affected sites, n (%)",25,2,3,No,1:No,1:No,,0.661
3162,2855860,Table 1,BaselineCharacteristic,"Receptor status, n (%)a",Patient characteristics ; ,None,None,26,0,24,No,1:No,1:No,,0.81
3162,2855860,Table 1,BaselineCharacteristic,"Receptor status, n (%)a",Sunitinib (N = xxx) ; ,"Receptor status, n (%)a",None,26,1,43,No,1:No,1:No,,0.81
3162,2855860,Table 1,BaselineCharacteristic,"Receptor status, n (%)a",Capecitabine (N = xxx) ; ,"Receptor status, n (%)a",None,26,2,43,No,1:No,1:No,,0.84
3162,2855860,Table 1,BaselineCharacteristic,,Patient characteristics ; ,," Receptor status, n (%)a",27,0,2,No,1:No,1:No,,0.85
3162,2855860,Table 1,BaselineCharacteristic,xxx (xx),Sunitinib (N = xxx) ; ,," Receptor status, n (%)a",27,1,3,No,1:No,1:No,,0.666
3162,2855860,Table 1,BaselineCharacteristic,xxx (xx),Capecitabine (N = xxx) ; ,," Receptor status, n (%)a",27,2,3,No,1:No,1:No,,0.681
3162,2855860,Table 1,BaselineCharacteristic,,Patient characteristics ; ,," Receptor status, n (%)a",28,0,2,No,1:No,1:No,,0.85
3162,2855860,Table 1,BaselineCharacteristic,xx (xx),Sunitinib (N = xxx) ; ,," Receptor status, n (%)a",28,1,3,No,1:No,1:No,,0.631
3162,2855860,Table 1,BaselineCharacteristic,xx (xx),Capecitabine (N = xxx) ; ,," Receptor status, n (%)a",28,2,3,No,1:No,1:No,,0.677
3162,2855860,Table 1,BaselineCharacteristic,,Patient characteristics ; ,," Receptor status, n (%)a",29,0,2,No,1:No,1:No,,0.85
3162,2855860,Table 1,BaselineCharacteristic,xx (xx),Sunitinib (N = xxx) ; ,," Receptor status, n (%)a",29,1,3,No,1:No,1:No,,0.631
3162,2855860,Table 1,BaselineCharacteristic,xx (xx),Capecitabine (N = xxx) ; ,," Receptor status, n (%)a",29,2,3,No,1:No,1:No,,0.677
3162,2855860,Table 1,BaselineCharacteristic,"Prior taxane treatment, n (%)a",Patient characteristics ; ,None,None,30,0,24,No,1:No,1:No,,0.82
3162,2855860,Table 1,BaselineCharacteristic,"Prior taxane treatment, n (%)a",Sunitinib (N = xxx) ; ,"Prior taxane treatment, n (%)a",None,30,1,43,No,1:No,1:No,,0.809
3162,2855860,Table 1,BaselineCharacteristic,"Prior taxane treatment, n (%)a",Capecitabine (N = xxx) ; ,"Prior taxane treatment, n (%)a",None,30,2,43,No,1:No,1:No,,0.825
3162,2855860,Table 1,BaselineCharacteristic,,Patient characteristics ; ,," Prior taxane treatment, n (%)a",31,0,2,No,1:No,1:No,,0.856
3162,2855860,Table 1,BaselineCharacteristic,xx (xx),Sunitinib (N = xxx) ; ,," Prior taxane treatment, n (%)a",31,1,3,No,1:No,1:No,,0.661
3162,2855860,Table 1,BaselineCharacteristic,xx (xx),Capecitabine (N = xxx) ; ,," Prior taxane treatment, n (%)a",31,2,3,No,1:No,1:No,,0.687
3162,2855860,Table 1,BaselineCharacteristic,,Patient characteristics ; ,," Prior taxane treatment, n (%)a",32,0,2,No,1:No,1:No,,0.856
3162,2855860,Table 1,BaselineCharacteristic,xxx (xx),Sunitinib (N = xxx) ; ,," Prior taxane treatment, n (%)a",32,1,3,No,1:No,1:No,,0.696
3162,2855860,Table 1,BaselineCharacteristic,xxx (xx),Capecitabine (N = xxx) ; ,," Prior taxane treatment, n (%)a",32,2,3,No,1:No,1:No,,0.701
3162,2855860,Table 1,BaselineCharacteristic,"Prior lines of systemic therapy for advanced disease, n (%)",Patient characteristics ; ,None,None,33,0,24,No,1:No,1:No,,0.87
3162,2855860,Table 1,BaselineCharacteristic,"Prior lines of systemic therapy for advanced disease, n (%)",Sunitinib (N = xxx) ; ,"Prior lines of systemic therapy for advanced disease, n (%)",None,33,1,43,No,1:No,1:No,,0.86
3162,2855860,Table 1,BaselineCharacteristic,"Prior lines of systemic therapy for advanced disease, n (%)",Capecitabine (N = xxx) ; ,"Prior lines of systemic therapy for advanced disease, n (%)",None,33,2,43,No,1:No,1:No,,0.89
3162,2855860,Table 1,BaselineCharacteristic,,Patient characteristics ; ,," Prior lines of systemic therapy for advanced disease, n (%)",34,0,2,No,1:No,1:No,,0.886
3162,2855860,Table 1,BaselineCharacteristic,xx (xx),Sunitinib (N = xxx) ; ,," Prior lines of systemic therapy for advanced disease, n (%)",34,1,3,No,1:No,1:No,,0.72
3162,2855860,Table 1,BaselineCharacteristic,xx (xx),Capecitabine (N = xxx) ; ,," Prior lines of systemic therapy for advanced disease, n (%)",34,2,3,No,1:No,1:No,,0.746
3162,2855860,Table 1,BaselineCharacteristic,,Patient characteristics ; ,," Prior lines of systemic therapy for advanced disease, n (%)",35,0,2,No,1:No,1:No,,0.886
3162,2855860,Table 1,BaselineCharacteristic,xxx (xx),Sunitinib (N = xxx) ; ,," Prior lines of systemic therapy for advanced disease, n (%)",35,1,3,No,1:No,1:No,,0.73
3162,2855860,Table 1,BaselineCharacteristic,xxx (xx),Capecitabine (N = xxx) ; ,," Prior lines of systemic therapy for advanced disease, n (%)",35,2,3,No,1:No,1:No,,0.736
3275,2894785,Table 1,BaselineCharacteristic,Characteristics,,None,None,0,0,,No,1:No,1:No,,0.907
3275,2894785,Table 1,BaselineCharacteristic,Intervention Groupn = xx,,None,None,0,1,,No,1:No,1:No,,0.587
3275,2894785,Table 1,BaselineCharacteristic,ControlGroupn = xxx,,None,None,0,2,,No,1:No,1:No,,0.683
3275,2894785,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,4,0,,No,1:No,1:No,,0.927
3275,2894785,Table 1,BaselineCharacteristic,,Intervention Groupn = xx ; ,None,None,4,1,,No,1:No,1:No,,0.699
3275,2894785,Table 1,BaselineCharacteristic,,ControlGroupn = xxx ; ,None,None,4,2,,No,1:No,1:No,,0.738
3275,2894785,Table 1,BaselineCharacteristic,"Sex, n (%)",Characteristics ; ,None,None,5,0,,No,1:No,1:No,,0.797
3275,2894785,Table 1,BaselineCharacteristic,,Intervention Groupn = xx ; ,None,None,5,1,,No,1:No,1:No,,0.681
3275,2894785,Table 1,BaselineCharacteristic,,ControlGroupn = xxx ; ,None,None,5,2,,No,1:No,1:No,,0.738
3275,2894785,Table 1,BaselineCharacteristic,?female,Characteristics ; ,?female," Age, mean ± SD (years)",6,0,,No,1:No,1:No,,0.516
3275,2894785,Table 1,BaselineCharacteristic,?male,Characteristics ; ,?male," Age, mean ± SD (years)",7,0,,No,1:No,1:No,,0.526
3275,2894785,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,8,0,,No,1:No,1:No,,0.98
3275,2894785,Table 1,BaselineCharacteristic,,Intervention Groupn = xx ; ,None,None,8,1,,No,1:No,1:No,,0.724
3275,2894785,Table 1,BaselineCharacteristic,,ControlGroupn = xxx ; ,None,None,8,2,,No,1:No,1:No,,0.778
3275,2894785,Table 1,BaselineCharacteristic,"subtype of cerebral ischemia, n (%)",Characteristics ; ,None,None,9,0,,No,1:No,1:No,,0.865
3275,2894785,Table 1,BaselineCharacteristic,,Intervention Groupn = xx ; ,None,None,9,1,,No,1:No,1:No,,0.734
3275,2894785,Table 1,BaselineCharacteristic,,ControlGroupn = xxx ; ,None,None,9,2,,No,1:No,1:No,,0.788
3275,2894785,Table 1,BaselineCharacteristic,?TIA,Characteristics ; ,?TIA," Age, mean ± SD (years)",10,0,,No,1:No,1:No,,0.587
3275,2894785,Table 1,BaselineCharacteristic,?Ischemic stroke,Characteristics ; ,?Ischemic stroke," Age, mean ± SD (years)",11,0,,No,1:No,1:No,,0.597
3275,2894785,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,12,0,,No,1:No,1:No,,0.999
3275,2894785,Table 1,BaselineCharacteristic,,Intervention Groupn = xx ; ,None,None,12,1,,No,1:No,1:No,,0.79
3275,2894785,Table 1,BaselineCharacteristic,,ControlGroupn = xxx ; ,None,None,12,2,,No,1:No,1:No,,0.821
3275,2894785,Table 1,BaselineCharacteristic,"Barthel Index, mean ± SD",Characteristics ; ,None,None,13,0,,No,1:No,1:No,,0.73
3275,2894785,Table 1,BaselineCharacteristic,"xx,x (± x,x)",Intervention Groupn = xx ; ,None,None,13,1,,No,1:No,1:No,,0.668
3275,2894785,Table 1,BaselineCharacteristic,"xx,x (± xx,x)",ControlGroupn = xxx ; ,None,None,13,2,,No,1:No,1:No,,0.644
3275,2894785,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,14,0,,No,1:No,1:No,,0.999
3275,2894785,Table 1,BaselineCharacteristic,,Intervention Groupn = xx ; ,None,None,14,1,,No,1:No,1:No,,0.81
3275,2894785,Table 1,BaselineCharacteristic,,ControlGroupn = xxx ; ,None,None,14,2,,No,1:No,1:No,,0.832
3275,2894785,Table 1,BaselineCharacteristic,cardiovascular risk factors,Characteristics ; ,None,None,15,0,,No,1:No,1:No,,0.999
3275,2894785,Table 1,BaselineCharacteristic,,Intervention Groupn = xx ; ,None,None,15,1,,No,1:No,1:No,,0.81
3275,2894785,Table 1,BaselineCharacteristic,,ControlGroupn = xxx ; ,None,None,15,2,,No,1:No,1:No,,0.822
3275,2894785,Table 1,BaselineCharacteristic,?hypertension,Characteristics ; ,?hypertension," Age, mean ± SD (years)",16,0,,No,1:No,1:No,,0.577
3275,2894785,Table 1,BaselineCharacteristic,?hyperlipidemia,Characteristics ; ,?hyperlipidemia," Age, mean ± SD (years)",17,0,,No,1:No,1:No,,0.577
3275,2894785,Table 1,BaselineCharacteristic,?diabetes mellitus,Characteristics ; ,?diabetes mellitus," Age, mean ± SD (years)",18,0,,No,1:No,1:No,,0.567
3275,2894785,Table 1,BaselineCharacteristic,?hypertension+hyperlipidemia,Characteristics ; ,?hypertension+hyperlipidemia," Age, mean ± SD (years)",19,0,,No,1:No,1:No,,0.577
3275,2894785,Table 1,BaselineCharacteristic,?hypertension+diabetes mellitus,Characteristics ; ,?hypertension+diabetes mellitus," Age, mean ± SD (years)",20,0,,No,1:No,1:No,,0.567
3275,2894785,Table 1,BaselineCharacteristic,?diabetes mellitus+hyperlipidemia,Characteristics ; ,?diabetes mellitus+hyperlipidemia," Age, mean ± SD (years)",21,0,,No,1:No,1:No,,0.577
3275,2894785,Table 1,BaselineCharacteristic,?hypertension+diabetes,Characteristics ; ,None,None,22,0,,No,1:No,1:No,,0.999
3275,2894785,Table 1,BaselineCharacteristic,,Intervention Groupn = xx ; ,None,None,22,1,,No,1:No,1:No,,0.806
3275,2894785,Table 1,BaselineCharacteristic,,ControlGroupn = xxx ; ,None,None,22,2,,No,1:No,1:No,,0.832
3275,2894785,Table 1,BaselineCharacteristic,?mellitus+hyperlipidemia,Characteristics ; ,?mellitus+hyperlipidemia," Age, mean ± SD (years)",23,0,,No,1:No,1:No,,0.577
3275,2894785,Table 1,BaselineCharacteristic,?None,Characteristics ; ,?None," Age, mean ± SD (years)",24,0,,No,1:No,1:No,,0.577
3276,2894820,Table 4,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
3276,2894820,Table 4,BaselineCharacteristic,Characteristic,,,None,0,1,1,No,1:No,1:No,,0.903
3276,2894820,Table 4,BaselineCharacteristic,Control(mean),,,None,0,2,1,No,1:No,1:No,,0.696
3276,2894820,Table 4,BaselineCharacteristic,Intervention(mean),,,None,0,3,1,No,1:No,1:No,,0.696
3276,2894820,Table 4,BaselineCharacteristic,p-value,,,None,0,4,1,No,1:No,1:No,,0.913
3276,2894820,Table 4,BaselineCharacteristic,Child, ; ,Child,,1,0,24,No,1:No,1:No,,0.897
3276,2894820,Table 4,BaselineCharacteristic,Age (yr),Characteristic ; ,Child,,1,1,43,No,1:No,1:No,,0.839
3276,2894820,Table 4,BaselineCharacteristic,x.xx,p-value ; ,Child,,1,4,43,No,1:No,1:No,,0.582
3276,2894820,Table 4,BaselineCharacteristic,, ; ,,,2,0,2,No,1:No,1:No,,0.95
3276,2894820,Table 4,BaselineCharacteristic,BMI z-score,Characteristic ; ,,,2,1,3,No,1:No,1:No,,0.89
3276,2894820,Table 4,BaselineCharacteristic,x.xx,p-value ; ,,,2,4,3,No,1:No,1:No,,0.642
3276,2894820,Table 4,BaselineCharacteristic,, ; ,,,3,0,2,No,1:No,1:No,,0.96
3276,2894820,Table 4,BaselineCharacteristic,Waist-to-hip ratio,Characteristic ; ,,,3,1,3,No,1:No,1:No,,0.9
3276,2894820,Table 4,BaselineCharacteristic,x.xx,p-value ; ,,,3,4,3,No,1:No,1:No,,0.646
3276,2894820,Table 4,BaselineCharacteristic,, ; ,,,4,0,2,No,1:No,1:No,,0.97
3276,2894820,Table 4,BaselineCharacteristic,% body fat,Characteristic ; ,,,4,1,3,No,1:No,1:No,,0.75
3276,2894820,Table 4,BaselineCharacteristic,xx.x,Control(mean) ; ,,,4,2,3,No,1:No,1:No,,0.61
3276,2894820,Table 4,BaselineCharacteristic,x.xx,p-value ; ,,,4,4,3,No,1:No,1:No,,0.746
3276,2894820,Table 4,BaselineCharacteristic,, ; ,,,5,0,2,No,1:No,1:No,,0.97
3276,2894820,Table 4,BaselineCharacteristic,Pubertal stage (x-x scale),Characteristic ; ,,,5,1,3,No,1:No,1:No,,0.9
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Control(mean) ; ,,,5,2,3,No,1:No,1:No,,0.63
3276,2894820,Table 4,BaselineCharacteristic,x.xx,p-value ; ,,,5,4,3,No,1:No,1:No,,0.746
3276,2894820,Table 4,BaselineCharacteristic,, ; ,,,6,0,2,No,1:No,1:No,,0.99
3276,2894820,Table 4,BaselineCharacteristic,Fasting HbAxc (%),Characteristic ; ,,,6,1,3,No,1:No,1:No,,0.81
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Control(mean) ; ,,,6,2,3,No,1:No,1:No,,0.65
3276,2894820,Table 4,BaselineCharacteristic,x.xx,p-value ; ,,,6,4,3,No,1:No,1:No,,0.756
3276,2894820,Table 4,BaselineCharacteristic,, ; ,,,7,0,2,No,1:No,1:No,,0.99
3276,2894820,Table 4,BaselineCharacteristic,Fasting HOMA-IR,Characteristic ; ,,,7,1,3,No,1:No,1:No,,0.96
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Control(mean) ; ,,,7,2,3,No,1:No,1:No,,0.66
3276,2894820,Table 4,BaselineCharacteristic,x.xx,p-value ; ,,,7,4,3,No,1:No,1:No,,0.806
3276,2894820,Table 4,BaselineCharacteristic,, ; ,,,8,0,2,No,1:No,1:No,,0.99
3276,2894820,Table 4,BaselineCharacteristic,Fasting ISI-FFA,Characteristic ; ,,,8,1,3,No,1:No,1:No,,0.96
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Control(mean) ; ,,,8,2,3,No,1:No,1:No,,0.7
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Intervention(mean) ; ,,,8,3,3,No,1:No,1:No,,0.53
3276,2894820,Table 4,BaselineCharacteristic,x.xx,p-value ; ,,,8,4,3,No,1:No,1:No,,0.826
3276,2894820,Table 4,BaselineCharacteristic,, ; ,,,9,0,2,No,1:No,1:No,,1
3276,2894820,Table 4,BaselineCharacteristic,Energy intake (kcal/day),Characteristic ; ,,,9,1,3,No,1:No,1:No,,0.97
3276,2894820,Table 4,BaselineCharacteristic,xxxx,Control(mean) ; ,,,9,2,3,No,1:No,1:No,,0.83
3276,2894820,Table 4,BaselineCharacteristic,xxxx,Intervention(mean) ; ,,,9,3,3,No,1:No,1:No,,0.8
3276,2894820,Table 4,BaselineCharacteristic,x.xx,p-value ; ,,,9,4,3,No,1:No,1:No,,0.866
3276,2894820,Table 4,BaselineCharacteristic,, ; ,,,10,0,2,No,1:No,1:No,,1
3276,2894820,Table 4,BaselineCharacteristic,Fat intake (g/day),Characteristic ; ,,,10,1,3,No,1:No,1:No,,0.99
3276,2894820,Table 4,BaselineCharacteristic,xx.x,Control(mean) ; ,,,10,2,3,No,1:No,1:No,,0.74
3276,2894820,Table 4,BaselineCharacteristic,xx.x,Intervention(mean) ; ,,,10,3,3,No,1:No,1:No,,0.6
3276,2894820,Table 4,BaselineCharacteristic,x.xx,p-value ; ,,,10,4,3,No,1:No,1:No,,0.886
3276,2894820,Table 4,BaselineCharacteristic,, ; ,,,11,0,2,No,1:No,1:No,,1
3276,2894820,Table 4,BaselineCharacteristic,Carbohydrate intake (g/day),Characteristic ; ,,,11,1,3,No,1:No,1:No,,0.99
3276,2894820,Table 4,BaselineCharacteristic,xxx,Control(mean) ; ,,,11,2,3,No,1:No,1:No,,0.8
3276,2894820,Table 4,BaselineCharacteristic,xxx,Intervention(mean) ; ,,,11,3,3,No,1:No,1:No,,0.8
3276,2894820,Table 4,BaselineCharacteristic,x.xx,p-value ; ,,,11,4,3,No,1:No,1:No,,0.886
3276,2894820,Table 4,BaselineCharacteristic,, ; ,,,12,0,2,No,1:No,1:No,,1
3276,2894820,Table 4,BaselineCharacteristic,Protein intake (g/day),Characteristic ; ,,,12,1,3,No,1:No,1:No,,0.99
3276,2894820,Table 4,BaselineCharacteristic,xx.x,Control(mean) ; ,,,12,2,3,No,1:No,1:No,,0.75
3276,2894820,Table 4,BaselineCharacteristic,xx.x,Intervention(mean) ; ,,,12,3,3,No,1:No,1:No,,0.6
3276,2894820,Table 4,BaselineCharacteristic,x.xx,p-value ; ,,,12,4,3,No,1:No,1:No,,0.886
3276,2894820,Table 4,BaselineCharacteristic,, ; ,,,13,0,2,No,1:No,1:No,,1
3276,2894820,Table 4,BaselineCharacteristic,Whole grains intake (servings/day),Characteristic ; ,,,13,1,3,No,1:No,1:No,,0.99
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Control(mean) ; ,,,13,2,3,No,1:No,1:No,,0.75
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Intervention(mean) ; ,,,13,3,3,No,1:No,1:No,,0.6
3276,2894820,Table 4,BaselineCharacteristic,x.xx,p-value ; ,,,13,4,3,No,1:No,1:No,,0.886
3276,2894820,Table 4,BaselineCharacteristic,, ; ,,,14,0,2,No,1:No,1:No,,1
3276,2894820,Table 4,BaselineCharacteristic,Fruit & vegetable intake (servings/day),Characteristic ; ,,,14,1,3,No,1:No,1:No,,0.99
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Control(mean) ; ,,,14,2,3,No,1:No,1:No,,0.76
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Intervention(mean) ; ,,,14,3,3,No,1:No,1:No,,0.61
3276,2894820,Table 4,BaselineCharacteristic,x.xx,p-value ; ,,,14,4,3,No,1:No,1:No,,0.896
3276,2894820,Table 4,BaselineCharacteristic,, ; ,,,15,0,2,No,1:No,1:No,,1
3276,2894820,Table 4,BaselineCharacteristic,Dairy intake (servings/day),Characteristic ; ,,,15,1,3,No,1:No,1:No,,0.98
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Control(mean) ; ,,,15,2,3,No,1:No,1:No,,0.75
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Intervention(mean) ; ,,,15,3,3,No,1:No,1:No,,0.6
3276,2894820,Table 4,BaselineCharacteristic,x.xx,p-value ; ,,,15,4,3,No,1:No,1:No,,0.896
3276,2894820,Table 4,BaselineCharacteristic,, ; ,,,16,0,2,No,1:No,1:No,,1
3276,2894820,Table 4,BaselineCharacteristic,Nutrition knowledge (x-xx scale),Characteristic ; ,,,16,1,3,No,1:No,1:No,,0.98
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Control(mean) ; ,,,16,2,3,No,1:No,1:No,,0.75
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Intervention(mean) ; ,,,16,3,3,No,1:No,1:No,,0.6
3276,2894820,Table 4,BaselineCharacteristic,x.xx,p-value ; ,,,16,4,3,No,1:No,1:No,,0.906
3276,2894820,Table 4,BaselineCharacteristic,, ; ,,,17,0,2,No,1:No,1:No,,1
3276,2894820,Table 4,BaselineCharacteristic,Food preferences (x-xx scale),Characteristic ; ,,,17,1,3,No,1:No,1:No,,0.98
3276,2894820,Table 4,BaselineCharacteristic,xx.x,Control(mean) ; ,,,17,2,3,No,1:No,1:No,,0.75
3276,2894820,Table 4,BaselineCharacteristic,xx.x,Intervention(mean) ; ,,,17,3,3,No,1:No,1:No,,0.6
3276,2894820,Table 4,BaselineCharacteristic,x.xx,p-value ; ,,,17,4,3,No,1:No,1:No,,0.906
3276,2894820,Table 4,BaselineCharacteristic,, ; ,,,18,0,2,No,1:No,1:No,,0.99
3276,2894820,Table 4,BaselineCharacteristic,Snack habits (x-x scale),Characteristic ; ,,,18,1,3,No,1:No,1:No,,0.98
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Control(mean) ; ,,,18,2,3,No,1:No,1:No,,0.74
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Intervention(mean) ; ,,,18,3,3,No,1:No,1:No,,0.585
3276,2894820,Table 4,BaselineCharacteristic,x.xx,p-value ; ,,,18,4,3,No,1:No,1:No,,0.891
3276,2894820,Table 4,BaselineCharacteristic,, ; ,,,19,0,2,No,1:No,1:No,,0.99
3276,2894820,Table 4,BaselineCharacteristic,Fitness (ml Ox/min/kg body wt),Characteristic ; ,,,19,1,3,No,1:No,1:No,,0.97
3276,2894820,Table 4,BaselineCharacteristic,xx.x,Control(mean) ; ,,,19,2,3,No,1:No,1:No,,0.74
3276,2894820,Table 4,BaselineCharacteristic,xx.x,Intervention(mean) ; ,,,19,3,3,No,1:No,1:No,,0.585
3276,2894820,Table 4,BaselineCharacteristic,x.xx,p-value ; ,,,19,4,3,No,1:No,1:No,,0.891
3276,2894820,Table 4,BaselineCharacteristic,, ; ,,,20,0,2,No,1:No,1:No,,0.99
3276,2894820,Table 4,BaselineCharacteristic,Moderate- & high-intensity physical activity (min/day),Characteristic ; ,,,20,1,3,No,1:No,1:No,,0.97
3276,2894820,Table 4,BaselineCharacteristic,xx.x,Control(mean) ; ,,,20,2,3,No,1:No,1:No,,0.74
3276,2894820,Table 4,BaselineCharacteristic,xxx.x,Intervention(mean) ; ,,,20,3,3,No,1:No,1:No,,0.77
3276,2894820,Table 4,BaselineCharacteristic,x.xx,p-value ; ,,,20,4,3,No,1:No,1:No,,0.891
3276,2894820,Table 4,BaselineCharacteristic,, ; ,,,21,0,2,No,1:No,1:No,,0.99
3276,2894820,Table 4,BaselineCharacteristic,Global self-worth (x-x scale),Characteristic ; ,,,21,1,3,No,1:No,1:No,,0.98
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Control(mean) ; ,,,21,2,3,No,1:No,1:No,,0.74
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Intervention(mean) ; ,,,21,3,3,No,1:No,1:No,,0.585
3276,2894820,Table 4,BaselineCharacteristic,x.xx,p-value ; ,,,21,4,3,No,1:No,1:No,,0.891
3276,2894820,Table 4,BaselineCharacteristic,, ; ,,,22,0,2,No,1:No,1:No,,1
3276,2894820,Table 4,BaselineCharacteristic,Athletic competence (x-x scale),Characteristic ; ,,,22,1,3,No,1:No,1:No,,0.99
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Control(mean) ; ,,,22,2,3,No,1:No,1:No,,0.75
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Intervention(mean) ; ,,,22,3,3,No,1:No,1:No,,0.595
3276,2894820,Table 4,BaselineCharacteristic,x.xx,p-value ; ,,,22,4,3,No,1:No,1:No,,0.901
3276,2894820,Table 4,BaselineCharacteristic,Family or Adult, ; ,Family or Adult,,23,0,24,No,1:No,1:No,,0.995
3276,2894820,Table 4,BaselineCharacteristic,Age of adult responder (yr),Characteristic ; ,Family or Adult,,23,1,43,No,1:No,1:No,,0.954
3276,2894820,Table 4,BaselineCharacteristic,xx.x,Control(mean) ; ,Family or Adult,,23,2,43,No,1:No,1:No,,0.73
3276,2894820,Table 4,BaselineCharacteristic,xx.x,Intervention(mean) ; ,Family or Adult,,23,3,43,No,1:No,1:No,,0.615
3276,2894820,Table 4,BaselineCharacteristic,x.xx,p-value ; ,Family or Adult,,23,4,43,No,1:No,1:No,,0.949
3276,2894820,Table 4,BaselineCharacteristic,, ; ,,,24,0,2,No,1:No,1:No,,1
3276,2894820,Table 4,BaselineCharacteristic,SEI (x-xx range),Characteristic ; ,,,24,1,3,No,1:No,1:No,,0.71
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Control(mean) ; ,,,24,2,3,No,1:No,1:No,,0.75
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Intervention(mean) ; ,,,24,3,3,No,1:No,1:No,,0.595
3276,2894820,Table 4,BaselineCharacteristic,x.xx,p-value ; ,,,24,4,3,No,1:No,1:No,,0.901
3276,2894820,Table 4,BaselineCharacteristic,, ; ,,,25,0,2,No,1:No,1:No,,1
3276,2894820,Table 4,BaselineCharacteristic,Family History of TxDM (x-x scale),Characteristic ; ,,,25,1,3,No,1:No,1:No,,0.98
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Control(mean) ; ,,,25,2,3,No,1:No,1:No,,0.75
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Intervention(mean) ; ,,,25,3,3,No,1:No,1:No,,0.595
3276,2894820,Table 4,BaselineCharacteristic,x.xx,p-value ; ,,,25,4,3,No,1:No,1:No,,0.901
3276,2894820,Table 4,BaselineCharacteristic,, ; ,,,26,0,2,No,1:No,1:No,,1
3276,2894820,Table 4,BaselineCharacteristic,Intrauterine risk for TxDM (x-x scale),Characteristic ; ,,,26,1,3,No,1:No,1:No,,1
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Control(mean) ; ,,,26,2,3,No,1:No,1:No,,0.75
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Intervention(mean) ; ,,,26,3,3,No,1:No,1:No,,0.595
3276,2894820,Table 4,BaselineCharacteristic,x.xx,p-value ; ,,,26,4,3,No,1:No,1:No,,0.901
3276,2894820,Table 4,BaselineCharacteristic,, ; ,,,27,0,2,No,1:No,1:No,,1
3276,2894820,Table 4,BaselineCharacteristic,Food habits (x-xx scale),Characteristic ; ,,,27,1,3,No,1:No,1:No,,0.98
3276,2894820,Table 4,BaselineCharacteristic,xx.x,Control(mean) ; ,,,27,2,3,No,1:No,1:No,,0.75
3276,2894820,Table 4,BaselineCharacteristic,xx.x,Intervention(mean) ; ,,,27,3,3,No,1:No,1:No,,0.595
3276,2894820,Table 4,BaselineCharacteristic,x.xx,p-value ; ,,,27,4,3,No,1:No,1:No,,0.901
3276,2894820,Table 4,BaselineCharacteristic,, ; ,,,28,0,2,No,1:No,1:No,,1
3276,2894820,Table 4,BaselineCharacteristic,Physical activity habits (x-xx scale),Characteristic ; ,,,28,1,3,No,1:No,1:No,,0.98
3276,2894820,Table 4,BaselineCharacteristic,xx.x,Control(mean) ; ,,,28,2,3,No,1:No,1:No,,0.75
3276,2894820,Table 4,BaselineCharacteristic,xx.x,Intervention(mean) ; ,,,28,3,3,No,1:No,1:No,,0.595
3276,2894820,Table 4,BaselineCharacteristic,x.xx,p-value ; ,,,28,4,3,No,1:No,1:No,,0.901
3276,2894820,Table 4,BaselineCharacteristic,, ; ,,,29,0,2,No,1:No,1:No,,1
3276,2894820,Table 4,BaselineCharacteristic,Family Cohesion (x-x scale),Characteristic ; ,,,29,1,3,No,1:No,1:No,,0.99
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Control(mean) ; ,,,29,2,3,No,1:No,1:No,,0.75
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Intervention(mean) ; ,,,29,3,3,No,1:No,1:No,,0.595
3276,2894820,Table 4,BaselineCharacteristic,x.xx,p-value ; ,,,29,4,3,No,1:No,1:No,,0.901
3276,2894820,Table 4,BaselineCharacteristic,, ; ,,,30,0,2,No,1:No,1:No,,1
3276,2894820,Table 4,BaselineCharacteristic,Family Conflict (x-x scale),Characteristic ; ,,,30,1,3,No,1:No,1:No,,0.99
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Control(mean) ; ,,,30,2,3,No,1:No,1:No,,0.75
3276,2894820,Table 4,BaselineCharacteristic,x.xx,Intervention(mean) ; ,,,30,3,3,No,1:No,1:No,,0.595
3276,2894820,Table 4,BaselineCharacteristic,x.xx,p-value ; ,,,30,4,3,No,1:No,1:No,,0.901
3291,2902493,Table 1,BaselineCharacteristic,Number of patients,,None,None,0,0,,No,1:No,1:No,,0.835
3291,2902493,Table 1,BaselineCharacteristic,,,None,None,0,1,,No,1:No,1:No,,0.874
3291,2902493,Table 1,BaselineCharacteristic,xx,,None,None,0,2,,No,1:No,1:No,,0.625
3291,2902493,Table 1,BaselineCharacteristic,Age [years](median and range),Number of patients ; ,None,None,1,0,,No,1:No,1:No,,0.606
3291,2902493,Table 1,BaselineCharacteristic,, ; ,None,None,1,1,,No,1:No,1:No,,0.871
3291,2902493,Table 1,BaselineCharacteristic,,Number of patients ; Age [years](median and range) ; ,None,None,2,0,,No,1:No,1:No,,0.608
3291,2902493,Table 1,BaselineCharacteristic,, ;  ; ,None,None,2,1,,No,1:No,1:No,,0.887
3291,2902493,Table 1,BaselineCharacteristic,Stage T,Number of patients ; Age [years](median and range) ;  ; ,Stage T,,3,0,,No,1:No,1:No,,0.598
3291,2902493,Table 1,BaselineCharacteristic,Txc, ;  ;  ; ,Stage T,,3,1,,No,1:No,1:No,,0.893
3291,2902493,Table 1,BaselineCharacteristic,,Number of patients ; Age [years](median and range) ;  ; ,,,4,0,,No,1:No,1:No,,0.59
3291,2902493,Table 1,BaselineCharacteristic,Txa-c, ;  ;  ; ,,,4,1,,No,1:No,1:No,,0.891
3291,2902493,Table 1,BaselineCharacteristic,xx (xx%),xx ; xx [xx-xx] ;  ; ,,,4,2,,No,1:No,1:No,,0.551
3291,2902493,Table 1,BaselineCharacteristic,,Number of patients ; Age [years](median and range) ;  ; ,,,5,0,,No,1:No,1:No,,0.61
3291,2902493,Table 1,BaselineCharacteristic,Txa-b, ;  ;  ; ,,,5,1,,No,1:No,1:No,,0.891
3291,2902493,Table 1,BaselineCharacteristic,x (xx%),xx ; xx [xx-xx] ;  ; ,,,5,2,,No,1:No,1:No,,0.626
3291,2902493,Table 1,BaselineCharacteristic,,Number of patients ; Age [years](median and range) ;  ; ,None,None,6,0,,No,1:No,1:No,,0.61
3291,2902493,Table 1,BaselineCharacteristic,, ;  ;  ; ,None,None,6,1,,No,1:No,1:No,,0.937
3291,2902493,Table 1,BaselineCharacteristic,,xx ; xx [xx-xx] ;  ; ,None,None,6,2,,No,1:No,1:No,,0.566
3291,2902493,Table 1,BaselineCharacteristic,Stage N,Number of patients ; Age [years](median and range) ;  ; ,Stage N,,7,0,,No,1:No,1:No,,0.618
3291,2902493,Table 1,BaselineCharacteristic,Nx, ;  ;  ; ,Stage N,,7,1,,No,1:No,1:No,,0.948
3291,2902493,Table 1,BaselineCharacteristic,xx (xx%),xx ; xx [xx-xx] ;  ; ,Stage N,,7,2,,No,1:No,1:No,,0.637
3291,2902493,Table 1,BaselineCharacteristic,,Number of patients ; Age [years](median and range) ;  ; ,,,8,0,,No,1:No,1:No,,0.616
3291,2902493,Table 1,BaselineCharacteristic,Nx, ;  ;  ; ,,,8,1,,No,1:No,1:No,,0.956
3291,2902493,Table 1,BaselineCharacteristic,x (x%),xx ; xx [xx-xx] ;  ; ,,,8,2,,No,1:No,1:No,,0.696
3291,2902493,Table 1,BaselineCharacteristic,,Number of patients ; Age [years](median and range) ;  ; ,,,9,0,,No,1:No,1:No,,0.624
3291,2902493,Table 1,BaselineCharacteristic,Nx, ;  ;  ; ,,,9,1,,No,1:No,1:No,,0.963
3291,2902493,Table 1,BaselineCharacteristic,x (x%),xx ; xx [xx-xx] ;  ; ,,,9,2,,No,1:No,1:No,,0.721
3291,2902493,Table 1,BaselineCharacteristic,,Number of patients ; Age [years](median and range) ;  ; ,None,None,10,0,,No,1:No,1:No,,0.633
3291,2902493,Table 1,BaselineCharacteristic,, ;  ;  ; ,None,None,10,1,,No,1:No,1:No,,0.978
3291,2902493,Table 1,BaselineCharacteristic,,xx ; xx [xx-xx] ;  ; ,None,None,10,2,,No,1:No,1:No,,0.692
3291,2902493,Table 1,BaselineCharacteristic,Stage M,Number of patients ; Age [years](median and range) ;  ; ,Stage M,,11,0,,No,1:No,1:No,,0.633
3291,2902493,Table 1,BaselineCharacteristic,Mx, ;  ;  ; ,Stage M,,11,1,,No,1:No,1:No,,0.978
3291,2902493,Table 1,BaselineCharacteristic,xx (xxx%),xx ; xx [xx-xx] ;  ; ,Stage M,,11,2,,No,1:No,1:No,,0.692
3291,2902493,Table 1,BaselineCharacteristic,,Number of patients ; Age [years](median and range) ;  ; ,,,12,0,,No,1:No,1:No,,0.633
3291,2902493,Table 1,BaselineCharacteristic,Mx, ;  ;  ; ,,,12,1,,No,1:No,1:No,,0.978
3291,2902493,Table 1,BaselineCharacteristic,x (x%),xx ; xx [xx-xx] ;  ; ,,,12,2,,No,1:No,1:No,,0.751
3291,2902493,Table 1,BaselineCharacteristic,,Number of patients ; Age [years](median and range) ;  ; ,None,None,13,0,,No,1:No,1:No,,0.633
3291,2902493,Table 1,BaselineCharacteristic,, ;  ;  ; ,None,None,13,1,,No,1:No,1:No,,0.978
3291,2902493,Table 1,BaselineCharacteristic,,xx ; xx [xx-xx] ;  ; ,None,None,13,2,,No,1:No,1:No,,0.692
3291,2902493,Table 1,BaselineCharacteristic,Gleason score,Number of patients ; Age [years](median and range) ;  ; ,Gleason score,,14,0,,No,1:No,1:No,,0.643
3291,2902493,Table 1,BaselineCharacteristic,x, ;  ;  ; ,Gleason score,,14,1,,No,1:No,1:No,,0.986
3291,2902493,Table 1,BaselineCharacteristic,xx (xx%),xx ; xx [xx-xx] ;  ; ,Gleason score,,14,2,,No,1:No,1:No,,0.759
3291,2902493,Table 1,BaselineCharacteristic,,Number of patients ; Age [years](median and range) ;  ; ,,,15,0,,No,1:No,1:No,,0.633
3291,2902493,Table 1,BaselineCharacteristic,x, ;  ;  ; ,,,15,1,,No,1:No,1:No,,0.973
3291,2902493,Table 1,BaselineCharacteristic,xx (xx%),xx ; xx [xx-xx] ;  ; ,,,15,2,,No,1:No,1:No,,0.735
3291,2902493,Table 1,BaselineCharacteristic,,Number of patients ; Age [years](median and range) ;  ; ,None,None,16,0,,No,1:No,1:No,,0.633
3291,2902493,Table 1,BaselineCharacteristic,, ;  ;  ; ,None,None,16,1,,No,1:No,1:No,,0.969
3291,2902493,Table 1,BaselineCharacteristic,,xx ; xx [xx-xx] ;  ; ,None,None,16,2,,No,1:No,1:No,,0.722
3291,2902493,Table 1,BaselineCharacteristic,PSA at staging (?g/l)(Median and range),Number of patients ; Age [years](median and range) ;  ; ,None,None,17,0,,No,1:No,1:No,,0.672
3291,2902493,Table 1,BaselineCharacteristic,, ;  ;  ; ,None,None,17,1,,No,1:No,1:No,,0.969
3291,2902493,Table 1,BaselineCharacteristic,"xx.x [x.x, xx.x]",xx ; xx [xx-xx] ;  ; ,None,None,17,2,,No,1:No,1:No,,0.747
3291,2902493,Table 1,BaselineCharacteristic,,Number of patients ; Age [years](median and range) ;  ; ,None,None,18,0,,No,1:No,1:No,,0.633
3291,2902493,Table 1,BaselineCharacteristic,, ;  ;  ; ,None,None,18,1,,No,1:No,1:No,,0.959
3291,2902493,Table 1,BaselineCharacteristic,,xx ; xx [xx-xx] ;  ; ,None,None,18,2,,No,1:No,1:No,,0.708
3291,2902493,Table 1,BaselineCharacteristic,Hormonotherapy,Number of patients ; Age [years](median and range) ;  ; ,Hormonotherapy,,19,0,,No,1:No,1:No,,0.633
3291,2902493,Table 1,BaselineCharacteristic,Yes, ;  ;  ; ,Hormonotherapy,,19,1,,No,1:No,1:No,,0.959
3291,2902493,Table 1,BaselineCharacteristic,xx (xx%),xx ; xx [xx-xx] ;  ; ,Hormonotherapy,,19,2,,No,1:No,1:No,,0.731
3291,2902493,Table 1,BaselineCharacteristic,,Number of patients ; Age [years](median and range) ;  ; ,,,20,0,,No,1:No,1:No,,0.633
3291,2902493,Table 1,BaselineCharacteristic,No, ;  ;  ; ,,,20,1,,No,1:No,1:No,,0.959
3291,2902493,Table 1,BaselineCharacteristic,xx (xx%),xx ; xx [xx-xx] ;  ; ,,,20,2,,No,1:No,1:No,,0.731
3291,2902493,Table 1,BaselineCharacteristic,,Number of patients ; Age [years](median and range) ;  ; ,None,None,21,0,,No,1:No,1:No,,0.633
3291,2902493,Table 1,BaselineCharacteristic,, ;  ;  ; ,None,None,21,1,,No,1:No,1:No,,0.959
3291,2902493,Table 1,BaselineCharacteristic,,xx ; xx [xx-xx] ;  ; ,None,None,21,2,,No,1:No,1:No,,0.708
3291,2902493,Table 1,BaselineCharacteristic,Surgery,Number of patients ; Age [years](median and range) ;  ; ,Surgery,,22,0,,No,1:No,1:No,,0.633
3291,2902493,Table 1,BaselineCharacteristic,Yes, ;  ;  ; ,Surgery,,22,1,,No,1:No,1:No,,0.969
3291,2902493,Table 1,BaselineCharacteristic,x (x%),xx ; xx [xx-xx] ;  ; ,Surgery,,22,2,,No,1:No,1:No,,0.777
3291,2902493,Table 1,BaselineCharacteristic,,Number of patients ; Age [years](median and range) ;  ; ,,,23,0,,No,1:No,1:No,,0.633
3291,2902493,Table 1,BaselineCharacteristic,No, ;  ;  ; ,,,23,1,,No,1:No,1:No,,0.969
3291,2902493,Table 1,BaselineCharacteristic,xx (xx%),xx ; xx [xx-xx] ;  ; ,,,23,2,,No,1:No,1:No,,0.741
3291,2902493,Table 1,BaselineCharacteristic,,Number of patients ; Age [years](median and range) ;  ; ,None,None,24,0,,No,1:No,1:No,,0.633
3291,2902493,Table 1,BaselineCharacteristic,, ;  ;  ; ,None,None,24,1,,No,1:No,1:No,,0.969
3291,2902493,Table 1,BaselineCharacteristic,,xx ; xx [xx-xx] ;  ; ,None,None,24,2,,No,1:No,1:No,,0.718
3291,2902493,Table 1,BaselineCharacteristic,Dose Prescription:,Number of patients ; Age [years](median and range) ;  ; ,None,None,25,0,,No,1:No,1:No,,0.633
3291,2902493,Table 1,BaselineCharacteristic,, ;  ;  ; ,None,None,25,1,,No,1:No,1:No,,0.969
3291,2902493,Table 1,BaselineCharacteristic,,xx ; xx [xx-xx] ;  ; ,None,None,25,2,,No,1:No,1:No,,0.718
3291,2902493,Table 1,BaselineCharacteristic,Group A,Number of patients ; Age [years](median and range) ;  ; ,Group A,,26,0,,No,1:No,1:No,,0.633
3291,2902493,Table 1,BaselineCharacteristic,xx+x Gy, ;  ;  ; ,Group A,,26,1,,No,1:No,1:No,,0.95
3291,2902493,Table 1,BaselineCharacteristic,x (xx%),xx ; xx [xx-xx] ;  ; ,Group A,,26,2,,No,1:No,1:No,,0.781
3291,2902493,Table 1,BaselineCharacteristic,,Number of patients ; Age [years](median and range) ;  ; ,,,27,0,,No,1:No,1:No,,0.633
3291,2902493,Table 1,BaselineCharacteristic,xx+x Gy, ;  ;  ; ,,,27,1,,No,1:No,1:No,,0.95
3291,2902493,Table 1,BaselineCharacteristic,x (xx%),xx ; xx [xx-xx] ;  ; ,,,27,2,,No,1:No,1:No,,0.781
3291,2902493,Table 1,BaselineCharacteristic,Group B,Number of patients ; Age [years](median and range) ;  ; ,Group B,,28,0,,No,1:No,1:No,,0.633
3291,2902493,Table 1,BaselineCharacteristic,xx Gy, ;  ;  ; ,Group B,,28,1,,No,1:No,1:No,,0.905
3291,2902493,Table 1,BaselineCharacteristic,xx (xx%),xx ; xx [xx-xx] ;  ; ,Group B,,28,2,,No,1:No,1:No,,0.741
3291,2902493,Table 2,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
3291,2902493,Table 2,BaselineCharacteristic,RA,,,None,0,1,1,No,1:No,1:No,,0.903
3291,2902493,Table 2,BaselineCharacteristic,Number of arcs, ; ,Number of arcs,None,1,0,2,No,1:No,1:No,,0.94
3291,2902493,Table 2,BaselineCharacteristic,x,RA ; ,Number of arcs,None,1,1,3,No,1:No,1:No,,0.89
3291,2902493,Table 2,BaselineCharacteristic,Arc length [°], ; ,Arc length [°],None,2,0,2,No,1:No,1:No,,0.95
3291,2902493,Table 2,BaselineCharacteristic,xxx ± x.x,RA ; ,Arc length [°],None,2,1,3,No,1:No,1:No,,0.78
3291,2902493,Table 2,BaselineCharacteristic,Beam energy, ; ,Beam energy,None,3,0,2,No,1:No,1:No,,0.96
3291,2902493,Table 2,BaselineCharacteristic,x MV (xx/xx),RA ; ,Beam energy,None,3,1,3,No,1:No,1:No,,0.93
3291,2902493,Table 2,BaselineCharacteristic,Beam on time [min], ; ,Beam on time [min],None,4,0,2,No,1:No,1:No,,0.97
3291,2902493,Table 2,BaselineCharacteristic,x.xx ± x.x,RA ; ,Beam on time [min],None,4,1,3,No,1:No,1:No,,0.66
3291,2902493,Table 2,BaselineCharacteristic,MU, ; ,MU,None,5,0,2,No,1:No,1:No,,0.97
3291,2902493,Table 2,BaselineCharacteristic,xxx ± xx,RA ; ,MU,None,5,1,3,No,1:No,1:No,,0.63
3291,2902493,Table 2,BaselineCharacteristic,MU/Gy, ; ,MU/Gy,None,6,0,2,No,1:No,1:No,,0.99
3291,2902493,Table 2,BaselineCharacteristic,xxx ± xx,RA ; ,MU/Gy,None,6,1,3,No,1:No,1:No,,0.69
3291,2902493,Table 2,BaselineCharacteristic,MU/deg, ; ,MU/deg,None,7,0,2,No,1:No,1:No,,0.99
3291,2902493,Table 2,BaselineCharacteristic,x.x ± x.x,RA ; ,MU/deg,None,7,1,3,No,1:No,1:No,,0.92
3291,2902493,Table 2,BaselineCharacteristic,Average Dose Rate [MU/min], ; ,Average Dose Rate [MU/min],None,8,0,2,No,1:No,1:No,,0.99
3291,2902493,Table 2,BaselineCharacteristic,xxx ± xx,RA ; ,Average Dose Rate [MU/min],None,8,1,3,No,1:No,1:No,,0.73
3291,2902493,Table 2,BaselineCharacteristic,Gantry speed [deg/sec], ; ,Gantry speed [deg/sec],None,9,0,2,No,1:No,1:No,,1
3291,2902493,Table 2,BaselineCharacteristic,x.x ± x.x,RA ; ,Gantry speed [deg/sec],None,9,1,3,No,1:No,1:No,,0.94
3291,2902493,Table 2,BaselineCharacteristic,Collimator angle [°], ; ,Collimator angle [°],None,10,0,2,No,1:No,1:No,,1
3291,2902493,Table 2,BaselineCharacteristic,xx ± x,RA ; ,Collimator angle [°],None,10,1,3,No,1:No,1:No,,0.84
3291,2902493,Table 2,BaselineCharacteristic,Mean CP area [cmx], ; ,Mean CP area [cmx],None,11,0,2,No,1:No,1:No,,1
3291,2902493,Table 2,BaselineCharacteristic,xx ± x,RA ; ,Mean CP area [cmx],None,11,1,3,No,1:No,1:No,,0.86
3291,2902493,Table 2,BaselineCharacteristic,Mean field area [cmx], ; ,Mean field area [cmx],None,12,0,2,No,1:No,1:No,,1
3291,2902493,Table 2,BaselineCharacteristic,xxx ± xx,RA ; ,Mean field area [cmx],None,12,1,3,No,1:No,1:No,,0.82
3291,2902493,Table 2,BaselineCharacteristic,GAI [%], ; ,GAI [%],None,13,0,2,No,1:No,1:No,,1
3291,2902493,Table 2,BaselineCharacteristic,xx.x ± x.x,RA ; ,GAI [%],None,13,1,3,No,1:No,1:No,,0.84
3308,2905428,Table 1,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
3308,2905428,Table 1,BaselineCharacteristic,,,,None,0,1,1,No,1:No,1:No,,0.903
3308,2905428,Table 1,BaselineCharacteristic,No (%),,,None,0,2,1,No,1:No,1:No,,0.803
3308,2905428,Table 1,BaselineCharacteristic,Age, ; ,None,None,1,0,24,No,1:No,1:No,,0.897
3308,2905428,Table 1,BaselineCharacteristic,, ; ,Age,None,1,1,43,No,1:No,1:No,,0.859
3308,2905428,Table 1,BaselineCharacteristic,,No (%) ; ,Age,None,1,2,43,No,1:No,1:No,,0.76
3308,2905428,Table 1,BaselineCharacteristic,, ; ,, Age,2,0,2,No,1:No,1:No,,0.95
3308,2905428,Table 1,BaselineCharacteristic,Range, ; ,, Age,2,1,3,No,1:No,1:No,,0.89
3308,2905428,Table 1,BaselineCharacteristic,, ; ,, Age,3,0,2,No,1:No,1:No,,0.96
3308,2905428,Table 1,BaselineCharacteristic,Median, ; ,, Age,3,1,3,No,1:No,1:No,,0.9
3308,2905428,Table 1,BaselineCharacteristic,Tumor size (cm), ; ,None,None,4,0,24,No,1:No,1:No,,0.93
3308,2905428,Table 1,BaselineCharacteristic,, ; ,Tumor size (cm),None,4,1,43,No,1:No,1:No,,0.902
3308,2905428,Table 1,BaselineCharacteristic,,No (%) ; ,Tumor size (cm),None,4,2,43,No,1:No,1:No,,0.794
3308,2905428,Table 1,BaselineCharacteristic,, ; ,, Tumor size (cm),5,0,2,No,1:No,1:No,,0.97
3308,2905428,Table 1,BaselineCharacteristic,Range, ; ,, Tumor size (cm),5,1,3,No,1:No,1:No,,0.91
3308,2905428,Table 1,BaselineCharacteristic,x.x - x.x,No (%) ; ,, Tumor size (cm),5,2,3,No,1:No,1:No,,0.78
3308,2905428,Table 1,BaselineCharacteristic,, ; ,, Tumor size (cm),6,0,2,No,1:No,1:No,,0.99
3308,2905428,Table 1,BaselineCharacteristic,Median, ; ,, Tumor size (cm),6,1,3,No,1:No,1:No,,0.96
3308,2905428,Table 1,BaselineCharacteristic,x.x,No (%) ; ,, Tumor size (cm),6,2,3,No,1:No,1:No,,0.87
3308,2905428,Table 1,BaselineCharacteristic,T classification, ; ,None,None,7,0,24,No,1:No,1:No,,0.974
3308,2905428,Table 1,BaselineCharacteristic,, ; ,T classification,None,7,1,43,No,1:No,1:No,,0.957
3308,2905428,Table 1,BaselineCharacteristic,,No (%) ; ,T classification,None,7,2,43,No,1:No,1:No,,0.913
3308,2905428,Table 1,BaselineCharacteristic,, ; ,, T classification,8,0,2,No,1:No,1:No,,0.99
3308,2905428,Table 1,BaselineCharacteristic,Tis, ; ,, T classification,8,1,3,No,1:No,1:No,,0.96
3308,2905428,Table 1,BaselineCharacteristic,x (xx.x),No (%) ; ,, T classification,8,2,3,No,1:No,1:No,,0.786
3308,2905428,Table 1,BaselineCharacteristic,, ; ,, T classification,9,0,2,No,1:No,1:No,,1
3308,2905428,Table 1,BaselineCharacteristic,Tx, ; ,, T classification,9,1,3,No,1:No,1:No,,0.97
3308,2905428,Table 1,BaselineCharacteristic,xx (xx.x),No (%) ; ,, T classification,9,2,3,No,1:No,1:No,,0.806
3308,2905428,Table 1,BaselineCharacteristic,, ; ,, T classification,10,0,2,No,1:No,1:No,,1
3308,2905428,Table 1,BaselineCharacteristic,Tx, ; ,, T classification,10,1,3,No,1:No,1:No,,0.99
3308,2905428,Table 1,BaselineCharacteristic,xx (xx.x),No (%) ; ,, T classification,10,2,3,No,1:No,1:No,,0.826
3308,2905428,Table 1,BaselineCharacteristic,N classification, ; ,None,None,11,0,24,No,1:No,1:No,,0.995
3308,2905428,Table 1,BaselineCharacteristic,, ; ,N classification,None,11,1,43,No,1:No,1:No,,0.978
3308,2905428,Table 1,BaselineCharacteristic,,No (%) ; ,N classification,None,11,2,43,No,1:No,1:No,,0.944
3308,2905428,Table 1,BaselineCharacteristic,, ; ,, N classification,12,0,2,No,1:No,1:No,,1
3308,2905428,Table 1,BaselineCharacteristic,Nx, ; ,, N classification,12,1,3,No,1:No,1:No,,0.99
3308,2905428,Table 1,BaselineCharacteristic,xx (xx.x),No (%) ; ,, N classification,12,2,3,No,1:No,1:No,,0.826
3308,2905428,Table 1,BaselineCharacteristic,, ; ,, N classification,13,0,2,No,1:No,1:No,,1
3308,2905428,Table 1,BaselineCharacteristic,Nx, ; ,, N classification,13,1,3,No,1:No,1:No,,0.99
3308,2905428,Table 1,BaselineCharacteristic,x (x.x),No (%) ; ,, N classification,13,2,3,No,1:No,1:No,,0.99
3308,2905428,Table 1,BaselineCharacteristic,Histological subtype, ; ,None,None,14,0,24,No,1:No,1:No,,0.995
3308,2905428,Table 1,BaselineCharacteristic,, ; ,Histological subtype,None,14,1,43,No,1:No,1:No,,0.977
3308,2905428,Table 1,BaselineCharacteristic,,No (%) ; ,Histological subtype,None,14,2,43,No,1:No,1:No,,0.919
3308,2905428,Table 1,BaselineCharacteristic,, ; ,, Histological subtype,15,0,2,No,1:No,1:No,,1
3308,2905428,Table 1,BaselineCharacteristic,Invasive ductal, ; ,, Histological subtype,15,1,3,No,1:No,1:No,,0.98
3308,2905428,Table 1,BaselineCharacteristic,xx (xx.x),No (%) ; ,, Histological subtype,15,2,3,No,1:No,1:No,,0.806
3308,2905428,Table 1,BaselineCharacteristic,, ; ,, Histological subtype,16,0,2,No,1:No,1:No,,1
3308,2905428,Table 1,BaselineCharacteristic,Invasive medullary, ; ,, Histological subtype,16,1,3,No,1:No,1:No,,0.98
3308,2905428,Table 1,BaselineCharacteristic,x (xx.x),No (%) ; ,, Histological subtype,16,2,3,No,1:No,1:No,,0.816
3308,2905428,Table 1,BaselineCharacteristic,, ; ,, Histological subtype,17,0,2,No,1:No,1:No,,1
3308,2905428,Table 1,BaselineCharacteristic,Ductal carcinoma in situ, ; ,, Histological subtype,17,1,3,No,1:No,1:No,,0.88
3308,2905428,Table 1,BaselineCharacteristic,x (xx.x),No (%) ; ,, Histological subtype,17,2,3,No,1:No,1:No,,0.816
3308,2905428,Table 1,BaselineCharacteristic,, ; ,, Histological subtype,18,0,2,No,1:No,1:No,,0.99
3308,2905428,Table 1,BaselineCharacteristic,Invasive tubular, ; ,, Histological subtype,18,1,3,No,1:No,1:No,,0.97
3308,2905428,Table 1,BaselineCharacteristic,x (x.x),No (%) ; ,, Histological subtype,18,2,3,No,1:No,1:No,,0.92
3308,2905428,Table 1,BaselineCharacteristic,Hormone receptor, ; ,None,None,19,0,24,No,1:No,1:No,,0.985
3308,2905428,Table 1,BaselineCharacteristic,, ; ,Hormone receptor,None,19,1,43,No,1:No,1:No,,0.957
3308,2905428,Table 1,BaselineCharacteristic,,No (%) ; ,Hormone receptor,None,19,2,43,No,1:No,1:No,,0.889
3308,2905428,Table 1,BaselineCharacteristic,, ; ,, Hormone receptor,20,0,2,No,1:No,1:No,,0.99
3308,2905428,Table 1,BaselineCharacteristic,ER + and PR +, ; ,, Hormone receptor,20,1,3,No,1:No,1:No,,0.97
3308,2905428,Table 1,BaselineCharacteristic,xx (xx.x),No (%) ; ,, Hormone receptor,20,2,3,No,1:No,1:No,,0.791
3308,2905428,Table 1,BaselineCharacteristic,, ; ,, Hormone receptor,21,0,2,No,1:No,1:No,,0.99
3308,2905428,Table 1,BaselineCharacteristic,ER + and PR -, ; ,, Hormone receptor,21,1,3,No,1:No,1:No,,0.92
3308,2905428,Table 1,BaselineCharacteristic,x (x.x),No (%) ; ,, Hormone receptor,21,2,3,No,1:No,1:No,,0.91
3308,2905428,Table 1,BaselineCharacteristic,, ; ,, Hormone receptor,22,0,2,No,1:No,1:No,,1
3308,2905428,Table 1,BaselineCharacteristic,ER - and PR -, ; ,, Hormone receptor,22,1,3,No,1:No,1:No,,0.93
3308,2905428,Table 1,BaselineCharacteristic,xx (xx.x),No (%) ; ,, Hormone receptor,22,2,3,No,1:No,1:No,,0.811
3308,2905428,Table 1,BaselineCharacteristic,Resection margin, ; ,None,None,23,0,24,No,1:No,1:No,,0.995
3308,2905428,Table 1,BaselineCharacteristic,, ; ,Resection margin,None,23,1,43,No,1:No,1:No,,0.967
3308,2905428,Table 1,BaselineCharacteristic,,No (%) ; ,Resection margin,None,23,2,43,No,1:No,1:No,,0.909
3308,2905428,Table 1,BaselineCharacteristic,, ; ,, Resection margin,24,0,2,No,1:No,1:No,,1
3308,2905428,Table 1,BaselineCharacteristic,Clear (? x.x cm), ; ,, Resection margin,24,1,3,No,1:No,1:No,,0.99
3308,2905428,Table 1,BaselineCharacteristic,xx (xx.x),No (%) ; ,, Resection margin,24,2,3,No,1:No,1:No,,0.811
3308,2905428,Table 1,BaselineCharacteristic,, ; ,, Resection margin,25,0,2,No,1:No,1:No,,1
3308,2905428,Table 1,BaselineCharacteristic,"Close (> x, < x.x cm)", ; ,, Resection margin,25,1,3,No,1:No,1:No,,0.99
3308,2905428,Table 1,BaselineCharacteristic,x (xx.x),No (%) ; ,, Resection margin,25,2,3,No,1:No,1:No,,0.811
3308,2905428,Table 1,BaselineCharacteristic,Radiation therapy, ; ,None,None,26,0,24,No,1:No,1:No,,0.995
3308,2905428,Table 1,BaselineCharacteristic,, ; ,Radiation therapy,None,26,1,43,No,1:No,1:No,,0.977
3308,2905428,Table 1,BaselineCharacteristic,,No (%) ; ,Radiation therapy,None,26,2,43,No,1:No,1:No,,0.919
3308,2905428,Table 1,BaselineCharacteristic,, ; ,, Radiation therapy,27,0,2,No,1:No,1:No,,1
3308,2905428,Table 1,BaselineCharacteristic,xx Gy (x.x Gy/fraction), ; ,, Radiation therapy,27,1,3,No,1:No,1:No,,0.885
3308,2905428,Table 1,BaselineCharacteristic,xx (xx.x),No (%) ; ,, Radiation therapy,27,2,3,No,1:No,1:No,,0.821
3308,2905428,Table 1,BaselineCharacteristic,, ; ,, Radiation therapy,28,0,2,No,1:No,1:No,,1
3308,2905428,Table 1,BaselineCharacteristic,xx Gy (x.x Gy/fraction), ; ,, Radiation therapy,28,1,3,No,1:No,1:No,,0.885
3308,2905428,Table 1,BaselineCharacteristic,x (xx.x),No (%) ; ,, Radiation therapy,28,2,3,No,1:No,1:No,,0.821
3308,2905428,Table 1,BaselineCharacteristic,Systemic therapy, ; ,None,None,29,0,24,No,1:No,1:No,,0.995
3308,2905428,Table 1,BaselineCharacteristic,, ; ,Systemic therapy,None,29,1,43,No,1:No,1:No,,0.977
3308,2905428,Table 1,BaselineCharacteristic,,No (%) ; ,Systemic therapy,None,29,2,43,No,1:No,1:No,,0.919
3308,2905428,Table 1,BaselineCharacteristic,, ; ,, Systemic therapy,30,0,2,No,1:No,1:No,,1
3308,2905428,Table 1,BaselineCharacteristic,Chemotherapy + Hormonal therapy, ; ,, Systemic therapy,30,1,3,No,1:No,1:No,,0.99
3308,2905428,Table 1,BaselineCharacteristic,xx (xx.x),No (%) ; ,, Systemic therapy,30,2,3,No,1:No,1:No,,0.821
3308,2905428,Table 1,BaselineCharacteristic,, ; ,, Systemic therapy,31,0,2,No,1:No,1:No,,1
3308,2905428,Table 1,BaselineCharacteristic,Hormonal therapy, ; ,, Systemic therapy,31,1,3,No,1:No,1:No,,0.99
3308,2905428,Table 1,BaselineCharacteristic,xx (xx.x),No (%) ; ,, Systemic therapy,31,2,3,No,1:No,1:No,,0.821
3308,2905428,Table 1,BaselineCharacteristic,, ; ,, Systemic therapy,32,0,2,No,1:No,1:No,,1
3308,2905428,Table 1,BaselineCharacteristic,Chemotherapy, ; ,, Systemic therapy,32,1,3,No,1:No,1:No,,0.99
3308,2905428,Table 1,BaselineCharacteristic,x (xx.x),No (%) ; ,, Systemic therapy,32,2,3,No,1:No,1:No,,0.821
3308,2905428,Table 1,BaselineCharacteristic,, ; ,, Systemic therapy,33,0,2,No,1:No,1:No,,1
3308,2905428,Table 1,BaselineCharacteristic,None, ; ,, Systemic therapy,33,1,3,No,1:No,1:No,,0.99
3308,2905428,Table 1,BaselineCharacteristic,x (x.x),No (%) ; ,, Systemic therapy,33,2,3,No,1:No,1:No,,0.94
3308,2905428,Table 2,BaselineCharacteristic,No,,None,None,0,0,12,No,1:No,1:No,,0.905
3308,2905428,Table 2,BaselineCharacteristic,Age,,No,None,0,1,1,No,1:No,1:No,,0.903
3308,2905428,Table 2,BaselineCharacteristic,Pathology,,No,None,0,2,1,No,1:No,1:No,,0.903
3308,2905428,Table 2,BaselineCharacteristic,Tumor size (cm),,No,None,0,3,1,No,1:No,1:No,,0.903
3308,2905428,Table 2,BaselineCharacteristic,pN,,No,None,0,4,1,No,1:No,1:No,,0.913
3308,2905428,Table 2,BaselineCharacteristic,ER,,No,None,0,5,1,No,1:No,1:No,,0.935
3308,2905428,Table 2,BaselineCharacteristic,PR,,No,None,0,6,1,No,1:No,1:No,,0.935
3308,2905428,Table 2,BaselineCharacteristic,RM,,No,None,0,7,1,No,1:No,1:No,,0.945
3308,2905428,Table 2,BaselineCharacteristic,Radiation therapy,,No,None,0,8,1,No,1:No,1:No,,0.956
3308,2905428,Table 2,BaselineCharacteristic,Systemic therapy,,No,None,0,9,1,No,1:No,1:No,,0.956
3308,2905428,Table 2,BaselineCharacteristic,Failure,,No,None,0,10,1,No,1:No,1:No,,0.945
3308,2905428,Table 2,BaselineCharacteristic,Time to failure (mo),,No,None,0,11,1,No,1:No,1:No,,0.965
3308,2905428,Table 2,BaselineCharacteristic,Salvage surgery,,No,None,0,12,1,No,1:No,1:No,,0.955
3308,2905428,Table 2,BaselineCharacteristic,Follow-up after salvage surgery (mo),,No,None,0,13,1,No,1:No,1:No,,0.965
3308,2905428,Table 2,BaselineCharacteristic,x,No ; ,x,None,1,0,2,No,1:No,1:No,,0.915
3308,2905428,Table 2,BaselineCharacteristic,xx,Age ; ,x,None,1,1,3,No,1:No,1:No,,0.612
3308,2905428,Table 2,BaselineCharacteristic,DCIS,Pathology ; ,x,None,1,2,3,No,1:No,1:No,,0.9
3308,2905428,Table 2,BaselineCharacteristic,x.x,Tumor size (cm) ; ,x,None,1,3,3,No,1:No,1:No,,0.9
3308,2905428,Table 2,BaselineCharacteristic,x,pN ; ,x,None,1,4,3,No,1:No,1:No,,0.88
3308,2905428,Table 2,BaselineCharacteristic,+,ER ; ,x,None,1,5,3,No,1:No,1:No,,0.9
3308,2905428,Table 2,BaselineCharacteristic,-,PR ; ,x,None,1,6,3,No,1:No,1:No,,0.83
3308,2905428,Table 2,BaselineCharacteristic,Close,RM ; ,x,None,1,7,3,No,1:No,1:No,,0.89
3308,2905428,Table 2,BaselineCharacteristic,xx Gy,Radiation therapy ; ,x,None,1,8,3,No,1:No,1:No,,0.656
3308,2905428,Table 2,BaselineCharacteristic,TAM,Systemic therapy ; ,x,None,1,9,3,No,1:No,1:No,,0.91
3308,2905428,Table 2,BaselineCharacteristic,TR/MM,Failure ; ,x,None,1,10,3,No,1:No,1:No,,0.9
3308,2905428,Table 2,BaselineCharacteristic,xx,Time to failure (mo) ; ,x,None,1,11,3,No,1:No,1:No,,0.736
3308,2905428,Table 2,BaselineCharacteristic,BCS,Salvage surgery ; ,x,None,1,12,3,No,1:No,1:No,,0.91
3308,2905428,Table 2,BaselineCharacteristic,xx,Follow-up after salvage surgery (mo) ; ,x,None,1,13,3,No,1:No,1:No,,0.706
3308,2905428,Table 2,BaselineCharacteristic,x,No ; ,x,None,2,0,2,No,1:No,1:No,,0.935
3308,2905428,Table 2,BaselineCharacteristic,xx,Age ; ,x,None,2,1,3,No,1:No,1:No,,0.632
3308,2905428,Table 2,BaselineCharacteristic,IDC,Pathology ; ,x,None,2,2,3,No,1:No,1:No,,0.92
3308,2905428,Table 2,BaselineCharacteristic,x.x,Tumor size (cm) ; ,x,None,2,3,3,No,1:No,1:No,,0.92
3308,2905428,Table 2,BaselineCharacteristic,x,pN ; ,x,None,2,4,3,No,1:No,1:No,,0.9
3308,2905428,Table 2,BaselineCharacteristic,+,ER ; ,x,None,2,5,3,No,1:No,1:No,,0.91
3308,2905428,Table 2,BaselineCharacteristic,+,PR ; ,x,None,2,6,3,No,1:No,1:No,,0.92
3308,2905428,Table 2,BaselineCharacteristic,Close,RM ; ,x,None,2,7,3,No,1:No,1:No,,0.9
3308,2905428,Table 2,BaselineCharacteristic,xx Gy,Radiation therapy ; ,x,None,2,8,3,No,1:No,1:No,,0.696
3308,2905428,Table 2,BaselineCharacteristic,CMF/TAM,Systemic therapy ; ,x,None,2,9,3,No,1:No,1:No,,0.92
3308,2905428,Table 2,BaselineCharacteristic,TR/MM,Failure ; ,x,None,2,10,3,No,1:No,1:No,,0.91
3308,2905428,Table 2,BaselineCharacteristic,xx,Time to failure (mo) ; ,x,None,2,11,3,No,1:No,1:No,,0.756
3308,2905428,Table 2,BaselineCharacteristic,MRM,Salvage surgery ; ,x,None,2,12,3,No,1:No,1:No,,0.92
3308,2905428,Table 2,BaselineCharacteristic,xx,Follow-up after salvage surgery (mo) ; ,x,None,2,13,3,No,1:No,1:No,,0.746
3324,2910694,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,0,,No,1:No,1:No,,0.907
3324,2910694,Table 1,BaselineCharacteristic,Number,,None,None,0,1,,No,1:No,1:No,,0.874
3324,2910694,Table 1,BaselineCharacteristic,Age,Characteristic ; ,None,None,1,0,,No,1:No,1:No,,0.905
3324,2910694,Table 1,BaselineCharacteristic,,Characteristic ; Age ; ,None,None,2,0,,No,1:No,1:No,,0.922
3324,2910694,Table 1,BaselineCharacteristic,ECOG PS x*,Characteristic ; Age ;  ; ,None,None,3,0,,No,1:No,1:No,,0.932
3324,2910694,Table 1,BaselineCharacteristic,,Characteristic ; Age ;  ; ECOG PS x* ; ,None,None,4,0,,No,1:No,1:No,,0.927
3324,2910694,Table 1,BaselineCharacteristic,,Number ; xx (range xx-xx) ;  ; x ; ,None,None,4,1,,No,1:No,1:No,,0.529
3324,2910694,Table 1,BaselineCharacteristic,ECOG PS x,Characteristic ; Age ;  ; ECOG PS x* ;  ; ,None,None,5,0,,No,1:No,1:No,,0.926
3324,2910694,Table 1,BaselineCharacteristic,xx,Number ; xx (range xx-xx) ;  ; x ;  ; ,None,None,5,1,,No,1:No,1:No,,0.538
3324,2910694,Table 1,BaselineCharacteristic,,Characteristic ; Age ;  ; ECOG PS x* ;  ; ECOG PS x ; ,None,None,6,0,,No,1:No,1:No,,0.945
3324,2910694,Table 1,BaselineCharacteristic,,Number ; xx (range xx-xx) ;  ; x ;  ; xx ; ,None,None,6,1,,No,1:No,1:No,,0.557
3324,2910694,Table 1,BaselineCharacteristic,Males,Characteristic ; Age ;  ; ECOG PS x* ;  ; ECOG PS x ;  ; ,None,None,7,0,,No,1:No,1:No,,0.882
3324,2910694,Table 1,BaselineCharacteristic,xx,Number ; xx (range xx-xx) ;  ; x ;  ; xx ;  ; ,None,None,7,1,,No,1:No,1:No,,0.557
3324,2910694,Table 1,BaselineCharacteristic,,Characteristic ; Age ;  ; ECOG PS x* ;  ; ECOG PS x ;  ; Males ; ,None,None,8,0,,No,1:No,1:No,,0.899
3324,2910694,Table 1,BaselineCharacteristic,,Number ; xx (range xx-xx) ;  ; x ;  ; xx ;  ; xx ; ,None,None,8,1,,No,1:No,1:No,,0.558
3324,2910694,Table 1,BaselineCharacteristic,Females,Characteristic ; Age ;  ; ECOG PS x* ;  ; ECOG PS x ;  ; Males ;  ; ,None,None,9,0,,No,1:No,1:No,,0.81
3324,2910694,Table 1,BaselineCharacteristic,x,Number ; xx (range xx-xx) ;  ; x ;  ; xx ;  ; xx ;  ; ,None,None,9,1,,No,1:No,1:No,,0.593
3324,2910694,Table 1,BaselineCharacteristic,,Characteristic ; Age ;  ; ECOG PS x* ;  ; ECOG PS x ;  ; Males ;  ; Females ; ,None,None,10,0,,No,1:No,1:No,,0.839
3324,2910694,Table 1,BaselineCharacteristic,,Number ; xx (range xx-xx) ;  ; x ;  ; xx ;  ; xx ;  ; x ; ,None,None,10,1,,No,1:No,1:No,,0.625
3324,2910694,Table 1,BaselineCharacteristic,White,Characteristic ; Age ;  ; ECOG PS x* ;  ; ECOG PS x ;  ; Males ;  ; Females ;  ; ,None,None,11,0,,No,1:No,1:No,,0.847
3324,2910694,Table 1,BaselineCharacteristic,xx,Number ; xx (range xx-xx) ;  ; x ;  ; xx ;  ; xx ;  ; x ;  ; ,None,None,11,1,,No,1:No,1:No,,0.625
3324,2910694,Table 1,BaselineCharacteristic,,Characteristic ; Age ;  ; ECOG PS x* ;  ; ECOG PS x ;  ; Males ;  ; Females ;  ; White ; ,None,None,12,0,,No,1:No,1:No,,0.847
3324,2910694,Table 1,BaselineCharacteristic,,Number ; xx (range xx-xx) ;  ; x ;  ; xx ;  ; xx ;  ; x ;  ; xx ; ,None,None,12,1,,No,1:No,1:No,,0.625
3324,2910694,Table 1,BaselineCharacteristic,Hispanic,Characteristic ; Age ;  ; ECOG PS x* ;  ; ECOG PS x ;  ; Males ;  ; Females ;  ; White ;  ; ,None,None,13,0,,No,1:No,1:No,,0.848
3324,2910694,Table 1,BaselineCharacteristic,x,Number ; xx (range xx-xx) ;  ; x ;  ; xx ;  ; xx ;  ; x ;  ; xx ;  ; ,None,None,13,1,,No,1:No,1:No,,0.625
3324,2910694,Table 1,BaselineCharacteristic,,Characteristic ; Age ;  ; ECOG PS x* ;  ; ECOG PS x ;  ; Males ;  ; Females ;  ; White ;  ; Hispanic ; ,None,None,14,0,,No,1:No,1:No,,0.848
3324,2910694,Table 1,BaselineCharacteristic,,Number ; xx (range xx-xx) ;  ; x ;  ; xx ;  ; xx ;  ; x ;  ; xx ;  ; x ; ,None,None,14,1,,No,1:No,1:No,,0.625
3324,2910694,Table 1,BaselineCharacteristic,Prior surgery,Characteristic ; Age ;  ; ECOG PS x* ;  ; ECOG PS x ;  ; Males ;  ; Females ;  ; White ;  ; Hispanic ;  ; ,None,None,15,0,,No,1:No,1:No,,0.881
3324,2910694,Table 1,BaselineCharacteristic,x,Number ; xx (range xx-xx) ;  ; x ;  ; xx ;  ; xx ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,15,1,,No,1:No,1:No,,0.625
3324,2910694,Table 1,BaselineCharacteristic,,Characteristic ; Age ;  ; ECOG PS x* ;  ; ECOG PS x ;  ; Males ;  ; Females ;  ; White ;  ; Hispanic ;  ; Prior surgery ; ,None,None,16,0,,No,1:No,1:No,,0.881
3324,2910694,Table 1,BaselineCharacteristic,,Number ; xx (range xx-xx) ;  ; x ;  ; xx ;  ; xx ;  ; x ;  ; xx ;  ; x ;  ; x ; ,None,None,16,1,,No,1:No,1:No,,0.625
3324,2910694,Table 1,BaselineCharacteristic,Prior radiation,Characteristic ; Age ;  ; ECOG PS x* ;  ; ECOG PS x ;  ; Males ;  ; Females ;  ; White ;  ; Hispanic ;  ; Prior surgery ;  ; ,None,None,17,0,,No,1:No,1:No,,0.881
3324,2910694,Table 1,BaselineCharacteristic,x,Number ; xx (range xx-xx) ;  ; x ;  ; xx ;  ; xx ;  ; x ;  ; xx ;  ; x ;  ; x ;  ; ,None,None,17,1,,No,1:No,1:No,,0.625
3324,2910694,Table 1,BaselineCharacteristic,,Characteristic ; Age ;  ; ECOG PS x* ;  ; ECOG PS x ;  ; Males ;  ; Females ;  ; White ;  ; Hispanic ;  ; Prior surgery ;  ; Prior radiation ; ,None,None,18,0,,No,1:No,1:No,,0.881
3324,2910694,Table 1,BaselineCharacteristic,,Number ; xx (range xx-xx) ;  ; x ;  ; xx ;  ; xx ;  ; x ;  ; xx ;  ; x ;  ; x ;  ; x ; ,None,None,18,1,,No,1:No,1:No,,0.601
3324,2910694,Table 1,BaselineCharacteristic,Prior chemotherapy regimens,Characteristic ; Age ;  ; ECOG PS x* ;  ; ECOG PS x ;  ; Males ;  ; Females ;  ; White ;  ; Hispanic ;  ; Prior surgery ;  ; Prior radiation ;  ; ,None,None,19,0,,No,1:No,1:No,,0.909
3324,2910694,Table 1,BaselineCharacteristic,,Number ; xx (range xx-xx) ;  ; x ;  ; xx ;  ; xx ;  ; x ;  ; xx ;  ; x ;  ; x ;  ; x ;  ; ,None,None,19,1,,No,1:No,1:No,,0.601
3324,2910694,Table 1,BaselineCharacteristic,,Characteristic ; Age ;  ; ECOG PS x* ;  ; ECOG PS x ;  ; Males ;  ; Females ;  ; White ;  ; Hispanic ;  ; Prior surgery ;  ; Prior radiation ;  ; ,None,None,20,0,,No,1:No,1:No,,0.881
3324,2910694,Table 1,BaselineCharacteristic,,Number ; xx (range xx-xx) ;  ; x ;  ; xx ;  ; xx ;  ; x ;  ; xx ;  ; x ;  ; x ;  ; x ;  ; ,None,None,20,1,,No,1:No,1:No,,0.601
3324,2910694,Table 1,BaselineCharacteristic,x,Characteristic ; Age ;  ; ECOG PS x* ;  ; ECOG PS x ;  ; Males ;  ; Females ;  ; White ;  ; Hispanic ;  ; Prior surgery ;  ; Prior radiation ;  ; ,x,,21,0,,No,1:No,1:No,,0.881
3324,2910694,Table 1,BaselineCharacteristic,x,Number ; xx (range xx-xx) ;  ; x ;  ; xx ;  ; xx ;  ; x ;  ; xx ;  ; x ;  ; x ;  ; x ;  ; ,x,,21,1,,No,1:No,1:No,,0.601
3324,2910694,Table 1,BaselineCharacteristic,,Characteristic ; Age ;  ; ECOG PS x* ;  ; ECOG PS x ;  ; Males ;  ; Females ;  ; White ;  ; Hispanic ;  ; Prior surgery ;  ; Prior radiation ;  ; ,None,None,22,0,,No,1:No,1:No,,0.881
3324,2910694,Table 1,BaselineCharacteristic,,Number ; xx (range xx-xx) ;  ; x ;  ; xx ;  ; xx ;  ; x ;  ; xx ;  ; x ;  ; x ;  ; x ;  ; ,None,None,22,1,,No,1:No,1:No,,0.611
3324,2910694,Table 1,BaselineCharacteristic,x,Characteristic ; Age ;  ; ECOG PS x* ;  ; ECOG PS x ;  ; Males ;  ; Females ;  ; White ;  ; Hispanic ;  ; Prior surgery ;  ; Prior radiation ;  ; ,x,,23,0,,No,1:No,1:No,,0.881
3324,2910694,Table 1,BaselineCharacteristic,x,Number ; xx (range xx-xx) ;  ; x ;  ; xx ;  ; xx ;  ; x ;  ; xx ;  ; x ;  ; x ;  ; x ;  ; ,x,,23,1,,No,1:No,1:No,,0.611
3324,2910694,Table 1,BaselineCharacteristic,,Characteristic ; Age ;  ; ECOG PS x* ;  ; ECOG PS x ;  ; Males ;  ; Females ;  ; White ;  ; Hispanic ;  ; Prior surgery ;  ; Prior radiation ;  ; ,None,None,24,0,,No,1:No,1:No,,0.881
3324,2910694,Table 1,BaselineCharacteristic,,Number ; xx (range xx-xx) ;  ; x ;  ; xx ;  ; xx ;  ; x ;  ; xx ;  ; x ;  ; x ;  ; x ;  ; ,None,None,24,1,,No,1:No,1:No,,0.611
3324,2910694,Table 1,BaselineCharacteristic,? x,Characteristic ; Age ;  ; ECOG PS x* ;  ; ECOG PS x ;  ; Males ;  ; Females ;  ; White ;  ; Hispanic ;  ; Prior surgery ;  ; Prior radiation ;  ; ,? x,,25,0,,No,1:No,1:No,,0.881
3324,2910694,Table 1,BaselineCharacteristic,x,Number ; xx (range xx-xx) ;  ; x ;  ; xx ;  ; xx ;  ; x ;  ; xx ;  ; x ;  ; x ;  ; x ;  ; ,? x,,25,1,,No,1:No,1:No,,0.611
3561,2990606,Table 1,BaselineCharacteristic,Number of patients,,None,None,0,0,12,No,1:No,1:No,,0.835
3561,2990606,Table 1,BaselineCharacteristic,,,Number of patients,None,0,1,1,No,1:No,1:No,,0.853
3561,2990606,Table 1,BaselineCharacteristic,?Total,,None,None,1,0,12,No,1:No,1:No,,0.898
3561,2990606,Table 1,BaselineCharacteristic,xx,,?Total,None,1,1,1,No,1:No,1:No,,0.722
3561,2990606,Table 1,BaselineCharacteristic,?Evaluable,,None,None,2,0,12,No,1:No,1:No,,0.913
3561,2990606,Table 1,BaselineCharacteristic,xx,,?Evaluable,None,2,1,1,No,1:No,1:No,,0.792
3561,2990606,Table 1,BaselineCharacteristic,,,None,None,3,0,2,No,1:No,1:No,,0.96
3561,2990606,Table 1,BaselineCharacteristic,,,None,None,3,1,3,No,1:No,1:No,,0.9
3561,2990606,Table 1,BaselineCharacteristic,,,None,None,5,0,2,No,1:No,1:No,,0.97
3561,2990606,Table 1,BaselineCharacteristic,,,None,None,5,1,3,No,1:No,1:No,,0.89
3561,2990606,Table 1,BaselineCharacteristic,Initial disease stage,,None,None,6,0,24,No,1:No,1:No,,0.969
3561,2990606,Table 1,BaselineCharacteristic,Initial disease stage,,Initial disease stage,None,6,1,43,No,1:No,1:No,,0.952
3561,2990606,Table 1,BaselineCharacteristic,?I,,?I, Initial disease stage,7,0,2,No,1:No,1:No,,0.98
3561,2990606,Table 1,BaselineCharacteristic,x,,?I, Initial disease stage,7,1,3,No,1:No,1:No,,0.94
3561,2990606,Table 1,BaselineCharacteristic,?II,,?II, Initial disease stage,8,0,2,No,1:No,1:No,,0.99
3561,2990606,Table 1,BaselineCharacteristic,x,,?II, Initial disease stage,8,1,3,No,1:No,1:No,,0.97
3561,2990606,Table 1,BaselineCharacteristic,?III,,?III, Initial disease stage,9,0,2,No,1:No,1:No,,1
3561,2990606,Table 1,BaselineCharacteristic,x,,?III, Initial disease stage,9,1,3,No,1:No,1:No,,0.98
3561,2990606,Table 1,BaselineCharacteristic,?IV,,?IV, Initial disease stage,10,0,2,No,1:No,1:No,,0.97
3561,2990606,Table 1,BaselineCharacteristic,x,,?IV, Initial disease stage,10,1,3,No,1:No,1:No,,0.97
3561,2990606,Table 1,BaselineCharacteristic,,,None,None,11,0,2,No,1:No,1:No,,1
3561,2990606,Table 1,BaselineCharacteristic,,,None,None,11,1,3,No,1:No,1:No,,0.99
3561,2990606,Table 1,BaselineCharacteristic,Hormone receptor status,,None,None,12,0,24,No,1:No,1:No,,0.995
3561,2990606,Table 1,BaselineCharacteristic,Hormone receptor status,,Hormone receptor status,None,12,1,43,No,1:No,1:No,,0.978
3561,2990606,Table 1,BaselineCharacteristic,?Positive,,?Positive, Hormone receptor status,13,0,2,No,1:No,1:No,,1
3561,2990606,Table 1,BaselineCharacteristic,x,,?Positive, Hormone receptor status,13,1,3,No,1:No,1:No,,1
3561,2990606,Table 1,BaselineCharacteristic,?Negative,,?Negative, Hormone receptor status,14,0,2,No,1:No,1:No,,1
3561,2990606,Table 1,BaselineCharacteristic,x,,?Negative, Hormone receptor status,14,1,3,No,1:No,1:No,,1
3561,2990606,Table 1,BaselineCharacteristic,,,None,None,15,0,2,No,1:No,1:No,,1
3561,2990606,Table 1,BaselineCharacteristic,,,None,None,15,1,3,No,1:No,1:No,,0.98
3561,2990606,Table 1,BaselineCharacteristic,HERx receptor positive,,HERx receptor positive,,16,0,2,No,1:No,1:No,,1
3561,2990606,Table 1,BaselineCharacteristic,xx,,HERx receptor positive,,16,1,3,No,1:No,1:No,,0.941
3561,2990606,Table 1,BaselineCharacteristic,Neoadjuvant chemotherapy,,Neoadjuvant chemotherapy,,17,0,24,No,1:No,1:No,,0.995
3561,2990606,Table 1,BaselineCharacteristic,x,,Neoadjuvant chemotherapy,,17,1,43,No,1:No,1:No,,0.974
3561,2990606,Table 1,BaselineCharacteristic,?Anthracycline-containing regimen only,,?Anthracycline-containing regimen only, Neoadjuvant chemotherapy,18,0,2,No,1:No,1:No,,1
3561,2990606,Table 1,BaselineCharacteristic,x,,?Anthracycline-containing regimen only, Neoadjuvant chemotherapy,18,1,3,No,1:No,1:No,,0.99
3561,2990606,Table 1,BaselineCharacteristic,?Anthracycline- and taxane-containing regimen,,?Anthracycline- and taxane-containing regimen, Neoadjuvant chemotherapy,19,0,2,No,1:No,1:No,,0.99
3561,2990606,Table 1,BaselineCharacteristic,x,,?Anthracycline- and taxane-containing regimen, Neoadjuvant chemotherapy,19,1,3,No,1:No,1:No,,0.98
3561,2990606,Table 1,BaselineCharacteristic,,,None,None,20,0,2,No,1:No,1:No,,0.99
3561,2990606,Table 1,BaselineCharacteristic,,,None,None,20,1,3,No,1:No,1:No,,0.97
3561,2990606,Table 1,BaselineCharacteristic,Adjuvant chemotherapy,,Adjuvant chemotherapy,,21,0,24,No,1:No,1:No,,0.985
3561,2990606,Table 1,BaselineCharacteristic,x,,Adjuvant chemotherapy,,21,1,43,No,1:No,1:No,,0.964
3561,2990606,Table 1,BaselineCharacteristic,?Anthracycline-containing regimen only,,?Anthracycline-containing regimen only, Adjuvant chemotherapy,22,0,2,No,1:No,1:No,,1
3561,2990606,Table 1,BaselineCharacteristic,x,,?Anthracycline-containing regimen only, Adjuvant chemotherapy,22,1,3,No,1:No,1:No,,0.99
3561,2990606,Table 1,BaselineCharacteristic,?Anthracycline- and taxane-containing regimen,,?Anthracycline- and taxane-containing regimen, Adjuvant chemotherapy,23,0,2,No,1:No,1:No,,1
3561,2990606,Table 1,BaselineCharacteristic,x,,?Anthracycline- and taxane-containing regimen, Adjuvant chemotherapy,23,1,3,No,1:No,1:No,,0.99
3561,2990606,Table 1,BaselineCharacteristic,?Taxane-containing regimen only,,?Taxane-containing regimen only, Adjuvant chemotherapy,24,0,2,No,1:No,1:No,,1
3561,2990606,Table 1,BaselineCharacteristic,x,,?Taxane-containing regimen only, Adjuvant chemotherapy,24,1,3,No,1:No,1:No,,0.99
3561,2990606,Table 1,BaselineCharacteristic,,,None,None,25,0,2,No,1:No,1:No,,1
3561,2990606,Table 1,BaselineCharacteristic,,,None,None,25,1,3,No,1:No,1:No,,0.98
3561,2990606,Table 1,BaselineCharacteristic,Adjuvant radiation therapy,,Adjuvant radiation therapy,,26,0,2,No,1:No,1:No,,1
3561,2990606,Table 1,BaselineCharacteristic,x,,Adjuvant radiation therapy,,26,1,3,No,1:No,1:No,,1
3561,2990606,Table 1,BaselineCharacteristic,Adjuvant hormone therapy,,Adjuvant hormone therapy,,27,0,2,No,1:No,1:No,,1
3561,2990606,Table 1,BaselineCharacteristic,x,,Adjuvant hormone therapy,,27,1,3,No,1:No,1:No,,1
3561,2990606,Table 1,BaselineCharacteristic,"Number of systemic regimens after metastasis, median (range)",,"Number of systemic regimens after metastasis, median (range)",,28,0,2,No,1:No,1:No,,0.662
3561,2990606,Table 1,BaselineCharacteristic,x (x–x),,"Number of systemic regimens after metastasis, median (range)",,28,1,3,No,1:No,1:No,,0.59
3561,2990606,Table 1,BaselineCharacteristic,"Number of trastuzumab-containing regimens after metastasis, median (range)",,"Number of trastuzumab-containing regimens after metastasis, median (range)",,29,0,2,No,1:No,1:No,,0.662
3561,2990606,Table 1,BaselineCharacteristic,x (x–x),,"Number of trastuzumab-containing regimens after metastasis, median (range)",,29,1,3,No,1:No,1:No,,0.59
3561,2990606,Table 1,BaselineCharacteristic,"Number of sites of metastasis, median (range)",,"Number of sites of metastasis, median (range)",,30,0,2,No,1:No,1:No,,0.692
3561,2990606,Table 1,BaselineCharacteristic,x (x–x),,"Number of sites of metastasis, median (range)",,30,1,3,No,1:No,1:No,,0.62
3561,2990606,Table 1,BaselineCharacteristic,,,None,None,31,0,2,No,1:No,1:No,,1
3561,2990606,Table 1,BaselineCharacteristic,,,None,None,31,1,3,No,1:No,1:No,,0.98
3561,2990606,Table 1,BaselineCharacteristic,Sites of metastasis,,None,None,32,0,24,No,1:No,1:No,,0.995
3561,2990606,Table 1,BaselineCharacteristic,Sites of metastasis,,Sites of metastasis,None,32,1,43,No,1:No,1:No,,0.977
3561,2990606,Table 1,BaselineCharacteristic,?Liver,,?Liver, Sites of metastasis,33,0,2,No,1:No,1:No,,1
3561,2990606,Table 1,BaselineCharacteristic,xx,,?Liver, Sites of metastasis,33,1,3,No,1:No,1:No,,0.951
3561,2990606,Table 1,BaselineCharacteristic,?Bone,,?Bone, Sites of metastasis,34,0,2,No,1:No,1:No,,1
3561,2990606,Table 1,BaselineCharacteristic,x,,?Bone, Sites of metastasis,34,1,3,No,1:No,1:No,,0.99
3561,2990606,Table 1,BaselineCharacteristic,?Lymph nodes,,?Lymph nodes, Sites of metastasis,35,0,2,No,1:No,1:No,,1
3561,2990606,Table 1,BaselineCharacteristic,x,,?Lymph nodes, Sites of metastasis,35,1,3,No,1:No,1:No,,0.99
3561,2990606,Table 1,BaselineCharacteristic,?Lung,,?Lung, Sites of metastasis,36,0,2,No,1:No,1:No,,1
3561,2990606,Table 1,BaselineCharacteristic,x,,?Lung, Sites of metastasis,36,1,3,No,1:No,1:No,,0.99
3561,2990606,Table 1,BaselineCharacteristic,?Chest wall,,?Chest wall, Sites of metastasis,37,0,2,No,1:No,1:No,,1
3561,2990606,Table 1,BaselineCharacteristic,x,,?Chest wall, Sites of metastasis,37,1,3,No,1:No,1:No,,0.99
3561,2990606,Table 1,BaselineCharacteristic,?Brain,,?Brain, Sites of metastasis,38,0,2,No,1:No,1:No,,1
3561,2990606,Table 1,BaselineCharacteristic,x,,?Brain, Sites of metastasis,38,1,3,No,1:No,1:No,,0.99
3561,2990606,Table 1,BaselineCharacteristic,?Peritoneum,,?Peritoneum, Sites of metastasis,39,0,2,No,1:No,1:No,,1
3561,2990606,Table 1,BaselineCharacteristic,x,,?Peritoneum, Sites of metastasis,39,1,3,No,1:No,1:No,,0.99
3652,3015370,Table 1.,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
3652,3015370,Table 1.,BaselineCharacteristic,Estrogen,,,None,0,1,1,No,1:No,1:No,,0.903
3652,3015370,Table 1.,BaselineCharacteristic,Placebo,,,None,0,2,1,No,1:No,1:No,,0.903
3652,3015370,Table 1.,BaselineCharacteristic,Age (years), ; ,Age (years),None,1,0,2,No,1:No,1:No,,0.65
3652,3015370,Table 1.,BaselineCharacteristic,Weight (pounds), ; ,Weight (pounds),None,2,0,2,No,1:No,1:No,,0.95
3652,3015370,Table 1.,BaselineCharacteristic,xxx (+/? xx),Estrogen ; ,Weight (pounds),None,2,1,3,No,1:No,1:No,,0.578
3652,3015370,Table 1.,BaselineCharacteristic,xxx (+/? xx),Placebo ; ,Weight (pounds),None,2,2,3,No,1:No,1:No,,0.578
3652,3015370,Table 1.,BaselineCharacteristic,Height (inches), ; ,Height (inches),None,3,0,2,No,1:No,1:No,,0.96
3652,3015370,Table 1.,BaselineCharacteristic,xx (+/? x),Estrogen ; ,Height (inches),None,3,1,3,No,1:No,1:No,,0.586
3652,3015370,Table 1.,BaselineCharacteristic,xx (+/? x),Placebo ; ,Height (inches),None,3,2,3,No,1:No,1:No,,0.596
3652,3015370,Table 1.,BaselineCharacteristic,Smoker, ; ,Smoker,None,4,0,2,No,1:No,1:No,,0.93
3652,3015370,Table 1.,BaselineCharacteristic,x/x,Estrogen ; ,Smoker,None,4,1,3,No,1:No,1:No,,0.88
3652,3015370,Table 1.,BaselineCharacteristic,x/x,Placebo ; ,Smoker,None,4,2,3,No,1:No,1:No,,0.9
3652,3015370,Table 1.,BaselineCharacteristic,Prior pregnancy, ; ,Prior pregnancy,None,5,0,2,No,1:No,1:No,,0.97
3652,3015370,Table 1.,BaselineCharacteristic,x/x,Estrogen ; ,Prior pregnancy,None,5,1,3,No,1:No,1:No,,0.9
3652,3015370,Table 1.,BaselineCharacteristic,x/x,Placebo ; ,Prior pregnancy,None,5,2,3,No,1:No,1:No,,0.92
3950,3080287,Table 1,BaselineCharacteristic,site,,None,None,0,0,12,No,1:No,1:No,,0.905
3950,3080287,Table 1,BaselineCharacteristic,maxillary sinus,,site,None,0,1,1,No,1:No,1:No,,0.903
3950,3080287,Table 1,BaselineCharacteristic,xx pts,,site,None,0,2,1,No,1:No,1:No,,0.67
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,1,0,12,No,1:No,1:No,,0.898
3950,3080287,Table 1,BaselineCharacteristic,nasal cavity,,,None,1,1,1,No,1:No,1:No,,0.895
3950,3080287,Table 1,BaselineCharacteristic,x pts,,,None,1,2,1,No,1:No,1:No,,0.841
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,2,0,12,No,1:No,1:No,,0.913
3950,3080287,Table 1,BaselineCharacteristic,ethmoid sinus,,,None,2,1,1,No,1:No,1:No,,0.905
3950,3080287,Table 1,BaselineCharacteristic,x pts,,,None,2,2,1,No,1:No,1:No,,0.861
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,3,0,12,No,1:No,1:No,,0.923
3950,3080287,Table 1,BaselineCharacteristic,sphenoid sinus,,,None,3,1,1,No,1:No,1:No,,0.889
3950,3080287,Table 1,BaselineCharacteristic,x pt,,,None,3,2,1,No,1:No,1:No,,0.851
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,4,0,12,No,1:No,1:No,,0.93
3950,3080287,Table 1,BaselineCharacteristic,pansinus,,,None,4,1,1,No,1:No,1:No,,0.899
3950,3080287,Table 1,BaselineCharacteristic,x pts,,,None,4,2,1,No,1:No,1:No,,0.881
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,5,0,2,No,1:No,1:No,,0.97
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,5,1,3,No,1:No,1:No,,0.89
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,5,2,3,No,1:No,1:No,,0.91
3950,3080287,Table 1,BaselineCharacteristic,histology,,histology,,6,0,24,No,1:No,1:No,,0.969
3950,3080287,Table 1,BaselineCharacteristic,adenoidcystic carcinoma,,histology,,6,1,43,No,1:No,1:No,,0.952
3950,3080287,Table 1,BaselineCharacteristic,xx pts,,histology,,6,2,43,No,1:No,1:No,,0.793
3950,3080287,Table 1,BaselineCharacteristic,,,,,7,0,2,No,1:No,1:No,,0.99
3950,3080287,Table 1,BaselineCharacteristic,malignant melanoma,,,,7,1,3,No,1:No,1:No,,0.95
3950,3080287,Table 1,BaselineCharacteristic,x pts,,,,7,2,3,No,1:No,1:No,,0.97
3950,3080287,Table 1,BaselineCharacteristic,,,,,8,0,2,No,1:No,1:No,,0.99
3950,3080287,Table 1,BaselineCharacteristic,undifferentiated carcinoma,,,,8,1,3,No,1:No,1:No,,0.96
3950,3080287,Table 1,BaselineCharacteristic,x pt,,,,8,2,3,No,1:No,1:No,,0.98
3950,3080287,Table 1,BaselineCharacteristic,,,,,9,0,2,No,1:No,1:No,,1
3950,3080287,Table 1,BaselineCharacteristic,chordoma,,,,9,1,3,No,1:No,1:No,,0.97
3950,3080287,Table 1,BaselineCharacteristic,x pt,,,,9,2,3,No,1:No,1:No,,0.99
3950,3080287,Table 1,BaselineCharacteristic,,,,,10,0,2,No,1:No,1:No,,1
3950,3080287,Table 1,BaselineCharacteristic,chondrosarcoma,,,,10,1,3,No,1:No,1:No,,0.99
3950,3080287,Table 1,BaselineCharacteristic,x pt,,,,10,2,3,No,1:No,1:No,,1
3950,3080287,Table 1,BaselineCharacteristic,,,,,11,0,2,No,1:No,1:No,,1
3950,3080287,Table 1,BaselineCharacteristic,osteosarcoma,,,,11,1,3,No,1:No,1:No,,0.99
3950,3080287,Table 1,BaselineCharacteristic,x pt,,,,11,2,3,No,1:No,1:No,,1
3950,3080287,Table 1,BaselineCharacteristic,,,,,12,0,2,No,1:No,1:No,,1
3950,3080287,Table 1,BaselineCharacteristic,ameloblastic carcinoma,,,,12,1,3,No,1:No,1:No,,0.99
3950,3080287,Table 1,BaselineCharacteristic,x pt,,,,12,2,3,No,1:No,1:No,,1
3950,3080287,Table 1,BaselineCharacteristic,,,,,13,0,2,No,1:No,1:No,,1
3950,3080287,Table 1,BaselineCharacteristic,malignant peripheral nerve sheath tumour,,,,13,1,3,No,1:No,1:No,,0.99
3950,3080287,Table 1,BaselineCharacteristic,x pt,,,,13,2,3,No,1:No,1:No,,1
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,14,0,2,No,1:No,1:No,,1
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,14,1,3,No,1:No,1:No,,0.99
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,14,2,3,No,1:No,1:No,,1
3950,3080287,Table 1,BaselineCharacteristic,stage,,stage,,15,0,24,No,1:No,1:No,,0.995
3950,3080287,Table 1,BaselineCharacteristic,Tx,,stage,,15,1,43,No,1:No,1:No,,0.967
3950,3080287,Table 1,BaselineCharacteristic,xx pts,,stage,,15,2,43,No,1:No,1:No,,0.934
3950,3080287,Table 1,BaselineCharacteristic,,,,,16,0,2,No,1:No,1:No,,1
3950,3080287,Table 1,BaselineCharacteristic,Tx,,,,16,1,3,No,1:No,1:No,,0.98
3950,3080287,Table 1,BaselineCharacteristic,x pts,,,,16,2,3,No,1:No,1:No,,0.99
3950,3080287,Table 1,BaselineCharacteristic,,,,,17,0,2,No,1:No,1:No,,1
3950,3080287,Table 1,BaselineCharacteristic,Tx,,,,17,1,3,No,1:No,1:No,,0.98
3950,3080287,Table 1,BaselineCharacteristic,x pt,,,,17,2,3,No,1:No,1:No,,0.99
3950,3080287,Table 1,BaselineCharacteristic,,,,,18,0,2,No,1:No,1:No,,0.99
3950,3080287,Table 1,BaselineCharacteristic,N+,,,,18,1,3,No,1:No,1:No,,0.97
3950,3080287,Table 1,BaselineCharacteristic,x pt,,,,18,2,3,No,1:No,1:No,,0.98
3950,3080287,Table 1,BaselineCharacteristic,,,,,19,0,2,No,1:No,1:No,,0.99
3950,3080287,Table 1,BaselineCharacteristic,not applicable,,,,19,1,3,No,1:No,1:No,,0.97
3950,3080287,Table 1,BaselineCharacteristic,x pts,,,,19,2,3,No,1:No,1:No,,0.98
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,20,0,2,No,1:No,1:No,,0.99
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,20,1,3,No,1:No,1:No,,0.97
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,20,2,3,No,1:No,1:No,,0.98
3950,3080287,Table 1,BaselineCharacteristic,therapy,,therapy,,21,0,24,No,1:No,1:No,,0.985
3950,3080287,Table 1,BaselineCharacteristic,primary,,therapy,,21,1,43,No,1:No,1:No,,0.975
3950,3080287,Table 1,BaselineCharacteristic,xx pts,,therapy,,21,2,43,No,1:No,1:No,,0.929
3950,3080287,Table 1,BaselineCharacteristic,,,,,22,0,2,No,1:No,1:No,,1
3950,3080287,Table 1,BaselineCharacteristic,local relapse,,,,22,1,3,No,1:No,1:No,,0.98
3950,3080287,Table 1,BaselineCharacteristic,x pts,,,,22,2,3,No,1:No,1:No,,0.99
3950,3080287,Table 1,BaselineCharacteristic,,,,,23,0,2,No,1:No,1:No,,1
3950,3080287,Table 1,BaselineCharacteristic,reirradiation,,,,23,1,3,No,1:No,1:No,,0.98
3950,3080287,Table 1,BaselineCharacteristic,x pts,,,,23,2,3,No,1:No,1:No,,0.99
3950,3080287,Table 1,BaselineCharacteristic,,,,,24,0,2,No,1:No,1:No,,1
3950,3080287,Table 1,BaselineCharacteristic,Rx-resected,,,,24,1,3,No,1:No,1:No,,0.98
3950,3080287,Table 1,BaselineCharacteristic,xx pts,,,,24,2,3,No,1:No,1:No,,0.937
3950,3080287,Table 1,BaselineCharacteristic,,,,,25,0,2,No,1:No,1:No,,1
3950,3080287,Table 1,BaselineCharacteristic,Rx-resected/definitive RT,,,,25,1,3,No,1:No,1:No,,0.98
3950,3080287,Table 1,BaselineCharacteristic,xx pts,,,,25,2,3,No,1:No,1:No,,0.937
3950,3080287,Table 1,BaselineCharacteristic,,,,,26,0,2,No,1:No,1:No,,1
3950,3080287,Table 1,BaselineCharacteristic,orbital exenteration,,,,26,1,3,No,1:No,1:No,,0.98
3950,3080287,Table 1,BaselineCharacteristic,x pts,,,,26,2,3,No,1:No,1:No,,0.99
3950,3080287,Table 1,BaselineCharacteristic,,,,,27,0,2,No,1:No,1:No,,1
3950,3080287,Table 1,BaselineCharacteristic,post-induction,,,,27,1,3,No,1:No,1:No,,0.98
3950,3080287,Table 1,BaselineCharacteristic,x pts,,,,27,2,3,No,1:No,1:No,,0.99
3950,3080287,Table 1,BaselineCharacteristic,,,,,28,0,2,No,1:No,1:No,,1
3950,3080287,Table 1,BaselineCharacteristic,comb. Radioimmunotherapy,,,,28,1,3,No,1:No,1:No,,0.98
3950,3080287,Table 1,BaselineCharacteristic,x pt,,,,28,2,3,No,1:No,1:No,,0.99
3950,3080287,Table 2,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
3950,3080287,Table 2,BaselineCharacteristic,median dose/GyE or Gy,,,None,0,1,1,No,1:No,1:No,,0.638
3950,3080287,Table 2,BaselineCharacteristic,range/GyE or Gy,,,None,0,2,1,No,1:No,1:No,,0.903
3950,3080287,Table 2,BaselineCharacteristic,Cxx, ; ,Cxx,,1,0,2,No,1:No,1:No,,0.94
3950,3080287,Table 2,BaselineCharacteristic,xx - xx,range/GyE or Gy ; ,Cxx,,1,2,3,No,1:No,1:No,,0.642
3950,3080287,Table 2,BaselineCharacteristic,IMRT, ; ,IMRT,,2,0,2,No,1:No,1:No,,0.95
3950,3080287,Table 2,BaselineCharacteristic,xx - xx,range/GyE or Gy ; ,IMRT,,2,2,3,No,1:No,1:No,,0.692
3950,3080287,Table 2,BaselineCharacteristic,total, ; ,total,,3,0,24,No,1:No,1:No,,0.902
3950,3080287,Table 2,BaselineCharacteristic,xx - xx,range/GyE or Gy ; ,total,,3,2,43,No,1:No,1:No,,0.731
3950,3080287,Table 2,BaselineCharacteristic,, ; ,,,4,0,2,No,1:No,1:No,,0.97
3950,3080287,Table 2,BaselineCharacteristic,median volume/cc,median dose/GyE or Gy ; ,,,4,1,3,No,1:No,1:No,,0.57
3950,3080287,Table 2,BaselineCharacteristic,range/cc,range/GyE or Gy ; ,,,4,2,3,No,1:No,1:No,,0.92
3950,3080287,Table 2,BaselineCharacteristic,CTVx, ; ,CTVx,,5,0,2,No,1:No,1:No,,0.97
3950,3080287,Table 2,BaselineCharacteristic,xxx.x,median dose/GyE or Gy ; ,CTVx,,5,1,3,No,1:No,1:No,,0.59
3950,3080287,Table 2,BaselineCharacteristic,xx.x - xxx.x,range/GyE or Gy ; ,CTVx,,5,2,3,No,1:No,1:No,,0.67
3950,3080287,Table 2,BaselineCharacteristic,CTVx, ; ,CTVx,,6,0,2,No,1:No,1:No,,0.99
3950,3080287,Table 2,BaselineCharacteristic,xxx.x,median dose/GyE or Gy ; ,CTVx,,6,1,3,No,1:No,1:No,,0.62
3950,3080287,Table 2,BaselineCharacteristic,xxx.x - xxxx.x,range/GyE or Gy ; ,CTVx,,6,2,3,No,1:No,1:No,,0.88
3950,3080287,Table 2,BaselineCharacteristic,, ; ,None,None,7,0,2,No,1:No,1:No,,0.99
3950,3080287,Table 2,BaselineCharacteristic,,median dose/GyE or Gy ; ,None,None,7,1,3,No,1:No,1:No,,0.63
3950,3080287,Table 2,BaselineCharacteristic,,range/GyE or Gy ; ,None,None,7,2,3,No,1:No,1:No,,0.96
3950,3080287,Table 2,BaselineCharacteristic,combined treatment, ; ,combined treatment,,8,0,2,No,1:No,1:No,,0.99
3950,3080287,Table 2,BaselineCharacteristic,xx pts,median dose/GyE or Gy ; ,combined treatment,,8,1,3,No,1:No,1:No,,0.52
3950,3080287,Table 2,BaselineCharacteristic,(x fractions Cxx),range/GyE or Gy ; ,combined treatment,,8,2,3,No,1:No,1:No,,0.97
3950,3080287,Table 2,BaselineCharacteristic,step& shoot IMRT, ; ,step& shoot IMRT,,9,0,2,No,1:No,1:No,,1
3950,3080287,Table 2,BaselineCharacteristic,xx pts,median dose/GyE or Gy ; ,step& shoot IMRT,,9,1,3,No,1:No,1:No,,0.51
3950,3080287,Table 2,BaselineCharacteristic,,range/GyE or Gy ; ,step& shoot IMRT,,9,2,3,No,1:No,1:No,,0.96
3950,3080287,Table 2,BaselineCharacteristic,tomotherapy, ; ,tomotherapy,,10,0,2,No,1:No,1:No,,1
3950,3080287,Table 2,BaselineCharacteristic,x pts,median dose/GyE or Gy ; ,tomotherapy,,10,1,3,No,1:No,1:No,,0.7
3950,3080287,Table 2,BaselineCharacteristic,,range/GyE or Gy ; ,tomotherapy,,10,2,3,No,1:No,1:No,,0.98
3950,3080287,Table 2,BaselineCharacteristic,Cxx only, ; ,Cxx only,,11,0,2,No,1:No,1:No,,1
3950,3080287,Table 2,BaselineCharacteristic,x pts,median dose/GyE or Gy ; ,Cxx only,,11,1,3,No,1:No,1:No,,0.74
3950,3080287,Table 2,BaselineCharacteristic,(xx-xx fractions),range/GyE or Gy ; ,Cxx only,,11,2,3,No,1:No,1:No,,0.7
3974,3086082,Table 1,BaselineCharacteristic,Parameter,,None,None,0,0,12,No,1:No,1:No,,0.915
3974,3086082,Table 1,BaselineCharacteristic,,,Parameter,None,0,1,1,No,1:No,1:No,,0.913
3974,3086082,Table 1,BaselineCharacteristic,"Sex, n (%)",Parameter ; ,None,None,4,0,24,No,1:No,1:No,,0.85
3974,3086082,Table 1,BaselineCharacteristic,"Sex, n (%)", ; ,"Sex, n (%)",None,4,1,43,No,1:No,1:No,,0.729
3974,3086082,Table 1,BaselineCharacteristic,?Women,Parameter ; ,?Women," Sex, n (%)",5,0,2,No,1:No,1:No,,0.856
3974,3086082,Table 1,BaselineCharacteristic,xx (xx%), ; ,?Women," Sex, n (%)",5,1,3,No,1:No,1:No,,0.551
3974,3086082,Table 1,BaselineCharacteristic,?Men,Parameter ; ,?Men," Sex, n (%)",6,0,2,No,1:No,1:No,,0.916
3974,3086082,Table 1,BaselineCharacteristic,x (xx%), ; ,?Men," Sex, n (%)",6,1,3,No,1:No,1:No,,0.776
3974,3086082,Table 1,BaselineCharacteristic,"Race, ethnicity, n (%)",Parameter ; ,None,None,7,0,24,No,1:No,1:No,,0.92
3974,3086082,Table 1,BaselineCharacteristic,"Race, ethnicity, n (%)", ; ,"Race, ethnicity, n (%)",None,7,1,43,No,1:No,1:No,,0.839
3974,3086082,Table 1,BaselineCharacteristic,"?White, non-Hispanic",Parameter ; ,"?White, non-Hispanic"," Race, ethnicity, n (%)",8,0,2,No,1:No,1:No,,0.936
3974,3086082,Table 1,BaselineCharacteristic,xx (xx%), ; ,"?White, non-Hispanic"," Race, ethnicity, n (%)",8,1,3,No,1:No,1:No,,0.73
3974,3086082,Table 1,BaselineCharacteristic,"?White, Hispanic",Parameter ; ,"?White, Hispanic"," Race, ethnicity, n (%)",9,0,2,No,1:No,1:No,,0.936
3974,3086082,Table 1,BaselineCharacteristic,x (xx%), ; ,"?White, Hispanic"," Race, ethnicity, n (%)",9,1,3,No,1:No,1:No,,0.89
3974,3086082,Table 1,BaselineCharacteristic,?African-American,Parameter ; ,?African-American," Race, ethnicity, n (%)",10,0,2,No,1:No,1:No,,0.926
3974,3086082,Table 1,BaselineCharacteristic,x (xx%), ; ,?African-American," Race, ethnicity, n (%)",10,1,3,No,1:No,1:No,,0.87
3974,3086082,Table 1,BaselineCharacteristic,"Disease duration, n, mean±SD",Parameter ; ,None,None,11,0,24,No,1:No,1:No,,0.922
3974,3086082,Table 1,BaselineCharacteristic,"Disease duration, n, mean±SD", ; ,"Disease duration, n, mean±SD",None,11,1,43,No,1:No,1:No,,0.905
3974,3086082,Table 1,BaselineCharacteristic,"?Whole group, n=xx",Parameter ; ,"?Whole group, n=xx"," Disease duration, n, mean±SD",12,0,2,No,1:No,1:No,,0.846
3974,3086082,Table 1,BaselineCharacteristic,x.x±x.x years, ; ,"?Whole group, n=xx"," Disease duration, n, mean±SD",12,1,3,No,1:No,1:No,,0.64
3974,3086082,Table 1,BaselineCharacteristic,"?Early group, n=xx (x–x years)",Parameter ; ,"?Early group, n=xx (x–x years)"," Disease duration, n, mean±SD",13,0,2,No,1:No,1:No,,0.706
3974,3086082,Table 1,BaselineCharacteristic,x.x±x.x years, ; ,"?Early group, n=xx (x–x years)"," Disease duration, n, mean±SD",13,1,3,No,1:No,1:No,,0.65
3974,3086082,Table 1,BaselineCharacteristic,"?Later group, n=xx (x–xx years)",Parameter ; ,"?Later group, n=xx (x–xx years)"," Disease duration, n, mean±SD",14,0,2,No,1:No,1:No,,0.696
3974,3086082,Table 1,BaselineCharacteristic,x.x±x.x years, ; ,"?Later group, n=xx (x–xx years)"," Disease duration, n, mean±SD",14,1,3,No,1:No,1:No,,0.62
3974,3086082,Table 1,BaselineCharacteristic,"Anti-Sclxx positive, n (%)",Parameter ; ,"Anti-Sclxx positive, n (%)",,15,0,2,No,1:No,1:No,,0.916
3974,3086082,Table 1,BaselineCharacteristic,x (xx%), ; ,"Anti-Sclxx positive, n (%)",,15,1,3,No,1:No,1:No,,0.836
3974,3086082,Table 1,BaselineCharacteristic,MRSS at baseline,Parameter ; ,MRSS at baseline,,16,0,2,No,1:No,1:No,,0.96
3974,3086082,Table 1,BaselineCharacteristic,xx.x±x.x, ; ,MRSS at baseline,,16,1,3,No,1:No,1:No,,0.86
3974,3086082,Table 1,BaselineCharacteristic,"Organ involvement, n (%)",Parameter ; ,None,None,17,0,24,No,1:No,1:No,,0.91
3974,3086082,Table 1,BaselineCharacteristic,, ; ,"Organ involvement, n (%)",None,17,1,43,No,1:No,1:No,,0.869
3974,3086082,Table 1,BaselineCharacteristic,?Gastrointestinal,Parameter ; ,?Gastrointestinal," Organ involvement, n (%)",18,0,2,No,1:No,1:No,,0.906
3974,3086082,Table 1,BaselineCharacteristic,xx (xx%), ; ,?Gastrointestinal," Organ involvement, n (%)",18,1,3,No,1:No,1:No,,0.717
3974,3086082,Table 1,BaselineCharacteristic,?ILD,Parameter ; ,?ILD," Organ involvement, n (%)",19,0,2,No,1:No,1:No,,0.896
3974,3086082,Table 1,BaselineCharacteristic,xx (xx%), ; ,?ILD," Organ involvement, n (%)",19,1,3,No,1:No,1:No,,0.707
3974,3086082,Table 1,BaselineCharacteristic,?Pulmonary artery Hypertension,Parameter ; ,?Pulmonary artery Hypertension," Organ involvement, n (%)",20,0,2,No,1:No,1:No,,0.896
3974,3086082,Table 1,BaselineCharacteristic,x (xx%), ; ,?Pulmonary artery Hypertension," Organ involvement, n (%)",20,1,3,No,1:No,1:No,,0.816
3974,3086082,Table 1,BaselineCharacteristic,?Cardiac,Parameter ; ,?Cardiac," Organ involvement, n (%)",21,0,2,No,1:No,1:No,,0.896
3974,3086082,Table 1,BaselineCharacteristic,x (xx%), ; ,?Cardiac," Organ involvement, n (%)",21,1,3,No,1:No,1:No,,0.816
3974,3086082,Table 1,BaselineCharacteristic,?Renal,Parameter ; ,?Renal," Organ involvement, n (%)",22,0,2,No,1:No,1:No,,0.916
3974,3086082,Table 1,BaselineCharacteristic,x (x%), ; ,?Renal," Organ involvement, n (%)",22,1,3,No,1:No,1:No,,0.846
3974,3086082,Table 1,BaselineCharacteristic,?Myopathy,Parameter ; ,?Myopathy," Organ involvement, n (%)",23,0,2,No,1:No,1:No,,0.916
3974,3086082,Table 1,BaselineCharacteristic,xx (xx%), ; ,?Myopathy," Organ involvement, n (%)",23,1,3,No,1:No,1:No,,0.727
3974,3086082,Table 1,BaselineCharacteristic,?Arthritis,Parameter ; ,?Arthritis," Organ involvement, n (%)",24,0,2,No,1:No,1:No,,0.916
3974,3086082,Table 1,BaselineCharacteristic,xx (xx%), ; ,?Arthritis," Organ involvement, n (%)",24,1,3,No,1:No,1:No,,0.727
3974,3086082,Table 1,BaselineCharacteristic,xx (xxx%), ; ,?Raynaud\'s phenomenon," Organ involvement, n (%)",25,1,3,No,1:No,1:No,,0.717
3974,3086082,Table 1,BaselineCharacteristic,?Digital ulceration,Parameter ; ,?Digital ulceration," Organ involvement, n (%)",26,0,2,No,1:No,1:No,,0.916
3974,3086082,Table 1,BaselineCharacteristic,xx (xx%), ; ,?Digital ulceration," Organ involvement, n (%)",26,1,3,No,1:No,1:No,,0.727
3974,3086082,Table 1,BaselineCharacteristic,"Previous treatment, n (%)",Parameter ; ,None,None,27,0,24,No,1:No,1:No,,0.91
3974,3086082,Table 1,BaselineCharacteristic,"Previous treatment, n (%)", ; ,"Previous treatment, n (%)",None,27,1,43,No,1:No,1:No,,0.869
3974,3086082,Table 1,BaselineCharacteristic,?Corticosteroids,Parameter ; ,?Corticosteroids," Previous treatment, n (%)",28,0,2,No,1:No,1:No,,0.916
3974,3086082,Table 1,BaselineCharacteristic,xx (xx.x%), ; ,?Corticosteroids," Previous treatment, n (%)",28,1,3,No,1:No,1:No,,0.777
3974,3086082,Table 1,BaselineCharacteristic,?Methotrexate,Parameter ; ,?Methotrexate," Previous treatment, n (%)",29,0,2,No,1:No,1:No,,0.916
3974,3086082,Table 1,BaselineCharacteristic,x (xx.x%), ; ,?Methotrexate," Previous treatment, n (%)",29,1,3,No,1:No,1:No,,0.737
3974,3086082,Table 1,BaselineCharacteristic,?Mycophenalate mofetil,Parameter ; ,?Mycophenalate mofetil," Previous treatment, n (%)",30,0,2,No,1:No,1:No,,0.916
3974,3086082,Table 1,BaselineCharacteristic,x (xx.x%), ; ,?Mycophenalate mofetil," Previous treatment, n (%)",30,1,3,No,1:No,1:No,,0.737
3974,3086082,Table 1,BaselineCharacteristic,?Cyclophosphamide,Parameter ; ,?Cyclophosphamide," Previous treatment, n (%)",31,0,2,No,1:No,1:No,,0.916
3974,3086082,Table 1,BaselineCharacteristic,x (xx.x%), ; ,?Cyclophosphamide," Previous treatment, n (%)",31,1,3,No,1:No,1:No,,0.737
3974,3086082,Table 1,BaselineCharacteristic,?Penicillamine,Parameter ; ,?Penicillamine," Previous treatment, n (%)",32,0,2,No,1:No,1:No,,0.916
3974,3086082,Table 1,BaselineCharacteristic,x (xx.x%), ; ,?Penicillamine," Previous treatment, n (%)",32,1,3,No,1:No,1:No,,0.737
3974,3086082,Table 1,BaselineCharacteristic,?IVIG,Parameter ; ,?IVIG," Previous treatment, n (%)",33,0,2,No,1:No,1:No,,0.916
3974,3086082,Table 1,BaselineCharacteristic,x (xx.x%), ; ,?IVIG," Previous treatment, n (%)",33,1,3,No,1:No,1:No,,0.737
3974,3086082,Table 1,BaselineCharacteristic,?Plaquenil,Parameter ; ,?Plaquenil," Previous treatment, n (%)",34,0,2,No,1:No,1:No,,0.916
3974,3086082,Table 1,BaselineCharacteristic,x (xx.x%), ; ,?Plaquenil," Previous treatment, n (%)",34,1,3,No,1:No,1:No,,0.737
3974,3086082,Table 1,BaselineCharacteristic,?Colchicine,Parameter ; ,?Colchicine," Previous treatment, n (%)",35,0,2,No,1:No,1:No,,0.916
3974,3086082,Table 1,BaselineCharacteristic,x (x.x%), ; ,?Colchicine," Previous treatment, n (%)",35,1,3,No,1:No,1:No,,0.846
3974,3086082,Table 1,BaselineCharacteristic,?Thalidomide,Parameter ; ,?Thalidomide," Previous treatment, n (%)",36,0,2,No,1:No,1:No,,0.916
3974,3086082,Table 1,BaselineCharacteristic,x (x.x%), ; ,?Thalidomide," Previous treatment, n (%)",36,1,3,No,1:No,1:No,,0.846
3974,3086082,Table 1,BaselineCharacteristic,?Minocycline,Parameter ; ,?Minocycline," Previous treatment, n (%)",37,0,2,No,1:No,1:No,,0.916
3974,3086082,Table 1,BaselineCharacteristic,x (x.x%), ; ,?Minocycline," Previous treatment, n (%)",37,1,3,No,1:No,1:No,,0.846
3974,3086082,Table 1,BaselineCharacteristic,?Autologous stem cell transplant,Parameter ; ,?Autologous stem cell transplant," Previous treatment, n (%)",38,0,2,No,1:No,1:No,,0.916
3974,3086082,Table 1,BaselineCharacteristic,x (x.x%), ; ,?Autologous stem cell transplant," Previous treatment, n (%)",38,1,3,No,1:No,1:No,,0.856
3974,3086082,Table 1,BaselineCharacteristic,?Oral collagen,Parameter ; ,?Oral collagen," Previous treatment, n (%)",39,0,2,No,1:No,1:No,,0.916
3974,3086082,Table 1,BaselineCharacteristic,x (x.x%), ; ,?Oral collagen," Previous treatment, n (%)",39,1,3,No,1:No,1:No,,0.846
3974,3086082,Table 1,BaselineCharacteristic,?Phototherapy,Parameter ; ,?Phototherapy," Previous treatment, n (%)",40,0,2,No,1:No,1:No,,0.916
3974,3086082,Table 1,BaselineCharacteristic,x (xx%), ; ,?Phototherapy," Previous treatment, n (%)",40,1,3,No,1:No,1:No,,0.836
3974,3086082,Table 1,BaselineCharacteristic,?No previous treatment,Parameter ; ,?No previous treatment," Previous treatment, n (%)",41,0,2,No,1:No,1:No,,0.936
3974,3086082,Table 1,BaselineCharacteristic,x (xx.x%), ; ,?No previous treatment," Previous treatment, n (%)",41,1,3,No,1:No,1:No,,0.771
4011,3097354,Table 1,BaselineCharacteristic,"Intervention group, N?=?xx",,None,None,0,0,12,No,1:No,1:No,,0.582
4011,3097354,Table 1,BaselineCharacteristic,"Intervention group, N?=?xx",,"Intervention group, N?=?xx",None,0,1,1,No,1:No,1:No,,0.508
4011,3097354,Table 1,BaselineCharacteristic,Uterine cancer,"Intervention group, N?=?xx ; ",Uterine cancer,None,2,0,2,No,1:No,1:No,,0.58
4011,3097354,Table 1,BaselineCharacteristic,Endometrial,"Intervention group, N?=?xx ; ",Uterine cancer,None,2,1,3,No,1:No,1:No,,0.533
4011,3097354,Table 1,BaselineCharacteristic,x,"Intervention group, N?=?xx ; ",Uterine cancer,None,2,2,3,No,1:No,1:No,,0.513
4011,3097354,Table 1,BaselineCharacteristic,,"Control group, N?=?xx ; ",Uterine cancer,None,2,3,3,No,1:No,1:No,,0.543
4011,3097354,Table 1,BaselineCharacteristic,x,"Control group, N?=?xx ; ",Uterine cancer,None,2,4,3,No,1:No,1:No,,0.593
4011,3097354,Table 1,BaselineCharacteristic,Uterine cancer,"Intervention group, N?=?xx ; ",Uterine cancer,None,3,0,2,No,1:No,1:No,,0.61
4011,3097354,Table 1,BaselineCharacteristic,Carcinosarcoma,"Intervention group, N?=?xx ; ",Uterine cancer,None,3,1,2,No,1:No,1:No,,0.545
4011,3097354,Table 1,BaselineCharacteristic,x,"Intervention group, N?=?xx ; ",Uterine cancer,None,3,2,3,No,1:No,1:No,,0.567
4011,3097354,Table 1,BaselineCharacteristic,,"Control group, N?=?xx ; ",Uterine cancer,None,3,3,3,No,1:No,1:No,,0.577
4011,3097354,Table 1,BaselineCharacteristic,,"Control group, N?=?xx ; ",Uterine cancer,None,3,4,3,No,1:No,1:No,,0.587
4011,3097354,Table 1,BaselineCharacteristic,FIGO stage,"Intervention group, N?=?xx ; ",FIGO stage,None,4,0,2,No,1:No,1:No,,0.709
4011,3097354,Table 1,BaselineCharacteristic,,"Intervention group, N?=?xx ; ",FIGO stage,None,4,1,3,No,1:No,1:No,,0.657
4011,3097354,Table 1,BaselineCharacteristic,,"Intervention group, N?=?xx ; ",FIGO stage,None,4,2,3,No,1:No,1:No,,0.647
4011,3097354,Table 1,BaselineCharacteristic,IC Gx,"Control group, N?=?xx ; ",FIGO stage,None,4,3,3,No,1:No,1:No,,0.687
4011,3097354,Table 1,BaselineCharacteristic,x,"Control group, N?=?xx ; ",FIGO stage,None,4,4,3,No,1:No,1:No,,0.737
4011,3097354,Table 1,BaselineCharacteristic,FIGO stage,"Intervention group, N?=?xx ; ",FIGO stage,None,5,0,2,No,1:No,1:No,,0.699
4011,3097354,Table 1,BaselineCharacteristic,IIA Gx,"Intervention group, N?=?xx ; ",FIGO stage,None,5,1,2,No,1:No,1:No,,0.642
4011,3097354,Table 1,BaselineCharacteristic,x,"Intervention group, N?=?xx ; ",FIGO stage,None,5,2,3,No,1:No,1:No,,0.677
4011,3097354,Table 1,BaselineCharacteristic,IC Gx,"Control group, N?=?xx ; ",FIGO stage,None,5,3,3,No,1:No,1:No,,0.677
4011,3097354,Table 1,BaselineCharacteristic,x,"Control group, N?=?xx ; ",FIGO stage,None,5,4,3,No,1:No,1:No,,0.737
4011,3097354,Table 1,BaselineCharacteristic,FIGO stage,"Intervention group, N?=?xx ; ",FIGO stage,None,6,0,2,No,1:No,1:No,,0.739
4011,3097354,Table 1,BaselineCharacteristic,IIIA,"Intervention group, N?=?xx ; ",FIGO stage,None,6,1,2,No,1:No,1:No,,0.682
4011,3097354,Table 1,BaselineCharacteristic,x,"Intervention group, N?=?xx ; ",FIGO stage,None,6,2,3,No,1:No,1:No,,0.687
4011,3097354,Table 1,BaselineCharacteristic,IIA Gx,"Control group, N?=?xx ; ",FIGO stage,None,6,3,3,No,1:No,1:No,,0.717
4011,3097354,Table 1,BaselineCharacteristic,x,"Control group, N?=?xx ; ",FIGO stage,None,6,4,3,No,1:No,1:No,,0.747
4011,3097354,Table 1,BaselineCharacteristic,FIGO stage,"Intervention group, N?=?xx ; ",FIGO stage,None,7,0,2,No,1:No,1:No,,0.739
4011,3097354,Table 1,BaselineCharacteristic,IIIC Gx,"Intervention group, N?=?xx ; ",FIGO stage,None,7,1,2,No,1:No,1:No,,0.682
4011,3097354,Table 1,BaselineCharacteristic,x,"Intervention group, N?=?xx ; ",FIGO stage,None,7,2,3,No,1:No,1:No,,0.687
4011,3097354,Table 1,BaselineCharacteristic,IIB Gx,"Control group, N?=?xx ; ",FIGO stage,None,7,3,3,No,1:No,1:No,,0.717
4011,3097354,Table 1,BaselineCharacteristic,x,"Control group, N?=?xx ; ",FIGO stage,None,7,4,3,No,1:No,1:No,,0.757
4011,3097354,Table 1,BaselineCharacteristic,FIGO stage,"Intervention group, N?=?xx ; ",FIGO stage,None,8,0,2,No,1:No,1:No,,0.768
4011,3097354,Table 1,BaselineCharacteristic,Recurrencea,"Intervention group, N?=?xx ; ",FIGO stage,None,8,1,2,No,1:No,1:No,,0.71
4011,3097354,Table 1,BaselineCharacteristic,x,"Intervention group, N?=?xx ; ",FIGO stage,None,8,2,3,No,1:No,1:No,,0.707
4011,3097354,Table 1,BaselineCharacteristic,IIIA Gx,"Control group, N?=?xx ; ",FIGO stage,None,8,3,3,No,1:No,1:No,,0.727
4011,3097354,Table 1,BaselineCharacteristic,x,"Control group, N?=?xx ; ",FIGO stage,None,8,4,3,No,1:No,1:No,,0.777
4011,3097354,Table 1,BaselineCharacteristic,FIGO stage,"Intervention group, N?=?xx ; ",FIGO stage,None,9,0,2,No,1:No,1:No,,0.778
4011,3097354,Table 1,BaselineCharacteristic,Carcinosarcoma IC,"Intervention group, N?=?xx ; ",FIGO stage,None,9,1,2,No,1:No,1:No,,0.72
4011,3097354,Table 1,BaselineCharacteristic,x,"Intervention group, N?=?xx ; ",FIGO stage,None,9,2,3,No,1:No,1:No,,0.707
4011,3097354,Table 1,BaselineCharacteristic,IVB,"Control group, N?=?xx ; ",FIGO stage,None,9,3,3,No,1:No,1:No,,0.747
4011,3097354,Table 1,BaselineCharacteristic,x,"Control group, N?=?xx ; ",FIGO stage,None,9,4,3,No,1:No,1:No,,0.777
4011,3097354,Table 1,BaselineCharacteristic,FIGO stage,"Intervention group, N?=?xx ; ",FIGO stage,None,10,0,2,No,1:No,1:No,,0.798
4011,3097354,Table 1,BaselineCharacteristic,,"Intervention group, N?=?xx ; ",FIGO stage,None,10,1,2,No,1:No,1:No,,0.75
4011,3097354,Table 1,BaselineCharacteristic,,"Intervention group, N?=?xx ; ",FIGO stage,None,10,2,3,No,1:No,1:No,,0.747
4011,3097354,Table 1,BaselineCharacteristic,Unknowna,"Control group, N?=?xx ; ",FIGO stage,None,10,3,3,No,1:No,1:No,,0.777
4011,3097354,Table 1,BaselineCharacteristic,x,"Control group, N?=?xx ; ",FIGO stage,None,10,4,3,No,1:No,1:No,,0.827
4011,3097354,Table 1,BaselineCharacteristic,Surgery,"Intervention group, N?=?xx ; ",Surgery,None,11,0,2,No,1:No,1:No,,0.789
4011,3097354,Table 1,BaselineCharacteristic,AUE?+?BSO,"Intervention group, N?=?xx ; ",Surgery,None,11,1,3,No,1:No,1:No,,0.757
4011,3097354,Table 1,BaselineCharacteristic,x,"Intervention group, N?=?xx ; ",Surgery,None,11,2,3,No,1:No,1:No,,0.757
4011,3097354,Table 1,BaselineCharacteristic,AUE?+?BSO,"Control group, N?=?xx ; ",Surgery,None,11,3,3,No,1:No,1:No,,0.767
4011,3097354,Table 1,BaselineCharacteristic,x,"Control group, N?=?xx ; ",Surgery,None,11,4,3,No,1:No,1:No,,0.847
4011,3097354,Table 1,BaselineCharacteristic,Surgery,"Intervention group, N?=?xx ; ",Surgery,None,12,0,2,No,1:No,1:No,,0.789
4011,3097354,Table 1,BaselineCharacteristic,AUE?±?LND,"Intervention group, N?=?xx ; ",Surgery,None,12,1,2,No,1:No,1:No,,0.682
4011,3097354,Table 1,BaselineCharacteristic,x,"Intervention group, N?=?xx ; ",Surgery,None,12,2,3,No,1:No,1:No,,0.757
4011,3097354,Table 1,BaselineCharacteristic,AUE?±?LND,"Control group, N?=?xx ; ",Surgery,None,12,3,3,No,1:No,1:No,,0.727
4011,3097354,Table 1,BaselineCharacteristic,x,"Control group, N?=?xx ; ",Surgery,None,12,4,3,No,1:No,1:No,,0.847
4011,3097354,Table 1,BaselineCharacteristic,Surgery,"Intervention group, N?=?xx ; ",Surgery,None,13,0,2,No,1:No,1:No,,0.789
4011,3097354,Table 1,BaselineCharacteristic,AUE?+?BSO?+?LND,"Intervention group, N?=?xx ; ",Surgery,None,13,1,2,No,1:No,1:No,,0.733
4011,3097354,Table 1,BaselineCharacteristic,x,"Intervention group, N?=?xx ; ",Surgery,None,13,2,3,No,1:No,1:No,,0.757
4011,3097354,Table 1,BaselineCharacteristic,,"Control group, N?=?xx ; ",Surgery,None,13,3,3,No,1:No,1:No,,0.767
4011,3097354,Table 1,BaselineCharacteristic,,"Control group, N?=?xx ; ",Surgery,None,13,4,3,No,1:No,1:No,,0.777
4011,3097354,Table 1,BaselineCharacteristic,Postoperative RT (Grays),"Intervention group, N?=?xx ; ",Postoperative RT (Grays),None,14,0,2,No,1:No,1:No,,0.809
4011,3097354,Table 1,BaselineCharacteristic,(xx),"Intervention group, N?=?xx ; ",Postoperative RT (Grays),None,14,1,3,No,1:No,1:No,,0.777
4011,3097354,Table 1,BaselineCharacteristic,x,"Intervention group, N?=?xx ; ",Postoperative RT (Grays),None,14,2,3,No,1:No,1:No,,0.767
4011,3097354,Table 1,BaselineCharacteristic,(xx),"Control group, N?=?xx ; ",Postoperative RT (Grays),None,14,3,3,No,1:No,1:No,,0.787
4011,3097354,Table 1,BaselineCharacteristic,x,"Control group, N?=?xx ; ",Postoperative RT (Grays),None,14,4,3,No,1:No,1:No,,0.857
4011,3097354,Table 1,BaselineCharacteristic,Postoperative RT (Grays),"Intervention group, N?=?xx ; ",Postoperative RT (Grays),None,15,0,2,No,1:No,1:No,,0.809
4011,3097354,Table 1,BaselineCharacteristic,(xx.x),"Intervention group, N?=?xx ; ",Postoperative RT (Grays),None,15,1,2,No,1:No,1:No,,0.754
4011,3097354,Table 1,BaselineCharacteristic,x,"Intervention group, N?=?xx ; ",Postoperative RT (Grays),None,15,2,3,No,1:No,1:No,,0.767
4011,3097354,Table 1,BaselineCharacteristic,(xx.x),"Control group, N?=?xx ; ",Postoperative RT (Grays),None,15,3,3,No,1:No,1:No,,0.837
4011,3097354,Table 1,BaselineCharacteristic,x,"Control group, N?=?xx ; ",Postoperative RT (Grays),None,15,4,3,No,1:No,1:No,,0.857
4011,3097354,Table 1,BaselineCharacteristic,Primary RT (Grays),"Intervention group, N?=?xx ; ",Primary RT (Grays),None,16,0,2,No,1:No,1:No,,0.809
4011,3097354,Table 1,BaselineCharacteristic,,"Intervention group, N?=?xx ; ",Primary RT (Grays),None,16,1,3,No,1:No,1:No,,0.777
4011,3097354,Table 1,BaselineCharacteristic,,"Intervention group, N?=?xx ; ",Primary RT (Grays),None,16,2,3,No,1:No,1:No,,0.777
4011,3097354,Table 1,BaselineCharacteristic,(xx.xx),"Control group, N?=?xx ; ",Primary RT (Grays),None,16,3,3,No,1:No,1:No,,0.797
4011,3097354,Table 1,BaselineCharacteristic,x,"Control group, N?=?xx ; ",Primary RT (Grays),None,16,4,3,No,1:No,1:No,,0.867
4011,3097354,Table 1,BaselineCharacteristic,Brachytherapy (Grays),"Intervention group, N?=?xx ; ",Brachytherapy (Grays),None,17,0,2,No,1:No,1:No,,0.809
4011,3097354,Table 1,BaselineCharacteristic,(xx),"Intervention group, N?=?xx ; ",Brachytherapy (Grays),None,17,1,3,No,1:No,1:No,,0.777
4011,3097354,Table 1,BaselineCharacteristic,x,"Intervention group, N?=?xx ; ",Brachytherapy (Grays),None,17,2,3,No,1:No,1:No,,0.777
4011,3097354,Table 1,BaselineCharacteristic,(xx),"Control group, N?=?xx ; ",Brachytherapy (Grays),None,17,3,3,No,1:No,1:No,,0.797
4011,3097354,Table 1,BaselineCharacteristic,x,"Control group, N?=?xx ; ",Brachytherapy (Grays),None,17,4,3,No,1:No,1:No,,0.867
4011,3097354,Table 1,BaselineCharacteristic,Brachytherapy (Grays),"Intervention group, N?=?xx ; ",Brachytherapy (Grays),None,18,0,2,No,1:No,1:No,,0.805
4011,3097354,Table 1,BaselineCharacteristic,(xx),"Intervention group, N?=?xx ; ",Brachytherapy (Grays),None,18,1,3,No,1:No,1:No,,0.772
4011,3097354,Table 1,BaselineCharacteristic,x,"Intervention group, N?=?xx ; ",Brachytherapy (Grays),None,18,2,3,No,1:No,1:No,,0.772
4011,3097354,Table 1,BaselineCharacteristic,(xx),"Control group, N?=?xx ; ",Brachytherapy (Grays),None,18,3,2,No,1:No,1:No,,0.79
4011,3097354,Table 1,BaselineCharacteristic,x,"Control group, N?=?xx ; ",Brachytherapy (Grays),None,18,4,3,No,1:No,1:No,,0.867
4011,3097354,Table 1,BaselineCharacteristic,Chemotherapy,"Intervention group, N?=?xx ; ",Chemotherapy,None,19,0,2,No,1:No,1:No,,0.805
4011,3097354,Table 1,BaselineCharacteristic,,"Intervention group, N?=?xx ; ",Chemotherapy,None,19,1,3,No,1:No,1:No,,0.772
4011,3097354,Table 1,BaselineCharacteristic,,"Intervention group, N?=?xx ; ",Chemotherapy,None,19,2,3,No,1:No,1:No,,0.772
4011,3097354,Table 1,BaselineCharacteristic,,"Control group, N?=?xx ; ",Chemotherapy,None,19,3,3,No,1:No,1:No,,0.797
4011,3097354,Table 1,BaselineCharacteristic,x,"Control group, N?=?xx ; ",Chemotherapy,None,19,4,3,No,1:No,1:No,,0.867
4011,3097354,Table 1,BaselineCharacteristic,Cervical cancer,"Intervention group, N?=?xx ; ",Cervical cancer,None,20,0,2,No,1:No,1:No,,0.795
4011,3097354,Table 1,BaselineCharacteristic,,"Intervention group, N?=?xx ; ",Cervical cancer,None,20,1,3,No,1:No,1:No,,0.762
4011,3097354,Table 1,BaselineCharacteristic,x,"Intervention group, N?=?xx ; ",Cervical cancer,None,20,2,3,No,1:No,1:No,,0.762
4011,3097354,Table 1,BaselineCharacteristic,,"Control group, N?=?xx ; ",Cervical cancer,None,20,3,3,No,1:No,1:No,,0.787
4011,3097354,Table 1,BaselineCharacteristic,x,"Control group, N?=?xx ; ",Cervical cancer,None,20,4,3,No,1:No,1:No,,0.857
4011,3097354,Table 1,BaselineCharacteristic,FIGO stage,"Intervention group, N?=?xx ; ",FIGO stage,None,21,0,2,No,1:No,1:No,,0.823
4011,3097354,Table 1,BaselineCharacteristic,IBI,"Intervention group, N?=?xx ; ",FIGO stage,None,21,1,3,No,1:No,1:No,,0.782
4011,3097354,Table 1,BaselineCharacteristic,x,"Intervention group, N?=?xx ; ",FIGO stage,None,21,2,3,No,1:No,1:No,,0.782
4011,3097354,Table 1,BaselineCharacteristic,IBI,"Control group, N?=?xx ; ",FIGO stage,None,21,3,3,No,1:No,1:No,,0.817
4011,3097354,Table 1,BaselineCharacteristic,x,"Control group, N?=?xx ; ",FIGO stage,None,21,4,3,No,1:No,1:No,,0.867
4011,3097354,Table 1,BaselineCharacteristic,FIGO stage,"Intervention group, N?=?xx ; ",FIGO stage,None,22,0,2,No,1:No,1:No,,0.823
4011,3097354,Table 1,BaselineCharacteristic,IBx,"Intervention group, N?=?xx ; ",FIGO stage,None,22,1,2,No,1:No,1:No,,0.776
4011,3097354,Table 1,BaselineCharacteristic,x,"Intervention group, N?=?xx ; ",FIGO stage,None,22,2,3,No,1:No,1:No,,0.782
4011,3097354,Table 1,BaselineCharacteristic,IIIB,"Control group, N?=?xx ; ",FIGO stage,None,22,3,3,No,1:No,1:No,,0.817
4011,3097354,Table 1,BaselineCharacteristic,x,"Control group, N?=?xx ; ",FIGO stage,None,22,4,3,No,1:No,1:No,,0.867
4011,3097354,Table 1,BaselineCharacteristic,FIGO stage,"Intervention group, N?=?xx ; ",FIGO stage,None,23,0,2,No,1:No,1:No,,0.823
4011,3097354,Table 1,BaselineCharacteristic,IIB,"Intervention group, N?=?xx ; ",FIGO stage,None,23,1,2,No,1:No,1:No,,0.776
4011,3097354,Table 1,BaselineCharacteristic,x,"Intervention group, N?=?xx ; ",FIGO stage,None,23,2,3,No,1:No,1:No,,0.782
4011,3097354,Table 1,BaselineCharacteristic,,"Control group, N?=?xx ; ",FIGO stage,None,23,3,3,No,1:No,1:No,,0.817
4011,3097354,Table 1,BaselineCharacteristic,,"Control group, N?=?xx ; ",FIGO stage,None,23,4,3,No,1:No,1:No,,0.817
4011,3097354,Table 1,BaselineCharacteristic,FIGO stage,"Intervention group, N?=?xx ; ",FIGO stage,None,24,0,2,No,1:No,1:No,,0.823
4011,3097354,Table 1,BaselineCharacteristic,IIIB,"Intervention group, N?=?xx ; ",FIGO stage,None,24,1,2,No,1:No,1:No,,0.776
4011,3097354,Table 1,BaselineCharacteristic,x,"Intervention group, N?=?xx ; ",FIGO stage,None,24,2,3,No,1:No,1:No,,0.782
4011,3097354,Table 1,BaselineCharacteristic,,"Control group, N?=?xx ; ",FIGO stage,None,24,3,3,No,1:No,1:No,,0.817
4011,3097354,Table 1,BaselineCharacteristic,,"Control group, N?=?xx ; ",FIGO stage,None,24,4,3,No,1:No,1:No,,0.817
4011,3097354,Table 1,BaselineCharacteristic,Surgery,"Intervention group, N?=?xx ; ",Surgery,None,25,0,2,No,1:No,1:No,,0.805
4011,3097354,Table 1,BaselineCharacteristic,LNDebulking,"Intervention group, N?=?xx ; ",Surgery,None,25,1,3,No,1:No,1:No,,0.772
4011,3097354,Table 1,BaselineCharacteristic,x,"Intervention group, N?=?xx ; ",Surgery,None,25,2,3,No,1:No,1:No,,0.772
4011,3097354,Table 1,BaselineCharacteristic,RH?+?LND,"Control group, N?=?xx ; ",Surgery,None,25,3,3,No,1:No,1:No,,0.797
4011,3097354,Table 1,BaselineCharacteristic,x,"Control group, N?=?xx ; ",Surgery,None,25,4,3,No,1:No,1:No,,0.867
4011,3097354,Table 1,BaselineCharacteristic,Surgery,"Intervention group, N?=?xx ; ",Surgery,None,26,0,2,No,1:No,1:No,,0.805
4011,3097354,Table 1,BaselineCharacteristic,,"Intervention group, N?=?xx ; ",Surgery,None,26,1,2,No,1:No,1:No,,0.757
4011,3097354,Table 1,BaselineCharacteristic,,"Intervention group, N?=?xx ; ",Surgery,None,26,2,3,No,1:No,1:No,,0.772
4011,3097354,Table 1,BaselineCharacteristic,VH,"Control group, N?=?xx ; ",Surgery,None,26,3,3,No,1:No,1:No,,0.797
4011,3097354,Table 1,BaselineCharacteristic,x,"Control group, N?=?xx ; ",Surgery,None,26,4,3,No,1:No,1:No,,0.867
4011,3097354,Table 1,BaselineCharacteristic,Postoperative RT (Grays),"Intervention group, N?=?xx ; ",Postoperative RT (Grays),None,27,0,2,No,1:No,1:No,,0.805
4011,3097354,Table 1,BaselineCharacteristic,(xx),"Intervention group, N?=?xx ; ",Postoperative RT (Grays),None,27,1,3,No,1:No,1:No,,0.772
4011,3097354,Table 1,BaselineCharacteristic,x,"Intervention group, N?=?xx ; ",Postoperative RT (Grays),None,27,2,3,No,1:No,1:No,,0.772
4011,3097354,Table 1,BaselineCharacteristic,(xx),"Control group, N?=?xx ; ",Postoperative RT (Grays),None,27,3,3,No,1:No,1:No,,0.797
4011,3097354,Table 1,BaselineCharacteristic,x,"Control group, N?=?xx ; ",Postoperative RT (Grays),None,27,4,3,No,1:No,1:No,,0.867
4011,3097354,Table 1,BaselineCharacteristic,Primary RT (Grays),"Intervention group, N?=?xx ; ",Primary RT (Grays),None,28,0,2,No,1:No,1:No,,0.805
4011,3097354,Table 1,BaselineCharacteristic,(xx),"Intervention group, N?=?xx ; ",Primary RT (Grays),None,28,1,3,No,1:No,1:No,,0.772
4011,3097354,Table 1,BaselineCharacteristic,x,"Intervention group, N?=?xx ; ",Primary RT (Grays),None,28,2,3,No,1:No,1:No,,0.772
4011,3097354,Table 1,BaselineCharacteristic,(xx),"Control group, N?=?xx ; ",Primary RT (Grays),None,28,3,3,No,1:No,1:No,,0.797
4011,3097354,Table 1,BaselineCharacteristic,x,"Control group, N?=?xx ; ",Primary RT (Grays),None,28,4,3,No,1:No,1:No,,0.867
4011,3097354,Table 1,BaselineCharacteristic,Brachytherapy (Grays),"Intervention group, N?=?xx ; ",Brachytherapy (Grays),None,29,0,2,No,1:No,1:No,,0.805
4011,3097354,Table 1,BaselineCharacteristic,(xx),"Intervention group, N?=?xx ; ",Brachytherapy (Grays),None,29,1,3,No,1:No,1:No,,0.772
4011,3097354,Table 1,BaselineCharacteristic,x,"Intervention group, N?=?xx ; ",Brachytherapy (Grays),None,29,2,3,No,1:No,1:No,,0.772
4011,3097354,Table 1,BaselineCharacteristic,(xx),"Control group, N?=?xx ; ",Brachytherapy (Grays),None,29,3,3,No,1:No,1:No,,0.797
4011,3097354,Table 1,BaselineCharacteristic,x,"Control group, N?=?xx ; ",Brachytherapy (Grays),None,29,4,3,No,1:No,1:No,,0.867
4011,3097354,Table 1,BaselineCharacteristic,Brachytherapy (Grays),"Intervention group, N?=?xx ; ",Brachytherapy (Grays),None,30,0,2,No,1:No,1:No,,0.805
4011,3097354,Table 1,BaselineCharacteristic,(xx),"Intervention group, N?=?xx ; ",Brachytherapy (Grays),None,30,1,3,No,1:No,1:No,,0.772
4011,3097354,Table 1,BaselineCharacteristic,x,"Intervention group, N?=?xx ; ",Brachytherapy (Grays),None,30,2,3,No,1:No,1:No,,0.772
4011,3097354,Table 1,BaselineCharacteristic,(xx),"Control group, N?=?xx ; ",Brachytherapy (Grays),None,30,3,2,No,1:No,1:No,,0.79
4011,3097354,Table 1,BaselineCharacteristic,x,"Control group, N?=?xx ; ",Brachytherapy (Grays),None,30,4,3,No,1:No,1:No,,0.867
4011,3097354,Table 1,BaselineCharacteristic,Brachytherapy (Grays),"Intervention group, N?=?xx ; ",Brachytherapy (Grays),None,31,0,2,No,1:No,1:No,,0.805
4011,3097354,Table 1,BaselineCharacteristic,(xx),"Intervention group, N?=?xx ; ",Brachytherapy (Grays),None,31,1,3,No,1:No,1:No,,0.772
4011,3097354,Table 1,BaselineCharacteristic,x,"Intervention group, N?=?xx ; ",Brachytherapy (Grays),None,31,2,3,No,1:No,1:No,,0.772
4011,3097354,Table 1,BaselineCharacteristic,(xx),"Control group, N?=?xx ; ",Brachytherapy (Grays),None,31,3,2,No,1:No,1:No,,0.79
4011,3097354,Table 1,BaselineCharacteristic,x,"Control group, N?=?xx ; ",Brachytherapy (Grays),None,31,4,3,No,1:No,1:No,,0.867
4011,3097354,Table 1,BaselineCharacteristic,Hyperthermia,"Intervention group, N?=?xx ; ",Hyperthermia,None,32,0,2,No,1:No,1:No,,0.805
4011,3097354,Table 1,BaselineCharacteristic,x h/week,"Intervention group, N?=?xx ; ",Hyperthermia,None,32,1,3,No,1:No,1:No,,0.772
4011,3097354,Table 1,BaselineCharacteristic,x,"Intervention group, N?=?xx ; ",Hyperthermia,None,32,2,3,No,1:No,1:No,,0.772
4011,3097354,Table 1,BaselineCharacteristic,,"Control group, N?=?xx ; ",Hyperthermia,None,32,3,3,No,1:No,1:No,,0.797
4011,3097354,Table 1,BaselineCharacteristic,x,"Control group, N?=?xx ; ",Hyperthermia,None,32,4,3,No,1:No,1:No,,0.867
4011,3097354,Table 1,BaselineCharacteristic,Surdosage parametria/LN,"Intervention group, N?=?xx ; ",Surdosage parametria/LN,None,33,0,2,No,1:No,1:No,,0.805
4011,3097354,Table 1,BaselineCharacteristic,,"Intervention group, N?=?xx ; ",Surdosage parametria/LN,None,33,1,3,No,1:No,1:No,,0.772
4011,3097354,Table 1,BaselineCharacteristic,x,"Intervention group, N?=?xx ; ",Surdosage parametria/LN,None,33,2,3,No,1:No,1:No,,0.772
4011,3097354,Table 1,BaselineCharacteristic,,"Control group, N?=?xx ; ",Surdosage parametria/LN,None,33,3,3,No,1:No,1:No,,0.797
4011,3097354,Table 1,BaselineCharacteristic,x,"Control group, N?=?xx ; ",Surdosage parametria/LN,None,33,4,3,No,1:No,1:No,,0.867
4011,3097354,Table 1,BaselineCharacteristic,Chemotherapy,"Intervention group, N?=?xx ; ",Chemotherapy,None,34,0,2,No,1:No,1:No,,0.805
4011,3097354,Table 1,BaselineCharacteristic,,"Intervention group, N?=?xx ; ",Chemotherapy,None,34,1,3,No,1:No,1:No,,0.772
4011,3097354,Table 1,BaselineCharacteristic,x,"Intervention group, N?=?xx ; ",Chemotherapy,None,34,2,3,No,1:No,1:No,,0.772
4011,3097354,Table 1,BaselineCharacteristic,,"Control group, N?=?xx ; ",Chemotherapy,None,34,3,3,No,1:No,1:No,,0.797
4011,3097354,Table 1,BaselineCharacteristic,x,"Control group, N?=?xx ; ",Chemotherapy,None,34,4,3,No,1:No,1:No,,0.867
4024,3102212,Table 2,BaselineCharacteristic,Characteristics,,None,None,0,0,12,No,1:No,1:No,,0.905
4024,3102212,Table 2,BaselineCharacteristic,No. patients (n = xx),,Characteristics,None,0,1,1,No,1:No,1:No,,0.784
4024,3102212,Table 2,BaselineCharacteristic,Age (y),Characteristics ; ,Age (y),None,1,0,2,No,1:No,1:No,,0.94
4024,3102212,Table 2,BaselineCharacteristic,,No. patients (n = xx) ; ,Age (y),None,1,1,3,No,1:No,1:No,,0.73
4024,3102212,Table 2,BaselineCharacteristic,,Characteristics ; ,None,None,2,0,2,No,1:No,1:No,,0.95
4024,3102212,Table 2,BaselineCharacteristic,Sex,Characteristics ; ,Sex,None,3,0,2,No,1:No,1:No,,0.96
4024,3102212,Table 2,BaselineCharacteristic,,No. patients (n = xx) ; ,Sex,None,3,1,3,No,1:No,1:No,,0.73
4024,3102212,Table 2,BaselineCharacteristic,,Characteristics ; ,None,None,4,0,2,No,1:No,1:No,,0.97
4024,3102212,Table 2,BaselineCharacteristic,xx:xx,No. patients (n = xx) ; ,None,None,4,1,3,No,1:No,1:No,,0.59
4024,3102212,Table 2,BaselineCharacteristic,ECOG performance status,Characteristics ; ,ECOG performance status,None,5,0,2,No,1:No,1:No,,0.97
4024,3102212,Table 2,BaselineCharacteristic,,No. patients (n = xx) ; ,ECOG performance status,None,5,1,3,No,1:No,1:No,,0.73
4024,3102212,Table 2,BaselineCharacteristic,,Characteristics ; ,None,None,6,0,2,No,1:No,1:No,,0.99
4024,3102212,Table 2,BaselineCharacteristic,xx,No. patients (n = xx) ; ,None,None,6,1,3,No,1:No,1:No,,0.6
4024,3102212,Table 2,BaselineCharacteristic,,Characteristics ; ,None,None,7,0,2,No,1:No,1:No,,0.99
4024,3102212,Table 2,BaselineCharacteristic,x,No. patients (n = xx) ; ,None,None,7,1,3,No,1:No,1:No,,0.75
4024,3102212,Table 2,BaselineCharacteristic,,Characteristics ; ,None,None,8,0,2,No,1:No,1:No,,0.99
4024,3102212,Table 2,BaselineCharacteristic,x,No. patients (n = xx) ; ,None,None,8,1,3,No,1:No,1:No,,0.75
4024,3102212,Table 2,BaselineCharacteristic,Tumor types,Characteristics ; ,Tumor types,None,9,0,2,No,1:No,1:No,,1
4024,3102212,Table 2,BaselineCharacteristic,,No. patients (n = xx) ; ,Tumor types,None,9,1,3,No,1:No,1:No,,0.76
4024,3102212,Table 2,BaselineCharacteristic,,Characteristics ; ,None,None,10,0,2,No,1:No,1:No,,1
4024,3102212,Table 2,BaselineCharacteristic,xx,No. patients (n = xx) ; ,None,None,10,1,3,No,1:No,1:No,,0.71
4024,3102212,Table 2,BaselineCharacteristic,,Characteristics ; ,None,None,11,0,2,No,1:No,1:No,,1
4024,3102212,Table 2,BaselineCharacteristic,x,No. patients (n = xx) ; ,None,None,11,1,3,No,1:No,1:No,,0.79
4024,3102212,Table 2,BaselineCharacteristic,,Characteristics ; ,None,None,12,0,2,No,1:No,1:No,,1
4024,3102212,Table 2,BaselineCharacteristic,x,No. patients (n = xx) ; ,None,None,12,1,3,No,1:No,1:No,,0.79
4024,3102212,Table 2,BaselineCharacteristic,,Characteristics ; ,None,None,13,0,2,No,1:No,1:No,,1
4024,3102212,Table 2,BaselineCharacteristic,x,No. patients (n = xx) ; ,None,None,13,1,3,No,1:No,1:No,,0.79
4024,3102212,Table 2,BaselineCharacteristic,Prior therapy,Characteristics ; ,Prior therapy,None,14,0,2,No,1:No,1:No,,1
4024,3102212,Table 2,BaselineCharacteristic,,No. patients (n = xx) ; ,Prior therapy,None,14,1,3,No,1:No,1:No,,0.8
4024,3102212,Table 2,BaselineCharacteristic,,Characteristics ; ,None,None,15,0,2,No,1:No,1:No,,1
4024,3102212,Table 2,BaselineCharacteristic,xx,No. patients (n = xx) ; ,None,None,15,1,3,No,1:No,1:No,,0.73
4024,3102212,Table 2,BaselineCharacteristic,,Characteristics ; ,None,None,16,0,2,No,1:No,1:No,,1
4024,3102212,Table 2,BaselineCharacteristic,x.x (x–x),No. patients (n = xx) ; ,None,None,16,1,3,No,1:No,1:No,,0.78
4024,3102212,Table 2,BaselineCharacteristic,,Characteristics ; ,None,None,17,0,2,No,1:No,1:No,,1
4024,3102212,Table 2,BaselineCharacteristic,xx,No. patients (n = xx) ; ,None,None,17,1,3,No,1:No,1:No,,0.73
4113,3128267,Table 1,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
4113,3128267,Table 1,BaselineCharacteristic,Patient I,,,None,0,1,1,No,1:No,1:No,,0.883
4113,3128267,Table 1,BaselineCharacteristic,Patient II,,,None,0,2,1,No,1:No,1:No,,0.893
4113,3128267,Table 1,BaselineCharacteristic,Age (years), ; ,Age (years),None,1,0,2,No,1:No,1:No,,0.65
4113,3128267,Table 1,BaselineCharacteristic,Arthroplasty, ; ,Arthroplasty,None,2,0,2,No,1:No,1:No,,0.95
4113,3128267,Table 1,BaselineCharacteristic,Left hip,Patient I ; ,Arthroplasty,None,2,1,3,No,1:No,1:No,,0.87
4113,3128267,Table 1,BaselineCharacteristic,Right hip,Patient II ; ,Arthroplasty,None,2,2,3,No,1:No,1:No,,0.89
4113,3128267,Table 1,BaselineCharacteristic,Surgical approach, ; ,Surgical approach,None,3,0,2,No,1:No,1:No,,0.96
4113,3128267,Table 1,BaselineCharacteristic,Lateral (transglutaeal; Hardinge),Patient I ; ,Surgical approach,None,3,1,3,No,1:No,1:No,,0.88
4113,3128267,Table 1,BaselineCharacteristic,Posterior (Kocher-Langenbeck),Patient II ; ,Surgical approach,None,3,2,3,No,1:No,1:No,,0.9
4113,3128267,Table 1,BaselineCharacteristic,Femoral device, ; ,Femoral device,None,4,0,2,No,1:No,1:No,,0.97
4113,3128267,Table 1,BaselineCharacteristic,Long shaft,Patient I ; ,Femoral device,None,4,1,3,No,1:No,1:No,,0.87
4113,3128267,Table 1,BaselineCharacteristic,Short shaft,Patient II ; ,Femoral device,None,4,2,3,No,1:No,1:No,,0.9
4185,3152943,Table 1,BaselineCharacteristic,Variable,,None,None,0,0,,No,1:No,1:No,,0.908
4185,3152943,Table 1,BaselineCharacteristic,"Placebo, n = xx",,None,None,0,4,,No,1:No,1:No,,0.571
4185,3152943,Table 1,BaselineCharacteristic,"Female sex, n (%)",Variable ; ,None,None,1,0,,No,1:No,1:No,,0.801
4185,3152943,Table 1,BaselineCharacteristic,xx (xx.x),"Placebo, n = xx ; ",None,None,1,4,,No,1:No,1:No,,0.543
4185,3152943,Table 1,BaselineCharacteristic,,"Variable ; Female sex, n (%) ; ",None,None,2,0,,No,1:No,1:No,,0.801
4185,3152943,Table 1,BaselineCharacteristic,,"Placebo, n = xx ; xx (xx.x) ; ",None,None,2,4,,No,1:No,1:No,,0.553
4185,3152943,Table 1,BaselineCharacteristic,,"Placebo, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ; ",None,None,4,4,,No,1:No,1:No,,0.539
4185,3152943,Table 1,BaselineCharacteristic,x.xx (x.xxx),"Placebo, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; ",None,None,5,4,,No,1:No,1:No,,0.539
4185,3152943,Table 1,BaselineCharacteristic,,"Variable ; Female sex, n (%) ;  ; Age, mean (SD) years ;  ; Duration of RA, mean (SD) years ; ",None,None,6,0,,No,1:No,1:No,,0.511
4185,3152943,Table 1,BaselineCharacteristic,,"Placebo, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ; ",None,None,6,4,,No,1:No,1:No,,0.56
4185,3152943,Table 1,BaselineCharacteristic,"Prior DMARDs, n (%)*","Variable ; Female sex, n (%) ;  ; Age, mean (SD) years ;  ; Duration of RA, mean (SD) years ;  ; ",None,None,7,0,,No,1:No,1:No,,0.521
4185,3152943,Table 1,BaselineCharacteristic,,"Placebo, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ",None,None,7,4,,No,1:No,1:No,,0.579
4185,3152943,Table 1,BaselineCharacteristic,,"Variable ; Female sex, n (%) ;  ; Age, mean (SD) years ;  ; Duration of RA, mean (SD) years ;  ; ",None,None,8,0,,No,1:No,1:No,,0.521
4185,3152943,Table 1,BaselineCharacteristic,,"Placebo, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ",None,None,8,4,,No,1:No,1:No,,0.622
4185,3152943,Table 1,BaselineCharacteristic,xx (xx.x),"Placebo, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ",?x, ,9,4,,No,1:No,1:No,,0.652
4185,3152943,Table 1,BaselineCharacteristic,,"Variable ; Female sex, n (%) ;  ; Age, mean (SD) years ;  ; Duration of RA, mean (SD) years ;  ; ",None,None,10,0,,No,1:No,1:No,,0.551
4185,3152943,Table 1,BaselineCharacteristic,,"Placebo, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ",None,None,10,4,,No,1:No,1:No,,0.692
4185,3152943,Table 1,BaselineCharacteristic,?x,"Variable ; Female sex, n (%) ;  ; Age, mean (SD) years ;  ; Duration of RA, mean (SD) years ;  ; ",?x, ,11,0,,No,1:No,1:No,,0.524
4185,3152943,Table 1,BaselineCharacteristic,xx (xx.x),"Placebo, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ",?x, ,11,4,,No,1:No,1:No,,0.722
4185,3152943,Table 1,BaselineCharacteristic,,"Variable ; Female sex, n (%) ;  ; Age, mean (SD) years ;  ; Duration of RA, mean (SD) years ;  ; ",None,None,12,0,,No,1:No,1:No,,0.551
4185,3152943,Table 1,BaselineCharacteristic,,"Placebo, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ",None,None,12,4,,No,1:No,1:No,,0.722
4185,3152943,Table 1,BaselineCharacteristic,?> x,"Variable ; Female sex, n (%) ;  ; Age, mean (SD) years ;  ; Duration of RA, mean (SD) years ;  ; ",?> x, ,13,0,,No,1:No,1:No,,0.525
4185,3152943,Table 1,BaselineCharacteristic,x (x.x),"Placebo, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ",?> x, ,13,4,,No,1:No,1:No,,0.764
4185,3152943,Table 1,BaselineCharacteristic,,"Variable ; Female sex, n (%) ;  ; Age, mean (SD) years ;  ; Duration of RA, mean (SD) years ;  ; ",None,None,14,0,,No,1:No,1:No,,0.551
4185,3152943,Table 1,BaselineCharacteristic,,"Placebo, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ",None,None,14,4,,No,1:No,1:No,,0.733
4185,3152943,Table 1,BaselineCharacteristic,"DASxx, mean (SD) score","Variable ; Female sex, n (%) ;  ; Age, mean (SD) years ;  ; Duration of RA, mean (SD) years ;  ; ","DASxx, mean (SD) score",,15,0,,No,1:No,1:No,,0.551
4185,3152943,Table 1,BaselineCharacteristic,,"Variable ; Female sex, n (%) ;  ; Age, mean (SD) years ;  ; Duration of RA, mean (SD) years ;  ; ",None,None,16,0,,No,1:No,1:No,,0.541
4185,3152943,Table 1,BaselineCharacteristic,,"Placebo, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ",None,None,16,4,,No,1:No,1:No,,0.733
4185,3152943,Table 1,BaselineCharacteristic,"RF (kIU/L), mean (SD)","Variable ; Female sex, n (%) ;  ; Age, mean (SD) years ;  ; Duration of RA, mean (SD) years ;  ; ","RF (kIU/L), mean (SD)",,17,0,,No,1:No,1:No,,0.541
4185,3152943,Table 1,BaselineCharacteristic,,"Variable ; Female sex, n (%) ;  ; Age, mean (SD) years ;  ; Duration of RA, mean (SD) years ;  ; ",None,None,18,0,,No,1:No,1:No,,0.541
4185,3152943,Table 1,BaselineCharacteristic,,"Placebo, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ",None,None,18,4,,No,1:No,1:No,,0.733
4185,3152943,Table 1,BaselineCharacteristic,"HAQ, mean (SD) score","Variable ; Female sex, n (%) ;  ; Age, mean (SD) years ;  ; Duration of RA, mean (SD) years ;  ; ","HAQ, mean (SD) score",,19,0,,No,1:No,1:No,,0.551
4185,3152943,Table 1,BaselineCharacteristic,,"Variable ; Female sex, n (%) ;  ; Age, mean (SD) years ;  ; Duration of RA, mean (SD) years ;  ; ",None,None,20,0,,No,1:No,1:No,,0.541
4185,3152943,Table 1,BaselineCharacteristic,,"Placebo, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ",None,None,20,4,,No,1:No,1:No,,0.723
4185,3152943,Table 1,BaselineCharacteristic,"Number of tender joints, mean (SD)","Variable ; Female sex, n (%) ;  ; Age, mean (SD) years ;  ; Duration of RA, mean (SD) years ;  ; ","Number of tender joints, mean (SD)",,21,0,,No,1:No,1:No,,0.541
4185,3152943,Table 1,BaselineCharacteristic,,"Variable ; Female sex, n (%) ;  ; Age, mean (SD) years ;  ; Duration of RA, mean (SD) years ;  ; ",None,None,22,0,,No,1:No,1:No,,0.541
4185,3152943,Table 1,BaselineCharacteristic,,"Placebo, n = xx ; xx (xx.x) ;  ; xx.xx (xx.xxx) ;  ; x.xx (x.xxx) ;  ; ",None,None,22,4,,No,1:No,1:No,,0.733
4185,3152943,Table 1,BaselineCharacteristic,"Number of swollen joints, mean (SD)","Variable ; Female sex, n (%) ;  ; Age, mean (SD) years ;  ; Duration of RA, mean (SD) years ;  ; ","Number of swollen joints, mean (SD)",,23,0,,No,1:No,1:No,,0.541
4246,3165084,Table 1,BaselineCharacteristic,Patient Characteristics,,None,None,0,0,,No,1:No,1:No,,0.907
4246,3165084,Table 1,BaselineCharacteristic,Number(percent),,None,None,0,1,,No,1:No,1:No,,0.903
4246,3165084,Table 1,BaselineCharacteristic,Total patients,Patient Characteristics ; ,None,None,1,0,,No,1:No,1:No,,0.843
4246,3165084,Table 1,BaselineCharacteristic,xx(xxx),Number(percent) ; ,None,None,1,1,,No,1:No,1:No,,0.697
4246,3165084,Table 1,BaselineCharacteristic,,Patient Characteristics ; Total patients ; ,None,None,2,0,,No,1:No,1:No,,0.842
4246,3165084,Table 1,BaselineCharacteristic,,Number(percent) ; xx(xxx) ; ,None,None,2,1,,No,1:No,1:No,,0.687
4246,3165084,Table 1,BaselineCharacteristic,,Patient Characteristics ; Total patients ;  ; ,,,4,0,,No,1:No,1:No,,0.845
4246,3165084,Table 1,BaselineCharacteristic,,Patient Characteristics ; Total patients ;  ; ,,,5,0,,No,1:No,1:No,,0.845
4246,3165084,Table 1,BaselineCharacteristic,xx (xx),Number(percent) ; xx(xxx) ;  ; ,,,5,1,,No,1:No,1:No,,0.7
4246,3165084,Table 1,BaselineCharacteristic,,Patient Characteristics ; Total patients ;  ; ,None,None,6,0,,No,1:No,1:No,,0.855
4246,3165084,Table 1,BaselineCharacteristic,,Number(percent) ; xx(xxx) ;  ; ,None,None,6,1,,No,1:No,1:No,,0.757
4246,3165084,Table 1,BaselineCharacteristic,Sex,Patient Characteristics ; Total patients ;  ; ,None,None,7,0,,No,1:No,1:No,,0.863
4246,3165084,Table 1,BaselineCharacteristic,,Number(percent) ; xx(xxx) ;  ; ,None,None,7,1,,No,1:No,1:No,,0.769
4246,3165084,Table 1,BaselineCharacteristic,,Patient Characteristics ; Total patients ;  ; ,,,8,0,,No,1:No,1:No,,0.87
4246,3165084,Table 1,BaselineCharacteristic,xx (xx),Number(percent) ; xx(xxx) ;  ; ,,,8,1,,No,1:No,1:No,,0.777
4246,3165084,Table 1,BaselineCharacteristic,,Patient Characteristics ; Total patients ;  ; ,,,9,0,,No,1:No,1:No,,0.87
4246,3165084,Table 1,BaselineCharacteristic,xx (xx),Number(percent) ; xx(xxx) ;  ; ,,,9,1,,No,1:No,1:No,,0.84
4246,3165084,Table 1,BaselineCharacteristic,,Patient Characteristics ; Total patients ;  ; ,None,None,10,0,,No,1:No,1:No,,0.888
4246,3165084,Table 1,BaselineCharacteristic,,Number(percent) ; xx(xxx) ;  ; ,None,None,10,1,,No,1:No,1:No,,0.877
4246,3165084,Table 1,BaselineCharacteristic,Race/ethnicity,Patient Characteristics ; Total patients ;  ; ,None,None,11,0,,No,1:No,1:No,,0.888
4246,3165084,Table 1,BaselineCharacteristic,,Number(percent) ; xx(xxx) ;  ; ,None,None,11,1,,No,1:No,1:No,,0.877
4246,3165084,Table 1,BaselineCharacteristic,,Patient Characteristics ; Total patients ;  ; ,,,12,0,,No,1:No,1:No,,0.888
4246,3165084,Table 1,BaselineCharacteristic,xx (xx),Number(percent) ; xx(xxx) ;  ; ,,,12,1,,No,1:No,1:No,,0.877
4246,3165084,Table 1,BaselineCharacteristic,,Patient Characteristics ; Total patients ;  ; ,,,13,0,,No,1:No,1:No,,0.888
4246,3165084,Table 1,BaselineCharacteristic,x(xx),Number(percent) ; xx(xxx) ;  ; ,,,13,1,,No,1:No,1:No,,0.788
4246,3165084,Table 1,BaselineCharacteristic,,Patient Characteristics ; Total patients ;  ; ,,,14,0,,No,1:No,1:No,,0.888
4246,3165084,Table 1,BaselineCharacteristic,x(x),Number(percent) ; xx(xxx) ;  ; ,,,14,1,,No,1:No,1:No,,0.799
4246,3165084,Table 1,BaselineCharacteristic,,Patient Characteristics ; Total patients ;  ; ,None,None,15,0,,No,1:No,1:No,,0.888
4246,3165084,Table 1,BaselineCharacteristic,,Number(percent) ; xx(xxx) ;  ; ,None,None,15,1,,No,1:No,1:No,,0.877
4246,3165084,Table 1,BaselineCharacteristic,"Median time from diagnosis, months",Patient Characteristics ; Total patients ;  ; ,None,None,16,0,,No,1:No,1:No,,0.935
4246,3165084,Table 1,BaselineCharacteristic,x.x,Number(percent) ; xx(xxx) ;  ; ,None,None,16,1,,No,1:No,1:No,,0.799
4246,3165084,Table 1,BaselineCharacteristic,,Patient Characteristics ; Total patients ;  ; ,None,None,17,0,,No,1:No,1:No,,0.888
4246,3165084,Table 1,BaselineCharacteristic,,Number(percent) ; xx(xxx) ;  ; ,None,None,17,1,,No,1:No,1:No,,0.877
4246,3165084,Table 1,BaselineCharacteristic,Karnofsky performance status (KPS),Patient Characteristics ; Total patients ;  ; ,None,None,18,0,,No,1:No,1:No,,0.893
4246,3165084,Table 1,BaselineCharacteristic,,Number(percent) ; xx(xxx) ;  ; ,None,None,18,1,,No,1:No,1:No,,0.877
4246,3165084,Table 1,BaselineCharacteristic,,Patient Characteristics ; Total patients ;  ; ,,,19,0,,No,1:No,1:No,,0.886
4246,3165084,Table 1,BaselineCharacteristic,xx (xx),Number(percent) ; xx(xxx) ;  ; ,,,19,1,,No,1:No,1:No,,0.877
4246,3165084,Table 1,BaselineCharacteristic,,Patient Characteristics ; Total patients ;  ; ,,,20,0,,No,1:No,1:No,,0.886
4246,3165084,Table 1,BaselineCharacteristic,xx(xx),Number(percent) ; xx(xxx) ;  ; ,,,20,1,,No,1:No,1:No,,0.877
4246,3165084,Table 1,BaselineCharacteristic,,Patient Characteristics ; Total patients ;  ; ,,,21,0,,No,1:No,1:No,,0.886
4246,3165084,Table 1,BaselineCharacteristic,xx (xx),Number(percent) ; xx(xxx) ;  ; ,,,21,1,,No,1:No,1:No,,0.886
4246,3165084,Table 1,BaselineCharacteristic,,Patient Characteristics ; Total patients ;  ; ,,,22,0,,No,1:No,1:No,,0.896
4246,3165084,Table 1,BaselineCharacteristic,x(x),Number(percent) ; xx(xxx) ;  ; ,,,22,1,,No,1:No,1:No,,0.808
4246,3165084,Table 1,BaselineCharacteristic,,Patient Characteristics ; Total patients ;  ; ,,,23,0,,No,1:No,1:No,,0.896
4246,3165084,Table 1,BaselineCharacteristic,x (x),Number(percent) ; xx(xxx) ;  ; ,,,23,1,,No,1:No,1:No,,0.808
4246,3165084,Table 1,BaselineCharacteristic,,Patient Characteristics ; Total patients ;  ; ,None,None,24,0,,No,1:No,1:No,,0.896
4246,3165084,Table 1,BaselineCharacteristic,,Number(percent) ; xx(xxx) ;  ; ,None,None,24,1,,No,1:No,1:No,,0.886
4246,3165084,Table 1,BaselineCharacteristic,Relapsed / refractory disease,Patient Characteristics ; Total patients ;  ; ,None,None,25,0,,No,1:No,1:No,,0.896
4246,3165084,Table 1,BaselineCharacteristic,xx(xx),Number(percent) ; xx(xxx) ;  ; ,None,None,25,1,,No,1:No,1:No,,0.886
4246,3165084,Table 1,BaselineCharacteristic,,Patient Characteristics ; Total patients ;  ; ,None,None,26,0,,No,1:No,1:No,,0.896
4246,3165084,Table 1,BaselineCharacteristic,,Number(percent) ; xx(xxx) ;  ; ,None,None,26,1,,No,1:No,1:No,,0.886
4246,3165084,Table 1,BaselineCharacteristic,Prior hematopoietic cell transplant,Patient Characteristics ; Total patients ;  ; ,Prior hematopoietic cell transplant,,27,0,,No,1:No,1:No,,0.896
4246,3165084,Table 1,BaselineCharacteristic,x(xx),Number(percent) ; xx(xxx) ;  ; ,Prior hematopoietic cell transplant,,27,1,,No,1:No,1:No,,0.818
4246,3165084,Table 1,BaselineCharacteristic,,Patient Characteristics ; Total patients ;  ; ,,,28,0,,No,1:No,1:No,,0.896
4246,3165084,Table 1,BaselineCharacteristic,x(xx),Number(percent) ; xx(xxx) ;  ; ,,,28,1,,No,1:No,1:No,,0.808
4246,3165084,Table 1,BaselineCharacteristic,,Patient Characteristics ; Total patients ;  ; ,,,29,0,,No,1:No,1:No,,0.896
4246,3165084,Table 1,BaselineCharacteristic,x(x),Number(percent) ; xx(xxx) ;  ; ,,,29,1,,No,1:No,1:No,,0.808
4305,3176247,Table 1,BaselineCharacteristic,Characteristics,,None,None,0,0,12,No,1:No,1:No,,0.905
4305,3176247,Table 1,BaselineCharacteristic,Characteristics,,Characteristics,None,0,1,1,No,1:No,1:No,,0.903
4305,3176247,Table 1,BaselineCharacteristic,First-line,,Characteristics,None,0,2,1,No,1:No,1:No,,0.903
4305,3176247,Table 1,BaselineCharacteristic,First-line,,Characteristics,None,0,3,1,No,1:No,1:No,,0.903
4305,3176247,Table 1,BaselineCharacteristic,Second-line,,Characteristics,None,0,4,1,No,1:No,1:No,,0.814
4305,3176247,Table 1,BaselineCharacteristic,Second-line,,Characteristics,None,0,5,1,No,1:No,1:No,,0.825
4305,3176247,Table 1,BaselineCharacteristic,All patients,,Characteristics,None,0,6,1,No,1:No,1:No,,0.816
4305,3176247,Table 1,BaselineCharacteristic,(%),,Characteristics,None,0,7,1,No,1:No,1:No,,0.855
4305,3176247,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,1,0,12,No,1:No,1:No,,0.898
4305,3176247,Table 1,BaselineCharacteristic,,Characteristics ; ,,None,1,1,1,No,1:No,1:No,,0.895
4305,3176247,Table 1,BaselineCharacteristic,,First-line ; ,,None,1,2,1,No,1:No,1:No,,0.896
4305,3176247,Table 1,BaselineCharacteristic,,First-line ; ,,None,1,3,1,No,1:No,1:No,,0.896
4305,3176247,Table 1,BaselineCharacteristic,,Second-line ; ,,None,1,4,1,No,1:No,1:No,,0.806
4305,3176247,Table 1,BaselineCharacteristic,,Second-line ; ,,None,1,5,1,No,1:No,1:No,,0.818
4305,3176247,Table 1,BaselineCharacteristic,,All patients ; ,,None,1,6,1,No,1:No,1:No,,0.809
4305,3176247,Table 1,BaselineCharacteristic,,(%) ; ,,None,1,7,1,No,1:No,1:No,,0.837
4305,3176247,Table 1,BaselineCharacteristic,,Characteristics ;  ; ,None,None,2,0,12,No,1:No,1:No,,0.913
4305,3176247,Table 1,BaselineCharacteristic,,Characteristics ;  ; ,,None,2,1,1,No,1:No,1:No,,0.905
4305,3176247,Table 1,BaselineCharacteristic,No,First-line ;  ; ,,None,2,2,1,No,1:No,1:No,,0.906
4305,3176247,Table 1,BaselineCharacteristic,(%),First-line ;  ; ,,None,2,3,1,No,1:No,1:No,,0.796
4305,3176247,Table 1,BaselineCharacteristic,No,Second-line ;  ; ,,None,2,4,1,No,1:No,1:No,,0.806
4305,3176247,Table 1,BaselineCharacteristic,(%),Second-line ;  ; ,,None,2,5,1,No,1:No,1:No,,0.708
4305,3176247,Table 1,BaselineCharacteristic,,All patients ;  ; ,,None,2,6,1,No,1:No,1:No,,0.799
4305,3176247,Table 1,BaselineCharacteristic,,(%) ;  ; ,,None,2,7,1,No,1:No,1:No,,0.827
4305,3176247,Table 1,BaselineCharacteristic,Sex,Characteristics ;  ;  ; ,Sex,,3,0,24,No,1:No,1:No,,0.922
4305,3176247,Table 1,BaselineCharacteristic,Male,Characteristics ;  ;  ; ,Sex,,3,1,43,No,1:No,1:No,,0.894
4305,3176247,Table 1,BaselineCharacteristic,xx,First-line ;  ; No ; ,Sex,,3,2,43,No,1:No,1:No,,0.71
4305,3176247,Table 1,BaselineCharacteristic,(xxx),First-line ;  ; (%) ; ,Sex,,3,3,43,No,1:No,1:No,,0.733
4305,3176247,Table 1,BaselineCharacteristic,xx,Second-line ;  ; No ; ,Sex,,3,4,43,No,1:No,1:No,,0.596
4305,3176247,Table 1,BaselineCharacteristic,(xxx),Second-line ;  ; (%) ; ,Sex,,3,5,43,No,1:No,1:No,,0.603
4305,3176247,Table 1,BaselineCharacteristic,xx,All patients ;  ;  ; ,Sex,,3,6,43,No,1:No,1:No,,0.617
4305,3176247,Table 1,BaselineCharacteristic,(xxx),(%) ;  ;  ; ,Sex,,3,7,43,No,1:No,1:No,,0.733
4305,3176247,Table 1,BaselineCharacteristic,,Characteristics ;  ;  ; ,,,4,0,2,No,1:No,1:No,,0.97
4305,3176247,Table 1,BaselineCharacteristic,Female,Characteristics ;  ;  ; ,,,4,1,3,No,1:No,1:No,,0.89
4305,3176247,Table 1,BaselineCharacteristic,x,First-line ;  ; No ; ,,,4,2,3,No,1:No,1:No,,0.94
4305,3176247,Table 1,BaselineCharacteristic,(x),First-line ;  ; (%) ; ,,,4,3,3,No,1:No,1:No,,0.79
4305,3176247,Table 1,BaselineCharacteristic,x,Second-line ;  ; No ; ,,,4,4,3,No,1:No,1:No,,0.82
4305,3176247,Table 1,BaselineCharacteristic,(x),Second-line ;  ; (%) ; ,,,4,5,3,No,1:No,1:No,,0.67
4305,3176247,Table 1,BaselineCharacteristic,x,All patients ;  ;  ; ,,,4,6,3,No,1:No,1:No,,0.69
4305,3176247,Table 1,BaselineCharacteristic,(x.x),(%) ;  ;  ; ,,,4,7,3,No,1:No,1:No,,0.78
4305,3176247,Table 1,BaselineCharacteristic,"Age, median",Characteristics ;  ;  ; ,"Age, median",,5,0,2,No,1:No,1:No,,0.77
4305,3176247,Table 1,BaselineCharacteristic,,Characteristics ;  ;  ; ,"Age, median",,5,1,3,No,1:No,1:No,,0.56
4305,3176247,Table 1,BaselineCharacteristic,ECOG PS,Characteristics ;  ;  ; ,ECOG PS,,6,0,24,No,1:No,1:No,,0.969
4305,3176247,Table 1,BaselineCharacteristic,x,Characteristics ;  ;  ; ,ECOG PS,,6,1,43,No,1:No,1:No,,0.942
4305,3176247,Table 1,BaselineCharacteristic,x,First-line ;  ; No ; ,ECOG PS,,6,2,43,No,1:No,1:No,,0.957
4305,3176247,Table 1,BaselineCharacteristic,(xx),First-line ;  ; (%) ; ,ECOG PS,,6,3,43,No,1:No,1:No,,0.738
4305,3176247,Table 1,BaselineCharacteristic,x,Second-line ;  ; No ; ,ECOG PS,,6,4,43,No,1:No,1:No,,0.817
4305,3176247,Table 1,BaselineCharacteristic,(xx),Second-line ;  ; (%) ; ,ECOG PS,,6,5,43,No,1:No,1:No,,0.688
4305,3176247,Table 1,BaselineCharacteristic,x,All patients ;  ;  ; ,ECOG PS,,6,6,43,No,1:No,1:No,,0.73
4305,3176247,Table 1,BaselineCharacteristic,(xx.x),(%) ;  ;  ; ,ECOG PS,,6,7,43,No,1:No,1:No,,0.639
4305,3176247,Table 1,BaselineCharacteristic,,Characteristics ;  ;  ; ,,,7,0,2,No,1:No,1:No,,0.99
4305,3176247,Table 1,BaselineCharacteristic,x,Characteristics ;  ;  ; ,,,7,1,3,No,1:No,1:No,,0.96
4305,3176247,Table 1,BaselineCharacteristic,x,First-line ;  ; No ; ,,,7,2,3,No,1:No,1:No,,0.97
4305,3176247,Table 1,BaselineCharacteristic,(xx),First-line ;  ; (%) ; ,,,7,3,3,No,1:No,1:No,,0.766
4305,3176247,Table 1,BaselineCharacteristic,xx,Second-line ;  ; No ; ,,,7,4,3,No,1:No,1:No,,0.741
4305,3176247,Table 1,BaselineCharacteristic,(xx),Second-line ;  ; (%) ; ,,,7,5,3,No,1:No,1:No,,0.726
4305,3176247,Table 1,BaselineCharacteristic,xx,All patients ;  ;  ; ,,,7,6,3,No,1:No,1:No,,0.64
4305,3176247,Table 1,BaselineCharacteristic,(xx.x),(%) ;  ;  ; ,,,7,7,3,No,1:No,1:No,,0.74
4305,3176247,Table 1,BaselineCharacteristic,,Characteristics ;  ;  ; ,,,8,0,2,No,1:No,1:No,,0.99
4305,3176247,Table 1,BaselineCharacteristic,x,Characteristics ;  ;  ; ,,,8,1,3,No,1:No,1:No,,0.97
4305,3176247,Table 1,BaselineCharacteristic,x,First-line ;  ; No ; ,,,8,2,3,No,1:No,1:No,,0.98
4305,3176247,Table 1,BaselineCharacteristic,(x),First-line ;  ; (%) ; ,,,8,3,3,No,1:No,1:No,,0.91
4305,3176247,Table 1,BaselineCharacteristic,x,Second-line ;  ; No ; ,,,8,4,3,No,1:No,1:No,,0.87
4305,3176247,Table 1,BaselineCharacteristic,(x),Second-line ;  ; (%) ; ,,,8,5,3,No,1:No,1:No,,0.8
4305,3176247,Table 1,BaselineCharacteristic,x,All patients ;  ;  ; ,,,8,6,3,No,1:No,1:No,,0.73
4305,3176247,Table 1,BaselineCharacteristic,(x.x),(%) ;  ;  ; ,,,8,7,3,No,1:No,1:No,,0.9
4305,3176247,Table 1,BaselineCharacteristic,Histology,Characteristics ;  ;  ; ,Histology,,9,0,2,No,1:No,1:No,,1
4305,3176247,Table 1,BaselineCharacteristic,Squamous,Characteristics ;  ;  ; ,Histology,,9,1,3,No,1:No,1:No,,0.97
4305,3176247,Table 1,BaselineCharacteristic,xx,First-line ;  ; No ; ,Histology,,9,2,3,No,1:No,1:No,,0.906
4305,3176247,Table 1,BaselineCharacteristic,(xxx),First-line ;  ; (%) ; ,Histology,,9,3,3,No,1:No,1:No,,0.87
4305,3176247,Table 1,BaselineCharacteristic,xx,Second-line ;  ; No ; ,Histology,,9,4,3,No,1:No,1:No,,0.801
4305,3176247,Table 1,BaselineCharacteristic,(xxx),Second-line ;  ; (%) ; ,Histology,,9,5,3,No,1:No,1:No,,0.76
4305,3176247,Table 1,BaselineCharacteristic,xx,All patients ;  ;  ; ,Histology,,9,6,3,No,1:No,1:No,,0.72
4305,3176247,Table 1,BaselineCharacteristic,(xxx),(%) ;  ;  ; ,Histology,,9,7,3,No,1:No,1:No,,0.88
4305,3176247,Table 1,BaselineCharacteristic,Smoking history,Characteristics ;  ;  ; ,Smoking history,,10,0,24,No,1:No,1:No,,0.995
4305,3176247,Table 1,BaselineCharacteristic,Never,Characteristics ;  ;  ; ,Smoking history,,10,1,43,No,1:No,1:No,,0.977
4305,3176247,Table 1,BaselineCharacteristic,x,First-line ;  ; No ; ,Smoking history,,10,2,43,No,1:No,1:No,,0.983
4305,3176247,Table 1,BaselineCharacteristic,(x),First-line ;  ; (%) ; ,Smoking history,,10,3,43,No,1:No,1:No,,0.93
4305,3176247,Table 1,BaselineCharacteristic,x,Second-line ;  ; No ; ,Smoking history,,10,4,43,No,1:No,1:No,,0.883
4305,3176247,Table 1,BaselineCharacteristic,(xx),Second-line ;  ; (%) ; ,Smoking history,,10,5,43,No,1:No,1:No,,0.804
4305,3176247,Table 1,BaselineCharacteristic,x,All patients ;  ;  ; ,Smoking history,,10,6,43,No,1:No,1:No,,0.8
4305,3176247,Table 1,BaselineCharacteristic,(x.x),(%) ;  ;  ; ,Smoking history,,10,7,43,No,1:No,1:No,,0.9
4305,3176247,Table 1,BaselineCharacteristic,,Characteristics ;  ;  ; ,,,11,0,2,No,1:No,1:No,,1
4305,3176247,Table 1,BaselineCharacteristic,Ever,Characteristics ;  ;  ; ,,,11,1,3,No,1:No,1:No,,0.99
4305,3176247,Table 1,BaselineCharacteristic,xx,First-line ;  ; No ; ,,,11,2,3,No,1:No,1:No,,0.936
4305,3176247,Table 1,BaselineCharacteristic,(xxx),First-line ;  ; (%) ; ,,,11,3,3,No,1:No,1:No,,0.89
4305,3176247,Table 1,BaselineCharacteristic,xx,Second-line ;  ; No ; ,,,11,4,3,No,1:No,1:No,,0.831
4305,3176247,Table 1,BaselineCharacteristic,(xx),Second-line ;  ; (%) ; ,,,11,5,3,No,1:No,1:No,,0.796
4305,3176247,Table 1,BaselineCharacteristic,xx,All patients ;  ;  ; ,,,11,6,3,No,1:No,1:No,,0.72
4305,3176247,Table 1,BaselineCharacteristic,(xx.x),(%) ;  ;  ; ,,,11,7,3,No,1:No,1:No,,0.82
4305,3176247,Table 1,BaselineCharacteristic,Prior therapy,Characteristics ;  ;  ; ,Prior therapy,,12,0,24,No,1:No,1:No,,0.995
4305,3176247,Table 1,BaselineCharacteristic,None,Characteristics ;  ;  ; ,Prior therapy,,12,1,43,No,1:No,1:No,,0.977
4305,3176247,Table 1,BaselineCharacteristic,x,First-line ;  ; No ; ,Prior therapy,,12,2,43,No,1:No,1:No,,0.983
4305,3176247,Table 1,BaselineCharacteristic,(xx),First-line ;  ; (%) ; ,Prior therapy,,12,3,43,No,1:No,1:No,,0.884
4305,3176247,Table 1,BaselineCharacteristic,N/A,Second-line ;  ; No ; ,Prior therapy,,12,4,43,No,1:No,1:No,,0.882
4305,3176247,Table 1,BaselineCharacteristic,,Second-line ;  ; (%) ; ,Prior therapy,,12,5,43,No,1:No,1:No,,0.829
4305,3176247,Table 1,BaselineCharacteristic,x,All patients ;  ;  ; ,Prior therapy,,12,6,43,No,1:No,1:No,,0.82
4305,3176247,Table 1,BaselineCharacteristic,,(%) ;  ;  ; ,Prior therapy,,12,7,43,No,1:No,1:No,,0.929
4305,3176247,Table 1,BaselineCharacteristic,,Characteristics ;  ;  ; ,,,13,0,2,No,1:No,1:No,,1
4305,3176247,Table 1,BaselineCharacteristic,Surgery,Characteristics ;  ;  ; ,,,13,1,3,No,1:No,1:No,,0.99
4305,3176247,Table 1,BaselineCharacteristic,x,First-line ;  ; No ; ,,,13,2,3,No,1:No,1:No,,1
4305,3176247,Table 1,BaselineCharacteristic,(xx),First-line ;  ; (%) ; ,,,13,3,3,No,1:No,1:No,,0.866
4305,3176247,Table 1,BaselineCharacteristic,x,Second-line ;  ; No ; ,,,13,4,3,No,1:No,1:No,,0.91
4305,3176247,Table 1,BaselineCharacteristic,(xx),Second-line ;  ; (%) ; ,,,13,5,3,No,1:No,1:No,,0.796
4305,3176247,Table 1,BaselineCharacteristic,xx,All patients ;  ;  ; ,,,13,6,3,No,1:No,1:No,,0.72
4305,3176247,Table 1,BaselineCharacteristic,,(%) ;  ;  ; ,,,13,7,3,No,1:No,1:No,,0.92
4305,3176247,Table 1,BaselineCharacteristic,,Characteristics ;  ;  ; ,,,14,0,2,No,1:No,1:No,,1
4305,3176247,Table 1,BaselineCharacteristic,Radiation,Characteristics ;  ;  ; ,,,14,1,3,No,1:No,1:No,,0.99
4305,3176247,Table 1,BaselineCharacteristic,x,First-line ;  ; No ; ,,,14,2,3,No,1:No,1:No,,1
4305,3176247,Table 1,BaselineCharacteristic,(x),First-line ;  ; (%) ; ,,,14,3,3,No,1:No,1:No,,0.94
4305,3176247,Table 1,BaselineCharacteristic,x,Second-line ;  ; No ; ,,,14,4,3,No,1:No,1:No,,0.91
4305,3176247,Table 1,BaselineCharacteristic,(xx),Second-line ;  ; (%) ; ,,,14,5,3,No,1:No,1:No,,0.806
4305,3176247,Table 1,BaselineCharacteristic,x,All patients ;  ;  ; ,,,14,6,3,No,1:No,1:No,,0.76
4305,3176247,Table 1,BaselineCharacteristic,,(%) ;  ;  ; ,,,14,7,3,No,1:No,1:No,,0.92
4305,3176247,Table 1,BaselineCharacteristic,,Characteristics ;  ;  ; ,,,15,0,2,No,1:No,1:No,,1
4305,3176247,Table 1,BaselineCharacteristic,Chemotherapy,Characteristics ;  ;  ; ,,,15,1,3,No,1:No,1:No,,0.98
4305,3176247,Table 1,BaselineCharacteristic,N/A,First-line ;  ; No ; ,,,15,2,3,No,1:No,1:No,,0.99
4305,3176247,Table 1,BaselineCharacteristic,,First-line ;  ; (%) ; ,,,15,3,3,No,1:No,1:No,,0.92
4305,3176247,Table 1,BaselineCharacteristic,xx,Second-line ;  ; No ; ,,,15,4,3,No,1:No,1:No,,0.841
4305,3176247,Table 1,BaselineCharacteristic,(xxx),Second-line ;  ; (%) ; ,,,15,5,3,No,1:No,1:No,,0.79
4305,3176247,Table 1,BaselineCharacteristic,xx,All patients ;  ;  ; ,,,15,6,3,No,1:No,1:No,,0.73
4305,3176247,Table 1,BaselineCharacteristic,,(%) ;  ;  ; ,,,15,7,3,No,1:No,1:No,,0.92
4305,3176247,Table 1,BaselineCharacteristic,No.of metastatic sites,Characteristics ;  ;  ; ,No.of metastatic sites,,16,0,24,No,1:No,1:No,,0.965
4305,3176247,Table 1,BaselineCharacteristic,x,Characteristics ;  ;  ; ,No.of metastatic sites,,16,1,43,No,1:No,1:No,,0.927
4305,3176247,Table 1,BaselineCharacteristic,x,First-line ;  ; No ; ,No.of metastatic sites,,16,2,43,No,1:No,1:No,,0.923
4305,3176247,Table 1,BaselineCharacteristic,(xx.x),First-line ;  ; (%) ; ,No.of metastatic sites,,16,3,43,No,1:No,1:No,,0.75
4305,3176247,Table 1,BaselineCharacteristic,x,Second-line ;  ; No ; ,No.of metastatic sites,,16,4,43,No,1:No,1:No,,0.873
4305,3176247,Table 1,BaselineCharacteristic,(xx),Second-line ;  ; (%) ; ,No.of metastatic sites,,16,5,43,No,1:No,1:No,,0.739
4305,3176247,Table 1,BaselineCharacteristic,x,All patients ;  ;  ; ,No.of metastatic sites,,16,6,43,No,1:No,1:No,,0.81
4305,3176247,Table 1,BaselineCharacteristic,(xx.x),(%) ;  ;  ; ,No.of metastatic sites,,16,7,43,No,1:No,1:No,,0.75
4305,3176247,Table 1,BaselineCharacteristic,,Characteristics ;  ;  ; ,,,17,0,2,No,1:No,1:No,,1
4305,3176247,Table 1,BaselineCharacteristic,x,Characteristics ;  ;  ; ,,,17,1,3,No,1:No,1:No,,0.99
4305,3176247,Table 1,BaselineCharacteristic,x,First-line ;  ; No ; ,,,17,2,3,No,1:No,1:No,,0.99
4305,3176247,Table 1,BaselineCharacteristic,(xx.x),First-line ;  ; (%) ; ,,,17,3,3,No,1:No,1:No,,0.82
4305,3176247,Table 1,BaselineCharacteristic,xx,Second-line ;  ; No ; ,,,17,4,3,No,1:No,1:No,,0.841
4305,3176247,Table 1,BaselineCharacteristic,(xx),Second-line ;  ; (%) ; ,,,17,5,3,No,1:No,1:No,,0.806
4305,3176247,Table 1,BaselineCharacteristic,xx,All patients ;  ;  ; ,,,17,6,3,No,1:No,1:No,,0.73
4305,3176247,Table 1,BaselineCharacteristic,(xx.x),(%) ;  ;  ; ,,,17,7,3,No,1:No,1:No,,0.82
4305,3176247,Table 1,BaselineCharacteristic,,Characteristics ;  ;  ; ,,,18,0,2,No,1:No,1:No,,0.99
4305,3176247,Table 1,BaselineCharacteristic,x,Characteristics ;  ;  ; ,,,18,1,3,No,1:No,1:No,,0.98
4305,3176247,Table 1,BaselineCharacteristic,x,First-line ;  ; No ; ,,,18,2,3,No,1:No,1:No,,0.98
4305,3176247,Table 1,BaselineCharacteristic,(x.x),First-line ;  ; (%) ; ,,,18,3,3,No,1:No,1:No,,0.93
4305,3176247,Table 1,BaselineCharacteristic,x,Second-line ;  ; No ; ,,,18,4,3,No,1:No,1:No,,0.9
4305,3176247,Table 1,BaselineCharacteristic,(xx),Second-line ;  ; (%) ; ,,,18,5,3,No,1:No,1:No,,0.791
4305,3176247,Table 1,BaselineCharacteristic,x,All patients ;  ;  ; ,,,18,6,3,No,1:No,1:No,,0.76
4305,3176247,Table 1,BaselineCharacteristic,(xx.x),(%) ;  ;  ; ,,,18,7,3,No,1:No,1:No,,0.815
4305,3176247,Table 1,BaselineCharacteristic,Locoregional,Characteristics ;  ;  ; ,Locoregional,,19,0,2,No,1:No,1:No,,0.99
4305,3176247,Table 1,BaselineCharacteristic,,Characteristics ;  ;  ; ,Locoregional,,19,1,3,No,1:No,1:No,,0.97
4305,3176247,Table 1,BaselineCharacteristic,x,First-line ;  ; No ; ,Locoregional,,19,2,3,No,1:No,1:No,,0.98
4305,3176247,Table 1,BaselineCharacteristic,(xx.x),First-line ;  ; (%) ; ,Locoregional,,19,3,3,No,1:No,1:No,,0.795
4305,3176247,Table 1,BaselineCharacteristic,x,Second-line ;  ; No ; ,Locoregional,,19,4,3,No,1:No,1:No,,0.9
4305,3176247,Table 1,BaselineCharacteristic,(x),Second-line ;  ; (%) ; ,Locoregional,,19,5,3,No,1:No,1:No,,0.82
4305,3176247,Table 1,BaselineCharacteristic,x,All patients ;  ;  ; ,Locoregional,,19,6,3,No,1:No,1:No,,0.76
4305,3176247,Table 1,BaselineCharacteristic,(xx.x),(%) ;  ;  ; ,Locoregional,,19,7,3,No,1:No,1:No,,0.805
4305,3176247,Table 1,BaselineCharacteristic,Metastatic,Characteristics ;  ;  ; ,Metastatic,,20,0,2,No,1:No,1:No,,0.99
4305,3176247,Table 1,BaselineCharacteristic,,Characteristics ;  ;  ; ,Metastatic,,20,1,3,No,1:No,1:No,,0.97
4305,3176247,Table 1,BaselineCharacteristic,x,First-line ;  ; No ; ,Metastatic,,20,2,3,No,1:No,1:No,,0.98
4305,3176247,Table 1,BaselineCharacteristic,(xx.x),First-line ;  ; (%) ; ,Metastatic,,20,3,3,No,1:No,1:No,,0.795
4305,3176247,Table 1,BaselineCharacteristic,xx,Second-line ;  ; No ; ,Metastatic,,20,4,3,No,1:No,1:No,,0.827
4305,3176247,Table 1,BaselineCharacteristic,(xx),Second-line ;  ; (%) ; ,Metastatic,,20,5,3,No,1:No,1:No,,0.781
4305,3176247,Table 1,BaselineCharacteristic,xx,All patients ;  ;  ; ,Metastatic,,20,6,3,No,1:No,1:No,,0.725
4305,3176247,Table 1,BaselineCharacteristic,(xx.x),(%) ;  ;  ; ,Metastatic,,20,7,3,No,1:No,1:No,,0.805
4305,3176247,Table 1,BaselineCharacteristic,Liver,Characteristics ;  ;  ; ,Liver,,21,0,2,No,1:No,1:No,,0.99
4305,3176247,Table 1,BaselineCharacteristic,,Characteristics ;  ;  ; ,Liver,,21,1,3,No,1:No,1:No,,0.97
4305,3176247,Table 1,BaselineCharacteristic,x,First-line ;  ; No ; ,Liver,,21,2,3,No,1:No,1:No,,0.98
4305,3176247,Table 1,BaselineCharacteristic,(xx.x),First-line ;  ; (%) ; ,Liver,,21,3,3,No,1:No,1:No,,0.795
4305,3176247,Table 1,BaselineCharacteristic,xx,Second-line ;  ; No ; ,Liver,,21,4,3,No,1:No,1:No,,0.827
4305,3176247,Table 1,BaselineCharacteristic,(xx),Second-line ;  ; (%) ; ,Liver,,21,5,3,No,1:No,1:No,,0.781
4305,3176247,Table 1,BaselineCharacteristic,xx,All patients ;  ;  ; ,Liver,,21,6,3,No,1:No,1:No,,0.725
4305,3176247,Table 1,BaselineCharacteristic,(xx.x),(%) ;  ;  ; ,Liver,,21,7,3,No,1:No,1:No,,0.805
4305,3176247,Table 1,BaselineCharacteristic,Lung,Characteristics ;  ;  ; ,Lung,,22,0,2,No,1:No,1:No,,1
4305,3176247,Table 1,BaselineCharacteristic,,Characteristics ;  ;  ; ,Lung,,22,1,3,No,1:No,1:No,,0.98
4305,3176247,Table 1,BaselineCharacteristic,x,First-line ;  ; No ; ,Lung,,22,2,3,No,1:No,1:No,,0.99
4305,3176247,Table 1,BaselineCharacteristic,(xx.x),First-line ;  ; (%) ; ,Lung,,22,3,3,No,1:No,1:No,,0.815
4305,3176247,Table 1,BaselineCharacteristic,xx,Second-line ;  ; No ; ,Lung,,22,4,3,No,1:No,1:No,,0.837
4305,3176247,Table 1,BaselineCharacteristic,(xx),Second-line ;  ; (%) ; ,Lung,,22,5,3,No,1:No,1:No,,0.801
4305,3176247,Table 1,BaselineCharacteristic,xx,All patients ;  ;  ; ,Lung,,22,6,3,No,1:No,1:No,,0.725
4305,3176247,Table 1,BaselineCharacteristic,(xx.x),(%) ;  ;  ; ,Lung,,22,7,3,No,1:No,1:No,,0.815
4305,3176247,Table 1,BaselineCharacteristic,Bone,Characteristics ;  ;  ; ,Bone,,23,0,2,No,1:No,1:No,,1
4305,3176247,Table 1,BaselineCharacteristic,,Characteristics ;  ;  ; ,Bone,,23,1,3,No,1:No,1:No,,0.98
4305,3176247,Table 1,BaselineCharacteristic,x,First-line ;  ; No ; ,Bone,,23,2,3,No,1:No,1:No,,0.99
4305,3176247,Table 1,BaselineCharacteristic,(xx.x),First-line ;  ; (%) ; ,Bone,,23,3,3,No,1:No,1:No,,0.815
4305,3176247,Table 1,BaselineCharacteristic,x,Second-line ;  ; No ; ,Bone,,23,4,3,No,1:No,1:No,,0.91
4305,3176247,Table 1,BaselineCharacteristic,(xx),Second-line ;  ; (%) ; ,Bone,,23,5,3,No,1:No,1:No,,0.801
4305,3176247,Table 1,BaselineCharacteristic,x,All patients ;  ;  ; ,Bone,,23,6,3,No,1:No,1:No,,0.76
4305,3176247,Table 1,BaselineCharacteristic,(xx.x),(%) ;  ;  ; ,Bone,,23,7,3,No,1:No,1:No,,0.815
4375,3195264,Table 1,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
4375,3195264,Table 1,BaselineCharacteristic,Total (n?=?xxx),,,None,0,3,1,No,1:No,1:No,,0.563
4375,3195264,Table 1,BaselineCharacteristic,Baseline characteristics, ; ,None,None,1,0,24,No,1:No,1:No,,0.824
4375,3195264,Table 1,BaselineCharacteristic,Baseline characteristics,Total (n?=?xxx) ; ,Baseline characteristics,None,1,3,43,No,1:No,1:No,,0.552
4375,3195264,Table 1,BaselineCharacteristic,, ; ,, Baseline characteristics,2,0,2,No,1:No,1:No,,0.88
4375,3195264,Table 1,BaselineCharacteristic,, ; ,, Baseline characteristics,3,0,2,No,1:No,1:No,,0.89
4375,3195264,Table 1,BaselineCharacteristic,, ; ,, Baseline characteristics,4,0,2,No,1:No,1:No,,0.9
4375,3195264,Table 1,BaselineCharacteristic,xx (xx.x%),Total (n?=?xxx) ; ,, Baseline characteristics,4,3,3,No,1:No,1:No,,0.556
4375,3195264,Table 1,BaselineCharacteristic,, ; ,, Baseline characteristics,5,0,2,No,1:No,1:No,,0.9
4375,3195264,Table 1,BaselineCharacteristic,, ; ,, Baseline characteristics,6,0,2,No,1:No,1:No,,0.92
4375,3195264,Table 1,BaselineCharacteristic,, ; ,, Baseline characteristics,7,0,2,No,1:No,1:No,,0.92
4375,3195264,Table 1,BaselineCharacteristic,"Indications for MDCT examination (N, %)", ; ,None,None,8,0,2,No,1:No,1:No,,0.94
4375,3195264,Table 1,BaselineCharacteristic,"Indications for MDCT examination (N, %)",Iobitridol xxx (n?=?xx) ; ,None,None,8,1,3,No,1:No,1:No,,0.666
4375,3195264,Table 1,BaselineCharacteristic,"Indications for MDCT examination (N, %)",Iodixanol xxx (n?=?xx) ; ,None,None,8,2,3,No,1:No,1:No,,0.676
4375,3195264,Table 1,BaselineCharacteristic,"Indications for MDCT examination (N, %)",Total (n?=?xxx) ; ,None,None,8,3,3,No,1:No,1:No,,0.76
4375,3195264,Table 1,BaselineCharacteristic,Congenital malformation, ; ,None,None,9,0,24,No,1:No,1:No,,0.984
4375,3195264,Table 1,BaselineCharacteristic,Congenital malformation,Iobitridol xxx (n?=?xx) ; ,Congenital malformation,None,9,1,43,No,1:No,1:No,,0.676
4375,3195264,Table 1,BaselineCharacteristic,Congenital malformation,Iodixanol xxx (n?=?xx) ; ,Congenital malformation,None,9,2,43,No,1:No,1:No,,0.676
4375,3195264,Table 1,BaselineCharacteristic,Congenital malformation,Total (n?=?xxx) ; ,Congenital malformation,None,9,3,43,No,1:No,1:No,,0.759
4375,3195264,Table 1,BaselineCharacteristic,, ; ,, Congenital malformation,10,0,2,No,1:No,1:No,,1
4375,3195264,Table 1,BaselineCharacteristic,xx (xx.x%),Iobitridol xxx (n?=?xx) ; ,, Congenital malformation,10,1,3,No,1:No,1:No,,0.757
4375,3195264,Table 1,BaselineCharacteristic,xx (xx.x%),Iodixanol xxx (n?=?xx) ; ,, Congenital malformation,10,2,3,No,1:No,1:No,,0.747
4375,3195264,Table 1,BaselineCharacteristic,xx (xx.x%),Total (n?=?xxx) ; ,, Congenital malformation,10,3,3,No,1:No,1:No,,0.771
4375,3195264,Table 1,BaselineCharacteristic,, ; ,, Congenital malformation,11,0,2,No,1:No,1:No,,1
4375,3195264,Table 1,BaselineCharacteristic,x (x.x %),Iobitridol xxx (n?=?xx) ; ,, Congenital malformation,11,1,3,No,1:No,1:No,,0.651
4375,3195264,Table 1,BaselineCharacteristic,x (x.x %),Iodixanol xxx (n?=?xx) ; ,, Congenital malformation,11,2,3,No,1:No,1:No,,0.641
4375,3195264,Table 1,BaselineCharacteristic,x (x.x %),Total (n?=?xxx) ; ,, Congenital malformation,11,3,3,No,1:No,1:No,,0.806
4375,3195264,Table 1,BaselineCharacteristic,, ; ,, Congenital malformation,12,0,2,No,1:No,1:No,,1
4375,3195264,Table 1,BaselineCharacteristic,x (x.x %),Iobitridol xxx (n?=?xx) ; ,, Congenital malformation,12,1,3,No,1:No,1:No,,0.651
4375,3195264,Table 1,BaselineCharacteristic,x (x.x %),Iodixanol xxx (n?=?xx) ; ,, Congenital malformation,12,2,3,No,1:No,1:No,,0.641
4375,3195264,Table 1,BaselineCharacteristic,x (x.x %),Total (n?=?xxx) ; ,, Congenital malformation,12,3,3,No,1:No,1:No,,0.806
4375,3195264,Table 1,BaselineCharacteristic,Tumors, ; ,None,None,13,0,24,No,1:No,1:No,,0.995
4375,3195264,Table 1,BaselineCharacteristic,Tumors,Iobitridol xxx (n?=?xx) ; ,Tumors,None,13,1,43,No,1:No,1:No,,0.716
4375,3195264,Table 1,BaselineCharacteristic,Tumors,Iodixanol xxx (n?=?xx) ; ,Tumors,None,13,2,43,No,1:No,1:No,,0.696
4375,3195264,Table 1,BaselineCharacteristic,Tumors,Total (n?=?xxx) ; ,Tumors,None,13,3,43,No,1:No,1:No,,0.789
4375,3195264,Table 1,BaselineCharacteristic,, ; ,, Tumors,14,0,2,No,1:No,1:No,,1
4375,3195264,Table 1,BaselineCharacteristic,x (x.x%),Iobitridol xxx (n?=?xx) ; ,, Tumors,14,1,3,No,1:No,1:No,,0.727
4375,3195264,Table 1,BaselineCharacteristic,x (x.x%),Iodixanol xxx (n?=?xx) ; ,, Tumors,14,2,3,No,1:No,1:No,,0.727
4375,3195264,Table 1,BaselineCharacteristic,x (x.x%),Total (n?=?xxx) ; ,, Tumors,14,3,3,No,1:No,1:No,,0.876
4375,3195264,Table 1,BaselineCharacteristic,, ; ,, Tumors,15,0,2,No,1:No,1:No,,1
4375,3195264,Table 1,BaselineCharacteristic,x (x.x %),Iobitridol xxx (n?=?xx) ; ,, Tumors,15,1,3,No,1:No,1:No,,0.661
4375,3195264,Table 1,BaselineCharacteristic,x (x.x%),Iodixanol xxx (n?=?xx) ; ,, Tumors,15,2,3,No,1:No,1:No,,0.727
4375,3195264,Table 1,BaselineCharacteristic,x (x.x %),Total (n?=?xxx) ; ,, Tumors,15,3,3,No,1:No,1:No,,0.796
4375,3195264,Table 1,BaselineCharacteristic,, ; ,, Tumors,16,0,2,No,1:No,1:No,,1
4375,3195264,Table 1,BaselineCharacteristic,x (x.x %),Iobitridol xxx (n?=?xx) ; ,, Tumors,16,1,3,No,1:No,1:No,,0.661
4375,3195264,Table 1,BaselineCharacteristic,x (x.x%),Iodixanol xxx (n?=?xx) ; ,, Tumors,16,2,3,No,1:No,1:No,,0.727
4375,3195264,Table 1,BaselineCharacteristic,x (x.x %),Total (n?=?xxx) ; ,, Tumors,16,3,3,No,1:No,1:No,,0.796
4375,3195264,Table 1,BaselineCharacteristic,, ; ,, Tumors,17,0,2,No,1:No,1:No,,1
4375,3195264,Table 1,BaselineCharacteristic,x (x.x%),Iobitridol xxx (n?=?xx) ; ,, Tumors,17,1,3,No,1:No,1:No,,0.727
4375,3195264,Table 1,BaselineCharacteristic,x (x.x %),Iodixanol xxx (n?=?xx) ; ,, Tumors,17,2,3,No,1:No,1:No,,0.641
4375,3195264,Table 1,BaselineCharacteristic,xx (x.x%),Total (n?=?xxx) ; ,, Tumors,17,3,3,No,1:No,1:No,,0.741
4375,3195264,Table 1,BaselineCharacteristic,, ; ,, Tumors,18,0,2,No,1:No,1:No,,0.99
4375,3195264,Table 1,BaselineCharacteristic,xx (xx.x%),Iobitridol xxx (n?=?xx) ; ,, Tumors,18,1,3,No,1:No,1:No,,0.777
4375,3195264,Table 1,BaselineCharacteristic,xx (xx.x%),Iodixanol xxx (n?=?xx) ; ,, Tumors,18,2,3,No,1:No,1:No,,0.767
4375,3195264,Table 1,BaselineCharacteristic,xx (xx.x%),Total (n?=?xxx) ; ,, Tumors,18,3,3,No,1:No,1:No,,0.791
4375,3195264,Table 1,BaselineCharacteristic,Patient disposition, ; ,None,None,19,0,24,No,1:No,1:No,,0.985
4375,3195264,Table 1,BaselineCharacteristic,Patient disposition,Iobitridol xxx (n?=?xx) ; ,Patient disposition,None,19,1,43,No,1:No,1:No,,0.726
4375,3195264,Table 1,BaselineCharacteristic,Patient disposition,Iodixanol xxx (n?=?xx) ; ,Patient disposition,None,19,2,43,No,1:No,1:No,,0.716
4375,3195264,Table 1,BaselineCharacteristic,Patient disposition,Total (n?=?xxx) ; ,Patient disposition,None,19,3,43,No,1:No,1:No,,0.799
4375,3195264,Table 1,BaselineCharacteristic,, ; ,, Patient disposition,20,0,2,No,1:No,1:No,,0.99
4375,3195264,Table 1,BaselineCharacteristic,xx,Iobitridol xxx (n?=?xx) ; ,, Patient disposition,20,1,3,No,1:No,1:No,,0.727
4375,3195264,Table 1,BaselineCharacteristic,xx,Iodixanol xxx (n?=?xx) ; ,, Patient disposition,20,2,3,No,1:No,1:No,,0.727
4375,3195264,Table 1,BaselineCharacteristic,xxx,Total (n?=?xxx) ; ,, Patient disposition,20,3,3,No,1:No,1:No,,0.796
4375,3195264,Table 1,BaselineCharacteristic,, ; ,, Patient disposition,21,0,2,No,1:No,1:No,,0.99
4375,3195264,Table 1,BaselineCharacteristic,xx (xxx%),Iobitridol xxx (n?=?xx) ; ,, Patient disposition,21,1,3,No,1:No,1:No,,0.737
4375,3195264,Table 1,BaselineCharacteristic,xx (xxx%),Iodixanol xxx (n?=?xx) ; ,, Patient disposition,21,2,3,No,1:No,1:No,,0.737
4375,3195264,Table 1,BaselineCharacteristic,xxx (xxx%),Total (n?=?xxx) ; ,, Patient disposition,21,3,3,No,1:No,1:No,,0.806
4375,3195264,Table 1,BaselineCharacteristic,, ; ,, Patient disposition,22,0,2,No,1:No,1:No,,1
4375,3195264,Table 1,BaselineCharacteristic,xx (xx.x% ),Iobitridol xxx (n?=?xx) ; ,, Patient disposition,22,1,3,No,1:No,1:No,,0.807
4375,3195264,Table 1,BaselineCharacteristic,xx (xx.x%),Iodixanol xxx (n?=?xx) ; ,, Patient disposition,22,2,3,No,1:No,1:No,,0.787
4375,3195264,Table 1,BaselineCharacteristic,xxx (xx.x%),Total (n?=?xxx) ; ,, Patient disposition,22,3,3,No,1:No,1:No,,0.811
4375,3195264,Table 1,BaselineCharacteristic,, ; ,, Patient disposition,23,0,2,No,1:No,1:No,,1
4375,3195264,Table 1,BaselineCharacteristic,xx (xx.x%),Iobitridol xxx (n?=?xx) ; ,, Patient disposition,23,1,3,No,1:No,1:No,,0.807
4375,3195264,Table 1,BaselineCharacteristic,xx (xx.x%),Iodixanol xxx (n?=?xx) ; ,, Patient disposition,23,2,3,No,1:No,1:No,,0.787
4375,3195264,Table 1,BaselineCharacteristic,xx (xx.x%),Total (n?=?xxx) ; ,, Patient disposition,23,3,3,No,1:No,1:No,,0.811
4375,3195264,Table 4,BaselineCharacteristic,Patients,,None,None,0,0,12,No,1:No,1:No,,0.905
4375,3195264,Table 4,BaselineCharacteristic,BMI (kg m?x),,Patients,None,0,2,1,No,1:No,1:No,,0.848
4375,3195264,Table 4,BaselineCharacteristic,Volume administered (mL),,Patients,None,0,3,1,No,1:No,1:No,,0.903
4375,3195264,Table 4,BaselineCharacteristic,Relative variation in creatinine clearance (%),,Patients,None,0,4,1,No,1:No,1:No,,0.774
4375,3195264,Table 4,BaselineCharacteristic,Indications for MDCT,,Patients,None,0,5,1,No,1:No,1:No,,0.946
4375,3195264,Table 4,BaselineCharacteristic,Iobitridol,Patients ; ,None,None,1,0,24,No,1:No,1:No,,0.857
4375,3195264,Table 4,BaselineCharacteristic,Iobitridol,BMI (kg m?x) ; ,Iobitridol,None,1,2,43,No,1:No,1:No,,0.847
4375,3195264,Table 4,BaselineCharacteristic,Iobitridol,Volume administered (mL) ; ,Iobitridol,None,1,3,43,No,1:No,1:No,,0.81
4375,3195264,Table 4,BaselineCharacteristic,Iobitridol,Relative variation in creatinine clearance (%) ; ,Iobitridol,None,1,4,43,No,1:No,1:No,,0.671
4375,3195264,Table 4,BaselineCharacteristic,Iobitridol,Indications for MDCT ; ,Iobitridol,None,1,5,43,No,1:No,1:No,,0.846
4375,3195264,Table 4,BaselineCharacteristic,#x,Patients ; ,#x, Iobitridol,2,0,2,No,1:No,1:No,,0.91
4375,3195264,Table 4,BaselineCharacteristic,xx.x,BMI (kg m?x) ; ,#x, Iobitridol,2,2,3,No,1:No,1:No,,0.682
4375,3195264,Table 4,BaselineCharacteristic,xx,Volume administered (mL) ; ,#x, Iobitridol,2,3,3,No,1:No,1:No,,0.628
4375,3195264,Table 4,BaselineCharacteristic,#NAME?,Relative variation in creatinine clearance (%) ; ,#x, Iobitridol,2,4,3,No,1:No,1:No,,0.65
4375,3195264,Table 4,BaselineCharacteristic,Bile-duct atresia with secondary cirrhosis complication,Indications for MDCT ; ,#x, Iobitridol,2,5,3,No,1:No,1:No,,0.89
4375,3195264,Table 4,BaselineCharacteristic,#x,Patients ; ,#x, Iobitridol,3,0,2,No,1:No,1:No,,0.92
4375,3195264,Table 4,BaselineCharacteristic,xx.x,BMI (kg m?x) ; ,#x, Iobitridol,3,2,3,No,1:No,1:No,,0.686
4375,3195264,Table 4,BaselineCharacteristic,xx,Volume administered (mL) ; ,#x, Iobitridol,3,3,3,No,1:No,1:No,,0.621
4375,3195264,Table 4,BaselineCharacteristic,#NAME?,Relative variation in creatinine clearance (%) ; ,#x, Iobitridol,3,4,3,No,1:No,1:No,,0.66
4375,3195264,Table 4,BaselineCharacteristic,Neck tumor,Indications for MDCT ; ,#x, Iobitridol,3,5,3,No,1:No,1:No,,0.91
4375,3195264,Table 4,BaselineCharacteristic,#x,Patients ; ,#x, Iobitridol,4,0,2,No,1:No,1:No,,0.93
4375,3195264,Table 4,BaselineCharacteristic,xx.x,BMI (kg m?x) ; ,#x, Iobitridol,4,2,3,No,1:No,1:No,,0.766
4375,3195264,Table 4,BaselineCharacteristic,xx,Volume administered (mL) ; ,#x, Iobitridol,4,3,3,No,1:No,1:No,,0.701
4375,3195264,Table 4,BaselineCharacteristic,#NAME?,Relative variation in creatinine clearance (%) ; ,#x, Iobitridol,4,4,3,No,1:No,1:No,,0.67
4375,3195264,Table 4,BaselineCharacteristic,Kawasaki disease,Indications for MDCT ; ,#x, Iobitridol,4,5,3,No,1:No,1:No,,0.89
4375,3195264,Table 4,BaselineCharacteristic,Iodixanol,Patients ; ,None,None,5,0,24,No,1:No,1:No,,0.929
4375,3195264,Table 4,BaselineCharacteristic,Iodixanol,BMI (kg m?x) ; ,Iodixanol,None,5,2,43,No,1:No,1:No,,0.932
4375,3195264,Table 4,BaselineCharacteristic,Iodixanol,Volume administered (mL) ; ,Iodixanol,None,5,3,43,No,1:No,1:No,,0.896
4375,3195264,Table 4,BaselineCharacteristic,Iodixanol,Relative variation in creatinine clearance (%) ; ,Iodixanol,None,5,4,43,No,1:No,1:No,,0.704
4375,3195264,Table 4,BaselineCharacteristic,Iodixanol,Indications for MDCT ; ,Iodixanol,None,5,5,43,No,1:No,1:No,,0.901
4375,3195264,Table 4,BaselineCharacteristic,#x,Patients ; ,#x, Iodixanol,6,0,2,No,1:No,1:No,,0.99
4375,3195264,Table 4,BaselineCharacteristic,xx.x,BMI (kg m?x) ; ,#x, Iodixanol,6,2,3,No,1:No,1:No,,0.826
4375,3195264,Table 4,BaselineCharacteristic,xx,Volume administered (mL) ; ,#x, Iodixanol,6,3,3,No,1:No,1:No,,0.791
4375,3195264,Table 4,BaselineCharacteristic,#NAME?,Relative variation in creatinine clearance (%) ; ,#x, Iodixanol,6,4,3,No,1:No,1:No,,0.77
4375,3195264,Table 4,BaselineCharacteristic,Liver transplantation,Indications for MDCT ; ,#x, Iodixanol,6,5,3,No,1:No,1:No,,0.95
4375,3195264,Table 4,BaselineCharacteristic,#x,Patients ; ,#x, Iodixanol,7,0,2,No,1:No,1:No,,0.99
4375,3195264,Table 4,BaselineCharacteristic,xx,BMI (kg m?x) ; ,#x, Iodixanol,7,2,3,No,1:No,1:No,,0.856
4375,3195264,Table 4,BaselineCharacteristic,xx,Volume administered (mL) ; ,#x, Iodixanol,7,3,3,No,1:No,1:No,,0.811
4375,3195264,Table 4,BaselineCharacteristic,#NAME?,Relative variation in creatinine clearance (%) ; ,#x, Iodixanol,7,4,3,No,1:No,1:No,,0.8
4375,3195264,Table 4,BaselineCharacteristic,Chronic osteomyelitis,Indications for MDCT ; ,#x, Iodixanol,7,5,3,No,1:No,1:No,,0.96
4375,3195264,Table 4,BaselineCharacteristic,#x,Patients ; ,#x, Iodixanol,8,0,2,No,1:No,1:No,,0.99
4375,3195264,Table 4,BaselineCharacteristic,xx.x,BMI (kg m?x) ; ,#x, Iodixanol,8,2,3,No,1:No,1:No,,0.866
4375,3195264,Table 4,BaselineCharacteristic,xx,Volume administered (mL) ; ,#x, Iodixanol,8,3,3,No,1:No,1:No,,0.821
4375,3195264,Table 4,BaselineCharacteristic,#NAME?,Relative variation in creatinine clearance (%) ; ,#x, Iodixanol,8,4,3,No,1:No,1:No,,0.81
4375,3195264,Table 4,BaselineCharacteristic,Cerebral tumor,Indications for MDCT ; ,#x, Iodixanol,8,5,3,No,1:No,1:No,,0.97
4375,3195264,Table 4,BaselineCharacteristic,#x,Patients ; ,#x, Iodixanol,9,0,2,No,1:No,1:No,,1
4375,3195264,Table 4,BaselineCharacteristic,xx.x,BMI (kg m?x) ; ,#x, Iodixanol,9,2,3,No,1:No,1:No,,0.886
4375,3195264,Table 4,BaselineCharacteristic,xx,Volume administered (mL) ; ,#x, Iodixanol,9,3,3,No,1:No,1:No,,0.881
4375,3195264,Table 4,BaselineCharacteristic,#NAME?,Relative variation in creatinine clearance (%) ; ,#x, Iodixanol,9,4,3,No,1:No,1:No,,0.82
4375,3195264,Table 4,BaselineCharacteristic,Cystic fibrosis,Indications for MDCT ; ,#x, Iodixanol,9,5,3,No,1:No,1:No,,0.98
4375,3195264,Table 4,BaselineCharacteristic,#x,Patients ; ,#x, Iodixanol,10,0,2,No,1:No,1:No,,1
4375,3195264,Table 4,BaselineCharacteristic,xx.x,BMI (kg m?x) ; ,#x, Iodixanol,10,2,3,No,1:No,1:No,,0.906
4375,3195264,Table 4,BaselineCharacteristic,xx,Volume administered (mL) ; ,#x, Iodixanol,10,3,3,No,1:No,1:No,,0.901
4375,3195264,Table 4,BaselineCharacteristic,#NAME?,Relative variation in creatinine clearance (%) ; ,#x, Iodixanol,10,4,3,No,1:No,1:No,,0.83
4375,3195264,Table 4,BaselineCharacteristic,Retroperitoneal tumor,Indications for MDCT ; ,#x, Iodixanol,10,5,3,No,1:No,1:No,,1
4375,3195264,Table 4,BaselineCharacteristic,#x,Patients ; ,#x, Iodixanol,11,0,2,No,1:No,1:No,,1
4375,3195264,Table 4,BaselineCharacteristic,xx.x,BMI (kg m?x) ; ,#x, Iodixanol,11,2,3,No,1:No,1:No,,0.906
4375,3195264,Table 4,BaselineCharacteristic,xx,Volume administered (mL) ; ,#x, Iodixanol,11,3,3,No,1:No,1:No,,0.901
4375,3195264,Table 4,BaselineCharacteristic,#NAME?,Relative variation in creatinine clearance (%) ; ,#x, Iodixanol,11,4,3,No,1:No,1:No,,0.83
4375,3195264,Table 4,BaselineCharacteristic,Pneumonia,Indications for MDCT ; ,#x, Iodixanol,11,5,3,No,1:No,1:No,,1
4375,3195264,Table 4,BaselineCharacteristic,#xx,Patients ; ,#xx, Iodixanol,12,0,2,No,1:No,1:No,,1
4375,3195264,Table 4,BaselineCharacteristic,xx.x,BMI (kg m?x) ; ,#xx, Iodixanol,12,2,3,No,1:No,1:No,,0.906
4375,3195264,Table 4,BaselineCharacteristic,xx,Volume administered (mL) ; ,#xx, Iodixanol,12,3,3,No,1:No,1:No,,0.901
4375,3195264,Table 4,BaselineCharacteristic,#NAME?,Relative variation in creatinine clearance (%) ; ,#xx, Iodixanol,12,4,3,No,1:No,1:No,,0.83
4375,3195264,Table 4,BaselineCharacteristic,Pulmonary graft versus host reaction,Indications for MDCT ; ,#xx, Iodixanol,12,5,3,No,1:No,1:No,,1
4428,3208500,Table 1,BaselineCharacteristic,Characteristics,,None,None,0,0,12,No,1:No,1:No,,0.905
4428,3208500,Table 1,BaselineCharacteristic,Number of patients,,Characteristics,None,0,1,1,No,1:No,1:No,,0.853
4428,3208500,Table 1,BaselineCharacteristic,Patients,Characteristics ; ,Patients,,1,0,2,No,1:No,1:No,,0.94
4428,3208500,Table 1,BaselineCharacteristic,xx,Number of patients ; ,Patients,,1,1,3,No,1:No,1:No,,0.67
4428,3208500,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,2,0,2,No,1:No,1:No,,0.95
4428,3208500,Table 1,BaselineCharacteristic,,Number of patients ; ,None,None,2,1,3,No,1:No,1:No,,0.81
4428,3208500,Table 1,BaselineCharacteristic,Gender,Characteristics ; ,None,None,3,0,24,No,1:No,1:No,,0.922
4428,3208500,Table 1,BaselineCharacteristic,Gender,Number of patients ; ,Gender,None,3,1,43,No,1:No,1:No,,0.844
4428,3208500,Table 1,BaselineCharacteristic,?Male,Characteristics ; ,?Male, Gender,4,0,2,No,1:No,1:No,,0.97
4428,3208500,Table 1,BaselineCharacteristic,xx,Number of patients ; ,?Male, Gender,4,1,3,No,1:No,1:No,,0.71
4428,3208500,Table 1,BaselineCharacteristic,?Female,Characteristics ; ,?Female, Gender,5,0,2,No,1:No,1:No,,0.97
4428,3208500,Table 1,BaselineCharacteristic,xx,Number of patients ; ,?Female, Gender,5,1,3,No,1:No,1:No,,0.71
4428,3208500,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,6,0,2,No,1:No,1:No,,0.99
4428,3208500,Table 1,BaselineCharacteristic,,Number of patients ; ,None,None,6,1,3,No,1:No,1:No,,0.82
4428,3208500,Table 1,BaselineCharacteristic,Age (years),Characteristics ; ,None,None,7,0,24,No,1:No,1:No,,0.705
4428,3208500,Table 1,BaselineCharacteristic,Age (years),Number of patients ; ,Age (years),None,7,1,43,No,1:No,1:No,,0.564
4428,3208500,Table 1,BaselineCharacteristic,?Mean,Characteristics ; ,?Mean, Age (years),8,0,2,No,1:No,1:No,,0.68
4428,3208500,Table 1,BaselineCharacteristic,?Range,Characteristics ; ,?Range, Age (years),9,0,2,No,1:No,1:No,,0.7
4428,3208500,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,10,0,2,No,1:No,1:No,,1
4428,3208500,Table 1,BaselineCharacteristic,,Number of patients ; ,None,None,10,1,3,No,1:No,1:No,,0.85
4428,3208500,Table 1,BaselineCharacteristic,Performance status,Characteristics ; ,None,None,11,0,24,No,1:No,1:No,,0.995
4428,3208500,Table 1,BaselineCharacteristic,Performance status,Number of patients ; ,Performance status,None,11,1,43,No,1:No,1:No,,0.865
4428,3208500,Table 1,BaselineCharacteristic,?x,Characteristics ; ,?x, Performance status,12,0,2,No,1:No,1:No,,0.982
4428,3208500,Table 1,BaselineCharacteristic,x,Number of patients ; ,?x, Performance status,12,1,3,No,1:No,1:No,,0.86
4428,3208500,Table 1,BaselineCharacteristic,?x,Characteristics ; ,?x, Performance status,13,0,2,No,1:No,1:No,,0.982
4428,3208500,Table 1,BaselineCharacteristic,xx,Number of patients ; ,?x, Performance status,13,1,3,No,1:No,1:No,,0.8
4428,3208500,Table 1,BaselineCharacteristic,?x,Characteristics ; ,?x, Performance status,14,0,2,No,1:No,1:No,,0.982
4428,3208500,Table 1,BaselineCharacteristic,x,Number of patients ; ,?x, Performance status,14,1,3,No,1:No,1:No,,0.86
4428,3208500,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,15,0,2,No,1:No,1:No,,1
4428,3208500,Table 1,BaselineCharacteristic,,Number of patients ; ,None,None,15,1,3,No,1:No,1:No,,0.84
4428,3208500,Table 1,BaselineCharacteristic,Smoking status,Characteristics ; ,None,None,16,0,24,No,1:No,1:No,,0.995
4428,3208500,Table 1,BaselineCharacteristic,Smoking status,Number of patients ; ,Smoking status,None,16,1,43,No,1:No,1:No,,0.865
4428,3208500,Table 1,BaselineCharacteristic,?Current,Characteristics ; ,?Current, Smoking status,17,0,2,No,1:No,1:No,,1
4428,3208500,Table 1,BaselineCharacteristic,x,Number of patients ; ,?Current, Smoking status,17,1,3,No,1:No,1:No,,0.86
4428,3208500,Table 1,BaselineCharacteristic,?Former,Characteristics ; ,?Former, Smoking status,18,0,2,No,1:No,1:No,,0.99
4428,3208500,Table 1,BaselineCharacteristic,x,Number of patients ; ,?Former, Smoking status,18,1,3,No,1:No,1:No,,0.86
4428,3208500,Table 1,BaselineCharacteristic,?Never,Characteristics ; ,?Never, Smoking status,19,0,2,No,1:No,1:No,,0.99
4428,3208500,Table 1,BaselineCharacteristic,xx,Number of patients ; ,?Never, Smoking status,19,1,3,No,1:No,1:No,,0.87
4428,3208500,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,20,0,2,No,1:No,1:No,,0.99
4428,3208500,Table 1,BaselineCharacteristic,,Number of patients ; ,None,None,20,1,3,No,1:No,1:No,,0.85
4428,3208500,Table 1,BaselineCharacteristic,Histology,Characteristics ; ,None,None,21,0,24,No,1:No,1:No,,0.985
4428,3208500,Table 1,BaselineCharacteristic,Histology,Number of patients ; ,Histology,None,21,1,43,No,1:No,1:No,,0.864
4428,3208500,Table 1,BaselineCharacteristic,?Adenocarcinoma,Characteristics ; ,?Adenocarcinoma, Histology,22,0,2,No,1:No,1:No,,1
4428,3208500,Table 1,BaselineCharacteristic,xx,Number of patients ; ,?Adenocarcinoma, Histology,22,1,3,No,1:No,1:No,,0.86
4428,3208500,Table 1,BaselineCharacteristic,?Squamous cell carcinoma,Characteristics ; ,?Squamous cell carcinoma, Histology,23,0,2,No,1:No,1:No,,1
4428,3208500,Table 1,BaselineCharacteristic,x,Number of patients ; ,?Squamous cell carcinoma, Histology,23,1,3,No,1:No,1:No,,0.84
4428,3208500,Table 1,BaselineCharacteristic,?Large cell carcinoma,Characteristics ; ,?Large cell carcinoma, Histology,24,0,2,No,1:No,1:No,,1
4428,3208500,Table 1,BaselineCharacteristic,x,Number of patients ; ,?Large cell carcinoma, Histology,24,1,3,No,1:No,1:No,,0.84
4428,3208500,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,25,0,2,No,1:No,1:No,,1
4428,3208500,Table 1,BaselineCharacteristic,,Number of patients ; ,None,None,25,1,3,No,1:No,1:No,,0.85
4428,3208500,Table 1,BaselineCharacteristic,EGFR mutation status,Characteristics ; ,None,None,26,0,24,No,1:No,1:No,,0.995
4428,3208500,Table 1,BaselineCharacteristic,EGFR mutation status,Number of patients ; ,EGFR mutation status,None,26,1,43,No,1:No,1:No,,0.875
4428,3208500,Table 1,BaselineCharacteristic,?Positive,Characteristics ; ,?Positive, EGFR mutation status,27,0,2,No,1:No,1:No,,1
4428,3208500,Table 1,BaselineCharacteristic,x,Number of patients ; ,?Positive, EGFR mutation status,27,1,3,No,1:No,1:No,,0.86
4428,3208500,Table 1,BaselineCharacteristic,?Negative,Characteristics ; ,?Negative, EGFR mutation status,28,0,2,No,1:No,1:No,,1
4428,3208500,Table 1,BaselineCharacteristic,x,Number of patients ; ,?Negative, EGFR mutation status,28,1,3,No,1:No,1:No,,0.86
4428,3208500,Table 1,BaselineCharacteristic,?Unknown,Characteristics ; ,?Unknown, EGFR mutation status,29,0,2,No,1:No,1:No,,1
4428,3208500,Table 1,BaselineCharacteristic,xx,Number of patients ; ,?Unknown, EGFR mutation status,29,1,3,No,1:No,1:No,,0.87
4428,3208500,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,30,0,2,No,1:No,1:No,,1
4428,3208500,Table 1,BaselineCharacteristic,,Number of patients ; ,None,None,30,1,3,No,1:No,1:No,,0.85
4428,3208500,Table 1,BaselineCharacteristic,Number of previous chemotherapy regimens,Characteristics ; ,None,None,31,0,24,No,1:No,1:No,,0.995
4428,3208500,Table 1,BaselineCharacteristic,Number of previous chemotherapy regimens,Number of patients ; ,Number of previous chemotherapy regimens,None,31,1,43,No,1:No,1:No,,0.914
4428,3208500,Table 1,BaselineCharacteristic,?x,Characteristics ; ,?x, Number of previous chemotherapy regimens,32,0,2,No,1:No,1:No,,0.991
4428,3208500,Table 1,BaselineCharacteristic,x,Number of patients ; ,?x, Number of previous chemotherapy regimens,32,1,3,No,1:No,1:No,,0.91
4428,3208500,Table 1,BaselineCharacteristic,?x,Characteristics ; ,?x, Number of previous chemotherapy regimens,33,0,2,No,1:No,1:No,,0.991
4428,3208500,Table 1,BaselineCharacteristic,xx,Number of patients ; ,?x, Number of previous chemotherapy regimens,33,1,3,No,1:No,1:No,,0.86
4428,3208500,Table 1,BaselineCharacteristic,?x,Characteristics ; ,?x, Number of previous chemotherapy regimens,34,0,2,No,1:No,1:No,,0.991
4428,3208500,Table 1,BaselineCharacteristic,x,Number of patients ; ,?x, Number of previous chemotherapy regimens,34,1,3,No,1:No,1:No,,0.91
4428,3208500,Table 1,BaselineCharacteristic,?x,Characteristics ; ,?x, Number of previous chemotherapy regimens,35,0,2,No,1:No,1:No,,0.991
4428,3208500,Table 1,BaselineCharacteristic,x,Number of patients ; ,?x, Number of previous chemotherapy regimens,35,1,3,No,1:No,1:No,,0.91
4428,3208500,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,36,0,2,No,1:No,1:No,,1
4428,3208500,Table 1,BaselineCharacteristic,,Number of patients ; ,None,None,36,1,3,No,1:No,1:No,,0.85
4428,3208500,Table 1,BaselineCharacteristic,Previous gefitinib response,Characteristics ; ,None,None,37,0,24,No,1:No,1:No,,0.925
4428,3208500,Table 1,BaselineCharacteristic,Previous gefitinib response,Number of patients ; ,Previous gefitinib response,None,37,1,43,No,1:No,1:No,,0.818
4428,3208500,Table 1,BaselineCharacteristic,?PR,Characteristics ; ,?PR, Previous gefitinib response,38,0,2,No,1:No,1:No,,0.877
4428,3208500,Table 1,BaselineCharacteristic,xx,Number of patients ; ,?PR, Previous gefitinib response,38,1,3,No,1:No,1:No,,0.8
4428,3208500,Table 1,BaselineCharacteristic,?SD,Characteristics ; ,?SD, Previous gefitinib response,39,0,2,No,1:No,1:No,,0.784
4428,3208500,Table 1,BaselineCharacteristic,x,Number of patients ; ,?SD, Previous gefitinib response,39,1,3,No,1:No,1:No,,0.72
4428,3208500,Table 1,BaselineCharacteristic,?PD,Characteristics ; ,?PD, Previous gefitinib response,40,0,2,No,1:No,1:No,,0.877
4428,3208500,Table 1,BaselineCharacteristic,x,Number of patients ; ,?PD, Previous gefitinib response,40,1,3,No,1:No,1:No,,0.8
4539,3231981,Table 1,BaselineCharacteristic,n°,,None,None,0,0,,No,1:No,1:No,,0.807
4539,3231981,Table 1,BaselineCharacteristic,Age (year),,None,None,0,1,,No,1:No,1:No,,0.874
4539,3231981,Table 1,BaselineCharacteristic,Gender,,None,None,0,2,,No,1:No,1:No,,0.875
4539,3231981,Table 1,BaselineCharacteristic,Duration of dialysis (years),,None,None,0,3,,No,1:No,1:No,,0.548
4539,3231981,Table 1,BaselineCharacteristic,Cause of renal failure,,None,None,0,4,,No,1:No,1:No,,0.889
4539,3231981,Table 1,BaselineCharacteristic,Dialysis membrane,,None,None,0,5,,No,1:No,1:No,,0.887
4539,3231981,Table 1,BaselineCharacteristic,Modality of dialysis,,None,None,0,6,,No,1:No,1:No,,0.906
4539,3231981,Table 1,BaselineCharacteristic,Risks factors for dialysis hypotension,,None,None,0,7,,No,1:No,1:No,,0.933
4539,3231981,Table 1,BaselineCharacteristic,x,n° ; ,None,None,1,0,,No,1:No,1:No,,0.774
4539,3231981,Table 1,BaselineCharacteristic,xx,Age (year) ; ,None,None,1,1,,No,1:No,1:No,,0.672
4539,3231981,Table 1,BaselineCharacteristic,F,Gender ; ,None,None,1,2,,No,1:No,1:No,,0.872
4539,3231981,Table 1,BaselineCharacteristic,x,Duration of dialysis (years) ; ,None,None,1,3,,No,1:No,1:No,,0.575
4539,3231981,Table 1,BaselineCharacteristic,SLE,Cause of renal failure ; ,None,None,1,4,,No,1:No,1:No,,0.887
4539,3231981,Table 1,BaselineCharacteristic,Polysufone (ARYLANE Hx - Hospal),Dialysis membrane ; ,None,None,1,5,,No,1:No,1:No,,0.831
4539,3231981,Table 1,BaselineCharacteristic,x h × x/Week,Modality of dialysis ; ,None,None,1,6,,No,1:No,1:No,,0.922
4539,3231981,Table 1,BaselineCharacteristic,"Long duration of dialysis (x years), SLE still active treated by steroïds and ciclosporin - Diastolic dysfunction",Risks factors for dialysis hypotension ; ,None,None,1,7,,No,1:No,1:No,,0.891
4539,3231981,Table 1,BaselineCharacteristic,,n° ; x ; ,None,None,2,0,,No,1:No,1:No,,0.793
4539,3231981,Table 1,BaselineCharacteristic,,Age (year) ; xx ; ,None,None,2,1,,No,1:No,1:No,,0.707
4539,3231981,Table 1,BaselineCharacteristic,,Gender ; F ; ,None,None,2,2,,No,1:No,1:No,,0.888
4539,3231981,Table 1,BaselineCharacteristic,,Duration of dialysis (years) ; x ; ,None,None,2,3,,No,1:No,1:No,,0.577
4539,3231981,Table 1,BaselineCharacteristic,,Cause of renal failure ; SLE ; ,None,None,2,4,,No,1:No,1:No,,0.903
4539,3231981,Table 1,BaselineCharacteristic,,Dialysis membrane ; Polysufone (ARYLANE Hx - Hospal) ; ,None,None,2,5,,No,1:No,1:No,,0.845
4539,3231981,Table 1,BaselineCharacteristic,,Modality of dialysis ; x h × x/Week ; ,None,None,2,6,,No,1:No,1:No,,0.932
4539,3231981,Table 1,BaselineCharacteristic,,"Risks factors for dialysis hypotension ; Long duration of dialysis (x years), SLE still active treated by steroïds and ciclosporin - Diastolic dysfunction ; ",None,None,2,7,,No,1:No,1:No,,0.891
4539,3231981,Table 1,BaselineCharacteristic,x,n° ; x ;  ; ,None,None,3,0,,No,1:No,1:No,,0.811
4539,3231981,Table 1,BaselineCharacteristic,xx,Age (year) ; xx ;  ; ,None,None,3,1,,No,1:No,1:No,,0.701
4539,3231981,Table 1,BaselineCharacteristic,F,Gender ; F ;  ; ,None,None,3,2,,No,1:No,1:No,,0.895
4539,3231981,Table 1,BaselineCharacteristic,x,Duration of dialysis (years) ; x ;  ; ,None,None,3,3,,No,1:No,1:No,,0.599
4539,3231981,Table 1,BaselineCharacteristic,Atherosclerotic nephropathy,Cause of renal failure ; SLE ;  ; ,None,None,3,4,,No,1:No,1:No,,0.911
4539,3231981,Table 1,BaselineCharacteristic,Diacetate (DICEAxxx-Baxter),Dialysis membrane ; Polysufone (ARYLANE Hx - Hospal) ;  ; ,None,None,3,5,,No,1:No,1:No,,0.842
4539,3231981,Table 1,BaselineCharacteristic,x h × x/Week,Modality of dialysis ; x h × x/Week ;  ; ,None,None,3,6,,No,1:No,1:No,,0.949
4539,3231981,Table 1,BaselineCharacteristic,"Very old age, severe ischemic cardiopathy - Diastolic dysfunction","Risks factors for dialysis hypotension ; Long duration of dialysis (x years), SLE still active treated by steroïds and ciclosporin - Diastolic dysfunction ;  ; ",None,None,3,7,,No,1:No,1:No,,0.775
4539,3231981,Table 1,BaselineCharacteristic,,n° ; x ;  ; x ; ,None,None,4,0,,No,1:No,1:No,,0.814
4539,3231981,Table 1,BaselineCharacteristic,,Age (year) ; xx ;  ; xx ; ,None,None,4,1,,No,1:No,1:No,,0.752
4539,3231981,Table 1,BaselineCharacteristic,,Gender ; F ;  ; F ; ,None,None,4,2,,No,1:No,1:No,,0.9
4539,3231981,Table 1,BaselineCharacteristic,,Duration of dialysis (years) ; x ;  ; x ; ,None,None,4,3,,No,1:No,1:No,,0.602
4539,3231981,Table 1,BaselineCharacteristic,,Cause of renal failure ; SLE ;  ; Atherosclerotic nephropathy ; ,None,None,4,4,,No,1:No,1:No,,0.914
4539,3231981,Table 1,BaselineCharacteristic,,Dialysis membrane ; Polysufone (ARYLANE Hx - Hospal) ;  ; Diacetate (DICEAxxx-Baxter) ; ,None,None,4,5,,No,1:No,1:No,,0.836
4539,3231981,Table 1,BaselineCharacteristic,,Modality of dialysis ; x h × x/Week ;  ; x h × x/Week ; ,None,None,4,6,,No,1:No,1:No,,0.957
4539,3231981,Table 1,BaselineCharacteristic,,"Risks factors for dialysis hypotension ; Long duration of dialysis (x years), SLE still active treated by steroïds and ciclosporin - Diastolic dysfunction ;  ; Very old age, severe ischemic cardiopathy - Diastolic dysfunction ; ",None,None,4,7,,No,1:No,1:No,,0.785
4539,3231981,Table 1,BaselineCharacteristic,x,n° ; x ;  ; x ;  ; ,None,None,5,0,,No,1:No,1:No,,0.813
4539,3231981,Table 1,BaselineCharacteristic,xx,Age (year) ; xx ;  ; xx ;  ; ,None,None,5,1,,No,1:No,1:No,,0.742
4539,3231981,Table 1,BaselineCharacteristic,F,Gender ; F ;  ; F ;  ; ,None,None,5,2,,No,1:No,1:No,,0.9
4539,3231981,Table 1,BaselineCharacteristic,x,Duration of dialysis (years) ; x ;  ; x ;  ; ,None,None,5,3,,No,1:No,1:No,,0.602
4539,3231981,Table 1,BaselineCharacteristic,Interstitial nephrotoxic nephritis (Ciclosporin),Cause of renal failure ; SLE ;  ; Atherosclerotic nephropathy ;  ; ,None,None,5,4,,No,1:No,1:No,,0.914
4539,3231981,Table 1,BaselineCharacteristic,PMMA (BKFxx-Toray),Dialysis membrane ; Polysufone (ARYLANE Hx - Hospal) ;  ; Diacetate (DICEAxxx-Baxter) ;  ; ,None,None,5,5,,No,1:No,1:No,,0.826
4539,3231981,Table 1,BaselineCharacteristic,x h × x/Week,Modality of dialysis ; x h × x/Week ;  ; x h × x/Week ;  ; ,None,None,5,6,,No,1:No,1:No,,0.947
4539,3231981,Table 1,BaselineCharacteristic,Cardiac graft for ten years-Diastolic dysfunction,"Risks factors for dialysis hypotension ; Long duration of dialysis (x years), SLE still active treated by steroïds and ciclosporin - Diastolic dysfunction ;  ; Very old age, severe ischemic cardiopathy - Diastolic dysfunction ;  ; ",None,None,5,7,,No,1:No,1:No,,0.793
4539,3231981,Table 1,BaselineCharacteristic,,n° ; x ;  ; x ;  ; x ; ,None,None,6,0,,No,1:No,1:No,,0.832
4539,3231981,Table 1,BaselineCharacteristic,,Age (year) ; xx ;  ; xx ;  ; xx ; ,None,None,6,1,,No,1:No,1:No,,0.798
4539,3231981,Table 1,BaselineCharacteristic,,Gender ; F ;  ; F ;  ; F ; ,None,None,6,2,,No,1:No,1:No,,0.946
4539,3231981,Table 1,BaselineCharacteristic,,Duration of dialysis (years) ; x ;  ; x ;  ; x ; ,None,None,6,3,,No,1:No,1:No,,0.602
4539,3231981,Table 1,BaselineCharacteristic,,Cause of renal failure ; SLE ;  ; Atherosclerotic nephropathy ;  ; Interstitial nephrotoxic nephritis (Ciclosporin) ; ,None,None,6,4,,No,1:No,1:No,,0.942
4539,3231981,Table 1,BaselineCharacteristic,,Dialysis membrane ; Polysufone (ARYLANE Hx - Hospal) ;  ; Diacetate (DICEAxxx-Baxter) ;  ; PMMA (BKFxx-Toray) ; ,None,None,6,5,,No,1:No,1:No,,0.874
4539,3231981,Table 1,BaselineCharacteristic,,Modality of dialysis ; x h × x/Week ;  ; x h × x/Week ;  ; x h × x/Week ; ,None,None,6,6,,No,1:No,1:No,,0.955
4539,3231981,Table 1,BaselineCharacteristic,,"Risks factors for dialysis hypotension ; Long duration of dialysis (x years), SLE still active treated by steroïds and ciclosporin - Diastolic dysfunction ;  ; Very old age, severe ischemic cardiopathy - Diastolic dysfunction ;  ; Cardiac graft for ten years-Diastolic dysfunction ; ",None,None,6,7,,No,1:No,1:No,,0.793
4539,3231981,Table 1,BaselineCharacteristic,x,n° ; x ;  ; x ;  ; x ;  ; ,None,None,7,0,,No,1:No,1:No,,0.84
4539,3231981,Table 1,BaselineCharacteristic,xx,Age (year) ; xx ;  ; xx ;  ; xx ;  ; ,None,None,7,1,,No,1:No,1:No,,0.819
4539,3231981,Table 1,BaselineCharacteristic,M,Gender ; F ;  ; F ;  ; F ;  ; ,None,None,7,2,,No,1:No,1:No,,0.947
4539,3231981,Table 1,BaselineCharacteristic,x,Duration of dialysis (years) ; x ;  ; x ;  ; x ;  ; ,None,None,7,3,,No,1:No,1:No,,0.612
4539,3231981,Table 1,BaselineCharacteristic,Atherosclerotic nephropathy,Cause of renal failure ; SLE ;  ; Atherosclerotic nephropathy ;  ; Interstitial nephrotoxic nephritis (Ciclosporin) ;  ; ,None,None,7,4,,No,1:No,1:No,,0.952
4539,3231981,Table 1,BaselineCharacteristic,Diacetate (DICEA xxx-Baxter),Dialysis membrane ; Polysufone (ARYLANE Hx - Hospal) ;  ; Diacetate (DICEAxxx-Baxter) ;  ; PMMA (BKFxx-Toray) ;  ; ,None,None,7,5,,No,1:No,1:No,,0.886
4539,3231981,Table 1,BaselineCharacteristic,x h × x/Week,Modality of dialysis ; x h × x/Week ;  ; x h × x/Week ;  ; x h × x/Week ;  ; ,None,None,7,6,,No,1:No,1:No,,0.977
4539,3231981,Table 1,BaselineCharacteristic,"Very old age, severe ischemic cardiopathy-Diastolic dysfunction","Risks factors for dialysis hypotension ; Long duration of dialysis (x years), SLE still active treated by steroïds and ciclosporin - Diastolic dysfunction ;  ; Very old age, severe ischemic cardiopathy - Diastolic dysfunction ;  ; Cardiac graft for ten years-Diastolic dysfunction ;  ; ",None,None,7,7,,No,1:No,1:No,,0.793
4539,3231981,Table 1,BaselineCharacteristic,,n° ; x ;  ; x ;  ; x ;  ; x ; ,None,None,8,0,,No,1:No,1:No,,0.847
4539,3231981,Table 1,BaselineCharacteristic,,Age (year) ; xx ;  ; xx ;  ; xx ;  ; xx ; ,None,None,8,1,,No,1:No,1:No,,0.828
4539,3231981,Table 1,BaselineCharacteristic,,Gender ; F ;  ; F ;  ; F ;  ; M ; ,None,None,8,2,,No,1:No,1:No,,0.961
4539,3231981,Table 1,BaselineCharacteristic,,Duration of dialysis (years) ; x ;  ; x ;  ; x ;  ; x ; ,None,None,8,3,,No,1:No,1:No,,0.655
4539,3231981,Table 1,BaselineCharacteristic,,Cause of renal failure ; SLE ;  ; Atherosclerotic nephropathy ;  ; Interstitial nephrotoxic nephritis (Ciclosporin) ;  ; Atherosclerotic nephropathy ; ,None,None,8,4,,No,1:No,1:No,,0.959
4539,3231981,Table 1,BaselineCharacteristic,,Dialysis membrane ; Polysufone (ARYLANE Hx - Hospal) ;  ; Diacetate (DICEAxxx-Baxter) ;  ; PMMA (BKFxx-Toray) ;  ; Diacetate (DICEA xxx-Baxter) ; ,None,None,8,5,,No,1:No,1:No,,0.913
4539,3231981,Table 1,BaselineCharacteristic,,Modality of dialysis ; x h × x/Week ;  ; x h × x/Week ;  ; x h × x/Week ;  ; x h × x/Week ; ,None,None,8,6,,No,1:No,1:No,,0.984
4539,3231981,Table 1,BaselineCharacteristic,,"Risks factors for dialysis hypotension ; Long duration of dialysis (x years), SLE still active treated by steroïds and ciclosporin - Diastolic dysfunction ;  ; Very old age, severe ischemic cardiopathy - Diastolic dysfunction ;  ; Cardiac graft for ten years-Diastolic dysfunction ;  ; Very old age, severe ischemic cardiopathy-Diastolic dysfunction ; ",None,None,8,7,,No,1:No,1:No,,0.793
4539,3231981,Table 1,BaselineCharacteristic,x,n° ; x ;  ; x ;  ; x ;  ; x ;  ; ,None,None,9,0,,No,1:No,1:No,,0.857
4539,3231981,Table 1,BaselineCharacteristic,xx,Age (year) ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; ,None,None,9,1,,No,1:No,1:No,,0.879
4539,3231981,Table 1,BaselineCharacteristic,M,Gender ; F ;  ; F ;  ; F ;  ; M ;  ; ,None,None,9,2,,No,1:No,1:No,,0.968
4539,3231981,Table 1,BaselineCharacteristic,x,Duration of dialysis (years) ; x ;  ; x ;  ; x ;  ; x ;  ; ,None,None,9,3,,No,1:No,1:No,,0.655
4539,3231981,Table 1,BaselineCharacteristic,Diabetes melitus type II,Cause of renal failure ; SLE ;  ; Atherosclerotic nephropathy ;  ; Interstitial nephrotoxic nephritis (Ciclosporin) ;  ; Atherosclerotic nephropathy ;  ; ,None,None,9,4,,No,1:No,1:No,,0.979
4539,3231981,Table 1,BaselineCharacteristic,Triacetate (TRICEAxxx-Baxter),Dialysis membrane ; Polysufone (ARYLANE Hx - Hospal) ;  ; Diacetate (DICEAxxx-Baxter) ;  ; PMMA (BKFxx-Toray) ;  ; Diacetate (DICEA xxx-Baxter) ;  ; ,None,None,9,5,,No,1:No,1:No,,0.913
4539,3231981,Table 1,BaselineCharacteristic,x h × x/Week,Modality of dialysis ; x h × x/Week ;  ; x h × x/Week ;  ; x h × x/Week ;  ; x h × x/Week ;  ; ,None,None,9,6,,No,1:No,1:No,,0.994
4539,3231981,Table 1,BaselineCharacteristic,"Old age, diabetes, pace-maker, panhypotuitarism - Diastolic dvsfunction","Risks factors for dialysis hypotension ; Long duration of dialysis (x years), SLE still active treated by steroïds and ciclosporin - Diastolic dysfunction ;  ; Very old age, severe ischemic cardiopathy - Diastolic dysfunction ;  ; Cardiac graft for ten years-Diastolic dysfunction ;  ; Very old age, severe ischemic cardiopathy-Diastolic dysfunction ;  ; ",None,None,9,7,,No,1:No,1:No,,0.803
4539,3231981,Table 1,BaselineCharacteristic,,n° ; x ;  ; x ;  ; x ;  ; x ;  ; x ; ,None,None,10,0,,No,1:No,1:No,,0.874
4539,3231981,Table 1,BaselineCharacteristic,,Age (year) ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ; ,None,None,10,1,,No,1:No,1:No,,0.912
4539,3231981,Table 1,BaselineCharacteristic,,Gender ; F ;  ; F ;  ; F ;  ; M ;  ; M ; ,None,None,10,2,,No,1:No,1:No,,0.987
4539,3231981,Table 1,BaselineCharacteristic,,Duration of dialysis (years) ; x ;  ; x ;  ; x ;  ; x ;  ; x ; ,None,None,10,3,,No,1:No,1:No,,0.667
4539,3231981,Table 1,BaselineCharacteristic,,Cause of renal failure ; SLE ;  ; Atherosclerotic nephropathy ;  ; Interstitial nephrotoxic nephritis (Ciclosporin) ;  ; Atherosclerotic nephropathy ;  ; Diabetes melitus type II ; ,None,None,10,4,,No,1:No,1:No,,0.996
4539,3231981,Table 1,BaselineCharacteristic,,Dialysis membrane ; Polysufone (ARYLANE Hx - Hospal) ;  ; Diacetate (DICEAxxx-Baxter) ;  ; PMMA (BKFxx-Toray) ;  ; Diacetate (DICEA xxx-Baxter) ;  ; Triacetate (TRICEAxxx-Baxter) ; ,None,None,10,5,,No,1:No,1:No,,0.932
4539,3231981,Table 1,BaselineCharacteristic,,Modality of dialysis ; x h × x/Week ;  ; x h × x/Week ;  ; x h × x/Week ;  ; x h × x/Week ;  ; x h × x/Week ; ,None,None,10,6,,No,1:No,1:No,,0.994
4539,3231981,Table 1,BaselineCharacteristic,,"Risks factors for dialysis hypotension ; Long duration of dialysis (x years), SLE still active treated by steroïds and ciclosporin - Diastolic dysfunction ;  ; Very old age, severe ischemic cardiopathy - Diastolic dysfunction ;  ; Cardiac graft for ten years-Diastolic dysfunction ;  ; Very old age, severe ischemic cardiopathy-Diastolic dysfunction ;  ; Old age, diabetes, pace-maker, panhypotuitarism - Diastolic dvsfunction ; ",None,None,10,7,,No,1:No,1:No,,0.813
4539,3231981,Table 1,BaselineCharacteristic,x,n° ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; ,None,None,11,0,,No,1:No,1:No,,0.874
4539,3231981,Table 1,BaselineCharacteristic,xx,Age (year) ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; ,None,None,11,1,,No,1:No,1:No,,0.912
4539,3231981,Table 1,BaselineCharacteristic,F,Gender ; F ;  ; F ;  ; F ;  ; M ;  ; M ;  ; ,None,None,11,2,,No,1:No,1:No,,0.987
4539,3231981,Table 1,BaselineCharacteristic,x,Duration of dialysis (years) ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; ,None,None,11,3,,No,1:No,1:No,,0.686
4539,3231981,Table 1,BaselineCharacteristic,Renal and urologic tuberculosis,Cause of renal failure ; SLE ;  ; Atherosclerotic nephropathy ;  ; Interstitial nephrotoxic nephritis (Ciclosporin) ;  ; Atherosclerotic nephropathy ;  ; Diabetes melitus type II ;  ; ,None,None,11,4,,No,1:No,1:No,,0.996
4539,3231981,Table 1,BaselineCharacteristic,Diacetate (DICEA xxx-Baxter),Dialysis membrane ; Polysufone (ARYLANE Hx - Hospal) ;  ; Diacetate (DICEAxxx-Baxter) ;  ; PMMA (BKFxx-Toray) ;  ; Diacetate (DICEA xxx-Baxter) ;  ; Triacetate (TRICEAxxx-Baxter) ;  ; ,None,None,11,5,,No,1:No,1:No,,0.932
4539,3231981,Table 1,BaselineCharacteristic,x hxx × x/Week,Modality of dialysis ; x h × x/Week ;  ; x h × x/Week ;  ; x h × x/Week ;  ; x h × x/Week ;  ; x h × x/Week ;  ; ,None,None,11,6,,No,1:No,1:No,,0.994
4539,3231981,Table 1,BaselineCharacteristic,"Very old age, severe ischemic and valvular cardiopathy - Diastolic dysfunction","Risks factors for dialysis hypotension ; Long duration of dialysis (x years), SLE still active treated by steroïds and ciclosporin - Diastolic dysfunction ;  ; Very old age, severe ischemic cardiopathy - Diastolic dysfunction ;  ; Cardiac graft for ten years-Diastolic dysfunction ;  ; Very old age, severe ischemic cardiopathy-Diastolic dysfunction ;  ; Old age, diabetes, pace-maker, panhypotuitarism - Diastolic dvsfunction ;  ; ",None,None,11,7,,No,1:No,1:No,,0.813
4539,3231981,Table 1,BaselineCharacteristic,,n° ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ; ,None,None,12,0,,No,1:No,1:No,,0.874
4539,3231981,Table 1,BaselineCharacteristic,,Age (year) ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ; ,None,None,12,1,,No,1:No,1:No,,0.912
4539,3231981,Table 1,BaselineCharacteristic,,Gender ; F ;  ; F ;  ; F ;  ; M ;  ; M ;  ; F ; ,None,None,12,2,,No,1:No,1:No,,0.987
4539,3231981,Table 1,BaselineCharacteristic,,Duration of dialysis (years) ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ; ,None,None,12,3,,No,1:No,1:No,,0.693
4539,3231981,Table 1,BaselineCharacteristic,,Cause of renal failure ; SLE ;  ; Atherosclerotic nephropathy ;  ; Interstitial nephrotoxic nephritis (Ciclosporin) ;  ; Atherosclerotic nephropathy ;  ; Diabetes melitus type II ;  ; Renal and urologic tuberculosis ; ,None,None,12,4,,No,1:No,1:No,,0.996
4539,3231981,Table 1,BaselineCharacteristic,,Dialysis membrane ; Polysufone (ARYLANE Hx - Hospal) ;  ; Diacetate (DICEAxxx-Baxter) ;  ; PMMA (BKFxx-Toray) ;  ; Diacetate (DICEA xxx-Baxter) ;  ; Triacetate (TRICEAxxx-Baxter) ;  ; Diacetate (DICEA xxx-Baxter) ; ,None,None,12,5,,No,1:No,1:No,,0.932
4539,3231981,Table 1,BaselineCharacteristic,,Modality of dialysis ; x h × x/Week ;  ; x h × x/Week ;  ; x h × x/Week ;  ; x h × x/Week ;  ; x h × x/Week ;  ; x hxx × x/Week ; ,None,None,12,6,,No,1:No,1:No,,0.994
4539,3231981,Table 1,BaselineCharacteristic,,"Risks factors for dialysis hypotension ; Long duration of dialysis (x years), SLE still active treated by steroïds and ciclosporin - Diastolic dysfunction ;  ; Very old age, severe ischemic cardiopathy - Diastolic dysfunction ;  ; Cardiac graft for ten years-Diastolic dysfunction ;  ; Very old age, severe ischemic cardiopathy-Diastolic dysfunction ;  ; Old age, diabetes, pace-maker, panhypotuitarism - Diastolic dvsfunction ;  ; Very old age, severe ischemic and valvular cardiopathy - Diastolic dysfunction ; ",None,None,12,7,,No,1:No,1:No,,0.813
4539,3231981,Table 1,BaselineCharacteristic,x,n° ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; ,None,None,13,0,,No,1:No,1:No,,0.874
4539,3231981,Table 1,BaselineCharacteristic,xx,Age (year) ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; ,None,None,13,1,,No,1:No,1:No,,0.912
4539,3231981,Table 1,BaselineCharacteristic,M,Gender ; F ;  ; F ;  ; F ;  ; M ;  ; M ;  ; F ;  ; ,None,None,13,2,,No,1:No,1:No,,0.987
4539,3231981,Table 1,BaselineCharacteristic,x,Duration of dialysis (years) ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; ,None,None,13,3,,No,1:No,1:No,,0.693
4539,3231981,Table 1,BaselineCharacteristic,Atherosclerotic nephropathy,Cause of renal failure ; SLE ;  ; Atherosclerotic nephropathy ;  ; Interstitial nephrotoxic nephritis (Ciclosporin) ;  ; Atherosclerotic nephropathy ;  ; Diabetes melitus type II ;  ; Renal and urologic tuberculosis ;  ; ,None,None,13,4,,No,1:No,1:No,,0.996
4539,3231981,Table 1,BaselineCharacteristic,Chemically modified Acetate (SMC xxx - Bellco),Dialysis membrane ; Polysufone (ARYLANE Hx - Hospal) ;  ; Diacetate (DICEAxxx-Baxter) ;  ; PMMA (BKFxx-Toray) ;  ; Diacetate (DICEA xxx-Baxter) ;  ; Triacetate (TRICEAxxx-Baxter) ;  ; Diacetate (DICEA xxx-Baxter) ;  ; ,None,None,13,5,,No,1:No,1:No,,0.885
4539,3231981,Table 1,BaselineCharacteristic,x × x h/Week,Modality of dialysis ; x h × x/Week ;  ; x h × x/Week ;  ; x h × x/Week ;  ; x h × x/Week ;  ; x h × x/Week ;  ; x hxx × x/Week ;  ; ,None,None,13,6,,No,1:No,1:No,,0.994
4539,3231981,Table 1,BaselineCharacteristic,"Old age, severe ischemic cardiopathy-Diastolic dysfunction","Risks factors for dialysis hypotension ; Long duration of dialysis (x years), SLE still active treated by steroïds and ciclosporin - Diastolic dysfunction ;  ; Very old age, severe ischemic cardiopathy - Diastolic dysfunction ;  ; Cardiac graft for ten years-Diastolic dysfunction ;  ; Very old age, severe ischemic cardiopathy-Diastolic dysfunction ;  ; Old age, diabetes, pace-maker, panhypotuitarism - Diastolic dvsfunction ;  ; Very old age, severe ischemic and valvular cardiopathy - Diastolic dysfunction ;  ; ",None,None,13,7,,No,1:No,1:No,,0.813
4539,3231981,Table 1,BaselineCharacteristic,,n° ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ; ,None,None,14,0,,No,1:No,1:No,,0.874
4539,3231981,Table 1,BaselineCharacteristic,,Age (year) ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ; ,None,None,14,1,,No,1:No,1:No,,0.932
4539,3231981,Table 1,BaselineCharacteristic,,Gender ; F ;  ; F ;  ; F ;  ; M ;  ; M ;  ; F ;  ; M ; ,None,None,14,2,,No,1:No,1:No,,0.988
4539,3231981,Table 1,BaselineCharacteristic,,Duration of dialysis (years) ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ; ,None,None,14,3,,No,1:No,1:No,,0.693
4539,3231981,Table 1,BaselineCharacteristic,,Cause of renal failure ; SLE ;  ; Atherosclerotic nephropathy ;  ; Interstitial nephrotoxic nephritis (Ciclosporin) ;  ; Atherosclerotic nephropathy ;  ; Diabetes melitus type II ;  ; Renal and urologic tuberculosis ;  ; Atherosclerotic nephropathy ; ,None,None,14,4,,No,1:No,1:No,,0.996
4539,3231981,Table 1,BaselineCharacteristic,,Dialysis membrane ; Polysufone (ARYLANE Hx - Hospal) ;  ; Diacetate (DICEAxxx-Baxter) ;  ; PMMA (BKFxx-Toray) ;  ; Diacetate (DICEA xxx-Baxter) ;  ; Triacetate (TRICEAxxx-Baxter) ;  ; Diacetate (DICEA xxx-Baxter) ;  ; Chemically modified Acetate (SMC xxx - Bellco) ; ,None,None,14,5,,No,1:No,1:No,,0.886
4539,3231981,Table 1,BaselineCharacteristic,,Modality of dialysis ; x h × x/Week ;  ; x h × x/Week ;  ; x h × x/Week ;  ; x h × x/Week ;  ; x h × x/Week ;  ; x hxx × x/Week ;  ; x × x h/Week ; ,None,None,14,6,,No,1:No,1:No,,0.994
4539,3231981,Table 1,BaselineCharacteristic,,"Risks factors for dialysis hypotension ; Long duration of dialysis (x years), SLE still active treated by steroïds and ciclosporin - Diastolic dysfunction ;  ; Very old age, severe ischemic cardiopathy - Diastolic dysfunction ;  ; Cardiac graft for ten years-Diastolic dysfunction ;  ; Very old age, severe ischemic cardiopathy-Diastolic dysfunction ;  ; Old age, diabetes, pace-maker, panhypotuitarism - Diastolic dvsfunction ;  ; Very old age, severe ischemic and valvular cardiopathy - Diastolic dysfunction ;  ; Old age, severe ischemic cardiopathy-Diastolic dysfunction ; ",None,None,14,7,,No,1:No,1:No,,0.813
4539,3231981,Table 1,BaselineCharacteristic,x,n° ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; ,None,None,15,0,,No,1:No,1:No,,0.874
4539,3231981,Table 1,BaselineCharacteristic,xx,Age (year) ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; ,None,None,15,1,,No,1:No,1:No,,0.932
4539,3231981,Table 1,BaselineCharacteristic,M,Gender ; F ;  ; F ;  ; F ;  ; M ;  ; M ;  ; F ;  ; M ;  ; ,None,None,15,2,,No,1:No,1:No,,0.978
4539,3231981,Table 1,BaselineCharacteristic,x,Duration of dialysis (years) ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; ,None,None,15,3,,No,1:No,1:No,,0.693
4539,3231981,Table 1,BaselineCharacteristic,Myeloma,Cause of renal failure ; SLE ;  ; Atherosclerotic nephropathy ;  ; Interstitial nephrotoxic nephritis (Ciclosporin) ;  ; Atherosclerotic nephropathy ;  ; Diabetes melitus type II ;  ; Renal and urologic tuberculosis ;  ; Atherosclerotic nephropathy ;  ; ,None,None,15,4,,No,1:No,1:No,,0.996
4539,3231981,Table 1,BaselineCharacteristic,Triacetate (TRICEAxxx-Baxter),Dialysis membrane ; Polysufone (ARYLANE Hx - Hospal) ;  ; Diacetate (DICEAxxx-Baxter) ;  ; PMMA (BKFxx-Toray) ;  ; Diacetate (DICEA xxx-Baxter) ;  ; Triacetate (TRICEAxxx-Baxter) ;  ; Diacetate (DICEA xxx-Baxter) ;  ; Chemically modified Acetate (SMC xxx - Bellco) ;  ; ,None,None,15,5,,No,1:No,1:No,,0.886
4539,3231981,Table 1,BaselineCharacteristic,x hxx × x/Week,Modality of dialysis ; x h × x/Week ;  ; x h × x/Week ;  ; x h × x/Week ;  ; x h × x/Week ;  ; x h × x/Week ;  ; x hxx × x/Week ;  ; x × x h/Week ;  ; ,None,None,15,6,,No,1:No,1:No,,0.994
4539,3231981,Table 1,BaselineCharacteristic,"Old age, severe ischemic cardiopathy, arythmia secondary to atrial fibrillation - chemotherapy for myeloma - Diastolic dysfunction","Risks factors for dialysis hypotension ; Long duration of dialysis (x years), SLE still active treated by steroïds and ciclosporin - Diastolic dysfunction ;  ; Very old age, severe ischemic cardiopathy - Diastolic dysfunction ;  ; Cardiac graft for ten years-Diastolic dysfunction ;  ; Very old age, severe ischemic cardiopathy-Diastolic dysfunction ;  ; Old age, diabetes, pace-maker, panhypotuitarism - Diastolic dvsfunction ;  ; Very old age, severe ischemic and valvular cardiopathy - Diastolic dysfunction ;  ; Old age, severe ischemic cardiopathy-Diastolic dysfunction ;  ; ",None,None,15,7,,No,1:No,1:No,,0.813
4539,3231981,Table 1,BaselineCharacteristic,,n° ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ; ,None,None,16,0,,No,1:No,1:No,,0.874
4539,3231981,Table 1,BaselineCharacteristic,,Age (year) ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ;  ; xx ; ,None,None,16,1,,No,1:No,1:No,,0.932
4539,3231981,Table 1,BaselineCharacteristic,,Gender ; F ;  ; F ;  ; F ;  ; M ;  ; M ;  ; F ;  ; M ;  ; M ; ,None,None,16,2,,No,1:No,1:No,,0.978
4539,3231981,Table 1,BaselineCharacteristic,,Duration of dialysis (years) ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ;  ; x ; ,None,None,16,3,,No,1:No,1:No,,0.693
4539,3231981,Table 1,BaselineCharacteristic,,Cause of renal failure ; SLE ;  ; Atherosclerotic nephropathy ;  ; Interstitial nephrotoxic nephritis (Ciclosporin) ;  ; Atherosclerotic nephropathy ;  ; Diabetes melitus type II ;  ; Renal and urologic tuberculosis ;  ; Atherosclerotic nephropathy ;  ; Myeloma ; ,None,None,16,4,,No,1:No,1:No,,0.996
4539,3231981,Table 1,BaselineCharacteristic,,Dialysis membrane ; Polysufone (ARYLANE Hx - Hospal) ;  ; Diacetate (DICEAxxx-Baxter) ;  ; PMMA (BKFxx-Toray) ;  ; Diacetate (DICEA xxx-Baxter) ;  ; Triacetate (TRICEAxxx-Baxter) ;  ; Diacetate (DICEA xxx-Baxter) ;  ; Chemically modified Acetate (SMC xxx - Bellco) ;  ; Triacetate (TRICEAxxx-Baxter) ; ,None,None,16,5,,No,1:No,1:No,,0.886
4539,3231981,Table 1,BaselineCharacteristic,,Modality of dialysis ; x h × x/Week ;  ; x h × x/Week ;  ; x h × x/Week ;  ; x h × x/Week ;  ; x h × x/Week ;  ; x hxx × x/Week ;  ; x × x h/Week ;  ; x hxx × x/Week ; ,None,None,16,6,,No,1:No,1:No,,0.994
4585,3247194,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,0,,No,1:No,1:No,,0.907
4585,3247194,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,1,,No,1:No,1:No,,0.88
4585,3247194,Table 1,BaselineCharacteristic,COPD Subjects,,None,None,0,2,,No,1:No,1:No,,0.875
4585,3247194,Table 1,BaselineCharacteristic,Smoker Controls,,None,None,0,3,,No,1:No,1:No,,0.835
4585,3247194,Table 1,BaselineCharacteristic,Non-smoker Controls,,None,None,0,4,,No,1:No,1:No,,0.799
4585,3247194,Table 1,BaselineCharacteristic,Number,Characteristic ; ,None,None,1,0,,No,1:No,1:No,,0.905
4585,3247194,Table 1,BaselineCharacteristic,Number,Characteristic ; ,None,None,1,1,,No,1:No,1:No,,0.877
4585,3247194,Table 1,BaselineCharacteristic,xxx,COPD Subjects ; ,None,None,1,2,,No,1:No,1:No,,0.803
4585,3247194,Table 1,BaselineCharacteristic,xx,Smoker Controls ; ,None,None,1,3,,No,1:No,1:No,,0.556
4585,3247194,Table 1,BaselineCharacteristic,xx,Non-smoker Controls ; ,None,None,1,4,,No,1:No,1:No,,0.543
4585,3247194,Table 1,BaselineCharacteristic,,Characteristic ; Number ; ,None,None,2,0,,No,1:No,1:No,,0.922
4585,3247194,Table 1,BaselineCharacteristic,,Characteristic ; Number ; ,None,None,2,1,,No,1:No,1:No,,0.887
4585,3247194,Table 1,BaselineCharacteristic,,COPD Subjects ; xxx ; ,None,None,2,2,,No,1:No,1:No,,0.795
4585,3247194,Table 1,BaselineCharacteristic,,Smoker Controls ; xx ; ,None,None,2,3,,No,1:No,1:No,,0.598
4585,3247194,Table 1,BaselineCharacteristic,,Non-smoker Controls ; xx ; ,None,None,2,4,,No,1:No,1:No,,0.595
4585,3247194,Table 1,BaselineCharacteristic,Age (yrs),Characteristic ; Number ;  ; ,None,None,3,0,,No,1:No,1:No,,0.834
4585,3247194,Table 1,BaselineCharacteristic,Age (yrs),Characteristic ; Number ;  ; ,None,None,3,1,,No,1:No,1:No,,0.798
4585,3247194,Table 1,BaselineCharacteristic,,Characteristic ; Number ;  ; Age (yrs) ; ,None,None,4,0,,No,1:No,1:No,,0.829
4585,3247194,Table 1,BaselineCharacteristic,,Characteristic ; Number ;  ; Age (yrs) ; ,None,None,4,1,,No,1:No,1:No,,0.793
4585,3247194,Table 1,BaselineCharacteristic,,COPD Subjects ; xxx ;  ; xx.x (x.x) ; ,None,None,4,2,,No,1:No,1:No,,0.624
4585,3247194,Table 1,BaselineCharacteristic,,Smoker Controls ; xx ;  ; xx.x (x.x) ; ,None,None,4,3,,No,1:No,1:No,,0.591
4585,3247194,Table 1,BaselineCharacteristic,,Non-smoker Controls ; xx ;  ; xx.x (x.x) ; ,None,None,4,4,,No,1:No,1:No,,0.593
4585,3247194,Table 1,BaselineCharacteristic,Male (%),Characteristic ; Number ;  ; Age (yrs) ;  ; ,None,None,5,0,,No,1:No,1:No,,0.73
4585,3247194,Table 1,BaselineCharacteristic,Male (%),Characteristic ; Number ;  ; Age (yrs) ;  ; ,None,None,5,1,,No,1:No,1:No,,0.659
4585,3247194,Table 1,BaselineCharacteristic,xx%,COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; ,None,None,5,2,,No,1:No,1:No,,0.697
4585,3247194,Table 1,BaselineCharacteristic,xx%,Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; ,None,None,5,3,,No,1:No,1:No,,0.655
4585,3247194,Table 1,BaselineCharacteristic,xx%,Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; ,None,None,5,4,,No,1:No,1:No,,0.648
4585,3247194,Table 1,BaselineCharacteristic,,Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ; ,None,None,6,0,,No,1:No,1:No,,0.79
4585,3247194,Table 1,BaselineCharacteristic,,Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ; ,None,None,6,1,,No,1:No,1:No,,0.727
4585,3247194,Table 1,BaselineCharacteristic,,COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ; ,None,None,6,2,,No,1:No,1:No,,0.726
4585,3247194,Table 1,BaselineCharacteristic,,Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ; ,None,None,6,3,,No,1:No,1:No,,0.692
4585,3247194,Table 1,BaselineCharacteristic,,Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ; ,None,None,6,4,,No,1:No,1:No,,0.674
4585,3247194,Table 1,BaselineCharacteristic,"Smoking, pack-years",Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; ,None,None,7,0,,No,1:No,1:No,,0.808
4585,3247194,Table 1,BaselineCharacteristic,"Smoking, pack-years",Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; ,None,None,7,1,,No,1:No,1:No,,0.746
4585,3247194,Table 1,BaselineCharacteristic,xx.x (xx.x),COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; ,None,None,7,2,,No,1:No,1:No,,0.754
4585,3247194,Table 1,BaselineCharacteristic,xx.x (xx.x),Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; ,None,None,7,3,,No,1:No,1:No,,0.72
4585,3247194,Table 1,BaselineCharacteristic,x.x (x.x),Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; ,None,None,7,4,,No,1:No,1:No,,0.722
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ; ",None,None,8,0,,No,1:No,1:No,,0.822
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ; ",None,None,8,1,,No,1:No,1:No,,0.769
4585,3247194,Table 1,BaselineCharacteristic,,COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ; ,None,None,8,2,,No,1:No,1:No,,0.789
4585,3247194,Table 1,BaselineCharacteristic,,Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ; ,None,None,8,3,,No,1:No,1:No,,0.747
4585,3247194,Table 1,BaselineCharacteristic,,Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ; ,None,None,8,4,,No,1:No,1:No,,0.747
4585,3247194,Table 1,BaselineCharacteristic,FEVx % predicted,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; ",None,None,9,0,,No,1:No,1:No,,0.842
4585,3247194,Table 1,BaselineCharacteristic,FEVx % predicted,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; ",None,None,9,1,,No,1:No,1:No,,0.789
4585,3247194,Table 1,BaselineCharacteristic,xx.x (xx.x),COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; ,None,None,9,2,,No,1:No,1:No,,0.808
4585,3247194,Table 1,BaselineCharacteristic,xxx.x (xx.x),Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; ,None,None,9,3,,No,1:No,1:No,,0.787
4585,3247194,Table 1,BaselineCharacteristic,xxx.x (xx.x),Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; ,None,None,9,4,,No,1:No,1:No,,0.764
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ; ",None,None,10,0,,No,1:No,1:No,,0.859
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ; ",None,None,10,1,,No,1:No,1:No,,0.806
4585,3247194,Table 1,BaselineCharacteristic,,COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ; ,None,None,10,2,,No,1:No,1:No,,0.819
4585,3247194,Table 1,BaselineCharacteristic,,Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ; ,None,None,10,3,,No,1:No,1:No,,0.798
4585,3247194,Table 1,BaselineCharacteristic,,Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ; ,None,None,10,4,,No,1:No,1:No,,0.795
4585,3247194,Table 1,BaselineCharacteristic,% Low attenuation area on CT (< -xxxHU),"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; ",None,None,11,0,,No,1:No,1:No,,0.838
4585,3247194,Table 1,BaselineCharacteristic,% Low attenuation area on CT (< -xxxHU),"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; ",None,None,11,1,,No,1:No,1:No,,0.788
4585,3247194,Table 1,BaselineCharacteristic,xx.x (xx.x),COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; ,None,None,11,2,,No,1:No,1:No,,0.819
4585,3247194,Table 1,BaselineCharacteristic,x.x (x.x),Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; ,None,None,11,3,,No,1:No,1:No,,0.798
4585,3247194,Table 1,BaselineCharacteristic,x.x (x.x),Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; ,None,None,11,4,,No,1:No,1:No,,0.795
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ; ",None,None,12,0,,No,1:No,1:No,,0.838
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ; ",None,None,12,1,,No,1:No,1:No,,0.788
4585,3247194,Table 1,BaselineCharacteristic,,COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ; ,None,None,12,2,,No,1:No,1:No,,0.819
4585,3247194,Table 1,BaselineCharacteristic,,Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ; ,None,None,12,3,,No,1:No,1:No,,0.798
4585,3247194,Table 1,BaselineCharacteristic,,Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ; ,None,None,12,4,,No,1:No,1:No,,0.795
4585,3247194,Table 1,BaselineCharacteristic,Radiologist Score,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; ",None,None,13,0,,No,1:No,1:No,,0.838
4585,3247194,Table 1,BaselineCharacteristic,< x% emphysema,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; ",None,None,13,1,,No,1:No,1:No,,0.805
4585,3247194,Table 1,BaselineCharacteristic,xx%,COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; ,None,None,13,2,,No,1:No,1:No,,0.819
4585,3247194,Table 1,BaselineCharacteristic,xx%,Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; ,None,None,13,3,,No,1:No,1:No,,0.798
4585,3247194,Table 1,BaselineCharacteristic,xx%,Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; ,None,None,13,4,,No,1:No,1:No,,0.795
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; Radiologist Score ; ",None,None,14,0,,No,1:No,1:No,,0.838
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; < x% emphysema ; ",None,None,14,1,,No,1:No,1:No,,0.806
4585,3247194,Table 1,BaselineCharacteristic,,COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx% ; ,None,None,14,2,,No,1:No,1:No,,0.839
4585,3247194,Table 1,BaselineCharacteristic,,Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ; ,None,None,14,3,,No,1:No,1:No,,0.818
4585,3247194,Table 1,BaselineCharacteristic,,Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ; ,None,None,14,4,,No,1:No,1:No,,0.805
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; Radiologist Score ;  ; ",None,None,15,0,,No,1:No,1:No,,0.838
4585,3247194,Table 1,BaselineCharacteristic,x-xx% emphysema,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; < x% emphysema ;  ; ",None,None,15,1,,No,1:No,1:No,,0.796
4585,3247194,Table 1,BaselineCharacteristic,xx%,COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx% ;  ; ,None,None,15,2,,No,1:No,1:No,,0.839
4585,3247194,Table 1,BaselineCharacteristic,x%,Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; ,None,None,15,3,,No,1:No,1:No,,0.858
4585,3247194,Table 1,BaselineCharacteristic,x,Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; ,None,None,15,4,,No,1:No,1:No,,0.805
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; Radiologist Score ;  ;  ; ",None,None,16,0,,No,1:No,1:No,,0.838
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; < x% emphysema ;  ; x-xx% emphysema ; ",None,None,16,1,,No,1:No,1:No,,0.796
4585,3247194,Table 1,BaselineCharacteristic,,COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx% ;  ; xx% ; ,None,None,16,2,,No,1:No,1:No,,0.839
4585,3247194,Table 1,BaselineCharacteristic,,Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x% ; ,None,None,16,3,,No,1:No,1:No,,0.858
4585,3247194,Table 1,BaselineCharacteristic,,Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x ; ,None,None,16,4,,No,1:No,1:No,,0.805
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; Radiologist Score ;  ;  ;  ; ",None,None,17,0,,No,1:No,1:No,,0.838
4585,3247194,Table 1,BaselineCharacteristic,xx-xx% emphysema,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; < x% emphysema ;  ; x-xx% emphysema ;  ; ",None,None,17,1,,No,1:No,1:No,,0.796
4585,3247194,Table 1,BaselineCharacteristic,xx%,COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx% ;  ; xx% ;  ; ,None,None,17,2,,No,1:No,1:No,,0.839
4585,3247194,Table 1,BaselineCharacteristic,x,Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x% ;  ; ,None,None,17,3,,No,1:No,1:No,,0.858
4585,3247194,Table 1,BaselineCharacteristic,x%,Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x ;  ; ,None,None,17,4,,No,1:No,1:No,,0.825
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; Radiologist Score ;  ;  ;  ;  ; ",None,None,18,0,,No,1:No,1:No,,0.828
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; < x% emphysema ;  ; x-xx% emphysema ;  ; xx-xx% emphysema ; ",None,None,18,1,,No,1:No,1:No,,0.786
4585,3247194,Table 1,BaselineCharacteristic,,COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx% ;  ; xx% ;  ; xx% ; ,None,None,18,2,,No,1:No,1:No,,0.839
4585,3247194,Table 1,BaselineCharacteristic,,Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x% ;  ; x ; ,None,None,18,3,,No,1:No,1:No,,0.858
4585,3247194,Table 1,BaselineCharacteristic,,Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x ;  ; x% ; ,None,None,18,4,,No,1:No,1:No,,0.825
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; Radiologist Score ;  ;  ;  ;  ;  ; ",None,None,19,0,,No,1:No,1:No,,0.818
4585,3247194,Table 1,BaselineCharacteristic,> xx% emphysema,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; < x% emphysema ;  ; x-xx% emphysema ;  ; xx-xx% emphysema ;  ; ",None,None,19,1,,No,1:No,1:No,,0.814
4585,3247194,Table 1,BaselineCharacteristic,xx%,COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx% ;  ; xx% ;  ; xx% ;  ; ,None,None,19,2,,No,1:No,1:No,,0.839
4585,3247194,Table 1,BaselineCharacteristic,x,Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x% ;  ; x ;  ; ,None,None,19,3,,No,1:No,1:No,,0.858
4585,3247194,Table 1,BaselineCharacteristic,x,Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x ;  ; x% ;  ; ,None,None,19,4,,No,1:No,1:No,,0.825
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; Radiologist Score ;  ;  ;  ;  ;  ;  ; ",None,None,20,0,,No,1:No,1:No,,0.818
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; < x% emphysema ;  ; x-xx% emphysema ;  ; xx-xx% emphysema ;  ; > xx% emphysema ; ",None,None,20,1,,No,1:No,1:No,,0.814
4585,3247194,Table 1,BaselineCharacteristic,,COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx% ;  ; xx% ;  ; xx% ;  ; xx% ; ,None,None,20,2,,No,1:No,1:No,,0.839
4585,3247194,Table 1,BaselineCharacteristic,,Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x% ;  ; x ;  ; x ; ,None,None,20,3,,No,1:No,1:No,,0.858
4585,3247194,Table 1,BaselineCharacteristic,,Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x ;  ; x% ;  ; x ; ,None,None,20,4,,No,1:No,1:No,,0.825
4585,3247194,Table 1,BaselineCharacteristic,% reversibility FEVx,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; Radiologist Score ;  ;  ;  ;  ;  ;  ;  ; ",None,None,21,0,,No,1:No,1:No,,0.818
4585,3247194,Table 1,BaselineCharacteristic,% reversibility FEVx,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; < x% emphysema ;  ; x-xx% emphysema ;  ; xx-xx% emphysema ;  ; > xx% emphysema ;  ; ",None,None,21,1,,No,1:No,1:No,,0.814
4585,3247194,Table 1,BaselineCharacteristic,x.x (xx.x),COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx% ;  ; xx% ;  ; xx% ;  ; xx% ;  ; ,None,None,21,2,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,x.x (x.x),Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x% ;  ; x ;  ; x ;  ; ,None,None,21,3,,No,1:No,1:No,,0.867
4585,3247194,Table 1,BaselineCharacteristic,x.x (x.x),Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x ;  ; x% ;  ; x ;  ; ,None,None,21,4,,No,1:No,1:No,,0.834
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; Radiologist Score ;  ;  ;  ;  ;  ;  ;  ; % reversibility FEVx ; ",None,None,22,0,,No,1:No,1:No,,0.838
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; < x% emphysema ;  ; x-xx% emphysema ;  ; xx-xx% emphysema ;  ; > xx% emphysema ;  ; % reversibility FEVx ; ",None,None,22,1,,No,1:No,1:No,,0.824
4585,3247194,Table 1,BaselineCharacteristic,,COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx% ;  ; xx% ;  ; xx% ;  ; xx% ;  ; x.x (xx.x) ; ,None,None,22,2,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,,Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x% ;  ; x ;  ; x ;  ; x.x (x.x) ; ,None,None,22,3,,No,1:No,1:No,,0.867
4585,3247194,Table 1,BaselineCharacteristic,,Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x ;  ; x% ;  ; x ;  ; x.x (x.x) ; ,None,None,22,4,,No,1:No,1:No,,0.834
4585,3247194,Table 1,BaselineCharacteristic,BMI,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; Radiologist Score ;  ;  ;  ;  ;  ;  ;  ; % reversibility FEVx ;  ; ",None,None,23,0,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,BMI,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; < x% emphysema ;  ; x-xx% emphysema ;  ; xx-xx% emphysema ;  ; > xx% emphysema ;  ; % reversibility FEVx ;  ; ",None,None,23,1,,No,1:No,1:No,,0.835
4585,3247194,Table 1,BaselineCharacteristic,xx.x (x.x),COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx% ;  ; xx% ;  ; xx% ;  ; xx% ;  ; x.x (xx.x) ;  ; ,None,None,23,2,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,xx.x (x.x),Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x% ;  ; x ;  ; x ;  ; x.x (x.x) ;  ; ,None,None,23,3,,No,1:No,1:No,,0.867
4585,3247194,Table 1,BaselineCharacteristic,xx.x (x.x),Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x ;  ; x% ;  ; x ;  ; x.x (x.x) ;  ; ,None,None,23,4,,No,1:No,1:No,,0.834
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; Radiologist Score ;  ;  ;  ;  ;  ;  ;  ; % reversibility FEVx ;  ; BMI ; ",None,None,24,0,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; < x% emphysema ;  ; x-xx% emphysema ;  ; xx-xx% emphysema ;  ; > xx% emphysema ;  ; % reversibility FEVx ;  ; BMI ; ",None,None,24,1,,No,1:No,1:No,,0.835
4585,3247194,Table 1,BaselineCharacteristic,,COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx% ;  ; xx% ;  ; xx% ;  ; xx% ;  ; x.x (xx.x) ;  ; xx.x (x.x) ; ,None,None,24,2,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,,Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x% ;  ; x ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ; ,None,None,24,3,,No,1:No,1:No,,0.867
4585,3247194,Table 1,BaselineCharacteristic,,Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x ;  ; x% ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ; ,None,None,24,4,,No,1:No,1:No,,0.834
4585,3247194,Table 1,BaselineCharacteristic,Fat free mass index,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; Radiologist Score ;  ;  ;  ;  ;  ;  ;  ; % reversibility FEVx ;  ; BMI ;  ; ",None,None,25,0,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,Fat free mass index,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; < x% emphysema ;  ; x-xx% emphysema ;  ; xx-xx% emphysema ;  ; > xx% emphysema ;  ; % reversibility FEVx ;  ; BMI ;  ; ",None,None,25,1,,No,1:No,1:No,,0.835
4585,3247194,Table 1,BaselineCharacteristic,xx.x (x.x),COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx% ;  ; xx% ;  ; xx% ;  ; xx% ;  ; x.x (xx.x) ;  ; xx.x (x.x) ;  ; ,None,None,25,2,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,xx.x (x.x),Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x% ;  ; x ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; ,None,None,25,3,,No,1:No,1:No,,0.867
4585,3247194,Table 1,BaselineCharacteristic,xx.x (x.x),Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x ;  ; x% ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; ,None,None,25,4,,No,1:No,1:No,,0.834
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; Radiologist Score ;  ;  ;  ;  ;  ;  ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ; ",None,None,26,0,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; < x% emphysema ;  ; x-xx% emphysema ;  ; xx-xx% emphysema ;  ; > xx% emphysema ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ; ",None,None,26,1,,No,1:No,1:No,,0.835
4585,3247194,Table 1,BaselineCharacteristic,,COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx% ;  ; xx% ;  ; xx% ;  ; xx% ;  ; x.x (xx.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ; ,None,None,26,2,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,,Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x% ;  ; x ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ; ,None,None,26,3,,No,1:No,1:No,,0.867
4585,3247194,Table 1,BaselineCharacteristic,,Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x ;  ; x% ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ; ,None,None,26,4,,No,1:No,1:No,,0.834
4585,3247194,Table 1,BaselineCharacteristic,Number of exacerbations in year prior to enrollment in ECLIPSE,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; Radiologist Score ;  ;  ;  ;  ;  ;  ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",Number of exacerbations in year prior to enrollment in ECLIPSE,,27,0,,No,1:No,1:No,,0.787
4585,3247194,Table 1,BaselineCharacteristic,x,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; < x% emphysema ;  ; x-xx% emphysema ;  ; xx-xx% emphysema ;  ; > xx% emphysema ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",Number of exacerbations in year prior to enrollment in ECLIPSE,,27,1,,No,1:No,1:No,,0.784
4585,3247194,Table 1,BaselineCharacteristic,xx%,COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx% ;  ; xx% ;  ; xx% ;  ; xx% ;  ; x.x (xx.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,Number of exacerbations in year prior to enrollment in ECLIPSE,,27,2,,No,1:No,1:No,,0.77
4585,3247194,Table 1,BaselineCharacteristic,xxx%,Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x% ;  ; x ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,Number of exacerbations in year prior to enrollment in ECLIPSE,,27,3,,No,1:No,1:No,,0.779
4585,3247194,Table 1,BaselineCharacteristic,xx%,Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x ;  ; x% ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,Number of exacerbations in year prior to enrollment in ECLIPSE,,27,4,,No,1:No,1:No,,0.761
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; Radiologist Score ;  ;  ;  ;  ;  ;  ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",None,None,28,0,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; < x% emphysema ;  ; x-xx% emphysema ;  ; xx-xx% emphysema ;  ; > xx% emphysema ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",None,None,28,1,,No,1:No,1:No,,0.835
4585,3247194,Table 1,BaselineCharacteristic,,COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx% ;  ; xx% ;  ; xx% ;  ; xx% ;  ; x.x (xx.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,None,None,28,2,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,,Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x% ;  ; x ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,None,None,28,3,,No,1:No,1:No,,0.867
4585,3247194,Table 1,BaselineCharacteristic,,Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x ;  ; x% ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,None,None,28,4,,No,1:No,1:No,,0.834
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; Radiologist Score ;  ;  ;  ;  ;  ;  ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",,,29,0,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,x,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; < x% emphysema ;  ; x-xx% emphysema ;  ; xx-xx% emphysema ;  ; > xx% emphysema ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",,,29,1,,No,1:No,1:No,,0.843
4585,3247194,Table 1,BaselineCharacteristic,xx%,COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx% ;  ; xx% ;  ; xx% ;  ; xx% ;  ; x.x (xx.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,,,29,2,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,x,Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x% ;  ; x ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,,,29,3,,No,1:No,1:No,,0.867
4585,3247194,Table 1,BaselineCharacteristic,x%,Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x ;  ; x% ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,,,29,4,,No,1:No,1:No,,0.834
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; Radiologist Score ;  ;  ;  ;  ;  ;  ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",None,None,30,0,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; < x% emphysema ;  ; x-xx% emphysema ;  ; xx-xx% emphysema ;  ; > xx% emphysema ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",None,None,30,1,,No,1:No,1:No,,0.835
4585,3247194,Table 1,BaselineCharacteristic,,COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx% ;  ; xx% ;  ; xx% ;  ; xx% ;  ; x.x (xx.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,None,None,30,2,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,,Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x% ;  ; x ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,None,None,30,3,,No,1:No,1:No,,0.867
4585,3247194,Table 1,BaselineCharacteristic,,Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x ;  ; x% ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,None,None,30,4,,No,1:No,1:No,,0.834
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; Radiologist Score ;  ;  ;  ;  ;  ;  ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",,,31,0,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,x,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; < x% emphysema ;  ; x-xx% emphysema ;  ; xx-xx% emphysema ;  ; > xx% emphysema ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",,,31,1,,No,1:No,1:No,,0.843
4585,3247194,Table 1,BaselineCharacteristic,xx%,COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx% ;  ; xx% ;  ; xx% ;  ; xx% ;  ; x.x (xx.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,,,31,2,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,x,Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x% ;  ; x ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,,,31,3,,No,1:No,1:No,,0.867
4585,3247194,Table 1,BaselineCharacteristic,x,Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x ;  ; x% ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,,,31,4,,No,1:No,1:No,,0.834
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; Radiologist Score ;  ;  ;  ;  ;  ;  ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",None,None,32,0,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; < x% emphysema ;  ; x-xx% emphysema ;  ; xx-xx% emphysema ;  ; > xx% emphysema ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",None,None,32,1,,No,1:No,1:No,,0.835
4585,3247194,Table 1,BaselineCharacteristic,,COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx% ;  ; xx% ;  ; xx% ;  ; xx% ;  ; x.x (xx.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,None,None,32,2,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,,Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x% ;  ; x ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,None,None,32,3,,No,1:No,1:No,,0.867
4585,3247194,Table 1,BaselineCharacteristic,,Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x ;  ; x% ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,None,None,32,4,,No,1:No,1:No,,0.834
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; Radiologist Score ;  ;  ;  ;  ;  ;  ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",,,33,0,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,x or more,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; < x% emphysema ;  ; x-xx% emphysema ;  ; xx-xx% emphysema ;  ; > xx% emphysema ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",,,33,1,,No,1:No,1:No,,0.853
4585,3247194,Table 1,BaselineCharacteristic,xx%,COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx% ;  ; xx% ;  ; xx% ;  ; xx% ;  ; x.x (xx.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,,,33,2,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,x,Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x% ;  ; x ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,,,33,3,,No,1:No,1:No,,0.867
4585,3247194,Table 1,BaselineCharacteristic,x,Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x ;  ; x% ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,,,33,4,,No,1:No,1:No,,0.834
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; Radiologist Score ;  ;  ;  ;  ;  ;  ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",None,None,34,0,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; < x% emphysema ;  ; x-xx% emphysema ;  ; xx-xx% emphysema ;  ; > xx% emphysema ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",None,None,34,1,,No,1:No,1:No,,0.835
4585,3247194,Table 1,BaselineCharacteristic,,COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx% ;  ; xx% ;  ; xx% ;  ; xx% ;  ; x.x (xx.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,None,None,34,2,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,,Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x% ;  ; x ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,None,None,34,3,,No,1:No,1:No,,0.867
4585,3247194,Table 1,BaselineCharacteristic,,Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x ;  ; x% ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,None,None,34,4,,No,1:No,1:No,,0.834
4585,3247194,Table 1,BaselineCharacteristic,x min walk (m),"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; Radiologist Score ;  ;  ;  ;  ;  ;  ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",None,None,35,0,,No,1:No,1:No,,0.847
4585,3247194,Table 1,BaselineCharacteristic,x min walk (m),"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; < x% emphysema ;  ; x-xx% emphysema ;  ; xx-xx% emphysema ;  ; > xx% emphysema ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",None,None,35,1,,No,1:No,1:No,,0.845
4585,3247194,Table 1,BaselineCharacteristic,xxx (xxx),COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx% ;  ; xx% ;  ; xx% ;  ; xx% ;  ; x.x (xx.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,None,None,35,2,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,,Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x% ;  ; x ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,None,None,35,3,,No,1:No,1:No,,0.867
4585,3247194,Table 1,BaselineCharacteristic,,Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x ;  ; x% ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,None,None,35,4,,No,1:No,1:No,,0.834
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; Radiologist Score ;  ;  ;  ;  ;  ;  ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",None,None,36,0,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; < x% emphysema ;  ; x-xx% emphysema ;  ; xx-xx% emphysema ;  ; > xx% emphysema ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",None,None,36,1,,No,1:No,1:No,,0.835
4585,3247194,Table 1,BaselineCharacteristic,,COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx% ;  ; xx% ;  ; xx% ;  ; xx% ;  ; x.x (xx.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,None,None,36,2,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,,Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x% ;  ; x ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,None,None,36,3,,No,1:No,1:No,,0.867
4585,3247194,Table 1,BaselineCharacteristic,,Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x ;  ; x% ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,None,None,36,4,,No,1:No,1:No,,0.834
4585,3247194,Table 1,BaselineCharacteristic,BODE Index,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; Radiologist Score ;  ;  ;  ;  ;  ;  ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",BODE Index,,37,0,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,BODE Index,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; < x% emphysema ;  ; x-xx% emphysema ;  ; xx-xx% emphysema ;  ; > xx% emphysema ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",BODE Index,,37,1,,No,1:No,1:No,,0.835
4585,3247194,Table 1,BaselineCharacteristic,x.x (x.x),COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx% ;  ; xx% ;  ; xx% ;  ; xx% ;  ; x.x (xx.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,BODE Index,,37,2,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,,Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x% ;  ; x ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,BODE Index,,37,3,,No,1:No,1:No,,0.867
4585,3247194,Table 1,BaselineCharacteristic,,Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x ;  ; x% ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,BODE Index,,37,4,,No,1:No,1:No,,0.834
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; Radiologist Score ;  ;  ;  ;  ;  ;  ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",None,None,38,0,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; < x% emphysema ;  ; x-xx% emphysema ;  ; xx-xx% emphysema ;  ; > xx% emphysema ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",None,None,38,1,,No,1:No,1:No,,0.835
4585,3247194,Table 1,BaselineCharacteristic,,COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx% ;  ; xx% ;  ; xx% ;  ; xx% ;  ; x.x (xx.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,None,None,38,2,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,,Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x% ;  ; x ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,None,None,38,3,,No,1:No,1:No,,0.867
4585,3247194,Table 1,BaselineCharacteristic,,Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x ;  ; x% ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,None,None,38,4,,No,1:No,1:No,,0.834
4585,3247194,Table 1,BaselineCharacteristic,mMRC score,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; Radiologist Score ;  ;  ;  ;  ;  ;  ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",mMRC score,,39,0,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,mMRC score,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; < x% emphysema ;  ; x-xx% emphysema ;  ; xx-xx% emphysema ;  ; > xx% emphysema ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",mMRC score,,39,1,,No,1:No,1:No,,0.835
4585,3247194,Table 1,BaselineCharacteristic,x.x (x.x),COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx% ;  ; xx% ;  ; xx% ;  ; xx% ;  ; x.x (xx.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,mMRC score,,39,2,,No,1:No,1:No,,0.883
4585,3247194,Table 1,BaselineCharacteristic,x.x (x.x),Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x% ;  ; x ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,mMRC score,,39,3,,No,1:No,1:No,,0.887
4585,3247194,Table 1,BaselineCharacteristic,x.x (x.x),Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x ;  ; x% ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,mMRC score,,39,4,,No,1:No,1:No,,0.849
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; Radiologist Score ;  ;  ;  ;  ;  ;  ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",None,None,40,0,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; < x% emphysema ;  ; x-xx% emphysema ;  ; xx-xx% emphysema ;  ; > xx% emphysema ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",None,None,40,1,,No,1:No,1:No,,0.835
4585,3247194,Table 1,BaselineCharacteristic,,COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx% ;  ; xx% ;  ; xx% ;  ; xx% ;  ; x.x (xx.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,None,None,40,2,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,,Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x% ;  ; x ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,None,None,40,3,,No,1:No,1:No,,0.867
4585,3247194,Table 1,BaselineCharacteristic,,Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x ;  ; x% ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,None,None,40,4,,No,1:No,1:No,,0.834
4585,3247194,Table 1,BaselineCharacteristic,CES-D score,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; Radiologist Score ;  ;  ;  ;  ;  ;  ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",CES-D score,,41,0,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,CES-D score,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; < x% emphysema ;  ; x-xx% emphysema ;  ; xx-xx% emphysema ;  ; > xx% emphysema ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",CES-D score,,41,1,,No,1:No,1:No,,0.835
4585,3247194,Table 1,BaselineCharacteristic,xx.x (x.x),COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx% ;  ; xx% ;  ; xx% ;  ; xx% ;  ; x.x (xx.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,CES-D score,,41,2,,No,1:No,1:No,,0.883
4585,3247194,Table 1,BaselineCharacteristic,x.x (x.x),Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x% ;  ; x ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,CES-D score,,41,3,,No,1:No,1:No,,0.887
4585,3247194,Table 1,BaselineCharacteristic,x.x (x.x),Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x ;  ; x% ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,CES-D score,,41,4,,No,1:No,1:No,,0.849
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; Radiologist Score ;  ;  ;  ;  ;  ;  ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",None,None,42,0,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; < x% emphysema ;  ; x-xx% emphysema ;  ; xx-xx% emphysema ;  ; > xx% emphysema ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",None,None,42,1,,No,1:No,1:No,,0.835
4585,3247194,Table 1,BaselineCharacteristic,,COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx% ;  ; xx% ;  ; xx% ;  ; xx% ;  ; x.x (xx.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,None,None,42,2,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,,Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x% ;  ; x ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,None,None,42,3,,No,1:No,1:No,,0.867
4585,3247194,Table 1,BaselineCharacteristic,,Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x ;  ; x% ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,None,None,42,4,,No,1:No,1:No,,0.834
4585,3247194,Table 1,BaselineCharacteristic,FACIT score,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; Radiologist Score ;  ;  ;  ;  ;  ;  ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",FACIT score,,43,0,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,FACIT score,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; < x% emphysema ;  ; x-xx% emphysema ;  ; xx-xx% emphysema ;  ; > xx% emphysema ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",FACIT score,,43,1,,No,1:No,1:No,,0.835
4585,3247194,Table 1,BaselineCharacteristic,xx.x (xx.x),COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx% ;  ; xx% ;  ; xx% ;  ; xx% ;  ; x.x (xx.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,FACIT score,,43,2,,No,1:No,1:No,,0.883
4585,3247194,Table 1,BaselineCharacteristic,xx.x (x.x),Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x% ;  ; x ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,FACIT score,,43,3,,No,1:No,1:No,,0.887
4585,3247194,Table 1,BaselineCharacteristic,xx.x (x.x),Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x ;  ; x% ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,FACIT score,,43,4,,No,1:No,1:No,,0.849
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; Radiologist Score ;  ;  ;  ;  ;  ;  ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",None,None,44,0,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; < x% emphysema ;  ; x-xx% emphysema ;  ; xx-xx% emphysema ;  ; > xx% emphysema ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",None,None,44,1,,No,1:No,1:No,,0.835
4585,3247194,Table 1,BaselineCharacteristic,,COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx% ;  ; xx% ;  ; xx% ;  ; xx% ;  ; x.x (xx.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,None,None,44,2,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,,Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x% ;  ; x ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,None,None,44,3,,No,1:No,1:No,,0.867
4585,3247194,Table 1,BaselineCharacteristic,,Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x ;  ; x% ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,None,None,44,4,,No,1:No,1:No,,0.834
4585,3247194,Table 1,BaselineCharacteristic,SGRQ-C Total score,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; Radiologist Score ;  ;  ;  ;  ;  ;  ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",SGRQ-C Total score,,45,0,,No,1:No,1:No,,0.848
4585,3247194,Table 1,BaselineCharacteristic,SGRQ-C Total score,"Characteristic ; Number ;  ; Age (yrs) ;  ; Male (%) ;  ; Smoking, pack-years ;  ; FEVx % predicted ;  ; % Low attenuation area on CT (< -xxxHU) ;  ; < x% emphysema ;  ; x-xx% emphysema ;  ; xx-xx% emphysema ;  ; > xx% emphysema ;  ; % reversibility FEVx ;  ; BMI ;  ; Fat free mass index ;  ; ",SGRQ-C Total score,,45,1,,No,1:No,1:No,,0.835
4585,3247194,Table 1,BaselineCharacteristic,xx.x (xx.x),COPD Subjects ; xxx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx.x (xx.x) ;  ; xx% ;  ; xx% ;  ; xx% ;  ; xx% ;  ; x.x (xx.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,SGRQ-C Total score,,45,2,,No,1:No,1:No,,0.883
4585,3247194,Table 1,BaselineCharacteristic,x.x (xx.x),Smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; xx.x (xx.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x% ;  ; x ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,SGRQ-C Total score,,45,3,,No,1:No,1:No,,0.887
4585,3247194,Table 1,BaselineCharacteristic,x.x (x.x),Non-smoker Controls ; xx ;  ; xx.x (x.x) ;  ; xx% ;  ; x.x (x.x) ;  ; xxx.x (xx.x) ;  ; x.x (x.x) ;  ; xx% ;  ; x ;  ; x% ;  ; x ;  ; x.x (x.x) ;  ; xx.x (x.x) ;  ; xx.x (x.x) ;  ; ,SGRQ-C Total score,,45,4,,No,1:No,1:No,,0.849
4713,3281202,Table 3,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
4713,3281202,Table 3,BaselineCharacteristic,ISSAAC,,,None,0,1,1,No,1:No,1:No,,0.893
4713,3281202,Table 3,BaselineCharacteristic,INSECT,,,None,0,2,1,No,1:No,1:No,,0.863
4713,3281202,Table 3,BaselineCharacteristic,p value,,,None,0,3,1,No,1:No,1:No,,0.883
4713,3281202,Table 3,BaselineCharacteristic,, ; ,None,None,1,0,12,No,1:No,1:No,,0.898
4713,3281202,Table 3,BaselineCharacteristic,N?=?xxx,ISSAAC ; ,,None,1,1,1,No,1:No,1:No,,0.638
4713,3281202,Table 3,BaselineCharacteristic,N?=?xxx,INSECT ; ,,None,1,2,1,No,1:No,1:No,,0.612
4713,3281202,Table 3,BaselineCharacteristic,p value,p value ; ,,None,1,3,1,No,1:No,1:No,,0.876
4713,3281202,Table 3,BaselineCharacteristic,"Age (years), mean?±?SD",p value ; p value ; ,"Age (years), mean?±?SD",None,2,3,43,No,1:No,1:No,,0.58
4713,3281202,Table 3,BaselineCharacteristic,Male, ;  ; ,Male," Age (years), mean?±?SD",3,0,2,No,1:No,1:No,,0.51
4713,3281202,Table 3,BaselineCharacteristic,Female, ;  ; ,Female," Age (years), mean?±?SD",4,0,2,No,1:No,1:No,,0.54
4713,3281202,Table 3,BaselineCharacteristic,x.xx,p value ; p value ; ,Female," Age (years), mean?±?SD",4,3,3,No,1:No,1:No,,0.51
4713,3281202,Table 3,BaselineCharacteristic,Gender, ;  ; ,None,None,5,0,24,No,1:No,1:No,,0.929
4713,3281202,Table 3,BaselineCharacteristic,Gender,ISSAAC ; N?=?xxx ; ,Gender,None,5,1,43,No,1:No,1:No,,0.735
4713,3281202,Table 3,BaselineCharacteristic,Gender,INSECT ; N?=?xxx ; ,Gender,None,5,2,43,No,1:No,1:No,,0.704
4713,3281202,Table 3,BaselineCharacteristic,Gender,p value ; p value ; ,Gender,None,5,3,43,No,1:No,1:No,,0.858
4713,3281202,Table 3,BaselineCharacteristic,Male, ;  ; ,Male, Gender,6,0,2,No,1:No,1:No,,0.99
4713,3281202,Table 3,BaselineCharacteristic,xx (xx.x%),ISSAAC ; N?=?xxx ; ,Male, Gender,6,1,3,No,1:No,1:No,,0.696
4713,3281202,Table 3,BaselineCharacteristic,xx (xx.x%),INSECT ; N?=?xxx ; ,Male, Gender,6,2,3,No,1:No,1:No,,0.716
4713,3281202,Table 3,BaselineCharacteristic,x.xxx,p value ; p value ; ,Male, Gender,6,3,3,No,1:No,1:No,,0.85
4713,3281202,Table 3,BaselineCharacteristic,Female, ;  ; ,Female, Gender,7,0,2,No,1:No,1:No,,0.99
4713,3281202,Table 3,BaselineCharacteristic,xx (xx.x%),ISSAAC ; N?=?xxx ; ,Female, Gender,7,1,3,No,1:No,1:No,,0.696
4713,3281202,Table 3,BaselineCharacteristic,xx (xx.x%),INSECT ; N?=?xxx ; ,Female, Gender,7,2,3,No,1:No,1:No,,0.716
4713,3281202,Table 3,BaselineCharacteristic,,p value ; p value ; ,Female, Gender,7,3,3,No,1:No,1:No,,0.89
4713,3281202,Table 3,BaselineCharacteristic,"BMI (kg/mx), mean?±?SD", ;  ; ,"BMI (kg/mx), mean?±?SD", Gender,8,0,2,No,1:No,1:No,,0.78
4713,3281202,Table 3,BaselineCharacteristic,x.xx,p value ; p value ; ,"BMI (kg/mx), mean?±?SD", Gender,8,3,3,No,1:No,1:No,,0.71
4713,3281202,Table 3,BaselineCharacteristic,Prior abdominal incisions, ;  ; ,Prior abdominal incisions, Gender,9,0,2,No,1:No,1:No,,1
4713,3281202,Table 3,BaselineCharacteristic,xx (xx.x%),ISSAAC ; N?=?xxx ; ,Prior abdominal incisions, Gender,9,1,3,No,1:No,1:No,,0.726
4713,3281202,Table 3,BaselineCharacteristic,xx (xx.x%),INSECT ; N?=?xxx ; ,Prior abdominal incisions, Gender,9,2,3,No,1:No,1:No,,0.746
4713,3281202,Table 3,BaselineCharacteristic,x.xxx,p value ; p value ; ,Prior abdominal incisions, Gender,9,3,3,No,1:No,1:No,,0.89
4713,3281202,Table 3,BaselineCharacteristic,Rectus diastasis, ;  ; ,Rectus diastasis, Gender,10,0,2,No,1:No,1:No,,1
4713,3281202,Table 3,BaselineCharacteristic,x (x.x%),ISSAAC ; N?=?xxx ; ,Rectus diastasis, Gender,10,1,3,No,1:No,1:No,,0.87
4713,3281202,Table 3,BaselineCharacteristic,x (x.x%),INSECT ; N?=?xxx ; ,Rectus diastasis, Gender,10,2,3,No,1:No,1:No,,0.84
4713,3281202,Table 3,BaselineCharacteristic,x.xx,p value ; p value ; ,Rectus diastasis, Gender,10,3,3,No,1:No,1:No,,0.86
4713,3281202,Table 3,BaselineCharacteristic,Umbilical hernia, ;  ; ,Umbilical hernia, Gender,11,0,2,No,1:No,1:No,,1
4713,3281202,Table 3,BaselineCharacteristic,x (x.x%),ISSAAC ; N?=?xxx ; ,Umbilical hernia, Gender,11,1,3,No,1:No,1:No,,0.88
4713,3281202,Table 3,BaselineCharacteristic,x (x.x%),INSECT ; N?=?xxx ; ,Umbilical hernia, Gender,11,2,3,No,1:No,1:No,,0.85
4713,3281202,Table 3,BaselineCharacteristic,x.xx,p value ; p value ; ,Umbilical hernia, Gender,11,3,3,No,1:No,1:No,,0.87
4713,3281202,Table 3,BaselineCharacteristic,Smokers, ;  ; ,Smokers, Gender,12,0,2,No,1:No,1:No,,1
4713,3281202,Table 3,BaselineCharacteristic,xx (xx.x%),ISSAAC ; N?=?xxx ; ,Smokers, Gender,12,1,3,No,1:No,1:No,,0.766
4713,3281202,Table 3,BaselineCharacteristic,xx (xx.x%),INSECT ; N?=?xxx ; ,Smokers, Gender,12,2,3,No,1:No,1:No,,0.776
4713,3281202,Table 3,BaselineCharacteristic,x.xx,p value ; p value ; ,Smokers, Gender,12,3,3,No,1:No,1:No,,0.87
4713,3281202,Table 3,BaselineCharacteristic,Surgical procedures, ;  ; ,None,None,13,0,24,No,1:No,1:No,,0.995
4713,3281202,Table 3,BaselineCharacteristic,Surgical procedures,ISSAAC ; N?=?xxx ; ,Surgical procedures,None,13,1,43,No,1:No,1:No,,0.81
4713,3281202,Table 3,BaselineCharacteristic,Surgical procedures,INSECT ; N?=?xxx ; ,Surgical procedures,None,13,2,43,No,1:No,1:No,,0.779
4713,3281202,Table 3,BaselineCharacteristic,Surgical procedures,p value ; p value ; ,Surgical procedures,None,13,3,43,No,1:No,1:No,,0.913
4713,3281202,Table 3,BaselineCharacteristic,Colon, ;  ; ,Colon, Surgical procedures,14,0,2,No,1:No,1:No,,1
4713,3281202,Table 3,BaselineCharacteristic,xx (xx.x%),ISSAAC ; N?=?xxx ; ,Colon, Surgical procedures,14,1,3,No,1:No,1:No,,0.776
4713,3281202,Table 3,BaselineCharacteristic,xx (xx.x%),INSECT ; N?=?xxx ; ,Colon, Surgical procedures,14,2,3,No,1:No,1:No,,0.786
4713,3281202,Table 3,BaselineCharacteristic,<x.xxxx,p value ; p value ; ,Colon, Surgical procedures,14,3,3,No,1:No,1:No,,0.92
4713,3281202,Table 3,BaselineCharacteristic,Rectum, ;  ; ,Rectum, Surgical procedures,15,0,2,No,1:No,1:No,,1
4713,3281202,Table 3,BaselineCharacteristic,xx (x.x%),ISSAAC ; N?=?xxx ; ,Rectum, Surgical procedures,15,1,3,No,1:No,1:No,,0.736
4713,3281202,Table 3,BaselineCharacteristic,xx (xx.x%),INSECT ; N?=?xxx ; ,Rectum, Surgical procedures,15,2,3,No,1:No,1:No,,0.786
4713,3281202,Table 3,BaselineCharacteristic,<x.xxxx,p value ; p value ; ,Rectum, Surgical procedures,15,3,3,No,1:No,1:No,,0.92
4713,3281202,Table 3,BaselineCharacteristic,Stomach and oesophagus, ;  ; ,Stomach and oesophagus, Surgical procedures,16,0,2,No,1:No,1:No,,1
4713,3281202,Table 3,BaselineCharacteristic,xx (xx.x%),ISSAAC ; N?=?xxx ; ,Stomach and oesophagus, Surgical procedures,16,1,3,No,1:No,1:No,,0.796
4713,3281202,Table 3,BaselineCharacteristic,xx (x.x%),INSECT ; N?=?xxx ; ,Stomach and oesophagus, Surgical procedures,16,2,3,No,1:No,1:No,,0.756
4713,3281202,Table 3,BaselineCharacteristic,<x.xxxx,p value ; p value ; ,Stomach and oesophagus, Surgical procedures,16,3,3,No,1:No,1:No,,0.93
4713,3281202,Table 3,BaselineCharacteristic,Abdominal aorta, ;  ; ,Abdominal aorta, Surgical procedures,17,0,2,No,1:No,1:No,,1
4713,3281202,Table 3,BaselineCharacteristic,x (x.x%),ISSAAC ; N?=?xxx ; ,Abdominal aorta, Surgical procedures,17,1,3,No,1:No,1:No,,0.88
4713,3281202,Table 3,BaselineCharacteristic,xx (x.x%),INSECT ; N?=?xxx ; ,Abdominal aorta, Surgical procedures,17,2,3,No,1:No,1:No,,0.726
4713,3281202,Table 3,BaselineCharacteristic,<x.xxxx,p value ; p value ; ,Abdominal aorta, Surgical procedures,17,3,3,No,1:No,1:No,,0.92
4713,3281202,Table 3,BaselineCharacteristic,Pancreas, ;  ; ,Pancreas, Surgical procedures,18,0,2,No,1:No,1:No,,0.99
4713,3281202,Table 3,BaselineCharacteristic,xx (xx.x%),ISSAAC ; N?=?xxx ; ,Pancreas, Surgical procedures,18,1,3,No,1:No,1:No,,0.776
4713,3281202,Table 3,BaselineCharacteristic,xx (xx.x%),INSECT ; N?=?xxx ; ,Pancreas, Surgical procedures,18,2,3,No,1:No,1:No,,0.786
4713,3281202,Table 3,BaselineCharacteristic,<x.xxxx,p value ; p value ; ,Pancreas, Surgical procedures,18,3,3,No,1:No,1:No,,0.92
4713,3281202,Table 3,BaselineCharacteristic,Small intestine, ;  ; ,Small intestine, Surgical procedures,19,0,2,No,1:No,1:No,,0.99
4713,3281202,Table 3,BaselineCharacteristic,x (x.x%),ISSAAC ; N?=?xxx ; ,Small intestine, Surgical procedures,19,1,3,No,1:No,1:No,,0.88
4713,3281202,Table 3,BaselineCharacteristic,x (x.x%),INSECT ; N?=?xxx ; ,Small intestine, Surgical procedures,19,2,3,No,1:No,1:No,,0.85
4713,3281202,Table 3,BaselineCharacteristic,<x.xxxx,p value ; p value ; ,Small intestine, Surgical procedures,19,3,3,No,1:No,1:No,,0.92
4713,3281202,Table 3,BaselineCharacteristic,Other, ;  ; ,Other, Surgical procedures,20,0,2,No,1:No,1:No,,0.99
4713,3281202,Table 3,BaselineCharacteristic,xx (xx.x%),ISSAAC ; N?=?xxx ; ,Other, Surgical procedures,20,1,3,No,1:No,1:No,,0.766
4713,3281202,Table 3,BaselineCharacteristic,xx (x.x%),INSECT ; N?=?xxx ; ,Other, Surgical procedures,20,2,3,No,1:No,1:No,,0.716
4713,3281202,Table 3,BaselineCharacteristic,<x.xxxx,p value ; p value ; ,Other, Surgical procedures,20,3,3,No,1:No,1:No,,0.92
4713,3281202,Table 3,BaselineCharacteristic,"Length of abdominal wound (cm)a, mean?±?SD", ;  ; ,"Length of abdominal wound (cm)a, mean?±?SD", Surgical procedures,21,0,2,No,1:No,1:No,,0.69
4713,3281202,Table 3,BaselineCharacteristic,x.xx,p value ; p value ; ,"Length of abdominal wound (cm)a, mean?±?SD", Surgical procedures,21,3,3,No,1:No,1:No,,0.61
4733,3285050,Table 1,BaselineCharacteristic,Age (years),,Age (years),None,0,0,2,No,1:No,1:No,,0.65
4733,3285050,Table 1,BaselineCharacteristic,Tumor stage,,Tumor stage,None,1,0,2,No,1:No,1:No,,0.94
4733,3285050,Table 1,BaselineCharacteristic,Tis/Tx/Tx,,Tumor stage,None,1,1,3,No,1:No,1:No,,0.87
4733,3285050,Table 1,BaselineCharacteristic,x/xx/x,,Tumor stage,None,1,2,3,No,1:No,1:No,,0.88
4733,3285050,Table 1,BaselineCharacteristic,Nodal stage,,Nodal stage,None,2,0,2,No,1:No,1:No,,0.95
4733,3285050,Table 1,BaselineCharacteristic,Nx/Nx,,Nodal stage,None,2,1,3,No,1:No,1:No,,0.89
4733,3285050,Table 1,BaselineCharacteristic,xx/x,,Nodal stage,None,2,2,3,No,1:No,1:No,,0.9
4733,3285050,Table 1,BaselineCharacteristic,Chemotherapy,,Chemotherapy,None,3,0,2,No,1:No,1:No,,0.96
4733,3285050,Table 1,BaselineCharacteristic,yes/no,,Chemotherapy,None,3,1,3,No,1:No,1:No,,0.9
4733,3285050,Table 1,BaselineCharacteristic,xx/xx,,Chemotherapy,None,3,2,3,No,1:No,1:No,,0.91
4733,3285050,Table 1,BaselineCharacteristic,Hormone-therapy,,Hormone-therapy,None,4,0,2,No,1:No,1:No,,0.97
4733,3285050,Table 1,BaselineCharacteristic,yes/no,,Hormone-therapy,None,4,1,3,No,1:No,1:No,,0.89
4733,3285050,Table 1,BaselineCharacteristic,xx/x,,Hormone-therapy,None,4,2,3,No,1:No,1:No,,0.91
4733,3285050,Table 1,BaselineCharacteristic,Follow-up (months),,Follow-up (months),None,5,0,2,No,1:No,1:No,,0.97
4733,3285050,Table 1,BaselineCharacteristic,xx (xx-xx),,Follow-up (months),None,5,2,3,No,1:No,1:No,,0.526
4744,3291838,Table 1,BaselineCharacteristic,Parameter,,None,None,0,0,12,No,1:No,1:No,,0.915
4744,3291838,Table 1,BaselineCharacteristic,Value,,Parameter,None,0,1,1,No,1:No,1:No,,0.913
4744,3291838,Table 1,BaselineCharacteristic,"Number of patients, n",Parameter ; ,"Number of patients, n",,1,0,2,No,1:No,1:No,,0.826
4744,3291838,Table 1,BaselineCharacteristic,xx,Value ; ,"Number of patients, n",,1,1,3,No,1:No,1:No,,0.56
4744,3291838,Table 1,BaselineCharacteristic,"Caucasian, n (%)",Parameter ; ,"Caucasian, n (%)",,2,0,2,No,1:No,1:No,,0.806
4744,3291838,Table 1,BaselineCharacteristic,"Black, n (%)",Parameter ; ,"Black, n (%)",,3,0,2,No,1:No,1:No,,0.826
4744,3291838,Table 1,BaselineCharacteristic,x (x.x),Value ; ,"Black, n (%)",,3,1,3,No,1:No,1:No,,0.69
4744,3291838,Table 1,BaselineCharacteristic,"Female, n (%)",Parameter ; ,"Female, n (%)",,4,0,2,No,1:No,1:No,,0.846
4744,3291838,Table 1,BaselineCharacteristic,xx (xx.x),Value ; ,"Female, n (%)",,4,1,3,No,1:No,1:No,,0.501
4744,3291838,Table 1,BaselineCharacteristic,"Age, years",Parameter ; ,"Age, years",,5,0,2,No,1:No,1:No,,0.68
4744,3291838,Table 1,BaselineCharacteristic,"BSA, mx",Parameter ; ,"BSA, mx",,6,0,2,No,1:No,1:No,,0.99
4744,3291838,Table 1,BaselineCharacteristic,x.xx (x.xx–x.xx),Value ; ,"BSA, mx",,6,1,3,No,1:No,1:No,,0.776
4744,3291838,Table 1,BaselineCharacteristic,"Height, cm",Parameter ; ,"Height, cm",,7,0,2,No,1:No,1:No,,0.99
4744,3291838,Table 1,BaselineCharacteristic,xxx (xxx–xxx),Value ; ,"Height, cm",,7,1,3,No,1:No,1:No,,0.88
4744,3291838,Table 1,BaselineCharacteristic,"Weight, kg",Parameter ; ,"Weight, kg",,8,0,2,No,1:No,1:No,,0.99
4744,3291838,Table 1,BaselineCharacteristic,xx (xx–xxx),Value ; ,"Weight, kg",,8,1,3,No,1:No,1:No,,0.831
4744,3291838,Table 1,BaselineCharacteristic,BMI,Parameter ; ,BMI,,9,0,2,No,1:No,1:No,,1
4744,3291838,Table 1,BaselineCharacteristic,xx (xx–xx),Value ; ,BMI,,9,1,3,No,1:No,1:No,,0.681
4744,3291838,Table 1,BaselineCharacteristic,INR,Parameter ; ,INR,,10,0,2,No,1:No,1:No,,1
4744,3291838,Table 1,BaselineCharacteristic,x.x (x.x–x.xx),Value ; ,INR,,10,1,3,No,1:No,1:No,,0.886
4744,3291838,Table 1,BaselineCharacteristic,"Daily phenprocoumon dose, mg/day",Parameter ; ,"Daily phenprocoumon dose, mg/day",,11,0,2,No,1:No,1:No,,0.99
4744,3291838,Table 1,BaselineCharacteristic,x.xx (x.xx–x.xx),Value ; ,"Daily phenprocoumon dose, mg/day",,11,1,3,No,1:No,1:No,,0.891
4744,3291838,Table 1,BaselineCharacteristic,"Total phenprocoumon plasma concentration, mg/l",Parameter ; ,"Total phenprocoumon plasma concentration, mg/l",,12,0,2,No,1:No,1:No,,0.92
4744,3291838,Table 1,BaselineCharacteristic,x.xx (x.xx–x.xx),Value ; ,"Total phenprocoumon plasma concentration, mg/l",,12,1,3,No,1:No,1:No,,0.856
4744,3291838,Table 1,BaselineCharacteristic,Nicotine habitsa,Parameter ; ,None,None,13,0,24,No,1:No,1:No,,0.995
4744,3291838,Table 1,BaselineCharacteristic,Nicotine habitsa,Value ; ,Nicotine habitsa,None,13,1,43,No,1:No,1:No,,0.977
4744,3291838,Table 1,BaselineCharacteristic,,Parameter ; ,, Nicotine habitsa,14,0,2,No,1:No,1:No,,1
4744,3291838,Table 1,BaselineCharacteristic,x (xx.x),Value ; ,, Nicotine habitsa,14,1,3,No,1:No,1:No,,0.936
4744,3291838,Table 1,BaselineCharacteristic,,Parameter ; ,, Nicotine habitsa,15,0,2,No,1:No,1:No,,1
4744,3291838,Table 1,BaselineCharacteristic,xx (xx.x),Value ; ,, Nicotine habitsa,15,1,3,No,1:No,1:No,,0.936
4744,3291838,Table 1,BaselineCharacteristic,Alcohol consumption,Parameter ; ,None,None,16,0,24,No,1:No,1:No,,0.995
4744,3291838,Table 1,BaselineCharacteristic,Alcohol consumption,Value ; ,Alcohol consumption,None,16,1,43,No,1:No,1:No,,0.967
4744,3291838,Table 1,BaselineCharacteristic,,Parameter ; ,, Alcohol consumption,17,0,2,No,1:No,1:No,,1
4744,3291838,Table 1,BaselineCharacteristic,xx (xx.x),Value ; ,, Alcohol consumption,17,1,3,No,1:No,1:No,,0.906
4744,3291838,Table 1,BaselineCharacteristic,,Parameter ; ,, Alcohol consumption,18,0,2,No,1:No,1:No,,0.99
4744,3291838,Table 1,BaselineCharacteristic,xx (xx.x),Value ; ,, Alcohol consumption,18,1,3,No,1:No,1:No,,0.891
4744,3291838,Table 1,BaselineCharacteristic,,Parameter ; ,, Alcohol consumption,19,0,2,No,1:No,1:No,,0.99
4744,3291838,Table 1,BaselineCharacteristic,xx (xx.x),Value ; ,, Alcohol consumption,19,1,3,No,1:No,1:No,,0.891
4744,3291838,Table 1,BaselineCharacteristic,,Parameter ; ,, Alcohol consumption,20,0,2,No,1:No,1:No,,0.99
4744,3291838,Table 1,BaselineCharacteristic,xx (xx.x),Value ; ,, Alcohol consumption,20,1,3,No,1:No,1:No,,0.891
4744,3291838,Table 1,BaselineCharacteristic,Concomitant medication,Parameter ; ,None,None,21,0,24,No,1:No,1:No,,0.985
4744,3291838,Table 1,BaselineCharacteristic,Concomitant medication,Value ; ,Concomitant medication,None,21,1,43,No,1:No,1:No,,0.957
4744,3291838,Table 1,BaselineCharacteristic,,Parameter ; ,, Concomitant medication,22,0,2,No,1:No,1:No,,1
4744,3291838,Table 1,BaselineCharacteristic,xx (xx.x),Value ; ,, Concomitant medication,22,1,3,No,1:No,1:No,,0.901
4744,3291838,Table 1,BaselineCharacteristic,,Parameter ; ,, Concomitant medication,23,0,2,No,1:No,1:No,,1
4744,3291838,Table 1,BaselineCharacteristic,xx (xx.x),Value ; ,, Concomitant medication,23,1,3,No,1:No,1:No,,0.901
4744,3291838,Table 1,BaselineCharacteristic,,Parameter ; ,, Concomitant medication,24,0,2,No,1:No,1:No,,1
4744,3291838,Table 1,BaselineCharacteristic,xx (xx.x),Value ; ,, Concomitant medication,24,1,3,No,1:No,1:No,,0.901
4744,3291838,Table 1,BaselineCharacteristic,,Parameter ; ,, Concomitant medication,25,0,2,No,1:No,1:No,,1
4744,3291838,Table 1,BaselineCharacteristic,x (x.x),Value ; ,, Concomitant medication,25,1,3,No,1:No,1:No,,0.99
4744,3291838,Table 1,BaselineCharacteristic,,Parameter ; ,, Concomitant medication,26,0,2,No,1:No,1:No,,1
4744,3291838,Table 1,BaselineCharacteristic,xx (xx.x),Value ; ,, Concomitant medication,26,1,3,No,1:No,1:No,,0.901
4744,3291838,Table 1,BaselineCharacteristic,"Indication for anticoagulation, n (%)",Parameter ; ,None,None,27,0,24,No,1:No,1:No,,0.94
4744,3291838,Table 1,BaselineCharacteristic,"Indication for anticoagulation, n (%)",Value ; ,"Indication for anticoagulation, n (%)",None,27,1,43,No,1:No,1:No,,0.93
4744,3291838,Table 1,BaselineCharacteristic,,Parameter ; ,," Indication for anticoagulation, n (%)",28,0,2,No,1:No,1:No,,0.936
4744,3291838,Table 1,BaselineCharacteristic,xx (xx.x),Value ; ,," Indication for anticoagulation, n (%)",28,1,3,No,1:No,1:No,,0.751
4744,3291838,Table 1,BaselineCharacteristic,,Parameter ; ,," Indication for anticoagulation, n (%)",29,0,2,No,1:No,1:No,,0.936
4744,3291838,Table 1,BaselineCharacteristic,xx (xx.x),Value ; ,," Indication for anticoagulation, n (%)",29,1,3,No,1:No,1:No,,0.751
4744,3291838,Table 1,BaselineCharacteristic,,Parameter ; ,," Indication for anticoagulation, n (%)",30,0,2,No,1:No,1:No,,0.936
4744,3291838,Table 1,BaselineCharacteristic,x (x.x),Value ; ,," Indication for anticoagulation, n (%)",30,1,3,No,1:No,1:No,,0.93
4744,3291838,Table 1,BaselineCharacteristic,,Parameter ; ,," Indication for anticoagulation, n (%)",31,0,2,No,1:No,1:No,,0.936
4744,3291838,Table 1,BaselineCharacteristic,xx (xx.x),Value ; ,," Indication for anticoagulation, n (%)",31,1,3,No,1:No,1:No,,0.751
4744,3291838,Table 3,BaselineCharacteristic,Parameter,,None,None,0,0,12,No,1:No,1:No,,0.915
4744,3291838,Table 3,BaselineCharacteristic,n,,Parameter,None,0,1,1,No,1:No,1:No,,0.744
4744,3291838,Table 3,BaselineCharacteristic,"Daily phenprocoumon dose, mg",,Parameter,None,0,2,1,No,1:No,1:No,,0.876
4744,3291838,Table 3,BaselineCharacteristic,p value*,,Parameter,None,0,3,1,No,1:No,1:No,,0.915
4744,3291838,Table 3,BaselineCharacteristic,"Phenprocoumon concentration, mg/l",,Parameter,None,0,4,1,No,1:No,1:No,,0.925
4744,3291838,Table 3,BaselineCharacteristic,p value*,,Parameter,None,0,5,1,No,1:No,1:No,,0.936
4744,3291838,Table 3,BaselineCharacteristic,VKORCx c.-xxxx,Parameter ; ,None,None,1,0,24,No,1:No,1:No,,0.897
4744,3291838,Table 3,BaselineCharacteristic,VKORCx c.-xxxx,n ; ,VKORCx c.-xxxx,None,1,1,43,No,1:No,1:No,,0.779
4744,3291838,Table 3,BaselineCharacteristic,VKORCx c.-xxxx,"Daily phenprocoumon dose, mg ; ",VKORCx c.-xxxx,None,1,2,43,No,1:No,1:No,,0.822
4744,3291838,Table 3,BaselineCharacteristic,VKORCx c.-xxxx,p value* ; ,VKORCx c.-xxxx,None,1,3,43,No,1:No,1:No,,0.874
4744,3291838,Table 3,BaselineCharacteristic,VKORCx c.-xxxx,"Phenprocoumon concentration, mg/l ; ",VKORCx c.-xxxx,None,1,4,43,No,1:No,1:No,,0.854
4744,3291838,Table 3,BaselineCharacteristic,VKORCx c.-xxxx,p value* ; ,VKORCx c.-xxxx,None,1,5,43,No,1:No,1:No,,0.864
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, VKORCx c.-xxxx,2,0,2,No,1:No,1:No,,0.94
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, VKORCx c.-xxxx,2,1,3,No,1:No,1:No,,0.566
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, VKORCx c.-xxxx,2,2,3,No,1:No,1:No,,0.732
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, VKORCx c.-xxxx,2,3,3,No,1:No,1:No,,0.88
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, VKORCx c.-xxxx,2,4,3,No,1:No,1:No,,0.682
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, VKORCx c.-xxxx,2,5,3,No,1:No,1:No,,0.89
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, VKORCx c.-xxxx,3,0,2,No,1:No,1:No,,0.94
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, VKORCx c.-xxxx,3,1,3,No,1:No,1:No,,0.556
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, VKORCx c.-xxxx,3,2,3,No,1:No,1:No,,0.736
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, VKORCx c.-xxxx,3,3,3,No,1:No,1:No,,0.88
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, VKORCx c.-xxxx,3,4,3,No,1:No,1:No,,0.686
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, VKORCx c.-xxxx,3,5,3,No,1:No,1:No,,0.89
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, VKORCx c.-xxxx,4,0,2,No,1:No,1:No,,0.95
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, VKORCx c.-xxxx,4,1,3,No,1:No,1:No,,0.611
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, VKORCx c.-xxxx,4,2,3,No,1:No,1:No,,0.766
4744,3291838,Table 3,BaselineCharacteristic,<x.xxx,p value* ; ,, VKORCx c.-xxxx,4,3,3,No,1:No,1:No,,0.8
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, VKORCx c.-xxxx,4,4,3,No,1:No,1:No,,0.756
4744,3291838,Table 3,BaselineCharacteristic,<x.xxx,p value* ; ,, VKORCx c.-xxxx,4,5,3,No,1:No,1:No,,0.8
4744,3291838,Table 3,BaselineCharacteristic,CYPxCx,Parameter ; ,None,None,5,0,24,No,1:No,1:No,,0.939
4744,3291838,Table 3,BaselineCharacteristic,CYPxCx,n ; ,CYPxCx,None,5,1,43,No,1:No,1:No,,0.782
4744,3291838,Table 3,BaselineCharacteristic,CYPxCx,"Daily phenprocoumon dose, mg ; ",CYPxCx,None,5,2,43,No,1:No,1:No,,0.874
4744,3291838,Table 3,BaselineCharacteristic,CYPxCx,p value* ; ,CYPxCx,None,5,3,43,No,1:No,1:No,,0.913
4744,3291838,Table 3,BaselineCharacteristic,CYPxCx,"Phenprocoumon concentration, mg/l ; ",CYPxCx,None,5,4,43,No,1:No,1:No,,0.883
4744,3291838,Table 3,BaselineCharacteristic,CYPxCx,p value* ; ,CYPxCx,None,5,5,43,No,1:No,1:No,,0.893
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, CYPxCx,6,0,2,No,1:No,1:No,,0.99
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, CYPxCx,6,1,3,No,1:No,1:No,,0.641
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, CYPxCx,6,2,3,No,1:No,1:No,,0.796
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, CYPxCx,6,3,3,No,1:No,1:No,,0.96
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, CYPxCx,6,4,3,No,1:No,1:No,,0.796
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, CYPxCx,6,5,3,No,1:No,1:No,,0.94
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, CYPxCx,7,0,2,No,1:No,1:No,,0.99
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, CYPxCx,7,1,3,No,1:No,1:No,,0.681
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, CYPxCx,7,2,3,No,1:No,1:No,,0.826
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, CYPxCx,7,3,3,No,1:No,1:No,,0.96
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, CYPxCx,7,4,3,No,1:No,1:No,,0.836
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, CYPxCx,7,5,3,No,1:No,1:No,,0.95
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, CYPxCx,8,0,2,No,1:No,1:No,,0.99
4744,3291838,Table 3,BaselineCharacteristic,x,n ; ,, CYPxCx,8,1,3,No,1:No,1:No,,0.856
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, CYPxCx,8,2,3,No,1:No,1:No,,0.836
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, CYPxCx,8,3,3,No,1:No,1:No,,0.97
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, CYPxCx,8,4,3,No,1:No,1:No,,0.846
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, CYPxCx,8,5,3,No,1:No,1:No,,0.97
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, CYPxCx,9,0,2,No,1:No,1:No,,1
4744,3291838,Table 3,BaselineCharacteristic,x,n ; ,, CYPxCx,9,1,3,No,1:No,1:No,,0.856
4744,3291838,Table 3,BaselineCharacteristic,–,"Daily phenprocoumon dose, mg ; ",, CYPxCx,9,2,3,No,1:No,1:No,,0.911
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, CYPxCx,9,3,3,No,1:No,1:No,,0.98
4744,3291838,Table 3,BaselineCharacteristic,–,"Phenprocoumon concentration, mg/l ; ",, CYPxCx,9,4,3,No,1:No,1:No,,0.96
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, CYPxCx,9,5,3,No,1:No,1:No,,0.98
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, CYPxCx,10,0,2,No,1:No,1:No,,1
4744,3291838,Table 3,BaselineCharacteristic,x,n ; ,, CYPxCx,10,1,3,No,1:No,1:No,,0.876
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx),"Daily phenprocoumon dose, mg ; ",, CYPxCx,10,2,3,No,1:No,1:No,,0.896
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, CYPxCx,10,3,3,No,1:No,1:No,,1
4744,3291838,Table 3,BaselineCharacteristic,x.x (x.x),"Phenprocoumon concentration, mg/l ; ",, CYPxCx,10,4,3,No,1:No,1:No,,1
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, CYPxCx,10,5,3,No,1:No,1:No,,1
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, CYPxCx,11,0,2,No,1:No,1:No,,1
4744,3291838,Table 3,BaselineCharacteristic,x,n ; ,, CYPxCx,11,1,3,No,1:No,1:No,,0.886
4744,3291838,Table 3,BaselineCharacteristic,–,"Daily phenprocoumon dose, mg ; ",, CYPxCx,11,2,3,No,1:No,1:No,,0.931
4744,3291838,Table 3,BaselineCharacteristic,x.xxx,p value* ; ,, CYPxCx,11,3,3,No,1:No,1:No,,0.97
4744,3291838,Table 3,BaselineCharacteristic,–,"Phenprocoumon concentration, mg/l ; ",, CYPxCx,11,4,3,No,1:No,1:No,,0.97
4744,3291838,Table 3,BaselineCharacteristic,<x.xxx,p value* ; ,, CYPxCx,11,5,3,No,1:No,1:No,,0.95
4744,3291838,Table 3,BaselineCharacteristic,CYPxFx c.xxxx,Parameter ; ,None,None,12,0,24,No,1:No,1:No,,0.975
4744,3291838,Table 3,BaselineCharacteristic,CYPxFx c.xxxx,n ; ,CYPxFx c.xxxx,None,12,1,43,No,1:No,1:No,,0.937
4744,3291838,Table 3,BaselineCharacteristic,CYPxFx c.xxxx,"Daily phenprocoumon dose, mg ; ",CYPxFx c.xxxx,None,12,2,43,No,1:No,1:No,,0.905
4744,3291838,Table 3,BaselineCharacteristic,CYPxFx c.xxxx,p value* ; ,CYPxFx c.xxxx,None,12,3,43,No,1:No,1:No,,0.964
4744,3291838,Table 3,BaselineCharacteristic,CYPxFx c.xxxx,"Phenprocoumon concentration, mg/l ; ",CYPxFx c.xxxx,None,12,4,43,No,1:No,1:No,,0.964
4744,3291838,Table 3,BaselineCharacteristic,CYPxFx c.xxxx,p value* ; ,CYPxFx c.xxxx,None,12,5,43,No,1:No,1:No,,0.964
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, CYPxFx c.xxxx,13,0,2,No,1:No,1:No,,0.98
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, CYPxFx c.xxxx,13,1,3,No,1:No,1:No,,0.826
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, CYPxFx c.xxxx,13,2,3,No,1:No,1:No,,0.901
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, CYPxFx c.xxxx,13,3,3,No,1:No,1:No,,0.96
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, CYPxFx c.xxxx,13,4,3,No,1:No,1:No,,0.91
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, CYPxFx c.xxxx,13,5,3,No,1:No,1:No,,0.97
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, CYPxFx c.xxxx,14,0,2,No,1:No,1:No,,0.98
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, CYPxFx c.xxxx,14,1,3,No,1:No,1:No,,0.846
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, CYPxFx c.xxxx,14,2,3,No,1:No,1:No,,0.901
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, CYPxFx c.xxxx,14,3,3,No,1:No,1:No,,0.96
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, CYPxFx c.xxxx,14,4,3,No,1:No,1:No,,0.92
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, CYPxFx c.xxxx,14,5,3,No,1:No,1:No,,0.97
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, CYPxFx c.xxxx,15,0,2,No,1:No,1:No,,0.98
4744,3291838,Table 3,BaselineCharacteristic,x,n ; ,, CYPxFx c.xxxx,15,1,3,No,1:No,1:No,,0.896
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, CYPxFx c.xxxx,15,2,3,No,1:No,1:No,,0.901
4744,3291838,Table 3,BaselineCharacteristic,x.xxx,p value* ; ,, CYPxFx c.xxxx,15,3,3,No,1:No,1:No,,0.95
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, CYPxFx c.xxxx,15,4,3,No,1:No,1:No,,0.92
4744,3291838,Table 3,BaselineCharacteristic,x.xxx,p value* ; ,, CYPxFx c.xxxx,15,5,3,No,1:No,1:No,,0.96
4744,3291838,Table 3,BaselineCharacteristic,CALU c.*x,Parameter ; ,None,None,16,0,24,No,1:No,1:No,,0.975
4744,3291838,Table 3,BaselineCharacteristic,CALU c.*x,n ; ,CALU c.*x,None,16,1,43,No,1:No,1:No,,0.899
4744,3291838,Table 3,BaselineCharacteristic,CALU c.*x,"Daily phenprocoumon dose, mg ; ",CALU c.*x,None,16,2,43,No,1:No,1:No,,0.889
4744,3291838,Table 3,BaselineCharacteristic,CALU c.*x,p value* ; ,CALU c.*x,None,16,3,43,No,1:No,1:No,,0.942
4744,3291838,Table 3,BaselineCharacteristic,CALU c.*x,"Phenprocoumon concentration, mg/l ; ",CALU c.*x,None,16,4,43,No,1:No,1:No,,0.952
4744,3291838,Table 3,BaselineCharacteristic,CALU c.*x,p value* ; ,CALU c.*x,None,16,5,43,No,1:No,1:No,,0.952
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, CALU c.*x,17,0,2,No,1:No,1:No,,0.98
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, CALU c.*x,17,1,3,No,1:No,1:No,,0.801
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, CALU c.*x,17,2,3,No,1:No,1:No,,0.866
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, CALU c.*x,17,3,3,No,1:No,1:No,,0.96
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, CALU c.*x,17,4,3,No,1:No,1:No,,0.896
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, CALU c.*x,17,5,3,No,1:No,1:No,,0.97
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, CALU c.*x,18,0,2,No,1:No,1:No,,0.98
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, CALU c.*x,18,1,3,No,1:No,1:No,,0.797
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, CALU c.*x,18,2,3,No,1:No,1:No,,0.862
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, CALU c.*x,18,3,3,No,1:No,1:No,,0.96
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, CALU c.*x,18,4,3,No,1:No,1:No,,0.891
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, CALU c.*x,18,5,3,No,1:No,1:No,,0.97
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, CALU c.*x,19,0,2,No,1:No,1:No,,0.98
4744,3291838,Table 3,BaselineCharacteristic,x,n ; ,, CALU c.*x,19,1,3,No,1:No,1:No,,0.856
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, CALU c.*x,19,2,3,No,1:No,1:No,,0.862
4744,3291838,Table 3,BaselineCharacteristic,x.xxx,p value* ; ,, CALU c.*x,19,3,3,No,1:No,1:No,,0.94
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, CALU c.*x,19,4,3,No,1:No,1:No,,0.891
4744,3291838,Table 3,BaselineCharacteristic,x.xxx,p value* ; ,, CALU c.*x,19,5,3,No,1:No,1:No,,0.95
4744,3291838,Table 3,BaselineCharacteristic,EPHXx c.xxx,Parameter ; ,None,None,20,0,24,No,1:No,1:No,,0.902
4744,3291838,Table 3,BaselineCharacteristic,EPHXx c.xxx,n ; ,EPHXx c.xxx,None,20,1,43,No,1:No,1:No,,0.842
4744,3291838,Table 3,BaselineCharacteristic,EPHXx c.xxx,"Daily phenprocoumon dose, mg ; ",EPHXx c.xxx,None,20,2,43,No,1:No,1:No,,0.842
4744,3291838,Table 3,BaselineCharacteristic,EPHXx c.xxx,p value* ; ,EPHXx c.xxx,None,20,3,43,No,1:No,1:No,,0.875
4744,3291838,Table 3,BaselineCharacteristic,EPHXx c.xxx,"Phenprocoumon concentration, mg/l ; ",EPHXx c.xxx,None,20,4,43,No,1:No,1:No,,0.885
4744,3291838,Table 3,BaselineCharacteristic,EPHXx c.xxx,p value* ; ,EPHXx c.xxx,None,20,5,43,No,1:No,1:No,,0.885
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, EPHXx c.xxx,21,0,2,No,1:No,1:No,,0.898
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, EPHXx c.xxx,21,1,3,No,1:No,1:No,,0.761
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, EPHXx c.xxx,21,2,3,No,1:No,1:No,,0.806
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, EPHXx c.xxx,21,3,3,No,1:No,1:No,,0.9
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, EPHXx c.xxx,21,4,3,No,1:No,1:No,,0.836
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, EPHXx c.xxx,21,5,3,No,1:No,1:No,,0.91
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, EPHXx c.xxx,22,0,2,No,1:No,1:No,,0.898
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, EPHXx c.xxx,22,1,3,No,1:No,1:No,,0.771
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, EPHXx c.xxx,22,2,3,No,1:No,1:No,,0.806
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, EPHXx c.xxx,22,3,3,No,1:No,1:No,,0.9
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, EPHXx c.xxx,22,4,3,No,1:No,1:No,,0.836
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, EPHXx c.xxx,22,5,3,No,1:No,1:No,,0.91
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, EPHXx c.xxx,23,0,2,No,1:No,1:No,,0.898
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, EPHXx c.xxx,23,1,3,No,1:No,1:No,,0.771
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, EPHXx c.xxx,23,2,3,No,1:No,1:No,,0.806
4744,3291838,Table 3,BaselineCharacteristic,x.xxx,p value* ; ,, EPHXx c.xxx,23,3,3,No,1:No,1:No,,0.94
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, EPHXx c.xxx,23,4,3,No,1:No,1:No,,0.836
4744,3291838,Table 3,BaselineCharacteristic,x.xxx,p value* ; ,, EPHXx c.xxx,23,5,3,No,1:No,1:No,,0.95
4744,3291838,Table 3,BaselineCharacteristic,Fx c.-xxx,Parameter ; ,None,None,24,0,24,No,1:No,1:No,,0.975
4744,3291838,Table 3,BaselineCharacteristic,Fx c.-xxx,n ; ,Fx c.-xxx,None,24,1,43,No,1:No,1:No,,0.909
4744,3291838,Table 3,BaselineCharacteristic,Fx c.-xxx,"Daily phenprocoumon dose, mg ; ",Fx c.-xxx,None,24,2,43,No,1:No,1:No,,0.889
4744,3291838,Table 3,BaselineCharacteristic,Fx c.-xxx,p value* ; ,Fx c.-xxx,None,24,3,43,No,1:No,1:No,,0.942
4744,3291838,Table 3,BaselineCharacteristic,Fx c.-xxx,"Phenprocoumon concentration, mg/l ; ",Fx c.-xxx,None,24,4,43,No,1:No,1:No,,0.952
4744,3291838,Table 3,BaselineCharacteristic,Fx c.-xxx,p value* ; ,Fx c.-xxx,None,24,5,43,No,1:No,1:No,,0.952
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, Fx c.-xxx,25,0,2,No,1:No,1:No,,0.98
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, Fx c.-xxx,25,1,3,No,1:No,1:No,,0.861
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.x–x.xx),"Daily phenprocoumon dose, mg ; ",, Fx c.-xxx,25,2,3,No,1:No,1:No,,0.866
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, Fx c.-xxx,25,3,3,No,1:No,1:No,,0.96
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, Fx c.-xxx,25,4,3,No,1:No,1:No,,0.896
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, Fx c.-xxx,25,5,3,No,1:No,1:No,,0.97
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, Fx c.-xxx,26,0,2,No,1:No,1:No,,0.98
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, Fx c.-xxx,26,1,3,No,1:No,1:No,,0.861
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, Fx c.-xxx,26,2,3,No,1:No,1:No,,0.866
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, Fx c.-xxx,26,3,3,No,1:No,1:No,,0.96
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, Fx c.-xxx,26,4,3,No,1:No,1:No,,0.896
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, Fx c.-xxx,26,5,3,No,1:No,1:No,,0.97
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, Fx c.-xxx,27,0,2,No,1:No,1:No,,0.98
4744,3291838,Table 3,BaselineCharacteristic,x,n ; ,, Fx c.-xxx,27,1,3,No,1:No,1:No,,0.876
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, Fx c.-xxx,27,2,3,No,1:No,1:No,,0.866
4744,3291838,Table 3,BaselineCharacteristic,x.xxx,p value* ; ,, Fx c.-xxx,27,3,3,No,1:No,1:No,,0.94
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, Fx c.-xxx,27,4,3,No,1:No,1:No,,0.896
4744,3291838,Table 3,BaselineCharacteristic,x.xxx,p value* ; ,, Fx c.-xxx,27,5,3,No,1:No,1:No,,0.95
4744,3291838,Table 3,BaselineCharacteristic,Fx c.-xxx,Parameter ; ,None,None,28,0,24,No,1:No,1:No,,0.975
4744,3291838,Table 3,BaselineCharacteristic,Fx c.-xxx,n ; ,Fx c.-xxx,None,28,1,43,No,1:No,1:No,,0.909
4744,3291838,Table 3,BaselineCharacteristic,Fx c.-xxx,"Daily phenprocoumon dose, mg ; ",Fx c.-xxx,None,28,2,43,No,1:No,1:No,,0.889
4744,3291838,Table 3,BaselineCharacteristic,Fx c.-xxx,p value* ; ,Fx c.-xxx,None,28,3,43,No,1:No,1:No,,0.942
4744,3291838,Table 3,BaselineCharacteristic,Fx c.-xxx,"Phenprocoumon concentration, mg/l ; ",Fx c.-xxx,None,28,4,43,No,1:No,1:No,,0.952
4744,3291838,Table 3,BaselineCharacteristic,Fx c.-xxx,p value* ; ,Fx c.-xxx,None,28,5,43,No,1:No,1:No,,0.952
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, Fx c.-xxx,29,0,2,No,1:No,1:No,,0.98
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, Fx c.-xxx,29,1,3,No,1:No,1:No,,0.861
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, Fx c.-xxx,29,2,3,No,1:No,1:No,,0.866
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, Fx c.-xxx,29,3,3,No,1:No,1:No,,0.96
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, Fx c.-xxx,29,4,3,No,1:No,1:No,,0.896
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, Fx c.-xxx,29,5,3,No,1:No,1:No,,0.97
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, Fx c.-xxx,30,0,2,No,1:No,1:No,,0.98
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, Fx c.-xxx,30,1,3,No,1:No,1:No,,0.861
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, Fx c.-xxx,30,2,3,No,1:No,1:No,,0.866
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, Fx c.-xxx,30,3,3,No,1:No,1:No,,0.96
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, Fx c.-xxx,30,4,3,No,1:No,1:No,,0.896
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, Fx c.-xxx,30,5,3,No,1:No,1:No,,0.97
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, Fx c.-xxx,31,0,2,No,1:No,1:No,,0.98
4744,3291838,Table 3,BaselineCharacteristic,x,n ; ,, Fx c.-xxx,31,1,3,No,1:No,1:No,,0.876
4744,3291838,Table 3,BaselineCharacteristic,–,"Daily phenprocoumon dose, mg ; ",, Fx c.-xxx,31,2,3,No,1:No,1:No,,0.871
4744,3291838,Table 3,BaselineCharacteristic,x.xxx,p value* ; ,, Fx c.-xxx,31,3,3,No,1:No,1:No,,0.94
4744,3291838,Table 3,BaselineCharacteristic,–,"Phenprocoumon concentration, mg/l ; ",, Fx c.-xxx,31,4,3,No,1:No,1:No,,0.94
4744,3291838,Table 3,BaselineCharacteristic,x.xxx,p value* ; ,, Fx c.-xxx,31,5,3,No,1:No,1:No,,0.95
4744,3291838,Table 3,BaselineCharacteristic,GGCX c.xxx+xxx,Parameter ; ,None,None,32,0,24,No,1:No,1:No,,0.975
4744,3291838,Table 3,BaselineCharacteristic,GGCX c.xxx+xxx,n ; ,GGCX c.xxx+xxx,None,32,1,43,No,1:No,1:No,,0.909
4744,3291838,Table 3,BaselineCharacteristic,GGCX c.xxx+xxx,"Daily phenprocoumon dose, mg ; ",GGCX c.xxx+xxx,None,32,2,43,No,1:No,1:No,,0.889
4744,3291838,Table 3,BaselineCharacteristic,GGCX c.xxx+xxx,p value* ; ,GGCX c.xxx+xxx,None,32,3,43,No,1:No,1:No,,0.949
4744,3291838,Table 3,BaselineCharacteristic,GGCX c.xxx+xxx,"Phenprocoumon concentration, mg/l ; ",GGCX c.xxx+xxx,None,32,4,43,No,1:No,1:No,,0.959
4744,3291838,Table 3,BaselineCharacteristic,GGCX c.xxx+xxx,p value* ; ,GGCX c.xxx+xxx,None,32,5,43,No,1:No,1:No,,0.959
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, GGCX c.xxx+xxx,33,0,2,No,1:No,1:No,,0.98
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, GGCX c.xxx+xxx,33,1,3,No,1:No,1:No,,0.827
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, GGCX c.xxx+xxx,33,2,3,No,1:No,1:No,,0.872
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, GGCX c.xxx+xxx,33,3,3,No,1:No,1:No,,0.96
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, GGCX c.xxx+xxx,33,4,3,No,1:No,1:No,,0.901
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, GGCX c.xxx+xxx,33,5,3,No,1:No,1:No,,0.97
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, GGCX c.xxx+xxx,34,0,2,No,1:No,1:No,,0.98
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, GGCX c.xxx+xxx,34,1,3,No,1:No,1:No,,0.827
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, GGCX c.xxx+xxx,34,2,3,No,1:No,1:No,,0.872
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, GGCX c.xxx+xxx,34,3,3,No,1:No,1:No,,0.96
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, GGCX c.xxx+xxx,34,4,3,No,1:No,1:No,,0.901
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, GGCX c.xxx+xxx,34,5,3,No,1:No,1:No,,0.97
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, GGCX c.xxx+xxx,35,0,2,No,1:No,1:No,,0.98
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, GGCX c.xxx+xxx,35,1,3,No,1:No,1:No,,0.827
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, GGCX c.xxx+xxx,35,2,3,No,1:No,1:No,,0.872
4744,3291838,Table 3,BaselineCharacteristic,x.xxx,p value* ; ,, GGCX c.xxx+xxx,35,3,3,No,1:No,1:No,,0.96
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, GGCX c.xxx+xxx,35,4,3,No,1:No,1:No,,0.901
4744,3291838,Table 3,BaselineCharacteristic,x.xxx,p value* ; ,, GGCX c.xxx+xxx,35,5,3,No,1:No,1:No,,0.97
4744,3291838,Table 3,BaselineCharacteristic,PROC c.-xxx,Parameter ; ,None,None,36,0,24,No,1:No,1:No,,0.975
4744,3291838,Table 3,BaselineCharacteristic,PROC c.-xxx,n ; ,PROC c.-xxx,None,36,1,43,No,1:No,1:No,,0.936
4744,3291838,Table 3,BaselineCharacteristic,PROC c.-xxx,"Daily phenprocoumon dose, mg ; ",PROC c.-xxx,None,36,2,43,No,1:No,1:No,,0.895
4744,3291838,Table 3,BaselineCharacteristic,PROC c.-xxx,p value* ; ,PROC c.-xxx,None,36,3,43,No,1:No,1:No,,0.95
4744,3291838,Table 3,BaselineCharacteristic,PROC c.-xxx,"Phenprocoumon concentration, mg/l ; ",PROC c.-xxx,None,36,4,43,No,1:No,1:No,,0.96
4744,3291838,Table 3,BaselineCharacteristic,PROC c.-xxx,p value* ; ,PROC c.-xxx,None,36,5,43,No,1:No,1:No,,0.96
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, PROC c.-xxx,37,0,2,No,1:No,1:No,,0.98
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, PROC c.-xxx,37,1,3,No,1:No,1:No,,0.901
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, PROC c.-xxx,37,2,3,No,1:No,1:No,,0.881
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, PROC c.-xxx,37,3,3,No,1:No,1:No,,0.96
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, PROC c.-xxx,37,4,3,No,1:No,1:No,,0.906
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, PROC c.-xxx,37,5,3,No,1:No,1:No,,0.97
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, PROC c.-xxx,38,0,2,No,1:No,1:No,,0.98
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, PROC c.-xxx,38,1,3,No,1:No,1:No,,0.901
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, PROC c.-xxx,38,2,3,No,1:No,1:No,,0.881
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, PROC c.-xxx,38,3,3,No,1:No,1:No,,0.96
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, PROC c.-xxx,38,4,3,No,1:No,1:No,,0.906
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, PROC c.-xxx,38,5,3,No,1:No,1:No,,0.97
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, PROC c.-xxx,39,0,2,No,1:No,1:No,,0.98
4744,3291838,Table 3,BaselineCharacteristic,x,n ; ,, PROC c.-xxx,39,1,3,No,1:No,1:No,,0.896
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, PROC c.-xxx,39,2,3,No,1:No,1:No,,0.881
4744,3291838,Table 3,BaselineCharacteristic,x.xxx,p value* ; ,, PROC c.-xxx,39,3,3,No,1:No,1:No,,0.95
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, PROC c.-xxx,39,4,3,No,1:No,1:No,,0.906
4744,3291838,Table 3,BaselineCharacteristic,x.xxx,p value* ; ,, PROC c.-xxx,39,5,3,No,1:No,1:No,,0.96
4744,3291838,Table 3,BaselineCharacteristic,PROC c.-xxx,Parameter ; ,None,None,40,0,24,No,1:No,1:No,,0.975
4744,3291838,Table 3,BaselineCharacteristic,PROC c.-xxx,n ; ,PROC c.-xxx,None,40,1,43,No,1:No,1:No,,0.936
4744,3291838,Table 3,BaselineCharacteristic,PROC c.-xxx,"Daily phenprocoumon dose, mg ; ",PROC c.-xxx,None,40,2,43,No,1:No,1:No,,0.895
4744,3291838,Table 3,BaselineCharacteristic,PROC c.-xxx,p value* ; ,PROC c.-xxx,None,40,3,43,No,1:No,1:No,,0.95
4744,3291838,Table 3,BaselineCharacteristic,PROC c.-xxx,"Phenprocoumon concentration, mg/l ; ",PROC c.-xxx,None,40,4,43,No,1:No,1:No,,0.96
4744,3291838,Table 3,BaselineCharacteristic,PROC c.-xxx,p value* ; ,PROC c.-xxx,None,40,5,43,No,1:No,1:No,,0.96
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, PROC c.-xxx,41,0,2,No,1:No,1:No,,0.98
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, PROC c.-xxx,41,1,3,No,1:No,1:No,,0.901
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, PROC c.-xxx,41,2,3,No,1:No,1:No,,0.881
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, PROC c.-xxx,41,3,3,No,1:No,1:No,,0.96
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, PROC c.-xxx,41,4,3,No,1:No,1:No,,0.906
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, PROC c.-xxx,41,5,3,No,1:No,1:No,,0.97
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, PROC c.-xxx,42,0,2,No,1:No,1:No,,0.98
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, PROC c.-xxx,42,1,3,No,1:No,1:No,,0.901
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, PROC c.-xxx,42,2,3,No,1:No,1:No,,0.881
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, PROC c.-xxx,42,3,3,No,1:No,1:No,,0.96
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, PROC c.-xxx,42,4,3,No,1:No,1:No,,0.906
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, PROC c.-xxx,42,5,3,No,1:No,1:No,,0.97
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, PROC c.-xxx,43,0,2,No,1:No,1:No,,0.98
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, PROC c.-xxx,43,1,3,No,1:No,1:No,,0.901
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, PROC c.-xxx,43,2,3,No,1:No,1:No,,0.881
4744,3291838,Table 3,BaselineCharacteristic,x.xxx,p value* ; ,, PROC c.-xxx,43,3,3,No,1:No,1:No,,0.95
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, PROC c.-xxx,43,4,3,No,1:No,1:No,,0.906
4744,3291838,Table 3,BaselineCharacteristic,x.xxx,p value* ; ,, PROC c.-xxx,43,5,3,No,1:No,1:No,,0.96
4744,3291838,Table 3,BaselineCharacteristic,Sex,Parameter ; ,None,None,44,0,24,No,1:No,1:No,,0.995
4744,3291838,Table 3,BaselineCharacteristic,Sex,n ; ,Sex,None,44,1,43,No,1:No,1:No,,0.885
4744,3291838,Table 3,BaselineCharacteristic,Sex,"Daily phenprocoumon dose, mg ; ",Sex,None,44,2,43,No,1:No,1:No,,0.919
4744,3291838,Table 3,BaselineCharacteristic,Sex,p value* ; ,Sex,None,44,3,43,No,1:No,1:No,,0.972
4744,3291838,Table 3,BaselineCharacteristic,Sex,"Phenprocoumon concentration, mg/l ; ",Sex,None,44,4,43,No,1:No,1:No,,0.982
4744,3291838,Table 3,BaselineCharacteristic,Sex,p value* ; ,Sex,None,44,5,43,No,1:No,1:No,,0.982
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, Sex,45,0,2,No,1:No,1:No,,1
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, Sex,45,1,3,No,1:No,1:No,,0.787
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, Sex,45,2,3,No,1:No,1:No,,0.872
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, Sex,45,3,3,No,1:No,1:No,,0.99
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, Sex,45,4,3,No,1:No,1:No,,0.911
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, Sex,45,5,3,No,1:No,1:No,,1
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, Sex,46,0,2,No,1:No,1:No,,1
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, Sex,46,1,3,No,1:No,1:No,,0.787
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, Sex,46,2,3,No,1:No,1:No,,0.872
4744,3291838,Table 3,BaselineCharacteristic,x.xxx,p value* ; ,, Sex,46,3,3,No,1:No,1:No,,0.96
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, Sex,46,4,3,No,1:No,1:No,,0.911
4744,3291838,Table 3,BaselineCharacteristic,x.xxx,p value* ; ,, Sex,46,5,3,No,1:No,1:No,,0.97
4744,3291838,Table 3,BaselineCharacteristic,Alcohol consumption,Parameter ; ,None,None,47,0,24,No,1:No,1:No,,0.995
4744,3291838,Table 3,BaselineCharacteristic,Alcohol consumption,n ; ,Alcohol consumption,None,47,1,43,No,1:No,1:No,,0.885
4744,3291838,Table 3,BaselineCharacteristic,Alcohol consumption,"Daily phenprocoumon dose, mg ; ",Alcohol consumption,None,47,2,43,No,1:No,1:No,,0.919
4744,3291838,Table 3,BaselineCharacteristic,Alcohol consumption,p value* ; ,Alcohol consumption,None,47,3,43,No,1:No,1:No,,0.972
4744,3291838,Table 3,BaselineCharacteristic,Alcohol consumption,"Phenprocoumon concentration, mg/l ; ",Alcohol consumption,None,47,4,43,No,1:No,1:No,,0.982
4744,3291838,Table 3,BaselineCharacteristic,Alcohol consumption,p value* ; ,Alcohol consumption,None,47,5,43,No,1:No,1:No,,0.982
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, Alcohol consumption,48,0,2,No,1:No,1:No,,1
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, Alcohol consumption,48,1,3,No,1:No,1:No,,0.787
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, Alcohol consumption,48,2,3,No,1:No,1:No,,0.872
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, Alcohol consumption,48,3,3,No,1:No,1:No,,0.99
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, Alcohol consumption,48,4,3,No,1:No,1:No,,0.911
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, Alcohol consumption,48,5,3,No,1:No,1:No,,1
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, Alcohol consumption,49,0,2,No,1:No,1:No,,1
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, Alcohol consumption,49,1,3,No,1:No,1:No,,0.787
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, Alcohol consumption,49,2,3,No,1:No,1:No,,0.872
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, Alcohol consumption,49,3,3,No,1:No,1:No,,0.99
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, Alcohol consumption,49,4,3,No,1:No,1:No,,0.911
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, Alcohol consumption,49,5,3,No,1:No,1:No,,1
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, Alcohol consumption,50,0,2,No,1:No,1:No,,1
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, Alcohol consumption,50,1,3,No,1:No,1:No,,0.787
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, Alcohol consumption,50,2,3,No,1:No,1:No,,0.872
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, Alcohol consumption,50,3,3,No,1:No,1:No,,0.99
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, Alcohol consumption,50,4,3,No,1:No,1:No,,0.911
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, Alcohol consumption,50,5,3,No,1:No,1:No,,1
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, Alcohol consumption,51,0,2,No,1:No,1:No,,1
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, Alcohol consumption,51,1,3,No,1:No,1:No,,0.787
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, Alcohol consumption,51,2,3,No,1:No,1:No,,0.872
4744,3291838,Table 3,BaselineCharacteristic,x.xxx,p value* ; ,, Alcohol consumption,51,3,3,No,1:No,1:No,,0.96
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, Alcohol consumption,51,4,3,No,1:No,1:No,,0.911
4744,3291838,Table 3,BaselineCharacteristic,x.xxx,p value* ; ,, Alcohol consumption,51,5,3,No,1:No,1:No,,0.97
4744,3291838,Table 3,BaselineCharacteristic,Nicotine habits,Parameter ; ,None,None,52,0,24,No,1:No,1:No,,0.995
4744,3291838,Table 3,BaselineCharacteristic,Nicotine habits,n ; ,Nicotine habits,None,52,1,43,No,1:No,1:No,,0.895
4744,3291838,Table 3,BaselineCharacteristic,Nicotine habits,"Daily phenprocoumon dose, mg ; ",Nicotine habits,None,52,2,43,No,1:No,1:No,,0.924
4744,3291838,Table 3,BaselineCharacteristic,Nicotine habits,p value* ; ,Nicotine habits,None,52,3,43,No,1:No,1:No,,0.972
4744,3291838,Table 3,BaselineCharacteristic,Nicotine habits,"Phenprocoumon concentration, mg/l ; ",Nicotine habits,None,52,4,43,No,1:No,1:No,,0.982
4744,3291838,Table 3,BaselineCharacteristic,Nicotine habits,p value* ; ,Nicotine habits,None,52,5,43,No,1:No,1:No,,0.982
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, Nicotine habits,53,0,2,No,1:No,1:No,,1
4744,3291838,Table 3,BaselineCharacteristic,x,n ; ,, Nicotine habits,53,1,3,No,1:No,1:No,,0.876
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, Nicotine habits,53,2,3,No,1:No,1:No,,0.886
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, Nicotine habits,53,3,3,No,1:No,1:No,,0.99
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, Nicotine habits,53,4,3,No,1:No,1:No,,0.931
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, Nicotine habits,53,5,3,No,1:No,1:No,,1
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, Nicotine habits,54,0,2,No,1:No,1:No,,1
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, Nicotine habits,54,1,3,No,1:No,1:No,,0.807
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, Nicotine habits,54,2,3,No,1:No,1:No,,0.886
4744,3291838,Table 3,BaselineCharacteristic,x.xxx,p value* ; ,, Nicotine habits,54,3,3,No,1:No,1:No,,0.96
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, Nicotine habits,54,4,3,No,1:No,1:No,,0.931
4744,3291838,Table 3,BaselineCharacteristic,x.xxx,p value* ; ,, Nicotine habits,54,5,3,No,1:No,1:No,,0.97
4744,3291838,Table 3,BaselineCharacteristic,Concomitant medication,Parameter ; ,None,None,55,0,24,No,1:No,1:No,,0.995
4744,3291838,Table 3,BaselineCharacteristic,Concomitant medication,n ; ,Concomitant medication,None,55,1,43,No,1:No,1:No,,0.885
4744,3291838,Table 3,BaselineCharacteristic,Concomitant medication,"Daily phenprocoumon dose, mg ; ",Concomitant medication,None,55,2,43,No,1:No,1:No,,0.919
4744,3291838,Table 3,BaselineCharacteristic,Concomitant medication,p value* ; ,Concomitant medication,None,55,3,43,No,1:No,1:No,,0.972
4744,3291838,Table 3,BaselineCharacteristic,Concomitant medication,"Phenprocoumon concentration, mg/l ; ",Concomitant medication,None,55,4,43,No,1:No,1:No,,0.982
4744,3291838,Table 3,BaselineCharacteristic,Concomitant medication,p value* ; ,Concomitant medication,None,55,5,43,No,1:No,1:No,,0.982
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, Concomitant medication,56,0,2,No,1:No,1:No,,1
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, Concomitant medication,56,1,3,No,1:No,1:No,,0.787
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, Concomitant medication,56,2,3,No,1:No,1:No,,0.872
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, Concomitant medication,56,3,3,No,1:No,1:No,,0.99
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, Concomitant medication,56,4,3,No,1:No,1:No,,0.911
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, Concomitant medication,56,5,3,No,1:No,1:No,,1
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, Concomitant medication,57,0,2,No,1:No,1:No,,1
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, Concomitant medication,57,1,3,No,1:No,1:No,,0.787
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, Concomitant medication,57,2,3,No,1:No,1:No,,0.872
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, Concomitant medication,57,3,3,No,1:No,1:No,,0.99
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, Concomitant medication,57,4,3,No,1:No,1:No,,0.911
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, Concomitant medication,57,5,3,No,1:No,1:No,,1
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, Concomitant medication,58,0,2,No,1:No,1:No,,1
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, Concomitant medication,58,1,3,No,1:No,1:No,,0.787
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, Concomitant medication,58,2,3,No,1:No,1:No,,0.872
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, Concomitant medication,58,3,3,No,1:No,1:No,,0.99
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, Concomitant medication,58,4,3,No,1:No,1:No,,0.911
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, Concomitant medication,58,5,3,No,1:No,1:No,,1
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, Concomitant medication,59,0,2,No,1:No,1:No,,1
4744,3291838,Table 3,BaselineCharacteristic,x,n ; ,, Concomitant medication,59,1,3,No,1:No,1:No,,0.866
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, Concomitant medication,59,2,3,No,1:No,1:No,,0.872
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, Concomitant medication,59,3,3,No,1:No,1:No,,0.99
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, Concomitant medication,59,4,3,No,1:No,1:No,,0.911
4744,3291838,Table 3,BaselineCharacteristic,,p value* ; ,, Concomitant medication,59,5,3,No,1:No,1:No,,1
4744,3291838,Table 3,BaselineCharacteristic,,Parameter ; ,, Concomitant medication,60,0,2,No,1:No,1:No,,1
4744,3291838,Table 3,BaselineCharacteristic,xx,n ; ,, Concomitant medication,60,1,3,No,1:No,1:No,,0.787
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Daily phenprocoumon dose, mg ; ",, Concomitant medication,60,2,3,No,1:No,1:No,,0.872
4744,3291838,Table 3,BaselineCharacteristic,x.xxx,p value* ; ,, Concomitant medication,60,3,3,No,1:No,1:No,,0.96
4744,3291838,Table 3,BaselineCharacteristic,x.xx (x.xx–x.xx),"Phenprocoumon concentration, mg/l ; ",, Concomitant medication,60,4,3,No,1:No,1:No,,0.911
4744,3291838,Table 3,BaselineCharacteristic,x.xxx,p value* ; ,, Concomitant medication,60,5,3,No,1:No,1:No,,0.97
4861,3321091,Table 2,BaselineCharacteristic, Patient ,, Patient ,None,0,0,2,No,1:No,1:No,,0.94
4861,3321091,Table 2,BaselineCharacteristic, x ,, Patient ,None,0,1,3,No,1:No,1:No,,0.89
4861,3321091,Table 2,BaselineCharacteristic, x ,, Patient ,None,0,2,3,No,1:No,1:No,,0.9
4861,3321091,Table 2,BaselineCharacteristic, x ,, Patient ,None,0,3,3,No,1:No,1:No,,0.89
4861,3321091,Table 2,BaselineCharacteristic, x ,, Patient ,None,0,4,3,No,1:No,1:No,,0.88
4861,3321091,Table 2,BaselineCharacteristic, x ,, Patient ,None,0,5,3,No,1:No,1:No,,0.89
4861,3321091,Table 2,BaselineCharacteristic, x ,, Patient ,None,0,6,3,No,1:No,1:No,,0.9
4861,3321091,Table 2,BaselineCharacteristic, x ,, Patient ,None,0,7,3,No,1:No,1:No,,0.89
4861,3321091,Table 2,BaselineCharacteristic, x ,, Patient ,None,0,8,3,No,1:No,1:No,,0.9
4861,3321091,Table 2,BaselineCharacteristic, x ,, Patient ,None,0,9,3,No,1:No,1:No,,0.9
4861,3321091,Table 2,BaselineCharacteristic, xx ,, Patient ,None,0,10,3,No,1:No,1:No,,0.702
4861,3321091,Table 2,BaselineCharacteristic, Gender ,, Gender ,None,1,0,2,No,1:No,1:No,,0.94
4861,3321091,Table 2,BaselineCharacteristic,M,, Gender ,None,1,1,3,No,1:No,1:No,,0.87
4861,3321091,Table 2,BaselineCharacteristic,M,, Gender ,None,1,2,3,No,1:No,1:No,,0.88
4861,3321091,Table 2,BaselineCharacteristic,M,, Gender ,None,1,3,3,No,1:No,1:No,,0.88
4861,3321091,Table 2,BaselineCharacteristic,M,, Gender ,None,1,4,3,No,1:No,1:No,,0.87
4861,3321091,Table 2,BaselineCharacteristic,M,, Gender ,None,1,5,3,No,1:No,1:No,,0.88
4861,3321091,Table 2,BaselineCharacteristic,M,, Gender ,None,1,6,3,No,1:No,1:No,,0.89
4861,3321091,Table 2,BaselineCharacteristic,M,, Gender ,None,1,7,3,No,1:No,1:No,,0.89
4861,3321091,Table 2,BaselineCharacteristic,M,, Gender ,None,1,8,3,No,1:No,1:No,,0.89
4861,3321091,Table 2,BaselineCharacteristic,M,, Gender ,None,1,9,3,No,1:No,1:No,,0.89
4861,3321091,Table 2,BaselineCharacteristic,M,, Gender ,None,1,10,3,No,1:No,1:No,,0.89
4861,3321091,Table 2,BaselineCharacteristic, Age (Years) ,, Age (Years) ,None,2,0,2,No,1:No,1:No,,0.95
4861,3321091,Table 2,BaselineCharacteristic,xx,, Age (Years) ,None,2,1,3,No,1:No,1:No,,0.688
4861,3321091,Table 2,BaselineCharacteristic,xx,, Age (Years) ,None,2,2,3,No,1:No,1:No,,0.678
4861,3321091,Table 2,BaselineCharacteristic,xx,, Age (Years) ,None,2,3,3,No,1:No,1:No,,0.668
4861,3321091,Table 2,BaselineCharacteristic,xx,, Age (Years) ,None,2,4,3,No,1:No,1:No,,0.688
4861,3321091,Table 2,BaselineCharacteristic,xx,, Age (Years) ,None,2,5,3,No,1:No,1:No,,0.712
4861,3321091,Table 2,BaselineCharacteristic,xx,, Age (Years) ,None,2,6,3,No,1:No,1:No,,0.712
4861,3321091,Table 2,BaselineCharacteristic,xx,, Age (Years) ,None,2,7,3,No,1:No,1:No,,0.742
4861,3321091,Table 2,BaselineCharacteristic,xx,, Age (Years) ,None,2,8,3,No,1:No,1:No,,0.752
4861,3321091,Table 2,BaselineCharacteristic,xx,, Age (Years) ,None,2,9,3,No,1:No,1:No,,0.752
4861,3321091,Table 2,BaselineCharacteristic,xx,, Age (Years) ,None,2,10,3,No,1:No,1:No,,0.752
4861,3321091,Table 2,BaselineCharacteristic, Mass (Kg) ,, Mass (Kg) ,None,3,0,2,No,1:No,1:No,,0.96
4861,3321091,Table 2,BaselineCharacteristic,xx,, Mass (Kg) ,None,3,1,3,No,1:No,1:No,,0.681
4861,3321091,Table 2,BaselineCharacteristic,xx,, Mass (Kg) ,None,3,2,3,No,1:No,1:No,,0.671
4861,3321091,Table 2,BaselineCharacteristic,xx,, Mass (Kg) ,None,3,3,3,No,1:No,1:No,,0.661
4861,3321091,Table 2,BaselineCharacteristic,xx,, Mass (Kg) ,None,3,4,3,No,1:No,1:No,,0.681
4861,3321091,Table 2,BaselineCharacteristic,xx,, Mass (Kg) ,None,3,5,3,No,1:No,1:No,,0.706
4861,3321091,Table 2,BaselineCharacteristic,xx,, Mass (Kg) ,None,3,6,3,No,1:No,1:No,,0.706
4861,3321091,Table 2,BaselineCharacteristic,xx,, Mass (Kg) ,None,3,7,3,No,1:No,1:No,,0.736
4861,3321091,Table 2,BaselineCharacteristic,xx,, Mass (Kg) ,None,3,8,3,No,1:No,1:No,,0.746
4861,3321091,Table 2,BaselineCharacteristic,xx,, Mass (Kg) ,None,3,9,3,No,1:No,1:No,,0.746
4861,3321091,Table 2,BaselineCharacteristic,xx,, Mass (Kg) ,None,3,10,3,No,1:No,1:No,,0.746
4861,3321091,Table 2,BaselineCharacteristic, Sitting Height  (cm) ,, Sitting Height  (cm) ,None,4,0,2,No,1:No,1:No,,0.97
4861,3321091,Table 2,BaselineCharacteristic,xx,, Sitting Height  (cm) ,None,4,1,3,No,1:No,1:No,,0.776
4861,3321091,Table 2,BaselineCharacteristic,xx,, Sitting Height  (cm) ,None,4,2,3,No,1:No,1:No,,0.786
4861,3321091,Table 2,BaselineCharacteristic,xx,, Sitting Height  (cm) ,None,4,3,3,No,1:No,1:No,,0.796
4861,3321091,Table 2,BaselineCharacteristic,xx,, Sitting Height  (cm) ,None,4,4,3,No,1:No,1:No,,0.816
4861,3321091,Table 2,BaselineCharacteristic,xx,, Sitting Height  (cm) ,None,4,5,3,No,1:No,1:No,,0.83
4861,3321091,Table 2,BaselineCharacteristic,xx,, Sitting Height  (cm) ,None,4,6,3,No,1:No,1:No,,0.83
4861,3321091,Table 2,BaselineCharacteristic,xx,, Sitting Height  (cm) ,None,4,7,3,No,1:No,1:No,,0.85
4861,3321091,Table 2,BaselineCharacteristic,xx,, Sitting Height  (cm) ,None,4,8,3,No,1:No,1:No,,0.85
4861,3321091,Table 2,BaselineCharacteristic,xx,, Sitting Height  (cm) ,None,4,9,3,No,1:No,1:No,,0.85
4861,3321091,Table 2,BaselineCharacteristic,xx,, Sitting Height  (cm) ,None,4,10,3,No,1:No,1:No,,0.85
4861,3321091,Table 2,BaselineCharacteristic,Ethiology *,,Ethiology *,None,5,0,2,No,1:No,1:No,,0.97
4861,3321091,Table 2,BaselineCharacteristic,TB,,Ethiology *,None,5,1,3,No,1:No,1:No,,0.89
4861,3321091,Table 2,BaselineCharacteristic,FAP,,Ethiology *,None,5,2,3,No,1:No,1:No,,0.91
4861,3321091,Table 2,BaselineCharacteristic,auto,,Ethiology *,None,5,3,3,No,1:No,1:No,,0.91
4861,3321091,Table 2,BaselineCharacteristic,FAP,,Ethiology *,None,5,4,3,No,1:No,1:No,,0.9
4861,3321091,Table 2,BaselineCharacteristic,auto,,Ethiology *,None,5,5,3,No,1:No,1:No,,0.89
4861,3321091,Table 2,BaselineCharacteristic,auto,,Ethiology *,None,5,6,3,No,1:No,1:No,,0.9
4861,3321091,Table 2,BaselineCharacteristic,auto,,Ethiology *,None,5,7,3,No,1:No,1:No,,0.9
4861,3321091,Table 2,BaselineCharacteristic,auto,,Ethiology *,None,5,8,3,No,1:No,1:No,,0.9
4861,3321091,Table 2,BaselineCharacteristic,auto,,Ethiology *,None,5,9,3,No,1:No,1:No,,0.9
4861,3321091,Table 2,BaselineCharacteristic,auto,,Ethiology *,None,5,10,3,No,1:No,1:No,,0.9
4861,3321091,Table 2,BaselineCharacteristic, Neurological  Level ,, Neurological  Level ,None,6,0,2,No,1:No,1:No,,0.99
4861,3321091,Table 2,BaselineCharacteristic,Txx,, Neurological  Level ,None,6,1,3,No,1:No,1:No,,0.94
4861,3321091,Table 2,BaselineCharacteristic,Tx,, Neurological  Level ,None,6,2,3,No,1:No,1:No,,0.96
4861,3321091,Table 2,BaselineCharacteristic,Tx,, Neurological  Level ,None,6,3,3,No,1:No,1:No,,0.96
4861,3321091,Table 2,BaselineCharacteristic,Txx,, Neurological  Level ,None,6,4,3,No,1:No,1:No,,0.95
4861,3321091,Table 2,BaselineCharacteristic,Txx,, Neurological  Level ,None,6,5,3,No,1:No,1:No,,0.94
4861,3321091,Table 2,BaselineCharacteristic,Tx,, Neurological  Level ,None,6,6,3,No,1:No,1:No,,0.95
4861,3321091,Table 2,BaselineCharacteristic,Tx,, Neurological  Level ,None,6,7,3,No,1:No,1:No,,0.95
4861,3321091,Table 2,BaselineCharacteristic,Tx,, Neurological  Level ,None,6,8,3,No,1:No,1:No,,0.95
4861,3321091,Table 2,BaselineCharacteristic,Tx,, Neurological  Level ,None,6,9,3,No,1:No,1:No,,0.95
4861,3321091,Table 2,BaselineCharacteristic,Tx,, Neurological  Level ,None,6,10,3,No,1:No,1:No,,0.95
4861,3321091,Table 2,BaselineCharacteristic,Total MotorASIA **,,Total MotorASIA **,None,7,0,2,No,1:No,1:No,,0.99
4861,3321091,Table 2,BaselineCharacteristic,xx,,Total MotorASIA **,None,7,1,3,No,1:No,1:No,,0.811
4861,3321091,Table 2,BaselineCharacteristic,xx,,Total MotorASIA **,None,7,2,3,No,1:No,1:No,,0.811
4861,3321091,Table 2,BaselineCharacteristic,xx,,Total MotorASIA **,None,7,3,3,No,1:No,1:No,,0.811
4861,3321091,Table 2,BaselineCharacteristic,xx,,Total MotorASIA **,None,7,4,3,No,1:No,1:No,,0.841
4861,3321091,Table 2,BaselineCharacteristic,xx,,Total MotorASIA **,None,7,5,3,No,1:No,1:No,,0.846
4861,3321091,Table 2,BaselineCharacteristic,xx,,Total MotorASIA **,None,7,6,3,No,1:No,1:No,,0.846
4861,3321091,Table 2,BaselineCharacteristic,xx,,Total MotorASIA **,None,7,7,3,No,1:No,1:No,,0.876
4861,3321091,Table 2,BaselineCharacteristic,xx,,Total MotorASIA **,None,7,8,3,No,1:No,1:No,,0.886
4861,3321091,Table 2,BaselineCharacteristic,xx,,Total MotorASIA **,None,7,9,3,No,1:No,1:No,,0.886
4861,3321091,Table 2,BaselineCharacteristic,xx,,Total MotorASIA **,None,7,10,3,No,1:No,1:No,,0.886
4861,3321091,Table 2,BaselineCharacteristic, Period of  neurological  impairement  (Years) ,, Period of  neurological  impairement  (Years) ,None,8,0,2,No,1:No,1:No,,0.99
4861,3321091,Table 2,BaselineCharacteristic,xx,, Period of  neurological  impairement  (Years) ,None,8,1,3,No,1:No,1:No,,0.841
4861,3321091,Table 2,BaselineCharacteristic,x,, Period of  neurological  impairement  (Years) ,None,8,2,3,No,1:No,1:No,,0.97
4861,3321091,Table 2,BaselineCharacteristic,x,, Period of  neurological  impairement  (Years) ,None,8,3,3,No,1:No,1:No,,0.96
4861,3321091,Table 2,BaselineCharacteristic,x,, Period of  neurological  impairement  (Years) ,None,8,4,3,No,1:No,1:No,,0.96
4861,3321091,Table 2,BaselineCharacteristic,xx,, Period of  neurological  impairement  (Years) ,None,8,5,3,No,1:No,1:No,,0.876
4861,3321091,Table 2,BaselineCharacteristic,x,, Period of  neurological  impairement  (Years) ,None,8,6,3,No,1:No,1:No,,0.97
4861,3321091,Table 2,BaselineCharacteristic,x,, Period of  neurological  impairement  (Years) ,None,8,7,3,No,1:No,1:No,,0.96
4861,3321091,Table 2,BaselineCharacteristic,xx,, Period of  neurological  impairement  (Years) ,None,8,8,3,No,1:No,1:No,,0.906
4861,3321091,Table 2,BaselineCharacteristic,x,, Period of  neurological  impairement  (Years) ,None,8,9,3,No,1:No,1:No,,0.97
4861,3321091,Table 2,BaselineCharacteristic,x,, Period of  neurological  impairement  (Years) ,None,8,10,3,No,1:No,1:No,,0.97
4861,3321091,Table 2,BaselineCharacteristic, Time interval  between  impairment and  NMES (Years)  *** ,, Time interval  between  impairment and  NMES (Years)  *** ,None,9,0,2,No,1:No,1:No,,1
4861,3321091,Table 2,BaselineCharacteristic,xx,, Time interval  between  impairment and  NMES (Years)  *** ,None,9,1,3,No,1:No,1:No,,0.891
4861,3321091,Table 2,BaselineCharacteristic,x,, Time interval  between  impairment and  NMES (Years)  *** ,None,9,2,3,No,1:No,1:No,,0.99
4861,3321091,Table 2,BaselineCharacteristic,x,, Time interval  between  impairment and  NMES (Years)  *** ,None,9,3,3,No,1:No,1:No,,0.99
4861,3321091,Table 2,BaselineCharacteristic,x,, Time interval  between  impairment and  NMES (Years)  *** ,None,9,4,3,No,1:No,1:No,,0.99
4861,3321091,Table 2,BaselineCharacteristic,x,, Time interval  between  impairment and  NMES (Years)  *** ,None,9,5,3,No,1:No,1:No,,0.99
4861,3321091,Table 2,BaselineCharacteristic,x,, Time interval  between  impairment and  NMES (Years)  *** ,None,9,6,3,No,1:No,1:No,,1
4861,3321091,Table 2,BaselineCharacteristic,x,, Time interval  between  impairment and  NMES (Years)  *** ,None,9,7,3,No,1:No,1:No,,0.99
4861,3321091,Table 2,BaselineCharacteristic,x,, Time interval  between  impairment and  NMES (Years)  *** ,None,9,8,3,No,1:No,1:No,,1
4861,3321091,Table 2,BaselineCharacteristic,x,, Time interval  between  impairment and  NMES (Years)  *** ,None,9,9,3,No,1:No,1:No,,1
4861,3321091,Table 2,BaselineCharacteristic,x,, Time interval  between  impairment and  NMES (Years)  *** ,None,9,10,3,No,1:No,1:No,,1
4861,3321091,Table 2,BaselineCharacteristic, Time interval of  NMES (Years) ,, Time interval of  NMES (Years) ,None,10,0,2,No,1:No,1:No,,0.99
4861,3321091,Table 2,BaselineCharacteristic,x,, Time interval of  NMES (Years) ,None,10,1,3,No,1:No,1:No,,0.98
4861,3321091,Table 2,BaselineCharacteristic,x,, Time interval of  NMES (Years) ,None,10,2,3,No,1:No,1:No,,0.98
4861,3321091,Table 2,BaselineCharacteristic,x,, Time interval of  NMES (Years) ,None,10,3,3,No,1:No,1:No,,0.98
4861,3321091,Table 2,BaselineCharacteristic,x,, Time interval of  NMES (Years) ,None,10,4,3,No,1:No,1:No,,0.98
4861,3321091,Table 2,BaselineCharacteristic,x,, Time interval of  NMES (Years) ,None,10,5,3,No,1:No,1:No,,0.98
4861,3321091,Table 2,BaselineCharacteristic,x,, Time interval of  NMES (Years) ,None,10,6,3,No,1:No,1:No,,0.98
4861,3321091,Table 2,BaselineCharacteristic,x,, Time interval of  NMES (Years) ,None,10,7,3,No,1:No,1:No,,0.97
4861,3321091,Table 2,BaselineCharacteristic,xx,, Time interval of  NMES (Years) ,None,10,8,3,No,1:No,1:No,,0.956
4861,3321091,Table 2,BaselineCharacteristic,x,, Time interval of  NMES (Years) ,None,10,9,3,No,1:No,1:No,,0.98
4861,3321091,Table 2,BaselineCharacteristic,x,, Time interval of  NMES (Years) ,None,10,10,3,No,1:No,1:No,,0.98
4908,3338391,Table 1,BaselineCharacteristic,Characteristics,,None,None,0,0,,No,1:No,1:No,,0.907
4908,3338391,Table 1,BaselineCharacteristic,Study sites,,None,None,0,1,,No,1:No,1:No,,0.845
4908,3338391,Table 1,BaselineCharacteristic,Study sites,,None,None,0,2,,No,1:No,1:No,,0.848
4908,3338391,Table 1,BaselineCharacteristic,Study sites,,None,None,0,3,,No,1:No,1:No,,0.857
4908,3338391,Table 1,BaselineCharacteristic,Study sites,,None,None,0,4,,No,1:No,1:No,,0.847
4908,3338391,Table 1,BaselineCharacteristic,P,,None,None,0,5,,No,1:No,1:No,,0.887
4908,3338391,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,1,0,,No,1:No,1:No,,0.905
4908,3338391,Table 1,BaselineCharacteristic,,Study sites ; ,None,None,1,1,,No,1:No,1:No,,0.842
4908,3338391,Table 1,BaselineCharacteristic,,Study sites ; ,None,None,1,2,,No,1:No,1:No,,0.845
4908,3338391,Table 1,BaselineCharacteristic,,Study sites ; ,None,None,1,3,,No,1:No,1:No,,0.854
4908,3338391,Table 1,BaselineCharacteristic,,Study sites ; ,None,None,1,4,,No,1:No,1:No,,0.844
4908,3338391,Table 1,BaselineCharacteristic,,P ; ,None,None,1,5,,No,1:No,1:No,,0.884
4908,3338391,Table 1,BaselineCharacteristic,,Characteristics ;  ; ,None,None,2,0,,No,1:No,1:No,,0.922
4908,3338391,Table 1,BaselineCharacteristic,High transmission,Study sites ;  ; ,None,None,2,1,,No,1:No,1:No,,0.621
4908,3338391,Table 1,BaselineCharacteristic,High transmission,Study sites ;  ; ,None,None,2,2,,No,1:No,1:No,,0.615
4908,3338391,Table 1,BaselineCharacteristic,Low transmission,Study sites ;  ; ,None,None,2,3,,No,1:No,1:No,,0.668
4908,3338391,Table 1,BaselineCharacteristic,Low transmission,Study sites ;  ; ,None,None,2,4,,No,1:No,1:No,,0.667
4908,3338391,Table 1,BaselineCharacteristic,,P ;  ; ,None,None,2,5,,No,1:No,1:No,,0.899
4908,3338391,Table 1,BaselineCharacteristic,,Characteristics ;  ;  ; ,None,None,3,0,,No,1:No,1:No,,0.932
4908,3338391,Table 1,BaselineCharacteristic,,Study sites ;  ; High transmission ; ,None,None,3,1,,No,1:No,1:No,,0.617
4908,3338391,Table 1,BaselineCharacteristic,,Study sites ;  ; High transmission ; ,None,None,3,2,,No,1:No,1:No,,0.611
4908,3338391,Table 1,BaselineCharacteristic,,Study sites ;  ; Low transmission ; ,None,None,3,3,,No,1:No,1:No,,0.664
4908,3338391,Table 1,BaselineCharacteristic,,Study sites ;  ; Low transmission ; ,None,None,3,4,,No,1:No,1:No,,0.663
4908,3338391,Table 1,BaselineCharacteristic,,P ;  ;  ; ,None,None,3,5,,No,1:No,1:No,,0.905
4908,3338391,Table 1,BaselineCharacteristic,,Characteristics ;  ;  ;  ; ,None,None,4,0,,No,1:No,1:No,,0.927
4908,3338391,Table 1,BaselineCharacteristic,Ampasimanjeva,Study sites ;  ; High transmission ;  ; ,None,None,4,1,,No,1:No,1:No,,0.581
4908,3338391,Table 1,BaselineCharacteristic,Vohimasy,Study sites ;  ; High transmission ;  ; ,None,None,4,2,,No,1:No,1:No,,0.574
4908,3338391,Table 1,BaselineCharacteristic,Ampasimpotsy,Study sites ;  ; Low transmission ;  ; ,None,None,4,3,,No,1:No,1:No,,0.616
4908,3338391,Table 1,BaselineCharacteristic,Andasibe,Study sites ;  ; Low transmission ;  ; ,None,None,4,4,,No,1:No,1:No,,0.613
4908,3338391,Table 1,BaselineCharacteristic,,P ;  ;  ;  ; ,None,None,4,5,,No,1:No,1:No,,0.899
4908,3338391,Table 1,BaselineCharacteristic,Cohort population,Characteristics ;  ;  ;  ;  ; ,None,None,5,0,,No,1:No,1:No,,0.849
4908,3338391,Table 1,BaselineCharacteristic,xxx,Study sites ;  ; Low transmission ;  ; Ampasimpotsy ; ,None,None,5,3,,No,1:No,1:No,,0.523
4908,3338391,Table 1,BaselineCharacteristic,xxx,Study sites ;  ; Low transmission ;  ; Andasibe ; ,None,None,5,4,,No,1:No,1:No,,0.522
4908,3338391,Table 1,BaselineCharacteristic,,P ;  ;  ;  ;  ; ,None,None,5,5,,No,1:No,1:No,,0.889
4908,3338391,Table 1,BaselineCharacteristic,,Characteristics ;  ;  ;  ;  ; Cohort population ; ,None,None,6,0,,No,1:No,1:No,,0.897
4908,3338391,Table 1,BaselineCharacteristic,,Study sites ;  ; High transmission ;  ; Ampasimanjeva ; xxx ; ,None,None,6,1,,No,1:No,1:No,,0.505
4908,3338391,Table 1,BaselineCharacteristic,,Study sites ;  ; Low transmission ;  ; Ampasimpotsy ; xxx ; ,None,None,6,3,,No,1:No,1:No,,0.561
4908,3338391,Table 1,BaselineCharacteristic,,Study sites ;  ; Low transmission ;  ; Andasibe ; xxx ; ,None,None,6,4,,No,1:No,1:No,,0.56
4908,3338391,Table 1,BaselineCharacteristic,,P ;  ;  ;  ;  ;  ; ,None,None,6,5,,No,1:No,1:No,,0.935
4908,3338391,Table 1,BaselineCharacteristic,Mean age (months),Characteristics ;  ;  ;  ;  ; Cohort population ;  ; ,None,None,7,0,,No,1:No,1:No,,0.699
4908,3338391,Table 1,BaselineCharacteristic,x.xxx,P ;  ;  ;  ;  ;  ;  ; ,None,None,7,5,,No,1:No,1:No,,0.894
4908,3338391,Table 1,BaselineCharacteristic,,Characteristics ;  ;  ;  ;  ; Cohort population ;  ; Mean age (months) ; ,None,None,8,0,,No,1:No,1:No,,0.696
4908,3338391,Table 1,BaselineCharacteristic,,P ;  ;  ;  ;  ;  ;  ; x.xxx ; ,None,None,8,5,,No,1:No,1:No,,0.918
4908,3338391,Table 1,BaselineCharacteristic,Sex ratio (M/F),Characteristics ;  ;  ;  ;  ; Cohort population ;  ; Mean age (months) ;  ; ,None,None,9,0,,No,1:No,1:No,,0.716
4908,3338391,Table 1,BaselineCharacteristic,NS,P ;  ;  ;  ;  ;  ;  ; x.xxx ;  ; ,None,None,9,5,,No,1:No,1:No,,0.936
4908,3338391,Table 1,BaselineCharacteristic,,Characteristics ;  ;  ;  ;  ; Cohort population ;  ; Mean age (months) ;  ; Sex ratio (M/F) ; ,None,None,10,0,,No,1:No,1:No,,0.735
4908,3338391,Table 1,BaselineCharacteristic,,Study sites ;  ; Low transmission ;  ; Andasibe ; xxx ;  ; xx.x ;  ; x.xx ; ,None,None,10,4,,No,1:No,1:No,,0.531
4908,3338391,Table 1,BaselineCharacteristic,,P ;  ;  ;  ;  ;  ;  ; x.xxx ;  ; NS ; ,None,None,10,5,,No,1:No,1:No,,0.959
4908,3338391,Table 1,BaselineCharacteristic,No. of febrile episodes,Characteristics ;  ;  ;  ;  ; Cohort population ;  ; Mean age (months) ;  ; Sex ratio (M/F) ;  ; ,None,None,11,0,,No,1:No,1:No,,0.735
4908,3338391,Table 1,BaselineCharacteristic,xx,Study sites ;  ; Low transmission ;  ; Andasibe ; xxx ;  ; xx.x ;  ; x.xx ;  ; ,None,None,11,4,,No,1:No,1:No,,0.531
4908,3338391,Table 1,BaselineCharacteristic,,P ;  ;  ;  ;  ;  ;  ; x.xxx ;  ; NS ;  ; ,None,None,11,5,,No,1:No,1:No,,0.959
4908,3338391,Table 1,BaselineCharacteristic,,Characteristics ;  ;  ;  ;  ; Cohort population ;  ; Mean age (months) ;  ; Sex ratio (M/F) ;  ; No. of febrile episodes ; ,None,None,12,0,,No,1:No,1:No,,0.735
4908,3338391,Table 1,BaselineCharacteristic,,Study sites ;  ; Low transmission ;  ; Andasibe ; xxx ;  ; xx.x ;  ; x.xx ;  ; xx ; ,None,None,12,4,,No,1:No,1:No,,0.531
4908,3338391,Table 1,BaselineCharacteristic,,P ;  ;  ;  ;  ;  ;  ; x.xxx ;  ; NS ;  ;  ; ,None,None,12,5,,No,1:No,1:No,,0.959
4908,3338391,Table 1,BaselineCharacteristic,PCR + (%),Characteristics ;  ;  ;  ;  ; Cohort population ;  ; Mean age (months) ;  ; Sex ratio (M/F) ;  ; No. of febrile episodes ;  ; ,None,None,13,0,,No,1:No,1:No,,0.725
4908,3338391,Table 1,BaselineCharacteristic,xx%,Study sites ;  ; Low transmission ;  ; Ampasimpotsy ; xxx ;  ; xx.x ;  ; x.xx ;  ; xx ;  ; ,None,None,13,3,,No,1:No,1:No,,0.5
4908,3338391,Table 1,BaselineCharacteristic,xx%,Study sites ;  ; Low transmission ;  ; Andasibe ; xxx ;  ; xx.x ;  ; x.xx ;  ; xx ;  ; ,None,None,13,4,,No,1:No,1:No,,0.712
4908,3338391,Table 1,BaselineCharacteristic,< x.xxxx,P ;  ;  ;  ;  ;  ;  ; x.xxx ;  ; NS ;  ;  ;  ; ,None,None,13,5,,No,1:No,1:No,,0.959
4908,3338391,Table 1,BaselineCharacteristic,,Characteristics ;  ;  ;  ;  ; Cohort population ;  ; Mean age (months) ;  ; Sex ratio (M/F) ;  ; No. of febrile episodes ;  ; PCR + (%) ; ,None,None,14,0,,No,1:No,1:No,,0.725
4908,3338391,Table 1,BaselineCharacteristic,,Study sites ;  ; Low transmission ;  ; Ampasimpotsy ; xxx ;  ; xx.x ;  ; x.xx ;  ; xx ;  ; xx% ; ,None,None,14,3,,No,1:No,1:No,,0.51
4908,3338391,Table 1,BaselineCharacteristic,,Study sites ;  ; Low transmission ;  ; Andasibe ; xxx ;  ; xx.x ;  ; x.xx ;  ; xx ;  ; xx% ; ,None,None,14,4,,No,1:No,1:No,,0.722
4908,3338391,Table 1,BaselineCharacteristic,,P ;  ;  ;  ;  ;  ;  ; x.xxx ;  ; NS ;  ;  ;  ; < x.xxxx ; ,None,None,14,5,,No,1:No,1:No,,0.959
4908,3338391,Table 1,BaselineCharacteristic,Microscopy + (%),Characteristics ;  ;  ;  ;  ; Cohort population ;  ; Mean age (months) ;  ; Sex ratio (M/F) ;  ; No. of febrile episodes ;  ; PCR + (%) ;  ; ,Microscopy + (%),,15,0,,No,1:No,1:No,,0.725
4908,3338391,Table 1,BaselineCharacteristic,xx%,Study sites ;  ; Low transmission ;  ; Ampasimpotsy ; xxx ;  ; xx.x ;  ; x.xx ;  ; xx ;  ; xx% ;  ; ,Microscopy + (%),,15,3,,No,1:No,1:No,,0.542
4908,3338391,Table 1,BaselineCharacteristic,xx%,Study sites ;  ; Low transmission ;  ; Andasibe ; xxx ;  ; xx.x ;  ; x.xx ;  ; xx ;  ; xx% ;  ; ,Microscopy + (%),,15,4,,No,1:No,1:No,,0.72
4908,3338391,Table 1,BaselineCharacteristic,NS,P ;  ;  ;  ;  ;  ;  ; x.xxx ;  ; NS ;  ;  ;  ; < x.xxxx ;  ; ,Microscopy + (%),,15,5,,No,1:No,1:No,,0.928
4914,3338924,Table 1,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
4914,3338924,Table 1,BaselineCharacteristic,Age (years),,,None,0,1,1,No,1:No,1:No,,0.557
4914,3338924,Table 1,BaselineCharacteristic,Sex,,,None,0,2,1,No,1:No,1:No,,0.903
4914,3338924,Table 1,BaselineCharacteristic,Parkinson’s disease duration (years),,,None,0,3,1,No,1:No,1:No,,0.635
4914,3338924,Table 1,BaselineCharacteristic,MMSE,,,None,0,4,1,No,1:No,1:No,,0.913
4914,3338924,Table 1,BaselineCharacteristic,R-UPDRS OFF meds/stim,,,None,0,5,1,No,1:No,1:No,,0.935
4914,3338924,Table 1,BaselineCharacteristic,ITxx-xx OFF meds/stim,,,None,0,6,1,No,1:No,1:No,,0.935
4914,3338924,Table 1,BaselineCharacteristic,GFQ,,,None,0,7,1,No,1:No,1:No,,0.945
4914,3338924,Table 1,BaselineCharacteristic,FOGQ,,,None,0,8,1,No,1:No,1:No,,0.945
4914,3338924,Table 1,BaselineCharacteristic,FallsQ,,,None,0,9,1,No,1:No,1:No,,0.945
4914,3338924,Table 1,BaselineCharacteristic,Healthy controls, ; ,Healthy controls,None,1,0,2,No,1:No,1:No,,0.727
4914,3338924,Table 1,BaselineCharacteristic,"xM, xF",Sex ; ,Healthy controls,None,1,2,3,No,1:No,1:No,,0.66
4914,3338924,Table 1,BaselineCharacteristic,,MMSE ; ,Healthy controls,None,1,4,3,No,1:No,1:No,,0.665
4914,3338924,Table 1,BaselineCharacteristic,,R-UPDRS OFF meds/stim ; ,Healthy controls,None,1,5,3,No,1:No,1:No,,0.675
4914,3338924,Table 1,BaselineCharacteristic,,ITxx-xx OFF meds/stim ; ,Healthy controls,None,1,6,3,No,1:No,1:No,,0.685
4914,3338924,Table 1,BaselineCharacteristic,,GFQ ; ,Healthy controls,None,1,7,3,No,1:No,1:No,,0.685
4914,3338924,Table 1,BaselineCharacteristic,,FOGQ ; ,Healthy controls,None,1,8,3,No,1:No,1:No,,0.685
4914,3338924,Table 1,BaselineCharacteristic,,FallsQ ; ,Healthy controls,None,1,9,3,No,1:No,1:No,,0.685
4914,3338924,Table 1,BaselineCharacteristic,Parkinson’s disease controls, ; ,Parkinson’s disease controls,None,2,0,2,No,1:No,1:No,,0.747
4914,3338924,Table 1,BaselineCharacteristic,"xM, xF",Sex ; ,Parkinson’s disease controls,None,2,2,3,No,1:No,1:No,,0.7
4914,3338924,Table 1,BaselineCharacteristic,x.x (x.x),ITxx-xx OFF meds/stim ; ,Parkinson’s disease controls,None,2,6,3,No,1:No,1:No,,0.675
4914,3338924,Table 1,BaselineCharacteristic,x.x (x.x),GFQ ; ,Parkinson’s disease controls,None,2,7,3,No,1:No,1:No,,0.675
4914,3338924,Table 1,BaselineCharacteristic,x.x (x.x),FOGQ ; ,Parkinson’s disease controls,None,2,8,3,No,1:No,1:No,,0.685
4914,3338924,Table 1,BaselineCharacteristic,x.x (x.x),FallsQ ; ,Parkinson’s disease controls,None,2,9,3,No,1:No,1:No,,0.685
4914,3338924,Table 1,BaselineCharacteristic,PD FOG, ; ,PD FOG,None,3,0,2,No,1:No,1:No,,0.97
4914,3338924,Table 1,BaselineCharacteristic,"xM, xF",Sex ; ,PD FOG,None,3,2,3,No,1:No,1:No,,0.91
4914,3338924,Table 1,BaselineCharacteristic,xx.x (x.x),Parkinson’s disease duration (years) ; ,PD FOG,None,3,3,3,No,1:No,1:No,,0.5
4914,3338924,Table 1,BaselineCharacteristic,xx.x (x.x),MMSE ; ,PD FOG,None,3,4,3,No,1:No,1:No,,0.656
4914,3338924,Table 1,BaselineCharacteristic,xx.x (x.x),R-UPDRS OFF meds/stim ; ,PD FOG,None,3,5,3,No,1:No,1:No,,0.68
4914,3338924,Table 1,BaselineCharacteristic,x.x (x.x)*,ITxx-xx OFF meds/stim ; ,PD FOG,None,3,6,3,No,1:No,1:No,,0.95
4914,3338924,Table 1,BaselineCharacteristic,xx.x (xx.x)*,GFQ ; ,PD FOG,None,3,7,3,No,1:No,1:No,,0.73
4914,3338924,Table 1,BaselineCharacteristic,xx.x (x.x)*,FOGQ ; ,PD FOG,None,3,8,3,No,1:No,1:No,,0.75
4914,3338924,Table 1,BaselineCharacteristic,x.x (x.x)*,FallsQ ; ,PD FOG,None,3,9,3,No,1:No,1:No,,0.95
4958,3349177,Table 1,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
4958,3349177,Table 1,BaselineCharacteristic,No. of patients,,,None,0,1,1,No,1:No,1:No,,0.853
4958,3349177,Table 1,BaselineCharacteristic,%,,,None,0,2,1,No,1:No,1:No,,0.803
4958,3349177,Table 1,BaselineCharacteristic,Total no., ; ,Total no.,,1,0,2,No,1:No,1:No,,0.875
4958,3349177,Table 1,BaselineCharacteristic,xx,No. of patients ; ,Total no.,,1,1,3,No,1:No,1:No,,0.645
4958,3349177,Table 1,BaselineCharacteristic,xxx,% ; ,Total no.,,1,2,3,No,1:No,1:No,,0.69
4958,3349177,Table 1,BaselineCharacteristic,Gender, ; ,None,None,3,0,24,No,1:No,1:No,,0.922
4958,3349177,Table 1,BaselineCharacteristic,Gender,No. of patients ; ,Gender,None,3,1,43,No,1:No,1:No,,0.844
4958,3349177,Table 1,BaselineCharacteristic,Gender,% ; ,Gender,None,3,2,43,No,1:No,1:No,,0.775
4958,3349177,Table 1,BaselineCharacteristic,?Male, ; ,?Male, Gender,4,0,2,No,1:No,1:No,,0.97
4958,3349177,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Male, Gender,4,1,3,No,1:No,1:No,,0.71
4958,3349177,Table 1,BaselineCharacteristic,xx.x,% ; ,?Male, Gender,4,2,3,No,1:No,1:No,,0.616
4958,3349177,Table 1,BaselineCharacteristic,?Female, ; ,?Female, Gender,5,0,2,No,1:No,1:No,,0.97
4958,3349177,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Female, Gender,5,1,3,No,1:No,1:No,,0.81
4958,3349177,Table 1,BaselineCharacteristic,xx.x,% ; ,?Female, Gender,5,2,3,No,1:No,1:No,,0.616
4958,3349177,Table 1,BaselineCharacteristic,ECOG performance status, ; ,None,None,6,0,24,No,1:No,1:No,,0.969
4958,3349177,Table 1,BaselineCharacteristic,ECOG performance status,No. of patients ; ,ECOG performance status,None,6,1,43,No,1:No,1:No,,0.855
4958,3349177,Table 1,BaselineCharacteristic,ECOG performance status,% ; ,ECOG performance status,None,6,2,43,No,1:No,1:No,,0.888
4958,3349177,Table 1,BaselineCharacteristic,?x, ; ,?x, ECOG performance status,7,0,2,No,1:No,1:No,,0.973
4958,3349177,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?x, ECOG performance status,7,1,3,No,1:No,1:No,,0.71
4958,3349177,Table 1,BaselineCharacteristic,xx.x,% ; ,?x, ECOG performance status,7,2,3,No,1:No,1:No,,0.736
4958,3349177,Table 1,BaselineCharacteristic,?x, ; ,?x, ECOG performance status,8,0,2,No,1:No,1:No,,0.972
4958,3349177,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?x, ECOG performance status,8,1,3,No,1:No,1:No,,0.73
4958,3349177,Table 1,BaselineCharacteristic,xx.x,% ; ,?x, ECOG performance status,8,2,3,No,1:No,1:No,,0.776
4958,3349177,Table 1,BaselineCharacteristic,Histology, ; ,None,None,9,0,24,No,1:No,1:No,,0.984
4958,3349177,Table 1,BaselineCharacteristic,Histology,No. of patients ; ,Histology,None,9,1,43,No,1:No,1:No,,0.844
4958,3349177,Table 1,BaselineCharacteristic,Histology,% ; ,Histology,None,9,2,43,No,1:No,1:No,,0.908
4958,3349177,Table 1,BaselineCharacteristic,?Well/moderately differentiated, ; ,?Well/moderately differentiated, Histology,10,0,2,No,1:No,1:No,,1
4958,3349177,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Well/moderately differentiated, Histology,10,1,3,No,1:No,1:No,,0.84
4958,3349177,Table 1,BaselineCharacteristic,xx.x,% ; ,?Well/moderately differentiated, Histology,10,2,3,No,1:No,1:No,,0.806
4958,3349177,Table 1,BaselineCharacteristic,?Poorly differentiated or signet-ring cell type, ; ,?Poorly differentiated or signet-ring cell type, Histology,11,0,2,No,1:No,1:No,,1
4958,3349177,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Poorly differentiated or signet-ring cell type, Histology,11,1,3,No,1:No,1:No,,0.86
4958,3349177,Table 1,BaselineCharacteristic,xx.x,% ; ,?Poorly differentiated or signet-ring cell type, Histology,11,2,3,No,1:No,1:No,,0.866
4958,3349177,Table 1,BaselineCharacteristic,?Unknown, ; ,?Unknown, Histology,12,0,2,No,1:No,1:No,,1
4958,3349177,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Unknown, Histology,12,1,3,No,1:No,1:No,,0.85
4958,3349177,Table 1,BaselineCharacteristic,xx.x,% ; ,?Unknown, Histology,12,2,3,No,1:No,1:No,,0.806
4958,3349177,Table 1,BaselineCharacteristic,Metastasis sites, ; ,None,None,13,0,24,No,1:No,1:No,,0.955
4958,3349177,Table 1,BaselineCharacteristic,Metastasis sites,No. of patients ; ,Metastasis sites,None,13,1,43,No,1:No,1:No,,0.864
4958,3349177,Table 1,BaselineCharacteristic,Metastasis sites,% ; ,Metastasis sites,None,13,2,43,No,1:No,1:No,,0.889
4958,3349177,Table 1,BaselineCharacteristic,?Liver, ; ,?Liver, Metastasis sites,14,0,2,No,1:No,1:No,,0.982
4958,3349177,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Liver, Metastasis sites,14,1,3,No,1:No,1:No,,0.78
4958,3349177,Table 1,BaselineCharacteristic,xx.x,% ; ,?Liver, Metastasis sites,14,2,3,No,1:No,1:No,,0.736
4958,3349177,Table 1,BaselineCharacteristic,?Peritoneum, ; ,?Peritoneum, Metastasis sites,15,0,2,No,1:No,1:No,,0.99
4958,3349177,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Peritoneum, Metastasis sites,15,1,3,No,1:No,1:No,,0.78
4958,3349177,Table 1,BaselineCharacteristic,xx.x,% ; ,?Peritoneum, Metastasis sites,15,2,3,No,1:No,1:No,,0.746
4958,3349177,Table 1,BaselineCharacteristic,?Distant abdominal lymph nodes, ; ,?Distant abdominal lymph nodes, Metastasis sites,16,0,2,No,1:No,1:No,,0.982
4958,3349177,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Distant abdominal lymph nodes, Metastasis sites,16,1,3,No,1:No,1:No,,0.78
4958,3349177,Table 1,BaselineCharacteristic,xx.x,% ; ,?Distant abdominal lymph nodes, Metastasis sites,16,2,3,No,1:No,1:No,,0.736
4958,3349177,Table 1,BaselineCharacteristic,?Lung, ; ,?Lung, Metastasis sites,17,0,2,No,1:No,1:No,,0.982
4958,3349177,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Lung, Metastasis sites,17,1,3,No,1:No,1:No,,0.85
4958,3349177,Table 1,BaselineCharacteristic,x.x,% ; ,?Lung, Metastasis sites,17,2,3,No,1:No,1:No,,0.89
4958,3349177,Table 1,BaselineCharacteristic,?Bone, ; ,?Bone, Metastasis sites,18,0,2,No,1:No,1:No,,0.972
4958,3349177,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Bone, Metastasis sites,18,1,3,No,1:No,1:No,,0.85
4958,3349177,Table 1,BaselineCharacteristic,x.x,% ; ,?Bone, Metastasis sites,18,2,3,No,1:No,1:No,,0.88
4958,3349177,Table 1,BaselineCharacteristic,No. of metastatic sites, ; ,None,None,19,0,24,No,1:No,1:No,,0.965
4958,3349177,Table 1,BaselineCharacteristic,No. of metastatic sites,No. of patients ; ,No. of metastatic sites,None,19,1,43,No,1:No,1:No,,0.864
4958,3349177,Table 1,BaselineCharacteristic,No. of metastatic sites,% ; ,No. of metastatic sites,None,19,2,43,No,1:No,1:No,,0.899
4958,3349177,Table 1,BaselineCharacteristic,?x, ; ,?x, No. of metastatic sites,20,0,2,No,1:No,1:No,,0.952
4958,3349177,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?x, No. of metastatic sites,20,1,3,No,1:No,1:No,,0.76
4958,3349177,Table 1,BaselineCharacteristic,xx.x,% ; ,?x, No. of metastatic sites,20,2,3,No,1:No,1:No,,0.736
4958,3349177,Table 1,BaselineCharacteristic,?x, ; ,?x, No. of metastatic sites,21,0,2,No,1:No,1:No,,0.952
4958,3349177,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?x, No. of metastatic sites,21,1,3,No,1:No,1:No,,0.76
4958,3349177,Table 1,BaselineCharacteristic,xx.x,% ; ,?x, No. of metastatic sites,21,2,3,No,1:No,1:No,,0.736
4958,3349177,Table 1,BaselineCharacteristic,??x, ; ,??x, No. of metastatic sites,22,0,2,No,1:No,1:No,,0.952
4958,3349177,Table 1,BaselineCharacteristic,xx,No. of patients ; ,??x, No. of metastatic sites,22,1,3,No,1:No,1:No,,0.76
4958,3349177,Table 1,BaselineCharacteristic,xx.x,% ; ,??x, No. of metastatic sites,22,2,3,No,1:No,1:No,,0.736
4958,3349177,Table 1,BaselineCharacteristic,Prior gastrectomy, ; ,Prior gastrectomy,,23,0,2,No,1:No,1:No,,1
4958,3349177,Table 1,BaselineCharacteristic,xx,No. of patients ; ,Prior gastrectomy,,23,1,3,No,1:No,1:No,,0.86
4958,3349177,Table 1,BaselineCharacteristic,xx.x,% ; ,Prior gastrectomy,,23,2,3,No,1:No,1:No,,0.811
4958,3349177,Table 1,BaselineCharacteristic,No. of previous treatment lines, ; ,None,None,24,0,24,No,1:No,1:No,,0.995
4958,3349177,Table 1,BaselineCharacteristic,No. of previous treatment lines,No. of patients ; ,No. of previous treatment lines,None,24,1,43,No,1:No,1:No,,0.904
4958,3349177,Table 1,BaselineCharacteristic,No. of previous treatment lines,% ; ,No. of previous treatment lines,None,24,2,43,No,1:No,1:No,,0.939
4958,3349177,Table 1,BaselineCharacteristic,?x, ; ,?x, No. of previous treatment lines,25,0,2,No,1:No,1:No,,0.984
4958,3349177,Table 1,BaselineCharacteristic,x,No. of patients ; ,?x, No. of previous treatment lines,25,1,3,No,1:No,1:No,,0.89
4958,3349177,Table 1,BaselineCharacteristic,xx.x,% ; ,?x, No. of previous treatment lines,25,2,3,No,1:No,1:No,,0.846
4958,3349177,Table 1,BaselineCharacteristic,?x, ; ,?x, No. of previous treatment lines,26,0,2,No,1:No,1:No,,0.984
4958,3349177,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?x, No. of previous treatment lines,26,1,3,No,1:No,1:No,,0.86
4958,3349177,Table 1,BaselineCharacteristic,xx.x,% ; ,?x, No. of previous treatment lines,26,2,3,No,1:No,1:No,,0.846
4958,3349177,Table 1,BaselineCharacteristic,First-line chemotherapy regimen, ; ,None,None,27,0,24,No,1:No,1:No,,0.995
4958,3349177,Table 1,BaselineCharacteristic,First-line chemotherapy regimen,No. of patients ; ,First-line chemotherapy regimen,None,27,1,43,No,1:No,1:No,,0.884
4958,3349177,Table 1,BaselineCharacteristic,First-line chemotherapy regimen,% ; ,First-line chemotherapy regimen,None,27,2,43,No,1:No,1:No,,0.939
4958,3349177,Table 1,BaselineCharacteristic,?T, ; ,?T, First-line chemotherapy regimen,28,0,2,No,1:No,1:No,,1
4958,3349177,Table 1,BaselineCharacteristic,x,No. of patients ; ,?T, First-line chemotherapy regimen,28,1,3,No,1:No,1:No,,0.87
4958,3349177,Table 1,BaselineCharacteristic,x.x,% ; ,?T, First-line chemotherapy regimen,28,2,3,No,1:No,1:No,,0.96
4958,3349177,Table 1,BaselineCharacteristic,?FP, ; ,?FP, First-line chemotherapy regimen,29,0,2,No,1:No,1:No,,1
4958,3349177,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?FP, First-line chemotherapy regimen,29,1,3,No,1:No,1:No,,0.9
4958,3349177,Table 1,BaselineCharacteristic,xx.x,% ; ,?FP, First-line chemotherapy regimen,29,2,3,No,1:No,1:No,,0.885
4958,3349177,Table 1,BaselineCharacteristic,?FT, ; ,?FT, First-line chemotherapy regimen,30,0,2,No,1:No,1:No,,1
4958,3349177,Table 1,BaselineCharacteristic,x,No. of patients ; ,?FT, First-line chemotherapy regimen,30,1,3,No,1:No,1:No,,0.87
4958,3349177,Table 1,BaselineCharacteristic,x.x,% ; ,?FT, First-line chemotherapy regimen,30,2,3,No,1:No,1:No,,0.96
4958,3349177,Table 1,BaselineCharacteristic,?TP, ; ,?TP, First-line chemotherapy regimen,31,0,2,No,1:No,1:No,,1
4958,3349177,Table 1,BaselineCharacteristic,x,No. of patients ; ,?TP, First-line chemotherapy regimen,31,1,3,No,1:No,1:No,,0.87
4958,3349177,Table 1,BaselineCharacteristic,xx.x,% ; ,?TP, First-line chemotherapy regimen,31,2,3,No,1:No,1:No,,0.885
4958,3349177,Table 1,BaselineCharacteristic,?FTP, ; ,?FTP, First-line chemotherapy regimen,32,0,2,No,1:No,1:No,,1
4958,3349177,Table 1,BaselineCharacteristic,x,No. of patients ; ,?FTP, First-line chemotherapy regimen,32,1,3,No,1:No,1:No,,0.87
4958,3349177,Table 1,BaselineCharacteristic,xx.x,% ; ,?FTP, First-line chemotherapy regimen,32,2,3,No,1:No,1:No,,0.885
5055,3368715,Table 1,BaselineCharacteristic,Variable,,None,None,0,0,12,No,1:No,1:No,,0.905
5055,3368715,Table 1,BaselineCharacteristic,Allopurinol xxx/xxx mgN = xxx,,Variable,None,0,3,1,No,1:No,1:No,,0.555
5055,3368715,Table 1,BaselineCharacteristic,"Gender, n (%)",Variable ; ,None,None,1,0,24,No,1:No,1:No,,0.83
5055,3368715,Table 1,BaselineCharacteristic,,Allopurinol xxx/xxx mgN = xxx ; ,"Gender, n (%)",None,1,3,43,No,1:No,1:No,,0.537
5055,3368715,Table 1,BaselineCharacteristic,Male,Variable ; ,Male," Gender, n (%)",2,0,2,No,1:No,1:No,,0.806
5055,3368715,Table 1,BaselineCharacteristic,Female,Variable ; ,Female," Gender, n (%)",3,0,2,No,1:No,1:No,,0.826
5055,3368715,Table 1,BaselineCharacteristic,,Variable ; ,None,None,4,0,2,No,1:No,1:No,,0.97
5055,3368715,Table 1,BaselineCharacteristic,,Allopurinol xxx/xxx mgN = xxx ; ,None,None,4,3,3,No,1:No,1:No,,0.562
5055,3368715,Table 1,BaselineCharacteristic,"Race, n (%)",Variable ; ,None,None,5,0,24,No,1:No,1:No,,0.87
5055,3368715,Table 1,BaselineCharacteristic,,Allopurinol xxx/xxx mgN = xxx ; ,"Race, n (%)",None,5,3,43,No,1:No,1:No,,0.557
5055,3368715,Table 1,BaselineCharacteristic,,Variable ; ,None,None,6,0,2,No,1:No,1:No,,0.99
5055,3368715,Table 1,BaselineCharacteristic,,Allopurinol xxx/xxx mgN = xxx ; ,None,None,6,3,3,No,1:No,1:No,,0.602
5055,3368715,Table 1,BaselineCharacteristic,American Indian or Alaska Native,Variable ; ,American Indian or Alaska Native,,7,0,2,No,1:No,1:No,,0.99
5055,3368715,Table 1,BaselineCharacteristic,x (x.x),Febuxostat xx mgN = xxx ; ,American Indian or Alaska Native,,7,2,3,No,1:No,1:No,,0.512
5055,3368715,Table 1,BaselineCharacteristic,x,Allopurinol xxx/xxx mgN = xxx ; ,American Indian or Alaska Native,,7,3,3,No,1:No,1:No,,0.647
5055,3368715,Table 1,BaselineCharacteristic,Asian,Variable ; ,Asian,,8,0,2,No,1:No,1:No,,0.99
5055,3368715,Table 1,BaselineCharacteristic,x (x.x),Allopurinol xxx/xxx mgN = xxx ; ,Asian,,8,3,3,No,1:No,1:No,,0.612
5055,3368715,Table 1,BaselineCharacteristic,Black or African American,Variable ; ,Black or African American,,9,0,2,No,1:No,1:No,,1
5055,3368715,Table 1,BaselineCharacteristic,x (x.x),Allopurinol xxx/xxx mgN = xxx ; ,Black or African American,,9,3,3,No,1:No,1:No,,0.617
5055,3368715,Table 1,BaselineCharacteristic,Native Hawaiian or Other Pacific Islander,Variable ; ,Native Hawaiian or Other Pacific Islander,,10,0,2,No,1:No,1:No,,1
5055,3368715,Table 1,BaselineCharacteristic,x,Allopurinol xxx/xxx mgN = xxx ; ,Native Hawaiian or Other Pacific Islander,,10,3,3,No,1:No,1:No,,0.627
5055,3368715,Table 1,BaselineCharacteristic,White,Variable ; ,White,,11,0,2,No,1:No,1:No,,1
5055,3368715,Table 1,BaselineCharacteristic,Other,Variable ; ,Other,,12,0,2,No,1:No,1:No,,1
5055,3368715,Table 1,BaselineCharacteristic,x (x.x),Allopurinol xxx/xxx mgN = xxx ; ,Other,,12,3,3,No,1:No,1:No,,0.622
5055,3368715,Table 1,BaselineCharacteristic,,Variable ; ,None,None,13,0,2,No,1:No,1:No,,1
5055,3368715,Table 1,BaselineCharacteristic,,Allopurinol xxx/xxx mgN = xxx ; ,None,None,13,3,3,No,1:No,1:No,,0.602
5055,3368715,Table 1,BaselineCharacteristic,"Ethnicity, n (%)",Variable ; ,None,None,14,0,24,No,1:No,1:No,,0.95
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,"Ethnicity, n (%)",None,14,1,43,No,1:No,1:No,,0.512
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,"Ethnicity, n (%)",None,14,2,43,No,1:No,1:No,,0.502
5055,3368715,Table 1,BaselineCharacteristic,,Allopurinol xxx/xxx mgN = xxx ; ,"Ethnicity, n (%)",None,14,3,43,No,1:No,1:No,,0.627
5055,3368715,Table 1,BaselineCharacteristic,Hispanic or Latino,Variable ; ,Hispanic or Latino," Ethnicity, n (%)",15,0,2,No,1:No,1:No,,0.936
5055,3368715,Table 1,BaselineCharacteristic,x (x.x),Febuxostat xx mgN = xxx ; ,Hispanic or Latino," Ethnicity, n (%)",15,1,3,No,1:No,1:No,,0.581
5055,3368715,Table 1,BaselineCharacteristic,x (x.x),Febuxostat xx mgN = xxx ; ,Hispanic or Latino," Ethnicity, n (%)",15,2,3,No,1:No,1:No,,0.571
5055,3368715,Table 1,BaselineCharacteristic,x (x.x),Allopurinol xxx/xxx mgN = xxx ; ,Hispanic or Latino," Ethnicity, n (%)",15,3,3,No,1:No,1:No,,0.676
5055,3368715,Table 1,BaselineCharacteristic,Not Hispanic or Latino,Variable ; ,Not Hispanic or Latino," Ethnicity, n (%)",16,0,2,No,1:No,1:No,,0.936
5055,3368715,Table 1,BaselineCharacteristic,xxx (xx.x),Febuxostat xx mgN = xxx ; ,Not Hispanic or Latino," Ethnicity, n (%)",16,1,3,No,1:No,1:No,,0.581
5055,3368715,Table 1,BaselineCharacteristic,xxx (xx.x),Febuxostat xx mgN = xxx ; ,Not Hispanic or Latino," Ethnicity, n (%)",16,2,3,No,1:No,1:No,,0.571
5055,3368715,Table 1,BaselineCharacteristic,xxx (xx.x),Allopurinol xxx/xxx mgN = xxx ; ,Not Hispanic or Latino," Ethnicity, n (%)",16,3,3,No,1:No,1:No,,0.571
5055,3368715,Table 1,BaselineCharacteristic,,Variable ; ,None,None,17,0,2,No,1:No,1:No,,1
5055,3368715,Table 1,BaselineCharacteristic,,Allopurinol xxx/xxx mgN = xxx ; ,None,None,17,3,3,No,1:No,1:No,,0.592
5055,3368715,Table 1,BaselineCharacteristic,Age (years),Variable ; ,None,None,18,0,2,No,1:No,1:No,,0.77
5055,3368715,Table 1,BaselineCharacteristic,,Allopurinol xxx/xxx mgN = xxx ; ,None,None,18,3,3,No,1:No,1:No,,0.592
5055,3368715,Table 1,BaselineCharacteristic,Mean ± SD,Variable ; ,Mean ± SD,,19,0,2,No,1:No,1:No,,0.82
5055,3368715,Table 1,BaselineCharacteristic,Range,Variable ; ,Range,,20,0,2,No,1:No,1:No,,1
5055,3368715,Table 1,BaselineCharacteristic,,Variable ; ,None,None,21,0,2,No,1:No,1:No,,1
5055,3368715,Table 1,BaselineCharacteristic,,Allopurinol xxx/xxx mgN = xxx ; ,None,None,21,3,3,No,1:No,1:No,,0.592
5055,3368715,Table 1,BaselineCharacteristic,Body mass index (kg/mx),Variable ; ,None,None,22,0,24,No,1:No,1:No,,0.995
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,Body mass index (kg/mx),None,22,1,43,No,1:No,1:No,,0.546
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,Body mass index (kg/mx),None,22,2,43,No,1:No,1:No,,0.555
5055,3368715,Table 1,BaselineCharacteristic,,Allopurinol xxx/xxx mgN = xxx ; ,Body mass index (kg/mx),None,22,3,43,No,1:No,1:No,,0.64
5055,3368715,Table 1,BaselineCharacteristic,Mean ± SD,Variable ; ,Mean ± SD, Body mass index (kg/mx),23,0,2,No,1:No,1:No,,0.82
5055,3368715,Table 1,BaselineCharacteristic,Range,Variable ; ,Range, Body mass index (kg/mx),24,0,2,No,1:No,1:No,,1
5055,3368715,Table 1,BaselineCharacteristic,,Variable ; ,None,None,25,0,2,No,1:No,1:No,,1
5055,3368715,Table 1,BaselineCharacteristic,,Allopurinol xxx/xxx mgN = xxx ; ,None,None,25,3,3,No,1:No,1:No,,0.602
5055,3368715,Table 1,BaselineCharacteristic,"Alcohol use, n (%)",Variable ; ,None,None,26,0,2,No,1:No,1:No,,0.926
5055,3368715,Table 1,BaselineCharacteristic,,Allopurinol xxx/xxx mgN = xxx ; ,None,None,26,3,3,No,1:No,1:No,,0.602
5055,3368715,Table 1,BaselineCharacteristic,Non-/Ex-drinker,Variable ; ,Non-/Ex-drinker,,27,0,2,No,1:No,1:No,,1
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Allopurinol xxx/xxx mgN = xxx ; ,Non-/Ex-drinker,,27,3,3,No,1:No,1:No,,0.517
5055,3368715,Table 1,BaselineCharacteristic,Drinker (x-xx drinks/week),Variable ; ,Drinker (x-xx drinks/week),,28,0,2,No,1:No,1:No,,1
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Allopurinol xxx/xxx mgN = xxx ; ,Drinker (x-xx drinks/week),,28,3,3,No,1:No,1:No,,0.517
5055,3368715,Table 1,BaselineCharacteristic,,Variable ; ,None,None,29,0,2,No,1:No,1:No,,1
5055,3368715,Table 1,BaselineCharacteristic,,Allopurinol xxx/xxx mgN = xxx ; ,None,None,29,3,3,No,1:No,1:No,,0.672
5055,3368715,Table 1,BaselineCharacteristic,Serum urate (mg/dL),Variable ; ,None,None,30,0,24,No,1:No,1:No,,0.995
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,Serum urate (mg/dL),None,30,1,43,No,1:No,1:No,,0.512
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,Serum urate (mg/dL),None,30,2,43,No,1:No,1:No,,0.521
5055,3368715,Table 1,BaselineCharacteristic,,Allopurinol xxx/xxx mgN = xxx ; ,Serum urate (mg/dL),None,30,3,43,No,1:No,1:No,,0.67
5055,3368715,Table 1,BaselineCharacteristic,Mean ± SD,Variable ; ,Mean ± SD, Serum urate (mg/dL),31,0,2,No,1:No,1:No,,0.82
5055,3368715,Table 1,BaselineCharacteristic,Range,Variable ; ,Range, Serum urate (mg/dL),32,0,2,No,1:No,1:No,,1
5055,3368715,Table 1,BaselineCharacteristic,x-xx,Allopurinol xxx/xxx mgN = xxx ; ,Range, Serum urate (mg/dL),32,3,3,No,1:No,1:No,,0.672
5055,3368715,Table 1,BaselineCharacteristic,,Variable ; ,None,None,33,0,2,No,1:No,1:No,,1
5055,3368715,Table 1,BaselineCharacteristic,,Allopurinol xxx/xxx mgN = xxx ; ,None,None,33,3,3,No,1:No,1:No,,0.672
5055,3368715,Table 1,BaselineCharacteristic,Years with gout,Variable ; ,None,None,34,0,2,No,1:No,1:No,,1
5055,3368715,Table 1,BaselineCharacteristic,,Allopurinol xxx/xxx mgN = xxx ; ,None,None,34,3,3,No,1:No,1:No,,0.672
5055,3368715,Table 1,BaselineCharacteristic,Mean ± SD,Variable ; ,Mean ± SD,,35,0,2,No,1:No,1:No,,0.82
5055,3368715,Table 1,BaselineCharacteristic,Range,Variable ; ,Range,,36,0,2,No,1:No,1:No,,1
5055,3368715,Table 1,BaselineCharacteristic,x-xx,Allopurinol xxx/xxx mgN = xxx ; ,Range,,36,3,3,No,1:No,1:No,,0.672
5055,3368715,Table 1,BaselineCharacteristic,,Variable ; ,None,None,37,0,2,No,1:No,1:No,,1
5055,3368715,Table 1,BaselineCharacteristic,,Allopurinol xxx/xxx mgN = xxx ; ,None,None,37,3,3,No,1:No,1:No,,0.672
5055,3368715,Table 1,BaselineCharacteristic,"Tophi present, n (%)",Variable ; ,None,None,38,0,24,No,1:No,1:No,,0.95
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,"Tophi present, n (%)",None,38,1,43,No,1:No,1:No,,0.542
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,"Tophi present, n (%)",None,38,2,43,No,1:No,1:No,,0.532
5055,3368715,Table 1,BaselineCharacteristic,,Allopurinol xxx/xxx mgN = xxx ; ,"Tophi present, n (%)",None,38,3,43,No,1:No,1:No,,0.667
5055,3368715,Table 1,BaselineCharacteristic,No,Variable ; ,No," Tophi present, n (%)",39,0,2,No,1:No,1:No,,0.926
5055,3368715,Table 1,BaselineCharacteristic,xxx (xx.x),Allopurinol xxx/xxx mgN = xxx ; ,No," Tophi present, n (%)",39,3,3,No,1:No,1:No,,0.531
5055,3368715,Table 1,BaselineCharacteristic,Yes,Variable ; ,Yes," Tophi present, n (%)",40,0,2,No,1:No,1:No,,0.926
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Allopurinol xxx/xxx mgN = xxx ; ,Yes," Tophi present, n (%)",40,3,3,No,1:No,1:No,,0.531
5055,3368715,Table 1,BaselineCharacteristic,,Variable ; ,None,None,41,0,2,No,1:No,1:No,,1
5055,3368715,Table 1,BaselineCharacteristic,,Allopurinol xxx/xxx mgN = xxx ; ,None,None,41,3,3,No,1:No,1:No,,0.672
5055,3368715,Table 1,BaselineCharacteristic,"Participated in a previous febuxostat studyb, n (%)",Variable ; ,None,None,42,0,2,No,1:No,1:No,,0.856
5055,3368715,Table 1,BaselineCharacteristic,,Allopurinol xxx/xxx mgN = xxx ; ,None,None,42,3,3,No,1:No,1:No,,0.672
5055,3368715,Table 1,BaselineCharacteristic,Yes,Variable ; ,Yes,,43,0,2,No,1:No,1:No,,1
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Allopurinol xxx/xxx mgN = xxx ; ,Yes,,43,3,3,No,1:No,1:No,,0.517
5055,3368715,Table 1,BaselineCharacteristic,,Variable ; ,None,None,44,0,2,No,1:No,1:No,,1
5055,3368715,Table 1,BaselineCharacteristic,,Allopurinol xxx/xxx mgN = xxx ; ,None,None,44,3,3,No,1:No,1:No,,0.672
5055,3368715,Table 1,BaselineCharacteristic,"Prior urate lowering therapies, n (%)",Variable ; ,None,None,45,0,24,No,1:No,1:No,,0.95
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,"Prior urate lowering therapies, n (%)",None,45,1,43,No,1:No,1:No,,0.542
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,"Prior urate lowering therapies, n (%)",None,45,2,43,No,1:No,1:No,,0.532
5055,3368715,Table 1,BaselineCharacteristic,,Allopurinol xxx/xxx mgN = xxx ; ,"Prior urate lowering therapies, n (%)",None,45,3,43,No,1:No,1:No,,0.667
5055,3368715,Table 1,BaselineCharacteristic,No,Variable ; ,No," Prior urate lowering therapies, n (%)",46,0,2,No,1:No,1:No,,0.926
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Allopurinol xxx/xxx mgN = xxx ; ,No," Prior urate lowering therapies, n (%)",46,3,3,No,1:No,1:No,,0.531
5055,3368715,Table 1,BaselineCharacteristic,Yes (any),Variable ; ,Yes (any)," Prior urate lowering therapies, n (%)",47,0,2,No,1:No,1:No,,0.926
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Allopurinol xxx/xxx mgN = xxx ; ,Yes (any)," Prior urate lowering therapies, n (%)",47,3,3,No,1:No,1:No,,0.531
5055,3368715,Table 1,BaselineCharacteristic,Febuxostat,Variable ; ,Febuxostat," Prior urate lowering therapies, n (%)",48,0,2,No,1:No,1:No,,0.906
5055,3368715,Table 1,BaselineCharacteristic,Allopurinol,Variable ; ,Allopurinol," Prior urate lowering therapies, n (%)",49,0,2,No,1:No,1:No,,0.916
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,Allopurinol," Prior urate lowering therapies, n (%)",49,1,3,No,1:No,1:No,,0.511
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Febuxostat xx mgN = xxx ; ,Allopurinol," Prior urate lowering therapies, n (%)",49,2,3,No,1:No,1:No,,0.511
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Allopurinol xxx/xxx mgN = xxx ; ,Allopurinol," Prior urate lowering therapies, n (%)",49,3,3,No,1:No,1:No,,0.531
5055,3368715,Table 1,BaselineCharacteristic,Probenecid,Variable ; ,Probenecid," Prior urate lowering therapies, n (%)",50,0,2,No,1:No,1:No,,0.926
5055,3368715,Table 1,BaselineCharacteristic,x (x.x),Allopurinol xxx/xxx mgN = xxx ; ,Probenecid," Prior urate lowering therapies, n (%)",50,3,3,No,1:No,1:No,,0.656
5055,3368715,Table 1,BaselineCharacteristic,Other,Variable ; ,Other," Prior urate lowering therapies, n (%)",51,0,2,No,1:No,1:No,,0.926
5055,3368715,Table 1,BaselineCharacteristic,x (x.x),Allopurinol xxx/xxx mgN = xxx ; ,Other," Prior urate lowering therapies, n (%)",51,3,3,No,1:No,1:No,,0.656
5055,3368715,Table 1,BaselineCharacteristic,,Variable ; ,None,None,52,0,2,No,1:No,1:No,,1
5055,3368715,Table 1,BaselineCharacteristic,,Allopurinol xxx/xxx mgN = xxx ; ,None,None,52,3,3,No,1:No,1:No,,0.672
5055,3368715,Table 1,BaselineCharacteristic,"Renal Functionc, n (%)",Variable ; ,None,None,53,0,2,No,1:No,1:No,,0.926
5055,3368715,Table 1,BaselineCharacteristic,,Allopurinol xxx/xxx mgN = xxx ; ,None,None,53,3,3,No,1:No,1:No,,0.672
5055,3368715,Table 1,BaselineCharacteristic,Moderately Impaired,Variable ; ,Moderately Impaired,,54,0,2,No,1:No,1:No,,1
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Allopurinol xxx/xxx mgN = xxx ; ,Moderately Impaired,,54,3,3,No,1:No,1:No,,0.517
5055,3368715,Table 1,BaselineCharacteristic,Mildly Impaired,Variable ; ,Mildly Impaired,,55,0,2,No,1:No,1:No,,1
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Allopurinol xxx/xxx mgN = xxx ; ,Mildly Impaired,,55,3,3,No,1:No,1:No,,0.517
5055,3368715,Table 1,BaselineCharacteristic,Normal,Variable ; ,Normal,,56,0,2,No,1:No,1:No,,1
5055,3368715,Table 1,BaselineCharacteristic,x (x.x),Allopurinol xxx/xxx mgN = xxx ; ,Normal,,56,3,3,No,1:No,1:No,,0.672
5055,3368715,Table 1,BaselineCharacteristic,,Variable ; ,None,None,57,0,2,No,1:No,1:No,,1
5055,3368715,Table 1,BaselineCharacteristic,,Allopurinol xxx/xxx mgN = xxx ; ,None,None,57,3,3,No,1:No,1:No,,0.672
5055,3368715,Table 1,BaselineCharacteristic,"Medical History, n (%)",Variable ; ,None,None,58,0,24,No,1:No,1:No,,0.95
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,"Medical History, n (%)",None,58,1,43,No,1:No,1:No,,0.542
5055,3368715,Table 1,BaselineCharacteristic,,Febuxostat xx mgN = xxx ; ,"Medical History, n (%)",None,58,2,43,No,1:No,1:No,,0.532
5055,3368715,Table 1,BaselineCharacteristic,,Allopurinol xxx/xxx mgN = xxx ; ,"Medical History, n (%)",None,58,3,43,No,1:No,1:No,,0.667
5055,3368715,Table 1,BaselineCharacteristic,Any cardiovascular diseased,Variable ; ,Any cardiovascular diseased," Medical History, n (%)",59,0,2,No,1:No,1:No,,0.926
5055,3368715,Table 1,BaselineCharacteristic,xxx (xx.x),Allopurinol xxx/xxx mgN = xxx ; ,Any cardiovascular diseased," Medical History, n (%)",59,3,3,No,1:No,1:No,,0.531
5055,3368715,Table 1,BaselineCharacteristic,Hypertension,Variable ; ,Hypertension," Medical History, n (%)",60,0,2,No,1:No,1:No,,0.926
5055,3368715,Table 1,BaselineCharacteristic,xxx (xx.x),Allopurinol xxx/xxx mgN = xxx ; ,Hypertension," Medical History, n (%)",60,3,3,No,1:No,1:No,,0.531
5055,3368715,Table 1,BaselineCharacteristic,Coronary artery disease,Variable ; ,Coronary artery disease," Medical History, n (%)",61,0,2,No,1:No,1:No,,0.926
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Allopurinol xxx/xxx mgN = xxx ; ,Coronary artery disease," Medical History, n (%)",61,3,3,No,1:No,1:No,,0.531
5055,3368715,Table 1,BaselineCharacteristic,,Variable ; ,None,None,62,0,2,No,1:No,1:No,,1
5055,3368715,Table 1,BaselineCharacteristic,,Allopurinol xxx/xxx mgN = xxx ; ,None,None,62,3,3,No,1:No,1:No,,0.672
5055,3368715,Table 1,BaselineCharacteristic,Cardiac arrhythmia,Variable ; ,Cardiac arrhythmia," Medical History, n (%)",63,0,2,No,1:No,1:No,,0.926
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Allopurinol xxx/xxx mgN = xxx ; ,Cardiac arrhythmia," Medical History, n (%)",63,3,3,No,1:No,1:No,,0.531
5055,3368715,Table 1,BaselineCharacteristic,Diabetes,Variable ; ,Diabetes," Medical History, n (%)",64,0,2,No,1:No,1:No,,0.926
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Allopurinol xxx/xxx mgN = xxx ; ,Diabetes," Medical History, n (%)",64,3,3,No,1:No,1:No,,0.531
5055,3368715,Table 1,BaselineCharacteristic,Hypercholesterolemia,Variable ; ,Hypercholesterolemia," Medical History, n (%)",65,0,2,No,1:No,1:No,,0.926
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Allopurinol xxx/xxx mgN = xxx ; ,Hypercholesterolemia," Medical History, n (%)",65,3,3,No,1:No,1:No,,0.531
5055,3368715,Table 1,BaselineCharacteristic,Hyperlipidemia,Variable ; ,Hyperlipidemia," Medical History, n (%)",66,0,2,No,1:No,1:No,,0.926
5055,3368715,Table 1,BaselineCharacteristic,xx (xx.x),Allopurinol xxx/xxx mgN = xxx ; ,Hyperlipidemia," Medical History, n (%)",66,3,3,No,1:No,1:No,,0.531
5055,3368715,Table 1,BaselineCharacteristic,Use of low-dose aspirin (?xxx mg daily),Variable ; ,Use of low-dose aspirin (?xxx mg daily)," Medical History, n (%)",67,0,2,No,1:No,1:No,,0.851
5162,3397213,Table 1,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
5162,3397213,Table 1,BaselineCharacteristic,Lapatinib plus bevacizumab,,,None,0,1,1,No,1:No,1:No,,0.804
5162,3397213,Table 1,BaselineCharacteristic,, ; ,None,None,1,0,12,No,1:No,1:No,,0.898
5162,3397213,Table 1,BaselineCharacteristic,(N = xx),Lapatinib plus bevacizumab ; ,,None,1,1,1,No,1:No,1:No,,0.797
5162,3397213,Table 1,BaselineCharacteristic,"Median age, years", ;  ; ,"Median age, years",None,2,0,2,No,1:No,1:No,,0.528
5162,3397213,Table 1,BaselineCharacteristic,"Race, n (%)", ;  ; ,"Race, n (%)",None,3,0,2,No,1:No,1:No,,0.796
5162,3397213,Table 1,BaselineCharacteristic,,Lapatinib plus bevacizumab ; (N = xx) ; ,"Race, n (%)",None,3,1,3,No,1:No,1:No,,0.63
5162,3397213,Table 1,BaselineCharacteristic,White, ;  ; ,White,None,4,0,2,No,1:No,1:No,,0.98
5162,3397213,Table 1,BaselineCharacteristic,xx (xx),Lapatinib plus bevacizumab ; (N = xx) ; ,White,None,4,1,3,No,1:No,1:No,,0.646
5162,3397213,Table 1,BaselineCharacteristic,African American, ;  ; ,African American,None,5,0,2,No,1:No,1:No,,0.97
5162,3397213,Table 1,BaselineCharacteristic,x (xx),Lapatinib plus bevacizumab ; (N = xx) ; ,African American,None,5,1,3,No,1:No,1:No,,0.59
5162,3397213,Table 1,BaselineCharacteristic,Asian, ;  ; ,Asian,None,6,0,2,No,1:No,1:No,,0.99
5162,3397213,Table 1,BaselineCharacteristic,x (x),Lapatinib plus bevacizumab ; (N = xx) ; ,Asian,None,6,1,3,No,1:No,1:No,,0.82
5162,3397213,Table 1,BaselineCharacteristic,"Stage IV, n (%)", ;  ; ,"Stage IV, n (%)",None,7,0,2,No,1:No,1:No,,0.86
5162,3397213,Table 1,BaselineCharacteristic,xx (xxx),Lapatinib plus bevacizumab ; (N = xx) ; ,"Stage IV, n (%)",None,7,1,3,No,1:No,1:No,,0.516
5162,3397213,Table 1,BaselineCharacteristic,"HERx FISH+ or IHC x+ (local), n (%)", ;  ; ,"HERx FISH+ or IHC x+ (local), n (%)",None,8,0,2,No,1:No,1:No,,0.886
5162,3397213,Table 1,BaselineCharacteristic,xx (xx)a,Lapatinib plus bevacizumab ; (N = xx) ; ,"HERx FISH+ or IHC x+ (local), n (%)",None,8,1,3,No,1:No,1:No,,0.546
5162,3397213,Table 1,BaselineCharacteristic,"ECOG x/x, n (%)", ;  ; ,"ECOG x/x, n (%)",None,9,0,2,No,1:No,1:No,,0.906
5162,3397213,Table 1,BaselineCharacteristic,xx (xx)/xx (xx),Lapatinib plus bevacizumab ; (N = xx) ; ,"ECOG x/x, n (%)",None,9,1,3,No,1:No,1:No,,0.656
5162,3397213,Table 1,BaselineCharacteristic,"Visceral ± nonvisceral sites, n (%)", ;  ; ,"Visceral ± nonvisceral sites, n (%)",None,10,0,2,No,1:No,1:No,,0.898
5162,3397213,Table 1,BaselineCharacteristic,xx (xx),Lapatinib plus bevacizumab ; (N = xx) ; ,"Visceral ± nonvisceral sites, n (%)",None,10,1,3,No,1:No,1:No,,0.61
5162,3397213,Table 1,BaselineCharacteristic,"ER/PR status, n (%)", ;  ; ,"ER/PR status, n (%)",None,11,0,2,No,1:No,1:No,,0.91
5162,3397213,Table 1,BaselineCharacteristic,,Lapatinib plus bevacizumab ; (N = xx) ; ,"ER/PR status, n (%)",None,11,1,3,No,1:No,1:No,,0.806
5162,3397213,Table 1,BaselineCharacteristic,ER-/PR-, ;  ; ,ER-/PR-,None,12,0,2,No,1:No,1:No,,1
5162,3397213,Table 1,BaselineCharacteristic,xx (xx),Lapatinib plus bevacizumab ; (N = xx) ; ,ER-/PR-,None,12,1,3,No,1:No,1:No,,0.796
5162,3397213,Table 1,BaselineCharacteristic,ER+/PR any, ;  ; ,ER+/PR any,None,13,0,2,No,1:No,1:No,,1
5162,3397213,Table 1,BaselineCharacteristic,xx (xx),Lapatinib plus bevacizumab ; (N = xx) ; ,ER+/PR any,None,13,1,3,No,1:No,1:No,,0.796
5162,3397213,Table 1,BaselineCharacteristic,"Prior chemotherapy regimens in the metastatic setting, n (range)", ;  ; ,"Prior chemotherapy regimens in the metastatic setting, n (range)",None,14,0,2,No,1:No,1:No,,0.662
5162,3397213,Table 1,BaselineCharacteristic,x (x–xx),Lapatinib plus bevacizumab ; (N = xx) ; ,"Prior chemotherapy regimens in the metastatic setting, n (range)",None,14,1,3,No,1:No,1:No,,0.59
5162,3397213,Table 1,BaselineCharacteristic,"Prior trastuzumab therapy, n (%)", ;  ; ,"Prior trastuzumab therapy, n (%)",None,15,0,2,No,1:No,1:No,,0.936
5162,3397213,Table 1,BaselineCharacteristic,xx (xx),Lapatinib plus bevacizumab ; (N = xx) ; ,"Prior trastuzumab therapy, n (%)",None,15,1,3,No,1:No,1:No,,0.706
5162,3397213,Table 1,BaselineCharacteristic,Neoadjuvant, ;  ; ,Neoadjuvant,None,16,0,2,No,1:No,1:No,,1
5162,3397213,Table 1,BaselineCharacteristic,x (x),Lapatinib plus bevacizumab ; (N = xx) ; ,Neoadjuvant,None,16,1,3,No,1:No,1:No,,0.86
5162,3397213,Table 1,BaselineCharacteristic,Adjuvant, ;  ; ,Adjuvant,None,17,0,2,No,1:No,1:No,,1
5162,3397213,Table 1,BaselineCharacteristic,x (xx),Lapatinib plus bevacizumab ; (N = xx) ; ,Adjuvant,None,17,1,3,No,1:No,1:No,,0.76
5162,3397213,Table 1,BaselineCharacteristic,Metastatic, ;  ; ,Metastatic,None,18,0,2,No,1:No,1:No,,0.99
5162,3397213,Table 1,BaselineCharacteristic,xx (xx),Lapatinib plus bevacizumab ; (N = xx) ; ,Metastatic,None,18,1,3,No,1:No,1:No,,0.801
5162,3397213,Table 1,BaselineCharacteristic,"Median duration of prior trastuzumab, weeks (range)", ;  ; ,"Median duration of prior trastuzumab, weeks (range)",None,19,0,2,No,1:No,1:No,,0.782
5162,3397213,Table 1,BaselineCharacteristic,xx.x (x.x–xxx.x),Lapatinib plus bevacizumab ; (N = xx) ; ,"Median duration of prior trastuzumab, weeks (range)",None,19,1,3,No,1:No,1:No,,0.66
5162,3397213,Table 1,BaselineCharacteristic,Neoadjuvant, ;  ; ,Neoadjuvant,None,20,0,2,No,1:No,1:No,,0.99
5162,3397213,Table 1,BaselineCharacteristic,x.x (x.x–xx.x),Lapatinib plus bevacizumab ; (N = xx) ; ,Neoadjuvant,None,20,1,3,No,1:No,1:No,,0.8
5162,3397213,Table 1,BaselineCharacteristic,Adjuvant, ;  ; ,Adjuvant,None,21,0,2,No,1:No,1:No,,0.99
5162,3397213,Table 1,BaselineCharacteristic,xx.x (x.x–xxx.x),Lapatinib plus bevacizumab ; (N = xx) ; ,Adjuvant,None,21,1,3,No,1:No,1:No,,0.745
5162,3397213,Table 1,BaselineCharacteristic,Metastatic, ;  ; ,Metastatic,None,22,0,2,No,1:No,1:No,,1
5162,3397213,Table 1,BaselineCharacteristic,xx.x(x.x–xxx.x),Lapatinib plus bevacizumab ; (N = xx) ; ,Metastatic,None,22,1,3,No,1:No,1:No,,0.755
5162,3397213,Table 1,BaselineCharacteristic,"Prior lapatinib in the metastatic setting, n (%)", ;  ; ,"Prior lapatinib in the metastatic setting, n (%)",None,23,0,2,No,1:No,1:No,,0.83
5162,3397213,Table 1,BaselineCharacteristic,xx (xx),Lapatinib plus bevacizumab ; (N = xx) ; ,"Prior lapatinib in the metastatic setting, n (%)",None,23,1,3,No,1:No,1:No,,0.605
5162,3397213,Table 1,BaselineCharacteristic,"Median treatment duration, weeks (range)", ;  ; ,"Median treatment duration, weeks (range)",None,24,0,2,No,1:No,1:No,,0.812
5162,3397213,Table 1,BaselineCharacteristic,xx.x (x.x–xx.x),Lapatinib plus bevacizumab ; (N = xx) ; ,"Median treatment duration, weeks (range)",None,24,1,3,No,1:No,1:No,,0.585
5162,3397213,Table 1,BaselineCharacteristic,"Prior hormonal therapy, n (%)", ;  ; ,"Prior hormonal therapy, n (%)",None,25,0,2,No,1:No,1:No,,0.916
5162,3397213,Table 1,BaselineCharacteristic,xx (xx),Lapatinib plus bevacizumab ; (N = xx) ; ,"Prior hormonal therapy, n (%)",None,25,1,3,No,1:No,1:No,,0.661
5267,3407730,Table 1,BaselineCharacteristic,Variable,,None,None,0,0,12,No,1:No,1:No,,0.905
5267,3407730,Table 1,BaselineCharacteristic,Result,,Variable,None,0,1,1,No,1:No,1:No,,0.834
5267,3407730,Table 1,BaselineCharacteristic,"Age, years, mean",Variable ; ,"Age, years, mean",,1,0,2,No,1:No,1:No,,0.57
5267,3407730,Table 1,BaselineCharacteristic,"Sex, n (%)",Variable ; ,None,None,2,0,24,No,1:No,1:No,,0.84
5267,3407730,Table 1,BaselineCharacteristic,"Sex, n (%)",Result ; ,"Sex, n (%)",None,2,1,43,No,1:No,1:No,,0.649
5267,3407730,Table 1,BaselineCharacteristic,??Male?,Variable ; ,??Male?," Sex, n (%) ",3,0,2,No,1:No,1:No,,0.826
5267,3407730,Table 1,BaselineCharacteristic,??Female?,Variable ; ,??Female?," Sex, n (%) ",4,0,2,No,1:No,1:No,,0.836
5267,3407730,Table 1,BaselineCharacteristic,Pulmonary masses,Variable ; ,Pulmonary masses,,5,0,2,No,1:No,1:No,,0.97
5267,3407730,Table 1,BaselineCharacteristic,xx,Result ; ,Pulmonary masses,,5,1,3,No,1:No,1:No,,0.581
5267,3407730,Table 1,BaselineCharacteristic,"NSCLC, n (%)",Variable ; ,None,None,6,0,24,No,1:No,1:No,,0.93
5267,3407730,Table 1,BaselineCharacteristic,"NSCLC, n (%)",Result ; ,"NSCLC, n (%)",None,6,1,43,No,1:No,1:No,,0.729
5267,3407730,Table 1,BaselineCharacteristic,??Stagea I?,Variable ; ,??Stagea I?," NSCLC, n (%) ",7,0,2,No,1:No,1:No,,0.896
5267,3407730,Table 1,BaselineCharacteristic,??Stagea II?,Variable ; ,??Stagea II?," NSCLC, n (%) ",8,0,2,No,1:No,1:No,,0.906
5267,3407730,Table 1,BaselineCharacteristic,xx (xx.xx),Result ; ,??Stagea II?," NSCLC, n (%) ",8,1,3,No,1:No,1:No,,0.581
5267,3407730,Table 1,BaselineCharacteristic,??Stagea III?,Variable ; ,??Stagea III?," NSCLC, n (%) ",9,0,2,No,1:No,1:No,,0.916
5267,3407730,Table 1,BaselineCharacteristic,xx (xx.xx),Result ; ,??Stagea III?," NSCLC, n (%) ",9,1,3,No,1:No,1:No,,0.581
5267,3407730,Table 1,BaselineCharacteristic,??Stagea IV?,Variable ; ,??Stagea IV?," NSCLC, n (%) ",10,0,2,No,1:No,1:No,,0.9
5267,3407730,Table 1,BaselineCharacteristic,x (xx.xx),Result ; ,??Stagea IV?," NSCLC, n (%) ",10,1,3,No,1:No,1:No,,0.561
5267,3407730,Table 1,BaselineCharacteristic,"Previous therapy, n (%)",Variable ; ,None,None,11,0,24,No,1:No,1:No,,0.95
5267,3407730,Table 1,BaselineCharacteristic,"Previous therapy, n (%)",Result ; ,"Previous therapy, n (%)",None,11,1,43,No,1:No,1:No,,0.819
5267,3407730,Table 1,BaselineCharacteristic,??No surgerya,Variable ; ,??No surgerya," Previous therapy, n (%) ",12,0,2,No,1:No,1:No,,0.936
5267,3407730,Table 1,BaselineCharacteristic,xx (xx.xx),Result ; ,??No surgerya," Previous therapy, n (%) ",12,1,3,No,1:No,1:No,,0.641
5267,3407730,Table 1,BaselineCharacteristic,??Lung resection (recurrent)?,Variable ; ,??Lung resection (recurrent)?," Previous therapy, n (%) ",13,0,2,No,1:No,1:No,,0.936
5267,3407730,Table 1,BaselineCharacteristic,xx (xx.xx),Result ; ,??Lung resection (recurrent)?," Previous therapy, n (%) ",13,1,3,No,1:No,1:No,,0.641
5267,3407730,Table 1,BaselineCharacteristic,"Reasons for no surgery, n (%)",Variable ; ,None,None,14,0,24,No,1:No,1:No,,0.895
5267,3407730,Table 1,BaselineCharacteristic,"Reasons for no surgery, n (%)",Result ; ,"Reasons for no surgery, n (%)",None,14,1,43,No,1:No,1:No,,0.805
5267,3407730,Table 1,BaselineCharacteristic,??Poor lung function?,Variable ; ,??Poor lung function?," Reasons for no surgery, n (%) ",15,0,2,No,1:No,1:No,,0.88
5267,3407730,Table 1,BaselineCharacteristic,xx (xx.xx),Result ; ,??Poor lung function?," Reasons for no surgery, n (%) ",15,1,3,No,1:No,1:No,,0.651
5267,3407730,Table 1,BaselineCharacteristic,??Sever cardiac risk?,Variable ; ,??Sever cardiac risk?," Reasons for no surgery, n (%) ",16,0,2,No,1:No,1:No,,0.88
5267,3407730,Table 1,BaselineCharacteristic,xx (xx.xx),Result ; ,??Sever cardiac risk?," Reasons for no surgery, n (%) ",16,1,3,No,1:No,1:No,,0.681
5267,3407730,Table 1,BaselineCharacteristic,??Poor performance status?,Variable ; ,??Poor performance status?," Reasons for no surgery, n (%) ",17,0,2,No,1:No,1:No,,0.883
5267,3407730,Table 1,BaselineCharacteristic,x (xx.xx),Result ; ,??Poor performance status?," Reasons for no surgery, n (%) ",17,1,3,No,1:No,1:No,,0.631
5267,3407730,Table 1,BaselineCharacteristic,??Multiple co-morbidities?,Variable ; ,??Multiple co-morbidities?," Reasons for no surgery, n (%) ",18,0,2,No,1:No,1:No,,0.88
5267,3407730,Table 1,BaselineCharacteristic,x (xx.xx),Result ; ,??Multiple co-morbidities?," Reasons for no surgery, n (%) ",18,1,3,No,1:No,1:No,,0.621
5267,3407730,Table 1,BaselineCharacteristic,Length of hospital stay (days),Variable ; ,None,None,19,0,24,No,1:No,1:No,,0.985
5267,3407730,Table 1,BaselineCharacteristic,Length of hospital stay (days),Result ; ,Length of hospital stay (days),None,19,1,43,No,1:No,1:No,,0.857
5267,3407730,Table 1,BaselineCharacteristic,??Mean (range)?,Variable ; ,??Mean (range)?, Length of hospital stay (days) ,20,0,2,No,1:No,1:No,,0.772
5267,3407730,Table 1,BaselineCharacteristic,x.x (x–xx),Result ; ,??Mean (range)?, Length of hospital stay (days) ,20,1,3,No,1:No,1:No,,0.63
5267,3407730,Table 2,BaselineCharacteristic,Variable,,None,None,0,0,12,No,1:No,1:No,,0.905
5267,3407730,Table 2,BaselineCharacteristic,Result,,Variable,None,0,1,1,No,1:No,1:No,,0.834
5267,3407730,Table 2,BaselineCharacteristic,"Age, years, mean",Variable ; ,"Age, years, mean",,1,0,2,No,1:No,1:No,,0.57
5267,3407730,Table 2,BaselineCharacteristic,"Sex, n (%)",Variable ; ,None,None,2,0,24,No,1:No,1:No,,0.84
5267,3407730,Table 2,BaselineCharacteristic,"Sex, n (%)",Result ; ,"Sex, n (%)",None,2,1,43,No,1:No,1:No,,0.649
5267,3407730,Table 2,BaselineCharacteristic,??Male?,Variable ; ,??Male?," Sex, n (%) ",3,0,2,No,1:No,1:No,,0.826
5267,3407730,Table 2,BaselineCharacteristic,??Female?,Variable ; ,??Female?," Sex, n (%) ",4,0,2,No,1:No,1:No,,0.836
5267,3407730,Table 2,BaselineCharacteristic,pulmonary masses,Variable ; ,pulmonary masses,,5,0,2,No,1:No,1:No,,0.97
5267,3407730,Table 2,BaselineCharacteristic,xx,Result ; ,pulmonary masses,,5,1,3,No,1:No,1:No,,0.581
5267,3407730,Table 2,BaselineCharacteristic,"Primary tumor, n (%)",Variable ; ,None,None,6,0,24,No,1:No,1:No,,0.93
5267,3407730,Table 2,BaselineCharacteristic,"Primary tumor, n (%)",Result ; ,"Primary tumor, n (%)",None,6,1,43,No,1:No,1:No,,0.759
5267,3407730,Table 2,BaselineCharacteristic,??Breast cancer?,Variable ; ,??Breast cancer?," Primary tumor, n (%) ",7,0,2,No,1:No,1:No,,0.916
5267,3407730,Table 2,BaselineCharacteristic,x (xx.xx),Result ; ,??Breast cancer?," Primary tumor, n (%) ",7,1,3,No,1:No,1:No,,0.531
5267,3407730,Table 2,BaselineCharacteristic,??Prostate cancer?,Variable ; ,??Prostate cancer?," Primary tumor, n (%) ",8,0,2,No,1:No,1:No,,0.916
5267,3407730,Table 2,BaselineCharacteristic,x (xx.xx),Result ; ,??Prostate cancer?," Primary tumor, n (%) ",8,1,3,No,1:No,1:No,,0.561
5267,3407730,Table 2,BaselineCharacteristic,??Liver cancer?,Variable ; ,??Liver cancer?," Primary tumor, n (%) ",9,0,2,No,1:No,1:No,,0.926
5267,3407730,Table 2,BaselineCharacteristic,x (xx.xx),Result ; ,??Liver cancer?," Primary tumor, n (%) ",9,1,3,No,1:No,1:No,,0.581
5267,3407730,Table 2,BaselineCharacteristic,??Gastrointestinal cancer?,Variable ; ,??Gastrointestinal cancer?," Primary tumor, n (%) ",10,0,2,No,1:No,1:No,,0.936
5267,3407730,Table 2,BaselineCharacteristic,x (xx.xx),Result ; ,??Gastrointestinal cancer?," Primary tumor, n (%) ",10,1,3,No,1:No,1:No,,0.601
5267,3407730,Table 2,BaselineCharacteristic,"Previous therapy, n (%)",Variable ; ,None,None,11,0,24,No,1:No,1:No,,0.95
5267,3407730,Table 2,BaselineCharacteristic,"Previous therapy, n (%)",Result ; ,"Previous therapy, n (%)",None,11,1,43,No,1:No,1:No,,0.819
5267,3407730,Table 2,BaselineCharacteristic,??No surgerya,Variable ; ,??No surgerya," Previous therapy, n (%) ",12,0,2,No,1:No,1:No,,0.936
5267,3407730,Table 2,BaselineCharacteristic,xx (xx.xx),Result ; ,??No surgerya," Previous therapy, n (%) ",12,1,3,No,1:No,1:No,,0.641
5267,3407730,Table 2,BaselineCharacteristic,??Surgery?,Variable ; ,??Surgery?," Previous therapy, n (%) ",13,0,2,No,1:No,1:No,,0.936
5267,3407730,Table 2,BaselineCharacteristic,xx (xx.xx),Result ; ,??Surgery?," Previous therapy, n (%) ",13,1,3,No,1:No,1:No,,0.641
5267,3407730,Table 2,BaselineCharacteristic,"Reasons for no surgery, n (%)",Variable ; ,None,None,14,0,24,No,1:No,1:No,,0.895
5267,3407730,Table 2,BaselineCharacteristic,"Reasons for no surgery, n (%)",Result ; ,"Reasons for no surgery, n (%)",None,14,1,43,No,1:No,1:No,,0.805
5267,3407730,Table 2,BaselineCharacteristic,??Poor lung function?,Variable ; ,??Poor lung function?," Reasons for no surgery, n (%) ",15,0,2,No,1:No,1:No,,0.88
5267,3407730,Table 2,BaselineCharacteristic,xx (xx.xx),Result ; ,??Poor lung function?," Reasons for no surgery, n (%) ",15,1,3,No,1:No,1:No,,0.651
5267,3407730,Table 2,BaselineCharacteristic,??Sever cardiac risk?,Variable ; ,??Sever cardiac risk?," Reasons for no surgery, n (%) ",16,0,2,No,1:No,1:No,,0.88
5267,3407730,Table 2,BaselineCharacteristic,x (xx.xx),Result ; ,??Sever cardiac risk?," Reasons for no surgery, n (%) ",16,1,3,No,1:No,1:No,,0.651
5267,3407730,Table 2,BaselineCharacteristic,??Poor performance status?,Variable ; ,??Poor performance status?," Reasons for no surgery, n (%) ",17,0,2,No,1:No,1:No,,0.883
5267,3407730,Table 2,BaselineCharacteristic,x (x.xx),Result ; ,??Poor performance status?," Reasons for no surgery, n (%) ",17,1,3,No,1:No,1:No,,0.631
5267,3407730,Table 2,BaselineCharacteristic,??Multiple co-morbidities?,Variable ; ,??Multiple co-morbidities?," Reasons for no surgery, n (%) ",18,0,2,No,1:No,1:No,,0.88
5267,3407730,Table 2,BaselineCharacteristic,x (x.xx),Result ; ,??Multiple co-morbidities?," Reasons for no surgery, n (%) ",18,1,3,No,1:No,1:No,,0.621
5267,3407730,Table 2,BaselineCharacteristic,Length of hospital stay (days),Variable ; ,None,None,19,0,24,No,1:No,1:No,,0.985
5267,3407730,Table 2,BaselineCharacteristic,Length of hospital stay (days),Result ; ,Length of hospital stay (days),None,19,1,43,No,1:No,1:No,,0.857
5267,3407730,Table 2,BaselineCharacteristic,??Mean (range)?,Variable ; ,??Mean (range)?, Length of hospital stay (days) ,20,0,2,No,1:No,1:No,,0.772
5267,3407730,Table 2,BaselineCharacteristic,x.x (x–xx),Result ; ,??Mean (range)?, Length of hospital stay (days) ,20,1,3,No,1:No,1:No,,0.63
5330,3414800,Table 1,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
5330,3414800,Table 1,BaselineCharacteristic,OSA,,,None,0,1,1,No,1:No,1:No,,0.894
5330,3414800,Table 1,BaselineCharacteristic,,,,None,0,2,1,No,1:No,1:No,,0.903
5330,3414800,Table 1,BaselineCharacteristic,,,,None,0,3,1,No,1:No,1:No,,0.903
5330,3414800,Table 1,BaselineCharacteristic,,,,None,0,4,1,No,1:No,1:No,,0.913
5330,3414800,Table 1,BaselineCharacteristic,, ; ,None,None,1,0,12,No,1:No,1:No,,0.898
5330,3414800,Table 1,BaselineCharacteristic,snorers,OSA ; ,,None,1,1,1,No,1:No,1:No,,0.857
5330,3414800,Table 1,BaselineCharacteristic,mild/moderate, ; ,,None,1,2,1,No,1:No,1:No,,0.877
5330,3414800,Table 1,BaselineCharacteristic,severe, ; ,,None,1,3,1,No,1:No,1:No,,0.868
5330,3414800,Table 1,BaselineCharacteristic,, ; ,,None,1,4,1,No,1:No,1:No,,0.906
5330,3414800,Table 1,BaselineCharacteristic,, ;  ; ,None,None,2,0,12,No,1:No,1:No,,0.913
5330,3414800,Table 1,BaselineCharacteristic,AHI<x n=xx,OSA ; snorers ; ,,None,2,1,1,No,1:No,1:No,,0.767
5330,3414800,Table 1,BaselineCharacteristic,AHI?xx n=xx, ; severe ; ,,None,2,3,1,No,1:No,1:No,,0.574
5330,3414800,Table 1,BaselineCharacteristic,P, ;  ; ,,None,2,4,1,No,1:No,1:No,,0.906
5330,3414800,Table 1,BaselineCharacteristic,Age, ;  ;  ; ,Age,None,3,0,2,No,1:No,1:No,,0.96
5330,3414800,Table 1,BaselineCharacteristic,NS, ;  ; P ; ,Age,None,3,4,3,No,1:No,1:No,,0.9
5330,3414800,Table 1,BaselineCharacteristic,Males (%), ;  ;  ; ,Males (%),None,4,0,2,No,1:No,1:No,,0.81
5330,3414800,Table 1,BaselineCharacteristic,NS, ;  ; P ; ,Males (%),None,4,4,3,No,1:No,1:No,,0.67
5330,3414800,Table 1,BaselineCharacteristic,AHI (events/h), ;  ;  ; ,AHI (events/h),None,5,0,2,No,1:No,1:No,,0.92
5330,3414800,Table 1,BaselineCharacteristic,x.x±x.x,OSA ; snorers ; AHI<x n=xx ; ,AHI (events/h),None,5,1,3,No,1:No,1:No,,0.66
5330,3414800,Table 1,BaselineCharacteristic,<x.xxx, ;  ; P ; ,AHI (events/h),None,5,4,3,No,1:No,1:No,,0.76
5330,3414800,Table 1,BaselineCharacteristic,Average SaO², ;  ;  ; ,Average SaO²,None,6,0,2,No,1:No,1:No,,0.99
5330,3414800,Table 1,BaselineCharacteristic,"xx,x±x,x",OSA ; snorers ; AHI<x n=xx ; ,Average SaO²,None,6,1,3,No,1:No,1:No,,0.566
5330,3414800,Table 1,BaselineCharacteristic,"xx,x±x,x", ; severe ; AHI?xx n=xx ; ,Average SaO²,None,6,3,3,No,1:No,1:No,,0.51
5330,3414800,Table 1,BaselineCharacteristic,"<x,xx", ;  ; P ; ,Average SaO²,None,6,4,3,No,1:No,1:No,,0.816
5330,3414800,Table 1,BaselineCharacteristic,Body Mass Index (kg/mx), ;  ;  ; ,Body Mass Index (kg/mx),None,7,0,2,No,1:No,1:No,,1
5330,3414800,Table 1,BaselineCharacteristic,"xx,x±x,x",OSA ; snorers ; AHI<x n=xx ; ,Body Mass Index (kg/mx),None,7,1,3,No,1:No,1:No,,0.646
5330,3414800,Table 1,BaselineCharacteristic,"xx,x±x,x", ; mild/moderate ; AHI x – xx n=xx ; ,Body Mass Index (kg/mx),None,7,2,3,No,1:No,1:No,,0.55
5330,3414800,Table 1,BaselineCharacteristic,"xx,x±x,x", ; severe ; AHI?xx n=xx ; ,Body Mass Index (kg/mx),None,7,3,3,No,1:No,1:No,,0.59
5330,3414800,Table 1,BaselineCharacteristic,"<x,xx", ;  ; P ; ,Body Mass Index (kg/mx),None,7,4,3,No,1:No,1:No,,0.866
5330,3414800,Table 1,BaselineCharacteristic,Waist circumference (cm), ;  ;  ; ,Waist circumference (cm),None,8,0,2,No,1:No,1:No,,0.99
5330,3414800,Table 1,BaselineCharacteristic,"xxx,x±xx,x",OSA ; snorers ; AHI<x n=xx ; ,Waist circumference (cm),None,8,1,3,No,1:No,1:No,,0.65
5330,3414800,Table 1,BaselineCharacteristic,"<x,xxx", ;  ; P ; ,Waist circumference (cm),None,8,4,3,No,1:No,1:No,,0.9
5330,3414800,Table 1,BaselineCharacteristic,Hip circumference (cm), ;  ;  ; ,Hip circumference (cm),None,9,0,2,No,1:No,1:No,,1
5330,3414800,Table 1,BaselineCharacteristic,"xxx,x±x,x",OSA ; snorers ; AHI<x n=xx ; ,Hip circumference (cm),None,9,1,3,No,1:No,1:No,,0.76
5330,3414800,Table 1,BaselineCharacteristic,"xxx,x±x,x", ; mild/moderate ; AHI x – xx n=xx ; ,Hip circumference (cm),None,9,2,3,No,1:No,1:No,,0.57
5330,3414800,Table 1,BaselineCharacteristic,"<x,xxx", ;  ; P ; ,Hip circumference (cm),None,9,4,3,No,1:No,1:No,,0.92
5330,3414800,Table 1,BaselineCharacteristic,Blood glucose (mg/dl), ;  ;  ; ,Blood glucose (mg/dl),None,10,0,2,No,1:No,1:No,,1
5330,3414800,Table 1,BaselineCharacteristic,xxx.x±xx.x,OSA ; snorers ; AHI<x n=xx ; ,Blood glucose (mg/dl),None,10,1,3,No,1:No,1:No,,0.69
5330,3414800,Table 1,BaselineCharacteristic,x.xxx, ;  ; P ; ,Blood glucose (mg/dl),None,10,4,3,No,1:No,1:No,,0.98
5330,3414800,Table 1,BaselineCharacteristic,Insulin (?U/mL), ;  ;  ; ,Insulin (?U/mL),None,11,0,2,No,1:No,1:No,,1
5330,3414800,Table 1,BaselineCharacteristic,xx.x±x.x,OSA ; snorers ; AHI<x n=xx ; ,Insulin (?U/mL),None,11,1,3,No,1:No,1:No,,0.686
5330,3414800,Table 1,BaselineCharacteristic,xx.x±xx.x, ; severe ; AHI?xx n=xx ; ,Insulin (?U/mL),None,11,3,3,No,1:No,1:No,,0.55
5330,3414800,Table 1,BaselineCharacteristic,<x.xx, ;  ; P ; ,Insulin (?U/mL),None,11,4,3,No,1:No,1:No,,0.926
5330,3414800,Table 1,BaselineCharacteristic,HOMA-IR, ;  ;  ; ,HOMA-IR,None,12,0,2,No,1:No,1:No,,1
5330,3414800,Table 1,BaselineCharacteristic,x.x±x.x,OSA ; snorers ; AHI<x n=xx ; ,HOMA-IR,None,12,1,3,No,1:No,1:No,,0.79
5330,3414800,Table 1,BaselineCharacteristic,x.x±x.x, ; mild/moderate ; AHI x – xx n=xx ; ,HOMA-IR,None,12,2,3,No,1:No,1:No,,0.59
5330,3414800,Table 1,BaselineCharacteristic,x.x±xx.x, ; severe ; AHI?xx n=xx ; ,HOMA-IR,None,12,3,3,No,1:No,1:No,,0.56
5330,3414800,Table 1,BaselineCharacteristic,<x.xx, ;  ; P ; ,HOMA-IR,None,12,4,3,No,1:No,1:No,,0.926
5330,3414800,Table 1,BaselineCharacteristic,Total cholesterol (mg/dl), ;  ;  ; ,Total cholesterol (mg/dl),None,13,0,2,No,1:No,1:No,,1
5330,3414800,Table 1,BaselineCharacteristic,xxx.x±xx.x,OSA ; snorers ; AHI<x n=xx ; ,Total cholesterol (mg/dl),None,13,1,3,No,1:No,1:No,,0.69
5330,3414800,Table 1,BaselineCharacteristic,NS, ;  ; P ; ,Total cholesterol (mg/dl),None,13,4,3,No,1:No,1:No,,1
5330,3414800,Table 1,BaselineCharacteristic,LDL-cholesterol (mg/dl), ;  ;  ; ,LDL-cholesterol (mg/dl),None,14,0,2,No,1:No,1:No,,1
5330,3414800,Table 1,BaselineCharacteristic,xxx.x±xx.x,OSA ; snorers ; AHI<x n=xx ; ,LDL-cholesterol (mg/dl),None,14,1,3,No,1:No,1:No,,0.69
5330,3414800,Table 1,BaselineCharacteristic,xxx.x±xx.x, ; severe ; AHI?xx n=xx ; ,LDL-cholesterol (mg/dl),None,14,3,3,No,1:No,1:No,,0.52
5330,3414800,Table 1,BaselineCharacteristic,NS, ;  ; P ; ,LDL-cholesterol (mg/dl),None,14,4,3,No,1:No,1:No,,1
5330,3414800,Table 1,BaselineCharacteristic,HDL-cholesterol (mg/dl), ;  ;  ; ,HDL-cholesterol (mg/dl),None,15,0,2,No,1:No,1:No,,1
5330,3414800,Table 1,BaselineCharacteristic,xx.x±xx.x,OSA ; snorers ; AHI<x n=xx ; ,HDL-cholesterol (mg/dl),None,15,1,3,No,1:No,1:No,,0.58
5330,3414800,Table 1,BaselineCharacteristic,xx.x±x.x, ; severe ; AHI?xx n=xx ; ,HDL-cholesterol (mg/dl),None,15,3,3,No,1:No,1:No,,0.66
5330,3414800,Table 1,BaselineCharacteristic,NS, ;  ; P ; ,HDL-cholesterol (mg/dl),None,15,4,3,No,1:No,1:No,,1
5330,3414800,Table 1,BaselineCharacteristic,Triglycerides (mg/dl), ;  ;  ; ,Triglycerides (mg/dl),None,16,0,2,No,1:No,1:No,,1
5330,3414800,Table 1,BaselineCharacteristic,xxx.x±xx.x,OSA ; snorers ; AHI<x n=xx ; ,Triglycerides (mg/dl),None,16,1,3,No,1:No,1:No,,0.68
5330,3414800,Table 1,BaselineCharacteristic,xxx.x±xxx.x, ; severe ; AHI?xx n=xx ; ,Triglycerides (mg/dl),None,16,3,3,No,1:No,1:No,,0.62
5330,3414800,Table 1,BaselineCharacteristic,NS, ;  ; P ; ,Triglycerides (mg/dl),None,16,4,3,No,1:No,1:No,,1
5330,3414800,Table 1,BaselineCharacteristic,Urinary x-iso-PGFx? (pg/mg creatinine), ;  ;  ; ,Urinary x-iso-PGFx? (pg/mg creatinine),None,17,0,2,No,1:No,1:No,,1
5330,3414800,Table 1,BaselineCharacteristic,"xxx.x±xx,x",OSA ; snorers ; AHI<x n=xx ; ,Urinary x-iso-PGFx? (pg/mg creatinine),None,17,1,3,No,1:No,1:No,,0.66
5330,3414800,Table 1,BaselineCharacteristic,xxx.x±xx.x, ; severe ; AHI?xx n=xx ; ,Urinary x-iso-PGFx? (pg/mg creatinine),None,17,3,3,No,1:No,1:No,,0.51
5330,3414800,Table 1,BaselineCharacteristic,<x.xxx, ;  ; P ; ,Urinary x-iso-PGFx? (pg/mg creatinine),None,17,4,3,No,1:No,1:No,,0.94
5330,3414800,Table 1,BaselineCharacteristic,sNOXx-dp (pg/ml), ;  ;  ; ,sNOXx-dp (pg/ml),None,18,0,2,No,1:No,1:No,,0.99
5330,3414800,Table 1,BaselineCharacteristic,"xx.x±x,x",OSA ; snorers ; AHI<x n=xx ; ,sNOXx-dp (pg/ml),None,18,1,3,No,1:No,1:No,,0.681
5330,3414800,Table 1,BaselineCharacteristic,xx.x±x.x, ; mild/moderate ; AHI x – xx n=xx ; ,sNOXx-dp (pg/ml),None,18,2,3,No,1:No,1:No,,0.59
5330,3414800,Table 1,BaselineCharacteristic,"xx,x±x.x", ; severe ; AHI?xx n=xx ; ,sNOXx-dp (pg/ml),None,18,3,3,No,1:No,1:No,,0.65
5330,3414800,Table 1,BaselineCharacteristic,NS, ;  ; P ; ,sNOXx-dp (pg/ml),None,18,4,3,No,1:No,1:No,,0.99
5330,3414800,Table 1,BaselineCharacteristic,Serum NOx (uM/ml), ;  ;  ; ,Serum NOx (uM/ml),None,19,0,2,No,1:No,1:No,,0.99
5330,3414800,Table 1,BaselineCharacteristic,xx.x±xx.x,OSA ; snorers ; AHI<x n=xx ; ,Serum NOx (uM/ml),None,19,1,3,No,1:No,1:No,,0.565
5330,3414800,Table 1,BaselineCharacteristic,"xx,x±xx.x", ; severe ; AHI?xx n=xx ; ,Serum NOx (uM/ml),None,19,3,3,No,1:No,1:No,,0.58
5330,3414800,Table 1,BaselineCharacteristic,NS, ;  ; P ; ,Serum NOx (uM/ml),None,19,4,3,No,1:No,1:No,,0.99
5330,3414800,Table 1,BaselineCharacteristic,FMD%, ;  ;  ; ,FMD%,None,20,0,2,No,1:No,1:No,,0.99
5330,3414800,Table 1,BaselineCharacteristic,x.x±x.x,OSA ; snorers ; AHI<x n=xx ; ,FMD%,None,20,1,3,No,1:No,1:No,,0.76
5330,3414800,Table 1,BaselineCharacteristic,x.x±x.x, ; mild/moderate ; AHI x – xx n=xx ; ,FMD%,None,20,2,3,No,1:No,1:No,,0.59
5330,3414800,Table 1,BaselineCharacteristic,x.x±x.x, ; severe ; AHI?xx n=xx ; ,FMD%,None,20,3,3,No,1:No,1:No,,0.65
5330,3414800,Table 1,BaselineCharacteristic,<x.xx, ;  ; P ; ,FMD%,None,20,4,3,No,1:No,1:No,,0.931
5330,3414800,Table 3,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
5330,3414800,Table 3,BaselineCharacteristic,AHI,,,None,0,1,1,No,1:No,1:No,,0.863
5330,3414800,Table 3,BaselineCharacteristic,AHI,,,None,0,2,1,No,1:No,1:No,,0.863
5330,3414800,Table 3,BaselineCharacteristic,, ; ,None,None,1,0,12,No,1:No,1:No,,0.898
5330,3414800,Table 3,BaselineCharacteristic,r,AHI ; ,,None,1,1,1,No,1:No,1:No,,0.877
5330,3414800,Table 3,BaselineCharacteristic,P,AHI ; ,,None,1,2,1,No,1:No,1:No,,0.856
5330,3414800,Table 3,BaselineCharacteristic,Age, ;  ; ,Age,None,2,0,2,No,1:No,1:No,,0.95
5330,3414800,Table 3,BaselineCharacteristic,x.xxx,AHI ; r ; ,Age,None,2,1,3,No,1:No,1:No,,0.78
5330,3414800,Table 3,BaselineCharacteristic,NS,AHI ; P ; ,Age,None,2,2,3,No,1:No,1:No,,0.83
5330,3414800,Table 3,BaselineCharacteristic,Average SaOx, ;  ; ,Average SaOx,None,3,0,2,No,1:No,1:No,,0.96
5330,3414800,Table 3,BaselineCharacteristic,#NAME?,AHI ; r ; ,Average SaOx,None,3,1,3,No,1:No,1:No,,0.83
5330,3414800,Table 3,BaselineCharacteristic,"<x,xx",AHI ; P ; ,Average SaOx,None,3,2,3,No,1:No,1:No,,0.62
5330,3414800,Table 3,BaselineCharacteristic,Body Mass Index (kg/mx), ;  ; ,Body Mass Index (kg/mx),None,4,0,2,No,1:No,1:No,,0.98
5330,3414800,Table 3,BaselineCharacteristic,x.xxx,AHI ; r ; ,Body Mass Index (kg/mx),None,4,1,3,No,1:No,1:No,,0.82
5330,3414800,Table 3,BaselineCharacteristic,"<x,xx",AHI ; P ; ,Body Mass Index (kg/mx),None,4,2,3,No,1:No,1:No,,0.7
5330,3414800,Table 3,BaselineCharacteristic,Waist circumference (cm), ;  ; ,Waist circumference (cm),None,5,0,2,No,1:No,1:No,,0.97
5330,3414800,Table 3,BaselineCharacteristic,x.xxx,AHI ; r ; ,Waist circumference (cm),None,5,1,3,No,1:No,1:No,,0.81
5330,3414800,Table 3,BaselineCharacteristic,<x.xxx,AHI ; P ; ,Waist circumference (cm),None,5,2,3,No,1:No,1:No,,0.77
5330,3414800,Table 3,BaselineCharacteristic,Hip circumference (cm), ;  ; ,Hip circumference (cm),None,6,0,2,No,1:No,1:No,,0.99
5330,3414800,Table 3,BaselineCharacteristic,x.xxx,AHI ; r ; ,Hip circumference (cm),None,6,1,3,No,1:No,1:No,,0.85
5330,3414800,Table 3,BaselineCharacteristic,<x.xxx,AHI ; P ; ,Hip circumference (cm),None,6,2,3,No,1:No,1:No,,0.83
5330,3414800,Table 3,BaselineCharacteristic,Blood glucose (mg/dl), ;  ; ,Blood glucose (mg/dl),None,7,0,2,No,1:No,1:No,,0.99
5330,3414800,Table 3,BaselineCharacteristic,x.xxx,AHI ; r ; ,Blood glucose (mg/dl),None,7,1,3,No,1:No,1:No,,0.87
5330,3414800,Table 3,BaselineCharacteristic,NS,AHI ; P ; ,Blood glucose (mg/dl),None,7,2,3,No,1:No,1:No,,0.9
5330,3414800,Table 3,BaselineCharacteristic,Insulin (?U/mL), ;  ; ,Insulin (?U/mL),None,8,0,2,No,1:No,1:No,,0.99
5330,3414800,Table 3,BaselineCharacteristic,x.xxx,AHI ; r ; ,Insulin (?U/mL),None,8,1,3,No,1:No,1:No,,0.88
5330,3414800,Table 3,BaselineCharacteristic,<x.xx,AHI ; P ; ,Insulin (?U/mL),None,8,2,3,No,1:No,1:No,,0.77
5330,3414800,Table 3,BaselineCharacteristic,HOMA-IR, ;  ; ,HOMA-IR,None,9,0,2,No,1:No,1:No,,1
5330,3414800,Table 3,BaselineCharacteristic,x.xxx,AHI ; r ; ,HOMA-IR,None,9,1,3,No,1:No,1:No,,0.92
5330,3414800,Table 3,BaselineCharacteristic,<x.xx,AHI ; P ; ,HOMA-IR,None,9,2,3,No,1:No,1:No,,0.84
5330,3414800,Table 3,BaselineCharacteristic,Total cholesterol (mg/dl), ;  ; ,Total cholesterol (mg/dl),None,10,0,2,No,1:No,1:No,,1
5330,3414800,Table 3,BaselineCharacteristic,#NAME?,AHI ; r ; ,Total cholesterol (mg/dl),None,10,1,3,No,1:No,1:No,,0.93
5330,3414800,Table 3,BaselineCharacteristic,NS,AHI ; P ; ,Total cholesterol (mg/dl),None,10,2,3,No,1:No,1:No,,0.94
5330,3414800,Table 3,BaselineCharacteristic,LDL-cholesterol (mg/dl), ;  ; ,LDL-cholesterol (mg/dl),None,11,0,2,No,1:No,1:No,,1
5330,3414800,Table 3,BaselineCharacteristic,#NAME?,AHI ; r ; ,LDL-cholesterol (mg/dl),None,11,1,3,No,1:No,1:No,,0.93
5330,3414800,Table 3,BaselineCharacteristic,NS,AHI ; P ; ,LDL-cholesterol (mg/dl),None,11,2,3,No,1:No,1:No,,0.94
5330,3414800,Table 3,BaselineCharacteristic,HDL-cholesterol (mg/dl), ;  ; ,HDL-cholesterol (mg/dl),None,12,0,2,No,1:No,1:No,,1
5330,3414800,Table 3,BaselineCharacteristic,#NAME?,AHI ; r ; ,HDL-cholesterol (mg/dl),None,12,1,3,No,1:No,1:No,,0.93
5330,3414800,Table 3,BaselineCharacteristic,NS,AHI ; P ; ,HDL-cholesterol (mg/dl),None,12,2,3,No,1:No,1:No,,0.94
5330,3414800,Table 3,BaselineCharacteristic,Triglycerides (mg/dl), ;  ; ,Triglycerides (mg/dl),None,13,0,2,No,1:No,1:No,,1
5330,3414800,Table 3,BaselineCharacteristic,x.xxx,AHI ; r ; ,Triglycerides (mg/dl),None,13,1,3,No,1:No,1:No,,0.93
5330,3414800,Table 3,BaselineCharacteristic,NS,AHI ; P ; ,Triglycerides (mg/dl),None,13,2,3,No,1:No,1:No,,0.94
5330,3414800,Table 3,BaselineCharacteristic,Urinary x-iso-PGFx? (pg/mg creatinine), ;  ; ,Urinary x-iso-PGFx? (pg/mg creatinine),None,14,0,2,No,1:No,1:No,,1
5330,3414800,Table 3,BaselineCharacteristic,x.xxx,AHI ; r ; ,Urinary x-iso-PGFx? (pg/mg creatinine),None,14,1,3,No,1:No,1:No,,0.93
5330,3414800,Table 3,BaselineCharacteristic,<x.xxx,AHI ; P ; ,Urinary x-iso-PGFx? (pg/mg creatinine),None,14,2,3,No,1:No,1:No,,0.87
5330,3414800,Table 3,BaselineCharacteristic,sNOXx-dp (pg/ml), ;  ; ,sNOXx-dp (pg/ml),None,15,0,2,No,1:No,1:No,,1
5330,3414800,Table 3,BaselineCharacteristic,x.xxx,AHI ; r ; ,sNOXx-dp (pg/ml),None,15,1,3,No,1:No,1:No,,0.92
5330,3414800,Table 3,BaselineCharacteristic,NS,AHI ; P ; ,sNOXx-dp (pg/ml),None,15,2,3,No,1:No,1:No,,0.93
5330,3414800,Table 3,BaselineCharacteristic,Serum NOx (uM/ml), ;  ; ,Serum NOx (uM/ml),None,16,0,2,No,1:No,1:No,,1
5330,3414800,Table 3,BaselineCharacteristic,#NAME?,AHI ; r ; ,Serum NOx (uM/ml),None,16,1,3,No,1:No,1:No,,0.92
5330,3414800,Table 3,BaselineCharacteristic,NS,AHI ; P ; ,Serum NOx (uM/ml),None,16,2,3,No,1:No,1:No,,0.93
5330,3414800,Table 3,BaselineCharacteristic,FMD%, ;  ; ,FMD%,None,17,0,2,No,1:No,1:No,,1
5330,3414800,Table 3,BaselineCharacteristic,#NAME?,AHI ; r ; ,FMD%,None,17,1,3,No,1:No,1:No,,0.92
5330,3414800,Table 3,BaselineCharacteristic,NS,AHI ; P ; ,FMD%,None,17,2,3,No,1:No,1:No,,0.93
5330,3414800,Table 3,BaselineCharacteristic,Metabolic score, ;  ; ,Metabolic score,None,18,0,2,No,1:No,1:No,,1
5330,3414800,Table 3,BaselineCharacteristic,x.xxx,AHI ; r ; ,Metabolic score,None,18,1,3,No,1:No,1:No,,0.92
5330,3414800,Table 3,BaselineCharacteristic,NS,AHI ; P ; ,Metabolic score,None,18,2,3,No,1:No,1:No,,0.93
5383,3427446,Table 1,BaselineCharacteristic,Characteristics,,None,None,0,0,12,No,1:No,1:No,,0.905
5383,3427446,Table 1,BaselineCharacteristic,Values (N?=?xx),,Characteristics,None,0,1,1,No,1:No,1:No,,0.583
5383,3427446,Table 1,BaselineCharacteristic,Gender (men/women),Characteristics ; ,Gender (men/women),None,1,0,2,No,1:No,1:No,,0.94
5383,3427446,Table 1,BaselineCharacteristic,xx (xx.x %) / xx (xx.x %),Values (N?=?xx) ; ,Gender (men/women),None,1,1,3,No,1:No,1:No,,0.549
5383,3427446,Table 1,BaselineCharacteristic,Age (mean ± SD),Characteristics ; ,Age (mean ± SD),None,2,0,2,No,1:No,1:No,,0.65
5383,3427446,Table 1,BaselineCharacteristic,Cortisone (yes/no),Characteristics ; ,Cortisone (yes/no),None,3,0,2,No,1:No,1:No,,0.96
5383,3427446,Table 1,BaselineCharacteristic,xx (xx.x %) / xx (xx.x %),Values (N?=?xx) ; ,Cortisone (yes/no),None,3,1,3,No,1:No,1:No,,0.573
5383,3427446,Table 1,BaselineCharacteristic,Ethoxysclerol (yes/no),Characteristics ; ,Ethoxysclerol (yes/no),None,4,0,2,No,1:No,1:No,,0.97
5383,3427446,Table 1,BaselineCharacteristic,x (xx.x %) / xx (xx.x %),Values (N?=?xx) ; ,Ethoxysclerol (yes/no),None,4,1,3,No,1:No,1:No,,0.627
5383,3427446,Table 1,BaselineCharacteristic,Surgical treatment (yes/no),Characteristics ; ,Surgical treatment (yes/no),None,5,0,2,No,1:No,1:No,,0.97
5383,3427446,Table 1,BaselineCharacteristic,x (xx.x %) / xx (xx.x %),Values (N?=?xx) ; ,Surgical treatment (yes/no),None,5,1,3,No,1:No,1:No,,0.657
5383,3427446,Table 1,BaselineCharacteristic,Duration of complaints in months (mean ± SD),Characteristics ; ,Duration of complaints in months (mean ± SD),None,6,0,2,No,1:No,1:No,,0.67
5383,3427446,Table 1,BaselineCharacteristic,VAS ADL score (mean ± SD),Characteristics ; ,VAS ADL score (mean ± SD),None,7,0,2,No,1:No,1:No,,0.73
5383,3427446,Table 1,BaselineCharacteristic,VAS work score (mean ± SD),Characteristics ; ,VAS work score (mean ± SD),None,8,0,2,No,1:No,1:No,,0.75
5383,3427446,Table 1,BaselineCharacteristic,VAS sport score (mean ± SD),Characteristics ; ,VAS sport score (mean ± SD),None,9,0,2,No,1:No,1:No,,0.75
5383,3427446,Table 1,BaselineCharacteristic,VISA-P total score (mean ± SD),Characteristics ; ,VISA-P total score (mean ± SD),None,10,0,2,No,1:No,1:No,,0.78
5383,3427446,Table 2,BaselineCharacteristic,Characteristics,,None,None,0,0,12,No,1:No,1:No,,0.905
5383,3427446,Table 2,BaselineCharacteristic,Group x (N?=?xx),,Characteristics,None,0,1,1,No,1:No,1:No,,0.538
5383,3427446,Table 2,BaselineCharacteristic,Group x (N?=?xx),,Characteristics,None,0,2,1,No,1:No,1:No,,0.52
5383,3427446,Table 2,BaselineCharacteristic,P-value,,Characteristics,None,0,3,1,No,1:No,1:No,,0.903
5383,3427446,Table 2,BaselineCharacteristic,Gender (men/women),Characteristics ; ,Gender (men/women),,1,0,2,No,1:No,1:No,,0.94
5383,3427446,Table 2,BaselineCharacteristic,x (xx.x) / x (xx.x),Group x (N?=?xx) ; ,Gender (men/women),,1,1,3,No,1:No,1:No,,0.549
5383,3427446,Table 2,BaselineCharacteristic,xx (xx.x) / x (xx.x),Group x (N?=?xx) ; ,Gender (men/women),,1,2,3,No,1:No,1:No,,0.539
5383,3427446,Table 2,BaselineCharacteristic,x.xxx,P-value ; ,Gender (men/women),,1,3,3,No,1:No,1:No,,0.83
5383,3427446,Table 2,BaselineCharacteristic,Age (mean ± SD),Characteristics ; ,Age (mean ± SD),,2,0,2,No,1:No,1:No,,0.65
5383,3427446,Table 2,BaselineCharacteristic,Cortisone (yes/no),Characteristics ; ,Cortisone (yes/no),,3,0,2,No,1:No,1:No,,0.96
5383,3427446,Table 2,BaselineCharacteristic,xx (xx.x) / x (x.x),Group x (N?=?xx) ; ,Cortisone (yes/no),,3,1,3,No,1:No,1:No,,0.602
5383,3427446,Table 2,BaselineCharacteristic,–,Group x (N?=?xx) ; ,Cortisone (yes/no),,3,2,3,No,1:No,1:No,,0.587
5383,3427446,Table 2,BaselineCharacteristic,–,P-value ; ,Cortisone (yes/no),,3,3,3,No,1:No,1:No,,0.89
5383,3427446,Table 2,BaselineCharacteristic,Ethoxy (yes/no),Characteristics ; ,Ethoxy (yes/no),,4,0,2,No,1:No,1:No,,0.97
5383,3427446,Table 2,BaselineCharacteristic,x (xx.x) / x (xx.x),Group x (N?=?xx) ; ,Ethoxy (yes/no),,4,1,3,No,1:No,1:No,,0.692
5383,3427446,Table 2,BaselineCharacteristic,–,Group x (N?=?xx) ; ,Ethoxy (yes/no),,4,2,3,No,1:No,1:No,,0.657
5383,3427446,Table 2,BaselineCharacteristic,–,P-value ; ,Ethoxy (yes/no),,4,3,3,No,1:No,1:No,,0.89
5383,3427446,Table 2,BaselineCharacteristic,Surgical treatment (yes/no),Characteristics ; ,Surgical treatment (yes/no),,5,0,2,No,1:No,1:No,,0.97
5383,3427446,Table 2,BaselineCharacteristic,x (xx.x) / x (xx.x),Group x (N?=?xx) ; ,Surgical treatment (yes/no),,5,1,3,No,1:No,1:No,,0.712
5383,3427446,Table 2,BaselineCharacteristic,–,Group x (N?=?xx) ; ,Surgical treatment (yes/no),,5,2,3,No,1:No,1:No,,0.677
5383,3427446,Table 2,BaselineCharacteristic,–,P-value ; ,Surgical treatment (yes/no),,5,3,3,No,1:No,1:No,,0.89
5383,3427446,Table 2,BaselineCharacteristic,Duration of complaints in months (mean ± SD),Characteristics ; ,Duration of complaints in months (mean ± SD),,6,0,2,No,1:No,1:No,,0.67
5383,3427446,Table 2,BaselineCharacteristic,x.xxx,P-value ; ,Duration of complaints in months (mean ± SD),,6,3,3,No,1:No,1:No,,0.55
5383,3427446,Table 2,BaselineCharacteristic,Tegner score (VISA-P item x),Characteristics ; ,None,None,7,0,24,No,1:No,1:No,,0.963
5383,3427446,Table 2,BaselineCharacteristic,Tegner score (VISA-P item x),Group x (N?=?xx) ; ,Tegner score (VISA-P item x),None,7,1,43,No,1:No,1:No,,0.744
5383,3427446,Table 2,BaselineCharacteristic,Tegner score (VISA-P item x),Group x (N?=?xx) ; ,Tegner score (VISA-P item x),None,7,2,43,No,1:No,1:No,,0.754
5383,3427446,Table 2,BaselineCharacteristic,Tegner score (VISA-P item x),P-value ; ,Tegner score (VISA-P item x),None,7,3,43,No,1:No,1:No,,0.95
5383,3427446,Table 2,BaselineCharacteristic,,Characteristics ; ,, Tegner score (VISA-P item x),8,0,2,No,1:No,1:No,,0.972
5383,3427446,Table 2,BaselineCharacteristic,x (xx.x),Group x (N?=?xx) ; ,, Tegner score (VISA-P item x),8,1,3,No,1:No,1:No,,0.747
5383,3427446,Table 2,BaselineCharacteristic,x (xx.x),Group x (N?=?xx) ; ,, Tegner score (VISA-P item x),8,2,3,No,1:No,1:No,,0.767
5383,3427446,Table 2,BaselineCharacteristic,x.xxx*,P-value ; ,, Tegner score (VISA-P item x),8,3,3,No,1:No,1:No,,0.98
5383,3427446,Table 2,BaselineCharacteristic,,Characteristics ; ,, Tegner score (VISA-P item x),9,0,2,No,1:No,1:No,,0.982
5383,3427446,Table 2,BaselineCharacteristic,x (xx.x),Group x (N?=?xx) ; ,, Tegner score (VISA-P item x),9,1,3,No,1:No,1:No,,0.767
5383,3427446,Table 2,BaselineCharacteristic,x (xx.x),Group x (N?=?xx) ; ,, Tegner score (VISA-P item x),9,2,3,No,1:No,1:No,,0.777
5383,3427446,Table 2,BaselineCharacteristic,x.xxx*,P-value ; ,, Tegner score (VISA-P item x),9,3,3,No,1:No,1:No,,1
5383,3427446,Table 2,BaselineCharacteristic,,Characteristics ; ,, Tegner score (VISA-P item x),10,0,2,No,1:No,1:No,,0.982
5383,3427446,Table 2,BaselineCharacteristic,x (xx.x),Group x (N?=?xx) ; ,, Tegner score (VISA-P item x),10,1,3,No,1:No,1:No,,0.797
5383,3427446,Table 2,BaselineCharacteristic,x (xx.x),Group x (N?=?xx) ; ,, Tegner score (VISA-P item x),10,2,3,No,1:No,1:No,,0.797
5383,3427446,Table 2,BaselineCharacteristic,x.xxx*,P-value ; ,, Tegner score (VISA-P item x),10,3,3,No,1:No,1:No,,1
5383,3427446,Table 2,BaselineCharacteristic,,Characteristics ; ,, Tegner score (VISA-P item x),11,0,2,No,1:No,1:No,,0.982
5383,3427446,Table 2,BaselineCharacteristic,x (x.x),Group x (N?=?xx) ; ,, Tegner score (VISA-P item x),11,1,3,No,1:No,1:No,,0.807
5383,3427446,Table 2,BaselineCharacteristic,x (xx.x),Group x (N?=?xx) ; ,, Tegner score (VISA-P item x),11,2,3,No,1:No,1:No,,0.807
5383,3427446,Table 2,BaselineCharacteristic,x.xxx*,P-value ; ,, Tegner score (VISA-P item x),11,3,3,No,1:No,1:No,,1
5469,3447603,Table 1.,BaselineCharacteristic,Characteristic of Interest at Enrollment,,None,None,0,0,12,No,1:No,1:No,,0.915
5469,3447603,Table 1.,BaselineCharacteristic,ATIV (%),,Characteristic of Interest at Enrollment,None,0,1,1,No,1:No,1:No,,0.864
5469,3447603,Table 1.,BaselineCharacteristic,TIV (%),,Characteristic of Interest at Enrollment,None,0,2,1,No,1:No,1:No,,0.845
5469,3447603,Table 1.,BaselineCharacteristic,Female,Characteristic of Interest at Enrollment ; ,Female,,1,0,2,No,1:No,1:No,,0.95
5469,3447603,Table 1.,BaselineCharacteristic,Influenza vaccine last year,Characteristic of Interest at Enrollment ; ,Influenza vaccine last year,,2,0,2,No,1:No,1:No,,0.96
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,ATIV (%) ; ,Influenza vaccine last year,,2,1,3,No,1:No,1:No,,0.512
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,TIV (%) ; ,Influenza vaccine last year,,2,2,3,No,1:No,1:No,,0.522
5469,3447603,Table 1.,BaselineCharacteristic,Smoking,Characteristic of Interest at Enrollment ; ,None,None,3,0,24,No,1:No,1:No,,0.937
5469,3447603,Table 1.,BaselineCharacteristic,,ATIV (%) ; ,Smoking,None,3,1,43,No,1:No,1:No,,0.771
5469,3447603,Table 1.,BaselineCharacteristic,,TIV (%) ; ,Smoking,None,3,2,43,No,1:No,1:No,,0.775
5469,3447603,Table 1.,BaselineCharacteristic,?Current,Characteristic of Interest at Enrollment ; ,?Current, Smoking,4,0,2,No,1:No,1:No,,0.97
5469,3447603,Table 1.,BaselineCharacteristic,x.x,ATIV (%) ; ,?Current, Smoking,4,1,3,No,1:No,1:No,,0.79
5469,3447603,Table 1.,BaselineCharacteristic,x.x,TIV (%) ; ,?Current, Smoking,4,2,3,No,1:No,1:No,,0.8
5469,3447603,Table 1.,BaselineCharacteristic,?Former,Characteristic of Interest at Enrollment ; ,?Former, Smoking,5,0,2,No,1:No,1:No,,0.97
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,ATIV (%) ; ,?Former, Smoking,5,1,3,No,1:No,1:No,,0.616
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,TIV (%) ; ,?Former, Smoking,5,2,3,No,1:No,1:No,,0.616
5469,3447603,Table 1.,BaselineCharacteristic,?Never,Characteristic of Interest at Enrollment ; ,?Never, Smoking,6,0,2,No,1:No,1:No,,0.99
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,ATIV (%) ; ,?Never, Smoking,6,1,3,No,1:No,1:No,,0.666
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,TIV (%) ; ,?Never, Smoking,6,2,3,No,1:No,1:No,,0.666
5469,3447603,Table 1.,BaselineCharacteristic,Functional limitation of daily activities,Characteristic of Interest at Enrollment ; ,None,None,7,0,24,No,1:No,1:No,,0.934
5469,3447603,Table 1.,BaselineCharacteristic,,ATIV (%) ; ,Functional limitation of daily activities,None,7,1,43,No,1:No,1:No,,0.853
5469,3447603,Table 1.,BaselineCharacteristic,,TIV (%) ; ,Functional limitation of daily activities,None,7,2,43,No,1:No,1:No,,0.868
5469,3447603,Table 1.,BaselineCharacteristic,?Severe,Characteristic of Interest at Enrollment ; ,?Severe, Functional limitation of daily activities,8,0,2,No,1:No,1:No,,0.95
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,ATIV (%) ; ,?Severe, Functional limitation of daily activities,8,1,3,No,1:No,1:No,,0.716
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,TIV (%) ; ,?Severe, Functional limitation of daily activities,8,2,3,No,1:No,1:No,,0.736
5469,3447603,Table 1.,BaselineCharacteristic,?Mild,Characteristic of Interest at Enrollment ; ,?Mild, Functional limitation of daily activities,9,0,2,No,1:No,1:No,,0.96
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,ATIV (%) ; ,?Mild, Functional limitation of daily activities,9,1,3,No,1:No,1:No,,0.746
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,TIV (%) ; ,?Mild, Functional limitation of daily activities,9,2,3,No,1:No,1:No,,0.756
5469,3447603,Table 1.,BaselineCharacteristic,?No,Characteristic of Interest at Enrollment ; ,?No, Functional limitation of daily activities,10,0,2,No,1:No,1:No,,0.96
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,ATIV (%) ; ,?No, Functional limitation of daily activities,10,1,3,No,1:No,1:No,,0.786
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,TIV (%) ; ,?No, Functional limitation of daily activities,10,2,3,No,1:No,1:No,,0.786
5469,3447603,Table 1.,BaselineCharacteristic,Functional limitation in climbing stairs,Characteristic of Interest at Enrollment ; ,None,None,11,0,24,No,1:No,1:No,,0.885
5469,3447603,Table 1.,BaselineCharacteristic,,ATIV (%) ; ,Functional limitation in climbing stairs,None,11,1,43,No,1:No,1:No,,0.824
5469,3447603,Table 1.,BaselineCharacteristic,,TIV (%) ; ,Functional limitation in climbing stairs,None,11,2,43,No,1:No,1:No,,0.829
5469,3447603,Table 1.,BaselineCharacteristic,?Severe,Characteristic of Interest at Enrollment ; ,?Severe, Functional limitation in climbing stairs,12,0,2,No,1:No,1:No,,0.9
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,ATIV (%) ; ,?Severe, Functional limitation in climbing stairs,12,1,3,No,1:No,1:No,,0.746
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,TIV (%) ; ,?Severe, Functional limitation in climbing stairs,12,2,3,No,1:No,1:No,,0.736
5469,3447603,Table 1.,BaselineCharacteristic,?Mild,Characteristic of Interest at Enrollment ; ,?Mild, Functional limitation in climbing stairs,13,0,2,No,1:No,1:No,,0.9
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,ATIV (%) ; ,?Mild, Functional limitation in climbing stairs,13,1,3,No,1:No,1:No,,0.746
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,TIV (%) ; ,?Mild, Functional limitation in climbing stairs,13,2,3,No,1:No,1:No,,0.736
5469,3447603,Table 1.,BaselineCharacteristic,?No,Characteristic of Interest at Enrollment ; ,?No, Functional limitation in climbing stairs,14,0,2,No,1:No,1:No,,0.9
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,ATIV (%) ; ,?No, Functional limitation in climbing stairs,14,1,3,No,1:No,1:No,,0.746
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,TIV (%) ; ,?No, Functional limitation in climbing stairs,14,2,3,No,1:No,1:No,,0.736
5469,3447603,Table 1.,BaselineCharacteristic,Sharing house environment with children,Characteristic of Interest at Enrollment ; ,None,None,15,0,24,No,1:No,1:No,,0.985
5469,3447603,Table 1.,BaselineCharacteristic,,ATIV (%) ; ,Sharing house environment with children,None,15,1,43,No,1:No,1:No,,0.914
5469,3447603,Table 1.,BaselineCharacteristic,,TIV (%) ; ,Sharing house environment with children,None,15,2,43,No,1:No,1:No,,0.919
5469,3447603,Table 1.,BaselineCharacteristic,?Always,Characteristic of Interest at Enrollment ; ,?Always, Sharing house environment with children,16,0,2,No,1:No,1:No,,0.99
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,ATIV (%) ; ,?Always, Sharing house environment with children,16,1,3,No,1:No,1:No,,0.826
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,TIV (%) ; ,?Always, Sharing house environment with children,16,2,3,No,1:No,1:No,,0.826
5469,3447603,Table 1.,BaselineCharacteristic,?Sometimes,Characteristic of Interest at Enrollment ; ,?Sometimes, Sharing house environment with children,17,0,2,No,1:No,1:No,,0.99
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,ATIV (%) ; ,?Sometimes, Sharing house environment with children,17,1,3,No,1:No,1:No,,0.826
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,TIV (%) ; ,?Sometimes, Sharing house environment with children,17,2,3,No,1:No,1:No,,0.826
5469,3447603,Table 1.,BaselineCharacteristic,?No,Characteristic of Interest at Enrollment ; ,?No, Sharing house environment with children,18,0,2,No,1:No,1:No,,0.99
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,ATIV (%) ; ,?No, Sharing house environment with children,18,1,3,No,1:No,1:No,,0.811
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,TIV (%) ; ,?No, Sharing house environment with children,18,2,3,No,1:No,1:No,,0.811
5469,3447603,Table 1.,BaselineCharacteristic,Recent flu symptoms,Characteristic of Interest at Enrollment ; ,Recent flu symptoms,,19,0,2,No,1:No,1:No,,0.99
5469,3447603,Table 1.,BaselineCharacteristic,x.x,ATIV (%) ; ,Recent flu symptoms,,19,1,3,No,1:No,1:No,,0.91
5469,3447603,Table 1.,BaselineCharacteristic,x.x,TIV (%) ; ,Recent flu symptoms,,19,2,3,No,1:No,1:No,,0.91
5469,3447603,Table 1.,BaselineCharacteristic,Recent infectious disease,Characteristic of Interest at Enrollment ; ,Recent infectious disease,,20,0,2,No,1:No,1:No,,0.99
5469,3447603,Table 1.,BaselineCharacteristic,x.x,ATIV (%) ; ,Recent infectious disease,,20,1,3,No,1:No,1:No,,0.91
5469,3447603,Table 1.,BaselineCharacteristic,x.x,TIV (%) ; ,Recent infectious disease,,20,2,3,No,1:No,1:No,,0.91
5469,3447603,Table 1.,BaselineCharacteristic,Recent transfusion,Characteristic of Interest at Enrollment ; ,Recent transfusion,,21,0,2,No,1:No,1:No,,0.99
5469,3447603,Table 1.,BaselineCharacteristic,x.x,ATIV (%) ; ,Recent transfusion,,21,1,3,No,1:No,1:No,,0.91
5469,3447603,Table 1.,BaselineCharacteristic,x.x,TIV (%) ; ,Recent transfusion,,21,2,3,No,1:No,1:No,,0.91
5469,3447603,Table 1.,BaselineCharacteristic,Recent intestinal disorder,Characteristic of Interest at Enrollment ; ,Recent intestinal disorder,,22,0,2,No,1:No,1:No,,0.99
5469,3447603,Table 1.,BaselineCharacteristic,x.x,ATIV (%) ; ,Recent intestinal disorder,,22,1,3,No,1:No,1:No,,0.93
5469,3447603,Table 1.,BaselineCharacteristic,x.x,TIV (%) ; ,Recent intestinal disorder,,22,2,3,No,1:No,1:No,,0.93
5469,3447603,Table 1.,BaselineCharacteristic,Chronic obstructive pulmonary disease,Characteristic of Interest at Enrollment ; ,Chronic obstructive pulmonary disease,,23,0,2,No,1:No,1:No,,0.99
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,ATIV (%) ; ,Chronic obstructive pulmonary disease,,23,1,3,No,1:No,1:No,,0.811
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,TIV (%) ; ,Chronic obstructive pulmonary disease,,23,2,3,No,1:No,1:No,,0.811
5469,3447603,Table 1.,BaselineCharacteristic,"History of pneumonia, influenza, or emphysema",Characteristic of Interest at Enrollment ; ,"History of pneumonia, influenza, or emphysema",,24,0,2,No,1:No,1:No,,1
5469,3447603,Table 1.,BaselineCharacteristic,x.x,ATIV (%) ; ,"History of pneumonia, influenza, or emphysema",,24,1,3,No,1:No,1:No,,0.94
5469,3447603,Table 1.,BaselineCharacteristic,x.x,TIV (%) ; ,"History of pneumonia, influenza, or emphysema",,24,2,3,No,1:No,1:No,,0.94
5469,3447603,Table 1.,BaselineCharacteristic,Chronic kidney disease,Characteristic of Interest at Enrollment ; ,Chronic kidney disease,,25,0,2,No,1:No,1:No,,0.99
5469,3447603,Table 1.,BaselineCharacteristic,x.x,ATIV (%) ; ,Chronic kidney disease,,25,1,3,No,1:No,1:No,,0.93
5469,3447603,Table 1.,BaselineCharacteristic,x.x,TIV (%) ; ,Chronic kidney disease,,25,2,3,No,1:No,1:No,,0.93
5469,3447603,Table 1.,BaselineCharacteristic,Cancer,Characteristic of Interest at Enrollment ; ,Cancer,,26,0,2,No,1:No,1:No,,0.99
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,ATIV (%) ; ,Cancer,,26,1,3,No,1:No,1:No,,0.811
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,TIV (%) ; ,Cancer,,26,2,3,No,1:No,1:No,,0.811
5469,3447603,Table 1.,BaselineCharacteristic,Diabetes,Characteristic of Interest at Enrollment ; ,Diabetes,,27,0,2,No,1:No,1:No,,0.99
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,ATIV (%) ; ,Diabetes,,27,1,3,No,1:No,1:No,,0.811
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,TIV (%) ; ,Diabetes,,27,2,3,No,1:No,1:No,,0.811
5469,3447603,Table 1.,BaselineCharacteristic,Heart disease,Characteristic of Interest at Enrollment ; ,Heart disease,,28,0,2,No,1:No,1:No,,0.99
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,ATIV (%) ; ,Heart disease,,28,1,3,No,1:No,1:No,,0.811
5469,3447603,Table 1.,BaselineCharacteristic,xx.x,TIV (%) ; ,Heart disease,,28,2,3,No,1:No,1:No,,0.811
5469,3447603,Table 1.,BaselineCharacteristic,Vascular disease,Characteristic of Interest at Enrollment ; ,Vascular disease,,29,0,2,No,1:No,1:No,,0.99
5469,3447603,Table 1.,BaselineCharacteristic,x.x,ATIV (%) ; ,Vascular disease,,29,1,3,No,1:No,1:No,,0.93
5469,3447603,Table 1.,BaselineCharacteristic,x.x,TIV (%) ; ,Vascular disease,,29,2,3,No,1:No,1:No,,0.93
5558,3464767,Table 1,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
5558,3464767,Table 1,BaselineCharacteristic,Trastuzumab,,,None,0,1,1,No,1:No,1:No,,0.903
5558,3464767,Table 1,BaselineCharacteristic,Trastuzumab,,,None,0,2,1,No,1:No,1:No,,0.903
5558,3464767,Table 1,BaselineCharacteristic,Lapatinib,,,None,0,3,1,No,1:No,1:No,,0.903
5558,3464767,Table 1,BaselineCharacteristic,Lapatinib,,,None,0,4,1,No,1:No,1:No,,0.913
5558,3464767,Table 1,BaselineCharacteristic,Parameter, ; ,None,None,1,0,12,No,1:No,1:No,,0.908
5558,3464767,Table 1,BaselineCharacteristic,No.,Trastuzumab ; ,Parameter,None,1,1,1,No,1:No,1:No,,0.905
5558,3464767,Table 1,BaselineCharacteristic,%,Trastuzumab ; ,Parameter,None,1,2,1,No,1:No,1:No,,0.798
5558,3464767,Table 1,BaselineCharacteristic,No.,Lapatinib ; ,Parameter,None,1,3,1,No,1:No,1:No,,0.908
5558,3464767,Table 1,BaselineCharacteristic,%,Lapatinib ; ,Parameter,None,1,4,1,No,1:No,1:No,,0.828
5558,3464767,Table 1,BaselineCharacteristic,Tumour size, ; Parameter ; ,None,None,2,0,24,No,1:No,1:No,,0.922
5558,3464767,Table 1,BaselineCharacteristic,Tumour size,Trastuzumab ; No. ; ,Tumour size,None,2,1,43,No,1:No,1:No,,0.884
5558,3464767,Table 1,BaselineCharacteristic,Tumour size,Trastuzumab ; % ; ,Tumour size,None,2,2,43,No,1:No,1:No,,0.765
5558,3464767,Table 1,BaselineCharacteristic,Tumour size,Lapatinib ; No. ; ,Tumour size,None,2,3,43,No,1:No,1:No,,0.879
5558,3464767,Table 1,BaselineCharacteristic,Tumour size,Lapatinib ; % ; ,Tumour size,None,2,4,43,No,1:No,1:No,,0.755
5558,3464767,Table 1,BaselineCharacteristic,?Tx, ; Parameter ; ,?Tx, Tumour size,3,0,2,No,1:No,1:No,,0.96
5558,3464767,Table 1,BaselineCharacteristic,xx,Trastuzumab ; No. ; ,?Tx, Tumour size,3,1,3,No,1:No,1:No,,0.686
5558,3464767,Table 1,BaselineCharacteristic,xx.x,Trastuzumab ; % ; ,?Tx, Tumour size,3,2,3,No,1:No,1:No,,0.54
5558,3464767,Table 1,BaselineCharacteristic,xx,Lapatinib ; No. ; ,?Tx, Tumour size,3,3,3,No,1:No,1:No,,0.666
5558,3464767,Table 1,BaselineCharacteristic,xx.x,Lapatinib ; % ; ,?Tx, Tumour size,3,4,3,No,1:No,1:No,,0.53
5558,3464767,Table 1,BaselineCharacteristic,?Tx, ; Parameter ; ,?Tx, Tumour size,4,0,2,No,1:No,1:No,,0.97
5558,3464767,Table 1,BaselineCharacteristic,xx,Trastuzumab ; No. ; ,?Tx, Tumour size,4,1,3,No,1:No,1:No,,0.746
5558,3464767,Table 1,BaselineCharacteristic,xx.x,Trastuzumab ; % ; ,?Tx, Tumour size,4,2,3,No,1:No,1:No,,0.63
5558,3464767,Table 1,BaselineCharacteristic,xx,Lapatinib ; No. ; ,?Tx, Tumour size,4,3,3,No,1:No,1:No,,0.746
5558,3464767,Table 1,BaselineCharacteristic,xx.x,Lapatinib ; % ; ,?Tx, Tumour size,4,4,3,No,1:No,1:No,,0.62
5558,3464767,Table 1,BaselineCharacteristic,?Tx, ; Parameter ; ,?Tx, Tumour size,5,0,2,No,1:No,1:No,,0.97
5558,3464767,Table 1,BaselineCharacteristic,xx,Trastuzumab ; No. ; ,?Tx, Tumour size,5,1,3,No,1:No,1:No,,0.736
5558,3464767,Table 1,BaselineCharacteristic,xx.x,Trastuzumab ; % ; ,?Tx, Tumour size,5,2,3,No,1:No,1:No,,0.63
5558,3464767,Table 1,BaselineCharacteristic,xx,Lapatinib ; No. ; ,?Tx, Tumour size,5,3,3,No,1:No,1:No,,0.736
5558,3464767,Table 1,BaselineCharacteristic,xx.x,Lapatinib ; % ; ,?Tx, Tumour size,5,4,3,No,1:No,1:No,,0.62
5558,3464767,Table 1,BaselineCharacteristic,?Txa–c, ; Parameter ; ,?Txa–c, Tumour size,6,0,2,No,1:No,1:No,,0.99
5558,3464767,Table 1,BaselineCharacteristic,x,Trastuzumab ; No. ; ,?Txa–c, Tumour size,6,1,3,No,1:No,1:No,,0.96
5558,3464767,Table 1,BaselineCharacteristic,x.x,Trastuzumab ; % ; ,?Txa–c, Tumour size,6,2,3,No,1:No,1:No,,0.87
5558,3464767,Table 1,BaselineCharacteristic,x,Lapatinib ; No. ; ,?Txa–c, Tumour size,6,3,3,No,1:No,1:No,,0.96
5558,3464767,Table 1,BaselineCharacteristic,x.x,Lapatinib ; % ; ,?Txa–c, Tumour size,6,4,3,No,1:No,1:No,,0.85
5558,3464767,Table 1,BaselineCharacteristic,?Txd, ; Parameter ; ,?Txd, Tumour size,7,0,2,No,1:No,1:No,,0.99
5558,3464767,Table 1,BaselineCharacteristic,xx,Trastuzumab ; No. ; ,?Txd, Tumour size,7,1,3,No,1:No,1:No,,0.816
5558,3464767,Table 1,BaselineCharacteristic,xx.x,Trastuzumab ; % ; ,?Txd, Tumour size,7,2,3,No,1:No,1:No,,0.73
5558,3464767,Table 1,BaselineCharacteristic,xx,Lapatinib ; No. ; ,?Txd, Tumour size,7,3,3,No,1:No,1:No,,0.816
5558,3464767,Table 1,BaselineCharacteristic,xx.x,Lapatinib ; % ; ,?Txd, Tumour size,7,4,3,No,1:No,1:No,,0.73
5558,3464767,Table 1,BaselineCharacteristic,?Missing, ; Parameter ; ,?Missing, Tumour size,8,0,2,No,1:No,1:No,,0.99
5558,3464767,Table 1,BaselineCharacteristic,x,Trastuzumab ; No. ; ,?Missing, Tumour size,8,1,3,No,1:No,1:No,,0.97
5558,3464767,Table 1,BaselineCharacteristic,,Trastuzumab ; % ; ,?Missing, Tumour size,8,2,3,No,1:No,1:No,,0.89
5558,3464767,Table 1,BaselineCharacteristic,x,Lapatinib ; No. ; ,?Missing, Tumour size,8,3,3,No,1:No,1:No,,0.97
5558,3464767,Table 1,BaselineCharacteristic,,Lapatinib ; % ; ,?Missing, Tumour size,8,4,3,No,1:No,1:No,,0.89
5558,3464767,Table 1,BaselineCharacteristic,, ; Parameter ; ,None,None,9,0,2,No,1:No,1:No,,1
5558,3464767,Table 1,BaselineCharacteristic,,Trastuzumab ; No. ; ,None,None,9,1,3,No,1:No,1:No,,0.97
5558,3464767,Table 1,BaselineCharacteristic,,Trastuzumab ; % ; ,None,None,9,2,3,No,1:No,1:No,,0.89
5558,3464767,Table 1,BaselineCharacteristic,,Lapatinib ; No. ; ,None,None,9,3,3,No,1:No,1:No,,0.98
5558,3464767,Table 1,BaselineCharacteristic,,Lapatinib ; % ; ,None,None,9,4,3,No,1:No,1:No,,0.9
5558,3464767,Table 1,BaselineCharacteristic,Grading, ; Parameter ; ,None,None,10,0,24,No,1:No,1:No,,0.995
5558,3464767,Table 1,BaselineCharacteristic,Grading,Trastuzumab ; No. ; ,Grading,None,10,1,43,No,1:No,1:No,,0.977
5558,3464767,Table 1,BaselineCharacteristic,Grading,Trastuzumab ; % ; ,Grading,None,10,2,43,No,1:No,1:No,,0.919
5558,3464767,Table 1,BaselineCharacteristic,Grading,Lapatinib ; No. ; ,Grading,None,10,3,43,No,1:No,1:No,,0.982
5558,3464767,Table 1,BaselineCharacteristic,Grading,Lapatinib ; % ; ,Grading,None,10,4,43,No,1:No,1:No,,0.929
5558,3464767,Table 1,BaselineCharacteristic,?Gx, ; Parameter ; ,?Gx, Grading,11,0,2,No,1:No,1:No,,1
5558,3464767,Table 1,BaselineCharacteristic,x,Trastuzumab ; No. ; ,?Gx, Grading,11,1,3,No,1:No,1:No,,1
5558,3464767,Table 1,BaselineCharacteristic,x.x,Trastuzumab ; % ; ,?Gx, Grading,11,2,3,No,1:No,1:No,,0.95
5558,3464767,Table 1,BaselineCharacteristic,x,Lapatinib ; No. ; ,?Gx, Grading,11,3,3,No,1:No,1:No,,1
5558,3464767,Table 1,BaselineCharacteristic,x.x,Lapatinib ; % ; ,?Gx, Grading,11,4,3,No,1:No,1:No,,0.94
5558,3464767,Table 1,BaselineCharacteristic,?Gx, ; Parameter ; ,?Gx, Grading,12,0,2,No,1:No,1:No,,1
5558,3464767,Table 1,BaselineCharacteristic,xx,Trastuzumab ; No. ; ,?Gx, Grading,12,1,3,No,1:No,1:No,,0.921
5558,3464767,Table 1,BaselineCharacteristic,xx.x,Trastuzumab ; % ; ,?Gx, Grading,12,2,3,No,1:No,1:No,,0.806
5558,3464767,Table 1,BaselineCharacteristic,xx,Lapatinib ; No. ; ,?Gx, Grading,12,3,3,No,1:No,1:No,,0.901
5558,3464767,Table 1,BaselineCharacteristic,xx.x,Lapatinib ; % ; ,?Gx, Grading,12,4,3,No,1:No,1:No,,0.806
5558,3464767,Table 1,BaselineCharacteristic,?Gx, ; Parameter ; ,?Gx, Grading,13,0,2,No,1:No,1:No,,1
5558,3464767,Table 1,BaselineCharacteristic,xx,Trastuzumab ; No. ; ,?Gx, Grading,13,1,3,No,1:No,1:No,,0.921
5558,3464767,Table 1,BaselineCharacteristic,xx.x,Trastuzumab ; % ; ,?Gx, Grading,13,2,3,No,1:No,1:No,,0.806
5558,3464767,Table 1,BaselineCharacteristic,xx,Lapatinib ; No. ; ,?Gx, Grading,13,3,3,No,1:No,1:No,,0.891
5558,3464767,Table 1,BaselineCharacteristic,xx.x,Lapatinib ; % ; ,?Gx, Grading,13,4,3,No,1:No,1:No,,0.806
5558,3464767,Table 1,BaselineCharacteristic,, ; Parameter ; ,None,None,14,0,2,No,1:No,1:No,,1
5558,3464767,Table 1,BaselineCharacteristic,,Trastuzumab ; No. ; ,None,None,14,1,3,No,1:No,1:No,,0.99
5558,3464767,Table 1,BaselineCharacteristic,,Trastuzumab ; % ; ,None,None,14,2,3,No,1:No,1:No,,0.91
5558,3464767,Table 1,BaselineCharacteristic,,Lapatinib ; No. ; ,None,None,14,3,3,No,1:No,1:No,,0.99
5558,3464767,Table 1,BaselineCharacteristic,,Lapatinib ; % ; ,None,None,14,4,3,No,1:No,1:No,,0.92
5558,3464767,Table 1,BaselineCharacteristic,Hormone receptor status, ; Parameter ; ,None,None,15,0,24,No,1:No,1:No,,0.995
5558,3464767,Table 1,BaselineCharacteristic,Hormone receptor status,Trastuzumab ; No. ; ,Hormone receptor status,None,15,1,43,No,1:No,1:No,,0.978
5558,3464767,Table 1,BaselineCharacteristic,Hormone receptor status,Trastuzumab ; % ; ,Hormone receptor status,None,15,2,43,No,1:No,1:No,,0.944
5558,3464767,Table 1,BaselineCharacteristic,Hormone receptor status,Lapatinib ; No. ; ,Hormone receptor status,None,15,3,43,No,1:No,1:No,,0.987
5558,3464767,Table 1,BaselineCharacteristic,Hormone receptor status,Lapatinib ; % ; ,Hormone receptor status,None,15,4,43,No,1:No,1:No,,0.954
5558,3464767,Table 1,BaselineCharacteristic,?ER positive/PR positive, ; Parameter ; ,?ER positive/PR positive, Hormone receptor status,16,0,2,No,1:No,1:No,,1
5558,3464767,Table 1,BaselineCharacteristic,xx,Trastuzumab ; No. ; ,?ER positive/PR positive, Hormone receptor status,16,1,3,No,1:No,1:No,,0.941
5558,3464767,Table 1,BaselineCharacteristic,xx.x,Trastuzumab ; % ; ,?ER positive/PR positive, Hormone receptor status,16,2,3,No,1:No,1:No,,0.826
5558,3464767,Table 1,BaselineCharacteristic,xx,Lapatinib ; No. ; ,?ER positive/PR positive, Hormone receptor status,16,3,3,No,1:No,1:No,,0.931
5558,3464767,Table 1,BaselineCharacteristic,xx.x,Lapatinib ; % ; ,?ER positive/PR positive, Hormone receptor status,16,4,3,No,1:No,1:No,,0.826
5558,3464767,Table 1,BaselineCharacteristic,?ER positive/PR negative, ; Parameter ; ,?ER positive/PR negative, Hormone receptor status,17,0,2,No,1:No,1:No,,1
5558,3464767,Table 1,BaselineCharacteristic,xx,Trastuzumab ; No. ; ,?ER positive/PR negative, Hormone receptor status,17,1,3,No,1:No,1:No,,0.941
5558,3464767,Table 1,BaselineCharacteristic,xx.x,Trastuzumab ; % ; ,?ER positive/PR negative, Hormone receptor status,17,2,3,No,1:No,1:No,,0.826
5558,3464767,Table 1,BaselineCharacteristic,xx,Lapatinib ; No. ; ,?ER positive/PR negative, Hormone receptor status,17,3,3,No,1:No,1:No,,0.931
5558,3464767,Table 1,BaselineCharacteristic,xx.x,Lapatinib ; % ; ,?ER positive/PR negative, Hormone receptor status,17,4,3,No,1:No,1:No,,0.826
5558,3464767,Table 1,BaselineCharacteristic,?ER negative/PR positive, ; Parameter ; ,?ER negative/PR positive, Hormone receptor status,18,0,2,No,1:No,1:No,,0.99
5558,3464767,Table 1,BaselineCharacteristic,x,Trastuzumab ; No. ; ,?ER negative/PR positive, Hormone receptor status,18,1,3,No,1:No,1:No,,0.99
5558,3464767,Table 1,BaselineCharacteristic,x.x,Trastuzumab ; % ; ,?ER negative/PR positive, Hormone receptor status,18,2,3,No,1:No,1:No,,0.95
5558,3464767,Table 1,BaselineCharacteristic,x,Lapatinib ; No. ; ,?ER negative/PR positive, Hormone receptor status,18,3,3,No,1:No,1:No,,0.99
5558,3464767,Table 1,BaselineCharacteristic,x.x,Lapatinib ; % ; ,?ER negative/PR positive, Hormone receptor status,18,4,3,No,1:No,1:No,,0.95
5558,3464767,Table 1,BaselineCharacteristic,?ER negative/PR negative, ; Parameter ; ,?ER negative/PR negative, Hormone receptor status,19,0,2,No,1:No,1:No,,0.99
5558,3464767,Table 1,BaselineCharacteristic,xx,Trastuzumab ; No. ; ,?ER negative/PR negative, Hormone receptor status,19,1,3,No,1:No,1:No,,0.927
5558,3464767,Table 1,BaselineCharacteristic,xx.x,Trastuzumab ; % ; ,?ER negative/PR negative, Hormone receptor status,19,2,3,No,1:No,1:No,,0.821
5558,3464767,Table 1,BaselineCharacteristic,xx,Lapatinib ; No. ; ,?ER negative/PR negative, Hormone receptor status,19,3,3,No,1:No,1:No,,0.917
5558,3464767,Table 1,BaselineCharacteristic,xx.x,Lapatinib ; % ; ,?ER negative/PR negative, Hormone receptor status,19,4,3,No,1:No,1:No,,0.821
5558,3464767,Table 1,BaselineCharacteristic,, ; Parameter ; ,None,None,20,0,2,No,1:No,1:No,,0.99
5558,3464767,Table 1,BaselineCharacteristic,,Trastuzumab ; No. ; ,None,None,20,1,3,No,1:No,1:No,,0.97
5558,3464767,Table 1,BaselineCharacteristic,,Trastuzumab ; % ; ,None,None,20,2,3,No,1:No,1:No,,0.88
5558,3464767,Table 1,BaselineCharacteristic,,Lapatinib ; No. ; ,None,None,20,3,3,No,1:No,1:No,,0.98
5558,3464767,Table 1,BaselineCharacteristic,,Lapatinib ; % ; ,None,None,20,4,3,No,1:No,1:No,,0.9
5558,3464767,Table 1,BaselineCharacteristic,Clinical nodal status, ; Parameter ; ,None,None,21,0,24,No,1:No,1:No,,0.985
5558,3464767,Table 1,BaselineCharacteristic,Clinical nodal status,Trastuzumab ; No. ; ,Clinical nodal status,None,21,1,43,No,1:No,1:No,,0.968
5558,3464767,Table 1,BaselineCharacteristic,Clinical nodal status,Trastuzumab ; % ; ,Clinical nodal status,None,21,2,43,No,1:No,1:No,,0.924
5558,3464767,Table 1,BaselineCharacteristic,Clinical nodal status,Lapatinib ; No. ; ,Clinical nodal status,None,21,3,43,No,1:No,1:No,,0.977
5558,3464767,Table 1,BaselineCharacteristic,Clinical nodal status,Lapatinib ; % ; ,Clinical nodal status,None,21,4,43,No,1:No,1:No,,0.934
5558,3464767,Table 1,BaselineCharacteristic,?Negative, ; Parameter ; ,?Negative, Clinical nodal status,22,0,2,No,1:No,1:No,,1
5558,3464767,Table 1,BaselineCharacteristic,xx,Trastuzumab ; No. ; ,?Negative, Clinical nodal status,22,1,3,No,1:No,1:No,,0.937
5558,3464767,Table 1,BaselineCharacteristic,xx.x,Trastuzumab ; % ; ,?Negative, Clinical nodal status,22,2,3,No,1:No,1:No,,0.821
5558,3464767,Table 1,BaselineCharacteristic,xx,Lapatinib ; No. ; ,?Negative, Clinical nodal status,22,3,3,No,1:No,1:No,,0.927
5558,3464767,Table 1,BaselineCharacteristic,xx.x,Lapatinib ; % ; ,?Negative, Clinical nodal status,22,4,3,No,1:No,1:No,,0.821
5558,3464767,Table 1,BaselineCharacteristic,?Positive, ; Parameter ; ,?Positive, Clinical nodal status,23,0,2,No,1:No,1:No,,1
5558,3464767,Table 1,BaselineCharacteristic,xx,Trastuzumab ; No. ; ,?Positive, Clinical nodal status,23,1,3,No,1:No,1:No,,0.937
5558,3464767,Table 1,BaselineCharacteristic,xx.x,Trastuzumab ; % ; ,?Positive, Clinical nodal status,23,2,3,No,1:No,1:No,,0.821
5558,3464767,Table 1,BaselineCharacteristic,xx,Lapatinib ; No. ; ,?Positive, Clinical nodal status,23,3,3,No,1:No,1:No,,0.927
5558,3464767,Table 1,BaselineCharacteristic,xx.x,Lapatinib ; % ; ,?Positive, Clinical nodal status,23,4,3,No,1:No,1:No,,0.821
5558,3464767,Table 1,BaselineCharacteristic,?Missing, ; Parameter ; ,?Missing, Clinical nodal status,24,0,2,No,1:No,1:No,,1
5558,3464767,Table 1,BaselineCharacteristic,x,Trastuzumab ; No. ; ,?Missing, Clinical nodal status,24,1,3,No,1:No,1:No,,1
5558,3464767,Table 1,BaselineCharacteristic,,Trastuzumab ; % ; ,?Missing, Clinical nodal status,24,2,3,No,1:No,1:No,,0.95
5558,3464767,Table 1,BaselineCharacteristic,x,Lapatinib ; No. ; ,?Missing, Clinical nodal status,24,3,3,No,1:No,1:No,,1
5558,3464767,Table 1,BaselineCharacteristic,,Lapatinib ; % ; ,?Missing, Clinical nodal status,24,4,3,No,1:No,1:No,,0.95
5558,3464767,Table 1,BaselineCharacteristic,, ; Parameter ; ,None,None,25,0,2,No,1:No,1:No,,1
5558,3464767,Table 1,BaselineCharacteristic,,Trastuzumab ; No. ; ,None,None,25,1,3,No,1:No,1:No,,0.98
5558,3464767,Table 1,BaselineCharacteristic,,Trastuzumab ; % ; ,None,None,25,2,3,No,1:No,1:No,,0.9
5558,3464767,Table 1,BaselineCharacteristic,,Lapatinib ; No. ; ,None,None,25,3,3,No,1:No,1:No,,0.99
5558,3464767,Table 1,BaselineCharacteristic,,Lapatinib ; % ; ,None,None,25,4,3,No,1:No,1:No,,0.92
5558,3464767,Table 1,BaselineCharacteristic,pCR, ; Parameter ; ,None,None,26,0,24,No,1:No,1:No,,0.995
5558,3464767,Table 1,BaselineCharacteristic,pCR,Trastuzumab ; No. ; ,pCR,None,26,1,43,No,1:No,1:No,,0.974
5558,3464767,Table 1,BaselineCharacteristic,pCR,Trastuzumab ; % ; ,pCR,None,26,2,43,No,1:No,1:No,,0.929
5558,3464767,Table 1,BaselineCharacteristic,pCR,Lapatinib ; No. ; ,pCR,None,26,3,43,No,1:No,1:No,,0.979
5558,3464767,Table 1,BaselineCharacteristic,pCR,Lapatinib ; % ; ,pCR,None,26,4,43,No,1:No,1:No,,0.949
5558,3464767,Table 1,BaselineCharacteristic,?Yes, ; Parameter ; ,?Yes, pCR,27,0,2,No,1:No,1:No,,1
5558,3464767,Table 1,BaselineCharacteristic,xx,Trastuzumab ; No. ; ,?Yes, pCR,27,1,3,No,1:No,1:No,,0.937
5558,3464767,Table 1,BaselineCharacteristic,xx,Trastuzumab ; % ; ,?Yes, pCR,27,2,3,No,1:No,1:No,,0.877
5558,3464767,Table 1,BaselineCharacteristic,xx,Lapatinib ; No. ; ,?Yes, pCR,27,3,3,No,1:No,1:No,,0.917
5558,3464767,Table 1,BaselineCharacteristic,xx,Lapatinib ; % ; ,?Yes, pCR,27,4,3,No,1:No,1:No,,0.887
5558,3464767,Table 1,BaselineCharacteristic,?No, ; Parameter ; ,?No, pCR,28,0,2,No,1:No,1:No,,1
5558,3464767,Table 1,BaselineCharacteristic,xx,Trastuzumab ; No. ; ,?No, pCR,28,1,3,No,1:No,1:No,,0.937
5558,3464767,Table 1,BaselineCharacteristic,xx,Trastuzumab ; % ; ,?No, pCR,28,2,3,No,1:No,1:No,,0.877
5558,3464767,Table 1,BaselineCharacteristic,xx,Lapatinib ; No. ; ,?No, pCR,28,3,3,No,1:No,1:No,,0.917
5558,3464767,Table 1,BaselineCharacteristic,xx,Lapatinib ; % ; ,?No, pCR,28,4,3,No,1:No,1:No,,0.887
5561,3465101,Table 1.,BaselineCharacteristic,Parameter,,None,None,0,0,12,No,1:No,1:No,,0.915
5561,3465101,Table 1.,BaselineCharacteristic,"Females, n (%)",Parameter ; ,"Females, n (%)",None,1,0,2,No,1:No,1:No,,0.712
5561,3465101,Table 1.,BaselineCharacteristic,"Age (years), median (IQR)",Parameter ; ,"Age (years), median (IQR)",None,2,0,2,No,1:No,1:No,,0.53
5561,3465101,Table 1.,BaselineCharacteristic,"Weight (kg), median (IQR)",Parameter ; ,"Weight (kg), median (IQR)",None,3,0,2,No,1:No,1:No,,0.76
5561,3465101,Table 1.,BaselineCharacteristic,"Height (cm), median (IQR)",Parameter ; ,"Height (cm), median (IQR)",None,4,0,2,No,1:No,1:No,,0.76
5561,3465101,Table 1.,BaselineCharacteristic,"BMI (kg/mx), median (IQR)",Parameter ; ,"BMI (kg/mx), median (IQR)",None,5,0,2,No,1:No,1:No,,0.8
5569,3466131,Table 1,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
5569,3466131,Table 1,BaselineCharacteristic,Group A,,,None,0,1,1,No,1:No,1:No,,0.903
5569,3466131,Table 1,BaselineCharacteristic,Group B,,,None,0,2,1,No,1:No,1:No,,0.903
5569,3466131,Table 1,BaselineCharacteristic,, ; ,None,None,1,0,12,No,1:No,1:No,,0.898
5569,3466131,Table 1,BaselineCharacteristic,(XELIRI-Bev),Group A ; ,,None,1,1,1,No,1:No,1:No,,0.895
5569,3466131,Table 1,BaselineCharacteristic,(FOLFIRI-Bev),Group B ; ,,None,1,2,1,No,1:No,1:No,,0.876
5569,3466131,Table 1,BaselineCharacteristic,, ;  ; ,None,None,2,0,12,No,1:No,1:No,,0.913
5569,3466131,Table 1,BaselineCharacteristic,N?=?xxx,Group A ; (XELIRI-Bev) ; ,,None,2,1,1,No,1:No,1:No,,0.648
5569,3466131,Table 1,BaselineCharacteristic,N?=?xxx,Group B ; (FOLFIRI-Bev) ; ,,None,2,2,1,No,1:No,1:No,,0.622
5569,3466131,Table 1,BaselineCharacteristic,Age, ;  ;  ; ,None,None,3,0,24,No,1:No,1:No,,0.922
5569,3466131,Table 1,BaselineCharacteristic,Age,Group A ; (XELIRI-Bev) ; N?=?xxx ; ,Age,None,3,1,43,No,1:No,1:No,,0.728
5569,3466131,Table 1,BaselineCharacteristic,Age,Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,Age,None,3,2,43,No,1:No,1:No,,0.687
5569,3466131,Table 1,BaselineCharacteristic,Median (range), ;  ;  ; ,Median (range), Age,4,0,2,No,1:No,1:No,,0.722
5569,3466131,Table 1,BaselineCharacteristic,, ;  ;  ; ,, Age,5,0,2,No,1:No,1:No,,0.97
5569,3466131,Table 1,BaselineCharacteristic,N (%),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,, Age,5,1,3,No,1:No,1:No,,0.677
5569,3466131,Table 1,BaselineCharacteristic,N (%),Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,, Age,5,2,3,No,1:No,1:No,,0.667
5569,3466131,Table 1,BaselineCharacteristic,<xx, ;  ;  ; ,<xx, Age,6,0,2,No,1:No,1:No,,0.99
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,<xx, Age,6,1,3,No,1:No,1:No,,0.678
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,<xx, Age,6,2,3,No,1:No,1:No,,0.658
5569,3466131,Table 1,BaselineCharacteristic,?xx, ;  ;  ; ,?xx, Age,7,0,2,No,1:No,1:No,,0.887
5569,3466131,Table 1,BaselineCharacteristic,xxx (xx),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,?xx, Age,7,1,3,No,1:No,1:No,,0.678
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,?xx, Age,7,2,3,No,1:No,1:No,,0.658
5569,3466131,Table 1,BaselineCharacteristic,Gender, ;  ;  ; ,None,None,8,0,24,No,1:No,1:No,,0.974
5569,3466131,Table 1,BaselineCharacteristic,Gender,Group A ; (XELIRI-Bev) ; N?=?xxx ; ,Gender,None,8,1,43,No,1:No,1:No,,0.79
5569,3466131,Table 1,BaselineCharacteristic,Gender,Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,Gender,None,8,2,43,No,1:No,1:No,,0.769
5569,3466131,Table 1,BaselineCharacteristic,Male, ;  ;  ; ,Male, Gender,9,0,2,No,1:No,1:No,,1
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,Male, Gender,9,1,3,No,1:No,1:No,,0.708
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,Male, Gender,9,2,3,No,1:No,1:No,,0.688
5569,3466131,Table 1,BaselineCharacteristic,Female, ;  ;  ; ,Female, Gender,10,0,2,No,1:No,1:No,,1
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,Female, Gender,10,1,3,No,1:No,1:No,,0.748
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,Female, Gender,10,2,3,No,1:No,1:No,,0.728
5569,3466131,Table 1,BaselineCharacteristic,PS (ECOG), ;  ;  ; ,None,None,11,0,24,No,1:No,1:No,,0.995
5569,3466131,Table 1,BaselineCharacteristic,PS (ECOG),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,PS (ECOG),None,11,1,43,No,1:No,1:No,,0.82
5569,3466131,Table 1,BaselineCharacteristic,PS (ECOG),Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,PS (ECOG),None,11,2,43,No,1:No,1:No,,0.799
5569,3466131,Table 1,BaselineCharacteristic,x, ;  ;  ; ,x, PS (ECOG),12,0,2,No,1:No,1:No,,0.982
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,x, PS (ECOG),12,1,3,No,1:No,1:No,,0.712
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,x, PS (ECOG),12,2,3,No,1:No,1:No,,0.672
5569,3466131,Table 1,BaselineCharacteristic,x, ;  ;  ; ,x, PS (ECOG),13,0,2,No,1:No,1:No,,0.982
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,x, PS (ECOG),13,1,3,No,1:No,1:No,,0.712
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,x, PS (ECOG),13,2,3,No,1:No,1:No,,0.672
5569,3466131,Table 1,BaselineCharacteristic,x, ;  ;  ; ,x, PS (ECOG),14,0,2,No,1:No,1:No,,0.982
5569,3466131,Table 1,BaselineCharacteristic,xx (x),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,x, PS (ECOG),14,1,3,No,1:No,1:No,,0.722
5569,3466131,Table 1,BaselineCharacteristic,x (x),Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,x, PS (ECOG),14,2,3,No,1:No,1:No,,0.847
5569,3466131,Table 1,BaselineCharacteristic,Missing data, ;  ;  ; ,Missing data, PS (ECOG),15,0,2,No,1:No,1:No,,1
5569,3466131,Table 1,BaselineCharacteristic,x (x),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,Missing data, PS (ECOG),15,1,3,No,1:No,1:No,,0.877
5569,3466131,Table 1,BaselineCharacteristic,x (x),Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,Missing data, PS (ECOG),15,2,3,No,1:No,1:No,,0.837
5569,3466131,Table 1,BaselineCharacteristic,Primary location, ;  ;  ; ,None,None,16,0,24,No,1:No,1:No,,0.995
5569,3466131,Table 1,BaselineCharacteristic,Primary location,Group A ; (XELIRI-Bev) ; N?=?xxx ; ,Primary location,None,16,1,43,No,1:No,1:No,,0.83
5569,3466131,Table 1,BaselineCharacteristic,Primary location,Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,Primary location,None,16,2,43,No,1:No,1:No,,0.809
5569,3466131,Table 1,BaselineCharacteristic,Colon, ;  ;  ; ,Colon, Primary location,17,0,2,No,1:No,1:No,,1
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,Colon, Primary location,17,1,3,No,1:No,1:No,,0.808
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,Colon, Primary location,17,2,3,No,1:No,1:No,,0.778
5569,3466131,Table 1,BaselineCharacteristic,Rectum, ;  ;  ; ,Rectum, Primary location,18,0,2,No,1:No,1:No,,0.99
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,Rectum, Primary location,18,1,3,No,1:No,1:No,,0.808
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,Rectum, Primary location,18,2,3,No,1:No,1:No,,0.778
5569,3466131,Table 1,BaselineCharacteristic,Rectosigmoid, ;  ;  ; ,Rectosigmoid, Primary location,19,0,2,No,1:No,1:No,,0.99
5569,3466131,Table 1,BaselineCharacteristic,x (x),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,Rectosigmoid, Primary location,19,1,3,No,1:No,1:No,,0.887
5569,3466131,Table 1,BaselineCharacteristic,x (x),Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,Rectosigmoid, Primary location,19,2,3,No,1:No,1:No,,0.847
5569,3466131,Table 1,BaselineCharacteristic,Rectosigmoid and cecum, ;  ;  ; ,Rectosigmoid and cecum, Primary location,20,0,2,No,1:No,1:No,,0.99
5569,3466131,Table 1,BaselineCharacteristic,x (x),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,Rectosigmoid and cecum, Primary location,20,1,3,No,1:No,1:No,,0.897
5569,3466131,Table 1,BaselineCharacteristic,–,Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,Rectosigmoid and cecum, Primary location,20,2,3,No,1:No,1:No,,0.807
5569,3466131,Table 1,BaselineCharacteristic,Misssing data, ;  ;  ; ,Misssing data, Primary location,21,0,2,No,1:No,1:No,,0.99
5569,3466131,Table 1,BaselineCharacteristic,x (x),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,Misssing data, Primary location,21,1,3,No,1:No,1:No,,0.887
5569,3466131,Table 1,BaselineCharacteristic,x (x),Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,Misssing data, Primary location,21,2,3,No,1:No,1:No,,0.847
5569,3466131,Table 1,BaselineCharacteristic,Stage at diagnosis, ;  ;  ; ,None,None,22,0,24,No,1:No,1:No,,0.995
5569,3466131,Table 1,BaselineCharacteristic,Stage at diagnosis,Group A ; (XELIRI-Bev) ; N?=?xxx ; ,Stage at diagnosis,None,22,1,43,No,1:No,1:No,,0.895
5569,3466131,Table 1,BaselineCharacteristic,Stage at diagnosis,Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,Stage at diagnosis,None,22,2,43,No,1:No,1:No,,0.874
5569,3466131,Table 1,BaselineCharacteristic,I, ;  ;  ; ,I, Stage at diagnosis,23,0,2,No,1:No,1:No,,1
5569,3466131,Table 1,BaselineCharacteristic,x (x),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,I, Stage at diagnosis,23,1,3,No,1:No,1:No,,0.927
5569,3466131,Table 1,BaselineCharacteristic,x (x),Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,I, Stage at diagnosis,23,2,3,No,1:No,1:No,,0.897
5569,3466131,Table 1,BaselineCharacteristic,II, ;  ;  ; ,II, Stage at diagnosis,24,0,2,No,1:No,1:No,,1
5569,3466131,Table 1,BaselineCharacteristic,x (x),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,II, Stage at diagnosis,24,1,3,No,1:No,1:No,,0.927
5569,3466131,Table 1,BaselineCharacteristic,xx (x),Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,II, Stage at diagnosis,24,2,3,No,1:No,1:No,,0.742
5569,3466131,Table 1,BaselineCharacteristic,III, ;  ;  ; ,III, Stage at diagnosis,25,0,2,No,1:No,1:No,,1
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,III, Stage at diagnosis,25,1,3,No,1:No,1:No,,0.838
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,III, Stage at diagnosis,25,2,3,No,1:No,1:No,,0.808
5569,3466131,Table 1,BaselineCharacteristic,IV, ;  ;  ; ,IV, Stage at diagnosis,26,0,2,No,1:No,1:No,,0.97
5569,3466131,Table 1,BaselineCharacteristic,xxx (xx),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,IV, Stage at diagnosis,26,1,3,No,1:No,1:No,,0.801
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,IV, Stage at diagnosis,26,2,3,No,1:No,1:No,,0.771
5569,3466131,Table 1,BaselineCharacteristic,Missing data, ;  ;  ; ,Missing data, Stage at diagnosis,27,0,2,No,1:No,1:No,,1
5569,3466131,Table 1,BaselineCharacteristic,x (x),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,Missing data, Stage at diagnosis,27,1,3,No,1:No,1:No,,0.937
5569,3466131,Table 1,BaselineCharacteristic,xx (x),Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,Missing data, Stage at diagnosis,27,2,3,No,1:No,1:No,,0.752
5569,3466131,Table 1,BaselineCharacteristic,Previous adjuvant chemotherapy, ;  ;  ; ,None,None,28,0,24,No,1:No,1:No,,0.995
5569,3466131,Table 1,BaselineCharacteristic,Previous adjuvant chemotherapy,Group A ; (XELIRI-Bev) ; N?=?xxx ; ,Previous adjuvant chemotherapy,None,28,1,43,No,1:No,1:No,,0.866
5569,3466131,Table 1,BaselineCharacteristic,Previous adjuvant chemotherapy,Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,Previous adjuvant chemotherapy,None,28,2,43,No,1:No,1:No,,0.835
5569,3466131,Table 1,BaselineCharacteristic,No, ;  ;  ; ,No, Previous adjuvant chemotherapy,29,0,2,No,1:No,1:No,,1
5569,3466131,Table 1,BaselineCharacteristic,xxx (xx),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,No, Previous adjuvant chemotherapy,29,1,3,No,1:No,1:No,,0.848
5569,3466131,Table 1,BaselineCharacteristic,xxx (xx),Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,No, Previous adjuvant chemotherapy,29,2,3,No,1:No,1:No,,0.808
5569,3466131,Table 1,BaselineCharacteristic,Yes, ;  ;  ; ,Yes, Previous adjuvant chemotherapy,30,0,2,No,1:No,1:No,,1
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,Yes, Previous adjuvant chemotherapy,30,1,3,No,1:No,1:No,,0.848
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,Yes, Previous adjuvant chemotherapy,30,2,3,No,1:No,1:No,,0.808
5569,3466131,Table 1,BaselineCharacteristic,Missing data, ;  ;  ; ,Missing data, Previous adjuvant chemotherapy,31,0,2,No,1:No,1:No,,1
5569,3466131,Table 1,BaselineCharacteristic,x (x),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,Missing data, Previous adjuvant chemotherapy,31,1,3,No,1:No,1:No,,0.917
5569,3466131,Table 1,BaselineCharacteristic,x (x),Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,Missing data, Previous adjuvant chemotherapy,31,2,3,No,1:No,1:No,,0.877
5569,3466131,Table 1,BaselineCharacteristic,Previous surgery, ;  ;  ; ,Previous surgery, Previous adjuvant chemotherapy,32,0,2,No,1:No,1:No,,1
5569,3466131,Table 1,BaselineCharacteristic,xxx (xx),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,Previous surgery, Previous adjuvant chemotherapy,32,1,3,No,1:No,1:No,,0.858
5569,3466131,Table 1,BaselineCharacteristic,xxx (xx),Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,Previous surgery, Previous adjuvant chemotherapy,32,2,3,No,1:No,1:No,,0.818
5569,3466131,Table 1,BaselineCharacteristic,Symptomatic disease, ;  ;  ; ,None,None,33,0,24,No,1:No,1:No,,0.995
5569,3466131,Table 1,BaselineCharacteristic,Symptomatic disease,Group A ; (XELIRI-Bev) ; N?=?xxx ; ,Symptomatic disease,None,33,1,43,No,1:No,1:No,,0.84
5569,3466131,Table 1,BaselineCharacteristic,Symptomatic disease,Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,Symptomatic disease,None,33,2,43,No,1:No,1:No,,0.819
5569,3466131,Table 1,BaselineCharacteristic,Yes, ;  ;  ; ,Yes, Symptomatic disease,34,0,2,No,1:No,1:No,,1
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,Yes, Symptomatic disease,34,1,3,No,1:No,1:No,,0.788
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,Yes, Symptomatic disease,34,2,3,No,1:No,1:No,,0.768
5569,3466131,Table 1,BaselineCharacteristic,No, ;  ;  ; ,No, Symptomatic disease,35,0,2,No,1:No,1:No,,1
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,No, Symptomatic disease,35,1,3,No,1:No,1:No,,0.788
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,No, Symptomatic disease,35,2,3,No,1:No,1:No,,0.768
5569,3466131,Table 1,BaselineCharacteristic,Missing data, ;  ;  ; ,Missing data, Symptomatic disease,36,0,2,No,1:No,1:No,,1
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,Missing data, Symptomatic disease,36,1,3,No,1:No,1:No,,0.788
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,Missing data, Symptomatic disease,36,2,3,No,1:No,1:No,,0.768
5569,3466131,Table 1,BaselineCharacteristic,Organs involved, ;  ;  ; ,None,None,37,0,24,No,1:No,1:No,,0.995
5569,3466131,Table 1,BaselineCharacteristic,Organs involved,Group A ; (XELIRI-Bev) ; N?=?xxx ; ,Organs involved,None,37,1,43,No,1:No,1:No,,0.84
5569,3466131,Table 1,BaselineCharacteristic,Organs involved,Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,Organs involved,None,37,2,43,No,1:No,1:No,,0.819
5569,3466131,Table 1,BaselineCharacteristic,Liver, ;  ;  ; ,Liver, Organs involved,38,0,2,No,1:No,1:No,,1
5569,3466131,Table 1,BaselineCharacteristic,xxx (xx),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,Liver, Organs involved,38,1,3,No,1:No,1:No,,0.788
5569,3466131,Table 1,BaselineCharacteristic,xxx (xx),Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,Liver, Organs involved,38,2,3,No,1:No,1:No,,0.768
5569,3466131,Table 1,BaselineCharacteristic,Lung, ;  ;  ; ,Lung, Organs involved,39,0,2,No,1:No,1:No,,1
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,Lung, Organs involved,39,1,3,No,1:No,1:No,,0.788
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,Lung, Organs involved,39,2,3,No,1:No,1:No,,0.768
5569,3466131,Table 1,BaselineCharacteristic,Other, ;  ;  ; ,Other, Organs involved,40,0,2,No,1:No,1:No,,1
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,Other, Organs involved,40,1,3,No,1:No,1:No,,0.788
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,Other, Organs involved,40,2,3,No,1:No,1:No,,0.768
5569,3466131,Table 1,BaselineCharacteristic,Number of organs involved, ;  ;  ; ,None,None,41,0,24,No,1:No,1:No,,0.985
5569,3466131,Table 1,BaselineCharacteristic,Number of organs involved,Group A ; (XELIRI-Bev) ; N?=?xxx ; ,Number of organs involved,None,41,1,43,No,1:No,1:No,,0.83
5569,3466131,Table 1,BaselineCharacteristic,Number of organs involved,Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,Number of organs involved,None,41,2,43,No,1:No,1:No,,0.799
5569,3466131,Table 1,BaselineCharacteristic,x, ;  ;  ; ,x, Number of organs involved,42,0,2,No,1:No,1:No,,0.974
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,x, Number of organs involved,42,1,3,No,1:No,1:No,,0.732
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,x, Number of organs involved,42,2,3,No,1:No,1:No,,0.692
5569,3466131,Table 1,BaselineCharacteristic,x, ;  ;  ; ,x, Number of organs involved,43,0,2,No,1:No,1:No,,0.974
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,x, Number of organs involved,43,1,3,No,1:No,1:No,,0.732
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,x, Number of organs involved,43,2,3,No,1:No,1:No,,0.692
5569,3466131,Table 1,BaselineCharacteristic,?x, ;  ;  ; ,?x, Number of organs involved,44,0,2,No,1:No,1:No,,0.974
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,?x, Number of organs involved,44,1,3,No,1:No,1:No,,0.732
5569,3466131,Table 1,BaselineCharacteristic,xx (xx),Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,?x, Number of organs involved,44,2,3,No,1:No,1:No,,0.692
5569,3466131,Table 1,BaselineCharacteristic,Missing data, ;  ;  ; ,Missing data, Number of organs involved,45,0,2,No,1:No,1:No,,0.99
5569,3466131,Table 1,BaselineCharacteristic,x (x),Group A ; (XELIRI-Bev) ; N?=?xxx ; ,Missing data, Number of organs involved,45,1,3,No,1:No,1:No,,0.867
5569,3466131,Table 1,BaselineCharacteristic,–,Group B ; (FOLFIRI-Bev) ; N?=?xxx ; ,Missing data, Number of organs involved,45,2,3,No,1:No,1:No,,0.787
5569,3466131,Table 3,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
5569,3466131,Table 3,BaselineCharacteristic,N,,,None,0,1,1,No,1:No,1:No,,0.903
5569,3466131,Table 3,BaselineCharacteristic,Mean,,,None,0,2,1,No,1:No,1:No,,0.903
5569,3466131,Table 3,BaselineCharacteristic,Median,,,None,0,3,1,No,1:No,1:No,,0.903
5569,3466131,Table 3,BaselineCharacteristic,SD,,,None,0,4,1,No,1:No,1:No,,0.775
5569,3466131,Table 3,BaselineCharacteristic,Min,,,None,0,5,1,No,1:No,1:No,,0.935
5569,3466131,Table 3,BaselineCharacteristic,Max,,,None,0,6,1,No,1:No,1:No,,0.935
5569,3466131,Table 3,BaselineCharacteristic,Wilcoxon’s p,,,None,0,7,1,No,1:No,1:No,,0.945
5569,3466131,Table 3,BaselineCharacteristic,NO (?mol/L), ; ,None,None,1,0,24,No,1:No,1:No,,0.897
5569,3466131,Table 3,BaselineCharacteristic,NO (?mol/L),N ; ,NO (?mol/L),None,1,1,43,No,1:No,1:No,,0.859
5569,3466131,Table 3,BaselineCharacteristic,NO (?mol/L),Mean ; ,NO (?mol/L),None,1,2,43,No,1:No,1:No,,0.854
5569,3466131,Table 3,BaselineCharacteristic,NO (?mol/L),Median ; ,NO (?mol/L),None,1,3,43,No,1:No,1:No,,0.854
5569,3466131,Table 3,BaselineCharacteristic,NO (?mol/L),SD ; ,NO (?mol/L),None,1,4,43,No,1:No,1:No,,0.742
5569,3466131,Table 3,BaselineCharacteristic,NO (?mol/L),Min ; ,NO (?mol/L),None,1,5,43,No,1:No,1:No,,0.854
5569,3466131,Table 3,BaselineCharacteristic,NO (?mol/L),Max ; ,NO (?mol/L),None,1,6,43,No,1:No,1:No,,0.864
5569,3466131,Table 3,BaselineCharacteristic,NO (?mol/L),Wilcoxon’s p ; ,NO (?mol/L),None,1,7,43,No,1:No,1:No,,0.875
5569,3466131,Table 3,BaselineCharacteristic,Baseline samples, ; ,Baseline samples, NO (?mol/L),2,0,2,No,1:No,1:No,,0.95
5569,3466131,Table 3,BaselineCharacteristic,xxx,N ; ,Baseline samples, NO (?mol/L),2,1,3,No,1:No,1:No,,0.8
5569,3466131,Table 3,BaselineCharacteristic,xxx.xx,Mean ; ,Baseline samples, NO (?mol/L),2,2,3,No,1:No,1:No,,0.618
5569,3466131,Table 3,BaselineCharacteristic,xxx.xx,Median ; ,Baseline samples, NO (?mol/L),2,3,3,No,1:No,1:No,,0.618
5569,3466131,Table 3,BaselineCharacteristic,x.xx,Min ; ,Baseline samples, NO (?mol/L),2,5,3,No,1:No,1:No,,0.656
5569,3466131,Table 3,BaselineCharacteristic,"x,xxx.xx",Max ; ,Baseline samples, NO (?mol/L),2,6,3,No,1:No,1:No,,0.586
5569,3466131,Table 3,BaselineCharacteristic,x.xx,Wilcoxon’s p ; ,Baseline samples, NO (?mol/L),2,7,3,No,1:No,1:No,,0.696
5569,3466131,Table 3,BaselineCharacteristic,On-treatment samples*, ; ,On-treatment samples*, NO (?mol/L),3,0,2,No,1:No,1:No,,0.97
5569,3466131,Table 3,BaselineCharacteristic,xx,N ; ,On-treatment samples*, NO (?mol/L),3,1,3,No,1:No,1:No,,0.691
5569,3466131,Table 3,BaselineCharacteristic,xxx.xx,Mean ; ,On-treatment samples*, NO (?mol/L),3,2,3,No,1:No,1:No,,0.631
5569,3466131,Table 3,BaselineCharacteristic,xxx.xx,Median ; ,On-treatment samples*, NO (?mol/L),3,3,3,No,1:No,1:No,,0.641
5569,3466131,Table 3,BaselineCharacteristic,xxx.xx,SD ; ,On-treatment samples*, NO (?mol/L),3,4,3,No,1:No,1:No,,0.501
5569,3466131,Table 3,BaselineCharacteristic,xx.xx,Min ; ,On-treatment samples*, NO (?mol/L),3,5,3,No,1:No,1:No,,0.726
5569,3466131,Table 3,BaselineCharacteristic,xxx.xx,Max ; ,On-treatment samples*, NO (?mol/L),3,6,3,No,1:No,1:No,,0.666
5569,3466131,Table 3,BaselineCharacteristic,,Wilcoxon’s p ; ,On-treatment samples*, NO (?mol/L),3,7,3,No,1:No,1:No,,0.94
5569,3466131,Table 3,BaselineCharacteristic,OPN (ng/mL), ; ,None,None,4,0,24,No,1:No,1:No,,0.954
5569,3466131,Table 3,BaselineCharacteristic,OPN (ng/mL),N ; ,OPN (ng/mL),None,4,1,43,No,1:No,1:No,,0.933
5569,3466131,Table 3,BaselineCharacteristic,OPN (ng/mL),Mean ; ,OPN (ng/mL),None,4,2,43,No,1:No,1:No,,0.929
5569,3466131,Table 3,BaselineCharacteristic,OPN (ng/mL),Median ; ,OPN (ng/mL),None,4,3,43,No,1:No,1:No,,0.929
5569,3466131,Table 3,BaselineCharacteristic,OPN (ng/mL),SD ; ,OPN (ng/mL),None,4,4,43,No,1:No,1:No,,0.85
5569,3466131,Table 3,BaselineCharacteristic,OPN (ng/mL),Min ; ,OPN (ng/mL),None,4,5,43,No,1:No,1:No,,0.919
5569,3466131,Table 3,BaselineCharacteristic,OPN (ng/mL),Max ; ,OPN (ng/mL),None,4,6,43,No,1:No,1:No,,0.929
5569,3466131,Table 3,BaselineCharacteristic,OPN (ng/mL),Wilcoxon’s p ; ,OPN (ng/mL),None,4,7,43,No,1:No,1:No,,0.939
5569,3466131,Table 3,BaselineCharacteristic,Baseline samples, ; ,Baseline samples, OPN (ng/mL),5,0,2,No,1:No,1:No,,0.98
5569,3466131,Table 3,BaselineCharacteristic,xxx,N ; ,Baseline samples, OPN (ng/mL),5,1,3,No,1:No,1:No,,0.84
5569,3466131,Table 3,BaselineCharacteristic,xx.xx,Mean ; ,Baseline samples, OPN (ng/mL),5,2,3,No,1:No,1:No,,0.751
5569,3466131,Table 3,BaselineCharacteristic,xx.xx,Median ; ,Baseline samples, OPN (ng/mL),5,3,3,No,1:No,1:No,,0.751
5569,3466131,Table 3,BaselineCharacteristic,xx.xx,SD ; ,Baseline samples, OPN (ng/mL),5,4,3,No,1:No,1:No,,0.641
5569,3466131,Table 3,BaselineCharacteristic,xx.xx,Min ; ,Baseline samples, OPN (ng/mL),5,5,3,No,1:No,1:No,,0.766
5569,3466131,Table 3,BaselineCharacteristic,xxx.xx,Max ; ,Baseline samples, OPN (ng/mL),5,6,3,No,1:No,1:No,,0.706
5569,3466131,Table 3,BaselineCharacteristic,x.xxx,Wilcoxon’s p ; ,Baseline samples, OPN (ng/mL),5,7,3,No,1:No,1:No,,0.89
5569,3466131,Table 3,BaselineCharacteristic,On-treatment samples, ; ,On-treatment samples, OPN (ng/mL),6,0,2,No,1:No,1:No,,1
5569,3466131,Table 3,BaselineCharacteristic,xx,N ; ,On-treatment samples, OPN (ng/mL),6,1,3,No,1:No,1:No,,0.801
5569,3466131,Table 3,BaselineCharacteristic,xx.xx,Mean ; ,On-treatment samples, OPN (ng/mL),6,2,3,No,1:No,1:No,,0.801
5569,3466131,Table 3,BaselineCharacteristic,xx.xx,Median ; ,On-treatment samples, OPN (ng/mL),6,3,3,No,1:No,1:No,,0.801
5569,3466131,Table 3,BaselineCharacteristic,xx.xx,SD ; ,On-treatment samples, OPN (ng/mL),6,4,3,No,1:No,1:No,,0.681
5569,3466131,Table 3,BaselineCharacteristic,xx.xx,Min ; ,On-treatment samples, OPN (ng/mL),6,5,3,No,1:No,1:No,,0.816
5569,3466131,Table 3,BaselineCharacteristic,xxx.xx,Max ; ,On-treatment samples, OPN (ng/mL),6,6,3,No,1:No,1:No,,0.766
5569,3466131,Table 3,BaselineCharacteristic,,Wilcoxon’s p ; ,On-treatment samples, OPN (ng/mL),6,7,3,No,1:No,1:No,,0.96
5569,3466131,Table 3,BaselineCharacteristic,TGF-?x(ng/mL), ; ,None,None,7,0,24,No,1:No,1:No,,0.972
5569,3466131,Table 3,BaselineCharacteristic,TGF-?x(ng/mL),N ; ,TGF-?x(ng/mL),None,7,1,43,No,1:No,1:No,,0.967
5569,3466131,Table 3,BaselineCharacteristic,TGF-?x(ng/mL),Mean ; ,TGF-?x(ng/mL),None,7,2,43,No,1:No,1:No,,0.952
5569,3466131,Table 3,BaselineCharacteristic,TGF-?x(ng/mL),Median ; ,TGF-?x(ng/mL),None,7,3,43,No,1:No,1:No,,0.952
5569,3466131,Table 3,BaselineCharacteristic,TGF-?x(ng/mL),SD ; ,TGF-?x(ng/mL),None,7,4,43,No,1:No,1:No,,0.843
5569,3466131,Table 3,BaselineCharacteristic,TGF-?x(ng/mL),Min ; ,TGF-?x(ng/mL),None,7,5,43,No,1:No,1:No,,0.952
5569,3466131,Table 3,BaselineCharacteristic,TGF-?x(ng/mL),Max ; ,TGF-?x(ng/mL),None,7,6,43,No,1:No,1:No,,0.962
5569,3466131,Table 3,BaselineCharacteristic,TGF-?x(ng/mL),Wilcoxon’s p ; ,TGF-?x(ng/mL),None,7,7,43,No,1:No,1:No,,0.952
5569,3466131,Table 3,BaselineCharacteristic,Baseline samples, ; ,Baseline samples, TGF-?x(ng/mL),8,0,2,No,1:No,1:No,,0.982
5569,3466131,Table 3,BaselineCharacteristic,xxx,N ; ,Baseline samples, TGF-?x(ng/mL),8,1,3,No,1:No,1:No,,0.94
5569,3466131,Table 3,BaselineCharacteristic,xx.xx,Mean ; ,Baseline samples, TGF-?x(ng/mL),8,2,3,No,1:No,1:No,,0.836
5569,3466131,Table 3,BaselineCharacteristic,xx.xx,Median ; ,Baseline samples, TGF-?x(ng/mL),8,3,3,No,1:No,1:No,,0.816
5569,3466131,Table 3,BaselineCharacteristic,xx.xx,SD ; ,Baseline samples, TGF-?x(ng/mL),8,4,3,No,1:No,1:No,,0.676
5569,3466131,Table 3,BaselineCharacteristic,x.xx,Min ; ,Baseline samples, TGF-?x(ng/mL),8,5,3,No,1:No,1:No,,0.86
5569,3466131,Table 3,BaselineCharacteristic,xxx.xx,Max ; ,Baseline samples, TGF-?x(ng/mL),8,6,3,No,1:No,1:No,,0.78
5569,3466131,Table 3,BaselineCharacteristic,x.xxx,Wilcoxon’s p ; ,Baseline samples, TGF-?x(ng/mL),8,7,3,No,1:No,1:No,,0.95
5569,3466131,Table 3,BaselineCharacteristic,On-treatment samples, ; ,On-treatment samples, TGF-?x(ng/mL),9,0,2,No,1:No,1:No,,0.982
5569,3466131,Table 3,BaselineCharacteristic,xx,N ; ,On-treatment samples, TGF-?x(ng/mL),9,1,3,No,1:No,1:No,,0.856
5569,3466131,Table 3,BaselineCharacteristic,xx.xx,Mean ; ,On-treatment samples, TGF-?x(ng/mL),9,2,3,No,1:No,1:No,,0.856
5569,3466131,Table 3,BaselineCharacteristic,xx.xx,Median ; ,On-treatment samples, TGF-?x(ng/mL),9,3,3,No,1:No,1:No,,0.836
5569,3466131,Table 3,BaselineCharacteristic,xx.xx,SD ; ,On-treatment samples, TGF-?x(ng/mL),9,4,3,No,1:No,1:No,,0.686
5569,3466131,Table 3,BaselineCharacteristic,x.xx,Min ; ,On-treatment samples, TGF-?x(ng/mL),9,5,3,No,1:No,1:No,,0.88
5569,3466131,Table 3,BaselineCharacteristic,xxx.xx,Max ; ,On-treatment samples, TGF-?x(ng/mL),9,6,3,No,1:No,1:No,,0.8
5569,3466131,Table 3,BaselineCharacteristic,,Wilcoxon’s p ; ,On-treatment samples, TGF-?x(ng/mL),9,7,3,No,1:No,1:No,,0.99
5569,3466131,Table 3,BaselineCharacteristic,VEGF-A (pg/mL), ; ,None,None,10,0,24,No,1:No,1:No,,0.995
5569,3466131,Table 3,BaselineCharacteristic,VEGF-A (pg/mL),N ; ,VEGF-A (pg/mL),None,10,1,43,No,1:No,1:No,,0.977
5569,3466131,Table 3,BaselineCharacteristic,VEGF-A (pg/mL),Mean ; ,VEGF-A (pg/mL),None,10,2,43,No,1:No,1:No,,0.982
5569,3466131,Table 3,BaselineCharacteristic,VEGF-A (pg/mL),Median ; ,VEGF-A (pg/mL),None,10,3,43,No,1:No,1:No,,0.982
5569,3466131,Table 3,BaselineCharacteristic,VEGF-A (pg/mL),SD ; ,VEGF-A (pg/mL),None,10,4,43,No,1:No,1:No,,0.862
5569,3466131,Table 3,BaselineCharacteristic,VEGF-A (pg/mL),Min ; ,VEGF-A (pg/mL),None,10,5,43,No,1:No,1:No,,0.982
5569,3466131,Table 3,BaselineCharacteristic,VEGF-A (pg/mL),Max ; ,VEGF-A (pg/mL),None,10,6,43,No,1:No,1:No,,0.982
5569,3466131,Table 3,BaselineCharacteristic,VEGF-A (pg/mL),Wilcoxon’s p ; ,VEGF-A (pg/mL),None,10,7,43,No,1:No,1:No,,0.983
5569,3466131,Table 3,BaselineCharacteristic,Baseline samples, ; ,Baseline samples, VEGF-A (pg/mL),11,0,2,No,1:No,1:No,,1
5569,3466131,Table 3,BaselineCharacteristic,xxx,N ; ,Baseline samples, VEGF-A (pg/mL),11,1,3,No,1:No,1:No,,0.92
5569,3466131,Table 3,BaselineCharacteristic,xxx.xx,Mean ; ,Baseline samples, VEGF-A (pg/mL),11,2,3,No,1:No,1:No,,0.841
5569,3466131,Table 3,BaselineCharacteristic,xx.xx,Median ; ,Baseline samples, VEGF-A (pg/mL),11,3,3,No,1:No,1:No,,0.901
5569,3466131,Table 3,BaselineCharacteristic,xxx.xx,SD ; ,Baseline samples, VEGF-A (pg/mL),11,4,3,No,1:No,1:No,,0.651
5569,3466131,Table 3,BaselineCharacteristic,xx.xx,Min ; ,Baseline samples, VEGF-A (pg/mL),11,5,3,No,1:No,1:No,,0.926
5569,3466131,Table 3,BaselineCharacteristic,"x,xxx.xx",Max ; ,Baseline samples, VEGF-A (pg/mL),11,6,3,No,1:No,1:No,,0.82
5569,3466131,Table 3,BaselineCharacteristic,<x.xxx,Wilcoxon’s p ; ,Baseline samples, VEGF-A (pg/mL),11,7,3,No,1:No,1:No,,0.94
5569,3466131,Table 3,BaselineCharacteristic,On-treatment samples, ; ,On-treatment samples, VEGF-A (pg/mL),12,0,2,No,1:No,1:No,,1
5569,3466131,Table 3,BaselineCharacteristic,xx,N ; ,On-treatment samples, VEGF-A (pg/mL),12,1,3,No,1:No,1:No,,0.921
5569,3466131,Table 3,BaselineCharacteristic,xx.xx,Mean ; ,On-treatment samples, VEGF-A (pg/mL),12,2,3,No,1:No,1:No,,0.911
5569,3466131,Table 3,BaselineCharacteristic,xx.xx,Median ; ,On-treatment samples, VEGF-A (pg/mL),12,3,3,No,1:No,1:No,,0.901
5569,3466131,Table 3,BaselineCharacteristic,xx.xx,SD ; ,On-treatment samples, VEGF-A (pg/mL),12,4,3,No,1:No,1:No,,0.731
5569,3466131,Table 3,BaselineCharacteristic,xx.xx,Min ; ,On-treatment samples, VEGF-A (pg/mL),12,5,3,No,1:No,1:No,,0.926
5569,3466131,Table 3,BaselineCharacteristic,xxx.xx,Max ; ,On-treatment samples, VEGF-A (pg/mL),12,6,3,No,1:No,1:No,,0.886
5569,3466131,Table 3,BaselineCharacteristic,,Wilcoxon’s p ; ,On-treatment samples, VEGF-A (pg/mL),12,7,3,No,1:No,1:No,,1
5578,3468079,Table 1.,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
5578,3468079,Table 1.,BaselineCharacteristic,"Cohort x (xxx mg of posaconazole), n?=?x",,,None,0,2,1,No,1:No,1:No,,0.538
5578,3468079,Table 1.,BaselineCharacteristic,"Placebo, n?=?x",,,None,0,3,1,No,1:No,1:No,,0.651
5578,3468079,Table 1.,BaselineCharacteristic,, ; ,None,None,1,0,2,No,1:No,1:No,,0.94
5578,3468079,Table 1.,BaselineCharacteristic,,"Cohort x (xxx mg of posaconazole), n?=?x ; ",None,None,1,2,3,No,1:No,1:No,,0.56
5578,3468079,Table 1.,BaselineCharacteristic,,"Placebo, n?=?x ; ",None,None,1,3,3,No,1:No,1:No,,0.74
5578,3468079,Table 1.,BaselineCharacteristic,"Gender, male, n (%)", ; ,"Gender, male, n (%)",,2,0,2,No,1:No,1:No,,0.776
5578,3468079,Table 1.,BaselineCharacteristic,x (xx),"Placebo, n?=?x ; ","Gender, male, n (%)",,2,3,3,No,1:No,1:No,,0.506
5578,3468079,Table 1.,BaselineCharacteristic,"Race, n (%)", ; ,None,None,3,0,24,No,1:No,1:No,,0.81
5578,3468079,Table 1.,BaselineCharacteristic,"Race, n (%)","Cohort x (xxx mg of posaconazole), n?=?x ; ","Race, n (%)",None,3,2,43,No,1:No,1:No,,0.577
5578,3468079,Table 1.,BaselineCharacteristic,"Race, n (%)","Placebo, n?=?x ; ","Race, n (%)",None,3,3,43,No,1:No,1:No,,0.74
5578,3468079,Table 1.,BaselineCharacteristic,"Race, n (%)","All subjects, n?=?xx ; ","Race, n (%)",None,3,4,43,No,1:No,1:No,,0.516
5578,3468079,Table 1.,BaselineCharacteristic,?White, ; ,?White," Race, n (%)",4,0,2,No,1:No,1:No,,0.836
5578,3468079,Table 1.,BaselineCharacteristic,xx (xxx),"Cohort x (xxx mg of posaconazole), n?=?xx ; ",?White," Race, n (%)",4,1,3,No,1:No,1:No,,0.52
5578,3468079,Table 1.,BaselineCharacteristic,x (xxx),"Cohort x (xxx mg of posaconazole), n?=?x ; ",?White," Race, n (%)",4,2,3,No,1:No,1:No,,0.61
5578,3468079,Table 1.,BaselineCharacteristic,x (xxx),"Placebo, n?=?x ; ",?White," Race, n (%)",4,3,3,No,1:No,1:No,,0.676
5578,3468079,Table 1.,BaselineCharacteristic,"Ethnicity, n (%)", ; ,None,None,5,0,24,No,1:No,1:No,,0.83
5578,3468079,Table 1.,BaselineCharacteristic,"Ethnicity, n (%)","Cohort x (xxx mg of posaconazole), n?=?x ; ","Ethnicity, n (%)",None,5,2,43,No,1:No,1:No,,0.597
5578,3468079,Table 1.,BaselineCharacteristic,"Ethnicity, n (%)","Placebo, n?=?x ; ","Ethnicity, n (%)",None,5,3,43,No,1:No,1:No,,0.76
5578,3468079,Table 1.,BaselineCharacteristic,"Ethnicity, n (%)","All subjects, n?=?xx ; ","Ethnicity, n (%)",None,5,4,43,No,1:No,1:No,,0.546
5578,3468079,Table 1.,BaselineCharacteristic,?Hispanic or Latino, ; ,?Hispanic or Latino," Ethnicity, n (%)",6,0,2,No,1:No,1:No,,0.896
5578,3468079,Table 1.,BaselineCharacteristic,xx (xxx),"Cohort x (xxx mg of posaconazole), n?=?xx ; ",?Hispanic or Latino," Ethnicity, n (%)",6,1,3,No,1:No,1:No,,0.69
5578,3468079,Table 1.,BaselineCharacteristic,x (xxx),"Cohort x (xxx mg of posaconazole), n?=?x ; ",?Hispanic or Latino," Ethnicity, n (%)",6,2,3,No,1:No,1:No,,0.74
5578,3468079,Table 1.,BaselineCharacteristic,x (xxx),"Placebo, n?=?x ; ",?Hispanic or Latino," Ethnicity, n (%)",6,3,3,No,1:No,1:No,,0.796
5578,3468079,Table 1.,BaselineCharacteristic,xx (xxx),"All subjects, n?=?xx ; ",?Hispanic or Latino," Ethnicity, n (%)",6,4,3,No,1:No,1:No,,0.636
5578,3468079,Table 1.,BaselineCharacteristic,"Age, years", ; ,None,None,7,0,24,No,1:No,1:No,,0.705
5578,3468079,Table 1.,BaselineCharacteristic,"Age, years","Placebo, n?=?x ; ","Age, years",None,7,3,43,No,1:No,1:No,,0.636
5578,3468079,Table 1.,BaselineCharacteristic,?mean (SD), ; ,?mean (SD)," Age, years",8,0,2,No,1:No,1:No,,0.58
5578,3468079,Table 1.,BaselineCharacteristic,"Weight, kg", ; ,None,None,10,0,24,No,1:No,1:No,,0.995
5578,3468079,Table 1.,BaselineCharacteristic,"Weight, kg","Cohort x (xxx mg of posaconazole), n?=?xx ; ","Weight, kg",None,10,1,43,No,1:No,1:No,,0.59
5578,3468079,Table 1.,BaselineCharacteristic,"Weight, kg","Cohort x (xxx mg of posaconazole), n?=?x ; ","Weight, kg",None,10,2,43,No,1:No,1:No,,0.674
5578,3468079,Table 1.,BaselineCharacteristic,"Weight, kg","Placebo, n?=?x ; ","Weight, kg",None,10,3,43,No,1:No,1:No,,0.882
5578,3468079,Table 1.,BaselineCharacteristic,"Weight, kg","All subjects, n?=?xx ; ","Weight, kg",None,10,4,43,No,1:No,1:No,,0.684
5578,3468079,Table 1.,BaselineCharacteristic,?mean (SD), ; ,?mean (SD)," Weight, kg",11,0,2,No,1:No,1:No,,0.77
5578,3468079,Table 1.,BaselineCharacteristic,?median (range), ; ,?median (range)," Weight, kg",12,0,2,No,1:No,1:No,,0.632
5578,3468079,Table 1.,BaselineCharacteristic,"Height, cm", ; ,None,None,13,0,24,No,1:No,1:No,,0.995
5578,3468079,Table 1.,BaselineCharacteristic,"Height, cm","Cohort x (xxx mg of posaconazole), n?=?xx ; ","Height, cm",None,13,1,43,No,1:No,1:No,,0.6
5578,3468079,Table 1.,BaselineCharacteristic,"Height, cm","Cohort x (xxx mg of posaconazole), n?=?x ; ","Height, cm",None,13,2,43,No,1:No,1:No,,0.694
5578,3468079,Table 1.,BaselineCharacteristic,"Height, cm","Placebo, n?=?x ; ","Height, cm",None,13,3,43,No,1:No,1:No,,0.912
5578,3468079,Table 1.,BaselineCharacteristic,"Height, cm","All subjects, n?=?xx ; ","Height, cm",None,13,4,43,No,1:No,1:No,,0.704
5578,3468079,Table 1.,BaselineCharacteristic,?mean (SD), ; ,?mean (SD)," Height, cm",14,0,2,No,1:No,1:No,,0.77
5578,3468079,Table 1.,BaselineCharacteristic,?median (range), ; ,?median (range)," Height, cm",15,0,2,No,1:No,1:No,,0.632
5636,3483202,Table 1,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
5636,3483202,Table 1,BaselineCharacteristic,"No diabetes mellitus, n?=?xxx",,,None,0,2,1,No,1:No,1:No,,0.583
5636,3483202,Table 1,BaselineCharacteristic,Age years, ; ,Age years,,1,0,2,No,1:No,1:No,,0.65
5636,3483202,Table 1,BaselineCharacteristic,Male gender %, ; ,Male gender %,,2,0,2,No,1:No,1:No,,0.87
5636,3483202,Table 1,BaselineCharacteristic,xx,"Diabetes mellitus, n?=?xx ; ",Male gender %,,2,1,3,No,1:No,1:No,,0.556
5636,3483202,Table 1,BaselineCharacteristic,xx,"No diabetes mellitus, n?=?xxx ; ",Male gender %,,2,2,3,No,1:No,1:No,,0.566
5636,3483202,Table 1,BaselineCharacteristic,Smokers, ; ,Smokers,,3,0,2,No,1:No,1:No,,0.96
5636,3483202,Table 1,BaselineCharacteristic,xx,"Diabetes mellitus, n?=?xx ; ",Smokers,,3,1,3,No,1:No,1:No,,0.551
5636,3483202,Table 1,BaselineCharacteristic,Married or cohabitant %, ; ,Married or cohabitant %,,4,0,2,No,1:No,1:No,,0.87
5636,3483202,Table 1,BaselineCharacteristic,xx,"Diabetes mellitus, n?=?xx ; ",Married or cohabitant %,,4,1,3,No,1:No,1:No,,0.711
5636,3483202,Table 1,BaselineCharacteristic,xx,"No diabetes mellitus, n?=?xxx ; ",Married or cohabitant %,,4,2,3,No,1:No,1:No,,0.701
5636,3483202,Table 1,BaselineCharacteristic,Body mass index kg/mx, ; ,Body mass index kg/mx,,5,0,2,No,1:No,1:No,,0.98
5636,3483202,Table 1,BaselineCharacteristic,xx.x (x.x),"Diabetes mellitus, n?=?xx ; ",Body mass index kg/mx,,5,1,3,No,1:No,1:No,,0.667
5636,3483202,Table 1,BaselineCharacteristic,xx.x (x.x),"No diabetes mellitus, n?=?xxx ; ",Body mass index kg/mx,,5,2,3,No,1:No,1:No,,0.607
5636,3483202,Table 1,BaselineCharacteristic,Haemoglobin g/dL, ; ,Haemoglobin g/dL,,6,0,2,No,1:No,1:No,,0.99
5636,3483202,Table 1,BaselineCharacteristic,xx.x (x.x),"Diabetes mellitus, n?=?xx ; ",Haemoglobin g/dL,,6,1,3,No,1:No,1:No,,0.637
5636,3483202,Table 1,BaselineCharacteristic,xx.x (x.x),"No diabetes mellitus, n?=?xxx ; ",Haemoglobin g/dL,,6,2,3,No,1:No,1:No,,0.577
5636,3483202,Table 1,BaselineCharacteristic,Albumin g/L, ; ,Albumin g/L,,7,0,2,No,1:No,1:No,,0.99
5636,3483202,Table 1,BaselineCharacteristic,xx.x (x.x),"Diabetes mellitus, n?=?xx ; ",Albumin g/L,,7,1,3,No,1:No,1:No,,0.657
5636,3483202,Table 1,BaselineCharacteristic,xx.x (x.x),"No diabetes mellitus, n?=?xxx ; ",Albumin g/L,,7,2,3,No,1:No,1:No,,0.597
5636,3483202,Table 1,BaselineCharacteristic,CRP mmol/L, ; ,CRP mmol/L,,8,0,2,No,1:No,1:No,,0.99
5636,3483202,Table 1,BaselineCharacteristic,x.x (x.x-xx.x),"Diabetes mellitus, n?=?xx ; ",CRP mmol/L,,8,1,3,No,1:No,1:No,,0.677
5636,3483202,Table 1,BaselineCharacteristic,x.x (x.x-xx.x),"No diabetes mellitus, n?=?xxx ; ",CRP mmol/L,,8,2,3,No,1:No,1:No,,0.751
5636,3483202,Table 1,BaselineCharacteristic,PTH pmol/L, ; ,PTH pmol/L,,9,0,2,No,1:No,1:No,,1
5636,3483202,Table 1,BaselineCharacteristic,xx.x (xx.x-xx.x),"Diabetes mellitus, n?=?xx ; ",PTH pmol/L,,9,1,3,No,1:No,1:No,,0.687
5636,3483202,Table 1,BaselineCharacteristic,xx.x (xx.x-xx.x),"No diabetes mellitus, n?=?xxx ; ",PTH pmol/L,,9,2,3,No,1:No,1:No,,0.617
5636,3483202,Table 1,BaselineCharacteristic,Dialysis vintage years, ; ,Dialysis vintage years,,10,0,2,No,1:No,1:No,,0.73
5636,3483202,Table 1,BaselineCharacteristic,Peritoneal dialysis %, ; ,Peritoneal dialysis %,,11,0,2,No,1:No,1:No,,0.97
5636,3483202,Table 1,BaselineCharacteristic,xx,"Diabetes mellitus, n?=?xx ; ",Peritoneal dialysis %,,11,1,3,No,1:No,1:No,,0.761
5636,3483202,Table 1,BaselineCharacteristic,xx,"No diabetes mellitus, n?=?xxx ; ",Peritoneal dialysis %,,11,2,3,No,1:No,1:No,,0.751
5636,3483202,Table 1,BaselineCharacteristic,Kt/V (haemodialysis), ; ,Kt/V (haemodialysis),,12,0,2,No,1:No,1:No,,1
5636,3483202,Table 1,BaselineCharacteristic,x.xx (x.xx),"Diabetes mellitus, n?=?xx ; ",Kt/V (haemodialysis),,12,1,3,No,1:No,1:No,,0.737
5636,3483202,Table 1,BaselineCharacteristic,x.xx (x.xx),"No diabetes mellitus, n?=?xxx ; ",Kt/V (haemodialysis),,12,2,3,No,1:No,1:No,,0.657
5636,3483202,Table 1,BaselineCharacteristic,Urea mmol/L, ; ,Urea mmol/L,,13,0,2,No,1:No,1:No,,1
5636,3483202,Table 1,BaselineCharacteristic,xx.x (x.x),"Diabetes mellitus, n?=?xx ; ",Urea mmol/L,,13,1,3,No,1:No,1:No,,0.737
5636,3483202,Table 1,BaselineCharacteristic,xx.x (x.x),"No diabetes mellitus, n?=?xxx ; ",Urea mmol/L,,13,2,3,No,1:No,1:No,,0.657
5636,3483202,Table 1,BaselineCharacteristic,Comorbidity, ; ,None,None,14,0,24,No,1:No,1:No,,0.995
5636,3483202,Table 1,BaselineCharacteristic,,"Diabetes mellitus, n?=?xx ; ",Comorbidity,None,14,1,43,No,1:No,1:No,,0.764
5636,3483202,Table 1,BaselineCharacteristic,,"No diabetes mellitus, n?=?xxx ; ",Comorbidity,None,14,2,43,No,1:No,1:No,,0.775
5636,3483202,Table 1,BaselineCharacteristic,Charlson comorbidity index, ; ,Charlson comorbidity index, Comorbidity,15,0,2,No,1:No,1:No,,1
5636,3483202,Table 1,BaselineCharacteristic,x.x (x.x),"Diabetes mellitus, n?=?xx ; ",Charlson comorbidity index, Comorbidity,15,1,3,No,1:No,1:No,,0.757
5636,3483202,Table 1,BaselineCharacteristic,x.x (x.x),"No diabetes mellitus, n?=?xxx ; ",Charlson comorbidity index, Comorbidity,15,2,3,No,1:No,1:No,,0.791
5636,3483202,Table 1,BaselineCharacteristic,Nephrosclerosis %, ; ,Nephrosclerosis %, Comorbidity,16,0,2,No,1:No,1:No,,0.96
5636,3483202,Table 1,BaselineCharacteristic,xx,"Diabetes mellitus, n?=?xx ; ",Nephrosclerosis %, Comorbidity,16,1,3,No,1:No,1:No,,0.781
5636,3483202,Table 1,BaselineCharacteristic,xx,"No diabetes mellitus, n?=?xxx ; ",Nephrosclerosis %, Comorbidity,16,2,3,No,1:No,1:No,,0.751
5636,3483202,Table 1,BaselineCharacteristic,Previous renal graft %, ; ,Previous renal graft %, Comorbidity,17,0,2,No,1:No,1:No,,0.96
5636,3483202,Table 1,BaselineCharacteristic,xx,"Diabetes mellitus, n?=?xx ; ",Previous renal graft %, Comorbidity,17,1,3,No,1:No,1:No,,0.781
5636,3483202,Table 1,BaselineCharacteristic,xx,"No diabetes mellitus, n?=?xxx ; ",Previous renal graft %, Comorbidity,17,2,3,No,1:No,1:No,,0.751
5636,3483202,Table 1,BaselineCharacteristic,Diabetes type x%, ; ,Diabetes type x%, Comorbidity,18,0,2,No,1:No,1:No,,0.99
5636,3483202,Table 1,BaselineCharacteristic,xx,"Diabetes mellitus, n?=?xx ; ",Diabetes type x%, Comorbidity,18,1,3,No,1:No,1:No,,0.802
5636,3483202,Table 1,BaselineCharacteristic,,"No diabetes mellitus, n?=?xxx ; ",Diabetes type x%, Comorbidity,18,2,3,No,1:No,1:No,,0.801
5636,3483202,Table 1,BaselineCharacteristic,Diabetes type x%, ; ,Diabetes type x%, Comorbidity,19,0,2,No,1:No,1:No,,0.99
5636,3483202,Table 1,BaselineCharacteristic,xx,"Diabetes mellitus, n?=?xx ; ",Diabetes type x%, Comorbidity,19,1,3,No,1:No,1:No,,0.802
5636,3483202,Table 1,BaselineCharacteristic,,"No diabetes mellitus, n?=?xxx ; ",Diabetes type x%, Comorbidity,19,2,3,No,1:No,1:No,,0.801
5637,3483844,Table 1.,BaselineCharacteristic,Variable,,None,None,0,0,12,No,1:No,1:No,,0.905
5637,3483844,Table 1.,BaselineCharacteristic,Value,,Variable,None,0,1,1,No,1:No,1:No,,0.924
5637,3483844,Table 1.,BaselineCharacteristic,Gender n,Variable ; ,None,None,1,0,24,No,1:No,1:No,,0.832
5637,3483844,Table 1.,BaselineCharacteristic,Gender n,Value ; ,Gender n,None,1,1,43,No,1:No,1:No,,0.735
5637,3483844,Table 1.,BaselineCharacteristic,?Male,Variable ; ,?Male, Gender n,2,0,2,No,1:No,1:No,,0.826
5637,3483844,Table 1.,BaselineCharacteristic,x (xx.x%),Value ; ,?Male, Gender n,2,1,3,No,1:No,1:No,,0.556
5637,3483844,Table 1.,BaselineCharacteristic,?Female,Variable ; ,?Female, Gender n,3,0,2,No,1:No,1:No,,0.846
5637,3483844,Table 1.,BaselineCharacteristic,x (xx.x%),Value ; ,?Female, Gender n,3,1,3,No,1:No,1:No,,0.606
5637,3483844,Table 1.,BaselineCharacteristic,Age (years),Variable ; ,None,None,4,0,24,No,1:No,1:No,,0.705
5637,3483844,Table 1.,BaselineCharacteristic,Age (years),Value ; ,Age (years),None,4,1,43,No,1:No,1:No,,0.634
5637,3483844,Table 1.,BaselineCharacteristic,?Mean,Variable ; ,?Mean, Age (years),5,0,2,No,1:No,1:No,,0.68
5637,3483844,Table 1.,BaselineCharacteristic,?Range,Variable ; ,?Range, Age (years),6,0,2,No,1:No,1:No,,0.68
5637,3483844,Table 1.,BaselineCharacteristic,T category n,Variable ; ,None,None,7,0,24,No,1:No,1:No,,0.922
5637,3483844,Table 1.,BaselineCharacteristic,T category n,Value ; ,T category n,None,7,1,43,No,1:No,1:No,,0.845
5637,3483844,Table 1.,BaselineCharacteristic,?Txa + Txb,Variable ; ,?Txa + Txb, T category n,8,0,2,No,1:No,1:No,,0.896
5637,3483844,Table 1.,BaselineCharacteristic,x (xx.x%),Value ; ,?Txa + Txb, T category n,8,1,3,No,1:No,1:No,,0.721
5637,3483844,Table 1.,BaselineCharacteristic,?Tx,Variable ; ,?Tx, T category n,9,0,2,No,1:No,1:No,,0.896
5637,3483844,Table 1.,BaselineCharacteristic,x (xx.x%),Value ; ,?Tx, T category n,9,1,3,No,1:No,1:No,,0.761
5637,3483844,Table 1.,BaselineCharacteristic,?Tx,Variable ; ,?Tx, T category n,10,0,2,No,1:No,1:No,,0.906
5637,3483844,Table 1.,BaselineCharacteristic,x (xx.x%),Value ; ,?Tx, T category n,10,1,3,No,1:No,1:No,,0.801
5637,3483844,Table 1.,BaselineCharacteristic,N category n,Variable ; ,None,None,11,0,24,No,1:No,1:No,,0.932
5637,3483844,Table 1.,BaselineCharacteristic,N category n,Value ; ,N category n,None,11,1,43,No,1:No,1:No,,0.895
5637,3483844,Table 1.,BaselineCharacteristic,?Nx,Variable ; ,?Nx, N category n,12,0,2,No,1:No,1:No,,0.906
5637,3483844,Table 1.,BaselineCharacteristic,x (xx.x%),Value ; ,?Nx, N category n,12,1,3,No,1:No,1:No,,0.821
5637,3483844,Table 1.,BaselineCharacteristic,?Nx,Variable ; ,?Nx, N category n,13,0,2,No,1:No,1:No,,0.906
5637,3483844,Table 1.,BaselineCharacteristic,x (xx.x%),Value ; ,?Nx, N category n,13,1,3,No,1:No,1:No,,0.821
5637,3483844,Table 1.,BaselineCharacteristic,?Nx,Variable ; ,?Nx, N category n,14,0,2,No,1:No,1:No,,0.906
5637,3483844,Table 1.,BaselineCharacteristic,x (xx.x%),Value ; ,?Nx, N category n,14,1,3,No,1:No,1:No,,0.831
5637,3483844,Table 1.,BaselineCharacteristic,?Nxa + Nxb,Variable ; ,?Nxa + Nxb, N category n,15,0,2,No,1:No,1:No,,0.906
5637,3483844,Table 1.,BaselineCharacteristic,x (xx.x%),Value ; ,?Nxa + Nxb, N category n,15,1,3,No,1:No,1:No,,0.811
5637,3483844,Table 1.,BaselineCharacteristic,AJCC stage group n,Variable ; ,None,None,16,0,24,No,1:No,1:No,,0.92
5637,3483844,Table 1.,BaselineCharacteristic,AJCC stage group n,Value ; ,AJCC stage group n,None,16,1,43,No,1:No,1:No,,0.899
5637,3483844,Table 1.,BaselineCharacteristic,?IIa + IIb,Variable ; ,?IIa + IIb, AJCC stage group n,17,0,2,No,1:No,1:No,,0.896
5637,3483844,Table 1.,BaselineCharacteristic,x (xx.x%),Value ; ,?IIa + IIb, AJCC stage group n,17,1,3,No,1:No,1:No,,0.806
5637,3483844,Table 1.,BaselineCharacteristic,?III,Variable ; ,?III, AJCC stage group n,18,0,2,No,1:No,1:No,,0.896
5637,3483844,Table 1.,BaselineCharacteristic,x (xx.x%),Value ; ,?III, AJCC stage group n,18,1,3,No,1:No,1:No,,0.791
5637,3483844,Table 1.,BaselineCharacteristic,?IVa + IVb,Variable ; ,?IVa + IVb, AJCC stage group n,19,0,2,No,1:No,1:No,,0.896
5637,3483844,Table 1.,BaselineCharacteristic,x (xx.x%),Value ; ,?IVa + IVb, AJCC stage group n,19,1,3,No,1:No,1:No,,0.791
5637,3483844,Table 1.,BaselineCharacteristic,Chemotherapy n,Variable ; ,None,None,20,0,24,No,1:No,1:No,,0.932
5637,3483844,Table 1.,BaselineCharacteristic,Chemotherapy n,Value ; ,Chemotherapy n,None,20,1,43,No,1:No,1:No,,0.875
5637,3483844,Table 1.,BaselineCharacteristic,?None,Variable ; ,?None, Chemotherapy n,21,0,2,No,1:No,1:No,,0.906
5637,3483844,Table 1.,BaselineCharacteristic,x (xx.x%),Value ; ,?None, Chemotherapy n,21,1,3,No,1:No,1:No,,0.797
5637,3483844,Table 1.,BaselineCharacteristic,?Induction + concurrent,Variable ; ,?Induction + concurrent, Chemotherapy n,22,0,2,No,1:No,1:No,,0.906
5637,3483844,Table 1.,BaselineCharacteristic,x (xx.x%),Value ; ,?Induction + concurrent, Chemotherapy n,22,1,3,No,1:No,1:No,,0.817
5637,3483844,Table 1.,BaselineCharacteristic,?Concurrent,Variable ; ,?Concurrent, Chemotherapy n,23,0,2,No,1:No,1:No,,0.906
5637,3483844,Table 1.,BaselineCharacteristic,x (xx.x%),Value ; ,?Concurrent, Chemotherapy n,23,1,3,No,1:No,1:No,,0.817
5666,3488983,Table 1,BaselineCharacteristic,Subject,,None,None,0,0,12,No,1:No,1:No,,0.905
5666,3488983,Table 1,BaselineCharacteristic,Sex,,Subject,None,0,1,1,No,1:No,1:No,,0.903
5666,3488983,Table 1,BaselineCharacteristic,Age,,Subject,None,0,2,1,No,1:No,1:No,,0.903
5666,3488983,Table 1,BaselineCharacteristic,Level,,Subject,None,0,3,1,No,1:No,1:No,,0.903
5666,3488983,Table 1,BaselineCharacteristic,MV Time,,Subject,None,0,4,1,No,1:No,1:No,,0.913
5666,3488983,Table 1,BaselineCharacteristic,MV Dependence,,Subject,None,0,5,1,No,1:No,1:No,,0.935
5666,3488983,Table 1,BaselineCharacteristic,LMFF,Subject ; ,LMFF,None,1,0,2,No,1:No,1:No,,0.94
5666,3488983,Table 1,BaselineCharacteristic,F,Sex ; ,LMFF,None,1,1,3,No,1:No,1:No,,0.87
5666,3488983,Table 1,BaselineCharacteristic,xx y,Age ; ,LMFF,None,1,2,3,No,1:No,1:No,,0.618
5666,3488983,Table 1,BaselineCharacteristic,Cx,Level ; ,LMFF,None,1,3,3,No,1:No,1:No,,0.88
5666,3488983,Table 1,BaselineCharacteristic,x y,MV Time ; ,LMFF,None,1,4,3,No,1:No,1:No,,0.88
5666,3488983,Table 1,BaselineCharacteristic,Complete,MV Dependence ; ,LMFF,None,1,5,3,No,1:No,1:No,,0.88
5666,3488983,Table 1,BaselineCharacteristic,PIS,Subject ; ,PIS,None,2,0,2,No,1:No,1:No,,0.95
5666,3488983,Table 1,BaselineCharacteristic,F,Sex ; ,PIS,None,2,1,3,No,1:No,1:No,,0.89
5666,3488983,Table 1,BaselineCharacteristic,xx y,Age ; ,PIS,None,2,2,3,No,1:No,1:No,,0.678
5666,3488983,Table 1,BaselineCharacteristic,CxCx,Level ; ,PIS,None,2,3,3,No,1:No,1:No,,0.9
5666,3488983,Table 1,BaselineCharacteristic,xx y,MV Time ; ,PIS,None,2,4,3,No,1:No,1:No,,0.688
5666,3488983,Table 1,BaselineCharacteristic,Complete,MV Dependence ; ,PIS,None,2,5,3,No,1:No,1:No,,0.9
5666,3488983,Table 1,BaselineCharacteristic,EFS,Subject ; ,EFS,None,3,0,2,No,1:No,1:No,,0.96
5666,3488983,Table 1,BaselineCharacteristic,M,Sex ; ,EFS,None,3,1,3,No,1:No,1:No,,0.9
5666,3488983,Table 1,BaselineCharacteristic,xx y,Age ; ,EFS,None,3,2,3,No,1:No,1:No,,0.706
5666,3488983,Table 1,BaselineCharacteristic,Cx,Level ; ,EFS,None,3,3,3,No,1:No,1:No,,0.91
5666,3488983,Table 1,BaselineCharacteristic,x y,MV Time ; ,EFS,None,3,4,3,No,1:No,1:No,,0.92
5666,3488983,Table 1,BaselineCharacteristic,Complete,MV Dependence ; ,EFS,None,3,5,3,No,1:No,1:No,,0.91
5666,3488983,Table 1,BaselineCharacteristic,VOS,Subject ; ,VOS,None,4,0,2,No,1:No,1:No,,0.97
5666,3488983,Table 1,BaselineCharacteristic,M,Sex ; ,VOS,None,4,1,3,No,1:No,1:No,,0.89
5666,3488983,Table 1,BaselineCharacteristic,xx y,Age ; ,VOS,None,4,2,3,No,1:No,1:No,,0.741
5666,3488983,Table 1,BaselineCharacteristic,CxCx,Level ; ,VOS,None,4,3,3,No,1:No,1:No,,0.91
5666,3488983,Table 1,BaselineCharacteristic,xx m,MV Time ; ,VOS,None,4,4,3,No,1:No,1:No,,0.801
5666,3488983,Table 1,BaselineCharacteristic,Partial (with supplemental oxygen),MV Dependence ; ,VOS,None,4,5,3,No,1:No,1:No,,0.9
5666,3488983,Table 1,BaselineCharacteristic,IFLS,Subject ; ,IFLS,None,5,0,2,No,1:No,1:No,,0.97
5666,3488983,Table 1,BaselineCharacteristic,F,Sex ; ,IFLS,None,5,1,3,No,1:No,1:No,,0.89
5666,3488983,Table 1,BaselineCharacteristic,xx y,Age ; ,IFLS,None,5,2,3,No,1:No,1:No,,0.731
5666,3488983,Table 1,BaselineCharacteristic,Cx,Level ; ,IFLS,None,5,3,3,No,1:No,1:No,,0.91
5666,3488983,Table 1,BaselineCharacteristic,x y,MV Time ; ,IFLS,None,5,4,3,No,1:No,1:No,,0.92
5666,3488983,Table 1,BaselineCharacteristic,Complete,MV Dependence ; ,IFLS,None,5,5,3,No,1:No,1:No,,0.89
5696,3493663,Table 1,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
5696,3493663,Table 1,BaselineCharacteristic,ITT xx (xxx.x %),,,None,0,1,1,No,1:No,1:No,,0.675
5696,3493663,Table 1,BaselineCharacteristic,PP xx (xxx.x %),,,None,0,2,1,No,1:No,1:No,,0.583
5696,3493663,Table 1,BaselineCharacteristic,Gender, ; ,None,None,1,0,24,No,1:No,1:No,,0.897
5696,3493663,Table 1,BaselineCharacteristic,Gender,ITT xx (xxx.x %) ; ,Gender,None,1,1,43,No,1:No,1:No,,0.694
5696,3493663,Table 1,BaselineCharacteristic,Gender,PP xx (xxx.x %) ; ,Gender,None,1,2,43,No,1:No,1:No,,0.568
5696,3493663,Table 1,BaselineCharacteristic,, ; ,, Gender,2,0,2,No,1:No,1:No,,0.95
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),ITT xx (xxx.x %) ; ,, Gender,2,1,3,No,1:No,1:No,,0.632
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),PP xx (xxx.x %) ; ,, Gender,2,2,3,No,1:No,1:No,,0.582
5696,3493663,Table 1,BaselineCharacteristic,, ; ,, Gender,3,0,2,No,1:No,1:No,,0.96
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),ITT xx (xxx.x %) ; ,, Gender,3,1,3,No,1:No,1:No,,0.606
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),PP xx (xxx.x %) ; ,, Gender,3,2,3,No,1:No,1:No,,0.566
5696,3493663,Table 1,BaselineCharacteristic,Median age/years (range), ; ,Median age/years (range), Gender,4,0,2,No,1:No,1:No,,0.69
5696,3493663,Table 1,BaselineCharacteristic,HLA typea, ; ,None,None,5,0,24,No,1:No,1:No,,0.929
5696,3493663,Table 1,BaselineCharacteristic,HLA typea,ITT xx (xxx.x %) ; ,HLA typea,None,5,1,43,No,1:No,1:No,,0.686
5696,3493663,Table 1,BaselineCharacteristic,HLA typea,PP xx (xxx.x %) ; ,HLA typea,None,5,2,43,No,1:No,1:No,,0.63
5696,3493663,Table 1,BaselineCharacteristic,, ; ,, HLA typea,6,0,2,No,1:No,1:No,,0.99
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),ITT xx (xxx.x %) ; ,, HLA typea,6,1,3,No,1:No,1:No,,0.686
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),PP xx (xxx.x %) ; ,, HLA typea,6,2,3,No,1:No,1:No,,0.676
5696,3493663,Table 1,BaselineCharacteristic,, ; ,, HLA typea,7,0,2,No,1:No,1:No,,0.99
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),ITT xx (xxx.x %) ; ,, HLA typea,7,1,3,No,1:No,1:No,,0.696
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),PP xx (xxx.x %) ; ,, HLA typea,7,2,3,No,1:No,1:No,,0.686
5696,3493663,Table 1,BaselineCharacteristic,, ; ,, HLA typea,8,0,2,No,1:No,1:No,,0.99
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),ITT xx (xxx.x %) ; ,, HLA typea,8,1,3,No,1:No,1:No,,0.706
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),PP xx (xxx.x %) ; ,, HLA typea,8,2,3,No,1:No,1:No,,0.696
5696,3493663,Table 1,BaselineCharacteristic,Serum LDH, ; ,None,None,9,0,24,No,1:No,1:No,,0.984
5696,3493663,Table 1,BaselineCharacteristic,Serum LDH,ITT xx (xxx.x %) ; ,Serum LDH,None,9,1,43,No,1:No,1:No,,0.801
5696,3493663,Table 1,BaselineCharacteristic,Serum LDH,PP xx (xxx.x %) ; ,Serum LDH,None,9,2,43,No,1:No,1:No,,0.765
5696,3493663,Table 1,BaselineCharacteristic,, ; ,, Serum LDH,10,0,2,No,1:No,1:No,,1
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),ITT xx (xxx.x %) ; ,, Serum LDH,10,1,3,No,1:No,1:No,,0.816
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),PP xx (xxx.x %) ; ,, Serum LDH,10,2,3,No,1:No,1:No,,0.796
5696,3493663,Table 1,BaselineCharacteristic,, ; ,, Serum LDH,11,0,2,No,1:No,1:No,,1
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),ITT xx (xxx.x %) ; ,, Serum LDH,11,1,3,No,1:No,1:No,,0.816
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),PP xx (xxx.x %) ; ,, Serum LDH,11,2,3,No,1:No,1:No,,0.796
5696,3493663,Table 1,BaselineCharacteristic,Performance status (ECOG), ; ,None,None,12,0,24,No,1:No,1:No,,0.995
5696,3493663,Table 1,BaselineCharacteristic,Performance status (ECOG),ITT xx (xxx.x %) ; ,Performance status (ECOG),None,12,1,43,No,1:No,1:No,,0.841
5696,3493663,Table 1,BaselineCharacteristic,Performance status (ECOG),PP xx (xxx.x %) ; ,Performance status (ECOG),None,12,2,43,No,1:No,1:No,,0.801
5696,3493663,Table 1,BaselineCharacteristic,, ; ,, Performance status (ECOG),13,0,2,No,1:No,1:No,,1
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),ITT xx (xxx.x %) ; ,, Performance status (ECOG),13,1,3,No,1:No,1:No,,0.816
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),PP xx (xxx.x %) ; ,, Performance status (ECOG),13,2,3,No,1:No,1:No,,0.796
5696,3493663,Table 1,BaselineCharacteristic,, ; ,, Performance status (ECOG),14,0,2,No,1:No,1:No,,1
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),ITT xx (xxx.x %) ; ,, Performance status (ECOG),14,1,3,No,1:No,1:No,,0.826
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),PP xx (xxx.x %) ; ,, Performance status (ECOG),14,2,3,No,1:No,1:No,,0.806
5696,3493663,Table 1,BaselineCharacteristic,, ; ,, Performance status (ECOG),15,0,2,No,1:No,1:No,,1
5696,3493663,Table 1,BaselineCharacteristic,x (x.x %),ITT xx (xxx.x %) ; ,, Performance status (ECOG),15,1,3,No,1:No,1:No,,0.79
5696,3493663,Table 1,BaselineCharacteristic,x (x.x %),PP xx (xxx.x %) ; ,, Performance status (ECOG),15,2,3,No,1:No,1:No,,0.79
5696,3493663,Table 1,BaselineCharacteristic,M category (AJCC), ; ,None,None,16,0,24,No,1:No,1:No,,0.995
5696,3493663,Table 1,BaselineCharacteristic,M category (AJCC),ITT xx (xxx.x %) ; ,M category (AJCC),None,16,1,43,No,1:No,1:No,,0.851
5696,3493663,Table 1,BaselineCharacteristic,M category (AJCC),PP xx (xxx.x %) ; ,M category (AJCC),None,16,2,43,No,1:No,1:No,,0.805
5696,3493663,Table 1,BaselineCharacteristic,, ; ,, M category (AJCC),17,0,2,No,1:No,1:No,,1
5696,3493663,Table 1,BaselineCharacteristic,x (x.x %),ITT xx (xxx.x %) ; ,, M category (AJCC),17,1,3,No,1:No,1:No,,0.78
5696,3493663,Table 1,BaselineCharacteristic,x (xx.x %),PP xx (xxx.x %) ; ,, M category (AJCC),17,2,3,No,1:No,1:No,,0.78
5696,3493663,Table 1,BaselineCharacteristic,, ; ,, M category (AJCC),18,0,2,No,1:No,1:No,,0.99
5696,3493663,Table 1,BaselineCharacteristic,x (xx.x %),ITT xx (xxx.x %) ; ,, M category (AJCC),18,1,3,No,1:No,1:No,,0.78
5696,3493663,Table 1,BaselineCharacteristic,x (xx.x %),PP xx (xxx.x %) ; ,, M category (AJCC),18,2,3,No,1:No,1:No,,0.78
5696,3493663,Table 1,BaselineCharacteristic,, ; ,, M category (AJCC),19,0,2,No,1:No,1:No,,0.99
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),ITT xx (xxx.x %) ; ,, M category (AJCC),19,1,3,No,1:No,1:No,,0.826
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),PP xx (xxx.x %) ; ,, M category (AJCC),19,2,3,No,1:No,1:No,,0.806
5696,3493663,Table 1,BaselineCharacteristic,Inflammatory reaction at vaccination sites, ; ,None,None,20,0,24,No,1:No,1:No,,0.955
5696,3493663,Table 1,BaselineCharacteristic,Inflammatory reaction at vaccination sites,ITT xx (xxx.x %) ; ,Inflammatory reaction at vaccination sites,None,20,1,43,No,1:No,1:No,,0.787
5696,3493663,Table 1,BaselineCharacteristic,Inflammatory reaction at vaccination sites,PP xx (xxx.x %) ; ,Inflammatory reaction at vaccination sites,None,20,2,43,No,1:No,1:No,,0.742
5696,3493663,Table 1,BaselineCharacteristic,, ; ,, Inflammatory reaction at vaccination sites,21,0,2,No,1:No,1:No,,0.982
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),ITT xx (xxx.x %) ; ,, Inflammatory reaction at vaccination sites,21,1,3,No,1:No,1:No,,0.78
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),PP xx (xxx.x %) ; ,, Inflammatory reaction at vaccination sites,21,2,3,No,1:No,1:No,,0.76
5696,3493663,Table 1,BaselineCharacteristic,, ; ,, Inflammatory reaction at vaccination sites,22,0,2,No,1:No,1:No,,0.992
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),ITT xx (xxx.x %) ; ,, Inflammatory reaction at vaccination sites,22,1,3,No,1:No,1:No,,0.78
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),PP xx (xxx.x %) ; ,, Inflammatory reaction at vaccination sites,22,2,3,No,1:No,1:No,,0.76
5696,3493663,Table 1,BaselineCharacteristic,Survivin-specific T-cell reactivity (SSTR)b, ; ,None,None,23,0,24,No,1:No,1:No,,0.935
5696,3493663,Table 1,BaselineCharacteristic,Survivin-specific T-cell reactivity (SSTR)b,ITT xx (xxx.x %) ; ,Survivin-specific T-cell reactivity (SSTR)b,None,23,1,43,No,1:No,1:No,,0.794
5696,3493663,Table 1,BaselineCharacteristic,Survivin-specific T-cell reactivity (SSTR)b,PP xx (xxx.x %) ; ,Survivin-specific T-cell reactivity (SSTR)b,None,23,2,43,No,1:No,1:No,,0.737
5696,3493663,Table 1,BaselineCharacteristic,, ; ,, Survivin-specific T-cell reactivity (SSTR)b,24,0,2,No,1:No,1:No,,0.95
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),ITT xx (xxx.x %) ; ,, Survivin-specific T-cell reactivity (SSTR)b,24,1,3,No,1:No,1:No,,0.766
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),PP xx (xxx.x %) ; ,, Survivin-specific T-cell reactivity (SSTR)b,24,2,3,No,1:No,1:No,,0.736
5696,3493663,Table 1,BaselineCharacteristic,, ; ,, Survivin-specific T-cell reactivity (SSTR)b,25,0,2,No,1:No,1:No,,0.95
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),ITT xx (xxx.x %) ; ,, Survivin-specific T-cell reactivity (SSTR)b,25,1,3,No,1:No,1:No,,0.766
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),PP xx (xxx.x %) ; ,, Survivin-specific T-cell reactivity (SSTR)b,25,2,3,No,1:No,1:No,,0.736
5696,3493663,Table 1,BaselineCharacteristic,, ; ,, Survivin-specific T-cell reactivity (SSTR)b,26,0,2,No,1:No,1:No,,0.95
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),ITT xx (xxx.x %) ; ,, Survivin-specific T-cell reactivity (SSTR)b,26,1,3,No,1:No,1:No,,0.766
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),PP xx (xxx.x %) ; ,, Survivin-specific T-cell reactivity (SSTR)b,26,2,3,No,1:No,1:No,,0.736
5696,3493663,Table 1,BaselineCharacteristic,Best overall responsec, ; ,None,None,27,0,24,No,1:No,1:No,,0.995
5696,3493663,Table 1,BaselineCharacteristic,Best overall responsec,ITT xx (xxx.x %) ; ,Best overall responsec,None,27,1,43,No,1:No,1:No,,0.911
5696,3493663,Table 1,BaselineCharacteristic,Best overall responsec,PP xx (xxx.x %) ; ,Best overall responsec,None,27,2,43,No,1:No,1:No,,0.881
5696,3493663,Table 1,BaselineCharacteristic,, ; ,, Best overall responsec,28,0,2,No,1:No,1:No,,1
5696,3493663,Table 1,BaselineCharacteristic,x (x.x %),ITT xx (xxx.x %) ; ,, Best overall responsec,28,1,3,No,1:No,1:No,,0.86
5696,3493663,Table 1,BaselineCharacteristic,x (x.x %),PP xx (xxx.x %) ; ,, Best overall responsec,28,2,3,No,1:No,1:No,,0.86
5696,3493663,Table 1,BaselineCharacteristic,, ; ,, Best overall responsec,29,0,2,No,1:No,1:No,,1
5696,3493663,Table 1,BaselineCharacteristic,x (x.x %),ITT xx (xxx.x %) ; ,, Best overall responsec,29,1,3,No,1:No,1:No,,0.86
5696,3493663,Table 1,BaselineCharacteristic,x (x.x %),PP xx (xxx.x %) ; ,, Best overall responsec,29,2,3,No,1:No,1:No,,0.86
5696,3493663,Table 1,BaselineCharacteristic,, ; ,, Best overall responsec,30,0,2,No,1:No,1:No,,1
5696,3493663,Table 1,BaselineCharacteristic,x (xx.x %),ITT xx (xxx.x %) ; ,, Best overall responsec,30,1,3,No,1:No,1:No,,0.86
5696,3493663,Table 1,BaselineCharacteristic,x (xx.x %),PP xx (xxx.x %) ; ,, Best overall responsec,30,2,3,No,1:No,1:No,,0.86
5696,3493663,Table 1,BaselineCharacteristic,, ; ,, Best overall responsec,31,0,2,No,1:No,1:No,,1
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),ITT xx (xxx.x %) ; ,, Best overall responsec,31,1,3,No,1:No,1:No,,0.906
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),PP xx (xxx.x %) ; ,, Best overall responsec,31,2,3,No,1:No,1:No,,0.876
5696,3493663,Table 1,BaselineCharacteristic,, ; ,, Best overall responsec,32,0,2,No,1:No,1:No,,1
5696,3493663,Table 1,BaselineCharacteristic,x (x.x %),ITT xx (xxx.x %) ; ,, Best overall responsec,32,1,3,No,1:No,1:No,,0.86
5696,3493663,Table 1,BaselineCharacteristic,x (x.x %),PP xx (xxx.x %) ; ,, Best overall responsec,32,2,3,No,1:No,1:No,,0.86
5696,3493663,Table 1,BaselineCharacteristic,, ; ,, Best overall responsec,33,0,2,No,1:No,1:No,,1
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),ITT xx (xxx.x %) ; ,, Best overall responsec,33,1,3,No,1:No,1:No,,0.906
5696,3493663,Table 1,BaselineCharacteristic,xx (xx.x %),PP xx (xxx.x %) ; ,, Best overall responsec,33,2,3,No,1:No,1:No,,0.876
5696,3493663,Table 1,BaselineCharacteristic,Median progression-free survival months (xx % CI)d, ; ,Median progression-free survival months (xx % CI)d, Best overall responsec,34,0,2,No,1:No,1:No,,1
5696,3493663,Table 1,BaselineCharacteristic,x.x (x.x–x.x),ITT xx (xxx.x %) ; ,Median progression-free survival months (xx % CI)d, Best overall responsec,34,1,3,No,1:No,1:No,,0.89
5696,3493663,Table 1,BaselineCharacteristic,x.x (x.x–x.x),PP xx (xxx.x %) ; ,Median progression-free survival months (xx % CI)d, Best overall responsec,34,2,3,No,1:No,1:No,,0.9
5696,3493663,Table 1,BaselineCharacteristic,Median overall survival months (xx % CI)d, ; ,Median overall survival months (xx % CI)d, Best overall responsec,35,0,2,No,1:No,1:No,,1
5696,3493663,Table 1,BaselineCharacteristic,x.x (x.x–xx.x),ITT xx (xxx.x %) ; ,Median overall survival months (xx % CI)d, Best overall responsec,35,1,3,No,1:No,1:No,,0.85
5696,3493663,Table 1,BaselineCharacteristic,x.x (x.x–xx.x),PP xx (xxx.x %) ; ,Median overall survival months (xx % CI)d, Best overall responsec,35,2,3,No,1:No,1:No,,0.87
5696,3493663,Table 2,BaselineCharacteristic,Sex,,None,None,0,0,12,No,1:No,1:No,,0.905
5696,3493663,Table 2,BaselineCharacteristic,Age (years),,Sex,None,0,1,1,No,1:No,1:No,,0.557
5696,3493663,Table 2,BaselineCharacteristic,Localization of primary melanoma,,Sex,None,0,2,1,No,1:No,1:No,,0.914
5696,3493663,Table 2,BaselineCharacteristic,Stage (AJCC),,Sex,None,0,3,1,No,1:No,1:No,,0.903
5696,3493663,Table 2,BaselineCharacteristic,HLA type,,Sex,None,0,4,1,No,1:No,1:No,,0.913
5696,3493663,Table 2,BaselineCharacteristic,Vaccination regimen,,Sex,None,0,5,1,No,1:No,1:No,,0.945
5696,3493663,Table 2,BaselineCharacteristic,OPS (ECOG),,Sex,None,0,6,1,No,1:No,1:No,,0.935
5696,3493663,Table 2,BaselineCharacteristic,Previous therapy in stage-IV,,Sex,None,0,7,1,No,1:No,1:No,,0.897
5696,3493663,Table 2,BaselineCharacteristic,Sites of metastases,,Sex,None,0,8,1,No,1:No,1:No,,0.935
5696,3493663,Table 2,BaselineCharacteristic,Number of vaccinations (ELISPOT)a,,Sex,None,0,9,1,No,1:No,1:No,,0.885
5696,3493663,Table 2,BaselineCharacteristic,Survivin-specific T-cell reactivity vaccination sites,,Sex,None,0,10,1,No,1:No,1:No,,0.908
5696,3493663,Table 2,BaselineCharacteristic,Inflammatory reaction at responseb,,Sex,None,0,11,1,No,1:No,1:No,,0.945
5696,3493663,Table 2,BaselineCharacteristic,Best overall,,Sex,None,0,12,1,No,1:No,1:No,,0.955
5696,3493663,Table 2,BaselineCharacteristic,PFS (months),,Sex,None,0,13,1,No,1:No,1:No,,0.946
5696,3493663,Table 2,BaselineCharacteristic,OS (months),,Sex,None,0,14,1,No,1:No,1:No,,0.953
5696,3493663,Table 2,BaselineCharacteristic,m,Sex ; ,m,None,1,0,2,No,1:No,1:No,,0.96
5696,3493663,Table 2,BaselineCharacteristic,Cutaneous,Localization of primary melanoma ; ,m,None,1,2,3,No,1:No,1:No,,0.93
5696,3493663,Table 2,BaselineCharacteristic,Mxa,Stage (AJCC) ; ,m,None,1,3,3,No,1:No,1:No,,0.92
5696,3493663,Table 2,BaselineCharacteristic,"Ax, Ax",HLA type ; ,m,None,1,4,3,No,1:No,1:No,,0.92
5696,3493663,Table 2,BaselineCharacteristic,Regimen I,Vaccination regimen ; ,m,None,1,5,3,No,1:No,1:No,,0.91
5696,3493663,Table 2,BaselineCharacteristic,x,OPS (ECOG) ; ,m,None,1,6,3,No,1:No,1:No,,0.93
5696,3493663,Table 2,BaselineCharacteristic,"Temozolomide, interferon-alpha",Previous therapy in stage-IV ; ,m,None,1,7,3,No,1:No,1:No,,0.88
5696,3493663,Table 2,BaselineCharacteristic,"LN, intramuscular",Sites of metastases ; ,m,None,1,8,3,No,1:No,1:No,,0.92
5696,3493663,Table 2,BaselineCharacteristic,xx+,Number of vaccinations (ELISPOT)a ; ,m,None,1,9,3,No,1:No,1:No,,0.87
5696,3493663,Table 2,BaselineCharacteristic,Negative,Survivin-specific T-cell reactivity vaccination sites ; ,m,None,1,10,3,No,1:No,1:No,,0.93
5696,3493663,Table 2,BaselineCharacteristic,Absent,Inflammatory reaction at responseb ; ,m,None,1,11,3,No,1:No,1:No,,0.94
5696,3493663,Table 2,BaselineCharacteristic,PR,Best overall ; ,m,None,1,12,3,No,1:No,1:No,,0.95
5696,3493663,Table 2,BaselineCharacteristic,xx+,PFS (months) ; ,m,None,1,13,3,No,1:No,1:No,,0.94
5696,3493663,Table 2,BaselineCharacteristic,xx+,OS (months) ; ,m,None,1,14,3,No,1:No,1:No,,0.95
5696,3493663,Table 2,BaselineCharacteristic,m,Sex ; ,m,None,2,0,2,No,1:No,1:No,,0.96
5696,3493663,Table 2,BaselineCharacteristic,Cutaneous,Localization of primary melanoma ; ,m,None,2,2,3,No,1:No,1:No,,0.93
5696,3493663,Table 2,BaselineCharacteristic,Mxb,Stage (AJCC) ; ,m,None,2,3,3,No,1:No,1:No,,0.93
5696,3493663,Table 2,BaselineCharacteristic,Ax,HLA type ; ,m,None,2,4,3,No,1:No,1:No,,0.93
5696,3493663,Table 2,BaselineCharacteristic,Regimen I,Vaccination regimen ; ,m,None,2,5,3,No,1:No,1:No,,0.92
5696,3493663,Table 2,BaselineCharacteristic,x,OPS (ECOG) ; ,m,None,2,6,3,No,1:No,1:No,,0.94
5696,3493663,Table 2,BaselineCharacteristic,"Temozolomide, interferon-alpha",Previous therapy in stage-IV ; ,m,None,2,7,3,No,1:No,1:No,,0.87
5696,3493663,Table 2,BaselineCharacteristic,"Lung, LN",Sites of metastases ; ,m,None,2,8,3,No,1:No,1:No,,0.93
5696,3493663,Table 2,BaselineCharacteristic,xx+,Number of vaccinations (ELISPOT)a ; ,m,None,2,9,3,No,1:No,1:No,,0.88
5696,3493663,Table 2,BaselineCharacteristic,Positive,Survivin-specific T-cell reactivity vaccination sites ; ,m,None,2,10,3,No,1:No,1:No,,0.93
5696,3493663,Table 2,BaselineCharacteristic,Present,Inflammatory reaction at responseb ; ,m,None,2,11,3,No,1:No,1:No,,0.95
5696,3493663,Table 2,BaselineCharacteristic,CR,Best overall ; ,m,None,2,12,3,No,1:No,1:No,,0.96
5696,3493663,Table 2,BaselineCharacteristic,xx+,PFS (months) ; ,m,None,2,13,3,No,1:No,1:No,,0.95
5696,3493663,Table 2,BaselineCharacteristic,xx+,OS (months) ; ,m,None,2,14,3,No,1:No,1:No,,0.95
5696,3493663,Table 2,BaselineCharacteristic,f,Sex ; ,f,None,3,0,2,No,1:No,1:No,,0.96
5696,3493663,Table 2,BaselineCharacteristic,Cutaneous,Localization of primary melanoma ; ,f,None,3,2,3,No,1:No,1:No,,0.93
5696,3493663,Table 2,BaselineCharacteristic,Mxc,Stage (AJCC) ; ,f,None,3,3,3,No,1:No,1:No,,0.91
5696,3493663,Table 2,BaselineCharacteristic,"Ax, Bxx",HLA type ; ,f,None,3,4,3,No,1:No,1:No,,0.9
5696,3493663,Table 2,BaselineCharacteristic,Regimen I,Vaccination regimen ; ,f,None,3,5,3,No,1:No,1:No,,0.91
5696,3493663,Table 2,BaselineCharacteristic,x,OPS (ECOG) ; ,f,None,3,6,3,No,1:No,1:No,,0.93
5696,3493663,Table 2,BaselineCharacteristic,"Temozolomide, interferon-alpha",Previous therapy in stage-IV ; ,f,None,3,7,3,No,1:No,1:No,,0.85
5696,3493663,Table 2,BaselineCharacteristic,"Liver, LN",Sites of metastases ; ,f,None,3,8,3,No,1:No,1:No,,0.92
5696,3493663,Table 2,BaselineCharacteristic,xx+,Number of vaccinations (ELISPOT)a ; ,f,None,3,9,3,No,1:No,1:No,,0.86
5696,3493663,Table 2,BaselineCharacteristic,Positive,Survivin-specific T-cell reactivity vaccination sites ; ,f,None,3,10,3,No,1:No,1:No,,0.89
5696,3493663,Table 2,BaselineCharacteristic,Present,Inflammatory reaction at responseb ; ,f,None,3,11,3,No,1:No,1:No,,0.93
5696,3493663,Table 2,BaselineCharacteristic,PR,Best overall ; ,f,None,3,12,3,No,1:No,1:No,,0.94
5696,3493663,Table 2,BaselineCharacteristic,xx+,PFS (months) ; ,f,None,3,13,3,No,1:No,1:No,,0.93
5696,3493663,Table 2,BaselineCharacteristic,xx+,OS (months) ; ,f,None,3,14,3,No,1:No,1:No,,0.94
5696,3493663,Table 2,BaselineCharacteristic,f,Sex ; ,f,None,4,0,2,No,1:No,1:No,,0.97
5696,3493663,Table 2,BaselineCharacteristic,Cutaneous,Localization of primary melanoma ; ,f,None,4,2,3,No,1:No,1:No,,0.93
5696,3493663,Table 2,BaselineCharacteristic,Mxb,Stage (AJCC) ; ,f,None,4,3,3,No,1:No,1:No,,0.91
5696,3493663,Table 2,BaselineCharacteristic,Ax,HLA type ; ,f,None,4,4,3,No,1:No,1:No,,0.9
5696,3493663,Table 2,BaselineCharacteristic,Regimen I,Vaccination regimen ; ,f,None,4,5,3,No,1:No,1:No,,0.9
5696,3493663,Table 2,BaselineCharacteristic,x,OPS (ECOG) ; ,f,None,4,6,3,No,1:No,1:No,,0.92
5696,3493663,Table 2,BaselineCharacteristic,"Dacarbazine, radiation",Previous therapy in stage-IV ; ,f,None,4,7,3,No,1:No,1:No,,0.85
5696,3493663,Table 2,BaselineCharacteristic,"Lung, LN, SC",Sites of metastases ; ,f,None,4,8,3,No,1:No,1:No,,0.86
5696,3493663,Table 2,BaselineCharacteristic,xx,Number of vaccinations (ELISPOT)a ; ,f,None,4,9,3,No,1:No,1:No,,0.746
5696,3493663,Table 2,BaselineCharacteristic,Positive,Survivin-specific T-cell reactivity vaccination sites ; ,f,None,4,10,3,No,1:No,1:No,,0.88
5696,3493663,Table 2,BaselineCharacteristic,Present,Inflammatory reaction at responseb ; ,f,None,4,11,3,No,1:No,1:No,,0.92
5696,3493663,Table 2,BaselineCharacteristic,PR,Best overall ; ,f,None,4,12,3,No,1:No,1:No,,0.93
5696,3493663,Table 2,BaselineCharacteristic,xx,PFS (months) ; ,f,None,4,13,3,No,1:No,1:No,,0.826
5696,3493663,Table 2,BaselineCharacteristic,xx+,OS (months) ; ,f,None,4,14,3,No,1:No,1:No,,0.94
5696,3493663,Table 2,BaselineCharacteristic,m,Sex ; ,m,None,5,0,2,No,1:No,1:No,,0.98
5696,3493663,Table 2,BaselineCharacteristic,Uveal,Localization of primary melanoma ; ,m,None,5,2,3,No,1:No,1:No,,0.94
5696,3493663,Table 2,BaselineCharacteristic,Mxc,Stage (AJCC) ; ,m,None,5,3,3,No,1:No,1:No,,0.94
5696,3493663,Table 2,BaselineCharacteristic,Bxx,HLA type ; ,m,None,5,4,3,No,1:No,1:No,,0.93
5696,3493663,Table 2,BaselineCharacteristic,Regimen I,Vaccination regimen ; ,m,None,5,5,3,No,1:No,1:No,,0.92
5696,3493663,Table 2,BaselineCharacteristic,x,OPS (ECOG) ; ,m,None,5,6,3,No,1:No,1:No,,0.95
5696,3493663,Table 2,BaselineCharacteristic,Imatinib,Previous therapy in stage-IV ; ,m,None,5,7,3,No,1:No,1:No,,0.86
5696,3493663,Table 2,BaselineCharacteristic,"Liver, lung",Sites of metastases ; ,m,None,5,8,3,No,1:No,1:No,,0.93
5696,3493663,Table 2,BaselineCharacteristic,xx,Number of vaccinations (ELISPOT)a ; ,m,None,5,9,3,No,1:No,1:No,,0.766
5696,3493663,Table 2,BaselineCharacteristic,n.a.,Survivin-specific T-cell reactivity vaccination sites ; ,m,None,5,10,3,No,1:No,1:No,,0.75
5696,3493663,Table 2,BaselineCharacteristic,Absent,Inflammatory reaction at responseb ; ,m,None,5,11,3,No,1:No,1:No,,0.95
5696,3493663,Table 2,BaselineCharacteristic,SD,Best overall ; ,m,None,5,12,3,No,1:No,1:No,,0.85
5696,3493663,Table 2,BaselineCharacteristic,x,PFS (months) ; ,m,None,5,13,3,No,1:No,1:No,,0.95
5696,3493663,Table 2,BaselineCharacteristic,xx,OS (months) ; ,m,None,5,14,3,No,1:No,1:No,,0.876
5696,3493663,Table 2,BaselineCharacteristic,f,Sex ; ,f,None,6,0,2,No,1:No,1:No,,0.99
5696,3493663,Table 2,BaselineCharacteristic,Cutaneous,Localization of primary melanoma ; ,f,None,6,2,3,No,1:No,1:No,,0.97
5696,3493663,Table 2,BaselineCharacteristic,Mxa,Stage (AJCC) ; ,f,None,6,3,3,No,1:No,1:No,,0.96
5696,3493663,Table 2,BaselineCharacteristic,"Ax, Bxx",HLA type ; ,f,None,6,4,3,No,1:No,1:No,,0.95
5696,3493663,Table 2,BaselineCharacteristic,Regimen I,Vaccination regimen ; ,f,None,6,5,3,No,1:No,1:No,,0.94
5696,3493663,Table 2,BaselineCharacteristic,x,OPS (ECOG) ; ,f,None,6,6,3,No,1:No,1:No,,0.93
5696,3493663,Table 2,BaselineCharacteristic,Dacarbazine,Previous therapy in stage-IV ; ,f,None,6,7,3,No,1:No,1:No,,0.88
5696,3493663,Table 2,BaselineCharacteristic,"LN, SC",Sites of metastases ; ,f,None,6,8,3,No,1:No,1:No,,0.89
5696,3493663,Table 2,BaselineCharacteristic,xx,Number of vaccinations (ELISPOT)a ; ,f,None,6,9,3,No,1:No,1:No,,0.796
5696,3493663,Table 2,BaselineCharacteristic,Positive,Survivin-specific T-cell reactivity vaccination sites ; ,f,None,6,10,3,No,1:No,1:No,,0.91
5696,3493663,Table 2,BaselineCharacteristic,Absent,Inflammatory reaction at responseb ; ,f,None,6,11,3,No,1:No,1:No,,0.95
5696,3493663,Table 2,BaselineCharacteristic,SD,Best overall ; ,f,None,6,12,3,No,1:No,1:No,,0.86
5696,3493663,Table 2,BaselineCharacteristic,x,PFS (months) ; ,f,None,6,13,3,No,1:No,1:No,,0.95
5696,3493663,Table 2,BaselineCharacteristic,xx,OS (months) ; ,f,None,6,14,3,No,1:No,1:No,,0.906
5696,3493663,Table 2,BaselineCharacteristic,f,Sex ; ,f,None,7,0,2,No,1:No,1:No,,0.99
5696,3493663,Table 2,BaselineCharacteristic,Cutaneous,Localization of primary melanoma ; ,f,None,7,2,3,No,1:No,1:No,,0.97
5696,3493663,Table 2,BaselineCharacteristic,Mxb,Stage (AJCC) ; ,f,None,7,3,3,No,1:No,1:No,,0.96
5696,3493663,Table 2,BaselineCharacteristic,Ax,HLA type ; ,f,None,7,4,3,No,1:No,1:No,,0.96
5696,3493663,Table 2,BaselineCharacteristic,Regimen I,Vaccination regimen ; ,f,None,7,5,3,No,1:No,1:No,,0.95
5696,3493663,Table 2,BaselineCharacteristic,x,OPS (ECOG) ; ,f,None,7,6,3,No,1:No,1:No,,0.96
5696,3493663,Table 2,BaselineCharacteristic,Dacarbazine,Previous therapy in stage-IV ; ,f,None,7,7,3,No,1:No,1:No,,0.89
5696,3493663,Table 2,BaselineCharacteristic,"Lung, LN",Sites of metastases ; ,f,None,7,8,3,No,1:No,1:No,,0.97
5696,3493663,Table 2,BaselineCharacteristic,xx,Number of vaccinations (ELISPOT)a ; ,f,None,7,9,3,No,1:No,1:No,,0.826
5696,3493663,Table 2,BaselineCharacteristic,Positive,Survivin-specific T-cell reactivity vaccination sites ; ,f,None,7,10,3,No,1:No,1:No,,0.92
5696,3493663,Table 2,BaselineCharacteristic,Present,Inflammatory reaction at responseb ; ,f,None,7,11,3,No,1:No,1:No,,0.96
5696,3493663,Table 2,BaselineCharacteristic,SD,Best overall ; ,f,None,7,12,3,No,1:No,1:No,,0.87
5696,3493663,Table 2,BaselineCharacteristic,xx,PFS (months) ; ,f,None,7,13,3,No,1:No,1:No,,0.896
5696,3493663,Table 2,BaselineCharacteristic,xx,OS (months) ; ,f,None,7,14,3,No,1:No,1:No,,0.926
5696,3493663,Table 2,BaselineCharacteristic,f,Sex ; ,f,None,8,0,2,No,1:No,1:No,,0.99
5696,3493663,Table 2,BaselineCharacteristic,xx,Age (years) ; ,f,None,8,1,3,No,1:No,1:No,,0.506
5696,3493663,Table 2,BaselineCharacteristic,Cutaneous,Localization of primary melanoma ; ,f,None,8,2,3,No,1:No,1:No,,0.97
5696,3493663,Table 2,BaselineCharacteristic,Mxa,Stage (AJCC) ; ,f,None,8,3,3,No,1:No,1:No,,0.97
5696,3493663,Table 2,BaselineCharacteristic,"Ax, Bxx",HLA type ; ,f,None,8,4,3,No,1:No,1:No,,0.97
5696,3493663,Table 2,BaselineCharacteristic,Regimen II,Vaccination regimen ; ,f,None,8,5,3,No,1:No,1:No,,0.98
5696,3493663,Table 2,BaselineCharacteristic,x,OPS (ECOG) ; ,f,None,8,6,3,No,1:No,1:No,,0.98
5696,3493663,Table 2,BaselineCharacteristic,Dacarbazine,Previous therapy in stage-IV ; ,f,None,8,7,3,No,1:No,1:No,,0.91
5696,3493663,Table 2,BaselineCharacteristic,"LN, SC, C",Sites of metastases ; ,f,None,8,8,3,No,1:No,1:No,,0.9
5696,3493663,Table 2,BaselineCharacteristic,xx,Number of vaccinations (ELISPOT)a ; ,f,None,8,9,3,No,1:No,1:No,,0.826
5696,3493663,Table 2,BaselineCharacteristic,Positive,Survivin-specific T-cell reactivity vaccination sites ; ,f,None,8,10,3,No,1:No,1:No,,0.94
5696,3493663,Table 2,BaselineCharacteristic,Present,Inflammatory reaction at responseb ; ,f,None,8,11,3,No,1:No,1:No,,0.98
5696,3493663,Table 2,BaselineCharacteristic,SD,Best overall ; ,f,None,8,12,3,No,1:No,1:No,,0.87
5696,3493663,Table 2,BaselineCharacteristic,x,PFS (months) ; ,f,None,8,13,3,No,1:No,1:No,,0.99
5696,3493663,Table 2,BaselineCharacteristic,xx,OS (months) ; ,f,None,8,14,3,No,1:No,1:No,,0.936
5696,3493663,Table 2,BaselineCharacteristic,m,Sex ; ,m,None,9,0,2,No,1:No,1:No,,1
5696,3493663,Table 2,BaselineCharacteristic,xx,Age (years) ; ,m,None,9,1,3,No,1:No,1:No,,0.606
5696,3493663,Table 2,BaselineCharacteristic,Cutaneous,Localization of primary melanoma ; ,m,None,9,2,3,No,1:No,1:No,,0.98
5696,3493663,Table 2,BaselineCharacteristic,Mxc,Stage (AJCC) ; ,m,None,9,3,3,No,1:No,1:No,,0.99
5696,3493663,Table 2,BaselineCharacteristic,Ax,HLA type ; ,m,None,9,4,3,No,1:No,1:No,,0.99
5696,3493663,Table 2,BaselineCharacteristic,Regimen I,Vaccination regimen ; ,m,None,9,5,3,No,1:No,1:No,,0.97
5696,3493663,Table 2,BaselineCharacteristic,x,OPS (ECOG) ; ,m,None,9,6,3,No,1:No,1:No,,1
5696,3493663,Table 2,BaselineCharacteristic,"Dacarbazine, fotemustine",Previous therapy in stage-IV ; ,m,None,9,7,3,No,1:No,1:No,,0.91
5696,3493663,Table 2,BaselineCharacteristic,"Brain, lung, LN, SC",Sites of metastases ; ,m,None,9,8,3,No,1:No,1:No,,0.92
5696,3493663,Table 2,BaselineCharacteristic,xx,Number of vaccinations (ELISPOT)a ; ,m,None,9,9,3,No,1:No,1:No,,0.886
5696,3493663,Table 2,BaselineCharacteristic,n.a.,Survivin-specific T-cell reactivity vaccination sites ; ,m,None,9,10,3,No,1:No,1:No,,0.83
5696,3493663,Table 2,BaselineCharacteristic,Absent,Inflammatory reaction at responseb ; ,m,None,9,11,3,No,1:No,1:No,,1
5696,3493663,Table 2,BaselineCharacteristic,SD,Best overall ; ,m,None,9,12,3,No,1:No,1:No,,0.88
5696,3493663,Table 2,BaselineCharacteristic,x,PFS (months) ; ,m,None,9,13,3,No,1:No,1:No,,1
5696,3493663,Table 2,BaselineCharacteristic,xx,OS (months) ; ,m,None,9,14,3,No,1:No,1:No,,0.966
5696,3493663,Table 2,BaselineCharacteristic,m,Sex ; ,m,None,10,0,2,No,1:No,1:No,,1
5696,3493663,Table 2,BaselineCharacteristic,xx,Age (years) ; ,m,None,10,1,3,No,1:No,1:No,,0.676
5696,3493663,Table 2,BaselineCharacteristic,Cutaneous,Localization of primary melanoma ; ,m,None,10,2,3,No,1:No,1:No,,0.99
5696,3493663,Table 2,BaselineCharacteristic,Mxb,Stage (AJCC) ; ,m,None,10,3,3,No,1:No,1:No,,1
5696,3493663,Table 2,BaselineCharacteristic,"Ax, Bxx",HLA type ; ,m,None,10,4,3,No,1:No,1:No,,1
5696,3493663,Table 2,BaselineCharacteristic,Regimen III,Vaccination regimen ; ,m,None,10,5,3,No,1:No,1:No,,1
5696,3493663,Table 2,BaselineCharacteristic,x,OPS (ECOG) ; ,m,None,10,6,3,No,1:No,1:No,,1
5696,3493663,Table 2,BaselineCharacteristic,Temozolomide,Previous therapy in stage-IV ; ,m,None,10,7,3,No,1:No,1:No,,0.91
5696,3493663,Table 2,BaselineCharacteristic,"Lung, LN, SC",Sites of metastases ; ,m,None,10,8,3,No,1:No,1:No,,0.92
5696,3493663,Table 2,BaselineCharacteristic,xx,Number of vaccinations (ELISPOT)a ; ,m,None,10,9,3,No,1:No,1:No,,0.906
5696,3493663,Table 2,BaselineCharacteristic,Positive,Survivin-specific T-cell reactivity vaccination sites ; ,m,None,10,10,3,No,1:No,1:No,,0.99
5696,3493663,Table 2,BaselineCharacteristic,Absent,Inflammatory reaction at responseb ; ,m,None,10,11,3,No,1:No,1:No,,1
5696,3493663,Table 2,BaselineCharacteristic,SD,Best overall ; ,m,None,10,12,3,No,1:No,1:No,,0.89
5696,3493663,Table 2,BaselineCharacteristic,x,PFS (months) ; ,m,None,10,13,3,No,1:No,1:No,,1
5696,3493663,Table 2,BaselineCharacteristic,xx,OS (months) ; ,m,None,10,14,3,No,1:No,1:No,,0.966
5696,3493663,Table 2,BaselineCharacteristic,m,Sex ; ,m,None,11,0,2,No,1:No,1:No,,1
5696,3493663,Table 2,BaselineCharacteristic,xx,Age (years) ; ,m,None,11,1,3,No,1:No,1:No,,0.706
5696,3493663,Table 2,BaselineCharacteristic,Uveal,Localization of primary melanoma ; ,m,None,11,2,3,No,1:No,1:No,,0.99
5696,3493663,Table 2,BaselineCharacteristic,Mxc,Stage (AJCC) ; ,m,None,11,3,3,No,1:No,1:No,,1
5696,3493663,Table 2,BaselineCharacteristic,Ax,HLA type ; ,m,None,11,4,3,No,1:No,1:No,,1
5696,3493663,Table 2,BaselineCharacteristic,Regimen I,Vaccination regimen ; ,m,None,11,5,3,No,1:No,1:No,,0.99
5696,3493663,Table 2,BaselineCharacteristic,x,OPS (ECOG) ; ,m,None,11,6,3,No,1:No,1:No,,1
5696,3493663,Table 2,BaselineCharacteristic,Imatinib,Previous therapy in stage-IV ; ,m,None,11,7,3,No,1:No,1:No,,0.91
5696,3493663,Table 2,BaselineCharacteristic,Liver,Sites of metastases ; ,m,None,11,8,3,No,1:No,1:No,,0.99
5696,3493663,Table 2,BaselineCharacteristic,x,Number of vaccinations (ELISPOT)a ; ,m,None,11,9,3,No,1:No,1:No,,0.95
5696,3493663,Table 2,BaselineCharacteristic,Negative,Survivin-specific T-cell reactivity vaccination sites ; ,m,None,11,10,3,No,1:No,1:No,,0.99
5696,3493663,Table 2,BaselineCharacteristic,Absent,Inflammatory reaction at responseb ; ,m,None,11,11,3,No,1:No,1:No,,1
5696,3493663,Table 2,BaselineCharacteristic,SD,Best overall ; ,m,None,11,12,3,No,1:No,1:No,,0.89
5696,3493663,Table 2,BaselineCharacteristic,x,PFS (months) ; ,m,None,11,13,3,No,1:No,1:No,,1
5696,3493663,Table 2,BaselineCharacteristic,x,OS (months) ; ,m,None,11,14,3,No,1:No,1:No,,1
5704,3494535,Table 1,BaselineCharacteristic,Donors,,None,None,0,0,12,No,1:No,1:No,,0.905
5704,3494535,Table 1,BaselineCharacteristic,Age,,Donors,None,0,1,1,No,1:No,1:No,,0.903
5704,3494535,Table 1,BaselineCharacteristic,Sex,,Donors,None,0,2,1,No,1:No,1:No,,0.903
5704,3494535,Table 1,BaselineCharacteristic,Smoking,,Donors,None,0,3,1,No,1:No,1:No,,0.917
5704,3494535,Table 1,BaselineCharacteristic,Vegetarian,,Donors,None,0,4,1,No,1:No,1:No,,0.913
5704,3494535,Table 1,BaselineCharacteristic,Vitamins,,Donors,None,0,5,1,No,1:No,1:No,,0.935
5704,3494535,Table 1,BaselineCharacteristic,Background diseases,,Donors,None,0,6,1,No,1:No,1:No,,0.935
5704,3494535,Table 1,BaselineCharacteristic,x,Donors ; ,x,None,1,0,2,No,1:No,1:No,,0.915
5704,3494535,Table 1,BaselineCharacteristic,xx,Age ; ,x,None,1,1,3,No,1:No,1:No,,0.612
5704,3494535,Table 1,BaselineCharacteristic,F,Sex ; ,x,None,1,2,3,No,1:No,1:No,,0.9
5704,3494535,Table 1,BaselineCharacteristic,No,Smoking ; ,x,None,1,3,3,No,1:No,1:No,,0.89
5704,3494535,Table 1,BaselineCharacteristic,no,Vegetarian ; ,x,None,1,4,3,No,1:No,1:No,,0.85
5704,3494535,Table 1,BaselineCharacteristic,no,Vitamins ; ,x,None,1,5,3,No,1:No,1:No,,0.86
5704,3494535,Table 1,BaselineCharacteristic,no,Background diseases ; ,x,None,1,6,3,No,1:No,1:No,,0.87
5704,3494535,Table 1,BaselineCharacteristic,x,Donors ; ,x,None,2,0,2,No,1:No,1:No,,0.935
5704,3494535,Table 1,BaselineCharacteristic,xx,Age ; ,x,None,2,1,3,No,1:No,1:No,,0.632
5704,3494535,Table 1,BaselineCharacteristic,M,Sex ; ,x,None,2,2,3,No,1:No,1:No,,0.92
5704,3494535,Table 1,BaselineCharacteristic,No,Smoking ; ,x,None,2,3,3,No,1:No,1:No,,0.91
5704,3494535,Table 1,BaselineCharacteristic,no,Vegetarian ; ,x,None,2,4,3,No,1:No,1:No,,0.86
5704,3494535,Table 1,BaselineCharacteristic,no,Vitamins ; ,x,None,2,5,3,No,1:No,1:No,,0.86
5704,3494535,Table 1,BaselineCharacteristic,no,Background diseases ; ,x,None,2,6,3,No,1:No,1:No,,0.87
5704,3494535,Table 1,BaselineCharacteristic,x,Donors ; ,x,None,3,0,2,No,1:No,1:No,,0.945
5704,3494535,Table 1,BaselineCharacteristic,xx,Age ; ,x,None,3,1,3,No,1:No,1:No,,0.646
5704,3494535,Table 1,BaselineCharacteristic,M,Sex ; ,x,None,3,2,3,No,1:No,1:No,,0.94
5704,3494535,Table 1,BaselineCharacteristic,No,Smoking ; ,x,None,3,3,3,No,1:No,1:No,,0.93
5704,3494535,Table 1,BaselineCharacteristic,no,Vegetarian ; ,x,None,3,4,3,No,1:No,1:No,,0.86
5704,3494535,Table 1,BaselineCharacteristic,yes,Vitamins ; ,x,None,3,5,3,No,1:No,1:No,,0.92
5704,3494535,Table 1,BaselineCharacteristic,no,Background diseases ; ,x,None,3,6,3,No,1:No,1:No,,0.87
5704,3494535,Table 1,BaselineCharacteristic,x,Donors ; ,x,None,4,0,2,No,1:No,1:No,,0.965
5704,3494535,Table 1,BaselineCharacteristic,xx,Age ; ,x,None,4,1,3,No,1:No,1:No,,0.726
5704,3494535,Table 1,BaselineCharacteristic,F,Sex ; ,x,None,4,2,3,No,1:No,1:No,,0.94
5704,3494535,Table 1,BaselineCharacteristic,No,Smoking ; ,x,None,4,3,3,No,1:No,1:No,,0.93
5704,3494535,Table 1,BaselineCharacteristic,no,Vegetarian ; ,x,None,4,4,3,No,1:No,1:No,,0.86
5704,3494535,Table 1,BaselineCharacteristic,no,Vitamins ; ,x,None,4,5,3,No,1:No,1:No,,0.85
5704,3494535,Table 1,BaselineCharacteristic,no,Background diseases ; ,x,None,4,6,3,No,1:No,1:No,,0.86
5704,3494535,Table 1,BaselineCharacteristic,x,Donors ; ,x,None,5,0,2,No,1:No,1:No,,0.963
5704,3494535,Table 1,BaselineCharacteristic,xx,Age ; ,x,None,5,1,3,No,1:No,1:No,,0.726
5704,3494535,Table 1,BaselineCharacteristic,F,Sex ; ,x,None,5,2,3,No,1:No,1:No,,0.94
5704,3494535,Table 1,BaselineCharacteristic,No,Smoking ; ,x,None,5,3,3,No,1:No,1:No,,0.93
5704,3494535,Table 1,BaselineCharacteristic,no,Vegetarian ; ,x,None,5,4,3,No,1:No,1:No,,0.86
5704,3494535,Table 1,BaselineCharacteristic,yes,Vitamins ; ,x,None,5,5,3,No,1:No,1:No,,0.9
5704,3494535,Table 1,BaselineCharacteristic,no,Background diseases ; ,x,None,5,6,3,No,1:No,1:No,,0.85
5704,3494535,Table 1,BaselineCharacteristic,x,Donors ; ,x,None,6,0,2,No,1:No,1:No,,0.973
5704,3494535,Table 1,BaselineCharacteristic,xx,Age ; ,x,None,6,1,3,No,1:No,1:No,,0.746
5704,3494535,Table 1,BaselineCharacteristic,M,Sex ; ,x,None,6,2,3,No,1:No,1:No,,0.96
5704,3494535,Table 1,BaselineCharacteristic,No,Smoking ; ,x,None,6,3,3,No,1:No,1:No,,0.95
5704,3494535,Table 1,BaselineCharacteristic,no,Vegetarian ; ,x,None,6,4,3,No,1:No,1:No,,0.925
5704,3494535,Table 1,BaselineCharacteristic,no,Vitamins ; ,x,None,6,5,3,No,1:No,1:No,,0.905
5704,3494535,Table 1,BaselineCharacteristic,no,Background diseases ; ,x,None,6,6,3,No,1:No,1:No,,0.905
5704,3494535,Table 1,BaselineCharacteristic,x,Donors ; ,x,None,7,0,2,No,1:No,1:No,,0.973
5704,3494535,Table 1,BaselineCharacteristic,xx,Age ; ,x,None,7,1,3,No,1:No,1:No,,0.786
5704,3494535,Table 1,BaselineCharacteristic,M,Sex ; ,x,None,7,2,3,No,1:No,1:No,,0.97
5704,3494535,Table 1,BaselineCharacteristic,No,Smoking ; ,x,None,7,3,3,No,1:No,1:No,,0.96
5704,3494535,Table 1,BaselineCharacteristic,no,Vegetarian ; ,x,None,7,4,3,No,1:No,1:No,,0.935
5704,3494535,Table 1,BaselineCharacteristic,no,Vitamins ; ,x,None,7,5,3,No,1:No,1:No,,0.925
5704,3494535,Table 1,BaselineCharacteristic,no,Background diseases ; ,x,None,7,6,3,No,1:No,1:No,,0.925
5704,3494535,Table 1,BaselineCharacteristic,x,Donors ; ,x,None,8,0,2,No,1:No,1:No,,0.972
5704,3494535,Table 1,BaselineCharacteristic,xx,Age ; ,x,None,8,1,3,No,1:No,1:No,,0.806
5704,3494535,Table 1,BaselineCharacteristic,F,Sex ; ,x,None,8,2,3,No,1:No,1:No,,0.98
5704,3494535,Table 1,BaselineCharacteristic,No,Smoking ; ,x,None,8,3,3,No,1:No,1:No,,0.97
5704,3494535,Table 1,BaselineCharacteristic,no,Vegetarian ; ,x,None,8,4,3,No,1:No,1:No,,0.935
5704,3494535,Table 1,BaselineCharacteristic,yes,Vitamins ; ,x,None,8,5,3,No,1:No,1:No,,0.97
5704,3494535,Table 1,BaselineCharacteristic,no,Background diseases ; ,x,None,8,6,3,No,1:No,1:No,,0.935
5704,3494535,Table 1,BaselineCharacteristic,x,Donors ; ,x,None,9,0,2,No,1:No,1:No,,0.982
5704,3494535,Table 1,BaselineCharacteristic,xx,Age ; ,x,None,9,1,3,No,1:No,1:No,,0.846
5704,3494535,Table 1,BaselineCharacteristic,M,Sex ; ,x,None,9,2,3,No,1:No,1:No,,0.99
5704,3494535,Table 1,BaselineCharacteristic,No,Smoking ; ,x,None,9,3,3,No,1:No,1:No,,0.99
5704,3494535,Table 1,BaselineCharacteristic,no,Vegetarian ; ,x,None,9,4,3,No,1:No,1:No,,0.945
5704,3494535,Table 1,BaselineCharacteristic,yes,Vitamins ; ,x,None,9,5,3,No,1:No,1:No,,0.99
5704,3494535,Table 1,BaselineCharacteristic,no,Background diseases ; ,x,None,9,6,3,No,1:No,1:No,,0.945
5704,3494535,Table 1,BaselineCharacteristic,xx,Donors ; ,xx,None,10,0,2,No,1:No,1:No,,0.935
5704,3494535,Table 1,BaselineCharacteristic,xx,Age ; ,xx,None,10,1,3,No,1:No,1:No,,0.921
5704,3494535,Table 1,BaselineCharacteristic,F,Sex ; ,xx,None,10,2,3,No,1:No,1:No,,0.911
5704,3494535,Table 1,BaselineCharacteristic,No,Smoking ; ,xx,None,10,3,3,No,1:No,1:No,,0.901
5704,3494535,Table 1,BaselineCharacteristic,no,Vegetarian ; ,xx,None,10,4,3,No,1:No,1:No,,0.751
5704,3494535,Table 1,BaselineCharacteristic,no,Vitamins ; ,xx,None,10,5,3,No,1:No,1:No,,0.751
5704,3494535,Table 1,BaselineCharacteristic,no,Background diseases ; ,xx,None,10,6,3,No,1:No,1:No,,0.761
5704,3494535,Table 1,BaselineCharacteristic,xx,Donors ; ,xx,None,11,0,2,No,1:No,1:No,,0.935
5704,3494535,Table 1,BaselineCharacteristic,xx,Age ; ,xx,None,11,1,3,No,1:No,1:No,,0.921
5704,3494535,Table 1,BaselineCharacteristic,F,Sex ; ,xx,None,11,2,3,No,1:No,1:No,,0.911
5704,3494535,Table 1,BaselineCharacteristic,x-x cig/day,Smoking ; ,xx,None,11,3,3,No,1:No,1:No,,0.906
5704,3494535,Table 1,BaselineCharacteristic,no,Vegetarian ; ,xx,None,11,4,3,No,1:No,1:No,,0.751
5704,3494535,Table 1,BaselineCharacteristic,no,Vitamins ; ,xx,None,11,5,3,No,1:No,1:No,,0.751
5704,3494535,Table 1,BaselineCharacteristic,no,Background diseases ; ,xx,None,11,6,3,No,1:No,1:No,,0.761
5704,3494535,Table 1,BaselineCharacteristic,xx,Donors ; ,xx,None,12,0,2,No,1:No,1:No,,0.935
5704,3494535,Table 1,BaselineCharacteristic,xx,Age ; ,xx,None,12,1,3,No,1:No,1:No,,0.921
5704,3494535,Table 1,BaselineCharacteristic,M,Sex ; ,xx,None,12,2,3,No,1:No,1:No,,0.911
5704,3494535,Table 1,BaselineCharacteristic,No,Smoking ; ,xx,None,12,3,3,No,1:No,1:No,,0.901
5704,3494535,Table 1,BaselineCharacteristic,no,Vegetarian ; ,xx,None,12,4,3,No,1:No,1:No,,0.751
5704,3494535,Table 1,BaselineCharacteristic,no,Vitamins ; ,xx,None,12,5,3,No,1:No,1:No,,0.751
5704,3494535,Table 1,BaselineCharacteristic,no,Background diseases ; ,xx,None,12,6,3,No,1:No,1:No,,0.761
5704,3494535,Table 1,BaselineCharacteristic,xx,Donors ; ,xx,None,13,0,2,No,1:No,1:No,,0.935
5704,3494535,Table 1,BaselineCharacteristic,xx,Age ; ,xx,None,13,1,3,No,1:No,1:No,,0.921
5704,3494535,Table 1,BaselineCharacteristic,F,Sex ; ,xx,None,13,2,3,No,1:No,1:No,,0.911
5704,3494535,Table 1,BaselineCharacteristic,No,Smoking ; ,xx,None,13,3,3,No,1:No,1:No,,0.891
5704,3494535,Table 1,BaselineCharacteristic,no,Vegetarian ; ,xx,None,13,4,3,No,1:No,1:No,,0.751
5704,3494535,Table 1,BaselineCharacteristic,no,Vitamins ; ,xx,None,13,5,3,No,1:No,1:No,,0.751
5704,3494535,Table 1,BaselineCharacteristic,no,Background diseases ; ,xx,None,13,6,3,No,1:No,1:No,,0.761
5704,3494535,Table 1,BaselineCharacteristic,xx,Donors ; ,xx,None,14,0,2,No,1:No,1:No,,0.955
5704,3494535,Table 1,BaselineCharacteristic,xx,Age ; ,xx,None,14,1,3,No,1:No,1:No,,0.941
5704,3494535,Table 1,BaselineCharacteristic,M,Sex ; ,xx,None,14,2,3,No,1:No,1:No,,0.931
5704,3494535,Table 1,BaselineCharacteristic,No,Smoking ; ,xx,None,14,3,3,No,1:No,1:No,,0.911
5704,3494535,Table 1,BaselineCharacteristic,no,Vegetarian ; ,xx,None,14,4,3,No,1:No,1:No,,0.741
5704,3494535,Table 1,BaselineCharacteristic,no,Vitamins ; ,xx,None,14,5,3,No,1:No,1:No,,0.741
5704,3494535,Table 1,BaselineCharacteristic,no,Background diseases ; ,xx,None,14,6,3,No,1:No,1:No,,0.751
5704,3494535,Table 1,BaselineCharacteristic,xx,Donors ; ,xx,None,15,0,2,No,1:No,1:No,,0.955
5704,3494535,Table 1,BaselineCharacteristic,xx,Age ; ,xx,None,15,1,3,No,1:No,1:No,,0.941
5704,3494535,Table 1,BaselineCharacteristic,M,Sex ; ,xx,None,15,2,3,No,1:No,1:No,,0.931
5704,3494535,Table 1,BaselineCharacteristic,No,Smoking ; ,xx,None,15,3,3,No,1:No,1:No,,0.911
5704,3494535,Table 1,BaselineCharacteristic,no,Vegetarian ; ,xx,None,15,4,3,No,1:No,1:No,,0.741
5704,3494535,Table 1,BaselineCharacteristic,no,Vitamins ; ,xx,None,15,5,3,No,1:No,1:No,,0.741
5704,3494535,Table 1,BaselineCharacteristic,no,Background diseases ; ,xx,None,15,6,3,No,1:No,1:No,,0.751
5758,3502482,Table 1,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
5758,3502482,Table 1,BaselineCharacteristic,Median age (years)(min-max), ; ,Median age (years)(min-max),,1,0,2,No,1:No,1:No,,0.528
5758,3502482,Table 1,BaselineCharacteristic,Median tumor size (mm) (min-max), ; ,Median tumor size (mm) (min-max),,2,0,2,No,1:No,1:No,,0.92
5758,3502482,Table 1,BaselineCharacteristic,Histology, ; ,None,None,3,0,24,No,1:No,1:No,,0.922
5758,3502482,Table 1,BaselineCharacteristic,Histology,xx Gy step (n?=?xx) ; ,Histology,None,3,1,43,No,1:No,1:No,,0.504
5758,3502482,Table 1,BaselineCharacteristic,Histology,xx Gy step (n?=?xx) ; ,Histology,None,3,2,43,No,1:No,1:No,,0.524
5758,3502482,Table 1,BaselineCharacteristic,Invasive ductal carcinoma (IDC), ; ,Invasive ductal carcinoma (IDC), Histology,4,0,2,No,1:No,1:No,,0.97
5758,3502482,Table 1,BaselineCharacteristic,xx%,xx Gy step (n?=?xx) ; ,Invasive ductal carcinoma (IDC), Histology,4,1,3,No,1:No,1:No,,0.551
5758,3502482,Table 1,BaselineCharacteristic,xx%,xx Gy step (n?=?xx) ; ,Invasive ductal carcinoma (IDC), Histology,4,2,3,No,1:No,1:No,,0.601
5758,3502482,Table 1,BaselineCharacteristic,Mucinous/tubular/other invasive carcinoma, ; ,Mucinous/tubular/other invasive carcinoma, Histology,5,0,2,No,1:No,1:No,,0.97
5758,3502482,Table 1,BaselineCharacteristic,x%,xx Gy step (n?=?xx) ; ,Mucinous/tubular/other invasive carcinoma, Histology,5,1,3,No,1:No,1:No,,0.611
5758,3502482,Table 1,BaselineCharacteristic,-,xx Gy step (n?=?xx) ; ,Mucinous/tubular/other invasive carcinoma, Histology,5,2,3,No,1:No,1:No,,0.566
5758,3502482,Table 1,BaselineCharacteristic,Ductal Carcinoma In Situ (DCIS), ; ,Ductal Carcinoma In Situ (DCIS), Histology,6,0,2,No,1:No,1:No,,0.99
5758,3502482,Table 1,BaselineCharacteristic,xx%,xx Gy step (n?=?xx) ; ,Ductal Carcinoma In Situ (DCIS), Histology,6,1,3,No,1:No,1:No,,0.591
5758,3502482,Table 1,BaselineCharacteristic,xx%,xx Gy step (n?=?xx) ; ,Ductal Carcinoma In Situ (DCIS), Histology,6,2,3,No,1:No,1:No,,0.641
5758,3502482,Table 1,BaselineCharacteristic,Nodal status, ; ,None,None,7,0,24,No,1:No,1:No,,0.974
5758,3502482,Table 1,BaselineCharacteristic,Nodal status,xx Gy step (n?=?xx) ; ,Nodal status,None,7,1,43,No,1:No,1:No,,0.634
5758,3502482,Table 1,BaselineCharacteristic,Nodal status,xx Gy step (n?=?xx) ; ,Nodal status,None,7,2,43,No,1:No,1:No,,0.634
5758,3502482,Table 1,BaselineCharacteristic,pNx, ; ,pNx, Nodal status,8,0,2,No,1:No,1:No,,0.99
5758,3502482,Table 1,BaselineCharacteristic,xxx%,xx Gy step (n?=?xx) ; ,pNx, Nodal status,8,1,3,No,1:No,1:No,,0.621
5758,3502482,Table 1,BaselineCharacteristic,xxx%,xx Gy step (n?=?xx) ; ,pNx, Nodal status,8,2,3,No,1:No,1:No,,0.641
5758,3502482,Table 1,BaselineCharacteristic,Scarff & Bloom histology grade, ; ,None,None,9,0,24,No,1:No,1:No,,0.984
5758,3502482,Table 1,BaselineCharacteristic,Scarff & Bloom histology grade,xx Gy step (n?=?xx) ; ,Scarff & Bloom histology grade,None,9,1,43,No,1:No,1:No,,0.668
5758,3502482,Table 1,BaselineCharacteristic,Scarff & Bloom histology grade,xx Gy step (n?=?xx) ; ,Scarff & Bloom histology grade,None,9,2,43,No,1:No,1:No,,0.678
5758,3502482,Table 1,BaselineCharacteristic,x, ; ,x, Scarff & Bloom histology grade,10,0,2,No,1:No,1:No,,0.982
5758,3502482,Table 1,BaselineCharacteristic,xx%,xx Gy step (n?=?xx) ; ,x, Scarff & Bloom histology grade,10,1,3,No,1:No,1:No,,0.701
5758,3502482,Table 1,BaselineCharacteristic,xx%,xx Gy step (n?=?xx) ; ,x, Scarff & Bloom histology grade,10,2,3,No,1:No,1:No,,0.751
5758,3502482,Table 1,BaselineCharacteristic,x, ; ,x, Scarff & Bloom histology grade,11,0,2,No,1:No,1:No,,0.982
5758,3502482,Table 1,BaselineCharacteristic,xx%,xx Gy step (n?=?xx) ; ,x, Scarff & Bloom histology grade,11,1,3,No,1:No,1:No,,0.711
5758,3502482,Table 1,BaselineCharacteristic,xx%,xx Gy step (n?=?xx) ; ,x, Scarff & Bloom histology grade,11,2,3,No,1:No,1:No,,0.761
5758,3502482,Table 1,BaselineCharacteristic,x, ; ,x, Scarff & Bloom histology grade,12,0,2,No,1:No,1:No,,0.982
5758,3502482,Table 1,BaselineCharacteristic,xx%,xx Gy step (n?=?xx) ; ,x, Scarff & Bloom histology grade,12,1,3,No,1:No,1:No,,0.711
5758,3502482,Table 1,BaselineCharacteristic,x%,xx Gy step (n?=?xx) ; ,x, Scarff & Bloom histology grade,12,2,3,No,1:No,1:No,,0.811
5758,3502482,Table 1,BaselineCharacteristic,ER status, ; ,None,None,13,0,24,No,1:No,1:No,,0.995
5758,3502482,Table 1,BaselineCharacteristic,ER status,xx Gy step (n?=?xx) ; ,ER status,None,13,1,43,No,1:No,1:No,,0.664
5758,3502482,Table 1,BaselineCharacteristic,ER status,xx Gy step (n?=?xx) ; ,ER status,None,13,2,43,No,1:No,1:No,,0.654
5758,3502482,Table 1,BaselineCharacteristic,Positive, ; ,Positive, ER status,14,0,2,No,1:No,1:No,,1
5758,3502482,Table 1,BaselineCharacteristic,xxx%,xx Gy step (n?=?xx) ; ,Positive, ER status,14,1,3,No,1:No,1:No,,0.681
5758,3502482,Table 1,BaselineCharacteristic,xxx%,xx Gy step (n?=?xx) ; ,Positive, ER status,14,2,3,No,1:No,1:No,,0.691
5758,3502482,Table 1,BaselineCharacteristic,PR status (+), ; ,None,None,15,0,24,No,1:No,1:No,,0.995
5758,3502482,Table 1,BaselineCharacteristic,PR status (+),xx Gy step (n?=?xx) ; ,PR status (+),None,15,1,43,No,1:No,1:No,,0.704
5758,3502482,Table 1,BaselineCharacteristic,PR status (+),xx Gy step (n?=?xx) ; ,PR status (+),None,15,2,43,No,1:No,1:No,,0.694
5758,3502482,Table 1,BaselineCharacteristic,Positive, ; ,Positive, PR status (+),16,0,2,No,1:No,1:No,,1
5758,3502482,Table 1,BaselineCharacteristic,xx%,xx Gy step (n?=?xx) ; ,Positive, PR status (+),16,1,3,No,1:No,1:No,,0.711
5758,3502482,Table 1,BaselineCharacteristic,xx%,xx Gy step (n?=?xx) ; ,Positive, PR status (+),16,2,3,No,1:No,1:No,,0.711
5758,3502482,Table 1,BaselineCharacteristic,Negative, ; ,Negative, PR status (+),17,0,2,No,1:No,1:No,,1
5758,3502482,Table 1,BaselineCharacteristic,xx%,xx Gy step (n?=?xx) ; ,Negative, PR status (+),17,1,3,No,1:No,1:No,,0.711
5758,3502482,Table 1,BaselineCharacteristic,xx%,xx Gy step (n?=?xx) ; ,Negative, PR status (+),17,2,3,No,1:No,1:No,,0.711
5758,3502482,Table 1,BaselineCharacteristic,Herx status, ; ,None,None,18,0,24,No,1:No,1:No,,0.985
5758,3502482,Table 1,BaselineCharacteristic,Herx status,xx Gy step (n?=?xx) ; ,Herx status,None,18,1,43,No,1:No,1:No,,0.674
5758,3502482,Table 1,BaselineCharacteristic,Herx status,xx Gy step (n?=?xx) ; ,Herx status,None,18,2,43,No,1:No,1:No,,0.664
5758,3502482,Table 1,BaselineCharacteristic,Negative, ; ,Negative, Herx status,19,0,2,No,1:No,1:No,,0.99
5758,3502482,Table 1,BaselineCharacteristic,xxx%,xx Gy step (n?=?xx) ; ,Negative, Herx status,19,1,3,No,1:No,1:No,,0.667
5758,3502482,Table 1,BaselineCharacteristic,xxx%,xx Gy step (n?=?xx) ; ,Negative, Herx status,19,2,3,No,1:No,1:No,,0.677
5758,3502482,Table 2,BaselineCharacteristic,Characteristic,,None,None,0,0,12,No,1:No,1:No,,0.905
5758,3502482,Table 2,BaselineCharacteristic,,Characteristic ; ,None,None,1,0,12,No,1:No,1:No,,0.898
5758,3502482,Table 2,BaselineCharacteristic,Min - max,"xx Gy (n?=?xx patients, xx tumors) ; ",,None,1,4,1,No,1:No,1:No,,0.5
5758,3502482,Table 2,BaselineCharacteristic,PTV coverage,Characteristic ;  ; ,PTV coverage,,2,0,2,No,1:No,1:No,,0.95
5758,3502482,Table 2,BaselineCharacteristic,PTV coverage,"xx Gy (n?=?xx patients, xx tumors) ; Median ; ",PTV coverage,,2,3,3,No,1:No,1:No,,0.51
5758,3502482,Table 2,BaselineCharacteristic,,"xx Gy (n?=?xx patients, xx tumors) ; Min - max ; ",PTV coverage,,2,4,3,No,1:No,1:No,,0.54
5758,3502482,Table 2,BaselineCharacteristic,Vxxx%,Characteristic ;  ; ,Vxxx%,,3,0,2,No,1:No,1:No,,0.96
5758,3502482,Table 2,BaselineCharacteristic,xx,"xx Gy (n?=?xx patients, xx tumors) ; Median ; ",Vxxx%,,3,3,3,No,1:No,1:No,,0.53
5758,3502482,Table 2,BaselineCharacteristic,Vxx%,Characteristic ;  ; ,Vxx%,,4,0,2,No,1:No,1:No,,0.97
5758,3502482,Table 2,BaselineCharacteristic,xxx - xxx,xx Gy (n?=?xx) ; Min - max ; ,Vxx%,,4,2,3,No,1:No,1:No,,0.516
5758,3502482,Table 2,BaselineCharacteristic,xxx,"xx Gy (n?=?xx patients, xx tumors) ; Median ; ",Vxx%,,4,3,3,No,1:No,1:No,,0.516
5758,3502482,Table 2,BaselineCharacteristic,xx - xxx,"xx Gy (n?=?xx patients, xx tumors) ; Min - max ; ",Vxx%,,4,4,3,No,1:No,1:No,,0.536
5758,3502482,Table 2,BaselineCharacteristic,Vxx%,Characteristic ;  ; ,Vxx%,,5,0,2,No,1:No,1:No,,0.97
5758,3502482,Table 2,BaselineCharacteristic,xxx - xxx,xx Gy (n?=?xx) ; Min - max ; ,Vxx%,,5,2,3,No,1:No,1:No,,0.516
5758,3502482,Table 2,BaselineCharacteristic,xxx,"xx Gy (n?=?xx patients, xx tumors) ; Median ; ",Vxx%,,5,3,3,No,1:No,1:No,,0.526
5758,3502482,Table 2,BaselineCharacteristic,xx - xxx,"xx Gy (n?=?xx patients, xx tumors) ; Min - max ; ",Vxx%,,5,4,3,No,1:No,1:No,,0.546
5758,3502482,Table 2,BaselineCharacteristic,Ipsilateral breast,Characteristic ;  ; ,None,None,6,0,24,No,1:No,1:No,,0.969
5758,3502482,Table 2,BaselineCharacteristic,Ipsilateral breast,xx Gy (n?=?xx) ; Median ; ,Ipsilateral breast,None,6,1,43,No,1:No,1:No,,0.654
5758,3502482,Table 2,BaselineCharacteristic,Ipsilateral breast,xx Gy (n?=?xx) ; Min - max ; ,Ipsilateral breast,None,6,2,43,No,1:No,1:No,,0.668
5758,3502482,Table 2,BaselineCharacteristic,Ipsilateral breast,"xx Gy (n?=?xx patients, xx tumors) ; Median ; ",Ipsilateral breast,None,6,3,43,No,1:No,1:No,,0.652
5758,3502482,Table 2,BaselineCharacteristic,Ipsilateral breast,"xx Gy (n?=?xx patients, xx tumors) ; Min - max ; ",Ipsilateral breast,None,6,4,43,No,1:No,1:No,,0.682
5758,3502482,Table 2,BaselineCharacteristic,Vxx Gy (%),Characteristic ;  ; ,Vxx Gy (%), Ipsilateral breast,7,0,2,No,1:No,1:No,,0.92
5758,3502482,Table 2,BaselineCharacteristic,xx,xx Gy (n?=?xx) ; Median ; ,Vxx Gy (%), Ipsilateral breast,7,1,3,No,1:No,1:No,,0.646
5758,3502482,Table 2,BaselineCharacteristic,xx - xx,xx Gy (n?=?xx) ; Min - max ; ,Vxx Gy (%), Ipsilateral breast,7,2,3,No,1:No,1:No,,0.666
5758,3502482,Table 2,BaselineCharacteristic,xx,"xx Gy (n?=?xx patients, xx tumors) ; Median ; ",Vxx Gy (%), Ipsilateral breast,7,3,3,No,1:No,1:No,,0.626
5758,3502482,Table 2,BaselineCharacteristic,xx - xx,"xx Gy (n?=?xx patients, xx tumors) ; Min - max ; ",Vxx Gy (%), Ipsilateral breast,7,4,3,No,1:No,1:No,,0.646
5758,3502482,Table 2,BaselineCharacteristic,Vxx Gy (%),Characteristic ;  ; ,Vxx Gy (%), Ipsilateral breast,8,0,2,No,1:No,1:No,,0.93
5758,3502482,Table 2,BaselineCharacteristic,xx,xx Gy (n?=?xx) ; Median ; ,Vxx Gy (%), Ipsilateral breast,8,1,3,No,1:No,1:No,,0.666
5758,3502482,Table 2,BaselineCharacteristic,xx - xx,xx Gy (n?=?xx) ; Min - max ; ,Vxx Gy (%), Ipsilateral breast,8,2,3,No,1:No,1:No,,0.676
5758,3502482,Table 2,BaselineCharacteristic,xx,"xx Gy (n?=?xx patients, xx tumors) ; Median ; ",Vxx Gy (%), Ipsilateral breast,8,3,3,No,1:No,1:No,,0.646
5758,3502482,Table 2,BaselineCharacteristic,xx - xx,"xx Gy (n?=?xx patients, xx tumors) ; Min - max ; ",Vxx Gy (%), Ipsilateral breast,8,4,3,No,1:No,1:No,,0.656
5758,3502482,Table 2,BaselineCharacteristic,Vxx Gy (%),Characteristic ;  ; ,Vxx Gy (%), Ipsilateral breast,9,0,2,No,1:No,1:No,,0.94
5758,3502482,Table 2,BaselineCharacteristic,xx,xx Gy (n?=?xx) ; Median ; ,Vxx Gy (%), Ipsilateral breast,9,1,3,No,1:No,1:No,,0.656
5758,3502482,Table 2,BaselineCharacteristic,xx - xx,xx Gy (n?=?xx) ; Min - max ; ,Vxx Gy (%), Ipsilateral breast,9,2,3,No,1:No,1:No,,0.676
5758,3502482,Table 2,BaselineCharacteristic,xx,"xx Gy (n?=?xx patients, xx tumors) ; Median ; ",Vxx Gy (%), Ipsilateral breast,9,3,3,No,1:No,1:No,,0.636
5758,3502482,Table 2,BaselineCharacteristic,xx - xx,"xx Gy (n?=?xx patients, xx tumors) ; Min - max ; ",Vxx Gy (%), Ipsilateral breast,9,4,3,No,1:No,1:No,,0.656
5758,3502482,Table 2,BaselineCharacteristic,Vx Gy (%),Characteristic ;  ; ,Vx Gy (%), Ipsilateral breast,10,0,2,No,1:No,1:No,,0.94
5758,3502482,Table 2,BaselineCharacteristic,xx,xx Gy (n?=?xx) ; Median ; ,Vx Gy (%), Ipsilateral breast,10,1,3,No,1:No,1:No,,0.686
5758,3502482,Table 2,BaselineCharacteristic,xx - xx,xx Gy (n?=?xx) ; Min - max ; ,Vx Gy (%), Ipsilateral breast,10,2,3,No,1:No,1:No,,0.696
5758,3502482,Table 2,BaselineCharacteristic,xx,"xx Gy (n?=?xx patients, xx tumors) ; Median ; ",Vx Gy (%), Ipsilateral breast,10,3,3,No,1:No,1:No,,0.636
5758,3502482,Table 2,BaselineCharacteristic,xx - xx,"xx Gy (n?=?xx patients, xx tumors) ; Min - max ; ",Vx Gy (%), Ipsilateral breast,10,4,3,No,1:No,1:No,,0.656
5758,3502482,Table 2,BaselineCharacteristic,Non target breast,Characteristic ;  ; ,None,None,11,0,24,No,1:No,1:No,,0.995
5758,3502482,Table 2,BaselineCharacteristic,Non target breast,xx Gy (n?=?xx) ; Median ; ,Non target breast,None,11,1,43,No,1:No,1:No,,0.704
5758,3502482,Table 2,BaselineCharacteristic,Non target breast,xx Gy (n?=?xx) ; Min - max ; ,Non target breast,None,11,2,43,No,1:No,1:No,,0.698
5758,3502482,Table 2,BaselineCharacteristic,Non target breast,"xx Gy (n?=?xx patients, xx tumors) ; Median ; ",Non target breast,None,11,3,43,No,1:No,1:No,,0.682
5758,3502482,Table 2,BaselineCharacteristic,Non target breast,"xx Gy (n?=?xx patients, xx tumors) ; Min - max ; ",Non target breast,None,11,4,43,No,1:No,1:No,,0.722
5758,3502482,Table 2,BaselineCharacteristic,Vxx Gy (%),Characteristic ;  ; ,Vxx Gy (%), Non target breast,12,0,2,No,1:No,1:No,,0.94
5758,3502482,Table 2,BaselineCharacteristic,xx,xx Gy (n?=?xx) ; Median ; ,Vxx Gy (%), Non target breast,12,1,3,No,1:No,1:No,,0.686
5758,3502482,Table 2,BaselineCharacteristic,x - xx,xx Gy (n?=?xx) ; Min - max ; ,Vxx Gy (%), Non target breast,12,2,3,No,1:No,1:No,,0.706
5758,3502482,Table 2,BaselineCharacteristic,x,"xx Gy (n?=?xx patients, xx tumors) ; Median ; ",Vxx Gy (%), Non target breast,12,3,3,No,1:No,1:No,,0.646
5758,3502482,Table 2,BaselineCharacteristic,x - xx,"xx Gy (n?=?xx patients, xx tumors) ; Min - max ; ",Vxx Gy (%), Non target breast,12,4,3,No,1:No,1:No,,0.656
5758,3502482,Table 2,BaselineCharacteristic,Vxx Gy (%),Characteristic ;  ; ,Vxx Gy (%), Non target breast,13,0,2,No,1:No,1:No,,0.94
5758,3502482,Table 2,BaselineCharacteristic,xx,xx Gy (n?=?xx) ; Median ; ,Vxx Gy (%), Non target breast,13,1,3,No,1:No,1:No,,0.686
5758,3502482,Table 2,BaselineCharacteristic,xx - xx,xx Gy (n?=?xx) ; Min - max ; ,Vxx Gy (%), Non target breast,13,2,3,No,1:No,1:No,,0.696
5758,3502482,Table 2,BaselineCharacteristic,xx,"xx Gy (n?=?xx patients, xx tumors) ; Median ; ",Vxx Gy (%), Non target breast,13,3,3,No,1:No,1:No,,0.636
5758,3502482,Table 2,BaselineCharacteristic,x - xx,"xx Gy (n?=?xx patients, xx tumors) ; Min - max ; ",Vxx Gy (%), Non target breast,13,4,3,No,1:No,1:No,,0.656
5758,3502482,Table 2,BaselineCharacteristic,Vxx Gy (%),Characteristic ;  ; ,Vxx Gy (%), Non target breast,14,0,2,No,1:No,1:No,,0.94
5758,3502482,Table 2,BaselineCharacteristic,xx,xx Gy (n?=?xx) ; Median ; ,Vxx Gy (%), Non target breast,14,1,3,No,1:No,1:No,,0.706
5758,3502482,Table 2,BaselineCharacteristic,xx - xx,xx Gy (n?=?xx) ; Min - max ; ,Vxx Gy (%), Non target breast,14,2,3,No,1:No,1:No,,0.716
5758,3502482,Table 2,BaselineCharacteristic,xx,"xx Gy (n?=?xx patients, xx tumors) ; Median ; ",Vxx Gy (%), Non target breast,14,3,3,No,1:No,1:No,,0.656
5758,3502482,Table 2,BaselineCharacteristic,x - xx,"xx Gy (n?=?xx patients, xx tumors) ; Min - max ; ",Vxx Gy (%), Non target breast,14,4,3,No,1:No,1:No,,0.666
5758,3502482,Table 2,BaselineCharacteristic,Vxx Gy (%),Characteristic ;  ; ,Vxx Gy (%), Non target breast,15,0,2,No,1:No,1:No,,0.94
5758,3502482,Table 2,BaselineCharacteristic,xx,xx Gy (n?=?xx) ; Median ; ,Vxx Gy (%), Non target breast,15,1,3,No,1:No,1:No,,0.706
5758,3502482,Table 2,BaselineCharacteristic,xx - xx,xx Gy (n?=?xx) ; Min - max ; ,Vxx Gy (%), Non target breast,15,2,3,No,1:No,1:No,,0.716
5758,3502482,Table 2,BaselineCharacteristic,xx,"xx Gy (n?=?xx patients, xx tumors) ; Median ; ",Vxx Gy (%), Non target breast,15,3,3,No,1:No,1:No,,0.656
5758,3502482,Table 2,BaselineCharacteristic,xx - xx,"xx Gy (n?=?xx patients, xx tumors) ; Min - max ; ",Vxx Gy (%), Non target breast,15,4,3,No,1:No,1:No,,0.676
5758,3502482,Table 2,BaselineCharacteristic,Ipsilateral lung,Characteristic ;  ; ,None,None,16,0,24,No,1:No,1:No,,0.995
5758,3502482,Table 2,BaselineCharacteristic,Ipsilateral lung,xx Gy (n?=?xx) ; Median ; ,Ipsilateral lung,None,16,1,43,No,1:No,1:No,,0.724
5758,3502482,Table 2,BaselineCharacteristic,Ipsilateral lung,xx Gy (n?=?xx) ; Min - max ; ,Ipsilateral lung,None,16,2,43,No,1:No,1:No,,0.718
5758,3502482,Table 2,BaselineCharacteristic,Ipsilateral lung,"xx Gy (n?=?xx patients, xx tumors) ; Median ; ",Ipsilateral lung,None,16,3,43,No,1:No,1:No,,0.702
5758,3502482,Table 2,BaselineCharacteristic,Ipsilateral lung,"xx Gy (n?=?xx patients, xx tumors) ; Min - max ; ",Ipsilateral lung,None,16,4,43,No,1:No,1:No,,0.742
5758,3502482,Table 2,BaselineCharacteristic,Vxx Gy (%),Characteristic ;  ; ,Vxx Gy (%), Ipsilateral lung,17,0,2,No,1:No,1:No,,0.94
5758,3502482,Table 2,BaselineCharacteristic,x,xx Gy (n?=?xx) ; Median ; ,Vxx Gy (%), Ipsilateral lung,17,1,3,No,1:No,1:No,,0.696
5758,3502482,Table 2,BaselineCharacteristic,x - x,xx Gy (n?=?xx) ; Min - max ; ,Vxx Gy (%), Ipsilateral lung,17,2,3,No,1:No,1:No,,0.726
5758,3502482,Table 2,BaselineCharacteristic,x,"xx Gy (n?=?xx patients, xx tumors) ; Median ; ",Vxx Gy (%), Ipsilateral lung,17,3,3,No,1:No,1:No,,0.676
5758,3502482,Table 2,BaselineCharacteristic,x - x,"xx Gy (n?=?xx patients, xx tumors) ; Min - max ; ",Vxx Gy (%), Ipsilateral lung,17,4,3,No,1:No,1:No,,0.686
5758,3502482,Table 2,BaselineCharacteristic,Vxx Gy (%),Characteristic ;  ; ,Vxx Gy (%), Ipsilateral lung,18,0,2,No,1:No,1:No,,0.93
5758,3502482,Table 2,BaselineCharacteristic,x,xx Gy (n?=?xx) ; Median ; ,Vxx Gy (%), Ipsilateral lung,18,1,3,No,1:No,1:No,,0.691
5758,3502482,Table 2,BaselineCharacteristic,x - x,xx Gy (n?=?xx) ; Min - max ; ,Vxx Gy (%), Ipsilateral lung,18,2,3,No,1:No,1:No,,0.721
5758,3502482,Table 2,BaselineCharacteristic,x,"xx Gy (n?=?xx patients, xx tumors) ; Median ; ",Vxx Gy (%), Ipsilateral lung,18,3,3,No,1:No,1:No,,0.671
5758,3502482,Table 2,BaselineCharacteristic,x - x,"xx Gy (n?=?xx patients, xx tumors) ; Min - max ; ",Vxx Gy (%), Ipsilateral lung,18,4,3,No,1:No,1:No,,0.681
5758,3502482,Table 2,BaselineCharacteristic,Vx Gy (%),Characteristic ;  ; ,Vx Gy (%), Ipsilateral lung,19,0,2,No,1:No,1:No,,0.92
5758,3502482,Table 2,BaselineCharacteristic,x,xx Gy (n?=?xx) ; Median ; ,Vx Gy (%), Ipsilateral lung,19,1,3,No,1:No,1:No,,0.681
5758,3502482,Table 2,BaselineCharacteristic,x - x,xx Gy (n?=?xx) ; Min - max ; ,Vx Gy (%), Ipsilateral lung,19,2,3,No,1:No,1:No,,0.711
5758,3502482,Table 2,BaselineCharacteristic,x,"xx Gy (n?=?xx patients, xx tumors) ; Median ; ",Vx Gy (%), Ipsilateral lung,19,3,3,No,1:No,1:No,,0.671
5758,3502482,Table 2,BaselineCharacteristic,x - xx,"xx Gy (n?=?xx patients, xx tumors) ; Min - max ; ",Vx Gy (%), Ipsilateral lung,19,4,3,No,1:No,1:No,,0.681
5758,3502482,Table 2,BaselineCharacteristic,Heart,Characteristic ;  ; ,None,None,20,0,24,No,1:No,1:No,,0.985
5758,3502482,Table 2,BaselineCharacteristic,Heart,xx Gy (n?=?xx) ; Median ; ,Heart,None,20,1,43,No,1:No,1:No,,0.714
5758,3502482,Table 2,BaselineCharacteristic,Heart,xx Gy (n?=?xx) ; Min - max ; ,Heart,None,20,2,43,No,1:No,1:No,,0.708
5758,3502482,Table 2,BaselineCharacteristic,Heart,"xx Gy (n?=?xx patients, xx tumors) ; Median ; ",Heart,None,20,3,43,No,1:No,1:No,,0.702
5758,3502482,Table 2,BaselineCharacteristic,Heart,"xx Gy (n?=?xx patients, xx tumors) ; Min - max ; ",Heart,None,20,4,43,No,1:No,1:No,,0.732
5758,3502482,Table 2,BaselineCharacteristic,Vxx Gy (%),Characteristic ;  ; ,Vxx Gy (%), Heart,21,0,2,No,1:No,1:No,,0.92
5758,3502482,Table 2,BaselineCharacteristic,x,xx Gy (n?=?xx) ; Median ; ,Vxx Gy (%), Heart,21,1,3,No,1:No,1:No,,0.671
5758,3502482,Table 2,BaselineCharacteristic,x - x,xx Gy (n?=?xx) ; Min - max ; ,Vxx Gy (%), Heart,21,2,3,No,1:No,1:No,,0.701
5758,3502482,Table 2,BaselineCharacteristic,x,"xx Gy (n?=?xx patients, xx tumors) ; Median ; ",Vxx Gy (%), Heart,21,3,3,No,1:No,1:No,,0.651
5758,3502482,Table 2,BaselineCharacteristic,x - x,"xx Gy (n?=?xx patients, xx tumors) ; Min - max ; ",Vxx Gy (%), Heart,21,4,3,No,1:No,1:No,,0.661
5758,3502482,Table 2,BaselineCharacteristic,Vxx Gy (%),Characteristic ;  ; ,Vxx Gy (%), Heart,22,0,2,No,1:No,1:No,,0.94
5758,3502482,Table 2,BaselineCharacteristic,x,xx Gy (n?=?xx) ; Median ; ,Vxx Gy (%), Heart,22,1,3,No,1:No,1:No,,0.681
5758,3502482,Table 2,BaselineCharacteristic,x - x,xx Gy (n?=?xx) ; Min - max ; ,Vxx Gy (%), Heart,22,2,3,No,1:No,1:No,,0.711
5758,3502482,Table 2,BaselineCharacteristic,x,"xx Gy (n?=?xx patients, xx tumors) ; Median ; ",Vxx Gy (%), Heart,22,3,3,No,1:No,1:No,,0.651
5758,3502482,Table 2,BaselineCharacteristic,x - x,"xx Gy (n?=?xx patients, xx tumors) ; Min - max ; ",Vxx Gy (%), Heart,22,4,3,No,1:No,1:No,,0.661
5758,3502482,Table 2,BaselineCharacteristic,Vx Gy (%),Characteristic ;  ; ,Vx Gy (%), Heart,23,0,2,No,1:No,1:No,,0.94
5758,3502482,Table 2,BaselineCharacteristic,x,xx Gy (n?=?xx) ; Median ; ,Vx Gy (%), Heart,23,1,3,No,1:No,1:No,,0.681
5758,3502482,Table 2,BaselineCharacteristic,x - x,xx Gy (n?=?xx) ; Min - max ; ,Vx Gy (%), Heart,23,2,3,No,1:No,1:No,,0.711
5758,3502482,Table 2,BaselineCharacteristic,x,"xx Gy (n?=?xx patients, xx tumors) ; Median ; ",Vx Gy (%), Heart,23,3,3,No,1:No,1:No,,0.651
5758,3502482,Table 2,BaselineCharacteristic,x - x,"xx Gy (n?=?xx patients, xx tumors) ; Min - max ; ",Vx Gy (%), Heart,23,4,3,No,1:No,1:No,,0.661
5758,3502482,Table 2,BaselineCharacteristic,"left breast cancer, n?=?x",Characteristic ;  ; ,"left breast cancer, n?=?x", Heart,24,0,2,No,1:No,1:No,,0.868
5758,3502482,Table 2,BaselineCharacteristic,,xx Gy (n?=?xx) ; Median ; ,"left breast cancer, n?=?x", Heart,24,1,3,No,1:No,1:No,,0.727
5758,3502482,Table 2,BaselineCharacteristic,,xx Gy (n?=?xx) ; Min - max ; ,"left breast cancer, n?=?x", Heart,24,2,3,No,1:No,1:No,,0.771
5758,3502482,Table 2,BaselineCharacteristic,"left breast cancer, n?=?xx","xx Gy (n?=?xx patients, xx tumors) ; Median ; ","left breast cancer, n?=?x", Heart,24,3,3,No,1:No,1:No,,0.671
5758,3502482,Table 2,BaselineCharacteristic,,"xx Gy (n?=?xx patients, xx tumors) ; Min - max ; ","left breast cancer, n?=?x", Heart,24,4,3,No,1:No,1:No,,0.691
5807,3511174,Table 1,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
5807,3511174,Table 1,BaselineCharacteristic,Group B (n?=?x),,,None,0,1,1,No,1:No,1:No,,0.627
5807,3511174,Table 1,BaselineCharacteristic,Group BT (n?=?x),,,None,0,2,1,No,1:No,1:No,,0.641
5807,3511174,Table 1,BaselineCharacteristic,Mean age (SD), ; ,Mean age (SD),None,1,0,2,No,1:No,1:No,,0.626
5807,3511174,Table 1,BaselineCharacteristic,Male/female (n), ; ,Male/female (n),None,2,0,2,No,1:No,1:No,,0.816
5807,3511174,Table 1,BaselineCharacteristic,x/x,Group B (n?=?x) ; ,Male/female (n),None,2,1,3,No,1:No,1:No,,0.696
5807,3511174,Table 1,BaselineCharacteristic,x/x,Group BT (n?=?x) ; ,Male/female (n),None,2,2,3,No,1:No,1:No,,0.736
5807,3511174,Table 1,BaselineCharacteristic,"CP type, hemiplegic/diplegic(n)", ; ,"CP type, hemiplegic/diplegic(n)",None,3,0,2,No,1:No,1:No,,0.836
5807,3511174,Table 1,BaselineCharacteristic,x/x,Group B (n?=?x) ; ,"CP type, hemiplegic/diplegic(n)",None,3,1,3,No,1:No,1:No,,0.766
5807,3511174,Table 1,BaselineCharacteristic,x/x,Group BT (n?=?x) ; ,"CP type, hemiplegic/diplegic(n)",None,3,2,3,No,1:No,1:No,,0.806
5842,3519573,Table 1,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
5842,3519573,Table 1,BaselineCharacteristic,Total (N?=?xxx),,,None,0,1,1,No,1:No,1:No,,0.656
5842,3519573,Table 1,BaselineCharacteristic,"Age (years), mean (SD)", ; ,"Age (years), mean (SD)",None,1,0,2,No,1:No,1:No,,0.5
5842,3519573,Table 1,BaselineCharacteristic,"Gender, n (%male)", ; ,"Gender, n (%male)",None,2,0,2,No,1:No,1:No,,0.816
5842,3519573,Table 1,BaselineCharacteristic,"Height (inches), mean (SD)", ; ,"Height (inches), mean (SD)",None,3,0,2,No,1:No,1:No,,0.69
5842,3519573,Table 1,BaselineCharacteristic,"Weight (pounds), mean (SD)", ; ,"Weight (pounds), mean (SD)",None,4,0,2,No,1:No,1:No,,0.71
5842,3519573,Table 1,BaselineCharacteristic,"Race, n (%)", ; ,"Race, n (%)",None,5,0,2,No,1:No,1:No,,0.826
5842,3519573,Table 1,BaselineCharacteristic,,Total (N?=?xxx) ; ,"Race, n (%)",None,5,1,3,No,1:No,1:No,,0.646
5842,3519573,Table 1,BaselineCharacteristic,White, ; ,White,None,6,0,2,No,1:No,1:No,,0.99
5842,3519573,Table 1,BaselineCharacteristic,xxx (xx.x%),Total (N?=?xxx) ; ,White,None,6,1,3,No,1:No,1:No,,0.74
5842,3519573,Table 1,BaselineCharacteristic,Black, ; ,Black,None,7,0,2,No,1:No,1:No,,0.99
5842,3519573,Table 1,BaselineCharacteristic,xx (xx.x%),Total (N?=?xxx) ; ,Black,None,7,1,3,No,1:No,1:No,,0.726
5842,3519573,Table 1,BaselineCharacteristic,Asian, ; ,Asian,None,8,0,2,No,1:No,1:No,,0.99
5842,3519573,Table 1,BaselineCharacteristic,x (x.x%),Total (N?=?xxx) ; ,Asian,None,8,1,3,No,1:No,1:No,,0.85
5842,3519573,Table 1,BaselineCharacteristic,Other, ; ,Other,None,9,0,2,No,1:No,1:No,,1
5842,3519573,Table 1,BaselineCharacteristic,x (x.x%),Total (N?=?xxx) ; ,Other,None,9,1,3,No,1:No,1:No,,0.85
5842,3519573,Table 1,BaselineCharacteristic,"Ethnicity, n (%)", ; ,"Ethnicity, n (%)",None,10,0,2,No,1:No,1:No,,0.906
5842,3519573,Table 1,BaselineCharacteristic,,Total (N?=?xxx) ; ,"Ethnicity, n (%)",None,10,1,3,No,1:No,1:No,,0.776
5842,3519573,Table 1,BaselineCharacteristic,Hispanic/Latino, ; ,Hispanic/Latino,None,11,0,2,No,1:No,1:No,,1
5842,3519573,Table 1,BaselineCharacteristic,xx (x.x%),Total (N?=?xxx) ; ,Hispanic/Latino,None,11,1,3,No,1:No,1:No,,0.746
5842,3519573,Table 1,BaselineCharacteristic,Not Hispanic/Latino, ; ,Not Hispanic/Latino,None,12,0,2,No,1:No,1:No,,1
5842,3519573,Table 1,BaselineCharacteristic,xxx (xx.x%),Total (N?=?xxx) ; ,Not Hispanic/Latino,None,12,1,3,No,1:No,1:No,,0.796
5842,3519573,Table 1,BaselineCharacteristic,"Primary diagnosis, n (%)", ; ,"Primary diagnosis, n (%)",None,13,0,2,No,1:No,1:No,,0.916
5842,3519573,Table 1,BaselineCharacteristic,,Total (N?=?xxx) ; ,"Primary diagnosis, n (%)",None,13,1,3,No,1:No,1:No,,0.796
5842,3519573,Table 1,BaselineCharacteristic,Dwarfism, ; ,Dwarfism,None,14,0,2,No,1:No,1:No,,1
5842,3519573,Table 1,BaselineCharacteristic,x (x.x%),Total (N?=?xxx) ; ,Dwarfism,None,14,1,3,No,1:No,1:No,,0.9
5842,3519573,Table 1,BaselineCharacteristic,Fetal growth retardation, ; ,Fetal growth retardation,None,15,0,2,No,1:No,1:No,,1
5842,3519573,Table 1,BaselineCharacteristic,x (x.x%),Total (N?=?xxx) ; ,Fetal growth retardation,None,15,1,3,No,1:No,1:No,,0.89
5842,3519573,Table 1,BaselineCharacteristic,Hypopituitarism, ; ,Hypopituitarism,None,16,0,2,No,1:No,1:No,,1
5842,3519573,Table 1,BaselineCharacteristic,x (x.x%),Total (N?=?xxx) ; ,Hypopituitarism,None,16,1,3,No,1:No,1:No,,0.89
5842,3519573,Table 1,BaselineCharacteristic,Hypopituitarism fetal, ; ,Hypopituitarism fetal,None,17,0,2,No,1:No,1:No,,1
5842,3519573,Table 1,BaselineCharacteristic,x (x.x%),Total (N?=?xxx) ; ,Hypopituitarism fetal,None,17,1,3,No,1:No,1:No,,0.89
5842,3519573,Table 1,BaselineCharacteristic,Small for gestational age, ; ,Small for gestational age,None,18,0,2,No,1:No,1:No,,0.786
5842,3519573,Table 1,BaselineCharacteristic,Turner\'s syndrome, ; ,Turner\'s syndrome,None,19,0,2,No,1:No,1:No,,0.99
5842,3519573,Table 1,BaselineCharacteristic,xx (x.x%),Total (N?=?xxx) ; ,Turner\'s syndrome,None,19,1,3,No,1:No,1:No,,0.756
5842,3519573,Table 1,BaselineCharacteristic,Growth retardation, ; ,Growth retardation,None,20,0,2,No,1:No,1:No,,0.99
5842,3519573,Table 1,BaselineCharacteristic,xx (xx.x%),Total (N?=?xxx) ; ,Growth retardation,None,20,1,3,No,1:No,1:No,,0.796
5842,3519573,Table 1,BaselineCharacteristic,Growth hormone deficiency, ; ,Growth hormone deficiency,None,21,0,2,No,1:No,1:No,,0.99
5842,3519573,Table 1,BaselineCharacteristic,xx (xx.x%),Total (N?=?xxx) ; ,Growth hormone deficiency,None,21,1,3,No,1:No,1:No,,0.846
5842,3519573,Table 1,BaselineCharacteristic,Body height below normal, ; ,Body height below normal,None,22,0,2,No,1:No,1:No,,1
5842,3519573,Table 1,BaselineCharacteristic,x (x.x%),Total (N?=?xxx) ; ,Body height below normal,None,22,1,3,No,1:No,1:No,,0.89
5842,3519573,Table 1,BaselineCharacteristic,Silver-Russell syndrome, ; ,Silver-Russell syndrome,None,23,0,2,No,1:No,1:No,,1
5842,3519573,Table 1,BaselineCharacteristic,x (x.x%),Total (N?=?xxx) ; ,Silver-Russell syndrome,None,23,1,3,No,1:No,1:No,,0.89
5842,3519573,Table 1,BaselineCharacteristic,"Time since diagnosis (years), mean (SD)", ; ,"Time since diagnosis (years), mean (SD)",None,24,0,2,No,1:No,1:No,,0.65
5842,3519573,Table 2,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
5842,3519573,Table 2,BaselineCharacteristic,Total (N?=?xxx),,,None,0,1,1,No,1:No,1:No,,0.656
5842,3519573,Table 2,BaselineCharacteristic,"Caregiver’s relationship to child, n (%)", ; ,"Caregiver’s relationship to child, n (%)",None,1,0,2,No,1:No,1:No,,0.756
5842,3519573,Table 2,BaselineCharacteristic,,Total (N?=?xxx) ; ,"Caregiver’s relationship to child, n (%)",None,1,1,3,No,1:No,1:No,,0.58
5842,3519573,Table 2,BaselineCharacteristic,Mother, ; ,Mother,None,2,0,2,No,1:No,1:No,,0.95
5842,3519573,Table 2,BaselineCharacteristic,xxx (xx.x%),Total (N?=?xxx) ; ,Mother,None,2,1,3,No,1:No,1:No,,0.592
5842,3519573,Table 2,BaselineCharacteristic,Father, ; ,Father,None,3,0,2,No,1:No,1:No,,0.96
5842,3519573,Table 2,BaselineCharacteristic,xx (xx.x%),Total (N?=?xxx) ; ,Father,None,3,1,3,No,1:No,1:No,,0.596
5842,3519573,Table 2,BaselineCharacteristic,Grandfather, ; ,Grandfather,None,4,0,2,No,1:No,1:No,,0.97
5842,3519573,Table 2,BaselineCharacteristic,x (x.x%),Total (N?=?xxx) ; ,Grandfather,None,4,1,3,No,1:No,1:No,,0.84
5842,3519573,Table 2,BaselineCharacteristic,Stepfather, ; ,Stepfather,None,5,0,2,No,1:No,1:No,,0.97
5842,3519573,Table 2,BaselineCharacteristic,x (x.x%),Total (N?=?xxx) ; ,Stepfather,None,5,1,3,No,1:No,1:No,,0.84
5842,3519573,Table 2,BaselineCharacteristic,"Length of time using reusable pen(years), mean (SD)", ; ,"Length of time using reusable pen(years), mean (SD)",None,6,0,2,No,1:No,1:No,,0.57
5842,3519573,Table 2,BaselineCharacteristic,"Type of Pen, n (%)", ; ,"Type of Pen, n (%)",None,7,0,2,No,1:No,1:No,,0.886
5842,3519573,Table 2,BaselineCharacteristic,,Total (N?=?xxx) ; ,"Type of Pen, n (%)",None,7,1,3,No,1:No,1:No,,0.716
5842,3519573,Table 2,BaselineCharacteristic,x MG, ; ,x MG,None,8,0,2,No,1:No,1:No,,0.972
5842,3519573,Table 2,BaselineCharacteristic,x (x.x%),Total (N?=?xxx) ; ,x MG,None,8,1,3,No,1:No,1:No,,0.85
5842,3519573,Table 2,BaselineCharacteristic,xx MG, ; ,xx MG,None,9,0,2,No,1:No,1:No,,0.935
5842,3519573,Table 2,BaselineCharacteristic,xxx (xx.x%),Total (N?=?xxx) ; ,xx MG,None,9,1,3,No,1:No,1:No,,0.756
5842,3519573,Table 2,BaselineCharacteristic,"Person responsible for preparing shot, n (%)", ; ,"Person responsible for preparing shot, n (%)",None,10,0,2,No,1:No,1:No,,0.916
5842,3519573,Table 2,BaselineCharacteristic,,Total (N?=?xxx) ; ,"Person responsible for preparing shot, n (%)",None,10,1,3,No,1:No,1:No,,0.79
5842,3519573,Table 2,BaselineCharacteristic,Child, ; ,Child,None,11,0,2,No,1:No,1:No,,1
5842,3519573,Table 2,BaselineCharacteristic,xx (xx.x%),Total (N?=?xxx) ; ,Child,None,11,1,3,No,1:No,1:No,,0.796
5842,3519573,Table 2,BaselineCharacteristic,Mother, ; ,Mother,None,12,0,2,No,1:No,1:No,,1
5842,3519573,Table 2,BaselineCharacteristic,xx (xx.x%),Total (N?=?xxx) ; ,Mother,None,12,1,3,No,1:No,1:No,,0.796
5842,3519573,Table 2,BaselineCharacteristic,Father, ; ,Father,None,13,0,2,No,1:No,1:No,,1
5842,3519573,Table 2,BaselineCharacteristic,xx (xx.x%),Total (N?=?xxx) ; ,Father,None,13,1,3,No,1:No,1:No,,0.796
5842,3519573,Table 2,BaselineCharacteristic,Grandmother, ; ,Grandmother,None,14,0,2,No,1:No,1:No,,1
5842,3519573,Table 2,BaselineCharacteristic,x (x.x%),Total (N?=?xxx) ; ,Grandmother,None,14,1,3,No,1:No,1:No,,0.9
5842,3519573,Table 2,BaselineCharacteristic,Stepfather, ; ,Stepfather,None,15,0,2,No,1:No,1:No,,1
5842,3519573,Table 2,BaselineCharacteristic,x (x.x%),Total (N?=?xxx) ; ,Stepfather,None,15,1,3,No,1:No,1:No,,0.89
5842,3519573,Table 2,BaselineCharacteristic,Other, ; ,Other,None,16,0,2,No,1:No,1:No,,1
5842,3519573,Table 2,BaselineCharacteristic,x (x.x%),Total (N?=?xxx) ; ,Other,None,16,1,3,No,1:No,1:No,,0.89
5842,3519573,Table 2,BaselineCharacteristic,"Person responsible for giving the shot, n (%)", ; ,"Person responsible for giving the shot, n (%)",None,17,0,2,No,1:No,1:No,,0.92
5842,3519573,Table 2,BaselineCharacteristic,,Total (N?=?xxx) ; ,"Person responsible for giving the shot, n (%)",None,17,1,3,No,1:No,1:No,,0.8
5842,3519573,Table 2,BaselineCharacteristic,Child, ; ,Child,None,18,0,2,No,1:No,1:No,,0.99
5842,3519573,Table 2,BaselineCharacteristic,xx (xx.x%),Total (N?=?xxx) ; ,Child,None,18,1,3,No,1:No,1:No,,0.806
5842,3519573,Table 2,BaselineCharacteristic,Mother, ; ,Mother,None,19,0,2,No,1:No,1:No,,0.99
5842,3519573,Table 2,BaselineCharacteristic,xx (xx.x%),Total (N?=?xxx) ; ,Mother,None,19,1,3,No,1:No,1:No,,0.806
5842,3519573,Table 2,BaselineCharacteristic,Father, ; ,Father,None,20,0,2,No,1:No,1:No,,0.99
5842,3519573,Table 2,BaselineCharacteristic,xx (xx.x%),Total (N?=?xxx) ; ,Father,None,20,1,3,No,1:No,1:No,,0.796
5842,3519573,Table 2,BaselineCharacteristic,Grandmother, ; ,Grandmother,None,21,0,2,No,1:No,1:No,,0.99
5842,3519573,Table 2,BaselineCharacteristic,x (x.x%),Total (N?=?xxx) ; ,Grandmother,None,21,1,3,No,1:No,1:No,,0.89
5842,3519573,Table 2,BaselineCharacteristic,Stepfather, ; ,Stepfather,None,22,0,2,No,1:No,1:No,,1
5842,3519573,Table 2,BaselineCharacteristic,x (x.x%),Total (N?=?xxx) ; ,Stepfather,None,22,1,3,No,1:No,1:No,,0.89
5842,3519573,Table 3,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
5842,3519573,Table 3,BaselineCharacteristic,N,,,None,0,1,1,No,1:No,1:No,,0.903
5842,3519573,Table 3,BaselineCharacteristic,Mean,,,None,0,2,1,No,1:No,1:No,,0.903
5842,3519573,Table 3,BaselineCharacteristic,SD,,,None,0,3,1,No,1:No,1:No,,0.765
5842,3519573,Table 3,BaselineCharacteristic,Floor (%),,,None,0,4,1,No,1:No,1:No,,0.833
5842,3519573,Table 3,BaselineCharacteristic,Ceiling (%),,,None,0,5,1,No,1:No,1:No,,0.856
5842,3519573,Table 3,BaselineCharacteristic,Range,,,None,0,6,1,No,1:No,1:No,,0.935
5842,3519573,Table 3,BaselineCharacteristic,x. Ease or difficulty of using the injection pen overall, ; ,x. Ease or difficulty of using the injection pen overall,None,1,0,2,No,1:No,1:No,,0.915
5842,3519573,Table 3,BaselineCharacteristic,xxx,N ; ,x. Ease or difficulty of using the injection pen overall,None,1,1,3,No,1:No,1:No,,0.88
5842,3519573,Table 3,BaselineCharacteristic,x.x,Mean ; ,x. Ease or difficulty of using the injection pen overall,None,1,2,3,No,1:No,1:No,,0.92
5842,3519573,Table 3,BaselineCharacteristic,x.x,SD ; ,x. Ease or difficulty of using the injection pen overall,None,1,3,3,No,1:No,1:No,,0.8
5842,3519573,Table 3,BaselineCharacteristic,x (x.x%),Floor (%) ; ,x. Ease or difficulty of using the injection pen overall,None,1,4,3,No,1:No,1:No,,0.86
5842,3519573,Table 3,BaselineCharacteristic,xx (xx.x%),Ceiling (%) ; ,x. Ease or difficulty of using the injection pen overall,None,1,5,3,No,1:No,1:No,,0.78
5842,3519573,Table 3,BaselineCharacteristic,x.x-x.x,Range ; ,x. Ease or difficulty of using the injection pen overall,None,1,6,3,No,1:No,1:No,,0.93
5842,3519573,Table 3,BaselineCharacteristic,xa. Attaching and removing the needle, ; ,xa. Attaching and removing the needle,None,2,0,2,No,1:No,1:No,,0.97
5842,3519573,Table 3,BaselineCharacteristic,xxx,N ; ,xa. Attaching and removing the needle,None,2,1,3,No,1:No,1:No,,0.85
5842,3519573,Table 3,BaselineCharacteristic,x.x,Mean ; ,xa. Attaching and removing the needle,None,2,2,3,No,1:No,1:No,,0.95
5842,3519573,Table 3,BaselineCharacteristic,x.x,SD ; ,xa. Attaching and removing the needle,None,2,3,3,No,1:No,1:No,,0.77
5842,3519573,Table 3,BaselineCharacteristic,x (x.x%),Floor (%) ; ,xa. Attaching and removing the needle,None,2,4,3,No,1:No,1:No,,0.86
5842,3519573,Table 3,BaselineCharacteristic,xx (xx.x%),Ceiling (%) ; ,xa. Attaching and removing the needle,None,2,5,3,No,1:No,1:No,,0.77
5842,3519573,Table 3,BaselineCharacteristic,x.x-x.x,Range ; ,xa. Attaching and removing the needle,None,2,6,3,No,1:No,1:No,,0.95
5842,3519573,Table 3,BaselineCharacteristic,xb. Preparing the injection pen by changing the cartridge or getting a new injection pen, ; ,xb. Preparing the injection pen by changing the cartridge or getting a new injection pen,None,3,0,2,No,1:No,1:No,,0.9
5842,3519573,Table 3,BaselineCharacteristic,xxx,N ; ,xb. Preparing the injection pen by changing the cartridge or getting a new injection pen,None,3,1,3,No,1:No,1:No,,0.81
5842,3519573,Table 3,BaselineCharacteristic,x.x,Mean ; ,xb. Preparing the injection pen by changing the cartridge or getting a new injection pen,None,3,2,3,No,1:No,1:No,,0.89
5842,3519573,Table 3,BaselineCharacteristic,x.x,SD ; ,xb. Preparing the injection pen by changing the cartridge or getting a new injection pen,None,3,3,3,No,1:No,1:No,,0.76
5842,3519573,Table 3,BaselineCharacteristic,x (x.x%),Floor (%) ; ,xb. Preparing the injection pen by changing the cartridge or getting a new injection pen,None,3,4,3,No,1:No,1:No,,0.84
5842,3519573,Table 3,BaselineCharacteristic,xx (xx.x%),Ceiling (%) ; ,xb. Preparing the injection pen by changing the cartridge or getting a new injection pen,None,3,5,3,No,1:No,1:No,,0.69
5842,3519573,Table 3,BaselineCharacteristic,x.x-x.x,Range ; ,xb. Preparing the injection pen by changing the cartridge or getting a new injection pen,None,3,6,3,No,1:No,1:No,,0.91
5842,3519573,Table 3,BaselineCharacteristic,xc. Mixing the medicine, ; ,xc. Mixing the medicine,None,4,0,2,No,1:No,1:No,,0.97
5842,3519573,Table 3,BaselineCharacteristic,xxx,N ; ,xc. Mixing the medicine,None,4,1,3,No,1:No,1:No,,0.86
5842,3519573,Table 3,BaselineCharacteristic,x.x,Mean ; ,xc. Mixing the medicine,None,4,2,3,No,1:No,1:No,,0.96
5842,3519573,Table 3,BaselineCharacteristic,x.x,SD ; ,xc. Mixing the medicine,None,4,3,3,No,1:No,1:No,,0.8
5842,3519573,Table 3,BaselineCharacteristic,x (x.x%),Floor (%) ; ,xc. Mixing the medicine,None,4,4,3,No,1:No,1:No,,0.85
5842,3519573,Table 3,BaselineCharacteristic,xx (xx.x%),Ceiling (%) ; ,xc. Mixing the medicine,None,4,5,3,No,1:No,1:No,,0.77
5842,3519573,Table 3,BaselineCharacteristic,x.x-x.x,Range ; ,xc. Mixing the medicine,None,4,6,3,No,1:No,1:No,,0.95
5842,3519573,Table 3,BaselineCharacteristic,xd. Removing the air bubbles, ; ,xd. Removing the air bubbles,None,5,0,2,No,1:No,1:No,,0.98
5842,3519573,Table 3,BaselineCharacteristic,xxx,N ; ,xd. Removing the air bubbles,None,5,1,3,No,1:No,1:No,,0.87
5842,3519573,Table 3,BaselineCharacteristic,x.x,Mean ; ,xd. Removing the air bubbles,None,5,2,3,No,1:No,1:No,,0.97
5842,3519573,Table 3,BaselineCharacteristic,x.x,SD ; ,xd. Removing the air bubbles,None,5,3,3,No,1:No,1:No,,0.82
5842,3519573,Table 3,BaselineCharacteristic,x (x.x%),Floor (%) ; ,xd. Removing the air bubbles,None,5,4,3,No,1:No,1:No,,0.86
5842,3519573,Table 3,BaselineCharacteristic,xx (xx.x%),Ceiling (%) ; ,xd. Removing the air bubbles,None,5,5,3,No,1:No,1:No,,0.77
5842,3519573,Table 3,BaselineCharacteristic,x.x-x.x,Range ; ,xd. Removing the air bubbles,None,5,6,3,No,1:No,1:No,,0.95
5842,3519573,Table 3,BaselineCharacteristic,xe. Remembering the dose that was prescribed by the doctor, ; ,xe. Remembering the dose that was prescribed by the doctor,None,6,0,2,No,1:No,1:No,,0.98
5842,3519573,Table 3,BaselineCharacteristic,xxx,N ; ,xe. Remembering the dose that was prescribed by the doctor,None,6,1,3,No,1:No,1:No,,0.96
5842,3519573,Table 3,BaselineCharacteristic,x.x,Mean ; ,xe. Remembering the dose that was prescribed by the doctor,None,6,2,3,No,1:No,1:No,,0.98
5842,3519573,Table 3,BaselineCharacteristic,x.x,SD ; ,xe. Remembering the dose that was prescribed by the doctor,None,6,3,3,No,1:No,1:No,,0.85
5842,3519573,Table 3,BaselineCharacteristic,x (x.x%),Floor (%) ; ,xe. Remembering the dose that was prescribed by the doctor,None,6,4,3,No,1:No,1:No,,0.92
5842,3519573,Table 3,BaselineCharacteristic,xxx (xx.x%),Ceiling (%) ; ,xe. Remembering the dose that was prescribed by the doctor,None,6,5,3,No,1:No,1:No,,0.81
5842,3519573,Table 3,BaselineCharacteristic,x.x-x.x,Range ; ,xe. Remembering the dose that was prescribed by the doctor,None,6,6,3,No,1:No,1:No,,0.99
5842,3519573,Table 3,BaselineCharacteristic,xf. Setting the dose, ; ,xf. Setting the dose,None,7,0,2,No,1:No,1:No,,0.98
5842,3519573,Table 3,BaselineCharacteristic,xxx,N ; ,xf. Setting the dose,None,7,1,3,No,1:No,1:No,,0.925
5842,3519573,Table 3,BaselineCharacteristic,x.x,Mean ; ,xf. Setting the dose,None,7,2,3,No,1:No,1:No,,0.965
5842,3519573,Table 3,BaselineCharacteristic,x.x,SD ; ,xf. Setting the dose,None,7,3,3,No,1:No,1:No,,0.825
5842,3519573,Table 3,BaselineCharacteristic,x (x.x%),Floor (%) ; ,xf. Setting the dose,None,7,4,3,No,1:No,1:No,,0.925
5842,3519573,Table 3,BaselineCharacteristic,xxx (xx.x%),Ceiling (%) ; ,xf. Setting the dose,None,7,5,3,No,1:No,1:No,,0.815
5842,3519573,Table 3,BaselineCharacteristic,x.x-x.x,Range ; ,xf. Setting the dose,None,7,6,3,No,1:No,1:No,,0.975
5842,3519573,Table 3,BaselineCharacteristic,xg. Changing the dose when the doctor changes the prescriptionx, ; ,xg. Changing the dose when the doctor changes the prescriptionx,None,8,0,2,No,1:No,1:No,,0.98
5842,3519573,Table 3,BaselineCharacteristic,xxx,N ; ,xg. Changing the dose when the doctor changes the prescriptionx,None,8,1,3,No,1:No,1:No,,0.915
5842,3519573,Table 3,BaselineCharacteristic,x.x,Mean ; ,xg. Changing the dose when the doctor changes the prescriptionx,None,8,2,3,No,1:No,1:No,,0.965
5842,3519573,Table 3,BaselineCharacteristic,x.x,SD ; ,xg. Changing the dose when the doctor changes the prescriptionx,None,8,3,3,No,1:No,1:No,,0.825
5842,3519573,Table 3,BaselineCharacteristic,x (x.x%),Floor (%) ; ,xg. Changing the dose when the doctor changes the prescriptionx,None,8,4,3,No,1:No,1:No,,0.925
5842,3519573,Table 3,BaselineCharacteristic,xx (xx.x%),Ceiling (%) ; ,xg. Changing the dose when the doctor changes the prescriptionx,None,8,5,3,No,1:No,1:No,,0.855
5842,3519573,Table 3,BaselineCharacteristic,x.x-x.x,Range ; ,xg. Changing the dose when the doctor changes the prescriptionx,None,8,6,3,No,1:No,1:No,,0.985
5842,3519573,Table 3,BaselineCharacteristic,xh. Using the needle guardx, ; ,xh. Using the needle guardx,None,9,0,2,No,1:No,1:No,,1
5842,3519573,Table 3,BaselineCharacteristic,xxx,N ; ,xh. Using the needle guardx,None,9,1,3,No,1:No,1:No,,0.92
5842,3519573,Table 3,BaselineCharacteristic,x.x,Mean ; ,xh. Using the needle guardx,None,9,2,3,No,1:No,1:No,,0.99
5842,3519573,Table 3,BaselineCharacteristic,x.x,SD ; ,xh. Using the needle guardx,None,9,3,3,No,1:No,1:No,,0.85
5842,3519573,Table 3,BaselineCharacteristic,x (x.x%),Floor (%) ; ,xh. Using the needle guardx,None,9,4,3,No,1:No,1:No,,0.97
5842,3519573,Table 3,BaselineCharacteristic,xx (xx.x%),Ceiling (%) ; ,xh. Using the needle guardx,None,9,5,3,No,1:No,1:No,,0.91
5842,3519573,Table 3,BaselineCharacteristic,x.x-x.x,Range ; ,xh. Using the needle guardx,None,9,6,3,No,1:No,1:No,,1
5842,3519573,Table 3,BaselineCharacteristic,xi. Injecting the medicine, ; ,xi. Injecting the medicine,None,10,0,2,No,1:No,1:No,,1
5842,3519573,Table 3,BaselineCharacteristic,xxx,N ; ,xi. Injecting the medicine,None,10,1,3,No,1:No,1:No,,0.95
5842,3519573,Table 3,BaselineCharacteristic,x.x,Mean ; ,xi. Injecting the medicine,None,10,2,3,No,1:No,1:No,,1
5842,3519573,Table 3,BaselineCharacteristic,x.x,SD ; ,xi. Injecting the medicine,None,10,3,3,No,1:No,1:No,,0.85
5842,3519573,Table 3,BaselineCharacteristic,x (x.x%),Floor (%) ; ,xi. Injecting the medicine,None,10,4,3,No,1:No,1:No,,0.96
5842,3519573,Table 3,BaselineCharacteristic,xx (xx.x%),Ceiling (%) ; ,xi. Injecting the medicine,None,10,5,3,No,1:No,1:No,,0.91
5842,3519573,Table 3,BaselineCharacteristic,x.x-x.x,Range ; ,xi. Injecting the medicine,None,10,6,3,No,1:No,1:No,,1
5842,3519573,Table 3,BaselineCharacteristic,xj. Knowing when the injection pen has finished injecting the medicine, ; ,xj. Knowing when the injection pen has finished injecting the medicine,None,11,0,2,No,1:No,1:No,,1
5842,3519573,Table 3,BaselineCharacteristic,xxx,N ; ,xj. Knowing when the injection pen has finished injecting the medicine,None,11,1,3,No,1:No,1:No,,0.96
5842,3519573,Table 3,BaselineCharacteristic,x.x,Mean ; ,xj. Knowing when the injection pen has finished injecting the medicine,None,11,2,3,No,1:No,1:No,,1
5842,3519573,Table 3,BaselineCharacteristic,x.x,SD ; ,xj. Knowing when the injection pen has finished injecting the medicine,None,11,3,3,No,1:No,1:No,,0.87
5842,3519573,Table 3,BaselineCharacteristic,xx (x.x%),Floor (%) ; ,xj. Knowing when the injection pen has finished injecting the medicine,None,11,4,3,No,1:No,1:No,,0.886
5842,3519573,Table 3,BaselineCharacteristic,xx (xx.x%),Ceiling (%) ; ,xj. Knowing when the injection pen has finished injecting the medicine,None,11,5,3,No,1:No,1:No,,0.92
5842,3519573,Table 3,BaselineCharacteristic,x.x-x.x,Range ; ,xj. Knowing when the injection pen has finished injecting the medicine,None,11,6,3,No,1:No,1:No,,1
5842,3519573,Table 3,BaselineCharacteristic,xk. Handling the injection pen while preparing and injecting the medicine, ; ,xk. Handling the injection pen while preparing and injecting the medicine,None,12,0,2,No,1:No,1:No,,1
5842,3519573,Table 3,BaselineCharacteristic,xxx,N ; ,xk. Handling the injection pen while preparing and injecting the medicine,None,12,1,3,No,1:No,1:No,,0.97
5842,3519573,Table 3,BaselineCharacteristic,x.x,Mean ; ,xk. Handling the injection pen while preparing and injecting the medicine,None,12,2,3,No,1:No,1:No,,1
5842,3519573,Table 3,BaselineCharacteristic,x.x,SD ; ,xk. Handling the injection pen while preparing and injecting the medicine,None,12,3,3,No,1:No,1:No,,0.87
5842,3519573,Table 3,BaselineCharacteristic,x (x.x%),Floor (%) ; ,xk. Handling the injection pen while preparing and injecting the medicine,None,12,4,3,No,1:No,1:No,,0.97
5842,3519573,Table 3,BaselineCharacteristic,xx (xx.x%),Ceiling (%) ; ,xk. Handling the injection pen while preparing and injecting the medicine,None,12,5,3,No,1:No,1:No,,0.93
5842,3519573,Table 3,BaselineCharacteristic,x.x-x.x,Range ; ,xk. Handling the injection pen while preparing and injecting the medicine,None,12,6,3,No,1:No,1:No,,1
5842,3519573,Table 3,BaselineCharacteristic,xl. Storing the injection pen in the refrigerator, ; ,xl. Storing the injection pen in the refrigerator,None,13,0,2,No,1:No,1:No,,0.91
5842,3519573,Table 3,BaselineCharacteristic,xxx,N ; ,xl. Storing the injection pen in the refrigerator,None,13,1,3,No,1:No,1:No,,0.85
5842,3519573,Table 3,BaselineCharacteristic,x.x,Mean ; ,xl. Storing the injection pen in the refrigerator,None,13,2,3,No,1:No,1:No,,0.91
5842,3519573,Table 3,BaselineCharacteristic,x.x,SD ; ,xl. Storing the injection pen in the refrigerator,None,13,3,3,No,1:No,1:No,,0.76
5842,3519573,Table 3,BaselineCharacteristic,x (x.x%),Floor (%) ; ,xl. Storing the injection pen in the refrigerator,None,13,4,3,No,1:No,1:No,,0.88
5842,3519573,Table 3,BaselineCharacteristic,xxx (xx.x%),Ceiling (%) ; ,xl. Storing the injection pen in the refrigerator,None,13,5,3,No,1:No,1:No,,0.83
5842,3519573,Table 3,BaselineCharacteristic,x.x-x.x,Range ; ,xl. Storing the injection pen in the refrigerator,None,13,6,3,No,1:No,1:No,,0.92
5842,3519573,Table 3,BaselineCharacteristic,xm. Disposing of the cartridge or disposing of the injection pen, ; ,xm. Disposing of the cartridge or disposing of the injection pen,None,14,0,2,No,1:No,1:No,,1
5842,3519573,Table 3,BaselineCharacteristic,xxx,N ; ,xm. Disposing of the cartridge or disposing of the injection pen,None,14,1,3,No,1:No,1:No,,0.94
5842,3519573,Table 3,BaselineCharacteristic,x.x,Mean ; ,xm. Disposing of the cartridge or disposing of the injection pen,None,14,2,3,No,1:No,1:No,,1
5842,3519573,Table 3,BaselineCharacteristic,x.x,SD ; ,xm. Disposing of the cartridge or disposing of the injection pen,None,14,3,3,No,1:No,1:No,,0.87
5842,3519573,Table 3,BaselineCharacteristic,x (x.x%),Floor (%) ; ,xm. Disposing of the cartridge or disposing of the injection pen,None,14,4,3,No,1:No,1:No,,0.97
5842,3519573,Table 3,BaselineCharacteristic,xx (xx.x%),Ceiling (%) ; ,xm. Disposing of the cartridge or disposing of the injection pen,None,14,5,3,No,1:No,1:No,,0.94
5842,3519573,Table 3,BaselineCharacteristic,x.x-x.x,Range ; ,xm. Disposing of the cartridge or disposing of the injection pen,None,14,6,3,No,1:No,1:No,,1
5842,3519573,Table 4,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
5842,3519573,Table 4,BaselineCharacteristic,N,,,None,0,1,1,No,1:No,1:No,,0.903
5842,3519573,Table 4,BaselineCharacteristic,Mean,,,None,0,2,1,No,1:No,1:No,,0.903
5842,3519573,Table 4,BaselineCharacteristic,SD,,,None,0,3,1,No,1:No,1:No,,0.765
5842,3519573,Table 4,BaselineCharacteristic,Floor (%),,,None,0,4,1,No,1:No,1:No,,0.833
5842,3519573,Table 4,BaselineCharacteristic,Ceiling (%),,,None,0,5,1,No,1:No,1:No,,0.856
5842,3519573,Table 4,BaselineCharacteristic,Range,,,None,0,6,1,No,1:No,1:No,,0.935
5842,3519573,Table 4,BaselineCharacteristic,x. Ease or difficulty of using the injection pen overall, ; ,x. Ease or difficulty of using the injection pen overall,None,1,0,2,No,1:No,1:No,,0.915
5842,3519573,Table 4,BaselineCharacteristic,xxx,N ; ,x. Ease or difficulty of using the injection pen overall,None,1,1,3,No,1:No,1:No,,0.88
5842,3519573,Table 4,BaselineCharacteristic,x.x,Mean ; ,x. Ease or difficulty of using the injection pen overall,None,1,2,3,No,1:No,1:No,,0.92
5842,3519573,Table 4,BaselineCharacteristic,x.x,SD ; ,x. Ease or difficulty of using the injection pen overall,None,1,3,3,No,1:No,1:No,,0.8
5842,3519573,Table 4,BaselineCharacteristic,x (x.x%),Floor (%) ; ,x. Ease or difficulty of using the injection pen overall,None,1,4,3,No,1:No,1:No,,0.86
5842,3519573,Table 4,BaselineCharacteristic,xx (xx.x%),Ceiling (%) ; ,x. Ease or difficulty of using the injection pen overall,None,1,5,3,No,1:No,1:No,,0.78
5842,3519573,Table 4,BaselineCharacteristic,x.x-x.x,Range ; ,x. Ease or difficulty of using the injection pen overall,None,1,6,3,No,1:No,1:No,,0.93
5842,3519573,Table 4,BaselineCharacteristic,xa. Attaching and removing the needle, ; ,xa. Attaching and removing the needle,None,2,0,2,No,1:No,1:No,,0.97
5842,3519573,Table 4,BaselineCharacteristic,xxx,N ; ,xa. Attaching and removing the needle,None,2,1,3,No,1:No,1:No,,0.85
5842,3519573,Table 4,BaselineCharacteristic,x.x,Mean ; ,xa. Attaching and removing the needle,None,2,2,3,No,1:No,1:No,,0.95
5842,3519573,Table 4,BaselineCharacteristic,x.x,SD ; ,xa. Attaching and removing the needle,None,2,3,3,No,1:No,1:No,,0.77
5842,3519573,Table 4,BaselineCharacteristic,x (x.x%),Floor (%) ; ,xa. Attaching and removing the needle,None,2,4,3,No,1:No,1:No,,0.86
5842,3519573,Table 4,BaselineCharacteristic,xxx (xx.x%),Ceiling (%) ; ,xa. Attaching and removing the needle,None,2,5,3,No,1:No,1:No,,0.73
5842,3519573,Table 4,BaselineCharacteristic,x.x-x.x,Range ; ,xa. Attaching and removing the needle,None,2,6,3,No,1:No,1:No,,0.95
5842,3519573,Table 4,BaselineCharacteristic,xb. Preparing the injection pen by changing the cartridge or getting a new injection pen, ; ,xb. Preparing the injection pen by changing the cartridge or getting a new injection pen,None,3,0,2,No,1:No,1:No,,0.9
5842,3519573,Table 4,BaselineCharacteristic,xxx,N ; ,xb. Preparing the injection pen by changing the cartridge or getting a new injection pen,None,3,1,3,No,1:No,1:No,,0.81
5842,3519573,Table 4,BaselineCharacteristic,x.x,Mean ; ,xb. Preparing the injection pen by changing the cartridge or getting a new injection pen,None,3,2,3,No,1:No,1:No,,0.89
5842,3519573,Table 4,BaselineCharacteristic,x.x,SD ; ,xb. Preparing the injection pen by changing the cartridge or getting a new injection pen,None,3,3,3,No,1:No,1:No,,0.76
5842,3519573,Table 4,BaselineCharacteristic,x (x.x%),Floor (%) ; ,xb. Preparing the injection pen by changing the cartridge or getting a new injection pen,None,3,4,3,No,1:No,1:No,,0.84
5842,3519573,Table 4,BaselineCharacteristic,xx (xx.x%),Ceiling (%) ; ,xb. Preparing the injection pen by changing the cartridge or getting a new injection pen,None,3,5,3,No,1:No,1:No,,0.69
5842,3519573,Table 4,BaselineCharacteristic,x.x-x.x,Range ; ,xb. Preparing the injection pen by changing the cartridge or getting a new injection pen,None,3,6,3,No,1:No,1:No,,0.91
5842,3519573,Table 4,BaselineCharacteristic,xc. Mixing the medicine, ; ,xc. Mixing the medicine,None,4,0,2,No,1:No,1:No,,0.97
5842,3519573,Table 4,BaselineCharacteristic,xxx,N ; ,xc. Mixing the medicine,None,4,1,3,No,1:No,1:No,,0.86
5842,3519573,Table 4,BaselineCharacteristic,x.x,Mean ; ,xc. Mixing the medicine,None,4,2,3,No,1:No,1:No,,0.96
5842,3519573,Table 4,BaselineCharacteristic,x.x,SD ; ,xc. Mixing the medicine,None,4,3,3,No,1:No,1:No,,0.8
5842,3519573,Table 4,BaselineCharacteristic,x (x.x%),Floor (%) ; ,xc. Mixing the medicine,None,4,4,3,No,1:No,1:No,,0.85
5842,3519573,Table 4,BaselineCharacteristic,xx (xx.x%),Ceiling (%) ; ,xc. Mixing the medicine,None,4,5,3,No,1:No,1:No,,0.77
5842,3519573,Table 4,BaselineCharacteristic,x.x-x.x,Range ; ,xc. Mixing the medicine,None,4,6,3,No,1:No,1:No,,0.95
5842,3519573,Table 4,BaselineCharacteristic,xd. Removing the air bubbles, ; ,xd. Removing the air bubbles,None,5,0,2,No,1:No,1:No,,0.98
5842,3519573,Table 4,BaselineCharacteristic,xxx,N ; ,xd. Removing the air bubbles,None,5,1,3,No,1:No,1:No,,0.87
5842,3519573,Table 4,BaselineCharacteristic,x.x,Mean ; ,xd. Removing the air bubbles,None,5,2,3,No,1:No,1:No,,0.97
5842,3519573,Table 4,BaselineCharacteristic,x.x,SD ; ,xd. Removing the air bubbles,None,5,3,3,No,1:No,1:No,,0.82
5842,3519573,Table 4,BaselineCharacteristic,x (x.x%),Floor (%) ; ,xd. Removing the air bubbles,None,5,4,3,No,1:No,1:No,,0.86
5842,3519573,Table 4,BaselineCharacteristic,xx (xx.x%),Ceiling (%) ; ,xd. Removing the air bubbles,None,5,5,3,No,1:No,1:No,,0.77
5842,3519573,Table 4,BaselineCharacteristic,x.x-x.x,Range ; ,xd. Removing the air bubbles,None,5,6,3,No,1:No,1:No,,0.95
5842,3519573,Table 4,BaselineCharacteristic,xe. Remembering the dose that was prescribed by the doctor, ; ,xe. Remembering the dose that was prescribed by the doctor,None,6,0,2,No,1:No,1:No,,0.98
5842,3519573,Table 4,BaselineCharacteristic,xxx,N ; ,xe. Remembering the dose that was prescribed by the doctor,None,6,1,3,No,1:No,1:No,,0.96
5842,3519573,Table 4,BaselineCharacteristic,x.x,Mean ; ,xe. Remembering the dose that was prescribed by the doctor,None,6,2,3,No,1:No,1:No,,0.98
5842,3519573,Table 4,BaselineCharacteristic,x.x,SD ; ,xe. Remembering the dose that was prescribed by the doctor,None,6,3,3,No,1:No,1:No,,0.85
5842,3519573,Table 4,BaselineCharacteristic,x (x.x%),Floor (%) ; ,xe. Remembering the dose that was prescribed by the doctor,None,6,4,3,No,1:No,1:No,,0.92
5842,3519573,Table 4,BaselineCharacteristic,xxx (xx.x%),Ceiling (%) ; ,xe. Remembering the dose that was prescribed by the doctor,None,6,5,3,No,1:No,1:No,,0.81
5842,3519573,Table 4,BaselineCharacteristic,x.x-x.x,Range ; ,xe. Remembering the dose that was prescribed by the doctor,None,6,6,3,No,1:No,1:No,,0.99
5842,3519573,Table 4,BaselineCharacteristic,xf. Setting the dose, ; ,xf. Setting the dose,None,7,0,2,No,1:No,1:No,,0.98
5842,3519573,Table 4,BaselineCharacteristic,xxx,N ; ,xf. Setting the dose,None,7,1,3,No,1:No,1:No,,0.925
5842,3519573,Table 4,BaselineCharacteristic,x.x,Mean ; ,xf. Setting the dose,None,7,2,3,No,1:No,1:No,,0.965
5842,3519573,Table 4,BaselineCharacteristic,x.x,SD ; ,xf. Setting the dose,None,7,3,3,No,1:No,1:No,,0.825
5842,3519573,Table 4,BaselineCharacteristic,x (x.x%),Floor (%) ; ,xf. Setting the dose,None,7,4,3,No,1:No,1:No,,0.925
5842,3519573,Table 4,BaselineCharacteristic,xxx (xx.x%),Ceiling (%) ; ,xf. Setting the dose,None,7,5,3,No,1:No,1:No,,0.815
5842,3519573,Table 4,BaselineCharacteristic,x.x-x.x,Range ; ,xf. Setting the dose,None,7,6,3,No,1:No,1:No,,0.975
5842,3519573,Table 4,BaselineCharacteristic,xg. Changing the dose when the doctor changes the prescription, ; ,xg. Changing the dose when the doctor changes the prescription,None,8,0,2,No,1:No,1:No,,0.98
5842,3519573,Table 4,BaselineCharacteristic,xx,N ; ,xg. Changing the dose when the doctor changes the prescription,None,8,1,3,No,1:No,1:No,,0.857
5842,3519573,Table 4,BaselineCharacteristic,x.x,Mean ; ,xg. Changing the dose when the doctor changes the prescription,None,8,2,3,No,1:No,1:No,,0.965
5842,3519573,Table 4,BaselineCharacteristic,x.x,SD ; ,xg. Changing the dose when the doctor changes the prescription,None,8,3,3,No,1:No,1:No,,0.825
5842,3519573,Table 4,BaselineCharacteristic,x (x.x%),Floor (%) ; ,xg. Changing the dose when the doctor changes the prescription,None,8,4,3,No,1:No,1:No,,0.925
5842,3519573,Table 4,BaselineCharacteristic,xx (xx.x%),Ceiling (%) ; ,xg. Changing the dose when the doctor changes the prescription,None,8,5,3,No,1:No,1:No,,0.855
5842,3519573,Table 4,BaselineCharacteristic,x.x-x.x,Range ; ,xg. Changing the dose when the doctor changes the prescription,None,8,6,3,No,1:No,1:No,,0.985
5842,3519573,Table 4,BaselineCharacteristic,xh. Using the needle guardx, ; ,xh. Using the needle guardx,None,9,0,2,No,1:No,1:No,,1
5842,3519573,Table 4,BaselineCharacteristic,xxx,N ; ,xh. Using the needle guardx,None,9,1,3,No,1:No,1:No,,0.92
5842,3519573,Table 4,BaselineCharacteristic,x.x,Mean ; ,xh. Using the needle guardx,None,9,2,3,No,1:No,1:No,,0.99
5842,3519573,Table 4,BaselineCharacteristic,x.x,SD ; ,xh. Using the needle guardx,None,9,3,3,No,1:No,1:No,,0.85
5842,3519573,Table 4,BaselineCharacteristic,x (x.x%),Floor (%) ; ,xh. Using the needle guardx,None,9,4,3,No,1:No,1:No,,0.97
5842,3519573,Table 4,BaselineCharacteristic,xx (xx.x%),Ceiling (%) ; ,xh. Using the needle guardx,None,9,5,3,No,1:No,1:No,,0.91
5842,3519573,Table 4,BaselineCharacteristic,x.x-x.x,Range ; ,xh. Using the needle guardx,None,9,6,3,No,1:No,1:No,,1
5842,3519573,Table 4,BaselineCharacteristic,xi. Injecting the medicine, ; ,xi. Injecting the medicine,None,10,0,2,No,1:No,1:No,,1
5842,3519573,Table 4,BaselineCharacteristic,xxx,N ; ,xi. Injecting the medicine,None,10,1,3,No,1:No,1:No,,0.95
5842,3519573,Table 4,BaselineCharacteristic,x.x,Mean ; ,xi. Injecting the medicine,None,10,2,3,No,1:No,1:No,,1
5842,3519573,Table 4,BaselineCharacteristic,x.x,SD ; ,xi. Injecting the medicine,None,10,3,3,No,1:No,1:No,,0.85
5842,3519573,Table 4,BaselineCharacteristic,x (x.x%),Floor (%) ; ,xi. Injecting the medicine,None,10,4,3,No,1:No,1:No,,0.96
5842,3519573,Table 4,BaselineCharacteristic,xx (xx.x%),Ceiling (%) ; ,xi. Injecting the medicine,None,10,5,3,No,1:No,1:No,,0.91
5842,3519573,Table 4,BaselineCharacteristic,x.x-x.x,Range ; ,xi. Injecting the medicine,None,10,6,3,No,1:No,1:No,,1
5842,3519573,Table 4,BaselineCharacteristic,xj. Knowing when the injection pen has finished injecting the medicine, ; ,xj. Knowing when the injection pen has finished injecting the medicine,None,11,0,2,No,1:No,1:No,,1
5842,3519573,Table 4,BaselineCharacteristic,xxx,N ; ,xj. Knowing when the injection pen has finished injecting the medicine,None,11,1,3,No,1:No,1:No,,0.96
5842,3519573,Table 4,BaselineCharacteristic,x.x,Mean ; ,xj. Knowing when the injection pen has finished injecting the medicine,None,11,2,3,No,1:No,1:No,,1
5842,3519573,Table 4,BaselineCharacteristic,x.x,SD ; ,xj. Knowing when the injection pen has finished injecting the medicine,None,11,3,3,No,1:No,1:No,,0.87
5842,3519573,Table 4,BaselineCharacteristic,x (x.x%),Floor (%) ; ,xj. Knowing when the injection pen has finished injecting the medicine,None,11,4,3,No,1:No,1:No,,0.97
5842,3519573,Table 4,BaselineCharacteristic,xx (xx.x%),Ceiling (%) ; ,xj. Knowing when the injection pen has finished injecting the medicine,None,11,5,3,No,1:No,1:No,,0.92
5842,3519573,Table 4,BaselineCharacteristic,x.x-x.x,Range ; ,xj. Knowing when the injection pen has finished injecting the medicine,None,11,6,3,No,1:No,1:No,,1
5842,3519573,Table 4,BaselineCharacteristic,xk. Handling the injection pen while preparing and injecting the medicine, ; ,xk. Handling the injection pen while preparing and injecting the medicine,None,12,0,2,No,1:No,1:No,,1
5842,3519573,Table 4,BaselineCharacteristic,xxx,N ; ,xk. Handling the injection pen while preparing and injecting the medicine,None,12,1,3,No,1:No,1:No,,0.97
5842,3519573,Table 4,BaselineCharacteristic,x.x,Mean ; ,xk. Handling the injection pen while preparing and injecting the medicine,None,12,2,3,No,1:No,1:No,,1
5842,3519573,Table 4,BaselineCharacteristic,x.x,SD ; ,xk. Handling the injection pen while preparing and injecting the medicine,None,12,3,3,No,1:No,1:No,,0.87
5842,3519573,Table 4,BaselineCharacteristic,x (x.x%),Floor (%) ; ,xk. Handling the injection pen while preparing and injecting the medicine,None,12,4,3,No,1:No,1:No,,0.97
5842,3519573,Table 4,BaselineCharacteristic,xx (xx.x%),Ceiling (%) ; ,xk. Handling the injection pen while preparing and injecting the medicine,None,12,5,3,No,1:No,1:No,,0.93
5842,3519573,Table 4,BaselineCharacteristic,x.x-x.x,Range ; ,xk. Handling the injection pen while preparing and injecting the medicine,None,12,6,3,No,1:No,1:No,,1
5842,3519573,Table 4,BaselineCharacteristic,xl. Storing the injection pen in the refrigerator, ; ,xl. Storing the injection pen in the refrigerator,None,13,0,2,No,1:No,1:No,,0.91
5842,3519573,Table 4,BaselineCharacteristic,xxx,N ; ,xl. Storing the injection pen in the refrigerator,None,13,1,3,No,1:No,1:No,,0.85
5842,3519573,Table 4,BaselineCharacteristic,x.x,Mean ; ,xl. Storing the injection pen in the refrigerator,None,13,2,3,No,1:No,1:No,,0.91
5842,3519573,Table 4,BaselineCharacteristic,x.x,SD ; ,xl. Storing the injection pen in the refrigerator,None,13,3,3,No,1:No,1:No,,0.76
5842,3519573,Table 4,BaselineCharacteristic,x (x.x%),Floor (%) ; ,xl. Storing the injection pen in the refrigerator,None,13,4,3,No,1:No,1:No,,0.88
5842,3519573,Table 4,BaselineCharacteristic,xx (xx.x%),Ceiling (%) ; ,xl. Storing the injection pen in the refrigerator,None,13,5,3,No,1:No,1:No,,0.83
5842,3519573,Table 4,BaselineCharacteristic,x.x-x.x,Range ; ,xl. Storing the injection pen in the refrigerator,None,13,6,3,No,1:No,1:No,,0.92
5842,3519573,Table 4,BaselineCharacteristic,xm. Disposing of the cartridge or disposing of the injection pen, ; ,xm. Disposing of the cartridge or disposing of the injection pen,None,14,0,2,No,1:No,1:No,,1
5842,3519573,Table 4,BaselineCharacteristic,xxx,N ; ,xm. Disposing of the cartridge or disposing of the injection pen,None,14,1,3,No,1:No,1:No,,0.94
5842,3519573,Table 4,BaselineCharacteristic,x.x,Mean ; ,xm. Disposing of the cartridge or disposing of the injection pen,None,14,2,3,No,1:No,1:No,,1
5842,3519573,Table 4,BaselineCharacteristic,x.x,SD ; ,xm. Disposing of the cartridge or disposing of the injection pen,None,14,3,3,No,1:No,1:No,,0.87
5842,3519573,Table 4,BaselineCharacteristic,x (x.x%),Floor (%) ; ,xm. Disposing of the cartridge or disposing of the injection pen,None,14,4,3,No,1:No,1:No,,0.97
5842,3519573,Table 4,BaselineCharacteristic,xx (xx.x%),Ceiling (%) ; ,xm. Disposing of the cartridge or disposing of the injection pen,None,14,5,3,No,1:No,1:No,,0.94
5842,3519573,Table 4,BaselineCharacteristic,x.x-x.x,Range ; ,xm. Disposing of the cartridge or disposing of the injection pen,None,14,6,3,No,1:No,1:No,,1
5842,3519573,Table 7,BaselineCharacteristic,Subscale/Total Score,,None,None,0,0,12,No,1:No,1:No,,0.905
5842,3519573,Table 7,BaselineCharacteristic,N,,Subscale/Total Score,None,0,1,1,No,1:No,1:No,,0.903
5842,3519573,Table 7,BaselineCharacteristic,Mean,,Subscale/Total Score,None,0,2,1,No,1:No,1:No,,0.904
5842,3519573,Table 7,BaselineCharacteristic,SD,,Subscale/Total Score,None,0,3,1,No,1:No,1:No,,0.765
5842,3519573,Table 7,BaselineCharacteristic,Floor (%),,Subscale/Total Score,None,0,4,1,No,1:No,1:No,,0.834
5842,3519573,Table 7,BaselineCharacteristic,Ceiling (%),,Subscale/Total Score,None,0,5,1,No,1:No,1:No,,0.857
5842,3519573,Table 7,BaselineCharacteristic,Range,,Subscale/Total Score,None,0,6,1,No,1:No,1:No,,0.935
5842,3519573,Table 7,BaselineCharacteristic,Overall ease of use,Subscale/Total Score ; ,Overall ease of use,None,1,0,2,No,1:No,1:No,,0.95
5842,3519573,Table 7,BaselineCharacteristic,xxx,N ; ,Overall ease of use,None,1,1,3,No,1:No,1:No,,0.81
5842,3519573,Table 7,BaselineCharacteristic,xx.x,Mean ; ,Overall ease of use,None,1,2,3,No,1:No,1:No,,0.652
5842,3519573,Table 7,BaselineCharacteristic,xx.x,SD ; ,Overall ease of use,None,1,3,3,No,1:No,1:No,,0.516
5842,3519573,Table 7,BaselineCharacteristic,x (x.x%),Floor (%) ; ,Overall ease of use,None,1,4,3,No,1:No,1:No,,0.78
5842,3519573,Table 7,BaselineCharacteristic,xx (xx.x%),Ceiling (%) ; ,Overall ease of use,None,1,5,3,No,1:No,1:No,,0.676
5842,3519573,Table 7,BaselineCharacteristic,x.x-xxx.x,Range ; ,Overall ease of use,None,1,6,3,No,1:No,1:No,,0.9
5842,3519573,Table 7,BaselineCharacteristic,Preparing the pen,Subscale/Total Score ; ,Preparing the pen,None,2,0,2,No,1:No,1:No,,0.95
5842,3519573,Table 7,BaselineCharacteristic,xxx,N ; ,Preparing the pen,None,2,1,3,No,1:No,1:No,,0.83
5842,3519573,Table 7,BaselineCharacteristic,xx.x,Mean ; ,Preparing the pen,None,2,2,3,No,1:No,1:No,,0.706
5842,3519573,Table 7,BaselineCharacteristic,x (x.x%),Floor (%) ; ,Preparing the pen,None,2,4,3,No,1:No,1:No,,0.82
5842,3519573,Table 7,BaselineCharacteristic,xx (xx.x%),Ceiling (%) ; ,Preparing the pen,None,2,5,3,No,1:No,1:No,,0.72
5842,3519573,Table 7,BaselineCharacteristic,xx.x-xxx.x,Range ; ,Preparing the pen,None,2,6,3,No,1:No,1:No,,0.7
5842,3519573,Table 7,BaselineCharacteristic,Setting the dose,Subscale/Total Score ; ,Setting the dose,None,3,0,2,No,1:No,1:No,,0.96
5842,3519573,Table 7,BaselineCharacteristic,xxx,N ; ,Setting the dose,None,3,1,3,No,1:No,1:No,,0.875
5842,3519573,Table 7,BaselineCharacteristic,xx.x,Mean ; ,Setting the dose,None,3,2,3,No,1:No,1:No,,0.751
5842,3519573,Table 7,BaselineCharacteristic,xx.x,SD ; ,Setting the dose,None,3,3,3,No,1:No,1:No,,0.551
5842,3519573,Table 7,BaselineCharacteristic,x (x.x%),Floor (%) ; ,Setting the dose,None,3,4,3,No,1:No,1:No,,0.845
5842,3519573,Table 7,BaselineCharacteristic,xx (xx.x%),Ceiling (%) ; ,Setting the dose,None,3,5,3,No,1:No,1:No,,0.725
5842,3519573,Table 7,BaselineCharacteristic,xx.x-xxx.x,Range ; ,Setting the dose,None,3,6,3,No,1:No,1:No,,0.735
5842,3519573,Table 7,BaselineCharacteristic,Injecting the medicine,Subscale/Total Score ; ,Injecting the medicine,None,4,0,2,No,1:No,1:No,,0.97
5842,3519573,Table 7,BaselineCharacteristic,xxx,N ; ,Injecting the medicine,None,4,1,3,No,1:No,1:No,,0.86
5842,3519573,Table 7,BaselineCharacteristic,xx.x,Mean ; ,Injecting the medicine,None,4,2,3,No,1:No,1:No,,0.806
5842,3519573,Table 7,BaselineCharacteristic,xx.x,SD ; ,Injecting the medicine,None,4,3,3,No,1:No,1:No,,0.586
5842,3519573,Table 7,BaselineCharacteristic,x (x.x%),Floor (%) ; ,Injecting the medicine,None,4,4,3,No,1:No,1:No,,0.85
5842,3519573,Table 7,BaselineCharacteristic,xx (xx.x%),Ceiling (%) ; ,Injecting the medicine,None,4,5,3,No,1:No,1:No,,0.77
5842,3519573,Table 7,BaselineCharacteristic,x.x-xxx.x,Range ; ,Injecting the medicine,None,4,6,3,No,1:No,1:No,,0.94
5842,3519573,Table 7,BaselineCharacteristic,Maintaining the pen,Subscale/Total Score ; ,Maintaining the pen,None,5,0,2,No,1:No,1:No,,0.97
5842,3519573,Table 7,BaselineCharacteristic,xxx,N ; ,Maintaining the pen,None,5,1,3,No,1:No,1:No,,0.85
5842,3519573,Table 7,BaselineCharacteristic,xx.x,Mean ; ,Maintaining the pen,None,5,2,3,No,1:No,1:No,,0.796
5842,3519573,Table 7,BaselineCharacteristic,xx.x,SD ; ,Maintaining the pen,None,5,3,3,No,1:No,1:No,,0.596
5842,3519573,Table 7,BaselineCharacteristic,x (x.x%),Floor (%) ; ,Maintaining the pen,None,5,4,3,No,1:No,1:No,,0.85
5842,3519573,Table 7,BaselineCharacteristic,xx (xx.x%),Ceiling (%) ; ,Maintaining the pen,None,5,5,3,No,1:No,1:No,,0.75
5842,3519573,Table 7,BaselineCharacteristic,xx.x-xxx.x,Range ; ,Maintaining the pen,None,5,6,3,No,1:No,1:No,,0.77
5842,3519573,Table 7,BaselineCharacteristic,Total IPAQ score,Subscale/Total Score ; ,Total IPAQ score,None,6,0,2,No,1:No,1:No,,0.99
5842,3519573,Table 7,BaselineCharacteristic,xxx,N ; ,Total IPAQ score,None,6,1,3,No,1:No,1:No,,0.89
5842,3519573,Table 7,BaselineCharacteristic,xx.x,Mean ; ,Total IPAQ score,None,6,2,3,No,1:No,1:No,,0.8
5842,3519573,Table 7,BaselineCharacteristic,xx.x,SD ; ,Total IPAQ score,None,6,3,3,No,1:No,1:No,,0.56
5842,3519573,Table 7,BaselineCharacteristic,x (x.x%),Floor (%) ; ,Total IPAQ score,None,6,4,3,No,1:No,1:No,,0.92
5842,3519573,Table 7,BaselineCharacteristic,xx (x.x%),Ceiling (%) ; ,Total IPAQ score,None,6,5,3,No,1:No,1:No,,0.76
5842,3519573,Table 7,BaselineCharacteristic,xx.x-xxx.x,Range ; ,Total IPAQ score,None,6,6,3,No,1:No,1:No,,0.78
5842,3519573,Table 8,BaselineCharacteristic,Subscale/Total Score,,None,None,0,0,12,No,1:No,1:No,,0.905
5842,3519573,Table 8,BaselineCharacteristic,N,,Subscale/Total Score,None,0,1,1,No,1:No,1:No,,0.903
5842,3519573,Table 8,BaselineCharacteristic,Mean,,Subscale/Total Score,None,0,2,1,No,1:No,1:No,,0.904
5842,3519573,Table 8,BaselineCharacteristic,SD,,Subscale/Total Score,None,0,3,1,No,1:No,1:No,,0.765
5842,3519573,Table 8,BaselineCharacteristic,Floor (%),,Subscale/Total Score,None,0,4,1,No,1:No,1:No,,0.834
5842,3519573,Table 8,BaselineCharacteristic,Ceiling (%),,Subscale/Total Score,None,0,5,1,No,1:No,1:No,,0.857
5842,3519573,Table 8,BaselineCharacteristic,Range,,Subscale/Total Score,None,0,6,1,No,1:No,1:No,,0.935
5842,3519573,Table 8,BaselineCharacteristic,Overall ease of use,Subscale/Total Score ; ,Overall ease of use,None,1,0,2,No,1:No,1:No,,0.95
5842,3519573,Table 8,BaselineCharacteristic,xxx,N ; ,Overall ease of use,None,1,1,3,No,1:No,1:No,,0.81
5842,3519573,Table 8,BaselineCharacteristic,xx.x,Mean ; ,Overall ease of use,None,1,2,3,No,1:No,1:No,,0.652
5842,3519573,Table 8,BaselineCharacteristic,xx.x,SD ; ,Overall ease of use,None,1,3,3,No,1:No,1:No,,0.516
5842,3519573,Table 8,BaselineCharacteristic,x (x.x%),Floor (%) ; ,Overall ease of use,None,1,4,3,No,1:No,1:No,,0.78
5842,3519573,Table 8,BaselineCharacteristic,xx (xx.x%),Ceiling (%) ; ,Overall ease of use,None,1,5,3,No,1:No,1:No,,0.676
5842,3519573,Table 8,BaselineCharacteristic,x.x-xxx.x,Range ; ,Overall ease of use,None,1,6,3,No,1:No,1:No,,0.9
5842,3519573,Table 8,BaselineCharacteristic,Preparing pen,Subscale/Total Score ; ,Preparing pen,None,2,0,2,No,1:No,1:No,,0.95
5842,3519573,Table 8,BaselineCharacteristic,xxx,N ; ,Preparing pen,None,2,1,3,No,1:No,1:No,,0.8
5842,3519573,Table 8,BaselineCharacteristic,xx.x,Mean ; ,Preparing pen,None,2,2,3,No,1:No,1:No,,0.652
5842,3519573,Table 8,BaselineCharacteristic,x (x.x%),Floor (%) ; ,Preparing pen,None,2,4,3,No,1:No,1:No,,0.79
5842,3519573,Table 8,BaselineCharacteristic,xx (xx.x%),Ceiling (%) ; ,Preparing pen,None,2,5,3,No,1:No,1:No,,0.686
5842,3519573,Table 8,BaselineCharacteristic,xx.x-xxx.x,Range ; ,Preparing pen,None,2,6,3,No,1:No,1:No,,0.656
5842,3519573,Table 8,BaselineCharacteristic,Setting the dose,Subscale/Total Score ; ,Setting the dose,None,3,0,2,No,1:No,1:No,,0.96
5842,3519573,Table 8,BaselineCharacteristic,xxx,N ; ,Setting the dose,None,3,1,3,No,1:No,1:No,,0.875
5842,3519573,Table 8,BaselineCharacteristic,xx.x,Mean ; ,Setting the dose,None,3,2,3,No,1:No,1:No,,0.751
5842,3519573,Table 8,BaselineCharacteristic,xx.x,SD ; ,Setting the dose,None,3,3,3,No,1:No,1:No,,0.551
5842,3519573,Table 8,BaselineCharacteristic,x (x.x%),Floor (%) ; ,Setting the dose,None,3,4,3,No,1:No,1:No,,0.845
5842,3519573,Table 8,BaselineCharacteristic,xx (xx.x%),Ceiling (%) ; ,Setting the dose,None,3,5,3,No,1:No,1:No,,0.725
5842,3519573,Table 8,BaselineCharacteristic,xx.x-xxx.x,Range ; ,Setting the dose,None,3,6,3,No,1:No,1:No,,0.735
5842,3519573,Table 8,BaselineCharacteristic,Injecting the medicine,Subscale/Total Score ; ,Injecting the medicine,None,4,0,2,No,1:No,1:No,,0.97
5842,3519573,Table 8,BaselineCharacteristic,xxx,N ; ,Injecting the medicine,None,4,1,3,No,1:No,1:No,,0.86
5842,3519573,Table 8,BaselineCharacteristic,xx.x,Mean ; ,Injecting the medicine,None,4,2,3,No,1:No,1:No,,0.806
5842,3519573,Table 8,BaselineCharacteristic,xx.x,SD ; ,Injecting the medicine,None,4,3,3,No,1:No,1:No,,0.586
5842,3519573,Table 8,BaselineCharacteristic,x (x.x%),Floor (%) ; ,Injecting the medicine,None,4,4,3,No,1:No,1:No,,0.85
5842,3519573,Table 8,BaselineCharacteristic,xx (xx.x%),Ceiling (%) ; ,Injecting the medicine,None,4,5,3,No,1:No,1:No,,0.77
5842,3519573,Table 8,BaselineCharacteristic,xx.x-xxx.x,Range ; ,Injecting the medicine,None,4,6,3,No,1:No,1:No,,0.8
5842,3519573,Table 8,BaselineCharacteristic,Maintaining the pen,Subscale/Total Score ; ,Maintaining the pen,None,5,0,2,No,1:No,1:No,,0.97
5842,3519573,Table 8,BaselineCharacteristic,xxx,N ; ,Maintaining the pen,None,5,1,3,No,1:No,1:No,,0.85
5842,3519573,Table 8,BaselineCharacteristic,xx.x,Mean ; ,Maintaining the pen,None,5,2,3,No,1:No,1:No,,0.796
5842,3519573,Table 8,BaselineCharacteristic,xx.x,SD ; ,Maintaining the pen,None,5,3,3,No,1:No,1:No,,0.596
5842,3519573,Table 8,BaselineCharacteristic,x (x.x%),Floor (%) ; ,Maintaining the pen,None,5,4,3,No,1:No,1:No,,0.85
5842,3519573,Table 8,BaselineCharacteristic,xx (xx.x%),Ceiling (%) ; ,Maintaining the pen,None,5,5,3,No,1:No,1:No,,0.75
5842,3519573,Table 8,BaselineCharacteristic,xx.x-xxx.x,Range ; ,Maintaining the pen,None,5,6,3,No,1:No,1:No,,0.77
5842,3519573,Table 8,BaselineCharacteristic,Total IPAQ score,Subscale/Total Score ; ,Total IPAQ score,None,6,0,2,No,1:No,1:No,,0.99
5842,3519573,Table 8,BaselineCharacteristic,xxx,N ; ,Total IPAQ score,None,6,1,3,No,1:No,1:No,,0.89
5842,3519573,Table 8,BaselineCharacteristic,xx.x,Mean ; ,Total IPAQ score,None,6,2,3,No,1:No,1:No,,0.8
5842,3519573,Table 8,BaselineCharacteristic,xx.x,SD ; ,Total IPAQ score,None,6,3,3,No,1:No,1:No,,0.56
5842,3519573,Table 8,BaselineCharacteristic,x (x.x%),Floor (%) ; ,Total IPAQ score,None,6,4,3,No,1:No,1:No,,0.92
5842,3519573,Table 8,BaselineCharacteristic,xx (xx.x%),Ceiling (%) ; ,Total IPAQ score,None,6,5,3,No,1:No,1:No,,0.82
5842,3519573,Table 8,BaselineCharacteristic,xx.x-xxx.x,Range ; ,Total IPAQ score,None,6,6,3,No,1:No,1:No,,0.78
5937,3539065,Table 3,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
5937,3539065,Table 3,BaselineCharacteristic,Cohort x,,,None,0,1,1,No,1:No,1:No,,0.788
5937,3539065,Table 3,BaselineCharacteristic,Cohort x,,,None,0,2,1,No,1:No,1:No,,0.77
5937,3539065,Table 3,BaselineCharacteristic,Cohort x,,,None,0,3,1,No,1:No,1:No,,0.76
5937,3539065,Table 3,BaselineCharacteristic,Cohort x,,,None,0,4,1,No,1:No,1:No,,0.77
5937,3539065,Table 3,BaselineCharacteristic,Cohort x,,,None,0,5,1,No,1:No,1:No,,0.801
5937,3539065,Table 3,BaselineCharacteristic,, ; ,None,None,1,0,12,No,1:No,1:No,,0.898
5937,3539065,Table 3,BaselineCharacteristic,"Lapatinib x,xxx mg + placebo",Cohort x ; ,,None,1,1,1,No,1:No,1:No,,0.73
5937,3539065,Table 3,BaselineCharacteristic,"Lapatinib x,xxx mg + pazopanib xxx mg",Cohort x ; ,,None,1,2,1,No,1:No,1:No,,0.743
5937,3539065,Table 3,BaselineCharacteristic,"Lapatinib x,xxx mg + placebo",Cohort x ; ,,None,1,3,1,No,1:No,1:No,,0.703
5937,3539065,Table 3,BaselineCharacteristic,"Lapatinib x,xxx mg + pazopanib xxx mg",Cohort x ; ,,None,1,4,1,No,1:No,1:No,,0.743
5937,3539065,Table 3,BaselineCharacteristic,Pazopanib xxx mg,Cohort x ; ,,None,1,5,1,No,1:No,1:No,,0.794
5937,3539065,Table 3,BaselineCharacteristic,"Modified intent-to-treat population, n", ;  ; ,"Modified intent-to-treat population, n",,2,0,2,No,1:No,1:No,,0.816
5937,3539065,Table 3,BaselineCharacteristic,"Mean age, years (SD)", ;  ; ,"Mean age, years (SD)",,3,0,2,No,1:No,1:No,,0.518
5937,3539065,Table 3,BaselineCharacteristic,"White, n (%)", ;  ; ,"White, n (%)",,4,0,2,No,1:No,1:No,,0.836
5937,3539065,Table 3,BaselineCharacteristic,xx (xx),"Cohort x ; Lapatinib x,xxx mg + pazopanib xxx mg ; ","White, n (%)",,4,4,3,No,1:No,1:No,,0.506
5937,3539065,Table 3,BaselineCharacteristic,x (xx),Cohort x ; Pazopanib xxx mg ; ,"White, n (%)",,4,5,3,No,1:No,1:No,,0.506
5937,3539065,Table 3,BaselineCharacteristic,"Asian, n (%)", ;  ; ,"Asian, n (%)",,5,0,2,No,1:No,1:No,,0.826
5937,3539065,Table 3,BaselineCharacteristic,"Radiologically measurable disease, n (%)a", ;  ; ,"Radiologically measurable disease, n (%)a",,6,0,2,No,1:No,1:No,,0.846
5937,3539065,Table 3,BaselineCharacteristic,xx (xx),"Cohort x ; Lapatinib x,xxx mg + pazopanib xxx mg ; ","Radiologically measurable disease, n (%)a",,6,4,3,No,1:No,1:No,,0.511
5937,3539065,Table 3,BaselineCharacteristic,xx (xx),Cohort x ; Pazopanib xxx mg ; ,"Radiologically measurable disease, n (%)a",,6,5,3,No,1:No,1:No,,0.516
5937,3539065,Table 3,BaselineCharacteristic,"Cutaneous disease, n (%)b", ;  ; ,"Cutaneous disease, n (%)b",,7,0,2,No,1:No,1:No,,0.836
5937,3539065,Table 3,BaselineCharacteristic,"Stage, n (%)", ;  ; ,None,None,8,0,24,No,1:No,1:No,,0.89
5937,3539065,Table 3,BaselineCharacteristic,,"Cohort x ; Lapatinib x,xxx mg + placebo ; ","Stage, n (%)",None,8,1,43,No,1:No,1:No,,0.759
5937,3539065,Table 3,BaselineCharacteristic,,"Cohort x ; Lapatinib x,xxx mg + pazopanib xxx mg ; ","Stage, n (%)",None,8,2,43,No,1:No,1:No,,0.775
5937,3539065,Table 3,BaselineCharacteristic,,"Cohort x ; Lapatinib x,xxx mg + placebo ; ","Stage, n (%)",None,8,3,43,No,1:No,1:No,,0.765
5937,3539065,Table 3,BaselineCharacteristic,,"Cohort x ; Lapatinib x,xxx mg + pazopanib xxx mg ; ","Stage, n (%)",None,8,4,43,No,1:No,1:No,,0.775
5937,3539065,Table 3,BaselineCharacteristic,,Cohort x ; Pazopanib xxx mg ; ,"Stage, n (%)",None,8,5,43,No,1:No,1:No,,0.785
5937,3539065,Table 3,BaselineCharacteristic,, ;  ; ,," Stage, n (%)",9,0,2,No,1:No,1:No,,0.896
5937,3539065,Table 3,BaselineCharacteristic,x (xx),"Cohort x ; Lapatinib x,xxx mg + placebo ; ",," Stage, n (%)",9,1,3,No,1:No,1:No,,0.561
5937,3539065,Table 3,BaselineCharacteristic,x (xx),"Cohort x ; Lapatinib x,xxx mg + pazopanib xxx mg ; ",," Stage, n (%)",9,2,3,No,1:No,1:No,,0.591
5937,3539065,Table 3,BaselineCharacteristic,x (xx),"Cohort x ; Lapatinib x,xxx mg + placebo ; ",," Stage, n (%)",9,3,3,No,1:No,1:No,,0.571
5937,3539065,Table 3,BaselineCharacteristic,xx (xx),"Cohort x ; Lapatinib x,xxx mg + pazopanib xxx mg ; ",," Stage, n (%)",9,4,3,No,1:No,1:No,,0.621
5937,3539065,Table 3,BaselineCharacteristic,x (xx),Cohort x ; Pazopanib xxx mg ; ,," Stage, n (%)",9,5,3,No,1:No,1:No,,0.636
5937,3539065,Table 3,BaselineCharacteristic,, ;  ; ,," Stage, n (%)",10,0,2,No,1:No,1:No,,0.906
5937,3539065,Table 3,BaselineCharacteristic,xx (xx),"Cohort x ; Lapatinib x,xxx mg + placebo ; ",," Stage, n (%)",10,1,3,No,1:No,1:No,,0.601
5937,3539065,Table 3,BaselineCharacteristic,xx (xx),"Cohort x ; Lapatinib x,xxx mg + pazopanib xxx mg ; ",," Stage, n (%)",10,2,3,No,1:No,1:No,,0.621
5937,3539065,Table 3,BaselineCharacteristic,xx (xx)c,"Cohort x ; Lapatinib x,xxx mg + placebo ; ",," Stage, n (%)",10,3,3,No,1:No,1:No,,0.621
5937,3539065,Table 3,BaselineCharacteristic,xx (xx)d,"Cohort x ; Lapatinib x,xxx mg + pazopanib xxx mg ; ",," Stage, n (%)",10,4,3,No,1:No,1:No,,0.651
5937,3539065,Table 3,BaselineCharacteristic,xx (xx),Cohort x ; Pazopanib xxx mg ; ,," Stage, n (%)",10,5,3,No,1:No,1:No,,0.666
5937,3539065,Table 3,BaselineCharacteristic,"Prior trastuzumab therapy, n (%)", ;  ; ,"Prior trastuzumab therapy, n (%)"," Stage, n (%)",11,0,2,No,1:No,1:No,,0.936
5937,3539065,Table 3,BaselineCharacteristic,xx (xx),"Cohort x ; Lapatinib x,xxx mg + placebo ; ","Prior trastuzumab therapy, n (%)"," Stage, n (%)",11,1,3,No,1:No,1:No,,0.671
5937,3539065,Table 3,BaselineCharacteristic,xx (xx),"Cohort x ; Lapatinib x,xxx mg + pazopanib xxx mg ; ","Prior trastuzumab therapy, n (%)"," Stage, n (%)",11,2,3,No,1:No,1:No,,0.681
5937,3539065,Table 3,BaselineCharacteristic,xx (xx),"Cohort x ; Lapatinib x,xxx mg + placebo ; ","Prior trastuzumab therapy, n (%)"," Stage, n (%)",11,3,3,No,1:No,1:No,,0.671
5937,3539065,Table 3,BaselineCharacteristic,xx (xx),"Cohort x ; Lapatinib x,xxx mg + pazopanib xxx mg ; ","Prior trastuzumab therapy, n (%)"," Stage, n (%)",11,4,3,No,1:No,1:No,,0.701
5937,3539065,Table 3,BaselineCharacteristic,x (xx),Cohort x ; Pazopanib xxx mg ; ,"Prior trastuzumab therapy, n (%)"," Stage, n (%)",11,5,3,No,1:No,1:No,,0.716
5937,3539065,Table 3,BaselineCharacteristic,"Prior chemotherapy, n (%)", ;  ; ,"Prior chemotherapy, n (%)"," Stage, n (%)",12,0,2,No,1:No,1:No,,0.916
5937,3539065,Table 3,BaselineCharacteristic,xx (xxx),"Cohort x ; Lapatinib x,xxx mg + placebo ; ","Prior chemotherapy, n (%)"," Stage, n (%)",12,1,3,No,1:No,1:No,,0.686
5937,3539065,Table 3,BaselineCharacteristic,xx (xx),"Cohort x ; Lapatinib x,xxx mg + pazopanib xxx mg ; ","Prior chemotherapy, n (%)"," Stage, n (%)",12,2,3,No,1:No,1:No,,0.696
5937,3539065,Table 3,BaselineCharacteristic,xx (xxx),"Cohort x ; Lapatinib x,xxx mg + placebo ; ","Prior chemotherapy, n (%)"," Stage, n (%)",12,3,3,No,1:No,1:No,,0.666
5937,3539065,Table 3,BaselineCharacteristic,xx (xx),"Cohort x ; Lapatinib x,xxx mg + pazopanib xxx mg ; ","Prior chemotherapy, n (%)"," Stage, n (%)",12,4,3,No,1:No,1:No,,0.716
5937,3539065,Table 3,BaselineCharacteristic,xx (xxx),Cohort x ; Pazopanib xxx mg ; ,"Prior chemotherapy, n (%)"," Stage, n (%)",12,5,3,No,1:No,1:No,,0.73
5937,3539065,Table 3,BaselineCharacteristic,"Prior biologic therapy, n (%)", ;  ; ,"Prior biologic therapy, n (%)"," Stage, n (%)",13,0,2,No,1:No,1:No,,0.916
5937,3539065,Table 3,BaselineCharacteristic,xx (xx),"Cohort x ; Lapatinib x,xxx mg + placebo ; ","Prior biologic therapy, n (%)"," Stage, n (%)",13,1,3,No,1:No,1:No,,0.621
5937,3539065,Table 3,BaselineCharacteristic,xx (xx),"Cohort x ; Lapatinib x,xxx mg + pazopanib xxx mg ; ","Prior biologic therapy, n (%)"," Stage, n (%)",13,2,3,No,1:No,1:No,,0.641
5937,3539065,Table 3,BaselineCharacteristic,xx (xx),"Cohort x ; Lapatinib x,xxx mg + placebo ; ","Prior biologic therapy, n (%)"," Stage, n (%)",13,3,3,No,1:No,1:No,,0.621
5937,3539065,Table 3,BaselineCharacteristic,xx (xx),"Cohort x ; Lapatinib x,xxx mg + pazopanib xxx mg ; ","Prior biologic therapy, n (%)"," Stage, n (%)",13,4,3,No,1:No,1:No,,0.671
5937,3539065,Table 3,BaselineCharacteristic,x (xx),Cohort x ; Pazopanib xxx mg ; ,"Prior biologic therapy, n (%)"," Stage, n (%)",13,5,3,No,1:No,1:No,,0.686
5937,3539065,Table 3,BaselineCharacteristic,"Prior radiotherapy, n (%)", ;  ; ,"Prior radiotherapy, n (%)"," Stage, n (%)",14,0,2,No,1:No,1:No,,0.906
5937,3539065,Table 3,BaselineCharacteristic,xx (xx),"Cohort x ; Lapatinib x,xxx mg + placebo ; ","Prior radiotherapy, n (%)"," Stage, n (%)",14,1,3,No,1:No,1:No,,0.601
5937,3539065,Table 3,BaselineCharacteristic,xx (xx),"Cohort x ; Lapatinib x,xxx mg + pazopanib xxx mg ; ","Prior radiotherapy, n (%)"," Stage, n (%)",14,2,3,No,1:No,1:No,,0.621
5937,3539065,Table 3,BaselineCharacteristic,xx (xx),"Cohort x ; Lapatinib x,xxx mg + placebo ; ","Prior radiotherapy, n (%)"," Stage, n (%)",14,3,3,No,1:No,1:No,,0.601
5937,3539065,Table 3,BaselineCharacteristic,xx (xx),"Cohort x ; Lapatinib x,xxx mg + pazopanib xxx mg ; ","Prior radiotherapy, n (%)"," Stage, n (%)",14,4,3,No,1:No,1:No,,0.641
5937,3539065,Table 3,BaselineCharacteristic,xx (xx),Cohort x ; Pazopanib xxx mg ; ,"Prior radiotherapy, n (%)"," Stage, n (%)",14,5,3,No,1:No,1:No,,0.656
5937,3539065,Table 3,BaselineCharacteristic,"Prior hormonal therapy, n (%)", ;  ; ,"Prior hormonal therapy, n (%)"," Stage, n (%)",15,0,2,No,1:No,1:No,,0.916
5937,3539065,Table 3,BaselineCharacteristic,x (xx),"Cohort x ; Lapatinib x,xxx mg + placebo ; ","Prior hormonal therapy, n (%)"," Stage, n (%)",15,1,3,No,1:No,1:No,,0.611
5937,3539065,Table 3,BaselineCharacteristic,x (xx),"Cohort x ; Lapatinib x,xxx mg + pazopanib xxx mg ; ","Prior hormonal therapy, n (%)"," Stage, n (%)",15,2,3,No,1:No,1:No,,0.631
5937,3539065,Table 3,BaselineCharacteristic,x (xx),"Cohort x ; Lapatinib x,xxx mg + placebo ; ","Prior hormonal therapy, n (%)"," Stage, n (%)",15,3,3,No,1:No,1:No,,0.611
5937,3539065,Table 3,BaselineCharacteristic,x (xx),"Cohort x ; Lapatinib x,xxx mg + pazopanib xxx mg ; ","Prior hormonal therapy, n (%)"," Stage, n (%)",15,4,3,No,1:No,1:No,,0.651
5937,3539065,Table 3,BaselineCharacteristic,x (xx),Cohort x ; Pazopanib xxx mg ; ,"Prior hormonal therapy, n (%)"," Stage, n (%)",15,5,3,No,1:No,1:No,,0.666
6034,3553405,Table 1,BaselineCharacteristic,Characteristics,,None,None,0,0,12,No,1:No,1:No,,0.905
6034,3553405,Table 1,BaselineCharacteristic,Cilengitide xxx mg/mxn?=?xx,,Characteristics,None,0,1,1,No,1:No,1:No,,0.547
6034,3553405,Table 1,BaselineCharacteristic,Cilengitide xxx mg/mxn?=?xx,,Characteristics,None,0,2,1,No,1:No,1:No,,0.527
6034,3553405,Table 1,BaselineCharacteristic,Cilengitide xxx mg/mxn?=?xx,,Characteristics,None,0,3,1,No,1:No,1:No,,0.537
6034,3553405,Table 1,BaselineCharacteristic,Docetaxel xx mg/mxn?=?xx,,Characteristics,None,0,4,1,No,1:No,1:No,,0.625
6034,3553405,Table 1,BaselineCharacteristic,Total n?=?xxx,,Characteristics,None,0,5,1,No,1:No,1:No,,0.593
6034,3553405,Table 1,BaselineCharacteristic,"Male/female, n (%)",Characteristics ; ,"Male/female, n (%)",,1,0,2,No,1:No,1:No,,0.776
6034,3553405,Table 1,BaselineCharacteristic,xx/xx (xx/xx),Cilengitide xxx mg/mxn?=?xx ; ,"Male/female, n (%)",,1,1,3,No,1:No,1:No,,0.546
6034,3553405,Table 1,BaselineCharacteristic,xx/xx (xx/xx),Cilengitide xxx mg/mxn?=?xx ; ,"Male/female, n (%)",,1,2,3,No,1:No,1:No,,0.566
6034,3553405,Table 1,BaselineCharacteristic,xx/xx (xx/xx),Cilengitide xxx mg/mxn?=?xx ; ,"Male/female, n (%)",,1,3,3,No,1:No,1:No,,0.576
6034,3553405,Table 1,BaselineCharacteristic,xx/xx (xx/xx),Docetaxel xx mg/mxn?=?xx ; ,"Male/female, n (%)",,1,4,3,No,1:No,1:No,,0.636
6034,3553405,Table 1,BaselineCharacteristic,xx/xx (xx/xx),Total n?=?xxx ; ,"Male/female, n (%)",,1,5,3,No,1:No,1:No,,0.62
6034,3553405,Table 1,BaselineCharacteristic,"Mean age (range), yrs",Characteristics ; ,"Mean age (range), yrs",,2,0,2,No,1:No,1:No,,0.53
6034,3553405,Table 1,BaselineCharacteristic,Karnofsky PS n (%),Characteristics ; ,None,None,3,0,24,No,1:No,1:No,,0.81
6034,3553405,Table 1,BaselineCharacteristic,Karnofsky PS n (%),Cilengitide xxx mg/mxn?=?xx ; ,Karnofsky PS n (%),None,3,1,43,No,1:No,1:No,,0.566
6034,3553405,Table 1,BaselineCharacteristic,Karnofsky PS n (%),Cilengitide xxx mg/mxn?=?xx ; ,Karnofsky PS n (%),None,3,2,43,No,1:No,1:No,,0.576
6034,3553405,Table 1,BaselineCharacteristic,Karnofsky PS n (%),Cilengitide xxx mg/mxn?=?xx ; ,Karnofsky PS n (%),None,3,3,43,No,1:No,1:No,,0.606
6034,3553405,Table 1,BaselineCharacteristic,Karnofsky PS n (%),Docetaxel xx mg/mxn?=?xx ; ,Karnofsky PS n (%),None,3,4,43,No,1:No,1:No,,0.696
6034,3553405,Table 1,BaselineCharacteristic,Karnofsky PS n (%),Total n?=?xxx ; ,Karnofsky PS n (%),None,3,5,43,No,1:No,1:No,,0.687
6034,3553405,Table 1,BaselineCharacteristic,,Characteristics ; ,, Karnofsky PS n (%),4,0,2,No,1:No,1:No,,0.816
6034,3553405,Table 1,BaselineCharacteristic,x (xx),Cilengitide xxx mg/mxn?=?xx ; ,, Karnofsky PS n (%),4,1,3,No,1:No,1:No,,0.591
6034,3553405,Table 1,BaselineCharacteristic,x (xx),Cilengitide xxx mg/mxn?=?xx ; ,, Karnofsky PS n (%),4,2,3,No,1:No,1:No,,0.641
6034,3553405,Table 1,BaselineCharacteristic,x (xx),Cilengitide xxx mg/mxn?=?xx ; ,, Karnofsky PS n (%),4,3,3,No,1:No,1:No,,0.651
6034,3553405,Table 1,BaselineCharacteristic,x (xx),Docetaxel xx mg/mxn?=?xx ; ,, Karnofsky PS n (%),4,4,3,No,1:No,1:No,,0.691
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Total n?=?xxx ; ,, Karnofsky PS n (%),4,5,3,No,1:No,1:No,,0.576
6034,3553405,Table 1,BaselineCharacteristic,,Characteristics ; ,, Karnofsky PS n (%),5,0,2,No,1:No,1:No,,0.826
6034,3553405,Table 1,BaselineCharacteristic,x (xx),Cilengitide xxx mg/mxn?=?xx ; ,, Karnofsky PS n (%),5,1,3,No,1:No,1:No,,0.591
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Cilengitide xxx mg/mxn?=?xx ; ,, Karnofsky PS n (%),5,2,3,No,1:No,1:No,,0.621
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Cilengitide xxx mg/mxn?=?xx ; ,, Karnofsky PS n (%),5,3,3,No,1:No,1:No,,0.631
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Docetaxel xx mg/mxn?=?xx ; ,, Karnofsky PS n (%),5,4,3,No,1:No,1:No,,0.721
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Total n?=?xxx ; ,, Karnofsky PS n (%),5,5,3,No,1:No,1:No,,0.576
6034,3553405,Table 1,BaselineCharacteristic,,Characteristics ; ,, Karnofsky PS n (%),6,0,2,No,1:No,1:No,,0.886
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Cilengitide xxx mg/mxn?=?xx ; ,, Karnofsky PS n (%),6,1,3,No,1:No,1:No,,0.671
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Cilengitide xxx mg/mxn?=?xx ; ,, Karnofsky PS n (%),6,2,3,No,1:No,1:No,,0.691
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Cilengitide xxx mg/mxn?=?xx ; ,, Karnofsky PS n (%),6,3,3,No,1:No,1:No,,0.701
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Docetaxel xx mg/mxn?=?xx ; ,, Karnofsky PS n (%),6,4,3,No,1:No,1:No,,0.781
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Total n?=?xxx ; ,, Karnofsky PS n (%),6,5,3,No,1:No,1:No,,0.636
6034,3553405,Table 1,BaselineCharacteristic,,Characteristics ; ,, Karnofsky PS n (%),7,0,2,No,1:No,1:No,,0.886
6034,3553405,Table 1,BaselineCharacteristic,x (xx),Cilengitide xxx mg/mxn?=?xx ; ,, Karnofsky PS n (%),7,1,3,No,1:No,1:No,,0.661
6034,3553405,Table 1,BaselineCharacteristic,x (xx),Cilengitide xxx mg/mxn?=?xx ; ,, Karnofsky PS n (%),7,2,3,No,1:No,1:No,,0.701
6034,3553405,Table 1,BaselineCharacteristic,x (xx),Cilengitide xxx mg/mxn?=?xx ; ,, Karnofsky PS n (%),7,3,3,No,1:No,1:No,,0.711
6034,3553405,Table 1,BaselineCharacteristic,x (xx),Docetaxel xx mg/mxn?=?xx ; ,, Karnofsky PS n (%),7,4,3,No,1:No,1:No,,0.741
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Total n?=?xxx ; ,, Karnofsky PS n (%),7,5,3,No,1:No,1:No,,0.646
6034,3553405,Table 1,BaselineCharacteristic,"Tumor stage, n (%)",Characteristics ; ,None,None,8,0,24,No,1:No,1:No,,0.91
6034,3553405,Table 1,BaselineCharacteristic,"Tumor stage, n (%)",Cilengitide xxx mg/mxn?=?xx ; ,"Tumor stage, n (%)",None,8,1,43,No,1:No,1:No,,0.74
6034,3553405,Table 1,BaselineCharacteristic,"Tumor stage, n (%)",Cilengitide xxx mg/mxn?=?xx ; ,"Tumor stage, n (%)",None,8,2,43,No,1:No,1:No,,0.75
6034,3553405,Table 1,BaselineCharacteristic,"Tumor stage, n (%)",Cilengitide xxx mg/mxn?=?xx ; ,"Tumor stage, n (%)",None,8,3,43,No,1:No,1:No,,0.78
6034,3553405,Table 1,BaselineCharacteristic,"Tumor stage, n (%)",Docetaxel xx mg/mxn?=?xx ; ,"Tumor stage, n (%)",None,8,4,43,No,1:No,1:No,,0.84
6034,3553405,Table 1,BaselineCharacteristic,"Tumor stage, n (%)",Total n?=?xxx ; ,"Tumor stage, n (%)",None,8,5,43,No,1:No,1:No,,0.797
6034,3553405,Table 1,BaselineCharacteristic,,Characteristics ; ,," Tumor stage, n (%)",9,0,2,No,1:No,1:No,,0.906
6034,3553405,Table 1,BaselineCharacteristic,x (x),Cilengitide xxx mg/mxn?=?xx ; ,," Tumor stage, n (%)",9,1,3,No,1:No,1:No,,0.746
6034,3553405,Table 1,BaselineCharacteristic,x (x),Cilengitide xxx mg/mxn?=?xx ; ,," Tumor stage, n (%)",9,2,3,No,1:No,1:No,,0.776
6034,3553405,Table 1,BaselineCharacteristic,x,Cilengitide xxx mg/mxn?=?xx ; ,," Tumor stage, n (%)",9,3,3,No,1:No,1:No,,0.786
6034,3553405,Table 1,BaselineCharacteristic,x (x),Docetaxel xx mg/mxn?=?xx ; ,," Tumor stage, n (%)",9,4,3,No,1:No,1:No,,0.786
6034,3553405,Table 1,BaselineCharacteristic,x (x),Total n?=?xxx ; ,," Tumor stage, n (%)",9,5,3,No,1:No,1:No,,0.826
6034,3553405,Table 1,BaselineCharacteristic,,Characteristics ; ,," Tumor stage, n (%)",10,0,2,No,1:No,1:No,,0.916
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Cilengitide xxx mg/mxn?=?xx ; ,," Tumor stage, n (%)",10,1,3,No,1:No,1:No,,0.786
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Cilengitide xxx mg/mxn?=?xx ; ,," Tumor stage, n (%)",10,2,3,No,1:No,1:No,,0.796
6034,3553405,Table 1,BaselineCharacteristic,xx (xxx),Cilengitide xxx mg/mxn?=?xx ; ,," Tumor stage, n (%)",10,3,3,No,1:No,1:No,,0.756
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Docetaxel xx mg/mxn?=?xx ; ,," Tumor stage, n (%)",10,4,3,No,1:No,1:No,,0.856
6034,3553405,Table 1,BaselineCharacteristic,xxx (xx),Total n?=?xxx ; ,," Tumor stage, n (%)",10,5,3,No,1:No,1:No,,0.786
6034,3553405,Table 1,BaselineCharacteristic,"Histologya, n (%)",Characteristics ; ,None,None,11,0,24,No,1:No,1:No,,0.91
6034,3553405,Table 1,BaselineCharacteristic,"Histologya, n (%)",Cilengitide xxx mg/mxn?=?xx ; ,"Histologya, n (%)",None,11,1,43,No,1:No,1:No,,0.696
6034,3553405,Table 1,BaselineCharacteristic,"Histologya, n (%)",Cilengitide xxx mg/mxn?=?xx ; ,"Histologya, n (%)",None,11,2,43,No,1:No,1:No,,0.686
6034,3553405,Table 1,BaselineCharacteristic,"Histologya, n (%)",Cilengitide xxx mg/mxn?=?xx ; ,"Histologya, n (%)",None,11,3,43,No,1:No,1:No,,0.726
6034,3553405,Table 1,BaselineCharacteristic,"Histologya, n (%)",Docetaxel xx mg/mxn?=?xx ; ,"Histologya, n (%)",None,11,4,43,No,1:No,1:No,,0.826
6034,3553405,Table 1,BaselineCharacteristic,"Histologya, n (%)",Total n?=?xxx ; ,"Histologya, n (%)",None,11,5,43,No,1:No,1:No,,0.837
6034,3553405,Table 1,BaselineCharacteristic,,Characteristics ; ,," Histologya, n (%)",12,0,2,No,1:No,1:No,,0.906
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Cilengitide xxx mg/mxn?=?xx ; ,," Histologya, n (%)",12,1,3,No,1:No,1:No,,0.721
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Cilengitide xxx mg/mxn?=?xx ; ,," Histologya, n (%)",12,2,3,No,1:No,1:No,,0.721
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Cilengitide xxx mg/mxn?=?xx ; ,," Histologya, n (%)",12,3,3,No,1:No,1:No,,0.731
6034,3553405,Table 1,BaselineCharacteristic,x (xx),Docetaxel xx mg/mxn?=?xx ; ,," Histologya, n (%)",12,4,3,No,1:No,1:No,,0.801
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Total n?=?xxx ; ,," Histologya, n (%)",12,5,3,No,1:No,1:No,,0.776
6034,3553405,Table 1,BaselineCharacteristic,,Characteristics ; ,," Histologya, n (%)",13,0,2,No,1:No,1:No,,0.906
6034,3553405,Table 1,BaselineCharacteristic,x (x),Cilengitide xxx mg/mxn?=?xx ; ,," Histologya, n (%)",13,1,3,No,1:No,1:No,,0.711
6034,3553405,Table 1,BaselineCharacteristic,x (xx),Cilengitide xxx mg/mxn?=?xx ; ,," Histologya, n (%)",13,2,3,No,1:No,1:No,,0.731
6034,3553405,Table 1,BaselineCharacteristic,x (xx),Cilengitide xxx mg/mxn?=?xx ; ,," Histologya, n (%)",13,3,3,No,1:No,1:No,,0.741
6034,3553405,Table 1,BaselineCharacteristic,x (xx),Docetaxel xx mg/mxn?=?xx ; ,," Histologya, n (%)",13,4,3,No,1:No,1:No,,0.801
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Total n?=?xxx ; ,," Histologya, n (%)",13,5,3,No,1:No,1:No,,0.776
6034,3553405,Table 1,BaselineCharacteristic,,Characteristics ; ,," Histologya, n (%)",14,0,2,No,1:No,1:No,,0.906
6034,3553405,Table 1,BaselineCharacteristic,x (xx),Cilengitide xxx mg/mxn?=?xx ; ,," Histologya, n (%)",14,1,3,No,1:No,1:No,,0.721
6034,3553405,Table 1,BaselineCharacteristic,x (x),Cilengitide xxx mg/mxn?=?xx ; ,," Histologya, n (%)",14,2,3,No,1:No,1:No,,0.741
6034,3553405,Table 1,BaselineCharacteristic,x (x),Cilengitide xxx mg/mxn?=?xx ; ,," Histologya, n (%)",14,3,3,No,1:No,1:No,,0.751
6034,3553405,Table 1,BaselineCharacteristic,x (x),Docetaxel xx mg/mxn?=?xx ; ,," Histologya, n (%)",14,4,3,No,1:No,1:No,,0.801
6034,3553405,Table 1,BaselineCharacteristic,xx (x),Total n?=?xxx ; ,," Histologya, n (%)",14,5,3,No,1:No,1:No,,0.706
6034,3553405,Table 1,BaselineCharacteristic,,Characteristics ; ,," Histologya, n (%)",15,0,2,No,1:No,1:No,,0.906
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Cilengitide xxx mg/mxn?=?xx ; ,," Histologya, n (%)",15,1,3,No,1:No,1:No,,0.741
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Cilengitide xxx mg/mxn?=?xx ; ,," Histologya, n (%)",15,2,3,No,1:No,1:No,,0.741
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Cilengitide xxx mg/mxn?=?xx ; ,," Histologya, n (%)",15,3,3,No,1:No,1:No,,0.751
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Docetaxel xx mg/mxn?=?xx ; ,," Histologya, n (%)",15,4,3,No,1:No,1:No,,0.841
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Total n?=?xxx ; ,," Histologya, n (%)",15,5,3,No,1:No,1:No,,0.776
6034,3553405,Table 1,BaselineCharacteristic,"Prior chemotherapy, n (%)",Characteristics ; ,None,None,16,0,24,No,1:No,1:No,,0.93
6034,3553405,Table 1,BaselineCharacteristic,"Prior chemotherapy, n (%)",Cilengitide xxx mg/mxn?=?xx ; ,"Prior chemotherapy, n (%)",None,16,1,43,No,1:No,1:No,,0.786
6034,3553405,Table 1,BaselineCharacteristic,"Prior chemotherapy, n (%)",Cilengitide xxx mg/mxn?=?xx ; ,"Prior chemotherapy, n (%)",None,16,2,43,No,1:No,1:No,,0.776
6034,3553405,Table 1,BaselineCharacteristic,"Prior chemotherapy, n (%)",Cilengitide xxx mg/mxn?=?xx ; ,"Prior chemotherapy, n (%)",None,16,3,43,No,1:No,1:No,,0.816
6034,3553405,Table 1,BaselineCharacteristic,"Prior chemotherapy, n (%)",Docetaxel xx mg/mxn?=?xx ; ,"Prior chemotherapy, n (%)",None,16,4,43,No,1:No,1:No,,0.906
6034,3553405,Table 1,BaselineCharacteristic,"Prior chemotherapy, n (%)",Total n?=?xxx ; ,"Prior chemotherapy, n (%)",None,16,5,43,No,1:No,1:No,,0.852
6034,3553405,Table 1,BaselineCharacteristic,,Characteristics ; ,," Prior chemotherapy, n (%)",17,0,2,No,1:No,1:No,,0.916
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Cilengitide xxx mg/mxn?=?xx ; ,," Prior chemotherapy, n (%)",17,1,3,No,1:No,1:No,,0.806
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Cilengitide xxx mg/mxn?=?xx ; ,," Prior chemotherapy, n (%)",17,2,3,No,1:No,1:No,,0.796
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Cilengitide xxx mg/mxn?=?xx ; ,," Prior chemotherapy, n (%)",17,3,3,No,1:No,1:No,,0.806
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Docetaxel xx mg/mxn?=?xx ; ,," Prior chemotherapy, n (%)",17,4,3,No,1:No,1:No,,0.886
6034,3553405,Table 1,BaselineCharacteristic,xxx (xx),Total n?=?xxx ; ,," Prior chemotherapy, n (%)",17,5,3,No,1:No,1:No,,0.83
6034,3553405,Table 1,BaselineCharacteristic,,Characteristics ; ,," Prior chemotherapy, n (%)",18,0,2,No,1:No,1:No,,0.906
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Cilengitide xxx mg/mxn?=?xx ; ,," Prior chemotherapy, n (%)",18,1,3,No,1:No,1:No,,0.801
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Cilengitide xxx mg/mxn?=?xx ; ,," Prior chemotherapy, n (%)",18,2,3,No,1:No,1:No,,0.791
6034,3553405,Table 1,BaselineCharacteristic,x (xx),Cilengitide xxx mg/mxn?=?xx ; ,," Prior chemotherapy, n (%)",18,3,3,No,1:No,1:No,,0.811
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Docetaxel xx mg/mxn?=?xx ; ,," Prior chemotherapy, n (%)",18,4,3,No,1:No,1:No,,0.881
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Total n?=?xxx ; ,," Prior chemotherapy, n (%)",18,5,3,No,1:No,1:No,,0.83
6034,3553405,Table 1,BaselineCharacteristic,"Prior radiation, n (%)",Characteristics ; ,"Prior radiation, n (%)"," Prior chemotherapy, n (%)",19,0,2,No,1:No,1:No,,0.906
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Cilengitide xxx mg/mxn?=?xx ; ,"Prior radiation, n (%)"," Prior chemotherapy, n (%)",19,1,3,No,1:No,1:No,,0.801
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Cilengitide xxx mg/mxn?=?xx ; ,"Prior radiation, n (%)"," Prior chemotherapy, n (%)",19,2,3,No,1:No,1:No,,0.791
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Cilengitide xxx mg/mxn?=?xx ; ,"Prior radiation, n (%)"," Prior chemotherapy, n (%)",19,3,3,No,1:No,1:No,,0.801
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Docetaxel xx mg/mxn?=?xx ; ,"Prior radiation, n (%)"," Prior chemotherapy, n (%)",19,4,3,No,1:No,1:No,,0.881
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Total n?=?xxx ; ,"Prior radiation, n (%)"," Prior chemotherapy, n (%)",19,5,3,No,1:No,1:No,,0.83
6034,3553405,Table 1,BaselineCharacteristic,"Tumor-related surgery, n (%)",Characteristics ; ,"Tumor-related surgery, n (%)"," Prior chemotherapy, n (%)",20,0,2,No,1:No,1:No,,0.916
6034,3553405,Table 1,BaselineCharacteristic,x (xx),Cilengitide xxx mg/mxn?=?xx ; ,"Tumor-related surgery, n (%)"," Prior chemotherapy, n (%)",20,1,3,No,1:No,1:No,,0.781
6034,3553405,Table 1,BaselineCharacteristic,x (xx),Cilengitide xxx mg/mxn?=?xx ; ,"Tumor-related surgery, n (%)"," Prior chemotherapy, n (%)",20,2,3,No,1:No,1:No,,0.791
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Cilengitide xxx mg/mxn?=?xx ; ,"Tumor-related surgery, n (%)"," Prior chemotherapy, n (%)",20,3,3,No,1:No,1:No,,0.791
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Docetaxel xx mg/mxn?=?xx ; ,"Tumor-related surgery, n (%)"," Prior chemotherapy, n (%)",20,4,3,No,1:No,1:No,,0.871
6034,3553405,Table 1,BaselineCharacteristic,xx (xx),Total n?=?xxx ; ,"Tumor-related surgery, n (%)"," Prior chemotherapy, n (%)",20,5,3,No,1:No,1:No,,0.82
6191,3588608,Table 1,BaselineCharacteristic,Group,,None,None,0,0,12,No,1:No,1:No,,0.905
6191,3588608,Table 1,BaselineCharacteristic,Gender (F/M),,Group,None,0,2,1,No,1:No,1:No,,0.903
6191,3588608,Table 1,BaselineCharacteristic,Years post diagnosis means ± SD,,Group,None,0,3,1,No,1:No,1:No,,0.678
6191,3588608,Table 1,BaselineCharacteristic,Paretic side (right/left),,Group,None,0,4,1,No,1:No,1:No,,0.913
6191,3588608,Table 1,BaselineCharacteristic,A (n = xx),Group ; ,A (n = xx),None,1,0,2,No,1:No,1:No,,0.564
6191,3588608,Table 1,BaselineCharacteristic,x/xx,Gender (F/M) ; ,A (n = xx),None,1,2,3,No,1:No,1:No,,0.521
6191,3588608,Table 1,BaselineCharacteristic,x/xx,Paretic side (right/left) ; ,A (n = xx),None,1,4,3,No,1:No,1:No,,0.576
6191,3588608,Table 1,BaselineCharacteristic,B (n = xx),Group ; ,B (n = xx),None,2,0,2,No,1:No,1:No,,0.554
6191,3588608,Table 1,BaselineCharacteristic,x/x,Gender (F/M) ; ,B (n = xx),None,2,2,3,No,1:No,1:No,,0.551
6191,3588608,Table 1,BaselineCharacteristic,xx/x,Paretic side (right/left) ; ,B (n = xx),None,2,4,3,No,1:No,1:No,,0.586
6191,3588608,Table 1,BaselineCharacteristic,C (n = x),Group ; ,C (n = x),None,3,0,2,No,1:No,1:No,,0.761
6191,3588608,Table 1,BaselineCharacteristic,x/x,Gender (F/M) ; ,C (n = x),None,3,2,3,No,1:No,1:No,,0.796
6191,3588608,Table 1,BaselineCharacteristic,x/x,Paretic side (right/left) ; ,C (n = x),None,3,4,3,No,1:No,1:No,,0.82
6191,3588608,Table 1,BaselineCharacteristic,Entire group (n = xx),Group ; ,Entire group (n = xx),None,4,0,2,No,1:No,1:No,,0.594
6191,3588608,Table 1,BaselineCharacteristic,xx/xx,Gender (F/M) ; ,Entire group (n = xx),None,4,2,3,No,1:No,1:No,,0.551
6191,3588608,Table 1,BaselineCharacteristic,xx/xx,Paretic side (right/left) ; ,Entire group (n = xx),None,4,4,3,No,1:No,1:No,,0.596
6195,3589659,Table 1,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
6195,3589659,Table 1,BaselineCharacteristic,Total patient population,,,None,0,1,1,No,1:No,1:No,,0.914
6195,3589659,Table 1,BaselineCharacteristic,Total treated, ; ,Total treated,,1,0,2,No,1:No,1:No,,0.94
6195,3589659,Table 1,BaselineCharacteristic,n (%),Total patient population ; ,Total treated,,1,1,3,No,1:No,1:No,,0.67
6195,3589659,Table 1,BaselineCharacteristic,Total treated, ; ,Total treated,,2,0,2,No,1:No,1:No,,0.95
6195,3589659,Table 1,BaselineCharacteristic,xx (xxx.x),Total patient population ; ,Total treated,,2,1,2,No,1:No,1:No,,0.645
6195,3589659,Table 1,BaselineCharacteristic,Gender, ; ,Gender,,3,0,24,No,1:No,1:No,,0.922
6195,3589659,Table 1,BaselineCharacteristic,n (%),Total patient population ; ,Gender,,3,1,43,No,1:No,1:No,,0.729
6195,3589659,Table 1,BaselineCharacteristic,, ; ,,,4,0,2,No,1:No,1:No,,0.97
6195,3589659,Table 1,BaselineCharacteristic,xx (xx.x),Total patient population ; ,,,4,1,3,No,1:No,1:No,,0.806
6195,3589659,Table 1,BaselineCharacteristic,, ; ,,,5,0,2,No,1:No,1:No,,0.97
6195,3589659,Table 1,BaselineCharacteristic,xx (xx.x),Total patient population ; ,,,5,1,3,No,1:No,1:No,,0.806
6195,3589659,Table 1,BaselineCharacteristic,Race, ; ,Race,,6,0,24,No,1:No,1:No,,0.969
6195,3589659,Table 1,BaselineCharacteristic,n (%),Total patient population ; ,Race,,6,1,43,No,1:No,1:No,,0.799
6195,3589659,Table 1,BaselineCharacteristic,, ; ,,,7,0,2,No,1:No,1:No,,0.99
6195,3589659,Table 1,BaselineCharacteristic,x (xx.x),Total patient population ; ,,,7,1,3,No,1:No,1:No,,0.856
6195,3589659,Table 1,BaselineCharacteristic,, ; ,,,8,0,2,No,1:No,1:No,,0.99
6195,3589659,Table 1,BaselineCharacteristic,x (x.x),Total patient population ; ,,,8,1,3,No,1:No,1:No,,0.98
6195,3589659,Table 1,BaselineCharacteristic,, ; ,,,9,0,2,No,1:No,1:No,,1
6195,3589659,Table 1,BaselineCharacteristic,xx (xx.x),Total patient population ; ,,,9,1,3,No,1:No,1:No,,0.906
6195,3589659,Table 1,BaselineCharacteristic,Age, ; ,Age,,10,0,24,No,1:No,1:No,,0.995
6195,3589659,Table 1,BaselineCharacteristic,years,Total patient population ; ,Age,,10,1,43,No,1:No,1:No,,0.734
6195,3589659,Table 1,BaselineCharacteristic,, ; ,,,11,0,2,No,1:No,1:No,,1
6195,3589659,Table 1,BaselineCharacteristic,xx.x (xx.x–xx.x),Total patient population ; ,,,11,1,3,No,1:No,1:No,,0.856
6195,3589659,Table 1,BaselineCharacteristic,Type of cancer, ; ,None,None,12,0,24,No,1:No,1:No,,0.985
6195,3589659,Table 1,BaselineCharacteristic,Type of cancer,Total patient population ; ,Type of cancer,None,12,1,43,No,1:No,1:No,,0.984
6195,3589659,Table 1,BaselineCharacteristic,, ; ,, Type of cancer,13,0,2,No,1:No,1:No,,0.99
6195,3589659,Table 1,BaselineCharacteristic,x (xx.x),Total patient population ; ,, Type of cancer,13,1,3,No,1:No,1:No,,0.936
6195,3589659,Table 1,BaselineCharacteristic,, ; ,, Type of cancer,14,0,2,No,1:No,1:No,,0.99
6195,3589659,Table 1,BaselineCharacteristic,xx (xx.x),Total patient population ; ,, Type of cancer,14,1,3,No,1:No,1:No,,0.946
6195,3589659,Table 1,BaselineCharacteristic,, ; ,, Type of cancer,15,0,2,No,1:No,1:No,,0.99
6195,3589659,Table 1,BaselineCharacteristic,x (x.x),Total patient population ; ,, Type of cancer,15,1,3,No,1:No,1:No,,0.98
6195,3589659,Table 1,BaselineCharacteristic,, ; ,, Type of cancer,16,0,2,No,1:No,1:No,,0.99
6195,3589659,Table 1,BaselineCharacteristic,x (x.x),Total patient population ; ,, Type of cancer,16,1,3,No,1:No,1:No,,0.98
6195,3589659,Table 1,BaselineCharacteristic,, ; ,, Type of cancer,17,0,2,No,1:No,1:No,,0.99
6195,3589659,Table 1,BaselineCharacteristic,xx (xx.x),Total patient population ; ,, Type of cancer,17,1,3,No,1:No,1:No,,0.946
6195,3589659,Table 1,BaselineCharacteristic,Number of prior therapies, ; ,Number of prior therapies, Type of cancer,18,0,2,No,1:No,1:No,,0.99
6195,3589659,Table 1,BaselineCharacteristic,n (%),Total patient population ; ,Number of prior therapies, Type of cancer,18,1,3,No,1:No,1:No,,0.86
6195,3589659,Table 1,BaselineCharacteristic,, ; ,, Type of cancer,19,0,2,No,1:No,1:No,,0.99
6195,3589659,Table 1,BaselineCharacteristic,x (x.x),Total patient population ; ,, Type of cancer,19,1,3,No,1:No,1:No,,0.98
6195,3589659,Table 1,BaselineCharacteristic,, ; ,, Type of cancer,20,0,2,No,1:No,1:No,,0.99
6195,3589659,Table 1,BaselineCharacteristic,x (xx.x),Total patient population ; ,, Type of cancer,20,1,3,No,1:No,1:No,,0.946
6195,3589659,Table 1,BaselineCharacteristic,, ; ,, Type of cancer,21,0,2,No,1:No,1:No,,0.99
6195,3589659,Table 1,BaselineCharacteristic,x (x.x),Total patient population ; ,, Type of cancer,21,1,3,No,1:No,1:No,,0.98
6195,3589659,Table 1,BaselineCharacteristic,, ; ,, Type of cancer,22,0,2,No,1:No,1:No,,0.99
6195,3589659,Table 1,BaselineCharacteristic,xx (xx.x),Total patient population ; ,, Type of cancer,22,1,3,No,1:No,1:No,,0.946
6286,3599166,Table 1,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
6286,3599166,Table 1,BaselineCharacteristic,Moderate (n = x),,,None,0,1,1,No,1:No,1:No,,0.883
6286,3599166,Table 1,BaselineCharacteristic,Moderate (n = x),,,None,0,2,1,No,1:No,1:No,,0.883
6286,3599166,Table 1,BaselineCharacteristic,High (n = xx),,,None,0,3,1,No,1:No,1:No,,0.766
6286,3599166,Table 1,BaselineCharacteristic,High (n = xx),,,None,0,4,1,No,1:No,1:No,,0.776
6286,3599166,Table 1,BaselineCharacteristic,p value time,,,None,0,5,1,No,1:No,1:No,,0.915
6286,3599166,Table 1,BaselineCharacteristic,, ; ,None,None,1,0,12,No,1:No,1:No,,0.898
6286,3599166,Table 1,BaselineCharacteristic,PRE,Moderate (n = x) ; ,,None,1,1,1,No,1:No,1:No,,0.875
6286,3599166,Table 1,BaselineCharacteristic,POST,Moderate (n = x) ; ,,None,1,2,1,No,1:No,1:No,,0.876
6286,3599166,Table 1,BaselineCharacteristic,PRE,High (n = xx) ; ,,None,1,3,1,No,1:No,1:No,,0.759
6286,3599166,Table 1,BaselineCharacteristic,POST,High (n = xx) ; ,,None,1,4,1,No,1:No,1:No,,0.769
6286,3599166,Table 1,BaselineCharacteristic,p value time,p value time ; ,,None,1,5,1,No,1:No,1:No,,0.907
6286,3599166,Table 1,BaselineCharacteristic,Age (years), ;  ; ,Age (years),None,2,0,2,No,1:No,1:No,,0.65
6286,3599166,Table 1,BaselineCharacteristic,–,Moderate (n = x) ; POST ; ,Age (years),None,2,2,3,No,1:No,1:No,,0.53
6286,3599166,Table 1,BaselineCharacteristic,–,p value time ; p value time ; ,Age (years),None,2,5,3,No,1:No,1:No,,0.61
6286,3599166,Table 1,BaselineCharacteristic,Height (cm), ;  ; ,Height (cm),None,3,0,2,No,1:No,1:No,,0.96
6286,3599166,Table 1,BaselineCharacteristic,xxx.x ± x.x,Moderate (n = x) ; PRE ; ,Height (cm),None,3,1,3,No,1:No,1:No,,0.82
6286,3599166,Table 1,BaselineCharacteristic,–,Moderate (n = x) ; POST ; ,Height (cm),None,3,2,3,No,1:No,1:No,,0.86
6286,3599166,Table 1,BaselineCharacteristic,xxx.x ± xx.x,High (n = xx) ; PRE ; ,Height (cm),None,3,3,3,No,1:No,1:No,,0.65
6286,3599166,Table 1,BaselineCharacteristic,–,High (n = xx) ; POST ; ,Height (cm),None,3,4,3,No,1:No,1:No,,0.75
6286,3599166,Table 1,BaselineCharacteristic,–,p value time ; p value time ; ,Height (cm),None,3,5,3,No,1:No,1:No,,0.86
6286,3599166,Table 1,BaselineCharacteristic,Weight (kg)*, ;  ; ,Weight (kg)*,None,4,0,2,No,1:No,1:No,,0.97
6286,3599166,Table 1,BaselineCharacteristic,xx.x ± xx.x,Moderate (n = x) ; PRE ; ,Weight (kg)*,None,4,1,3,No,1:No,1:No,,0.686
6286,3599166,Table 1,BaselineCharacteristic,xx.x ± x.x,Moderate (n = x) ; POST ; ,Weight (kg)*,None,4,2,3,No,1:No,1:No,,0.656
6286,3599166,Table 1,BaselineCharacteristic,xx.x ± xx.x,High (n = xx) ; PRE ; ,Weight (kg)*,None,4,3,3,No,1:No,1:No,,0.54
6286,3599166,Table 1,BaselineCharacteristic,xx.x ± xx.x,High (n = xx) ; POST ; ,Weight (kg)*,None,4,4,3,No,1:No,1:No,,0.57
6286,3599166,Table 1,BaselineCharacteristic,–,p value time ; p value time ; ,Weight (kg)*,None,4,5,3,No,1:No,1:No,,0.85
6286,3599166,Table 1,BaselineCharacteristic,BMI (kg m?x)*, ;  ; ,BMI (kg m?x)*,None,5,0,2,No,1:No,1:No,,0.963
6286,3599166,Table 1,BaselineCharacteristic,xx.x ± x.x,Moderate (n = x) ; PRE ; ,BMI (kg m?x)*,None,5,1,3,No,1:No,1:No,,0.696
6286,3599166,Table 1,BaselineCharacteristic,xx.x ± x.x,Moderate (n = x) ; POST ; ,BMI (kg m?x)*,None,5,2,3,No,1:No,1:No,,0.716
6286,3599166,Table 1,BaselineCharacteristic,xx.x ± x.x,High (n = xx) ; PRE ; ,BMI (kg m?x)*,None,5,3,3,No,1:No,1:No,,0.62
6286,3599166,Table 1,BaselineCharacteristic,xx.x ± x.x,High (n = xx) ; POST ; ,BMI (kg m?x)*,None,5,4,3,No,1:No,1:No,,0.65
6286,3599166,Table 1,BaselineCharacteristic,–,p value time ; p value time ; ,BMI (kg m?x)*,None,5,5,3,No,1:No,1:No,,0.87
6286,3599166,Table 1,BaselineCharacteristic,LV ejection duration (ms), ;  ; ,LV ejection duration (ms),None,6,0,2,No,1:No,1:No,,1
6286,3599166,Table 1,BaselineCharacteristic,xxx ± xx,Moderate (n = x) ; PRE ; ,LV ejection duration (ms),None,6,1,3,No,1:No,1:No,,0.92
6286,3599166,Table 1,BaselineCharacteristic,xxx ± xx,Moderate (n = x) ; POST ; ,LV ejection duration (ms),None,6,2,3,No,1:No,1:No,,0.94
6286,3599166,Table 1,BaselineCharacteristic,xxx ± xx,High (n = xx) ; PRE ; ,LV ejection duration (ms),None,6,3,3,No,1:No,1:No,,0.8
6286,3599166,Table 1,BaselineCharacteristic,xxx ± xx,High (n = xx) ; POST ; ,LV ejection duration (ms),None,6,4,3,No,1:No,1:No,,0.82
6286,3599166,Table 1,BaselineCharacteristic,x.xx,p value time ; p value time ; ,LV ejection duration (ms),None,6,5,3,No,1:No,1:No,,0.82
6286,3599166,Table 1,BaselineCharacteristic,Brachial SBP (mmHg)†, ;  ; ,Brachial SBP (mmHg)†,None,7,0,2,No,1:No,1:No,,0.99
6286,3599166,Table 1,BaselineCharacteristic,xxx.x ± x,Moderate (n = x) ; PRE ; ,Brachial SBP (mmHg)†,None,7,1,3,No,1:No,1:No,,0.82
6286,3599166,Table 1,BaselineCharacteristic,xxx.x ± x.x,Moderate (n = x) ; POST ; ,Brachial SBP (mmHg)†,None,7,2,3,No,1:No,1:No,,0.87
6286,3599166,Table 1,BaselineCharacteristic,xxx.x ± x,High (n = xx) ; PRE ; ,Brachial SBP (mmHg)†,None,7,3,3,No,1:No,1:No,,0.67
6286,3599166,Table 1,BaselineCharacteristic,xxx.x ± x.x,High (n = xx) ; POST ; ,Brachial SBP (mmHg)†,None,7,4,3,No,1:No,1:No,,0.7
6286,3599166,Table 1,BaselineCharacteristic,x.xx,p value time ; p value time ; ,Brachial SBP (mmHg)†,None,7,5,3,No,1:No,1:No,,0.86
6286,3599166,Table 1,BaselineCharacteristic,Brachial MAP (mmHg)†, ;  ; ,Brachial MAP (mmHg)†,None,8,0,2,No,1:No,1:No,,0.99
6286,3599166,Table 1,BaselineCharacteristic,xx.x ± x,Moderate (n = x) ; PRE ; ,Brachial MAP (mmHg)†,None,8,1,3,No,1:No,1:No,,0.771
6286,3599166,Table 1,BaselineCharacteristic,xx.x ± x.x,Moderate (n = x) ; POST ; ,Brachial MAP (mmHg)†,None,8,2,3,No,1:No,1:No,,0.746
6286,3599166,Table 1,BaselineCharacteristic,xx.x ± x,High (n = xx) ; PRE ; ,Brachial MAP (mmHg)†,None,8,3,3,No,1:No,1:No,,0.616
6286,3599166,Table 1,BaselineCharacteristic,xx.x ± x.x,High (n = xx) ; POST ; ,Brachial MAP (mmHg)†,None,8,4,3,No,1:No,1:No,,0.59
6286,3599166,Table 1,BaselineCharacteristic,x.xx,p value time ; p value time ; ,Brachial MAP (mmHg)†,None,8,5,3,No,1:No,1:No,,0.87
6286,3599166,Table 1,BaselineCharacteristic,Brachial DBP (mmHg)†, ;  ; ,Brachial DBP (mmHg)†,None,9,0,2,No,1:No,1:No,,1
6286,3599166,Table 1,BaselineCharacteristic,xx.x ± x,Moderate (n = x) ; PRE ; ,Brachial DBP (mmHg)†,None,9,1,3,No,1:No,1:No,,0.821
6286,3599166,Table 1,BaselineCharacteristic,xx.x ± x.x,Moderate (n = x) ; POST ; ,Brachial DBP (mmHg)†,None,9,2,3,No,1:No,1:No,,0.776
6286,3599166,Table 1,BaselineCharacteristic,xx.x ± x,High (n = xx) ; PRE ; ,Brachial DBP (mmHg)†,None,9,3,3,No,1:No,1:No,,0.666
6286,3599166,Table 1,BaselineCharacteristic,xx.x ± x.x,High (n = xx) ; POST ; ,Brachial DBP (mmHg)†,None,9,4,3,No,1:No,1:No,,0.65
6286,3599166,Table 1,BaselineCharacteristic,x.xx,p value time ; p value time ; ,Brachial DBP (mmHg)†,None,9,5,3,No,1:No,1:No,,0.89
6286,3599166,Table 1,BaselineCharacteristic,Carotid PP (mmHg), ;  ; ,Carotid PP (mmHg),None,10,0,2,No,1:No,1:No,,1
6286,3599166,Table 1,BaselineCharacteristic,xx.x,Moderate (n = x) ; PRE ; ,Carotid PP (mmHg),None,10,1,3,No,1:No,1:No,,0.846
6286,3599166,Table 1,BaselineCharacteristic,xx.x,Moderate (n = x) ; POST ; ,Carotid PP (mmHg),None,10,2,3,No,1:No,1:No,,0.836
6286,3599166,Table 1,BaselineCharacteristic,xx.x,High (n = xx) ; PRE ; ,Carotid PP (mmHg),None,10,3,3,No,1:No,1:No,,0.69
6286,3599166,Table 1,BaselineCharacteristic,xx.x,High (n = xx) ; POST ; ,Carotid PP (mmHg),None,10,4,3,No,1:No,1:No,,0.72
6286,3599166,Table 1,BaselineCharacteristic,x.xx,p value time ; p value time ; ,Carotid PP (mmHg),None,10,5,3,No,1:No,1:No,,0.89
6286,3599166,Table 1,BaselineCharacteristic,Peripheral PWV (m/s), ;  ; ,Peripheral PWV (m/s),None,11,0,2,No,1:No,1:No,,1
6286,3599166,Table 1,BaselineCharacteristic,x.x ± x.x,Moderate (n = x) ; PRE ; ,Peripheral PWV (m/s),None,11,1,3,No,1:No,1:No,,0.94
6286,3599166,Table 1,BaselineCharacteristic,x.x ± x.x,Moderate (n = x) ; POST ; ,Peripheral PWV (m/s),None,11,2,3,No,1:No,1:No,,0.94
6286,3599166,Table 1,BaselineCharacteristic,x.x ± x.x,High (n = xx) ; PRE ; ,Peripheral PWV (m/s),None,11,3,3,No,1:No,1:No,,0.8
6286,3599166,Table 1,BaselineCharacteristic,x.x ± x.x,High (n = xx) ; POST ; ,Peripheral PWV (m/s),None,11,4,3,No,1:No,1:No,,0.82
6286,3599166,Table 1,BaselineCharacteristic,x.xx,p value time ; p value time ; ,Peripheral PWV (m/s),None,11,5,3,No,1:No,1:No,,0.91
6286,3599166,Table 1,BaselineCharacteristic,Carotid AIx (%), ;  ; ,Carotid AIx (%),None,12,0,2,No,1:No,1:No,,0.96
6286,3599166,Table 1,BaselineCharacteristic,?x.x ± xx.x,Moderate (n = x) ; PRE ; ,Carotid AIx (%),None,12,1,3,No,1:No,1:No,,0.91
6286,3599166,Table 1,BaselineCharacteristic,?x.x ± xx.x,Moderate (n = x) ; POST ; ,Carotid AIx (%),None,12,2,3,No,1:No,1:No,,0.91
6286,3599166,Table 1,BaselineCharacteristic,?xx.x ± xx.x,High (n = xx) ; PRE ; ,Carotid AIx (%),None,12,3,3,No,1:No,1:No,,0.62
6286,3599166,Table 1,BaselineCharacteristic,?xx.x ± xx.x,High (n = xx) ; POST ; ,Carotid AIx (%),None,12,4,3,No,1:No,1:No,,0.64
6286,3599166,Table 1,BaselineCharacteristic,x.xx,p value time ; p value time ; ,Carotid AIx (%),None,12,5,3,No,1:No,1:No,,0.86
6286,3599166,Table 1,BaselineCharacteristic,Carotid wave reflection time (ms), ;  ; ,Carotid wave reflection time (ms),None,13,0,2,No,1:No,1:No,,1
6286,3599166,Table 1,BaselineCharacteristic,xxx ± xx,Moderate (n = x) ; PRE ; ,Carotid wave reflection time (ms),None,13,1,3,No,1:No,1:No,,0.95
6286,3599166,Table 1,BaselineCharacteristic,xxx ± xx,Moderate (n = x) ; POST ; ,Carotid wave reflection time (ms),None,13,2,3,No,1:No,1:No,,0.96
6286,3599166,Table 1,BaselineCharacteristic,xxx ± xx,High (n = xx) ; PRE ; ,Carotid wave reflection time (ms),None,13,3,3,No,1:No,1:No,,0.8
6286,3599166,Table 1,BaselineCharacteristic,xxx ± xx,High (n = xx) ; POST ; ,Carotid wave reflection time (ms),None,13,4,3,No,1:No,1:No,,0.83
6286,3599166,Table 1,BaselineCharacteristic,x.xx,p value time ; p value time ; ,Carotid wave reflection time (ms),None,13,5,3,No,1:No,1:No,,0.91
6286,3599166,Table 1,BaselineCharacteristic,Carotid IMT (mm), ;  ; ,Carotid IMT (mm),None,14,0,2,No,1:No,1:No,,1
6286,3599166,Table 1,BaselineCharacteristic,x.xx ± x.xx,Moderate (n = x) ; PRE ; ,Carotid IMT (mm),None,14,1,3,No,1:No,1:No,,0.846
6286,3599166,Table 1,BaselineCharacteristic,x.xx ± x.xx,Moderate (n = x) ; POST ; ,Carotid IMT (mm),None,14,2,3,No,1:No,1:No,,0.836
6286,3599166,Table 1,BaselineCharacteristic,x.xx ± x.xx,High (n = xx) ; PRE ; ,Carotid IMT (mm),None,14,3,3,No,1:No,1:No,,0.66
6286,3599166,Table 1,BaselineCharacteristic,x.xx ± x.xx,High (n = xx) ; POST ; ,Carotid IMT (mm),None,14,4,3,No,1:No,1:No,,0.69
6286,3599166,Table 1,BaselineCharacteristic,x.xx,p value time ; p value time ; ,Carotid IMT (mm),None,14,5,3,No,1:No,1:No,,0.92
6311,3600043,Table 1,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
6311,3600043,Table 1,BaselineCharacteristic,Global N?=?xxx,,,None,0,5,1,No,1:No,1:No,,0.68
6311,3600043,Table 1,BaselineCharacteristic,Sociodemographic characteristics, ; ,None,None,1,0,24,No,1:No,1:No,,0.774
6311,3600043,Table 1,BaselineCharacteristic,,Global N?=?xxx ; ,Sociodemographic characteristics,None,1,5,43,No,1:No,1:No,,0.599
6311,3600043,Table 1,BaselineCharacteristic,"Sex, female (n,%)", ; ,"Sex, female (n,%)", Sociodemographic characteristics,2,0,2,No,1:No,1:No,,0.696
6311,3600043,Table 1,BaselineCharacteristic,"Age (mean, SD)", ; ,"Age (mean, SD)", Sociodemographic characteristics,3,0,2,No,1:No,1:No,,0.64
6311,3600043,Table 1,BaselineCharacteristic,"BMI (mean, SD)", ; ,"BMI (mean, SD)", Sociodemographic characteristics,4,0,2,No,1:No,1:No,,0.68
6311,3600043,Table 1,BaselineCharacteristic,"Status, inpatient (n,%)", ; ,"Status, inpatient (n,%)", Sociodemographic characteristics,5,0,2,No,1:No,1:No,,0.746
6311,3600043,Table 1,BaselineCharacteristic,Psychiatric history, ; ,None,None,6,0,2,No,1:No,1:No,,0.99
6311,3600043,Table 1,BaselineCharacteristic,,Manic n?=?xx ; ,None,None,6,1,3,No,1:No,1:No,,0.667
6311,3600043,Table 1,BaselineCharacteristic,,Hypomanic n?=?xx ; ,None,None,6,2,3,No,1:No,1:No,,0.717
6311,3600043,Table 1,BaselineCharacteristic,,Mixed n?=?xx ; ,None,None,6,3,3,No,1:No,1:No,,0.651
6311,3600043,Table 1,BaselineCharacteristic,,Depressive n?=?xx ; ,None,None,6,4,3,No,1:No,1:No,,0.741
6311,3600043,Table 1,BaselineCharacteristic,,Global N?=?xxx ; ,None,None,6,5,3,No,1:No,1:No,,0.787
6311,3600043,Table 1,BaselineCharacteristic,"Bipolar type (n,%)", ; ,None,None,7,0,24,No,1:No,1:No,,0.89
6311,3600043,Table 1,BaselineCharacteristic,,Manic n?=?xx ; ,"Bipolar type (n,%)",None,7,1,43,No,1:No,1:No,,0.686
6311,3600043,Table 1,BaselineCharacteristic,,Hypomanic n?=?xx ; ,"Bipolar type (n,%)",None,7,2,43,No,1:No,1:No,,0.696
6311,3600043,Table 1,BaselineCharacteristic,,Mixed n?=?xx ; ,"Bipolar type (n,%)",None,7,3,43,No,1:No,1:No,,0.676
6311,3600043,Table 1,BaselineCharacteristic,,Depressive n?=?xx ; ,"Bipolar type (n,%)",None,7,4,43,No,1:No,1:No,,0.746
6311,3600043,Table 1,BaselineCharacteristic,,Global N?=?xxx ; ,"Bipolar type (n,%)",None,7,5,43,No,1:No,1:No,,0.737
6311,3600043,Table 1,BaselineCharacteristic,?I, ; ,?I," Psychiatric history Bipolar type (n,%)",8,0,2,No,1:No,1:No,,0.89
6311,3600043,Table 1,BaselineCharacteristic,xx (xxx.x),Manic n?=?xx ; ,?I," Psychiatric history Bipolar type (n,%)",8,1,3,No,1:No,1:No,,0.586
6311,3600043,Table 1,BaselineCharacteristic,xx (xx.x),Hypomanic n?=?xx ; ,?I," Psychiatric history Bipolar type (n,%)",8,2,3,No,1:No,1:No,,0.686
6311,3600043,Table 1,BaselineCharacteristic,xx (xxx.x),Mixed n?=?xx ; ,?I," Psychiatric history Bipolar type (n,%)",8,3,3,No,1:No,1:No,,0.586
6311,3600043,Table 1,BaselineCharacteristic,xx (xx.x),Depressive n?=?xx ; ,?I," Psychiatric history Bipolar type (n,%)",8,4,3,No,1:No,1:No,,0.706
6311,3600043,Table 1,BaselineCharacteristic,xxx (xx.x),Global N?=?xxx ; ,?I," Psychiatric history Bipolar type (n,%)",8,5,3,No,1:No,1:No,,0.636
6311,3600043,Table 1,BaselineCharacteristic,?II, ; ,?II," Psychiatric history Bipolar type (n,%)",9,0,2,No,1:No,1:No,,0.91
6311,3600043,Table 1,BaselineCharacteristic,x (x.x),Manic n?=?xx ; ,?II," Psychiatric history Bipolar type (n,%)",9,1,3,No,1:No,1:No,,0.661
6311,3600043,Table 1,BaselineCharacteristic,xx (xx.x),Hypomanic n?=?xx ; ,?II," Psychiatric history Bipolar type (n,%)",9,2,3,No,1:No,1:No,,0.701
6311,3600043,Table 1,BaselineCharacteristic,x (x.x),Mixed n?=?xx ; ,?II," Psychiatric history Bipolar type (n,%)",9,3,3,No,1:No,1:No,,0.661
6311,3600043,Table 1,BaselineCharacteristic,xx (xx.x),Depressive n?=?xx ; ,?II," Psychiatric history Bipolar type (n,%)",9,4,3,No,1:No,1:No,,0.731
6311,3600043,Table 1,BaselineCharacteristic,xx (xx.x),Global N?=?xxx ; ,?II," Psychiatric history Bipolar type (n,%)",9,5,3,No,1:No,1:No,,0.656
6311,3600043,Table 1,BaselineCharacteristic,"Age at onset (mean, SD)", ; ,"Age at onset (mean, SD)",,10,0,2,No,1:No,1:No,,0.79
6311,3600043,Table 1,BaselineCharacteristic,"Duration of illness in years (mean, SD)", ; ,"Duration of illness in years (mean, SD)",,11,0,2,No,1:No,1:No,,0.59
6311,3600043,Table 1,BaselineCharacteristic,"Number of episodes lifetime (mean, SD)", ; ,"Number of episodes lifetime (mean, SD)",,12,0,2,No,1:No,1:No,,0.77
6311,3600043,Table 1,BaselineCharacteristic,x.x (x.x),Global N?=?xxx ; ,"Number of episodes lifetime (mean, SD)",,12,5,3,No,1:No,1:No,,0.58
6311,3600043,Table 1,BaselineCharacteristic,"Duration of current episode in months (mean, SD)", ; ,"Duration of current episode in months (mean, SD)",,13,0,2,No,1:No,1:No,,0.72
6311,3600043,Table 1,BaselineCharacteristic,x.x (x.x),Global N?=?xxx ; ,"Duration of current episode in months (mean, SD)",,13,5,3,No,1:No,1:No,,0.59
6311,3600043,Table 1,BaselineCharacteristic,"Lifetime substance-use disorder (n,%)", ; ,None,None,14,0,24,No,1:No,1:No,,0.91
6311,3600043,Table 1,BaselineCharacteristic,,Manic n?=?xx ; ,"Lifetime substance-use disorder (n,%)",None,14,1,43,No,1:No,1:No,,0.756
6311,3600043,Table 1,BaselineCharacteristic,,Hypomanic n?=?xx ; ,"Lifetime substance-use disorder (n,%)",None,14,2,43,No,1:No,1:No,,0.746
6311,3600043,Table 1,BaselineCharacteristic,,Mixed n?=?xx ; ,"Lifetime substance-use disorder (n,%)",None,14,3,43,No,1:No,1:No,,0.736
6311,3600043,Table 1,BaselineCharacteristic,,Depressive n?=?xx ; ,"Lifetime substance-use disorder (n,%)",None,14,4,43,No,1:No,1:No,,0.806
6311,3600043,Table 1,BaselineCharacteristic,,Global N?=?xxx ; ,"Lifetime substance-use disorder (n,%)",None,14,5,43,No,1:No,1:No,,0.837
6311,3600043,Table 1,BaselineCharacteristic,?Alcohol dependence, ; ,?Alcohol dependence," Psychiatric history Lifetime substance-use disorder (n,%)",15,0,2,No,1:No,1:No,,0.93
6311,3600043,Table 1,BaselineCharacteristic,x (x.x),Manic n?=?xx ; ,?Alcohol dependence," Psychiatric history Lifetime substance-use disorder (n,%)",15,1,3,No,1:No,1:No,,0.721
6311,3600043,Table 1,BaselineCharacteristic,x (x.x),Hypomanic n?=?xx ; ,?Alcohol dependence," Psychiatric history Lifetime substance-use disorder (n,%)",15,2,3,No,1:No,1:No,,0.741
6311,3600043,Table 1,BaselineCharacteristic,x (xx.x),Mixed n?=?xx ; ,?Alcohol dependence," Psychiatric history Lifetime substance-use disorder (n,%)",15,3,3,No,1:No,1:No,,0.701
6311,3600043,Table 1,BaselineCharacteristic,x (x.x),Depressive n?=?xx ; ,?Alcohol dependence," Psychiatric history Lifetime substance-use disorder (n,%)",15,4,3,No,1:No,1:No,,0.781
6311,3600043,Table 1,BaselineCharacteristic,xx (x.x),Global N?=?xxx ; ,?Alcohol dependence," Psychiatric history Lifetime substance-use disorder (n,%)",15,5,3,No,1:No,1:No,,0.716
6311,3600043,Table 1,BaselineCharacteristic,?Alcohol abuse, ; ,?Alcohol abuse," Psychiatric history Lifetime substance-use disorder (n,%)",16,0,2,No,1:No,1:No,,0.93
6311,3600043,Table 1,BaselineCharacteristic,x (xx.x),Manic n?=?xx ; ,?Alcohol abuse," Psychiatric history Lifetime substance-use disorder (n,%)",16,1,3,No,1:No,1:No,,0.721
6311,3600043,Table 1,BaselineCharacteristic,x (xx.x),Hypomanic n?=?xx ; ,?Alcohol abuse," Psychiatric history Lifetime substance-use disorder (n,%)",16,2,3,No,1:No,1:No,,0.741
6311,3600043,Table 1,BaselineCharacteristic,x (xx.x),Mixed n?=?xx ; ,?Alcohol abuse," Psychiatric history Lifetime substance-use disorder (n,%)",16,3,3,No,1:No,1:No,,0.701
6311,3600043,Table 1,BaselineCharacteristic,xx (xx.x),Depressive n?=?xx ; ,?Alcohol abuse," Psychiatric history Lifetime substance-use disorder (n,%)",16,4,3,No,1:No,1:No,,0.781
6311,3600043,Table 1,BaselineCharacteristic,xx (xx.x),Global N?=?xxx ; ,?Alcohol abuse," Psychiatric history Lifetime substance-use disorder (n,%)",16,5,3,No,1:No,1:No,,0.716
6311,3600043,Table 1,BaselineCharacteristic,?Other substances, ; ,?Other substances," Psychiatric history Lifetime substance-use disorder (n,%)",17,0,2,No,1:No,1:No,,0.93
6311,3600043,Table 1,BaselineCharacteristic,x (x.x),Manic n?=?xx ; ,?Other substances," Psychiatric history Lifetime substance-use disorder (n,%)",17,1,3,No,1:No,1:No,,0.721
6311,3600043,Table 1,BaselineCharacteristic,x (x.x),Hypomanic n?=?xx ; ,?Other substances," Psychiatric history Lifetime substance-use disorder (n,%)",17,2,3,No,1:No,1:No,,0.741
6311,3600043,Table 1,BaselineCharacteristic,x (x.x),Mixed n?=?xx ; ,?Other substances," Psychiatric history Lifetime substance-use disorder (n,%)",17,3,3,No,1:No,1:No,,0.701
6311,3600043,Table 1,BaselineCharacteristic,x (x.x),Depressive n?=?xx ; ,?Other substances," Psychiatric history Lifetime substance-use disorder (n,%)",17,4,3,No,1:No,1:No,,0.781
6311,3600043,Table 1,BaselineCharacteristic,x (x.x),Global N?=?xxx ; ,?Other substances," Psychiatric history Lifetime substance-use disorder (n,%)",17,5,3,No,1:No,1:No,,0.826
6311,3600043,Table 1,BaselineCharacteristic,"Lifetime suicide attempts (n,%)", ; ,"Lifetime suicide attempts (n,%)",,18,0,2,No,1:No,1:No,,0.896
6311,3600043,Table 1,BaselineCharacteristic,xx (xx.x),Manic n?=?xx ; ,"Lifetime suicide attempts (n,%)",,18,1,3,No,1:No,1:No,,0.697
6311,3600043,Table 1,BaselineCharacteristic,x (xx.x),Hypomanic n?=?xx ; ,"Lifetime suicide attempts (n,%)",,18,2,3,No,1:No,1:No,,0.727
6311,3600043,Table 1,BaselineCharacteristic,xx (xx.x),Mixed n?=?xx ; ,"Lifetime suicide attempts (n,%)",,18,3,3,No,1:No,1:No,,0.687
6311,3600043,Table 1,BaselineCharacteristic,xx (xx.x),Depressive n?=?xx ; ,"Lifetime suicide attempts (n,%)",,18,4,3,No,1:No,1:No,,0.757
6311,3600043,Table 1,BaselineCharacteristic,xx (xx.x),Global N?=?xxx ; ,"Lifetime suicide attempts (n,%)",,18,5,3,No,1:No,1:No,,0.696
6311,3600043,Table 1,BaselineCharacteristic,"Previous olanzapine treatment (n,%)", ; ,"Previous olanzapine treatment (n,%)",,19,0,2,No,1:No,1:No,,0.886
6311,3600043,Table 1,BaselineCharacteristic,xx (xx.x),Manic n?=?xx ; ,"Previous olanzapine treatment (n,%)",,19,1,3,No,1:No,1:No,,0.697
6311,3600043,Table 1,BaselineCharacteristic,xx (xx.x),Hypomanic n?=?xx ; ,"Previous olanzapine treatment (n,%)",,19,2,3,No,1:No,1:No,,0.717
6311,3600043,Table 1,BaselineCharacteristic,x (xx.x),Mixed n?=?xx ; ,"Previous olanzapine treatment (n,%)",,19,3,3,No,1:No,1:No,,0.677
6311,3600043,Table 1,BaselineCharacteristic,xx (xx.x),Depressive n?=?xx ; ,"Previous olanzapine treatment (n,%)",,19,4,3,No,1:No,1:No,,0.747
6311,3600043,Table 1,BaselineCharacteristic,xx (xx.x),Global N?=?xxx ; ,"Previous olanzapine treatment (n,%)",,19,5,3,No,1:No,1:No,,0.686
6311,3600043,Table 1,BaselineCharacteristic,Rating scales, ; ,None,None,20,0,2,No,1:No,1:No,,0.99
6311,3600043,Table 1,BaselineCharacteristic,,Manic n?=?xx ; ,None,None,20,1,3,No,1:No,1:No,,0.752
6311,3600043,Table 1,BaselineCharacteristic,,Hypomanic n?=?xx ; ,None,None,20,2,3,No,1:No,1:No,,0.782
6311,3600043,Table 1,BaselineCharacteristic,,Mixed n?=?xx ; ,None,None,20,3,3,No,1:No,1:No,,0.697
6311,3600043,Table 1,BaselineCharacteristic,,Depressive n?=?xx ; ,None,None,20,4,3,No,1:No,1:No,,0.807
6311,3600043,Table 1,BaselineCharacteristic,,Global N?=?xxx ; ,None,None,20,5,3,No,1:No,1:No,,0.857
6311,3600043,Table 1,BaselineCharacteristic,"MAThyS total score (mean, SD)", ; ,"MAThyS total score (mean, SD)",,21,0,2,No,1:No,1:No,,0.81
6311,3600043,Table 1,BaselineCharacteristic,xx.x (xx.x),Depressive n?=?xx ; ,"MAThyS total score (mean, SD)",,21,4,3,No,1:No,1:No,,0.505
6311,3600043,Table 1,BaselineCharacteristic,"HAMD-xx total score (mean, SD)", ; ,"HAMD-xx total score (mean, SD)",,22,0,2,No,1:No,1:No,,0.81
6311,3600043,Table 1,BaselineCharacteristic,x.x (x.x),Manic n?=?xx ; ,"HAMD-xx total score (mean, SD)",,22,1,3,No,1:No,1:No,,0.515
6311,3600043,Table 1,BaselineCharacteristic,x.x (x.x),Hypomanic n?=?xx ; ,"HAMD-xx total score (mean, SD)",,22,2,3,No,1:No,1:No,,0.525
6311,3600043,Table 1,BaselineCharacteristic,xx.x (x.x),Depressive n?=?xx ; ,"HAMD-xx total score (mean, SD)",,22,4,3,No,1:No,1:No,,0.505
6311,3600043,Table 1,BaselineCharacteristic,"YMRS total score (mean, SD)", ; ,"YMRS total score (mean, SD)",,23,0,2,No,1:No,1:No,,0.81
6311,3600043,Table 1,BaselineCharacteristic,xx.x (xx.x),Manic n?=?xx ; ,"YMRS total score (mean, SD)",,23,1,3,No,1:No,1:No,,0.515
6311,3600043,Table 1,BaselineCharacteristic,xx.x (x.x),Hypomanic n?=?xx ; ,"YMRS total score (mean, SD)",,23,2,3,No,1:No,1:No,,0.525
6311,3600043,Table 1,BaselineCharacteristic,x. x (x.x),Depressive n?=?xx ; ,"YMRS total score (mean, SD)",,23,4,3,No,1:No,1:No,,0.505
6311,3600043,Table 1,BaselineCharacteristic,"HAMA total score (mean, SD)", ; ,"HAMA total score (mean, SD)",,24,0,2,No,1:No,1:No,,0.81
6311,3600043,Table 1,BaselineCharacteristic,x.x (x.x),Manic n?=?xx ; ,"HAMA total score (mean, SD)",,24,1,3,No,1:No,1:No,,0.515
6311,3600043,Table 1,BaselineCharacteristic,xx.x (x.x),Hypomanic n?=?xx ; ,"HAMA total score (mean, SD)",,24,2,3,No,1:No,1:No,,0.525
6311,3600043,Table 1,BaselineCharacteristic,xx.x (x.x),Depressive n?=?xx ; ,"HAMA total score (mean, SD)",,24,4,3,No,1:No,1:No,,0.505
6382,394324,Table 1,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
6382,394324,Table 1,BaselineCharacteristic,pts.,,,None,0,1,1,No,1:No,1:No,,0.903
6382,394324,Table 1,BaselineCharacteristic,CDAI*,,,None,0,2,1,No,1:No,1:No,,0.903
6382,394324,Table 1,BaselineCharacteristic,CRP* in mg/l,,,None,0,3,1,No,1:No,1:No,,0.844
6382,394324,Table 1,BaselineCharacteristic,remission,,,None,0,4,1,No,1:No,1:No,,0.913
6382,394324,Table 1,BaselineCharacteristic,sustained remission,,,None,0,5,1,No,1:No,1:No,,0.935
6382,394324,Table 1,BaselineCharacteristic,Relapse,,,None,0,6,1,No,1:No,1:No,,0.935
6382,394324,Table 1,BaselineCharacteristic,mean time to relapse (in weeks),,,None,0,7,1,No,1:No,1:No,,0.736
6382,394324,Table 1,BaselineCharacteristic,L. GG, ; ,L. GG,None,1,0,2,No,1:No,1:No,,0.94
6382,394324,Table 1,BaselineCharacteristic,n = x,pts. ; ,L. GG,None,1,1,3,No,1:No,1:No,,0.686
6382,394324,Table 1,BaselineCharacteristic,xxx ± xx,CDAI* ; ,L. GG,None,1,2,3,No,1:No,1:No,,0.566
6382,394324,Table 1,BaselineCharacteristic,xx ± xx,CRP* in mg/l ; ,L. GG,None,1,3,3,No,1:No,1:No,,0.526
6382,394324,Table 1,BaselineCharacteristic,x/x,remission ; ,L. GG,None,1,4,3,No,1:No,1:No,,0.88
6382,394324,Table 1,BaselineCharacteristic,x/x,sustained remission ; ,L. GG,None,1,5,3,No,1:No,1:No,,0.89
6382,394324,Table 1,BaselineCharacteristic,x/x,Relapse ; ,L. GG,None,1,6,3,No,1:No,1:No,,0.9
6382,394324,Table 1,BaselineCharacteristic,Placebo, ; ,Placebo,None,2,0,2,No,1:No,1:No,,0.95
6382,394324,Table 1,BaselineCharacteristic,n = x,pts. ; ,Placebo,None,2,1,3,No,1:No,1:No,,0.686
6382,394324,Table 1,BaselineCharacteristic,xxx ± xx,CDAI* ; ,Placebo,None,2,2,3,No,1:No,1:No,,0.576
6382,394324,Table 1,BaselineCharacteristic,xx ± xx,CRP* in mg/l ; ,Placebo,None,2,3,3,No,1:No,1:No,,0.556
6382,394324,Table 1,BaselineCharacteristic,x/x,remission ; ,Placebo,None,2,4,3,No,1:No,1:No,,0.9
6382,394324,Table 1,BaselineCharacteristic,x/x,sustained remission ; ,Placebo,None,2,5,3,No,1:No,1:No,,0.91
6382,394324,Table 1,BaselineCharacteristic,x/x,Relapse ; ,Placebo,None,2,6,3,No,1:No,1:No,,0.92
6405,420259,Table 1,BaselineCharacteristic,Epithelial Characteristics – Graded x–x,,None,None,0,0,12,No,1:No,1:No,,0.865
6405,420259,Table 1,BaselineCharacteristic,Epithelial Characteristics – Graded x–x,,Epithelial Characteristics – Graded x–x,None,0,1,1,No,1:No,1:No,,0.867
6405,420259,Table 1,BaselineCharacteristic,x. Epithelial abundance – the amount of epithelium found within the sample,Epithelial Characteristics – Graded x–x ; ,x. Epithelial abundance – the amount of epithelium found within the sample,None,1,0,2,No,1:No,1:No,,0.875
6405,420259,Table 1,BaselineCharacteristic,xx. Cell separation – at times cells are observed to be separate rather than tightly clustered together,Epithelial Characteristics – Graded x–x ; ,x. Epithelial abundance – the amount of epithelium found within the sample,None,1,1,3,No,1:No,1:No,,0.73
6405,420259,Table 1,BaselineCharacteristic,x. Tissue heterogeneity – the variability of tissue surfaces within the sample,Epithelial Characteristics – Graded x–x ; ,x. Tissue heterogeneity – the variability of tissue surfaces within the sample,None,2,0,2,No,1:No,1:No,,0.895
6405,420259,Table 1,BaselineCharacteristic,"xx. Denuded apices – cell surfaces are devoid of surface modifications such as microvilli, cilia (excluding uterdomes)",Epithelial Characteristics – Graded x–x ; ,x. Tissue heterogeneity – the variability of tissue surfaces within the sample,None,2,1,3,No,1:No,1:No,,0.69
6405,420259,Table 1,BaselineCharacteristic,x. Cell heterogeneitiy – the variability of the appearance of the cell types within each field,Epithelial Characteristics – Graded x–x ; ,x. Cell heterogeneitiy – the variability of the appearance of the cell types within each field,None,3,0,2,No,1:No,1:No,,0.905
6405,420259,Table 1,BaselineCharacteristic,xx. Flattened cells – degree to which cells display a flattened topography,Epithelial Characteristics – Graded x–x ; ,x. Cell heterogeneitiy – the variability of the appearance of the cell types within each field,None,3,1,3,No,1:No,1:No,,0.67
6405,420259,Table 1,BaselineCharacteristic,x. Gland abundance – the relative number of glands observed within each field,Epithelial Characteristics – Graded x–x ; ,x. Gland abundance – the relative number of glands observed within each field,None,4,0,2,No,1:No,1:No,,0.865
6405,420259,Table 1,BaselineCharacteristic,xx. Deflated cells – whether cell apices appear to have collapsed or withered,Epithelial Characteristics – Graded x–x ; ,x. Gland abundance – the relative number of glands observed within each field,None,4,1,3,No,1:No,1:No,,0.72
6405,420259,Table 1,BaselineCharacteristic,"x. Gland opening – the types of gland opening, whether wide, raised, narrow",Epithelial Characteristics – Graded x–x ; ,"x. Gland opening – the types of gland opening, whether wide, raised, narrow",None,5,0,2,No,1:No,1:No,,0.925
6405,420259,Table 1,BaselineCharacteristic,xx. Apical protrusion – the degree to which the cell surface protrudes into the lumen of the uterus,Epithelial Characteristics – Graded x–x ; ,"x. Gland opening – the types of gland opening, whether wide, raised, narrow",None,5,1,3,No,1:No,1:No,,0.74
6405,420259,Table 1,BaselineCharacteristic,x. Cilia groups – the relative number of ciliated cells clustered together,Epithelial Characteristics – Graded x–x ; ,x. Cilia groups – the relative number of ciliated cells clustered together,None,6,0,2,No,1:No,1:No,,0.875
6405,420259,Table 1,BaselineCharacteristic,xx. Uterodomes – shape (see Uterodome Assessment),Epithelial Characteristics – Graded x–x ; ,x. Cilia groups – the relative number of ciliated cells clustered together,None,6,1,3,No,1:No,1:No,,0.68
6405,420259,Table 1,BaselineCharacteristic,x. Single cilium – presence of these indicate a senescent or atrophying epithelium,Epithelial Characteristics – Graded x–x ; ,x. Single cilium – presence of these indicate a senescent or atrophying epithelium,None,7,0,2,No,1:No,1:No,,0.895
6405,420259,Table 1,BaselineCharacteristic,xx. Uterodomes – abundance (see Uterodome Assessment),Epithelial Characteristics – Graded x–x ; ,x. Single cilium – presence of these indicate a senescent or atrophying epithelium,None,7,1,3,No,1:No,1:No,,0.73
6405,420259,Table 1,BaselineCharacteristic,"x. Microvilli height – the relative length of microvilli, from short and blebbed to long",Epithelial Characteristics – Graded x–x ; ,"x. Microvilli height – the relative length of microvilli, from short and blebbed to long",None,8,0,2,No,1:No,1:No,,0.972
6405,420259,Table 1,BaselineCharacteristic,xx. Cell borders -may be obvious or deeply recessed between cells,Epithelial Characteristics – Graded x–x ; ,"x. Microvilli height – the relative length of microvilli, from short and blebbed to long",None,8,1,3,No,1:No,1:No,,0.87
6405,420259,Table 1,BaselineCharacteristic,"x. Microvilli density – relative number of microvilli per cell, from few to many",Epithelial Characteristics – Graded x–x ; ,"x. Microvilli density – relative number of microvilli per cell, from few to many",None,9,0,2,No,1:No,1:No,,0.885
6405,420259,Table 1,BaselineCharacteristic,xx. Secretion – the presence of secretory product within the field or on cell surfaces,Epithelial Characteristics – Graded x–x ; ,"x. Microvilli density – relative number of microvilli per cell, from few to many",None,9,1,3,No,1:No,1:No,,0.79
6405,420259,Table 1,BaselineCharacteristic,xx. Apical membrane defects – include observation of porosity and degeneration,Epithelial Characteristics – Graded x–x ; ,xx. Apical membrane defects – include observation of porosity and degeneration,None,10,0,2,No,1:No,1:No,,0.943
6405,420259,Table 1,BaselineCharacteristic,xx. Plicae – are microvillous folds or ridges on the cell surfaces,Epithelial Characteristics – Graded x–x ; ,xx. Apical membrane defects – include observation of porosity and degeneration,None,10,1,3,No,1:No,1:No,,0.946
6405,420259,Table 2,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
6405,420259,Table 2,BaselineCharacteristic,Epithelial abundance,,,None,0,1,1,No,1:No,1:No,,0.903
6405,420259,Table 2,BaselineCharacteristic,Tissue inhomogeneity,,,None,0,2,1,No,1:No,1:No,,0.903
6405,420259,Table 2,BaselineCharacteristic,Cell inhomogeneity,,,None,0,3,1,No,1:No,1:No,,0.903
6405,420259,Table 2,BaselineCharacteristic,Gland abundance,,,None,0,4,1,No,1:No,1:No,,0.913
6405,420259,Table 2,BaselineCharacteristic,Gland opening,,,None,0,5,1,No,1:No,1:No,,0.935
6405,420259,Table 2,BaselineCharacteristic,Cilia groups,,,None,0,6,1,No,1:No,1:No,,0.935
6405,420259,Table 2,BaselineCharacteristic,Single cilium,,,None,0,7,1,No,1:No,1:No,,0.945
6405,420259,Table 2,BaselineCharacteristic,Microvilli height,,,None,0,8,1,No,1:No,1:No,,0.945
6405,420259,Table 2,BaselineCharacteristic,Microvilli density,,,None,0,9,1,No,1:No,1:No,,0.945
6405,420259,Table 2,BaselineCharacteristic,Apical membrane defects,,,None,0,10,1,No,1:No,1:No,,0.945
6405,420259,Table 2,BaselineCharacteristic,Cell separation,,,None,0,11,1,No,1:No,1:No,,0.945
6405,420259,Table 2,BaselineCharacteristic,Denuded apices,,,None,0,12,1,No,1:No,1:No,,0.945
6405,420259,Table 2,BaselineCharacteristic,Flattened cells,,,None,0,13,1,No,1:No,1:No,,0.945
6405,420259,Table 2,BaselineCharacteristic,Deflated cells,,,None,0,14,1,No,1:No,1:No,,0.945
6405,420259,Table 2,BaselineCharacteristic,Apical protrusion,,,None,0,15,1,No,1:No,1:No,,0.945
6405,420259,Table 2,BaselineCharacteristic,Uterodome – shape,,,None,0,16,1,No,1:No,1:No,,0.906
6405,420259,Table 2,BaselineCharacteristic,Uterodome – abundance,,,None,0,17,1,No,1:No,1:No,,0.906
6405,420259,Table 2,BaselineCharacteristic,Cell borders,,,None,0,18,1,No,1:No,1:No,,0.945
6405,420259,Table 2,BaselineCharacteristic,Secretion,,,None,0,19,1,No,1:No,1:No,,0.945
6405,420259,Table 2,BaselineCharacteristic,Plicae,,,None,0,20,1,No,1:No,1:No,,0.945
6405,420259,Table 2,BaselineCharacteristic,group x vs group x, ; ,group x vs group x,None,1,0,2,No,1:No,1:No,,0.895
6405,420259,Table 2,BaselineCharacteristic,"SD (x.x,x)",Epithelial abundance ; ,group x vs group x,None,1,1,3,No,1:No,1:No,,0.7
6405,420259,Table 2,BaselineCharacteristic,,Tissue inhomogeneity ; ,group x vs group x,None,1,2,3,No,1:No,1:No,,0.88
6405,420259,Table 2,BaselineCharacteristic,"SD (x.x,x)",Cell inhomogeneity ; ,group x vs group x,None,1,3,3,No,1:No,1:No,,0.71
6405,420259,Table 2,BaselineCharacteristic,,Gland abundance ; ,group x vs group x,None,1,4,3,No,1:No,1:No,,0.87
6405,420259,Table 2,BaselineCharacteristic,,Gland opening ; ,group x vs group x,None,1,5,3,No,1:No,1:No,,0.88
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Cilia groups ; ,group x vs group x,None,1,6,3,No,1:No,1:No,,0.73
6405,420259,Table 2,BaselineCharacteristic,,Single cilium ; ,group x vs group x,None,1,7,3,No,1:No,1:No,,0.88
6405,420259,Table 2,BaselineCharacteristic,,Microvilli height ; ,group x vs group x,None,1,8,3,No,1:No,1:No,,0.89
6405,420259,Table 2,BaselineCharacteristic,"SD (x.x,x)",Microvilli density ; ,group x vs group x,None,1,9,3,No,1:No,1:No,,0.73
6405,420259,Table 2,BaselineCharacteristic,,Apical membrane defects ; ,group x vs group x,None,1,10,3,No,1:No,1:No,,0.89
6405,420259,Table 2,BaselineCharacteristic,,Cell separation ; ,group x vs group x,None,1,11,3,No,1:No,1:No,,0.89
6405,420259,Table 2,BaselineCharacteristic,,Denuded apices ; ,group x vs group x,None,1,12,3,No,1:No,1:No,,0.89
6405,420259,Table 2,BaselineCharacteristic,,Flattened cells ; ,group x vs group x,None,1,13,3,No,1:No,1:No,,0.89
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Deflated cells ; ,group x vs group x,None,1,14,3,No,1:No,1:No,,0.73
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Apical protrusion ; ,group x vs group x,None,1,15,3,No,1:No,1:No,,0.73
6405,420259,Table 2,BaselineCharacteristic,,Uterodome – shape ; ,group x vs group x,None,1,16,3,No,1:No,1:No,,0.87
6405,420259,Table 2,BaselineCharacteristic,,Uterodome – abundance ; ,group x vs group x,None,1,17,3,No,1:No,1:No,,0.87
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Cell borders ; ,group x vs group x,None,1,18,3,No,1:No,1:No,,0.73
6405,420259,Table 2,BaselineCharacteristic,"SD (x.x,x)",Secretion ; ,group x vs group x,None,1,19,3,No,1:No,1:No,,0.73
6405,420259,Table 2,BaselineCharacteristic,,Plicae ; ,group x vs group x,None,1,20,3,No,1:No,1:No,,0.89
6405,420259,Table 2,BaselineCharacteristic,group x vs group x, ; ,group x vs group x,None,2,0,2,No,1:No,1:No,,0.905
6405,420259,Table 2,BaselineCharacteristic,"SD (x.x,x)",Epithelial abundance ; ,group x vs group x,None,2,1,3,No,1:No,1:No,,0.7
6405,420259,Table 2,BaselineCharacteristic,,Tissue inhomogeneity ; ,group x vs group x,None,2,2,3,No,1:No,1:No,,0.9
6405,420259,Table 2,BaselineCharacteristic,,Cell inhomogeneity ; ,group x vs group x,None,2,3,3,No,1:No,1:No,,0.9
6405,420259,Table 2,BaselineCharacteristic,,Gland abundance ; ,group x vs group x,None,2,4,3,No,1:No,1:No,,0.89
6405,420259,Table 2,BaselineCharacteristic,,Gland opening ; ,group x vs group x,None,2,5,3,No,1:No,1:No,,0.89
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x.x)",Cilia groups ; ,group x vs group x,None,2,6,3,No,1:No,1:No,,0.73
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x.x)",Single cilium ; ,group x vs group x,None,2,7,3,No,1:No,1:No,,0.72
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Microvilli height ; ,group x vs group x,None,2,8,3,No,1:No,1:No,,0.74
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Microvilli density ; ,group x vs group x,None,2,9,3,No,1:No,1:No,,0.73
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Apical membrane defects ; ,group x vs group x,None,2,10,3,No,1:No,1:No,,0.73
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x.x)",Cell separation ; ,group x vs group x,None,2,11,3,No,1:No,1:No,,0.73
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Denuded apices ; ,group x vs group x,None,2,12,3,No,1:No,1:No,,0.73
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Flattened cells ; ,group x vs group x,None,2,13,3,No,1:No,1:No,,0.73
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Deflated cells ; ,group x vs group x,None,2,14,3,No,1:No,1:No,,0.73
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Apical protrusion ; ,group x vs group x,None,2,15,3,No,1:No,1:No,,0.73
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Uterodome – shape ; ,group x vs group x,None,2,16,3,No,1:No,1:No,,0.73
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Uterodome – abundance ; ,group x vs group x,None,2,17,3,No,1:No,1:No,,0.73
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Cell borders ; ,group x vs group x,None,2,18,3,No,1:No,1:No,,0.73
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Secretion ; ,group x vs group x,None,2,19,3,No,1:No,1:No,,0.73
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x.x)",Plicae ; ,group x vs group x,None,2,20,3,No,1:No,1:No,,0.73
6405,420259,Table 2,BaselineCharacteristic,group x vs group x, ; ,group x vs group x,None,3,0,2,No,1:No,1:No,,0.915
6405,420259,Table 2,BaselineCharacteristic,,Epithelial abundance ; ,group x vs group x,None,3,1,3,No,1:No,1:No,,0.91
6405,420259,Table 2,BaselineCharacteristic,,Tissue inhomogeneity ; ,group x vs group x,None,3,2,3,No,1:No,1:No,,0.92
6405,420259,Table 2,BaselineCharacteristic,,Cell inhomogeneity ; ,group x vs group x,None,3,3,3,No,1:No,1:No,,0.92
6405,420259,Table 2,BaselineCharacteristic,,Gland abundance ; ,group x vs group x,None,3,4,3,No,1:No,1:No,,0.91
6405,420259,Table 2,BaselineCharacteristic,,Gland opening ; ,group x vs group x,None,3,5,3,No,1:No,1:No,,0.91
6405,420259,Table 2,BaselineCharacteristic,,Cilia groups ; ,group x vs group x,None,3,6,3,No,1:No,1:No,,0.92
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x.x)",Single cilium ; ,group x vs group x,None,3,7,3,No,1:No,1:No,,0.75
6405,420259,Table 2,BaselineCharacteristic,,Microvilli height ; ,group x vs group x,None,3,8,3,No,1:No,1:No,,0.92
6405,420259,Table 2,BaselineCharacteristic,,Microvilli density ; ,group x vs group x,None,3,9,3,No,1:No,1:No,,0.92
6405,420259,Table 2,BaselineCharacteristic,,Apical membrane defects ; ,group x vs group x,None,3,10,3,No,1:No,1:No,,0.92
6405,420259,Table 2,BaselineCharacteristic,,Cell separation ; ,group x vs group x,None,3,11,3,No,1:No,1:No,,0.92
6405,420259,Table 2,BaselineCharacteristic,,Denuded apices ; ,group x vs group x,None,3,12,3,No,1:No,1:No,,0.92
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Flattened cells ; ,group x vs group x,None,3,13,3,No,1:No,1:No,,0.76
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Deflated cells ; ,group x vs group x,None,3,14,3,No,1:No,1:No,,0.76
6405,420259,Table 2,BaselineCharacteristic,,Apical protrusion ; ,group x vs group x,None,3,15,3,No,1:No,1:No,,0.92
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Uterodome – shape ; ,group x vs group x,None,3,16,3,No,1:No,1:No,,0.76
6405,420259,Table 2,BaselineCharacteristic,,Uterodome – abundance ; ,group x vs group x,None,3,17,3,No,1:No,1:No,,0.9
6405,420259,Table 2,BaselineCharacteristic,,Cell borders ; ,group x vs group x,None,3,18,3,No,1:No,1:No,,0.92
6405,420259,Table 2,BaselineCharacteristic,,Secretion ; ,group x vs group x,None,3,19,3,No,1:No,1:No,,0.92
6405,420259,Table 2,BaselineCharacteristic,,Plicae ; ,group x vs group x,None,3,20,3,No,1:No,1:No,,0.92
6405,420259,Table 2,BaselineCharacteristic,group x vs group x, ; ,group x vs group x,None,4,0,2,No,1:No,1:No,,0.955
6405,420259,Table 2,BaselineCharacteristic,,Epithelial abundance ; ,group x vs group x,None,4,1,3,No,1:No,1:No,,0.93
6405,420259,Table 2,BaselineCharacteristic,,Tissue inhomogeneity ; ,group x vs group x,None,4,2,3,No,1:No,1:No,,0.95
6405,420259,Table 2,BaselineCharacteristic,,Cell inhomogeneity ; ,group x vs group x,None,4,3,3,No,1:No,1:No,,0.95
6405,420259,Table 2,BaselineCharacteristic,,Gland abundance ; ,group x vs group x,None,4,4,3,No,1:No,1:No,,0.94
6405,420259,Table 2,BaselineCharacteristic,,Gland opening ; ,group x vs group x,None,4,5,3,No,1:No,1:No,,0.93
6405,420259,Table 2,BaselineCharacteristic,,Cilia groups ; ,group x vs group x,None,4,6,3,No,1:No,1:No,,0.93
6405,420259,Table 2,BaselineCharacteristic,,Single cilium ; ,group x vs group x,None,4,7,3,No,1:No,1:No,,0.92
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Microvilli height ; ,group x vs group x,None,4,8,3,No,1:No,1:No,,0.8
6405,420259,Table 2,BaselineCharacteristic,,Microvilli density ; ,group x vs group x,None,4,9,3,No,1:No,1:No,,0.93
6405,420259,Table 2,BaselineCharacteristic,,Apical membrane defects ; ,group x vs group x,None,4,10,3,No,1:No,1:No,,0.93
6405,420259,Table 2,BaselineCharacteristic,,Cell separation ; ,group x vs group x,None,4,11,3,No,1:No,1:No,,0.93
6405,420259,Table 2,BaselineCharacteristic,,Denuded apices ; ,group x vs group x,None,4,12,3,No,1:No,1:No,,0.93
6405,420259,Table 2,BaselineCharacteristic,,Flattened cells ; ,group x vs group x,None,4,13,3,No,1:No,1:No,,0.93
6405,420259,Table 2,BaselineCharacteristic,,Deflated cells ; ,group x vs group x,None,4,14,3,No,1:No,1:No,,0.93
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Apical protrusion ; ,group x vs group x,None,4,15,3,No,1:No,1:No,,0.79
6405,420259,Table 2,BaselineCharacteristic,,Uterodome – shape ; ,group x vs group x,None,4,16,3,No,1:No,1:No,,0.91
6405,420259,Table 2,BaselineCharacteristic,,Uterodome – abundance ; ,group x vs group x,None,4,17,3,No,1:No,1:No,,0.91
6405,420259,Table 2,BaselineCharacteristic,,Cell borders ; ,group x vs group x,None,4,18,3,No,1:No,1:No,,0.93
6405,420259,Table 2,BaselineCharacteristic,,Secretion ; ,group x vs group x,None,4,19,3,No,1:No,1:No,,0.93
6405,420259,Table 2,BaselineCharacteristic,,Plicae ; ,group x vs group x,None,4,20,3,No,1:No,1:No,,0.93
6405,420259,Table 2,BaselineCharacteristic,group x vs group x, ; ,group x vs group x,None,5,0,2,No,1:No,1:No,,0.953
6405,420259,Table 2,BaselineCharacteristic,,Epithelial abundance ; ,group x vs group x,None,5,1,3,No,1:No,1:No,,0.94
6405,420259,Table 2,BaselineCharacteristic,,Tissue inhomogeneity ; ,group x vs group x,None,5,2,3,No,1:No,1:No,,0.96
6405,420259,Table 2,BaselineCharacteristic,,Cell inhomogeneity ; ,group x vs group x,None,5,3,3,No,1:No,1:No,,0.96
6405,420259,Table 2,BaselineCharacteristic,,Gland abundance ; ,group x vs group x,None,5,4,3,No,1:No,1:No,,0.95
6405,420259,Table 2,BaselineCharacteristic,,Gland opening ; ,group x vs group x,None,5,5,3,No,1:No,1:No,,0.93
6405,420259,Table 2,BaselineCharacteristic,,Cilia groups ; ,group x vs group x,None,5,6,3,No,1:No,1:No,,0.93
6405,420259,Table 2,BaselineCharacteristic,,Single cilium ; ,group x vs group x,None,5,7,3,No,1:No,1:No,,0.92
6405,420259,Table 2,BaselineCharacteristic,,Microvilli height ; ,group x vs group x,None,5,8,3,No,1:No,1:No,,0.93
6405,420259,Table 2,BaselineCharacteristic,,Microvilli density ; ,group x vs group x,None,5,9,3,No,1:No,1:No,,0.93
6405,420259,Table 2,BaselineCharacteristic,,Apical membrane defects ; ,group x vs group x,None,5,10,3,No,1:No,1:No,,0.93
6405,420259,Table 2,BaselineCharacteristic,,Cell separation ; ,group x vs group x,None,5,11,3,No,1:No,1:No,,0.93
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Denuded apices ; ,group x vs group x,None,5,12,3,No,1:No,1:No,,0.79
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Flattened cells ; ,group x vs group x,None,5,13,3,No,1:No,1:No,,0.79
6405,420259,Table 2,BaselineCharacteristic,,Deflated cells ; ,group x vs group x,None,5,14,3,No,1:No,1:No,,0.93
6405,420259,Table 2,BaselineCharacteristic,,Apical protrusion ; ,group x vs group x,None,5,15,3,No,1:No,1:No,,0.93
6405,420259,Table 2,BaselineCharacteristic,,Uterodome – shape ; ,group x vs group x,None,5,16,3,No,1:No,1:No,,0.91
6405,420259,Table 2,BaselineCharacteristic,,Uterodome – abundance ; ,group x vs group x,None,5,17,3,No,1:No,1:No,,0.91
6405,420259,Table 2,BaselineCharacteristic,,Cell borders ; ,group x vs group x,None,5,18,3,No,1:No,1:No,,0.93
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Secretion ; ,group x vs group x,None,5,19,3,No,1:No,1:No,,0.79
6405,420259,Table 2,BaselineCharacteristic,,Plicae ; ,group x vs group x,None,5,20,3,No,1:No,1:No,,0.93
6405,420259,Table 2,BaselineCharacteristic,group x vs group x, ; ,group x vs group x,None,6,0,2,No,1:No,1:No,,0.963
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Epithelial abundance ; ,group x vs group x,None,6,1,3,No,1:No,1:No,,0.78
6405,420259,Table 2,BaselineCharacteristic,,Tissue inhomogeneity ; ,group x vs group x,None,6,2,3,No,1:No,1:No,,0.97
6405,420259,Table 2,BaselineCharacteristic,,Cell inhomogeneity ; ,group x vs group x,None,6,3,3,No,1:No,1:No,,0.97
6405,420259,Table 2,BaselineCharacteristic,,Gland abundance ; ,group x vs group x,None,6,4,3,No,1:No,1:No,,0.96
6405,420259,Table 2,BaselineCharacteristic,,Gland opening ; ,group x vs group x,None,6,5,3,No,1:No,1:No,,0.94
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x.x)",Cilia groups ; ,group x vs group x,None,6,6,3,No,1:No,1:No,,0.8
6405,420259,Table 2,BaselineCharacteristic,,Single cilium ; ,group x vs group x,None,6,7,3,No,1:No,1:No,,0.93
6405,420259,Table 2,BaselineCharacteristic,,Microvilli height ; ,group x vs group x,None,6,8,3,No,1:No,1:No,,0.94
6405,420259,Table 2,BaselineCharacteristic,,Microvilli density ; ,group x vs group x,None,6,9,3,No,1:No,1:No,,0.94
6405,420259,Table 2,BaselineCharacteristic,,Apical membrane defects ; ,group x vs group x,None,6,10,3,No,1:No,1:No,,0.94
6405,420259,Table 2,BaselineCharacteristic,,Cell separation ; ,group x vs group x,None,6,11,3,No,1:No,1:No,,0.94
6405,420259,Table 2,BaselineCharacteristic,,Denuded apices ; ,group x vs group x,None,6,12,3,No,1:No,1:No,,0.94
6405,420259,Table 2,BaselineCharacteristic,,Flattened cells ; ,group x vs group x,None,6,13,3,No,1:No,1:No,,0.94
6405,420259,Table 2,BaselineCharacteristic,,Deflated cells ; ,group x vs group x,None,6,14,3,No,1:No,1:No,,0.94
6405,420259,Table 2,BaselineCharacteristic,,Apical protrusion ; ,group x vs group x,None,6,15,3,No,1:No,1:No,,0.94
6405,420259,Table 2,BaselineCharacteristic,,Uterodome – shape ; ,group x vs group x,None,6,16,3,No,1:No,1:No,,0.92
6405,420259,Table 2,BaselineCharacteristic,,Uterodome – abundance ; ,group x vs group x,None,6,17,3,No,1:No,1:No,,0.92
6405,420259,Table 2,BaselineCharacteristic,,Cell borders ; ,group x vs group x,None,6,18,3,No,1:No,1:No,,0.94
6405,420259,Table 2,BaselineCharacteristic,,Secretion ; ,group x vs group x,None,6,19,3,No,1:No,1:No,,0.94
6405,420259,Table 2,BaselineCharacteristic,,Plicae ; ,group x vs group x,None,6,20,3,No,1:No,1:No,,0.94
6405,420259,Table 2,BaselineCharacteristic,group x vs group x, ; ,group x vs group x,None,7,0,2,No,1:No,1:No,,0.963
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Epithelial abundance ; ,group x vs group x,None,7,1,3,No,1:No,1:No,,0.79
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x.x)",Tissue inhomogeneity ; ,group x vs group x,None,7,2,3,No,1:No,1:No,,0.8
6405,420259,Table 2,BaselineCharacteristic,,Cell inhomogeneity ; ,group x vs group x,None,7,3,3,No,1:No,1:No,,0.97
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x.x)",Gland abundance ; ,group x vs group x,None,7,4,3,No,1:No,1:No,,0.82
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Gland opening ; ,group x vs group x,None,7,5,3,No,1:No,1:No,,0.82
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x.x)",Cilia groups ; ,group x vs group x,None,7,6,3,No,1:No,1:No,,0.82
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x.x)",Single cilium ; ,group x vs group x,None,7,7,3,No,1:No,1:No,,0.81
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Microvilli height ; ,group x vs group x,None,7,8,3,No,1:No,1:No,,0.83
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Microvilli density ; ,group x vs group x,None,7,9,3,No,1:No,1:No,,0.82
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Apical membrane defects ; ,group x vs group x,None,7,10,3,No,1:No,1:No,,0.82
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x.x)",Cell separation ; ,group x vs group x,None,7,11,3,No,1:No,1:No,,0.82
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Denuded apices ; ,group x vs group x,None,7,12,3,No,1:No,1:No,,0.82
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Flattened cells ; ,group x vs group x,None,7,13,3,No,1:No,1:No,,0.82
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Deflated cells ; ,group x vs group x,None,7,14,3,No,1:No,1:No,,0.82
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Apical protrusion ; ,group x vs group x,None,7,15,3,No,1:No,1:No,,0.82
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Uterodome – shape ; ,group x vs group x,None,7,16,3,No,1:No,1:No,,0.82
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Uterodome – abundance ; ,group x vs group x,None,7,17,3,No,1:No,1:No,,0.82
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Cell borders ; ,group x vs group x,None,7,18,3,No,1:No,1:No,,0.82
6405,420259,Table 2,BaselineCharacteristic,"SD (x.x,x)",Secretion ; ,group x vs group x,None,7,19,3,No,1:No,1:No,,0.82
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x.x)",Plicae ; ,group x vs group x,None,7,20,3,No,1:No,1:No,,0.82
6405,420259,Table 2,BaselineCharacteristic,group x vs group x, ; ,group x vs group x,None,8,0,2,No,1:No,1:No,,0.972
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Epithelial abundance ; ,group x vs group x,None,8,1,3,No,1:No,1:No,,0.81
6405,420259,Table 2,BaselineCharacteristic,,Tissue inhomogeneity ; ,group x vs group x,None,8,2,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Cell inhomogeneity ; ,group x vs group x,None,8,3,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Gland abundance ; ,group x vs group x,None,8,4,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Gland opening ; ,group x vs group x,None,8,5,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Cilia groups ; ,group x vs group x,None,8,6,3,No,1:No,1:No,,0.84
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x.x)",Single cilium ; ,group x vs group x,None,8,7,3,No,1:No,1:No,,0.83
6405,420259,Table 2,BaselineCharacteristic,,Microvilli height ; ,group x vs group x,None,8,8,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Microvilli density ; ,group x vs group x,None,8,9,3,No,1:No,1:No,,0.84
6405,420259,Table 2,BaselineCharacteristic,,Apical membrane defects ; ,group x vs group x,None,8,10,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Cell separation ; ,group x vs group x,None,8,11,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Denuded apices ; ,group x vs group x,None,8,12,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Flattened cells ; ,group x vs group x,None,8,13,3,No,1:No,1:No,,0.84
6405,420259,Table 2,BaselineCharacteristic,,Deflated cells ; ,group x vs group x,None,8,14,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Apical protrusion ; ,group x vs group x,None,8,15,3,No,1:No,1:No,,0.84
6405,420259,Table 2,BaselineCharacteristic,,Uterodome – shape ; ,group x vs group x,None,8,16,3,No,1:No,1:No,,0.96
6405,420259,Table 2,BaselineCharacteristic,,Uterodome – abundance ; ,group x vs group x,None,8,17,3,No,1:No,1:No,,0.96
6405,420259,Table 2,BaselineCharacteristic,,Cell borders ; ,group x vs group x,None,8,18,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Secretion ; ,group x vs group x,None,8,19,3,No,1:No,1:No,,0.84
6405,420259,Table 2,BaselineCharacteristic,,Plicae ; ,group x vs group x,None,8,20,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,group x vs group x, ; ,group x vs group x,None,9,0,2,No,1:No,1:No,,0.972
6405,420259,Table 2,BaselineCharacteristic,,Epithelial abundance ; ,group x vs group x,None,9,1,3,No,1:No,1:No,,0.98
6405,420259,Table 2,BaselineCharacteristic,,Tissue inhomogeneity ; ,group x vs group x,None,9,2,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Cell inhomogeneity ; ,group x vs group x,None,9,3,3,No,1:No,1:No,,0.82
6405,420259,Table 2,BaselineCharacteristic,,Gland abundance ; ,group x vs group x,None,9,4,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Gland opening ; ,group x vs group x,None,9,5,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Cilia groups ; ,group x vs group x,None,9,6,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Single cilium ; ,group x vs group x,None,9,7,3,No,1:No,1:No,,0.98
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Microvilli height ; ,group x vs group x,None,9,8,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Microvilli density ; ,group x vs group x,None,9,9,3,No,1:No,1:No,,0.84
6405,420259,Table 2,BaselineCharacteristic,,Apical membrane defects ; ,group x vs group x,None,9,10,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Cell separation ; ,group x vs group x,None,9,11,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Denuded apices ; ,group x vs group x,None,9,12,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Flattened cells ; ,group x vs group x,None,9,13,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Deflated cells ; ,group x vs group x,None,9,14,3,No,1:No,1:No,,0.84
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Apical protrusion ; ,group x vs group x,None,9,15,3,No,1:No,1:No,,0.84
6405,420259,Table 2,BaselineCharacteristic,,Uterodome – shape ; ,group x vs group x,None,9,16,3,No,1:No,1:No,,0.96
6405,420259,Table 2,BaselineCharacteristic,,Uterodome – abundance ; ,group x vs group x,None,9,17,3,No,1:No,1:No,,0.96
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Cell borders ; ,group x vs group x,None,9,18,3,No,1:No,1:No,,0.84
6405,420259,Table 2,BaselineCharacteristic,"SD (x.x,x)",Secretion ; ,group x vs group x,None,9,19,3,No,1:No,1:No,,0.84
6405,420259,Table 2,BaselineCharacteristic,"SD (x.x,x)",Plicae ; ,group x vs group x,None,9,20,3,No,1:No,1:No,,0.84
6405,420259,Table 2,BaselineCharacteristic,group x vs group x, ; ,group x vs group x,None,10,0,2,No,1:No,1:No,,0.972
6405,420259,Table 2,BaselineCharacteristic,,Epithelial abundance ; ,group x vs group x,None,10,1,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Tissue inhomogeneity ; ,group x vs group x,None,10,2,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Cell inhomogeneity ; ,group x vs group x,None,10,3,3,No,1:No,1:No,,0.82
6405,420259,Table 2,BaselineCharacteristic,,Gland abundance ; ,group x vs group x,None,10,4,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Gland opening ; ,group x vs group x,None,10,5,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Cilia groups ; ,group x vs group x,None,10,6,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,,Single cilium ; ,group x vs group x,None,10,7,3,No,1:No,1:No,,0.98
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Microvilli height ; ,group x vs group x,None,10,8,3,No,1:No,1:No,,0.86
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Microvilli density ; ,group x vs group x,None,10,9,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,,Apical membrane defects ; ,group x vs group x,None,10,10,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Cell separation ; ,group x vs group x,None,10,11,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Denuded apices ; ,group x vs group x,None,10,12,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Flattened cells ; ,group x vs group x,None,10,13,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Deflated cells ; ,group x vs group x,None,10,14,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Apical protrusion ; ,group x vs group x,None,10,15,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,,Uterodome – shape ; ,group x vs group x,None,10,16,3,No,1:No,1:No,,0.97
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Uterodome – abundance ; ,group x vs group x,None,10,17,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Cell borders ; ,group x vs group x,None,10,18,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x.x,x)",Secretion ; ,group x vs group x,None,10,19,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,,Plicae ; ,group x vs group x,None,10,20,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,group x vs group x, ; ,group x vs group x,None,11,0,2,No,1:No,1:No,,0.972
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Epithelial abundance ; ,group x vs group x,None,11,1,3,No,1:No,1:No,,0.82
6405,420259,Table 2,BaselineCharacteristic,"SD (x.x,x)",Tissue inhomogeneity ; ,group x vs group x,None,11,2,3,No,1:No,1:No,,0.82
6405,420259,Table 2,BaselineCharacteristic,,Cell inhomogeneity ; ,group x vs group x,None,11,3,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Gland abundance ; ,group x vs group x,None,11,4,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x.x)",Gland opening ; ,group x vs group x,None,11,5,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x.x,x)",Cilia groups ; ,group x vs group x,None,11,6,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,,Single cilium ; ,group x vs group x,None,11,7,3,No,1:No,1:No,,0.98
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Microvilli height ; ,group x vs group x,None,11,8,3,No,1:No,1:No,,0.86
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Microvilli density ; ,group x vs group x,None,11,9,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Apical membrane defects ; ,group x vs group x,None,11,10,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x.x,x)",Cell separation ; ,group x vs group x,None,11,11,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Denuded apices ; ,group x vs group x,None,11,12,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Flattened cells ; ,group x vs group x,None,11,13,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Deflated cells ; ,group x vs group x,None,11,14,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Apical protrusion ; ,group x vs group x,None,11,15,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Uterodome – shape ; ,group x vs group x,None,11,16,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Uterodome – abundance ; ,group x vs group x,None,11,17,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Cell borders ; ,group x vs group x,None,11,18,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Secretion ; ,group x vs group x,None,11,19,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,,Plicae ; ,group x vs group x,None,11,20,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,group x vs group x, ; ,group x vs group x,None,12,0,2,No,1:No,1:No,,0.972
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Epithelial abundance ; ,group x vs group x,None,12,1,3,No,1:No,1:No,,0.82
6405,420259,Table 2,BaselineCharacteristic,,Tissue inhomogeneity ; ,group x vs group x,None,12,2,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Cell inhomogeneity ; ,group x vs group x,None,12,3,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Gland abundance ; ,group x vs group x,None,12,4,3,No,1:No,1:No,,0.84
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x.x)",Gland opening ; ,group x vs group x,None,12,5,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x.x,x)",Cilia groups ; ,group x vs group x,None,12,6,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x.x,x)",Single cilium ; ,group x vs group x,None,12,7,3,No,1:No,1:No,,0.84
6405,420259,Table 2,BaselineCharacteristic,,Microvilli height ; ,group x vs group x,None,12,8,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Microvilli density ; ,group x vs group x,None,12,9,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,"SD (x.x,x)",Apical membrane defects ; ,group x vs group x,None,12,10,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x.x,x)",Cell separation ; ,group x vs group x,None,12,11,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Denuded apices ; ,group x vs group x,None,12,12,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Flattened cells ; ,group x vs group x,None,12,13,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Deflated cells ; ,group x vs group x,None,12,14,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Apical protrusion ; ,group x vs group x,None,12,15,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Uterodome – shape ; ,group x vs group x,None,12,16,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Uterodome – abundance ; ,group x vs group x,None,12,17,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Cell borders ; ,group x vs group x,None,12,18,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Secretion ; ,group x vs group x,None,12,19,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,,Plicae ; ,group x vs group x,None,12,20,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,group x vs group x, ; ,group x vs group x,None,13,0,2,No,1:No,1:No,,0.972
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Epithelial abundance ; ,group x vs group x,None,13,1,3,No,1:No,1:No,,0.82
6405,420259,Table 2,BaselineCharacteristic,,Tissue inhomogeneity ; ,group x vs group x,None,13,2,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,"SD (x.x,x)",Cell inhomogeneity ; ,group x vs group x,None,13,3,3,No,1:No,1:No,,0.82
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Gland abundance ; ,group x vs group x,None,13,4,3,No,1:No,1:No,,0.84
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Gland opening ; ,group x vs group x,None,13,5,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x.x,x)",Cilia groups ; ,group x vs group x,None,13,6,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Single cilium ; ,group x vs group x,None,13,7,3,No,1:No,1:No,,0.84
6405,420259,Table 2,BaselineCharacteristic,,Microvilli height ; ,group x vs group x,None,13,8,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Microvilli density ; ,group x vs group x,None,13,9,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,"SD (x.x,x)",Apical membrane defects ; ,group x vs group x,None,13,10,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x.x,x)",Cell separation ; ,group x vs group x,None,13,11,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Denuded apices ; ,group x vs group x,None,13,12,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Flattened cells ; ,group x vs group x,None,13,13,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Deflated cells ; ,group x vs group x,None,13,14,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Apical protrusion ; ,group x vs group x,None,13,15,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Uterodome – shape ; ,group x vs group x,None,13,16,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Uterodome – abundance ; ,group x vs group x,None,13,17,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Cell borders ; ,group x vs group x,None,13,18,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Secretion ; ,group x vs group x,None,13,19,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,,Plicae ; ,group x vs group x,None,13,20,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,group x vs group x, ; ,group x vs group x,None,14,0,2,No,1:No,1:No,,0.972
6405,420259,Table 2,BaselineCharacteristic,,Epithelial abundance ; ,group x vs group x,None,14,1,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Tissue inhomogeneity ; ,group x vs group x,None,14,2,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Cell inhomogeneity ; ,group x vs group x,None,14,3,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Gland abundance ; ,group x vs group x,None,14,4,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Gland opening ; ,group x vs group x,None,14,5,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Cilia groups ; ,group x vs group x,None,14,6,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,"SD (x.x,x)",Single cilium ; ,group x vs group x,None,14,7,3,No,1:No,1:No,,0.84
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Microvilli height ; ,group x vs group x,None,14,8,3,No,1:No,1:No,,0.86
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Microvilli density ; ,group x vs group x,None,14,9,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,,Apical membrane defects ; ,group x vs group x,None,14,10,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Cell separation ; ,group x vs group x,None,14,11,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Denuded apices ; ,group x vs group x,None,14,12,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Flattened cells ; ,group x vs group x,None,14,13,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Deflated cells ; ,group x vs group x,None,14,14,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Apical protrusion ; ,group x vs group x,None,14,15,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,,Uterodome – shape ; ,group x vs group x,None,14,16,3,No,1:No,1:No,,0.97
6405,420259,Table 2,BaselineCharacteristic,,Uterodome – abundance ; ,group x vs group x,None,14,17,3,No,1:No,1:No,,0.97
6405,420259,Table 2,BaselineCharacteristic,,Cell borders ; ,group x vs group x,None,14,18,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Secretion ; ,group x vs group x,None,14,19,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Plicae ; ,group x vs group x,None,14,20,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,group x vs group x, ; ,group x vs group x,None,15,0,2,No,1:No,1:No,,0.972
6405,420259,Table 2,BaselineCharacteristic,,Epithelial abundance ; ,group x vs group x,None,15,1,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Tissue inhomogeneity ; ,group x vs group x,None,15,2,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,"SD (x.x,x)",Cell inhomogeneity ; ,group x vs group x,None,15,3,3,No,1:No,1:No,,0.82
6405,420259,Table 2,BaselineCharacteristic,,Gland abundance ; ,group x vs group x,None,15,4,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Gland opening ; ,group x vs group x,None,15,5,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Cilia groups ; ,group x vs group x,None,15,6,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,"SD (x.x,x)",Single cilium ; ,group x vs group x,None,15,7,3,No,1:No,1:No,,0.84
6405,420259,Table 2,BaselineCharacteristic,,Microvilli height ; ,group x vs group x,None,15,8,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Microvilli density ; ,group x vs group x,None,15,9,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,,Apical membrane defects ; ,group x vs group x,None,15,10,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Cell separation ; ,group x vs group x,None,15,11,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Denuded apices ; ,group x vs group x,None,15,12,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Flattened cells ; ,group x vs group x,None,15,13,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Deflated cells ; ,group x vs group x,None,15,14,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,,Apical protrusion ; ,group x vs group x,None,15,15,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Uterodome – shape ; ,group x vs group x,None,15,16,3,No,1:No,1:No,,0.97
6405,420259,Table 2,BaselineCharacteristic,,Uterodome – abundance ; ,group x vs group x,None,15,17,3,No,1:No,1:No,,0.97
6405,420259,Table 2,BaselineCharacteristic,,Cell borders ; ,group x vs group x,None,15,18,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Secretion ; ,group x vs group x,None,15,19,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,,Plicae ; ,group x vs group x,None,15,20,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,group x vs group x, ; ,group x vs group x,None,16,0,2,No,1:No,1:No,,0.972
6405,420259,Table 2,BaselineCharacteristic,,Epithelial abundance ; ,group x vs group x,None,16,1,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Tissue inhomogeneity ; ,group x vs group x,None,16,2,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Cell inhomogeneity ; ,group x vs group x,None,16,3,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Gland abundance ; ,group x vs group x,None,16,4,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Gland opening ; ,group x vs group x,None,16,5,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Cilia groups ; ,group x vs group x,None,16,6,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Single cilium ; ,group x vs group x,None,16,7,3,No,1:No,1:No,,0.98
6405,420259,Table 2,BaselineCharacteristic,,Microvilli height ; ,group x vs group x,None,16,8,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Microvilli density ; ,group x vs group x,None,16,9,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Apical membrane defects ; ,group x vs group x,None,16,10,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Cell separation ; ,group x vs group x,None,16,11,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Denuded apices ; ,group x vs group x,None,16,12,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Flattened cells ; ,group x vs group x,None,16,13,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Deflated cells ; ,group x vs group x,None,16,14,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Apical protrusion ; ,group x vs group x,None,16,15,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,,Uterodome – shape ; ,group x vs group x,None,16,16,3,No,1:No,1:No,,0.97
6405,420259,Table 2,BaselineCharacteristic,,Uterodome – abundance ; ,group x vs group x,None,16,17,3,No,1:No,1:No,,0.97
6405,420259,Table 2,BaselineCharacteristic,,Cell borders ; ,group x vs group x,None,16,18,3,No,1:No,1:No,,0.99
6405,420259,Table 2,BaselineCharacteristic,"SD (x,x)",Secretion ; ,group x vs group x,None,16,19,3,No,1:No,1:No,,0.85
6405,420259,Table 2,BaselineCharacteristic,,Plicae ; ,group x vs group x,None,16,20,3,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,,,None,None,0,0,12,No,1:No,1:No,,0.905
6405,420259,Table 3,BaselineCharacteristic,,,,None,0,1,1,No,1:No,1:No,,0.903
6405,420259,Table 3,BaselineCharacteristic,Epithelial abundance,,,None,0,2,1,No,1:No,1:No,,0.903
6405,420259,Table 3,BaselineCharacteristic,Tissue heterogeneity,,,None,0,3,1,No,1:No,1:No,,0.903
6405,420259,Table 3,BaselineCharacteristic,Cell heterogeneity,,,None,0,4,1,No,1:No,1:No,,0.913
6405,420259,Table 3,BaselineCharacteristic,Gland abundance,,,None,0,5,1,No,1:No,1:No,,0.935
6405,420259,Table 3,BaselineCharacteristic,Gland opening,,,None,0,6,1,No,1:No,1:No,,0.935
6405,420259,Table 3,BaselineCharacteristic,Cilia groups,,,None,0,7,1,No,1:No,1:No,,0.945
6405,420259,Table 3,BaselineCharacteristic,Single cilium,,,None,0,8,1,No,1:No,1:No,,0.945
6405,420259,Table 3,BaselineCharacteristic,Microvilli height,,,None,0,9,1,No,1:No,1:No,,0.945
6405,420259,Table 3,BaselineCharacteristic,Microvilli density,,,None,0,10,1,No,1:No,1:No,,0.945
6405,420259,Table 3,BaselineCharacteristic,Apical membrane defects,,,None,0,11,1,No,1:No,1:No,,0.945
6405,420259,Table 3,BaselineCharacteristic,Cell separation,,,None,0,12,1,No,1:No,1:No,,0.945
6405,420259,Table 3,BaselineCharacteristic,Denuded apices,,,None,0,13,1,No,1:No,1:No,,0.945
6405,420259,Table 3,BaselineCharacteristic,Flattened cells,,,None,0,14,1,No,1:No,1:No,,0.945
6405,420259,Table 3,BaselineCharacteristic,Deflated cells,,,None,0,15,1,No,1:No,1:No,,0.945
6405,420259,Table 3,BaselineCharacteristic,Apical protrusion,,,None,0,16,1,No,1:No,1:No,,0.945
6405,420259,Table 3,BaselineCharacteristic,Uterodome – shape,,,None,0,17,1,No,1:No,1:No,,0.906
6405,420259,Table 3,BaselineCharacteristic,Uterodome – abundance,,,None,0,18,1,No,1:No,1:No,,0.906
6405,420259,Table 3,BaselineCharacteristic,Cell borders,,,None,0,19,1,No,1:No,1:No,,0.945
6405,420259,Table 3,BaselineCharacteristic,Secretion,,,None,0,20,1,No,1:No,1:No,,0.945
6405,420259,Table 3,BaselineCharacteristic,Plicae,,,None,0,21,1,No,1:No,1:No,,0.945
6405,420259,Table 3,BaselineCharacteristic,,,None,None,1,0,2,No,1:No,1:No,,0.94
6405,420259,Table 3,BaselineCharacteristic,,,None,None,1,1,3,No,1:No,1:No,,0.87
6405,420259,Table 3,BaselineCharacteristic,,,None,None,1,2,3,No,1:No,1:No,,0.88
6405,420259,Table 3,BaselineCharacteristic,,,None,None,1,3,3,No,1:No,1:No,,0.88
6405,420259,Table 3,BaselineCharacteristic,,,None,None,1,4,3,No,1:No,1:No,,0.87
6405,420259,Table 3,BaselineCharacteristic,,,None,None,1,5,3,No,1:No,1:No,,0.88
6405,420259,Table 3,BaselineCharacteristic,,,None,None,1,6,3,No,1:No,1:No,,0.89
6405,420259,Table 3,BaselineCharacteristic,,,None,None,1,7,3,No,1:No,1:No,,0.89
6405,420259,Table 3,BaselineCharacteristic,,,None,None,1,8,3,No,1:No,1:No,,0.89
6405,420259,Table 3,BaselineCharacteristic,,,None,None,1,9,3,No,1:No,1:No,,0.89
6405,420259,Table 3,BaselineCharacteristic,,,None,None,1,10,3,No,1:No,1:No,,0.89
6405,420259,Table 3,BaselineCharacteristic,,,None,None,1,11,3,No,1:No,1:No,,0.89
6405,420259,Table 3,BaselineCharacteristic,,,None,None,1,12,3,No,1:No,1:No,,0.89
6405,420259,Table 3,BaselineCharacteristic,,,None,None,1,13,3,No,1:No,1:No,,0.89
6405,420259,Table 3,BaselineCharacteristic,,,None,None,1,14,3,No,1:No,1:No,,0.89
6405,420259,Table 3,BaselineCharacteristic,,,None,None,1,15,3,No,1:No,1:No,,0.89
6405,420259,Table 3,BaselineCharacteristic,,,None,None,1,16,3,No,1:No,1:No,,0.89
6405,420259,Table 3,BaselineCharacteristic,,,None,None,1,17,3,No,1:No,1:No,,0.89
6405,420259,Table 3,BaselineCharacteristic,,,None,None,1,18,3,No,1:No,1:No,,0.89
6405,420259,Table 3,BaselineCharacteristic,,,None,None,1,19,3,No,1:No,1:No,,0.89
6405,420259,Table 3,BaselineCharacteristic,,,None,None,1,20,3,No,1:No,1:No,,0.89
6405,420259,Table 3,BaselineCharacteristic,,,None,None,21,1,3,No,1:No,1:No,,0.97
6405,420259,Table 3,BaselineCharacteristic,Group x,,Group x,,2,0,2,No,1:No,1:No,,0.935
6405,420259,Table 3,BaselineCharacteristic,Median,,Group x,,2,1,3,No,1:No,1:No,,0.91
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,2,2,3,No,1:No,1:No,,0.92
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,2,3,3,No,1:No,1:No,,0.91
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,2,4,3,No,1:No,1:No,,0.9
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,2,5,3,No,1:No,1:No,,0.9
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,2,6,3,No,1:No,1:No,,0.91
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,2,7,3,No,1:No,1:No,,0.9
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,2,8,3,No,1:No,1:No,,0.91
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,2,9,3,No,1:No,1:No,,0.91
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,2,10,3,No,1:No,1:No,,0.91
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,2,11,3,No,1:No,1:No,,0.91
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,2,12,3,No,1:No,1:No,,0.91
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,2,13,3,No,1:No,1:No,,0.91
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,2,14,3,No,1:No,1:No,,0.91
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,2,15,3,No,1:No,1:No,,0.91
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,2,16,3,No,1:No,1:No,,0.91
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,2,17,3,No,1:No,1:No,,0.91
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,2,18,3,No,1:No,1:No,,0.91
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,2,19,3,No,1:No,1:No,,0.91
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,2,20,3,No,1:No,1:No,,0.91
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,2,21,3,No,1:No,1:No,,0.91
6405,420259,Table 3,BaselineCharacteristic,Combined,,Combined,,3,0,2,No,1:No,1:No,,0.96
6405,420259,Table 3,BaselineCharacteristic,Minimum,,Combined,,3,1,3,No,1:No,1:No,,0.89
6405,420259,Table 3,BaselineCharacteristic,x,,Combined,,3,2,3,No,1:No,1:No,,0.94
6405,420259,Table 3,BaselineCharacteristic,x,,Combined,,3,3,3,No,1:No,1:No,,0.93
6405,420259,Table 3,BaselineCharacteristic,x,,Combined,,3,4,3,No,1:No,1:No,,0.92
6405,420259,Table 3,BaselineCharacteristic,x,,Combined,,3,5,3,No,1:No,1:No,,0.92
6405,420259,Table 3,BaselineCharacteristic,x,,Combined,,3,6,3,No,1:No,1:No,,0.93
6405,420259,Table 3,BaselineCharacteristic,x,,Combined,,3,7,3,No,1:No,1:No,,0.92
6405,420259,Table 3,BaselineCharacteristic,x,,Combined,,3,8,3,No,1:No,1:No,,0.93
6405,420259,Table 3,BaselineCharacteristic,x,,Combined,,3,9,3,No,1:No,1:No,,0.93
6405,420259,Table 3,BaselineCharacteristic,x,,Combined,,3,10,3,No,1:No,1:No,,0.93
6405,420259,Table 3,BaselineCharacteristic,x,,Combined,,3,11,3,No,1:No,1:No,,0.93
6405,420259,Table 3,BaselineCharacteristic,x,,Combined,,3,12,3,No,1:No,1:No,,0.93
6405,420259,Table 3,BaselineCharacteristic,x,,Combined,,3,13,3,No,1:No,1:No,,0.93
6405,420259,Table 3,BaselineCharacteristic,x,,Combined,,3,14,3,No,1:No,1:No,,0.93
6405,420259,Table 3,BaselineCharacteristic,x,,Combined,,3,15,3,No,1:No,1:No,,0.93
6405,420259,Table 3,BaselineCharacteristic,x,,Combined,,3,16,3,No,1:No,1:No,,0.93
6405,420259,Table 3,BaselineCharacteristic,x,,Combined,,3,17,3,No,1:No,1:No,,0.93
6405,420259,Table 3,BaselineCharacteristic,x,,Combined,,3,18,3,No,1:No,1:No,,0.93
6405,420259,Table 3,BaselineCharacteristic,x,,Combined,,3,19,3,No,1:No,1:No,,0.93
6405,420259,Table 3,BaselineCharacteristic,x,,Combined,,3,20,3,No,1:No,1:No,,0.93
6405,420259,Table 3,BaselineCharacteristic,x,,Combined,,3,21,3,No,1:No,1:No,,0.93
6405,420259,Table 3,BaselineCharacteristic,n = xx,,n = xx,,4,0,2,No,1:No,1:No,,0.654
6405,420259,Table 3,BaselineCharacteristic,Maximum,,n = xx,,4,1,3,No,1:No,1:No,,0.617
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,4,2,3,No,1:No,1:No,,0.707
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,4,3,3,No,1:No,1:No,,0.711
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,4,4,3,No,1:No,1:No,,0.721
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,4,5,3,No,1:No,1:No,,0.736
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,4,6,3,No,1:No,1:No,,0.736
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,4,7,3,No,1:No,1:No,,0.746
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,4,8,3,No,1:No,1:No,,0.756
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,4,9,3,No,1:No,1:No,,0.766
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,4,10,3,No,1:No,1:No,,0.766
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,4,11,3,No,1:No,1:No,,0.766
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,4,12,3,No,1:No,1:No,,0.766
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,4,13,3,No,1:No,1:No,,0.766
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,4,14,3,No,1:No,1:No,,0.766
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,4,15,3,No,1:No,1:No,,0.766
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,4,16,3,No,1:No,1:No,,0.766
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,4,17,3,No,1:No,1:No,,0.766
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,4,18,3,No,1:No,1:No,,0.766
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,4,19,3,No,1:No,1:No,,0.766
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,4,20,3,No,1:No,1:No,,0.766
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,4,21,3,No,1:No,1:No,,0.766
6405,420259,Table 3,BaselineCharacteristic,(Group x),,(Group x),,5,0,2,No,1:No,1:No,,0.963
6405,420259,Table 3,BaselineCharacteristic,Median,,(Group x),,5,1,3,No,1:No,1:No,,0.92
6405,420259,Table 3,BaselineCharacteristic,x.x,,(Group x),,5,2,3,No,1:No,1:No,,0.94
6405,420259,Table 3,BaselineCharacteristic,x.x,,(Group x),,5,3,3,No,1:No,1:No,,0.93
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,5,4,3,No,1:No,1:No,,0.92
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,5,5,3,No,1:No,1:No,,0.9
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,5,6,3,No,1:No,1:No,,0.91
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,5,7,3,No,1:No,1:No,,0.9
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,5,8,3,No,1:No,1:No,,0.91
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,5,9,3,No,1:No,1:No,,0.91
6405,420259,Table 3,BaselineCharacteristic,x.x,,(Group x),,5,10,3,No,1:No,1:No,,0.91
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,5,11,3,No,1:No,1:No,,0.91
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,5,12,3,No,1:No,1:No,,0.91
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,5,13,3,No,1:No,1:No,,0.91
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,5,14,3,No,1:No,1:No,,0.91
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,5,15,3,No,1:No,1:No,,0.91
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,5,16,3,No,1:No,1:No,,0.91
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,5,17,3,No,1:No,1:No,,0.91
6405,420259,Table 3,BaselineCharacteristic,x.x,,(Group x),,5,18,3,No,1:No,1:No,,0.91
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,5,19,3,No,1:No,1:No,,0.91
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,5,20,3,No,1:No,1:No,,0.91
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,5,21,3,No,1:No,1:No,,0.91
6405,420259,Table 3,BaselineCharacteristic,n = xx,,n = xx,,6,0,24,No,1:No,1:No,,0.732
6405,420259,Table 3,BaselineCharacteristic,Minimum,,n = xx,,6,1,43,No,1:No,1:No,,0.67
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,6,2,43,No,1:No,1:No,,0.67
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,6,3,43,No,1:No,1:No,,0.694
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,6,4,43,No,1:No,1:No,,0.714
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,6,5,43,No,1:No,1:No,,0.732
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,6,6,43,No,1:No,1:No,,0.732
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,6,7,43,No,1:No,1:No,,0.742
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,6,8,43,No,1:No,1:No,,0.762
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,6,9,43,No,1:No,1:No,,0.772
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,6,10,43,No,1:No,1:No,,0.772
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,6,11,43,No,1:No,1:No,,0.772
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,6,12,43,No,1:No,1:No,,0.772
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,6,13,43,No,1:No,1:No,,0.772
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,6,14,43,No,1:No,1:No,,0.772
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,6,15,43,No,1:No,1:No,,0.772
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,6,16,43,No,1:No,1:No,,0.772
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,6,17,43,No,1:No,1:No,,0.772
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,6,18,43,No,1:No,1:No,,0.772
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,6,19,43,No,1:No,1:No,,0.772
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,6,20,43,No,1:No,1:No,,0.772
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,6,21,43,No,1:No,1:No,,0.772
6405,420259,Table 3,BaselineCharacteristic,,,,,7,0,2,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,Maximum,,,,7,1,3,No,1:No,1:No,,0.95
6405,420259,Table 3,BaselineCharacteristic,x,,,,7,2,3,No,1:No,1:No,,0.97
6405,420259,Table 3,BaselineCharacteristic,x,,,,7,3,3,No,1:No,1:No,,0.96
6405,420259,Table 3,BaselineCharacteristic,x,,,,7,4,3,No,1:No,1:No,,0.96
6405,420259,Table 3,BaselineCharacteristic,x,,,,7,5,3,No,1:No,1:No,,0.95
6405,420259,Table 3,BaselineCharacteristic,x,,,,7,6,3,No,1:No,1:No,,0.96
6405,420259,Table 3,BaselineCharacteristic,x,,,,7,7,3,No,1:No,1:No,,0.95
6405,420259,Table 3,BaselineCharacteristic,x,,,,7,8,3,No,1:No,1:No,,0.96
6405,420259,Table 3,BaselineCharacteristic,x,,,,7,9,3,No,1:No,1:No,,0.96
6405,420259,Table 3,BaselineCharacteristic,x,,,,7,10,3,No,1:No,1:No,,0.96
6405,420259,Table 3,BaselineCharacteristic,x,,,,7,11,3,No,1:No,1:No,,0.96
6405,420259,Table 3,BaselineCharacteristic,x,,,,7,12,3,No,1:No,1:No,,0.96
6405,420259,Table 3,BaselineCharacteristic,x,,,,7,13,3,No,1:No,1:No,,0.96
6405,420259,Table 3,BaselineCharacteristic,x,,,,7,14,3,No,1:No,1:No,,0.96
6405,420259,Table 3,BaselineCharacteristic,x,,,,7,15,3,No,1:No,1:No,,0.96
6405,420259,Table 3,BaselineCharacteristic,x,,,,7,16,3,No,1:No,1:No,,0.96
6405,420259,Table 3,BaselineCharacteristic,x,,,,7,17,3,No,1:No,1:No,,0.96
6405,420259,Table 3,BaselineCharacteristic,x,,,,7,18,3,No,1:No,1:No,,0.96
6405,420259,Table 3,BaselineCharacteristic,x,,,,7,19,3,No,1:No,1:No,,0.96
6405,420259,Table 3,BaselineCharacteristic,x,,,,7,20,3,No,1:No,1:No,,0.96
6405,420259,Table 3,BaselineCharacteristic,x,,,,7,21,3,No,1:No,1:No,,0.96
6405,420259,Table 3,BaselineCharacteristic,(Group x),,(Group x),,8,0,2,No,1:No,1:No,,0.972
6405,420259,Table 3,BaselineCharacteristic,Median,,(Group x),,8,1,3,No,1:No,1:No,,0.97
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,8,2,3,No,1:No,1:No,,0.98
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,8,3,3,No,1:No,1:No,,0.97
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,8,4,3,No,1:No,1:No,,0.97
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,8,5,3,No,1:No,1:No,,0.97
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,8,6,3,No,1:No,1:No,,0.98
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,8,7,3,No,1:No,1:No,,0.97
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,8,8,3,No,1:No,1:No,,0.98
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,8,9,3,No,1:No,1:No,,0.98
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,8,10,3,No,1:No,1:No,,0.98
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,8,11,3,No,1:No,1:No,,0.98
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,8,12,3,No,1:No,1:No,,0.98
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,8,13,3,No,1:No,1:No,,0.98
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,8,14,3,No,1:No,1:No,,0.98
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,8,15,3,No,1:No,1:No,,0.98
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,8,16,3,No,1:No,1:No,,0.98
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,8,17,3,No,1:No,1:No,,0.98
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,8,18,3,No,1:No,1:No,,0.98
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,8,19,3,No,1:No,1:No,,0.98
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,8,20,3,No,1:No,1:No,,0.98
6405,420259,Table 3,BaselineCharacteristic,x,,(Group x),,8,21,3,No,1:No,1:No,,0.98
6405,420259,Table 3,BaselineCharacteristic,n = xx,,n = xx,,9,0,24,No,1:No,1:No,,0.762
6405,420259,Table 3,BaselineCharacteristic,Minimum,,n = xx,,9,1,43,No,1:No,1:No,,0.73
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,9,2,43,No,1:No,1:No,,0.73
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,9,3,43,No,1:No,1:No,,0.754
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,9,4,43,No,1:No,1:No,,0.794
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,9,5,43,No,1:No,1:No,,0.822
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,9,6,43,No,1:No,1:No,,0.822
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,9,7,43,No,1:No,1:No,,0.822
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,9,8,43,No,1:No,1:No,,0.842
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,9,9,43,No,1:No,1:No,,0.852
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,9,10,43,No,1:No,1:No,,0.862
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,9,11,43,No,1:No,1:No,,0.862
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,9,12,43,No,1:No,1:No,,0.862
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,9,13,43,No,1:No,1:No,,0.862
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,9,14,43,No,1:No,1:No,,0.862
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,9,15,43,No,1:No,1:No,,0.862
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,9,16,43,No,1:No,1:No,,0.862
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,9,17,43,No,1:No,1:No,,0.862
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,9,18,43,No,1:No,1:No,,0.862
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,9,19,43,No,1:No,1:No,,0.862
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,9,20,43,No,1:No,1:No,,0.862
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,9,21,43,No,1:No,1:No,,0.862
6405,420259,Table 3,BaselineCharacteristic,,,,,10,0,2,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,Maximum,,,,10,1,3,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,x,,,,10,2,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,10,3,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,10,4,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,10,5,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,10,6,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,10,7,3,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,x,,,,10,8,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,10,9,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,10,10,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,10,11,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,10,12,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,10,13,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,10,14,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,10,15,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,10,16,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,10,17,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,10,18,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,10,19,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,10,20,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,10,21,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,Group x,,Group x,,11,0,2,No,1:No,1:No,,0.982
6405,420259,Table 3,BaselineCharacteristic,Median,,Group x,,11,1,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,11,2,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,11,3,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,11,4,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,11,5,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,11,6,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,11,7,3,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,11,8,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,11,9,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,11,10,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,11,11,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,11,12,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,11,13,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,11,14,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,11,15,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,11,16,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,11,17,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,11,18,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,11,19,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,11,20,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,11,21,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,n = x,,n = x,,12,0,24,No,1:No,1:No,,0.89
6405,420259,Table 3,BaselineCharacteristic,Minimum,,n = x,,12,1,43,No,1:No,1:No,,0.878
6405,420259,Table 3,BaselineCharacteristic,x,,n = x,,12,2,43,No,1:No,1:No,,0.888
6405,420259,Table 3,BaselineCharacteristic,x,,n = x,,12,3,43,No,1:No,1:No,,0.902
6405,420259,Table 3,BaselineCharacteristic,x,,n = x,,12,4,43,No,1:No,1:No,,0.932
6405,420259,Table 3,BaselineCharacteristic,x,,n = x,,12,5,43,No,1:No,1:No,,0.936
6405,420259,Table 3,BaselineCharacteristic,x,,n = x,,12,6,43,No,1:No,1:No,,0.936
6405,420259,Table 3,BaselineCharacteristic,x,,n = x,,12,7,43,No,1:No,1:No,,0.936
6405,420259,Table 3,BaselineCharacteristic,x,,n = x,,12,8,43,No,1:No,1:No,,0.946
6405,420259,Table 3,BaselineCharacteristic,x,,n = x,,12,9,43,No,1:No,1:No,,0.956
6405,420259,Table 3,BaselineCharacteristic,x,,n = x,,12,10,43,No,1:No,1:No,,0.956
6405,420259,Table 3,BaselineCharacteristic,x,,n = x,,12,11,43,No,1:No,1:No,,0.956
6405,420259,Table 3,BaselineCharacteristic,x,,n = x,,12,12,43,No,1:No,1:No,,0.956
6405,420259,Table 3,BaselineCharacteristic,x,,n = x,,12,13,43,No,1:No,1:No,,0.956
6405,420259,Table 3,BaselineCharacteristic,x,,n = x,,12,14,43,No,1:No,1:No,,0.956
6405,420259,Table 3,BaselineCharacteristic,x,,n = x,,12,15,43,No,1:No,1:No,,0.956
6405,420259,Table 3,BaselineCharacteristic,x,,n = x,,12,16,43,No,1:No,1:No,,0.956
6405,420259,Table 3,BaselineCharacteristic,x,,n = x,,12,17,43,No,1:No,1:No,,0.956
6405,420259,Table 3,BaselineCharacteristic,x,,n = x,,12,18,43,No,1:No,1:No,,0.956
6405,420259,Table 3,BaselineCharacteristic,x,,n = x,,12,19,43,No,1:No,1:No,,0.956
6405,420259,Table 3,BaselineCharacteristic,x,,n = x,,12,20,43,No,1:No,1:No,,0.956
6405,420259,Table 3,BaselineCharacteristic,x,,n = x,,12,21,43,No,1:No,1:No,,0.956
6405,420259,Table 3,BaselineCharacteristic,,,,,13,0,2,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,Maximum,,,,13,1,3,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,x,,,,13,2,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,13,3,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,13,4,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,13,5,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,13,6,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,13,7,3,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,x,,,,13,8,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,13,9,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,13,10,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,13,11,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,13,12,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,13,13,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,13,14,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,13,15,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,13,16,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,13,17,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,13,18,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,13,19,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,13,20,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,13,21,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,Group x,,Group x,,14,0,2,No,1:No,1:No,,0.982
6405,420259,Table 3,BaselineCharacteristic,Median,,Group x,,14,1,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,14,2,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,14,3,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,14,4,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,14,5,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,14,6,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,14,7,3,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,14,8,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,14,9,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,14,10,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,14,11,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,14,12,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,14,13,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,14,14,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,14,15,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,14,16,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,14,17,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,14,18,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,14,19,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x.x,,Group x,,14,20,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,14,21,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,n = xx,,n = xx,,15,0,24,No,1:No,1:No,,0.792
6405,420259,Table 3,BaselineCharacteristic,Minimum,,n = xx,,15,1,43,No,1:No,1:No,,0.76
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,15,2,43,No,1:No,1:No,,0.77
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,15,3,43,No,1:No,1:No,,0.804
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,15,4,43,No,1:No,1:No,,0.854
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,15,5,43,No,1:No,1:No,,0.872
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,15,6,43,No,1:No,1:No,,0.872
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,15,7,43,No,1:No,1:No,,0.872
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,15,8,43,No,1:No,1:No,,0.892
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,15,9,43,No,1:No,1:No,,0.902
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,15,10,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,15,11,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,15,12,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,15,13,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,15,14,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,15,15,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,15,16,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,15,17,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,15,18,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,15,19,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,15,20,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,15,21,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,,,,,16,0,2,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,Maximum,,,,16,1,3,No,1:No,1:No,,0.98
6405,420259,Table 3,BaselineCharacteristic,x,,,,16,2,3,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,x,,,,16,3,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,16,4,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,16,5,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,16,6,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,16,7,3,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,x,,,,16,8,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,16,9,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,16,10,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,16,11,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,16,12,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,16,13,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,16,14,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,16,15,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,16,16,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,16,17,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,16,18,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,16,19,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,16,20,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,16,21,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,Group x,,Group x,,17,0,2,No,1:No,1:No,,0.982
6405,420259,Table 3,BaselineCharacteristic,Median,,Group x,,17,1,3,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,17,2,3,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,x.x,,Group x,,17,3,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x.x,,Group x,,17,4,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,17,5,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,17,6,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x.x,,Group x,,17,7,3,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,x.x,,Group x,,17,8,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,17,9,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,17,10,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,17,11,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x.x,,Group x,,17,12,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,17,13,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,17,14,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,17,15,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,17,16,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,17,17,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,17,18,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,17,19,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,17,20,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x.x,,Group x,,17,21,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,n = xx,,n = xx,,18,0,24,No,1:No,1:No,,0.792
6405,420259,Table 3,BaselineCharacteristic,Minimum,,n = xx,,18,1,43,No,1:No,1:No,,0.76
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,18,2,43,No,1:No,1:No,,0.77
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,18,3,43,No,1:No,1:No,,0.804
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,18,4,43,No,1:No,1:No,,0.854
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,18,5,43,No,1:No,1:No,,0.872
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,18,6,43,No,1:No,1:No,,0.872
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,18,7,43,No,1:No,1:No,,0.872
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,18,8,43,No,1:No,1:No,,0.892
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,18,9,43,No,1:No,1:No,,0.902
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,18,10,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,18,11,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,18,12,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,18,13,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,18,14,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,18,15,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,18,16,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,18,17,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,18,18,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,18,19,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,18,20,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,18,21,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,,,,,19,0,2,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,Maximum,,,,19,1,3,No,1:No,1:No,,0.97
6405,420259,Table 3,BaselineCharacteristic,x,,,,19,2,3,No,1:No,1:No,,0.98
6405,420259,Table 3,BaselineCharacteristic,x,,,,19,3,3,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,x,,,,19,4,3,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,x,,,,19,5,3,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,x,,,,19,6,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,19,7,3,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,x,,,,19,8,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,19,9,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,19,10,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,19,11,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,19,12,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,19,13,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,19,14,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,19,15,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,19,16,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,19,17,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,19,18,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,19,19,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,19,20,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,19,21,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,Group x,,Group x,,20,0,2,No,1:No,1:No,,0.972
6405,420259,Table 3,BaselineCharacteristic,Median,,Group x,,20,1,3,No,1:No,1:No,,0.98
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,20,2,3,No,1:No,1:No,,0.98
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,20,3,3,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,x.x,,Group x,,20,4,3,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,20,5,3,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,x.x,,Group x,,20,6,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,20,7,3,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,x.x,,Group x,,20,8,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,20,9,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,20,10,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,20,11,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,20,12,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,20,13,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,20,14,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,20,15,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,20,16,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,20,17,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,20,18,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,20,19,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,20,20,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,20,21,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,n = xx,,n = xx,,21,0,24,No,1:No,1:No,,0.792
6405,420259,Table 3,BaselineCharacteristic,Minimum,,n = xx,,21,1,43,No,1:No,1:No,,0.76
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,21,2,43,No,1:No,1:No,,0.77
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,21,3,43,No,1:No,1:No,,0.804
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,21,4,43,No,1:No,1:No,,0.854
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,21,5,43,No,1:No,1:No,,0.872
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,21,6,43,No,1:No,1:No,,0.872
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,21,7,43,No,1:No,1:No,,0.872
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,21,8,43,No,1:No,1:No,,0.892
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,21,9,43,No,1:No,1:No,,0.902
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,21,10,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,21,11,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,21,12,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,21,13,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,21,14,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,21,15,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,21,16,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,21,17,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,21,18,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,21,19,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,21,20,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,21,21,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,,,,,22,0,2,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,Maximum,,,,22,1,3,No,1:No,1:No,,0.98
6405,420259,Table 3,BaselineCharacteristic,x,,,,22,2,3,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,x,,,,22,3,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,22,4,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,22,5,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,22,6,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,22,7,3,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,x,,,,22,8,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,22,9,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,22,10,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,22,11,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,22,12,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,22,13,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,22,14,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,22,15,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,22,16,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,22,17,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,22,18,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,22,19,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,22,20,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,22,21,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,Group x,,Group x,,23,0,2,No,1:No,1:No,,0.982
6405,420259,Table 3,BaselineCharacteristic,Median,,Group x,,23,1,3,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,23,2,3,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,23,3,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,23,4,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,23,5,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,23,6,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,23,7,3,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,23,8,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,23,9,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,23,10,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,23,11,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,23,12,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,23,13,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,23,14,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,23,15,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,23,16,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,23,17,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,23,18,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,23,19,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,23,20,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,23,21,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,n = xx,,n = xx,,24,0,24,No,1:No,1:No,,0.792
6405,420259,Table 3,BaselineCharacteristic,Minimum,,n = xx,,24,1,43,No,1:No,1:No,,0.76
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,24,2,43,No,1:No,1:No,,0.77
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,24,3,43,No,1:No,1:No,,0.804
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,24,4,43,No,1:No,1:No,,0.854
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,24,5,43,No,1:No,1:No,,0.872
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,24,6,43,No,1:No,1:No,,0.872
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,24,7,43,No,1:No,1:No,,0.872
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,24,8,43,No,1:No,1:No,,0.892
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,24,9,43,No,1:No,1:No,,0.902
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,24,10,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,24,11,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,24,12,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,24,13,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,24,14,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,24,15,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,24,16,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,24,17,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,24,18,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,24,19,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,24,20,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,24,21,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,,,,,25,0,2,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,Maximum,,,,25,1,3,No,1:No,1:No,,0.98
6405,420259,Table 3,BaselineCharacteristic,x,,,,25,2,3,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,x,,,,25,3,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,25,4,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,25,5,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,25,6,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,25,7,3,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,x,,,,25,8,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,25,9,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,25,10,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,25,11,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,25,12,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,25,13,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,25,14,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,25,15,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,25,16,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,25,17,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,25,18,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,25,19,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,25,20,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,25,21,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,Group x,,Group x,,26,0,2,No,1:No,1:No,,0.982
6405,420259,Table 3,BaselineCharacteristic,Median,,Group x,,26,1,3,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,26,2,3,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,26,3,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,26,4,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,26,5,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,26,6,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,26,7,3,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,26,8,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,26,9,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,26,10,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,26,11,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,26,12,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,26,13,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,26,14,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,26,15,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,26,16,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,26,17,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,26,18,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,26,19,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,26,20,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,Group x,,26,21,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,n = xx,,n = xx,,27,0,24,No,1:No,1:No,,0.792
6405,420259,Table 3,BaselineCharacteristic,Minimum,,n = xx,,27,1,43,No,1:No,1:No,,0.76
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,27,2,43,No,1:No,1:No,,0.77
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,27,3,43,No,1:No,1:No,,0.804
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,27,4,43,No,1:No,1:No,,0.854
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,27,5,43,No,1:No,1:No,,0.872
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,27,6,43,No,1:No,1:No,,0.872
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,27,7,43,No,1:No,1:No,,0.872
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,27,8,43,No,1:No,1:No,,0.892
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,27,9,43,No,1:No,1:No,,0.902
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,27,10,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,27,11,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,27,12,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,27,13,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,27,14,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,27,15,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,27,16,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,27,17,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,27,18,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,27,19,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,27,20,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,x,,n = xx,,27,21,43,No,1:No,1:No,,0.912
6405,420259,Table 3,BaselineCharacteristic,,,,,28,0,2,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,Maximum,,,,28,1,3,No,1:No,1:No,,0.98
6405,420259,Table 3,BaselineCharacteristic,x,,,,28,2,3,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,x,,,,28,3,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,28,4,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,28,5,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,28,6,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,28,7,3,No,1:No,1:No,,0.99
6405,420259,Table 3,BaselineCharacteristic,x,,,,28,8,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,28,9,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,28,10,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,28,11,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,28,12,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,28,13,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,28,14,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,28,15,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,28,16,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,28,17,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,28,18,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,28,19,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,28,20,3,No,1:No,1:No,,1
6405,420259,Table 3,BaselineCharacteristic,x,,,,28,21,3,No,1:No,1:No,,1
6540,60660,Table 1,BaselineCharacteristic,Volunteers,,None,None,0,0,12,No,1:No,1:No,,0.905
6540,60660,Table 1,BaselineCharacteristic,Sex female (f); male (m),,Volunteers,None,0,1,1,No,1:No,1:No,,0.903
6540,60660,Table 1,BaselineCharacteristic,Tx,,Volunteers,None,0,3,1,No,1:No,1:No,,0.903
6540,60660,Table 1,BaselineCharacteristic,Tx,,Volunteers,None,0,4,1,No,1:No,1:No,,0.913
6540,60660,Table 1,BaselineCharacteristic,Tx,,Volunteers,None,0,5,1,No,1:No,1:No,,0.935
6540,60660,Table 1,BaselineCharacteristic,UV exposed,Volunteers ; ,UV exposed,None,1,0,2,No,1:No,1:No,,0.94
6540,60660,Table 1,BaselineCharacteristic,xx f; x m,Sex female (f); male (m) ; ,UV exposed,None,1,1,3,No,1:No,1:No,,0.642
6540,60660,Table 1,BaselineCharacteristic,xx.x ± x (x.x–xx)*,Tx ; ,UV exposed,None,1,4,3,No,1:No,1:No,,0.526
6540,60660,Table 1,BaselineCharacteristic,xx.x+x.x (x.x–xx.x)*,Tx ; ,UV exposed,None,1,5,3,No,1:No,1:No,,0.616
6540,60660,Table 1,BaselineCharacteristic,Non-exposed,Volunteers ; ,Non-exposed,None,2,0,2,No,1:No,1:No,,0.95
6540,60660,Table 1,BaselineCharacteristic,x f; x m,Sex female (f); male (m) ; ,Non-exposed,None,2,1,3,No,1:No,1:No,,0.92
6540,60660,Table 1,BaselineCharacteristic,xx.x ± x.x (x.x–xx)*,Tx ; ,Non-exposed,None,2,4,3,No,1:No,1:No,,0.526
6540,60660,Table 1,BaselineCharacteristic,xx ± x.x (x.x–xx.x)*,Tx ; ,Non-exposed,None,2,5,3,No,1:No,1:No,,0.566
